<SEC-DOCUMENT>0001125345-21-000035.txt : 20210225
<SEC-HEADER>0001125345-21-000035.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225160625
ACCESSION NUMBER:		0001125345-21-000035
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		21680263

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mgnx-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:027e117c-75c0-47f2-bc63-7ee727579094,g:55d8aba6-2c39-4104-9032-126eaff6334c,d:cb3df34c6cd545b49b40a9d09c99e0a0--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:mgnx="http://macrogenics.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF80L2ZyYWc6OGRjMzU2ZmJhZDdkNDgwOGI5YTI3ZTAxZTYzZjFkMmIvdGFibGU6Zjc3NDBjNjM3N2JlNDdjYzgxZGIyZTM3NmExMGZiZTEvdGFibGVyYW5nZTpmNzc0MGM2Mzc3YmU0N2NjODFkYjJlMzc2YTEwZmJlMV8xLTEtMS0xLTA_e7562db9-2e13-4f99-8b68-a627e8801ae0">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF80L2ZyYWc6OGRjMzU2ZmJhZDdkNDgwOGI5YTI3ZTAxZTYzZjFkMmIvdGFibGU6Zjc3NDBjNjM3N2JlNDdjYzgxZGIyZTM3NmExMGZiZTEvdGFibGVyYW5nZTpmNzc0MGM2Mzc3YmU0N2NjODFkYjJlMzc2YTEwZmJlMV8yLTEtMS0xLTA_81d970d0-8ea9-44cf-9364-9336e298497d">2020</ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF80L2ZyYWc6OGRjMzU2ZmJhZDdkNDgwOGI5YTI3ZTAxZTYzZjFkMmIvdGFibGU6Zjc3NDBjNjM3N2JlNDdjYzgxZGIyZTM3NmExMGZiZTEvdGFibGVyYW5nZTpmNzc0MGM2Mzc3YmU0N2NjODFkYjJlMzc2YTEwZmJlMV8zLTEtMS0xLTA_e60bbf62-3a03-4280-9047-c40fada89aa6">FY</ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF80L2ZyYWc6OGRjMzU2ZmJhZDdkNDgwOGI5YTI3ZTAxZTYzZjFkMmIvdGFibGU6Zjc3NDBjNjM3N2JlNDdjYzgxZGIyZTM3NmExMGZiZTEvdGFibGVyYW5nZTpmNzc0MGM2Mzc3YmU0N2NjODFkYjJlMzc2YTEwZmJlMV80LTEtMS0xLTA_36faa437-0ff3-462d-ab4f-ceddf42d0e34">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="ic9c6bda6395f466b9aeb7ea0c330cb71_I20201231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzQxNA_c7bd66aa-5f7d-4552-b4e9-c0686ecd66a9">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ibc371ef99f5f4a54a624cc69d77a088b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iee4457baa35447a49304e676fa213609_I20210222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8c8761deec04f95aecb8597243730f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3d808e02b5414fd683b155299253411e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id64fda6eae444b93b571cf566d3a92d0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaef0c61fb24481cbdacd565ae79023e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied1559cf83494ef1ad022048d27be8c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24fcde07e22449f18988a9bb4909c03b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3742a3dcd1cd4e018f4a0e55e544bf88_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e9de6b275e1488fb3fb628e6f009da2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e401a1ba9e34e4b90951902947848c6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d36892fdb74f70add306d4b9acf8f2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide6e365cd9374fd0bc37f252d29fd753_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c020d90e65547508df10ef8295c9c46_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia662d353fd8d45c0b6ef76a73d9eab63_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c8abb81fc54045a728f7789e5eb590_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ef7adb07344ad083846bfb3d0940f6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id00868bdc70444b5996012f6dc5d03f8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03dc58ff992a4affb3ae912e7726fd5f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32cb1a93d9784446861b4351c65a06ab_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34837cef321c44a6880d4682ed958ef8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a43579b4d5441d9adfda3882db2702_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c88315085b4a6b86cc704010cbb3b8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ffdf5a5082a4f03a6ddd2697f0ab3aa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a45855556604f00a3ab1c5a555208a8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i826687038ea842c986973786b645a9e0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ad1dc4801847e1b315ea5729b88e91_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i901563a826804698862205071e209880_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a1a0c6402b943b9b4b2ba26940be870_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e6db4aa25b74df5abc90db0f02b82a6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09fcd6ed15e4fc0be1acdc77c4500f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ef16e4c63d6480f96951c6f7eac9ca2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff38bc7672c14b59938322f49d658a0c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0267b9d993f432e9f8c8b2e9d4c1098_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9104c83bf7314b29a4d988eed8111854_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ca2685a1e44ec89c539d7bc50c9ed0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedec7a9d1790449ea17afb27d64d25ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51c8e9f97bb45179d0e2ff8204fe9a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148cd0120f7c4ce5b2a1fe9a8db994bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibddef6e763f54b939c512d3cd30c5215_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mgnx:Segment</xbrli:measure></xbrli:unit><xbrli:context id="ice95d2414f2f4667ad6a137abdaf65e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if031a3629d9d479b8b2e1574bc24c45e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if51e190b234e40b892b75daf5576b090_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icea874c5381443b5b673e08d90e90c40_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a9f46e4b864266974d1b6fcd23b90e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552151630ecd479daefd899d23524d35_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i005b3bb8d084456ca8d49ff0bad27cfb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0947be2b25de4cfd818cbc871c8cf1e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9446d440a99142d189e04019aee224ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b532567296e49e3bdaf3330f2450754_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ae57da2f7894541b48732b70a7018b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51251d2fc1ee4652bb119cd46a05d7a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d860c4ec4674c37864b79c7a8a1c51c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58a8fbc39ff647a59227c8eecd606e91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e38b6ae03674f649d3803b90d7ecfea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed6dd67ee254fca90e4fe1683b8a032_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae333e83a0b4c128a73b9846f7961d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b35d230e32a43dfba261f095d9b94a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46eba3f4322a4bbca90a630e001423f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie97ced64b0db4ea9832f1407780172eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib963d0612f344980abb58b7bbfdec3d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a721e8181644e798dc6e4780d90abcb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i271fe1de3f1742e1ad5139de5d7b263e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68822e067a8340dfbe694836cdf653da_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80b9fa1115d242cb8ff80ac0457e0b0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb40a146a60543f19cb68d866fb7a671_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db1598c868945aa9827bc1240c7542f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72ea4b2f306047a48020bb482e53e79f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41258fa77ab4a088f6a5f9eb5a20970_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c0cc75cee534fd1a8112f063a35cb0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i531f3aa6b1134103965b1b4eda0c293b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4891f769084a18ac2931ba572ae079_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5588a07194ab4de79f27e05259cfb283_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i100b91d4dd344890967b03a9795b715a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97d18cede0b144daac71f46d3da90aef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee3f25bbd99943aa9498aad2fe62b342_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c1d63dd293345108c3e566e01ade176_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i969a47c5754c4c6985ffd28981d702a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if953214a30c54a4ab6b4b51e83fde241_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c1b1bc8c454a148cb38c5196d6024e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613ecacdf38948c6a00165721abcb9ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e8408688034e0cace6fc6275751598_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a9f85aa087344ca8008b4576a668e22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30f500d13f114fd6b9ece35c3c1ddbbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eee20aa82a04eb881c0f50c7193c079_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d23911aba345f1b5c80d016b475232_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db0ce0a36bd44c89f32be0a7f6f3ccf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2e19ae8025c48e5b2df7b9cd421d21d_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6be239fac74a39a6efe1cf2153245a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id41ac2377a9e406db348d5b48d784025_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f933200f33a49139ed9cdf99b46accb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f3c1f82e424f279963729cfc905770_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f26754d1c12437385b6f0b131ab7e1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eda115843604d8ab1d5b0ec51dd4f34_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8932c76412aa40acaf76c7c665350985_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5794801343ac425dbba4fec50029d947_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibce024e3e9fa467bb2616f6adf5778e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ae1c0908e54561a39ca4b4e76062a3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f8089d6e3024b72b2fa7b1b126799d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2336b1857bf400c9efe189f44310e5f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5172dbbe4a1a40ffae37000e9a89f01c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b1a45648e254a7dbb5b5d67c3ef2ec1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f77e8a6d744b82b3f3741e0299c45d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08fe2220367435fa71093334d9c684a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9c6bda6395f466b9aeb7ea0c330cb71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibafe419048424d72ba9dcb437c36a6fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewaloption"><xbrli:measure>mgnx:renewalOption</xbrli:measure></xbrli:unit><xbrli:context id="ic72a8361cda6471c8e38d658753f0573_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id073a704e63548588d4eeca08d057674_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40138f5330944173b29c88382128a064_D20180402-20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-02</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d7688a5ca1483790dd77c9300f82c4_I20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica23de68e9494461b000d56dee219d8f_D20180402-20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-02</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52765134bddd477d901a12882bde3b9d_I20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if094d8df39954207bb5391061c867477_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3c43517af54165896bef6f429afdf8_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b54527c45444217a8e26ea5f21c66dc_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fc973fcb7d148828513059e1601a77a_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66b02d54eed4262b672c427d7af10e9_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70810fe71eab4695bfbdd5efe0c1c9b3_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97895a6a80e148b1a904880526f25594_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e277b27463146b29c014a1f9710d329_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie71f6f7825d94e5b829714cea61564c2_I20170518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i194f187d59c94fd0be7ab2993ff54938_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f99a9224f74d71a7ddf204e8b0610e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb896738d1f544f3af00d62fa6613580_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if65e3aa5584c442f98a84ac8dcd7ea53_I20131031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0302cc9696d04655b132ed6718400098_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a3833260ec34d169d4087f7cc599a38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2267b398358d40628d513e840da1acd3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ef4253bc71484f944278fc62928061_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eaa927f30f243e1bc5fa261ed93065a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b6e20121a2f4c0abc7b278e428bded7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c05145d2dd243aa946509d98e419c02_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03544544417f4f4c9d465e8f28185dc4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0b4fc7e6824deba0edf9c15b602152_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847642b8e010448c92e39737e6b98cd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f613cb53e594b4ea341386947101b5a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie734a52f70924b7d8ef283a737651cf5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7975540d8d9b4164b34b19720b17c21c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3fea8f715e94127942cb6f892c9f8d7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdfaf6831a2d4d289947607db7469eff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2a4fb10b7154f3ebaf1b668d5d5333c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia12ba1f486ee48b387eed8cf479dabb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede31b1fe9ba4eb59488549ad0ed810f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8760a3584cb24373bea7740e94ca3528_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4deebaa10a1a47c48da755ae23565886_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i787eb452c45b49288fbda9f5890e9106_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eced2ea218c49c0a97e0443fe143c83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d5390f0831417aaa47113ae87c3835_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35285b9536cb42819f07a5e10f10a803_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if008047c1927420f94d6d0b9470befc2_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if40f0f15e6a24dc0ae3308ba4fd42d06_D20171001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3801ae5b2b4734b7b504e59402757a_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88b6f87de8b48c1aefa96bec6d6e029_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ca36c995024fcda45aec3f3a112ef3_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9abc33023e44114b55b4f12898b8282_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921686739722463c9fad09ea5aea9c8f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a4db4be284f4edfaa25820bc601700f_D20170101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0274a39f90984b378198325f447e1d04_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic43e5cf8fc164202a6ba3322517e2e89_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia989b7cb90484d43be29e03fd1165709_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4744971aa884484b209865c89d5a5d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic889e33f540545a6a24b79e6435032eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19c7230b384645a48a881abee6fc9595_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31b103b2021742a2aa611443cc804a22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69b00209713a42919d237bd84b5347ff_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b5d258671b4db29f62cd54a91316b0_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i761691dda30f487faa377ea767d90b27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2421978c32548a692cbb679e16f1769_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40903b6d1a844575b81590c15ea6ad69_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaa6b8a1bef549409289b02f594e0e03_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i264b652dc2a449aaad3d8d44d6eac051_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7528a17162cd4516ba9f826eb391dfe2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdb32608cb0a4fa2ab949afb86d7f2ea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5002f370ab2410aa505e7023a7c03b1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b5491ae6264b9a977e0986eb5f5f09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79fe409dced14166bc3d283feb339c66_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf709b6a97f4324bf07c7b35ff8dcf8_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4936e447493b4718a73a3e856e8466cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d4cb3c32ee4849af0342d8ac09701d_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f6817da3524d99a079cfc05dadfb58_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if317058b73fa4c929dab128dd0783ce9_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib65817edf9ea4a70a15c2ee1b06d2435_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5198817fd6ce48d5b36e1a65aa5dceb0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i883a0b58cc464c758fb7cd4f1a43cde7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2794f662b6aa4beaa84d0ce6906344ec_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66268ce470743409fc8e1e2f94e9801_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b51b6783874d27a5e578d32a2386c7_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc2607458784ba0a39a83024e0690aa_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5506bcb7455143afb88326e2bc2e1766_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bdcb76501ca490393d206ec8477ba60_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf67de44e2a04b7c9869197b5d5a8db3_D20120901-20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-09-01</xbrli:startDate><xbrli:endDate>2012-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e923f8da4f403d9f71bbc5dcacf4c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0913a1b864a54032af94f46428788ecb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b4293b73e6b48ab8ca56a0aa4f4a336_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b72bb5c40c49d9b35cc590ba9cafc3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799c2d0004184beeab2fb18bb2844605_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6f1db210074fa491c51e6386544604_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff5d8a80f0b24b2f8b060afc429d38e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36820e64f4634e7892f209af43a3a307_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i481a6c266fd34525a08d8b19efb3a3a5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i311557add6db476c974b15fe543b53a3_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b5a53b426d4596a8deebbcbbd64643_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="performanceobligation"><xbrli:measure>mgnx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:context id="i50ebf3ffdbfd4f73a07d547a319c5d2c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68fe313822074061be5bf3c037d98d1e_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ab5ff2130a40b1a0aec0d6d8f54c67_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd0782694ada422ca317357bc074882c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9bbec66f02a478c848c4c9082abfa02_D20101001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="productcandidate"><xbrli:measure>mgnx:productCandidate</xbrli:measure></xbrli:unit><xbrli:context id="i1d18f8528615463aa7159bbb5c8c9ca7_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dfc6229eff84fc5bc5f1546988286eb_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3620e7cdab24c1b9ca940443012e7d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="i33759800192341f2aad1c701d3f8d023_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa516c3811054de6a63d0438076fc6d1_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9149ccf8fad640259305ee4963fe44d6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73fce89d7ee84c7f9e43c656a72d517e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6be2dbbda2c4a37b4060f380fd2b3b1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i541afd290f08418499ed50f29b1803fc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3639bf682f4179b89f96aa342a7e53_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM184Ng_858b0a52-6729-4451-ba04-ba1783d054bf">10-K</ix:nonNumeric> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6NmI2MWViYTAzMmRhNGQwYmEyMDkwZGU1N2E1MzY1ZWQvdGFibGVyYW5nZTo2YjYxZWJhMDMyZGE0ZDBiYTIwOTBkZTU3YTUzNjVlZF8wLTAtMS0xLTA_91bf2672-9022-4002-a98c-366833d9cdf1">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xMzE_545ed643-fad9-4f17-b5a8-99f5e686b3c1"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xMzE_d26bed40-e4d9-48aa-8b82-5e947a9a0181">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6ZWVjYzNmN2RiMDQ4NGYwYTkwY2FkZjFiMzIzZTY3MTUvdGFibGVyYW5nZTplZWNjM2Y3ZGIwNDg0ZjBhOTBjYWRmMWIzMjNlNjcxNV8wLTAtMS0xLTA_da0d685b-d671-46e2-b6ae-36f668082eae">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yMTQ_2a20c65a-f75a-4417-9349-29266849d627">001-36112</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yMTg_e018c280-b44f-42c5-aaa0-dac33a006d17">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6OWQ1YTQ1NmM0N2VmNGU0YmE0OTlhMjNmOWJjNzJhMTcvdGFibGVyYW5nZTo5ZDVhNDU2YzQ3ZWY0ZTRiYTQ5OWEyM2Y5YmM3MmExN18wLTAtMS0xLTA_ca6d2572-91b6-46b7-8e19-78ec797d772b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6OWQ1YTQ1NmM0N2VmNGU0YmE0OTlhMjNmOWJjNzJhMTcvdGFibGVyYW5nZTo5ZDVhNDU2YzQ3ZWY0ZTRiYTQ5OWEyM2Y5YmM3MmExN18wLTItMS0xLTA_ea28e984-5599-48e9-9aa0-2bc7c0ed7acc">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State of organization)&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNTM_b7685c3e-01c2-47e5-9f31-4cbf56174420">9704 Medical Center Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNTc_b2e8ee66-d38a-45ec-8612-464b09f62071">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNjE_adbd3cb5-fae5-48da-a8c8-5a5212e1d247">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNjQ_8d320041-469e-4374-afe9-ad52cf56a6eb">20850</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18zMjQ_8f015a39-6b67-4741-b222-9bbd13035bdc">301</ix:nonNumeric>)&#160;&#160;<ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18zMjk_be3f8625-5c49-4209-9bc0-135fb49843cc">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:37.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6MjVmMzcyNjJlNmYzNDE3MGJiNjgxNjBhMTFmM2Q5MTQvdGFibGVyYW5nZToyNWYzNzI2MmU2ZjM0MTcwYmI2ODE2MGExMWYzZDkxNF8xLTAtMS0xLTA_8de0be68-f1db-42cb-be28-2c7c2a8501eb">Common stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6MjVmMzcyNjJlNmYzNDE3MGJiNjgxNjBhMTFmM2Q5MTQvdGFibGVyYW5nZToyNWYzNzI2MmU2ZjM0MTcwYmI2ODE2MGExMWYzZDkxNF8xLTEtMS0xLTA_bc782b9f-0e3c-4410-8ca3-62a51829d2dd">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6MjVmMzcyNjJlNmYzNDE3MGJiNjgxNjBhMTFmM2Q5MTQvdGFibGVyYW5nZToyNWYzNzI2MmU2ZjM0MTcwYmI2ODE2MGExMWYzZDkxNF8xLTItMS0xLTA_3ff1e921-756e-4a9d-ad6c-f965f39fba70">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM182MTg_d6b05f53-3980-4bb9-8fce-eb5393c90fac">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM183Njk_b73afc2b-10d9-4cde-a65b-a321008adc5c">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xMTIx_72b323c0-4b89-4fd1-9779-5a0f74f83bc8">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xNDE5_2a53d6a0-871b-4339-97a7-59a0d21431fd">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company"  in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:22.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6NjQyYTM3N2U2Mjg4NDQzMThlOTE4MDFmYTBlZWRiZmUvdGFibGVyYW5nZTo2NDJhMzc3ZTYyODg0NDMxOGU5MTgwMWZhMGVlZGJmZV8wLTAtMS0xLTA_2a3bb969-62bd-43ca-b0f0-522c1ba5253e">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6NjQyYTM3N2U2Mjg4NDQzMThlOTE4MDFmYTBlZWRiZmUvdGFibGVyYW5nZTo2NDJhMzc3ZTYyODg0NDMxOGU5MTgwMWZhMGVlZGJmZV8yLTQtMS0xLTA_62a16613-99a4-4fe2-b4fd-fa26de757843">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6NjQyYTM3N2U2Mjg4NDQzMThlOTE4MDFmYTBlZWRiZmUvdGFibGVyYW5nZTo2NDJhMzc3ZTYyODg0NDMxOGU5MTgwMWZhMGVlZGJmZV80LTEtMS0xLTA_79c67990-5a8e-4ce3-a579-199e2e791658">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt:booleantrue" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xMzc0Mzg5NTM1MDY3Mw_1846ed15-807f-4e27-911b-3d0a3e309dec">&#9745;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yMTYz_730d5ec0-c81a-415e-9474-26960dbc2729">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the registrant's common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&#160;30, 2020, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="ibc371ef99f5f4a54a624cc69d77a088b_I20200630" decimals="-8" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNDI3_8f48be96-a844-485a-9b02-3953d2e88816">1.5</ix:nonFraction>&#160;billion based on the closing price of the registrant's common stock on the Nasdaq Global Select Market on that date.&#160;&#160;Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant's common stock outstanding on February&#160;22, 2021 was <ix:nonFraction unitRef="shares" contextRef="iee4457baa35447a49304e676fa213609_I20210222" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yOTEw_b1343aad-d7b8-4c84-a68d-faa0c4e03915">56,258,468</ix:nonFraction>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18zMTE5_aaa5dd46-40ef-41d4-ac51-4ca8d97f83e3" escape="true">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2021 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_13">PART I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_16">Business</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_19">Risk Factors</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_22">Unresolved Staff Comments</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_25">Properties</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_28">Legal Proceedings</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_31">Mine Safety Disclosures</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_34">PART II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_37">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_40">Selected Financial Data</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_43">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_70">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_73">Financial Statements and Supplementary Data</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_76">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_79">Controls and Procedures</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_82">Other Information</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_88">PART III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_91">Directors, Executive Officers and Corporate Governance</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_94">Executive Compensation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_97">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_100">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_103">Principal Accountant Fees and Services</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_106">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_109">Exhibits and Financial Statement Schedules</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_112">Form 10-K Summary</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_115">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report on Form 10-K. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of the COVID-19 global pandemic on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_16"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries.</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MacroGenics&#174;, the MacroGenics logo, DART&#174;, TRIDENT</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, MARGENZA</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> and the phrases Breakthrough Biologics, Life-Changing Medicines</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> and Developing Breakthrough Biologics, Life-Changing Medicines</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> are our trademark</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">s. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. We expect to launch MARGENZA in collaboration with our commercialization partner, Eversana Life Science Services, LLC (EVERSANA), in March 2021. In addition, we have a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, that have been created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing product candidates that target various tumor-associated antigens. These include tumor-associated antigens that have been well characterized, such as HER2, which is expressed on some breast, gastroesophageal and other cancer types. Other product candidates that we are developing, with our collaboration partners in certain cases, target tumor-associated antigens against which there are currently no approved products, such as B7-H3, a molecule in the B7 family of immune regulator proteins widely expressed by several different tumor types, and ADAM9, a cell surface protein over-expressed in several solid tumor types. We are also developing molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system&#8217;s response to cancer. Monoclonal antibodies that inhibit PD-1 have been approved by the FDA for the treatment of numerous cancers. Our clinical pipeline includes an anti-PD-1 monoclonal antibody that we have out-licensed to a partner, for which a Biologics License Application (BLA) filed with the FDA is subject to a Prescription Drug User Fee Act (PDUFA) target action date of July 25, 2021, and two bispecific DART product candidates that co-engage PD-1 and LAG-3, or PD-1 and CTLA-4. We are also developing a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia (AML).</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have created our product candidates based on the following antibody-based technologies:</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fc Optimization platform, which introduces certain mutations into the Fc domain of a monoclonal antibody in order to modulate antibody interaction with immune effector cells to enhance the killing of cancer cells; </span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multi-specific platforms, which enable us to design antibodies that can bind to two (in the case of our bispecific DART product candidates) or more distinct targets; and</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Antibody drug conjugate (ADC) platforms, which we have licensed from collaboration partners, and which link monoclonal antibodies that specifically target cytotoxins to cancer cells that are designed to trigger cell death in the cancer cell.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to be a fully-integrated biotechnology company leading in the discovery, development and commercialization of breakthrough antibody-based biologics for the treatment of patients with cancer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline of Immuno-Oncology Product Candidates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below depicts the current status of our immuno-oncology product candidates that are in clinical development and for which we retain all or some commercial rights:</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><img src="mgnx-20201231_g1.jpg" alt="mgnx-20201231_g1.jpg" style="height:314px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Margetuximab</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Margetuximab is an Fc-engineered, monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors. Similar to trastuzumab, margetuximab inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC). However, through our Fc Optimization technology, margetuximab has been engineered to enhance the engagement of the immune system. In vitro, the modified Fc region of margetuximab increases binding to the activating Fc receptor FCGR3A (CD16A) and decreases binding to the inhibitory Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and natural killer (NK) cell activation.  The clinical significance of in vitro data is unknown. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced that the FDA approved MARGENZA (margetuximab-cmkb), in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is the first product approved from our promising pipeline. The approval was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial, as described below. We expect to launch MARGENZA in March of 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Margetuximab is being evaluated in combination with checkpoint blockade in the Phase 2/3 MAHOGANY trial for the treatment of patients with HER2-positive gastroesophageal cancer, and in combination with tebotelimab (our PD-1 &#215; LAG-3 bispecific DART molecule) in various HER2-positive tumors. We are partnered with Zai Lab for the development and commercialization of margetuximab in Greater China. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HER2-positive Breast Cancer. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HER2 is a protein found on the surface of some cancer cells that promotes growth and is associated with aggressive disease and poor prognosis. Approximately 15-20% of breast cancer cases are HER2-positive, representing approximately 45,000 new cases annually in the U.S. according to the American Cancer Society</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Breast Cancer Facts &amp; Figures 2019-2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Monoclonal antibody-based therapies targeting HER2 have greatly improved outcomes of patients with HER2-positive breast cancer and are now standard of care in both early- and late-stage disease. Ongoing HER2 blockade is recommended for patients who have relapsed or refractory HER2-positive disease; after progression occurs during treatment with other HER2-directed therapies, the need for additional agents in later lines remains.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA approval of MARGENZA was based on safety and efficacy results from the SOPHIA study, a randomized, open-label Phase 3 clinical trial evaluating MARGENZA plus chemotherapy compared to trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer, who have previously been treated with anti-HER2-targeted therapies. All study patients had previously received trastuzumab; all but one patient had previously received pertuzumab, and 91% had previously received ado-trastuzumab emtansine, or T-DM1.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study enrolled 536 patients who were randomized 1:1 to receive either MARGENZA (n=266) given intravenously at 15 mg/kg every three weeks or trastuzumab (n=270) given intravenously at 6 mg/kg (or 8 mg/kg for loading dose) every three weeks in combination with one of four chemotherapy agents (capecitabine, eribulin, gemcitabine or vinorelbine) given at the standard doses. Intent-to-treat progression-free survival (PFS) analysis occurred after 265 PFS events.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of the study was PFS, determined by blinded, centrally-reviewed radiological review, followed by a second sequential endpoint of overall survival (OS). Additional key secondary endpoints are PFS by investigator assessment, objective response rate (ORR) and duration of response. Tertiary endpoints include ORR by investigator assessment and safety. PFS and ORR were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SOPHIA study showed a statistically significant 24% reduction in the risk of disease progression or death with MARGENZA plus chemotherapy compared with trastuzumab plus chemotherapy (hazard ratio [HR]=0.76; 95% CI, 0.59-0.98; P=0.033; median PFS 5.8 vs 4.9 months).  The objective response rate for MARGENZA plus chemotherapy was 22% and for trastuzumab plus chemotherapy was 16%. The final OS analysis is expected in the second half of 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse reactions occurring in greater than twenty percent of patients with MARGENZA in combination with chemotherapy were fatigue/asthenia (57%), nausea (33%), diarrhea (25%), and vomiting (21%). The MARGENZA U.S. Prescribing Information has a BOXED WARNING for left ventricular dysfunction and embryo-fetal toxicity. In addition, MARGENZA can cause infusion-related reactions (IRRs). IRRs occurred in 13% of patients treated with MARGENZA, with the majority reported as Grade 2 or less. Grade 3 IRRs occurred in 1.5% of patients. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Gastric Cancer. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer of the stomach, also called gastric cancer (GC), and cancer of the gastroesophageal junction (GEJ), which is where the esophagus joins the stomach, are collectively referred to as gastroesophageal adenocarcinoma, which is the third leading cause of cancer death worldwide according to the World Health Organization in 2020. Both GC and GEJ cancer are often diagnosed at an advanced stage and therefore have very poor prognosis, with a 5-year survival of 5-20%. Chemotherapy is the standard of care for first-line therapy and may be combined with trastuzumab for the approximately 20% of patients whose tumors are HER2-positive.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating the combination of margetuximab plus PD-1 checkpoint blockade as a chemotherapy-free regimen in patients with advanced HER2-positive GC or GEJ cancer in two separate clinical studies. We believe that combining checkpoint blockade and margetuximab may create synergistic anti-tumor activity through enhanced tumor-specific T-cell immunity.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, results were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lancet Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from our Phase 2 study of margetuximab plus pembrolizumab as a chemotherapy-free regimen for patients with advanced HER2-positive gastroesophageal adenocarcinoma (GEA) who have previously been treated with chemotherapy and trastuzumab. The Phase 2 study enrolled patients with GC or GEJ cancer whose tumors were IHC3-positive or IHC2-positive/FISH-positive at diagnosis. Enrollment was regardless of PD-L1 expression status, which was subsequently determined from available archived tumor tissue. Safety and activity analyses were based on data from a July 10, 2019, data cutoff.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tolerability of margetuximab and pembrolizumab was acceptable in patients treated in this study. Grade 3 or higher treatment-related adverse events (TRAEs) were reported in 20% of patients, with anemia (4%) and IRRs (3%) being the most common. No treatment-related deaths were reported.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this study, patients who had received margetuximab plus pembrolizumab at the recommended Phase 2 dose of 15 mg/kg every three weeks were evaluable for response. In this overall population, the ORR was 18% (17/92 patients), including complete responses  and partial responses. The disease control rate (DCR), which includes complete responses, partial responses, and stable disease, was 53% (49/92 patients). Median PFS was 2.7 months (95% CI 1.6&#8211;4.3) and median OS was 12.5 months (95% CI 9.1&#8211;14.1).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity of margetuximab and anti-PD-1 in this study was more pronounced in key biomarker-positive subgroups. The most pronounced benefit was observed in patients whose tumors had high HER2 expression at diagnosis (HER2 IHC3-positive) and were PD-L1-positive. In this double-positive subgroup, the ORR was 44% (11/25 patients) and the DCR was 72% (18/25 patients). Median PFS was 4.8 months (95% CI 1.6&#8211;13.9) and median OS was 20.5 months (95% CI 8.1&#8211;NR).</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with initial HER2-positive GEA may lose HER2 expression after trastuzumab-based therapy. In this second-line study, HER2 amplification was not detectable in circulating tumor DNA (ctDNA) in 42% of patients who were tested, suggesting loss of HER2 following prior trastuzumab and before treatment with margetuximab and pembrolizumab. The presence of HER2 amplification in ctDNA was associated with better response rates in this study. HER2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">amp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-positive/HER2 IHC3-positive/PD-L1-positive ORR was 60% (9/15 patients) and DCR was 80% (12/15 patients).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with prior studies of margetuximab in other tumor types, correlative analyses of samples from GEA patients treated in the study showed an increase in anti-HER2 specific T-cell immunity, suggesting the potential for engagement of both innate and adaptive immune responses.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on these results in second-line patients who were refractory to trastuzumab, in September 2019, we initiated the MAHOGANY study, a Phase 2/3 registration-directed clinical trial to evaluate, in Module A, margetuximab in combination with retifanlimab, an anti-PD-1 monoclonal antibody, in patients with tumors that are both HER2 IHC3-positive and PD-L1 positive. This approach is designed as a chemotherapy-free regimen that engages both innate and adaptive immunity for the treatment of patients with GC or GEJ cancer in the first-line setting. The primary outcome measure for efficacy in Module A is ORR per RECIST. We expect to obtain initial data in the first half of 2021 to enable a decision whether to enroll additional patients into the study to support a potential accelerated approval of the U.S. in the future. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to evaluate margetuximab with chemotherapy and retifanlimab or tebotelimab, a PD-1 &#215; LAG-3 bispecific DART molecule, compared to standard of care therapy of trastuzumab with chemotherapy in Module B of the MAHOGANY study. In this portion of the randomized, controlled study, patients are planned to be enrolled irrespective of PD-L1 expression. The primary outcome measure for efficacy in Module B is planned to be OS.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we licensed the right to develop and commercialize margetuximab in mainland China, Hong Kong, Macau and Taiwan to Zai Lab Limited (Zai Lab). Zai Lab will lead clinical development in its territory by leveraging its regulatory and clinical development expertise and broad regional network of investigators. We are prioritizing enrollment of MAHOGANY Module A in the U.S. Zai Lab initiated Module B in Greater China in 2020. In February 2020, Zai Lab announced that it had dosed a first patient in a registrational bridging study of margetuximab, in combination with chemotherapy, for the treatment of patients with metastatic HER2-positive breast cancer. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has granted Orphan Drug Designation to margetuximab for the treatment of gastric and gastroesophageal junction cancer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Flotetuzumab</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flotetuzumab is an investigational bispecific, humanized DART molecule that recognizes both CD123 and CD3. CD123, the interleukin-3 receptor alpha chain, has been reported to be over-expressed on cancer cells in a wide range of hematological malignancies, including AML and myelodysplastic syndrome (MDS). CD3 is expressed on immune effector cells, such as T cells. Flotetuzumab is designed to engage and redirect T cells to kill CD123-expressing malignant cells. The molecule is being evaluated in a clinical study of up to 200 AML patients who are refractory to induction therapy or relapse within six months of a complete remission (CR). This study is intended to support registration in the U.S. The FDA has granted Orphan Drug Designation to flotetuzumab for the treatment of AML.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Acute Myeloid Leukemia</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AML is a hematopoietic malignancy characterized by uncontrolled clonal proliferation of neoplastic myeloid precursors and differentiation arrest that prevent normal bone marrow hematopoiesis. AML is thought to arise in and be perpetuated by a small population of leukemic stem cells (LSCs) that generally resist conventional chemotherapeutic agents. LSCs are characterized by high levels of CD123 expression that is low or absent in the corresponding hematopoietic progenitors and stem cell populations in normal human bone marrow. Flotetuzumab was designed to redirect T lymphocytes, specialized white blood cells of the human immune system, to kill CD123-expressing cells. To achieve this, the DART molecule combines an arm that recognizes CD123 on the target cells with a portion of an antibody recognizing CD3, an activating protein expressed by T cells.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 20,000 new cases of AML were diagnosed in the U.S. in 2020, with a median age of 68 years at diagnosis, according to the Surveillance, Epidemiology, and End Results Program of the National Institutes of Health (NIH). Hematopoietic stem cell transplantation represents the only treatment modality with reliable curative potential. Approximately 40-50% of newly diagnosed patients fail to achieve a CR with intensive induction therapy (primary induction failure, or PIF) or experience disease recurrence after an initial remission of short duration of less than six months (early relapsed, or ER6). Only a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">very small number of these patients are expected to respond to salvage therapy. While some patients may be eligible to receive new targeted agents that have been approved for the treatment of first-line or relapsed/refractory AML in recent years, approximately 50% of patients have no known targetable mutations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we presented data from our ongoing open-label Phase 1/2 dose expansion study of flotetuzumab in 44 relapsed/refractory patients having either primary induction failure or early relapsed AML. Of these patients, 72.7% (32 of 44) had adverse risk cytogenetics by ELN Risk Stratification (2017). Patients were treated with flotetuzumab at the recommended Phase 2 dose of 500 ng/kg/day by continuous infusion, following step-up, daily dose escalation during the first week. Data were reported as of the cut-off date of November 10, 2020. The study is ongoing, with a total of up to 200 patients planned for enrollment for registrational purposes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median time to achieve a response to flotetuzumab in the study was one cycle (range of 1-3 cycles). Responses, including CR, CRh (CR with partial hematological recovery) and CRi (CR with incomplete hematological improvement) per a modified International Working Group (IWG) Response Criteria for AML, are summarized in the table below. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #666666;border-left:1pt solid #666666;border-top:1pt solid #666666;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #666666;border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PIF/ER6<br/>(n=44)</span></td><td colspan="3" style="border-bottom:1pt solid #666666;border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PIF<br/>(n=27)</span></td><td colspan="3" style="border-bottom:1pt solid #666666;border-left:1pt solid #666666;border-right:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ER6<br/>(n=17)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CR/CRh</span></td><td colspan="3" style="border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25.0% (11)</span></td><td colspan="3" style="border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33.3% (9)</span></td><td colspan="3" style="border-left:1pt solid #666666;border-right:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.8% (2)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CR/CRh/CRi</span></td><td colspan="3" style="border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.8% (14)</span></td><td colspan="3" style="border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37.0% (10)</span></td><td colspan="3" style="border-left:1pt solid #666666;border-right:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.5% (4)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">HSCT</span></td><td colspan="3" style="border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1% (8/14)</span></td><td colspan="3" style="border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70.0% (7/10)</span></td><td colspan="3" style="border-left:1pt solid #666666;border-right:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25.0% (1/4)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #666666;border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Median Duration of Response</span></td><td colspan="3" style="border-bottom:1pt solid #666666;border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.13 months (n=14)</span></td><td colspan="3" style="border-bottom:1pt solid #666666;border-left:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.2 months (n=10)</span></td><td colspan="3" style="border-bottom:1pt solid #666666;border-left:1pt solid #666666;border-right:1pt solid #666666;border-top:1pt solid #666666;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.4 months (n=4)</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eight of 14 responders (57%) received allogeneic hematopoietic stem cell transplantation (HSCT) as consolidation therapy and remained in remission after 6 to 21 months (median not reached). Overall, among the PIF/ER6 patients who achieved remission (CR, CRh or CRi), the median duration of response was 8.13 months, with a median overall survival of 10.7 months. Within the PIF/ER6 population, five of ten patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TP53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutated AML, a mutation associated with very poor prognosis, achieved CR/CRh/CRi responses, three of whom went on to receive HSCT.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common TRAE was infusion-related reaction/cytokine release syndrome (IRR/CRS). While all patients experienced some levels of IRR/CRS, most events were of short duration and mild to moderate (Grade 1 or 2) in severity, with only a single Grade 3 event reported.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retifanlimab</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Retifanlimab is an investigational monoclonal antibody targeting PD-1. Marketed antibodies targeting this checkpoint molecule have shown clinical efficacy in the treatment of various tumors by releasing the "brakes" of the immune system and help to restore the immune system's ability to detect and kill tumor cells. In 2017, we licensed retifanlimab to Incyte Corporation (Incyte) under a global collaboration and license agreement, although we retain the right to develop the molecule in combination with product candidates from our pipeline. In January 2021, Incyte announced that the FDA had accepted for Priority Review its BLA for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The PDUFA target action date for retifanlimab is July 25, 2021. In addition, Incyte has stated it is pursuing development of retifanlimab as monotherapy in potentially registration-enabling studies in patients with MSI-high endometrial cancer and Merkel cell carcinoma.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, Incyte initiated two Phase 3 studies of retifanlimab in combination with chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and in patients with metastatic SCAC, known as POD1UM-304 and POD1UM-303, respectively. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating retifanlimab in combination with margetuximab in a potentially registration-enabling study of patients with HER2-positive GC and GEJ. We plan to initiate a study of retifanlimab in combination with enoblituzumab, an investigational Fc-engineered, anti-B7-H3 mAb, in patients with squamous cell carcinoma of the head and neck (SCCHN).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enoblituzumab</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enoblituzumab is an investigational monoclonal antibody that targets B7-H3 that has been engineered using our Fc Optimization platform. B7-H3 (CD276) belongs to the B7 family of immune regulator proteins that is widely expressed by different tumor types and may play a key role in regulating the immune response to various cancers. There are no currently approved therapeutic agents directed against B7-H3.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted a Phase 1b/2 clinical study of enoblituzumab and pembrolizumab, an anti-PD-1 monoclonal antibody, to evaluate this combination in patients with B7-H3-expressing melanoma, SCCHN, NSCLC and urothelial cancer. The combination of enoblituzumab and immune checkpoint blockade is designed to engage innate and adaptive immunity to enhance tumor cell killing. A total of 133 patients were treated in the study; the data cut-off date was October 12, 2018.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As presented in November 2018, in the SCCHN dose expansion cohort, confirmed partial responses were observed in 6 of 18 (33%) of patients evaluable for response who had not previously received anti-PD-1 or anti-PD-L1 therapy. For the subset of patients with B7-H3 tumor expression &#8805; 10%, 6 of 15 (40%) had confirmed partial responses. ORRs ranging from 13% to 16% have previously been reported in SCCHN patients treated with anti-PD-1 agents alone. The combination of enoblituzumab and an anti-PD-1 monoclonal antibody demonstrated acceptable tolerability, with any adverse event &#8805; Grade 3 occurring in 27.1% of patients as of the October 12, 2018 data cut-off date. The rate of immune-related adverse events experienced in the trial was comparable to that historically observed by others in patients who received pembrolizumab as monotherapy.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To further inform the development of enoblituzumab, we expect to initiate a Phase 2 study of this agent in patients with relapsed or metastatic SCCHN not curable by local therapy in the first quarter of 2021. This trial will include enoblituzumab in a chemotherapy-free regimen in combination with either retifanlimab in patients who are PD-L1 positive or with tebotelimab in patients who are PD-L1 negative.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we licensed the right to develop and commercialize enoblituzumab in mainland China, Hong Kong, Macau and Taiwan to I-Mab Biopharma (I-Mab). I-Mab plans to both lead regional studies in its territories as well as participate in global studies conducted by us.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tebotelimab</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tebotelimab is an investigational, first-in-class bispecific, tetravalent DART molecule targeting PD-1 and LAG-3, or lymphocyte-activation gene 3. We have engineered tebotelimab to concomitantly or independently bind to PD-1 and LAG-3 and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function. Tebotelimab is being evaluated in a Phase 1 dose expansion study as both monotherapy in several tumor types as well as in combination with margetuximab in HER2-positive neoplasms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, initial data was presented from a Phase 1 study in which 53 patients with advanced tumors were treated with tebotelimab given intravenously in cohorts of escalating flat doses of 1-1200 mg every two weeks. A maximum tolerated dose was not identified. A flat dose of 600 mg every two weeks was selected for tumor-specific expansion cohorts. At the April 25, 2020 data cut-off, 205 patients with advanced solid and hematologic neoplasms had been treated with tebotelimab monotherapy in the ongoing dose-expansion part of the study, of which 152 were evaluable for response. Anti-tumor activity was assessed by RECIST.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-tumor activity of tebotelimab as monotherapy was observed in evaluable patients across several of the tumor types in the selected dose expansion cohorts. ORRs, including both confirmed and unconfirmed responses, and DCR, comprising both confirmed objective responses and stable disease, were observed as follows: triple negative breast cancer (17% ORR, 4 of 23 patients; 39% DCR, 9 of 23 patients), epithelial ovarian cancer (9% ORR, 2 of 23 patients; 52% DCR, 12 of 23 patients) and NSCLC (checkpoint inhibitor na&#239;ve: 21% ORR, 3 of 14 patients; 64% DCR, 9 of 14 patients; and post anti-PD-1: 13% ORR, 2 of 15 patients; 53% DCR, 8 of 15 patients). Response to tebotelimab monotherapy was associated with LAG-3 expression and an IFN-&#947; gene signature at baseline. The overall safety profile of tebotelimab in the Phase 1 study, including the incidence of immune-mediated adverse events, appeared generally consistent with anti-PD-1 antibody monotherapy with respect to event type and frequency.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immune effector cell activation and LAG-3, PD-1 and PD-L1 expression has been shown to be enhanced in vitro by Fc-engineered margetuximab. An expansion cohort of patients with advanced HER2-positive tumors is being treated with margetuximab plus tebotelimab to evaluate whether Fc-engineering can enhance tumor responsiveness to checkpoint blockade and improve clinical outcomes in patients.  In November 2020, updated data was presented from the ongoing combination study of tebotelimab and margetuximab in patients with advanced HER2-positive neoplasms.  In this study, 41 patients had been enrolled. As of the October 5, 2020 data cut-off, there were 28 response-evaluable patients. Evidence of antitumor activity was observed among refractory patients with various HER2-positive tumor types, including eight objective responses (six </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confirmed) observed in multiple advanced HER2-positive tumor types. The ORR (including unconfirmed responses) was 28.6%, while 64.3% of response-evaluable patients experienced a decrease in target lesion tumor burden. The duration of response for confirmed responders was 4.21&#8211;8.97 months, with three patients remaining on treatment as of the data cut-off. Of particular interest, a majority of responding patients had a baseline PD-L1 combined positive score (CPS) &#8804; 1.  All responding patients carried the less favorable CD16A-158F allotype (i.e., V/F or F/F). Evaluation of baseline LAG-3 and PD-1 mRNA expression and potential association with clinical response analyses are ongoing, and will be important for defining patient enrichment biomarker strategies for further development. The combination of tebotelimab and margetuximab was generally well tolerated, with a safety profile consistent with that of tebotelimab monotherapy. Enrollment in HER2-positive tumor-specific cohorts is ongoing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, data was presented from the ongoing tebotelimab Phase 1 dose expansion study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). LAG-3 has been shown to be highly expressed in DLBCL and has emerged as a therapeutic target of interest in this population, while PD-1-targeted therapy has yielded modest efficacy. There remains significant unmet need for patients with relapsed/refractory (R/R) DLBCL. In this study, 20 DLBCL patients were enrolled, half of whom were chimeric antigen receptor (CAR) T cell therapy experienced. As of the October 23, 2020 data cut-off, there were 13 response-evaluable patients. A preliminary ORR of 53.8% (7 of 13 patients) was observed, including responses in five of seven CAR T cell-na&#239;ve patients and in two of six CAR T cell experienced patients, the latter of whom both had complete responses. A preliminary duration of response of up to 168 days was observed, with six of seven ongoing responses as of the cut-off date. In the study, baseline LAG-3 expression appeared to associate with clinical response, with additional analyses ongoing. Tebotelimab was generally well-tolerated among heavily pre-treated R/R DLBCL patients, with manageable infusion-related reactions and no evidence of tumor lysis syndrome. The most common TRAE was pyrexia, which occurred in three (15%) patients. A single Grade 3 TRAE of anemia was observed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to provide clinical updates on tebotelimab in 2021, including future development plans.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our November 2018 license and collaboration agreement with Zai Lab, we also licensed to them the right to develop and commercialize tebotelimab in mainland China, Hong Kong, Macau and Taiwan. In February 2020, Zai Lab dosed the first patient with niraparib, a PARP (poly [ADP-ribose] polymerase) inhibitor, in the Phase 1b proof-of-concept, China-only study, in combination with tebotelimab. In April 2020, Zai Lab initiated a study of tebotelimab in combination with brivanib in a Phase 1 proof-of-concept China-only dose escalation and expansion trial in patients with advanced hepatocellular carcinoma (HCC). The dose escalation phase to determine the recommended Phase 2 dose of tebotelimab as monotherapy and in combination with brivanib was completed, with related data presented in late 2020. In November 2020, Zai Lab enrolled the first patient in a Phase 1 proof-of-concept clinical trial in China of tebotelimab as second-line therapy for melanoma patients after treatment with checkpoint inhibitors. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MGC018</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGC018 is an investigational ADC with a cleavable peptide linker designed to deliver a DNA-alkylating duocarmycin payload to dividing and non-dividing cells on solid tumors that express B7-H3. The underlying ADC technology was licensed from Byondis B.V. (formerly Synthon Biopharmaceuticals). We are conducting a Phase 1 dose expansion study of MGC018.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, data from the dose escalation study of MGC018 was presented. At the May 6, 2020 data cut-off, 23 evaluable patients with advanced solid tumors had been enrolled in four dose escalation cohorts of 0.5 mg/kg to 3 mg/kg given intravenously every three weeks. Treatment is ongoing in an expanded fifth cohort of patients at 4 mg/kg every three weeks. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary evidence of anti-tumor activity by MGC018 has been observed, particularly in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Reductions in PSA levels of &#8805; 50% were observed in five of seven mCRPC patients treated, including one with substantial regression of bone disease. Six mCRPC patients had bone only disease, and one patient with measurable peripheral disease had a 29% reduction in target lesions that did not qualify as a response per RECIST. Four PSA responders remained on therapy as of the data cut-off. Patients with mCRPC had received a median of four therapies prior to MGC018, including taxane chemotherapy (six patients) and next-generation hormonal agents (six patients were treated with both abiraterone and enzalutamide, and one with abiraterone only).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety profile of MGC018, which includes hematologic and skin toxicities, has been generally manageable to date. At least one TRAE occurred in 22 of 23 patients (96%), including Grade &#8805; 3 reported in 14 of 23 patients (61%). Three treatment-related serious adverse events occurred in one patient each: pneumonitis in a patient with concurrent bacterial pneumonia; non-infectious gastroenteritis; and stasis dermatitis in a patient with chronic venous insufficiency. One dose-limiting toxicity of Grade 4 neutropenia that resolved to baseline was reported. No febrile neutropenia was observed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced the Phase 1 dose expansion study of MGC018 in patients with mCRPC, triple negative breast cancer (TNBC) and NSCLC in the fourth quarter of 2020 and expects to provide an update on this study in mid-2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MGD019</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved monoclonal antibodies that target the immune checkpoints PD-1 and CTLA-4, or cytotoxic T-lymphocyte-associated protein 4, have shown enhanced clinical antitumor activity when given in combination in various cancers, including renal cell carcinoma and NSCLC with high tumor mutational burden. MGD019 is an investigational, bispecific tetravalent DART molecule designed to enable simultaneous and/or independent blockade of PD-1 and CTLA-4, with potentially enhanced CTLA-4 blockade on T cells co-expressing these immune checkpoint molecules.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, data from the Phase 1 dose escalation study of MGD019 were reported. Forty-three patients were enrolled in the study within a dose range of 0.03 &#8211; 10.0 mg/kg, administered every three weeks initially, in a population of heavily pre-treated patients representing a broad range of different types (23) of solid tumors. A total of 28 patients were treated at doses &#8805; 3.0 mg/kg administered every three weeks initially. Of the 18 evaluable patients who received doses &#8805; 3.0 mg/kg as of the July 21, 2020 cut-off date, four objective responses were reported, including a confirmed complete response in mCRPC, confirmed partial responses in microsatellite stable colorectal cancer (MSS CRC) and metastatic type AB thymoma, and an unconfirmed partial response in serous fallopian tube carcinoma. MGD019 was well-tolerated in patients who received less than 10 mg/kg. The most common TRAEs observed were pruritus (23.3%), arthralgia (18.6%), fatigue (18.6%), rash (18.6%), nausea (16.3%) and infusion-related reaction (16.3%). Several Grade 3 adverse events were observed at the 10.0 mg/kg level; however, none were considered dose limiting.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this study, full and sustained peripheral PD-1 blockade was evident at doses &#8805; 1.0 mg/kg over a 3-week dosing interval. In addition, dose-dependent upregulation of the inducible costimulator (ICOS) molecule was evident in treated patients, including those who responded to MGD019 therapy. This is consistent with an observation previously reported in the literature that anti-CTLA-4 therapy increases the frequency of CD4 T cells expressing the ICOS molecule.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating MGD019 in a Phase 1 dose expansion study initially in patients with MSS CRC and checkpoint-naive NSCLC at the recommended Phase 2 dose of 6.0 mg/kg and expect to provide an update on this study in mid-2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMGC936</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IMGC936 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">is an ADC that targets ADAM9, a cell surface protein over-expressed in several solid tumor types. IMGC936 is being advanced under a co-development agreement with ImmunoGen, Inc. (ImmunoGen).  Under the 50/50 collaboration, ImmunoGen is leading clinical development and the Phase 1 dose escalation study is currently enrolling patients with select advanced solid tumors.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Clinical Product Candidates (Non-Immuno-Oncology)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our immuno-oncology programs described above, through collaborations and government contracts, we retain economic rights to other clinical product candidates as described below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MGD014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing MGD014 under a contract awarded to us in September 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (contract number HHSN272201500032C). This DART molecule was designed to target the envelope protein of human immunodeficiency virus (HIV) infected cells (Env) and T cells, via their CD3 components, to redirect the immune system's T cells to kill HIV-infected cells. MGD014 could be used independently or become a key part of a "shock-and-kill" strategy in conjunction with HIV latency-reversing agents currently under development. MGD014 is our first clinical DART molecule designed to target virus-infected cells. A Phase 1 dose escalation study of MGD014 is ongoing. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teplizumab </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into an asset purchase agreement with Provention Bio, Inc. (Provention) pursuant to which they acquired our interest in teplizumab, a monoclonal antibody we had been developing for the treatment of type 1 diabetes. Teplizumab has been granted Breakthrough Therapy Designation by the FDA and PRIority MEdicines (PRIME) designation by the European Medicines Agency. In January 2021, Provention announced that a BLA for teplizumab for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals had been filed by the FDA, which granted Provention's request for Priority Review and assigned a PDUFA target action date of July 2, 2021. Provention has disclosed that the FDA indicated that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it is planning to hold an advisory committee meeting, tentatively scheduled for May 27, 2021. Provention is currently also evaluating teplizumab in patients with newly diagnosed insulin-dependent T1D in the Phase 3 PROTECT study.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRV-3279 </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we also entered into a license agreement with Provention pursuant to which we granted them exclusive global rights for the purpose of developing and commercializing PRV-3279 (previously known as MGD010), a CD32B &#215; CD79B DART molecule being developed for the treatment of autoimmune indications. Provention is initially developing PRV-3279 for the interception of systemic lupus erythematosus (SLE), a chronic autoimmune disorder characterized by an abnormal overactivation of B cells and subsequent pathologic production of auto-antibodies. Provention has disclosed that it believes PRV-3279 also has the potential to prevent or reduce the immunogenicity of biotherapeutics, including but not limited to gene therapy vectors and transgenes.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Therapeutic Area Focus: Cancer</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled manner, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell division or proliferation that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate, and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it generally becomes more difficult to treat and may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin. Cancer is the second leading cause of death in the United States, exceeded only by heart disease. An increasing number of people are also living longer with cancer. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our platforms position us very well strategically to actively develop approaches for the treatment of both solid tumors and hematologic malignancies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Platforms and Technology Expertise</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART and Fc Optimization platforms. Through these platforms we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes: (1) multiple specificities; (2) increased abilities to interact with the body's immune system to fight tumors; (3) capacity to bind more avidly to antigen targets: (4) increased potency; (5) reduced immunogenicity or (6) the ability to target and kill cancer cells that are resistant to standard treatments. Moreover, these technology platforms are complementary and can be combined to address the complex biology of cancer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DART and TRIDENT Platforms: Our Proprietary Approach to Engineer Multi-Specific Antibodies</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single one found in traditional monoclonal antibodies. DART product candidates are therefore bispecific. An example of a bispecific molecule from our DART platform is illustrated below:</span></div><div style="margin-bottom:9pt;text-align:center"><img src="mgnx-20201231_g2.jpg" alt="mgnx-20201231_g2.jpg" style="height:208px;margin-bottom:5pt;vertical-align:text-bottom;width:466px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because cancer cells have developed ways to escape the immune system, we have created DART molecules, which are alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are capable of targeting two antigens or epitopes (i.e., specific part of an antigen bound by the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bispecific molecules and their inherently short half-lives, as well as the inefficiencies in manufacturing these compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This is designed to provide a structure with enhanced manufacturability, long-term structural stability and the ability to tailor the half-lives of the DART molecules to their clinical needs. This engineered antibody-like protein has a compact and stable structure and enables the targeting of two different antigens with a single recombinant molecule.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DART platform has been specifically engineered to accommodate virtually any variable region sequence with predictable expression, folding and antigen recognition. We believe our multi-specific platforms may provide a significant advantage over current biological interventions in cancer, autoimmune disorders and infectious disease by enabling a range of modalities, including those described below.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DART platform enables us to design multi-specific molecules that seek to exploit different mechanisms of action, including those set forth below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:10pt">Redirected T cell activation and killing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In this version of the DART molecule, we are engaging the cancer-fighting properties of the immune effector cells, such as T lymphocytes to: (1)&#160;recognize and bind to proteins expressed on a cancer cell, or tumor associated antigens (e.g., CD123), (2)&#160;enable the recruitment of all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor) and (3)&#160;trigger T cell activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body's T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific T cells that might have been generated in response to cancer to kill tumor cells. Furthermore, given the design of a DART molecule, since any T cell could be recruited for this killing process, relatively small amounts of a DART molecule may be required to trigger this potent immune response. Additionally, the compact structure of the DART protein makes it well suited for maintaining cell-to-cell contact, which we believe contributes to the high level of target cell killing. Our DART molecules that redirect T cells against cancer or other targets, including flotetuzumab, are manufactured using a conventional antibody platform without the complexity of having to genetically modify T cells from individual patients, as would be required by approaches such as CAR T cells. We have continued to evolve our bispecific platform with the introduction of a next-generation CD3-engaging DART technology designed to recruit, engage and activate T cells to kill tumor target cells with reduced release of pro-inflammatory cytokines. This next-generation CD3 DART platform is aimed at addressing cytokine-release syndrome, the most frequent and often dose-limiting adverse event associated with CD3-engaging molecules. We believe the next-generation CD3 DART platform could expand the therapeutic window of CD3-engaing DART molecules and further increase their potential application in oncology.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="mgnx-20201231_g3.jpg" alt="mgnx-20201231_g3.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:140px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:115%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Targeting of multiple co-inhibitory receptors or checkpoints, such as those involved in inhibiting T cell responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The immune system generally prevents the development of autoimmune phenomena by regulating activated immune cells that have responded to non-self or foreign antigens. This negative feedback loop is triggered by the interactions of co-inhibitory receptors, or checkpoint molecules, expressed on the immune cells with ligands expressed by other cells, such as antigen-presenting cells. This phenomenon is exploited by cancer, whereby tumor cells express checkpoint ligands that block the development of an immune response against the tumor. Antibodies that block the interaction of checkpoint molecules with their ligands have been shown to significantly improve the clinical outcomes of patients with certain advanced cancers. Because of the diversity of immune checkpoint pathways, blockade of a single axis, while clinically significant, as shown in the case of the blockade of the PD-1/PD-L1 axis with pembrolizumab or nivolumab, will not benefit all patients. In fact, combinations of checkpoint inhibitors, such as nivolumab and ipilimumab, a CTLA-4 blocker, have resulted in significantly enhanced benefit compared to ipilimumab or nivolumab alone. We believe that DART molecules targeting two immunoregulatory pathways, such as two checkpoints in a single molecule, could afford the clinical benefit of the combination together with the potential for synergistic activity, as well as significant advantages in manufacturing, simplified clinical development, and enhanced patient convenience.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:9pt;text-align:center"><img src="mgnx-20201231_g4.jpg" alt="mgnx-20201231_g4.jpg" style="height:259px;margin-bottom:5pt;vertical-align:text-bottom;width:155px"/></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the ability to tailor a DART molecule's valency, we have the capacity to modify the strength by which the binding sites attach to their targets and the molecule's half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is coupled with a DART molecule, additional changes can be included that can modulate the DART molecule's engagement with different immune cells.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing specific product candidates using this technology, including flotetuzumab, tebotelimab, MGD019 and MGD014 in clinical trials, as well as others in preclinical development. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also advanced beyond our DART platform to establish a TRIDENT platform, which reflects the continuing evolution of our multi-specific antibody-based targeting expertise. Built on the DART module, the trivalent TRIDENT platform incorporates in an Ig-like format an additional domain capable of engaging an independent antigen. With the inclusion of a third targeting arm, TRIDENT molecules enable a broader range of mechanisms of action than bispecific targeting, allowing, for instance, the engagement of multiple antigens on a single or on different cells or enabling enhanced target selectivity by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modulating the avidity of one of two antigens. Product candidates using this technology are currently in preclinical development.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To enhance the body's immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with immune effector cells. Such interaction enhances the body's immune ability to mediate the killing of cancer cells through ADCC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADCC</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><img src="mgnx-20201231_g5.jpg" alt="mgnx-20201231_g5.jpg" style="height:185px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"/></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Fc region mediates the function of IgG antibodies by binding to different activating and inhibitory receptors, referred to as Fc&#947;Rs, on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the activating Fc&#947;Rs and with a reduced affinity to the inhibitory Fc&#947;Rs, we have been able to impart a more effective immune response and improve effector functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a proprietary platform to engineer, screen, identify and test antibodies' Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc&#947;Rs. These mice can be used for in vivo testing of antibodies that incorporate Fc domain variants, including those antibodies intended for cancer therapy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have successfully incorporated our Fc variants in two of our antibody-based molecules, margetuximab and enoblituzumab. In vitro, the modified Fc region of margetuximab increases binding to the activating Fc receptor FCGR3A (CD16A) and decreases binding to the inhibitor Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and NK cell activation. The clinical significance of in vitro data is unknown.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout our company's history, we have entered into collaborations with other biopharmaceutical companies and plan to continue to do so. We enter into collaborations when there is a strategic advantage to us and when we believe the financial terms of the collaboration are favorable for meeting our short-term and long-term strategic objectives. We are not dependent upon any one of these collaborations, but in many cases we have rights to receive sales royalties and other significant financial payments if the partnered product candidates achieve certain development and sales milestones. We endeavor to establish collaborations that preserve our right to participate in future commercialization, for example by securing co-promotion or profit-sharing rights under certain circumstances.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Each of our collaborations has a unique set of terms and conditions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patents intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets, confidentiality and invention assignment agreements and careful monitoring of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business.  In addition, there is cost and risk to our business in defending and enforcing our patents, maintaining our licenses to use intellectual property owned by third parties and preserving the confidentiality of our trade secrets and operating without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office (USPTO) filings for any applications by third parties that may infringe on our patents.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold patents or other intellectual property rights that are important to or necessary for the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, invalid, and unenforceable, should a court find that they cover margetuximab or enoblituzumab and we are unable to invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications in the United States and certain other jurisdictions can be maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. In the ordinary course of business we participate in post-grant challenge proceedings, such as oppositions, that challenge the patentability of third party patents. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Patent Protection</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we held 82 patents in the United States with 50 patent applications pending and 534 patents in other countries of the world with 563 patent applications pending. In addition to patents and patent applications generally providing protection for various aspects of our Fc Optimization, DART, and TRIDENT platforms, we have patent and patent applications for the composition of matter of each of our clinical pipeline product candidates and, in some cases, we also have other patents and patent application related to various aspects of the technology underlying these product candidates or their methods of use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may be adjusted or extended, as described in greater detail below, in certain circumstances. However, assuming no adjustments or extensions, the primary composition of matter patent for each of our clinical pipeline product candidates is expected to expire in the following timeframes:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product Candidate</span></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">margetuximab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">enoblituzumab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">flotetuzumab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">retifanlimab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">tebotelimab</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD019</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC018</span></td><td colspan="3" style="padding:2px 1pt 2px 67pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037*</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* pending</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extension and Reference Product Exclusivity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs, including biological products, of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive FDA approval, we have applied or expect to apply for patent term extensions on patents covering those products. We intend to seek, and are seeking, patent term extensions to our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act (collectively the ACA) created a regulatory scheme authorizing the FDA to approve biosimilars via an abbreviated licensure pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is "biosimilar to" or "interchangeable with" a previously approved biological product or "reference product." The "biosimilar" application must include specific information demonstrating biosimilarity based on data derived from: (1) analytical studies, (2) animal studies, and&#160;(3) a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed, except that FDA may waive some of these requirements for a given application. Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years after the date of first licensure. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. The law does not change the duration of patents granted on biological products. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. There have been recent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if approved, would affect these provisions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-Licensed Intellectual Property</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into patent and know-how license agreements that grant us the rights to use certain technologies related to biological manufacturing for our clinical product candidates. We anticipate using these technologies for future product candidates. These licensors have businesses dedicated to licensing this type of technology and we anticipate that licenses to use these technologies for our future products will be available. The licenses typically include yearly maintenance payments and sales royalties, and may also include upfront payments or milestone payments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture drug substance for most of our clinical trials at our manufacturing facilities located in Rockville, Maryland. We also rely on contract manufacturers, primarily Byondis, for production of our ADC candidates. We have supplemented our drug substance manufacturing capacity through an arrangement with AGC Biologics, Inc. (AGC, formerly CMC Biologics, Inc.), a contract manufacturing organization, and are commercially producing margetuximab at AGC. We also intend to commercially produce material for our and our partner&#8217;s product candidates, when and if approved by the FDA. In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily Ajinomoto Bio-Pharma Services and Baxter Healthcare Corporation, to fulfill our fill-finish needs for our current and future product candidates.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production processes for biological therapeutic products are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at one of our own facilities, extended failure of a contract supplier or contract manufacturing organization, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA is currently our only approved product in the U.S. In November 2020, we partnered with EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the U.S. by leveraging their integrated commercial services. Under the terms of the agreement, we maintain ownership of margetuximab, including all manufacturing, regulatory and development responsibilities for the product. EVERSANA received a co-exclusive right to conduct approved commercialization activities. EVERSANA will utilize its internal capabilities to support sales and marketing, market access, channel management services, data and analytics, medical affairs, and other patient access related services; we will book MARGENZA sales. We and EVERSANA equally share in funding EVERSANA&#8217;s commercialization expenses. In exchange for co-funding these expenses, EVERSANA will earn future revenue share payments which shall be capped at 125% of EVERSANA&#8217;s cumulative service fees. The term of the agreement is five years following the date of FDA approval, subject to predefined termination provisions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot market or promote a new product in a country until a marketing application has been approved by the appropriate regulatory authority for that jurisdiction. Subject to receiving marketing authorization in a jurisdiction, we believe we will be able to commercialize in that market through arrangements with third-party commercial partners. Other than through our arrangement with EVERSANA for MARGENZA, we have not established a sales, marketing or distribution capabilities. If we are unable to enter into third-party commercial arrangements for other product candidates with respect to the United States, we believe that we could potentially put in place an appropriately sized organization to commercialize our approved product or products. Outside the United States, our strategy is to enter into arrangements with third-party commercial partners for any of our product candidates that obtain marketing approval.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In particular, MARGENZA is directed against HER2 and several companies have cancer therapeutics directed against HER2 that are either currently approved and on the market or in development, such as F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), particularly through its affiliate, Genentech, Inc., as well as Puma Biotechnology, Inc., Daiichi Sankyo </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company, Limited and AstraZeneca plc. (AstraZeneca), Seagen Inc., Zymeworks, Inc., and Byondis, many of which have significantly greater resources than we do. Market competition may limit the utilization of MARGENZA  as a therapeutic, even if market approval and adequate reimbursement is obtained, and competition among development-stage programs for patients enrolling in clinical trials for HER2-directed therapies may delay expected timelines for our clinical trials.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the immuno-oncology field is competitive, with treatments currently approved and on the market or in development for various tumor types and patient populations from a variety of different companies such as Merck &amp; Co., Inc. (Merck), The Bristol-Myers Squibb Company (BMS), and Roche, all of which have significantly greater resources than we do. Many of our pipeline programs, if successful, will likely face significant competition both by therapeutics that are already being marketed as well as those that will be approved for marketing before our programs. In particular, we are developing PD-1-directed product candidates, including a monoclonal antibody that we have outlicensed and two DART molecules. Merck, BMS, Roche, AstraZeneca, Pfizer Inc., Merck KGaA, and Regeneron Pharmaceuticals, Inc. all have approved products that target either the PD-1 receptor or its ligand, PD-L1, and there are several other companies that have anti-PD-1 or anti-PD-L1 antibodies in clinical development, all of which would compete with our PD-1-directed programs. In addition, these and other companies are developing product candidates directed against other immuno-oncology targets that we are pursuing through our bispecific approaches.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, several companies are also developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen Inc. has obtained marketing approval for one product that works by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells, and has other product candidates in development that use this mechanism. In addition, other companies are developing new treatments for cancer that utilize multi-specific approaches, including Abbvie Inc., Affimed Therapeutics AG Corporation, Eli Lilly and Company, Genmab A/S, Merus B.V., Regeneron, Roche, AstraZeneca, Xencor, Inc. and Zymeworks, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic or biosimilar competition and the availability of reimbursement from government and other third-party payors. In addition, the standard of medical care provided to cancer patients continues to evolve as more scientific and medical information becomes available. These changes in medical care relate to pharmaceutical products, but are also affected by other factors, and such changes can positively or negatively affect the prospects of our product candidates as well as those of our competitors.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop, or the standards of care for cancer patients change while our clinical trials are ongoing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, trastuzumab biosimilars have been approved in the U.S. by FDA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third party payors. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent an approved drug is ultimately used in combination with or as an adjunct to these therapies, our product candidates will not be competitive with the approved drug.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our current product candidates are subject to regulation in the United States by the FDA as biological products (biologics). The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act, the Federal Food, Drug, and Cosmetic Act (FDCA) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Drug development in our industry is complex, challenging and risky; failure rates are high. Product development cycles are long - approximately 10 to 15 years from discovery to market. A potential new biological product must undergo many years of preclinical and clinical testing to establish it is pure, potent and safe.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including FDA's good laboratory practice (GLP) regulations and the U.S. Department of Agriculture's regulations implementing the Animal Welfare Act. After laboratory analysis and preclinical testing in animals, we file an Investigational New Drug (IND) application with the FDA to begin human testing. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND application. Certain preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND application is submitted. An IND application automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold or agrees on an alternate approach with us. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND application may not result in the FDA allowing clinical trials to commence.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Clinical trials involve the administration of the investigational drug to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice (GCP) standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, investigators, and monitors; as well as (ii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the United States (whether in patients or healthy volunteers) must be included in the IND application submission, and FDA must be notified of subsequent protocol amendments. In addition, the protocol must be reviewed and approved by an institutional review board (IRB) and all study subjects must provide informed consent prior to participating in the study. Typically, each institution participating in the clinical trial will require review of the protocol before any clinical trial commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (NIH) for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for suspected unexpected serious adverse events.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. The FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support BLAs for marketing approval are typically conducted in three pre-approval phases, but the phases may overlap or be combined, particularly in testing for oncology indications. In Phase 1, testing is conducted in a small group of subjects who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase 2, the drug is given to a larger group of subjects with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase 3 studies typically last multiple years for oncology indications. In Phase 3, the drug is given to a large group of subjects with the target disease or condition (several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collect data to support drug approval. In some cases, FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. After completion of the required clinical testing, a BLA can be prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of preclinical, clinical and other testing and a compilation of data relating to the product's chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial application user fee, and annual program user fees also apply. These fees are typically increased annually.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review, and the review period under the PDUFA begins. The standard for reviewing a BLA is whether the product is safe, pure and potent, which has been interpreted to include that the product is safe and effective and has a favorable benefit-risk profile. FDA's current performance goals call for FDA to complete review of 90 percent of standard (non-priority) BLAs within 10 months of filing and within six months for priority BLAs, which is 12 months and eight months, respectively, if the 60-day review of the initial application is included in the timeline. In addition, the FDA has developed approaches intended to make certain qualifying products available to patients rapidly - Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track. While the timelines for approval under these pathways may be shorter, there are requirements and conditions associated with each pathway, and there can be no assurance that any of our investigational products will be able to meet the conditions or requirements necessary to receive any such designation or be able to receive the review or approval benefits associated with such designations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether sufficient data exist in the application to support product approval. The FDA is not bound by the recommendation of an advisory committee, but it generally gives significant deference to such recommendations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect one or more clinical sites and possibly the sponsor itself  to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is manufactured. FDA will not approve the product unless compliance with current Good Manufacturing Practices (cGMPs) is satisfactory. FDA also reviews the proposed labeling submitted with the BLA and typically requires changes in the labeling text.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the BLA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when deficiencies outlined in a complete response letter have been addressed to the FDA's satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two or six months from receipt depending on the type of information included.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the product. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy (REMS) to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other U.S. Post-Marketing Regulatory Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Once a BLA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and cGMPs, as well as registration, listing, and inspection. There also are continuing, annual program user fee requirements for marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. FDA also establishes parameters for permissible non-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promotional communications between industry and the medical community, including industry-supported scientific and educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act. See "Other Healthcare Laws and Compliance Requirements" below for more information.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of pharmaceutical manufacture must conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, in some cases before the change may be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of a BLA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, or failure of Phase 4 studies to meet their specified endpoints, may result in revisions to the approved labeling to add new safety information, the need to conduct additional post-market studies or clinical trials to assess new safety risks, imposition of distribution or other restrictions under a REMS program, or recall of the product and withdrawal of the BLA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with post-marketing requirements can result in one or more of the following consequences:</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Warning letters;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Holds on post-approval clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA) which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. The law establishes a period of 12 years of exclusivity for reference products in order to preserve incentives for future innovation,  and outlines statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, exclusivity protects innovator products by prohibiting others, for a period of 12 years, from being granted FDA approval based in part on reliance on or reference to the innovator's data in their application to the FDA. The law does not change the duration of patents granted on biological products. There are regular legislative proposals to rescind or reduce the biologics exclusivity provisions of the ACA and it is uncertain whether or if any of those proposals may be approved, and if approved, how exclusivity for biologics would be affected. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, certain financial interactions with healthcare professionals may be subject to the anti-kickback and fraud and abuse provisions of the Social Security Act and the False Claims Act, and in addition our activities may be affected by the privacy regulations issued under the Health Insurance Portability and Accountability Act, as amended, and similar state laws.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we and our collaborators, may be subject to a variety of foreign regulations governing clinical trials, drug registration, commercial sales and distribution of our product candidates outside the United States. These regulations can vary between jurisdictions and can be more onerous than regulations in the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the European Union (EU) before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time to approval may be longer or shorter than that required for FDA approval. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries outside of the United States have a process that requires the submission of a clinical trial application (CTA) much like an IND prior to the commencement of human clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed in that country. In all cases, the clinical trials must be conducted in accordance with GCP, and other applicable regulatory requirements. A separate CTA must be submitted for each clinical trial to be conducted.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, for example, to obtain regulatory approval of an investigational medicinal product, we must submit a marketing authorisation application (MAA). The content of the MAA is similar to that of a New Drug Application or BLA filed in the United States, with the exception of, among other things, EU-specific document requirements. Under the EU regulatory system, a company may submit marketing authorisation applications either under a centralised or decentralised procedure. Under the centralised procedure in the EU, a MAA is submitted to the European Medicines Agency (EMA) where it will be evaluated by the Committee for Medicinal Products for Human Use (CHMP). The maximum timeframe for a CHMP evaluation of an MAA that has been validated is 210 days, excluding time taken by an applicant to respond to questions. A favorable opinion on the application by the CHMP will typically result in the granting of the marketing authorisation by the European Commission within 67 days of receipt of the opinion. Generally, the entire review process takes approximately 13-14 months. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150 days, excluding time taken by an applicant to respond to questions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we or our collaborators may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the MAA is made. Orphan drugs in Europe enjoy certain benefits, including up to 10 years of exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan designated product. The PRIME initiative was established by the EMA to help promote and foster the development of new medicines in the EU that demonstrate potential for a major therapeutic advantage in areas of unmet medical need. Benefits from the PRIME designation include early confirmation of potential for accelerated assessment, early dialogue and increased interaction with relevant regulatory committees to discuss development options, scientific advice at key development milestones, and proactive regulatory support from the EMA.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or our collaborators, fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioPharmaceutical Coverage, Pricing, and Reimbursement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other countries, sales of any future products for which we receive regulatory approval for commercial sale will depend in part on the availability of adequate reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available or optimal for our products.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices have become a subject of increased focus in recent years. Although there are currently no direct government price controls over private sector purchases in the U.S., federal law requires pharmaceutical manufacturers to pay prescribed rebates on certain government or Medicaid-reimbursed drugs to enable them to be eligible for reimbursement under certain public healthcare programs such as Medicaid and Medicare Part B. Various states have adopted further mechanisms that seek to control drug prices, including by disfavoring certain higher priced drugs or by seeking supplemental rebates from manufacturers. Managed care has also become a potent force in the market place that increases downward pressure on the prices of pharmaceutical products.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and private healthcare payers control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payers also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had 370 full-time employees, 314 of whom were primarily engaged in research, development and manufacturing activities, and  73 of whom had an M.D. and/or Ph.D.   Our employees are critically important to the achievement of our company&#8217;s mission and goals. We periodically conduct employee engagement surveys to understand our employees&#8217; perspectives and endeavor to address, improve, or build on how we work together in response to these perspectives. We face significant competition for experienced and talented individuals in our area due to the growth of local companies. We monitor our compensation, benefits, and exit interview data and make changes as needed to enable the ongoing recruitment and selection of talented new employees, as well as to retain existing talent. We strive to offer our employees an intellectually challenging and diverse work environment, opportunities to expand their knowledge and skills and receive feedback on performance, and for career advancement. Our Living Values, which focus on patients, honest and transparent communications, innovation, ethics, collaboration, our sense of urgency and getting results, set the tone for how we work together.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We empowered a cross-functional team in the early days of the ongoing pandemic to recommend safety protocols, ensure timely communications, and make decisions related to the effect of COVID-19 on our employees and work environment. We believe management&#8217;s relationships with our employees is very positive and they are not subject to a collective bargaining agreement or represented by a trade or labor union.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is www.macrogenics.com. We post links to our website to the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission (SEC): annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and any amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. In addition, the SEC makes available at its website (www.sec.gov), free of charge, reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The discussion below addresses material factors, of which we are currently aware, that could have a material and adverse effect on our business, results of operations and financial condition. Many of the following risks and uncertainties are, and will be, exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. These risk factors and other forward-looking statements that relate to future events, expectations, trends and operating periods involve certain factors that are subject to change, and important risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties should not be considered a complete discussion of all the risks and uncertainties we may face and although the risks are organized by headings and each risk is discussed separately, many are interrelated.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors Affecting Our Business </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks. The following summary highlights some of the risks you should consider with respect to our business and prospects. This summary is not complete and the risks summarized below are not the only risks we face. You should review and consider carefully the risks and uncertainties described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, which includes a more complete discussion of the risks summarized below as well as a discussion of other risks related to our business and an investment in our common stock, as well as our other SEC filings. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend substantially on the success of the clinical development of our products and product candidates. If we are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our products and product candidates, or experience significant delays in doing so, our business will be materially harmed. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MARGENZA, or any other product candidate that we may develop, may fail to achieve market acceptance by physicians, patients, third-party payors and others in the medical community necessary, diminishing any potential commercial success. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience in launching and marketing biopharmaceutical products. If we are unable to further develop marketing and sales or other commercialization capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate substantial product sales revenue. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition and if our competitors develop and market products that are more effective, have a more favorable safety profile, or are less expensive than MARGENZA and our product candidates, our commercial opportunities may be negatively impacted. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our products and product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification based the complete analysis of data. In addition, the results of our current or planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use or may use novel technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved or may not approve products that utilize these technologies. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and/or our collaboration partners may never obtain approval of, or commercialize, our products outside of the United States, which would limit our ability to realize the products full market potential. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacture of MARGENZA and our product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture clinical or commercial quantities of our products. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reimbursement decisions by third-party payors, including government payors, may have an adverse effect on pricing and market acceptance. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The current or future impact of the COVID-19 (or any variant thereof) pandemic may have significant negative impact on our clinical trials, preclinical studies, commercialization of MARGENZA, development, manufacturing and commercialization of our product candidates and other aspects of our business, staff, and operations. The extent to which the COVID-19 pandemic, both now and in the future, adversely affects our financial condition, results of operations, and liquidity, will depend on future developments, including but not limited to the measures taken by public and private entities in response to the pandemic, which remain highly uncertain and cannot be predicted. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability, or the inability of third-party contractors, to successfully develop or commercialize companion diagnostics, assays, or other tests either for use with our product candidates, or to aid physicians and patients in making treatment decisions, could harm our ability to commercialize our product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We contract with third parties for the manufacturing, distribution and commercialization of MARGENZA and we may contract with third parties for the manufacture, distribution, or commercialization of some of our product candidates for clinical testing in the future. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and enforce adequate patent protection for MARGENZA and our other product candidates and related technologies, our business could be materially harmed. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not comply with the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, our business could be adversely affected.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to securities litigation, which is expensive and could divert management attention and adversely impact our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and the Development and Commercialization of Our Products and Product Candidates </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend substantially on the success of the clinical development of our products and product candidates. If we are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our products and product candidates, or experience significant delays in doing so, our business will be materially harmed. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on the successful development, regulatory approval and commercialization of our products and product candidates, such as MARGENZA, for which in December 2020 we obtained FDA approval, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is our first product approved for sale and we expect MARGENZA will be available to patients in the U.S. in March 2021. We have invested a significant portion of our efforts and financial resources in the development of our products and product candidates, including MARGENZA. The success of our products and product candidates depends on many factors, including but not limited to: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in, and completion of, clinical trials, as well as completion of preclinical studies; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and favorable efficacy and acceptable safety data from our clinical trials and other studies; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of regulatory approvals; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities, either by building out and expanding our current manufacturing facilities or making arrangements with third-party manufacturers; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance by clinical research organizations (CROs) or other third parties we may retain of their duties to us in a manner that complies with our protocols and applicable laws and that protects the integrity of the resulting data; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring we do not infringe, misappropriate or otherwise violate the valid patent, trade secret or other intellectual property rights of third parties; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching our products, such as MARGENZA, and our other product candidates, if and when approved; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining favorable reimbursement from third-party payors for products and product candidates; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition with other products; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing commitments to regulatory agencies following regulatory approval; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued acceptable safety profile following regulatory approval; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing or obtaining sufficient supplies of our products and product candidates that may be necessary for use in clinical trials for evaluation of our product candidates and commercialization of our products. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve and maintain one or more of these factors in a timely manner or at all, we could experience significant delays in our ability to, or be unable to obtain additional regulatory approvals for, and/or to successfully commercialize our products and product candidates, which would materially harm our business and we may not be able to generate sufficient revenues and cash flows to continue our operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA or any other product candidate that we develop may fail to achieve market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA or any other product candidates that we develop may fail to gain market acceptance by physicians, patients, third-party payors and others in the medical community. If MARGENZA or any such product candidate that we develop does not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of MARGENZA or any other product candidates that we develop will depend on a number of factors, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages compared to alternative treatments; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products for sale at competitive prices; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians to prescribe MARGENZA or other new therapies, and of the patient population to try MARGENZA or these therapies; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing, sales, and distribution support; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects; any safety events that may have occurred in connection with the development of the product candidate; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA&#8217;s market acceptance depends significantly on the medical community&#8217;s determination of clinical benefit and safety compared to alternative therapies available both now and in the future. Several new therapies for the treatment of HER2-positive breast cancer have recently been approved.  Certain of these therapies may have or may be perceived to have greater efficacy benefits than MARGENZA in clinical trials. Competition from recently approved therapies may adversely impact the market acceptance of MARGENZA. In addition, market acceptance and the medical community determination of clinical benefit may depend significantly on the pending results of the final Overall Survival (OS) endpoint data from the SOPHIA trial, which MARGENZA result may not be favorable compared to trastuzumab, or, even if favorable compared to trastuzumab, may not be statistically significant, clinically meaningful or favorable when compared to other available or future therapies.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the potential market opportunity for MARGENZA is difficult to precisely estimate. Our internal estimates of the potential market opportunity for MARGENZA include several key assumptions based on our industry knowledge, industry publications, third-party research reports, assessment of competition, and other surveys. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of these assumptions proves to be inaccurate, then the actual market for MARGENZA could be smaller than our estimates of our potential market opportunity. If the actual market for MARGENZA is small, and/or smaller than we expect, our product revenue may be limited and it may be more difficult for us to achieve or maintain profitability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in launching and marketing our internally developed products. If we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products, or our existing arrangements are not successful, we may not be able to generate substantial product sales revenue. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the FDA approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. We expect to launch MARGENZA in March 2021.  In conjunction with EVERSANA we continue to build commercialization support in United States to commercialize MARGENZA. We have limited internal commercialization capabilities, and any additional products or product candidates that we may develop or in-license, will require significant capital expenditures, management resources and time. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in commercializing our internally developed products, such as MARGENZA. For example, we have limited experience in building and managing a commercial team, conducting a comprehensive market analysis, obtaining state licenses and reimbursement, or managing distributors and a sales force for our products. We will be competing with many companies that currently have extensive and well-funded sales and marketing operations. As a result, although we have partnered with EVERSANA to commercialize MARGENZA, our ability to successfully commercialize </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA or any of our products may involve more inherent risk, take longer, and cost more than it would if we were a company with substantial experience launching products. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercialization of  any or all of our product candidates, we will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel,  If we are unable to, or decide not to, further develop internal sales, marketing, and commercial distribution capabilities for any or all of our products, we will likely pursue additional collaborative arrangements regarding the sales and marketing of our products. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties. We would have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our products ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts for our products. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to further develop and successfully maintain internal sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to generate substantial product sales revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than MARGENZA and our product candidates, our commercial opportunities will be negatively impacted. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences industry is highly competitive and subject to rapid and significant technological change. Our approved product, MARGENZA, competes with, and our product candidates under development (if approved) will compete with, drugs and therapies that currently exist or are being developed. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed, or may have succeeded, in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, there are a large number of companies developing or marketing potential treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. See &#8220;Competition&#8221; above for additional information. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. For example, Daiichi Sankyo Inc.'s product ENHERTU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fam-trastuzumab deruxtecan-nxki) and Seagen&#8217;s product TUKYSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tucatinib) both recently launched in the United States in patient populations that potentially compete with the patient population for MARGENZA. This could result in, or has resulted in, our competitors establishing a strong market position before we are able to enter the market. In addition, both ENHERTU and TUKYSA demonstrated greater efficacy results than MARGENZA in clinical trials.  In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products.  For example, certain HER2 biosimilar products are approved in certain countries, including the United States, and others may be approved prior to commercialization of, or market acceptance of,  MARGENZA. MARGENZA and product candidates, if approved, may be priced at a significant premium over competitive biosimilar products. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable to compete effectively. Technological advances or products developed by our competitors may render our technologies, products or product candidates obsolete, less competitive or not economical. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our products and product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application (BLA) from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. For example, in December 2020, the FDA approved the BLA for MARGENZA. MARGENZA is our first product approved for sale in any jurisdiction. In addition, our collaborator Incyte submitted a BLA for retifanlimab in January 2021.  Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, subject our company or our collaborators to administrative or judicially imposed sanctions, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the products, manufacturers, manufacturing facilities or manufacturing process;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures, detentions or import bans;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements; and  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending BLAs or supplements to approved BLAs or analogous marketing approvals outside the United States.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be deemed safe or effective;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not confirm the positive results from earlier preclinical studies or clinical trials;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may not find the data from preclinical studies and clinical trials sufficient or meaningful;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may change their approval policies or adopt new regulations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indicated uses for which we may market the product. These limitations may limit the size of the potential market for a product candidate, if approved. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Even if we and our collaborators obtain regulatory approvals to market our current and any future approved products, we and our collaborators will remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in significant additional expense and could negatively impact our and our collaborators' ability to commercialize our current and any future approved products. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators  are subject to extensive ongoing obligations and continued regulatory review from applicable regulatory agencies with respect to any product  obtaining  regulatory approval, including MARGENZA, such as continued adverse event reporting requirements and post-marketing commitments, all of which may result in significant expense and limit our and our collaborators' ability to commercialize our current and any future approved products. For example, the FDA's approval of MARGENZA included a requirement that we provide to the FDA the data from the final overall survival endpoint from our SOPHIA study, when available. Unfavorable overall survival results could result in the withdrawal of approval of MARGENZA or the inclusion of unfavorable safety information in our product labeling, or diminished market opportunity or acceptance, which could seriously harm our business. Moreover, in connection with MARGENZA&#8217;s approval, the labeling and advertising and promotion of MARGENZA are subject to additional regulatory requirements, which could entail significant expense and could negatively impact the potential commercialization of MARGENZA. In addition, the use of MARGENZA may uncover additional adverse events that limit or prevent MARGENZA&#8217;s widespread use or that force us to withdraw MARGENZA from the market, and any problems with MARGENZA or any violation of ongoing regulatory obligations could result in restrictions on MARGENZA, including its withdrawal from the market.  To the extent other product candidates or those of our partners are approved by the FDA, we or our collaborators may be subject to similar post-marketing obligations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the manufacturers of our current and any future approved products are also required, or will be required, to comply with current Good Manufacturing Practices, or cGMP, regulations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory agencies must approve these manufacturing facilities before they can be used to manufacture our products and product candidates, and these facilities are subject to ongoing regulatory inspections. In addition, regulatory agencies subject an approved product, its manufacturer and the manufacturer&#8217;s facilities to continual review and inspections, including periodic unannounced inspections. The subsequent discovery of previously unknown problems with our current or any future approved products, including adverse events of unanticipated severity or frequency, or problems with the facilities where our current or any future approved products are manufactured, may result in restrictions on the marketing of our current or any such future approved products, up to and including withdrawal of the affected product from the market. If our manufacturing facilities, our collaborators' manufacturing facilities, or those of our respective suppliers, fail to comply with applicable regulatory requirements, such noncompliance could result in regulatory action and additional costs to us. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable FDA and other regulatory requirements may subject us to administrative or judicially imposed sanctions, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of Form FDA 483 notices or Warning Letters by the FDA or other regulatory agencies; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of fines and other civil penalties; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecutions; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions, suspensions or revocations of regulatory approvals;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any ongoing clinical trials; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of manufacturing; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in commercialization; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusals to permit drugs to be imported into or exported from the United States; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on operations, including costly new manufacturing requirements; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or seizures. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA and other regulatory agencies may change and additional government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or of MARGENZA in any additional indications or territories, or further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we or our collaborators might not be permitted to market our current or any future approved products and our business would suffer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are either currently enrolling patients in clinical trials or anticipate initiating or continuing clinical trials for molecules that include margetuximab, enoblituzumab, flotetuzumab, retifanlimab, tebotelimab,MGC018, MGD014, and MGD019, as monotherapies or in combination with other product candidates in 2021. In addition, Incyte Corporation is currently enrolling patients in clinical trials for retifanlimab, and other collaborators outside the United States are developing our product candidates and enrolling patients in clinical trials. We anticipate our collaborators will initiate or continue clinical trials including our other product candidates. The continuation, modification, or commencement of existing or new clinical trials could be substantially delayed or prevented by several factors, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay or failure in patient recruitment or enrollment in our or our collaborators&#8217; trials for any reason, including as a result of public health crises such as the evolving COVID-19 pandemic;   </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain sufficient funds required for a clinical trial;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to reach agreement on acceptable clinical trial terms or clinical trial protocols with prospective sites or CROs the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; and  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to obtain institutional review board (IRB) approval to conduct a clinical trial at a prospective site. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progress or completion of our, or our collaborators', clinical trials could also be substantially delayed or prevented by many factors, including:  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in expected site initiation, patient recruitment and enrollment, for any reason,  including as a result of public health crises such as the evolving COVID-19 pandemic </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of patients to complete the clinical trial; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of efficacy during clinical trials; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of our clinical trials by one or more clinical trial sites; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to monitor patients adequately during or after treatment by us, our collaboration partners and/or our CROs; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of our product candidates are subject to partial or full clinical holds from time to time.  A clinical hold may delay the timing of a clinical trial, or may require us to modify or discontinue such trial. Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a  complete analysis of data, or in the case of interim analysis, the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or preclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may publicly disclose top line or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, in October 2019 we announced second interim overall survival data for the SOPHIA trial of margetuximab for the treatment of certain metastatic breast cancer patients. The top line or interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top line and interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In addition, the achievement of one primary endpoint for a trial does not guarantee that additional co-primary endpoints or secondary endpoints will be achieved. For example, the achievement by margetuximab of its first sequential endpoint for progression-free survival events in the SOPHIA trial does not indicate whether the second sequential endpoint of overall survival will be achieved. In particular, the second interim overall survival analysis, based on 270 events, did not show statistically significant results. We currently expect to receive final overall survival analysis in the second half of 2021, and such results may not show statistical significance. Failure to achieve statistical significance in this second sequential endpoint of overall survival in the SOPHIA trial may have an adverse effect on our ability to obtain or retain regulatory approval of margetuximab in the U.S. or in other jurisdictions. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use novel technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products in development are based on our technology platforms, including Fc Optimization, DART and TRIDENT technologies. Given the novelty of these technologies, we intend to work closely with the FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. Even though MARGENZA, which incorporates an Fc variation created using our Fc Optimization platform, was approved by the FDA, there is no assurance that the FDA will approve future product candidates using such technology.  The validation process takes time and resources, may require independent third-party analyses, and may not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory approval path and requirements may not be clear or evolve as more data becomes available for this product candidates, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the product candidates that we develop would adversely affect our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our technology platforms to build a pipeline of product candidates and progress several of these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers, as well as autoimmune disorders and infectious diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for initial or continued clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock price. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and/or our collaboration partners may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we and our current and potential collaboration partners must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and may require additional preclinical studies or clinical trials or additional administrative review periods, which could result in significant delays, difficulties and costs for us. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. Although we obtained FDA approval or MARGENZA in December 2020, we do not have any product candidates approved for sale in any international market. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8239;Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or after the approved product has been marketed. Ongoing or future trials of our product candidates may not support the conclusion that one or more of these product candidates have acceptable safety profiles. The results of future clinical or preclinical trials may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential product liability claims. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others later identify undesirable or unacceptable side effects caused by such products: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require us to take our approved product off the market; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to limitations on how we may promote the product; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the product may decrease significantly; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the prescribing information for MARGENZA include warnings and precautions for infusion-related reactions, as well as a boxed warning related to left ventricular dysfunction and embryo-fetal toxicity.  Further, based on the identification of future adverse events, we may be required to further revise the prescribing information, including MARGENZA&#8217;s boxed warning, which could negatively impact sales of MARGENZA or adversely affect MARGENZA&#8217;s acceptance in the market. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of MARGENZA and our product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production.&#8239;If we encounter any such difficulties, our ability to supply MARGENZA and our product candidates for clinical trials or, if approved, for commercial sale could be delayed or halted entirely, and our business, financial results, and reputation could be materially harmed.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA is currently manufactured by a third party, and we are currently manufacturing retifanlimab and other product candidates for ourselves and our collaborators.  The process of manufacturing MARGENZA and our product candidates for ourselves and our collaborators is extremely susceptible to delays or product loss due to a variety of factors, including but not limited to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, difficulties in scaling the production process, and vendor supply chain disruptions or fluctuations. Even minor deviations from manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in MARGENZA and our product candidates or in the manufacturing facilities in which MARGENZA and our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting manufacturing operations for MARGENZA and our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. In addition, if we fail to supply required quantities of MARGENZA and a product candidate for one of our collaborators, our collaborator may terminate our agreement.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. If there were to be a catastrophic event or failure of our manufacturing facilities or processes, we may be unable to meet our requirements for supply of MARGENZA and our product candidates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture clinical or commercial quantities of our products. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two current Good Manufacturing Practice (cGMP) manufacturing facilities located in Rockville, Maryland, one of which is a commercial scale facility which is intended to support future clinical and commercial production of our and our collaborators&#8217; product candidates. Although some of our employees have experience in the manufacturing of pharmaceutical products from prior employment at other companies, we as a company have limited experience in large-scale manufacturing and no experience in commercial manufacturing. The design and build of a large scale manufacturing facility was time-consuming and expensive, and we may not realize the benefit of this investment. As a manufacturer of pharmaceutical products, we are required to demonstrate and maintain compliance with cGMPs which include requirements related to production processes, quality control and assurance and recordkeeping. Furthermore, establishing and maintaining manufacturing operations requires a reallocation of other resources, particularly the time and attention of certain of our senior management. Any failure or delay in our manufacturing capabilities could adversely impact the clinical development or commercialization of our or our collaborators&#8217; product candidates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with the FDA&#8217;s cGMP requirements, as set out in statute, regulations and interpreted through guidance. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. See &#8220;Other U.S. Post-Marketing Regulatory Requirements&#8221; above for additional information. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product or product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product or product candidates, including leading to significant delays in the availability of drug product for sale and our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation or negatively impact a product&#8217;s commercial success. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our products and product candidates, if approved for sale by the appropriate regulatory authorities, may depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels and, in some cases, utilization management strategies, such as tiered formularies and prior authorization. We cannot be certain that reimbursement will be available for our products or any products that we develop or that the reimbursement level will be adequate to allow us to operate profitably. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. Our ability to commercialize our products may depend, in part, on the extent to which reimbursement for the products will be available from government authorities and third-party payors. If reimbursement for our products is not available or is available on a limited basis, or if the reimbursement amount for our products is inadequate, we may not be able to successfully commercialize any of our approved products. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare&#8239;&amp; Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage and reimbursement determination process is often time-consuming and costly. This process may require us to provide scientific and clinical information to support the coverage or reimbursement of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As federal and state governments implement additional health care cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that MARGENZA and our product candidates, if approved, will be covered, or remain covered, by private or public payors, and if covered, whether the reimbursement will be perceived by product purchasers as adequate. Health reform actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for MARGENZA and our product candidates, if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical products . There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific products and product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our products may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any approved product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs through lowering prescription drug prices, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA), which became law in 2010. While it is difficult to assess the impact of the ACA in isolation, either in general or on our business specifically, it is widely thought that the ACA increases the likelihood of downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. Further, the United State and foreign governments regularly consider additional reform measures that affect healthcare coverage and costs. Such reforms may include changes to the coverage and reimbursement of healthcare services and products. In particular, there have been recent executive, judicial and Congressional challenges to the ACA, which could have an impact on coverage and reimbursement for healthcare services covered by plans authorized by the ACA. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; The United States Supreme Court is currently reviewing the constitutionality of the ACA, although it is unclear when a decision will be made. Although the U.S. Supreme Court has yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Affordable Care Act. It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, on November 20, 2020, CMS issued an interim final rule implementing former President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, however, government and other regulatory oversight and future regulatory and government interference with the healthcare systems could adversely impact our business and results of operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of various and evolving payor models and additional legislative proposals.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA, and other government employees and pause or stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our products or product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability lawsuits related to the sale of our products to, use of our products by, and testing of our product candidates in, seriously ill patients. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our future approved products; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased regulatory scrutiny; </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant litigation costs; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to or costly settlement with patients or other claimants; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or a change in the indications for which they may be used; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management and scientific resources from our business operations; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to MARGENZA and any of our other product candidates that are approved for commercial sale, we are, and will be, highly dependent upon physician and patient perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we hold $20 million in product liability insurance coverage in the aggregate, with a per incident limit of $20 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our contract with the National Institute of Allergy and Infectious Diseases (NIAID)&#8239;makes us a government contractor. Laws and regulations affecting government contracts&#8239;may&#8239;make it more costly and difficult for us to successfully conduct our business.&#8239; </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. Failure to comply with these laws could result in significant civil and criminal penalties. Among the most significant government contracting regulations that may affect our business are: the Federal Acquisition Regulation (FAR) and NIH-NIAID-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts; business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, and the False Claims Act; export and import control laws and regulations; and laws, regulations and executive orders restricting the use and dissemination of sensitive information we may receive pursuant to our performance of the government contract. U.S. government agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. If we are audited, such audit could result in disallowance of expected cost reimbursement, or if such audit were to uncover improper or illegal activities, we could be subject to civil and criminal penalties, administrative sanctions, including suspension or debarment from government contracting and significant reputational harm. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. tax law may have a material adverse effect on our business, financial condition and results of operations, and changes in international trade relations may have a material adverse effect on the commercialization of some or all of our product candidates.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and policy relating to taxes may have an adverse effect on our business, financial condition and results of operations. Recent tax reforms in the United States have resulted in significant changes to preexisting U.S. tax rules and regulations. These changes may trigger an adverse effect on our business, financial conditions and results of operations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. government may seek to implement more protective trade measures with countries in which we plan to conduct business in, with great deal of uncertainty regarding trade policies, tariffs and government regulations, which if altered could have the potential to create a significant adverse effect on trade between the United States and other countries. Overall, changes in international trade relations, such as the imposition of or increase in tariffs or other trade barriers, could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materially and adversely impact our costs, the ability to make sales of our product candidates to any of our significant customers in other countries, and reduce the competitiveness of our product candidates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has had, and may continue to have, a material impact on our clinical trials, preclinical studies, commercialization of MARGENZA, manufacturing, development and commercialization of our product candidates and other aspects of our business, staff, and operations, which in turn may, materially adversely affect our financial condition, results of operations and liquidity. The extent to which the COVID-19 pandemic continues to adversely affect our business, staff, operations, financial condition, results of operations and liquidity, will depend on future developments, including the measures taken by public and private entities in response to the pandemic, which remain highly uncertain and cannot be predicted. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks could adversely impact our business. The COVID-19 pandemic, which is continuing to evolve, and to date has led to the implementation of various responses, including government-imposed quarantines, work and travel restrictions and other public health safety measures at the federal, state and local levels. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of the COVID-19 pandemic has had, and may continue to have, a material impact on our clinical trials, preclinical studies, commercialization efforts, manufacturing and development of our product candidates and other aspects of our business, staff, and operations, which in turn may impact our financial condition, results of operations and liquidity. For instance, the COVID-19 pandemic impaired the ability to enroll patients in clinical trials, continue ongoing clinical trials or activate clinical trial sites, and MARGENZA commercialization, due to, for example, heightened exposure to COVID-19 if an outbreak occurs in a specific geography, the shifting of healthcare resources toward the pandemic or the closing of or limiting of access to clinical facilities, and reduced or non-existent in-person access to physicians and health care centers. Furthermore, patients may be unable or unwilling to enroll in our clinical trials or be unable to comply with clinical trial protocols if COVID-19 related restrictions impede patient movement or interrupt healthcare services. Government-imposed quarantines and other restrictions may also require us to temporarily suspend activity at our clinical sites. The COVID-19 pandemic may also negatively affect the operations of third-party CROs that we rely upon to carry out our clinical trials, or the operations of other service providers, which could result in delays or disruptions in the supply of our product candidates or other aspects of our business or that of our collaborators. Any negative impact the COVID-19 pandemic has had, or will have, on patient enrollment or treatment or the timing and execution of our clinical trials could cause delays to our clinical trial activities, which could adversely affect our ability to seek and obtain regulatory approval for and to commercialize any approved product candidates, increase our operating expenses and have a material adverse effect on our business and financial results. In particular, enrollment of our registrational path trial of flotetuzumab has been slower than expected due to the COVID-19 pandemic. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the COVID-19 pandemic has increased the risk that a portion of the workforce, including ours, may suffer illness or otherwise be unable to work due to close contact related precautions. There has been limited business impact from COVID-19 related absences, but there can be no assurance that there will not be additional or significant employee COVID-19 related absences with negative business impact in the future. We have maintained an on-site workforce and implemented stay-at-home orders consistent with the requirements of the jurisdictions in which we operate, with arrangements such as remote work and flexible schedules for certain functions, as well as other measures intended to reduce the risks to our employees from the impact of the pandemic while maintaining our operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also face increased cybersecurity risks due to the shifting of a majority of our corporate functions operating remotely in regions impacted by stay-at-home orders. Increased levels of remote access may create additional opportunities for cybercriminals to attempt to exploit vulnerabilities, and our employees may be more susceptible to phishing and social engineering attempts.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic impacts our business, staff, operations, financial condition, results of operations and liquidity, or those of our collaborators, will largely depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the pandemic, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions to contain COVID-19 or treat its impact, among others. We cannot presently predict the scope and severity of any potential government or business shutdowns or disruptions. If we or any of the third parties with whom we engage experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. Our first commercial product was only recently approved.  We may never achieve or sustain profitability. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since our inception. As of December&#8239;31, 2020, our accumulated deficit was approximately $771.8 million. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, prepare for and begin to commercialize any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders' deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. Our expenses would significantly increase to the extent we build out a sales force and other commercially relevant functions to support the commercialization of MARGENZA or any of our product candidates.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. For example, revenues from MARGENZA may not be sufficient to enable us to reach profitability. In order to commercialize any additional product candidates, we will need to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling approved products and product candidates for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing our product candidates through clinical development and are commercializing MARGENZA in collaboration with EVERSANA. Developing and commercializing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. In order to obtain such regulatory approval, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what was raised in our public offerings and through our collaborations and license agreements to complete the development and commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2020, combined with anticipated and potential collaboration payments, will enable us to fund our operations into 2023, assuming all of our programs and collaborations advance as currently contemplated. Because successful commercialization of MARGENZA and development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to commercialize MARGENZA and complete research, development and clinical testing to commercialize our product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including but not limited to: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of other product candidates and indications that we pursue; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, timing, cost and results of research, preclinical development, and clinical trials; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with manufacturing our product candidates; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing sales, marketing, and distribution capabilities; </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need and ability to hire additional management, scientific, and medical personnel; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing products that may limit market penetration of our product candidates; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, MARGENZA, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market MARGENZA or product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to utilize our federal net operating losses (NOLs) and federal tax credits is currently limited, and may be limited further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an ownership change, as defined by Section&#8239;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&#8239;382 limitations due to acquisitions we made in 2002 and 2008.&#8239;As of December&#160;31, 2020, we had federal and state NOL carryforwards of $648 million and federal research and development tax credits of $69.6 million available. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&#8239;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug development and have little to no internal capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our agreements with, for example, Incyte Corporation, Zai Lab Limited and I-Mab Biopharma. These current collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements may be terminated for convenience upon the completion of a specified notice period. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. For example, in January 2020 our arrangement terminated with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier), to which we had previously granted exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules.  All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of our program collaborators.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of MARGENZA or any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For MARGENZA and our product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for MARGENZA or the subject product candidate, the costs and complexities of manufacturing and delivering MARGENZA or such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative products, product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for MARGENZA or our product candidate. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of MARGENZA or a product candidate, reduce or delay one or more of our other development programs, delay the commercialization of MARGENZA or a product candidate or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop MARGENZA or our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be restricted under collaboration agreements from entering into additional agreements on certain terms with potential collaborators.  Most of our existing therapeutic collaborations contain a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice (GCP) for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely affect the clinical development of our product candidates and harm our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure of third-party contractors and/or our inability to successfully develop and commercialize companion diagnostics for use with our product candidates could harm our ability to commercialize our product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop companion diagnostics for our product candidates where appropriate. At least in some cases, the FDA and similar regulatory authorities outside the United States may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and are relying, and in the future plan to continue to rely, in large part on third parties to perform these functions. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may not perform their obligations as expected; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may encounter production difficulties that could constrain the supply of the companion diagnostic; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may not commit sufficient resources to the marketing and distribution of such product; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may terminate their relationship with us. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any companion diagnostic for use with one of our  product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently contract with third parties for the manufacturing of MARGENZA and we expect to contract with third parties for the manufacture of some of our product candidates for clinical testing in the future in addition to commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two cGMP manufacturing facilities located in Rockville, Maryland, one of which was completed in 2018 and is designed to increase our internal capacity to manufacture more drug substance lots, at larger scale and in full compliance with cGMP to support future clinical and commercial production of our and our collaborators&#8217; product candidates.  We manufacture drug substance lots at these facilities that we use for research and development purposes and for clinical trials of our and our collaborators&#8217; product candidates. Although we believe we currently have capacity to produce all of the material required for our and our collaborators&#8217; clinical trials, we may not be able to do so in the future, and may rely on arrangements with third parties. Our current facilities may also be insufficient to support our needs for commercial quantities of MARGENZA and such candidates, and we may rely on arrangements with third parties. We have limited experience in manufacturing products at commercial scale. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have entered into agreements with contract manufacturing organizations to supplement our clinical supply and internal capacity as we commercialize MARGENZA and advance our product candidate pipeline.  MARGENZA is currently manufactured by third parties.  In the future, we may transition some of the manufacturing of MARGENZA to our internal facilities.  We may use third parties for the manufacture of some of our product candidates for clinical testing, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by us or one of our third party collaborators. We have entered into supply agreements with manufacturers for commercial supply and may in the future enter into one or more additional supply agreements for our product candidates. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#8217;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#8217; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured MARGENZA or the product candidates ourselves, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could cause adversely impact the commercialization of MARGENZA and the delay of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for MARGENZA or our product candidates and to have any such new source approved by the FDA or any other relevant regulatory authorities. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercialization collaboration with EVERSANA for MARGENZA is important to our business, and future commercialization collaborations may also be important to us. If we are unable to maintain this or other commercialization collaborations, or if commercialization collaborations are not successful, our business could be adversely affected. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug commercialization, with little to no internal capability for sales, marketing or distribution. We have entered into a collaboration with EVERSANA for the commercialization of MARGENZA in the United States that we believe can provide such capabilities, and may enter into commercial collaborations in the future for MARGENZA or our product candidates.  Our existing commercialization collaboration, and any future commercialization collaborations we enter into, may pose a number of risks, including the following: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue commercialization of MARGENZA or any product candidates that achieve regulatory approval or may elect not to continue commercialization based on clinical trial results, changes in the collaborators' strategic focus or other factors that divert resources or create competing priorities; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently commercialize products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully commercialized under terms that are more economically attractive than ours; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators  with marketing and distribution rights to MARGENZA or our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements on contract interpretation, commercialization strategy or tactics,  might cause delays or termination of the commercialization of MARGENZA or product candidates, might lead to additional responsibilities for us with respect to MARGENZA or product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly utilize our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may violate, or be investigated for potentially violating, health care compliance and related laws and regulations, which may expose us to litigation, enforcement actions or inquiries, or other potential liability; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further commercialization of MARGNEZA or applicable product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  All of the risks relating to commercialization, and health care legal compliance described in this Annual Report on Form 10-K also apply to the commercialization activities of our collaborators.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of MARGENZA or any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators.   We may also be restricted under commercialization collaboration agreements from entering into future agreements on certain terms with potential collaborators.  For example, our collaboration with EVERSANA contains a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time among other conditions </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the commercialization of MARGENZA or a product candidate, reduce the scope of any sales or marketing activities, or increase our expenditures and undertake or commercialization activities at our own expense. If in the future we elect to fund and undertake commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations to commercialize our product candidates and do not have sufficient funds or expertise to undertake the necessary  commercialization activities, we may not be able to commercialize our product candidates or bring them to market or continue  and our business may be materially and adversely affected. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Cybersecurity</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A disruption in our computer networks, including those related to cybersecurity, could adversely affect our financial performance as well as our research, development and commercialization efforts. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security breaches, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches can create system disruptions or shutdowns or the unauthorized disclosure of confidential information. In addition, due to the COVID-19 pandemic a significant portion of our employees have been working remotely, either from home or elsewhere.  If personal information or protected health information is improperly accessed, tampered with or disclosed as a result of a security breach, we may incur significant costs to notify and mitigate potential harm to the affected individuals, and we may be subject to sanctions and civil or criminal penalties if we are found to be in violation of the privacy or security federal or state laws protecting confidential personal information. In addition, a cybersecurity breach could hurt our reputation, subject us to liability claims or regulatory penalties for compromised personal information and could have a material adverse effect on our business, financial condition and results of operations. In order to reduce such risks, our information security program employs a policy-driven information systems security architecture based on National Institute of Standards and Technology (NIST) Cybersecurity Framework and references the NIST 800-53 guidelines for risk-based assessments and implementation of information security controls. The program is managed by dedicated Information Security personnel with the primary mission to implement, maintain, and improve the capabilities and practices to ensure the confidentiality, integrity, and availability of the sensitive information it maintains. &#8239; </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, and/or are invalid and/or unenforceable, if a court should find that they cover MARGENZA or enoblituzumab and we are unable to invalidate such patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include: </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties' patents; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#8217;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent does not ensure that a court or agency finds or will find the patent valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards which the United States Patent and Trademark Office (USPTO) and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any competitive advantage. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after they have been issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our approved products and product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate opposition, reexamination or inter partes review proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us; </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#8217;s activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to make the inventions covered by patents or pending patent applications; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to file patent applications for these inventions; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently party to various intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements that grant us the right to use certain technologies related to biological manufacturing to manufacture our clinical product candidates. These licenses typically include an obligation to pay yearly maintenance payments and royalties on sales, and may also include upfront and milestone payments. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel or our agents to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we may be responsible for the payment of patent fees for patent rights that we license from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially,  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Legal Compliance Matters </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#8217; compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators are subject to various healthcare laws, and our failure, or the failure of our collaborators, to comply with those laws could result in significant penalties and adversely affect our business, operations and financial condition. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our operations, and those of our collaborators, are subject to regulation by  various local, state, federal authorities in addition to the FDA, including but not limited to, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), other divisions of HHS (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice (&#8220;DOJ&#8221;) and individual U.S. Attorney offices within the DOJ, and state and local governments.  We and our collaborators are or may be subject to broadly applicable &#8220;fraud and abuse&#8221; laws , such as false claims, anti-kickback laws, transparency laws, and privacy and security laws.. Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a claim paid.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal anti-kickback statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices, or those of our collaborators, may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the intent standard under the federal anti-kickback statute and the criminal healthcare fraud statutes (discussed below) was amended by the ACA to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil false claims act. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal anti-kickback statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Sunshine Act provisions of the ACA, covered manufacturers of drugs, devices, biological and medical supplies for which payment is available under a federal health care program (with certain exceptions) are subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">annual federal reporting and disclosure requirements with regard to payments or other transfers of value made to physicians defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as certain ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Some state laws also prohibit certain gifts to healthcare providers, require pharmaceutical companies to report payments to healthcare professionals, and/or require companies to adopt compliance programs or codes of conduct.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, improper consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time as we or our collaborators market MARGENZA or any of our future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these &#8220;fraud and abuse&#8221; laws. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators may also be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business, as well as foreign jurisdictions.  In the United States, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, impose requirements on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security and transmission of individually identifiable health information.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in order to distribute products commercially in the United States, we or our collaborators must also comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers, and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, track, and report gifts, compensation and other remuneration made to physicians and other healthcare providers, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit certain other sales and marketing practices.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations, or those of our collaborators marketing, distributing or commercializing any of our products on our behalf,  are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our operations and those of our collaborators may be subject to analogous foreign health care laws in the jurisdictions in which we operate.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, (FCPA) and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that pose a risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or other anti-corruption laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws. If we violate provisions of the FCPA or other anti-corruption laws or are subject to an investigation or audit pursuant to these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses, which could have an adverse impact on our business, financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA or other agencies, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Employee Matters and Managing Growth </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our President and Chief Executive Officer, as well as the other members of our senior management team. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development, manufacturing and commercialization objectives and seriously harm our ability to successfully implement our business strategy. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. In addition, we will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our commercialization of MARGENZA and research, development and commercialization efforts for our existing and future product candidates. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to provide meaningful equity incentives to our key employees, it could adversely affect our ability to retain these key employees, which in turn could affect our ability to implement our business strategies.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon the members of our senior management team and other key employees. In our industry, it is common to attract and retain executive and other key employees with compensation packages that include a significant equity component. As a result, we may have difficulty retaining key personnel, which would have a material adverse effect on our ability to execute our business strategy. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had 370 full-time employees. As our development and commercialization plans and strategies develop, we may choose to expand our employee base for managerial, operational, manufacturing, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Any such growth could require significant capital expenditures and may divert financial resources from other projects, such as the commercialization of MARGENZA and the development of existing and additional product candidates. If our management is unable to effectively manage such growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize MARGENZA, our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any such growth. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Common Stock </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to securities litigation, which is expensive and could divert management attention and adversely impact our business.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been and may continue to be volatile. Companies that have experienced volatility in the market price of their common stock are often subject to securities class action litigation. For example, on  September 13, 2019, a securities class action complaint was filed against us, and certain of our officers and/or directors in the U.S. District Court for the District of Maryland, which case is still pending. This or any future securities litigation could result in substantial costs and diversion of management&#8217;s attention and resources, which could adversely impact our business. Any adverse determination in litigation could also subject us to significant liabilities. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance. The stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the market price of our common stock to fluctuate include: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results and timing of our clinical trials and clinical trials of our competitors&#8217; products; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure or discontinuation of any of our development programs; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues in manufacturing our product candidates or future approved products; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#8217; products; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from existing products or new products that may emerge; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of technological innovations or new commercial products by us or our competitors; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates or recommendations by securities analysts, if any cover our common stock; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern over our product candidates or any future approved products; </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">threatened or actual litigation; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future or anticipated sales of our common stock; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems in the United States or overseas; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of MARGENZA or our product candidates, if approved, to achieve commercial success; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and other external factors or other disasters or crises; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions and market conditions for biopharmaceutical stocks; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall fluctuations in U.S. equity markets; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of the COVID-19 pandemic as well as mandatory and voluntary actions taken to mitigate the evolving public health impact of the pandemic. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the company that issued the stock. For example, we currently have one such securities class action lawsuit brought against us.  We could incur substantial costs defending this or similar lawsuits, as well as diversion of the time and attention of our management, any or all of which could seriously harm our business  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our charter, bylaws, third-party agreements and Delaware law may make an acquisition of us or a change in our management more difficult. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our restated certificate of incorporation and amended and restated bylaws could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of directors to be changed only by resolution of our board of directors; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors, providing that not all members of the board of directors be elected at one time; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings; and </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the ordinary course of our business, from time to time we discuss and enter into collaborations, licenses and other transactions with various third parties, including other pharmaceutical companies and biotechnology companies. When we deem it appropriate, our agreements with such third parties may include standstill provisions. These standstill provisions, several of which may be in force from time-to-time, typically prohibit such parties from acquiring our securities for a period of time, which may discourage such parties from acquiring MacroGenics even if doing so would be beneficial to our stockholders. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#8239;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_22"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160; UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_25"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160; PROPERTIES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a total of approximately 235,000 square feet of manufacturing, office, laboratory and warehouse space in Maryland and California. Our headquarters building in Rockville, Maryland currently houses laboratory, office and manufacturing operations to support clinical, and potentially commercial, quantities and scale. This location is occupied under a lease that expires in 2027. We also lease another space supporting smaller-scale manufacturing operations in Rockville. The lease of that space expires in December 2024. These leases and all of the leases on our other properties include one or more options to renew, with those renewal periods ranging from five to fourteen years. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business. We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_28"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or  class actions related to alleged patent infringements and other  intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See note 10, Commitments and Contingencies, to the consolidated financial statements for more information. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_31"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160; MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_37"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY,&#160;RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the symbol "MGNX".&#160;As of February&#160;22, 2021, we had 56,258,468 shares of common stock outstanding held by approximately 63 holders of record, which include shares held by a broker, bank or other nominee.&#160;We have never declared or paid any cash dividends.&#160;We do not anticipate declaring or paying cash dividends for the foreseeable future.&#160;Instead, we will retain our earnings, if any, for the future operation and expansion of our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the five-year cumulative total return of our common stock with the  Nasdaq Composite Index (U.S.) and the Nasdaq Biotechnology Index.&#160;The comparison assumes a $100 investment on December 31, 2015 in our common stock, the stocks comprising the Nasdaq Composite Index, and the stocks comprising the Nasdaq Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any.&#160;Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.</span></div><div style="margin-bottom:9pt;text-align:center"><img src="mgnx-20201231_g6.jpg" alt="mgnx-20201231_g6.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading "Performance Graph" shall not be deemed to be "soliciting material" or to be "filed" with the SEC or subject to liabilities of Section 18 of the Exchange Act, except to the extent that we specifically request that such information be treated as soliciting material or specifically be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_40"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;SELECTED FINANCIAL DATA</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_43"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors including, but not limited to, those set forth under the sections entitled "Risk Factors" and "Forward-Looking Statements", our actual results may differ materially from those anticipated in such forward-looking statements.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the discussion of our financial condition and results of operations for the year ended December&#160;31, 2019 compared to the year ended December&#160;31, 2018, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC on February 25, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_46"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. We expect to initiate the commercial launch of MARGENZA late in the first quarter of 2021. In addition, we have a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, that have been created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2020, combined with anticipated and potential collaboration payments and product revenues, should enable us to fund our operations into 2023, assuming our programs and collaborations advance as currently contemplated. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2020, we had an accumulated deficit of $771.8 million.&#160;We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus (COVID-19) as a pandemic, which continues to spread throughout the world. Developments have been occurring rapidly with respect to the spread of COVID-19 and its impact on human health and businesses. To date, the COVID-19 pandemic has negatively impacted the global economy, created significant financial market volatility, disrupted global supply chains, and resulted in a significant number of infections and deaths worldwide.  In addition, several national, state and local governments have placed restrictions on people from gathering in groups or interacting within a certain physical distance and in certain cases, have ordered businesses to close, limit operations or mandate that people stay at home. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, although there has been some negative impact on our business and operations, including, for example, slowed clinical trial enrollment, we have been able to mitigate against more severe impacts of the COVID-19 pandemic on our business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on our business in the future depending on the depth of the effects and the duration of the crisis. In response to the COVID-19 pandemic, we have been focused on keeping our employees safe, continuing patients on trials, and maintaining our manufacturing capabilities and research efforts.  The COVID-19 pandemic is an evolving situation and we continue to monitor our business very closely to try and mitigate any potential impacts. We expect the pandemic to continue to have some near-term impact on the initiation of new studies and on clinical trial enrollment. For example, in consideration of the current COVID-19 pandemic, we delayed our planned Phase 2 study of enoblituzumab, an investigational, Fc-engineered, anti-B7-H3 monoclonal antibody, in combination with checkpoint blockade in patients with advanced head and neck cancer until the first quarter of 2021. In addition, we stopped </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enrollment in a Phase 1/2 study combining flotetuzumab with retifanlimab in patients with relapsed or refractory acute myeloid leukemia being conducted outside of the U.S.  Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize the product candidates in our pipeline. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we cannot precisely predict the impact that the COVID-19 pandemic will have in the future due to numerous uncertainties, including the severity of the disease, the duration of the outbreak, actions that may be taken by governmental authorities, the impact to the business of potential variations or disruptions in our supply chain, and other factors identified in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Form 10-K. Given these uncertainties, the COVID-19 pandemic could disrupt the business of certain of our collaborators and impact our business operations and our ability to execute on our associated business strategies and initiatives, and adversely impact our consolidated results of operations and/or our financial condition in the future. We will continue to closely monitor and evaluate the nature and extent of the impact of the COVID-19 pandemic to our business, consolidated results of operations, and financial condition. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. Incyte paid us an upfront payment of $150.0 million under the terms of the agreement. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte leads global development of retifanlimab. Assuming successful development and commercialization of retifanlimab by Incyte, we could receive total development and regulatory milestones of up to approximately $420.0 million and up to $330.0 million in commercial milestones. We received $55.0 million of the total development milestones through December 31, 2020 and an additional development milestone of $10.0 million was earned in February 2021. If retifanlimab is approved and commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement).</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Zai Lab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development in its territory. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million. Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones, of which we have already received $4.0 million ($3.6 million net of foreign withholding tax). In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">I-Mab Biopharma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In July 2019, we entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates our proprietary Fc Optimization technology platform. I-Mab obtained regional development and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by us. <br/><br/>Under the terms of the agreement, I-Mab paid us an upfront payment of $15.0&#160;million. Assuming successful development and commercialization of enoblituzumab, we could receive up to $135.0&#160;million in development and regulatory milestones. In addition, I-Mab would pay us tiered royalties ranging from mid teens to 20% on annual net sales in its territories.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Janssen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. (Janssen). The research collaboration will incorporate our proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the agreement, Janssen paid us an upfront payment of $20.0 million and will be responsible for funding all expenses. We will also be eligible to receive up to $312.0 million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_52"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue consists primarily of collaboration revenue, including amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, amounts earned by performing development and manufacturing services, research and development funding and milestone payments earned under our collaboration and license agreements with our strategic collaborators. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other research institutions on behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of expenses incurred in performing research and development activities. These expenses include conducting preclinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and development expense on a program-by-program basis for our product candidates and recognize these expenses as they are incurred. The following are items we include in research and development expense:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, such as salaries and benefits;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related overhead expenses, such as facilities and other allocated items;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock-based compensation expense to employees engaged in research and development activities;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">depreciation of laboratory and manufacturing equipment, computers and leasehold improvements;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our preclinical and clinical trials including, but not limited to, investigator grants, laboratory work and analysis, database management, statistical analysis, and other items;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts paid to vendors and suppliers for laboratory supplies;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal and third party costs related to manufacturing clinical trial materials, including vialing, packaging and testing;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">license fees and other third party vendor payments related to in-licensed product candidates and technology; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval.  The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance, legal and intellectual property, business development, human resources, information technology and other support functions, travel expenses and other legal and professional fees.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists of realized and unrealized gains and losses on equity securities and interest income earned on our cash, cash equivalents and marketable securities, offset by other expenses.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_55"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management's discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. The results of any material revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and the effect of the estimates and judgments we used in preparing our consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to launch MARGENZA in March 2021, but have not generated any revenue from product sales to date.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue under Accounting Standards Update (ASU) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s and all related amendments (collectively ASC 606) when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing agreements that are within the scope of ASC 606, under which we may license rights to research, develop, manufacture and commercialize our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. We may also enter into development and manufacturing service agreements with our collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, we identify all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, management estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, management considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. We must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, management&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. We do not include a financing component to its estimated transaction price at contract inception unless we estimate that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we grant a license to our intellectual property, we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to our intellectual property.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, we consider whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, management utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue we record in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under our agreements may include research and development or manufacturing services to be performed by us on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by us does not create an asset with an alternative use and we have an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, we evaluate whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, management evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, management reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by management. We account for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. We account for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs we incur for our own research and development activities and costs incurred by our collaborators under cost sharing arrangements. Research and development costs consist of salaries and benefits, including related stock-based compensation, laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on our behalf, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CROs and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract manufacturing organizations (CMOs). Research and development costs are expensed as incurred. We receive estimates from our collaborators when we are sharing development expenses, and use these estimates to record an increase or decrease in research and development expense, depending on how much we have each spent during the period. </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial expenses are a significant component of research and development expenses, and we outsource a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> When evaluating the adequacy of the accrued expenses, we analyze progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the largest amount that is more than 50% likely to be realized upon ultimate settlement. Our policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation awards in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 718). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the consolidated statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of each option award using the Black-Scholes option pricing model. The resulting fair value is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the option. The use of a Black-Scholes model requires us to make assumptions with respect to the expected term of the option, the expected volatility of our common stock consistent with the expected term of the option, the risk-free interest rate consistent with the expected term of the option, the expected dividend yield of our common stock and the expected forfeiture rate. </span></div><div style="margin-bottom:9pt;padding-left:10pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements for information under the caption "Recently Issued Accounting Standards."</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_58"></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:43.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $35.8 million in revenue from collaborative and other agreements for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 was primarily due to:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $40.0 million in development milestones from Incyte</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of the $20.0 million upfront license fee under the  Janssen Agreement;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of a $12.0 million payment from Boehringer Ingelheim International GmbH (BII) for retention of rights to two DART molecules during 2020;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $3.6 million in milestones under the Zai Lab collaboration and license agreement (Zai Lab Agreement) during the year ended December&#160;31, 2020; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.4 million recognized under the Incyte Commercial Supply Agreement which was executed in 2020.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $13.5 million in revenue recognized under the Incyte Clinical Supply Agreement due to decreased development activity;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $11.1 million in revenue recognition of the deferred upfront payment under the Zai Lab Agreement during the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased revenue recognition of approximately $10.6 million of the Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) flotetuzumab license grant fee during the year ended December&#160;31, 2020 due to Servier's notice of their intention to terminate the agreement effective January 15, 2020; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased revenue recognition of $6.0 million of the F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche) upfront payment during the year ended December&#160;31, 2020 due to Roche's termination of the agreement effective November 2019.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $4.9&#160;million in revenue from government agreements for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 was primarily due to increased clinical trial activity of MGD014 and development of the second DART molecule.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expenses for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:43.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flotetuzumab (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DART molecules under HIV government contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMGC936</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">195.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) 2019 expenses are shown net of reimbursements from collaboration partner.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Includes research and discovery projects, as well as early preclinical and terminated molecules.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the year ended December&#160;31, 2020 decreased by $2.1 million compared to the year ended December&#160;31, 2019. This decrease was primarily attributable to:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial costs related to our enoblituzumab studies;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased costs related to margetuximab postBiologics License Application submission; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased spend on certain preclinical programs as well as decreased clinical trial costs related to MGD007 and MGD009 as these programs have been discontinued; </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased flotetuzumab development costs due to increased clinical trial enrollment and regulatory costs, and the end of cost sharing with Servier; </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development and manufacturing costs related to the second DART molecule under our contract with the National Institute of Allergy and Infectious Diseases (NIAID); and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development and manufacturing costs related to retifanlimab due to timing of manufacturing activities for Incyte.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our general and administrative expenses for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses decreased for the year ended December&#160;31, 2020 by $3.4 million compared to 2019 primarily due to decreased spend on external expenses, including consulting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in other income of $24.1 million for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 is primarily due to  the revaluation at June 30, 2019 of the warrants received under the Provention License Agreement and Asset Purchase Agreement and decreased investment income.  The warrants were exercised, and the acquired shares subsequently sold, during 2019, therefore no such revaluation is reflected in other income during the year ended December&#160;31, 2020. </span></div><div><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_61"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from NIAID.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments,  to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization.  Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2020, anticipated and potential collaboration payments, and product revenues should enable us to fund our operations into 2023, assuming our programs and collaborations advance as currently contemplated.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to our business, the COVID-19 outbreak might unfavorably impact our ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, we will continue to evaluate the nature and extent of the impact of the outbreak on our business and financial position.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:48.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(93.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by or used in operating activities reflects, among other things, the amounts used to advance our clinical trials and preclinical activities. The principal use of cash in operating activities for all periods presented was primarily the result of our net loss, adjusted for non-cash items, with the year ended December 31, 2020 benefiting from the $40.0 million in milestone payments received from Incyte, the $20.0 million upfront payment from Janssen, and the $12.0 million received from BII.  The year ended December 31, 2019 benefited from the $22.5 million net upfront payment from Zai Lab and the $15.0 million upfront payment from I-Mab. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities during the years ended December&#160;31, 2020 and 2019 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the years ended December&#160;31, 2020 and 2019 reflects net cash proceeds from our securities offerings of approximately $170.5 million and $118.7 million, respectively, and cash from stock option exercises and the purchase of shares under our employee stock purchase plan.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_64"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Contingent Liabilities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current obligations and contingent liabilities are limited to the operating leases at our facilities in Maryland and California.&#160;The following table represents future minimum operating lease payments under non-cancelable operating leases as of December&#160;31, 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:28.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 1 year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1 to 3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3 to 5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 5 years</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_67"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_70"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;As of December&#160;31, 2020, we had cash, cash equivalents and marketable securities of $272.5 million.&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_73"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is set forth beginning on page F-1 in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_76"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL DISCLOSURE</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_79"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this Annual Report on Form 10-K has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure.&#160;Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and has concluded that there was no change that occurred during the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2020 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company's principal executive and principal financial officers and effected by the Company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2020.&#160;In making this assessment, the Company's management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in Internal Control-Integrated Framework.&#160;Based on our assessment, management believes that, as of December&#160;31, 2020, the Company's internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2020 has been audited by Ernst &amp; Young, LLP, an independent registered public accounting firm, as stated in their report which is included herein on the following page.</span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_82"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited MacroGenics, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, MacroGenics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2020, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2020, and the related notes and our report dated February&#160;25, 2021, expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baltimore, Maryland</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_91"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the 2021 annual meeting of stockholders (the 2021 Proxy Statement).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_94"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning executive compensation to be included in the 2021 Proxy Statement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_97"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be included in the 2021 Proxy Statement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_100"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. &#160;&#160;&#160;&#160; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the 2021 Proxy Statement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_103"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning principal accountant fees and services to be included in the 2021 Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_109"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. &#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Consolidated Financial Statements:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_121">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_121">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_124">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_124">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations and Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders' Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_139">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb3df34c6cd545b49b40a9d09c99e0a0_139">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statement Schedules:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.&#160;</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Exhibits</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_112"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:47.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MacroGenics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and CEO and Director</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:29.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and CEO and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Financial</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officer and Secretary (Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lynn Cilinski</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Controller and Treasurer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lynn Cilinski</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paulo Costa</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paulo Costa</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kenneth Galbraith</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth Galbraith</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Edward Hurwitz</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edward Hurwitz</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Stump, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stump, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_121">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_121">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_121">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_124">Consolidated Balance Sheets at December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_124">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_124"> and December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_124">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_124">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_124">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_124">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130">, 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130">9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130"> and 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130">8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_130">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133">Consolidated Statements of Stockholders' Equity for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133">, 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133">9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133"> and 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133">8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_133">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136">Consolidated Statements of Cash Flows for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136">, 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136">9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136"> and 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136">8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_136">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_139">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_139">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb3df34c6cd545b49b40a9d09c99e0a0_139">7</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. (the Company) as of December&#160;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;25, 2021 expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated</span><span style="background-color:#f4f4f4;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Accruals</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Note 2 to the consolidated financial statements, the Company expenses research and development expenditures as incurred, which include costs relating to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the clinical research organizations (CROs), investigators, professional service providers, and other vendors providing development services (collectively, the &#8220;service providers&#8221;). The Company&#8217;s clinical trial accrual balance at December&#160;31, 2020 is included in accrued expenses and other current liabilities of $34.2&#160;million on the consolidated balance sheet, and the Company&#8217;s related 2020 clinical trial expenses are included in research and development costs and expenses of $193.2&#160;million on the consolidated statement of operations and comprehensive loss for the year ended December&#160;31, 2020.  </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s accruals for clinical trial costs involved complex and subjective auditor judgment due to the significant estimation required by management in determining the progress to completion of services that have been performed by the service providers and the associated costs that will be invoiced by the service providers subsequent to the date that the consolidated financial statements are issued.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls addressing the identified risks related to the Company&#8217;s process for estimating accrued clinical trial costs. For example, we tested controls over management&#8217;s review of the clinical trial expense calculations, the significant assumptions about the status of research and development services incurred, and the completeness and accuracy of the data used to calculate the estimates.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the clinical trial accruals, our audit procedures included, among others, reviewing a sample of agreements with the service providers to corroborate key financial and contractual terms, and testing the accuracy and completeness of the underlying data used in the accrual computations. We also evaluated management&#8217;s estimates of the progress of a sample of clinical trials by making direct inquiries of the Company&#8217;s operations personnel that oversee the clinical trials and obtaining information directly from certain service providers about  the service providers&#8217; estimate of costs that had been incurred through December&#160;31, 2020. To evaluate the completeness of the accruals, we also examined subsequent invoices from the service providers and cash disbursements to the service providers, to the extent such invoices were received, or payments were made prior to the date that the consolidated financial statements were issued.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernst &amp; Young LLP</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2006.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baltimore, Maryland</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 2</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzQtMS0xLTEtMA_69cd1bf5-2d48-4e70-918a-8b0d4dcfefdb">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzQtMy0xLTEtMA_9b6d7e54-f5b8-4b85-8cd5-f157f807e890">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzUtMS0xLTEtMA_bae57728-4a23-4559-8231-3c98559ae88f">91,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzUtMy0xLTEtMA_c5a77be7-785c-44b3-94f8-c32222b55c95">89,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzYtMS0xLTEtMA_a99e62e9-ec2f-4c35-8392-5e4e870fb35f">23,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzYtMy0xLTEtMA_228d9040-7db1-46e9-865d-7860115801f1">12,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzctMS0xLTEtMA_f7d17490-79f6-4f8f-b09a-95a101a31c2b">16,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzctMy0xLTEtMA_5aa78ce5-731c-4eb4-883d-ffac5fa770d0">11,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzgtMS0xLTEtMA_a97f545f-8f32-4146-89ec-9246cd6d1a2f">312,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzgtMy0xLTEtMA_091b7ded-38da-45b7-8584-fbfefdc66a78">239,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEwLTEtMS0xLTA_fa63bbd3-38e0-40c2-b50c-dd863e01ffce">42,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEwLTMtMS0xLTA_ab6ec637-72e6-43dc-aa78-e73b97d6611d">48,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEyLTEtMS0xLTA_721bc0cf-2d3a-4ab1-9b0e-e9e023a0129e">23,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEyLTMtMS0xLTA_0f6b328e-ab84-434b-8ec3-8709b160706f">24,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEzLTEtMS0xLTA_8d443e8c-2adc-40fb-9f71-32e59379edd3">378,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEzLTMtMS0xLTA_6c69417c-19f5-44de-8335-1c0678aab9c8">312,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE3LTEtMS0xLTA_bd144eca-1aef-4e0a-830d-790e65cc3cb1">8,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE3LTMtMS0xLTA_3dfe91a0-576d-44bf-8fcd-b53c17472bc1">4,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE4LTEtMS0xLTA_de9e0b8d-a7fc-4f9d-a6ff-2de65358582d">34,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE4LTMtMS0xLTA_7dab686c-4e2e-4a2f-97f1-5851cb06a22a">27,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE5LTEtMS0xLTA_9858a8b2-85da-4e53-9d0c-ef9768eed325">4,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE5LTMtMS0xLTA_7951e1e6-a26e-48a1-893b-792ba9992fa6">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzIxLTEtMS0xLTA_be198c08-2552-475e-b72c-e75c3abb7937">3,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzIxLTMtMS0xLTA_9c3cf3e2-ae74-4b2e-9fca-64f13744c19b">3,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzIyLTEtMS0xLTA_83f553df-f943-4e57-a969-054ab8d5a1b6">50,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzIyLTMtMS0xLTA_ca58380c-bb0b-4091-8545-33ae31a49449">45,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI0LTEtMS0xLTA_fcb4cffe-6656-4465-8519-f55c7f519b07">6,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI0LTMtMS0xLTA_6eca7302-1c02-48e7-9821-476319ed2179">9,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI1LTEtMS0xLTA_3b01757d-8ba1-4466-bd26-c6fc8ca995aa">25,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI1LTMtMS0xLTA_74ee6b7d-96b9-42d3-8f3c-5d2391f05506">27,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI3LTEtMS0xLTA_233e0f52-f70f-4f4c-b17c-64566971b4fb">82,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI3LTMtMS0xLTA_991bf9d7-c282-4e23-b89b-8552d7f76179">81,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YTQxNjYxMTkxOTE0ZWU2YTZhNGE5YmQ4MzZkMDk0Ml8xMjA5NDYyNzkwNTcxMA_c74e454c-fcf2-4815-b7bb-230f3a8455e7">0.01</ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YTQxNjYxMTkxOTE0ZWU2YTZhNGE5YmQ4MzZkMDk0Ml8xMjA5NDYyNzkwNTcyNA_1badbbec-521c-46a9-8eeb-8f4fd81e0295">125,000,000</ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YTQxNjYxMTkxOTE0ZWU2YTZhNGE5YmQ4MzZkMDk0Ml8xMjA5NDYyNzkwNTczNw_87091f99-9164-4b73-9d69-149921b6063c">56,244,771</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YTQxNjYxMTkxOTE0ZWU2YTZhNGE5YmQ4MzZkMDk0Ml8xMjA5NDYyNzkwNTc1MA_181da95b-8567-48e5-93b8-e585d458ed13">48,958,763</ix:nonFraction> shares outstanding at December&#160;31, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTEtMS0xLTA_dcb77079-7f26-4f0d-aadb-5da7dc702cf7">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTMtMS0xLTA_b2bc59a3-3f21-4b86-9707-23854e34e493">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMxLTEtMS0xLTA_9749ecf0-3550-4c67-9ac7-387dbf0db54a">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMxLTMtMS0xLTA_24309a09-5bf2-4987-9fc7-eaafde64061d">872,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMyLTEtMS0xLTA_e98d4bd7-c1d5-4f88-b603-84d3a2ee3809">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMyLTMtMS0xLTA_0c264a54-be69-4598-a973-1695e5356893">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMzLTEtMS0xLTA_b66f3f1b-dd15-4d5b-99ec-05a007bfd5a7">771,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMzLTMtMS0xLTA_51b5dbed-5328-400d-a3eb-e4c889faa9e7">642,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzM0LTEtMS0xLTA_e22a51d9-37ed-4166-9aee-e492205d5eef">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzM0LTMtMS0xLTA_cdb28905-d9e8-4788-9120-0001e1bae6cb">230,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzM1LTEtMS0xLTA_13656696-ede5-418f-b484-f1e849c8ba2f">378,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzM1LTMtMS0xLTA_0455d6b5-2e5b-49f2-a38f-61ec1770465f">312,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 3</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d808e02b5414fd683b155299253411e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzMtMS0xLTEtMA_7498dffe-4ab4-4f64-a1bd-56eefbca3562">97,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64fda6eae444b93b571cf566d3a92d0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzMtMy0xLTEtMA_5e3513bd-eb56-4fae-b59a-e4220114ae8d">62,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaef0c61fb24481cbdacd565ae79023e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzMtNS0xLTEtMA_02141b58-7e27-47c3-9e40-e67984ab5484">58,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1559cf83494ef1ad022048d27be8c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzQtMS0xLTEtMA_64399e32-81e4-43b7-899e-6778c45aa3b6">7,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24fcde07e22449f18988a9bb4909c03b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzQtMy0xLTEtMA_262331b6-2224-402d-bd24-f43168b02d4e">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3742a3dcd1cd4e018f4a0e55e544bf88_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzQtNS0xLTEtMA_1eda37e2-dbd5-4da7-a6ff-c046b76c097f">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzUtMS0xLTEtMA_48ef908d-e677-4e52-88d8-1b1d2513f647">104,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzUtMy0xLTEtMA_bbacd4d1-805a-4d28-a80b-7784e5520439">64,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzUtNS0xLTEtMA_21ae7cc4-14d0-42da-a7a6-0fb4a9a426bf">60,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzgtMS0xLTEtMA_e0128c10-716a-4c55-9229-89b428a6fc83">193,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzgtMy0xLTEtMA_e9643b9e-308b-49ad-bbf1-50b3dd79570c">195,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzgtNS0xLTEtMA_2bd21668-f088-452d-a6be-e478590aef0e">190,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzktMS0xLTEtMA_fdb2a10d-bf3e-4382-aee5-7f24fb98a479">42,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzktMy0xLTEtMA_78b0e341-5e0a-477e-8ca0-d71b41d4f36b">46,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzktNS0xLTEtMA_6a07773d-a0be-4709-8f02-c0b75bf66e5c">40,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEwLTEtMS0xLTA_13dcc533-024f-4266-8bb0-a0dc43cf3954">235,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEwLTMtMS0xLTA_8e88c751-b71b-4548-b030-c222d88054a0">241,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEwLTUtMS0xLTA_b40708de-80d5-4c90-b698-f59f300f786c">231,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEyLTEtMS0xLTA_895c256a-24f7-4d4a-b238-6953d49ecdb4">131,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEyLTMtMS0xLTA_dfe27487-06ab-4871-a911-2a8ac00061c8">177,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEyLTUtMS0xLTA_bd26dada-3025-4956-86d0-9a8f4da92996">171,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE0LTEtMS0xLTA_8e372d93-0362-4a90-852c-e719ad9dc5cd">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE0LTMtMS0xLTA_f5392724-90ee-4c41-b4aa-748d8835bfa7">25,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE0LTUtMS0xLTA_80109485-963c-48d5-a9e2-0f516394c214">247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTEtMS0xLTA_ccdf9bae-4b08-4de2-8718-17bde981d665">129,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTMtMS0xLTA_7938d377-40c4-4d50-bb48-94f980e068e4"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTMtMS0xLTA_87bc885e-4bb6-47f5-b432-1c88b8fdad11">151,811</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTUtMS0xLTA_18676b7a-f21d-4f3e-b3ea-de5ae60b1d90"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTUtMS0xLTA_722bad81-c7bb-4101-85c3-682ff2680af3">171,453</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE4LTEtMS0xLTA_9e8d0925-9b02-4a08-b70f-80a0f13afeb7">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE4LTMtMS0xLTA_3dea409f-6f6d-4c94-9042-46a4c47f484c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE4LTUtMS0xLTA_7394003c-d985-4b43-9453-75045994e29a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE5LTEtMS0xLTA_b2f5930b-e590-47fc-9cec-75f0e0596b24">129,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE5LTMtMS0xLTA_cfb9bc7f-96bd-438b-8b6e-f41b78d447a4">151,792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE5LTUtMS0xLTA_8fb12bce-643a-47fc-aaea-d91ed7cc9e0e">171,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIyLTEtMS0xLTA_9ae5542d-487f-43c8-8f93-499780197076">2.47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIyLTMtMS0xLTA_2d40f29b-c4dd-4410-9632-38130bb1e344">3.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIyLTUtMS0xLTA_59ce7e99-4283-479e-8207-e6f2436ae6a9">4.19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average number of common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIzLTEtMS0xLTA_915ac1a4-3724-4f9b-a689-d19cea95d0e8">52,442,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIzLTMtMS0xLTA_11338f96-78ad-493e-9519-e757f6507771">48,082,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIzLTUtMS0xLTA_5d383816-df58-4dee-bd64-f91cf7840b5b">40,925,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 4</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.134%"><tr><td style="width:1.0%"></td><td style="width:32.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.298%"></td><td style="width:0.1%"></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e9de6b275e1488fb3fb628e6f009da2_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMS0xLTEtMA_17abb31d-eb9e-452b-88d0-7b93f4c2306f">36,859,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9de6b275e1488fb3fb628e6f009da2_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMy0xLTEtMA_721dc3c9-ecd9-4664-b03b-2aabaca762d6">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e401a1ba9e34e4b90951902947848c6_I20171231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtNS0xLTEtMA_c5f5742a-a095-42d6-a76f-7e29d5875352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e401a1ba9e34e4b90951902947848c6_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtNy0xLTEtMA_d7d23fd3-65a0-4696-b92c-fd409a71c616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d36892fdb74f70add306d4b9acf8f2_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtOS0xLTEtMA_f08c2ad6-ffb8-4608-ac73-5ead95bec810">611,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide6e365cd9374fd0bc37f252d29fd753_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMTEtMS0xLTA_0d46bcd8-8067-422e-b26a-7c942f751f4f">312,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c020d90e65547508df10ef8295c9c46_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMTMtMS0xLTA_507bdb4f-84ea-4e22-ae94-a91e991919de">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia662d353fd8d45c0b6ef76a73d9eab63_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMTUtMS0xLTA_d6a0287b-99be-44c1-91eb-e41e4907d92f">299,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of adoption of accounting standards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c8abb81fc54045a728f7789e5eb590_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzQtMTEtMS0xLTI5NjQ_c1f0f23a-7f3b-42da-8d1f-1a5927309f8d">6,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92ef7adb07344ad083846bfb3d0940f6_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzQtMTUtMS0xLTI5NjQ_a3282664-3cfb-4400-8ccf-b3725f8dfd1b">6,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzQtOS0xLTEtMA_befe111f-0199-4110-9891-d1a90fc4fde7">16,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzQtMTUtMS0xLTA_c915002d-fde1-4c0c-b8b5-99e130bf39a4">16,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzUtMS0xLTEtMA_ca37a27d-2be7-4890-956c-4e8348b05fb8">5,175,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzUtMy0xLTEtMA_d6330369-5986-47c8-ba6a-f3c05bb50b24">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzUtOS0xLTEtMA_a4f440c3-c197-4fe2-bfdc-239abbda274e">103,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzUtMTUtMS0xLTA_21c1bd45-c68c-4075-8f9c-f4dcddd77d88">103,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtMS0xLTEtMA_2233279b-8966-4079-a23c-29a20ad68a89">319,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtMy0xLTEtMA_a76ca471-9bb5-42e2-9e57-2e0e32064aec">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtNS0xLTEtMA_bb75434f-9e5b-47cc-a226-153e021239b5">11,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231" decimals="-3" sign="-" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtNy0xLTEtMA_21449a88-820b-499d-b667-c08a0de48709">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtOS0xLTEtMA_0c3bced3-ad8a-4f2d-8023-d1ff7a4f5740">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtMTUtMS0xLTA_7e44b43d-e629-4143-b0e5-2631f670b65c">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzctNS0xLTEtMA_7c6597e8-c03f-4ad0-8e4c-d6f16e664dc1">11,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzctNy0xLTEtMA_318b691e-a980-432f-b083-e938c5f3faf9">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231" decimals="-3" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzctOS0xLTEtMA_4e08f7f6-3ef4-4e98-9185-f3241e48eded">260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzctMTUtMS0xLTA_eee1d6de-98c6-4f97-8a46-fa1f5eac57b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00868bdc70444b5996012f6dc5d03f8_D20180101-20181231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzgtMTMtMS0xLTA_2a440000-8048-455d-af62-9c99e1bd5d2a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzgtMTUtMS0xLTA_e953070b-48b1-4540-8ae9-fa678ee05f4f">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03dc58ff992a4affb3ae912e7726fd5f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzktMTEtMS0xLTA_5f35e5b4-4960-4970-bc96-5475190742e5">171,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzktMTUtMS0xLTA_991844bf-e554-4459-9636-1e4d587c6c1a">171,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32cb1a93d9784446861b4351c65a06ab_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTEtMS0xLTA_96846b4d-aa44-4116-bc25-cdd176c3936a">42,353,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32cb1a93d9784446861b4351c65a06ab_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTMtMS0xLTA_acabf7a0-a879-474c-a8d3-7464164471ea">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34837cef321c44a6880d4682ed958ef8_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTUtMS0xLTA_15490734-0773-4070-917e-2d8ca7f82e45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34837cef321c44a6880d4682ed958ef8_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTctMS0xLTA_d9eef554-4be7-4ace-8a87-4f1080b6717d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9a43579b4d5441d9adfda3882db2702_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTktMS0xLTA_6fe0ce15-a4ce-48b0-ae36-3e717529082a">732,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17c88315085b4a6b86cc704010cbb3b8_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTExLTEtMS0w_101048f6-e654-4df8-8c03-cee3371b661b">490,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ffdf5a5082a4f03a6ddd2697f0ab3aa_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTEzLTEtMS0w_39f0eaa4-1c7b-427e-b6fe-b6715f0ec9bf">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTE1LTEtMS0w_67867ee9-0dd7-420c-99e7-0344fef25b03">242,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826687038ea842c986973786b645a9e0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEyLTktMS0xLTA_963a983b-bc1a-449a-8eac-67300ff70af3">19,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEyLTE1LTEtMS0w_8353e228-d556-4aa4-b2bd-80251882f704">19,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEzLTEtMS0xLTA_72c41cee-8f28-4eb2-ada4-a5d7eb0d502d">6,325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEzLTMtMS0xLTA_31feae28-899c-4089-bbb4-c64ec5559449">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826687038ea842c986973786b645a9e0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEzLTktMS0xLTA_78e3a52c-bf34-422e-8e77-0a36667c49aa">118,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEzLTE1LTEtMS0w_cc9ee109-fce3-498f-beb0-d48783cbd05a">118,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE0LTEtMS0xLTA_f0d66c37-affc-4d47-966e-f7a548d72759">280,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE0LTMtMS0xLTA_8e590438-91f8-4dcc-b7f5-c0ddf4b724d2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826687038ea842c986973786b645a9e0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE0LTktMS0xLTA_d911ff74-c0e5-4915-92a1-cd9887f8bfc3">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE0LTE1LTEtMS0w_a7d079f8-0952-4aa1-9e23-61b3f512d1b2">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ad1dc4801847e1b315ea5729b88e91_D20190101-20191231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE2LTEzLTEtMS0w_d958116b-d7b8-406b-9894-9384a8d5f5fc">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE2LTE1LTEtMS0w_a3142c06-5860-4210-80a5-2c8e1ad3e2ca">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i901563a826804698862205071e209880_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE3LTExLTEtMS0w_9f998843-815e-4ef9-a18e-384bb76f1f66">151,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE3LTE1LTEtMS0w_799cdbd5-4d19-4a59-83d5-b7c0833cfb75">151,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a1a0c6402b943b9b4b2ba26940be870_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTEtMS0xLTA_c4e886a4-88be-48b2-ab35-89d4d01595be">48,958,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a0c6402b943b9b4b2ba26940be870_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTMtMS0xLTA_3b5dff68-56cf-42d3-be40-457f1af854da">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e6db4aa25b74df5abc90db0f02b82a6_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTUtMS0xLTA_89dd57f0-3444-472a-a200-43c185eaaa85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e6db4aa25b74df5abc90db0f02b82a6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTctMS0xLTA_aa3c539c-4133-41f6-841e-38385df32e68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09fcd6ed15e4fc0be1acdc77c4500f9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTktMS0xLTA_ef9fe4f5-0015-4eea-95ba-3049f169f91f">872,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ef16e4c63d6480f96951c6f7eac9ca2_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTExLTEtMS0w_8edb270f-f81d-46d4-ac08-0dd4f4546d13">642,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff38bc7672c14b59938322f49d658a0c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTEzLTEtMS0w_7bf9ec6b-e1d3-4608-b847-fb2229847354">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTE1LTEtMS0w_3f5df558-3851-49e8-8e79-9f949c6a27d3">230,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIwLTktMS0xLTA_dc596316-b3ea-4bb0-9e27-5fc50909e9c0">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIwLTE1LTEtMS0w_38c3a676-2ed4-494e-8c62-68734b918c5f">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIxLTEtMS0xLTA_d070db29-6bb4-4f01-b8f9-443bcf986669">6,612,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIxLTMtMS0xLTA_2ea13662-6072-4e6d-924b-d050ea242d29">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIxLTktMS0xLTA_04e9bd92-f2eb-42c8-a4a2-c81bc9404fd1">170,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIxLTE1LTEtMS0w_2cc9738d-c3f1-4995-82f6-044cc1983af9">170,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTEtMS0xLTA_ef62218e-857e-408d-8846-38fea3356a3f">673,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTMtMS0xLTA_4666944f-72dd-4b36-aff5-332dd58dc3eb">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTUtMS0xLTA_bcdbc68f-2bc8-446e-9396-c887f5306fa5">74,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTctMS0xLTA_d40ad346-064f-4ba9-800a-92c186c8c389">2,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTktMS0xLTA_47a9c84d-cc36-4ebf-bcb8-28f14b0db2fe">5,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTE1LTEtMS0w_a41c4eff-5307-4414-a05f-b25caed6648f">3,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIzLTUtMS0xLTA_de6f7547-b25c-41d5-92ed-e2dff60b2aef">74,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIzLTctMS0xLTA_0f62d69d-dde2-4745-af68-35a5005a203d">2,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIzLTktMS0xLTA_4c0f98a4-7f02-4a5d-846f-9331cb84f6e8">2,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIzLTE1LTEtMS0w_92ff219c-932b-4cf3-8ac8-9d5fe10d3722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0267b9d993f432e9f8c8b2e9d4c1098_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI0LTEzLTEtMS0w_b6379234-084a-4a7f-9638-4fea0796fc3e">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI0LTE1LTEtMS0w_ae696ad1-2c45-4ec9-82a5-056fa66493fd">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9104c83bf7314b29a4d988eed8111854_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI1LTExLTEtMS0w_f0ce53a6-1ebd-4a20-8667-2750299eb13c">129,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI1LTE1LTEtMS0w_bd0e7ae9-c579-4c2d-a6ad-3d08e8d8405c">129,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1ca2685a1e44ec89c539d7bc50c9ed0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTEtMS0xLTA_6d3c4bfe-67e0-40d9-a96a-cdff67d3b87c">56,244,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ca2685a1e44ec89c539d7bc50c9ed0_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTMtMS0xLTA_37cd0303-dc41-489c-a83c-1e59f8175834">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedec7a9d1790449ea17afb27d64d25ef_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTUtMS0xLTA_b010fe68-df8a-4c77-9ffc-c900c50de2d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedec7a9d1790449ea17afb27d64d25ef_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTctMS0xLTA_c3f6d226-275e-4d20-a281-a39dfa178c87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib51c8e9f97bb45179d0e2ff8204fe9a8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTktMS0xLTA_71fd483c-7780-4709-a868-edad79f75ca3">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148cd0120f7c4ce5b2a1fe9a8db994bf_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTExLTEtMS0w_0913d12f-beb5-4533-ba56-2fa5d4f865f0">771,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibddef6e763f54b939c512d3cd30c5215_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTEzLTEtMS0w_62712a81-ddc4-4ef6-ba34-188be0051cca">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTE1LTEtMS0w_22a43ba2-341f-4b5b-b824-b5d18adba80b">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 5</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMtMS0xLTEtMA_5b0ec87f-8a14-438c-9bb5-145057a189ad">129,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMtMy0xLTEtMA_729c37be-d48a-438e-ab6c-a0c36602f144">151,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMtNS0xLTEtMA_2c15afda-468b-4ed7-8ffb-cff5021311f0">171,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzUtMS0xLTEtMA_7780a488-028c-4f86-ba45-11e560071594">11,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzUtMy0xLTEtMA_a26a338d-c3a3-467b-a88a-157ccc327f35">12,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzUtNS0xLTEtMA_49a1ebfd-3d06-4d4c-9cab-a80f769e37b8">9,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtMS0xLTEtMTI5_dfcbdfb8-110a-46e2-ab4e-5bc97439f9f6">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtMy0xLTEtMTI5_fac96b43-57f6-405a-a002-b3a364f86c09">1,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtNS0xLTEtMTI5_fc2833ec-7013-4bc1-b92e-e755734cd6a7">881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtMS0xLTEtMA_897d65f4-814a-48f3-8721-94e7d2fdd249">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtMy0xLTEtMA_484ac33d-3e25-482d-be8f-ba4a8cb4df34">19,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtNS0xLTEtMA_a1b3fd80-a50d-4029-b02f-718352187ca2">16,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzgtMS0xLTEtMA_cc353fe8-c642-4fa5-89a0-40b7d336cc96">10,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzgtMy0xLTEtMA_7b030849-5b91-479d-9ca1-bf66828e6408">16,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzgtNS0xLTEtMA_b25d1adb-5ee9-408e-9552-017eb64875a3">15,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzktMS0xLTEtMA_14ffcce3-c698-4cb1-83b0-b5be62a98b80">5,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzktMy0xLTEtMA_21a6242b-f07c-4a03-8851-f24c11b38142">4,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzktNS0xLTEtMA_65d5059a-742e-4071-a6fa-8fdfb92ea109">3,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzExLTEtMS0xLTA_1f8df8bf-e276-41bf-a823-0b6ea0cd65a3">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzExLTMtMS0xLTA_c59fcfea-1548-4d6e-8cfa-3a05915dab33">1,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzExLTUtMS0xLTA_db3de445-8898-4aec-8e65-83a2a632df7f">4,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEyLTEtMS0xLTA_b60cedf9-bdeb-4afc-a014-86b5edd8943c">3,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEyLTMtMS0xLTA_a9b4f7fb-e880-43dd-96bb-8410aa5c699e">787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEyLTUtMS0xLTA_d3165823-8c72-4cf8-ba51-2a65899da7b3">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEzLTEtMS0xLTA_c465acc0-3cb5-4fc7-bf47-7930bcb45527">6,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEzLTMtMS0xLTA_9ddbaac7-83ca-4008-8f95-968c0a166a25">6,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEzLTUtMS0xLTA_758614e7-da3b-41e2-ae40-b70035ae4a68">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE0LTEtMS0xLTA_e27cd8c3-48ee-4436-8920-f83b8727750e">1,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE0LTMtMS0xLTA_c7aefd63-8a4b-4b5f-87b7-817ae6c869b8">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE0LTUtMS0xLTA_e6f6cd19-3fbe-4bab-abf1-15d9b75cc3ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE1LTEtMS0xLTA_911ecf16-532d-45d1-b308-66c730c3013d">8,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE1LTMtMS0xLTA_b28b918b-b720-4d44-8c33-6c39fe8ba04b">20,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE1LTUtMS0xLTA_e145becc-5503-4959-84e1-a7629a9a293c">13,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE2LTEtMS0xLTA_e3cc61af-1531-445e-a94c-73a87fa51b9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE2LTMtMS0xLTA_4b3ceee2-1dd8-4cee-bdbf-01c2b4510281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE2LTUtMS0xLTA_18fdc29e-6790-43b5-9217-3358e2648bcc">971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE4LTEtMS0xLTA_629926d8-253d-4d75-b958-c7f32e0ddc0f">111,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE4LTMtMS0xLTA_7a7d0575-acf7-4ce5-a8d3-af0194f9983a">134,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE4LTUtMS0xLTA_91a644a0-1bb6-4e35-b020-03288bfcc713">153,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIxLTEtMS0xLTA_d3a0b061-8244-4fe0-9e40-d4360a084f19">223,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIxLTMtMS0xLTA_d5ae7b41-b60e-4331-b190-b469c95c4adb">264,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIxLTUtMS0xLTA_7f6abb49-b4c5-4382-9c12-5c9b9b1bfebd">132,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIyLTEtMS0xLTA_ef90b096-95bb-4430-a305-f6bb7ca07de2">221,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIyLTMtMS0xLTA_934ed471-4b24-4494-94fd-473e79c64786">189,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIyLTUtMS0xLTA_8fc32be3-a722-44b0-afd0-58c425690e33">214,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIzLTEtMS0xLTA_8536e411-ad28-4f09-b483-1a22b7c901b7">5,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIzLTMtMS0xLTA_a30eba95-bd95-42d6-a6c0-25315476be0d">4,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIzLTUtMS0xLTA_687f8b58-d566-4909-874a-153ed176c089">24,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI0LTEtMS0xLTA_87bb87fb-d9c5-416b-9d94-0f05b8d4af46">7,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI0LTMtMS0xLTA_88be25fb-89aa-44dd-ac1a-626d3e6cec36">79,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI0LTUtMS0xLTA_eea1d5c9-6f94-4927-ab41-b4e62eff553b">56,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI3LTEtMS0xLTA_643029cf-2696-462a-a7b7-72a4f0c77263">170,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI3LTMtMS0xLTA_cad2f146-095c-4b26-8c04-eeffc4478105">118,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI3LTUtMS0xLTA_d2d7fadc-284c-49cc-8616-44b83639da46">103,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI4LTEtMS0xLTA_c6f3fd34-ba94-43ae-afd0-d79fe93c3aa6">5,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI4LTMtMS0xLTA_2b5818e2-13da-4023-a50a-a59319674993">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI4LTUtMS0xLTA_39459c22-9df5-4766-8d2e-552c376640e6">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI5LTEtMS0xLTA_97b13c1c-df89-4d9a-885c-ed8f2a48177e">2,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI5LTMtMS0xLTA_fa439d26-c6f3-4dea-911e-6cfd00be0af9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI5LTUtMS0xLTA_05a783cd-6bf9-4bb2-ae82-e4d2fc61df32">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMwLTEtMS0xLTA_0c3347f0-137e-4539-939a-4874a2c0002c">174,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMwLTMtMS0xLTA_0196a387-7074-4c67-b7b5-03ded124bdd7">119,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMwLTUtMS0xLTA_dacc2c0f-37ac-4992-8b14-3ada1ccdcbff">104,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMxLTEtMS0xLTA_f33546bc-c8f7-42b3-ae0f-140ca92947c2">54,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMxLTMtMS0xLTA_8f97ab70-c504-4a70-a7ff-c48ad7cc1fe8">93,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMxLTUtMS0xLTA_8925c884-381f-4782-a37d-0f0f18dce602">8,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMyLTEtMS0xLTA_6d7835bf-4e3b-4d28-b166-2aebef0dd9e3">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMyLTMtMS0xLTA_26a06462-2909-47ce-8095-df2afa089319">220,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia662d353fd8d45c0b6ef76a73d9eab63_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMyLTUtMS0xLTA_3c7e6491-7f5a-4d4d-bdd8-a4b91373d0de">211,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMzLTEtMS0xLTA_ce66c715-c961-415c-b4c1-fd75d3407bff">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMzLTMtMS0xLTA_9274b7bd-883c-4631-a8ac-7b2830e9ccc9">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMzLTUtMS0xLTA_9f5d091c-05f6-4b2b-b782-33e0d0c02bdb">220,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash operating and investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets modified in exchange for operating lease obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM2LTEtMS0xLTA_3d500518-58d5-4205-8d3d-5142683c5cb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM2LTMtMS0xLTA_b631f9f4-c857-4f94-bd29-bf8a5ad26197">6,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM2LTUtMS0xLTA_892b824c-dc84-4f74-bf1b-cff7aa01acae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of warrants received</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM3LTEtMS0xLTA_66ac7c44-1350-477e-bec7-55d5f55efe10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM3LTMtMS0xLTA_3eac1d89-db1e-43f9-8a5b-c493869feb88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM3LTUtMS0xLTA_628be2f4-bf48-4f6b-9126-2d83cca26bd1">6,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 6</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_142"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDIvZnJhZzpjYzhjMjA3ZGNjMjY0OGM3YTQ4MDU5OTVhYTI3YTQ0OC90ZXh0cmVnaW9uOmNjOGMyMDdkY2MyNjQ4YzdhNDgwNTk5NWFhMjdhNDQ4XzcxMg_0b9c0551-6dc2-4490-8f91-25131233c1c4" continuedAt="ie072aab2a9d54113a495b62b57209540" escape="true">Organization and Nature of Operations</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie072aab2a9d54113a495b62b57209540">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb).  In addition, the Company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_145"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjI0_3c42dac9-8181-452c-8003-106bd09ee167" continuedAt="if9d24896d7a84ad2b8836936e992a449" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if9d24896d7a84ad2b8836936e992a449" continuedAt="i230232e819754859a83d7c32bf945bda"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjEy_85cad632-743c-4149-80bf-b3fdc87d35c2" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM3OA_5a690c8f-534d-4bc7-b67f-54808279928d">one</ix:nonFraction> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzcwOQ_5a690c8f-534d-4bc7-b67f-54808279928d">one</ix:nonFraction> segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjI5_f1eaabb3-aca9-4fa0-9874-395bf05ab461" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjIw_d18039b8-5145-4d02-9db0-ce3a96740f0e" continuedAt="ib70a780c90c8434aa29d60d897a7ee60" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:25pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU) 2016-13,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2016-13), which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i230232e819754859a83d7c32bf945bda" continuedAt="i159845551ba441ed909ed7256602dcab"><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib70a780c90c8434aa29d60d897a7ee60">from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 3, Marketable Securities, for additional information.</ix:continuation></span></div><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjMw_f3d14cbc-7327-41d9-b597-b2fbc775c97f" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. <ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzQ3MTQ_3f5c87d4-914a-4fb1-ab40-3267073b8616"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzQ3MTQ_41001eb2-839b-41e2-b070-ca55e89e0d18">No</ix:nonFraction></ix:nonFraction> allowance was recorded as of December&#160;31, 2020 or 2019, as the Company has a history of collecting on all outstanding accounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE3_ceb8742e-3643-47e0-9673-6f0e522feb0a" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjI1_f2b0cb53-02d8-4613-97f2-539592da5a74" continuedAt="ia4d5d67d8c204a7f9065be7287e27da9" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Active Markets for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identical Assets</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Inputs</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice95d2414f2f4667ad6a137abdaf65e6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzQtMS0xLTEtMA_5927dffa-cfc1-4494-b0bb-c91f29d85a2d">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if031a3629d9d479b8b2e1574bc24c45e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzQtMy0xLTEtMA_8d7f61da-9277-412c-acdc-c036ff158c30">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if51e190b234e40b892b75daf5576b090_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzQtNS0xLTEtMA_d7df2d4a-d182-4155-9880-64c89081e03e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea874c5381443b5b673e08d90e90c40_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzQtNy0xLTEtMA_820b3258-f2ea-476f-8a1d-064998d9477f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a9f46e4b864266974d1b6fcd23b90e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzUtMS0xLTEtMA_776d89ec-0bec-4399-b57d-8051137c8d28">60,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552151630ecd479daefd899d23524d35_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzUtMy0xLTEtMA_99fe60c2-d031-413b-8ca2-969a51b2706b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i005b3bb8d084456ca8d49ff0bad27cfb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzUtNS0xLTEtMA_368be1b4-8626-42bd-b8cb-e492bcf3ff2a">60,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947be2b25de4cfd818cbc871c8cf1e2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzUtNy0xLTEtMA_73099bcf-2fca-4e03-a74a-03aae2003a56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9446d440a99142d189e04019aee224ae_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzctMS0xLTEtMA_1b8aec1c-8492-4ea7-9185-ecf939b3713f">33,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b532567296e49e3bdaf3330f2450754_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzctMy0xLTEtMA_722a6995-e2d8-4385-9081-f55fa52dcb29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ae57da2f7894541b48732b70a7018b4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzctNS0xLTEtMA_f7421d3d-de38-47d3-841b-19f54e1fd1a8">33,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51251d2fc1ee4652bb119cd46a05d7a0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzctNy0xLTEtMA_6951ca52-e21a-4ed5-b7fe-fbf3364a1f81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzktMS0xLTEtMA_3166acb5-da21-4e13-a074-df9c5d12a2ca">143,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d860c4ec4674c37864b79c7a8a1c51c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzktMy0xLTEtMA_83882795-46b2-43b5-8160-976950aaba73">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a8fbc39ff647a59227c8eecd606e91_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzktNS0xLTEtMA_607643f3-62ea-42c1-b2e6-f85391539376">94,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e38b6ae03674f649d3803b90d7ecfea_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzktNy0xLTEtMA_28998a4d-c198-44e9-ad25-1b777c0ba383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i159845551ba441ed909ed7256602dcab" continuedAt="i8fd511514b534740bdf03f90ce1d6333"><ix:continuation id="ia4d5d67d8c204a7f9065be7287e27da9"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Active Markets for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identical Assets</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Inputs</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed6dd67ee254fca90e4fe1683b8a032_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzQtMS0xLTEtMA_7c45f8d3-1235-4cc8-94e7-b4850ffb946c">46,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae333e83a0b4c128a73b9846f7961d2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzQtMy0xLTEtMA_879755b5-5335-47ef-a27b-e93df0c428aa">46,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b35d230e32a43dfba261f095d9b94a7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzQtNS0xLTEtMA_89592c9f-602e-4258-93a4-e369cf2cdf4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46eba3f4322a4bbca90a630e001423f3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzQtNy0xLTEtMA_4a33b373-eae9-4cb7-b75f-79920152f71d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97ced64b0db4ea9832f1407780172eb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzYtMS0xLTEtMA_93da4b97-498d-4503-8f41-1cee79c147ec">13,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib963d0612f344980abb58b7bbfdec3d2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzYtMy0xLTEtMA_663703b8-1f83-491b-b368-b7ed5b5fec39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a721e8181644e798dc6e4780d90abcb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzYtNS0xLTEtMA_80dca987-853e-42b9-ae1b-56b07839da1e">13,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271fe1de3f1742e1ad5139de5d7b263e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzYtNy0xLTEtMA_c88fe28d-0994-4f87-abb5-59c70ebd2e13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68822e067a8340dfbe694836cdf653da_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzctMS0xLTEtMA_628a1c2a-91b2-48d0-8ac8-1c47362f945e">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b9fa1115d242cb8ff80ac0457e0b0d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzctMy0xLTEtMA_cd5d17d0-3ead-4f85-a7e1-bf6452057f47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb40a146a60543f19cb68d866fb7a671_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzctNS0xLTEtMA_47817d81-085b-43ae-a50c-85c73fe45258">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db1598c868945aa9827bc1240c7542f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzctNy0xLTEtMA_23832efd-0cd9-4495-bdb5-0c747212f0a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzktMS0xLTEtMA_854ccafe-693e-4a68-8a94-6f3d4b534e57">162,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ea4b2f306047a48020bb482e53e79f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzktMy0xLTEtMA_8ca6d2ce-bc4a-48d1-ad06-04740a025548">46,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41258fa77ab4a088f6a5f9eb5a20970_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzktNS0xLTEtMA_c8188ab0-3aba-4b6e-bd52-b14a954153b7">116,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0cc75cee534fd1a8112f063a35cb0d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzktNy0xLTEtMA_fe1e8e4e-830f-4e07-b451-635855a120c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2020 includes approximately $<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzczNjY_47ded896-6379-4373-b2d9-c39bd9425940">52.0</ix:nonFraction> million reported in cash and cash equivalents on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0Xzc0OTg_76ffe55e-38b7-4c48-8033-c2562362b764">73.2</ix:nonFraction> million reported in cash and cash equivalents on the balance sheet.</span></div></ix:continuation><div style="margin-bottom:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model. There were no transfers between levels during the periods presented. </span></div><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjIy_15a2965d-4d40-48f2-8176-9339f8a6281a" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;<ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjMz_26a57e1a-817c-47ad-8177-b015e5a6c238" continuedAt="i079d0817137e4dbdac05c475bd04de4e" escape="true">The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</ix:nonNumeric></span></div><ix:continuation id="i079d0817137e4dbdac05c475bd04de4e"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:68.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i531f3aa6b1134103965b1b4eda0c293b_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzItMS0xLTEtMA_bd6c59c2-fda9-4343-b47d-d38760becc8a">47</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a4891f769084a18ac2931ba572ae079_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzItMy0xLTEtMA_740c040f-f2d6-42fe-8929-fe090f42b443">35</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5588a07194ab4de79f27e05259cfb283_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzItNS0xLTEtMA_8a9e9b00-0eb7-4489-ade6-201760778d18">68</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i100b91d4dd344890967b03a9795b715a_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzMtMS0xLTEtMjYyMw_4c69fdc1-8b86-4c70-8e4d-30786aab2bf3">19</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97d18cede0b144daac71f46d3da90aef_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzMtMS0xLTEtMA_80ad3ac1-7d6b-49cd-bd60-c8cfd479a2e4">11</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee3f25bbd99943aa9498aad2fe62b342_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzMtMy0xLTEtMA_181a3f28-eb9d-456a-a4a1-c8a96af020e9">29</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c1d63dd293345108c3e566e01ade176_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzUtMy0xLTEtMA_9867943f-2444-47b2-bd59-ede2e2529a07">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i969a47c5754c4c6985ffd28981d702a1_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo3MTZiZTc3MThlNTk0YjVhYmVhYjIzZDNhMzZmYmM0Yi90YWJsZXJhbmdlOjcxNmJlNzcxOGU1OTRiNWFiZWFiMjNkM2EzNmZiYzRiXzItMS0xLTEtMjYzOQ_25d4a353-a478-4ada-bbb1-325702254276">87</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if953214a30c54a4ab6b4b51e83fde241_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo3MTZiZTc3MThlNTk0YjVhYmVhYjIzZDNhMzZmYmM0Yi90YWJsZXJhbmdlOjcxNmJlNzcxOGU1OTRiNWFiZWFiMjNkM2EzNmZiYzRiXzItMy0xLTEtMA_a07465f4-5108-4912-a9d5-dfa4b53078be">62</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72c1b1bc8c454a148cb38c5196d6024e_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo3MTZiZTc3MThlNTk0YjVhYmVhYjIzZDNhMzZmYmM0Yi90YWJsZXJhbmdlOjcxNmJlNzcxOGU1OTRiNWFiZWFiMjNkM2EzNmZiYzRiXzMtMy0xLTEtMA_0c82a4c6-93e5-4f12-bfaf-a5ebc10c3636">23</ix:nonFraction>%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i8fd511514b534740bdf03f90ce1d6333" continuedAt="i912c91e888ea4c05b500ac412be60b69"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjIz_9c3a1dc5-c9e8-470f-acd6-6968c9b65531" continuedAt="iff3acb637be74febb514ae0d9d516894" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff3acb637be74febb514ae0d9d516894">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</ix:continuation> <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE4_964c85b7-d831-4064-9bb0-db6b0f53f657" continuedAt="iba99a3cae46c4509a54b3b85ea424825" escape="true">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="iba99a3cae46c4509a54b3b85ea424825"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i613ecacdf38948c6a00165721abcb9ae_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxM2ViZWNiOWQ2MTY0MTk1ODkzY2IzOGZiMTFiNzUxZi90YWJsZXJhbmdlOjEzZWJlY2I5ZDYxNjQxOTU4OTNjYjM4ZmIxMWI3NTFmXzAtMS0xLTEtMA_337e3a1b-e72c-4f08-b544-3131cb8a3d63">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16e8408688034e0cace6fc6275751598_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxM2ViZWNiOWQ2MTY0MTk1ODkzY2IzOGZiMTFiNzUxZi90YWJsZXJhbmdlOjEzZWJlY2I5ZDYxNjQxOTU4OTNjYjM4ZmIxMWI3NTFmXzEtMS0xLTEtMA_72924e2d-72ab-425d-a24f-648b056c4934">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a9f85aa087344ca8008b4576a668e22_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxM2ViZWNiOWQ2MTY0MTk1ODkzY2IzOGZiMTFiNzUxZi90YWJsZXJhbmdlOjEzZWJlY2I5ZDYxNjQxOTU4OTNjYjM4ZmIxMWI3NTFmXzItMS0xLTEtMA_b5eef1cd-19f0-43c5-ada8-dc3d12dedfb3">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i30f500d13f114fd6b9ece35c3c1ddbbb_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxM2ViZWNiOWQ2MTY0MTk1ODkzY2IzOGZiMTFiNzUxZi90YWJsZXJhbmdlOjEzZWJlY2I5ZDYxNjQxOTU4OTNjYjM4ZmIxMWI3NTFmXzMtMS0xLTEtMA_3e0cdff1-4b30-4dbd-b981-b6d57781ac75">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjA5_66de764e-253d-4a0e-ba4f-4f06995b9d38" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2020, 2019 and 2018, the Company determined that there were <ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzEwODYy_24140375-8cc4-4938-8dc3-b879d0d2e14a"><ix:nonFraction unitRef="usd" contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzEwODYy_51f81f65-ff7c-471d-8da0-1201bcbc97a0"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzEwODYy_572bfc3a-7f30-46f7-ad86-a361ba95c13b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impaired assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjI2_3c3e3b39-5dc8-4e05-9015-380add5090f0" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE0_27a36990-62e7-45d6-9052-4742e28a7158" continuedAt="i5016e6abbe284609b97d92e3ded1815c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASU No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i912c91e888ea4c05b500ac412be60b69" continuedAt="i9a5731c0e9c247e19951a46bbf2003a1"><ix:continuation id="i5016e6abbe284609b97d92e3ded1815c" continuedAt="ib683766f90044aafa61bd31d9b3da8cd"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i9a5731c0e9c247e19951a46bbf2003a1" continuedAt="i064d3e59efa64de89338dff97537516b"><ix:continuation id="ib683766f90044aafa61bd31d9b3da8cd"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Collaboration and Other Agreements.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i064d3e59efa64de89338dff97537516b" continuedAt="ia918d06b151849e0b59c1225c9742f15"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjAz_bc04dc98-735d-4d58-968f-6e56e6298810" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjEw_c29a09bd-f61b-4f49-a4c3-7cff380ea200" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE1_df75d2d0-2a89-4118-a735-9e7b7e1fdd0c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE5_e8168622-4033-46df-a3eb-e25cea5a1736" continuedAt="ib479a9b160724f598be37f29224a398a" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib479a9b160724f598be37f29224a398a">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</ix:continuation> <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjA0_09a74f33-76eb-499e-9a35-94821fe8ceaf" continuedAt="i2e65fafbe881441cb3c292d75656eb27" escape="true">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="i2e65fafbe881441cb3c292d75656eb27"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:44.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9eee20aa82a04eb881c0f50c7193c079_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTpmYzU4ZjlmYWY5ZTU0MDBkOWM0MDEwYjQzZTE1MDY2My90YWJsZXJhbmdlOmZjNThmOWZhZjllNTQwMGQ5YzQwMTBiNDNlMTUwNjYzXzItMS0xLTEtMA_1b31419e-eee5-4edb-bc6a-744e1e1af500">7,467,603</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29d23911aba345f1b5c80d016b475232_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTpmYzU4ZjlmYWY5ZTU0MDBkOWM0MDEwYjQzZTE1MDY2My90YWJsZXJhbmdlOmZjNThmOWZhZjllNTQwMGQ5YzQwMTBiNDNlMTUwNjYzXzItMy0xLTEtMA_d7d3e464-e61e-4d9d-bb0e-cabb571458c3">7,159,494</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6db0ce0a36bd44c89f32be0a7f6f3ccf_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTpmYzU4ZjlmYWY5ZTU0MDBkOWM0MDEwYjQzZTE1MDY2My90YWJsZXJhbmdlOmZjNThmOWZhZjllNTQwMGQ5YzQwMTBiNDNlMTUwNjYzXzItNS0xLTEtMA_b5ed4421-210c-411c-902d-a466045adf6a">5,273,964</ix:nonFraction></span></td></tr></table></ix:continuation></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ia918d06b151849e0b59c1225c9742f15"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjEx_bc20275b-738b-4535-b9cf-e6aaaf17bcf0" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $<ix:nonFraction unitRef="usd" contextRef="ie2e19ae8025c48e5b2df7b9cd421d21d_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzMyMTc0_4f3fa643-67a2-4f06-8d38-ebd18f79325e">16.4</ix:nonFraction>&#160;million and operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="ie2e19ae8025c48e5b2df7b9cd421d21d_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzMyMjEy_2647cadc-bbeb-48f9-9343-e9f80408e0d2">27.7</ix:nonFraction>&#160;million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets. Refer to Note 5, Leases, for additional disclosures required by ASC 842. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_151"></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzY4OA_ae130106-6e4c-4347-b10b-1358045ba9d9" continuedAt="i87a59fe4c3344722b6b75370dd04c04f" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i87a59fe4c3344722b6b75370dd04c04f"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzY4OQ_7d679a8a-14c0-48a1-afe7-f432e226ffd6" continuedAt="id50d1291c8fa42c5b7b6edb53143dbd3" escape="true"><div style="margin-bottom:9pt;text-indent:31.5pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6be239fac74a39a6efe1cf2153245a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzItMS0xLTEtMA_651d66e2-2fec-4a25-8625-6aeac81c4014">60,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6be239fac74a39a6efe1cf2153245a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzItMy0xLTEtMA_2e54df03-7325-43e8-8821-f456a07fac7f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c6be239fac74a39a6efe1cf2153245a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzItNS0xLTEtMA_2f4df206-c880-4437-ae6b-77f9e1c322ba">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6be239fac74a39a6efe1cf2153245a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzItNy0xLTEtMA_54d1b027-ea5e-4507-97ac-d0c3a6b9800a">60,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41ac2377a9e406db348d5b48d784025_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzQtMS0xLTEtMA_18fd960c-d8ab-4655-8c05-30b1a5e1610b">30,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41ac2377a9e406db348d5b48d784025_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzQtMy0xLTEtMA_255b4aaa-f796-4fd7-98bb-b9df8a69e868">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id41ac2377a9e406db348d5b48d784025_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzQtNS0xLTEtMA_7fc2dddd-815a-4567-a5ec-b3e829467b6d">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41ac2377a9e406db348d5b48d784025_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzQtNy0xLTEtMA_3723fb76-74c1-4081-8fa6-7bcd7221a7ce">30,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzUtMS0xLTEtMA_bfff9a42-c154-48a7-af01-5d92135d048b">91,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzUtMy0xLTEtMA_98258613-35b8-4ae8-8f49-4817a3c83310">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzUtNS0xLTEtMA_ec65920d-2a0c-4f00-b7c5-10ab62eaa08f">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzUtNy0xLTEtMA_9c40251a-05db-4fd1-b684-44ee21c9d7fd">91,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f933200f33a49139ed9cdf99b46accb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzMtMS0xLTEtMA_ca5a7fb6-52a1-4fc1-a6a9-3b09372b6c96">13,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f933200f33a49139ed9cdf99b46accb_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzMtMy0xLTEtMA_75835472-669b-45db-8949-94affd2c5c36">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f933200f33a49139ed9cdf99b46accb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzMtNS0xLTEtMA_b3bac36d-fbc8-47f8-9fbc-c939e73d1944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f933200f33a49139ed9cdf99b46accb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzMtNy0xLTEtMA_b7ed40b9-9b42-48c0-9af4-da6fa288024a">13,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f3c1f82e424f279963729cfc905770_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzQtMS0xLTEtMA_498a5572-0476-47f8-a62e-a3224108a9e7">76,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f3c1f82e424f279963729cfc905770_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzQtMy0xLTEtMA_6d81647d-1181-42fb-87ce-797ebf99f011">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3f3c1f82e424f279963729cfc905770_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzQtNS0xLTEtMA_af96520c-5a97-4c61-ad62-a297bdbe0ab3">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f3c1f82e424f279963729cfc905770_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzQtNy0xLTEtMA_cf1d0348-f9b3-4084-bf1b-ad46c1383805">76,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzUtMS0xLTEtMA_fec84f31-6538-40d4-9dd1-6effc80e953f">89,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzUtMy0xLTEtMA_54a8dd6e-b573-4273-b163-83e094cb87cb">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzUtNS0xLTEtMA_a044e0e1-67a1-4638-882f-f07aeb86e42d">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzUtNy0xLTEtMA_1b60618c-00fd-4594-80bd-3960c43bb797">89,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="id50d1291c8fa42c5b7b6edb53143dbd3" continuedAt="ic8a4999c490f423f92940c021e674e42"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8a4999c490f423f92940c021e674e42"> and 2019 had contractual maturities of less than one year.</ix:continuation>  All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2019 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020 were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, <ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzE2NDkyNjc0NDI3MDU_5060ba12-4aa2-4c1e-a420-b60077cc66d9">no</ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzM4Mg_aea569ce-17dd-4c78-a26d-d7ab5603f011">No</ix:nonFraction>  losses related to other-than-temporary impairments of the Company&#8217;s available-for-sale debt securities were recorded in Accumulated other comprehensive income during the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recorded interest income of $<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzUxMQ_8e9227dc-4d83-4a03-9414-6583b8ba7005">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzUxNQ_9af7527c-1cd0-4c47-9b5e-11535235fcde">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzUyMg_53268c33-89d2-4b9d-b5c1-b03e294b0f2d">2.3</ix:nonFraction> million during the years ended December&#160;31, 2020, 2019 and 2018, respectively, which is included in Other income (expense) on the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_157"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUyOA_3c2be250-c5fd-4843-aecc-c0b011b96774" continuedAt="i65439eea539b48e7ada780918d90b0af" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><ix:continuation id="i65439eea539b48e7ada780918d90b0af"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUyOQ_5ab5d6c3-e6fa-4488-baf7-1ac11213b046" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f26754d1c12437385b6f0b131ab7e1d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzItMS0xLTEtMA_805b3848-0382-45ec-8774-29c86c4081fb">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eda115843604d8ab1d5b0ec51dd4f34_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzItMy0xLTEtMA_78772c9a-15af-494c-8dcd-6b24bea446a7">2,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8932c76412aa40acaf76c7c665350985_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzMtMS0xLTEtMA_eab73c5f-d907-40ab-8665-0159287526d1">8,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5794801343ac425dbba4fec50029d947_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzMtMy0xLTEtMA_156288b2-576b-42eb-bdd6-cea46f99a68b">7,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce024e3e9fa467bb2616f6adf5778e1_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzQtMS0xLTEtMA_9d290891-042b-42d9-81f4-e63e5fac82ca">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ae1c0908e54561a39ca4b4e76062a3_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzQtMy0xLTEtMA_cb7d70f3-65ad-4b95-a485-07927a902c08">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8089d6e3024b72b2fa7b1b126799d6_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzUtMS0xLTEtMA_0c64fa76-8505-4b39-baf8-852f6f08d676">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2336b1857bf400c9efe189f44310e5f_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzUtMy0xLTEtMA_83fc97f8-c7b3-45ff-8ff3-2cc3cd8c5ede">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5172dbbe4a1a40ffae37000e9a89f01c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzYtMS0xLTEtMA_f8b548e4-58af-45bb-8ebb-3b0b24d8448e">41,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b1a45648e254a7dbb5b5d67c3ef2ec1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzYtMy0xLTEtMA_e0fcf98b-b665-4e02-b211-5be2033d7cc9">38,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f77e8a6d744b82b3f3741e0299c45d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzctMS0xLTEtMA_280c99b7-bc47-4670-a458-5753a01e8427">48,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08fe2220367435fa71093334d9c684a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzctMy0xLTEtMA_5a6f7ce2-8807-4f2c-9873-ee5effe562f7">48,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzgtMS0xLTEtMA_d77fd80a-2d44-40e5-9dc3-848c3bdd4ab8">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzgtMy0xLTEtMA_a1d7a2e6-a493-47e0-8902-3959d84a97fc">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzktMS0xLTEtMA_978d9ac0-519f-47d6-a497-8ee6be35b921">103,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzktMy0xLTEtMA_15fe2bbc-2fb2-4385-af0f-ac06908183b5">97,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzEwLTEtMS0xLTA_12f32371-5f7b-4222-b2c3-46ff4185ace9">61,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzEwLTMtMS0xLTA_c6efcabb-a5d6-4474-8b9b-4b462bc487cd">49,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzExLTEtMS0xLTA_3c62b5b1-2f63-45bc-b12b-7d8fde6740e1">42,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzExLTMtMS0xLTA_530b2480-8686-4fc0-8c6a-c5982eb444bd">48,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUwMQ_468b6025-9c6c-4029-b48c-9906ebe15936">12.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUwNQ_dc3a2c8e-1758-4b2c-b139-d706246db2bd">12.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUxMg_6ad4ad3c-7b19-4bc2-a9b6-74c4cae53bea">9.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 15</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzE0NzA_7a5cdb26-ee4b-4e64-a5f2-a2f4d83cc970" continuedAt="i05ecfba9434149a09cecdcb71084085f" escape="true">Leases</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:continuation id="i05ecfba9434149a09cecdcb71084085f" continuedAt="i4e8af5a7b1904af980fb5bea5a36c8de">&#160;&#160;&#160;&#160;</ix:continuation></span></div><ix:continuation id="i4e8af5a7b1904af980fb5bea5a36c8de"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2. Summary of Significant Accounting Policies, the Company adopted </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 842</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of January 1, 2019. Prior period amounts have not been adjusted and continue to be reported in accordance with historic accounting under </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 840</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in  Maryland and a non-cancelable operating lease for laboratory and office space in California. A portion of the space under one of these leases is subleased to a third party. All of these leases include one or more options to renew, with those renewal periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzQxNA_c7bd66aa-5f7d-4552-b4e9-c0686ecd66a9">five</span> to <ix:nonNumeric contextRef="ibafe419048424d72ba9dcb437c36a6fd_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzEzNzQzODk1MzUwNTMz_1bb21eaa-d2f6-471e-83e5-6b3431e3b971">fourteen years</ix:nonNumeric>.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:74.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTo5ZTY5ZjQzMTg3MWI0OTYyOGFkNGFhMmEyNmQyYWE3My90YWJsZXJhbmdlOjllNjlmNDMxODcxYjQ5NjI4YWQ0YWEyYTI2ZDJhYTczXzItMS0xLTEtMzg2Mg_41d7c68a-e5c2-498f-8207-791dfaa84374">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTo5ZTY5ZjQzMTg3MWI0OTYyOGFkNGFhMmEyNmQyYWE3My90YWJsZXJhbmdlOjllNjlmNDMxODcxYjQ5NjI4YWQ0YWEyYTI2ZDJhYTczXzItMy0xLTEtMzg3OA_82a83b52-f55d-467b-b6e0-a2921f76533d">5.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTo5ZTY5ZjQzMTg3MWI0OTYyOGFkNGFhMmEyNmQyYWE3My90YWJsZXJhbmdlOjllNjlmNDMxODcxYjQ5NjI4YWQ0YWEyYTI2ZDJhYTczXzMtMS0xLTEtMzg3NA_73765d13-58fc-4732-aa4e-dd5d3f8c938c">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTo5ZTY5ZjQzMTg3MWI0OTYyOGFkNGFhMmEyNmQyYWE3My90YWJsZXJhbmdlOjllNjlmNDMxODcxYjQ5NjI4YWQ0YWEyYTI2ZDJhYTczXzMtMy0xLTEtMzg4Nw_6e402c91-398e-4a25-8cd0-779abbd16ef5">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption of ASC 842 on January 1, 2019, it was not reasonably certain that the Company would extend any of its operating leases, therefore the options to extend the lease terms were not recognized as part of the ROU assets or lease liabilities. During the year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019, the Company exercised the options to extend <ix:nonFraction unitRef="renewaloption" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:LesseeOperatingLeaseNumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzE2NDkyNjc0NDUyNTU_6c28f68f-c06b-4b7c-974e-86d7cc6a74bc">two</ix:nonFraction> leases for an additional <ix:nonNumeric contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzEzNzQzODk1MzUwNTM0_61706e4b-321b-43ea-b2af-8ad2c736dbc6">five years</ix:nonNumeric> each, therefore the Company remeasured the lease liability and adjusted the carrying amount of the ROU asset related to these leases. During the years ended December&#160;31, 2020 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2019, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzExMDA_6dbe7a91-0aeb-4f30-898d-9235db2f1393">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzM4NDgyOTA3MDAxMDE_0a7f4c7f-ac65-41c0-90de-97c49c22647b">6.4</ix:nonFraction> million, respectively. As of December&#160;31, 2020 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2019,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzEyMDg_4e02540b-72b0-4c55-9654-51617cc8f209">19.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzM4NDgyOTA2OTkwMzY_9b53446d-83d9-46ab-87d9-377fcac6e5b5">20.2</ix:nonFraction> million, respectively,  and are included in Other assets on the consolidated balance sheet.</span></div><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzE0NzE_ad5f0846-51f1-4732-811a-a84e18a4e777" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  and 2019 were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzAtMS0xLTEtMA_f7ec1003-283d-4767-a95d-ecc2f88318aa">5,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzItMy0xLTEtMzY1Nw_fdf7997d-0780-40e9-8667-9a95b2fd33f1">5,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzEtMS0xLTEtMA_d7e5d258-16bb-4b2e-862c-69084a9cf50e">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzMtMy0xLTEtMzY1Nw_d75029ab-d374-416e-8245-0e52a874ab62">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzItMS0xLTEtMA_c45cb6c0-f9c7-492c-8b1a-f7674fe5fe60">770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzQtMy0xLTEtMzY1Nw_bc4abe13-b3ba-4574-823d-80194ba2d3d5">942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzMtMS0xLTEtMA_42b6fd64-fffe-40cd-9477-e2e9db285dee">5,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzUtMy0xLTEtMzY1Nw_51bfa763-f88c-4b1c-b580-89d133fc2ddb">5,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span><br/></span></div><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzE0Njk_775dff51-4ee0-430c-9c31-8822918686b5" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzAtMS0xLTEtMA_9b68ad0a-5bc3-4ace-a8cd-9f0c3d50c3e5">6,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzEtMS0xLTEtMA_a240dd6d-348f-4835-9ec7-35d3e35c79f0">6,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzItMS0xLTEtMA_aae84cfa-9ab2-4898-9bce-6f47206336c1">6,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzMtMS0xLTEtMA_0600eeb6-05c2-49e7-be70-a5abf628149f">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzQtMS0xLTEtMA_be56c2aa-d5d1-4bbf-84b3-15103621093e">5,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzUtMS0xLTEtMA_f575c006-97e5-40db-95e0-7eb8d71c93dc">7,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzYtMS0xLTEtMA_a9772435-5184-4ebb-99ce-061f1a80ef45">39,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzctMS0xLTEtMA_f573840e-84f5-4e98-b475-d0ad8961bc5e">9,918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzgtMS0xLTEtMA_c785e13d-7f15-4a54-a58c-22f0b64307f7">29,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_163"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzI1MDM_cf464f77-a8c9-484a-ba67-01ee24e23df0" continuedAt="i0d920440a00c466585fa21ad53ef551c" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i0d920440a00c466585fa21ad53ef551c" continuedAt="id7315841ed0a4a84908303348ae7bab3"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzEwNA_905c5585-dc68-4b8b-a5cc-3c45e200e77a">125,000,000</ix:nonFraction> shares of common stock, and <ix:nonFraction unitRef="shares" contextRef="ic72a8361cda6471c8e38d658753f0573_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzEzNQ_52f2a0a0-d613-45dc-b0f5-c1dd9b6fa393">5,000,000</ix:nonFraction> shares of undesignated preferred stock, both with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic72a8361cda6471c8e38d658753f0573_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIwMw_63b88725-053c-4fc0-b702-b358f3bbff2e"><ix:nonFraction unitRef="usdPerShare" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIwMw_916eb128-580e-4be5-97ae-99ca90f7a3bb">.01</ix:nonFraction></ix:nonFraction> per share.&#160;There were <ix:nonFraction unitRef="shares" contextRef="id073a704e63548588d4eeca08d057674_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyOA_78f3687e-0a7a-45f9-b141-6d6540a859af"><ix:nonFraction unitRef="shares" contextRef="ic72a8361cda6471c8e38d658753f0573_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyOA_b6e2dc51-3d36-4d81-9b3c-d8db68179bfa"><ix:nonFraction unitRef="shares" contextRef="id073a704e63548588d4eeca08d057674_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyOA_c36dc595-860a-4713-8caf-0c8ef20ef302"><ix:nonFraction unitRef="shares" contextRef="ic72a8361cda6471c8e38d658753f0573_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyOA_e41c9998-9fcb-41dc-95ea-43334c935ce7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2020 or 2019.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold <ix:nonFraction unitRef="shares" contextRef="i40138f5330944173b29c88382128a064_D20180402-20180402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE1Mzc_26d08eab-748a-4f13-b940-94049154c712">4,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia4d7688a5ca1483790dd77c9300f82c4_I20180402" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE1ODE_c2895c65-f503-4d82-876f-b7234b62f303">21.25</ix:nonFraction> per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional <ix:nonFraction unitRef="shares" contextRef="ica23de68e9494461b000d56dee219d8f_D20180402-20180402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE3Mzg_0d5536ca-39b6-460d-8627-a9874aa44f09">675,000</ix:nonFraction> shares of the Company's common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i52765134bddd477d901a12882bde3b9d_I20180402" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE3OTI_2dd53181-f329-4c98-b564-182c435c506c">21.25</ix:nonFraction> per share. Upon closing, the Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i40138f5330944173b29c88382128a064_D20180402-20180402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE4NzE_ef973415-3e43-4eb4-a4cd-0a09ff1459cb">103.3</ix:nonFraction>&#160;million from this offering, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company completed a </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">firm-commitment underwritten public</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offering, in which the Company sold <ix:nonFraction unitRef="shares" contextRef="if094d8df39954207bb5391061c867477_D20190201-20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIwODU_1b94deae-7286-4ebd-8011-601bd33c661d">5,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5d3c43517af54165896bef6f429afdf8_I20190228" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIxMjk_909adf08-3476-4054-b585-2b2d75bf46f7">20.00</ix:nonFraction> per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional <ix:nonFraction unitRef="shares" contextRef="i3b54527c45444217a8e26ea5f21c66dc_D20190201-20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyODY_bb359bb7-c5a4-4e5f-9c56-2633b23856ba">825,000</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0fc973fcb7d148828513059e1601a77a_I20190228" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIzNDA_f5ef94c3-6815-415b-8609-b1b081deced6">20.00</ix:nonFraction> per share. The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="if094d8df39954207bb5391061c867477_D20190201-20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzI0MDU_d7f4f408-9140-4cee-8a29-60fb884ef19f">118.7</ix:nonFraction>&#160;million from this offering, net of underwriting discounts and commissions and other offering expenses.</span></div></ix:continuation><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id7315841ed0a4a84908303348ae7bab3">In December 2019, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock in amounts of up to $<ix:nonFraction unitRef="usd" contextRef="ib66b02d54eed4262b672c427d7af10e9_D20191201-20191231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDkzMTA_19149966-71ae-4e1e-a170-1617804a819f">50.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. This agreement was amended in June 2020 to increase the  maximum amount of the offering to $<ix:nonFraction unitRef="usd" contextRef="i70810fe71eab4695bfbdd5efe0c1c9b3_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDkzMzA_1ad79133-1673-4490-96db-60119b0803ce">175.0</ix:nonFraction> million. The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on December 23, 2019. During the year ended December&#160;31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i97895a6a80e148b1a904880526f25594_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDkzOTY_ca98d132-2a60-4363-81b6-aefc1f3aea84">6,612,815</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0e277b27463146b29c014a1f9710d329_I20201231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDk0MDU_d5043e35-2aa9-447b-bbd4-d0fb610a1df3">26.46</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i97895a6a80e148b1a904880526f25594_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDk0MjI_a131a7ad-ed74-465c-9cd2-fe4d08721df1">170.5</ix:nonFraction> million, net of underwriting discounts and commissions and other offering expenses.</ix:continuation>  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_169"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5Mzk_3b3f872f-e8e2-4cee-9de5-1bcf9b253b3c" continuedAt="i0ee2dd25065445448b69673ebfa3e8db" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="i0ee2dd25065445448b69673ebfa3e8db" continuedAt="i42e9c969e6ca43609b221d5210bdca95"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved <ix:nonFraction unitRef="shares" contextRef="ie71f6f7825d94e5b829714cea61564c2_I20170518" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzQyMA_0e48b6b7-7ea5-4bdc-aba6-70f580eb7d89">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i194f187d59c94fd0be7ab2993ff54938_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzYxOQ_074bb7c0-37d3-40af-ad7c-305000a74074">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="i194f187d59c94fd0be7ab2993ff54938_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzg2NQ_a9dc4ff1-834d-4b3f-879c-25395ca73fb3">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2020, employees purchased <ix:nonFraction unitRef="shares" contextRef="i57f99a9224f74d71a7ddf204e8b0610e_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzEwMDk_1ff207d4-8ce2-4568-9ce5-c61509241a86">32,430</ix:nonFraction> shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i57f99a9224f74d71a7ddf204e8b0610e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzExMDQ_4b7503c5-4c74-4019-b120-4ac04844f8b4">0.6</ix:nonFraction> million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of December&#160;31, 2020, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="icb896738d1f544f3af00d62fa6613580_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzE5ODk_d43be4ba-0942-410c-82ac-799a3668c39d">249,959</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icb896738d1f544f3af00d62fa6613580_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzIwNjc_f614828c-1ad1-469e-b51f-c048bdd6811e">2.79</ix:nonFraction> per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was <ix:nonFraction unitRef="shares" contextRef="if65e3aa5584c442f98a84ac8dcd7ea53_I20131031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzIzODc_2149e7aa-00c2-4dba-8631-1a8c15756655">1,960,168</ix:nonFraction> shares.&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="i0302cc9696d04655b132ed6718400098_I20201231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzI1OTI_10e17dd3-2419-485a-9f83-e353e3d0fd9b">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="i8a3833260ec34d169d4087f7cc599a38_D20200101-20201231" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzI2MDc_2ede6f70-1462-410f-87ea-960ccdfe0079">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2020, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="i8a3833260ec34d169d4087f7cc599a38_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzI5NDQ_77cfd556-933e-4b0f-b87d-515e0c0c32cb">11,896,613</ix:nonFraction>.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i42e9c969e6ca43609b221d5210bdca95" continuedAt="i636213adac7847e08acbb893531e6203"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2020, under the 2013 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0302cc9696d04655b132ed6718400098_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzM1Mzg_3f252ee5-dc01-4c48-aeb9-1a4affaa52f1">7,008,394</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0302cc9696d04655b132ed6718400098_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzM2MTY_3f4b57b5-c108-4c9c-b7c5-75d459f9b485">22.14</ix:nonFraction> per share. </span></div><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5MzU_8c134ded-58e5-41ec-b7d3-61a300fedd0f" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2267b398358d40628d513e840da1acd3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzMtMS0xLTEtMA_cfa0bf27-8892-4547-aff9-22e98525057a">10,833</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ef4253bc71484f944278fc62928061_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzMtMy0xLTEtMA_34fa5910-f70f-45e5-9828-baafdc9119e9">10,023</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eaa927f30f243e1bc5fa261ed93065a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzMtNS0xLTEtMA_025c30c0-0530-4830-ac5c-46048739be9b">7,919</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6e20121a2f4c0abc7b278e428bded7_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzQtMS0xLTEtMA_3a23e501-caec-4f79-8ee0-c8865694d760">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c05145d2dd243aa946509d98e419c02_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzQtMy0xLTEtMA_f2809d5f-8d08-4f18-9379-425b1b725d1e">9,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03544544417f4f4c9d465e8f28185dc4_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzQtNS0xLTEtMA_ebf1d0ab-aac2-46f6-a7bc-49afedaead31">8,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzUtMS0xLTEtMA_9855b465-99a7-41e6-b60c-24bf6df5f604">20,676</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzUtMy0xLTEtMA_eed5b35a-b630-4aa7-bd16-bf581a4081da">19,571</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzUtNS0xLTEtMA_53740af2-2f99-406a-89c9-b04865d5ab10">16,520</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Options</span></div><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5NDE_b3dd2f34-36f7-4388-a3e2-e31bfe596c36" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzItMS0xLTEtMA_102b81b0-bb03-4882-9226-e12a07585497">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzItMy0xLTEtMA_b513f20f-5710-4cfe-9079-b4e78963ea5d">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzItNS0xLTEtMA_f6192624-28a3-4b1d-ab58-379439eeee85">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb0b4fc7e6824deba0edf9c15b602152_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjAzOTU4NDM4ZTVlMDRhOWU5ZjMzMzU5YzhkZWQ3ZTk4XzExNTQ0ODcyMDkxNjY1_3f06e838-7eef-4e4b-a595-0418400e3038">67</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i847642b8e010448c92e39737e6b98cd4_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjAzOTU4NDM4ZTVlMDRhOWU5ZjMzMzU5YzhkZWQ3ZTk4XzExNTQ0ODcyMDkxNjcy_9b83715f-9fe6-463a-961f-aa456dd2a30d">109</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f613cb53e594b4ea341386947101b5a_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtMy0xLTEtMC90ZXh0cmVnaW9uOmQ1ODExNDEwNjIxNDRiY2FiMGJjMzU5Mzg0YjZmZDk5XzExNTQ0ODcyMDkxNjY0_ce91ccdf-3f73-43cc-b6e4-daeeb634ae54">74</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie734a52f70924b7d8ef283a737651cf5_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtMy0xLTEtMC90ZXh0cmVnaW9uOmQ1ODExNDEwNjIxNDRiY2FiMGJjMzU5Mzg0YjZmZDk5XzExNTQ0ODcyMDkxNjY5_1b3ab835-b7fd-4386-a1fe-f05f708138a2">76</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7975540d8d9b4164b34b19720b17c21c_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtNS0xLTEtMC90ZXh0cmVnaW9uOjQxZDMwMDJjMjY1MzRhNWZiY2QwMzg1MmE5NzMzZjZkXzExNTQ0ODcyMDkxNjY0_b61fc7cb-f7ae-4766-8ba2-c7b0f83ba803">68</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id3fea8f715e94127942cb6f892c9f8d7_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtNS0xLTEtMC90ZXh0cmVnaW9uOjQxZDMwMDJjMjY1MzRhNWZiY2QwMzg1MmE5NzMzZjZkXzExNTQ0ODcyMDkxNjcw_a6edf57f-d7f3-49bf-892c-f32c331cbf21">72</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb0b4fc7e6824deba0edf9c15b602152_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmJmZDE3NTg3YTk5NzQ4OGQ5MTdmNTAwZDdhMDE3MTk4XzExNTQ0ODcyMDkxNjc0_ac998f05-5739-46f4-adff-869509a95ca5">0.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i847642b8e010448c92e39737e6b98cd4_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmJmZDE3NTg3YTk5NzQ4OGQ5MTdmNTAwZDdhMDE3MTk4XzExNTQ0ODcyMDkxNjY3_06664023-09de-423e-b208-7f9c32ec6e98">1.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f613cb53e594b4ea341386947101b5a_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmNiNWUwZThlOGM3ZjRkNzA4Y2I2MzZiMDIxYWQzMzQwXzExNTQ0ODcyMDkxNjc0_b29abf5d-5015-435c-a18a-243c9a147a7d">1.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie734a52f70924b7d8ef283a737651cf5_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmNiNWUwZThlOGM3ZjRkNzA4Y2I2MzZiMDIxYWQzMzQwXzExNTQ0ODcyMDkxNjY3_fe362b14-2a1f-49d2-acba-d56b35e7b735">2.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7975540d8d9b4164b34b19720b17c21c_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtNS0xLTEtMC90ZXh0cmVnaW9uOjFmNjZiZThhNzQxODRkMGQ4NDUzOGM2NDBkNmZiNDcwXzExNTQ0ODcyMDkxNjc0_48d75c59-5cb3-46c6-b445-b113e89b5a62">2.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id3fea8f715e94127942cb6f892c9f8d7_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtNS0xLTEtMC90ZXh0cmVnaW9uOjFmNjZiZThhNzQxODRkMGQ4NDUzOGM2NDBkNmZiNDcwXzExNTQ0ODcyMDkxNjY3_57094d57-752b-4571-86c2-a9a18472c927">3.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzUtMS0xLTEtMA_372a248f-99fd-4eee-a61a-70ca90ff3e40">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzUtMy0xLTEtMA_5df9df6d-fd9c-4dc7-af56-88d495ecd0be">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzUtNS0xLTEtMA_5b7730d8-e6af-4ba5-86e3-919035e2c79f">6.25</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods through December 31, 2019, the computation of expected volatility is based on the historical volatility of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several public entities of similar size, complexity and stage of development, as the Company did not have sufficient history of its own volatility.  </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the Company had sufficient company-specific historical and implied volatility information.  As such, beginning the first quarter of 2020, the computation of expected volatility is based only on the historical volatility of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of <ix:nonNumeric contextRef="i847642b8e010448c92e39737e6b98cd4_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzQ4NDQ_4506d773-c381-4bc0-84cc-4434e77c0585">ten years</ix:nonNumeric>. The Company uses a simplified method to calculate the average expected term.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i636213adac7847e08acbb893531e6203"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5Mzc_05f799b4-75b7-4611-940b-c74b0606da54" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzEtMS0xLTEtMA_b94fbad2-e58a-4226-a061-6d2873b25138">6,706,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzEtMy0xLTEtMA_f2e51185-0b50-4d74-aa4f-0a096dbb2980">22.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzEtNS0xLTEtMA_d82624fc-6f22-4be7-92cd-621be1461dc8">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzItMS0xLTEtMA_261304e5-78b3-4302-acee-a74124448e66">1,851,327</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzItMy0xLTEtMA_68a8df7a-7de3-4a1a-a44a-edf329d1ba82">15.11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzMtMS0xLTEtMA_ddf8b29e-011c-43d0-9321-e1ba3984b7a6">504,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzMtMy0xLTEtMA_005c418a-ca36-4196-91be-d78dab7ff2a8">10.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzQtMS0xLTEtMA_a7d21839-3602-48fb-a912-bcdbb11e5613">795,523</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzQtMy0xLTEtMA_043de83a-c364-4ded-a9d8-0511e36195d6">20.72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzUtMS0xLTEtMA_ad528403-8034-4da6-9455-8079f1657057">7,258,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzUtMy0xLTEtMA_c0977dc4-a946-42e9-af0b-32db79ba8ffb">21.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzUtNS0xLTEtMA_8b88f162-a809-4b40-820f-e2a7d0e83e70">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzUtNy0xLTEtMA_49891b77-7bd9-4750-9456-225b9117a674">27,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzgtMS0xLTEtMA_e68377c3-10b6-4ef0-8b08-edc8d751a1e3">4,660,921</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzgtMy0xLTEtMA_ed12ac5f-97f5-4544-ad63-1275b0408ef0">22.92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzgtNS0xLTEtMA_ab01098f-744d-480d-859f-05bdc4acbf42">5.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzgtNy0xLTEtMA_4623b03e-1671-40d3-8fed-5e6b2f962017">13,906</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzktMS0xLTEtMA_eb1e4394-6a3c-4cd8-8964-64ead01f3db6">6,973,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzktMy0xLTEtMA_87ecf432-0de4-41bb-9c9e-d74694ad04ba">21.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzktNS0xLTEtMA_9aefc305-1335-4f79-85d9-d8a3a03a60cb">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzktNy0xLTEtMA_30992fbf-137c-4b8c-a57d-1c2257c6e4ba">26,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018 the Company issued <ix:nonFraction unitRef="shares" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzUzODk_9b9b8350-1c31-4bbe-aabe-0bd6af4c63cd">504,445</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzUzOTM_5bac09ee-7c24-40e9-80b6-56c72ddd1f8d">219,045</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU0MDA_dd4d116d-c093-4534-8c19-0860cd570c49">274,362</ix:nonFraction> net shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU1NzY_394c546c-b7a7-4b05-a59f-98191fd09346">5.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU1ODA_4f414824-4712-427d-bd0c-ecdd5f4c5b68">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU1ODc_2d9e17e8-3488-417e-ae12-59c349858d8e">0.9</ix:nonFraction> million during 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU3MTM_9c73edb7-96f1-4fc9-9b76-fe0ecb1982b4">10.68</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU3MTc_c47d8b1d-23cc-466f-a2b1-50867f399101">13.98</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU3MjQ_1f032af2-9032-4792-a8e2-9fd0dea1ff20">17.90</ix:nonFraction> per share, respectively. The total intrinsic value of options exercised during 2020, 2019 and 2018 was approximately $<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU4Mzg_d633dc4a-7dbb-4a14-aa72-0a0db4d5d094">4.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU4NDI_52d8085c-5766-499a-85a2-d30c5397d97d">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU4NDk_d20e88de-78b1-459d-8125-ab21703fca77">5.2</ix:nonFraction> million, respectively.&#160;The total fair value of stock options which vested during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU5NDM_47f84773-8503-4feb-a472-10c205335e13">16.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU5NDc_40587cfe-e5ca-4ee1-a6e4-397a10de798e">17.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU5NTQ_4c075771-63c2-4220-a17a-e6c0b981ee8c">16.4</ix:nonFraction> million, respectively.&#160;As of December&#160;31, 2020, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzYxMDQ_5cb3187b-3343-4106-b63a-e812318a3127">27.5</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzYxOTU_2c940fb2-7e98-4bfd-9f59-2033d30a5ea3">2.4</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded RSUs under the 2013 Plan to all employees except executive officers and employees with less than six months of service as of the grant date. Each RSU entitles the holder to receive one share of the Company's common stock when the RSU vests. The RSUs vest in two equal installments on the first and second anniversary of the grant date. Compensation expense is recognized on a straight-line basis. </span></div><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5Mzg_38fb23a4-61c1-421c-adc4-e10424724580" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2020:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdfaf6831a2d4d289947607db7469eff_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzEtMS0xLTEtMA_8d62149b-ca3f-4182-9605-87a76092207c">452,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifdfaf6831a2d4d289947607db7469eff_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzEtMy0xLTEtMA_7c86ea61-0b7f-4a85-9811-0a6bd75ae09f">15.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzItMS0xLTEtMA_7c1f5f0d-2e1b-4433-a89c-0b634529edc5">15,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzItMy0xLTEtMA_b250df52-7e46-4f6d-999b-a8e7cc4034e4">23.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzMtMS0xLTEtMA_5516588f-8f35-4d43-b629-50bb71b23ff1">210,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzMtMy0xLTEtMA_26b0ea46-627f-424e-a066-d8cb645c46ef">15.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzQtMS0xLTEtMA_d181da71-6074-4328-a1d0-97c6fd7589dd">47,300</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzQtMy0xLTEtMA_aff138cf-0463-40a5-af34-2a2c7482d77d">15.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2a4fb10b7154f3ebaf1b668d5d5333c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzUtMS0xLTEtMA_041afdfe-5b8c-45c0-a4a4-bf605d89eeb0">209,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2a4fb10b7154f3ebaf1b668d5d5333c_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzUtMy0xLTEtMA_cf3fe9ce-dcc1-4e01-a1e2-4679055263ba">15.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="if2a4fb10b7154f3ebaf1b668d5d5333c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY3ODA_44169134-6eaf-4a4c-a9c4-eeb0783e7460">2.0</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5MzI_3d200630-ba25-490f-955a-51e1aec09374">eight months</ix:nonNumeric>.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_175"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;<ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzMzMjY_c005e6b3-0ba1-4ccc-aa5d-e1e88a167525" continuedAt="i9d8311ed8cce45a7a0b13510b82f90bc" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9d8311ed8cce45a7a0b13510b82f90bc" continuedAt="i7fe38498700c45de9d87572599c5c0a5">For the years ended December&#160;31, 2020, 2019 and 2018 there was <ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzY2_5ef256e9-cc05-4fa5-9897-fce81bd0a9b1"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzY2_6bf8fd7a-92f3-4cd4-ab24-2f9896741b12"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzY2_b8d84fca-cd16-4209-b078-3ba60cff412b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i7fe38498700c45de9d87572599c5c0a5" continuedAt="i4daec5005e784aeeb1cd5277aab95975"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzMzMjE_07d4b954-00f5-41ce-a65b-f68d3380119e" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzMtMS0xLTEtMA_f153485b-ccc0-434b-a7fb-8eea7bffd40c">136,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzMtMy0xLTEtMA_74da60ab-fb18-4322-87d8-476a71756871">116,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzQtMS0xLTEtMA_ffea8365-309b-4000-be3a-4b48c39d8c49">37,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzQtMy0xLTEtMA_d7285d44-d3d8-492b-a599-175a63e9896f">31,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzUtMS0xLTEtMA_f046abc5-66a8-45d7-96e9-e631ff025240">50,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzUtMy0xLTEtMA_9f23a0d1-376b-4d6b-8b98-53866b73df0b">35,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzYtMS0xLTEtMA_0ef2dc4f-4462-4d28-b7b8-074424f360d2">23,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzYtMy0xLTEtMA_a774f83e-5b95-4be8-84b8-f518f87f8cd7">22,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzctMS0xLTEtMA_48a71f56-97df-44c7-9d3a-846bb1e481bd">8,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzctMy0xLTEtMA_92ccec19-1b41-47ce-844d-bfe7b7a5991b">8,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzgtMS0xLTEtMA_93579692-d59c-4252-b62c-23071139b48f">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzgtMy0xLTEtMA_18b7039c-e6c1-490d-93ae-b503a9e9128a">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEwLTEtMS0xLTA_ae098346-a455-4924-94c4-f8d8bf72fd02">14,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEwLTMtMS0xLTA_fa23f3b1-59c8-44f1-bbbb-197f3c228878">9,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzExLTEtMS0xLTA_c2acb574-48ce-48d4-8c93-eb13b91adc13">272,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzExLTMtMS0xLTA_c6a5bced-2de0-4a75-a168-c476324d47b6">223,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEyLTEtMS0xLTA_549d8963-2357-49d6-94c2-b0ef0e9a2d54">263,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEyLTMtMS0xLTA_f445c4bf-6a73-474f-a246-6b0fa3506153">214,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEzLTEtMS0xLTA_3ce3d551-3341-4472-8652-1a0d8667910d">9,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEzLTMtMS0xLTA_32d5fb86-8f70-432c-b8ec-c531cf98160e">9,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE2LTEtMS0xLTA_0811a382-adc5-482c-815c-36bb3c6256bf">2,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE2LTMtMS0xLTA_f3696096-4733-4e73-8167-1220050696f5">438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE3LTEtMS0xLTA_e0a08fc9-5a43-4641-abec-65af971e9dad">5,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE3LTMtMS0xLTA_8df7bf7f-09fd-4d9e-b2b8-956371ad628a">5,547</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE4LTEtMS0xLTA_1d099c26-535d-4110-a4d8-d5b9757e4dc1">1,854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE4LTMtMS0xLTA_f614a963-49d1-4e5d-a54d-41a681974bcb">3,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE5LTEtMS0xLTA_4f8b751c-e450-43b9-aa54-e441452dfdeb">9,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE5LTMtMS0xLTA_b609d3c0-fe49-45c2-9986-61aae5edb92f">9,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzIwLTEtMS0xLTA_b2115db3-fe81-4dd6-989e-773ebc1855d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzIwLTMtMS0xLTA_dabc62db-15d6-449e-a17c-6d6f836d3b0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ia12ba1f486ee48b387eed8cf479dabb6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzEwOTA_5864957b-bf48-42b9-9cf4-3e322d5c1f0c">648.0</ix:nonFraction> million. Of these NOLs, $<ix:nonFraction unitRef="usd" contextRef="iede31b1fe9ba4eb59488549ad0ed810f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzExMDk_66cd1a18-0cce-4d15-a8c7-7ffa8e21c647">237.7</ix:nonFraction> million will expire in various years beginning in 2025 through 2037. $<ix:nonFraction unitRef="usd" contextRef="i8760a3584cb24373bea7740e94ca3528_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzExNjk_c294cd90-e20b-4bc0-a4af-151c76498fe6">410.3</ix:nonFraction> million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $<ix:nonFraction unitRef="usd" contextRef="i4deebaa10a1a47c48da755ae23565886_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzEzMDY_e9b1b683-7213-4301-9082-bc0c88d50fb6">69.6</ix:nonFraction> million which will expire in various years beginning in 2022 through 2039.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i787eb452c45b49288fbda9f5890e9106_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE1OTA_a1de2d04-3a3f-4e30-892b-915f49416d7a">13.5</ix:nonFraction> million of the Company's U.S. Federal NOLs are limited for use over the years 2021 &#8211; 2028 in which a range of such amounts could be utilized on an annual basis of $<ix:nonFraction unitRef="usd" contextRef="i0eced2ea218c49c0a97e0443fe143c83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OperatingLossCarryforwardsAnnualLimitationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE3NDQ_0af53157-8e7e-4e16-b7ad-3510d28fcbf9">0.2</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i02d5390f0831417aaa47113ae87c3835_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OperatingLossCarryforwardsAnnualLimitationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE3NTA_ea37e691-0e91-488b-a94a-0d394d59430f">1.4</ix:nonFraction> million. The remaining $<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OperatingLossCarryforwardsNotSubjectToLimitation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE3Njg_bcd0686c-d02d-4b6f-b8b6-9800f6f4d936">634.5</ix:nonFraction> million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i4daec5005e784aeeb1cd5277aab95975"><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzMzMjM_e9c96dc1-f72e-4a81-a45d-45cbc7b48d53" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzMtMS0xLTEtMA_ac6bbcff-bb75-499e-a1c4-6a924de12c2d">27,245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzMtMy0xLTEtMA_450554ee-5337-421b-9beb-a966db6c9268">31,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzMtNS0xLTEtMA_fba5eaaa-0973-489f-a5d3-c2ef383ef8fb">36,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzQtMS0xLTEtMA_1c1d6771-ff98-4a8a-bb93-1c40f713cd88">8,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzQtMy0xLTEtMA_764b4363-76e5-41e0-8fe5-c61f7d93bbdf">9,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzQtNS0xLTEtMA_ee705d37-5a32-4499-8599-26968f3d9cef">11,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzUtMS0xLTEtMA_9ab20d0c-5a89-45dc-89ba-8d88781c5092">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzUtMy0xLTEtMA_f721449f-75a1-42be-9681-32e2fbc54022">2,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzUtNS0xLTEtMA_9862e2c0-34bb-4651-b48e-7b8d9b9bdfb9">4,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzgtMS0xLTEtMA_0dd3affd-8045-40a2-aa6f-b6b16d79f6f0">14,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzgtMy0xLTEtMA_ea64a2f0-1138-408e-8563-4f5a297c2f6a">5,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzgtNS0xLTEtMA_4fd41a46-4ccf-46e3-bb93-13b9019be141">8,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzktMS0xLTEtMA_09029abf-08b8-4359-a198-fc085f9a107f">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzktMy0xLTEtMA_fd21d6a7-4e39-4e94-93b5-ca04e7109c5f">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzktNS0xLTEtMA_30cdfbfc-5760-453e-b018-2760dacfe8f6">872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEwLTEtMS0xLTA_0cd9d05f-850c-4424-b005-63181453c6b5">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEwLTMtMS0xLTA_7c089986-66bb-4720-90b4-71f95ecd689b">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEwLTUtMS0xLTA_47e913d5-b13b-4b19-b1a8-3bf6896e9270">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzExLTEtMS0xLTA_4d44431a-3d18-4b4f-a106-57d74d8c70e4">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzExLTMtMS0xLTA_4e5a4cb5-b0fa-4d41-9f11-4c44b0a98911">1,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzExLTUtMS0xLTA_dab715f8-a0b7-400c-ad65-2f1fcccb8224">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEyLTEtMS0xLTA_48d6fc5c-a84f-4647-8267-82d6137a5b3f">48,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEyLTMtMS0xLTA_4c23239a-3976-4f5e-907e-2c4247273ec3">42,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEyLTUtMS0xLTA_b14d180c-d4fe-4ac0-ade1-65f196a76b8b">60,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEzLTEtMS0xLTA_8f5ad022-1c78-44c8-9986-d9ef95a48669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEzLTMtMS0xLTA_42190e3f-e4c3-4171-8918-fe23853602bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEzLTUtMS0xLTA_6885d486-7539-45eb-b442-e89af975edfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzMzMjU_303e6884-8444-4dea-a52b-525638cc6072" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzItMS0xLTEtMA_8b7153e3-7d87-4bc8-8308-f4456ee38c31">4,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzItMy0xLTEtMA_7f9523af-fe14-42aa-bd4f-872574063591">4,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia662d353fd8d45c0b6ef76a73d9eab63_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzItNS0xLTEtMA_3c5ebbb3-b6a5-4cb8-8ef5-630a8bb27f5e">3,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzMtMS0xLTEtMA_716379a9-6ec6-4fb6-989f-ee2dabeabf49">839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzMtMy0xLTEtMA_bf858099-b7e4-4de1-afee-b29e2e6db8b7">637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzMtNS0xLTEtMA_2b9d500f-0bd3-4eb1-8814-ef830bfae9c8">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzQtMS0xLTEtMA_11e6539d-4b59-4b4d-ae14-307c5d2daddc">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzQtMy0xLTEtMA_03cd3998-ade3-44e4-9a22-0ed73b074404">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzQtNS0xLTEtMA_23a4eeea-7820-4d28-9660-2fc0f1065591">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzUtMS0xLTEtMA_47159093-5588-4c9d-bd5c-39712c3e8e6c">6,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzUtMy0xLTEtMA_f672762c-0b58-497e-8637-d2a9730bd73d">4,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzUtNS0xLTEtMA_fba7ce18-583e-484c-bed9-b94f3a10f997">4,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, of the total gross unrecognized tax benefits, approximately $<ix:nonFraction unitRef="usd" contextRef="if8c8761deec04f95aecb8597243730f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzIzMDA_0e3587cc-2b36-4b86-95f1-c5d76003664f">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzIzMDc_47be3c90-1b07-45d3-ab71-95a3f0a2f344">4.9</ix:nonFraction> million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, the Company has <ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE2NDkyNjc0NDUzNzg_7eb742ff-3f9e-4bab-a671-a4a062b66cba"><ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE2NDkyNjc0NDUzNzg_8dde6608-5b01-42d3-94d3-d7c416599ef3"><ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE2NDkyNjc0NDUzNzg_d8a793bb-51e9-4ae1-9349-0764f2a1ae05">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">The Company's U.S. Federal and state income tax returns from 2001 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_181"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzMyMzM2_777cf963-6a0d-4105-8887-c509bf8911b1" continuedAt="id31354fa2d01415580f6ed8709b662ce" escape="true">Collaboration and Other Agreements </ix:nonNumeric></span></div><ix:continuation id="id31354fa2d01415580f6ed8709b662ce" continuedAt="if2298aaebfd6475e988deefffe115dcb"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte for retifanlimab (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i35285b9536cb42819f07a5e10f10a803_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzYyOQ_b5afcc00-3f1d-46fd-bdf5-0220fa8bc721">150.0</ix:nonFraction> million in 2017.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="if008047c1927420f94d6d0b9470befc2_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzg0OA_9f16fb06-9a2e-473f-86e8-f376f92ea771">420.0</ix:nonFraction> million in development and regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="if008047c1927420f94d6d0b9470befc2_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzkwMw_a8d68e74-d343-4f18-a6c9-5fb1c5967972">330.0</ix:nonFraction> million in commercial milestones. From its inception through December&#160;31, 2020, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="if40f0f15e6a24dc0ae3308ba4fd42d06_D20171001-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzk2OQ_2f6bac21-6f24-4ad4-8b7e-22199515d74e">55.0</ix:nonFraction> million in development milestones under this agreement, and another $<ix:nonFraction unitRef="usd" contextRef="if40f0f15e6a24dc0ae3308ba4fd42d06_D20171001-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYyMzk_add63174-e648-4ea9-b39b-3577adbddcc2">10.0</ix:nonFraction> million milestone was achieved related to development progress of retifanlimab outside the U.S. subsequent to December 31, 2020.   If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="i4d3801ae5b2b4734b7b504e59402757a_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzExMDA_8037b945-ebb2-4c87-97e0-cd21ed4ceab5">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic88b6f87de8b48c1aefa96bec6d6e029_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzExMDY_91c29194-3d58-49d0-a9eb-4dc077a6288e">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="if2298aaebfd6475e988deefffe115dcb" continuedAt="icb4dbd63d7254814986b81f67d5073b3"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i79ca36c995024fcda45aec3f3a112ef3_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI2NDQ_f85c7057-547a-4073-8709-755e5a9cc085">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic9abc33023e44114b55b4f12898b8282_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzUzMDM_0ffc64f2-05d2-458d-ba6c-8bd979101973">15.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retifanlimab</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> meeting certain clinical proof-of-concept criteria. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. During the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for two development milestones totaling $<ix:nonFraction unitRef="usd" contextRef="i921686739722463c9fad09ea5aea9c8f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzUzMjA_72fc3d48-966a-42b8-bf2f-2c0167b3f50d">40.0</ix:nonFraction> million related to clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i35285b9536cb42819f07a5e10f10a803_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzQ1NTU_b5afcc00-3f1d-46fd-bdf5-0220fa8bc721">150.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $<ix:nonFraction unitRef="usd" contextRef="i5a4db4be284f4edfaa25820bc601700f_D20170101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzQ2Nzk_4d260b7d-9c1c-4e18-a290-b56b86470f03">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed over a period spanning 2017 and 2018. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i0274a39f90984b378198325f447e1d04_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzU4NzU_a42d0021-b352-47f4-9594-c792ee043b82">40.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic43e5cf8fc164202a6ba3322517e2e89_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzU4NjY_df54fd0a-71c6-4ef1-b376-b3f4c4c9554f">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia989b7cb90484d43be29e03fd1165709_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzU4NzA_dfb4afd2-361c-4c55-bf97-9864d1dba2d1">18.8</ix:nonFraction>&#160;million under the Incyte Agreement during the years ended December&#160;31, 2020, 2019 and 2018, respectively. The revenue recognized during the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reflected milestone revenue of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i921686739722463c9fad09ea5aea9c8f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDc2NjI_72fc3d48-966a-42b8-bf2f-2c0167b3f50d">40.0</ix:nonFraction> million, and t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he revenue recognized during the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included milestone revenue of $<ix:nonFraction unitRef="usd" contextRef="ic9abc33023e44114b55b4f12898b8282_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzY0MDI_0ffc64f2-05d2-458d-ba6c-8bd979101973">15.0</ix:nonFraction> million.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ia4744971aa884484b209865c89d5a5d1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzcxODE_8be19928-a24a-4866-ad90-29cdf3a3e78a">8.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic889e33f540545a6a24b79e6435032eb_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzcxNzY_91e80a32-47a8-4f93-ac3a-163b0ba33af3">22.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i19c7230b384645a48a881abee6fc9595_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzYyOTU_893d6c3e-c0ae-4f92-bb83-17e8c86dfe68">22.2</ix:nonFraction>&#160;million, respectively, for services performed under this agreement. </span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="icb4dbd63d7254814986b81f67d5073b3" continuedAt="ifefe237c02894c6ebc1f2354fd4b5a1b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expended) related to the manufacturing services.   During the year ended December&#160;31, 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i31b103b2021742a2aa611443cc804a22_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODAyNzY_fdf67cd0-0b01-4ab8-a922-2a6eb875ce66">1.4</ix:nonFraction> million for services performed under this agreement. </span></div><div style="text-indent:42pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i69b00209713a42919d237bd84b5347ff_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk2NDI_a4ddb75f-8152-4bd5-942e-cc21ff164f24">25.0</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="if5b5d258671b4db29f62cd54a91316b0_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk2NDc_5bbe7480-2b42-4834-8388-03de8d48fe13">22.5</ix:nonFraction> million after netting value-added tax withholdings of  $<ix:nonFraction unitRef="usd" contextRef="i69b00209713a42919d237bd84b5347ff_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundablePaymentTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk2OTg_ebfa01d6-e174-4e21-9002-4282ddcae9ad">2.5</ix:nonFraction>&#160;million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i761691dda30f487faa377ea767d90b27_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk4NDU_afcc773f-2bf2-42b3-9dd2-9cddf5d5fdc7">140.0</ix:nonFraction> million in development and regulatory milestones, $<ix:nonFraction unitRef="usd" contextRef="if2421978c32548a692cbb679e16f1769_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk4OTE_d4bc646e-067f-451b-b270-0fdb14913043">4.0</ix:nonFraction>&#160;million of which ($<ix:nonFraction unitRef="usd" contextRef="i40903b6d1a844575b81590c15ea6ad69_I20200229" decimals="-5" format="ixt:numdotdecimal" name="mgnx:EntitledMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk5MDU_4df4f7d7-e969-46a4-bed0-1870c55eed42">3.6</ix:nonFraction>&#160;million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="if2421978c32548a692cbb679e16f1769_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenuesTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk5NTU_2ed39e74-2e74-4e50-965f-bc9e1bb4377f">0.4</ix:nonFraction>&#160;million) was earned during the year ended December 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to <ix:nonFraction unitRef="number" contextRef="idaa6b8a1bef549409289b02f594e0e03_D20181101-20181130" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYyMTU_f8f7ac93-6989-4d32-855f-073e74f3be5e">20</ix:nonFraction>% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and <ix:nonFraction unitRef="number" contextRef="i264b652dc2a449aaad3d8d44d6eac051_D20181101-20181130" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYyMjE_0de1b178-4d02-44a9-be62-776d2f0f6611">10</ix:nonFraction>% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $<ix:nonFraction unitRef="usd" contextRef="if5b5d258671b4db29f62cd54a91316b0_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzE1MzM_5bbe7480-2b42-4834-8388-03de8d48fe13">22.5</ix:nonFraction> million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the  short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also  recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i7528a17162cd4516ba9f826eb391dfe2_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM2Mjc_eb20ff6d-0461-437f-b3d6-17eeaac00b64">8.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="icdb32608cb0a4fa2ab949afb86d7f2ea_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM2MzI_393b59ea-a641-4fe8-b36a-a51145d1d7b2">16.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if5002f370ab2410aa505e7023a7c03b1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM2NDA_f6340eea-314b-4762-9f1a-599967baf9d9">1.3</ix:nonFraction>&#160;million, respectively, related to the Zai Lab Agreement. Revenue recognized during 2020 included net milestone revenue of $<ix:nonFraction unitRef="usd" contextRef="i40903b6d1a844575b81590c15ea6ad69_I20200229" decimals="-5" format="ixt:numdotdecimal" name="mgnx:EntitledMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM3NTg_4df4f7d7-e969-46a4-bed0-1870c55eed42">3.6</ix:nonFraction> million, whereas revenue during 2019 and 2018 reflected the recognition of the deferred upfront payment. At December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i761691dda30f487faa377ea767d90b27_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM4Njc_cc1a6f86-70c6-4f94-aa78-5645528a2d5a">5.0</ix:nonFraction> million of revenue was deferred under this agreement, all of which was current and recognized in 2020. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within the contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab. The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ifefe237c02894c6ebc1f2354fd4b5a1b" continuedAt="i0c381254f705457d89409889ef94026a"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with an alternative use and the Company has an enforceable right to payment for the performance completed to date. During the years ended December&#160;31, 2020 and 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ie5b5491ae6264b9a977e0986eb5f5f09_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzQ4NzQ_8d86cd5d-9cd8-4558-879f-aad896c30d02">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i79fe409dced14166bc3d283feb339c66_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzQ4ODI_a222e674-7c7a-4074-a78d-8652d3dca9c3">2.2</ix:nonFraction>&#160;million, respectively, related to the Zai Lab Clinical Supply Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i4cf709b6a97f4324bf07c7b35ff8dcf8_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwMjU_7fcefad2-b6b8-4be3-8e8e-0bd42356038d">20.0</ix:nonFraction>&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i4936e447493b4718a73a3e856e8466cd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwNDQ_5bea22e9-c5f7-4a9d-af90-3a0bbd5bb523">312.0</ix:nonFraction>&#160;million in potential milestone payments and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="i4cf709b6a97f4324bf07c7b35ff8dcf8_D20201201-20201231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwNTQ_67d1cd0e-d454-4709-b4ac-07eb71232592">10</ix:nonFraction>% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i4936e447493b4718a73a3e856e8466cd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwNzA_11ebc659-b7a9-4295-ad79-8d0851137c8e">22.2</ix:nonFraction>&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="ia8d4cb3c32ee4849af0342d8ac09701d_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwODk_314a9225-8f2e-4a89-8e63-d21700c248ad">20.0</ix:nonFraction>&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $<ix:nonFraction unitRef="usd" contextRef="i4cf709b6a97f4324bf07c7b35ff8dcf8_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYxMDc_e59934c5-1920-49a7-bb15-811a4b5d1cb8">2.2</ix:nonFraction>&#160;million allocated to the research and development activities will be recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i28f6817da3524d99a079cfc05dadfb58_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE5OTU1_4600688a-2184-443e-b8da-d5de3dbe9326">15.0</ix:nonFraction>&#160;million. Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIwMDYz_c8c5d54b-33d1-410c-b613-7a796b20b310">135.0</ix:nonFraction>&#160;million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to <ix:nonFraction unitRef="number" contextRef="if317058b73fa4c929dab128dd0783ce9_D20190701-20190731" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYxOTY_26f863a6-430a-4f46-9daa-a93f0bde53a6">20</ix:nonFraction>% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="i28f6817da3524d99a079cfc05dadfb58_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIxMDA1_4600688a-2184-443e-b8da-d5de3dbe9326">15.0</ix:nonFraction>&#160;million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i0c381254f705457d89409889ef94026a" continuedAt="i2918c02ad75a45838d2bc0694a361ec0"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="ib65817edf9ea4a70a15c2ee1b06d2435_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIxNDIw_215c312f-fbd2-4e60-bc7d-be115ae0aeb4">1.0</ix:nonFraction>&#160;million. I-Mab paid the Company for the cost of this study as the costs were incurred during 2019 and 2020, and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. During the years ended December&#160;31, 2020 and 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ib65817edf9ea4a70a15c2ee1b06d2435_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM0NDQ_303f8106-5469-45d3-96de-1fe9cdcdca0e">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5198817fd6ce48d5b36e1a65aa5dceb0_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM0Mzk_47854ddd-f6ea-4d58-bd22-e4581bfdd3fe">2.3</ix:nonFraction>&#160;million, respectively, related to the I-Mab Agreement. At December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIyODk2_474c67e5-9070-44cf-b420-2a183f5793a8">11.4</ix:nonFraction>&#160;million in revenue was deferred under the I-Mab Agreement, $<ix:nonFraction unitRef="usd" contextRef="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIyOTUw_5e40788a-e98e-4058-b692-a13993dc2f3e">4.5</ix:nonFraction>&#160;million of which was current and $<ix:nonFraction unitRef="usd" contextRef="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIyOTc4_a93836c3-06d5-4b59-b343-a72f7f3ce59a">6.9</ix:nonFraction>&#160;million of which was non-current. At December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i883a0b58cc464c758fb7cd4f1a43cde7_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM2MzY_3e5ce385-fcac-41ca-9a2a-ca4c5cee579a">13.5</ix:nonFraction>&#160;million in revenue was deferred under the I-Mab Agreement, $<ix:nonFraction unitRef="usd" contextRef="i883a0b58cc464c758fb7cd4f1a43cde7_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM2NDE_9d297296-1e41-4a67-b51c-e55f2c6abbb4">4.4</ix:nonFraction>&#160;million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i883a0b58cc464c758fb7cd4f1a43cde7_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM2NDY_852724ba-f44a-4487-b57a-1c3c163b1c1c">9.1</ix:nonFraction>&#160;million of which was non-current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention Bio, Inc. (Provention) pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2794f662b6aa4beaa84d0ce6906344ec_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NTg4NTM_ce3dd18b-4539-4d24-9ec9-a21fdf209aba">2.50</ix:nonFraction> per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="id66268ce470743409fc8e1e2f94e9801_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NTkwMTM_543e3f58-ddc8-430e-92e9-1cfb84323383">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="id66268ce470743409fc8e1e2f94e9801_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NTkwNjg_dad11bd0-ad19-43df-b98e-5f45b089927b">225.0</ix:nonFraction> million in commercial milestones. As of December&#160;31, 2020, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic6b51b6783874d27a5e578d32a2386c7_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjAwODc_62b7f6fa-2d46-484f-bbbd-1e0ad4633839">2.50</ix:nonFraction> per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i0bc2607458784ba0a39a83024e0690aa_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjAyNDY_cc008c5a-00a1-4f7b-8070-c9b983c183fb">170.0</ix:nonFraction> million in regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i0bc2607458784ba0a39a83024e0690aa_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjAyODU_02b263c0-a33e-463c-9240-106cece9c304">225.0</ix:nonFraction> million in commercial milestones. As of December&#160;31, 2020, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i0bc2607458784ba0a39a83024e0690aa_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjA3Mzc_e27c900c-4624-4d98-b6c8-5ec65746add8">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="i5506bcb7455143afb88326e2bc2e1766_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjE1MTE_b32614f3-8d74-4297-8c53-705d4bdec4e9">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase a total of <ix:nonFraction unitRef="shares" contextRef="i5506bcb7455143afb88326e2bc2e1766_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjE1OTI_b54f8b1b-1a1f-4817-980a-cd5f39c7f00c">2,432,688</ix:nonFraction> shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i2918c02ad75a45838d2bc0694a361ec0" continuedAt="ic801bc4db94446a39c41d5c83f780130"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i8bdcb76501ca490393d206ec8477ba60_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjI1MzA_95f5c55e-315f-4642-ad70-28baf9516f00">6.1</ix:nonFraction> million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018.  The warrants were revalued at each reporting period based on the current Black-Scholes parameters until the warrants were exercised in July 2019. The resulting increase or decrease in the value of the warrants is reflected in Other income (expense) on the 2019 consolidated statement of operations and comprehensive loss.  In July 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servier </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In  2012, the Company entered into a collaboration agreement with Servier and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). In 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab. During the term of the agreement, Servier did not exercise its options for either MGD007 or the third DART molecule. In July 2019, Servier informed the Company of its intention to terminate the Servier Agreement and the agreement was terminated effective January 15, 2020. As a result of this termination, the Company will regain full exclusive, worldwide commercialization rights to develop and market flotetuzumab. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, Servier made a nonrefundable payment of $<ix:nonFraction unitRef="usd" contextRef="iaf67de44e2a04b7c9869197b5d5a8db3_D20120901-20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjkyMTM_72958b94-3869-4ce0-90fb-0018eee6556f">20.0</ix:nonFraction> million to the Company. The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options. The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package. The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights. As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="iaf67de44e2a04b7c9869197b5d5a8db3_D20120901-20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzA2MTY_dac16f26-d8fd-400b-bd0d-8a2686510343">20.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two milestones were achieved in 2014 when the Investigational New Drug (IND) applications for flotetuzumab and MGD007 were cleared by the FDA. Upon achievement of each milestone, the constraint related to the $<ix:nonFraction unitRef="usd" contextRef="iaf67de44e2a04b7c9869197b5d5a8db3_D20120901-20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:MilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzEzMDE_9a7b34ac-17bc-4af8-a45c-0f26955ada40">5.0</ix:nonFraction> million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue associated with each performance obligation was recognized as the research and development services were provided using a cost-based input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurred over this time period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligation. <ix:nonFraction unitRef="usd" contextRef="i22e923f8da4f403d9f71bbc5dcacf4c5_D20200101-20201231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzE5Mjk_5f53a1e2-4595-443c-ad41-1f4a5122747c">No</ix:nonFraction> revenue was recognized related to the MGD007 option during the years ended December&#160;31, 2020 and 2019. During the year ended December&#160;31, 2018 the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i0913a1b864a54032af94f46428788ecb_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzIwODE_ead5e8a4-e1a3-485f-83c0-d980946b6ca4">1.9</ix:nonFraction> million related to the MGD007 option. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $<ix:nonFraction unitRef="usd" contextRef="i1b4293b73e6b48ab8ca56a0aa4f4a336_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzIyNzg_e82195a8-1708-4725-bcca-e4310d59ce6d">15.0</ix:nonFraction> million license grant fee. Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808. The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ic801bc4db94446a39c41d5c83f780130" continuedAt="i87ba2bf37c1b4db8a853e97e2f23993c"><div style="margin-bottom:9pt;margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license. The Company evaluated its performance obligation to provide Servier with an exclusive license to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of $<ix:nonFraction unitRef="usd" contextRef="i1b4293b73e6b48ab8ca56a0aa4f4a336_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYxODg_e82195a8-1708-4725-bcca-e4310d59ce6d">15.0</ix:nonFraction> million and Servier consumes the benefits of the license over time as the research and development activities are performed. Therefore, the Company was recognizing the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. As noted above, in July 2019, Servier informed the Company of its intention to terminate the Servier Agreement and the agreement was terminated effective January 15, 2020. Therefore, the Company reassessed the end date of its performance obligations under the contract to be January 15, 2020. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018 the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i78b72bb5c40c49d9b35cc590ba9cafc3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQyNzI_f00aaf0d-b18a-4dae-91fe-391c1f675821">1.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i799c2d0004184beeab2fb18bb2844605_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQyNzc_26f7454d-2c19-4ab2-ad3f-87d10f5076e5">11.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="idd6f1db210074fa491c51e6386544604_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQyODY_c0f215ce-1ddb-4d2e-911e-5164772cfe3e">1.2</ix:nonFraction> million, respectively, related to the flotetuzumab license grant fee. At December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="iff5d8a80f0b24b2f8b060afc429d38e9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQzNjA_bc7d11f1-6926-478e-8c51-ccd19c3d1343">1.0</ix:nonFraction> million of revenue related to the flotetuzumab license grant fee was deferred, all of which was current and recognized in 2020.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company follows its policy to record expense incurred as research and development expense and record reimbursements received from Servier as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period. During the years ended December&#160;31, 2019 and 2018, the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i36820e64f4634e7892f209af43a3a307_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQ5NTQ_7f933db4-566a-45c1-9e82-d7c3b8497fd7">3.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i481a6c266fd34525a08d8b19efb3a3a5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQ5NjI_ff01067e-5380-4906-9c18-b65e098d9c9a">6.0</ix:nonFraction> million, respectively, as an offset to research and development expense under this collaborative arrangement. No offset to research and development expense under this collaborative arrangement was recorded during the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets (Roche Agreement). During the research term, both companies would leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate. Each company would be responsible for their own expenses during the research period. In 2019, Roche informed the Company of its intention to terminate the Roche Agreement, and the agreement was terminated effective November 21, 2019. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i311557add6db476c974b15fe543b53a3_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI0MDMy_0079263b-e913-4496-a007-1a7b65c020fe">10.0</ix:nonFraction> million. The Company would also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i81b5a53b426d4596a8deebbcbbd64643_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI0MTIy_cc80280b-6067-459c-a6be-2f5e875d355c">370.0</ix:nonFraction> million in potential milestone payments and royalties on future sales. As of December&#160;31, 2020, the Company has not recognized any milestone revenue under this agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period. The Company determined that the license was capable of being distinct, but was not distinct in the context of the contract because it had limited value to Roche without the research activities required to be performed by the Company. Therefore, the Company concluded that there was <ix:nonFraction unitRef="performanceobligation" contextRef="i50ebf3ffdbfd4f73a07d547a319c5d2c_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI0ODY5_77599e9f-6a31-4802-9a47-129e00a3db30">one</ix:nonFraction> performance obligation under the agreement. The Company determined that the transaction price of the Roche Agreement was $<ix:nonFraction unitRef="usd" contextRef="i50ebf3ffdbfd4f73a07d547a319c5d2c_I20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI0OTkz_319f9b04-db5c-4664-b283-1b773f8cddc1">10.0</ix:nonFraction> million. The potential milestone payments were </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and were excluded from the transaction price. Any consideration related to sales-based royalties would be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore were also excluded from the transaction price. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i50ebf3ffdbfd4f73a07d547a319c5d2c_I20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI1MzQ1_319f9b04-db5c-4664-b283-1b773f8cddc1">10.0</ix:nonFraction> million transaction price was being recognized over the expected research period, which was originally <ix:nonNumeric contextRef="i68fe313822074061be5bf3c037d98d1e_D20171201-20171231" format="ixt-sec:durmonth" name="mgnx:UpfrontPaymentRecognitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI1NDQz_91d80a38-a062-499b-8bf1-13678c3c2aa2">30</ix:nonNumeric> months, using a cost-based input method to measure performance. Upon notice of Roche's intent to terminate the agreement in August 2019, the recognition period was adjusted to end in November 2019. There was <ix:nonFraction unitRef="usd" contextRef="i81b5a53b426d4596a8deebbcbbd64643_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDc4Mzc_dbc5f4df-ad01-4116-8e39-ab72365c59af">no</ix:nonFraction> revenue recognized under this agreement during the year ended at December&#160;31, 2020.  The Company recognized revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="i42ab5ff2130a40b1a0aec0d6d8f54c67_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI1Njky_a486fe93-b5ce-4d0d-8a8f-921836032be9">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd0782694ada422ca317357bc074882c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI1Njk5_152642e5-58cc-4404-85d0-a74e6dd8407e">4.0</ix:nonFraction>&#160;million, respectively, during the years ended December&#160;31, 2019 and 2018. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boehringer Ingelheim International GmbH</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a <ix:nonNumeric contextRef="ie9bbec66f02a478c848c4c9082abfa02_D20101001-20151031" format="ixt-sec:durwordsen" name="mgnx:CollaborationAndLicenseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzEzNzQzODk1NTIxNTAw_2f5d7d95-4a49-4b4c-9c51-e838e0002e99">five-year</ix:nonNumeric> period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.  During the evaluation period, BII selected <ix:nonFraction unitRef="productcandidate" contextRef="i1d18f8528615463aa7159bbb5c8c9ca7_I20151031" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfProductCandidates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODQyMDQ_fcb321a0-2802-4c70-8957-372a7cc6ef60">two</ix:nonFraction> product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie9bbec66f02a478c848c4c9082abfa02_D20101001-20151031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODQzMzk_098e2343-a8c6-4d60-8dea-44d1a49f70e3">15.0</ix:nonFraction>&#160;million which was fully recognized </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i87ba2bf37c1b4db8a853e97e2f23993c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to December 31, 2015. The variable consideration under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, BII agreed to a payment of $<ix:nonFraction unitRef="usd" contextRef="i8dfc6229eff84fc5bc5f1546988286eb_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentMilestonesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODQ2NTc_9c7fcf38-948f-42aa-a884-e82771e633b6">12.0</ix:nonFraction> million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $<ix:nonFraction unitRef="usd" contextRef="ic3620e7cdab24c1b9ca940443012e7d1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODQ4MDU_2964edd5-dfd1-477f-bd15-13a3d497e917">12.0</ix:nonFraction> million during the year ended December&#160;31, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September&#160;15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="i33759800192341f2aad1c701d3f8d023_D20150915-20150915" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDkwNTQ_8ea7cd27-1a50-497b-92de-6e4b6cfcf8a1">two</ix:nonFraction> DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This contract includes a base period of $<ix:nonFraction unitRef="usd" contextRef="i33759800192341f2aad1c701d3f8d023_D20150915-20150915" decimals="-5" format="ixt:numdotdecimal" name="mgnx:FundedValueOfBasePeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDk1ODY_2439c55b-d4eb-492b-9c48-3461dc6afd35">7.5</ix:nonFraction> million to support development of MGD014 through IND application submission with the FDA, as well as up to $<ix:nonFraction unitRef="usd" contextRef="iaa516c3811054de6a63d0438076fc6d1_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDk2ODk_2ee01320-ae12-4264-812a-7e3ed690325c">17.0</ix:nonFraction> million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $<ix:nonFraction unitRef="usd" contextRef="iaa516c3811054de6a63d0438076fc6d1_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:TotalPotentialValueUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDk4Mzg_c158595a-3b33-44ad-950a-7674ecc357b5">24.5</ix:nonFraction> million. The total potential period of performance under the award is from September 15, 2015 through December&#160;31, 2024. In 2017, NIAID exercised the first option in the amount of up to $<ix:nonFraction unitRef="usd" contextRef="i9149ccf8fad640259305ee4963fe44d6_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MTAwMDY_8b43fae3-6545-43aa-a9c1-2312d3ec41b5">10.8</ix:nonFraction> million to fund the commencement of the MGD014 clinical trial and development of the second DART molecule. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i73fce89d7ee84c7f9e43c656a72d517e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MTAxNDM_17fc08ab-7476-41b3-acf8-c70fbf98f597">7.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia6be2dbbda2c4a37b4060f380fd2b3b1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MTAxNDg_436ba199-a5bc-4920-9aad-c2e93ea0dc6c">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i541afd290f08418499ed50f29b1803fc_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MTAxNTY_3bb4343f-3d9c-42ff-b903-36a549372d25">1.3</ix:nonFraction> million under the NIAID contract during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_187"></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODcvZnJhZzplMzljOWVhMTVmYTQ0NTU5OWRhMzU1Y2VmMzVkZWM1MC90ZXh0cmVnaW9uOmUzOWM5ZWExNWZhNDQ1NTk5ZGEzNTVjZWYzNWRlYzUwXzk2Ng_b0bcfa71-629a-4bfa-a875-06c1b613a7a1" continuedAt="i9b71c096982349a5b741167774e1a877" escape="true">Commitments and Contingencies</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9b71c096982349a5b741167774e1a877" continuedAt="ib9f70edadb9648369065c50e08154035">&#160;</ix:continuation></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib9f70edadb9648369065c50e08154035">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  Plaintiff filed an Opposition brief on January 29, 2021, to which the Company plans to file a timely reply. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_190"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzY0NA_dda375c2-85cd-4d97-b4b9-c9818d0a57b4" continuedAt="i5c004b03e12b41aeaebe37dbe596ab1e" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="i5c004b03e12b41aeaebe37dbe596ab1e"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least <ix:nonNumeric contextRef="i7d3639bf682f4179b89f96aa342a7e53_D20140101-20141231" format="ixt-sec:duryear" name="mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzE5NA_b9ba7282-bd4a-44e6-a4e2-7186848e50b1">21</ix:nonNumeric> years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to <ix:nonFraction unitRef="number" contextRef="i7d3639bf682f4179b89f96aa342a7e53_D20140101-20141231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzMyMw_fc717973-dc63-485f-a504-4148627f1002">100</ix:nonFraction>% of their salary, subject to government maximums.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees are <ix:nonFraction unitRef="number" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="INF" name="mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzM4OQ_29bcf327-ae73-4293-8cf5-eed189d5dafa">100</ix:nonFraction>% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled $<ix:nonFraction unitRef="usd" contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzU4Mg_4c2ee153-b4eb-41bc-8c60-92110763e3b8"><ix:nonFraction unitRef="usd" contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzU4Mg_ffa4ff03-6ef8-4914-af2e-4fcd5bbaadb0">1.4</ix:nonFraction></ix:nonFraction> million in each of the years ended December&#160;31, 2020 and 2019, and $<ix:nonFraction unitRef="usd" contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzU5Mw_11265534-6116-4253-8a35-3984ead2b8ec">1.3</ix:nonFraction> million for the year ended December&#160;31, 2018.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 28</span></div></div></div><div id="icb3df34c6cd545b49b40a9d09c99e0a0_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation of the Company and Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex31.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex33.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, respectively, to the Company's Current Report on Form 8-K filed on October 18, 2013)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex34.htm">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513394786/d575431dex42.htm">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit4-2202010xk.htm">Description of Common Stock</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312515075224/d838054dex43.htm">Investor Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated December 19, 2014 (incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K filed on March 3, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex1014.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated October 24, 2017 (incorporated by reference to Exhibit 10.3 to the Company's Annual Report on Form 10-K filed on February 27, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex103.htm">Company 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex104.htm">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex105.htm">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex106.htm">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex107.htm">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534515000013/exhibit10-2.htm">Form of Restricted Stock Units Grant Notice under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 6, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000155278116002035/e00576_ex4-1.htm">2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-214386) filed by the Company on November 2, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1015.htm">Employment Agreement between the Company and James Karrels (incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-3.htm">Employment Agreement between the Company and Ezio Bonvini, M.D. (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534517000041/exhibit1016.htm">Employment Agreement between the Company and Eric Risser (incorporated by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K filed on February 28, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">Amendment No, 1 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated March 15, 2018 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">(incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 7, 2017)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1015cmcagreement.htm">Commercial Supply Agreement by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1015cmcagreement.htm">AGC Biologics (f/k/a </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1015cmcagreement.htm">CMC ICOS Biologics, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1015cmcagreement.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1015cmcagreement.htm"> and the Company, dated December 11, 2017</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016incytecommercia.htm">Commercial Supply Agreement by and between Incyte Corporation and the Company, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016incytecommercia.htm">October 13</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016incytecommercia.htm">, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1017eversanaagreeme.htm">Product Commercialization Agreement by and between the Company and Eversana Life Science Service</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1017eversanaagreeme.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1017eversanaagreeme.htm">, LLC, dated November 13, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit23-1202010xk.htm">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-1202010xk.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-2202010xk.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-1202010xk.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-2202010xk.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">#&#160;&#160;&#160;&#160;Portions of this document (indicated by &#8220;[***]&#8221; have been omitted because they are not material and would likely cause competitive harm to the Company if disclosed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>mgnxexhibit4-2202010xk.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id0afd2036ee64e82a784437ae8e2395c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REGISTERED UNDER SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, MacroGenics, Inc. (&#8220;we&#8221;, &#8220;our&#8221; and &#8220;us&#8221;), has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended&#58; common stock, par value of $0.01 per share (Common Stock). </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description of our Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (our Certificate of Incorporation), our Certificate of Correction of our Certificate of Incorporation (our Certificate of Correction), our Amended and Restated By-laws (our By-laws) and applicable provisions of the Delaware General Corporation Law (DGCL). Our Certificate of Incorporation, Certificate of Correction and By-laws are included as exhibits to the Annual Report on Form 10-K of which this Exhibit 4.2 forms a part. We encourage you to carefully read our Certificate of Incorporation, Certificate of Correction and By-laws and the applicable provisions of the DGCL for additional information. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our Certificate of Incorporation, we have the authority to issue 125,000,000 shares of our Common Stock. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Common Stock is listed on the Nasdaq Global Select Market under the symbol &#8220;MGNX.&#8221; The rights, preferences and privileges of holders of our Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock we may issue in the future.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Common Stock Outstanding</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The outstanding shares of our Common Stock are duly authorized, validly issued, fully paid and non-assessable. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Voting Rights</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividend Rights</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of our Common Stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any outstanding preferred stock.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidation Rights</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event of our liquidation or dissolution, the holders of our Common Stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other Rights</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of our Common Stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Transfer Agent and Registrar</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Computershare Trust Company, Inc. is the transfer agent and registrar for our Common Stock.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Provisions of our Certificate of Incorporation and By-laws and Delaware Law that may have Anti-Takeover Effects</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware law contains, and our Certificate of Incorporation and our By-laws contain, provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Authorized but Unissued Shares. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The authorized but unissued shares of our Common Stock will be available for future issuance without obtaining stockholder approval and the authorized but unissued shares of our preferred stock are available for future issuance. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions, and employee benefit plans. The existence of authorized but unissued shares of our Common Stock and preferred stock could render more difficult or discourage an attempt to obtain control over us by means of a proxy contest, tender offer, merger or otherwise</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Removal of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> A director may be removed only for cause and only by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Staggered Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our Certificate of Incorporation provides for a staggered board of directors consisting of three classes of directors. Directors of each class are chosen for three-year terms upon the expiration of their current terms and each year one class of our directors will be elected by our stockholders. Additionally, there is no cumulative voting in the election of directors. This classified board provision could have the effect of making the replacement of incumbent directors more time consuming and difficult. At least two annual meetings of stockholders, instead of one, will generally be required to effect a change in a majority of our board of directors. Thus, the classified board provision could increase the likelihood that incumbent directors will retain their positions. The staggered terms of directors may delay, defer or prevent a tender offer or an attempt to change control of us, even though a tender offer or change in control might be believed by our stockholders to be in their best interest.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stockholder Action by Written Consent&#59; Special Meetings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our Certificate of Incorporation provides that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Our Certificate of Incorporation and By-laws also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by our chairman of the board, our chief executive officer or our board of directors.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Advance Notice Requirements for Stockholder Proposals. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our by-laws have established an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Amendment of Our Certificate of Incorporation and By-laws. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or by-laws, unless a corporation&#8217;s restated certificate of incorporation or by-laws, as the case may be, requires a greater percentage. Our By-laws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our Certificate of Incorporation described above under &#8220;Removal of Directors&#8221; and &#8220;Stockholder Action by Written Consent&#59; Special Meetings.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Delaware Business Combination Statute. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to Section 203 of the DGCL. Subject to specified exceptions, Section 203 of the DGCL restricts some types of transactions and business combinations between a corporation and a 15% stockholder. A 15% stockholder is generally considered by Section 203 to be a person owning 15% or more of the corporation&#8217;s outstanding voting stock. Section 203 refers to a 15% stockholder as an &#8220;interested stockholder.&#8221; Section 203 restricts these transactions for a period of three years from the date the stockholder acquires 15% or more of our outstanding voting stock. With some exceptions, unless the transaction is approved by the board of directors and the holders of at least two-thirds of the outstanding voting stock of the corporation, Section 203 prohibits significant business transactions such as&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">a merger with, disposition of significant assets to or receipt of disproportionate financial benefits by the interested stockholder&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">any other transaction that would increase the interested stockholder&#8217;s proportionate ownership of any class or series of our capital stock.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The shares held by the interested stockholder are not counted as outstanding when calculating the two-thirds of the outstanding voting stock needed for approval.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The prohibition against these transactions does not apply if&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">prior to the time that any stockholder became an interested stockholder, the board of directors approved either the business combination or the transaction in which such stockholder acquired 15% or more of our outstanding voting stock&#59; or</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the interested stockholder owns at least 85% of our outstanding voting stock as a result of a transaction in which such stockholder acquired 15% or more of our outstanding voting stock. Shares held by persons who are both directors and officers or by some types of employee stock plans are not counted as outstanding when making this calculation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>exhibit1015cmcagreement.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7b9384f2e499484faab3dd4303a67be0_1"></div><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.65pt;padding-left:5.75pt;padding-right:1pt;text-indent:399.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.15 </font></div><div style="margin-top:3.65pt;padding-left:9pt;padding-right:1pt;text-indent:-1.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH &#8220;&#91;***&#93;&#8221;.</font></div><div style="margin-top:6.95pt;padding-left:11.75pt"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:66px;margin-bottom:5pt;vertical-align:text-bottom;width:143px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONFIDENTIAL</font></div><div style="margin-top:12.65pt;padding-right:10.55pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTION COPY</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:161.82pt;padding-right:161.82pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:190%">COMMERCIAL SUPPLY AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.45pt;padding-left:161.75pt;padding-right:161.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BETWEEN</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:161.7pt;padding-right:161.7pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CMC ICOS BIOLOGICS, INC.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:161.82pt;padding-right:161.82pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:161.7pt;padding-right:161.7pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:5.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONFIDENTIAL</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-right:20.4pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTION COPY</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.3pt;padding-left:49.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:400;line-height:120%">CONTENTS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:49.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONTENTS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;DEFINITIONS AND INTERPRETATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;MANUFACTURING SUPPLY AND APPLICABLE STANDARDS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;RAW MATERIALS, CUSTOMER MATERIALS AND EQUIPMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;TIMELINE, SPECIFICATION AND PROJECT MANAGEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;FORECASTS, ORDERS, MANUFACTURING CAPACITY AND FAILURE TO SUPPLY18</font></div><div><font><br></font></div><div style="padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;DELIVERY AND EXAMINATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;BATCH PRICE, PAYMENT TERMS AND MILESTONE PAYMENTS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;CUSTOMER AUDITS, REGULATORY INSPECTIONS &#38; MATTERS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;WARRANTIES</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</font></div><div style="margin-top:12.3pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;CONFIDENTIAL INFORMATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</font></div><div style="margin-top:11.8pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;INTELLECTUAL PROPERTY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</font></div><div style="margin-top:12pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;INDEMNITIES AND LIABILITY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</font></div><div style="margin-top:12.05pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;PRODUCT RECALL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</font></div><div style="margin-top:12.25pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;TERM AND TERMINATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</font></div><div style="margin-top:11.8pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;TECHNOLOGY TRANSFER</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</font></div><div style="margin-top:12pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;FORCE MAJEURE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</font></div><div style="margin-top:12.05pt;padding-left:85pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;APPLICABLE LAW, JURISDICTION AND DISPUTE RESOLUTION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</font></div><div style="margin-top:12.05pt;padding-left:85.25pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;MISCELLANEOUS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</font></div><div style="margin-top:12pt;padding-left:49.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX ONE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</font></div><div style="margin-top:11.8pt;padding-left:49.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX TWO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:49.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX THREE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:20.65pt;padding-right:56.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">THIS COMMERCIAL SUPPLY AGREEMENT </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">is made as of December 11, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:20.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BETWEEN</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:56.65pt;padding-right:27.45pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">(1)&#160;&#160;&#160;&#160;CMC ICOS BIOLOGICS, INC., </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">duly incorporated under the laws of the state of Washington and having its principal place of business at 22021 20</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:152%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">Ave SE, Bothell, Washington, USA (hereinafter referred to as &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">CMC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">&#34;)&#59; and,</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:56.65pt;padding-right:27.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">(2)&#160;&#160;&#160;&#160;MACROGENICS, INC., </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">duly incorporated under the laws of the state of Delaware and having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (hereinafter referred to as &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Customer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">&#34;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:56.65pt;padding-right:58.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">CMC and Customer may each be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:152%">&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">and collectively as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">.&#8221;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:20.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:56.65pt;padding-right:28pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">(A)&#160;&#160;&#160;&#160;Customer is engaged in the research, development, manufacture and sale of pharmaceuticals and biologics, including the product designated by Customer as margetuximab (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">MGAH22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;)&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:56.65pt;padding-right:27.3pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(B)&#160;&#160;&#160;&#160;CMC and Customer have previously entered into a Master Services Agreement for the development and manufacture (for clinical evaluation) of MGAH22&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:56.65pt;padding-right:27.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">(C)&#160;&#160;&#160;&#160;In addition to development and scale-up activities, CMC also provides commercial manufacturing activities for biological products to pharmaceutical and biotechnology companies&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:56.65pt;padding-right:28.25pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(D)&#160;&#160;&#160;&#160;Customer wishes to contract with CMC for the provision of the commercial supply of Product (as defined below) as more clearly defined by the Services (as defined below)&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:56.65pt;padding-right:27.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(E)&#160;&#160;&#160;&#160;CMC is willing to provide the Services to the Customer on the terms and conditions set out in this Agreement in exchange for the Batch Price.</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:20.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW THEREFORE, THE PARTIES AGREE </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as follows&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-top:4.8pt;padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;DEFINITIONS AND INTERPRETATION</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.8pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">1.1&#160;&#160;&#160;&#160;For the purposes of this Agreement, the terms defined in this clause shall have the respective meanings set forth below.</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.381%"><tr><td style="width:1.0%"></td><td style="width:30.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:113%">Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:10.1pt;padding-right:10.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">any company, partnership or other entity which directly or indirectly through one or more intermediaries controls or is controlled by, or is under common control with a Party. For the purpose of this definition control means the direct or indirect beneficial ownership of more than fifty percent (50%) of the voting share capital in such company, partnership or entity or the legal power to control the general management and policies of such company, partnership or entity&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:10.1pt;padding-right:10.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">this Agreement including all Appendices and any amendments to the foregoing made in accordance with this Agreement&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:10pt;padding-right:33.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:147%">Appendix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">&#34; or &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:147%">Appendices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one or more of the Appendices to this Agreement&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Applicable Laws&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:10.1pt;padding-right:9.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">all applicable ordinances, rules, regulations, laws, guidelines, requirements and court orders of any kind whatsoever of any national (e.g., the FDA, EPA, etc,), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity of the US or EU applicable to the Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:149%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.5pt;padding-left:10pt;padding-right:39.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Authority Submission&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.25pt;padding-left:10.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 8.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Batch</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10.1pt;padding-right:10.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">BDS that is intended to be of uniform character and quality, within specific limits, and is produced in one cell culture run using the Cell Line at a specified bioreactor scale, and such purification, analytical and further processing steps as described in a Work Statement applicable to the BDS harvested from that run resulting in</font></div><div style="padding-left:10.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:102%">one lot of BDS&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:0.05pt;margin-top:0.4pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.381%"><tr><td style="width:1.0%"></td><td style="width:32.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:113%">&#8220;Batch Price&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:8.2pt;padding-right:10.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">the price payable for each Batch as initially described in the Appendix Two and as may be amended by agreement between the Parties or by operation of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%;text-decoration:underline">7</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Binding Batch&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:8.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 5.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;BLA&#8221;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:8.2pt;padding-right:10.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a Biologics License Application and any amendments or supplements thereto filed with the FDA pursuant to 21</font></div><div style="padding-left:8.2pt;padding-right:10.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">C.F.R. Part 601 or any other application required for the purpose of marketing and selling a biological product filed with a Regulatory Authority outside the United States, including with respect to the EU a Marketing Authorization Application&#59;</font></div></td></tr></table></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.381%"><tr><td style="width:1.0%"></td><td style="width:32.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Bulk Drug</font></div><div style="margin-top:3.4pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Substance or BDS&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:8.2pt;padding-right:10.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">means the Product in bulk, as expressed by the Cell Line and harvested and purified in bulk from a cell culture run pursuant to the applicable Process&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;Business Day&#34;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:10pt;padding-right:8.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:300%">&#8220;Calendar Day&#8221; &#8220;Calendar Quarter&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:8.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">any day which is not a Saturday, a Sunday or a U.S. public holiday&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:8.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any day&#59;</font></div><div><font><br></font></div><div style="padding-left:8.2pt;padding-right:12.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:145%">a 3-month period beginning on January 1, April 1, July 1, or October 1 of each year&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Calendar Year&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.8pt;padding-left:8.2pt;padding-right:9.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a period of time commencing on January 1 and ending on the following December 31&#59; provided that the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31 thereafter, and the last Calendar Year during the Term shall end upon the expiration of the Term&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Campaign&#8221;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:8.2pt;padding-right:41pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">a series of Batches manufactured consecutively in accordance with the Process&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Cancellation Fee&#8221;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cell Line</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:8.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 5.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">the mammalian cell line &#91;***&#93; and any progeny clone of the foregoing cell line(s)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.25pt;padding-left:10pt;padding-right:34.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:150%">Certificate of Analysis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.25pt;padding-left:8.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">CMC&#8217;s standard form certificate of analysis confirming that Product to which the certificate relates meets the</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.55pt;padding-right:18.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Specification and such other criteria as identified on the certificate&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt;padding-right:35.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Certificate of Compliance&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:7.55pt;padding-right:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">means a document, signed by an authorized representative of CMC, attesting that a particular Batch was manufactured in accordance with cGMP and other</font></div><div style="padding-left:7.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable Laws&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.55pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">cGMP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.8pt;padding-left:7.55pt;padding-right:10.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">Current Good Manufacturing Practices as promulgated under each of the following as in effect on the Effective Date and as amended or revised after the Effective Date&#58;</font></div><div style="margin-top:0.6pt;padding-left:7.55pt;padding-right:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">(a) the U.S. Food, Drug &#38; Cosmetics Act (21 U.S.C. &#167; 301 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:151%">et seq.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">) and related U.S. regulations, including 21 Code of Federal Regulations (Chapters 210, 211, 600 and 610) and other FDA regulations, policies, or guidelines in effect at a particular time for the manufacture, testing and quality control of investigational drugs&#59; (b) EudraLex Volume 4&#59;</font></div><div style="margin-top:0.35pt;padding-left:7.55pt;padding-right:9.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(c) the ICH guide Q7 &#8220;ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients&#59;&#8221; and (d) any other laws, regulations and statutes set forth by a Government Authority applicable to the manufacture of compounds and products by CMC under this Agreement&#59;</font></div></td></tr></table></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.381%"><tr><td style="width:1.0%"></td><td style="width:32.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:7.55pt;padding-right:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">in relation to a body corporate, the occurrence of an event or circumstance where a person who is not presently able to do any of the following things becomes able to do one of the following things (whether directly or indirectly or through one or more intervening persons, companies or trusts)&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:7.55pt;padding-right:10.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(a)&#160;&#160;&#160;&#160;control the composition of more than one half of the body's board of directors&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.55pt;padding-right:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">(b)&#160;&#160;&#160;&#160;be in a position to cast, or control the casting of, more than one half of the maximum number of votes that might be cast at a general meeting of the members of the body&#59; or</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.55pt;padding-right:10.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(c)&#160;&#160;&#160;&#160;hold or have a beneficial interest in more than onehalf of the issued share capital of the body&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMC Facility</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:7.55pt;padding-right:22.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">CMC&#8217;s manufacturing facility in Bothell, Washington or another facility agreed on by the Parties in writing&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8.65pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:105%">&#8220;CMC Failure&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8.65pt;padding-left:7.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Clause 13.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.237%"><tr><td style="width:1.0%"></td><td style="width:31.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;padding-right:19.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:153%">CMC Intellectual Property Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.45pt;padding-right:9.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">Intellectual Property rights and CMC Know-How owned by CMC and used in the Services&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8.85pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMC Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:6.45pt;padding-right:13.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">all information, techniques, trade secrets, data and technical information known to CMC which is not of general public knowledge, other than provided to CMC by Customer, or developed during the Services&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt;padding-right:24.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in respect of a cGMP Batch the date on which (i) &#91;***&#93;, or</font></div><div style="margin-top:3.65pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) &#91;***&#93;&#59; whichever is the earlier&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;padding-right:3.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Commercial Quality Agreement&#34; (QAg)&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.45pt;padding-right:13.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">the agreement between the Parties defining the quality responsibilities, including cGMP standards, regarding the performance of the Services&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:6.45pt;padding-right:13pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">with respect to CMC, such level of efforts and resources required to carry out an obligation under this Agreement in a sustained manner consistent with the efforts normally used by companies that provide manufacturing and related services in the biopharmaceutical industry, as applicable, of comparable size and resources to CMC, for a similar activity with respect to the scope of Services to be provided under this Agreement&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.45pt;padding-left:10pt;padding-right:47.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Committee Member&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:6.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 4.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;padding-right:42.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.45pt;padding-right:13.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">means all information disclosed by, or on behalf of, the Disclosing Party to Recipient Party relating to this Agreement and includes&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:42.7pt;padding-right:13.15pt;text-indent:-18.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(I)&#160;&#160;&#160;&#160;information disclosed in writing, orally or by any other means&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:42.7pt;padding-right:13.3pt;text-indent:-18.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">(II)&#160;&#160;&#160;&#160;information disclosed before, after or on the date of this Agreement&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:42.7pt;padding-right:13.1pt;text-align:justify;text-indent:-18.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">(iii) information relating to the Disclosing Party&#8217;s operations, processes, plans, intentions, production information, know how, data, formulae, expertise, methodology, drawings, specifications,</font></div><div style="margin-top:0.25pt;padding-left:42.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">design rights, trade secrets, market opportunities</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.237%"><tr><td style="width:1.0%"></td><td style="width:31.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.2pt;padding-right:30pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">and business affairs, and any new and novel combinations thereof&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Customer Intellectual Property Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:6.2pt;padding-right:9.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Intellectual Property rights and Customer Know-How owned by Customer or licensed to Customer by a Third Party covering any aspect of the Services, Cell Line, BDS or materials, techniques or processes used in the Services&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:10pt;padding-right:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Customer Know- How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:6.2pt;padding-right:10.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">all information, techniques, trade secrets, data and technical information known to Customer in connection with the Cell Line, Customer Materials, Process and Product which are (i) not known to CMC prior to being provided to CMC by or on behalf of Customer&#59; or (ii) not of general public knowledge&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:10pt;padding-right:51.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Customer Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:6.2pt;padding-right:10.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">the Cell Line, vectors, plasmids and all other materials and equipment supplied by Customer, its Affiliate or agent to CMC or made available to CMC by or on behalf of Customer or purchased by CMC on behalf of Customer&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;Defect&#34;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:6.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 6.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;Defect Notice&#34;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:7.55pt;padding-left:6.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 6.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:7.65pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deliverables</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:7.9pt;padding-left:6.2pt;padding-right:10.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">the data, results and materials generated from the performance of the Services including Drug History Record and Product&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:10pt;padding-right:43.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:147%">Delivery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">&#34; or &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:147%">Delivered</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Delivery Date&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.35pt;padding-left:10pt;padding-right:46.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">&#8220;Disputed Deliverable&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.6pt;padding-left:6.2pt;padding-right:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">means, as applicable, the date a Batch is to be delivered or is actually Delivered&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 6.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt;padding-right:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Drug History Record&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:6.2pt;padding-right:10.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">all lot disposition documentation relevant to a cGMP Batch to be provided to Customer with the Product from that cGMP Batch, including but not limited to manufacturing batch records, Certificates of Compliance and Certificates</font></div><div style="margin-top:0.2pt;padding-left:6.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">of Analysis&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:0.05pt;margin-top:0.4pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.237%"><tr><td style="width:1.0%"></td><td style="width:31.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:113%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:5.7pt;padding-right:20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">the date set forth on page 3 as the effective date of this Agreement&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;EMA&#8221;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Medicines Agency or any successor agency&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:10pt;padding-right:44.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#34;Exceptional Batches&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:5.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 5.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt;padding-right:47.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Existing Agreement&#8221;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:41.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">&#8220;Facility Modification&#8221;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:5.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">&#8220;Facility Modification Notice&#8221;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;FDA&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:5.7pt;padding-right:32.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">the Master Services Agreement between the Parties dated June 4, 2014&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 4.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:5.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 4.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.55pt;padding-left:5.7pt;padding-right:16.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">means the United States Food and Drug Administration, or its successor agency&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Firm Order&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">5.3.1&#59;</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;Forecast&#34;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">5.1&#59;</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt;padding-right:38.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Fundamental Change&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:5.7pt;padding-right:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">means a Change of Control, merger, acquisition or change of management of CMC or Affiliates&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:5.7pt;padding-right:11.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">in respect of the relevant Party, its Affiliates and holding companies and the Affiliates of those holding companies&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt;padding-right:49.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Intellectual Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.7pt;padding-right:9.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">all intellectual property rights, including, without limitation, patents, supplementary protection certificates, petty patents, utility models, trademarks, database rights, rights in designs, copyrights (whether or not any of these are registered or capable of being registered) and including all applications and the right to apply for registered protection of the foregoing and all inventions, trade secrets, know- how, techniques and confidential information and other proprietary knowledge and information, and all rights and forms of protection of a similar nature or having equivalent or similar effect to any of these which may subsist anywhere in the world, in each case for their full term and</font></div><div style="padding-left:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:102%">together with any renewals or extensions&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:0.05pt;margin-top:0.4pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.237%"><tr><td style="width:1.0%"></td><td style="width:31.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:10pt;padding-right:31pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:153%">&#34;Joint Steering Committee&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:113%">Clause 4.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8.85pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;Minimum Volumes&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.3pt;padding-right:10.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">the minimum number of Batches that must be ordered per Calendar Year by Customer as stipulated in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 5.3.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;Non-Fault Delays&#34;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Order&#8221;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Firm Order or a Semi-Firm Order&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Other Customers&#8221;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:10pt;padding-right:48.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Permitted Recipients</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in Clause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.3pt;padding-right:13.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">(a)&#160;&#160;&#160;&#160;the directors, officers, employees, Testing Laboratories or professional advisers who are required, on a strict need to know basis, in the course of their duties to receive and consider the Confidential Information of the other Party for the purpose of enabling the relevant Party to perform its obligations under this this Agreement&#59; and</font></div><div style="margin-top:0.6pt;padding-left:5.3pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">(b)&#160;&#160;&#160;&#160;in communications with existing or prospective licensees, sublicensees or collaborators, and consultants and advisors of each Party in connection with transactions or prospective transactions or pursuant to the conduct of such Party&#8217;s business&#59; provided that in the case of (a) and (b), such Persons are under obligations of confidence no less onerous than those set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 10 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">imposed on the recipient Party&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Person(s)&#8221;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.45pt;padding-left:5.3pt;padding-right:13.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PPQ-Batches&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.25pt;padding-left:5.3pt;padding-right:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">the process performance qualification batches required for registration of the Product.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Process</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="padding-left:5.3pt;padding-right:13.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">the method for manufacture, harvesting and purification of the Product as defined in Customer approved manufacturing batch records&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:5.3pt;padding-right:13.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">Customer&#8217;s&#160;&#160;&#160;&#160;biologic&#160;&#160;&#160;&#160;known&#160;&#160;&#160;&#160;as&#160;&#160;&#160;&#160;margetuximab manufactured in Batch form as Bulk Drug Substance&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8.65pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Project Manager&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8.65pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Clause 4.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:0.05pt;margin-top:0.4pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.164%"><tr><td style="width:1.0%"></td><td style="width:31.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:113%">Project Team</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#34;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Purchase Order&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:113%">Clause 4.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 5.6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Quality Release(d)&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:5.65pt;padding-right:10.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">certification by CMC&#8217;s Quality Department that a Batch of BDS complies with its Specifications as confirmed by release testing&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raw Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.25pt;padding-left:5.65pt;padding-right:10.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">media, resins, chemicals, solvents, filters, membranes, disposable analytical test kits, disposable bags, and other items consumed for the manufacture of Products in accordance with this Agreement as well as any subcontracted analytical testing performed by Testing Laboratories during the performance of the Services&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Recall&#8221;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:5.65pt;padding-right:10.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">any action to withdraw from supply or distribution or to recover title to or possession of quantities of Product sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Product from the market or correction) or the detention or destruction of any Product by any Regulatory Authorities&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:10pt;padding-right:47.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Regulatory Approval&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:5.65pt;padding-right:10.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">the approval, license or authorization of the applicable Regulatory Authority necessary for commercialization of the Product, including approval of a Biologics License Application or Market Authorization Application for the</font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">Product&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:10pt;padding-right:43.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Regulatory Approval Submission&#8221;</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:43.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Regulatory Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:5.65pt;padding-right:10.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">the earlier of the first submission of a Biologics License Application or Market Authorization Application for the Product&#59;</font></div><div><font><br></font></div><div style="padding-left:5.65pt;padding-right:9.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">those mandatory regulatory requirements applicable in Europe and the United States of America and Canada to the manufacture of cGMP Product for human use&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:10pt;padding-right:47.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Regulatory Authority&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:5.65pt;padding-right:10.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">the FDA in the United States or any health regulatory authority in another country in Europe and Canada that is a counterpart to the FDA and holds responsibility for allowing development of the Product and&#47;or granting Regulatory Approval for a Product, including the EMA, and any successor(s) thereto&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.75pt;padding-left:10pt;padding-right:6.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:150%">&#8220;Release For Further Processing&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 6.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:0.05pt;margin-top:0.4pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.164%"><tr><td style="width:1.0%"></td><td style="width:31.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Representative(s)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:113%">Clause 4.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.25pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;Semi-Firm Order&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.25pt;padding-left:5.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clauses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">5.3.2 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:5.85pt;padding-right:10.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">manufacturing of the Product by CMC and all activities to be conducted by CMC related to the manufacturing of the Product under this Agreement&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt;padding-right:53.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">&#8220;Shipping Company&#8221;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:47.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Shipping Guidelines</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.85pt;padding-right:10.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">a shipping company or other agent designated by Customer to receive a Delivery on behalf of Customer&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.85pt;padding-right:10.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">the storage and transport guidelines for the Product that are determined by mutual written agreement of the Parties&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Slot</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:5.85pt;padding-right:10.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">in respect of CMC&#8217;s cGMP manufacturing suite the period of time the suite is reserved in preparation for and the performance of a Batch&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:5.85pt;padding-right:9.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">the specification for the Product as defined in Appendix 1 or as may otherwise be agreed between the Parties or modified in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 4.5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">which includes (i) specifications for BDS and Raw Materials, (ii) manufacturing, testing and packaging instructions and specifications for Product in accordance with the Process,</font></div><div style="margin-top:0.35pt;padding-left:5.85pt;padding-right:10.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(iii) storage and shipping requirements, and (iv) any other technical information necessary to manufacture a Batch&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt;padding-right:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Standard Operating Procedures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34; or &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">SOPs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.85pt;padding-right:10.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">the standard operating procedures of CMC which define CMC's methods of performing activities applicable to the Services&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Storage Cost</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:5.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 7.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Supply Failure&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:5.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the meaning set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 5.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Term&#8221;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:5.85pt;padding-right:41.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">the Initial Term (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">14.1</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">) and all Additional Terms (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">14.1</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt;padding-right:40.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Testing Laboratories</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.35pt;padding-left:5.85pt;padding-right:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">the Third Parties listed in the Quality Agreement which shall conduct testing or provide other services to support Quality Release&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Timelines</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.75pt;padding-left:5.85pt;padding-right:29.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">collectively and individually the dates to manufacture Product and render other Services to Deliver Product according to the Forecast and&#47;or each accepted Commencement Date and Delivery Date&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.164%"><tr><td style="width:1.0%"></td><td style="width:31.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Third Party(ies)&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.05pt;padding-right:16.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">any person, company, organization or entity other than CMC, Customer or their Affiliates&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8.85pt;padding-left:6.35pt;padding-right:10.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Work Statement&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.2pt;padding-left:11.05pt;padding-right:9.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">the Work Statement #1 effective between the Parties, dated &#91;***&#93;, and all amendments thereto and the subsequent agreement between the Parties, effective</font></div><div style="margin-top:9.1pt;padding-left:11.05pt;padding-right:21.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#91;***&#93;.</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:28.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">1.2&#160;&#160;&#160;&#160;Additional Definitions. Each of the following definitions is set forth in the clause of this Agreement indicated below&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.979%"><tr><td style="width:1.0%"></td><td style="width:59.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Definition&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 61.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Clause&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:7.65pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Binding Batches</font></div><div style="margin-top:0.15pt;padding-left:10pt;padding-right:60.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:260%;text-decoration:underline">Reserve Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:260%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:260%;text-decoration:underline">Producer Price Index</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:7.65pt;padding-left:60.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:60.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">7.3</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:63.85pt;text-indent:-22.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;In this Agreement (except where the context otherwise requires)&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:110.65pt;padding-right:27.55pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">1.3.1&#160;&#160;&#160;&#160;any reference to a recital, clause or appendix is to the relevant recital, clause or appendix of or to this Agreement and any reference to a sub-clause or paragraph is to the relevant sub-clause or paragraph of the clause or appendix in which it appears&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111.4pt;padding-right:28.25pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">1.3.2&#160;&#160;&#160;&#160;the table of contents and clause headings are included for convenience only and shall not affect the interpretation of this Agreement&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:28.3pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">1.3.3&#160;&#160;&#160;&#160;use of the singular includes the plural and vice versa and use of any gender includes the other genders&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.85pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">1.3.4&#160;&#160;&#160;&#160;a reference to a &#34;Party&#34; is a reference to a party to this Agreement and a reference to a &#34;Party&#34; includes a reference to that Party's successors in title, permitted assignees and transferees (if any)&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.4pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">1.3.5&#160;&#160;&#160;&#160;a reference to &#8220;records&#8221;, &#8220;data&#8221;, &#8220;documents&#8221; and &#8220;information&#8221; refers to such items in tangible, and electronic and visual mediums unless specified to the contrary&#59; and</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:111.4pt;padding-right:28.15pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">1.3.6&#160;&#160;&#160;&#160;any phrase introduced by the terms &#34;including&#34;, &#34;include&#34;, &#34;in particular&#34; or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms.</font></div><div><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.7pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:126%">1.4&#160;&#160;&#160;&#160;The Appendices form an integral part of this Agreement shall have effect as if set out in full in the body of this Agreement and any reference to this Agreement includes the Appendices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:126%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">1.5&#160;&#160;&#160;&#160;Where there is any inconsistency between the Appendices and the main body of this Agreement, the conflicting terms of the main body of this Agreement shall, unless expressly specified to the contrary, prevail.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;MANUFACTURING SUPPLY AND APPLICABLE STANDARDS</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.9pt;text-align:justify;text-indent:-32.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;During the Term CMC shall use Commercially Reasonable Efforts to manufacture Product&#58;</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(a)&#160;&#160;&#160;&#160;according to the Process&#59; (b) that meets Specifications&#59; (c) in compliance with Applicable Laws and Regulatory Obligations&#59; and (d) in accordance with the terms of this Agreement and the Commercial Quality Agreement.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:27.45pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.2&#160;&#160;&#160;&#160;During the Term, CMC shall use Commercially Reasonable Efforts to manufacture Product in the quantity of Batches that are the subject of each Firm Order and Semi-Firm Order pursuant to the forecast mechanism set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">5 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">and in accordance with the terms and requirements set out in this Agreement. Customer shall purchase from CMC and CMC shall supply to Customer the Product in the quantity of Batches in accordance with the terms of this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;&#160;&#160;&#160;CMC will comply with quality standards as agreed to in the Commercial Quality Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.5pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.4&#160;&#160;&#160;&#160;CMC shall maintain a completed Drug History Record and such other records as specified in the Commercial Quality Agreement for the period of time specified in the Commercial Quality Agreement. CMC shall retain and store samples of all Quality Released Product for such period as may be required by Applicable Laws and Regulatory Obligations and the Commercial Quality Agreement, which in the absence of a definitive time period shall be &#91;***&#93; from the date of release or Delivery. If the Parties agree, CMC shall retain such samples for a longer period at the Customer's cost.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party Subcontractors</font></div><div style="margin-top:3.45pt;padding-left:74.65pt;text-indent:-32.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5&#160;&#160;&#160;&#160;CMC may subcontract&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:102.05pt;padding-right:27.6pt;text-align:justify;text-indent:-27.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.5.1&#160;&#160;&#160;&#160;to its Affiliates, any part of the Services (provided that the Affiliates may not further subcontract those parts of the Services), with the prior written consent of Customer (such consent not to be unreasonably withheld, delayed or conditioned)&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:102.05pt;text-indent:-27.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5.2&#160;&#160;&#160;&#160;to Testing Laboratories&#59; and&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:102.05pt;padding-right:27.75pt;text-align:justify;text-indent:-27.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.5.3&#160;&#160;&#160;&#160;to any other reputable qualified Third Party, any part(s) of the Services (provided CMC identifies the specific Services to be performed) with the prior written consent of Customer (such consent not to be unreasonably withheld, delayed or conditioned).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:63.85pt;padding-right:27.5pt;text-align:justify;text-indent:1.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">CMC shall remain responsible for the Services to be rendered by Third Parties to whom it subcontracts and shall ensure such Third Parties perform such subcontracted Services in compliance with the terms and conditions of this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;RAW MATERIALS, CUSTOMER MATERIALS, AND EQUIPMENT</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">3.1&#160;&#160;&#160;&#160;CMC shall be responsible for obtaining Raw Materials required for the manufacture of Product in reasonable quantities consistent with the Forecast and Purchase Orders. </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:74.45pt;padding-right:27.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">CMC shall ensure that all Raw Materials (i) conform to their respective Specifications&#59; and (ii) are stored and handled in accordance with cGMP, Applicable Laws and Regulatory Obligations and the Commercial Quality Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div><font><br></font></div><div style="padding-left:74.65pt;text-indent:-32.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;&#160;&#160;&#160;CMC will be responsible for risk of loss of Customer Materials while in CMC&#8217;s control.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.65pt;padding-right:27.1pt;text-align:justify;text-indent:-32.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">3.4&#160;&#160;&#160;&#160;All equipment acquired by CMC to perform Services for which the entire purchase cost is paid for or charged to Customer, shall be owned by Customer. Customer shall be responsible for all delivery, installation, maintenance (except as provided in the immediately following sentence) and storage costs associated with such equipment. CMC shall use such equipment solely to render the Services and in accordance with Customer&#8217;s instructions CMC shall maintain such equipment and be responsible for any damage to (excluding normal wear and tear), or loss or theft of, the equipment while in its possession and shall insure it accordingly, except to the extent such damage, loss or theft is caused by the negligence or wilful misconduct of Customer. Upon termination or expiration of this</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.65pt;padding-right:41.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Agreement, CMC shall transfer such equipment to Customer at Customer&#8217;s cost unless otherwise agreed.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;TIMELINE, SPECIFICATION AND PROJECT MANAGEMENT</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Timeline</font></div><div style="margin-top:3.6pt;padding-left:74.65pt;padding-right:27.25pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">4.1&#160;&#160;&#160;&#160;CMC shall use Commercially Reasonable Efforts to maintain the Timeline. Notwithstanding that obligation, the Parties acknowledge and agree that the Timeline may be varied as agreed by CMC and the Customer in writing in order to accommodate delays or changes caused by or contributed to by (i) actions or omissions of the Customer (or its agents)&#59; and&#47;or</font></div><div style="margin-top:0.45pt;padding-left:74.65pt;padding-right:27.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(ii) additional activities added to the Services&#59; and&#47;or (iii) Force Majeure Situations or other circumstances beyond CMC's reasonable control (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Non-Fault Delays</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;). Non-Fault Delays shall exclude delays caused by (i) &#91;***&#93;&#59; (ii) &#91;***&#93;&#59; and&#47;or (iii) &#91;***&#93; (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Fault-Based Failures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#8221;).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.5pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.2&#160;&#160;&#160;&#160;In the event of any Non-Fault Delays, CMC shall update the Timeline as agreed with the Customer and, shall endeavour to keep the revised Timeline as close as possible to the Timeline in its form as it existed immediately prior to the Non-Fault Delays.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.5pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">4.3&#160;&#160;&#160;&#160;The Timeline may be amended by agreement between CMC and Customer provided that the revised Timeline is set out in writing and agreed by the Project Team.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.6pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">4.4&#160;&#160;&#160;&#160;Where the Timeline has been amended in accordance with this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline">4,</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%"> it shall be automatically binding upon the Parties. CMC shall keep Customer updated as to the current Timeline on a reasonable frequency. Customer may at any time on a </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:74.45pt;padding-right:27.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">reasonable basis request an update on the progress of the Services compared to the current Timeline.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Specification, Process &#38; Quantities</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.5&#160;&#160;&#160;&#160;The Specifications shall be amended only as agreed upon in writing by the Parties and signed by an authorized representative of each Party&#59; provided, however, that the Parties agree to cooperate to amend or supplement the Specifications to the extent reasonably necessary to comply with changes in Applicable Laws or as Customer may reasonably request from time to time (provided such request is made in good faith). CMC shall follow the change control procedures set forth in the Commercial Quality Agreement for any proposed changes in the Specifications. For the avoidance of doubt, where the Parties cannot agree to modify, amend or update the Specification, the previous Specification as agreed to by the Parties shall apply.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.6&#160;&#160;&#160;&#160;For clarity the Parties acknowledge that all quantities of Product derived from a Batch are &#91;***&#93;, except to the extent caused by a breach of this Agreement or CMC&#8217;s negligence or wilful misconduct.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.7&#160;&#160;&#160;&#160;CMC shall not make any change to the Process, except by prior written approval of Customer for such change. The Parties agree to cooperate to amend or supplement the Process to the extent reasonably necessary to comply with changes in Applicable Laws and&#47;or Regulatory Obligations. CMC shall follow the change control procedures set forth in the Commercial Quality Agreement for any proposed changes in the Process.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.25pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.8&#160;&#160;&#160;&#160;In the event that CMC intends to change or modify the CMC Facility in a manner that is likely to have an impact on the Process or Product or require submissions to or approvals from any Regulatory Authority related to the Process or Product (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Facility Modification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;), CMC &#91;***&#93; and shall work with Customer through the JSC to ensure disruptions to the Timeline and Product Delivery are minimized and impact to the validated state of the Product and Process are evaluated and minimized.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:20.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Project Manager, Joint Steering Committee and Project Team</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.5pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.9&#160;&#160;&#160;&#160;Each Party shall, &#91;***&#93;, appoint an individual as a project leader (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Project Manager</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;) who shall be responsible for leading and co-ordinating the day to day operation of the Services. In addition, &#91;***&#93;, each Party shall select two of their senior technical staff (each a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Committee Member</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;), one of whom (for each Party) may be a Project Manager, to form the steering committee who shall have responsibility for providing leadership and strategic oversight of the Services governed by this Agreement (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Joint Steering Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">JSC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:27.7pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.10&#160;&#160;&#160;&#160;Separate from the Joint Steering Committee, the Parties shall each name and notify the other of representatives (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Representatives</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) who shall form the project team and will be responsible for the day to day performance of the Services including planning, executing and discussing issues regarding the Forecast, Timeline, the Services and </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:27.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">communicating between the Parties (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Project Team</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;). Any disputes or issues that cannot be readily resolved by the Project Team shall be referred to the Joint Steering Committee for resolution.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.75pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.11&#160;&#160;&#160;&#160;Each Party's Project Manager shall, subject to the oversight of the Joint Steering Committee, (i) manage the relationship between the Parties, (ii) oversee the performance of the Services and the activities of the Project Team, (iii) undertake actions delegated to them by the Joint Steering Committee and (iv) be the principal point of contact for the Services. The Project Managers shallmeet upon reasonable request either in person or by telephone or video-conference and each Party shall bear its own costs for attending such meetings.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.12&#160;&#160;&#160;&#160;The Joint Steering Committee shall be responsible for (i) making decisions regarding issues outside the scope of the Project Team or Project Managers, (ii) reviewing the decisions of the Project Team and&#47;or Project Managers, (iii) providing a forum for the Parties to exchange information and coordinate their respective activities regarding the Services, (iv) providing a forum to discuss any technical difficulties or changes to Services or Batch Price triggered by a change to the Services or in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">7.4 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">as well as resolving</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">any disputes or disagreements before escalation to the dispute resolution provided for in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">17, </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">and (v) ensure that intent of this Agreement is maintained throughout the Term. The Joint Steering Committee shall meet on a reasonably regular basis during the Term.</font></div><div><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.5pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.13&#160;&#160;&#160;&#160;At regular intervals the Representatives shall schedule Project Team meetings for the purpose of overcoming any issues with Forecasts, delivery of Product or the performance of all other aspects of the Services and providing an initial forum for discussing and resolving any difficulties or hurdles encountered in the performance of the Services. Such meetings shall be conducted by telephone conference or, if necessary, by face-to-face meetings at an agreed frequency unless particular difficulties arise which dictate the need for more frequent meetings. Each Party shall be responsible for their own costs in attending and conducting the Project Team meetings.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.14&#160;&#160;&#160;&#160;Any decision by the Project Team, the Project Managers or Joint Steering Committee which has the effect of amending the Services in any way must, before it becomes binding, be recorded in writing and signed by both Parties in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">18.4 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">and </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">18.5.</a></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41.75pt;text-indent:-21.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;FORECASTS, ORDERS, MANUFACTURING CAPACITY AND FAILURE TO SUPPLY</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Forecasts</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.65pt;padding-left:74.65pt;padding-right:27.45pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.1&#160;&#160;&#160;&#160;Commencing on the Effective Date, and thereafter &#91;***&#93;, Customer shall, subject to the provisions of this clause, deliver to CMC a &#91;***&#93; forecast of Customer's requirements for CMC to manufacture Product &#91;***&#93; (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Forecast</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.35pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.2&#160;&#160;&#160;&#160;Each Forecast shall set out the number of Batches of Product to be manufactured for Customer &#91;***&#93; covered by the Forecast together with the requested Commencement Date and Delivery Date for each Batch covered by the Forecast. In preparing a Forecast Customer shall attempt to aggregate the number of Batches required throughout the period covered by the Forecast into contiguous Campaigns.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.65pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;&#160;&#160;&#160;In respect of each Forecast&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:116.7pt;padding-right:27.55pt;text-align:justify;text-indent:-42.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.3.1&#160;&#160;&#160;&#160;&#91;***&#93; by the Forecast shall be a definitive and binding order on Customer (a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Firm Order</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#34;)&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:116.7pt;text-indent:-42.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3.2&#160;&#160;&#160;&#160;&#91;***&#93; by the Forecast shall be &#91;***&#93; binding on Customer (a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Semi-Firm Order&#8221;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:115.25pt;text-indent:-40.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3.3&#160;&#160;&#160;&#160;&#91;***&#93; by the Forecast shall be &#91;***&#93; binding on Customer (the order referred to in this</font></div><div style="margin-top:3.6pt;padding-left:115.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 5.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Semi-Firm Order</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:115.25pt;padding-right:27.55pt;text-align:justify;text-indent:-40.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.3.4&#160;&#160;&#160;&#160;(i) &#91;***&#93;, the Minimum Volumes shall &#91;***&#93;, (ii) &#91;***&#93;, the Minimum Volumes shall be &#91;***&#93;, and (iii) subject to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 5.3.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">, during &#91;***&#93;, without the prior written consent of CMC, the Minimum Volume shall be &#91;***&#93;&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:116.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMC shall reserve the Slots for the Minimum Volumes as described in Clause</font></div><div style="margin-top:3.65pt;padding-left:116.7pt;padding-right:27.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.3.4&#160;&#160;&#160;&#160;and manufacture the Batches ordered for such Minimum Volumes. Customer shall be entitled to reserve additional slots that CMC may have available or &#91;***&#93;.</font></div><div style="margin-top:0.05pt;padding-left:116.7pt;padding-right:27.25pt;text-align:justify;text-indent:-29.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.3.5&#160;&#160;&#160;&#160; Customer shall have &#91;***&#93; option &#91;***&#93;. Customer may exercise this option &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#8221;)&#59; provided that &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">Provided that Customer has &#91;***&#93; in accordance with the preceding sentence, Customer shall have the right to exercise the Option &#91;***&#93;. If Customer exercises the Option, &#91;***&#93;.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:114.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer shall also have the option &#91;***&#93;. The &#91;***&#93; to the Minimum Volume.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.4pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.4&#160;&#160;&#160;&#160;The Forecasts are prepared for and intended to provide CMC with clarity as to the Customer's requirements for Product. Forecasts shall be provided by Customer on &#91;***&#93; as provided above and each subsequent Forecast shall reflect the previous relevant Forecasts provided by Customer such that&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:116.7pt;padding-right:27.5pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">5.4.1&#160;&#160;&#160;&#160;the quantity of Product set out in &#91;***&#93; shall, respectively, in the next Forecast, &#91;***&#93; (other than with CMC's prior written consent)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:116.7pt;padding-right:27.25pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.4.2&#160;&#160;&#160;&#160;the quantity of Product set out in &#91;***&#93; shall, respectively, in the next Forecast, &#91;***&#93; in the next Forecast and &#91;***&#93;&#59; and (ii) &#91;***&#93; and may &#91;***&#93;&#59;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:4.75pt;padding-left:116.7pt;padding-right:27.5pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.4.3&#160;&#160;&#160;&#160;the quantity of Product set out in &#91;***&#93; shall, respectively, in the next Forecast, &#91;***&#93; and may be &#91;***&#93;&#59; and (ii) &#91;***&#93; and may be &#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:116.7pt;padding-right:27.6pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">5.4.4&#160;&#160;&#160;&#160;Customer shall provide a new projection for the &#91;***&#93; in accordance with the principles set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:147%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:147%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:147%;text-decoration:underline">5.3.</a></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.65pt;padding-right:27.35pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">5.5&#160;&#160;&#160;&#160;Should Customer &#91;***&#93; Forecast in accordance with the preceding provisions of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline">5, </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">a Forecast &#91;***&#93; under this clause by Customer where&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5.1&#160;&#160;&#160;&#160;&#91;***&#93;&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5.2&#160;&#160;&#160;&#160;&#91;***&#93;&#59; and</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5.3&#160;&#160;&#160;&#160;the &#91;***&#93; of the &#91;***&#93; Forecast shall be the &#91;***&#93; of the &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Orders</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.65pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;&#160;&#160;&#160;Orders for Product shall be provided by Customer and accepted by CMC as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:119.8pt;padding-right:27.1pt;text-align:justify;text-indent:-45.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">5.6.1&#160;&#160;&#160;&#160;Customer shall provide written or electronic purchase orders (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Purchase Order</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">&#8221;) for each Firm Order in conformance with the relevant Forecast &#91;***&#93; Forecast submitted by Customer under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause 5.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:119.8pt;padding-right:27.3pt;text-align:justify;text-indent:-45.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.6.2&#160;&#160;&#160;&#160;Each Purchase Order shall include&#58; (a) a Commencement Date &#91;***&#93; for each Batch subject to such Purchase Order&#59; and (b) a &#91;***&#93; subject to such Purchase Order, unless otherwise agreed by CMC.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:119.8pt;padding-right:27.25pt;text-align:justify;text-indent:-45.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">5.6.3&#160;&#160;&#160;&#160;CMC shall be deemed to accept each Purchase Order and its Commencement Date and Delivery Date, &#91;***&#93;, CMC provides written notice to Customer with an alternative Commencement Date &#91;***&#93; Commencement Date and the corresponding</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:128.7pt;padding-right:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Delivery Date shall be &#91;***&#93; as the time difference between the &#91;***&#93;. Upon acceptance of each Purchase Order, CMC shall provide the confirmed Commencement Date of each Batch in the Purchase Order.</font></div><div><font><br></font></div><div style="padding-left:128.7pt;padding-right:27.65pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.6.4&#160;&#160;&#160;&#160;No terms contained in any Purchase Order, order acknowledgment or similar document shall be construed to amend or modify the terms of this Agreement and in the event of any conflict, this Agreement shall prevail and control, unless the Parties otherwise expressly agree in writing by making reference to both this Agreement and the alternative terms.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.7&#160;&#160;&#160;&#160;Notwithstanding the limits on ordering under a Forecast, CMC may, in response to Customer's written request, elect to manufacture additional Batches of Product in a &#91;***&#93; beyond the quantity submitted in a Firm Order for that same &#91;***&#93; (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Exceptional Batches</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;). CMC's obligation to manufacture Exceptional Batches shall only arise </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:74.65pt;padding-right:27.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">upon CMC's written acceptance whereby the Exceptional Batches accepted by CMC shall be deemed part of the Firm Order(s) for the relevant &#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.65pt;padding-right:27.1pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.8&#160;&#160;&#160;&#160;All quantities of Batches that are the subject of a Firm Order or a Semi-Firm Order (i.e., the binding portion of a Semi-Firm Order) shall (i) be binding (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Binding Batches</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) upon Customer and CMC and (ii) may not be delayed or cancelled by Customer or CMC except as provided for in this Agreement. Partial Batches subject of a Firm or a Semi-Firm Order shall be rounded up to the nearest whole Batch.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.35pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.9&#160;&#160;&#160;&#160;Should Customer fail to order the Minimum Volume in any Calendar Year (as determined based on the Commencement Date of each Batch in any Calendar Year), then Customer shall pay to CMC a sum calculated as &#91;***&#93;. CMC shall be entitled to invoice in December of each Calendar Year, and Customer shall pay such invoice &#91;***&#93; in accordance with the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 7. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Notwithstanding the foregoing, in the event that, in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 5.6.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, CMC provides an alternative Commencement Date and Delivery Date that &#91;***&#93;, the Batches affected by such change shall &#91;***&#93; Commencement Date and Delivery Date &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.6pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.10&#160;&#160;&#160;&#160;Should Customer delay or cancel a Binding Batch in any Calendar Year, then Customer &#91;***&#93; (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">&#8220;Cancellation Fee&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">)&#59; provided that if Customer cancels any Batch(es), for the purpose of determining the Cancellation Fee, &#91;***&#93;. CMC shall be entitled to invoice the cancelled or delayed Batch &#91;***&#93;, and Customer shall pay such invoice &#91;***&#93; in accordance with the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%;text-decoration:underline">7. </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">For the purposes of determining the Minimum Volume, &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:30.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.11&#160;&#160;&#160;&#160;Notwithstanding the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 5.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">, &#91;***&#93;. In the event the &#91;***&#93;, Customer shall not owe CMC the Cancellation Fee for such cancelled Batch. &#91;***&#93; under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 5.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:74.65pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.12&#160;&#160;&#160;&#160;Notwithstanding the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 5.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CMC shall &#91;***&#93; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 5.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.75pt;text-align:justify;text-indent:-40.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">5.13&#160;&#160;&#160;&#160;In the case of cancelled Batches for which Raw Materials have been purchased by CMC and paid by Customer and which cannot be used to manufacture future Batches subject to the Forecast, Customer shall be entitled to elect to either &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:25.95pt;text-align:justify;text-indent:-40.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.14&#160;&#160;&#160;&#160;CMC shall use the Forecasts to plan for and, as appropriate, reserve Slots in its cGMP manufacturing suite for those Batches to be manufactured under Firm Orders and Semi- Firm Orders according to the then current Timeline.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.55pt;text-align:justify;text-indent:-43.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">5.15&#160;&#160;&#160;&#160;Where a Timeline is amended and such amendment affects the scheduled Slot(s) for those Batches which are the subject of a Firm Order, CMC shall update its manufacturing schedule and reserve a new Slot for each affected Batch which, subject to reserved slots under CMC's existing manufacturing schedule for the entire CMC Facility, shall be reserved as near in time to the existing vacated Slots as CMC&#8217;s then current schedule will permit.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supply Uncertainty and Supply Failure</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.65pt;padding-left:74.65pt;padding-right:27.3pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.16&#160;&#160;&#160;&#160;Should CMC become aware or conclude that it will be unable to meet the Timeline for manufacture or Delivery of one or more Binding Batch(es) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Supply Uncertainty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#8221;), then CMC shall as soon as reasonably practicable provide notification in writing to Customer of such circumstances, identify the Batches that may be affected bysuch Supply Uncertainty, identify what CMC believes will cause such Supply Uncertainty and explain what efforts CMC is taking to minimize such Supply Uncertainty (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Supply Uncertainty Notification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#8221;). In the event that Customer receives a Supply Uncertainty Notification or a Supply Uncertainty occurs, CMC and Customer &#91;***&#93; in accordance with the current Forecast and any Purchase Orders accepted by CMC for Batches that may be or are affected by such Supply Uncertainty.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.2pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.17&#160;&#160;&#160;&#160;In the event the manufacture of the Product is &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Supply Failure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) or Customer receives a Supply Uncertainty Notification stating that the manufacture of the Product &#91;***&#93;, Customer shall be entitled to engage an alternate supplier to manufacture the Batchesand CMC shall support transfer of the Process and test methods to such alternate supplier (including conducting a technology transfer consistent with the transfer of information described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">)&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:70.1pt;padding-right:27.65pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.18&#160;&#160;&#160;&#160;If the Supply Failure results primarily from any Fault-Based Failure or other cause within CMC&#8217;s reasonable control (including any default or failure with respect to the Facility), the following shall apply until the Supply Failure is resolved&#58;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:128.7pt;padding-right:27.6pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.18.1&#160;&#160;&#160;&#160;The Forecast and Customer&#8217;s obligations thereunder will be suspended such &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:128.7pt;padding-right:27.9pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.18.2&#160;&#160;&#160;&#160;CMC will reserve capacity for the &#91;***&#93;, CMC and Customer shall agree on allocation of the reserved Minimum Volume capacity across each remaining Calendar Year of the Term.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:128.7pt;padding-right:27.75pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.18.3&#160;&#160;&#160;&#160;If Customer engages an alternate supplier, &#91;***&#93;, up to the applicable number of Batches included in the Minimum Volume for the relevant Calendar Year.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.18.4&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.18.5&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:128.7pt;padding-right:27.65pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.18.6 At Customer&#8217;s sole option, any &#91;***&#93; that cannot be manufactured due to a Supply Failure shall be credited against other payments owed by Customer to CMC under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:65.8pt;text-indent:-27.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.19&#160;&#160;&#160;&#160;If the cause of a Supply Failure results primarily from Customer&#8217;s act or omission&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:128.7pt;padding-right:27.8pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">5.19.1&#160;&#160;&#160;&#160;CMC shall use Commercially Reasonable Efforts to adjust the Timeline to allow for time to resolve the cause for the Supply Failure. Until the Supply </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:128.7pt;padding-right:27.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">Failure is resolved Customer shall continue to be obligated to pay for Binding Batches.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:128.7pt;padding-right:27.6pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.19.2&#160;&#160;&#160;&#160;The Minimum Volume obligation shall be unaffected during the Supply Failure and &#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:65.8pt;text-indent:-27.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.20&#160;&#160;&#160;&#160;If the cause of a Supply Failure results primarily from a Force Majeure Situation&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:128.7pt;padding-right:27.45pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.20.1&#160;&#160;&#160;&#160;CMC and Customer shall work collaboratively through the JSC to discuss and find ways for CMC to promptly minimize such Supply Failure and ensure supply of Product as soon as practicable in accordance with the current Forecast and any Purchase Orders currently in effect for Batches that are affected by such Supply Failure.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:128.7pt;padding-right:27.8pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.20.2&#160;&#160;&#160;&#160;CMC shall use Commercially Reasonable Efforts to adjust the Timeline to allow for time to resolve the cause for the Supply Failure. Until the Supply Failure is resolved &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:128.7pt;padding-right:27.8pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">5.20.3&#160;&#160;&#160;&#160;The Forecast and Customer&#8217;s obligations thereunder will be suspended such &#91;***&#93; until CMC and Customer agree the Supply Failure has been resolved and manufacturing resumes.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.20.4&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.20.5&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.55pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.21&#160;&#160;&#160;&#160;If CMC is able to utilize uncommitted capacity of the CMC Facility to remedy any Supply Failure, but at the time when that capacity arises CMC is under an obligation to endeavour to remedy similar deficiencies for any other customer(s) of the CMC Facility, CMC shall liaise with all customers concerned to try to agree on an appropriate arrangement for using that (or that and other) available capacity for all concerned. In the event that no agreement can be reached, then the capacity shall be allocated taking into consideration each</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.65pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">customer&#8217;s number of batches subject to firm orders, CMC&#8217;s manufacturing schedule and availability of raw materials.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41.75pt;text-indent:-21.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;DELIVERY AND EXAMINATION</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery and Examination</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">6.1&#160;&#160;&#160;&#160;CMC shall provide Customer with advance written notice of each anticipated Delivery Date and, in any event, &#91;***&#93;.</font></div><div style="margin-top:3.75pt;padding-left:74.45pt;padding-right:27.35pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:151%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Except as set out in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 6.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">or in the Specifications, the Product that CMC manufactures pursuant to this Agreement shall be released to Customer &#91;***&#93; Customer that the Product is available for collection. The Deliverables will be deemed to have been delivered in accordance with the following&#58; (a) with respect to Product, </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.75pt;padding-left:74.45pt;padding-right:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">delivery will be deemed to have occurred &#91;***&#93;&#59; and (b) with respect to all other Deliverables, delivery will be deemed to have occurred &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Deliver</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;, &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Delivery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34; or &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Delivered</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;). Collection may be arranged at any time during normal business hours on Business Days or such other time as may be agreed by the Parties.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">6.3&#160;&#160;&#160;&#160;Upon Delivery of the relevant Batch, and no later than &#91;***&#93; after such Delivery, CMC shall provide the &#91;***&#93; shall be delivered by courier with registered delivery or by other electronic means agreed by Customer.</font></div><div><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.3pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">6.4&#160;&#160;&#160;&#160;&#91;***&#93; examine and&#47;or test the Deliverables for any defect or non-conformity, including in the case of Product non-conformity with the Specifications and cGMP standards which Deliverables are specified to meet (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Defect</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Defective</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">). Where any alleged Defect is identified, Customer shall notify CMC by written notice (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Defect Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) &#91;***&#93;&#59; provided that with respect to any defect in the Deliverables that was not, and could not reasonably be expected to have been found upon Delivery by exercise of ordinary care in inspection and testing, Customer shall provide written notice &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">6.5&#160;&#160;&#160;&#160;A Defect Notice must identify (i) the Deliverable and, in the case of Product, the Batch from which the Product was derived, (ii) the date(s) of Delivery, (iii) reasonable detail, including, as applicable, test results, of the Defect, (iv) where applicable full disclosure of the methodology of all analytical tests performed on the Deliverables and the results of those tests, (v) confirmation that, after Delivery to Customer, the Deliverables have been stored</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">and transported in accordance with applicable Shipping Guidelines, and (vi) where the Customer asserts that the Defect is due to CMC, the reasons why the Customer makes that assertion. If a Defect in any Deliverable is not notified to CMC in accordance with the provisions and time limits stipulated in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">6.4 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">the Deliverable shall be deemed accepted and free of Defect and Customer shall have no further remedy against CMC in respect of that Deliverable.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.25pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">6.6&#160;&#160;&#160;&#160;CMC shall store at the CMC Facility any such Deliverable &#91;***&#93; on behalf of Customer. Storage of a Deliverable at CMC&#8217;s premises after Delivery shall be at Customer&#8217;s sole risk and liability except that CMC shall be responsible for damage to such Deliverables to the extent any damage is caused during such storage solely by an act of CMC's negligence, wilful misconduct and&#47;or illegal conduct. If Deliverables have not been collected by Customer or Customer's Shipping Company &#91;***&#93;, CMC shall notify Customer of the outstanding collection. CMC shall be entitled &#91;***&#93; to continue to store it &#91;***&#93;, unless the Parties have previously negotiated for longer term storage or Customer informs CMC in writing to dispose of such Deliverables.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consequences of Defective Product</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.75pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">6.7&#160;&#160;&#160;&#160;Upon receipt of the Defect Notice CMC shall promptly investigate whether or not the Defect is due to CMC&#8217;s negligence or failure to comply with its obligations hereunder and shall report to Customer &#91;***&#93;.</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">6.8&#160;&#160;&#160;&#160;If a Defect is primarily due to CMC&#8217;s fault, and not as a result of Customer action or inaction or any Third Party (other than an agent of CMC performing Services) then CMC shall replace the Defective Deliverables at no charge to Customer. CMC shall use Commercially Reasonable Efforts, having regard to its other obligations and commercial commitments to third parties and subject to availability of Raw Materials in the timing of such replacement, to replace such Defective Deliverables &#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.3pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:151%">6.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">If there is a dispute regarding whether or not a Deliverable is Defective (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Disputed Deliverable</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;), then (a) analysts from both parties will directly communicate to determine the Parties' respective methods of analysis are the same and are being executed in the same manner, and to attempt to determine whether any non-compliance may have been caused during the shipment of the sample from the CMC Facility, and (b) carefully controlled and split samples as agreed should be sent from one site to another for testing in an attempt to reach agreement (which may involve Customer sending a representative and a sample of the Disputed Deliverable to CMC, and the Parties conducting jointly agreed upon tests on the Customer sample of the Disputed Deliverable and a sample of the Disputed Deliverable retained by CMC). The Parties will use good faith efforts &#91;***&#93; to resolve whether the Disputed Deliverable is Defective due to CMC's failure to manufacture in accordance with this Agreement.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.65pt;padding-right:27.3pt;text-align:justify;text-indent:-32.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">6.10&#160;&#160;&#160;&#160;In the event the Parties cannot resolve their dispute in the manner described, a mutually agreed-upon independent laboratory, acting as an expert and not as an arbitrator, shall be asked to test the Disputed Deliverable. The costs of such independent laboratory shall be borne by the Parties equally&#59; provided, however, the Party that is determined to be incorrect in the dispute shall be responsible for all such reasonable costs and shall reimburse the correct Party for its share of such reasonable costs incurred. The decision of such independent laboratory shall be in writing and shall be binding on both CMC and Customer. During the further dispute resolution described above in this section, at Customer&#8217;s request, CMC shall use Commercially Reasonable Efforts to supply Customer with replacement Product subject to availability of Raw Materials and capacity in CMC&#8217;s Facility, which replacement Product Customer shall purchase on the same terms as Product that is the subject of the independent testing. With respect to all Product that Customer properly rejects, Customer shall destroy all remaining unused Product as soon as possible after CMC&#8217;s request and at CMC&#8217;s expense. In no event may Customer use any of the rejected Product for any human clinical testing or trials after it becomes aware of the basis for such rejection (and Customer shall indemnify CMC for all liabilities, costs and damages incurred by CMC resulting from Customer&#8217;s breach of this limitation on use).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Release For Further Processing</font></div><div style="margin-top:4.85pt;padding-left:74.65pt;text-indent:-32.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.11&#160;&#160;&#160;&#160;Subject &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Title and Risk</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.4pt;padding-left:74.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.12&#160;&#160;&#160;&#160;Subject to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 6.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, title and risk in the Deliverables shall pass to Customer on Delivery.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Packaging, Storage and Transport</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">6.13&#160;&#160;&#160;&#160;Unless otherwise agreed, all Product and Deliverables shall be packaged by CMC in accordance with its applicable packaging SOPs and Applicable Laws. Customer shall inform CMC in advance of any special packaging and labeling requirements and CMC shall accommodate reasonable customer specific packaging requests.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:28.05pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">6.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:152%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">Customer shall, prior to the collection of the Deliverables, inform CMC of its Shipping Company. Customer shall coordinate with such Shipping Company for the shipment of the Product and CMC shall not be responsible for any shipping costs of the Shipping Company.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Upon collection, Customer shall be responsible for ensuring that the Deliverables are stored and transported in accordance with the Shipping Guidelines.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.95pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">6.15&#160;&#160;&#160;&#160;Except as otherwise agreed by the Parties, CMC shall not be responsible for or have an obligation to clear for export or import any Deliverables that CMC (or its subcontractors) generates or manufactures pursuant to this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;BATCH PRICE, PAYMENT TERMS AND MILESTONE PAYMENTS</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reserve Payment and Batch Price</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.35pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">7.1&#160;&#160;&#160;&#160;Customer shall pay CMC&#58; (a) &#91;***&#93;, and (b) &#91;***&#93; under the Amended Agreement effective between the parties on or about the Effective Date (the foregoing payments &#91;***&#93;, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Reserve Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;). CMC shall invoice Customer for such amounts upon the occurrence of the above-referenced events and Customer shall &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">7.2&#160;&#160;&#160;&#160;Additional payment for Batches will be due as described in Appendix Two. The Batch Price in Appendix Two is stated in U.S. Dollars and is exclusive of all taxes, duties, or other fees of whatever nature imposed by or under the authority of any state, government or public authority (other than taxes on CMC&#8217;s income), or any external costs, Raw Materials or shipping and associated costs that CMC incurs to provide the Services, which Customer agrees to pay in addition to the Batch Price.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:27.6pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:151%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">The Batch Price stated in Appendix Two may be adjusted on an annual basis, commencing with the first anniversary of the Effective Date and thereafter on each anniversary of the Effective Date in an amount not to exceed &#91; * * * &#93; . For the avoidance of doubt, if the &#91;***&#93;. For example, the Batch Price stated in Appendix Two shall &#91;***&#93;, the Batch Price shall be &#91;***&#93;. The &#91;***&#93; Batch Price shall be &#91;***&#93;. The Batch Price &#91;***&#93;. CMC shall give written notice to the Customer of the new Batch Price schedule &#91;***&#93;&#59; provided however that CMC &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:74.45pt;padding-right:28.45pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">7.4&#160;&#160;&#160;&#160;If there are any material and unforeseen changes in cGMP or manufacturing regulations promulgated pursuant to enabling legislation under a statute that&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:110.65pt;padding-right:27.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">7.4.1&#160;&#160;&#160;&#160;are specific to the Product and not of general requirement for biologics contract manufacturing services&#59; or</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:110.65pt;padding-right:27.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">7.4.2&#160;&#160;&#160;&#160;which result in the financial returns under this Agreement being substantially affected to CMC's detriment other than by the acts or omissions of CMC, then the Parties shall negotiate in good faith a way to continue the Services while overcoming such financial investment or detriment. For purposes of clarity, CMC &#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Invoicing &#38; Payment Terms</font></div><div style="margin-top:3.4pt;padding-left:74.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;&#160;&#160;&#160;All invoices will be in U.S. Dollars and Customer agrees to pay all sums due hereunder in</font></div><div style="margin-top:3.6pt;padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Dollars.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;&#160;&#160;&#160;CMC will issue invoices in accordance with the provisions of Appendix Two.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.7&#160;&#160;&#160;&#160;All invoices shall be paid by wire transfer to the following account&#58;</font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration:underline">ACCOUNT DETAILS&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:99.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Unless expressly stated on an invoice to the contrary, all invoices are issued net and if not disputed in good faith in writing before the due date, will be paid in full without any deductions, deferment or set off by Customer &#91;***&#93;. If Customer disputes an invoice, Customer shall notify CMC in writing of the dispute, which notice must include a description of the dispute&#59; provided that if Customer disputes an invoice and intends to withhold payment of such invoice, Customer shall notify CMC in writing of the dispute prior to the due date of such invoice. The Parties shall use commercially reasonable efforts to resolve the dispute as quickly as possible. If the dispute &#91;***&#93;, the CEOs of the parties shall meet and resolve the dispute. Customer shall, subject</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.65pt;padding-right:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">to the other terms and conditions of this Agreement, pay amounts due that are not in dispute.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.85pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">7.8&#160;&#160;&#160;&#160;Raw Materials costs for all Services will be invoiced to Customer as set forth in Appendix Two. If Customer requests CMC purchase Raw Materials in excess of what is needed to meet the Forecast (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Excess Raw Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;), Customer shall pay to CMC, &#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.65pt;text-indent:-30.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shipping &#91;***&#93;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Late Payments</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">7.10&#160;&#160;&#160;&#160;If the undisputed portion of an invoice is not settled by Customer in full in accordance with this Agreement and after providing the Customer &#91;***&#93;, CMC may, at its discretion&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:111.4pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.10.1&#160;&#160;&#160;&#160;charge Customer, which Customer will pay, &#91;***&#93; and&#47;or&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:111.4pt;padding-right:27.15pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">7.10.2&#160;&#160;&#160;&#160;&#91;***&#93;, suspend the performance of the Services. Where performance is suspended, CMC shall have no liability to Customer for such suspension or delay in the Timeline and the Batch Price for any Batches that are the subject of a Firm Order or a Semi- Firm Order which are delayed as a result of the suspension shall become due and payable by Customer.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payments due to Customer</font></div><div style="margin-top:3.6pt;padding-left:74.65pt;padding-right:27.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">7.11&#160;&#160;&#160;&#160;Where any payment, credit or refund is properly due to the Customer under this Agreement, the Customer can elect to&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:110.65pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.11.1&#160;&#160;&#160;&#160;have that amount refunded to it by CMC &#91;***&#93;&#59; or</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:110.65pt;padding-right:27.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">7.11.2&#160;&#160;&#160;&#160;have that amount set-off against any further amount payable by the Customer under this Agreement or any future agreement the Parties enter into.</font></div><div><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.5pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">7.12&#160;&#160;&#160;&#160;Where Customer elects to have an amount set-off against any further amount payable by the Customer under this Agreement and, subsequent to that credit, the Customer remains entitled to a payment, credit or refund, CMC shall refund that amount to the Customer &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;CUSTOMER AUDITS, REGULATORY INSPECTIONS &#38; MATTERS</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Audits</font></div><div style="margin-top:3.4pt;padding-left:74.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1&#160;&#160;&#160;&#160;Customer&#8217;s audit rights are as set forth in the Commercial Quality Agreement.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Inspections</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.35pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Regulatory inspections are addressed in the Commercial Quality Agreement. CMC shall use Commercially Reasonable Efforts to make available the CMC Facility, subcontractor facilities, records, data, documents, information and&#47;or personnel as are reasonably necessary or useful pursuant to and during regulatory inspections by government authorities as further set forth in the Commercial Quality Agreement. For the purposes of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause</font></div><div style="padding-left:74.45pt;padding-right:27.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:153%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">records, data, documents and information refers to copies in tangible, and electronic and visual mediums.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:77.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Filings and Standards</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.45pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">During the preparation for filing with any Regulatory Authority of any documentation for the Product which is or is equivalent to the Regulatory Authority&#8217;s Chemistry and Manufacturing Controls portion of an approval application, including any BLA (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Authority Submission</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;), Customer shall provide CMC with &#91;***&#93;. CMC shall provide Customer with its comments &#91;***&#93;. For clarity, CMC&#8217;s &#91;***&#93; applies to &#91;***&#93; shall be provided by CMC to the Customer &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.3pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">For clarity, the Parties agree that in reviewing the documents referred to in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline">8.3</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">above, CMC&#8217;s role will be limited to &#91;***&#93;. As such, CMC shall not assume responsibility or liability for the accuracy of the filings with Regulatory Authorities other than for </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:74.45pt;padding-right:27.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">information provided by CMC in writing and intended for inclusion in regulatory filings. The sole responsibility of the preparation and filing of all regulatory documents with the Regulatory Authorities with respect to the Product shall be borne by Customer.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.75pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Customer shall provide to CMC all documents relating to the Product and services performed hereunder by CMC that are reasonably requested by CMC and required to comply with any Regulatory Authority&#8217;s pre-approval inspection of the CMC Facility, including but not limited to, development reports, Chemistry and Manufacturing Controls documentation and stability data, subject to Customer being able to legally provide such documents to CMC.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">8.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">&#91;***&#93;, Customer shall provide CMC with a copy of the documents incorporating such data so as to permit CMC to verify the accuracy and regulatory validity of such documents as it related to the CMC-generated data.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.95pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">8.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">CMC will provide Customer with information and data regarding the manufacture of Product to the extent reasonably requested by Customer or necessary for Customer to prepare and</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.65pt;padding-right:47.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">defend any inquiries from the FDA or other Regulatory Authorities to satisfy regulatory requirements with respect to Product. Without limiting the foregoing,</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:184.9pt;padding-right:27.2pt;text-align:justify;text-indent:-65.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">8.7.1&#160;&#160;&#160;&#160;CMC shall provide regulatory support to Customer for a Regulatory Authority&#8217;s pre-approval inspection of the CMC Facility and during review of any Authority Submission &#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:184.9pt;padding-right:27.2pt;text-align:justify;text-indent:-65.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">8.7.2&#160;&#160;&#160;&#160;Customer will inform CMC of requests for information from Regulatory Authorities during review of an Authority Submission for which CMC support is needed. CMC will use diligent efforts to adhere with the turn-around times requested by Customer to support such regulatory responses.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.35pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">8.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">If CMC is required by the FDA, EMA, or any other Regulatory Authority to modify the CMC Facility or validate or re-validate the Process that will impact the manufacturing of the Product, CMC shall notify Customer and consult with Customer regarding the required activities. Customer shall &#91;***&#93; and not generally for CMC&#8217;s manufacturing activities for other customers, provided, however that CMC shall be responsible for the costs of any such validation or re-validation arising primarily from (a) CMC&#8217;s breach of this Agreement or CMC&#8217;s negligence or wilful misconduct or (b) a modification to the CMC Facility that is generally required for CMC&#8217;s manufacturing activities.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Person in Plant</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.8pt;padding-left:74.65pt;padding-right:27.4pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">8.8&#160;&#160;&#160;&#160;CMC shall permit &#91;***&#93; with reasonable advance notice &#91;***&#93; to observe manufacturing or packaging pursuant to this Agreement on-site at the CMC Facility during the Term. </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:4.8pt;padding-left:74.65pt;padding-right:27.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Customer&#8217;s representatives shall have access to CMC&#8217;s production and quality control and storage areas related to the Product (including when in operation) and to Product related documentation. Customer agrees that Customer&#8217;s representatives shall comply with CMC&#8217;s reasonable rules, regulations and safety procedures (that are provided to Customer) and cGMP while on CMC&#8217;s premises. In addition, CMC shall provide reasonable accommodations for Customer&#8217;s representatives, including a desk and access to the internet, phones, copiers, fax machines and other miscellaneous office equipment as requested.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:56.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Validation</font></div><div style="margin-top:3.65pt;padding-left:74.65pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9&#160;&#160;&#160;&#160;The Parties recognize &#91;***&#93;.</font></div><div style="margin-top:3.6pt;padding-left:86.2pt;text-indent:-29.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.10&#160;&#160;&#160;&#160;Upon successful completion of &#91;***&#93; as specified in the Work Statement.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.65pt;padding-right:27.9pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">8.11&#160;&#160;&#160;&#160;CMC is responsible to ensure that all equipment, facilities, utilities and computer systems used for the production of the GMP steps of the Product are qualified or validated in accordance with all applicable GMP regulations and guidance documents and are maintained in a validated state</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:38.65pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;WARRANTIES</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Customer Warranties</font></div><div style="margin-top:3.4pt;padding-left:85.45pt;text-indent:-43.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;&#160;&#160;&#160;Customer warrants and represents to CMC that&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111.4pt;padding-right:27.65pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">9.1.1&#160;&#160;&#160;&#160;to its knowledge, it has the right to supply and deliver to CMC the Customer Materials (including the Cell Line provided by or on behalf of Customer where applicable) and the Customer Intellectual Property Rights for use in the performance of the Services and the manufacture of Product pursuant to this Agreement&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111.4pt;padding-right:27.5pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.1.2&#160;&#160;&#160;&#160;to its knowledge, the Materials and Safety Data Sheet for the BDS is accurate and the Cell Line provided by or on behalf of Customer and any Customer Materials are free from all contaminants including, without limitation, virus, bacteria or other vectors and if handled and used in accordance with the recommendations and guidelines in the Materials and Safety Data Sheet supplied by Customer will not cause a health hazard or biohazard&#59; and</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:99.65pt;padding-right:27.65pt;text-align:justify;text-indent:-43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.1.3&#160;&#160;&#160;&#160;to its knowledge the use of any of the Cell Line, Customer Materials, Customer Intellectual Property Rights, and the Process and the manufacture of the Product in accordance with this Agreement does not infringe any valid Intellectual Property rights of third parties, except that no warranty is given with respect to any CMC Intellectual Property Rights&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:99.65pt;padding-right:28.15pt;text-align:justify;text-indent:-43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">9.1.4&#160;&#160;&#160;&#160;the license of Customer Intellectual Property Rights to CMC for the Services is lawfully granted&#59; and</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:99.65pt;padding-right:27.75pt;text-align:justify;text-indent:-43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.1.5&#160;&#160;&#160;&#160;to its knowledge the Cell Line provided by or on behalf of the Customer and Customer Materials are viable, adequate and suitable for the effective performance of the Services and manufacture of the Product according to the Specification and the information regarding the Cell Line and the Process provided to CMC by or on behalf of the Customer is complete and accurate.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CMC Warranties</font></div><div style="margin-top:3.4pt;padding-left:74.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.2&#160;&#160;&#160;&#160;CMC warrants and represents to Customer that&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.55pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.2.1&#160;&#160;&#160;&#160;it has the necessary permits, facilities, Third Party contractors and skilled personnel necessary of a biologics contract manufacturer for the regular provision of manufacturing and development services of biologic material and required for performance of the Services in accordance with this Agreement&#59;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:111.4pt;padding-right:27.4pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.2.2&#160;&#160;&#160;&#160;all Deliverables shall be Delivered free of encumbrances or liens but for the avoidance of doubt no warranty is given in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">9.2.2 i</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">n respect (i) non- infringement of Third Party Intellectual Property Rights, or (ii) freedom to use&#59;</font></div><div><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.25pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.2.3&#160;&#160;&#160;&#160;to its knowledge, the CMC Intellectual Property Rights used in the Services and the performance of the Services do not infringe Third Party Intellectual Property rights, except that no warranty is given with respect to the Cell Line, Process, Customer Materials and Customer Intellectual Property Rights&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:28.2pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">9.2.4&#160;&#160;&#160;&#160;where the Services are to be performed according to cGMP, CMC shall apply the appropriate cGMP standards to the performance of such Services&#59; and</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.7pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">9.2.5&#160;&#160;&#160;&#160;Services and Manufacture of Product will be performed in accordance with applicable industry standards and all Applicable Laws&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.8pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">9.2.6&#160;&#160;&#160;&#160;the Product at the time of Delivery shall comply with the Specifications, cGMP and any other criteria specified in the Certificate of Analysis for such Product&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.3pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.2.7&#160;&#160;&#160;&#160;none of CMC or its Affiliates, or any officer of CMC or its Affiliates or any employee, consultant or other contractor engaged by CMC to perform activities under this Agreement, (a) have been debarred, or are subject to a pending debarment, or will use in any capacity in connection with this Agreement any person who has been debarred pursuant to section 306 of the FDCA, 21 U.S.C. &#167; 335a, (c) has been listed by any federal and&#47;or state agencies as excluded, debarred, suspended or otherwise been made ineligible to participate in federal or state healthcare programs or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. 1320a-7b(f), (c) has been convicted of a criminal offense related to the provision of healthcare items or services, or (d) is subject to any such pending action or is the subject of a conviction or pending action described in such sections. CMC shall notify Customer in writing immediately if CMC, its </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:111.4pt;padding-right:27.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Affiliates or any of their respective officers or any person or entity used by CMC or its Affiliates to perform activities under this Agreement is subject to any of the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending, or to the best of CMC&#8217;s knowledge, is threatened.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:20.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mutual Warranties</font></div><div style="margin-top:3.4pt;padding-left:85.45pt;text-indent:-43.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;&#160;&#160;&#160;Each Party warrants and represents to the other that&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.25pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.3.1&#160;&#160;&#160;&#160;it has the right and corporate authority to enter into this Agreement and the execution, delivery and performance of this Agreement does not conflict with any agreement, instrument or understanding, oral or written, to which such Party may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it&#59;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:111.4pt;padding-right:27.65pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.3.2&#160;&#160;&#160;&#160;it shall obtain and during the Term maintain in force all appropriate permits and regulatory licenses required in connection with such Party&#8217;s handling, transport and storage of the Cell Line and Product&#59;</font></div><div><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.4pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.3.3&#160;&#160;&#160;&#160;neither Party shall perform any actions that are prohibited by local and other anti- corruption laws (including the U.S. Foreign Corrupt Practices Act, collectively &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Anti- Corruption Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) that may be applicable to one or both Parties. Without limiting the foregoing, neither Party shall make any payments, or offer or transfer anything of value, to any government official or government employee, to any political party official or candidate for political office or to any other third party related to the transaction in a manner that would violate Anti-Corruption Laws.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:43.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusion of other express and implied warranties</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.9pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">9.4&#160;&#160;&#160;&#160;Except as provided in this Agreement, to the maximum extent permitted by the applicable law of this Agreement, except for those express warranties set out above, the Parties neither make nor give any other express or implied (whether by statute, custom or otherwise) warranties in relation to each of their respective obligations, duties or activities owed or performed under this Agreement and hereby exclude any other such express or implied warranty in respect of that subject matter.</font></div><div><font><br></font></div><div style="padding-left:38.65pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;CONFIDENTIAL INFORMATION</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.7pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.1&#160;&#160;&#160;&#160;In consideration of one Party (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Disclosing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) making available its Confidential Information to the other (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Recipient Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;), the Recipient Party hereby undertakes that it shall, and shall procure that each of its Permitted Recipients, shall&#58;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.95pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">10.1.1&#160;&#160;&#160;&#160;treat and safeguard as private and confidential all the Confidential Information of the Disclosing Party&#59;</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.6pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.1.2&#160;&#160;&#160;&#160;use the Confidential Information of the Disclosing Party only during the Term for those purposes reasonably necessary to perform its obligations or exercise its rights under this Agreement and without prejudice to the generality of the foregoing, not use any Confidential Information of the Disclosing Party to obtain any commercial advantage over the Disclosing Party&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.8pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">10.1.3&#160;&#160;&#160;&#160;ensure the proper and secure storage of all Confidential Information of the Disclosing Party applying standards of care reasonably expected and no less stringent than standards applied to protection of Recipient Party's own confidential information&#59; and</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111.4pt;padding-right:27.4pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.1.4&#160;&#160;&#160;&#160;not at any time without the Disclosing Party&#8217;s prior written consent disclose or reveal, whether directly or indirectly, any of the Confidential Information of the Disclosing Party to any person whatsoever except its Permitted Recipients, and then only on a limited need to know basis, who shall be informed by it of the confidential nature of such Confidential Information and of the confidentiality terms</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:111.4pt;padding-right:39.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">of this Agreement and for whom it hereby accepts full responsibility in the event that any such person shall breach the duty of confidence imposed upon them&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:28pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">10.2&#160;&#160;&#160;&#160;The obligations in this Agreement regarding Confidential Information do not apply to information&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:28.2pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">10.2.1&#160;&#160;&#160;&#160;which, at the time of its disclosure by the Disclosing Party, was wholly available to the public&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.45pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.2.2&#160;&#160;&#160;&#160;which becomes generally available to the public after such disclosure otherwise than by reason of a breach of any of the undertakings in this Agreement, including any breaches of confidence by the Recipient Party or its Permitted Recipients&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:28.05pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.2.3&#160;&#160;&#160;&#160;which is, at the time of such disclosure and as evidenced by the Recipient Party's written records, lawfully already within its possession&#59; or</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:111.4pt;padding-right:27.1pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">10.2.4&#160;&#160;&#160;&#160;was independently discovered or developed by the Recipient Party without the use of or reference to the Disclosing Party&#8217;s Confidential Information as evidenced by written records.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.3&#160;&#160;&#160;&#160;In addition, notwithstanding </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 10.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, the Recipient Party may disclose Confidential Information to the extent the disclosure is required by Applicable Law or a valid order of a court or other governmental body having jurisdiction&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:151%">provided, however, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">that the Recipient Party gives reasonable prior written notice to the </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:74.45pt;padding-right:27.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Disclosing Party of such required disclosure and makes a reasonable effort to assist the Disclosing Party in obtaining, a protective order preventing or limiting the disclosure and&#47;or requiring that the Confidential Information so disclosed be used only for the purposes for which the law or regulation requires, or for which the order was issued. Notwithstanding anything to the contrary herein, Customer may use and disclose Confidential Information of CMC (a) in preparing and submitting BLAs to Regulatory Authorities or marketing Products subject to Section 8.3, or</font></div><div style="padding-left:74.45pt;padding-right:27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">in communications with existing or prospective investors, acquirers, merger partners, consultants, advisors, licensees or collaborators under obligations of confidentiality and non-use consistent with this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause 10.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.8pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">10.4&#160;&#160;&#160;&#160;Other than the limited and restricted rights of use set out in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline">10 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">nothing in this Agreement intends to or has the effect of granting any right, title, license or interest in or to the Recipient Party or Permitted Recipients in respect of the Disclosing Party's Confidential Information.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.5&#160;&#160;&#160;&#160;If the Recipient Party or any of its Permitted Recipients is&#47;are compelled to disclose any Confidential Information in the circumstances described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 10.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">of this Agreement or a breach or threatened breach of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">10</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">occurs or becomes apparent, the Recipient Party shall inform the Disclosing Party in writing of such obligation or fact as soon as possible after it is informed, or becomes aware, of it and if possible, before any Confidential Information is disclosed, so that (if the Disclosing Party in its absolute discretion shall see fit) a protective order or other appropriate remedy may be sought. The Recipient</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Party agrees to assist and co-operate (and shall procure that each of its Permitted Recipients shall, as appropriate, assist and co-operate) in any action which the Disclosing Party may decide to take.</font></div><div><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.6&#160;&#160;&#160;&#160;Each Party shall be permitted to disclose the terms of this Agreement, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement, to any actual or potential acquirers, merger partners, licensees, sublicensees, investors and professional advisors on a need to know basis and to its board of directors in connection with the corporate governance of such Party. Except as otherwise provided for in this Agreement (including this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 10.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">) or otherwise required by law or administrative authorities, neither Customer nor CMC shall disclose any terms or conditions of the Agreement to any Third Party without the prior written consent of the other Party.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:27.35pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.7&#160;&#160;&#160;&#160;At the request of the Disclosing Party, the Recipient Party shall promptly destroy (on request) or return to the Disclosing Party any and all Confidential Information (including copies of documents, computer records and records on all other media) then in its possession or under its control except where such Confidential Information is covered under surviving license rights between the Parties. Notwithstanding the foregoing, the Parties may retain copies of any document containing the Disclosing </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Party's Confidential Information solely for the purpose of determining the scope of the obligations under this Agreement or to comply with regulatory obligations. Further, the Recipient Party shall not be required to return or destroy any electronic back-up tapes or other electronic back-up files that have been created solely by their automatic or routine archiving and back-up procedures.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.95pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">10.8&#160;&#160;&#160;&#160;The Parties acknowledge that they have received Confidential Information under other agreements between each other. The Parties hereby agree that Confidential Information received under those earlier agreements may be used for the purposes of performing the Services under this Agreement or exercising rights under this Agreement.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">10.9&#160;&#160;&#160;&#160;The provisions of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%;text-decoration:underline">10 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">shall survive expiration or termination of the Agreement for a period of 10 years.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.7pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">10.10&#160;&#160;&#160;&#160;For the avoidance of doubt, the provisions of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline">10 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">do not restrict the Customer&#8217;s right to disclose or otherwise deal with the Deliverables after such Deliverables have been Delivered to the Customer.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:38.65pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;INTELLECTUAL PROPERTY</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pre-Existing Intellectual Property</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.35pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">11.1&#160;&#160;&#160;&#160;Any Intellectual Property owned by a Party or licensed by a Third Party to a Party as of the Effective Date or before the commencement of the Services (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Pre-Existing IPR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) shall remain the sole and absolute property of the Party that owned or was licensed to use such Pre-Existing IPR. Nothing in this Agreement shall act as any assignment or transfer of the Pre-Existing IPR. The Pre-Existing IPR shall not be licensed to the other Party under this Agreement unless an express license is granted hereunder.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Customer's grant of Intellectual Property License for the Services</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">11.2&#160;&#160;&#160;&#160;The Customer hereby grants to CMC for the Term a non-exclusive, royalty-free, non- sublicensable (except to CMC&#8217;s Affiliates performing Services in accordance with this Agreement), limited license in respect of Customer Intellectual Property Rights and Customer Agreement IPR solely to the extent the same is required and necessary for the proper performance of the Services. This license&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:28.25pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">11.2.1&#160;&#160;&#160;&#160;does not prevent the Customer from granting a license to or making any use of its Pre-Existing IPR&#59; and</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.9pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">11.2.2&#160;&#160;&#160;&#160;terminates automatically upon the expiry or termination of this Agreement, whichever is the earlier.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property created in the course of the Services</font></div><div style="margin-top:3.4pt;padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">11.3&#160;&#160;&#160;&#160;Without affecting </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clauses 11.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">11.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">, all data, results, information, processes, materials, trade secrets, know-how and corresponding Intellectual Property newly generated by CMC exclusively in its performance of the Services and which &#91;***&#93; shall </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">35</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.4pt;padding-left:74.45pt;padding-right:27.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">be owned by Customer (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Customer Agreement IPR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">&#8221;). CMC shall cooperate with Customer and execute any appropriate documents to fully effect the foregoing.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.8pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">11.4&#160;&#160;&#160;&#160;All Intellectual Property other than Customer Agreement IPR generated by CMC under the Services shall be owned by CMC (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">CMC IPR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#8221;).</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">License to CMC IPR</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.5pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">11.5&#160;&#160;&#160;&#160;CMC hereby grants to Customer a general, royalty free, sub-licensable, worldwide license to use CMC Intellectual Property Rights or CMC IPR to the extent that the same is necessary or useful for the exploitation (including to make, have made, use, sell, offer for sale, distribute or import) of the Product or use of the Cell Line or Process to manufacture Product. Except to Permitted Recipients or as otherwise provided in this Agreement, nothing in the foregoing shall permit Customer to make any disclosure of Confidential Information or CMC's Know-How to a Third Party without the express prior written consent of CMC. This license does not prevent CMC granting a license to or making any use of CMC Intellectual Property Rights or CMC Agreement IPR.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Right to file for protection</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">11.6&#160;&#160;&#160;&#160;Each Party may file patent protection on any Intellectual Property it owns in accordance with this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 11 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">above and the other Party shall promptly upon request co-operate at the requesting Party&#8217;s reasonable expense, with any requests to assist or enable the Party&#8217;s protection including but not limited to signing and delivering documents and other information necessary for the valid application and prosecution of any such patent.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Party&#8217;s Names &#38; Press Release</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.95pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">11.7&#160;&#160;&#160;&#160;Except as otherwise provided for in this Agreement or required by Applicable Law, neither Party shall use the name of the other Party or of the other Party&#8217;s Affiliates, directors, officers</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">or employees in any advertising, news release, publication or other without the prior consent of the other Party, which shall not be unreasonably withheld or delayed.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:38.65pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;INDEMNITIES AND LIABILITY</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CMC&#8217;s Indemnity</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.1pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.1&#160;&#160;&#160;&#160;Customer shall indemnify, defend and hold harmless CMC and each of its directors, officers, employees and Testing Laboratories (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">CMC Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) against any and all losses, demands, liabilities, damages, costs and expenses (including but not limited to, court costs and reasonable documented attorney&#8217;s fees and expenses together with any applicable taxes thereon) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">(&#34;Losses&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">) arising out of any Third Party claim, action of proceeding (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) that the CMC Parties may or have suffered or incurred directly as a result of the following&#58;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:111.4pt;padding-right:27.2pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.1.1&#160;&#160;&#160;&#160;any infringement or alleged infringement (including direct, contributory, inducement and wilful infringement) or breach of any Third Party Intellectual Property rights by CMC&#8217;s use of the Cell Line, Process, Customer Intellectual Property Rights, Customer Materials in the performance of the Services or manufacture of Product hereunder&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.9pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.1.2&#160;&#160;&#160;&#160;any claims resulting from the use, handling, distribution, marketing, safety or sale of the Product or BDS, including any derivative, conjugated form or formulation of the same, by or on behalf of Customer&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.7pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">12.1.3&#160;&#160;&#160;&#160;any use, handling, distribution, marketing, safety or sale by or on behalf of Customer of Product which was the subject of a &#91;***&#93; in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause 6.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">&#59; or</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111.4pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1.4&#160;&#160;&#160;&#160;any acts or omissions of an auditor of Customer while on CMC&#8217;s premises.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">In addition, Customer agrees to indemnify and hold harmless CMC from and against any Losses arising out of contamination or damage to the CMC Facility to the extent caused by the Customer Materials except to the extent such Losses are caused by the Customer Materials not being handled in accordance with the Materials and Safety Data Sheet. The foregoing indemnities shall not apply to the extent the Losses or Claims arose from CMC's or any of its representatives or contractors (including Testing Laboratories) negligence, gross negligence, breach of this Agreement, or wilful misconduct (other than wilful infringement covered by Section 12.1.1) or are covered by an indemnity under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">12.2.</a></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Customer&#8217;s Indemnity</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.2&#160;&#160;&#160;&#160;CMC shall promptly indemnify, defend and hold harmless Customer and each of its directors and officers, employees, agents, contractors or representatives (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Customer Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) against any and all Losses arising out of any Claim that the Customer Parties may or have suffered or incurred directly as a result of the following&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:111.4pt;padding-right:27.9pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.2.1&#160;&#160;&#160;&#160;the negligence or wilful misconduct (other than wilful infringement covered by Section 12.1.1) of CMC or any CMC representative or CMC Parties or a breach of this Agreement by CMC&#59;</font></div><div><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.55pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.2.2&#160;&#160;&#160;&#160;a material inaccuracy in a Certificate of Analysis such that certified Product at the time of Delivery does not meet Specification when certified to meet Specification or CMC&#8217;s failure to manufacture Product or BDS according to cGMP, the Process or the Specifications&#59; or</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.3pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.2.3&#160;&#160;&#160;&#160;the infringement or alleged infringement or breach of any Third Party rights, including Intellectual Property rights, by CMC to the extent such infringement is due to CMC&#8217;s use of the CMC Intellectual Property Rights in the performance of the Services, but excluding claims where such use is caused </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:111.4pt;padding-right:27.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">by the combination of the CMC Intellectual Property Rights with the Cell Line, Customer Materials, Process or Customer Intellectual Property Rights.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">The foregoing indemnities shall not apply to the extent the Losses or Claims arose from the Customer or any of the Customer Parties' negligence, gross negligence, breach of this Agreement or wilful default or are covered by an indemnity under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">12.1.</a></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Procedure</font></div><div style="margin-top:3.35pt;padding-left:74.65pt;text-indent:-32.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Party (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) that intends to claim indemnification under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">12</a></font></div><div style="margin-top:3.65pt;padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.45pt;text-align:justify;text-indent:-36.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.3.1&#160;&#160;&#160;&#160;promptly, &#91;***&#93;, notify the other Party (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Indemnitor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) in writing in general terms of any Claim, threat or action which has or has the potential to give rise to the Indemnitee seeking to rely on and claim the benefit of the indemnification together with notification of the Indemnitee's intention to rely on such indemnity, provided that, failure to give such notice shall not relieve the Indemnitor of its indemnification obligations except and only to the extent such failure actually and materially prejudices the ability of the Indemnitor to defend against such Claims&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:28pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">12.3.2&#160;&#160;&#160;&#160;not prejudice any defence to any Claim or attempt to settle or compromise such claim&#59;</font></div><div><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.55pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">12.3.3&#160;&#160;&#160;&#160;shall comply with the procedure in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline">12.3.1 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">except that nothing shall prevent it from complying with the procedural requirement of any proceedings which have been commenced&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.55pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.3.4&#160;&#160;&#160;&#160;subject to its other rights and obligations and compliance with the procedures set out in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">12 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">permit the Indemnitor to have overall control of the conduct of the negotiations and the proceedings including any counterclaim&#59;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:111.4pt;padding-right:27.7pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.3.5&#160;&#160;&#160;&#160;cooperate as reasonably requested by the Indemnitor, at the Indemnitor's expense, in the conduct of such Claim (and any counterclaim)&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.65pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.3.6&#160;&#160;&#160;&#160;have the right (at the Indemnitor's expense) to instruct independent counsel and participate in all proceedings and negotiations whether named or not as a party in the Claim or proceedings.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.75pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">12.4&#160;&#160;&#160;&#160;Notwithstanding any other provision in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline">12, </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">the Indemnitor shall not settle or consent to an adverse judgement in any such claim, demand, action or other proceeding that adversely affects the rights or interests of any Indemnitee or imposes additional obligations (financial or otherwise) on such Indemnitee, without the prior express written consent of such Indemnitee (such consent to be at the Indemnitee's sole discretion).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:74.45pt;padding-right:27.5pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">12.5&#160;&#160;&#160;&#160;In the event of a claim under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause 12.1.1 or 12.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">, the Parties shall promptly and in good faith discuss ways, whether by modifications to the Services or Product, licensing or otherwise, to settle or overcome the Claim. In the event that legal proceedings are commenced by a Third Party, the Parties shall &#91;***&#93;. If the Parties are unable to agree to a solution to avoid the infringement &#91;***&#93;, the Parties shall discuss and consider whether to suspend the infringing Services before &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">12.6&#160;&#160;&#160;&#160;In the event that Customer challenges its obligation to indemnify the CMC Parties for a Claim arising under Clause 12.1.1, Customer agrees to promptly pay CMC for all costs and expenses of the action or proceeding, including reasonable attorneys&#8217; fees and court costs and collection expenses.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.65pt;padding-right:27.6pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.7&#160;&#160;&#160;&#160;Customer shall procure from a reputable insurance carrier commercial general liability insurance including coverage for product liability &#91;***&#93;. Customer will maintain such insurance during the Term of this Agreement &#91;***&#93;. Upon reasonable request, Customer will deliver a certificate of insurance evidencing such coverage and an endorsement of additional insured in favour of CMC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.3pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:151%">12.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">CMC shall maintain, at its expense comprehensive general liability insurance and workers compensation insurance, including product liability insurance, &#91;***&#93;. All insurance required under this Agreement shall be maintained during the Term, and CMC shall from time to time provide copies of certificates of such insurance to Customer upon reasonable request. Notwithstanding the preceding sentence, CMC shall be obligated to maintain product liability insurance obtained by it pursuant to this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 12.8 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">during the Term and after expiration or termination of this Agreement &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:74.65pt;padding-right:27.55pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.9&#160;&#160;&#160;&#160;Each Party will provide the other Party evidence of such coverage upon request. Each Party will provide the other Party &#91;***&#93; to non-renewal, termination or modification of their respective insurance coverage as described above.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:20.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation of Liability</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.10&#160;&#160;&#160;&#160;The Parties represent and acknowledge that they have negotiated the terms of this</font></div><div style="padding-left:74.45pt;padding-right:27.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%"> Agreement and have reached agreement on the terms based on their own assessment of their own risks, liabilities and rewards in connection with this Agreement and the Product in addition to having had the benefit of professional legal advice and accordingly the Parties agree that without prejudice to the terms of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clauses 16, 12.10 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">and </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">12.12 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">CMC&#8217;s aggregate liability to Customer for any loss or damage suffered by the Customer as a result of breach of this Agreement or of any other liability (including but not limited to negligence, misrepresentation or claim under the indemnities) in respect to any claim arising under this Agreement or in connection with the Services shall be limited, in the aggregate, to the &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:74.45pt;padding-right:27.7pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">12.11&#160;&#160;&#160;&#160;Without prejudice to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">12.12 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">neither CMC nor Customer shall be liable for any loss or damage howsoever caused (even if foreseeable or in the contemplation of CMC or Customer) in respect of&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.11.1 &#91;***&#93;&#59; and</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.11.2 &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">12.12&#160;&#160;&#160;&#160;Nothing in this Agreement shall purport or attempt or serve to exclude or restrict any liability &#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:38.65pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;PRODUCT RECALL</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:77.3pt;padding-right:27.55pt;text-align:justify;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">13.1&#160;&#160;&#160;&#160;Subject to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%;text-decoration:underline">13.3.1, </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">the costs and obligations with respect to any Recall of Product and handling enquiries and contacts from any Regulatory Authority relating to any Recall of Product shall be the responsibility of Customer. Customer shall notify all Regulatory Authorities having jurisdiction over Product (whether or not the issue arose in the jurisdiction controlled by the Regulatory Authority) of any Recall, and shall be responsible for coordinating all necessary activities regarding the action taken. CMC shall, &#91;***&#93;, provide all reasonable assistance to Customer in connection with any</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:77.3pt;padding-right:27.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Recall. The Parties agree to keep each other advised of any Recall, the progress of undertaking any Recall, and to exchange copies of such documentation as may be reasonably required, to assure regulatory compliance with a Recall.</font></div><div><font><br></font></div><div style="padding-left:77.3pt;padding-right:27.55pt;text-align:justify;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">13.2&#160;&#160;&#160;&#160;If either Party has reason to believe that any Product (whether the Product itself or particular Batch(es)) should be Recalled, such Party shall promptly inform the other in writing, to also include the reasons and explanations for the Recall, prior to taking any such action. In addition, Customer shall give CMC prompt written notice of any Recalls that Customer believes were caused by or may have been caused by CMC&#8217;s failure to comply with its obligations under this Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:77.3pt;padding-right:27.35pt;text-align:justify;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">13.3&#160;&#160;&#160;&#160;If any Product is Recalled for safety reasons or due to a mandatory notification from a Regulatory Authority dictating the Recall and, in either case, such reasons are as a result of CMC&#8217;s failure to manufacture Product in accordance with the terms of this Agreement or otherwise as a result of CMC&#8217;s negligence or wilful misconduct (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">CMC Failure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;), then CMC shall, subject to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">12, </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">reimburse Customer for all reasonable expenses incurred by Customer in undertaking the Recall of those specific Products which are the subject of a CMC Failure. Such payment shall be made &#91;***&#93;. If CMC disputes that the Recall is&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:134.2pt;padding-right:27.7pt;text-align:justify;text-indent:-56.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">13.3.1&#160;&#160;&#160;&#160;due to safety reasons or mandatory notification from a Regulatory Authority dictating the Recall then the Parties shall mutually select a regulatory expert to evaluate whether the Recall was appropriate to address the safety reason or comply with the Regulatory Authority&#8217;s notice (as applicable)&#59; and&#47;or</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:134.2pt;padding-right:27.75pt;text-align:justify;text-indent:-56.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">13.3.2&#160;&#160;&#160;&#160;due to CMC&#8217;s CMC Failure, then the Parties shall mutually select an independent laboratory to evaluate whether the Product is defective due to CMC&#8217;s CMC Failure&#59; and</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77.3pt;padding-right:27.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">the evaluation(s) by the regulatory expert and&#47;or independent laboratory shall be binding on the Parties (other than where such decision is a manifest error). If such evaluation substantially supports CMC&#8217;s basis(es) for the dispute, then CMC shall not be responsible for any costs of the Recall. Subject to Clauses 9 and 12, any payment by CMC under this Clause 13.3 shall be Customer&#8217;s sole remedy for the costs of the Recall.</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;TERM AND TERMINATION</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.5pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">14.1&#160;&#160;&#160;&#160;This Agreement shall commence on and have effect as of the Effective Date and will, subject to earlier termination in accordance with this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 14 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">or otherwise, continue for an initial term of four (4) years (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Initial Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) commencing on the Effective Date. The term of this Agreement may be extended by Customer beyond the then current term for further periods of up to two (2) years duration (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Additional Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) provided that (i) Customer is not in material breach of this Agreement and (ii) Customer provides CMC with</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">written notice to extend the current Term &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">14.2&#160;&#160;&#160;&#160;Upon Customer reaching a decision not to extend the Initial Term or extend the Term with an Additional Term (i) &#91;***&#93;&#59; and (ii) Customer shall not be entitled to seek extension of the Term under the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">14.1.</a></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Events of Termination</font></div><div style="margin-top:3.4pt;padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">14.3&#160;&#160;&#160;&#160;Either Party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Non-Defaulting Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">&#8221;) may terminate this Agreement before expiry of the Term with immediate effect upon prior written notice to the other Party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Defaulting Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">&#8221;) if&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.7pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">14.3.1&#160;&#160;&#160;&#160;the Defaulting Party fails to pay any undisputed sum payable under this Agreement &#91;***&#93;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.45pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">14.3.2&#160;&#160;&#160;&#160;the Defaulting Party commits a material breach of its obligations under this Agreement and if the breach is capable of remedy, &#91;***&#93;&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:111.4pt;text-align:justify;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.3.3&#160;&#160;&#160;&#160;the Defaulting Party is (i) generally unable to pay its debts as they become due&#59; or</font></div><div style="margin-top:3.6pt;padding-left:111.4pt;padding-right:27.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">(ii) has an administrator appointed or administration order made against it or an order for winding-up or dissolution made (otherwise than in the course of a bona fide reorganisation previously approved in writing by the Non-Defaulting Party) &#91;***&#93;&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">41</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:111.4pt;padding-right:27.95pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">14.3.4&#160;&#160;&#160;&#160;any material permit or regulatory license is permanently revoked preventing the performance of the Services by the Defaulting Party.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:28.25pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">14.4&#160;&#160;&#160;&#160;Customer may terminate this Agreement before expiry of the Term with immediate effect upon prior written notice to CMC&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effect of Termination</font></div><div style="margin-top:3.4pt;padding-left:74.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.5&#160;&#160;&#160;&#160;Upon termination of this Agreement, Customer shall pay to CMC&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111.4pt;padding-right:27.7pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">14.5.1&#160;&#160;&#160;&#160;Unless such termination was by CMC according to Customer being the Defaulting Party under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 14.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:164.7pt;padding-right:27.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">14.5.1.1&#160;&#160;&#160;&#160;payments due by Customer to CMC in respect of Services performed in accordance with the terms and conditions of this Agreement up to and including the day of such termination, in full for all completed Services and for partially completed Services a sum calculated on a pro-rata basis having regard to the Price for the cancelled Services (fairly determined by the Project Team having regard to man hours, materials, profit element and irreversible commitments incurred by CMC)&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:27.75pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">14.5.2&#160;&#160;&#160;&#160;If such termination was by CMC according to Customer being the Defaulting Party under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 14.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">&#58;</font></div><div style="padding-left:156.05pt;padding-right:27.4pt;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">14.5.2.1&#160;&#160;&#160;&#160; in respect of Firm Orders and Semi-Firm Orders in existence at the date of termination, a payment calculated as &#91;***&#93;&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:156.05pt;padding-right:27.45pt;text-indent:-43.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">14.5.2.2&#160;&#160;&#160;&#160;In the event that Customer failed to order the Minimum Volume in the Calendar Year of such termination, then Customer shall pay to CMC &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:110.65pt;padding-right:27.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">14.5.3&#160;&#160;&#160;&#160;Subject to Section 14.6, CMC shall invoice Customer for all payments due at the time of termination pursuant to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clauses 7.5 and </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">14 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">and&#47;or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Appendix Two &#91;***&#93; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">of termination and Customer shall pay all undisputed amounts &#91;***&#93;&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:27.7pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">14.6&#160;&#160;&#160;&#160;In the event of the expiration or termination of this Agreement for any reason, all amounts for which Customer is entitled to a credit pursuant to this Agreement shall be credited to any amounts due to CMC under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause 14.5. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">In the event of the termination of this Agreement by Customer under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause 14.4.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">14.4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">, to the extent paid to CMC, &#91;***&#93; to any undisputed payments due to CMC under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Clause 14.5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">with &#91;***&#93; and any other amounts for which Customer has paid for Services that were not rendered, returned to Customer &#91;***&#93;.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">42</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">14.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#91;***&#93; under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 14.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">primarily due to CMC being the Defaulting Party or if this Agreement expires, CMC shall &#91;***&#93;. In the event of termination of this Agreement by CMC under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause</font></div><div style="padding-left:74.45pt;padding-right:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">14.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">due to Customer being the Defaulting Party, &#91;***&#93; CMC under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 14.5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">with the remainder &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:74.45pt;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.8&#160;&#160;&#160;&#160;In the event of a termination of this Agreement under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clause 14.4.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Customer &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.65pt;padding-right:27.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">Upon termination of this Agreement for any reason, provided the Customer has paid all undisputed sums outstanding and which are properly due under this Agreement, CMC &#91;***&#93;, provide the Customer with all Deliverables then manufactured or generated and all transferable work in progress and all Product then manufactured. CMC shall not be obliged to transfer any materials pursuant to this Clause where the Customer has not paid CMC all undisputed invoiced sums due &#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.35pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">14.9&#160;&#160;&#160;&#160;Termination or expiry of this Agreement for whatever reason shall not affect the accrued rights of either CMC or Customer arising under or out of this Agreement before the effective date of termination. The provisions of this Agreement which are expressed to survive this Agreement including </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clauses 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">3.4, 10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">11, 12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">14.5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">through </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">14.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, this Section </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">14.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">15, 17 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">18.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">through </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">18.13 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">shall survive termination or expiry of this Agreement to the degree necessary to permit their complete fulfilment or discharge.</font></div><div><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;TECHNOLOGY TRANSFER</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.35pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">15.1&#160;&#160;&#160;&#160;Upon (i) termination or during the notice period regarding termination of this Agreement or the Services other than where termination is for material breach by Customer or (ii) on expiry of this Agreement&#59; Customer may by written notice to CMC seek assistance from CMC with respect to the transfer to another manufacturer of the then-current Process and test methods solely for the purpose of manufacturing and testing the Product (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Technology Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#34;). Following CMC&#8217;s receipt of such notice, the Parties will establish, in good faith, a schedule and plan for effecting such transfer and CMC will thereafter co-operate with Customer in implementing such plan as agreed by the Parties. As part of the Technology Transfer, CMC will make available for collection, subject to any Regulatory Obligations, all Customer Materials, Cell Line and one copy of all documentation (to the extent not previously delivered to Customer) generated pursuant to the Services up to the date of</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">termination or expiry including batch records, development and validation reports and production process documentation, test method SOPs and method development and validation reports.</font></div><div><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">15.2&#160;&#160;&#160;&#160;The obligations on CMC in respect of the Technology Transfer shall only be exercisable by Customer &#91;***&#93;. Customer shall pay, CMC's costs providing the Technology Transfer &#91;***&#93;. The Customer will not, and CMC will not be obliged to, </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">43</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:74.45pt;padding-right:27.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">transfer any CMC Know-How pursuant to this Technology Transfer until the contract manufacturer to whom the process is transferred enters into a limited royalty-free license and confidentiality agreement reasonably acceptable to and with CMC in order to protect CMC's Know-How and Confidential Information.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;FORCE MAJEURE</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">16.1&#160;&#160;&#160;&#160;Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement or the Services to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the other Party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Impeded Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;) including but not limited to fires, earthquakes, floods, embargoes, wars, acts of war (whether war is declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts or other labour disturbances, other substantial similar acts of nature, omissions or delays in acting by any administrative authority, government agency or other Party (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Force Majeure Situation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8221;).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">(b)   The Impeded Party shall notify the other Party in writing of any Force Majeure Situation which prevents the Impeded Party from complying with an obligation under this Agreement. If a Force Majeure Situation &#91;***&#93;, and is adversely affecting the performance of this Agreement, the Party which is not the Impeded Party will have the right, on written notice to the other Party, to immediately terminate this Agreement. In the case of such termination, Customer will not have a right to reimbursement for any sums paid under this Agreement for which Services have been rendered or any claim for damages solely as a result of the termination of this Agreement or non-performance of the Services due to such Force Majeure Situation. Notwithstanding any other provision under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 16.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">, in the event this Agreement is terminated under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 16.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">, (a) CMC shall refund Customer for any and all amounts for which Customer has paid Services that were not rendered, &#91;***&#93; if the Customer&#8217;s termination due to Force Majeure occurs &#91;***&#93; after notice of the Force Majeure Situation&#59; and (b) Customer shall pay to CMC any sums due under this Agreement in respect of Services performed up to and including the date of termination in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:149%">Clause 14.5.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-top:4.8pt;padding-left:74.45pt;padding-right:27.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%">This </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:155%">Clause 16.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%">shall not apply to excuse either Party&#8217;s payment obligations under this Agreement which have accrued prior to termination.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;APPLICABLE LAW, JURISDICTION AND DISPUTE RESOLUTION</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Law</font></div><div style="margin-top:3.6pt;padding-left:74.65pt;padding-right:27.8pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">17.1&#160;&#160;&#160;&#160;This Agreement shall be interpreted and governed, and all rights and obligations of the Parties shall be determined, in accordance with the laws of &#91;***&#93; (regardless of choice of law provisions). The Parties waive application of the provisions of the 1980 U.N. Convention on Contracts for the International Sale of Goods, as amended.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:74.65pt;padding-right:27.25pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">17.2&#160;&#160;&#160;&#160;Before resorting to litigation, unless emergency relief is required by either Party when either Party shall be free to resort to litigation, the Parties shall use their reasonable efforts to negotiate in good faith and settle amicably any dispute that may arise out of or relate to this Agreement (or its construction, validity or termination) (a &#34;Dispute&#34;). If a Dispute cannot be settled through negotiations by appropriate representatives of each of the Parties, either Party may give to the other a notice in writing (a &#34;Dispute Notice&#34;). &#91;***&#93; shall each refer the Dispute to their respective Chief Executive Officers who shall meet in order to attempt to resolve the dispute. If &#91;***&#93; (i) the Dispute is not settled by agreement in writing between the Parties or (ii) the Parties have failed to discuss the Dispute or use good faith negotiations, the Dispute may be submitted to and finally be settled &#91;***&#93;. Nothing in this MSA shall prohibit (nor force) the Parties to submit to any other dispute resolution forums as they may between themselves subsequently agree to or discuss.</font></div><div><font><br></font></div><div style="padding-left:42pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;MISCELLANEOUS</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fundamental Change</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.85pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">18.1&#160;&#160;&#160;&#160;The occurrence of a Fundamental Change shall not relieve CMC of its responsibility for performance of its obligations under this Agreement. CMC must promptly&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:128.7pt;padding-right:28.3pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">18.1.1&#160;&#160;&#160;&#160;notify Customer as soon as CMC is aware that a Fundamental Change has occurred or is reasonably likely to occur&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:128.7pt;padding-right:27.3pt;text-align:justify;text-indent:-54.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.1.2&#160;&#160;&#160;&#160;upon request, provide to Customer such further information and written assurances, from CMC and its successors that there will be no adverse consequences to the supply of Product to Customer or the performance of CMC obligations under this Agreement resulting from the occurrence of the Fundamental Change. Without prejudice to the generality of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause 18.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">, Customer may seek written assurances from CMC and its successors relating to CMC&#8217;s ongoing corporate and management culture, capacity, capability and financial viability.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.75pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">18.2&#160;&#160;&#160;&#160;Neither CMC not its successor shall be entitled to terminate this Agreement as a result of a Fundamental Change.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-top:4.8pt;padding-left:74.45pt;padding-right:27.9pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%">18.3&#160;&#160;&#160;&#160;For the avoidance of doubt, a breach of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:155%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:155%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:155%;text-decoration:underline">18.1, </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%">shall be deemed to be a material breach of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Binding Agreement</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.4&#160;&#160;&#160;&#160;Each party agrees that this Agreement is legal and valid and the obligations binding upon such party are enforceable by their terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors&#59; and other than as provided for elsewhere in this Agreement in respect of the Timeline, any modification, extension or variation of this Agreement (or any document entered into pursuant to or in connection with this Agreement) shall only be valid if it is in writing and signed by or on </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">behalf of each Party to this Agreement. No modification or variation of this Agreement shall be valid if made by e-mail.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.75pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.5&#160;&#160;&#160;&#160;Unless expressly so agreed, no modification or variation of this Agreement shall constitute or be construed as a general waiver of any provisions of this Agreement, nor shall it affect any rights, obligations or liabilities under this Agreement which have already accrued up to the date of such modification or waiver, and the rights and obligations of the Parties under this Agreement shall remain in full force and effect, except and only to the extent that they are so modified or varied.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.3pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.6&#160;&#160;&#160;&#160;This Agreement may not be assigned by either Party without the prior written consent of the other Party except that a Party may otherwise assign its respective rights and transfer its respective duties to any assignee of all or substantially all of its business (or that portion thereof to which this Agreement relates) or in the event of its merger or consolidation or similar transaction.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:27.65pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">18.7&#160;&#160;&#160;&#160;An assignment by either Party will not release that Party of any obligation to the other Party under the terms of this Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.8&#160;&#160;&#160;&#160;This Agreement, and the documents referred to in it, constitutes the entire Agreement and understanding of the Parties and supersedes any previous agreement between the Parties relating to the subject matter of this Agreement. If any term of this Agreement conflicts with any term of the Commercial Quality Agreement, the conflicting term of this Agreement shall prevail.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver and amendment</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.55pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.9&#160;&#160;&#160;&#160;In no event will any delay, failure or omission (in whole or in part) in enforcing, exercising or pursuing any right, power, privilege, claim or remedy conferred by or arising under this Agreement or by law, be deemed to be or construed as a waiver of that or any other right, power, privilege, claim or remedy in respect of the circumstances in question, or operate so as to bar the enforcement of that, or any other right, power, privilege, claim or remedy, in any other instance at any time or times subsequently.</font></div><div><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.4pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.10&#160;&#160;&#160;&#160;If any provision of this Agreement shall be found by any court or administrative body of competent jurisdiction to be invalid or unenforceable, such invalidity or unenforceability shall not affect the other provisions of this Agreement which shall remain in full force and effect. The Parties agree, in the circumstances referred to in this clause to attempt to substitute for any invalid or unenforceable provision a valid or enforceable provision which achieves to the greatest extent possible the same effect as would have been </font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:4.75pt;padding-left:74.45pt;padding-right:27.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">achieved by the invalid or unenforceable provision. The obligations of the Parties under any invalid or unenforceable provision of this Agreement shall be suspended while an attempt at such substitution is made.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:27.7pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.11&#160;&#160;&#160;&#160;Any notice or other communication given or made under this Agreement shall be in writing and in English and signed by or on behalf of the Party giving it and shall be served by (a) hand, (b) delivering it or sending it by prepaid recorded or special delivery post or prepaid international recorded airmail, or (c) facsimile or e-mail transmission provided the recipient provides a confirmation of receipt of such facsimile or e-mail transmission, to the address and for the attention of the relevant Party set out in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:151%;text-decoration:underline">18.11 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">(or as otherwise notified by that Party hereunder). Any such notice shall be deemed to have been received&#58;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:111.4pt;padding-right:28.2pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">18.11.1&#160;&#160;&#160;&#160;if hand delivered or sent by prepaid recorded or special delivery post or prepaid international recorded airmail, at the time of delivery&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:111.4pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.11.2&#160;&#160;&#160;&#160;if sent by post (other than by prepaid recorded or special delivery post), &#91;***&#93;&#59; or</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:111.4pt;text-indent:-37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.11.3&#160;&#160;&#160;&#160;if sent by airmail (other than by prepaid international recorded airmail), &#91;***&#93;&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">Provided that if deemed receipt &#91;***&#93; the notice shall be deemed to have been received &#91;***&#93;, and if deemed receipt &#91;***&#93;, the notice shall be deemed to have been received &#91;***&#93;.</font></div><div style="margin-top:0.4pt;padding-left:74.45pt;padding-right:111.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:300%">The addresses of the Parties for the purposes of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:300%">Clause </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:300%;text-decoration:underline"><a href="#i7b9384f2e499484faab3dd4303a67be0_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:300%;text-decoration:underline">18.11 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:300%">are&#58; CMC ICOS Biologics, Inc.</font></div><div style="margin-top:0.25pt;padding-left:74.45pt;padding-right:267.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">22021 20th AVENUE SE, BOTHELL, WA, USA 98021</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:341.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:152%">For the attention of&#58; Legal Department</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc.</font></div><div style="margin-top:3.65pt;padding-left:74.45pt;padding-right:310.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">9704 Medical Center Drive Rockville, MD 20850</font></div><div style="margin-top:0.1pt;padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the attention of&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.45pt;padding-right:346.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">With a copy to MacroGenics, Inc.</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.3pt;padding-left:74.45pt;padding-right:310.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">9704 Medical Center Drive Rockville, MD 20850</font></div><div style="margin-top:0.1pt;padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the attention of&#58; General Counsel</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;padding-right:22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:149%">or such other address as may be notified in writing from time to time by the relevant Party to the other Party. Any such change to the place of service shall take effect &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:74.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.9pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:151%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">This Agreement may be executed in any number of counterparts and by the Parties to it on separate counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument. This Agreement is not effective until each Party has executed at least one counterpart.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No partnership or agency</font></div><div style="margin-top:3.6pt;padding-left:74.45pt;padding-right:27.35pt;text-align:justify;text-indent:-32.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:151%">18.13&#160;&#160;&#160;&#160;Nothing in this Agreement is intended to or shall operate to create a partnership or joint venture of any kind between the Parties or to authorise either Party to act as agent for the other, and no Party shall have authority to act in the name or on behalf of or otherwise to bind the other in any way (including but not limited to the making of any representation or warranty, the assumption of any obligation or liability and the exercise of any right or power). Each Party is entering into this Agreement as principal not agent, and may not enforce any of its rights under or in connection with this Agreement for the benefit of any other person.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.8pt;padding-left:20.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THIS AGREEMENT </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been executed by or on behalf of the Parties as of the Effective Date.</font></div><div><font><br></font></div><div style="margin-bottom:0.05pt"><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.752%"><tr><td style="width:1.0%"></td><td style="width:74.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">Signed on behalf of</font></div><div style="margin-top:3.35pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMC ICOS BIOLOGICS, INC.</font></div><div style="margin-top:3.65pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Gustavo Mahler</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:10pt;padding-right:60.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:303%">Name &#58; Gustavo Mahler, Ph.D. Position &#58; CEO &#38; President</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">)</font></div><div style="margin-top:3.35pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.65pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.35pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.65pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.4pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.6pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.4pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.6pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signed on behalf of</font></div><div style="margin-top:3.4pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="margin-top:3.65pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div><font><br></font></div><div style="margin-top:9.45pt;padding-left:10pt;padding-right:53.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:303%">Name &#58; Scott Koenig, MD, Ph.D. Position &#58; President &#38; CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9.1pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.4pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.65pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.35pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.65pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.35pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.65pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.4pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.6pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.4pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:3.6pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:2.45pt;padding-right:9.85pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONFIDENTIAL</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:195.02pt;padding-right:195.02pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APPENDIX ONE</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:192.15pt;padding-right:192.15pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONFIDENTIAL</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:195.1pt;padding-right:195.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APPENDIX TWO</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:192.15pt;padding-right:192.15pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">51</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONFIDENTIAL</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.7pt;padding-left:195.12pt;padding-right:195.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APPENDIX THREE</font></div><div><font><br></font></div><div style="padding-left:194.97pt;padding-right:194.97pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:66pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial Supply Agreement</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244238347 v3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>4
<FILENAME>exhibit1016incytecommercia.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if9b1d7d4933545e0aa73895fad5d65bf_1"></div><div style="min-height:67pt;width:100%"><div style="padding-left:9pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 10.16</font></div><div style="padding-left:9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH &#8220;&#91;***&#93;&#8221;.</font></div></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:41.75pt"><img alt="incytelogo1a.jpg" src="incytelogo1a.jpg" style="height:89px;margin-bottom:5pt;vertical-align:text-bottom;width:123px"></div><div style="margin-top:4.65pt;padding-left:182.8pt;padding-right:182.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMERCIAL SUPPLY AGREEMENT</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Commercial Supply Agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is entered into as of September 30, 2020 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), by and between Incyte Corporation, with an address of 1801 Augustine Cut-off, Wilmington, DE 19803 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incyte</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and MacroGenics, Inc., with an address of 9704 Medical Center Drive, Rockville, MD 20850 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MacroGenics&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Incyte and MacroGenics are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and collectively as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:182.8pt;padding-right:182.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics discovered and was developing the Licensed Compound (defined below), coded by MacroGenics as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MGA012</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, for various human therapeutic uses&#59;</font></div><div><font><br></font></div><div style="padding-left:39pt;padding-right:38.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics has granted certain licenses to Incyte, and Incyte has obtained certain licenses from MacroGenics, to develop, manufacture and commercialize the Licensed Compound and products and treatment regimens incorporating the Licensed Compound, pursuant to the Global Collaboration and License Agreement, dated as of October 24, 2017, between the Parties (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Parties entered into a Development Manufacturing &#38; Clinical Supply Agreement dated August 31, 2018 pursuant to which MacroGenics manufactured and&#47;or supplied to Incyte, and Incyte purchased from MacroGenics, the Licensed Compound Bulk Drug Substance and the Licensed Compound Drug Product (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Supply Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">, pursuant to the Collaboration Agreement, MacroGenics will Manufacture and supply to Incyte and Incyte will purchase from MacroGenics according to the terms of this Agreement, Licensed Compound Drug Substance for use under the Collaboration Agreement by Incyte and Incyte&#8217;s and its Affiliates, Collaborators and licensee&#8217;s&#59;</font></div><div><font><br></font></div><div style="padding-left:39pt;padding-right:38.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Parties now also wish to set forth the terms by which MacroGenics will perform certain ongoing Manufacturing Development activities as set forth in an approved development plan as may be updated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMC Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as hereafter further defined) and MacroGenics, as further set forth herein, will Manufacture and&#47;or supply to Incyte the Licensed Compound Bulk Drug Substance which Incyte will purchase for Commercialization&#59; and</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:39pt;padding-right:39.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for valuable consideration and the mutual covenants, terms and conditions hereinafter expressed, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;DEFINITIONS</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:39pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined terms are used throughout this Agreement&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Global Commercial Supply Forecast</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the total amount of Licensed Compound Bulk Drug Substance needed to fulfill the annual projected global commercial supply of Licensed Compound Drug Product.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="padding-left:39pt;padding-right:38.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">&#8220;Applicable Law&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">means all applicable statutes, ordinances, regulations, directives, rules, or orders of any kind whatsoever of any Governmental Authority applicable to any activity hereunder, including the EU Data</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_4"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:39pt;padding-right:38.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protection Directive and the regulations issued under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), the U.S. Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;301 et seq.) (&#8220;FFDCA&#8221;), the Prescription Drug Marketing Act of 1987 (21 U.S.C. &#167;&#167;331, 333, 353, 381), the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;335(a) et seq.), U.S. Patent Act (35 U.S.C. &#167;1 et seq.), the Federal False Claims Act (31 U.S.C. &#167;3729 et seq.), and the Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b et seq.), and the Foreign Corrupt Practices Act of 1977 (15 U.S.C. &#167;&#167; 78dd-1, et seq.), all as amended from time to time, together with any rules, regulations, and guidance documents, and regulatory standards (including GCP, GLP, and GMP) promulgated relating to any of the foregoing, all as amended from time to time.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:39pt;padding-right:43.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Batch</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means a specific quantity of Licensed Compound Bulk Drug Substance that is intended to be of uniform character and quality, within specific limits, and is produced during the same cycle of Manufacture as defined by the applicable Batch Record.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:39pt;padding-right:66.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Batch Failure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means the failure of a Batch to be Delivered because (i) it failed meet its Product Specifications&#59; or (ii) Manufacturing of such Batch was discontinued prior to release testing, or (iii) a deviation from the Manufacturing Process results in rejection of the Batch.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:39pt;padding-right:68.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Batch Record</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means the final executed batch production and quality control records, prepared in accordance with GMP, for each Batch of Licensed Compound Bulk Drug Substance, as applicable, Manufactured under this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Certificate of Analysis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means a document certifying that a Batch meets the applicable Product Specifications, as signed and dated by a duly authorized representative of MacroGenics&#8217; quality assurance department.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">CMC Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means for the purposes of this Agreement, the development plan attached to this Agreement as Exhibit D.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Commercial Quality Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the written agreement entered into by the Parties on or within &#91;***&#93; after the Effective Date defining pharmaceutical and certain operational responsibilities of the Parties with respect to the quality that is applicable to the Manufacture and Supply of the Licensed Compound Bulk Drug Substance under GMP.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Deliver(ed) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means to deliver (or have delivered) a Batch EXW (as defined in Incoterms 2020), the MacroGenics Manufacturing Facility according to the date provided in written a notification to Incyte of such delivery. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delivery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means delivery of a Batch by in such manner.</font></div><div><font><br></font></div><div style="padding-left:39pt;padding-right:38.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Force Majeure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any event beyond the reasonable control of the affected Party, which may include embargoes&#59; war or acts of war, including terrorism&#59; insurrections, riots, or civil unrest&#59; labor strikes or lockouts&#59; epidemics, fire, floods, earthquakes or other severe acts of nature&#59; widespread unavailability of raw materials or reagents affecting manufacturers generally, actions by a Regulatory Authority affecting the manufacture of Monoclonal Antibodies generally, and the Licensed Compound Bulk Drug Substance specifically, federal, state and local governmental actions and orders that halt, curtail or impede commercial activity and omissions or delays in acting by any Governmental Authority, other than any such Governmental Authority omissions or delays resulting from the negligence or omission by the Party affected by Force Majeure.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FTE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93; of work devoted to or in direct support of specified Manufacturing Development, Manufacturing Related Activities or other specified activities under this Agreement, conducted by one or more qualified employees, contractors, consultants or other personnel of a Party or its Affiliates. For clarity, any individual contributing &#91;***&#93; (or equivalent pro-rata portion thereof for the period beginning on the Effective Date and ending on the last day of the first Calendar Year) will be deemed a fraction of an FTE on a pro- rata basis.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_7"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:39pt;padding-right:38.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FTE Cost</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any period and a Party or its Affiliate, the FTE Rate multiplied by the number of FTEs expended by such Party or its Affiliate during such period&#59; provided that a Party will not be charged twice for any FTE Cost if such FTE Cost is already included as a component of the Price for Licensed Compound Bulk Drug Substance under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FTE Rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a rate of &#91;***&#93; (pro-rated for the period beginning on &#91;***&#93; and ending on the &#91;***&#93;)&#59; provided, however, that such rate will be &#91;***&#93;, by the applicable CPI Adjustment. The FTE Rate is &#8220;fully burdened&#8221; and covers employee salaries, benefits, travel and other such costs.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Good Manufacturing Practices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GMP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the then-current good manufacturing practices required by the (i) Commission Directive 2003&#47;94&#47;EC laying down the principles and guidelines of good manufacturing practice for medicine Products for human use as more specifically detailed in EUDRALEX Volume IV Part II and its Annexes, (ii) EU Guidelines on principles of Good Distribution Practices of active substances for medicinal Products for human use, (2015&#47;C95&#47;01) and (iii) 21 C.F.R. Parts 210 and 211, as promulgated by the FDA&#59; (iv) the ICH (International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use) guidelines, including without limitation, ICH Q7 &#34;ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients&#34; and (iv) comparable Applicable Law related to the manufacture and testing of pharmaceutical materials in such jurisdictions as the Parties may hereinafter agree.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:39pt;padding-right:74.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incyte Manufacturing Facility</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Incyte&#8217;s GMP Manufacturing plant located at Avenue des Sciences 12, 1400 Yverdon-les-Bains, Switzerland.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Latent Defect</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means a non-obvious defect in a Batch not reasonably susceptible to discovery upon receipt of such Batch.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensed Compound</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MGA012</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, for purposes of this Agreement and the Commercial Quality Agreement, the specific anti-PD-1 Monoclonal Antibody designated by MacroGenics as &#8220;MGA012&#8221;, as further described in IND # 130952, and designated by Incyte as &#8220;retifanlimab&#8221;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:39pt;padding-right:39.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Licensed Compound API</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means the Licensed Compound active pharmaceutical ingredient of a Licensed Product.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Licensed Compound Bulk Drug Substance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means the Licensed Compound API as produced in bulk, in accordance with this Agreement, as well as the Commercial Quality Agreement and the applicable Quality Assurance Measures.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Licensed Compound Drug Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means the Licensed Compound Bulk Drug Substance in its final finished form.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:39pt;padding-right:43.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">MacroGenics Manufacturing Facility</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means MacroGenics&#8217; GMP Manufacturing plant located at 9704 Medical Center Drive, Rockville, Maryland.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any and all activities and processes related to the manufacturing of Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product for, labeling, packaging, in-process and testing of such Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product, release of the Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product, quality assurance activities related to manufacturing and release of Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; will exclude Manufacturing Development and Manufacturing Related Activities.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:39pt;padding-right:35.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Manufacturing Development</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means any of the following with respect to the Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product, as applicable&#58; manufacturing process development</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_10"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:39pt;padding-right:39.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and validation, process improvements, formulation development, associated analytical development and validation and the manufacture and testing of stability and consistency lots (including process development, qualification, and test Batches).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Manufacturing Process</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means the manufacturing process for (including any associated Know-How owned or Controlled by MacroGenics or Incyte relating to the then-current process), and necessary or useful for, the Manufacture of the Licensed Compound Bulk Drug Substance and as further Developed under the Collaboration Agreement, the Clinical Supply Agreement and this Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Manufacturing Related Activities&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means those &#91;***&#93; activities specifically related to &#91;***&#93;, including, but not limited to, &#91;***&#93; of which are not otherwise included &#91;***&#93;. &#8220;Manufacturing Related Activities&#8221; will specifically exclude &#91;***&#93;, which is deemed to be a separate and distinct &#91;***&#93; Manufacturing Related Activities.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means the starting materials or components, raw materials, ingredients and any other materials used in the Manufacture of the Licensed Compound Bulk Drug Substance.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Personnel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means any person or entity employed or engaged by MacroGenics, including without limitation, its employees, contractors, consultants or agents who may perform Manufacturing Related Activities, Manufacturing Development or Manufacturing or otherwise have obligations or rights pursuant to this Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;&#91;***&#93;&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:39pt;padding-right:38.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Product Specifications</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means the written specifications for the Licensed Compound Bulk Drug Substance, as set forth in the Commercial Quality Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">&#8220;Price Schedule&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">means a list that includes &#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Project Manager&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means the project managers coordinating the activities to perform be performed hereunder and acting as central contact between Incyte and MacroGenics, and who will lead the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Joint Project Team</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Documentation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Compound or Product under the Collaboration Agreement, all regulatory filings, applications, notifications, registrations, licenses, regulatory drug lists, advertising and promotion documents, adverse event files, complaint files, Manufacturing records, Regulatory Approvals or other regulatory submissions or supporting documents, including any written correspondence or meeting minutes, made to, made with, or received from an applicable governmental agency or Regulatory Authority relating to such Compound or Product, and all data contained therein.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_13"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:39pt;padding-right:39pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Third Party Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221; means out-of-pocket expenses incurred by a Party or any of its Affiliates for purchases of items or for services performed by a Third Party on behalf of Incyte or MacroGenics in the course of such Party&#8217;s performance of this Agreement.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:39pt;padding-right:38.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:39pt;padding-right:39.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Agreement, the following terms will have the meanings ascribed thereto in the respective Sections of this Agreement set forth opposite each such term below. In addition, capitalized terms used but not defined herein will have the meanings set forth in the Collaboration Agreement. In the event of a conflict between a term defined herein and the same term as defined in the Collaboration Agreement, the definition ascribed to such term in this Agreement will control. Capitalized terms not specifically defined in this Agreement or the Collaboration Agreement will have the meaning commonly recognized in the biotechnology industry.</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.945%"><tr><td style="width:1.0%"></td><td style="width:64.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TERM</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliate</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual Global Commercial Supply Forecast</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3.b.i (1)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved CMO</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditee</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditor</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batch Price</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Binding Portion</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3(e)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual Product Review</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.16</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business Day</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calendar Quarter</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calendar Year</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMC Development Budget</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMC Development Plan</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborator</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborator Combination Studies</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercially Reasonable Efforts</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compound</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Confidential Information</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Control&#8221; or &#8220;Controlled&#8221;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deficiency Notice</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discretionary Specification Change</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3(b)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance Subcommittee</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funded Collaborator Combination Studies</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1(a)(i)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Good Clinical Practices&#8221; or &#8220;GCP&#8221;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Good Laboratory Practices&#8221; or &#8220;GLP&#8221;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental Authority</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte Combination Studies</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte Facility</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IND</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr></table></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_16"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.945%"><tr><td style="width:1.0%"></td><td style="width:64.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TERM</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insolvency Event</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2(b)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JMC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JPT</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Know-How</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics Draft Production Schedule Update</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics Combination Studies</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing Technology Transfer</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing Transition Plan</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monoclonal Antibody</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monotherapy Studies</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-Conforming Licensed Compound</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notified Law</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1(c)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Order</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Party, Parties</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase I Study</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase II Study</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase III Study</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pipeline Asset</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pivotal Study</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior CDA</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production Schedule</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1(c)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality Assurance Measures</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.4(b)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation Report</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1(f)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory Approval Application</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory Authority</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Required Specification Change</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory Submission</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Response Notice</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rolling Forecast</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1(a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Territory</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third Party</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNANCE. </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JMC established by the Parties will oversee, coordinate and facilitate the Manufacture of the Licensed Compound Bulk Substance under this Agreement according to the Collaboration Agreement, including with respect to Section 2.3 of the Collaboration Agreement, except as otherwise specifically set forth in this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;MANUFACTURE AND SUPPLY</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;General Principles</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:111pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, during the Term,</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_19"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:147pt;padding-right:39.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics agrees to use Commercially Reasonable Efforts to Manufacture each Binding Portion&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:147pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;Incyte agrees to &#91;***&#93; of each Binding Portion.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;For clarity, Incyte will be entitled, in its sole discretion, to &#91;***&#93; of Licensed Product for &#91;***&#93;&#59; provided, that, to the extent Incyte releases &#91;***&#93;, such Batches will be subject to the terms of the Commercial Quality Agreement. Notwithstanding the preceding, any lots manufactured &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The Parties acknowledge and agree that Batches of Licensed Compound Bulk Drug Substance supplied hereunder by MacroGenics shall be Manufactured in accordance with the acceptance criteria &#91;***&#93; in this Agreement, which may be updated as mutually agreed to by the JMC (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acceptance Criteria</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Parties agree that for each Batch Manufactured by MacroGenics for &#91;***&#93; Acceptance Criteria, Incyte will pay &#91;***&#93;. If the &#91;***&#93;, Incyte will be &#91;***&#93;, including instances in which &#91;***&#93;. The Parties also acknowledge and agree that MacroGenics will have &#91;***&#93; Incyte, its Affiliates or to any of their respective Collaborators and&#47;or licensees &#91;***&#93; the Acceptance Criteria, provided that such Batch &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:112.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;In the event the Manufacturing Process is modified the Parties will mutually agree to updated &#91;***&#93;. Incyte will be solely responsible for, &#91;***&#93;, and shall use Commercially Reasonable Efforts to Manufacture &#91;***&#93; of the Licensed Compound Drug Product. including amounts reasonably forecasted by MacroGenics for Commercialization of MacroGenics Combination Regimens.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;Each Party will use Commercially Reasonable Efforts to perform certain Manufacturing Related Activities as the Parties will mutually agree to in writing as set forth in this Agreement and the Commercial Quality Agreement, as applicable&#59; provided, however, &#91;***&#93; Manufacturing Related Activities &#91;***&#93; to be used in a &#91;***&#93; of such costs and expenses. For the avoidance of doubt, Manufacturing Related Activities will &#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;MacroGenics Responsibilities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MacroGenics will use Commercially Reasonable Efforts to ensure that the MacroGenics Manufacturing Facility and equipment at the MacroGenics Manufacturing Facility required for the Manufacture of the Licensed Compound Bulk Drug Substance, are maintained in a state of repair and operating efficiency in accordance with the requirements of GMP and Applicable Law. MacroGenics will obtain, at its expense, any facility or other licenses or permits, and any Governmental Authority approvals necessary for the Manufacture and supply of the Licensed Compound Bulk Drug Substance. Unless otherwise agreed by the Parties, MacroGenics will be responsible for procuring all Materials necessary to meet its supply obligations under this Agreement. A delay in delivery by a vendor of Materials to be supplied by MacroGenics will not be considered a delay by MacroGenics. MacroGenics will notify Incyte of any such delay in the delivery of Materials that will result in MacroGenics&#8217; inability</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_22"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:75pt;padding-right:35.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to meet its supply obligations hereunder. Notwithstanding the following, &#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Incyte Responsibilities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Incyte will provide &#91;***&#93; to MacroGenics in order for MacroGenics to Manufacture Licensed Compound Bulk Drug Substance and Deliver the Batches according &#91;***&#93; set forth in each Binding Portion.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Subcontracting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MacroGenics may appoint subcontractors to perform its obligations and&#47;or exercise its rights under this Agreement provided that the applicable subcontractor will be required to comply with the applicable terms and conditions of this Agreement. &#91;***&#93; Each Party will be responsible for the compliance of any of its subcontractors with this Agreement. Notwithstanding the foregoing, (i) &#91;***&#93;&#59; and (ii) such appointment will be made in compliance with Section 9.1.</font></div><div style="padding-left:75pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.5&#160;&#160;&#160;&#160;Operation of Manufacturing Facilities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to MacroGenics&#8217; compliance with its obligations under this Agreement, MacroGenics will have the sole discretion in the operation and use of the MacroGenics Manufacturing Facility to fulfill its respective obligations to supply the Licensed Compound Bulk Drug Substance under this Agreement, including with respect to the following&#58;&#91;***&#93;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.6&#160;&#160;&#160;&#160;Same Manufacturing Facility</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MacroGenics will Manufacture all quantities of Licensed Compound Bulk Drug Substance that are required per the terms of this Agreement from the MacroGenics Manufacturing Facility. For clarity, MacroGenics will &#91;***&#93; Licensed Compound Bulk Drug Substance is Manufactured &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.55pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.7&#160;&#160;&#160;&#160;Accommodation. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, &#91;***&#93;, Incyte may &#91;***&#93; in a Binding Portion. In response to such purchase orders, MacroGenics, &#91;***&#93; Licensed Compound Bulk Drug Substance volumes. If MacroGenics &#91;***&#93; it will use Commercially Reasonable Efforts to do so.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.8&#160;&#160;&#160;&#160;Shelf Life Requirements. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics will use reasonable efforts to supply Batches (i) Manufactured &#91;***&#93;&#59; provided, however, that if the shelf life &#91;***&#93; for the Licensed Compound Drug Substance &#91;***&#93;, the Parties &#91;***&#93; for Batches when Delivered.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">3.9&#160;&#160;&#160;&#160;Manufacturing Related Activities. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">MacroGenics will perform Manufacturing Related Activities pursuant to Incyte&#8217;s written requests, or as required by the Product Specifications, GMPs or</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_25"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable Law relating to the regular course of Manufacturing Batches. Manufacturing Related Activities &#91;***&#93;.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:80.5pt;text-indent:-41.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;FORECASTING&#59; PRODUCTION SCHEDULE&#59; DELIVERY</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Rolling Drug Substance Forecast</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The amounts of Licensed Compound Bulk Drug Substance to be Manufactured by MacroGenics &#91;***&#93; to supply Incyte under this Agreement will be set forth in a &#91;***&#93; rolling forecast (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rolling Drug Substance Forecast</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). &#91;***&#93; Calendar Years of each Rolling Drug Substance Forecast are designated (i) &#91;***&#93; as a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forecast Year</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; individually and &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forecast Years</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; collectively.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:147pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;Each Rolling Drug Substance Forecast shall include the components listed and defined in Table 4.1.a.i.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.071%"><tr><td style="width:1.0%"></td><td style="width:39.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;padding-right:150.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table 4.1.a.i</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Component</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_28"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.071%"><tr><td style="width:1.0%"></td><td style="width:39.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.35pt;padding-right:19.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual Global Commercial Supply Forecast</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:147pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;&#91;***&#93; and the Annual Global Commercial Supply &#91;***&#93;&#59;</font></div><div style="padding-left:111pt;padding-right:38.8pt;text-align:justify"><font><br></font></div><div style="padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;For the &#91;***&#93; and each Calendar Year thereafter, MacroGenics, at its &#91;***&#93;, shall &#91;***&#93; Manufacture &#91;***&#93; Annual Global Commercial Supply Forecast. In instances where &#91;***&#93;, the number of Batches for &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Initial Rolling Drug Substance Forecast</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The initial Rolling Drug Substance Forecast (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Drug Substance Forecast</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is attached to this Agreement as Exhibit B. &#91;***&#93; Drug Substance Rolling Forecast.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:39pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Updated Rolling Drug Substance Forecast &#91;***&#93; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calendar Quarter the Parties will update the current Rolling Drug Substance Forecast to generate a new Rolling Drug Substance Forecast (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Updated Rolling Drug Substance Forecast&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</font></div><div><font><br></font></div><div style="padding-left:111pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Subject to Sections 4.1 and 4.2, upon the expiration of the Calendar Year in which it is created, each Updated Rolling Drug Substance Forecast will &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Incyte will &#91;***&#93; Updated Rolling Drug Substance Forecast and &#91;***&#93; MacroGenics &#91;***&#93; Incyte will&#58;</font></div><div><font><br></font></div><div style="padding-left:147pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;Identify for each Calendar Year of such Updated Rolling Drug Substance Forecast&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:183.05pt;padding-right:46.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Annual Global Commercial Supply Forecast&#59; provided that the Annual Global Commercial Supply Forecast for &#91;***&#93; Rolling Drug Substance Forecast respectively.</font></div><div style="padding-left:183.05pt;padding-right:46.1pt"><font><br></font></div><div style="padding-left:183.05pt;padding-right:46.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;&#91;***&#93;&#59; and</font></div><div style="padding-left:75pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:183.05pt;padding-right:46.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batches requested for &#91;***&#93;&#59; provided that, &#91;***&#93; from &#91;***&#93; Rolling Drug Substance Forecast respectively.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:147pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;For each Batch Manufactured &#91;***&#93;, the Calendar Quarter during which &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;MacroGenics will have the following rights in revising each draft of the Updated Rolling Drug Substance Forecast received from Incyte&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:147pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;&#91;***&#93; Calendar Years, provided that the Parties &#91;***&#93; to address &#91;***&#93; by MacroGenics under this Section 4.3(c)(i) for a Forecast Year will &#91;***&#93; Global Supply Forecast &#91;***&#93; Forecast Year &#91;***&#93; Updated Rolling Drug Substance Forecast&#59;&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:147pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;&#91;***&#93; Calendar Years in which in the event the &#91;***&#93; Annual Global Commercial Supply Forecast&#59; provided that &#91;***&#93; of the Annual Global Commercial Supply Forecast. In instances where the &#91;***&#93;, the number of Batches for the &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:147pt;padding-right:39.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;&#91;***&#93; Licensed Compound Bulk Drug Substance and&#47;or Licensed Drug Product as provided under Section 9.1(d).</font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:147pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.&#160;&#160;&#160;&#160;&#91;***&#93; the Calendar Quarter &#91;***&#93; in Section 4.3(b)(ii) to reflect available Manufacturing slots. The &#91;***&#93; Calendar Quarter shall be &#91;***&#93;, unless mutually agreed by the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:75pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;After reviewing and revising each draft Updated Rolling Drug Substance Forecast received from Incyte, MacroGenics shall forward such Updated Drug Substance Forecast to Incyte. Upon receipt by Incyte, the binding portions of such Updated Rolling Drug Substance Forecast shall become binding on both Parties with respect to the Calendar Years covered by such Updated Drug Substance Forecast (&#8220;Binding Portion&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;In the event that an Updated Rolling Drug Substance Forecast is not timely completed, the Binding Portions of the current Rolling Drug Substance Forecast will remain in effect until the earlier of its expiration or such Updated Rolling Drug Substance Forecast is completed. In addition, at MacroGenics&#8217; sole discretion, Year 4 of the Rolling Drug Substance Forecast currently in effect will become binding as Reserved Capacity, with addition of any additional lots as calculated in 4.3(c).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:75pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">4.4&#160;&#160;&#160;&#160;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. During &#91;***&#93; Rolling Drug Substance Forecast &#91;***&#93; Updated Rolling Drug Substance Forecast by the Parties under Section 4.3.e that same Calendar Year, Incyte will be &#91;***&#93; of such Rolling Drug Substance Forecast by &#91;***&#93;&#59; provided that the &#91;***&#93; for &#91;***&#93; such Rolling Drug Substance Forecast cannot be lower than the current binding &#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.25pt;padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.5&#160;&#160;&#160;&#160;Purchase Orders. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Batches to be supplied per the Binding Portions, Incyte will submit a written purchase order prior &#91;***&#93; Calendar Month (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Order Month</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) &#91;***&#93; in which such Batches will be Delivered. &#91;***&#93; Purchase Order Month, MacroGenics will forward the Delivery dates &#91;***&#93;. Within &#91;***&#93; after &#91;***&#93;, Incyte will &#91;***&#93; that &#91;***&#93; that is &#91;***&#93; of the Delivery &#91;***&#93;. Upon receipt of such notification, the date identified by such notification will be binding upon both Parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;If Incyte fails to submit the purchase order for a single Batch or multiple Batches &#91;***&#93;, MacroGenics will have the sole discretion to determine the Delivery date for such Batch(es).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">4.6&#160;&#160;&#160;&#160;Purchase by Affiliates. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Incyte&#8217;s Affiliate, &#91;***&#93; may submit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Purchase Orders Purchase Order for Manufacture of a Batch. Upon the mutual written agreement of the Parties, other Affiliates of Incyte may also submit Purchase Orders for a Batch. For Purchase Orders submitted by Affiliates of Incyte&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Each Affiliate submitting a Purchase Order shall be identified in writing to MacroGenics prior to or at the time such Purchase Order is submitted&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Incyte shall be responsible and liable for paying all amounts due to MacroGenics resulting from Purchase Orders submitted by Affiliates of Incyte and none of its Affiliates will have responsibility or liability to MacroGenics for such payments&#59;</font></div><div><font><br></font></div><div style="padding-left:111pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Any &#91;***&#93; that result from any Purchase Orders submitted by Affiliates of Incyte &#91;***&#93; shall be deemed under &#91;***&#93; of the Collaboration Agreement to be &#91;***&#93; of the &#91;***&#93; that would have been payable had Incyte submitted such Purchase Orders so that Incyte will pay MacroGenics such additional amounts as necessary to ensure MacroGenics receives the amounts it would have received if &#91;***&#93;&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;All other terms and conditions of this Agreement shall continue to apply to the Parties.</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.7&#160;&#160;&#160;&#160;Batch Cancellations or Delays in Receipt of Batches. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Incyte wishes to cancel or delay Manufacture of one or more Batches set out in a Binding Portion, Incyte will promptly notify MacroGenics in writing. Notwithstanding anything to the contrary set forth herein, Incyte will be liable for and &#91;***&#93; of the Batch Price of such cancelled or delayed Batch(es) and any non-cancelable Material charges. Notwithstanding the above, MacroGenics will use Commercially Reasonable Efforts to mitigate any costs associated with the cancellation or delay of Manufacture of any Batch (whether in whole or in part) by Incyte. To the extent MacroGenics is able to reallocate such capacity to manufacture of other products, Incyte will have &#91;***&#93; with respect to cancellation compensation. For clarity, Incyte will remain liable for the performance of the Manufacturing Related Activities &#91;***&#93; by MacroGenics.</font></div><div style="margin-top:0.25pt;padding-left:39pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.8&#160;&#160;&#160;&#160;Delivery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MacroGenics will Deliver each Batch in accordance with the Delivery date specified for such Batch in the applicable purchase order. Incyte will bear the risk of loss or damage to each Batch upon its Delivery. Incyte will arrange to have Batches promptly shipped from the MacroGenics Manufacturing Facility upon their Delivery. If Incyte fails to take Delivery of a Batch within &#91;***&#93; after its Delivery, unless otherwise agreed in writing MacroGenics, may charge a storage fee as outlined in the Price Schedule</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_31"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;ACCEPTANCE&#59; NON-CONFORMING LICENSED COMPOUND</font></div><div><font><br></font></div><div style="padding-left:90pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;Product Warranty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MacroGenics hereby warrants that, at the time and place of Delivery pursuant to Section 4.7, that each Batch, will be transferred to Incyte free and clear of any security interests, liens or encumbrances.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.2&#160;&#160;&#160;&#160;Inspection and Acceptance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. &#91;***&#93; after Delivery of each Batch, Incyte will, in its sole discretion, (a) conduct a visual inspection of such Batch for &#91;***&#93;&#59; and (b) conduct an inspection of &#91;***&#93; pursuant to the terms of the Commercial Quality Agreement (as applicable). Incyte may reject the Batch in the event that it fails to meet the applicable Product Specifications (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Conforming Licensed Compound</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) by providing written notice to MacroGenics (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deficiency Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Any Deficiency Notice will state in reasonable detail (reasonably sufficient to enable MacroGenics to identify the nature of the problem or to dispute the same) the nature of such alleged defect. If Incyte does not reject such Batch by providing a Deficiency Notice to MacroGenics within &#91;***&#93; of Incyte&#8217;s receipt of all documentation per the terms of the Commercial Quality Agreement, Incyte will be deemed to have accepted such Batch. For the avoidance of doubt, Incyte&#8217;s Quality Assurance group will release &#91;***&#93; of the commercial supplies of Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product&#59; provided that for any Batches, Incyte&#8217;s Quality Assurance group will complete such release &#91;***&#93; of receipt of all documents required pursuant to the terms set out in the Commercial Quality Agreement.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:39pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.3&#160;&#160;&#160;&#160;Replacement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon receipt of a Deficiency Notice, MacroGenics will have &#91;***&#93; to advise Incyte in writing whether it disagrees in good faith with the contents of such Deficiency Notice (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Response Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If MacroGenics does not respond &#91;***&#93;, the Deficiency Notice will be deemed accepted by MacroGenics. If the Parties &#91;***&#93; after Incyte&#8217;s receipt of a Response Notice from MacroGenics whether the Batch at issue is Non-Conforming Licensed Compound, then the Parties will promptly select a mutually acceptable, independent laboratory to evaluate whether the Batch is Non-Conforming Licensed Compound. If the independent laboratory determines that the Batch is Non-Conforming Licensed Compound, and the non-conformance is due solely to MacroGenics&#8217; gross negligence or willful misconduct in the Manufacture of such Batch, MacroGenics will replace, at no additional expense to Incyte, such Non-Conforming Licensed Compound Bulk with a Batch that meets the Product Specifications. If the independent laboratory determines that the Batch is not Non- Conforming Licensed Compound, then Incyte will be deemed to have accepted Delivery of such Batch.</font></div><div><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">5.4&#160;&#160;&#160;&#160;Batch Failure. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Notwithstanding Section 5.3, the allocation of liability for Batch Failures is as follows&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:111pt;padding-right:39.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;In the case of any Batch Failure resulting from MacroGenics&#8217; gross negligence or willful misconduct, MacroGenics will be &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;In the case of Batch Failures that occur when MacroGenics &#91;***&#93;, Incyte will be &#91;***&#93;. For avoidance of doubt, this includes a &#91;***&#93; resulting from &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:111pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;In the case of all other Batch Failures, the liability will be allocated as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:147pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If &#91;***&#93;, Incyte will be liable for the &#91;***&#93; and MacroGenics will be responsible &#91;***&#93;.&#160;&#160;&#160;&#160;Thereafter, if there are any &#91;***&#93;, the Parties will escalate such issue in accordance with Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_70" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">14.10.</a></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:147pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;&#91;***&#93; Batches are Manufactured per year, Incyte &#91;***&#93; and MacroGenics &#91;***&#93;. Thereafter, if there are any &#91;***&#93;, the Parties will escalate such issue in accordance with Section 14.10.</font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div><font><br></font></div><div style="padding-left:147pt;padding-right:38.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;If &#91;***&#93; Batches are Manufactured &#91;***&#93;, Incyte &#91;***&#93; and MacroGenics &#91;***&#93;. Thereafter, if there are any &#91;***&#93;, the Parties will escalate such issue in accordance with Section 14.10.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During each &#91;***&#93;, the Parties will reconcile the costs associated with Batch Failures that occurred during the prior Calendar Year in accordance with Section 5.4. For clarity, the allocation of liability for Batch Failures set forth herein will exclude (i) in the case of Incyte, any Batch Failures resulting from MacroGenics&#8217; gross negligence or willful misconduct&#59; and (ii) in the case of MacroGenics, any Batch Failures that occur when MacroGenics adheres to the Manufacturing Process and&#47;or or Incyte&#8217;s instructions.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.6&#160;&#160;&#160;&#160;Sole Remedy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary set forth in this Agreement or the Collaboration Agreement, the remedies set forth in Sections 5.3 and 5.4 will be the exclusive remedies of Incyte, its Affiliates and their respective Collaborators and licensees and will constitute fulfillment of all obligations by MacroGenics to Incyte, its Affiliates and their respective Collaborators and licensees (including any liability for direct, indirect, special, incidental or consequential damages or lost profits), whether in warranty, contract, negligence, tort, strict liability, or otherwise with respect to any nonconformities, defect or deficiency of the Batches.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;MANUFACTURING DEVELOPMENT ACTIVITIES</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.1&#160;&#160;&#160;&#160;Governance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parties hereby agree to maintain the Joint Project Team (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JPT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) established under the Clinical Supply Agreement, consisting of technical representatives from each Party, with its primary purpose being to plan, execute and discuss issues regarding the CMC Development Plan. Any disputes or issues that cannot be readily resolved by the JPT will be referred to the JMC for resolution. Any decision by the JPT which has the effect of amending the CMC Development Plan must be reviewed and approved by the JMC. Each Party will appoint an individual as a Project Manager who will be responsible for leading and coordinating the activities of the JPT and the CMC Development Plan.</font></div><div style="padding-left:75pt;padding-right:38.8pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.2&#160;&#160;&#160;&#160;CMC Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All new Manufacturing Development activities to be conducted by MacroGenics under this Agreement will be set forth in the CMC Development Plan which includes an estimated budget for the costs to be incurred by MacroGenics in performing such Manufacturing Development work (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMC Development Budget</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), including any Third Party Expenses. Updates to the CMC Development Plan will be mutually approved by the JMC prior to initiation of any activities not already mutually approved by the JMC. MacroGenics will use Commercially Reasonable Efforts to perform the Manufacturing Development activities set forth in the CMC Development Plan. MacroGenics may not exceed the CMC Development Budget &#91;***&#93; without the Parties agreeing to an amendment to the CMC Development Plan in accordance with Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_31" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">6.3</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. MacroGenics will not be obligated to perform any Manufacturing Development activities if the Parties cannot agree to an increase in the CMC Development Budget. In addition, MacroGenics will not be obligated to perform any Manufacturing Development activities that are not specifically set forth in the CMC Development Plan</font></div><div><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of clarification, the CMC Development Plan undertaken by the Parties under the Clinical Supply Agreement shall continue to be conducted under and governed by the Clinical Supply Agreement.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.4&#160;&#160;&#160;&#160;Amendments to CMC Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If a Party anticipates or becomes aware of any needed material change needed in the scope or timing of a Manufacturing Development </font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="padding-left:90pt;padding-right:38.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activity in order to accomplish its purpose, such Party will promptly notify the other Party in writing. The JMC will then mutually agree whether the CMC Development Plan is to be modified. If the Parties agree with an identified change in the scope or timing of the CMC Development Plan, the Parties through the JMC will execute a written amendment to the CMC Development Plan showing or indicating the needed changes in the Manufacturing Development activities, their timelines and the CMC Development Budget. If the JMC declines to amend the CMC Development Plan, including, as applicable, the CMC Development Budget, MacroGenics will not be obligated to perform, and Incyte will not be obligated to pay for, any activities that would have been affected by the amendment until such an amendment has been executed by the Parties. Any amendments to the CMC Development Plan, including to the CMC Development Budget, must be approved by the JMC in writing. Both Parties will act in good faith and respond promptly when considering an amendment requested by the other Party.</font></div><div><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.5&#160;&#160;&#160;&#160;Incyte Responsibilities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As set forth in the CMC Development Plan, Incyte will be responsible for</font></div><div style="margin-top:0.15pt;padding-left:75pt;padding-right:38.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) providing information or materials to MacroGenics&#59; and (ii) reviewing and approving any deliverables, documents or other items as promptly as practicable, but &#91;***&#93; applicable item to be reviewed or the request for approval unless otherwise specified by the CMC Development Plan.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.6&#160;&#160;&#160;&#160;Delays&#59; Cancellation of Work</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MacroGenics will not be responsible for any delays caused by failure of Incyte to meet its obligations set forth in Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_31" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">6.4, </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including delays caused by Incyte&#8217;s failure to respond to any requests for approvals within the time frame set forth in Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_31" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">6.4. </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte may not cancel any Manufacturing Development activities without the Parties mutually agreeing in writing to an amendment to the CMC Development Plan to cancel or terminate such activities. Upon the Parties&#8217; mutual written agreement to an amendment to cancel or terminate any Manufacturing Development activities, any materials, FTE Costs to the extent such FTEs are unable to be reallocated &#91;***&#93;, Third Party Expenses and other items that cannot reasonably be cancelled or used by MacroGenics for other purposes will be invoiced to and paid for by Incyte.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.7&#160;&#160;&#160;&#160;No Guarantees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Parties hereby agree that MacroGenics does not provide any guarantees of success with regard to any of the Manufacturing Development activities or deliverables relating thereto, including that the Manufacturing Development activities can be completed as contemplated in the CMC Development Plan after MacroGenics has used Commercially Reasonable Efforts to do so.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:90pt;padding-right:39pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte will use Commercially Reasonable Efforts to plan for making Drug Product presentations required for MacroGenics Combination Regimens (including, but not limited to &#91;***&#93;) commercially available in a timeline consistent with MacroGenics&#8217; anticipated regulatory filings. Such plans shall include, but not be limited to, the following Manufacturing Development activities&#58; &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;PRICE&#59; PAYMENT&#59; TAXES</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:39pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.1&#160;&#160;&#160;&#160;Batch Manufacture. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purchase of each Batch, Incyte will pay a price (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Batch Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) consisting of &#91;***&#93;. &#91;***&#93; are included in the Price Schedule. The &#91;***&#93; include all corresponding invoices &#91;***&#93; Drug Substance &#91;***&#93;. The &#91;***&#93; includes all charges associated with labor, repairs and maintenance, rent, utilities, depreciation and &#91;***&#93;. The &#91;***&#93; will be invoiced as &#91;***&#93; as set forth in Section in 7.2.a. For sake of clarity, MacroGenics &#91;***&#93;. Both the costs for &#91;***&#93; during Manufacture will be &#91;***&#93;. The Parties will subsequently &#91;***&#93; paid by Incyte with the &#91;***&#93; by MacroGenics for such items. Other than for &#91;***&#93;, invoiced costs for &#91;***&#93; will not include &#91;***&#93;. The cost of &#91;***&#93; Manufacture Batches and costs &#91;***&#93; will not be included in &#91;***&#93; and will be invoiced separately.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="padding-left:111pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Batch Price Adjustments</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:147pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;&#91;***&#93;&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:183.05pt;padding-right:40pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Each Calendar Year &#91;***&#93; after the &#91;***&#93; for the prior Calendar Year&#59; and</font></div><div><font><br></font></div><div style="padding-left:183.05pt;padding-right:44.7pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;to reflect changes in the costs to Manufacture Licensed Compound Bulk Drug Substance resulting from Notified Laws, Required Specification Changes and Discretionary Specification Changes or Process Changes due to other reasons or causes.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:147pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;&#91;***&#93;&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:183.05pt;padding-right:47.8pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;&#91;***&#93; of each Calendar Year, MacroGenics will send Incyte a written report setting forth (i) &#91;***&#93;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:183.05pt;padding-right:51.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:147pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:183.05pt;padding-right:47.8pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The &#91;***&#93; for a Batch that will be used to Manufacture License Compound Drug Product to supply</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_34"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:183.05pt;padding-right:43.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. &#91;***&#93; will be invoiced upon receipt and separately from the Batch Price and will include &#91;***&#93; reimbursement fee to cover costs associated with &#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Incyte will pay for activities performed herein at the FTE Rate, plus any Third Party Expenses incurred by MacroGenics to perform regulatory activities and&#47;or address regulatory matters specifically related to each Batch (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Activity Costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The costs of Manufacturing Related Activities and Manufacturing Development Costs are excluded from Regulatory Activity Costs.</font></div><div style="padding-left:75pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Batch Shipping</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cost of &#91;***&#93;. Should MacroGenics &#91;***&#93; (at MacroGenics&#8217; discretion if requested by Incyte), costs incurred by MacroGenics &#91;***&#93;. Costs incurred by MacroGenics for &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Development. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte will pay for Manufacturing Development activities performed herein at the FTE Rate, plus any Third Party Expenses incurred by MacroGenics in the performance of such Manufacturing Development activities (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Development Costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). For clarity, the Manufacturing Development costs will include, but will not be limited to, process optimization, analytical characterization and technical transfer support and will exclude costs incurred to Manufacture Batches.</font></div><div><font><br></font></div><div style="padding-left:111pt;padding-right:49.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Manufacturing Related Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Incyte will pay for Manufacturing Related Activities performed herein at the FTE rate, plus any Third Party Expenses incurred by MacroGenics in the performance of such Manufacturing Development activities, except as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:147pt;padding-right:68.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%">The costs for MacroGenics to conduct the following Manufacturing Related Activities are included &#91;***&#93;&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:183.05pt;padding-right:45.4pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;retrieval, storage and analysis of data and maintenance of such data for mutually agreed upon periods in a database containing applicable information&#59;</font></div><div><font><br></font></div><div style="padding-left:183.05pt;padding-right:39.15pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;reporting to &#91;***&#93;, or his&#47;her designee, in accordance with the terms of the Commercial Quality Agreement, any significant atypical results, deviations or adverse trends exhibited during testing&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:183.05pt;padding-right:39.95pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Annual Product Review that conforms to MacroGenics standard protocol. At Incyte&#8217;s option and cost, Annual Product Reviews can be performed beyond the scope of MacroGenics&#8217; standard protocol at the FTE Rate plus any Third Party Expenses.)&#59;</font></div><div><font><br></font></div><div style="padding-left:183.05pt;padding-right:48.75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;continued process verification that conforms to MacroGenics&#8217; standard protocol. At Incyte&#8217;s option and cost, continued process verification can be performed beyond the scope of MacroGenics&#8217; standard protocol at the FTE Rate plus any Third Party Expenses.</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_37"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.65pt;padding-left:147pt;padding-right:54.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">ii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Stability pulls will be invoiced &#91;***&#93; included in the Price Schedule.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.2&#160;&#160;&#160;&#160;Invoicing by MacroGenics</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:111pt;padding-right:72.75pt;text-align:right;text-indent:-111.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Payment for the Batch Price shall be invoiced according to the following schedule&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:147pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;During the &#91;***&#93;, the &#91;***&#93; during Manufacture will be invoiced&#59;</font></div><div><font><br></font></div><div style="padding-left:147pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;&#91;***&#93; will be invoiced &#91;***&#93; to Delivery&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:147pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;&#91;***&#93; will be invoiced &#91;***&#93; to Delivery&#59;</font></div><div style="padding-left:75pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:147pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.&#160;&#160;&#160;&#160;&#91;***&#93; will be invoiced &#91;***&#93;&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:147pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.&#160;&#160;&#160;&#160;&#91;***&#93; be invoiced &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Manufacturing Development, Manufacturing Related Activities, &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:147pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;&#91;***&#93;, MacroGenics will submit an invoice that includes the following costs incurred by MacroGenics during the prior Calendar Quarter&#58;</font></div><div><font><br></font></div><div style="padding-left:165.05pt;padding-right:39.3pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The total costs (including Third Party Expenses and FTE Costs) incurred by MacroGenics to conduct Manufacturing Development, Manufacturing Related Activities and &#91;***&#93;&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:165.05pt;padding-right:49.9pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;&#91;***&#93; to cover costs associated with &#91;***&#93; for purchased &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.3&#160;&#160;&#160;&#160;Payment.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:39.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All invoices issued by a Party to the other Party will be sent by electronic means and be sent in accordance with any written instructions provided the other Party.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Payment of all undisputed amounts due will be due &#91;***&#93; from a Party&#8217;s receipt of an invoice consistent with the requirements of subsection (a) above. Each Party will &#91;***&#93; of any disputed invoice, setting out in full the reasons such invoice is disputed.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;All payments due to a Party hereunder will be made in U.S. Dollars by wire transfer of immediately available funds into an account designated by such Party. If a Party does not receive payment of any sum due to it on or before the due date, such Party will notify the other Party, and such other Party will have &#91;***&#93; following receipt of such notice to pay any undisputed amount. Thereafter, interest will accrue on the undisputed sum due to the Party seeking payment until the date of payment &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_40"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:90pt;padding-right:38.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.4&#160;&#160;&#160;&#160;Financial Audit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Incyte shall have the right to conduct financial audits of MacroGenics&#8217; records to confirm the accuracy of invoices submitted to Incyte for payment of amounts under this Agreement other than those for &#91;***&#93;. The conduct of any such audits by Incyte shall be governed by Section 8.12 of the Collaboration Agreement. Incyte shall not have the right to conduct audits of MacroGenics records to confirm the accuracy of or otherwise assess invoices submitted to Incyte for payment of amounts under this Agreement for &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">7.5&#160;&#160;&#160;&#160;Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Subject to Section 4.6(c), Section 8.11 of the Collaboration Agreement will govern all tax matters under this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;QUALITY CONTROL&#59; REGULATORY&#59; COMPLIANCE</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.1&#160;&#160;&#160;&#160;General</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:111pt;padding-right:39pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;MacroGenics will Manufacture the Batches in accordance with (a) the Product Specifications&#59; (b) the GMPs&#59; (c) Applicable Laws in the United States&#59; and (d) subject to Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_40" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">8.1</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c), any Notified Law.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;In the event that Incyte requests MacroGenics to comply with an Applicable Law in the Territory that is not required in the United States, Europe or such other country(-ies) mutually agreed upon by the Parties as subject to GMP as defined herein, Incyte will identify such Applicable Law to MacroGenics (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notified Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), together with all available information regarding such Notified Law, so that MacroGenics may understand the nature, scope and requirements of such Notified Law. Incyte and MacroGenics will discuss and work together as to how MacroGenics may come into compliance with such Notified Law using Commercially Reasonable Efforts. All costs and expenses necessary to comply with a Notified Law will be paid by Incyte.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:111pt;padding-right:39.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;If the Parties fail to agree &#91;***&#93; after Incyte&#8217;s request to comply with a Notified Law as to how MacroGenics may come into compliance with such Notified Law, then MacroGenics will have the final decision-making authority with respect to the resolution of such disagreement, including the ability to decline implementing such compliance with Notified Law.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">8.2&#160;&#160;&#160;&#160;Testing of Batches. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Prior to release of a Batch to Incyte, MacroGenics or its permitted subcontractor will test such Batch in accordance with the procedures described in the Product Specifications, and will provide Incyte with the applicable executed master batch record and a copy of applicable deviation or other investigatory report, if any, on or before the Delivery date.</font></div><div><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">8.3&#160;&#160;&#160;&#160;Certificates. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">MacroGenics will provide Incyte with a Certificate of Analysis and Certificate of Compliance for each Batch released for Delivery to Incyte hereunder. Such certificates will include the information as specified in the Commercial Quality Agreement. Incyte will be under no obligation to accept any Batch without the accompanying certificate.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.4&#160;&#160;&#160;&#160;Latent Defects. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte will have the right to reject a Batch if &#91;***&#93;, it discovers a Latent Defect in such Batch which, through the process of root cause analysis, has been determined to have arisen as a direct result of MacroGenics&#8217; failure to Manufacture such Batch in accordance with the Product Specifications and Incyte provides notice to MacroGenics of such Latent Defect &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.5&#160;&#160;&#160;&#160;Product Specification Changes.</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_43"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:111pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required Specification Changes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If a Governmental Authority in the Territory requires a change to the Product Specifications (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required Specification Change</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Incyte will promptly notify MacroGenics of such change. MacroGenics will use reasonable efforts to implement such Required Specification Change as promptly as possible within the time frame requested by the Governmental Authority at Incyte&#8217;s sole cost and expense.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discretionary Specification Change</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party will be entitled to request a change to the Product Specifications that is not a Required Specification Change (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discretionary Specification Change</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The requesting Party will submit a written request to the other Party for any such Discretionary Specification Change. If the Parties agree to make such Discretionary Specification Change, MacroGenics will then determine (a) one-time and&#47;or ongoing costs that would be incurred resulting from such Discretionary Specification Change, (b) any resulting planned changes in timing for the Delivery of the Licensed Compound Bulk Drug Substance and (c) the estimated time of implementing such Discretionary Specification Change. MacroGenics will provide such information to Incyte and set forth the costs and other terms on which MacroGenics would be willing to make the Discretionary Specification Change. Upon written approval by Incyte to such terms, the Parties will cooperate in good faith in implementing such Discretionary Specification Change. All costs and expenses incurred by MacroGenics to implement any such Discretionary Specification Change will be at the sole cost and expense of Incyte, which MacroGenics will invoice as Manufacturing Development activities and to the extent the cost to Manufacture Licensed Compound Bulk Drug Substance changes, reflected in the Batch Price.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.6&#160;&#160;&#160;&#160;Quality Matters.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Quality Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party will perform its obligations under the Commercial Quality Agreement to be negotiated in good faith and entered into by and among the Parties on or &#91;***&#93;. In the event of any conflict between this Agreement and the Commercial Quality Agreement, with respect to any quality-related terms and conditions, the Commercial Quality Agreement will control. In the event of a conflict of any other term or conditions, this Agreement will control, unless otherwise agreed to by the Parties in writing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Assurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MacroGenics will use Commercially Reasonable Efforts to implement and perform operating procedures and controls for sampling, stability and other testing of the Licensed Compound Bulk Drug Substance and for validation, documentation and release of the Batches and such other quality assurance and quality control procedures as are required by the specifications, GMP and the Commercial Quality Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Assurance Measures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), for Commercial supply purposes. . The Quality Assurance Measures shall also govern the manufacturing process used at the &#91;***&#93; to Manufacture Licensed Compound Bulk Drug Substance Manufactured at the &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.7&#160;&#160;&#160;&#160;Audit by Incyte</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the reasonable prior written request of Incyte, Incyte will have the right to inspect and audit the MacroGenics Manufacturing Facility and Third Party facilities where the Batches are Manufactured (provided that for such Third Party facilities, to the extent MacroGenics is contractually permitted to grant Incyte such audit right) as set forth in Commercial Quality Agreement, as applicable, and pursuant to such requests to inspect and audit data, records, reports, information, licenses, permits and other documentation relating to the Manufacturing Processes for the purpose of assuring MacroGenics&#8217; compliance with its obligations under this Agreement, including compliance with GMPs, as set forth in the Commercial Quality Agreement, &#91;***&#93;, or more frequently for cause (i.e., for cause being defined as any instance or reasonable suspicion of existing or imminent violation of the Applicable Laws in the U.S. as demonstrated by reasonably detailed documentation). To the </font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="padding-left:90pt;padding-right:38.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extent such audit or inspection requires the disclosure of Confidential Information of MacroGenics that specifically references</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_46"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:75pt;padding-right:39pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products or compounds other than the Licensed Compound or Licensed Product, MacroGenics will have the right to require Incyte to engage a Third Party consultant to conduct such audit or inspection who will be contractually obligated by Incyte not to disclose any Confidential Information of MacroGenics that could reasonably lead to the identification of such product.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.8&#160;&#160;&#160;&#160;Regulatory Authority Inspections.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;MacroGenics will be responsible for inspections of the MacroGenics Manufacturing Facility by Regulatory Authorities, and will, as soon as reasonably possible following receipt of notice of inspection from a Regulatory Authority, notify Incyte if such inspections are directly related to the Manufacture of the Licensed Compound Bulk Drug Substance or if the results of a non-related inspection could materially impair the ability of MacroGenics to perform in accordance with this Agreement. With respect to inspections specifically related to the Manufacture of Licensed Compound Bulk Drug Substance, MacroGenics will (a) provide Incyte with copies of all documents, reports or communications received from or given to any Regulatory Authority associated therewith&#59; (b) subject to confidentiality obligations as requested by MacroGenics, permit Incyte&#8217;s representatives to be present on site and participate, as appropriate, based on questions or requests specific to Incyte or Licensed Compound Bulk Drug Substance and as permitted by Regulatory Authorities, in such inspections&#59; and (c) allow Incyte the opportunity and sufficient time &#91;***&#93; to review and provide comments to MacroGenics with respect to matters related to the manufacture of Licensed Compound Bulk Drug Substance and MacroGenics will draft any such correspondence to Regulatory Authorities taking into account Incyte&#8217;s reasonable comments.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Incyte will notify MacroGenics of any inspection of the &#91;***&#93; by a Regulatory Authority related to the Licensed Product and provide a written summary of the outcome of such inspection which will detail instances in which the Manufacture of the Licensed Compound Bulk Drug Substance was not compliant with Applicable Law and the basis of such non-compliance.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.9&#160;&#160;&#160;&#160;Cure of Deficiencies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MacroGenics will be responsible, at its own expense, for promptly correcting any deficiencies solely related to the MacroGenics Manufacturing Facility identified in any audit or inspection conducted by any Regulatory Authority under this Agreement. Incyte will be responsible for any expenses incurred by MacroGenics in correcting any Product specific deficiencies identified in any audit or inspection conducted by any Regulatory Authority subject to this Agreement,</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.10&#160;&#160;&#160;&#160;Interactions with Regulatory Authorities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except (a) for approvals and licenses required with respect to the MacroGenics Manufacturing Facility, which will be the responsibility of MacroGenics, or (b) as otherwise provided in the Collaboration Agreement, Incyte will be responsible for the preparation and filing of any Regulatory Documentation, if any, and for all contacts and communications with any Regulatory Authorities with respect to matters specifically relating to the Manufacture of Licensed Product&#59; provided that as set forth in the Collaboration Agreement MacroGenics will continue to be responsible for submissions and interactions with Regulatory Authorities with respect to matters specifically relating to MacroGenics Pipeline Assets. MacroGenics will assist Incyte upon request with any interactions with Regulatory Authorities regarding the Manufacturing Related Activities or Manufacture of the Licensed Compound Bulk Drug Substance. Notwithstanding the foregoing, Incyte will identify, reference and include MacroGenics&#8217; subcontractors in Exhibit A in the Regulatory Documentation. MacroGenics will notify Incyte &#91;***&#93; MacroGenics receives any contact or communication from any Regulatory Authority related in any way to the Manufacturing Related Activities or Manufacture of the Licensed Compound Bulk Drug Substance, or which could be reasonably expected to have a materially adverse effect on the Manufacturing Related Activities or Licensed Compound Bulk Drug Substance. MacroGenics </font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="padding-left:90pt;padding-right:38.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will provide Incyte with copies of any such correspondence or other communication &#91;***&#93; of such communication by MacroGenics. MacroGenics will consult with Incyte regarding</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_49"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:75pt;padding-right:38.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the response to any inquiry or observation from any Regulatory Authority relating to the Manufacturing Related Activities or Manufacture of the Licensed Compound Bulk Drug Substance and, except with respect to matters related to the MacroGenics Manufacturing Facility, will allow Incyte, as appropriate, to participate in any further contacts or communications relating to the Manufacturing Related Activities or Manufacture of the Licensed Compound Bulk Drug Substance. MacroGenics will comply with all reasonable requests and comments by Incyte with respect to all contacts and communications with any Regulatory Authority relating in any way to the Manufacturing Related Activities or Manufacture of the Licensed Compound Bulk Drug Substance. MacroGenics will assist Incyte with drafts of any correspondence or other reports to be submitted to Regulatory Authorities concerning the Manufacturing Related Activities or Manufacture of the Licensed Compound Bulk Drug Substance, for review prior to submission, will consider in good faith Incyte&#8217;s comments, and will provide final copies to Incyte promptly after submission.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.11&#160;&#160;&#160;&#160;Regulatory Submission</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. &#91;***&#93; for Licensed Compound Bulk Drug Substance, which is, or is the equivalent to, the Chemistry, Manufacturing Controls (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) portion of an application (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Submission</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) that incorporates data generated by MacroGenics, Incyte will provide MacroGenics a copy of the Regulatory Submission to permit MacroGenics to verify its accuracy as it relates to MacroGenics-generated data and that it accurately describes the work that MacroGenics performed under this Agreement. A final copy of the Regulatory Submission will be provided by Incyte to MacroGenics upon submission to the Regulatory Authority.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">8.12&#160;&#160;&#160;&#160;Licensed Compound Records&#59; Audit Rights. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Section 7.4 of the Collaboration Agreement will govern each Party&#8217;s record-keeping obligations and audit rights with regard the Licensed Compound.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">8.13&#160;&#160;&#160;&#160;Recalls and Voluntary Withdrawals</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Section 5.7(a) of the Collaboration Agreement will govern any recalls or voluntary withdrawals of the Licensed Product.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.14&#160;&#160;&#160;&#160;Product Returns. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte will instruct its distributors and customers to direct any returns of Licensed Products to Incyte in accordance with Incyte&#8217;s standard return policy. MacroGenics will promptly notify Incyte in writing (including all information MacroGenics has relating thereto) if any distributor, customer or other Third Party returns any Licensed Product to MacroGenics. MacroGenics will, at Incyte&#8217;s expense, promptly forward all such Licensed Product to the location specified by Incyte, and shall take no other action regarding such Licensed Product, unless requested, in writing, by Incyte or required by Applicable Law. After a commercially reasonable period of time safeguarding the Licensed Product so held, MacroGenics may destroy the Licensed Product if it has given written notice of its intention to Incyte and Incyte has not directed otherwise &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:90pt;padding-right:39.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.15&#160;&#160;&#160;&#160;Retained Samples</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MacroGenics will retain samples from each Batch &#91;***&#93; from the date of Delivery to Incyte, or for such longer period required by Applicable Law for recordkeeping, testing and regulatory purposes or specified in the Commercial Quality Agreement for the Licensed Compound Bulk Drug Substance. Prior to the destruction of any samples no longer required to be retained, MacroGenics will obtain written approval from Incyte.</font></div><div style="padding-left:75pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:90pt;padding-right:39.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.16&#160;&#160;&#160;&#160;Annual Product Review. &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to the Licensed Compound Bulk Drug Substance during the Term &#91;***&#93; thereafter or so long as MacroGenics Manufactures Licensed Compound Bulk Drug Substance for Incyte, whichever is later, MacroGenics will prepare, and provide to Incyte, an annual review for the Products as required by GMPs and Applicable Laws (each, an &#8220; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Product Review</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as more particularly set forth in the Commercial Quality Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_52"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;MANUFACTURING TECHNOLOGY TRANSFER</font></div><div><font><br></font></div><div style="padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.1&#160;&#160;&#160;&#160;Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Incyte may request, &#91;***&#93; to MacroGenics that MacroGenics transfer or have transferred the then-current Manufacturing Process to the &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). MacroGenics shall not unreasonably withhold its agreement to such request.</font></div><div><font><br></font></div><div style="padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The Manufacturing Technology Transfer will be sufficient to enable Incyte or such designee to perform the Manufacturing Process and Manufacture of Licensed Compound Bulk Drug Substance, as applicable, in accordance with Applicable Law, as more fully described in this Article 9 and will be subject to a written plan approved by the JMC with respect to such Manufacturing Technology Transfer (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Transition Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;), with Incyte having final decision-making authority on the Manufacturing Technology Transfer (provided that Incyte may not expand the scope of the Know-How and Information to be transferred pursuant to Section 9.1.b. beyond that which is required hereunder or under the Collaboration Agreement). MacroGenics will have no obligation to perform any activity that is not within the scope of the Manufacturing Transition Plan including with respect to its type, volume, timing and&#47;or completion date that has not been agreed to in writing by MacroGenics. The Parties will use Commercially Reasonable Efforts to effect a Manufacturing Technology Transfer to Incyte pursuant to this Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_52" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9.1.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The implementation of the Manufacturing Technology Transfer and Manufacturing Transition Plan will be subject to &#91;***&#93; being in an operational state that is suitable for the Manufacture of the Licensed Compound Bulk Drug Substance.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;MacroGenics will provide all reasonable assistance requested by Incyte to enable Incyte to implement the Manufacturing Technology Transfer, including by transferring to Incyte all Know-How and Information necessary for such Manufacturing Technology Transfer. In connection with a Manufacturing Technology Transfer, MacroGenics will cause its appropriate employees and representatives of MacroGenics to meet with employees and&#47;or representatives of Incyte at reasonable times to assist with the implementation and use of such Manufacturing Process and with the training of the personnel of the &#91;***&#93; to the extent reasonably necessary or useful for the use and practice of such Manufacturing Process. Incyte will reimburse MacroGenics' FTE Costs and reimburse all reasonable travel and Third Party Expenses incurred by MacroGenics in order to complete the Manufacturing Technology Transfer, &#91;***&#93; from MacroGenics setting forth such costs. Subsequent to the occurrence of the Manufacturing Technology Transfer, at any time during the Term, upon either Party's reasonable request, the other Party will provide to the requesting Party the updated Manufacturing Process (including associated Know-How) Controlled by such other Party necessary or useful for the Manufacture of the Licensed Compound Bulk Drug Substance at Incyte&#8217;s sole cost and expense.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The Manufacturing Technology Transfer will be conducted once. MacroGenics will have no obligation to undertake or assist with any other transfer of the Manufacturing Process whether to the &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;In the event the Clinical Supply Agreement expires or is terminated before this Agreement, MacroGenics shall have the right to include in the Updated Rolling Drug Substance Forecast amounts of &#91;***&#93; to be used for its Development purposes in each case.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:147pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;The Manufacture of, conduct of Related Manufacturing Activities for and purchase of such amounts of Licensed Compound Bulk Drug Substance shall be governed by the provisions of this Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_55"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:147pt;padding-right:39.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;The Manufacture of, conduct of Related Manufacturing Activities for and purchase of such amounts of Licensed Compound Bulk Drug Product shall be governed by the provisions of the Clinical Supply Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.2&#160;&#160;&#160;&#160;Modifications to the Manufacturing Process. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any time after the completion of the Manufacturing Technology Transfer during the Term, to the extent that either Party wishes to make any material modifications, improvements or other alterations to the Manufacturing Process (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Process Change(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Parties shall meet to discuss and agree upon implementation of the same. All costs associated with Process Changes will be at Incyte&#8217;s sole cost. Subject to the aforementioned, the Party implementing a Process Change will use Commercially Reasonable Efforts at Incyte&#8217;s sole cost and expense to provide access to such Process Change to the other Party, and to reasonably cooperate with the other Party in its efforts to ensure (including through the implementation of subsequent modifications to such Process Change, to the extent required) that the Incyte Manufacturing Facility and the MacroGenics Manufacturing Facilities (as applicable) Manufacture the Licensed Compound Bulk Drug Substance using such Process Change and yield comparable License Compound Bulk Drug Substance as a result. Incyte will be responsible for obtaining any required regulatory approvals resulting from implementation of such modifications.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.3&#160;&#160;&#160;&#160;Assignability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte will require that all agreements executed between Incyte and any Third Party with respect to such Third Party&#8217;s performance under this Agreement will permit the assignment of such agreement, in its entirety in the event of termination of the Collaboration Agreement (other than by Incyte pursuant to Section 12.3 or 12.6 of the Collaboration Agreement), to MacroGenics, without any consent rights by such Third Party (subject to MacroGenics agreeing to such assignment and the assumption of relevant obligations under such agreement).</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;CONFIDENTIAL INFORMATION&#59; INTELLECTUAL PROPERTY MATTERS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">10.1&#160;&#160;&#160;&#160;Confidentiality. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Article 11 of the Collaboration Agreement will govern the confidentiality obligations and use restrictions of the Parties with respect to Confidential Information disclosed under this Agreement and the Commercial Quality Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">10.2&#160;&#160;&#160;&#160;Intellectual Property Matters</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Article 9 of the Collaboration Agreement will govern all intellectual property matters arising under this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;REPRESENTATIONS, WARRANTIES AND DISCLAIMERS</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.1&#160;&#160;&#160;&#160;Corporate Action</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party represents to the other Party that (a) it is a corporation duly organized and validly existing under the laws of its jurisdiction of organization&#59; (b) the execution and delivery of this Agreement has been authorized by all requisite corporate action&#59; and (c) this Agreement is and will remain a valid and binding obligation of such Party, enforceable in accordance with its terms.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.65pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.2&#160;&#160;&#160;&#160;Absence of Other Contractual Restrictions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party represents and warrants that it is under no contractual or other obligation or restriction that is inconsistent with its execution or performance of this Agreement or the rights granted to such Party under this Agreement. Neither Party will enter into any agreement, either written or oral, that would conflict with its obligations under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="padding-left:90pt;padding-right:39.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">11.3&#160;&#160;&#160;&#160;Qualifications of Manufacturer Personnel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. MacroGenics represents and covenants that all Personnel will have the proper skill, training and experience to Manufacture and supply the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_58"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:75pt;padding-right:43.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensed Compound Drug Bulk Substance, perform the Manufacturing Related Activities and conduct the Manufacturing Development activities.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:90pt;padding-right:39.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.4&#160;&#160;&#160;&#160;No Debarment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party represents and covenants that it has not been debarred, and has not been threatened with debarment, under Section 306(a) or (b) of the U.S. Generic Drug Enforcement Act of 1992, as amended, or under any comparable law of any other jurisdiction in the Territory, and that it will not knowingly use in any capacity under this Agreement any debarred person or entity.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.5&#160;&#160;&#160;&#160;Compliance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics represents and warrants that the Manufacture, generation, processing, packaging, distribution, transport, treatment, storage, disposal and other handling of any Batches and Materials used to Manufacture or for their Manufacture, until Delivery of such Batches to Incyte will&#58; (i) be in accordance with and conform to GMPs&#59; (ii) be in accordance with and conform to any applicable standards specified by the United States Pharmacopeia and Pharmacopeia Forum and the European Pharmacopeia and Pharmacopeial Forum (and their equivalent standards, Applicable Laws in other jurisdictions, where applicable), and (iii) otherwise conform to any provisions of such Applicable Laws not reflected in GMPs&#59; provided that the Manufacturing Process is in accordance and otherwise conforms with (i) through (iii) of this Section 11.5.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">11.6&#160;&#160;&#160;&#160;Maintenance of Manufacturing Facility. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">During the Term, MacroGenics will maintain the MacroGenics Manufacturing Facility in good condition and in accordance with GMP and all other Applicable Laws.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:90pt;padding-right:39.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.7&#160;&#160;&#160;&#160;Security Measures. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise provided herein with respect to data or Incyte Confidential Information, MacroGenics will maintain reasonable security policies at the MacroGenics Manufacturing Facility to protect the integrity of the Materials, Products and all other Incyte assets, tangible and intangible.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.8&#160;&#160;&#160;&#160;Origin of Materials. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent it relies upon materials of foreign origin in its performance of the services or supply of the goods or materials hereunder, MacroGenics has accurately identified, to the best of its knowledge, the ultimate source of such services, goods or materials, including, but not limited to, information relating to its downstream MacroGenics&#8217; subcontractors.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.9&#160;&#160;&#160;&#160;Exclusion of Other Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, MACROGENICS DOES NOT MAKE ANY WARRANTY IN RESPECT OF THE MANUFACTURE AND SUPPLY OF THE LICENSED COMPOUND DRUG BULK SUBSTANCE OR THE PERFORMANCE OF THE MANUFACTURING RELATED ACTIVITIES OR THE MANUFACTURING DEVELOPMENT OR REGULATORY ACTIVITIES CONDUCTED BY MACROGENICS HEREIN, WHETHER EXPRESS OR IMPLIED BY STATUTE, CUSTOM OF THE TRADE OR OTHERWISE, THEIR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE UNDER ANY CONDITIONS, AND ANY SUCH WARRANTIES ARE HEREBY EXPRESSLY EXCLUDED.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;INDEMNIFICATION AND LIMITATION OF LIABILITY</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">12.1&#160;&#160;&#160;&#160;Indemnification and Indemnification Procedures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Sections 14.1, 14.2 and 14.3 of the Collaboration Agreement will govern all indemnification matters and indemnification procedures arising from this Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.2&#160;&#160;&#160;&#160;LIMITATION OF LIABILITY</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="padding-left:75pt;padding-right:38.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;EXCEPT TO THE EXTENT INCLUDED IN LOSSES RESULTING FROM A THIRD PARTY CLAIM FOR WHICH ONE PARTY IS OBLIGATED TO INDEMNIFY THE OTHER PARTY (OR AN</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_61"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:75pt;padding-right:38.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEMNITEE OF SUCH OTHER PARTY) PURSUANT TO SECTION </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_58" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">12.1 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AND ANY BREACH OF ARTICLE 10 (CONFIDENTIAL INFORMATION&#59; INTELLECTUAL PROPERTY MATTERS), IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY&#8217;S AFFILIATES, COLLABORATORS, LICENSEES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES UNDER ANY THEORY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:75pt;padding-right:38.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;MacroGenics&#8217; aggregate liability to Incyte, its Affiliates and their respective Collaborators or licensees for any loss or damage suffered by any of them as a result of breach of this Agreement or any other liability (including negligence, misrepresentation or claims under the indemnities) under this Agreement is limited, in the aggregate, to the payments for the Delivery of Licensed Compound Bulk Drug Substance payable to MacroGenics &#91;***&#93; the occurrence of the event giving rise to the claim.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;TERM AND TERMINATION</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.1&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The term (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of this Agreement will expire upon expiration of the Royalty Term unless otherwise terminated in accordance with Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_61" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">13.2 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below or otherwise extended upon mutual written agreement of the Parties&#59; provided, however, if this Agreement is terminated or expires, but the CMC Development Plan is not terminated or completed, then the terms of this Agreement will continue to apply to the then-current CMC Development Plan until such CMC Development Plan is either terminated or completed. For the avoidance of doubt, if this Agreement is terminated or expires, the terms of this Agreement will continue to apply during wrap up activities related to regulatory, patient safety and quality aspects of Commercialization.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90pt;padding-right:39.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">13.2&#160;&#160;&#160;&#160;Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. This Agreement may be terminated prior to the expiration of the Term under the following conditions&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Either Party may, without prejudice to any other remedies available to it in law or equity, terminate this Agreement in the event that the other Party has materially breached or defaulted in the performance of any of its obligations under this Agreement. The breaching Party will have &#91;***&#93; after written notice thereof was provided to the breaching Party by the non-breaching Party to remedy such default. Any such termination will become effective at the end of such &#91;***&#93; unless the breaching Party has cured any such breach or default prior to the expiration of such period&#59; or</font></div><div><font><br></font></div><div style="padding-left:111pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Either Party may terminate this Agreement in its entirety upon providing written notice to the other Party on or after the time that such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors, or becomes a party to any proceeding or action of the type described above (each, an </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Insolvency Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and such proceeding or action remains un- dismissed or un-stayed for a period &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_64"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.3&#160;&#160;&#160;&#160;Effects of Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the expiration or earlier termination of this Agreement (a) Incyte will promptly pay to MacroGenics (i) all amounts outstanding and remaining to be paid for the Licensed Compound Bulk Drug Substance Delivered, (ii) activities performed prior to the date of expiration or termination to conduct Manufacturing Related Activities, Manufacturing Development, Batch shipping and regulatory activities, and (iii) the applicable amounts for all work in process and Licensed Compound Bulk Drug Substance Manufactured, but not then Delivered, by MacroGenics&#59; and (b) any Materials purchased by MacroGenics to Manufacture Licensed Compound Bulk Drug Substance in accordance with the then-current Rolling Forecast that cannot be reasonably used for other purposes, and (c) any cancelled Batches.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.4&#160;&#160;&#160;&#160;Accrued Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Neither the termination nor expiration of this Agreement will release either of the Parties from any liability which at the time of such termination or expiration has already accrued to such Party, nor affect in any way the survival of any other right, duty or obligation of either of the Parties which is expressly stated elsewhere in this Agreement to survive such termination or such non-renewal.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">13.5&#160;&#160;&#160;&#160;Survival</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. The following provisions will continue in force in accordance with their respective terms notwithstanding the expiration or the termination of this Agreement for any reason&#58; Articles 1, 10 and 12 and Sections 5.2, 5.3, 5.4, 8.10, 8.11, 13.1, 13.3, 13.4, 13.5, 14.5, 14.6, 14.7, 14.8, 14.9, 14.10, 14.11, 14.12.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;MISCELLANEOUS</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.1&#160;&#160;&#160;&#160;Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except that a Party may make such an assignment or transfer without the other Party&#8217;s consent to an Affiliate or to any Third Party that acquires all or substantially all of the business or assets of such Party to which this Agreement relates (whether by merger, reorganization, acquisition, sale or otherwise). Any successor or assignee of rights and&#47;or obligations permitted hereunder will, in writing to the other Party, expressly assume performance of such rights and&#47;or obligations. Any permitted assignment will be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_64" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">14.1 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be null, void and of no legal effect.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.2&#160;&#160;&#160;&#160;Relationship of the Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. It is expressly agreed that MacroGenics, on the one hand, and Incyte, on the other hand, are independent contractors and that the relationship between the two Parties will not constitute a partnership, joint venture or agency. Neither MacroGenics nor Incyte will have the authority to make any statements, representations or commitments of any kind, or to take any action which will be binding on the other, without the prior written consent of the other Party to do so. All individuals employed by a Party will be employees of that Party and not of the other Party and all costs and obligations incurred by reason of such employment will be for the account and expense of such Party will be null, void and of no legal effect.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90pt;padding-right:39.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">14.3&#160;&#160;&#160;&#160;Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Section 14.4 of the Collaboration Agreement will govern the insurance obligations of each Party under this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.4&#160;&#160;&#160;&#160;Force Majeure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Both Parties will be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by Force Majeure and the nonperforming Party promptly provides notice of such Force Majeure circumstances to the other Party. Such excuse will be continued so long as the condition constituting Force Majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. Notwithstanding the foregoing, a Party will not be excused from making payments owed </font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="padding-left:90pt;padding-right:38.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hereunder because of a Force Majeure affecting such Party. If a Force Majeure persists &#91;***&#93;, then the Parties will discuss in good faith the modification of the Parties&#8217; obligations under this Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_67"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:75pt;padding-right:38.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to mitigate the delays caused by such Force Majeure. In the event a Party is prevented from performing its obligations under this Agreement due to Force Majeure &#91;***&#93; according to this Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_64" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">14.4 </a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the other Party will have the right to terminate this Agreement upon &#91;***&#93; notice after the expiration of such period. A termination under this Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_64" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">14.4</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by either Party will be treated as a termination under Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_61" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">13.2</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) above and the corresponding provisions for termination under Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_61" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">13.2</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) will apply except to the extent the affected Party is prevented from performing due to the Force Majeure.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.5&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All notices and other communications given or made pursuant hereto will be in writing and will be deemed to have been duly given on the date delivered, if delivered personally, or on the next Business Day after being sent by reputable overnight courier (with delivery tracking provided, signature required and delivery prepaid), in each case, to the Parties at the following addresses, or on the date sent and confirmed by electronic transmission to the fax number specified below (or at such other address or fax number for a Party as will be specified by notice given in accordance with this Section </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if9b1d7d4933545e0aa73895fad5d65bf_67" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">14.5</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If to Incyte&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:75pt;padding-right:182.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:231%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If to MacroGenics&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:75pt;padding-right:338pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.6&#160;&#160;&#160;&#160;Collaboration Agreement&#59; Entire Agreement&#59; Amendments.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The Collaboration Agreement shall govern the provisions of this Agreement and the Parties&#8217; rights and obligations hereunder except to the extent a provision of this Agreement amends, modifies or is contrary to a specific provision of the Collaboration Agreement. In particular, the provisions of this Agreement shall take precedent over the provisions of Section 14.5 and Article 7 (Manufacturing) of the Collaboration Agreement. Notwithstanding any other provision of this Agreement, the rights and obligations of the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_70"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:111pt;padding-right:35.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties to receive and to pay amounts under Article 8 (Consideration) of the Collaboration Agreement shall remain unaffected by this Agreement</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Subject to Section 14.6(a), this Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and with respect to the. Manufacture and supply of Licensed Compound Drug Substance by MacroGenics to Incyte. No subsequent alteration, amendment, change or addition to this Agreement will be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. In the event of any inconsistency between the body of this Agreement and either any Exhibits to this Agreement or any subsequent agreements ancillary to this Agreement, unless otherwise expressly stated to the contrary in such Exhibit or ancillary agreement, the terms contained in this Agreement will control.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Notwithstanding any other provision in this Agreement, the Clinical Supply Agreement will, until its expiration or termination in accordance with the terms set forth therein, remain in effect and continue to obligate the Parties with respect to</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:147pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics&#8217; right to Manufacture Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product for its own, its Affiliates and their licensees&#8217; Development and Commercialization purposes respectively&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:147pt;padding-right:39pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;MacroGenics&#8217; right to purchase Licensed Compound Drug Bulk Drug Substance and Licensed Compound Drug Product from Incyte&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:147pt;padding-right:39pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;the conduct of the CMC Development Plan set forth under the Clinical Supply Agreement as updated by the Parties&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.7&#160;&#160;&#160;&#160;Waiver and Non-Exclusion of Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver will be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party will not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.8&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is timely taken, the provision will be considered severed from this Agreement and will not serve to invalidate any remaining provisions hereof. The Parties will make good faith efforts to replace any such invalidated or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90pt;padding-right:39.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">14.9&#160;&#160;&#160;&#160;Governing Law&#47;Jurisdiction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof will be governed by and construed under the laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.10&#160;&#160;&#160;&#160;Dispute Resolution.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="padding-left:111pt;padding-right:38.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;If the Parties fail to resolve any claim, dispute, or controversy of whatever nature arising out of or relating to this Agreement, such claim, dispute or controversy will be resolved  in</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_73"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.25pt;padding-left:111pt;padding-right:39.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordance with the dispute resolution provisions set forth in Article 13 of the Collaboration Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:111pt;padding-right:38.7pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Notwithstanding the above, in the event of a dispute between the Parties with respect to a Batch Failure, the Parties will meet to discuss and agree upon the feasibility of the release of further Batches. Thereafter, if the Parties still disagree as to whether further Batches can be released, the Parties&#8217; most senior quality assurance officer, or their respective designated representatives, will confer to review samples and&#47;or batch records, as appropriate. If the disagreement is not resolved, then samples, batch records and other data relating to the batch in dispute will promptly be submitted for testing and evaluation to an independent Third Party (including a testing laboratory qualified to perform such testing using validated methods) approved in writing by both Parties. The cost of testing and evaluation by the Third Party will be borne (x) by MacroGenics if the Products in question are ultimately found to fail to meet the Product Specification as a result of MacroGenics&#8217; failure to adhere to the applicable Manufacturing Process and&#47;or Incyte&#8217;s instructions, or</font></div><div style="margin-top:0.05pt;padding-left:111pt;padding-right:39pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(y) by Incyte if MacroGenics is found to have adhered to the applicable Manufacturing Process and, if applicable, Incyte&#8217;s instructions.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:90pt;padding-right:38.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">14.11&#160;&#160;&#160;&#160;Counterparts&#47;Signatures. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">This Agreement may be executed in two (2) or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Agreement may be executed by .pdf or other electronically transmitted signatures and such signatures will be deemed to bind each Party as if they were the original signatures.</font></div><div><font><br></font></div><div style="padding-left:90pt;padding-right:39.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">14.12&#160;&#160;&#160;&#160;Construction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Whenever this Agreement refers to a number of days without using a term otherwise defined herein, such number refers to calendar days. Except where the context otherwise requires, (a) wherever used, the singular will include the plural, the plural will include the singular&#59;</font></div><div style="padding-left:75pt;padding-right:38.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) the use of any gender will be applicable to all genders&#59; (c) the terms &#8220;including,&#8221; &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;for example&#8221; will not limit the generality of any description preceding such term and, as used herein, will have the same meaning as &#8220;including, but not limited to,&#8221; or &#8220;including, without limitation&#8221;&#59; (d) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof&#59; (e) the word &#8220;or&#8221; has the inclusive meaning that is typically associated with the phrase &#8220;and&#47;or&#8221;&#59; (f) the word &#8220;will&#8221; means &#8220;will&#8221;&#59; (g) if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day&#59; (h) &#8220;Dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221; means U.S. Dollars&#59; (i) references to a particular Person include such Person&#8217;s successors and assigns to the extent not prohibited by this Agreement&#59; (j) a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein will be interpreted in a correlative manner&#59; (k) &#8220;written&#8221; includes communications sent and received by facsimile or electronic mail&#59; (l) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein) and (m) references herein to pharmaceutical products, therapies, ingredients, and the like, will include biologics and biopharmaceutical products, therapies, ingredients, and the like, as applicable. The language of this Agreement will be deemed to be the language mutually chosen by the Parties and no rule of strict construction will be applied for or against either Party. Whenever a provision of this Agreement requires an approval or consent by a Party to this Agreement within a specified time period and notification of such approval or consent is not delivered within such time period, then, unless otherwise specified, the Party whose approval or consent is required will be conclusively deemed to have withheld its approval or consent. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof.</font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:39pt;padding-right:35.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">IN WITNESS HEREOF</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">, the Parties have read and agree to be bound by the above terms and conditions and have entered into this Agreement effective as of the Effective Date set forth above.</font></div><div><font><br></font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_76"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.065%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Incyte Corporation</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.1pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Herve Hoppenot</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">MacroGenics, Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.1pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Scott Koenig</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Printed Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:117%">Herve Hoppenot</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:87%">Printed Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:87%">Scott Koenig, MD, PhD</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:113%">CEO</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; &#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; &#91;***&#93;</font></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div><font><br></font></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_79"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_82"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:182.72pt;padding-right:182.72pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#91;***&#93;</font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_85"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:182.77pt;padding-right:182.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_88"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:182.77pt;padding-right:182.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT C</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:267%">&#91;***&#93;</font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if9b1d7d4933545e0aa73895fad5d65bf_91"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="padding-left:36pt"><font><br></font></div></div><div style="margin-top:4.1pt;padding-left:182.77pt;padding-right:182.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT D</font></div><div style="padding-left:39pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:59pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244242908 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>5
<FILENAME>exhibit1017eversanaagreeme.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id3c2354f6c9742398eb666febd80394a_1"></div><div style="min-height:31pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 10.17</font></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH &#8220;&#91;***&#93;&#8221;.</font></div></div><div style="margin-top:4pt;padding-left:382.35pt;padding-right:5.85pt;text-align:right;text-indent:-34.95pt"><font><br></font></div><div style="padding-right:5.85pt;text-align:right"><font><br></font></div><div style="padding-right:5.85pt;text-align:right"><font><br></font></div><div style="padding-right:5.85pt;text-align:right"><font><br></font></div><div style="padding-right:5.85pt;text-align:right"><font><br></font></div><div style="padding-right:5.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">EXECUTION VERSION CONFIDENTIAL</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.8pt;padding-right:96.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PRODUCT COMMERCIALIZATION AGREEMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Product Commercialization Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made on November 13, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation with a place of business at 9704 Medical Center Drive, Rockville, MD 20850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Life Science Services, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Wisconsin limited liability company with a place of business at 190 N. Milwaukee Street, Milwaukee, WI 53202 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). MacroGenics and Eversana are hereinafter referred to individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">y&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="padding-left:96.75pt;padding-right:96.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BACKGROUND</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whereas, MacroGenics is a pharmaceutical company that will seek to market, promote and Commercialize (as defined below) the Product (as defined below) in the Territory (as defined below) upon its approval by the FDA (as defined below)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whereas, Eversana is a life sciences services company that has experience providing commercialization services related to pharmaceutical products&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whereas, MacroGenics wishes to engage Eversana to supervise and manage the day to day Commercialization of the Product in the Territory under the terms and conditions set forth herein.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:0.05pt;padding-left:5pt;padding-right:6.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, and other consideration received by the Parties, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:6pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;DEFINITIONS</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:6.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the purposes of this Agreement, the following words and expressions shall have the stated definitions&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 16.3.b.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:6.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), as amended from time to time, together with any rules, regulations, guidances, guidelines and requirements of the FDA as may be in effect from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Unreimbursed Commercial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.2.d.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adjusted Net Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.5.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adjusted Revenue Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.5.a.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adjusted Revenue Share Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.4.</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_4"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.7.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adjusted Revenue Sharing Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period beginning on the BLA Approval Date and ending on the earlier of (a) the occurrence of the Revenue Threshold, and (b) the expiration or termination of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.8.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Administrative Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93; MacroGenics&#8217;s administrative costs, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.9.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adverse Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to the Product, whether or not considered causally related to the Product, the exacerbation of any pre-existing condition(s) occurring following or during the use of the Product or any other adverse event, adverse experience or adverse drug experience described in the FDA&#8217;s Investigational New Drug safety reporting and post-marketing reporting regulations, 21</font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.F.R. &#167; 312.32 and &#167; 314.80, respectively, as they may be amended from time to time. For purposes of this Agreement, without limiting the forgoing, &#8220;undesirable medical condition&#8221; includes symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver) or the abnormal results of an investigation (e.g., laboratory findings, electrocardiogram), including unfavorable side effects, toxicity, injury, overdose, sensitivity reactions or failure of the Product to exhibit its expected pharmacologic&#47;biologic effect.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.10.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Person means any other Person which (directly or indirectly) is controlled by, controls or is under common control with such Person. For the purposes of this definition, the term &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) as used with respect to a Person, means (a) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise, (b) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of a Person, or (c) the power to elect or appoint more than fifty percent (50%) of the members of the board of directors or other governing body of such Person.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.11.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Preamble.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.12.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement Details</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 1.34.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.13.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.1.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.14.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Foreign Corrupt Practices Act of 1977, as amended, the Anti-Kickback Statute, the False Claims Act, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, released April 2003, the healthcare fraud and false statements provisions of the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), and any other applicable law, rule, regulation or industry code governing anti-bribery and anti-corruption laws and laws applicable in the Territory for the prevention of kickbacks, fraud, abuse, racketeering, money laundering or terrorism.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.15.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appellate Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 16.3.b.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_7"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.16.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicable Compliance&#47;Review Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to each Party, its written code of ethics and conduct and such policies and standard operating procedures that are adhered to by such Party in connection with the Product and any payments or activities contemplated by this Agreement, as the same may be amended from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.17.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) all applicable laws, rules and regulations, including any applicable rules, regulations, guidelines or other requirements of Governmental Authorities that may be in effect in the Territory from time to time during the Term, including (i) the Act,</font></div><div style="padding-left:33.3pt;padding-right:5.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) the PDMA, (iii) Anti-Corruption Laws, (iv) Medicare and Medicaid coverage and reimbursement provisions of titles XVIII and XIX of the Social Security Act, (v) the federal healthcare program civil money penalty and exclusion authorities, (vi) the Physician Payments Sunshine Act, 42 U.S.C. &#167; 1320a-7h, (vii) all federal, state or local statutes, laws, ordinances, regulations or guidelines relating to employment, safety and health of employees and the withholding and payment of required taxes with respect to employees, and (viii) all federal, state or local statutes, laws, ordinances, regulations or guidelines relating to data protection and privacy, including the United States Department of Health and Human Services privacy rules under the Health Insurance Portability and Accountability Act and the Health Information Technology for Economic and Clinical Health Act, and (b) the PhRMA Code on Interactions with Healthcare Professionals, PhRMA Principles on Direct To Consumer Advertisements&#59; PhRMA Principles on Interactions with Patient Organizations, and PhRMA Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.18.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Approved Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.5.b.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.19.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Arbitration Request</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 16.3.b.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:4.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.20.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Arising Product Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Know-How (i) specific to the Product arising out of or in connection with either Party&#8217;s or their respective Affiliates&#8217; (including, with respect to Eversana, any Approved Subcontractors&#8217;) activities under or in connection with this Agreement, (ii) constituting deliverables provided by or on behalf of Eversana or its Affiliates or Approved Subcontractors to MacroGenics as part of the Services, (iii) created or developed by Eversana using MacroGenics Confidential Information and&#47;or MacroGenics Know-How&#59; or (iv) developed or created by Eversana according to MacroGenics&#8217; specifications. Arising Product Know-How shall include but not be limited to the following&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:50pt;padding-right:5.75pt;text-align:justify;text-indent:-13.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;written and electronic materials (including but not limited to Promotional Materials), and their associated copyrights, that are intended to be used for activities to promote the Product, including for activities such as, but not limited to, presentations during detailing (whether in-person or electronically), conducting display booths, conducting meetings with prescribers in exhibits at conferences and trade shows and sponsoring advertising in journals and publications directed to prescribers&#59;</font></div><div><font><br></font></div><div style="padding-left:50pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;written and electronic Training Materials&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:50pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;trademarks, logos and Product labeling that identify the Product or MacroGenics.</font></div><div style="margin-top:4.5pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_10"></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:32pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, Arising Product Know-How (x) includes Know-How that Eversana creates under or in connection with this Agreement that emphasizes, focuses on or relies on an aspect, characteristic, trait or activity of the Product or discusses the Product in terms of its product class or in comparison to other products, and (y) excludes Eversana Know-How.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.21.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Biologics License Application (as more fully described in 21 CFR &#167;601, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or its successor regulation) filed with the FDA (or any successor application thereto) for approval to market and sell a biologic in the Territory, and all amendments or supplements filed pursuant to the requirements of the FDA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.22.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BLA Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the approval by the FDA of a BLA for the Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.23.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BLA Approval Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date on which MacroGenics receives BLA Approval.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.24.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a day on which companies in the United States are generally open for business.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.25.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Channel Management Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the channel management services described in the 3PL Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.26.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.1.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.27.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COC Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 14.2.f.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.28.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Launch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the earlier of (a) the Business Day immediately following the date of the initial Product launch meeting, or (b) &#91;***&#93; the Product first becomes available for purchase in the Territory for therapeutic use.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.29.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; mean any and all customary processes and activities undertaken by a pharmaceutical company to accomplish the commercialization of a pharmaceutical product, including without limitation the storage, third party logistics and distribution, sales, promotion and marketing of the Product, Medical Affairs Activities, managing returns of the Product, Patient Access Programs, and reimbursements. Commercialization expressly excludes activities related to development or testing of the Product or Manufacturing, including but not limited to the conduct of a Phase 4 Study.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.30.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.4.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.31.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.4.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.32.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Service Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) &#91;***&#93;, and</font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-top:8.4pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_13"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.33.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the services set forth in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.34.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) means all business, operational, marketing, financial, technical, manufacturing, scientific, or other information, that, in each case, is confidential or proprietary to the Disclosing Party or any of its Affiliates, is not generally known to the public, and is furnished to the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by or on behalf of the Disclosing Party pursuant to this Agreement &#91;***&#93;, whether in written, electronic, oral, visual or other form. Confidential Information of a Party may include such Party&#8217;s and its Affiliates&#8217; processes and methods, process specifications and designs, inventions, Know-How, intellectual property, business and marketing plans, financial information, customer data, research and development activities and other materials or information relating to business or activities which are not generally known to the public, and confidential information of Third Parties in the possession of the Disclosing Party. Without limiting the generality of the foregoing, Confidential Information of MacroGenics includes Manufacturing Data regarding the Product. This Agreement, including its provisions, terms and conditions hereof (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement Details</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), shall be deemed the Confidential Information of both Parties, and each Party shall be deemed both a Disclosing Party and a Receiving Party with respect thereto.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.35.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Controlled by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Know-How, Patent Rights or other intellectual property rights, possession by a Party of the ability (whether by ownership, license or other right, other than pursuant to a license granted to such Party under this Agreement) to grant to the other Party a license, sublicense or other access without violating the terms of any agreement or other arrangement with any Third Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.36.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the trade names, corporate names and corporate logos of MacroGenics or MacroGenics&#8217;s Affiliates (a) used in the Prescribing Information, or</font></div><div style="padding-left:33.3pt;padding-right:6.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;authorized or approved by MacroGenics for use in Materials that may be provided or generated hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.37.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dedicated Eversana Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.6.a.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.38.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Deficiency&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall have the meaning set forth in Section 3.7.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.39.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 1.34.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.40.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disputed Report Response</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.5.b.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.41.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Preamble.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.42.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Estimated Reimbursed Commercial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set  forth  in  Section 5.2.a.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_16"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.43.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Estimated Unreimbursed Commercial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.2.a.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.44.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Preamble.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.45.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Compliance&#47;Review Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Eversana&#8217;s Applicable Compliance&#47;Review Policies, as approved by the JMC.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.46.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.2.a.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.47.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Know-How that either&#58; (a) is in Eversana&#8217;s possession and Control of as of the Effective Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Pre-Existing Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; or (b) after the Effective Date during the Term, is independently developed by Eversana outside of providing the Services or performing other activities under this Agreement and without use of any MacroGenics Confidential Information or MacroGenics Know-How and is not specific to the Product. In addition, Eversana Know-How includes any improvement, modification or enhancement of the Eversana Pre-Existing Know-How that is made, generated, developed or invented by Eversana in the course of providing the Services or performing other activities under this Agreement, and is generally applicable to the services Eversana provides to its clients, but (i) does not constitute deliverables provided by or on behalf of Eversana or its Affiliates or Approved Subcontractors to MacroGenics as part of the Services, (ii) is not created or developed by Eversana using MacroGenics Confidential Information and&#47;or MacroGenics Know-How. and (iii) is not developed or created by Eversana according to MacroGenics&#8217; specifications.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.48.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Key Account Directors, Medical Science Liaisons and any other personnel employed or engaged by Eversana (including supervisory personnel overseeing the activities of such personnel and legal, regulatory and other support personnel) who are or may be involved with activities under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.49.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Pre-Existing Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 1.47.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.50.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to MacroGenics, its Chief Executive Officer, and with respect to Eversana, its Chief Executive Officer.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.51.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Unites States Food and Drug Administration and any successor agency thereto.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.52.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fee-for-Service Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.4.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.53.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Pre-Approval Service Fees, the Reconciled Reimbursed Commercial Costs, the Adjusted Revenue Share Payments and the Fee-for-Service Fees.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.54.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Field Alert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a field alert report, as required under 21 C.F.R. &#167; 314.81(b)(1), as such regulation may be amended from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.55.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Functional Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the services set forth in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:10.7pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_19"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.56.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means generally accepted accounting principles in the United States.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:11.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.57.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; to be broadly interpreted, shall mean (a) any elected or appointed government official (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a member of a ministry of health)&#59; (b) any employee or person acting for or on behalf of a government, government-controlled entity or enterprise performing a governmental function&#59; (c) any political party, candidate for public office, officer, employee, or person acting for or on behalf of a political party or candidate for public office&#59; (d) any employee or person acting for or on behalf of a public international organization (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the United Nations)&#59; or (e) any individual who holds himself or herself out to be the authorized intermediary of any of the foregoing. For clarity, healthcare providers employed by government-owned hospitals shall be considered Government Officials.</font></div><div style="margin-top:10pt;padding-left:33.3pt;padding-right:6.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.58.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any federal, state or local court, administrative agency, commission or other governmental authority or instrumentality, including the FDA, having authority in the United States over the activities contemplated hereunder. Governmental Authority shall include any Regulatory Authority.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.59.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all healthcare professionals, including any physician, physician&#8217;s assistant, pharmacist, nurse practitioner, clinical nurse specialist or registered nurse holding a degree in an area of nursing, certified registered nurse anesthetist, or certified nurse-midwife.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.60.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Higher Cost Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.7.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.61.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.3.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.62.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.3.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.63.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.1.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.64.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.1.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.65.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all intellectual property rights anywhere in the Territory, whether or not registered, including patents, utility models, rights in inventions, trademarks, service marks, rights in trade dress (including product configuration and packaging), rights in business and trade names, rights in domain names, designs, copyrights, trade secrets, rights in Know-How and confidential information, and, in each case, rights of a similar or corresponding character.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.66.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Management Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 4.1.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.67.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Key Account Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Eversana Personnel designated as &#8220;Key Account Directors&#8221; under the Commercialization Plan and having the qualifications and responsibilities set forth in the Commercialization Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.68.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means patentable and non-patentable inventions, discoveries, technologies, knowledge, trade secrets, experience, skill, techniques, methods, processes (including manufacturing processes), procedures, formulas, compounds, compositions of matter,</font></div><div style="margin-top:10.45pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_22"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:4.5pt;padding-left:33.3pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">assays, tests (including diagnostic tests), materials, specifications, descriptions, results and data (including Manufacturing Data), business or financial information or information of any type whatsoever, in any tangible or intangible form, marketing reports, business plans, standard operating procedures, and procedures&#59; that, in each case, are not generally known to the public.</font></div><div style="margin-bottom:6pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.69.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 9.7.a.</font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.70.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.1.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.71.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Preamble.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.72.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to MacroGenics, (a) the acquisition of MacroGenics by another entity by means of any transaction or series of related transactions (including, without limitation, any merger, consolidation in which the majority of the outstanding shares of MacroGenics are exchanged for securities or other consideration issued or provided, or caused to be issued or provided, by the acquiring entity or its subsidiary, but excluding any transaction effected primarily for the purpose of changing MacroGenics&#8217;s jurisdiction of incorporation), unless MacroGenics&#8217;s shareholders of record as constituted immediately prior to such transaction or series of related transactions will, immediately after such transaction or series of related transactions hold at least a majority of the voting power of the surviving or acquiring entity, (b) a sale of all or substantially all of the assets of MacroGenics to which this Agreement pertains, or (c) the execution by MacroGenics of a MacroGenics Third Party Exclusive Commercial License Agreement.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.73.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Change of Control Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the entity engaging in a MacroGenics Change of Control.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.74.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Know-How necessary or useful for the Commercialization of the Product that either&#58; (a) is in MacroGenics&#8217;s possession and Control as of the Effective Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Pre-Existing Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; or (b) after the Effective Date, (i) is independently developed by MacroGenics without use of any Eversana Confidential Information or Eversana Know-How, or (ii) is acquired by MacroGenics from a Third Party, and, in each case ((i) and (ii)), comes into MacroGenics&#8217;s possession and Control during the Term.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.75.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Patent Rights Controlled by MacroGenics as of the Effective Date or during the Term that claim the composition, a method of making, a method of using, the sale or the importation of the Product.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.76.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Pre-Existing Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 1.74.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.77.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means MacroGenics Know-How and MacroGenics Patents.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.78.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Third Party Exclusive Commercial License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an agreement between MacroGenics and a Third Party which includes an exclusive license to such Third Party or exclusive appointment of such Third Party to be responsible for the majority of the activities comprising the Commercialization Services (which may exclude</font></div><div style="margin-top:4.8pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_25"></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">distribution trade and channel management) for the Territory. MacroGenics&#8217; retention of certain specified rights to Commercialize the Product in the Territory or the obligation to perform certain activities in connection with and in furtherance of such exclusive license shall not be construed as a non-exclusive license or non-exclusive appointment of such Third Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that if MacroGenics retains the right to sell, and book sales of, the Product in the Territory, such agreement shall not be considered a MacroGenics Third Party Exclusive Commercial License Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.79.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; mean all activities related to the manufacture of a pharmaceutical product for the Territory, including without limitation manufacturing for clinical use or commercial sale, as well as compliance with Applicable Laws relating to the foregoing activities, but expressly excludes activities related to Commercialization.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.80.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all data, information, material, and documentation developed or generated with respect to the Manufacturing of a pharmaceutical product, including manufacturing and control data and other data and documentation requested by or submitted to a Regulatory Authority.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.81.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Promotional Materials and Other Materials.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.82.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materials Review Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.3.i.</font></div><div style="padding-left:33.3pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.83.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means activities, including Medical Education Activities, occurring during Commercialization of the Product in connection with the following activities&#58;&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.84.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Education Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means activities designed to ensure or improve safe and appropriate medical use of, conduct medical education about, or further research regarding,</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_28"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Product sold in the Territory or the associated disease states or conditions generally, including by way of example&#58; &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.85.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Science Liaisons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;MSLs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the Eversana Personnel designated as &#8220;Medical Science Liaisons&#8221; to engage in Medical Affairs Activities under the Commercialization Plan and having the qualifications and responsibilities set forth in the Commercialization Plan.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.86.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Profit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Net Sales, less the following&#58; &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.87.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the gross amounts invoiced by or on behalf of MacroGenics and its Affiliates (including by Eversana or its Affiliates on behalf of MacroGenics), on sales of Products to Third Party purchasers, less the following deductions, if not previously deducted from the invoiced amount, to the extent attributable to the Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Sales Deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:68pt;padding-right:6.15pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Normal and customary trade, quantity, and prompt pay discounts (including initial launch stocking discounts, chargebacks and allowances) actually allowed&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:6.05pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Amounts repaid or credited by reason of rejection, returns or recalls of Product, rebates or bona fide price reductions&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:6pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Rebates and similar payments made with respect to the sales paid for by any Governmental Authority, including but not limited to Federal or state Medicaid, Medicare or similar state program&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:68pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Redemption costs associated with any voucher, coupon, loyalty card or other co-pay assistance programs for the Product&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:5.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;Administrative fees paid during the relevant time period to group purchasing organizations, pharmacy benefit managers or other relevant customers&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:6.25pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;Service fees payable under any wholesaler agreement, distribution services agreement, inventory management agreement or similar agreement&#59;</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_31"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:68pt;padding-right:6.05pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;Taxes, tariffs, excises, customs duties, and&#47;or other charges imposed by a Governmental Authority on the production, sales, import, delivery or use of the Product (including sales, use, excise and consumption taxes and value added tax)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.&#160;&#160;&#160;&#160;Deductions to gross invoice price of such Product required by Governmental Authorities, and the annual fee on branded prescription pharmaceutical manufacturers and importers under the Affordable Care Act (or, if MacroGenics has other marketed products in addition to the Product, a portion thereof based on an equitable allocation among the Product and all other products sold by MacroGenics)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:6.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;A reasonable reserve up to &#91;***&#93; of the amount invoiced to cover bad debt&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:68pt;padding-right:5.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.&#160;&#160;&#160;&#160;The actual cost for transportation costs, distribution expenses, special packaging and related insurance charges&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:5.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.&#160;&#160;&#160;&#160;Any other customary deductions that are consistent with both GAAP and MacroGenics&#8217; actual practice (or its Affiliates&#8217; or licensees&#8217;) at the time in calculating and reporting its actual product net sales throughout its businesses, provided that no item shall be deducted pursuant to this clause (k) if included in any another deduction provided for under this definition.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.88.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Sales Deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning provided in Section 1.87.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.89.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Reimbursable Budget Overages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular calendar quarter during the Adjusted Revenue Sharing Period resulting in an &#91;***&#93; for such calendar quarter that is &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.90.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all written, printed, graphic, electronic, audio, video or other materials to be used in connection with Commercialization activities for the Product (or disease state treated by the Product) in the Territory other than Promotional Materials, as developed and approved in accordance with Section 3.9. Other Materials includes Training Materials and materials to be used in connection with Medical Affairs Activities.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.91.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Reportable Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, other than Adverse Events, any communication or other information that is required to be reported by Eversana to MacroGenics in accordance with the training to be provided under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.92.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Out of Scope Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.7.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.93.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.2.d.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.94.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Preamble.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.95.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pass-Through Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means amounts payable by Eversana to Third Parties in order to perform the Services, including, without limitation, (a) fees payable to Approved Subcontractors, (b) amounts payable to acquire materials or other resources, (c) travel expenses, and (d) expenses of the types listed under the heading &#8220;Pass-Through Expenses&#8221;</font></div><div style="margin-top:8.4pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_34"></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For clarity, Pass-Through Costs shall not include &#91;***&#93; or, except as expressly set forth in clause (d) of the preceding sentence, amounts paid in connection with &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.96.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Rights&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean patents and patent applications, including provisional applications, continuations, continuations-in-part, continued prosecution applications, divisions, substitutions, reissues, additions, renewals, reexaminations, extensions, term restorations, confirmations, registrations, revalidations, revisions, priority rights, requests for continued examination and supplementary protection certificates granted in relation thereto, as well as utility models, innovation patents, petty patents, patents of addition, inventor&#8217;s certificates, and equivalents in any country or jurisdiction.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.65pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.97.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patient Access Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means programs to assist prescription fulfillment, &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excluded Pharmacy Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). For the avoidance of doubt, Excluded Pharmacy Services does not include any of the Patient Access Programs or services related to those programs as described in Exhibits A, B, and C. MacroGenics will enter into a separate agreement with a specialty pharmacy selected by MacroGenics to administer the Excluded Pharmacy Services, and Eversana will coordinate and work cooperatively with such specialty pharmacy, as necessary to fully implement the Excluded Pharmacy Services. The parties agree and understand that if MacroGenics chooses a specialty pharmacy to administer the Excluded Pharmacy Services that is an Affiliate of, controlled or operated by Eversana, such agreement will be entirely separate from the financial and other arrangements made hereunder and that this Agreement and the payments hereunder are not dependent in any way on the execution of a specialty pharmacy agreement with Eversana, or vice-versa.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.98.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PDMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Prescription Drug Marketing Act of 1987, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder and in effect from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.99.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any individual, partnership, limited partnership, limited liability company, joint venture, syndicate, sole proprietorship, corporation, unincorporated association, trust, trustee, executor, administrator or other legal personal representative, or any other legal entity, including a Governmental Authority.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.100.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase 4 Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a clinical trial of a product which trial (a) is not required to be completed prior to obtaining marketing approval of such product&#59; and (b) either (i) is required by the applicable Regulatory Authority as mandatory to be conducted on or after the marketing approval of such product, or (ii) is conducted voluntarily by MacroGenics or an investigator to enhance scientific knowledge of such product (e.g., providing additional</font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_37"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:6.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">drug profile, safety data or marketing support information, or supporting expansion of product labeling).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.65pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.101.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pre-Approval Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the services set forth in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to be performed by Eversana before the BLA Approval Date, as the same may be amended, modified or supplemented from time to time in accordance with Section 3.3.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.102.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pre-Approval Service Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the fees actually incurred by Eversana to perform the Pre-Approval Services according to the fee estimate and the fee structure set forth in</font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as the same may be amended, modified or supplemented from time to time in accordance with Section 3.3. The Pre-Approval Services performed by a dedicated launch manager shall be at no cost to MacroGenics.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.103.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Eversana&#8217;s corporate office and its warehouse facilities located at either&#58; (a) 10887 Commerce Way, Unit B, Fontana, CA 92336&#59; (b) 4550 and 4580 Mendenhall Road, Memphis, Tennessee 38141&#59; (c) 5650 Challenge Drive, Memphis, TN 38118&#59; or (d) such other facilities as Eversana and MacroGenics may mutually agree.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.104.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prescribing Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the FDA-approved labeling for the Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.105.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior CDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Confidential Disclosure Agreement, dated as of &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.106.&#160;&#160;&#160;&#160;&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.107.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior Quarter Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.5.a.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.108.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 12.3.c.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.109.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means margetuximab.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.110.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all copyrightable subject matter related to the Product included in the Prescribing Information, the Promotional Materials, the Training Materials or other Materials provided hereunder or otherwise authorized or approved by MacroGenics under this Agreement for use by Eversana in performing the Services.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.111.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Quality Complaint</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all manufacturing or packaging-related complaints related to the Product, including (a) any complaint involving the possible failure of the Product to meet any of the specifications for the Product, and (b) any dissatisfaction with the design, package or labeling of the Product.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.65pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.112.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Product-specific trademarks owned or Controlled by MacroGenics during the Term in the Territory, including any such Product-specific trademarks (a) used in the Prescribing Information, or (b) authorized or approved by MacroGenics for use in Promotional Materials, Training Materials, or other Materials relating to the Product that may be provided or generated hereunder&#59; but, in each case, excluding the Corporate Trademarks.</font></div><div style="margin-top:8.4pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_40"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.113.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Training</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Product-specific training program for Eversana Personnel conducted in accordance with the Commercialization Plan and Applicable Law, which may include, as determined by the JMC or set forth in the Commercialization Plan, training concerning &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.114.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all written, printed, graphic, electronic, audio, video or other materials to be used in connection with any promotion activities for the Product in the Territory, as developed and approved in accordance with Section 3.9. For clarity, Promotional Materials may include materials such as detail aids, reprints, and advertisements, as applicable, as approved in accordance with Section 3.9.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.115.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quarterly Invoice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.2.a.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.116.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rate Sheet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.4.b(i).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.117.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 1.34.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.118.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciled Reimbursed Commercial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to each calendar quarter occurring during the Adjusted Revenue Sharing Period, &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.65pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.119.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciled Unreimbursed Commercial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to each calendar quarter occurring during the Adjusted Revenue Sharing Period, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.120.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Refund Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.2.c.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.121.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any national, federal, state, or local governmental or regulatory authority, agency, department, bureau, commission, council or other government entity located in the Territory, including FDA, Centers for Medicare and Medicaid Services (CMS), and the Office of Inspector General of the U.S. Department of Health and Human Services, regulating or otherwise (a) exercising authority with respect to the development, Manufacture, approval, registrations, licensing, or Commercialization of the Product in such regulatory jurisdiction in the Territory, or (b) having legal authority with respect to the exploitation of the Product in the Territory.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.122.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all applications, registrations, licenses, authorizations and approvals, all correspondence submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents and all clinical studies and tests, relating to the Product, and all data contained in any of the foregoing, including all</font></div><div style="margin-top:3pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_43"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Authority approvals, regulatory drug lists, advertising and promotion documents and related FDA submissions and correspondence, adverse event files and complaint files and related FDA submissions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.123.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reimbursable Budget Overages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular calendar quarter during the Adjusted Revenue Sharing Period resulting in an Overage, the portion of the Overage for such calendar quarter to the extent attributable to&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.85pt;text-align:justify;text-indent:-12.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;&#91;***&#93; as set forth in the Commercialization Plan and the Commercialization Budget&#59; provided, that (i) the Commercialization Service Fees for such &#91;***&#93;, and (ii) &#91;***&#93; as set forth in the Commercialization Plan and the Commercialization Budget &#91;***&#93;&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6pt;text-align:justify;text-indent:-12.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> set forth in the Commercialization Plan and the Commercialization Budget&#59; provided, that the foregoing shall not apply to any &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.124.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Report Response Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.5.b.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.125.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue Measurement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 14.2.b.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.126.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.4.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.127.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.7 Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.7.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.128.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.7 Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.7.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.129.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58; (a) the day-to-day supervision and management by Eversana of the Commercialization of the Product in the Territory, including the Pre-Approval Services, the Commercialization Services, and the Functional Services&#59; and (b) the Channel Management Services.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.130.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 14.1.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.131.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States and all of its territories and possessions.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.132.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person other than MacroGenics, Eversana and their respective Affiliates.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.133.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Commercial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.7.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.134.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all royalties on sales of the Product in the Territory and other payments that directly attributable or allocable to the Product in the</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_46"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Territory that, in each case, MacroGenics is required to pay to a Third Party for a license under issued and unexpired Patent Rights controlled by such Third Party, which license is &#91;***&#93;. For clarity, Third Party Royalties &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.05pt;padding-right:5.9pt;text-align:justify;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.135.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Training Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the materials &#91;***&#93; to be used in Product Training for Eversana Personnel regarding the Product, as approved pursuant to Section 3.9.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.136.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">True-Up Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.2.d.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.137.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3PL Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.11.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;APPOINTMENT AND LICENSE.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:6.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On and from the Effective Date and for the duration of the Term, MacroGenics hereby appoints Eversana to perform the Services, and Eversana hereby agrees to perform the Services, in accordance with this Agreement and Applicable Law.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.05pt;padding-right:5.7pt;text-align:justify;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Eversana&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.75pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;a co-exclusive (with MacroGenics), limited, non-transferable, non-sublicensable (except to Affiliates and Approved Subcontractors as permitted in accordance with Section 3.5), license (i) under the MacroGenics Technology to sell, have sold, offer for sale and otherwise Commercialize the Product in the Territory solely to the extent necessary for Eversana to perform its obligations and provide the Services under this Agreement, and</font></div><div style="padding-left:40.4pt;padding-right:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) to use the Product Trademarks and Product Copyrights in connection with the Commercialization of the Product in the Territory solely to the extent necessary for Eversana to perform its obligations and provide the Services under this Agreement&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.95pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;a non-exclusive, limited, non-transferable, non-sublicensable (except to Affiliates and Approved Subcontractors as permitted in accordance with Section 3.5), license to use the Corporate Trademarks in connection with the Commercialization of the Product in the Territory solely to the extent necessary for Eversana to perform its obligations and provide the Services under this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.05pt;padding-right:5.85pt;text-align:justify;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as specifically set forth in this Agreement, Eversana shall have no other rights with respect to the Product, and for clarity, shall not promote, market or otherwise Commercialize the Product except as Eversana is expressly authorized to do under this Agreement. MacroGenics reserves and retains, for itself, its Affiliates and for any Third Party, all rights in and relating to the Product not expressly granted to Eversana under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Rights and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Eversana acknowledges and agrees that, as between the Parties, MacroGenics owns all right, title and interest in and to (a) the Intellectual Property</font></div><div style="margin-top:4.8pt;padding-left:233.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_49"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rights in the Product, including the MacroGenics Technology, the Arising Product Know- How, the Product Trademarks, the Corporate Trademarks, and the Product Copyrights, and</font></div><div style="padding-left:33.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) all Regulatory Documentation for the Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Provision of Information and Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. MacroGenics shall promptly provide to Eversana at Eversana&#8217;s request such reasonable and currently available information and materials in MacroGenics&#8217; possession and Control relating to the Product as is necessary for Eversana to perform the Services in the Territory in accordance with the terms and conditions of this Agreement and Applicable Law.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assignment of Arising Product Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, MacroGenics shall own all right, title and interest in the Arising Product Know-How. Eversana shall assign and hereby assigns (and shall cause any applicable Affiliate or Approved Subcontractor to assign) to MacroGenics all of its right, title and interest in and to the Arising Product Know-How arising out of Eversana&#8217;s (or its Affiliates&#8217; or Approved Subcontractors&#8217;) activities under or in connection with this Agreement. Eversana agrees to (and shall cause any applicable Affiliate or Approved Subcontractor to) execute all documents and take all actions as are reasonably requested by MacroGenics to vest title to the Arising Product Know-How (and content) in MacroGenics (or its designated Affiliate). Upon MacroGenics reasonable request, Eversana shall provide copies of any tangible or electronic Arising Product Know- How specified in such request to MacroGenics.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;COMMERCIALIZATION</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall designate a single person (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to oversee contact between the Parties for all matters related to Commercialization of the Product. The Alliance Managers shall&#58; (a) function as a single point of contact in all substantive communications with the other Party&#59; and (b) perform any other functions agreed by the Parties. Each Party may replace its Alliance Manager at any time by written notice to the other Party. The initial Alliance Managers are set forth on</font></div><div style="padding-left:33.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2.&#160;&#160;&#160;&#160;Overview of Roles and Responsibilities.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, Eversana shall perform the Services in accordance with the then-current Commercialization Plan and Commercialization Budget and the terms of this Agreement and shall be responsible for all costs incurred with respect thereto, subject to the reimbursement and payment obligations set forth in Article 5, Section 14.2.c and Section 14.2.f. Without limiting the foregoing, Eversana shall (i) employ a sufficient number of Eversana Personnel, and ensure that such Eversana Personnel devote the necessary time in promoting, marketing and providing market access for and otherwise Commercializing the Product in the Territory to meet the requirements of the Commercialization Plan, and (ii) perform promotional activities in accordance with the targeting and frequency requirements set forth in the Commercialization Plan.</font></div><div><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.05pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;MacroGenics shall provide the functions and responsibilities set forth herein, including Product Manufacturing and obtaining and maintaining all regulatory approvals for the</font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_52"></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product as required by Applicable Law for the Territory, and as is necessary for Eversana to provide the Services in accordance with this Agreement and Applicable Law. Notwithstanding anything to the contrary set forth in this Agreement, MacroGenics makes no guarantee that BLA Approval will occur and that the Product will be Commercialized under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pre-Approval Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In anticipation of BLA Approval and the Commercial Launch of the Product in the Territory, Eversana shall provide the Pre-Approval Services described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto. The Pre-Approval Services shall &#91;***&#93;. The Parties acknowledge and agree that, in &#91;***&#93; the Pre-Approval Services will be performed and the anticipated collaboration between the Parties with respect to the scope and timeline for the activities to be included in the Pre-Approval Services, (a) MacroGenics may update</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> from time to time upon written notice to Eversana, subject to mutual written agreement on the applicable fees if not already addressed by the fee structure set forth on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and (b) although the Parties may discuss the status of Pre-Approval Services at the JMC, &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Plan and Commercialization Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Eversana shall Commercialize the Product for the approved indication(s) set forth in the label for the Product as part of the Services in accordance with an agreed Commercialization plan (as such plan may be amended from time to time in accordance with this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and a corresponding Commercialization budget (as such budget may be amended from time to time in accordance with this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Content of Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Commercialization Plan shall set forth in detail the activities and the timing and resource deployments necessary to Commercialize the Product in the Territory and otherwise perform the Commercialization Services, Functional Services and Channel Management Services, including, among other things&#58;&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Eversana is responsible for all activities under the Commercialization Plan, except for those activities set forth in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The preliminary version of the Commercialization Plan is attached hereto as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which includes a high-level description of the Commercialization Services, Functional Services and Channel Management Services.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Content of Commercialization Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Commercialization Budget shall set forth a &#91;***&#93; of the fees and Pass-Through Costs corresponding to the activities set forth in the Commercialization Plan, including, among other things&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the estimated Pass-Through Costs to be incurred in order to perform the Commercialization Services, Functional Services and Channel Management Services&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:95pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;other supportive detail as reasonably requested by MacroGenics.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Commercialization Budget shall be organized &#91;***&#93;. The preliminary version of the Commercialization Budget is attached hereto as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which includes a high-level </font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="padding-left:47pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">estimate of the fees and Pass-Through Costs for the Commercialization Services, Functional Services and Channel Management Services, including Eversana&#8217;s current Rate Sheet for the types of services included in the Commercialization Services, Functional Services and Channel Management Services.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to Commercial Launch and on an annual basis thereafter &#91;***&#93;, Eversana shall update each Commercialization Plan and Commercialization Budget for the following year. Additionally, Eversana shall update the Commercialization Budget &#91;***&#93;. Eversana shall submit such updated Commercialization Plans and Commercialization Budgets to the JMC for review and approval. &#91;***&#93;, the JMC shall either approve the Commercialization Plan and Commercialization Budget prepared by Eversana or approve a modified Commercialization Plan and Commercialization Budget. Any proposed</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_55"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">material changes to a previously approved Commercialization Plan or Commercialization Budget shall not take effect unless and until reviewed and approved by the JMC.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.5.&#160;&#160;&#160;&#160;Use of Affiliates and Third Party Subcontractors.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.8pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Eversana shall have the right to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its Affiliates that have been previously disclosed to MacroGenics in writing&#59; provided, that (a) any such Affiliate shall be bound by the obligations set forth in this Agreement, (b) any actions, omissions or conduct by such Affiliate shall be deemed to be actions, omissions or conduct of Eversana, and (c) Eversana shall remain responsible for the performance of its obligations under this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.7pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Eversana shall be permitted to utilize Third Party subcontractors or agents to perform the Services on Eversana&#8217;s behalf, subject to this Section 3.5.b. Eversana shall include in the Commercialization Plan and the Commercialization Budget the names of any Third Party subcontractors or agents that Eversana proposes to use to perform the Services, the specific Services to be performed by such Third Parties and the estimate for the cost of such Services, including all applicable Pass-Through Costs. The JMC shall have the right to review and approve (or modify) such portions of the Commercialization Plan and Commercialization Budget in accordance with Section 3.4c and Section 4.4. If Eversana desires to engage a Third Party subcontractor or agent to perform the Services outside of the regular process to update the Commercialization Plan and Commercialization Budget, then Eversana shall provide to the JMC in writing the name of such Third Party, the specific Services to be performed by such Third Party and the estimate for the cost of such Services, including all applicable Pass-Through Costs, and the JMC shall have the right to review and approve (or reject) the use of such Third Party in accordance with Section 3.4c and Section 4.4. The following terms and conditions shall apply with respect to any Third Party subcontractor or agent that has been approved by the JMC to perform the Services on Eversana&#8217;s behalf (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Approved Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58; (a) each Approved Subcontractor shall be engaged pursuant to a written agreement consistent with the terms of this Agreement to the extent applicable to the Services to be performed by such Approved Subcontractor, including Section 2.6 and Article 11&#59; (b) any actions, omissions or conduct by such Approved Subcontractor shall be deemed to be actions, omissions or conduct of Eversana&#59; and (c) Eversana shall remain responsible for the performance of its obligations under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.6.&#160;&#160;&#160;&#160;Eversana Personnel and Training.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.3pt;padding-right:5.85pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;In performing the Services, Eversana shall maintain an adequate number of qualified and trained (as specifically required by this Agreement) staff to execute the Services according to the Commercialization Plan and Commercialization Budget and as directed by the JMC. As part of the Commercialization Plan, Eversana shall designate the Eversana Personnel that will be exclusively performing promotional activities for the Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dedicated Eversana Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_58"></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:6pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;The Commercialization Plan shall include &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.75pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Eversana shall develop and provide all Training Materials for use hereunder&#59; provided, that the content and format of all Training Materials shall be reviewed and approved by the JMC prior to any use, and the Training Materials shall at all times be in compliance with all applicable Legal Requirements. Eversana shall not use any materials in providing Product Training to Personnel other than the Training Materials reviewed and approved by the JMC. Eversana&#8217;s use of the Training Materials in connection with training Eversana Personnel under this Agreement shall be in compliance with the terms of this Agreement and the Commercialization Plan. MacroGenics shall own all copyrights and other right, title and interest in and to all Training Materials&#59; provided, that Eversana may use the Training Materials solely for the purposes of performing its obligations under this Agreement and for no other purposes.</font></div><div><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Eversana shall maintain records related to Product Training &#91;***&#93;. Eversana shall maintain all such attendance records and other Product Training records, including copies of Training Materials used at each Product Training session.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.7.&#160;&#160;&#160;&#160;Use of Third Parties for Commercialization Support.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;If at any time during the Term, MacroGenics determines in good faith that&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Eversana&#8217;s performance of particular Commercialization activities for the Product &#91;***&#93;&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:5.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93; for particular Commercialization activities for the Product being provided by Eversana &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or</font></div><div><font><br></font></div><div style="padding-left:68pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the scope of services required by MacroGenics for particular Commercialization activities for the Product in the &#91;***&#93;,</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_61"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and, in any of such cases, MacroGenics desires &#91;***&#93;, then MacroGenics shall first notify Eversana in writing of the alleged Deficiency and the basis therefor, the &#91;***&#93; (a &#8220;Section 3.7 Notice&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Within &#91;***&#93;, Eversana may provide to MacroGenics a written proposal (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.7 Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to &#91;***&#93;, in each case, if Eversana desires to do so in its sole discretion. For clarity, Eversana shall have no obligation to provide any Section 3.7 Proposal. Any Section 3.7 Proposal that Eversana elects to provide shall, as applicable, set forth in reasonable detail (1) &#91;***&#93; set forth in the Section 3.7 Notice, (2) the basis for &#91;***&#93; set forth in the Section 3.7 Notice, or (3) &#91;***&#93; set forth in the Section 3.7 Notice and Eversana&#8217;s proposed fee structure relating thereto, as applicable. If (a) Eversana does not submit a Section 3.7 Proposal, (b) Eversana notifies MacroGenics that it is not interested in or able to provide the requested support, or (c) MacroGenics determines in its sole discretion that the Section 3.7 Proposal &#91;***&#93; set forth in the Section 3.7 Notice, or provide the &#91;***&#93;, as applicable, then MacroGenics shall be entitled &#91;***&#93; and the Commercialization Plan and Commercialization Budget shall be updated accordingly&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that if any and all such Commercialization activities for which MacroGenics engages support from any and all such &#91;***&#93;, then Eversana shall be entitled to reasonably &#91;***&#93; Eversana remains responsible for performing under this Agreement &#91;***&#93;. Any amounts paid to such Third Party vendor for such support will &#91;***&#93; and shall constitute &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Commercial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; hereunder. For clarity, this Section 3.7 shall not apply to any Commercialization activities included under (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or (ii) any services that are not included in the Services. Third Party Commercial Costs &#91;***&#93; of any the aforementioned activities included under (i) and (ii) of this sentence.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:5.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. &#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_64"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Eversana will develop and produce all Materials to be used by Eversana as set forth in the Commercialization Plan, including Promotional Materials and, to the extent compliant with Applicable Laws, Other Materials. All information relating to the Product and MacroGenics provided by MacroGenics to Eversana for use in the Materials shall be accurate and complete in all material respects&#59; provided, that MacroGenics &#91;***&#93;. Following formation of the JMC and prior to the adoption of the Materials Review Process, Eversana shall submit all Materials to the JMC for review and approval before they are used in the performance of the Services. Following the adoption of the Materials Review Process, Eversana shall submit all Materials for review and approval in accordance with the Materials Review Process. All Materials to be used by Eversana pursuant to this Agreement shall at all times be in compliance with Applicable Laws. MacroGenics shall own all Materials and all copyrights therein&#59; provided, that Eversana may use the Materials solely for the purposes of performing its obligations under this Agreement and for no other purposes. Eversana shall promptly notify MacroGenics, and provide MacroGenics with a copy, of any correspondence or other report or complaint received by Eversana from any Regulatory Authority, including the FDA, or any Third Party claiming that any oral or written statements about the Product or any Materials are in violation of Applicable Law or that Eversana Personnel conducting promotion or other Commercialization activities under this Agreement are making statements or claims regarding the Product that are inconsistent with the Materials or permitted use of the Product under Applicable Law.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Registration of Trademarks and Copyrights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Eversana shall not use (other than in connection with the Services as approved by the JMC), seek to register or register, nor permit any of its Affiliates or Approved Subcontractors to use, seek to register or register, any trademark, service mark, name or logo, including as part of any domain name, social media handle or other identifiers, which is confusingly similar to, or a colorable imitation of, the Product Trademarks, Corporate Trademarks or Product Copyrights in any jurisdiction worldwide. &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Channel Management Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. &#91;***&#93; of a channel management services agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3PL Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) whereby Eversana shall &#91;***&#93;. The specific terms and conditions related to such Channel Management Services will be set forth in the 3PL Agreement entered into by the Parties. Notwithstanding the foregoing, the Parties acknowledge and agree that, even though the Channel Management Services will be set forth in the 3PL Agreement, the general terms and</font></div><div style="margin-top:6pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_67"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">conditions set forth in this Agreement shall apply to such Channel Management Services except as expressly agreed otherwise by the Parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.12.&#160;&#160;&#160;&#160;Commercialization Covenants.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.1pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Eversana hereby covenants to MacroGenics that, during the Term in the Territory, it, its Affiliates and the Eversana Personnel will not (i) promote the Product outside of the Territory, (ii) promote the Product other than in compliance with Applicable Law, or</font></div><div style="padding-left:40.4pt;padding-right:6.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) disparage or present in a negative light the Product in the performance of its obligations hereunder&#59; provided, that nothing herein shall be interpreted to preclude Eversana from</font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x) describing any risks of the Product set forth in the label for the Product, or (y) making truthful statements about the Product to the extent required by Applicable Laws, in connection with any litigation or in response to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Eversana hereby covenants to MacroGenics that during the Term&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.95pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;it will immediately remove any Eversana Personnel from having any responsibilities relating to promotion of the Product under this Agreement if required by Applicable Laws&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.75pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;it will promptly remove any Eversana Personnel from having any responsibilities relating to the promotion of the Product under this Agreement if, following an investigation, it is determined that there has been a significant violation of any Applicable Laws or the Sales and Promotion Policies by such Person&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:95pt;padding-right:6.15pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;it will not knowingly make any untrue or misleading statements or comments about the Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Information Data Security Privacy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Eversana shall process, handle and store, and shall take the measures to ensure the security of, Sensitive Personal Information as provided in Exhibit H (Information) hereto.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;MANAGEMENT OF THE COLLABORATION</font></div><div style="padding-left:33.3pt;padding-right:5.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Management Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties shall establish a committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Management Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as more fully described in this Article 3.13. The JMC shall have review, oversight, and decision-making responsibilities for all Commercialization activities performed under this Agreement. Each Party agrees to keep the JMC informed of its progress and activities under this Agreement. The JMC shall convene at least once per calendar quarter, or more frequently as requested by either Party&#8217;s Alliance Manager, to discharge its responsibilities. The Alliance Managers shall meet at least once per month.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The JMC shall be comprised &#91;***&#93;. Each Party may replace any or all of its representatives on the JMC at any time</font></div><div style="margin-top:4.8pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_70"></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">upon written notice to the other Party. Each representative of a Party shall have relevant expertise in pharmaceutical drug product Commercialization, and be suitable in seniority and experience and have been delegated the authority to make decisions on behalf of the applicable Party with respect to matters within the scope of the JMC&#8217;s responsibilities. Any member of the JMC may designate a substitute to attend and perform the functions of that member at any meeting of the JMC. MacroGenics shall designate a chairperson to oversee the operation of the JMC. Such chairperson shall confer with the Alliance Managers of both Parties prior to each JMC meeting to identify issues for review and discussion at each JMC meeting, and circulate a meeting agenda &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The JMC shall perform the following functions&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.3pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;oversee and guide the Services to be provided under this Agreement and confirm Eversana&#8217;s compliance with the Commercialization Plan&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;recommend, review and approve amendments or revisions to the Commercialization Plan and the Commercialization Budget&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.2pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;discuss the Services previously performed by Eversana and the Services to be performed by Eversana&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;discuss the actual costs incurred by Eversana and the Fees paid to Eversana under this Agreement as compared to the estimated budget set forth in the Commercialization Budget&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.1pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;review and discuss Eversana&#8217;s plans for selecting, training and supervising Eversana Personnel, including Eversana Personnel conducting promotional activities&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.95pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">review and discuss Eversana&#8217;s plans to promote the Product in the Territory in accordance with the Commercialization Plan&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.1pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;review and discuss Eversana&#8217;s &#91;***&#93; related to the Product&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.&#160;&#160;&#160;&#160;review and approve the Eversana Compliance&#47;Review Policies&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.95pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;subject to Section 3.9, (i) review and approve Materials, and (ii) develop, adopt and oversee the implementation of a process for the review and approval of Materials, including any necessary legal, regulatory and medical review (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materials Review Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:40.4pt;padding-right:5.95pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.&#160;&#160;&#160;&#160;form such other subcommittees as the JMC may deem appropriate, provided that all actions and decisions of any such subcommittee shall be subject to the approval of the JMC&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.&#160;&#160;&#160;&#160;attempt to resolve any disputes on an informal basis&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.&#160;&#160;&#160;&#160;perform such other functions as expressly set forth in this Agreement.</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="padding-left:32pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The JMC shall further serve as a forum for discussion and shall perform such other functions agreed to by the Parties. A calendar quarterly business review will be presented by Eversana</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_73"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to the JMC. Any changes to the Commercialization Plan or Budget (e.g. Product pricing, marketing, distribution plan, etc.) shall require final approval from the JMC.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise provided herein, with respect to Commercialization of the Product, &#91;***&#93;. If the JMC cannot agree on a matter within its authority hereunder after it has met and attempted to reach such decision, then, either Party may, by written notice to the other, have such issue referred to the Executive Officers for resolution. The Parties&#8217; respective Executive Officers shall meet &#91;***&#93;, and shall negotiate in good faith to resolve the matter. If the Executive Officers are unable to resolve the matter &#91;***&#93;, then the issue shall be finally resolved by MacroGenics, unless the issue or decision increases Eversana&#8217;s aggregate annual financial or capital expenditures in excess of &#91;***&#93; of the annual aggregate amount set forth in the then- current and approved Commercialization Budget, in which event the issue shall be resolved &#91;***&#93;. The JMC shall have only such rights, powers and authority as are expressly delegated to it under this Agreement, and such rights, powers and authority shall be subject to the terms and conditions of this Agreement. The JMC shall not be a substitute for the rights of the Parties hereunder. Notwithstanding any other provision of this Agreement to the contrary, the JMC shall not have any right, power or authority&#58; (a) to determine any issue in a manner that would conflict with the express terms and conditions of this Agreement&#59; or (b) to waive, modify or amend the terms and conditions of this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Fees and Payments</font></div><div style="margin-top:0.05pt;padding-left:33.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1.&#160;&#160;&#160;&#160;Pre-Approval Service Fees. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MacroGenics shall be responsible for &#91;***&#93;, Eversana shall invoice MacroGenics for the Pre-Approval Service Fees that were incurred during such month. MacroGenics shall pay each such invoice &#91;***&#93;, provided that if MacroGenics in good faith disputes the invoiced amount or any portion thereof, MacroGenics shall provide written notice thereof, including the amount in dispute and MacroGenics&#8217; basis for disputing such amount, and shall pay the undisputed portion of such invoice, in each case, &#91;***&#93;. The Parties shall promptly attempt in good faith to resolve such dispute.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:33.05pt;padding-right:6pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">5.2.&#160;&#160;&#160;&#160;Reconciled Reimbursed Commercial Costs and Reconciled Unreimbursed Commercial Costs during the Adjusted Revenue Sharing Period.</font></div><div><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.95pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;&#91;***&#93;, Eversana shall invoice MacroGenics (each such invoice, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quarterly Invoice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for fifty percent (50%) of the estimated fees and Pass-Through Costs allocated to such calendar quarter for the Commercialization Services, the Functional Services and Channel Management Services according to the Commercialization Budget (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Estimated Reimbursed Commercial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The remaining fifty percent (50%) of the estimated fees and Pass-Through Costs allocated to such calendar quarter shall be referred</font></div><div style="margin-top:9.6pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_76"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Estimated Unreimbursed Commercial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and shall be the sole responsibility of Eversana, subject to the payment of any Refund Amounts or True-Up Amounts and Sections 14.2.c and 14.2.f.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reporting of Product Volume Sold. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise agreed by the JMC, on a monthly basis, Eversana shall report to MacroGenics, &#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_79"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the number of vials of the Product sold through Eversana&#8217;s distribution and pharmacy networks during such month.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sharing of Adjusted Net Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Eversana shall be entitled to receive payments based on tiers of Adjusted Net Revenue (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adjusted Revenue Share Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in each calendar year (or portion thereof) during the Adjusted Revenue Sharing Period at the following incremental rates&#58;</font></div><div style="margin-bottom:0.05pt;margin-top:0.2pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.718%"><tr><td style="width:1.0%"></td><td style="width:46.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Adjusted Net Revenue</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue Share Payment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On that portion of Adjusted Net Revenue in a calendar year &#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:89.8pt;padding-right:89.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On that portion of Adjusted Net Revenue in  a  calendar  year  &#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:89.8pt;padding-right:89.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:0.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On that portion of Adjusted Net Revenue in a calendar year &#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:89.8pt;padding-right:89.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#91;***&#93;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:10.55pt;padding-left:33.3pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By way of illustration, if Adjusted Net Revenue in a given calendar year is &#91;***&#93;, Eversana would be entitled to receive an Adjusted Revenue Share Payment of &#91;***&#93;, calculated as follows&#58; &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">When the total cumulative sum of all Reconciled Reimbursed Commercial Costs and Adjusted Revenue Share Payments equals one hundred twenty five percent (125%) of the total cumulative sum of Reconciled Reimbursed Commercial Costs and Reconciled Unreimbursed Commercial Costs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the consideration payable to Eversana for the performance of the Services shall convert to a fee-for-service arrangement under which MacroGenics shall pay to Eversana &#91;***&#93; for the Services performed during the remainder of the Term in accordance with the Commercialization Plan, &#91;***&#93; (the fees and costs payable under such arrangement, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fee-for-Service Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.5.&#160;&#160;&#160;&#160;Payment of Adjusted Revenue Payments.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.95pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;&#91;***&#93; the Adjusted Net Revenue Sharing Period, MacroGenics shall submit a written report to Eversana that provides the following information regarding such calendar quarter (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adjusted Revenue Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_82"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:95pt;padding-right:6pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;total Net Sales, including the types and total amount of each type of Net Sales Deduction taken to calculate the total Net Sales&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;text-indent:-36.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Third Party Commercial Costs&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:6.1pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the Adjusted Revenue Share Payment due to Eversana and the calculations to support such amount&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;text-indent:-36.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any adjustments to Net Sales from the prior calendar quarter&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.55pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;any adjustments to the Adjusted Revenue Share Payment from the prior calendar quarter and the calculations to support such amount (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior Quarter Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Concurrently with delivery of each Adjusted Revenue Report, MacroGenics shall pay to Eversana &#91;***&#93;, in each case as calculated in such Adjusted Revenue Report. Eversana&#8217;s receipt and acceptance of any such payment shall be without prejudice to Eversana&#8217;s rights or MacroGenics&#8217; obligations under Sections 5.5.b, 5.5.c, 5.5.d and 10.2.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;If Eversana in good faith disputes the amounts set forth in any Adjusted Revenue Report and paid by MacroGenics pursuant to Section 5.5.a, Eversana shall deliver written notice to MacroGenics of such dispute (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disputed Report Response</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) &#91;***&#93; Adjusted Revenue Report (&#91;***&#93;, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Report Response Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). In each Disputed Report Response, Eversana shall state the basis(es) of its dispute(s), identify the specific aspects of such Adjusted Revenue Report with which it disagrees or that it believes are incorrect and provide what it deems to be the proper calculation of the Adjusted Revenue Share Payment and&#47;or Prior Quarter Adjustments. If Eversana fails to submit a Disputed Report Response with respect to an Adjusted Revenue Report before the expiration of the applicable Report Response Period, such Adjusted Revenue Report shall be deemed to have been accepted by Eversana, provided that such deemed acceptance shall be without prejudice to Eversana&#8217;s rights or MacroGenics&#8217; obligations under Section 10.2.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.95pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;&#91;***&#93; Disputed Report Response disputing an Adjusted Revenue Report, MacroGenics shall respond to Eversana in writing as to whether it accepts or rejects such Disputed Report Response. If MacroGenics accepts such Disputed Report Response, it shall pay to Eversana the difference between the amount that Eversana claims is actually due for the applicable calendar quarter as set forth in such Disputed Report Response and the amount paid by MacroGenics to Eversana for such calendar quarter pursuant to Section 5.5.a. If MacroGenics disagrees with such Disputed Report Response, MacroGenics shall state in its response the basis(es) of its rejection(s) and identify the specific aspects of the Disputed Report Response with which it disagrees or believes is incorrect.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.8pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;The Parties shall rely on the dispute resolution procedures provided in Section 16.3 to resolve disagreements regarding an Adjusted Revenue Report for which Eversana has</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_85"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:40.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">issued a Disputed Report Response and MacroGenics has rejected such Disputed Response Report.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payment of Fee-for-Service Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Following achievement of the Revenue Threshold, &#91;***&#93;, Eversana shall submit a report to MacroGenics that details the Services performed during such calendar quarter and an invoice for the Fee-for-Service Fees due with respect thereto. MacroGenics shall pay each such invoice &#91;***&#93;, provided that if MacroGenics in good faith disputes the invoiced amount or any portion thereof, MacroGenics shall provide written notice thereof, including the amount in dispute and MacroGenics&#8217; basis for disputing such amount, and shall pay the undisputed portion of such invoice, in each case, &#91;***&#93;. The Parties shall promptly attempt in good faith to resolve such dispute.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The amounts payable by a Party to the other Party pursuant to this Agreement shall be paid free and clear of any and all taxes, except for any withholding taxes required by Applicable Law. Except as provided in this Section 5.7, the receiving Party shall be solely responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be deducted from payments and remitted by the paying Party) levied on account of, or measured in whole or in part by reference to, any payments it receives. The paying Party shall deduct or withhold from the payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if the receiving Party is entitled under any applicable tax treaty to a rate reduction of, or the elimination of, applicable withholding tax, it may deliver to the paying Party or the appropriate Governmental Authority (with the assistance of the paying Party to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve the paying Party of its obligation to withhold such tax and the paying Party shall apply the reduced rate of withholding or dispense with withholding, as the case may be&#59; provided that the paying Party has received evidence, in a form satisfactory to the paying Party, of the receiving Party&#8217;s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) &#91;***&#93;. If, in accordance with the foregoing, the paying Party withholds any amount, it shall pay to the receiving Party the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to the receiving Party proof of such payment &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fee Increases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. &#91;***&#93;, Eversana shall have the right to increase any then-current transaction or monthly fees for a Service provided under this Agreement (excluding Services compensated on an FTE basis) by &#91;***&#93;&#59; provided, that unless MacroGenics&#8217; provides its written consent, in no event shall such percentage increase &#91;***&#93;.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_88"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.9.&#160;&#160;&#160;&#160;Fee Structure.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.8pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a. The Parties agree that, with respect to the fees for the Services set forth in the Commercialization Plan&#58; (a) the fees charged by Eversana to MacroGenics hereunder shall be &#91;***&#93;&#59; (b) upon the request of MacroGenics, Eversana shall provide supporting documentation relating to Approved Subcontractors and Pass-Through Costs&#59; (c) for any Service that utilizes shared resources across multiple clients of Eversana, Eversana agrees to charge MacroGenics &#91;***&#93;&#59; and (d) Eversana shall not double count Fees that are charged to MacroGenics &#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;REGULATORY MATTERS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:5.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ownership of Regulatory Documentation and Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. MacroGenics is solely responsible for and owns all right, title and interest in and to all Regulatory Documentation concerning the Product, including any BLA Approval, and all information contained therein.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.2.&#160;&#160;&#160;&#160;Responsibility for Regulatory Approvals and Regulatory Communications.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.15pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;MacroGenics has the sole right and responsibility for obtaining and maintaining all regulatory approvals, including BLA Approvals, for the Product, and for complying with all regulatory reporting obligations with respect to the Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.5pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;MacroGenics has the sole right and obligation to&#58; (i) make any communications, reports, submissions and responses to FDA concerning the Product, including by reporting Adverse Events, Other Reportable Information, Field Alerts, and other Regulatory Documentation&#59; and (ii) take any action (including any investigations) and conduct all communications with all Third Parties that relate to all Product Quality Complaints or complaints related to tampering or contamination with respect to the Product, Adverse Events, Other Reportable Information and Field Alerts with respect to the Product&#59; provided, however, that Eversana shall be responsible for any communications, reports, submissions or responses to Regulatory Authorities that it may be required to make under Applicable Law in connection with performing the Services&#59; and provided, further that Eversana shall, to the extent permitted by Applicable Law, provide MacroGenics with (x) reasonable advance written notice of, and an opportunity to discuss in good faith, any proposed communication with FDA in advance thereof with respect to the Product or any activities of MacroGenics hereunder, or (y) written notice to MacroGenics of any communication with FDA concerning the Product or any activities of MacroGenics hereunder promptly following such communication and attach copies of such communication (whether by FDA or Eversana) to such notice. Notwithstanding the above, all investigations of Eversana employees or agents related to employment matters and Eversana internal policies and procedures may be conducted independently (with prompt notice to MacroGenics) by Eversana, and investigations relating to the Product or potential violations of Applicable Law shall be conducted in collaboration with MacroGenics.</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_91"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:5.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Eversana shall cooperate with reasonable requests by MacroGenics and assist MacroGenics in connection with&#58; (i) preparing any and all reports to FDA concerning the Product&#59; (ii) preparing and disseminating all communications to Third Parties concerning the Product&#59; and (iii) investigating and responding to any Product Quality Complaint, Adverse Event, Other Reportable Information, Field Alert, or other compliance inquiry or investigation related to the Product. Except as expressly set forth in Section 6.2.b above, MacroGenics is solely responsible for any and all communications with a Governmental Authority and for ensuring that all such communications comply with Applicable Laws. For purposes of clarification, MacroGenics shall be responsible for any and all regulatory reporting requirements including but not limited to aggregate spend reporting, reporting required by any State, as applicable, and pursuant to the disclosures required under the Patient Protection and Affordable Care Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PPACA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), even if there are joint disclosure obligations&#59; &#91;***&#93;, MacroGenics shall provide Eversana with confirmation that such disclosures were properly made. MacroGenics is also solely responsible for&#58; (x) all state and other municipal disclosures, including those related to drug samples, marketing expenses, product pricing, etc., and (y) all state and local municipal disposal laws related to the Product. Eversana shall reasonably cooperate with and assist MacroGenics, as reasonably requested in connection with such reporting requirements, including by providing MacroGenics, on a monthly basis, with details of Eversana&#8217;s aggregate spending in connection with the Services provided hereunder, to allow MacroGenics to comply with the reporting requirements set forth above.</font></div><div><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.8pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;MacroGenics shall be responsible for (i) making statements, whether written, oral or electronic, to Third Parties regarding Product Quality Complaints, Adverse Events, Other Reportable Information, Field Alerts, or other compliance inquiries or investigations with respect to the Product, and (ii) taking any action concerning any Regulatory Authority approval under which the Product is sold. For clarification, in the event Eversana becomes aware of a Product Quality Complaint, Adverse Event, Other Reportable Information, Field Alert, or other compliance inquiry or investigation with respect to the Product, Eversana is only responsible for informing the Third Party that information in respect thereof has been or will be conveyed by Eversana to MacroGenics.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.3.&#160;&#160;&#160;&#160;Adverse Events, Other Reports and Threatened Governmental Authority Action.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.95pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Eversana shall report to MacroGenics &#91;***&#93;&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:63.55pt;padding-right:6pt;text-align:justify;text-indent:-19.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;an Adverse Event or Other Reportable Information associated with the use of the Product or information in or coming into its possession or control concerning such Adverse Event or Other Reportable Information&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:63.55pt;text-indent:-23.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;information that might necessitate the filing by MacroGenics of a Field Alert&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:63.55pt;text-indent:-26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;information relating to an actual or threatened recall of the Product&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:63.55pt;text-indent:-25.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.&#160;&#160;&#160;&#160;any Product Quality Complaint associated with the use of the Product.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_94"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All such reports shall be made to the attention &#91;***&#93;. MacroGenics may update the individual to whom such reports shall be made by providing written notice thereof to Eversana.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.2pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Unless restricted or prohibited by Applicable Law or Governmental Authority, Eversana shall promptly notify MacroGenics if it receives information regarding any threatened or pending action regarding the Product by any Governmental Authority in the Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.75pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;All training materials regarding Adverse Events, Other Reportable Information, Field Alerts and Product Quality Complaints to be utilized by Eversana in connection with its provision of the Services shall either be provided by MacroGenics to Eversana or, to the extent Eversana prepares such materials, shall be approved by MacroGenics. These training materials shall include the contact number and method of transferring potential reports and any specific product information related to the Product.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:26.6pt;text-indent:-21.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;PRODUCT MATTERS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:5.65pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Orders for Product&#59; Terms of Sale&#59; Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All sales will be recorded in MacroGenics&#8217;s name. MacroGenics shall have the ultimate responsibility and right to take, accept, reject or cancel orders, fill orders and establish and modify the terms and conditions of the sale of the Product (including with regard to any patient assistance programs and returns), subject to compliance with the approved Commercialization Plan and all action plans previously approved by the JMC. Notwithstanding the foregoing, Eversana shall have the day-to-day responsibility and right to take, accept, reject or cancel orders, and fill orders so long as such actions are consistent with the approved Commercialization Plan, Commercialization Budget and all action plans previously approved by the JMC.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Returned Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Eversana shall notify MacroGenics of any returned Product, cooperate with MacroGenics regarding the handling of such Product, and follow such other Product return procedures as set forth in the 3PL Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recalled Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall promptly notify the other Party in writing of any facts relating to the advisability of the recall, withdrawal or withholding from the market of the Product in the Territory. MacroGenics shall have the sole responsibility and right to determine if any recall, withdrawal or other form of market action is necessary with respect to the Product and shall be solely responsible for taking all actions to effect such recall, withdrawal or market action. At MacroGenics&#8217;s request, Eversana will cooperate with MacroGenics regarding MacroGenics&#8217;s handling of any recalls, withdrawals or similar market actions. MacroGenics shall be responsible for all costs incurred in connection with any recalls, withdrawals or market actions concerning the Product except that Eversana shall be responsible for such costs to the extent such recalls, withdrawals or market actions are caused by Eversana&#8217;s negligence, failure to comply with Applicable Law, or breach of this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_97"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:26.6pt;text-indent:-21.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;COMPLIANCE MATTERS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Obligation to Notify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall promptly notify the other Party upon becoming aware of any potential breach or potential violation by such Party&#8217;s employees of the Anti- Corruption Laws in the performance of such Party&#8217;s obligations under this Agreement and shall take such steps as the Parties may reasonably agree to avoid a potential violation of the Anti-Corruption Laws in the performance of obligations under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance with Law and Ethical Business Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In addition to the other representations, warranties and covenants made by each Party under this Agreement, each Party hereby represents, warrants and covenants to the other Party that, during the Term in the Territory&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.95pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;it is, and will remain during the Term, licensed, registered and&#47;or qualified under Applicable Law to do business, and has obtained such licenses, consents, authorizations or completed such registrations or made such notifications as may be necessary or required by Applicable Law to perform its obligations under this Agreement&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.75pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;it will perform its obligations under this Agreement in material compliance with this Agreement (including, with respect to Eversana, the Commercialization Plan), Applicable Laws (including the FD&#38;C Act, the Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. &#167; 1320a-7a), the False Claims Act (31 U.S.C. &#167; 3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes, and the regulations issued by the FDA), and such Party&#8217;s Applicable Compliance&#47;Review Policies and&#47;or any agreed to compliance related policies or procedures governing Commercialization&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;with respect to the Product and any payments or Services provided under this Agreement, such Party has not taken, and during the Term will not take, any action, directly or indirectly, to offer, promise or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official in order to gain an improper advantage, and has not accepted, and will not accept in the future such payment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Eversana Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In addition to the other representations, warranties and covenants made by Eversana under this Agreement, Eversana hereby represents, warrants and covenants to MacroGenics that, during the Term in the Territory&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:40.4pt;padding-right:6.05pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Eversana has implemented and will maintain and enforce a compliance and ethics program designed to prevent and detect violations of Applicable Laws throughout its operations (including Affiliates) and the operations of Eversana Personnel that have responsibility for the payments or the Services provided under this Agreement, including by implementing policies and procedures setting out rules governing interactions with HCPs and Government Officials&#59; the engagement of Third Parties, and where appropriate, due diligence&#59; and the investigation, documentation, and remediation of any allegations, findings, or reports related to a potential violation of its Applicable Compliance&#47;Review Policies. Such compliance program shall include at a minimum, compliance officer,</font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_100"></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:6.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">compliance committee(s), policies and procedures relating to (i) sales, medical, promotional and marketing activities for the Product, (ii) regular auditing and monitoring,</font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;training on sales, medical, promotional and marketing activities and the relevant legal requirements regarding such activities, (iv) methods to raise questions or concerns internally (e.g., via a hotline) without fear of retribution or retaliation, (v) processes for investigating and documenting any compliance concerns or allegations raised, findings or reports related to a potential violation of Applicable Laws, and (vi) taking remedial, corrective action and&#47;or disciplinary action, as appropriate&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;in the event that Eversana receives a report of or otherwise becomes aware of a potential violation of its Applicable Compliance&#47;Review Policies, Eversana will perform an investigation in accordance with its established policies and procedures and will take all necessary and appropriate responsive, and corrective actions, including disciplinary actions (up to and including termination of any employee, contractor, agent, sub-contractor, customer, vendor or other Person that Eversana believes was responsible)&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.75pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Eversana has implemented, and will at all times during the Term maintain, adequate policies and procedures describing the materials and information that may be distributed or discussed by the Eversana Personnel related to the Product and the manner in which such Persons should handle unsolicited requests for information related to off-label uses of the Product, which policies and procedures shall be designed to ensure compliance with Applicable Laws&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.05pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Eversana regularly reviews its Applicable Compliance&#47;Review Policies as part of its internal processes of improvement, and, from time to time, benchmarks them against the standards of the industry&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;Eversana has implemented, and will at all times during the Term maintain, adequate systems, policies, and procedures to screen before hire and annually thereafter all prospective and current Eversana Personnel conducting activities with respect to the Product against (i) the List of Excluded Individuals&#47;Entities compiled by the Office of the Inspector General in the Department of Health and Human Services and (ii) the General Services Administration&#8217;s List of Parties Excluded from Federal Programs, which policies and procedures require Eversana&#8217;s prospective and current Eversana Personnel conducting activities with respect to the Product to disclose immediately to Eversana that such Representative is or may become debarred, suspended or excluded&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;in connection with this Agreement, Eversana&#8217;s compensation system for the Eversana Personnel that perform any marketing, promotion or sales activities related to the Product is designed to ensure that financial incentives do not inappropriately motivate such Eversana Personnel to engage in improper or illegal promotion, sales or marketing of the Product (including off-label promotion of the Product)&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;in connection with this Agreement, Eversana&#8217;s call planning system for the Eversana Personnel that call upon HCPs or health care institutions for any promotional or sales activities related to the Product is designed to ensure that such Eversana Personnel do not</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_103"></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">call upon HCPs or health care institutions that are not likely to prescribe or use the Product for an on-label use.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notice of Investigations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall promptly notify the other Party in the event that it becomes subject to or aware of any FDA or other Governmental Authority inspection, investigation, or other inquiry or a FDA warning letter, untitled letter, or other material governmental notice or communication relating to the Services or the Product promptly after the Party becomes aware of such inspection, investigation, inquiry, letter, notice, or communication, except to the extent that the disclosing Party&#8217;s counsel reasonably believes that such disclosure to the other Party could violate Applicable Laws (including privacy laws) or have a significant adverse impact on the disclosing Party&#8217;s legal position or defense (including the loss of attorney-client privilege) with respect to any such inspection, investigation or other inquiry. In the event that the Party determines that disclosure could violate Applicable Laws (including privacy laws) or have a significant adverse impact on the disclosing Party&#8217;s legal position or defense (including the loss of attorney-client privilege), the Party shall promptly notify the other Party that it is exercising its right not to make such disclosure.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:26.6pt;text-indent:-21.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;INDEPENDENT CONTRACTOR</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Independent Contractor Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The status of each Party under this Agreement shall be that of an independent contractor. Except as otherwise set forth herein, neither Party shall have the right to enter into any agreements on behalf of the other Party, nor shall it represent to any Person that it has any such right or authority.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.&#160;&#160;&#160;&#160;Eversana and its directors, officers, employees and any persons providing Services under the Agreement are at all times independent contractors with respect to MacroGenics. Persons provided by Eversana to perform the Services shall not be deemed employees of MacroGenics. Neither this Agreement nor the Services to be rendered hereunder shall for any purpose whatsoever or in any way or manner create any employer-employee relationship between Eversana, its directors, officers, employees and any persons providing Services under this Agreement, on the one hand, and MacroGenics, on the other hand. MacroGenics understands that Eversana may utilize independent contractors in connection with its performance of the Services, subject to Section 3.5.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.&#160;&#160;&#160;&#160;Eversana is, and at all times shall remain, solely responsible for the human resource and performance management functions of all Eversana personnel provided to perform the Services. Eversana shall be solely responsible for all disciplinary, probationary and termination actions taken by it, and for the formulation, content and dissemination of all employment policies and rules (including written disciplinary, probationary and termination policies) applicable to its employees, agents and contractors, including its employees, agents and contractors who perform the Services hereunder.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4.&#160;&#160;&#160;&#160;Eversana shall obtain and maintain worker&#8217;s compensation insurance and other insurance required for Eversana Personnel and acknowledges that under this Agreement MacroGenics does not, and shall not, obtain or maintain such insurance, all of which shall be Eversana&#8217;s sole responsibility.</font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_106"></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5.&#160;&#160;&#160;&#160;The Parties agree that Eversana Personnel are not, and are not intended to be or be treated as employees of MacroGenics and that no such individual is, or is intended to be, eligible to participate in any benefits programs or in any MacroGenics &#8220;employee benefit plans&#8221; (as defined in Section 3(3) of ERISA).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6.&#160;&#160;&#160;&#160;Except as otherwise set out in this Agreement, MacroGenics shall have no responsibility to Eversana or any Eversana Personnel for any compensation, expense reimbursements or benefits (including, without limitation, vacation and holiday remuneration, healthcare coverage or insurance, life insurance, pension or profit-sharing benefits and disability benefits, payroll-related or withholding taxes, or any governmental charges or benefits (including, without limitation, unemployment and disability insurance contributions or benefits and workers compensation contributions or benefits) that may be imposed upon or be related to the performance by Eversana or its employees, agents or contractors of Eversana&#8217;s obligations under this Agreement, all of which shall be the sole responsibility of Eversana. To clarify, MacroGenics will not withhold any income tax or payroll tax of any kind on behalf of Eversana.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.7.&#160;&#160;&#160;&#160;Limitations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.65pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Article 9, Eversana shall have no obligation or responsibility for any damages, liability, loss and costs, including but not limited to attorney&#8217;s fees (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the extent such Liability is attributed to either&#58; (i) discriminatory and&#47;or intentional acts of MacroGenics, its employees, agents or contractors&#59; or (ii) any benefits payable under any MacroGenics benefit plan, including any bonus, stock option, stock purchase, incentive, deferred compensation, supplemental retirement, severance or other similar fringe or employee benefit plan, program or arrangements that may be sponsored at any time by MacroGenics that cause, or are either alleged to cause or interpreted by any court or Governmental Authority to cause, any Eversana Personnel to be reclassified as an employee of MacroGenics. In the event any Liability is alleged against Eversana or its employees that is attributable to MacroGenics (as set forth in clauses (i) and (ii) of this Section 9.7.a), MacroGenics shall indemnify, defend, and hold harmless Eversana and its directors, officers, employees and contractors.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.65pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Article 9, MacroGenics shall have no obligation or responsibility for any Liability to the extent such Liability is attributed to either&#58; (i) discriminatory and&#47;or intentional acts of Eversana, its employees, agents or contractors&#59; or (ii) any benefits payable under any Eversana benefit plan, including any bonus, stock option, stock purchase, incentive, deferred compensation, supplemental retirement, severance or other similar fringe or employee benefit plan, program or arrangements that may be sponsored at any time by Eversana that cause, or are either alleged to cause or interpreted by any court or Governmental Authority to cause, any MacroGenics personnel to be reclassified as an employee of Eversana. In the event any Liability is alleged against MacroGenics or its employees that is attributable to Eversana (as set forth in clauses (i) and (ii) of this Section 9.7.b), Eversana shall indemnify, defend, and hold harmless MacroGenics and its directors, officers, employees and contractors.</font></div><div><font><br></font></div><div style="padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="id3c2354f6c9742398eb666febd80394a_109"></div><div style="margin-top:4.5pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;STATEMENTS, RECORD-KEEPING AND AUDITS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. MacroGenics shall keep complete and accurate books and records of Net Profits (including all amounts used to calculate Net Profits), Adjusted Net Revenue, Revenue Share Payments and all other financial information necessary to determine the payments to be made under this Agreement. MacroGenics shall keep such books and records, or shall cause such books and records to be kept, for a period &#91;***&#93;. All financial books and records kept by MacroGenics hereunder shall be maintained in accordance with GAAP, consistently applied.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Audits of MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At the request of Eversana, MacroGenics shall, and shall cause its Affiliates to, permit an independent auditor designated by Eversana, at reasonable times and upon at least &#91;***&#93; prior notice, to audit the books and records maintained pursuant to Section 10.1 to ensure the accuracy of all calendar quarterly reports and payments made hereunder. Each such audit may occur &#91;***&#93; and &#91;***&#93;. Eversana may exercise its audit right during the Term &#91;***&#93;. The cost of any such audit shall be borne by Eversana unless the audit reveals that Eversana has been underpaid &#91;***&#93;, in which case MacroGenics shall reimburse Eversana for any third party costs reasonably incurred in connection with the audit, &#91;***&#93;.</font></div><div style="padding-left:33.3pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Eversana shall keep, or shall cause to be kept, complete and accurate books and records (financial and otherwise) pertaining to the performance of the Services, including with respect to regulatory and compliance matters and any amounts used to calculate the Fees, in sufficient detail to verify compliance with its obligations hereunder and to calculate and verify all amounts payable hereunder. Eversana shall keep such books and records, or shall cause such books and records to be kept, &#91;***&#93;. All financial books and records kept by Eversana hereunder shall be maintained in accordance with GAAP, consistently applied.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Audits of Eversana</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At the request of MacroGenics, Eversana shall, and shall cause its Affiliates to, permit an independent auditor designated by MacroGenics, at reasonable times and &#91;***&#93;, to audit the books and records maintained pursuant to Section 10.3 to ensure Eversana&#8217;s compliance with this Agreement, including the accuracy of all reports and payments made hereunder. Each such audit &#91;***&#93;&#59; provided, that if any such audit reveals that Eversana is or was not in material compliance with Applicable Law or the Eversana Compliance&#47;Review Policies with respect to the performance of its obligations under this Agreement, MacroGenics shall have the right to conduct such additional audits as may be reasonably required by MacroGenics to determine whether Eversana has appropriately remedied such non-compliance. MacroGenics may exercise its audit right during the Term and &#91;***&#93;. The cost of such audit shall be borne by MacroGenics unless the audit reveals that Eversana has been overpaid as a result of an</font></div><div style="margin-top:7.85pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_112"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:6.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">inaccuracy in Eversana&#8217;s reports to MacroGenics &#91;***&#93;, in which case Eversana shall reimburse MacroGenics for any third party costs reasonably incurred in connection with the audit, &#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;CONFIDENTIALITY</font></div><div style="margin-top:0.05pt;padding-left:33.1pt;text-indent:-28.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Maintaining Confidentiality. Confidential Information disclosed under this Agreement shall remain the property of the Disclosing Party. At all times during the Term &#91;***&#93;, the Receiving Party shall use the Confidential Information solely for the purposes set forth in this Agreement and shall not disclose such Confidential Information to any Third Party except as permitted under this Agreement or with the Disclosing Party&#8217;s prior written consent. The Receiving Party shall use at least the same care for maintaining confidentiality of the Confidential Information as it uses to maintain the confidentiality of its own Confidential Information of similar value, but in no event less than commercially reasonable measures within the pharmaceutical industry.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exceptions to Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Receiving Party&#8217;s obligations set forth in this Agreement shall not extend to any Confidential Information of the Disclosing Party that the Receiving Party can demonstrate by competent evidence&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.1pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;was in the Receiving Party&#8217;s possession and at its free disposal prior to disclosure by the Disclosing Party&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;was in the public domain at the time of disclosure by the Disclosing Party&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;subsequently comes into the public domain through no fault, action or omission of the Receiving Party in breach of this Agreement&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.25pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;becomes available to the Receiving Party without any obligation of confidentiality from a Third Party that is not known to have a confidentiality obligation to the Disclosing Party&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;was developed independently by the Receiving Party without use of or reliance on any Confidential Information disclosed or furnished by the Disclosing Party, as evidenced by the Receiving Party&#8217;s contemporaneously-maintained written records.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Receiving Party may disclose Confidential Information, including the Agreement Details, to the extent that such disclosure is&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;to its directors, officers, employees, advisers, consultants, attorneys, auditors, agents, contractors, or representatives that reasonably need to know the information for the purposes set out in this Agreement, and who are subject to obligations of confidentiality and non-use substantially as protective as those set forth in this Agreement&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_115"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:5.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;to its Affiliates, including their directors, officers, employees, advisors, consultants, agents, contractors or representatives, to the extent they reasonably need to know the information for the purposes set out in this Agreement, and who are subject to confidentiality and non- use obligations substantially as protective as those set forth in this Agreement&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.8pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;to its directors, officers, employees, advisers, consultants, legal counsel or auditors who need to know the Confidential Information for the purpose of the Receiving Party&#8217;s internal compliance or auditing functions and who are subject to obligations of confidentiality and non-use substantially as protective as those set forth in this Agreement&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;&#91;***&#93;, who are subject to confidentiality and non-use obligations substantially as protective as those set forth in this Agreement&#59; except that with respect to Third Party investors, under obligations of confidentiality and non-use that are typical for the circumstances&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.8pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;&#91;***&#93; who are subject to obligations of confidentiality and non-use substantially as protective as those set forth in this Agreement&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.7pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;as required by laws, rules of public stock exchanges or court orders, provided that the Receiving Party may disclose only such portion of the Confidential Information as is legally required, and provided further that (i) the Receiving Party shall provide the Disclosing Party with as much advance written notice of such requirement as is reasonably possible and a reasonable opportunity to object to or limit such disclosure, and (ii) at the Disclosing Party&#8217;s request and expense, cooperates with the Disclosing Party&#8217;s lawful efforts to contest such requirement or to obtain a protective order or other confidential treatment of the Confidential Information required to be disclosed. The Parties shall coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with any securities authority or other Governmental Authority or any stock exchange on which securities issued by a Party or its Affiliate are traded, and each Party will use reasonable efforts to seek and obtain confidential treatment for the terms proposed to be redacted&#59; provided, that nothing herein shall prevent a Party from making disclosures to any securities authority or stock exchange, as the case may be, to the extent such Party determines, on the advice of legal counsel, that disclosure is reasonably necessary to comply with Applicable Laws, including disclosure requirements of the U.S. Securities and Exchange Commission, or with the requirements of any stock exchange on which securities issued by a Party or its Affiliates are traded&#59; and provided further that the Parties will use their reasonable efforts to file redacted versions with any Governmental Authorities which are consistent with redacted versions previously filed with any other Governmental Authority.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Return or Destruction of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On or after the effective date of the expiration or termination of this Agreement for any reason, at the Disclosing Party&#8217;s written</font></div><div style="margin-top:9.6pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_118"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:6.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">request, the Receiving Party shall either, with respect to Confidential Information to which such Receiving Party does not retain rights under the surviving provisions of this Agreement&#58;</font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;promptly destroy all copies of such Confidential Information in the possession or control of the Receiving Party and confirm such destruction in writing to the Disclosing Party&#59; or</font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;promptly deliver to the Disclosing Party, at the Receiving Party&#8217;s sole cost and expense, all copies of such Confidential Information in the possession or control of the Receiving Party. Notwithstanding the foregoing, the Receiving Party shall be permitted to retain such Confidential Information (i) to the extent necessary or useful for purposes of performing any continuing obligations or exercising any ongoing rights hereunder and, in any event, a single copy of such Confidential Information for archival purposes, and (ii) any computer records or files containing such Confidential Information that have been created solely by the Receiving Party&#8217;s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with the Receiving Party&#8217;s standard archiving and back-up procedures, but not for any other uses or purposes. All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section 11.1.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.5.&#160;&#160;&#160;&#160;Use of Name and Disclosure of Agreement Details.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to this Section 11.5, except as necessary to perform a Party&#8217;s obligations under this Agreement or as expressly permitted under this Agreement, each Party (a) shall keep the existence, terms, and the subject matter (including the applicable transactions) covered by this Agreement confidential and shall not disclose such information to any other Person through a press release or otherwise, and (b) shall not mention or otherwise use the name or any trademark of the other Party or its Affiliates in connection with this Agreement, in each case ((a) and (b)), without the prior written consent of the other Party in each instance (which shall not be unreasonably withheld, conditioned or delayed). The restrictions imposed by this Section 11.5 shall not prohibit either Party from making any disclosure identifying the other Party that is required by Applicable Law or the requirements of a national securities exchange or another similar regulatory body, provided that any such disclosure shall be governed by Section 11.3f. Nor shall the restrictions imposed by this Section 11.5 prohibit either Party from announcing this Agreement to the public promptly following the Effective Date, including such key terms and other items appropriate for such a public release, in each case subject to the written consent of the other Party, which shall not be unreasonably withheld. Further, the restrictions imposed on each Party under this Section 11.5 are not intended, and shall not be construed, to prohibit a Party from (x) identifying the other Party in its internal business communications, provided that any Confidential Information in such communications remains subject to this Article 11, or (y) disclosing (i) information for which consent has previously been obtained, and (ii) information of a similar nature to that which has been previously disclosed publicly with respect to this Agreement, each of which ((i) and (ii)) shall not require advance approval.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party represents and warrants to the other Party that as of the Effective Date&#58;</font></div><div style="padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_121"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:6pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;it is duly organized, validly existing in good standing under the laws of the place of its establishment or incorporation&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;it has full authority to enter into this Agreement and to perform its obligations under this Agreement and the provisions of this Agreement are legally binding upon it from the Effective Date&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;its execution of this Agreement and performance of its obligations under it will not violate</font></div><div style="padding-left:40.4pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any provision of its business license, articles of incorporation, articles of association or similar organizational documents&#59; (ii) any Applicable Laws or any authorization or approval from a Governmental Authority&#59; and (iii) any contract to which it is a party or to which it is subject, or result in a default under any such contract&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.1pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;no lawsuit, arbitration or other legal or governmental proceeding is pending or, to its knowledge, threatened against it that would affect its ability to perform its obligations under this Agreement&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.1pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;it has not been debarred and is not subject to debarment pursuant to Section 306 of the Act or who is the subject of a conviction described in such section&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.25pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;it and its Affiliates are in compliance with (x) the PhRMA Code on Interactions with Healthcare Professionals and (y) all state codes or requirements that limit or regulate interactions with HCPs&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.7pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;it has not been debarred, suspended or excluded from any federal health care program, including Medicare, Medicaid and the Civilian Health and Medical Program of the Uniformed Services. If it or any of its employees who are involved in performing the Services or working with the other Party in connection with the program described herein, is debarred, suspended or excluded during the Term or such Party reasonably believes debarment, suspension or exclusion is contemplated, such Party shall immediately notify the other Party in writing upon it becoming aware of such debarment, suspension or exclusion. If a Party is so debarred, suspended or excluded, or in the case of any employee of such Party who is debarred, suspended or excluded, if the applicable Party permits such employee to continue to perform any Services or work on the program described herein, then the other Party shall have the right to terminate this Agreement upon written notice to such Party. Any termination of this Agreement pursuant to this Section 12.1.g shall be treated as a termination by the terminating Party pursuant to Section 14.2.d as if the other Party had committed a material breach, except that in such event no cure period shall apply and the terminating Party shall have the right to effect such termination immediately upon written notice to other Party&#59; and</font></div><div><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.15pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.&#160;&#160;&#160;&#160;it will comply in all material respects with Applicable Laws in performing its obligations and exercising its rights hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. MacroGenics represents and warrants to Eversana that as of the Effective Date&#58;</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_124"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:40.4pt;padding-right:5.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;MacroGenics has not received any written communication alleging that the manufacture, packaging, distribution, sale or use of the Product in the Territory, or that the use of any registered trademark or registered copyright within the Product Trademarks, Corporate Trademarks or Product Copyrights, infringes or misappropriates the Intellectual Property Rights or other rights of any Third Party&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.2pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;MacroGenics has the right to Commercialize the Product in the Territory and to grant to Eversana the right to provide the Services as set forth herein.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana&#8217;s Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Eversana represents and warrants to MacroGenics that as of the Effective Date&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.2pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;it has adequate cash flow and otherwise has the financial resources, capacity and capabilities to timely and adequately perform its obligations hereunder&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;it has not received written notice from any Third Party alleging that the use of the Eversana Pre-Existing Know-How infringes or misappropriates the Intellectual Property Rights or other rights of any Third Party&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.25pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;except as would not reasonably be expected to have a material adverse effect on the performance of the Services, (i) as of the Effective Date, neither it nor any of its Affiliates</font></div><div style="padding-left:40.4pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x) is being investigated, and there are no ongoing investigations, by any Regulatory Authority or other Governmental Authority in the Territory specifically or primarily relating to the promotion of any pharmaceutical or biologic product in the Territory, nor (y) has it or any of its Affiliates received written notice that any Regulatory Authority or other Governmental Authority in the Territory intends to conduct any such investigation, and (ii) neither it nor any of its Affiliates (x) is a party or the subject of any action, suit or other proceeding (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that is pending as of the Effective Date or was pending or filed at any time &#91;***&#93;, that alleges that it or any of its Affiliates have violated any Applicable Laws in the Territory in connection with the promotion of any pharmaceutical or biologic product in the Territory, nor (y) has it or any of its Affiliates received any threats in writing of any such Proceeding as of the Effective Date or at any time &#91;***&#93;&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.05pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;there is no action, suit, proceeding or investigation pending or, to its knowledge, threatened before any court or administrative agency against MacroGenics or its Affiliates which could, directly or indirectly, reasonably be expected to materially affect its ability to perform its obligations hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:5.5pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DISCLAIMER OF WARRANTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_127"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WITHOUT LIMITATION OF THE FOREGOING, MACROGENICS MAKES NO WARRANTY THAT THE BLA APPROVAL WILL OCCUR, THAT THE PRODUCT WILL BE SUCCESSFUL OR THAT EVERSANA WILL RECEIVE ANY, OR ANY AMOUNT OF, ADJUSTED REVENUE SHARE PAYMENTS.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;INDEMNIFICATION, LIMITATION OF LIABILITY AND INSURANCE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Mutual Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall indemnify, hold harmless and defend the other Party, its Affiliates, and its and their respective directors, officers, employees, representatives and agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), from and against any and all losses, damages, liabilities, judgments, fines, and amounts paid in settlement, including any associated costs and expenses, including reasonable attorneys&#8217; fees (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), to which any Indemnitee may become subject as a result of any claim, demand, suit, action or proceeding brought or initiated by a Third Party against them (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the extent that such Losses arise out of&#58; (a) the negligence, fraud or willful misconduct of any of the Indemnitor, its Affiliates, or its or their respective directors, officers, employees, representatives and agents in performing any obligations under this Agreement&#59; or (b) a breach by the Indemnitor of any representation, warranty, covenant or other agreement made by the Indemnitor in this Agreement&#59; except, in each case, to the extent such Losses result from the negligence, recklessness or willful misconduct of any Indemnitee or the breach by any Indemnitee of any warranty, representation, covenant or agreement made by the Indemnitee in this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.2.&#160;&#160;&#160;&#160;MacroGenics Indemnity.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;MacroGenics shall indemnify, hold harmless and defend Eversana, its Affiliates, and its and their respective directors, officers, employees, representatives and agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from and against any and all Losses to which any Eversana Indemnitee may become subject as a result of any Claim to the extent that such Losses arise out of any infringement of the Intellectual Property Rights of a Third Party based on the Commercialization of the Product under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;The Parties hereto acknowledge that Eversana has not had and will not have any role in the development, Manufacture, selection of a brand name, labeling or packaging of the Product and that, as between the Parties, MacroGenics shall have the sole liability for any product liability or similar claims (regardless of the legal theory (including but not limited to strict liability) upon which such claims may be brought) with respect to Product. Accordingly, MacroGenics shall indemnify, hold harmless and defend Eversana Indemnitees from and against any and all Losses to which any Eversana Indemnitee may become subject as a result of any Claim caused by or attributable in whole or part to, or alleged to have been caused by or attributable in whole or part to&#58;</font></div><div><font><br></font></div><div style="padding-left:95pt;padding-right:6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any defect(s) in the Manufacture of any Product, inherent safety risks of any Product or dangerous side effects of the Product&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Manufacturing, selection of a brand name, labeling and packaging of the Product&#59; &#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_130"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:95pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any actual or asserted violation of the Federal Food, Drug and Cosmetic Act or any other Applicable Law by virtue of which the Product is alleged or determined to be adulterated, misbranded, mislabeled or otherwise not in full compliance with Applicable Law&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Eversana&#8217;s use of or reliance, in accordance with this Agreement, upon&#58; (A) the Prescribing Information as determined by the FDA&#59; or (B) and Promotional Materials&#59; or (C) Other Materials provided by MacroGenics hereunder or otherwise authorized or approved by MacroGenics under this Agreement for use by Eversana in performing the Services.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;MacroGenics shall indemnify, hold harmless and defend Eversana Indemnitees from and against any and all Losses incurred by Eversana in connection with any of the following events or circumstances, except to the extent that a breach by Eversana of its express obligations or covenants contained in this Agreement is a cause of such event or occurrence&#58; (i) any inspection, investigation or inquiry by any Regulatory Authority or other Governmental Authority regarding or directed to MacroGenics or the Product or its business practices&#59; or (ii) any court, Regulatory Authority or Governmental Authority order, subpoena, interrogatory, demand, request for admission or other process of law directed to Eversana and specifically attributable to MacroGenics or its Product or business practices.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any indemnified party submitting an indemnity claim under this Section 13, as applicable (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall&#58; (a) promptly notify the indemnifying Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), of such claim in writing and furnish the Indemnifying Party with a copy of the applicable communication, notice or other action relating to the event for which indemnity is sought&#59; provided, that no failure to provide such notice pursuant to this clause</font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;shall relieve the Indemnifying Party of its indemnification obligations, except to the extent such failure materially prejudices the Indemnifying Party&#8217;s ability to defend or settle the claim&#59; (b) give the Indemnifying Party the authority, information and assistance necessary to defend or settle such suit or proceeding in such a manner as the Indemnifying Party shall determine&#59; and (c) give the Indemnifying Party sole control of the defense (including the right to select counsel, at the Indemnifying Party&#8217;s expense) and the sole right to compromise and settle such suit or proceeding&#59; provided, however, that in the case of the foregoing clauses (b) and (c), the Indemnifying Party shall not, without the written consent of the Indemnified Party, compromise or settle any suit or proceeding unless such compromise or settlement (i) is solely for monetary damages (for which the Indemnifying Party shall be responsible), (ii) does not impose injunctive or other equitable relief against the Indemnified Party, (iii) does not acknowledge any fault by the Indemnified Party, and</font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:6.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;includes an unconditional release of the Indemnified Party from all liability on claims that are the subject matter of such proceeding. The Indemnified Party (in its capacity as such) may participate in the defense at its own expense.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.5pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW AND EXCEPT IN THE CASE OF FRAUD OR WILLFUL MISCONDUCT, OR A BREACH OF ARTICLE 11, NEITHER PARTY NOR ANY OF ITS</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.8pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_133"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY OR THEIR AFFILIATES, FOR ANY CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE, INDIRECT OR MULTIPLE DAMAGES, AND OTHER THAN MACROGENICS&#8217;S PAYMENT OBLIGATIONS HEREUNDER, FOR&#58; (i) LOSS OF PROFITS, REVENUE OR INCOME, DIMINUTION IN VALUE OR LOSS OF BUSINESS OPPORTUNITY (IN EACH CASE, WHETHER OR NOT FORESEEABLE AT THE EFFECTIVE DATE) OR (ii) ANY DAMAGES CALCULATED BY REFERENCE TO A MULTIPLIER OF REVENUE, PROFITS, OR SIMILAR METHODOLOGY, CONNECTED WITH OR RESULTING FROM ANY BREACH OF THIS AGREEMENT, OR ANY ACTIONS UNDERTAKEN IN CONNECTION WITH, OR RELATED HERETO, INCLUDING ANY SUCH DAMAGES WHICH ARE BASED UPON BREACH OF CONTRACT, TORT, BREACH OF WARRANTY, STRICT LIABILITY, STATUTE, OPERATION OF LAW OR ANY OTHER</font></div><div style="padding-left:33.3pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THEORY OF RECOVERY&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the foregoing shall not be construed to limit either Party&#8217;s indemnification obligations set forth above in this Section 13.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:32pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EACH PARTY FURTHER ACKNOWLEDGES AND AGREES THAT EACH PARTY&#8217;S &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the foregoing shall not be construed to limit either Party&#8217;s indemnification obligations set forth above in this Section 13 or either Party&#8217;s liability in the case of fraud or willful misconduct.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall at all times maintain general liability insurance policies or self- insurance in such amounts and with such scope of coverage as are normal and customary in the pharmaceutical industry for a Person of comparable size and engaged in activities comparable to the activities in which such Party engages hereunder. As of the BLA Approval Date, MacroGenics shall maintain Product Liability insurance &#91;***&#93;, it being understood and agreed that Eversana shall not need to obtain any product liability insurance during the Term. If requested by the other Party, the insured Party shall furnish a certificate of insurance or other reasonable proof of coverage (which may be a certificate or other evidence issued by a Party under a program of self-insurance) evidencing the requisite coverage required under this Section 13.5 during the Term. The insurance policies shall be under an occurrence form, but if only a claims-made form is available to a Party, then such Party shall continue to maintain such insurance after the expiration or termination of this Agreement for a period of &#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;TERM AND TERMINATION</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Agreement shall take effect as of the Effective Date and shall remain in effect for a term of five (5) years from the BLA Approval Date unless earlier terminated as provided hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_136"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be terminated as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination for Late Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Eversana shall have the right to terminate this Agreement if BLA Approval does not occur by June 30, 2021 by providing written notice thereof &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.55pt;padding-left:40.4pt;padding-right:5.9pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination for Revenue Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At any time after &#91;***&#93; following the date of Commercial Launch (the date when such period ends, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue Measurement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), either Party shall be entitled to terminate this Agreement if Net Profits are &#91;***&#93;, by providing the other Party with &#91;***&#93; prior written notice.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.4pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination for Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No earlier than twenty four (24) months from the BLA Approval Date, MacroGenics may terminate this Agreement by providing Eversana with &#91;***&#93; (which notice may not be provided earlier than &#91;***&#93;) and making a one-time payment to Eversana equal to the difference between&#58; (i) one hundred twenty-five percent (125%) of the sum of the cumulative Reconciled Reimbursed Commercial Costs received by Eversana and the cumulative Reconciled Unreimbursed Commercial Costs incurred by Eversana, in each case during the thirty (30) month period following the BLA Approval Date&#59; and (ii) the sum of the cumulative Reconciled Reimbursed Commercial Costs and the cumulative Adjusted Revenue Share Payments received by Eversana or payable to Eversana up to the effective date of such termination. However, &#91;***&#93;, then no payment shall be due to Eversana pursuant to this Section 14.2.c.</font></div><div style="padding-left:33.3pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.4pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination upon Material Breach. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Either Party may terminate this Agreement if the other Party materially breaches this Agreement, and such breach is not cured &#91;***&#93; from the other Party of written notice specifying in detail the nature and extent of the alleged material breach.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.8pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination for Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Either Party may terminate this Agreement &#91;***&#93; on written notice if the other Party (or, if applicable, a parent of such other Party) shall file in any court or Governmental Authority, pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the other Party or of its assets, or if the other Party (or, if applicable, a parent of such other Party) shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall &#91;***&#93;, or if the other Party (or, if applicable, a parent of such other Party) shall be a party to any dissolution or liquidation, or if the other Party (or, if applicable, a parent of such other Party) shall make a general assignment for the benefit of its creditors.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.65pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination for MacroGenics Change of Control. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of a MacroGenics Change of Control, MacroGenics will have the option to terminate this Agreement by</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">47</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_139"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:40.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">providing Eversana &#91;***&#93; written notice of such termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COC Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;During the COC Notice Period, the Parties shall cooperate with each other to ensure an orderly transition of responsibilities for the Services to an entity specified by MacroGenics as the MacroGenics Change of Control Partner.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93; of providing Eversana with written notice of such termination, MacroGenics shall pay Eversana for any unpaid Services rendered through the date of such notice, which shall be defined as follows&#58; (x) if the &#91;***&#93; through the date of such notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> less</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the cumulative &#91;***&#93;, provided that if such calculated amount is a negative number, then no payment shall be due to Eversana pursuant to this subsection&#59; or (y) if the &#91;***&#93;, any unpaid &#91;***&#93; due to Eversana for performance of the Services through the date of such notice.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Following written notice of  termination  by  MacroGenics  under  this  Section 14.2.f, MacroGenics (x) shall cease making &#91;***&#93;, and (y) shall be invoiced for &#91;***&#93; for the Services performed during the COC Notice Period, such amounts to be paid in advance of the Services &#91;***&#93;.</font></div><div style="padding-left:33.3pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;If (x) the &#91;***&#93; of the &#91;***&#93; earned by Eversana for Services performed during the COC Notice Period is &#91;***&#93; and the &#91;***&#93;, the sum of the &#91;***&#93; earned by Eversana) &#91;***&#93;, then MacroGenics shall make an &#91;***&#93;, provided that if such &#91;***&#93; is more than such &#91;***&#93;, then no payment shall be due to Eversana pursuant to this subsection. Such &#91;***&#93; shall be due once the applicable Commercialization responsibilities have been transitioned back to MacroGenics and&#47;or the MacroGenics Change of Control Partner, but in any event, &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.75pt;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;Either Party may terminate this Agreement &#91;***&#93; to the other Party if&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:6.05pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Product is subject to a recall in the Territory based on material safety concerns and such recall continues &#91;***&#93;&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_142"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:95pt;padding-right:6.15pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;MacroGenics withdraws the Product from the market in the Territory for a &#91;***&#93;&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Commercial Launch has not occurred &#91;***&#93;, provided that a written notice of termination is given &#91;***&#93;, and provided further that the foregoing termination right shall not be available to Eversana if Commercial Launch has not occurred within such time period due primarily to Eversana&#8217;s failure to perform its obligations under this Agreement&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;there is any change in Applicable Law that makes performance of a Party&#8217;s material obligations as contemplated in this Agreement illegal or commercially impractical.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.3.&#160;&#160;&#160;&#160;Effect of Termination or Expiration.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.1pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Upon the expiration or termination of this Agreement, the following terms and conditions shall apply, subject in all cases to Section 14.3.b below&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The appointment of Eversana to perform the Services under Section 2.1 shall terminate and Eversana shall promptly cease all performance of the Services.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The licenses granted to Eversana under Section 2.2 shall terminate and Eversana shall promptly discontinue the use of any MacroGenics Know-How, Product Trademarks, Product Copyrights, and Corporate Trademarks.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;At MacroGenics&#8217;s election and subject to compliance with Section 10.3, Eversana either shall (x) promptly return to MacroGenics, or (y) promptly destroy and certify to MacroGenics such destruction of, all Arising Product Know-How, Materials and other documentation related to the Product or the activities provided for by this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;At MacroGenics&#8217; request, Eversana either shall (x) destroy or (y) return any remaining Product supply.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:6.25pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof shall not limit any remedies that may otherwise be available in law or equity.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accrued Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration, including, without limitation, each Party&#8217;s rights to any amounts owed by the other Party hereunder. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement. If payments attributable to Services or reconciliations under Section 5.2.b performed before the termination or expiration remain unpaid upon the termination or expiration of the Agreement, including but not limited to reimbursement of Reconciled Reimbursed Commercial Costs (if applicable) and Adjusted Revenue Share Payments, the</font></div><div style="margin-top:4.8pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">49</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_145"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:6.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party owing such payments shall make such payments promptly after the termination or expiration of this Agreement. In the event of termination, Eversana will use reasonable efforts to terminate work being performed by Approved Subcontractors and other related commitments entered into by Eversana but MacroGenics will be responsible for all non-refundable costs and non-cancelable commitments incurred by Eversana with respect thereto (according to the Commercialization Budget if such termination occurs before the occurrence of the Revenue Threshold).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.65pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The rights and obligations of the Parties set forth in Section 1 (Definitions), Section 2.3 (Retained Rights), Section 2.4 (Other Rights and Obligations), Section 2.6 (Assignment of Arising Product Know-How) the last sentence of Section 3.6.c (Eversana Personnel and Training) (to the extent relating to MacroGenics&#8217;s ownership of all Training Materials and all copyrights therein), Section 3.8 (Employment Covenants), Section 3.9 (Materials) (to the extent relating to MacroGenics&#8217;s ownership of all Materials and all copyrights therein), Section 3.13 (Information Data Security Privacy), Article 5 (Fees and Payments) (subject to Section 14.4 above), Section 6.1 (Ownership of Regulatory Documentation and Approvals), Section 7.3 (Recalled Product) Section 8.4 (Notice of Investigations), Section 9.6, Section 9.7 (Limitations), Section 10.1 (MacroGenics Records), Section 10.2 (Audits of MacroGenics), Section 10.3 (Eversana Records), Section 10.4 (Audits of Eversana), Section 11 (Confidentiality), Section 12.4 (Disclaimer of Warranties), Section 13 (Indemnification, Limitation of Liability and Insurance), Section 14.2 (Termination), Section 14.3 (Effect of Termination or Expiration), Section 14.4 (Accrued Rights), Section 14.5 (Survival), Section 15 (Notice), and Section 16 (General Provisions) shall survive the termination or expiration of this Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;NOTICE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any notice or written communication provided for in this Agreement by a Party to the other Party, including but not limited to any and all offers, writings, or notices to be given hereunder, shall be made by registered mail or by courier service delivered letter, promptly transmitted or addressed to the appropriate Party. The date of receipt of a notice or communication hereunder shall be the date of delivery confirmed by the USPS or the courier service in the case of a courier service delivered letter. All notices and communications shall be sent to the appropriate address set forth below, until the same is changed by notice given in writing to the other Party effective as above</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notice to MacroGenics&#58;</font></div><div style="padding-left:186.45pt;padding-right:160.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Address&#58;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_148"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="padding-left:186.45pt;padding-right:162.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With a copy to&#58;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div><font><br></font></div><div style="padding-left:185.05pt;padding-right:172.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notice to Eversana&#58;&#160;&#160;&#160;&#160;&#91;***&#93; Address&#58;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div><font><br></font></div><div style="padding-left:185.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With a copy to&#58;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-top:11.1pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise set out in this Agreement, no Party to this Agreement shall have any liability whatsoever or (without prejudice to any payments of monies due) be deemed to be in default for any delays or failures in performance of any of its obligations under this Agreement to the extent such delay or failure is caused by or results from causes beyond the reasonable control of the affected Party, potentially including pandemics. embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any Governmental Authority (including government shut down) or the other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical. The affected Party shall use all commercially reasonable efforts to remedy the event or limit the effects of the said event of force majeure upon the other Party in a timely manner. When such circumstances arise, the Parties shall negotiate in good faith any modifications of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution. If any force majeure event continues &#91;***&#93; that prevents the performance of any material obligation of or receipt of any material benefit (including, without limitation, payment) by a Party under this Agreement, the Party not affected by the force majeure event shall have the right to terminate this Agreement upon &#91;***&#93; to the other Party.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall in all respects be governed by and interpreted according to the laws of the State of New York and the United States without regard to or application of conflict-of-law rules or principles.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_151"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.3.&#160;&#160;&#160;&#160;Dispute Resolution.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:40.3pt;padding-right:5.55pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;In the event that there is a dispute, controversy, or claim between the Parties arising out of or relating to this Agreement, or its interpretation, performance, nonperformance or any breach of any respective obligations hereunder, excluding any dispute at the JMC level (to which the procedures in Section 4.4 shall apply), then the Parties shall seek to resolve such dispute through prompt negotiations between the Executive Officers. The Executive Officers will meet in-person and use good faith efforts to resolve any such dispute (for clarity, excluding any dispute at the JMC level) &#91;***&#93;. If the Executive Officers are unable to resolve such dispute within &#91;***&#93;, then either Party may have the dispute settled by binding arbitration pursuant to Section 16.3.b.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:5.8pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;A Party intending to commence an arbitration proceeding to resolve a dispute must first provide written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Arbitration Request</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the other Party of such intention, setting forth the issues for resolution. From the date of the Arbitration Request until such time as the dispute has become finally settled, the time period during which a Breaching Party must cure an alleged breach that is the subject matter of the dispute shall be suspended.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.9pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Unless otherwise agreed by the Parties, either Party may bring an action in any court of competent jurisdiction to resolve disputes pertaining &#91;***&#93;, and no such claim shall be subject to arbitration pursuant to this Section, and &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.7pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The arbitration shall be held &#91;***&#93;. The arbitration shall be conducted &#91;***&#93;, (b) not be or have been an employee, consultant, officer, director or stockholder of either Party or any Affiliate of either Party, and (c) not have a conflict of interest under any applicable rules of ethics. The arbitrator shall be selected by mutual agreement of the Parties, provided that if the Parties cannot agree on the arbitrator &#91;***&#93;, the arbitrator shall be selected by the &#91;***&#93;. The arbitrator may proceed to an award, notwithstanding the failure of either Party to participate in the proceedings. The arbitrator shall, &#91;***&#93;, issue a written award. The arbitrator shall be authorized to &#91;***&#93;. The arbitrator also shall be authorized to &#91;***&#93;, but is not authorized</font></div><div style="margin-top:7.85pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">52</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_154"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:95pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to reform, modify or change this Agreement. The award of the arbitrator &#91;***&#93;, and &#91;***&#93; that are the subject of the arbitration proceeding and the award (except for those remedies set forth in this Agreement)&#59; provided, however, &#91;***&#93;. Judgment on the award rendered by the arbitrator may be enforced in any court having competent jurisdiction thereof following the conclusion of the appeal process or the expiration of time for filing a notice of appeal pursuant to the Appellate Rules, whichever is later. Notwithstanding anything contained in this Section 16.3.b to the contrary, each Party shall have the right to institute judicial proceedings against the other Party or anyone acting by, through or under such other Party, in order to confirm an award of the arbitrator, to enforce the instituting Party&#8217;s rights hereunder through specific performance, injunction or other equitable relief, or to collect any monetary award of the arbitrator.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:95pt;padding-right:5.8pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Each Party shall bear its own attorneys&#8217; fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:95pt;padding-right:6.05pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrators on the ultimate merits of any dispute.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:95pt;padding-right:6pt;text-align:justify;text-indent:-36.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;All proceedings and decisions of the arbitrators shall be deemed Confidential Information of each of the Parties, and shall be subject to Article 11.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.65pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement together with the Exhibits attached hereto, constitutes the entire agreement between the Parties relating to the subject matter hereof and supersedes all prior agreements, understandings and discussions, whether oral or written, of the Parties with respect to the subject matter hereof, including the &#91;***&#93;. All activities undertaken by the Parties under the &#91;***&#93; under this Agreement and governed and subject to the terms and conditions of this Agreement. Any modification of this Agreement shall be effective only when in writing and signed by the Parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither Party may assign this Agreement without the prior written consent of the other Party, except either Party may assign this Agreement in whole or in part to any Affiliate of such Party without the consent of the other Party. Further, either Party may assign this Agreement, and all of its rights and obligations, without the consent of the other Party, to its successor in interest by way of merger, acquisition, or sale of all or substantially all of its business or assets&#59; provided, that the assigning Party provides the other Party with written notice of such assignment &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_157"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any provision contained in this Agreement shall, for any reason, be held invalid, illegal or unenforceable, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement, but this Agreement shall be construed by limiting such invalid, illegal or unenforceable provision, or if such is not possible, by deleting such invalid, illegal or unenforceable provision from this Agreement&#59; provided that (a) such provision shall be deemed to be replaced by a provision which achieves the original intent of the Parties to the fullest extent possible&#59; (ii) should this Agreement as a result of such deletion no longer reasonably correspond to the good faith intent of the Parties, either Party may propose amendments to the other provisions of this Agreement in order to have the Agreement correspond to such good faith intent and the Parties shall negotiate in good faith such amendments.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:6.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No course of dealing or failing of either Party to strictly enforce any term, right or condition of this Agreement in any instance shall be construed as a general waiver or relinquishment of such term, right or condition. Such waiver or relinquishment (either generally or any given instance and either retroactively or prospectively) shall only be effective if made expressly in writing by the Party with reference to the specific term, right or condition.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:6pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Third Party Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement are for the sole benefit of the Parties, their successors and permitted assignees, and they shall not be construed as conferring any rights in any other Persons except as otherwise expressly provided in this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this Agreement to the singular shall include the plural where applicable. The term &#8220;including&#8221; or &#8220;includes&#8221; as used in this Agreement means including, without limiting the generality of any description preceding such term, and the word &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and&#47;or.&#8221; Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection. All references to days in this Agreement shall mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its interpretation. In addition, all notices, reports and disclosures required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement, shall be in the English language.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;padding-right:5.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Costs and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall, unless specifically otherwise agreed hereunder, bear their own costs and expenses connected with such Party&#8217;s activities and performance under this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_160"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:33.3pt;padding-right:5.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement &#91;***&#93;, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile or electronically transmitted signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.67pt;padding-right:96.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">55</font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_163"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics, Inc.</font></div><div style="padding-left:5pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></div><div style="margin-top:0.05pt;padding-left:5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eversana Life Science Services, LLC</font></div><div style="padding-left:5pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Gregory Skalicky</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Gregory Skalicky</font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Chief Revenue Officer</font></div><div><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_166"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.65pt;padding-right:96.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:46pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_169"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.6pt;padding-right:96.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_172"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:168.15pt;padding-right:168.15pt;text-align:center;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT C </font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="height:57pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_175"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT D </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="height:57pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_178"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.6pt;padding-right:96.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT E</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">***&#93;</font></div><div style="height:57pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_181"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:151.9pt;padding-right:90.75pt;text-indent:56.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT F </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%">&#91;***&#93;</font></div><div style="height:58pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_184"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:99.3pt;padding-right:90.75pt;text-indent:107.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT G </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:58pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_187"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:145.05pt;padding-right:141.6pt;text-indent:62.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT H INFORMATION DATA SECURITY</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:27.55pt;text-indent:-22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Definitions</font></div><div><font><br></font></div><div style="padding-left:23pt;padding-right:5.85pt;text-align:justify;text-indent:17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Authorized Persons&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means Eversana&#8217;s employees, contractors, subcontractors, agents, representatives and auditors who have a need to know or otherwise access Secure Information to enable Eversana to perform its obligations under the Product Commercialization Agreement, and who are bound in writing by confidentiality and other obligations sufficient to protect Secure Information in accordance with the terms and conditions of the Product Commercialization Agreement.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:23pt;padding-right:5.75pt;text-align:justify;text-indent:17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Data Breach&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any unauthorized access to or disclosure or acquisition of Secure Information.</font></div><div><font><br></font></div><div style="padding-left:23pt;padding-right:5.85pt;text-align:justify;text-indent:17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Personal Information&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means information that Eversana receives pursuant to providing the Services that&#58; (a) directly or indirectly identifies an individual (including, for example, names, signatures, addresses, telephone numbers, email addresses, and other unique identifiers)&#59; or (b) can be used to authenticate an individual (including, without limitation, employee identification numbers, and other personal identifiers), in case of both subclauses (a) and (b), including Sensitive Personal Information as defined herein. MacroGenics&#8217; or Eversana&#8217;s business contact information is not by itself Personal Information.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:23pt;padding-right:5.9pt;text-align:justify;text-indent:17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Secure Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Confidential Information and Sensitive Personal Information.</font></div><div><font><br></font></div><div style="padding-left:23pt;padding-right:5.65pt;text-align:justify;text-indent:17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Security Incident&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any act or omission that materially compromises the security, confidentiality, or integrity of Secure Information stored or managed on MacroGenics behalf or the physical, technical, administrative, or organizational safeguards put in place by Eversana (or any Authorized Persons), that relate to the protection of the security, confidentiality, or integrity of Secure Information. The parties agree that &#8220;Security Incident&#8221; does not include the existence and occurrence of unsuccessful Security Incidents, including, without limitation, activity such as pings and other broadcast attacks on Eversana&#8217;s firewall, port scans, unsuccessful log-on attempts, denial of service and any combination of the above, so long as no such unsuccessful Security Incident results in unauthorized access, use, disclosure, modification or destruction of Secure Information or interference with information system operations related to the Secure Information.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:23pt;padding-right:5.75pt;text-align:justify;text-indent:17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Sensitive Personal Information&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means an individual&#8217;s (a) state or government- issued identification number, including Social Security number, driver&#8217;s license number&#59; (b) financial or credit information&#59; or (c) biometric, genetic, health, or health insurance data</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:26.25pt;text-indent:-21.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Information Security.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:25.05pt;padding-right:6.2pt;text-align:justify;text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Eversana will comply with Applicable Laws in its creation, collection, receipt, access, use, storage, disposal, and disclosure of Secure Information.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:58pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%">Exhibit H-1</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_190"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:25.05pt;padding-right:5.75pt;text-align:justify;text-indent:15.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Eversana will employ commercially reasonable security measures to protect Secure Information in accordance with accepted applicable industry standards and Eversana&#8217;s information security policy as amended from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Information Security Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a current copy of which will be provided to MacroGenics upon written request. As necessary, Eversana will employ additional security measures to protect Secure Information.</font></div><div><font><br></font></div><div style="padding-left:25.05pt;padding-right:5.75pt;text-align:justify;text-indent:15.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Eversana agrees and warrants that it will implement administrative, physical and technical safeguards to protect Secure Information that are no less rigorous than accepted industry practices, including, as an example, the International Organizational Standardization's standards&#58; ISO 27001 and ISO 27002 or other applicable established industry standards for information security and shall ensure that all such safeguards comply with Applicable Laws, as well as the terms and conditions of the Product Commercialization Agreement. At a minimum, Eversana's safeguards for the protection of Secure Information shall include&#58; (i) limiting access of Secure Information to authorized employees and Authorized Persons&#59; (ii) securing business facilities, data centers, paper files, servers, back-up systems and computing equipment, including but not limited to all mobile devices and other equipment with information storage capability&#59; (iii) implementing network, device, application, database and platform security&#59; (iv) securing information transmission, storage and disposal&#59; (v) implementing authentication and access controls within media, applications, operating systems and equipment&#59; (vi) encrypting transmitted Secure Information pursuant to accepted industry practices&#59; (vii) strictly segregating Sensitive Personal Information from information from Eversana or its other customers so Sensitive Personal Information is not comingled&#59; (viii) implementing appropriate personnel security and integrity procedures and practices, including but not limited to, conducting background checks consistent with Applicable Laws and Regulations&#59; and (ix) providing privacy and information security training to Eversana&#8217;s Authorized Persons.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:26pt;text-indent:-21.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Data Breach or Security Incident Procedures.</font></div><div><font><br></font></div><div style="padding-left:27.55pt;padding-right:5.75pt;text-align:justify;text-indent:16.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Eversana currently maintains and will continue to maintain a cyber incident breach response plan in accordance with industry standards (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cyber Incident Response Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). &#91;***&#93; and Eversana will implement the procedures required under such Cyber Incident Response Plan on the occurrence of an actual Data Breach or Security Incident.</font></div><div><font><br></font></div><div style="padding-left:27.55pt;padding-right:5.95pt;text-align:justify;text-indent:16.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Eversana will provide MacroGenics with the &#91;***&#93; and &#91;***&#93; with an actual Data Breach of Security Incident.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:27.55pt;padding-right:5.9pt;text-align:justify;text-indent:16.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Eversana will &#91;***&#93; (i) an actual Data Breach or Security Incident or (ii) a potential Data Breach or Security Incident &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:58pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%">Exhibit H-2</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div><div id="id3c2354f6c9742398eb666febd80394a_193"></div><hr style="page-break-after:always"><div style="min-height:31pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:7%">DocuSign Envelope ID&#58; B8D54E84-77C2-4AF1-95CE-BF3693463974</font></div><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:27.55pt;padding-right:5.9pt;text-align:justify;text-indent:16.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#91;***&#93;, the parties will coordinate with each other, as necessary, to investigate the Data Breach or Security Incident in accordance with Eversana&#8217;s current Cyber Incident Response Plan.</font></div><div><font><br></font></div><div style="padding-left:27.55pt;padding-right:6pt;text-align:justify;text-indent:16.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;To the extent Eversana &#91;***&#93; Data Breach or Security Incident, Eversana &#91;***&#93; by an actual Data Breach or Security Incident.</font></div><div><font><br></font></div><div style="padding-left:27.55pt;padding-right:5.75pt;text-align:justify;text-indent:16.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Other than as required by Applicable Laws, Eversana agrees that &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:18.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Security Controls Review or Audit. &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As part of this assessment, MacroGenics will &#91;***&#93;. In the event of a Data Breach or Security Incident, MacroGenics &#91;***&#93;.</font></div><div style="height:58pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:7%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%">244253989 v3</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%">Exhibit H-3</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#92;&#92;BA - 043788&#47;000003 - 857958 v27</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>mgnxexhibit23-1202010xk.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie8e00e03433f490c9b7ede83fd04d918_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 23.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-192277) pertaining to the 2000 Stock Option and Incentive Plan, the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc.&#59; </font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-202470, Form S-8 No. 333-209812, Form S-8 No. 333-217620, Form S-8 No. 333-223682 and Form S-8 No. 333-230292, Form S-8 No. 333-237127) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-214386) pertaining to the 2016 Employee Stock Purchase Plan of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-249851) of MacroGenics, Inc.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;25, 2021, with respect to the consolidated financial statements of MacroGenics, Inc. and the effectiveness of internal control over financial reporting of MacroGenics, Inc.&#160;included in this Annual Report (Form 10-K) of MacroGenics, Inc. for the year ended December&#160;31, 2020.</font></div><div style="margin-top:18pt"><font><br></font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young LLP</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baltimore, Maryland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>mgnxexhibit31-1202010xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i18caa7b08a39472483fbc6354b8da281_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2020 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:126pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott&#160;Koenig</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;February&#160;25, 2021&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>mgnxexhibit31-2202010xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="idc1ae574f4eb41ef8495540d7a9d40a7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2020 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;February&#160;25, 2021&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>mgnxexhibit32-1202010xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6c90481cf49b4ff791173ff37d763c45_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2020 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig </font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  February&#160;25, 2021 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>mgnxexhibit32-2202010xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2358db9e163d422f82d6febe96efc484_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2020 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels&#160;&#160;&#160;&#160;</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>mgnx-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:027e117c-75c0-47f2-bc63-7ee727579094,g:55d8aba6-2c39-4104-9032-126eaff6334c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandNatureofOperations" roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations">
        <link:definition>2101101 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2110103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2311302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2412406 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails">
        <link:definition>2413407 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftware" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware">
        <link:definition>2114104 - Disclosure - Property, Equipment and Software</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareTables" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables">
        <link:definition>2315303 - Disclosure - Property, Equipment and Software (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareDetails" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails">
        <link:definition>2416408 - Disclosure - Property, Equipment and Software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://macrogenics.com/role/Leases">
        <link:definition>2117105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://macrogenics.com/role/LeasesTables">
        <link:definition>2318304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://macrogenics.com/role/LeasesNarrativeDetails">
        <link:definition>2419409 - Disclosure - Leases Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseCostsDetails" roleURI="http://macrogenics.com/role/LeaseCostsDetails">
        <link:definition>2420410 - Disclosure - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>2421411 - Disclosure - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>2421411 - Disclosure - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2122106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2423412 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://macrogenics.com/role/StockbasedCompensation">
        <link:definition>2124107 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://macrogenics.com/role/StockbasedCompensationTables">
        <link:definition>2325305 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2426413 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2427414 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2428415 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails">
        <link:definition>2429416 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://macrogenics.com/role/IncomeTaxes">
        <link:definition>2130108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://macrogenics.com/role/IncomeTaxesTables">
        <link:definition>2331306 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>2432417 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails">
        <link:definition>2433418 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>2434419 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements">
        <link:definition>2135109 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteCorporationDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails">
        <link:definition>2436420 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsServierDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails">
        <link:definition>2437421 - Disclosure - Collaboration and Other Agreements - Servier (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsZaiLabDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails">
        <link:definition>2438422 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsJanssenDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails">
        <link:definition>2439423 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails">
        <link:definition>2440424 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsRocheDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails">
        <link:definition>2441425 - Disclosure - Collaboration and Other Agreements - Roche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsProventionDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails">
        <link:definition>2442426 - Disclosure - Collaboration and Other Agreements - Provention (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2443427 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails">
        <link:definition>2444428 - Disclosure - Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>2145110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://macrogenics.com/role/EmployeeBenefitPlan">
        <link:definition>2146111 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2447429 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_IncyteMGA012SupplyAgreementMember" abstract="true" name="IncyteMGA012SupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ServierAgreementMGD007OptionMember" abstract="true" name="ServierAgreementMGD007OptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ServierDARTMember" abstract="true" name="ServierDARTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_EquityIncentivePlan2003Member" abstract="true" name="EquityIncentivePlan2003Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_UpfrontPaymentRecognitionPeriod" abstract="false" name="UpfrontPaymentRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" abstract="false" name="OperatingLossCarryforwardsNotSubjectToLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_UndesignatedPreferredStockMember" abstract="true" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_TaxYear2025To2037Member" abstract="true" name="TaxYear2025To2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" abstract="true" name="F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LaboratoryAndOfficeEquipmentMember" abstract="true" name="LaboratoryAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsMember" abstract="true" name="ZaiLabsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" abstract="true" name="DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_EntitledMilestonePaymentsUnderAgreement" abstract="false" name="EntitledMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DevelopmentMilestonesAmount" abstract="false" name="DevelopmentMilestonesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" abstract="false" name="CollaborationArrangementOffsetToResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" abstract="false" name="EmployeesEligibleAgeToParticipateInBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" abstract="false" name="DefinedContributionPlanEmployeesContributionVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" abstract="false" name="OperatingLossCarryforwardsAnnualLimitationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_OptionExerciseFee" abstract="false" name="OptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" abstract="true" name="BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" abstract="false" name="NonrefundableUpfrontFeesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" abstract="false" name="OperatingLossCarryforwardsLimitationsOnUseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndLicenseAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_FairValueOfWarrantsReceived" abstract="false" name="FairValueOfWarrantsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementTerm" abstract="false" name="CollaborationAndLicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabLimitedMember" abstract="true" name="ZaiLabLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="AdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesTaxWithholding" abstract="false" name="RevenuesTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" abstract="true" name="LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_FundedValueOfBasePeriod" abstract="false" name="FundedValueOfBasePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ServierMember" abstract="true" name="ServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_BoehringerIngelheimInternationalGmbHMember" abstract="true" name="BoehringerIngelheimInternationalGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012ClinicalServicesMember" abstract="true" name="IncyteMGA012ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_JanssenCollaborationAndLicenseAgreementMember" abstract="true" name="JanssenCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionBioMember" abstract="true" name="ProventionBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" abstract="false" name="PotentialMilestonePaymentsAndRoyaltiesOnProductSales" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_FirmCommitmentPublicUnderwrittenOfferMember" abstract="true" name="FirmCommitmentPublicUnderwrittenOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" abstract="false" name="PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabClinicalSupplyAgreementsMember" abstract="true" name="ZaiLabClinicalSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_FollowOnEquityOfferingMember" abstract="true" name="FollowOnEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>mgnx-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:027e117c-75c0-47f2-bc63-7ee727579094,g:55d8aba6-2c39-4104-9032-126eaff6334c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6ea9ede2-baed-491f-9d9f-4f5c8afb0433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2649045c-64d0-4947-9a7d-fbdb4547a534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ea9ede2-baed-491f-9d9f-4f5c8afb0433" xlink:to="loc_us-gaap_AccountsPayableCurrent_2649045c-64d0-4947-9a7d-fbdb4547a534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ff67f944-aff1-4e33-ab72-1d01a9e167b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ea9ede2-baed-491f-9d9f-4f5c8afb0433" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ff67f944-aff1-4e33-ab72-1d01a9e167b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_60d53d55-6cc7-4834-93f9-089c3d54bfaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ea9ede2-baed-491f-9d9f-4f5c8afb0433" xlink:to="loc_us-gaap_DeferredRevenueCurrent_60d53d55-6cc7-4834-93f9-089c3d54bfaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91bb25e-a880-4937-bf8e-e96e56a81cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ea9ede2-baed-491f-9d9f-4f5c8afb0433" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91bb25e-a880-4937-bf8e-e96e56a81cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6e8b1a7-d7c5-4fc7-bdaf-7ae3a41fa0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f0ede7bb-8441-457e-aa83-1ea86e97f73f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6e8b1a7-d7c5-4fc7-bdaf-7ae3a41fa0d0" xlink:to="loc_us-gaap_Liabilities_f0ede7bb-8441-457e-aa83-1ea86e97f73f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_51e5012c-eb54-4082-97f7-821888ab96d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6e8b1a7-d7c5-4fc7-bdaf-7ae3a41fa0d0" xlink:to="loc_us-gaap_StockholdersEquity_51e5012c-eb54-4082-97f7-821888ab96d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c314a131-25fa-4b2d-8921-a0220f45c11f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_45a1644d-aa9d-4e9c-9549-b7a116154841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c314a131-25fa-4b2d-8921-a0220f45c11f" xlink:to="loc_us-gaap_AssetsCurrent_45a1644d-aa9d-4e9c-9549-b7a116154841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1570d7a0-607b-45e5-8f6e-316e3ac913cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c314a131-25fa-4b2d-8921-a0220f45c11f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1570d7a0-607b-45e5-8f6e-316e3ac913cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_12a36497-b2f0-4a79-8c63-2822509611c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c314a131-25fa-4b2d-8921-a0220f45c11f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_12a36497-b2f0-4a79-8c63-2822509611c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b31ba374-b07c-4eab-a2d3-85bd5bd61bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fdba02dd-c9c0-475a-a1db-262666a2831e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b31ba374-b07c-4eab-a2d3-85bd5bd61bd7" xlink:to="loc_us-gaap_LiabilitiesCurrent_fdba02dd-c9c0-475a-a1db-262666a2831e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_7eed6bbe-09b1-4b83-a54f-ffebb7c1e0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b31ba374-b07c-4eab-a2d3-85bd5bd61bd7" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_7eed6bbe-09b1-4b83-a54f-ffebb7c1e0ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_64c5264c-58e6-4737-bba0-9c384ca0ad11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b31ba374-b07c-4eab-a2d3-85bd5bd61bd7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_64c5264c-58e6-4737-bba0-9c384ca0ad11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_08cd70c3-5502-41bc-8348-29629879defb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_e6dd70ab-3430-47ab-999a-2d96091de79d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_08cd70c3-5502-41bc-8348-29629879defb" xlink:to="loc_us-gaap_Investments_e6dd70ab-3430-47ab-999a-2d96091de79d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cd546513-0ef1-47a2-a180-cfdb52767f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_08cd70c3-5502-41bc-8348-29629879defb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cd546513-0ef1-47a2-a180-cfdb52767f11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c8c79e34-0008-4c80-b911-6c119c30154c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_08cd70c3-5502-41bc-8348-29629879defb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c8c79e34-0008-4c80-b911-6c119c30154c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_c90c520a-ac75-42f0-a33d-0b94a0350143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_08cd70c3-5502-41bc-8348-29629879defb" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_c90c520a-ac75-42f0-a33d-0b94a0350143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_102bcb04-c0ba-4037-aeea-b5167f8653bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cc1135e7-8ed9-415e-804a-1fb55e06730a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_102bcb04-c0ba-4037-aeea-b5167f8653bc" xlink:to="loc_us-gaap_CommonStockValue_cc1135e7-8ed9-415e-804a-1fb55e06730a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7ea03c89-a85a-4129-80bf-f09b17f27e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_102bcb04-c0ba-4037-aeea-b5167f8653bc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7ea03c89-a85a-4129-80bf-f09b17f27e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_30b1e853-20ec-410c-8a18-87d57b9c06c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_102bcb04-c0ba-4037-aeea-b5167f8653bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_30b1e853-20ec-410c-8a18-87d57b9c06c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a08b7796-7d9b-485e-8dcd-47cef9d2f9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_102bcb04-c0ba-4037-aeea-b5167f8653bc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a08b7796-7d9b-485e-8dcd-47cef9d2f9cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4da02f46-03bf-4456-aa0b-16d05a2105b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_75db2de4-7665-4206-9015-ddcfd02b70ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4da02f46-03bf-4456-aa0b-16d05a2105b8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_75db2de4-7665-4206-9015-ddcfd02b70ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9a0f05f4-5471-4b95-a136-02d7308c1c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4da02f46-03bf-4456-aa0b-16d05a2105b8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9a0f05f4-5471-4b95-a136-02d7308c1c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3dfd15d2-89c9-4334-b1e3-6bd7a84e695e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e6e9b05-c855-40e0-b9f6-143d1c8a30bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3dfd15d2-89c9-4334-b1e3-6bd7a84e695e" xlink:to="loc_us-gaap_NetIncomeLoss_4e6e9b05-c855-40e0-b9f6-143d1c8a30bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f90355d8-3c7c-47b1-8ec7-819d5b0b3f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3dfd15d2-89c9-4334-b1e3-6bd7a84e695e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f90355d8-3c7c-47b1-8ec7-819d5b0b3f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d13b1a13-8148-4f84-a0df-86c2233efc9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d58359e2-3e51-49da-93a7-4d5f16092517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d13b1a13-8148-4f84-a0df-86c2233efc9e" xlink:to="loc_us-gaap_OperatingIncomeLoss_d58359e2-3e51-49da-93a7-4d5f16092517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_74516846-0ae7-47f1-951c-3cc4f5c601e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d13b1a13-8148-4f84-a0df-86c2233efc9e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_74516846-0ae7-47f1-951c-3cc4f5c601e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_efddc406-df0f-4c33-8cf7-2395493bf684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3700a2b6-0c3d-4144-9cd7-be1144630f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_efddc406-df0f-4c33-8cf7-2395493bf684" xlink:to="loc_us-gaap_Revenues_3700a2b6-0c3d-4144-9cd7-be1144630f95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_59f2f7a9-b11c-4c21-b2b8-afcb6b11558d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_efddc406-df0f-4c33-8cf7-2395493bf684" xlink:to="loc_us-gaap_CostsAndExpenses_59f2f7a9-b11c-4c21-b2b8-afcb6b11558d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c0bda2-506d-4c94-938d-a2a5320755e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6604ef33-697d-472e-a785-981fab1078ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c0bda2-506d-4c94-938d-a2a5320755e8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6604ef33-697d-472e-a785-981fab1078ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5b492aef-e41d-4b24-b842-363d3d57d9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c0bda2-506d-4c94-938d-a2a5320755e8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5b492aef-e41d-4b24-b842-363d3d57d9cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_149dc32c-8be3-4774-bd71-aa4b2fc175c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c0bda2-506d-4c94-938d-a2a5320755e8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_149dc32c-8be3-4774-bd71-aa4b2fc175c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69b340ae-267d-419e-9454-bbc6fc79497f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_951640ce-2d17-445e-9b57-6775e615ea90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69b340ae-267d-419e-9454-bbc6fc79497f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_951640ce-2d17-445e-9b57-6775e615ea90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_496c761d-f0ce-4842-8f28-9cbb29c98771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69b340ae-267d-419e-9454-bbc6fc79497f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_496c761d-f0ce-4842-8f28-9cbb29c98771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32944a14-71b8-4301-a3ba-142a0947def4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69b340ae-267d-419e-9454-bbc6fc79497f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32944a14-71b8-4301-a3ba-142a0947def4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4010701c-2703-46d1-947c-bb20f7e29c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f80526b-978c-48e2-bead-af85ae45d64c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4010701c-2703-46d1-947c-bb20f7e29c37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f80526b-978c-48e2-bead-af85ae45d64c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_178d05ce-7373-48ad-ba41-a71473cad025" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4010701c-2703-46d1-947c-bb20f7e29c37" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_178d05ce-7373-48ad-ba41-a71473cad025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_72439408-33bf-45c7-b2f3-ebb541152a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4010701c-2703-46d1-947c-bb20f7e29c37" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_72439408-33bf-45c7-b2f3-ebb541152a96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8e175f78-c990-4f1c-b184-9150f60bb8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8e175f78-c990-4f1c-b184-9150f60bb8a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2822779f-3f35-4e7a-9dab-0d3f0337352f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2822779f-3f35-4e7a-9dab-0d3f0337352f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_58858a9e-c270-49e5-83d1-8eea91c6a6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_NetIncomeLoss_58858a9e-c270-49e5-83d1-8eea91c6a6d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9b85e494-1d0a-4119-af22-4d8dff0f4242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9b85e494-1d0a-4119-af22-4d8dff0f4242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a4e901ad-ab79-4c6b-8a43-55120eb1dae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a4e901ad-ab79-4c6b-8a43-55120eb1dae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9b7c5e19-43fb-4e0f-9f57-100298849da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9b7c5e19-43fb-4e0f-9f57-100298849da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_8c94328e-c1e1-4451-b542-5deb7017464c" xlink:href="mgnx-20201231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_8c94328e-c1e1-4451-b542-5deb7017464c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_05db3ee6-d759-47f3-96ce-d398fa1fd799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_05db3ee6-d759-47f3-96ce-d398fa1fd799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4a3e5f8a-ef98-4286-b0c6-0682777338ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4a3e5f8a-ef98-4286-b0c6-0682777338ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_514c4484-f24a-4cea-83ec-267d51bf9dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_514c4484-f24a-4cea-83ec-267d51bf9dfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3d5d93aa-f13b-42ec-a051-95fce8ad9057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_us-gaap_ShareBasedCompensation_3d5d93aa-f13b-42ec-a051-95fce8ad9057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_d99beb08-b2cc-461a-bd44-aee05f8f8c11" xlink:href="mgnx-20201231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1376359-8cf3-48e6-b414-1e0ccb686000" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_d99beb08-b2cc-461a-bd44-aee05f8f8c11" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20201231.xsd#OrganizationandNatureofOperations"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5bb57adb-52a6-41c0-8229-0bedf4f2800f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_46d4888a-4c79-473e-aae4-9dd5861e18d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5bb57adb-52a6-41c0-8229-0bedf4f2800f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_46d4888a-4c79-473e-aae4-9dd5861e18d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b9ed01ad-b926-4b3b-8afa-25c0c9c3251e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5bb57adb-52a6-41c0-8229-0bedf4f2800f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b9ed01ad-b926-4b3b-8afa-25c0c9c3251e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4b965018-d39a-409e-baf5-3560cf388f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_abeeafd0-f805-4c90-8b4a-a116370e6937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4b965018-d39a-409e-baf5-3560cf388f6f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_abeeafd0-f805-4c90-8b4a-a116370e6937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49e183db-b586-4af0-adb5-0a5e2c629910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4b965018-d39a-409e-baf5-3560cf388f6f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49e183db-b586-4af0-adb5-0a5e2c629910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10863554-2464-440c-b8c9-44b264837691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4b965018-d39a-409e-baf5-3560cf388f6f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10863554-2464-440c-b8c9-44b264837691" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20201231.xsd#PropertyEquipmentandSoftware"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1fec4e25-9d0a-4c72-9b5f-4ecf3a7649ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b0cd6626-8ff7-4f13-a56e-8475aae16f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1fec4e25-9d0a-4c72-9b5f-4ecf3a7649ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b0cd6626-8ff7-4f13-a56e-8475aae16f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_81057249-5d33-426c-ab01-38d92b92f4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1fec4e25-9d0a-4c72-9b5f-4ecf3a7649ca" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_81057249-5d33-426c-ab01-38d92b92f4d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Leases" xlink:type="simple" xlink:href="mgnx-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#LeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a720c029-f0cd-44b0-985a-507001858fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_811ed84d-2b36-4682-921b-4d4f9c75e04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_a720c029-f0cd-44b0-985a-507001858fb1" xlink:to="loc_us-gaap_SubleaseIncome_811ed84d-2b36-4682-921b-4d4f9c75e04a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4329492e-7cb4-4bae-bc77-13fab057c12d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_a720c029-f0cd-44b0-985a-507001858fb1" xlink:to="loc_us-gaap_OperatingLeaseCost_4329492e-7cb4-4bae-bc77-13fab057c12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_38138fd4-a8f6-41e7-ab29-8d80c8680e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_a720c029-f0cd-44b0-985a-507001858fb1" xlink:to="loc_us-gaap_VariableLeaseCost_38138fd4-a8f6-41e7-ab29-8d80c8680e4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7adfd923-c219-4426-8538-8df0bfb9d28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1f8b1f46-9503-4d97-b89c-8747ca625c22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7adfd923-c219-4426-8538-8df0bfb9d28d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1f8b1f46-9503-4d97-b89c-8747ca625c22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3232b5eb-248c-4ae9-b9b9-b85850fa8c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7adfd923-c219-4426-8538-8df0bfb9d28d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3232b5eb-248c-4ae9-b9b9-b85850fa8c98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_447b065f-6be3-4dc6-8939-ad80f2eca5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7adfd923-c219-4426-8538-8df0bfb9d28d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_447b065f-6be3-4dc6-8939-ad80f2eca5bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fdbc1672-ac96-4c9e-b0af-41bcc5efc2f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7adfd923-c219-4426-8538-8df0bfb9d28d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fdbc1672-ac96-4c9e-b0af-41bcc5efc2f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f456bfe5-4edf-4da2-ac2c-a41cbd22115d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7adfd923-c219-4426-8538-8df0bfb9d28d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f456bfe5-4edf-4da2-ac2c-a41cbd22115d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_20a02ea0-b6bc-4239-9c2f-d5af48a32650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7adfd923-c219-4426-8538-8df0bfb9d28d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_20a02ea0-b6bc-4239-9c2f-d5af48a32650" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65269a3a-0279-4db4-a588-6093d327db22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_69042812-31b9-4af2-923c-e8d032182177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65269a3a-0279-4db4-a588-6093d327db22" xlink:to="loc_us-gaap_OperatingLeaseLiability_69042812-31b9-4af2-923c-e8d032182177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_53350448-d190-4086-b700-116e95f4edf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65269a3a-0279-4db4-a588-6093d327db22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_53350448-d190-4086-b700-116e95f4edf7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensation"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7a8ddf68-ce55-4daf-a9a8-ddfd487590e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b9632394-82f2-4aca-94fe-eb4545fdc3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7a8ddf68-ce55-4daf-a9a8-ddfd487590e9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b9632394-82f2-4aca-94fe-eb4545fdc3d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_926822fb-ba24-4813-8c93-e7b4e2db10c4" xlink:href="mgnx-20201231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7a8ddf68-ce55-4daf-a9a8-ddfd487590e9" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_926822fb-ba24-4813-8c93-e7b4e2db10c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_e10f99c1-1db0-42cc-8ac8-c12cae6fde11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7a8ddf68-ce55-4daf-a9a8-ddfd487590e9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_e10f99c1-1db0-42cc-8ac8-c12cae6fde11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_11707774-d13d-438b-8a06-6d931d70f954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d24037bb-138e-4ae7-afd3-ef64825adfa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_11707774-d13d-438b-8a06-6d931d70f954" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d24037bb-138e-4ae7-afd3-ef64825adfa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b02952c0-a510-4e19-ae36-1ccc4f4579e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_11707774-d13d-438b-8a06-6d931d70f954" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b02952c0-a510-4e19-ae36-1ccc4f4579e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_96ea686b-3786-4e37-8ab5-aef0b78800ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c37581d8-4dd0-49c5-9152-deea07d9cf1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_96ea686b-3786-4e37-8ab5-aef0b78800ce" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c37581d8-4dd0-49c5-9152-deea07d9cf1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1089c499-aaea-4e33-a41e-a5e2e7b7afc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_96ea686b-3786-4e37-8ab5-aef0b78800ce" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1089c499-aaea-4e33-a41e-a5e2e7b7afc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_157d081a-4149-44e2-9b9b-50e06180e43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_38a4f892-bca1-41f8-91e8-61dd39148bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_157d081a-4149-44e2-9b9b-50e06180e43b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_38a4f892-bca1-41f8-91e8-61dd39148bfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_cd9f9681-a29f-4d5f-b458-6c3525ff1956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_157d081a-4149-44e2-9b9b-50e06180e43b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_cd9f9681-a29f-4d5f-b458-6c3525ff1956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f29a064b-8b5c-490a-a92f-b5635e4e37a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_157d081a-4149-44e2-9b9b-50e06180e43b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f29a064b-8b5c-490a-a92f-b5635e4e37a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_fff0cd17-b727-4d96-8b4c-c7d1fb6d0102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_157d081a-4149-44e2-9b9b-50e06180e43b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_fff0cd17-b727-4d96-8b4c-c7d1fb6d0102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_799d789f-05d2-4a14-b2f1-2d0be25a771c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_157d081a-4149-44e2-9b9b-50e06180e43b" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_799d789f-05d2-4a14-b2f1-2d0be25a771c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_8eef3032-8a7a-43ea-8b22-5e62f65c1352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_157d081a-4149-44e2-9b9b-50e06180e43b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_8eef3032-8a7a-43ea-8b22-5e62f65c1352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_0c1b9cbe-c15e-46d7-a898-75812d525183" xlink:href="mgnx-20201231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_157d081a-4149-44e2-9b9b-50e06180e43b" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_0c1b9cbe-c15e-46d7-a898-75812d525183" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8eb08f4d-9285-426d-a3c9-34a664b24f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_02cd8371-cd52-4b26-b090-17e7aa715dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8eb08f4d-9285-426d-a3c9-34a664b24f84" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_02cd8371-cd52-4b26-b090-17e7aa715dfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d811fde8-d8c0-40bf-9e14-48307f9635cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8eb08f4d-9285-426d-a3c9-34a664b24f84" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d811fde8-d8c0-40bf-9e14-48307f9635cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_029fff79-576a-46e5-b875-db7bee171270" xlink:href="mgnx-20201231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8eb08f4d-9285-426d-a3c9-34a664b24f84" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_029fff79-576a-46e5-b875-db7bee171270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_b3945920-6b2c-4b67-8b51-da616e9a94dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8eb08f4d-9285-426d-a3c9-34a664b24f84" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_b3945920-6b2c-4b67-8b51-da616e9a94dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_9d082d87-f1ee-49af-a9a3-16b84ea515cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8eb08f4d-9285-426d-a3c9-34a664b24f84" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_9d082d87-f1ee-49af-a9a3-16b84ea515cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_9d07662f-3b66-4a9c-bad5-2b7c8c658597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8eb08f4d-9285-426d-a3c9-34a664b24f84" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_9d07662f-3b66-4a9c-bad5-2b7c8c658597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bd511c58-1882-4fde-982e-a0c2cd96afee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8eb08f4d-9285-426d-a3c9-34a664b24f84" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bd511c58-1882-4fde-982e-a0c2cd96afee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6f96ce4d-a369-47c8-a684-9b61a25a33f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8eb08f4d-9285-426d-a3c9-34a664b24f84" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6f96ce4d-a369-47c8-a684-9b61a25a33f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreements"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsServierDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20201231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>mgnx-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:027e117c-75c0-47f2-bc63-7ee727579094,g:55d8aba6-2c39-4104-9032-126eaff6334c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended" id="i87715798b7c3429282ab82c83493e6e4_CoverPage"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="ifce06ea23b3441eb8e911d9cd0cea9c4_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="iccfd97301dfb4dc6a03dc2bdef7a21b7_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="if98600a380d54c6d9d468a8c24d0d045_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bb9cb3f9-6ede-4694-8361-b8be8def2eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_RevenuesAbstract_bb9cb3f9-6ede-4694-8361-b8be8def2eda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4eb138f8-6575-4978-8af3-496dd9da9932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_bb9cb3f9-6ede-4694-8361-b8be8def2eda" xlink:to="loc_us-gaap_Revenues_4eb138f8-6575-4978-8af3-496dd9da9932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_621644ab-3670-4a93-b4a8-d3101cbb212c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_621644ab-3670-4a93-b4a8-d3101cbb212c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2ed6e011-fecf-4f0f-8487-a8596d00c95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2ed6e011-fecf-4f0f-8487-a8596d00c95a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_69bcc680-e84f-4e0b-8e2a-e01dd2f83f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:to="loc_us-gaap_CostsAndExpenses_69bcc680-e84f-4e0b-8e2a-e01dd2f83f0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f4b593a-55e7-4fc9-9323-2f511b256407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_OperatingIncomeLoss_3f4b593a-55e7-4fc9-9323-2f511b256407" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fd3c9071-b510-4818-930a-f9d919f78488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fd3c9071-b510-4818-930a-f9d919f78488" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_977a440e-b65b-40c0-b4a1-71f873891ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_NetIncomeLoss_977a440e-b65b-40c0-b4a1-71f873891ab8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6fe4d71f-2087-4d28-8208-564cf8631ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6fe4d71f-2087-4d28-8208-564cf8631ded" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_47477e94-c566-408f-9fd8-0d1280d5bfd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6fe4d71f-2087-4d28-8208-564cf8631ded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_47477e94-c566-408f-9fd8-0d1280d5bfd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_95c7e289-ab0f-4ec2-8c8c-edbbc28b38d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_95c7e289-ab0f-4ec2-8c8c-edbbc28b38d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_84b57609-8eae-4bcc-8c94-2c1c44386369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_84b57609-8eae-4bcc-8c94-2c1c44386369" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6bca035c-94fe-4e32-9cbc-19b0853ba337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6bca035c-94fe-4e32-9cbc-19b0853ba337" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_099bb727-275c-41f0-82d7-ac72db79d7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_StatementTable_099bb727-275c-41f0-82d7-ac72db79d7bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bad804be-811a-4772-a582-6fa32a27ff83" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_099bb727-275c-41f0-82d7-ac72db79d7bc" xlink:to="loc_srt_ProductOrServiceAxis_bad804be-811a-4772-a582-6fa32a27ff83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bad804be-811a-4772-a582-6fa32a27ff83_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bad804be-811a-4772-a582-6fa32a27ff83" xlink:to="loc_srt_ProductsAndServicesDomain_bad804be-811a-4772-a582-6fa32a27ff83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_406963bc-1bed-474b-a041-1c43aab51c22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bad804be-811a-4772-a582-6fa32a27ff83" xlink:to="loc_srt_ProductsAndServicesDomain_406963bc-1bed-474b-a041-1c43aab51c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_488427f1-aeef-4930-9c96-0573d837f984" xlink:href="mgnx-20201231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_406963bc-1bed-474b-a041-1c43aab51c22" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_488427f1-aeef-4930-9c96-0573d837f984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_fca0f419-25bf-410d-96b2-21099a01262e" xlink:href="mgnx-20201231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_406963bc-1bed-474b-a041-1c43aab51c22" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_fca0f419-25bf-410d-96b2-21099a01262e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i2b9b3b423382436d857cfd5aea3730a3_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8e8fd202-19f3-4c51-9f9f-9a255798ee75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_SharesIssued_8e8fd202-19f3-4c51-9f9f-9a255798ee75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3c7774b0-0105-4b29-b0b6-f48f6e3a2218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_StockholdersEquity_3c7774b0-0105-4b29-b0b6-f48f6e3a2218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1b738373-9e76-4c94-8fa0-f810aea7f2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1b738373-9e76-4c94-8fa0-f810aea7f2b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa370125-e1f4-406b-8962-6e7af71cda18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa370125-e1f4-406b-8962-6e7af71cda18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27b8c7b8-bbe4-4570-ab06-61282914bef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27b8c7b8-bbe4-4570-ab06-61282914bef1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_fcd5e14a-3757-42e9-892b-e2baaf8e8ae0" xlink:href="mgnx-20201231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_fcd5e14a-3757-42e9-892b-e2baaf8e8ae0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_f1db5d6e-cc2a-4510-b0e8-229d1be15f9e" xlink:href="mgnx-20201231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_f1db5d6e-cc2a-4510-b0e8-229d1be15f9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_0ec657ce-e08c-41be-ad5a-3b2b6bb00e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_0ec657ce-e08c-41be-ad5a-3b2b6bb00e65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_d8ccabd6-512f-45b9-a06c-7b57e2e1410d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_d8ccabd6-512f-45b9-a06c-7b57e2e1410d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2d2ae2ef-fbff-4433-8e10-ec91e742f957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2d2ae2ef-fbff-4433-8e10-ec91e742f957" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e2c2ef9-492a-4f65-a111-53f47ad4b99b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_NetIncomeLoss_6e2c2ef9-492a-4f65-a111-53f47ad4b99b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0c8519dc-b4ea-43f9-a3ad-619344713c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_699a3dec-c2da-42aa-ae87-4d06c3451d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d0d4600c-4592-415e-8c47-6743298e2034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_StatementTable_d0d4600c-4592-415e-8c47-6743298e2034" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_342a8931-2336-4e31-b07d-7d92a600b215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d0d4600c-4592-415e-8c47-6743298e2034" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_342a8931-2336-4e31-b07d-7d92a600b215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_342a8931-2336-4e31-b07d-7d92a600b215_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_342a8931-2336-4e31-b07d-7d92a600b215" xlink:to="loc_us-gaap_EquityComponentDomain_342a8931-2336-4e31-b07d-7d92a600b215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_342a8931-2336-4e31-b07d-7d92a600b215" xlink:to="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc079f23-290d-4794-8142-5dd95e908a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_CommonStockMember_bc079f23-290d-4794-8142-5dd95e908a3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2b1d69ac-2bab-4463-88cf-a438f08bfded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_TreasuryStockMember_2b1d69ac-2bab-4463-88cf-a438f08bfded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6858e1f0-8998-4372-b31d-19a17b04cdd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6858e1f0-8998-4372-b31d-19a17b04cdd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad1937d2-293a-435a-92a5-750b9b77f509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_RetainedEarningsMember_ad1937d2-293a-435a-92a5-750b9b77f509" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f92ff70-e0fb-4d74-a111-6b4634df965c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f92ff70-e0fb-4d74-a111-6b4634df965c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3de9577b-b2b4-4891-9b77-6681d992719a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d0d4600c-4592-415e-8c47-6743298e2034" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3de9577b-b2b4-4891-9b77-6681d992719a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3de9577b-b2b4-4891-9b77-6681d992719a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3de9577b-b2b4-4891-9b77-6681d992719a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3de9577b-b2b4-4891-9b77-6681d992719a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_197be2bd-e6bd-47fa-b48d-5def3bf27c88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3de9577b-b2b4-4891-9b77-6681d992719a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_197be2bd-e6bd-47fa-b48d-5def3bf27c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_43c5f071-484c-4ddc-8e04-17f819c00372" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_197be2bd-e6bd-47fa-b48d-5def3bf27c88" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_43c5f071-484c-4ddc-8e04-17f819c00372" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="icb977057c1524424a3107ffb8f1c09e2_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20201231.xsd#OrganizationandNatureofOperations"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended" id="i19904dc6d24e408eb86fde96c56d2bc9_OrganizationandNatureofOperations"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i12162292315d403f9cefb0e621c990e8_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i7a466b4a13e8438c8ef03141c3f36ad3_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="id687aa91208047f190235dc8eb078f64_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i8c120a015c9041f491a99826fb8a55f4_SummaryofSignificantAccountingPoliciesDetails"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended" id="ib0e9485f15db43f7bd0afb5686aa649f_SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b570e5f-676e-4b02-bee7-b72c57c93d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b570e5f-676e-4b02-bee7-b72c57c93d41" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ef21096c-81c5-4eae-ac52-f15cc8692e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ef21096c-81c5-4eae-ac52-f15cc8692e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b290b57-2337-4d31-a4f6-86a73f53ab85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b290b57-2337-4d31-a4f6-86a73f53ab85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_96e8d337-8368-4cab-818a-6cea598264e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_96e8d337-8368-4cab-818a-6cea598264e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41ba53c4-0603-46ba-8139-96b13e68306e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b570e5f-676e-4b02-bee7-b72c57c93d41" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41ba53c4-0603-46ba-8139-96b13e68306e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55999aac-93ad-4718-aa35-96765f3a1c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41ba53c4-0603-46ba-8139-96b13e68306e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55999aac-93ad-4718-aa35-96765f3a1c29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55999aac-93ad-4718-aa35-96765f3a1c29_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55999aac-93ad-4718-aa35-96765f3a1c29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55999aac-93ad-4718-aa35-96765f3a1c29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55999aac-93ad-4718-aa35-96765f3a1c29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_72ffbf49-aa50-464f-8f6e-7a7c8fae8ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_72ffbf49-aa50-464f-8f6e-7a7c8fae8ca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_63fc0799-531f-4d31-946f-394687942042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_63fc0799-531f-4d31-946f-394687942042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8de2dc27-5f7b-41d8-8948-979210627157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8de2dc27-5f7b-41d8-8948-979210627157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b72c2f31-0a1f-4e06-b532-1c6a7b96cb66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41ba53c4-0603-46ba-8139-96b13e68306e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b72c2f31-0a1f-4e06-b532-1c6a7b96cb66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b72c2f31-0a1f-4e06-b532-1c6a7b96cb66_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b72c2f31-0a1f-4e06-b532-1c6a7b96cb66" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b72c2f31-0a1f-4e06-b532-1c6a7b96cb66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b72c2f31-0a1f-4e06-b532-1c6a7b96cb66" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_aa264ecc-896d-4684-aee5-fc03674a30f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_aa264ecc-896d-4684-aee5-fc03674a30f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5b2c6e9f-548e-4760-b677-891a07dbd69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5b2c6e9f-548e-4760-b677-891a07dbd69b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_51f354d2-7ffe-4ce7-aebc-d8554202af7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_51f354d2-7ffe-4ce7-aebc-d8554202af7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_bf78040b-30c3-4a41-b615-2dd16047af8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_bf78040b-30c3-4a41-b615-2dd16047af8f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended" id="i4697a6e34a8a4184abe1b9f413089a15_SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_150b6380-ed13-4a75-b08e-ca7a686286fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_af4ef31a-cd4f-41a9-9c47-dabc4d5af078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_150b6380-ed13-4a75-b08e-ca7a686286fe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_af4ef31a-cd4f-41a9-9c47-dabc4d5af078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_150b6380-ed13-4a75-b08e-ca7a686286fe" xlink:to="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f51f41-3d6f-4ce3-bb44-0dcc859d523d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f51f41-3d6f-4ce3-bb44-0dcc859d523d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c4f51f41-3d6f-4ce3-bb44-0dcc859d523d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f51f41-3d6f-4ce3-bb44-0dcc859d523d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c4f51f41-3d6f-4ce3-bb44-0dcc859d523d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_30e5d38f-1cd4-430b-a1f1-8d1391f4661a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f51f41-3d6f-4ce3-bb44-0dcc859d523d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_30e5d38f-1cd4-430b-a1f1-8d1391f4661a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_94e781ba-3f16-49af-aa00-ca398428ae88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_30e5d38f-1cd4-430b-a1f1-8d1391f4661a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_94e781ba-3f16-49af-aa00-ca398428ae88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e4e26e1d-bb91-4a0c-b808-1f44d17bf0e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e4e26e1d-bb91-4a0c-b808-1f44d17bf0e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e4e26e1d-bb91-4a0c-b808-1f44d17bf0e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e4e26e1d-bb91-4a0c-b808-1f44d17bf0e9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e4e26e1d-bb91-4a0c-b808-1f44d17bf0e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8c9200e-2a15-462c-b8f5-59ae64e1eb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e4e26e1d-bb91-4a0c-b808-1f44d17bf0e9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8c9200e-2a15-462c-b8f5-59ae64e1eb2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a571435b-3b5d-4d93-bf0a-c51696dc83ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8c9200e-2a15-462c-b8f5-59ae64e1eb2d" xlink:to="loc_us-gaap_SalesRevenueNetMember_a571435b-3b5d-4d93-bf0a-c51696dc83ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_80aa14d2-f20c-472c-9338-f8e87f84b3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8c9200e-2a15-462c-b8f5-59ae64e1eb2d" xlink:to="loc_us-gaap_AccountsReceivableMember_80aa14d2-f20c-472c-9338-f8e87f84b3b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e16d1235-3724-4912-80bc-a7c5969caf90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:to="loc_srt_MajorCustomersAxis_e16d1235-3724-4912-80bc-a7c5969caf90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e16d1235-3724-4912-80bc-a7c5969caf90_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e16d1235-3724-4912-80bc-a7c5969caf90" xlink:to="loc_srt_NameOfMajorCustomerDomain_e16d1235-3724-4912-80bc-a7c5969caf90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e16d1235-3724-4912-80bc-a7c5969caf90" xlink:to="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_e07e4f65-959e-4a72-b76a-de3bec68b8fe" xlink:href="mgnx-20201231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:to="loc_mgnx_IncyteCorporationMember_e07e4f65-959e-4a72-b76a-de3bec68b8fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_67cb1eec-9ea8-4af6-bfef-ee9a0fdec98f" xlink:href="mgnx-20201231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:to="loc_mgnx_JanssenBiotechIncMember_67cb1eec-9ea8-4af6-bfef-ee9a0fdec98f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_cf6a6ee0-aa08-42b9-87a7-c778dc903017" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:to="loc_mgnx_ZaiLabLimitedMember_cf6a6ee0-aa08-42b9-87a7-c778dc903017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_f941450c-bade-43a6-adc6-bcbc377b96d5" xlink:href="mgnx-20201231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:to="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_f941450c-bade-43a6-adc6-bcbc377b96d5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" id="i241e2e577e484f21b4aa82e695949b0e_SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36ff0641-2b7e-4a77-afa8-d89e928a6f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4fe5a8a5-8e8b-4345-b8ef-b502c8d2cacf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36ff0641-2b7e-4a77-afa8-d89e928a6f33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4fe5a8a5-8e8b-4345-b8ef-b502c8d2cacf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01a32b3c-12e3-40fc-b2e0-3fb0688d95db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36ff0641-2b7e-4a77-afa8-d89e928a6f33" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01a32b3c-12e3-40fc-b2e0-3fb0688d95db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd551520-20fd-494b-92de-6c64cbcd38c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01a32b3c-12e3-40fc-b2e0-3fb0688d95db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd551520-20fd-494b-92de-6c64cbcd38c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd551520-20fd-494b-92de-6c64cbcd38c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd551520-20fd-494b-92de-6c64cbcd38c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd551520-20fd-494b-92de-6c64cbcd38c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd551520-20fd-494b-92de-6c64cbcd38c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_cef33eda-a5fb-4fdf-9a8d-ef5b0c56d3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:to="loc_us-gaap_ComputerEquipmentMember_cef33eda-a5fb-4fdf-9a8d-ef5b0c56d3ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_033e3259-395b-4bd4-b7c4-4bcf9d0c1b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_033e3259-395b-4bd4-b7c4-4bcf9d0c1b7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_13bcb660-32a1-477c-9129-2f8ffc3d86ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_13bcb660-32a1-477c-9129-2f8ffc3d86ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_ad956cc5-31d4-48af-8e1f-f60621f70d1b" xlink:href="mgnx-20201231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_ad956cc5-31d4-48af-8e1f-f60621f70d1b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended" id="i2380e036d7a14f978bedfebdbe69996a_SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa92bf05-3eb2-41fb-90e3-a080ddf9beb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d7d19180-91dd-46ba-be1b-0fc42dbe1700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa92bf05-3eb2-41fb-90e3-a080ddf9beb6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d7d19180-91dd-46ba-be1b-0fc42dbe1700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1836ad45-4fcf-4ab0-9d1c-af7cd6dc1654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa92bf05-3eb2-41fb-90e3-a080ddf9beb6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1836ad45-4fcf-4ab0-9d1c-af7cd6dc1654" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7592184-d06b-4f74-93f5-56b5dfe009a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1836ad45-4fcf-4ab0-9d1c-af7cd6dc1654" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7592184-d06b-4f74-93f5-56b5dfe009a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b7592184-d06b-4f74-93f5-56b5dfe009a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7592184-d06b-4f74-93f5-56b5dfe009a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b7592184-d06b-4f74-93f5-56b5dfe009a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2b90ae57-ccda-4008-ae9b-0bf9de676c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7592184-d06b-4f74-93f5-56b5dfe009a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2b90ae57-ccda-4008-ae9b-0bf9de676c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_a42e03f0-536b-4bdc-a7bd-68b874f577a5" xlink:href="mgnx-20201231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2b90ae57-ccda-4008-ae9b-0bf9de676c27" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_a42e03f0-536b-4bdc-a7bd-68b874f577a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended" id="i93da8c6ebe5d403bbd1179b62e815fbe_MarketableSecurities"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended" id="i568aaea1550d4608adb7c28580acf417_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i7abef769f38c4827a8c934d9d990aff4_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cde3ebdc-05cf-4e61-b216-a7a42ff41839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cde3ebdc-05cf-4e61-b216-a7a42ff41839" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ef720292-c576-4926-878a-3683aa02fd4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ef720292-c576-4926-878a-3683aa02fd4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d3bddab3-d9c1-4154-85bb-d844a38a5a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d3bddab3-d9c1-4154-85bb-d844a38a5a8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6277ea89-1730-49ec-a4a1-6a39b45c1985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6277ea89-1730-49ec-a4a1-6a39b45c1985" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb279967-5b9c-4060-a777-83b3a2daadc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb279967-5b9c-4060-a777-83b3a2daadc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_51b3807a-a2e6-4bef-8f7a-11e5c7415166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb279967-5b9c-4060-a777-83b3a2daadc1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_51b3807a-a2e6-4bef-8f7a-11e5c7415166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_51b3807a-a2e6-4bef-8f7a-11e5c7415166_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_51b3807a-a2e6-4bef-8f7a-11e5c7415166" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_51b3807a-a2e6-4bef-8f7a-11e5c7415166_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_51b3807a-a2e6-4bef-8f7a-11e5c7415166" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2fce4961-a751-40f5-835f-098d62eb0a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2fce4961-a751-40f5-835f-098d62eb0a3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_905523aa-3eea-4c89-9442-509ef09866c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_905523aa-3eea-4c89-9442-509ef09866c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_731d64a7-e874-4f61-9d5e-6565ffca0a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_731d64a7-e874-4f61-9d5e-6565ffca0a7e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended" id="i6abd7069a8914e8c9ad1ddfec19d17ea_MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20201231.xsd#PropertyEquipmentandSoftware"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended" id="i13320ee61bcf4217977c02719175036b_PropertyEquipmentandSoftware"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended" id="ia8d26555b34f43199812e1778c871d14_PropertyEquipmentandSoftwareTables"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended" id="ic8a8587857a64402827d28e4dcb08a4a_PropertyEquipmentandSoftwareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78dcd7c1-6562-4503-a29a-9f374240fb7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78dcd7c1-6562-4503-a29a-9f374240fb7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e121a9d5-d5b6-443d-ab08-324f4d566f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_ConstructionInProgressGross_e121a9d5-d5b6-443d-ab08-324f4d566f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f7ef6916-e1c9-4362-bdbc-6d760e526c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f7ef6916-e1c9-4362-bdbc-6d760e526c63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_744b7665-ac1f-4f6a-a6df-06f1563424b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_744b7665-ac1f-4f6a-a6df-06f1563424b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_49c2ef1e-898d-4194-8580-e05628c10f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_Depreciation_49c2ef1e-898d-4194-8580-e05628c10f40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_696fe031-fde5-40e5-a3d1-1c0da1583795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_696fe031-fde5-40e5-a3d1-1c0da1583795" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f8c6b31-8f0f-4490-b6af-f9f0573e5d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_696fe031-fde5-40e5-a3d1-1c0da1583795" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f8c6b31-8f0f-4490-b6af-f9f0573e5d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f8c6b31-8f0f-4490-b6af-f9f0573e5d18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f8c6b31-8f0f-4490-b6af-f9f0573e5d18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f8c6b31-8f0f-4490-b6af-f9f0573e5d18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f8c6b31-8f0f-4490-b6af-f9f0573e5d18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_39533e2b-775b-441d-a62e-4960a155de10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_ComputerEquipmentMember_39533e2b-775b-441d-a62e-4960a155de10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7884ea17-06cd-4447-a119-a64dedda4d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7884ea17-06cd-4447-a119-a64dedda4d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_2dd8e100-f816-4ec5-82e3-8bd5aa596048" xlink:href="mgnx-20201231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_2dd8e100-f816-4ec5-82e3-8bd5aa596048" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_c90b5b2b-68f3-4129-98f5-a48072ed6bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_VehiclesMember_c90b5b2b-68f3-4129-98f5-a48072ed6bdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_3f48019e-cb12-41eb-8b39-6961cc4c93dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_EquipmentMember_3f48019e-cb12-41eb-8b39-6961cc4c93dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_63789c5a-4335-429b-acdc-7c7eb40f7d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_63789c5a-4335-429b-acdc-7c7eb40f7d22" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Leases" xlink:type="simple" xlink:href="mgnx-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/Leases" xlink:type="extended" id="i204286575367442891079215421657a5_Leases"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeasesTables" xlink:type="extended" id="i9b0b423011ec4786a94c233caf07a0a4_LeasesTables"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i4a4ab5c890744c4baee2660fef929a98_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_887aae4f-64cb-4475-8fff-4446ba2e9599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_887aae4f-64cb-4475-8fff-4446ba2e9599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7e0dffd0-d18c-4bf0-bb4c-f811f0d15bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7e0dffd0-d18c-4bf0-bb4c-f811f0d15bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_56e61410-ca5b-476b-8e7a-2641f02b8999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_56e61410-ca5b-476b-8e7a-2641f02b8999" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions_bf2cb6bc-1ea2-43ef-b238-390b845b1456" xlink:href="mgnx-20201231.xsd#mgnx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions_bf2cb6bc-1ea2-43ef-b238-390b845b1456" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2a15f714-2706-46c5-86ab-9edb1c5502f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_OperatingLeasePayments_2a15f714-2706-46c5-86ab-9edb1c5502f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2a1b3ff-6b69-47a3-8ee5-2881bbafad9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2a1b3ff-6b69-47a3-8ee5-2881bbafad9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b9e03186-b928-4b9e-b6c3-36c480ebd6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b9e03186-b928-4b9e-b6c3-36c480ebd6a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3666b37e-9b94-4f53-bc2f-cdbc4bb6831d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b9e03186-b928-4b9e-b6c3-36c480ebd6a8" xlink:to="loc_srt_RangeAxis_3666b37e-9b94-4f53-bc2f-cdbc4bb6831d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3666b37e-9b94-4f53-bc2f-cdbc4bb6831d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3666b37e-9b94-4f53-bc2f-cdbc4bb6831d" xlink:to="loc_srt_RangeMember_3666b37e-9b94-4f53-bc2f-cdbc4bb6831d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d6a8888-b118-44c1-b350-bd74e76dca8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3666b37e-9b94-4f53-bc2f-cdbc4bb6831d" xlink:to="loc_srt_RangeMember_9d6a8888-b118-44c1-b350-bd74e76dca8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_49d7d7c3-09d3-4421-a305-9b8a30a8dba5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9d6a8888-b118-44c1-b350-bd74e76dca8d" xlink:to="loc_srt_MinimumMember_49d7d7c3-09d3-4421-a305-9b8a30a8dba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66f6c97a-c7b2-4273-8489-1a6af901a378" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9d6a8888-b118-44c1-b350-bd74e76dca8d" xlink:to="loc_srt_MaximumMember_66f6c97a-c7b2-4273-8489-1a6af901a378" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#LeaseCostsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="extended" id="i3c499de5d78d4647bb565b261d4998d5_LeaseCostsDetails"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended" id="ic0a43dde1d5c4f478967e9c48052af56_MaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended" id="i6f834f94426448f0850952d12472dfec_StockholdersEquity"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="i559fa4e04d4e4a3e831e90c45ec98433_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3921299d-bc23-4b60-87f7-3bd2f657bd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3921299d-bc23-4b60-87f7-3bd2f657bd54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ae9adfe6-c47e-493c-aff3-b0cd141db475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ae9adfe6-c47e-493c-aff3-b0cd141db475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ce8f2c39-3367-478f-ae13-85e0e04fd8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ce8f2c39-3367-478f-ae13-85e0e04fd8c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_eefc20e4-96c0-44a5-a1a7-5e71235d4e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_eefc20e4-96c0-44a5-a1a7-5e71235d4e9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_221e2c58-45b2-4751-8ebf-6a66240a7cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_221e2c58-45b2-4751-8ebf-6a66240a7cc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_64e8cd9c-556b-4281-af58-65e920c68a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_64e8cd9c-556b-4281-af58-65e920c68a2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2d448ece-8d50-4b81-855d-6f93ead8fc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2d448ece-8d50-4b81-855d-6f93ead8fc0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7eeaca86-f21c-465b-bf9d-6333a2ef4659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_3dcd3384-5d80-4730-8ff7-0643b377ad2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_3dcd3384-5d80-4730-8ff7-0643b377ad2d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e864e846-6dc7-47a1-8713-3753d6d70089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e864e846-6dc7-47a1-8713-3753d6d70089" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_dd485cc6-481b-4ac1-b7f8-56b0db947aae" xlink:href="mgnx-20201231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_dd485cc6-481b-4ac1-b7f8-56b0db947aae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_73ad3008-3da8-45f6-9d87-37cad70ea4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_73ad3008-3da8-45f6-9d87-37cad70ea4fd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7155ad9c-d559-4597-ba30-a73940646ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7155ad9c-d559-4597-ba30-a73940646ff5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40199b60-ac5f-4498-a2a9-2a079b5add94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40199b60-ac5f-4498-a2a9-2a079b5add94" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_53d47f4b-4745-4310-bbf8-5c097fbae425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_53d47f4b-4745-4310-bbf8-5c097fbae425" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_65464dfd-415a-4d37-9f22-c9c127e5d2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53d47f4b-4745-4310-bbf8-5c097fbae425" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_65464dfd-415a-4d37-9f22-c9c127e5d2f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65464dfd-415a-4d37-9f22-c9c127e5d2f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_65464dfd-415a-4d37-9f22-c9c127e5d2f1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65464dfd-415a-4d37-9f22-c9c127e5d2f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_65464dfd-415a-4d37-9f22-c9c127e5d2f1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_af732f19-0b63-420f-9386-acb7273b27fa" xlink:href="mgnx-20201231.xsd#mgnx_FirmCommitmentPublicUnderwrittenOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:to="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_af732f19-0b63-420f-9386-acb7273b27fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2b338c96-d8f6-4f8d-b1e8-b3644ac9d5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2b338c96-d8f6-4f8d-b1e8-b3644ac9d5a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowOnEquityOfferingMember_15518772-69aa-4aab-bec8-b0688869a8c8" xlink:href="mgnx-20201231.xsd#mgnx_FollowOnEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:to="loc_mgnx_FollowOnEquityOfferingMember_15518772-69aa-4aab-bec8-b0688869a8c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_bbe84446-ef3a-4f07-afc1-60a5429b1117" xlink:href="mgnx-20201231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:to="loc_mgnx_AtTheMarketOfferingMember_bbe84446-ef3a-4f07-afc1-60a5429b1117" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ace19daf-1611-4e50-804f-aec14076440a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53d47f4b-4745-4310-bbf8-5c097fbae425" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ace19daf-1611-4e50-804f-aec14076440a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ace19daf-1611-4e50-804f-aec14076440a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ace19daf-1611-4e50-804f-aec14076440a" xlink:to="loc_us-gaap_ClassOfStockDomain_ace19daf-1611-4e50-804f-aec14076440a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_986ab4fb-3894-4611-a569-c7e73efda033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ace19daf-1611-4e50-804f-aec14076440a" xlink:to="loc_us-gaap_ClassOfStockDomain_986ab4fb-3894-4611-a569-c7e73efda033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_8687b431-20d4-4c8d-a407-b7e07e72087e" xlink:href="mgnx-20201231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_986ab4fb-3894-4611-a569-c7e73efda033" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_8687b431-20d4-4c8d-a407-b7e07e72087e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensation"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended" id="i830bbffeb32c4c39acec0fbae0e46176_StockbasedCompensation"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended" id="ie7fb9ec2b5e24720bafef41cc42b3eb9_StockbasedCompensationTables"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i74b0c0500ed946039e256058958e697a_StockbasedCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b7f09dea-20cb-48c8-bc0d-ab0b162a397f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b7f09dea-20cb-48c8-bc0d-ab0b162a397f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_dcc2cd8e-4090-4f25-931c-d6ed8f1eb47e" xlink:href="mgnx-20201231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_dcc2cd8e-4090-4f25-931c-d6ed8f1eb47e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_aa2273aa-a905-4157-839f-d661ed4e2990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_aa2273aa-a905-4157-839f-d661ed4e2990" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_11202d3c-59e7-4df8-9d46-0363ddbf4e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_11202d3c-59e7-4df8-9d46-0363ddbf4e9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9bef5699-4916-46e1-854d-04ac5a7e5b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9bef5699-4916-46e1-854d-04ac5a7e5b1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a3ae3f9-81c0-41f7-a50e-40bc9d88512f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a3ae3f9-81c0-41f7-a50e-40bc9d88512f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_665cb6d0-67ce-4f66-b4ac-d3836fe47430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a3ae3f9-81c0-41f7-a50e-40bc9d88512f" xlink:to="loc_us-gaap_PlanNameAxis_665cb6d0-67ce-4f66-b4ac-d3836fe47430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_665cb6d0-67ce-4f66-b4ac-d3836fe47430_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_665cb6d0-67ce-4f66-b4ac-d3836fe47430" xlink:to="loc_us-gaap_PlanNameDomain_665cb6d0-67ce-4f66-b4ac-d3836fe47430_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d2be0039-1d8b-4b6e-a986-18ef9ca58166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_665cb6d0-67ce-4f66-b4ac-d3836fe47430" xlink:to="loc_us-gaap_PlanNameDomain_d2be0039-1d8b-4b6e-a986-18ef9ca58166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b6743f80-177b-4736-a57f-ac662d6884dc" xlink:href="mgnx-20201231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d2be0039-1d8b-4b6e-a986-18ef9ca58166" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b6743f80-177b-4736-a57f-ac662d6884dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="icac91ebf2dd9475eaac4569be84fb130_StockbasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_47feef74-4ddc-4f89-835b-ab18135005d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_47feef74-4ddc-4f89-835b-ab18135005d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_0e705708-8f63-48cb-9252-88e388511acd" xlink:href="mgnx-20201231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_0e705708-8f63-48cb-9252-88e388511acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_394ef4e8-e5da-4bec-a270-9cc881c53f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_394ef4e8-e5da-4bec-a270-9cc881c53f4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_416467a1-7fca-4ca1-aa04-dc4b6280b98f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_416467a1-7fca-4ca1-aa04-dc4b6280b98f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_9b09f826-669a-4030-8b04-2557e8f86d8f" xlink:href="mgnx-20201231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_9b09f826-669a-4030-8b04-2557e8f86d8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_f1a26556-cde3-47af-876b-2bc25d5aec46" xlink:href="mgnx-20201231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_f1a26556-cde3-47af-876b-2bc25d5aec46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7cd49bb-ff85-4840-adbf-83982391f4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7cd49bb-ff85-4840-adbf-83982391f4cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_49d69145-e475-44a0-96c2-b037f9b0da00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7cd49bb-ff85-4840-adbf-83982391f4cb" xlink:to="loc_us-gaap_PlanNameAxis_49d69145-e475-44a0-96c2-b037f9b0da00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_49d69145-e475-44a0-96c2-b037f9b0da00_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_49d69145-e475-44a0-96c2-b037f9b0da00" xlink:to="loc_us-gaap_PlanNameDomain_49d69145-e475-44a0-96c2-b037f9b0da00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_404c785b-cc34-4c83-b375-d20cb832cf58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_49d69145-e475-44a0-96c2-b037f9b0da00" xlink:to="loc_us-gaap_PlanNameDomain_404c785b-cc34-4c83-b375-d20cb832cf58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_82750355-8474-4e05-8485-fc6d474ee1b5" xlink:href="mgnx-20201231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_404c785b-cc34-4c83-b375-d20cb832cf58" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_82750355-8474-4e05-8485-fc6d474ee1b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_2ceee07b-4896-482c-a54d-698b323f41b3" xlink:href="mgnx-20201231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_404c785b-cc34-4c83-b375-d20cb832cf58" xlink:to="loc_mgnx_StockIncentivePlan2013Member_2ceee07b-4896-482c-a54d-698b323f41b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9fea2f79-4879-49e1-ad86-154b14630511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_066e4c5a-1d01-43d2-ad02-0c6688ec4a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9fea2f79-4879-49e1-ad86-154b14630511" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_066e4c5a-1d01-43d2-ad02-0c6688ec4a52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61366755-1926-45c6-8933-f7cb0a56e6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9fea2f79-4879-49e1-ad86-154b14630511" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61366755-1926-45c6-8933-f7cb0a56e6b0" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6dd7191a-b2ca-4eb5-9d8a-ccb6a952773b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61366755-1926-45c6-8933-f7cb0a56e6b0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6dd7191a-b2ca-4eb5-9d8a-ccb6a952773b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6dd7191a-b2ca-4eb5-9d8a-ccb6a952773b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dd7191a-b2ca-4eb5-9d8a-ccb6a952773b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6dd7191a-b2ca-4eb5-9d8a-ccb6a952773b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_caaac522-fb62-4390-baef-169bbd9b323b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dd7191a-b2ca-4eb5-9d8a-ccb6a952773b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_caaac522-fb62-4390-baef-169bbd9b323b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cab3e37a-21f0-452a-ae5f-d402f8d0264c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_caaac522-fb62-4390-baef-169bbd9b323b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cab3e37a-21f0-452a-ae5f-d402f8d0264c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_47859c11-f0be-41e9-99ab-d290f331e10e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_caaac522-fb62-4390-baef-169bbd9b323b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_47859c11-f0be-41e9-99ab-d290f331e10e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="ibb814719a8124569b457cb62b62e181a_StockbasedCompensationOptionPricingAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9530e4f1-3fc6-4be2-b51b-17bfc536a928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9530e4f1-3fc6-4be2-b51b-17bfc536a928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_93a2291d-1add-499a-b0d2-55b68f8cf44d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_93a2291d-1add-499a-b0d2-55b68f8cf44d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_90f538ba-f268-43d1-b14f-0d058780b548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_90f538ba-f268-43d1-b14f-0d058780b548" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7d070be9-22a4-4475-9469-99cbf218ea1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7d070be9-22a4-4475-9469-99cbf218ea1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3869ebc7-9343-40fa-ba7d-036730f41215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3869ebc7-9343-40fa-ba7d-036730f41215" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575158e7-61b3-4192-ae2e-4725545011d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575158e7-61b3-4192-ae2e-4725545011d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94b10d8e-1d24-4db4-9224-2bdf97befb2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575158e7-61b3-4192-ae2e-4725545011d1" xlink:to="loc_srt_RangeAxis_94b10d8e-1d24-4db4-9224-2bdf97befb2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94b10d8e-1d24-4db4-9224-2bdf97befb2e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_94b10d8e-1d24-4db4-9224-2bdf97befb2e" xlink:to="loc_srt_RangeMember_94b10d8e-1d24-4db4-9224-2bdf97befb2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8bbaec5c-c96d-4dc2-b0df-cbe14e691e05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_94b10d8e-1d24-4db4-9224-2bdf97befb2e" xlink:to="loc_srt_RangeMember_8bbaec5c-c96d-4dc2-b0df-cbe14e691e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4971f3be-5146-4b24-b15e-d863244083ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8bbaec5c-c96d-4dc2-b0df-cbe14e691e05" xlink:to="loc_srt_MinimumMember_4971f3be-5146-4b24-b15e-d863244083ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3c6bb5db-abcf-4038-b984-7d4fa34e33dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8bbaec5c-c96d-4dc2-b0df-cbe14e691e05" xlink:to="loc_srt_MaximumMember_3c6bb5db-abcf-4038-b984-7d4fa34e33dc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended" id="ib3436f1b6bff4337bd20e7a0c0d97d72_StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5d6ef749-1c82-4aa8-88d1-806b25a4c183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5d6ef749-1c82-4aa8-88d1-806b25a4c183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_674f5f1c-53e3-4bff-920b-6087f5d1afa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_674f5f1c-53e3-4bff-920b-6087f5d1afa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_169bdb9c-bd6c-42f6-8d44-7425175bf561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_169bdb9c-bd6c-42f6-8d44-7425175bf561" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2234c1c7-c729-4ee0-a762-f7d97313bcb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2234c1c7-c729-4ee0-a762-f7d97313bcb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2bd752ca-7408-45ff-9ea1-94a6f6d6c3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a55affae-e927-4371-b1de-00d210319d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a55affae-e927-4371-b1de-00d210319d0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15a9da7d-634c-41e8-aabf-5d8830e1c842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15a9da7d-634c-41e8-aabf-5d8830e1c842" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_940e2a7b-c63a-4b3a-815b-565b8556764d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_940e2a7b-c63a-4b3a-815b-565b8556764d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_64d5d5a8-fc42-461c-86e0-7d9462395fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_64d5d5a8-fc42-461c-86e0-7d9462395fe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2236a60f-5414-40dd-bf31-38b9f38eb3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2236a60f-5414-40dd-bf31-38b9f38eb3f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c7a26bac-4a8d-46c7-97d5-b8521b334402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c7a26bac-4a8d-46c7-97d5-b8521b334402" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d52964c1-ac9b-4ef2-9059-c4e99b7fce35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_398a4dd1-f905-429a-bc6e-eaae3dfd1db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_398a4dd1-f905-429a-bc6e-eaae3dfd1db9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1dd282c4-e2ca-465f-9c69-b9bfaffd6ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1dd282c4-e2ca-465f-9c69-b9bfaffd6ce4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1ebfae34-f7b5-45b4-8719-55cc184c9cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1ebfae34-f7b5-45b4-8719-55cc184c9cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_db067eac-ec66-44b8-ad6d-9a317ad4b4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_db067eac-ec66-44b8-ad6d-9a317ad4b4c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd88f0c7-ffa2-4e44-a6e2-26d9c587ee58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd88f0c7-ffa2-4e44-a6e2-26d9c587ee58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7e747b05-e302-4f59-a92e-448ab4ef9d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7e747b05-e302-4f59-a92e-448ab4ef9d8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_58103228-eaaa-48dd-bee1-bf24b3fc55ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_58103228-eaaa-48dd-bee1-bf24b3fc55ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_087d3903-254e-4a40-bdd4-a829368f41cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_087d3903-254e-4a40-bdd4-a829368f41cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d18adc0-d048-45d7-bc76-0c71495d12bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d18adc0-d048-45d7-bc76-0c71495d12bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33c363ec-a5da-49f6-b4cb-6de94fa798ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33c363ec-a5da-49f6-b4cb-6de94fa798ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_a957835e-16d0-4213-b127-c23cd0ffaf3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_a957835e-16d0-4213-b127-c23cd0ffaf3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b8278d0b-0c43-4311-afb2-a7d78ad3e738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b8278d0b-0c43-4311-afb2-a7d78ad3e738" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_54fd67fb-14ed-405c-a7bf-ca1a45c035ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95decb6b-ea6d-4e91-8d7c-2a6e2e28ebe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95decb6b-ea6d-4e91-8d7c-2a6e2e28ebe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39835b91-dfab-4066-9aed-6f12a276ed4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39835b91-dfab-4066-9aed-6f12a276ed4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cfce2ab6-138c-45ec-a9ee-ce699aa1ea38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cfce2ab6-138c-45ec-a9ee-ce699aa1ea38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a9870a1c-2362-4ae8-874a-56a2ad840835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a9870a1c-2362-4ae8-874a-56a2ad840835" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_53db40c2-ee2d-4c58-92b5-5b250beee9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d731577-e08a-4541-add2-38d10328ced6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d731577-e08a-4541-add2-38d10328ced6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_54e473af-6204-40ff-9dd0-a68e14ba325d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_54e473af-6204-40ff-9dd0-a68e14ba325d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bc6d2bf-d602-43a6-a1ab-062ade80dfba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bc6d2bf-d602-43a6-a1ab-062ade80dfba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1f5c9d40-517d-4867-a324-6dd29fb09169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1f5c9d40-517d-4867-a324-6dd29fb09169" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a6cfc807-c0af-4958-994d-31a06c0c5d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a6cfc807-c0af-4958-994d-31a06c0c5d8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99e4fad0-523c-4faf-8c8f-2aaee8fa0e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99e4fad0-523c-4faf-8c8f-2aaee8fa0e0c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e7673e2-d958-4c27-8efb-d6bc0891b793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e7673e2-d958-4c27-8efb-d6bc0891b793" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06255185-7182-426d-bdab-c69093821cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9be762a7-90ad-4b7d-8250-691c37d874a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9be762a7-90ad-4b7d-8250-691c37d874a9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_47d2182c-74d7-47ab-ae0f-da1c95683915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4334457-b288-4343-993e-d06a8fdb58e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4334457-b288-4343-993e-d06a8fdb58e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_87153bd0-ebb7-4a16-a25a-772303acfe4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4334457-b288-4343-993e-d06a8fdb58e9" xlink:to="loc_us-gaap_AwardTypeAxis_87153bd0-ebb7-4a16-a25a-772303acfe4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87153bd0-ebb7-4a16-a25a-772303acfe4b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_87153bd0-ebb7-4a16-a25a-772303acfe4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87153bd0-ebb7-4a16-a25a-772303acfe4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43880e54-e600-47f2-98da-470d5a5dd4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_87153bd0-ebb7-4a16-a25a-772303acfe4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43880e54-e600-47f2-98da-470d5a5dd4f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_be5c9cbd-df28-4a53-a717-7a6d656a496d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43880e54-e600-47f2-98da-470d5a5dd4f3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_be5c9cbd-df28-4a53-a717-7a6d656a496d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_09ab7bcf-71cc-4a8e-a50a-ddc150eff08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4334457-b288-4343-993e-d06a8fdb58e9" xlink:to="loc_us-gaap_PlanNameAxis_09ab7bcf-71cc-4a8e-a50a-ddc150eff08e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_09ab7bcf-71cc-4a8e-a50a-ddc150eff08e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_09ab7bcf-71cc-4a8e-a50a-ddc150eff08e" xlink:to="loc_us-gaap_PlanNameDomain_09ab7bcf-71cc-4a8e-a50a-ddc150eff08e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_added44c-846f-44c8-8c6d-0c1769edcac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_09ab7bcf-71cc-4a8e-a50a-ddc150eff08e" xlink:to="loc_us-gaap_PlanNameDomain_added44c-846f-44c8-8c6d-0c1769edcac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_ac49cf42-6f1a-4ee1-8dd1-247e1a5d5892" xlink:href="mgnx-20201231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_added44c-846f-44c8-8c6d-0c1769edcac9" xlink:to="loc_mgnx_StockIncentivePlan2013Member_ac49cf42-6f1a-4ee1-8dd1-247e1a5d5892" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended" id="i777f8a69e6a145aa9707668844b46cb6_IncomeTaxes"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended" id="iede31b1798d6490a839cf67c0238c037_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended" id="i888cda0354654f75b9e851dc264c8be0_IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_7a5d5b21-f603-438f-b5fa-0178979f567d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_7a5d5b21-f603-438f-b5fa-0178979f567d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_66aaeee4-7b4a-4ded-9c71-3cd3e234336e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_66aaeee4-7b4a-4ded-9c71-3cd3e234336e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_1f4aebc9-b739-4353-98c3-7c5d1efe3d29" xlink:href="mgnx-20201231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_1f4aebc9-b739-4353-98c3-7c5d1efe3d29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_d5a57025-68ee-4bbd-ad84-626b518501f2" xlink:href="mgnx-20201231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_d5a57025-68ee-4bbd-ad84-626b518501f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_47ae8ce7-ebe9-41b3-acd2-a402bb4884b9" xlink:href="mgnx-20201231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_47ae8ce7-ebe9-41b3-acd2-a402bb4884b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_88719ed3-2165-4ded-b59e-88b5810b0a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:to="loc_us-gaap_TaxPeriodAxis_88719ed3-2165-4ded-b59e-88b5810b0a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_88719ed3-2165-4ded-b59e-88b5810b0a9b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_88719ed3-2165-4ded-b59e-88b5810b0a9b" xlink:to="loc_us-gaap_TaxPeriodDomain_88719ed3-2165-4ded-b59e-88b5810b0a9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_a7f91f66-676a-47ec-9e04-6e0fe567a481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_88719ed3-2165-4ded-b59e-88b5810b0a9b" xlink:to="loc_us-gaap_TaxPeriodDomain_a7f91f66-676a-47ec-9e04-6e0fe567a481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_bffe973e-0d6f-4855-a07a-3eb568290a37" xlink:href="mgnx-20201231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_a7f91f66-676a-47ec-9e04-6e0fe567a481" xlink:to="loc_mgnx_TaxYear2025To2037Member_bffe973e-0d6f-4855-a07a-3eb568290a37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_5d2b54bf-db3d-4d7d-8d4f-bfc6d41f528f" xlink:href="mgnx-20201231.xsd#mgnx_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_a7f91f66-676a-47ec-9e04-6e0fe567a481" xlink:to="loc_mgnx_IndefiniteMember_5d2b54bf-db3d-4d7d-8d4f-bfc6d41f528f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3492e00e-9cf1-4bde-ad80-a21eadda7e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3492e00e-9cf1-4bde-ad80-a21eadda7e25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3492e00e-9cf1-4bde-ad80-a21eadda7e25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3492e00e-9cf1-4bde-ad80-a21eadda7e25" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3492e00e-9cf1-4bde-ad80-a21eadda7e25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_31f1e9e5-faf7-4c91-902b-e4d38f00fde2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3492e00e-9cf1-4bde-ad80-a21eadda7e25" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_31f1e9e5-faf7-4c91-902b-e4d38f00fde2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_50ffd2d6-80ba-476a-9c6d-62c725b89865" xlink:href="mgnx-20201231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_31f1e9e5-faf7-4c91-902b-e4d38f00fde2" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_50ffd2d6-80ba-476a-9c6d-62c725b89865" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_436ca719-a049-4d76-9fb1-63460bc3e2c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_50ffd2d6-80ba-476a-9c6d-62c725b89865" xlink:to="loc_us-gaap_DomesticCountryMember_436ca719-a049-4d76-9fb1-63460bc3e2c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b99a545-af74-4e64-818e-47383e049e14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:to="loc_srt_RangeAxis_3b99a545-af74-4e64-818e-47383e049e14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b99a545-af74-4e64-818e-47383e049e14_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3b99a545-af74-4e64-818e-47383e049e14" xlink:to="loc_srt_RangeMember_3b99a545-af74-4e64-818e-47383e049e14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4babd0a-aa80-430e-82e5-59869eda75b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3b99a545-af74-4e64-818e-47383e049e14" xlink:to="loc_srt_RangeMember_e4babd0a-aa80-430e-82e5-59869eda75b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f643e004-1d56-4b9d-9336-a883dcbcb0d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e4babd0a-aa80-430e-82e5-59869eda75b3" xlink:to="loc_srt_MinimumMember_f643e004-1d56-4b9d-9336-a883dcbcb0d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_582b6aa7-c1bb-4b33-8516-58dfbf1d8350" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e4babd0a-aa80-430e-82e5-59869eda75b3" xlink:to="loc_srt_MaximumMember_582b6aa7-c1bb-4b33-8516-58dfbf1d8350" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended" id="i7ed823bad44a475a9d327bd9d1313326_IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i234bcb9ac47c40ccb6cfdcb43484653f_IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_861db3ec-36b8-4c7f-8853-d28501474047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_861db3ec-36b8-4c7f-8853-d28501474047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_324bf0e5-cc4e-4368-a3bc-dd6d72134874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_324bf0e5-cc4e-4368-a3bc-dd6d72134874" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d9c93e92-cf34-4ab7-b63f-e5398fedc536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d9c93e92-cf34-4ab7-b63f-e5398fedc536" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_56ec3518-6bb8-4897-875c-761e6dc9f483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_56ec3518-6bb8-4897-875c-761e6dc9f483" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_df30bee1-631c-442d-a004-35ece228fede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2a680cbb-ae9a-4bb6-87da-1454d6e4a5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2a680cbb-ae9a-4bb6-87da-1454d6e4a5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_580eed2d-45ed-4e44-ab35-97ad3a746d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_580eed2d-45ed-4e44-ab35-97ad3a746d48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_2a060c23-9094-4fcc-abd7-f615ae816a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_2a060c23-9094-4fcc-abd7-f615ae816a04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56087d59-e9c0-40ad-84cb-d600c198b58c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_2a060c23-9094-4fcc-abd7-f615ae816a04" xlink:to="loc_srt_RangeAxis_56087d59-e9c0-40ad-84cb-d600c198b58c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56087d59-e9c0-40ad-84cb-d600c198b58c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_56087d59-e9c0-40ad-84cb-d600c198b58c" xlink:to="loc_srt_RangeMember_56087d59-e9c0-40ad-84cb-d600c198b58c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05e18c70-7b34-49dd-80b1-91e9b19ce700" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_56087d59-e9c0-40ad-84cb-d600c198b58c" xlink:to="loc_srt_RangeMember_05e18c70-7b34-49dd-80b1-91e9b19ce700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88a49549-0a73-434c-b055-207adb91200b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_05e18c70-7b34-49dd-80b1-91e9b19ce700" xlink:to="loc_srt_MinimumMember_88a49549-0a73-434c-b055-207adb91200b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreements"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended" id="i7cdd5f4fc75645b1ae742ae6baebfd11_CollaborationandOtherAgreements"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended" id="i82afc205fc3b4f478acc4c0ea57b8efe_CollaborationandOtherAgreementsIncyteCorporationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_28c64443-e418-4bed-8287-4da135a8a62c" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_NonRefundableUpfrontFees_28c64443-e418-4bed-8287-4da135a8a62c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_02412ca4-1c10-4665-99b6-ddef85a653a6" xlink:href="mgnx-20201231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_02412ca4-1c10-4665-99b6-ddef85a653a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_071e8aac-d413-450d-b8ac-df634412750d" xlink:href="mgnx-20201231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_071e8aac-d413-450d-b8ac-df634412750d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_10f4345a-41fa-4840-b0f8-f4e268485996" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_10f4345a-41fa-4840-b0f8-f4e268485996" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized_684a4118-92a6-45a2-b7c0-98e6c0d47b84" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized_684a4118-92a6-45a2-b7c0-98e6c0d47b84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_23945176-ae13-4663-9b82-2aaf2e89d9b5" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_23945176-ae13-4663-9b82-2aaf2e89d9b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_d56fd159-44d4-4c05-bdaf-1e51df2c0260" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_NumberOfPerformanceObligations_d56fd159-44d4-4c05-bdaf-1e51df2c0260" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_ea183719-8c92-4650-9853-21500132dc8f" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_ea183719-8c92-4650-9853-21500132dc8f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_6c7ad48a-f24e-4e03-abd2-3cc4314776c6" xlink:href="mgnx-20201231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_6c7ad48a-f24e-4e03-abd2-3cc4314776c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2c2288b8-da4e-4416-8de7-9366eb04f271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_us-gaap_Revenues_2c2288b8-da4e-4416-8de7-9366eb04f271" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1bf39b04-f620-4edf-b7fd-7382696c6d35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:to="loc_srt_ProductOrServiceAxis_1bf39b04-f620-4edf-b7fd-7382696c6d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1bf39b04-f620-4edf-b7fd-7382696c6d35_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1bf39b04-f620-4edf-b7fd-7382696c6d35" xlink:to="loc_srt_ProductsAndServicesDomain_1bf39b04-f620-4edf-b7fd-7382696c6d35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c38d918d-85d2-40c1-a672-ea841fa9525d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1bf39b04-f620-4edf-b7fd-7382696c6d35" xlink:to="loc_srt_ProductsAndServicesDomain_c38d918d-85d2-40c1-a672-ea841fa9525d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_9c3ae73e-26b8-4ec2-86a1-ef3961a5b255" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c38d918d-85d2-40c1-a672-ea841fa9525d" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_9c3ae73e-26b8-4ec2-86a1-ef3961a5b255" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d11dbf27-447a-4044-bf38-eabdb432a5d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:to="loc_srt_RangeAxis_d11dbf27-447a-4044-bf38-eabdb432a5d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d11dbf27-447a-4044-bf38-eabdb432a5d8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d11dbf27-447a-4044-bf38-eabdb432a5d8" xlink:to="loc_srt_RangeMember_d11dbf27-447a-4044-bf38-eabdb432a5d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d79b12c8-7e40-472f-86a5-f725139ce6c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d11dbf27-447a-4044-bf38-eabdb432a5d8" xlink:to="loc_srt_RangeMember_d79b12c8-7e40-472f-86a5-f725139ce6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e3380326-8207-4051-82bf-6116e0328854" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d79b12c8-7e40-472f-86a5-f725139ce6c7" xlink:to="loc_srt_MaximumMember_e3380326-8207-4051-82bf-6116e0328854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eca96caa-8a17-4baa-946b-1bb22bf5c79d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d79b12c8-7e40-472f-86a5-f725139ce6c7" xlink:to="loc_srt_MinimumMember_eca96caa-8a17-4baa-946b-1bb22bf5c79d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_09e68542-ddfb-493b-86e6-07ba21c1dfe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_09e68542-ddfb-493b-86e6-07ba21c1dfe5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09e68542-ddfb-493b-86e6-07ba21c1dfe5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_09e68542-ddfb-493b-86e6-07ba21c1dfe5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09e68542-ddfb-493b-86e6-07ba21c1dfe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_09e68542-ddfb-493b-86e6-07ba21c1dfe5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_5b6878e2-d027-4d3e-8c4f-4932162c8949" xlink:href="mgnx-20201231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_5b6878e2-d027-4d3e-8c4f-4932162c8949" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_826cb5b0-61d1-45f5-9f86-0928c46685ea" xlink:href="mgnx-20201231.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_826cb5b0-61d1-45f5-9f86-0928c46685ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_07024c16-389e-42b0-ba3c-4912ea707a99" xlink:href="mgnx-20201231.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_07024c16-389e-42b0-ba3c-4912ea707a99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_591c78e0-e0fa-4c48-84c1-a94986f39cee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:to="loc_srt_CounterpartyNameAxis_591c78e0-e0fa-4c48-84c1-a94986f39cee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_591c78e0-e0fa-4c48-84c1-a94986f39cee_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_591c78e0-e0fa-4c48-84c1-a94986f39cee" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_591c78e0-e0fa-4c48-84c1-a94986f39cee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee79537f-819c-4018-b4eb-3e42cfdac9a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_591c78e0-e0fa-4c48-84c1-a94986f39cee" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee79537f-819c-4018-b4eb-3e42cfdac9a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_3c0dddef-73e7-41f8-8516-4dbbad0c2630" xlink:href="mgnx-20201231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee79537f-819c-4018-b4eb-3e42cfdac9a7" xlink:to="loc_mgnx_IncyteCorporationMember_3c0dddef-73e7-41f8-8516-4dbbad0c2630" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsServierDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="extended" id="i4ecbda7662df436abe8ad110a7491c9a_CollaborationandOtherAgreementsServierDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_3b54f2df-48e7-40bc-b53c-cd04a5ce7091" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_mgnx_NonRefundableUpfrontFees_3b54f2df-48e7-40bc-b53c-cd04a5ce7091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment_27a435fd-b491-41fe-b615-d038eb15c2d9" xlink:href="mgnx-20201231.xsd#mgnx_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_mgnx_MilestonePayment_27a435fd-b491-41fe-b615-d038eb15c2d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6482f8b4-de15-498b-9bfc-9a9bbfe85dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_us-gaap_Revenues_6482f8b4-de15-498b-9bfc-9a9bbfe85dd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_09a157b4-dc4b-4de3-8ee7-fa312c0b798d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_us-gaap_ContractWithCustomerLiability_09a157b4-dc4b-4de3-8ee7-fa312c0b798d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f267f4df-001b-4130-9150-003f1c6db69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f267f4df-001b-4130-9150-003f1c6db69b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee_ec44d878-390b-4042-96bd-f824abd2848e" xlink:href="mgnx-20201231.xsd#mgnx_OptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_mgnx_OptionExerciseFee_ec44d878-390b-4042-96bd-f824abd2848e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_157256d4-2ca0-48f0-b669-1ae7a2f652f6" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_157256d4-2ca0-48f0-b669-1ae7a2f652f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c17d6b90-51f4-4edf-9bef-75499954a1c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:to="loc_srt_ProductOrServiceAxis_c17d6b90-51f4-4edf-9bef-75499954a1c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c17d6b90-51f4-4edf-9bef-75499954a1c1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c17d6b90-51f4-4edf-9bef-75499954a1c1" xlink:to="loc_srt_ProductsAndServicesDomain_c17d6b90-51f4-4edf-9bef-75499954a1c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34d5f427-215c-4b43-8869-fbf4b2a22bc6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c17d6b90-51f4-4edf-9bef-75499954a1c1" xlink:to="loc_srt_ProductsAndServicesDomain_34d5f427-215c-4b43-8869-fbf4b2a22bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_9cd029aa-c4d9-43fd-8ef9-c21abeb2595a" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_34d5f427-215c-4b43-8869-fbf4b2a22bc6" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_9cd029aa-c4d9-43fd-8ef9-c21abeb2595a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_20039c5f-b87d-47af-bddb-c26c7c4f6a38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:to="loc_srt_CounterpartyNameAxis_20039c5f-b87d-47af-bddb-c26c7c4f6a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20039c5f-b87d-47af-bddb-c26c7c4f6a38_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_20039c5f-b87d-47af-bddb-c26c7c4f6a38" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20039c5f-b87d-47af-bddb-c26c7c4f6a38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e595c7af-a00f-4bb7-aae2-92216efd930d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_20039c5f-b87d-47af-bddb-c26c7c4f6a38" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e595c7af-a00f-4bb7-aae2-92216efd930d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember_1000b650-5914-45ad-b136-5fba63a049ca" xlink:href="mgnx-20201231.xsd#mgnx_ServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e595c7af-a00f-4bb7-aae2-92216efd930d" xlink:to="loc_mgnx_ServierMember_1000b650-5914-45ad-b136-5fba63a049ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_954c4f1b-a87d-491c-8ce0-c3c037eb2d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_954c4f1b-a87d-491c-8ce0-c3c037eb2d7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_954c4f1b-a87d-491c-8ce0-c3c037eb2d7e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_954c4f1b-a87d-491c-8ce0-c3c037eb2d7e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_954c4f1b-a87d-491c-8ce0-c3c037eb2d7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b16a68b6-05f6-468e-85ea-012728acc56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_954c4f1b-a87d-491c-8ce0-c3c037eb2d7e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b16a68b6-05f6-468e-85ea-012728acc56b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember_9dc445aa-a122-4aeb-8f67-923267f2f86c" xlink:href="mgnx-20201231.xsd#mgnx_ServierDARTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b16a68b6-05f6-468e-85ea-012728acc56b" xlink:to="loc_mgnx_ServierDARTMember_9dc445aa-a122-4aeb-8f67-923267f2f86c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierAgreementMGD007OptionMember_f1105bcc-9ecf-4e94-b58a-3f25a8fc105c" xlink:href="mgnx-20201231.xsd#mgnx_ServierAgreementMGD007OptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b16a68b6-05f6-468e-85ea-012728acc56b" xlink:to="loc_mgnx_ServierAgreementMGD007OptionMember_f1105bcc-9ecf-4e94-b58a-3f25a8fc105c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended" id="i99d044f52232489694e6cd3c2017a577_CollaborationandOtherAgreementsZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_a900928a-9e7d-4fbb-a031-c068b7c791ec" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_NonRefundableUpfrontFees_a900928a-9e7d-4fbb-a031-c068b7c791ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_3b18ed5e-5e59-42a3-bf10-388e7fdfc819" xlink:href="mgnx-20201231.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_3b18ed5e-5e59-42a3-bf10-388e7fdfc819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_dbf48bd0-7808-4ef5-81b3-585b44772c9a" xlink:href="mgnx-20201231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_dbf48bd0-7808-4ef5-81b3-585b44772c9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_b0cf0a04-a230-4d8f-b831-a21afb129717" xlink:href="mgnx-20201231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_b0cf0a04-a230-4d8f-b831-a21afb129717" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_b52595ce-aa7f-4663-93c9-5b73c39aa9b9" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_b52595ce-aa7f-4663-93c9-5b73c39aa9b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_934eceba-fe7a-49e8-b096-c05b00f183fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_us-gaap_Revenues_934eceba-fe7a-49e8-b096-c05b00f183fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_668fdfbb-73a3-4702-8339-e54a32e58169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_668fdfbb-73a3-4702-8339-e54a32e58169" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EntitledMilestonePaymentsUnderAgreement_f053dd2b-99da-4f89-bf11-ebdee7f770a4" xlink:href="mgnx-20201231.xsd#mgnx_EntitledMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_EntitledMilestonePaymentsUnderAgreement_f053dd2b-99da-4f89-bf11-ebdee7f770a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_b2309410-4ee0-466d-bff8-f9f483151891" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_RevenuesTaxWithholding_b2309410-4ee0-466d-bff8-f9f483151891" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0ef8e995-79de-4f68-8645-1005267b4325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0ef8e995-79de-4f68-8645-1005267b4325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0ef8e995-79de-4f68-8645-1005267b4325_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0ef8e995-79de-4f68-8645-1005267b4325" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0ef8e995-79de-4f68-8645-1005267b4325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0ef8e995-79de-4f68-8645-1005267b4325" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_484a90f0-61c7-4f08-855e-3e30d9265d65" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_484a90f0-61c7-4f08-855e-3e30d9265d65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_48c549d4-d40d-4f8b-b473-c7af48f4e574" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_48c549d4-d40d-4f8b-b473-c7af48f4e574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_138a2263-8669-463c-9662-ef0b2f627c09" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_138a2263-8669-463c-9662-ef0b2f627c09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_451ec044-5677-41ad-b189-dd2a56398502" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_451ec044-5677-41ad-b189-dd2a56398502" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_77e8e657-f564-46a2-9bb8-2ee682071b35" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_77e8e657-f564-46a2-9bb8-2ee682071b35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e415e574-2bba-4873-aa85-3ace87bdc720" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:to="loc_srt_CounterpartyNameAxis_e415e574-2bba-4873-aa85-3ace87bdc720" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e415e574-2bba-4873-aa85-3ace87bdc720_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e415e574-2bba-4873-aa85-3ace87bdc720" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e415e574-2bba-4873-aa85-3ace87bdc720_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2591feec-3dbf-4835-af11-8984b8b1d987" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e415e574-2bba-4873-aa85-3ace87bdc720" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2591feec-3dbf-4835-af11-8984b8b1d987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember_99a26c8c-cbc7-4191-a103-4a4a598eddcf" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2591feec-3dbf-4835-af11-8984b8b1d987" xlink:to="loc_mgnx_ZaiLabsMember_99a26c8c-cbc7-4191-a103-4a4a598eddcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_efa72648-0f91-41ca-ace2-c082c48347d3" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2591feec-3dbf-4835-af11-8984b8b1d987" xlink:to="loc_mgnx_ZaiLabMember_efa72648-0f91-41ca-ace2-c082c48347d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed8c7d9c-09e2-4caa-8f06-bd3df871387f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:to="loc_srt_RangeAxis_ed8c7d9c-09e2-4caa-8f06-bd3df871387f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed8c7d9c-09e2-4caa-8f06-bd3df871387f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ed8c7d9c-09e2-4caa-8f06-bd3df871387f" xlink:to="loc_srt_RangeMember_ed8c7d9c-09e2-4caa-8f06-bd3df871387f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62342d92-4318-4d98-ac1e-0c4079730825" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ed8c7d9c-09e2-4caa-8f06-bd3df871387f" xlink:to="loc_srt_RangeMember_62342d92-4318-4d98-ac1e-0c4079730825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b62a4fd-a8ea-4c65-8d79-b6751f234123" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_62342d92-4318-4d98-ac1e-0c4079730825" xlink:to="loc_srt_MaximumMember_5b62a4fd-a8ea-4c65-8d79-b6751f234123" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended" id="i9933c3a76a094b48a726523f7a0dd181_CollaborationandOtherAgreementsJanssenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_b142f1cc-cf05-4221-8214-52590aad7239" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_NonRefundableUpfrontFees_b142f1cc-cf05-4221-8214-52590aad7239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_23a961c1-fc0e-4fa7-8812-1491492f1ad7" xlink:href="mgnx-20201231.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_23a961c1-fc0e-4fa7-8812-1491492f1ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_2c9494e4-22f2-4e43-829d-942a2b510883" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_2c9494e4-22f2-4e43-829d-942a2b510883" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0935ff0c-a509-470e-9f3c-f4df43510528" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0935ff0c-a509-470e-9f3c-f4df43510528" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0143cef-36c3-43aa-91d5-da65c6177523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_us-gaap_Revenues_f0143cef-36c3-43aa-91d5-da65c6177523" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b4a4973f-3bce-4019-b9f5-47b3e9d2f2de" xlink:href="mgnx-20201231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b4a4973f-3bce-4019-b9f5-47b3e9d2f2de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e4ee4825-9870-4fcd-832a-41af33a6a7cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:to="loc_srt_CounterpartyNameAxis_e4ee4825-9870-4fcd-832a-41af33a6a7cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4ee4825-9870-4fcd-832a-41af33a6a7cb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e4ee4825-9870-4fcd-832a-41af33a6a7cb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4ee4825-9870-4fcd-832a-41af33a6a7cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53db4cbf-6d55-4a68-bcf1-d9c6c40977a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e4ee4825-9870-4fcd-832a-41af33a6a7cb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53db4cbf-6d55-4a68-bcf1-d9c6c40977a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_908fdf59-20e3-493b-b198-54a893fc7680" xlink:href="mgnx-20201231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53db4cbf-6d55-4a68-bcf1-d9c6c40977a3" xlink:to="loc_mgnx_JanssenBiotechIncMember_908fdf59-20e3-493b-b198-54a893fc7680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a42cb4ee-1df1-4cf3-965c-97850bbb71e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a42cb4ee-1df1-4cf3-965c-97850bbb71e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a42cb4ee-1df1-4cf3-965c-97850bbb71e1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a42cb4ee-1df1-4cf3-965c-97850bbb71e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a42cb4ee-1df1-4cf3-965c-97850bbb71e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc15f5a-72ab-45b0-b144-9930178153da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a42cb4ee-1df1-4cf3-965c-97850bbb71e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc15f5a-72ab-45b0-b144-9930178153da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_934c532a-9fc6-4f0f-8738-30c038531368" xlink:href="mgnx-20201231.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc15f5a-72ab-45b0-b144-9930178153da" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_934c532a-9fc6-4f0f-8738-30c038531368" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c9316a6c-f63e-47a0-82de-19158d20f2e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:to="loc_srt_ProductOrServiceAxis_c9316a6c-f63e-47a0-82de-19158d20f2e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c9316a6c-f63e-47a0-82de-19158d20f2e8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c9316a6c-f63e-47a0-82de-19158d20f2e8" xlink:to="loc_srt_ProductsAndServicesDomain_c9316a6c-f63e-47a0-82de-19158d20f2e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_30d09ee8-e3c8-498f-833d-688ccf78bd97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c9316a6c-f63e-47a0-82de-19158d20f2e8" xlink:to="loc_srt_ProductsAndServicesDomain_30d09ee8-e3c8-498f-833d-688ccf78bd97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_72535e48-c80a-496b-b8e7-c94d52d6d422" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_30d09ee8-e3c8-498f-833d-688ccf78bd97" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_72535e48-c80a-496b-b8e7-c94d52d6d422" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended" id="i6f32cbec6d38461f8e59ade36423047e_CollaborationandOtherAgreementsIMabBiopharmaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_689b1ac4-0bd7-46cc-95a9-faae117397b7" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_mgnx_NonRefundableUpfrontFees_689b1ac4-0bd7-46cc-95a9-faae117397b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_60bc949d-63c6-473d-9340-dd31d9ddf196" xlink:href="mgnx-20201231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_60bc949d-63c6-473d-9340-dd31d9ddf196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_532d602d-23fa-4852-abd0-d3eea21bfb27" xlink:href="mgnx-20201231.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_532d602d-23fa-4852-abd0-d3eea21bfb27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4c35ef3f-a282-4886-8693-47bee61fe377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_us-gaap_Revenues_4c35ef3f-a282-4886-8693-47bee61fe377" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1a7d1669-1485-450e-8f85-a78f97300744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1a7d1669-1485-450e-8f85-a78f97300744" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_761c5514-dc25-4f0f-98d6-f29081553cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_761c5514-dc25-4f0f-98d6-f29081553cae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a01e84a6-5437-48e7-96f7-e4952e35ff24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a01e84a6-5437-48e7-96f7-e4952e35ff24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_49354cf9-dd7f-4857-afde-757e1ab310ef" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_49354cf9-dd7f-4857-afde-757e1ab310ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3106309b-b42d-48b8-9a32-edf4e0f91c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3106309b-b42d-48b8-9a32-edf4e0f91c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3106309b-b42d-48b8-9a32-edf4e0f91c82_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3106309b-b42d-48b8-9a32-edf4e0f91c82" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3106309b-b42d-48b8-9a32-edf4e0f91c82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0cdc54f3-0176-4eb9-960c-b0b2fca779a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3106309b-b42d-48b8-9a32-edf4e0f91c82" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0cdc54f3-0176-4eb9-960c-b0b2fca779a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_03323e6e-8865-4046-898a-d013c6d1df58" xlink:href="mgnx-20201231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0cdc54f3-0176-4eb9-960c-b0b2fca779a0" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_03323e6e-8865-4046-898a-d013c6d1df58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9aa45a5d-4250-4062-83e7-28ecab9292aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:to="loc_srt_CounterpartyNameAxis_9aa45a5d-4250-4062-83e7-28ecab9292aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9aa45a5d-4250-4062-83e7-28ecab9292aa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9aa45a5d-4250-4062-83e7-28ecab9292aa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9aa45a5d-4250-4062-83e7-28ecab9292aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194a76a4-daf1-49b8-8950-3983ff89f2c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9aa45a5d-4250-4062-83e7-28ecab9292aa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194a76a4-daf1-49b8-8950-3983ff89f2c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_e99df3f9-22e0-4098-a61e-ee5d444ed66a" xlink:href="mgnx-20201231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194a76a4-daf1-49b8-8950-3983ff89f2c0" xlink:to="loc_mgnx_IMabBiopharmaMember_e99df3f9-22e0-4098-a61e-ee5d444ed66a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5ea12b22-16fb-4631-a12e-bb1a13ba81b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:to="loc_srt_RangeAxis_5ea12b22-16fb-4631-a12e-bb1a13ba81b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5ea12b22-16fb-4631-a12e-bb1a13ba81b2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5ea12b22-16fb-4631-a12e-bb1a13ba81b2" xlink:to="loc_srt_RangeMember_5ea12b22-16fb-4631-a12e-bb1a13ba81b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5420e00f-634e-485a-a6c4-cf513da287b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5ea12b22-16fb-4631-a12e-bb1a13ba81b2" xlink:to="loc_srt_RangeMember_5420e00f-634e-485a-a6c4-cf513da287b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fbbcc060-d800-4c03-8fa8-32932107ab65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5420e00f-634e-485a-a6c4-cf513da287b0" xlink:to="loc_srt_MaximumMember_fbbcc060-d800-4c03-8fa8-32932107ab65" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended" id="ied01dd7a192a4932bb14bb91e5adb7e5_CollaborationandOtherAgreementsRocheDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ce79f164-3699-4f45-b29a-34869c71b369" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ce79f164-3699-4f45-b29a-34869c71b369" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_327ffb92-314a-47ee-8f51-37d88e45ddac" xlink:href="mgnx-20201231.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_327ffb92-314a-47ee-8f51-37d88e45ddac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_836e5b96-25d0-4e3d-91ef-fbda71e4d0aa" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_NumberOfPerformanceObligations_836e5b96-25d0-4e3d-91ef-fbda71e4d0aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_68be85c7-cda5-4bc8-bf6e-deb0e94edb17" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_68be85c7-cda5-4bc8-bf6e-deb0e94edb17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_c8d46572-e85e-40a7-9eeb-243de45b8d02" xlink:href="mgnx-20201231.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_c8d46572-e85e-40a7-9eeb-243de45b8d02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2175830f-0569-4aa3-9f70-086edd846d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_us-gaap_Revenues_2175830f-0569-4aa3-9f70-086edd846d5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8055baff-c39f-4300-92bb-bd87f4f319e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8055baff-c39f-4300-92bb-bd87f4f319e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_3389ae89-69b1-4e5f-a1a7-37e1efee8aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_us-gaap_DeferredRevenueCurrent_3389ae89-69b1-4e5f-a1a7-37e1efee8aa4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_de58a650-46d8-4152-992e-6aaa67e9be1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_de58a650-46d8-4152-992e-6aaa67e9be1b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37c34be3-8f60-4083-a8e3-5faf2969335f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37c34be3-8f60-4083-a8e3-5faf2969335f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_68db4d07-1ef9-43da-b1c1-4c71405f6b41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37c34be3-8f60-4083-a8e3-5faf2969335f" xlink:to="loc_srt_CounterpartyNameAxis_68db4d07-1ef9-43da-b1c1-4c71405f6b41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68db4d07-1ef9-43da-b1c1-4c71405f6b41_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_68db4d07-1ef9-43da-b1c1-4c71405f6b41" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68db4d07-1ef9-43da-b1c1-4c71405f6b41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b74e415-4c51-4e64-9003-bb774647508f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_68db4d07-1ef9-43da-b1c1-4c71405f6b41" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b74e415-4c51-4e64-9003-bb774647508f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_9004be94-23db-4947-8418-c41441eae190" xlink:href="mgnx-20201231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b74e415-4c51-4e64-9003-bb774647508f" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_9004be94-23db-4947-8418-c41441eae190" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended" id="ifc180b64dfc241f99d2af40a065de720_CollaborationandOtherAgreementsProventionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_0ed91402-40b1-4126-817d-a29ea5131bf9" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_0ed91402-40b1-4126-817d-a29ea5131bf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_10cbae17-ac47-4f51-9f6d-685243e4bf0b" xlink:href="mgnx-20201231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_10cbae17-ac47-4f51-9f6d-685243e4bf0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_490345bf-130e-4e24-b179-ed559f8e5e8e" xlink:href="mgnx-20201231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_490345bf-130e-4e24-b179-ed559f8e5e8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_e81bf69e-b6e7-416f-8f17-fdee9ae96213" xlink:href="mgnx-20201231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_e81bf69e-b6e7-416f-8f17-fdee9ae96213" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_241a259e-74d5-4726-8d95-467c2503e6c0" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_NumberOfPerformanceObligations_241a259e-74d5-4726-8d95-467c2503e6c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a61b2a39-d988-4239-930b-1c047075e1b0" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a61b2a39-d988-4239-930b-1c047075e1b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_1b0a7cb8-13fa-4561-b2b8-cb241db3597c" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_1b0a7cb8-13fa-4561-b2b8-cb241db3597c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_02d18167-0176-41f0-9dee-ff88e950d73b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_us-gaap_Revenues_02d18167-0176-41f0-9dee-ff88e950d73b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_381161a9-54c1-4bf1-a808-b02ee2ebf160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_us-gaap_DeferredRevenueCurrent_381161a9-54c1-4bf1-a808-b02ee2ebf160" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_cf358cb1-2ea5-4658-8810-84d5d730188f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_cf358cb1-2ea5-4658-8810-84d5d730188f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_99194649-cf43-442e-a93a-01193e8f06fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:to="loc_srt_ProductOrServiceAxis_99194649-cf43-442e-a93a-01193e8f06fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99194649-cf43-442e-a93a-01193e8f06fe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_99194649-cf43-442e-a93a-01193e8f06fe" xlink:to="loc_srt_ProductsAndServicesDomain_99194649-cf43-442e-a93a-01193e8f06fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18b528cc-b0a5-446d-bddc-2cd4fa504025" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_99194649-cf43-442e-a93a-01193e8f06fe" xlink:to="loc_srt_ProductsAndServicesDomain_18b528cc-b0a5-446d-bddc-2cd4fa504025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_8e3aba89-7125-4dba-9fb7-832dc248a881" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18b528cc-b0a5-446d-bddc-2cd4fa504025" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_8e3aba89-7125-4dba-9fb7-832dc248a881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_31842baf-e2ab-44d6-8d75-ba2c6e411d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_31842baf-e2ab-44d6-8d75-ba2c6e411d6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31842baf-e2ab-44d6-8d75-ba2c6e411d6b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_31842baf-e2ab-44d6-8d75-ba2c6e411d6b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31842baf-e2ab-44d6-8d75-ba2c6e411d6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef3a6e18-937d-4d0c-9bfa-10267c2cef51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_31842baf-e2ab-44d6-8d75-ba2c6e411d6b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef3a6e18-937d-4d0c-9bfa-10267c2cef51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_8fa496f0-d53b-4178-b869-c90089607cd7" xlink:href="mgnx-20201231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef3a6e18-937d-4d0c-9bfa-10267c2cef51" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_8fa496f0-d53b-4178-b869-c90089607cd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_b6fc8041-23eb-43ad-b4fd-e6a357284ae0" xlink:href="mgnx-20201231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef3a6e18-937d-4d0c-9bfa-10267c2cef51" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_b6fc8041-23eb-43ad-b4fd-e6a357284ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f03f1081-4ed5-410e-a69f-f922d34e3b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f03f1081-4ed5-410e-a69f-f922d34e3b0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f03f1081-4ed5-410e-a69f-f922d34e3b0d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f03f1081-4ed5-410e-a69f-f922d34e3b0d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f03f1081-4ed5-410e-a69f-f922d34e3b0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3b851748-d517-40ea-ac2c-a97dea48b4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f03f1081-4ed5-410e-a69f-f922d34e3b0d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3b851748-d517-40ea-ac2c-a97dea48b4ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_34bfc909-9f0d-4139-8b08-dd470096548b" xlink:href="mgnx-20201231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3b851748-d517-40ea-ac2c-a97dea48b4ba" xlink:to="loc_mgnx_ProventionPRV3279Member_34bfc909-9f0d-4139-8b08-dd470096548b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_c402c678-4e1d-4005-8ba8-2521a16d4493" xlink:href="mgnx-20201231.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3b851748-d517-40ea-ac2c-a97dea48b4ba" xlink:to="loc_mgnx_ProventionPRV031Member_c402c678-4e1d-4005-8ba8-2521a16d4493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2684de9c-2c65-4ccb-b66a-3897092ee17d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2684de9c-2c65-4ccb-b66a-3897092ee17d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f62cc0fa-26a7-4701-bffe-6f575285e5b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_cf69ae39-c020-4cac-8374-714547f68db0" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ff12c3d5-1979-4bbf-879a-25e141483fce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:to="loc_srt_CounterpartyNameAxis_ff12c3d5-1979-4bbf-879a-25e141483fce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff12c3d5-1979-4bbf-879a-25e141483fce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ff12c3d5-1979-4bbf-879a-25e141483fce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff12c3d5-1979-4bbf-879a-25e141483fce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90b19504-9f1e-4572-9d01-d1caaaf0be96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ff12c3d5-1979-4bbf-879a-25e141483fce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90b19504-9f1e-4572-9d01-d1caaaf0be96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_72dc5618-82ee-4936-bae8-3bb993a9575d" xlink:href="mgnx-20201231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90b19504-9f1e-4572-9d01-d1caaaf0be96" xlink:to="loc_mgnx_ProventionBioMember_72dc5618-82ee-4936-bae8-3bb993a9575d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="ib02b5ba9575a4797801616b813b4b7d2_CollaborationandOtherAgreementsNIAIDContractDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_fed94799-b059-4762-9680-21deecbd07ca" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_fed94799-b059-4762-9680-21deecbd07ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_f04aa75e-553f-4266-a597-9c16ba38e5a8" xlink:href="mgnx-20201231.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_FundedValueOfBasePeriod_f04aa75e-553f-4266-a597-9c16ba38e5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_6c2659b6-6874-43c2-9a3c-37e0712ba7ca" xlink:href="mgnx-20201231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_6c2659b6-6874-43c2-9a3c-37e0712ba7ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_8775e0ca-320a-4781-93b8-cdcbee2f0619" xlink:href="mgnx-20201231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_8775e0ca-320a-4781-93b8-cdcbee2f0619" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_13603b55-f71b-4918-bd69-f8453c8bec0c" xlink:href="mgnx-20201231.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_13603b55-f71b-4918-bd69-f8453c8bec0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dbecccb4-b67a-40ab-a3c4-9ceea1661b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_us-gaap_Revenues_dbecccb4-b67a-40ab-a3c4-9ceea1661b76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ccbfc3f-4f31-4b8d-8edd-7b559f9c32cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:to="loc_srt_ProductOrServiceAxis_8ccbfc3f-4f31-4b8d-8edd-7b559f9c32cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8ccbfc3f-4f31-4b8d-8edd-7b559f9c32cd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8ccbfc3f-4f31-4b8d-8edd-7b559f9c32cd" xlink:to="loc_srt_ProductsAndServicesDomain_8ccbfc3f-4f31-4b8d-8edd-7b559f9c32cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a292c76-5f61-4846-b49e-f109bdab698d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8ccbfc3f-4f31-4b8d-8edd-7b559f9c32cd" xlink:to="loc_srt_ProductsAndServicesDomain_8a292c76-5f61-4846-b49e-f109bdab698d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_5503703e-7384-4010-9e49-3a975af7cf59" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a292c76-5f61-4846-b49e-f109bdab698d" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_5503703e-7384-4010-9e49-3a975af7cf59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ff14a4d3-9dd9-4bbd-bf97-49d8f354ec91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:to="loc_srt_CounterpartyNameAxis_ff14a4d3-9dd9-4bbd-bf97-49d8f354ec91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff14a4d3-9dd9-4bbd-bf97-49d8f354ec91_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ff14a4d3-9dd9-4bbd-bf97-49d8f354ec91" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff14a4d3-9dd9-4bbd-bf97-49d8f354ec91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7448c20-4e5c-4348-a1d2-2e959a0814b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ff14a4d3-9dd9-4bbd-bf97-49d8f354ec91" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7448c20-4e5c-4348-a1d2-2e959a0814b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_87a3a51b-9249-4cca-942d-591e89aca577" xlink:href="mgnx-20201231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7448c20-4e5c-4348-a1d2-2e959a0814b8" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_87a3a51b-9249-4cca-942d-591e89aca577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e39812d9-f303-4284-9efa-fa705a8b8032" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:to="loc_srt_RangeAxis_e39812d9-f303-4284-9efa-fa705a8b8032" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e39812d9-f303-4284-9efa-fa705a8b8032_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e39812d9-f303-4284-9efa-fa705a8b8032" xlink:to="loc_srt_RangeMember_e39812d9-f303-4284-9efa-fa705a8b8032_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40379132-41cf-4155-8b1f-de1d42c0a60c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e39812d9-f303-4284-9efa-fa705a8b8032" xlink:to="loc_srt_RangeMember_40379132-41cf-4155-8b1f-de1d42c0a60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ffd9aff-96ac-46e3-a694-e6b164004157" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_40379132-41cf-4155-8b1f-de1d42c0a60c" xlink:to="loc_srt_MaximumMember_0ffd9aff-96ac-46e3-a694-e6b164004157" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended" id="i56d600bd6b924ad78a4321c31851ee93_CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm_45fca647-1ebf-4afc-8c46-1e23f74b2eb9" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementTerm_45fca647-1ebf-4afc-8c46-1e23f74b2eb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_cca5f1ba-131c-4655-bc2b-b122ca0879ac" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_NumberOfProductCandidates_cca5f1ba-131c-4655-bc2b-b122ca0879ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_7bec6ae6-e78b-49ce-832c-44e944f68063" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_NonRefundableUpfrontFees_7bec6ae6-e78b-49ce-832c-44e944f68063" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount_5692c414-b3e6-4373-b800-d54622ba9c24" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_DevelopmentMilestonesAmount_5692c414-b3e6-4373-b800-d54622ba9c24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_3ae248ac-3c10-4c37-9e29-f5863c594eaf" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_3ae248ac-3c10-4c37-9e29-f5863c594eaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a8452278-4457-418f-a9e1-5d93453cea63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a8452278-4457-418f-a9e1-5d93453cea63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baa3672d-0f0a-449a-bfe7-172fe7da7f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a8452278-4457-418f-a9e1-5d93453cea63" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baa3672d-0f0a-449a-bfe7-172fe7da7f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_baa3672d-0f0a-449a-bfe7-172fe7da7f4a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baa3672d-0f0a-449a-bfe7-172fe7da7f4a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_baa3672d-0f0a-449a-bfe7-172fe7da7f4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_833edc29-67eb-46a3-95fe-5626f2172b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baa3672d-0f0a-449a-bfe7-172fe7da7f4a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_833edc29-67eb-46a3-95fe-5626f2172b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_6c4ae3ff-3d4e-42ea-87ce-29b99668b729" xlink:href="mgnx-20201231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_833edc29-67eb-46a3-95fe-5626f2172b1e" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_6c4ae3ff-3d4e-42ea-87ce-29b99668b729" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e831e95e-2d96-42f7-88c2-82a64770ec27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a8452278-4457-418f-a9e1-5d93453cea63" xlink:to="loc_srt_CounterpartyNameAxis_e831e95e-2d96-42f7-88c2-82a64770ec27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e831e95e-2d96-42f7-88c2-82a64770ec27_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e831e95e-2d96-42f7-88c2-82a64770ec27" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e831e95e-2d96-42f7-88c2-82a64770ec27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e15c625f-f28d-438e-801c-4cf1ca25302d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e831e95e-2d96-42f7-88c2-82a64770ec27" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e15c625f-f28d-438e-801c-4cf1ca25302d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_a38ac48d-c1e8-48df-aea6-bca79d273972" xlink:href="mgnx-20201231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e15c625f-f28d-438e-801c-4cf1ca25302d" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_a38ac48d-c1e8-48df-aea6-bca79d273972" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended" id="i8afcfa2f6e3b4ef0a3571b91005f64ed_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20201231.xsd#EmployeeBenefitPlan"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended" id="ieade3768e8ab45db962442658637d567_EmployeeBenefitPlan"/>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" id="i08558d9858bd428f9b61018168d1660a_EmployeeBenefitPlanDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>mgnx-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:027e117c-75c0-47f2-bc63-7ee727579094,g:55d8aba6-2c39-4104-9032-126eaff6334c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_aa22e42a-0bb6-48e0-b309-5c6070233469_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_197bec0d-8415-44fa-8f8e-67006061ceac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_129e2c2e-0254-4add-bb81-454766655698_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_f6900e55-cb65-497b-8042-a1941d56a966_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6f149e15-7da7-40f9-a8ff-02c3ee39e992_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ae5a5b34-df55-436d-b502-f7b0e7126d5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_519e98b9-5d63-40db-9135-3ba073d09c08_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_41bf3419-56f2-46be-af31-444454aa2e0a_terseLabel_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employee vested contribution</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_label_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employees Contribution, Vested Percentage</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_documentation_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage vested of employee's contributions to defined contribution plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:href="mgnx-20201231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:to="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_003a82da-8cf0-467f-b6f1-575b776ea3da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_ad910fe2-e4c9-4101-8665-b9eb865a46fb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4b840cb4-40c3-4ea2-ae40-e70c35a6d257_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_260c1b53-717c-41aa-b2ef-5ec7ee133392_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_93fb9e89-c027-4dca-be05-20a41671a350_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_85e9b6e1-ec94-42f8-8a03-277cf223d55c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_d8764fde-1ba1-4a6a-a0fc-8ded65cd5760_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:href="mgnx-20201231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cb28d533-cb06-4adc-bf32-1c2764524f54_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4cb181b0-5d32-45a3-afae-c957e427c7b2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e99befe-2d1d-463b-8109-9c6530eb43c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_b8a08ddd-bc41-49ae-a706-12a2008e424b_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20201231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_0e5c3723-5b7f-482a-ac12-77aa4f31a91f_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20201231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_a46e21ef-5d50-4e57-9a58-911f27c930c7_terseLabel_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="mgnx-20201231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2185720b-d645-4de6-b46b-dfe4a254c3d4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_211fb2ff-c4f4-41c9-8df3-808c438e49ab_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment, net of tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:href="mgnx-20201231.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:to="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5f82ac9c-254e-4dbd-a0c1-e22d38f76d56_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_697fea26-966d-48e0-a692-cf6e58164b48_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_e059925e-c018-4f33-8d9d-625fc112b7e1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8efe0a1b-3579-4e19-b78b-909d36f23297_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_81b855b9-a8c2-4805-95c8-9184ab89e8fa_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_984aa98c-cddd-4782-8ba2-132bbf9be630_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_080c0d4f-2526-48a8-b210-5d32adb41df9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a5e748aa-fb30-42e3-a4d6-2873c2f6e55d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employee contribution to salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7165e0cb-1ab0-4cfb-84cc-1b56e51429ef_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions_4ce95c35-9fd3-4485-b555-db2e90a6aa23_terseLabel_en-US" xlink:label="lab_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extension options</link:label>
    <link:label id="lab_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="mgnx-20201231.xsd#mgnx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5823f129-6086-43de-847e-b43b1109febd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f0317281-8949-4903-b52a-767cd02df4d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_e405104b-b0dd-4059-9b89-1a3dc1e4e844_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:href="mgnx-20201231.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:to="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_46110448-b76d-4f9c-aa33-1a2cdefee274_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_d0830e84-c5ee-4840-aaa7-dfc79ce999de_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ffc9db6d-6410-461e-a5b5-ba54ff338455_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d8255c58-0581-4908-a2ce-c122274dbb0d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_b282c83f-31da-4989-b320-747eb4c0adb7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_341ef466-5d59-48f0-92f0-2190c4ecfd03_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_e506b92c-07d2-4d9d-9cb9-5bf9e885caca_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_182b6a5d-2931-4dfb-83bf-a7477d315e0d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e1973db1-abb3-4bdc-b934-9fe8bad5552e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, ROU Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c96dc1e7-cee6-4050-9eb9-e2e70c3fb82f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_206af0c1-b9cb-46f8-8b43-e758b9cd2eee_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Disclosure [Text Block]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f9e6e0eb-226a-435c-92d1-922acccb0e0e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_822580d8-1959-487c-b5f6-f9a929a1cb7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e1c49cbc-3a30-4598-a203-3e0f2a07f3ff_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cdef6fd0-55e3-4420-a09f-e01f4b4fa1dc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_08af986f-d8c1-4fc3-a985-118b4f8fcf12_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_39a18071-1938-4bba-8489-3763b8212b67_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_34589617-baa1-470d-adc1-d3bb17cc260f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired assets</link:label>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_label_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:to="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_ff8a2d50-0891-4f36-aba8-403418e18364_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_ea5672e2-2f2e-40b1-9b1e-7571db91f95b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Federal tax credits carry forward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5a6c67ee-9fb0-487f-a146-0a690f023de9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_431f28f5-7699-4517-88f6-c03c9089fa57_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_documentation_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial fee received from collaboration or license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_f89b24bf-51d2-448d-8390-a88bb7425d99_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d3646788-fcdd-4492-b47e-4c71fdb68f0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c8d3bcc7-f46d-48a2-bcca-644ba37a0508_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5872040d-7303-41f2-acbe-8b17beed939b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f1e081ad-aa8d-4817-83a6-4bf4163a748d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_b1988b64-cae5-4e22-baf4-799eef60341c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e5f1a2ed-bdb2-4dda-8941-e81ea6e4bdaa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_0b81b40b-4130-400d-99dd-576d1345c745_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_111c66fe-892e-4f4c-921e-b1f437da179f_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement (in years)</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Term</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementTerm" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_37d97e34-786a-4003-93a7-708c2c38fdb4_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d003fbca-a810-4594-853b-cc72acf023f7_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of significant accounts receivable</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_afdfe8b4-8aa6-457c-ae46-849c315470b4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_3e48c38b-4ce8-4a9b-af5d-99a3f5768d21_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20201231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_8e4ee8c3-76cc-434b-8cd5-8b59aa27db27_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:href="mgnx-20201231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f05b99ca-e5fa-4ff3-9a84-8199d1bdfcd9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_373463b3-6ea8-4b09-8aab-ecc46ae8901d_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:href="mgnx-20201231.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:to="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3aa06b19-2f5a-4c9b-b28f-42d86c58fbfc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_613f33fa-0d66-4010-b4d0-b45da51b6618_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IndefiniteMember_c661053c-a48c-4e4d-8b6a-04022f83e2f8_terseLabel_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_label_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_documentation_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember" xlink:href="mgnx-20201231.xsd#mgnx_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IndefiniteMember" xlink:to="lab_mgnx_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_71061e14-db80-4b78-a646-7f06a56b48d7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_b8d0adc0-9b99-48c7-a19d-3c3b24d3ce00_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_46cd8b17-0175-428a-9167-1d3df9dfbca8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87f8ffe8-8334-48d5-b6e5-e9dc6b57b41f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b14b970e-60ca-4975-b4af-5b8a1c181b8e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_210bee0b-c101-4d4b-bc64-a591fb2f5096_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_b4624330-6316-4bca-992c-4c70aa1462d1_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Estimated Useful Life Table [Text Block]</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment estimated useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="mgnx-20201231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_51e6c1e4-13b3-4cab-811b-18645f7e2c9f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_768c8910-a86d-444b-9a71-ded5af1da928_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offset to research and development costs under collaboration arrangement</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Offset to Research and Development Costs</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to collaboration arrangement offset to research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:to="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bc4bbad7-0d23-4263-a710-89af7f1a0cbc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b22d3628-3977-4ff8-9532-c032e97e1839_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_9b1377d8-9c24-4380-9ea0-414d5531c08b_terseLabel_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfProductCandidates_e2daf49f-5a0c-4bb2-ba03-5c83ceb24904_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates to develop</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_label_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfProductCandidates" xlink:to="lab_mgnx_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2b03dac0-7e8c-42b2-a463-5bd3f4ac60d8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_f2ea9c10-c76e-420c-a1cd-d14566bdf3bd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_056d03e9-00f9-44e4-9063-ab08b2eabf5b_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20201231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_646068fe-8231-4e89-bf75-313fb42d8d1e_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20201231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ea3d5221-8535-4fd0-bc49-66a100af311a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierMember_9d2da046-cab8-4ed4-8c07-35d927e8a4e4_terseLabel_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_mgnx_ServierMember_label_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier [Member]</link:label>
    <link:label id="lab_mgnx_ServierMember_documentation_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember" xlink:href="mgnx-20201231.xsd#mgnx_ServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierMember" xlink:to="lab_mgnx_ServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_955d9d98-c993-4b65-82e3-d29c61d0f540_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable Payment, Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable Payment, Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20201231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e31e8de3-bfe1-4881-b35d-fd75c403482b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84f1a71a-6535-4c91-9440-fb71b58a01de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1bb5f4b0-2e9a-441d-994f-8e61622d2a32_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_9d81c431-4e0d-43b9-8e3e-ad7ccdf4aa98_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_2edf98d7-18f1-4d28-bcb1-e37be258c5e3_verboseLabel_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base period value</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_label_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded Value of Base Period</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_documentation_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded value of base period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod" xlink:href="mgnx-20201231.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FundedValueOfBasePeriod" xlink:to="lab_mgnx_FundedValueOfBasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_07b0ec21-55e3-43e6-8251-d5988a2b0a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_45f95062-a6c9-4148-ac2c-1eba7976d58a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9d620479-e7e0-43bb-847e-06c7fd410722_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4705e540-cda1-492e-ad55-b0ebf16d4a01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_89bd897e-85e1-4d4a-bd9d-4a2fae9439aa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Including Clinical Trial Accruals/Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_57e37ce4-d622-4b74-8dc0-caf21dd4c670_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20201231.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_daab8ea7-8a8e-48e8-a718-d938ee866903_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_77108eab-d770-4150-bd89-64e40cb658c7_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20201231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_51b1c246-f77a-44b0-b71d-587ec787c3cc_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:to="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_15395f4a-85c3-4d72-b851-d8d9d8b7b6ff_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_feccf82f-c813-469e-a38f-99bd8f3082ae_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_24d34646-5125-4921-8df0-1aba7aa93483_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment to third parties for intellectual property under agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20201231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_faf83e14-24a7-4700-a98b-b80f3fb0cb16_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_c0642c2f-96eb-4beb-a21e-a1529d8ddfa4_terseLabel_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_label_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037 [Member]</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_documentation_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member" xlink:href="mgnx-20201231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TaxYear2025To2037Member" xlink:to="lab_mgnx_TaxYear2025To2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_8740fa3e-1655-4726-8162-65f1dded3bb9_negatedLabel_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:href="mgnx-20201231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bdc74c3c-b230-4e1f-a30e-66212c8586db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased by employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e7b91a70-926c-4343-aaf5-636f13ac48ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f4a3ceb7-f35c-4fa8-8680-1734457ac47f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_db754e4b-4628-422a-83cf-e4ef7a56f1a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dc6da15b-83d5-445d-b500-dcb761958f6e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_6c7399a9-0a40-4730-907d-f1c0b6a04c43_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones</link:label>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_label_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones, Amount</link:label>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_documentation_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentMilestonesAmount" xlink:to="lab_mgnx_DevelopmentMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_0bb495e9-4387-4075-9028-cefd8f153ca3_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e1802208-9e1f-48d0-9246-5c5accd05e04_verboseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_41c37f7b-1be3-454d-b549-0322fa1ccbdd_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on product sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:href="mgnx-20201231.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:to="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d600d71c-15a5-4530-a97f-feb6013a4df9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_227e3b24-46da-4b45-8c0f-ff2acac60dde_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4e2f5ef7-d0f1-48f1-a187-41312ad4c208_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_8b06185c-5c24-4c88-bdb2-202a9f54a718_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on future sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties on Future Sales under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties on Future Sales under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:href="mgnx-20201231.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_87e65f0c-c659-4960-89e6-35001d4fdd27_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_aef858ae-a7c3-4373-bdca-94131ce1fd79_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2979a3c9-1e4a-42f2-ad73-da5076a5eca7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e353856f-9eef-4b4e-ae21-67ea629caf1c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MilestonePayment_6a4f05a2-7d53-4a65-bcb3-e9de6508c517_terseLabel_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment removed</link:label>
    <link:label id="lab_mgnx_MilestonePayment_label_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_mgnx_MilestonePayment_documentation_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment" xlink:href="mgnx-20201231.xsd#mgnx_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MilestonePayment" xlink:to="lab_mgnx_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_2f63e0db-a5c7-4dd0-83de-a0ece8348adb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_459cc42f-05ca-4c40-b9d5-07d40df2e0e8_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20201231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_0f0b36d2-7842-49fa-9eeb-6cd728d8b0d7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_d61db47c-c1f3-4084-89c3-505df973971c_terseLabel_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_label_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_documentation_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember" xlink:href="mgnx-20201231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UndesignatedPreferredStockMember" xlink:to="lab_mgnx_UndesignatedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5cb6712a-055c-4e10-895a-70217d9b3fe8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b9c8841e-8a81-4c82-9b16-88b0fed0ec88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9593c8ac-c03b-4931-8dbe-200e2d19b4ba_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_878d4658-ebe7-4d81-ab57-2572e1cfe804_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7e328f99-2519-4dd1-ae87-43e1569dbe12_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_3c781a25-ddea-4af1-8e56-872c45886228_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2de10552-4863-40e0-9b40-554a3177b55e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_add718b7-a707-4605-bb86-7a78e058c0e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a05dc397-0061-44ed-94a1-d01e41cb40bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FollowOnEquityOfferingMember_630ebd10-77d7-41df-80ef-64b7453d421f_terseLabel_en-US" xlink:label="lab_mgnx_FollowOnEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Equity Offering</link:label>
    <link:label id="lab_mgnx_FollowOnEquityOfferingMember_label_en-US" xlink:label="lab_mgnx_FollowOnEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Equity Offering [Member]</link:label>
    <link:label id="lab_mgnx_FollowOnEquityOfferingMember_documentation_en-US" xlink:label="lab_mgnx_FollowOnEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowOnEquityOfferingMember" xlink:href="mgnx-20201231.xsd#mgnx_FollowOnEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FollowOnEquityOfferingMember" xlink:to="lab_mgnx_FollowOnEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_54cd9daf-79b3-4c1a-8ff5-fa6b23819fc1_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation (Incyte)</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20201231.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8a03a659-7dc8-4558-9717-744f1f9cc772_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_54e0c520-bdb2-43fb-a2a2-41678ae64fe8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3fe529e0-0506-458c-8557-3b8e128a3186_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized_4340021d-c243-4e3b-a17c-4f832d23ef43_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of development progress recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Progress And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Progress And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a13d9079-d33f-4724-b94b-4aa4505acd69_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2b2894ac-b0e6-445c-9790-576c9d9500fa_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_353addbc-1115-4b14-bd43-3690c1d33b92_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f7d8285b-9c65-4a41-b119-66ac455ed147_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_04dd9416-22a4-4325-b3cb-fb1d715b0a20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_847e75ba-36d9-4ebb-a3b3-1aece3f18811_terseLabel_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible age to participate in plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_label_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees Eligible Age To Participate In Benefit Plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_documentation_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to minimum eligible age of employee to participate in benefit plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:href="mgnx-20201231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:to="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0183ec29-5fa2-4ec1-b5c5-5db1e0ba71a3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e9e1539d-f635-48d9-9de9-d949579cf3ca_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_937370b2-e8ec-4f07-bd09-1070a28f1a84_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_05148f24-79d5-45e2-9576-50ef98e52808_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_80a8b4e4-c70c-40a2-9ebd-e611ec946bd6_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increased number of shares authorized (in shares)</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares authorized after increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:href="mgnx-20201231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7892b948-5bf6-4607-a75c-92a295261fde_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a5750183-6587-4718-a7d7-9738bf9b04de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_67c1c79f-ff6c-49a7-8cad-a4e808f350e4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_847ccc46-700f-48ad-8c9f-4cb1e547f67e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4d429a91-910e-40d3-a9fb-d6757d5da80a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_cebe8fcb-40ab-457f-9928-327302d2feb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d4b86204-4dbd-411e-8486-c4b287eae946_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_2fef4bf6-7d38-4648-a799-1eb76c2d7da5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_2e59bd6b-d424-47b2-8949-44b90f00bf98_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue included in long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_7f2caa2b-6aec-48f0-b30a-eddc9180da5d_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20201231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_d1e8e95c-1f7d-423e-8626-14ef9d4e0900_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited (Zai Lab)</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_label_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabLimitedMember" xlink:to="lab_mgnx_ZaiLabLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1f83e84b-0fe0-4bad-91ec-7302bd489695_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ec27dcd0-de03-4920-8fd2-0d54e0fdebef_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_50cfea89-aa61-4675-865f-46fb9541dedb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_23e3a58e-7ee8-43bb-a013-a6bc34bfe4b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_3ad81978-a33f-4d94-b2a6-fa07d6585f7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dedf39-0f8d-432e-96ff-bee57f9a2f03_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_c7f8a34c-eeae-4de4-b042-5f268cb0aecc_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_6edfa815-966a-4296-b612-296129c77d95_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_26e11282-be59-4d1c-977a-cd518f7545d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a7f811a3-1d28-4c90-881e-451921cb32cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_538f1a97-6146-46d1-9362-bbb31ed9ac6c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c01113e4-e417-4365-8eb8-2a81b3a2e1bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptionExerciseFee_54777fcb-e08d-4f67-886e-1855ecec9b7a_terseLabel_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_label_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_documentation_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment from collaborator upon exercise of option to develop and commercialize product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee" xlink:href="mgnx-20201231.xsd#mgnx_OptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionExerciseFee" xlink:to="lab_mgnx_OptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b47c34d0-e517-410a-9bef-86ee42e4cb7f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fcedd3d2-1325-4466-b6ee-ee412e33f23b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_67a383e0-2606-4e95-980d-390bebde03c0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_525275dc-b815-48ba-b053-e4b20c77da59_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_ec6386e5-dd63-4482-acf0-8b0d6fd28fa9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_0a22d5a9-8176-422f-9695-034b5f11acc0_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal Government</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_951e3e01-e65b-4fcd-9317-20d42ca75fd6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_81305424-e7d7-4772-a771-1d69b71f07ce_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_03efc3bd-881c-404a-9ca1-10d2dd4a8742_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8bf9994c-7a72-4368-aa2f-c70a3dd2c515_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_cfd5d799-3326-46b1-961d-6527251a384b_terseLabel_en-US" xlink:label="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Commitment Public Underwritten Offer</link:label>
    <link:label id="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_label_en-US" xlink:label="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Commitment Public Underwritten Offer [Member]</link:label>
    <link:label id="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_documentation_en-US" xlink:label="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Commitment Public Underwritten Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:href="mgnx-20201231.xsd#mgnx_FirmCommitmentPublicUnderwrittenOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:to="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_38caa6ff-06ba-4c55-b922-255c0fcc5499_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_4a56034d-7386-48c4-8eaf-a8ab4594dee2_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock warrants (in shares)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_cac57ebc-03af-4fe5-b231-a1c89c9cc8e2_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining portion of net operating losses</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Not Subject To Limitation</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards not subject to limitation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:href="mgnx-20201231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:to="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe8f95d4-7bdf-4ad6-a26b-e8efecd4dfb6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_11c18a64-497b-4342-b7d6-70086f735a48_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_432c3af5-96bc-4f09-b511-d66986b9c9de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_95f51098-f438-4df7-b569-2ca98a97da9f_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_f3950c7e-b332-4160-ad2d-54be04359b39_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3707861d-0ad7-4be7-8f41-b11edfbe641f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_93ccb310-d781-41e1-a472-00803f2474c3_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:href="mgnx-20201231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_bb0ddfc3-bd4a-4d97-91db-441067b71b99_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0a7837e5-0160-4795-b349-63e10321676f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_135430f7-b282-4df3-b36a-f87aee8b585c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f3c8fb14-c039-4f32-86f3-965a0e25a7da_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_dd638c04-029e-4bac-a804-77f95f3ca19f_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_29789a76-566e-4a78-a0f7-ac8e2831f660_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20201231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1991f184-3e7a-4b75-a42c-0bbf0f2f9b90_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_5a160bd3-037e-48a3-a872-cc0b36939d60_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received common stock warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aeda14b1-79cf-4671-9c91-6f302f5cbfb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_de34fb0e-a047-4343-a54b-48065a9ff697_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_47aa0265-cf69-4cdc-9d72-957252c4d4b3_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_da375e24-8c20-471e-b6b8-78678f7af4b2_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_149c2e50-5311-465e-9cb0-cc54a8c3b561_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1a7724b1-004f-477e-8259-8b73a5aaa5d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Reported Estimated Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_77bf3d3d-101b-49ad-bd58-9e0f77785845_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ab761ce5-0963-481f-9a1d-a7a7fe6404de_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9d402ed7-a0e4-4879-a2ed-7438d3440b93_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_d4541d97-7c10-4392-9215-6902807aeb7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5f8eb56c-5cb8-40c3-b96a-cc8a4aa3421b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_9e1314e2-fde7-4db4-b7ba-9af426b080a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_50d1a6b9-9fc8-4845-bf55-475d8fe8a7a4_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value of agreement</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to total potential value under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20201231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d6070ac4-f949-4c4e-9b65-659aff00fabc_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_da560083-b36e-42b8-8fb1-857860cde04f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_d3cb833a-a96a-4dcd-a457-f00c317fba65_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_92abd201-b2b8-4451-b4e6-099ec33f5b48_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum annual increase (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20201231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7f04b255-21ec-4581-b925-72c27ac3c2fe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal U.S. net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_a64538ff-f054-4b80-a2f2-a1afb85cf144_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bdbf3152-85ec-4709-9db6-6f4066e7233d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_46e602e7-bd50-481c-aa0c-66c197b5d9f3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_563869b7-9b5c-475f-949b-cc29e9dd9b43_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d038b278-b17b-42ce-bc7a-d73497730e80_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_63aba081-144c-4349-9878-3517d5937d57_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_718aef8e-b5fb-49c1-ad87-3320da402053_terseLabel_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal and State</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_label_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_documentation_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:href="mgnx-20201231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:to="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d372888-f6b9-4cab-9041-8a141e9719a0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_15b4cd43-5e85-437d-aab5-bf79dc1b21b8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bac375ad-2e94-43ef-8268-ee21a399acf4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_49016bf4-d2e4-4523-94fd-15c7b2d61e71_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_669a02a6-b67c-451d-a90f-e7bbdc322f02_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_02c7db25-56c0-4549-b532-33fc5904f295_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_83166228-f7e7-42ae-9d56-abe3c70222b3_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20201231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_b89d2ea8-3e12-4e9e-bd0f-5b154afbe004_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax asset/(liability)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b517e101-71ed-4694-a05a-11e425ab39c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cf4c40bc-72e5-4969-895a-37164ba256a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79222ddb-79fa-4f55-af5c-c741a2de4aba_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c44eaa10-0ef0-41a3-8e97-62b9254bb836_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_25beb400-7230-49f0-965f-63282bdcc12b_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8ddba7f4-0387-485d-9c07-1b6d1ecf8f03_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0bdcdefb-8425-485d-921e-35a6cb5a6280_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_b8501d22-edf1-4aba-ad38-6df0d3aeacbc_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_19d94b27-baee-4250-b9e1-66f70cea946a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_318b90bf-4116-4b50-814b-ec0a47116c56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f00207f2-daeb-4ca8-b7a0-afcb852e8b6f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_ae7fa06b-557e-402c-9dd3-5b25beaeceaf_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_42137e8f-fc83-48e9-8712-2e6838f89360_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses limited for use utilized on an annual basis</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Annual Limitation Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss which are limited for use, utilized on a annual basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:href="mgnx-20201231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:to="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9e546661-00e5-4f6e-89a0-f8ccadd42a23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4151eda6-b0c2-46fa-9bc1-8089cd732288_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Options Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a834c5fb-999d-40a4-a379-c5ad7bf17138_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b7436e11-6fd5-4fcb-821c-8021d06ba8d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_d08c4ba7-99a8-4d27-9544-b891231a66e2_terseLabel_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_label_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003 [Member]</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_documentation_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member" xlink:href="mgnx-20201231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EquityIncentivePlan2003Member" xlink:to="lab_mgnx_EquityIncentivePlan2003Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f1668dce-17ec-421c-b2e0-c5639b28fa1e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_27117703-01c0-4cbe-a2c9-8ee398ddf597_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_811e60f2-af59-4ca1-9387-72c92a0a60b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_354a13ee-04a5-4207-8fa5-491ef0d9c20e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierAgreementMGD007OptionMember_c60e5da4-d153-4f15-b424-83045246495d_terseLabel_en-US" xlink:label="lab_mgnx_ServierAgreementMGD007OptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier Agreement - MGD007 Option</link:label>
    <link:label id="lab_mgnx_ServierAgreementMGD007OptionMember_label_en-US" xlink:label="lab_mgnx_ServierAgreementMGD007OptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier Agreement - MGD007 Option [Member]</link:label>
    <link:label id="lab_mgnx_ServierAgreementMGD007OptionMember_documentation_en-US" xlink:label="lab_mgnx_ServierAgreementMGD007OptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier Agreement - MGD007 Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierAgreementMGD007OptionMember" xlink:href="mgnx-20201231.xsd#mgnx_ServierAgreementMGD007OptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierAgreementMGD007OptionMember" xlink:to="lab_mgnx_ServierAgreementMGD007OptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7b3d84f0-db5a-46fc-82a2-36ec238c0713_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9523a591-2067-4261-b792-a65eef87574c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_d5f11a86-6584-4330-a4ef-19748355d976_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_d4c5a7c2-6322-4b14-aec4-29c86ce113b5_verboseLabel_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants received</link:label>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_label_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Received</link:label>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_documentation_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FairValueOfWarrantsReceived" xlink:href="mgnx-20201231.xsd#mgnx_FairValueOfWarrantsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FairValueOfWarrantsReceived" xlink:to="lab_mgnx_FairValueOfWarrantsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_991586d3-6899-46b0-b8c8-48008ab5a0d2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_374c4780-2036-4775-b7d6-f64d140c2ed8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_0c6b7a19-c178-4b3a-9cf7-1fd173882743_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EntitledMilestonePaymentsUnderAgreement_c11636ea-20f5-4e44-a7cf-8779e8f2ee09_terseLabel_en-US" xlink:label="lab_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entitled milestone payments</link:label>
    <link:label id="lab_mgnx_EntitledMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entitled Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_EntitledMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entitled Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:href="mgnx-20201231.xsd#mgnx_EntitledMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_EntitledMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_8cbc11b9-31a1-40c5-a08f-f3eaad2f2068_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_dcb47cad-b3da-413f-9a3a-e6c9b7b1a89d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_872313c5-8f68-4236-85b9-7a0280c9b327_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, tax withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesTaxWithholding" xlink:to="lab_mgnx_RevenuesTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_51fe097e-0a67-485d-8d8b-cb922ffce505_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20201231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_4bffb241-fd56-494d-a093-b83a416b5a9d_terseLabel_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised Additional Development Funding Options Under Agreement</link:label>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised Additional Development Funding Options Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20201231.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_7f309989-00d4-4dad-a882-2777d464ad5d_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Motor vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_312ac09f-6114-43a8-8e11-368e30d3c528_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d142abdc-8e50-4bd8-9548-41a3b142cdb0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5ad2e64c-332e-4528-9336-c8674a2e1409_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f801fb6f-a059-4dca-b01c-17758c520442_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_981bb6c9-3ff9-4794-a204-26baefa5f414_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_6cf9c95a-a65b-4ebf-934c-5f4f17db1323_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_4168b7f0-f3e4-4aba-9306-04590e8807fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_45c02480-995e-41a2-a30c-3f8d01211b5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_c0434803-aaa8-455e-a5f1-ed0c85c09a4b_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1b997e0a-44b1-4024-9eee-1fe00f3568b8_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_609cb6e1-91ed-4e6c-9abf-1f1d18d49521_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b18361f0-abf8-42a5-a81d-510d79e0e8ff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_86be1dd4-11a4-47c8-b346-5e5f13afb65b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_981c6fb7-303a-4f92-83c3-45e72bc1b1fe_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted weighted average number of common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_e9d3ce06-9e74-47a9-9007-3b336d0866a1_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_2a6ba431-56fb-4409-ac8c-bdaa9ad090a1_terseLabel_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and office equipment</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:href="mgnx-20201231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:to="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6f5a42e6-5a8e-4a40-968b-248542dfb2c1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of fair market value to purchase shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5b2aed0-f3be-435d-9e56-bc145a291853_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4a04ad14-3d65-4d13-a589-4a33a2765dcb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_6116fa39-9afa-4043-81d5-81d2e5aa09a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_05e51dd8-4ad2-417c-877b-a1778312ce96_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_24bc4e6d-21e2-4c78-8868-87a0a3b25433_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_7e9d6c24-6278-4fbc-b0e5-37cc266a473c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_6b5af5b0-d83f-4e0d-a194-f9f5036b4c6c_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period of development</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_label_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Recognition Period</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_documentation_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to upfront payment recognition period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod" xlink:href="mgnx-20201231.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPaymentRecognitionPeriod" xlink:to="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_81d2d06d-779f-4acb-ba91-074b684d1ae3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_1a1888b6-b0dd-4b8c-87ae-acd6698c2827_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20201231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0610c4eb-78c6-4d3e-83de-fe4f0776e157_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1d03f1d9-c870-4c51-bff8-bd692c763b16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_077838d4-5955-40f4-b9b8-3e2cbf512157_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_0b50d0ce-4acd-4f63-be25-a361448a47a5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_cabc0120-c0b6-4bf8-9133-58dc5c594ba3_terseLabel_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:href="mgnx-20201231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d17bcf10-2a2d-4ecd-9c76-73e59a715e00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_59a0ce81-a3b4-4579-ae77-c4b4c5895530_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc.</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember" xlink:href="mgnx-20201231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember" xlink:to="lab_mgnx_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_723dde7f-da6d-45e9-b300-b7816adccefc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f1a112da-fdc2-4faf-83ce-7ea01641f3d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_c7be0e61-98ed-4139-8e3f-71309c7867b9_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_3d000326-d35a-46c6-8977-e4f194f0b4af_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f71cbcdb-0044-4be8-8b74-a23c416e199e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_59b7ec0c-2ade-4399-abe3-b07b792f8ac8_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f10a8449-e53a-4264-9634-eb8081651ed0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurement Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2fa5f121-bb9d-46dc-aff5-4e73c618aea7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d166f090-4a2f-4ea5-87f0-e5d20d9809c1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_3a58072d-50a8-4c23-9594-9917d303f5d3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_80a052f5-5c9a-4030-b290-565075fc8d04_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ae4b69e6-0cb5-4870-9f4a-4b7ff6eca7c0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4a41d986-6f6f-4f23-aa29-e919384638bf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_3bd6d8f1-aa82-4507-ba69-2edf7bb4a02e_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:href="mgnx-20201231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d11ae035-2ac0-4e88-bccd-c9f3c234bdff_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3ac1ce5-d37e-464b-8f8c-64e643ed2cc0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_444816f0-0335-47f4-ba19-d804fc6d0e35_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a0add511-30a5-4f2d-a0d6-2cc8f74a2cec_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_900d0c13-3e02-454c-8888-c684fbb53102_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_10eea12a-2d82-4a0e-bafb-b586f0991c0c_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5f036737-d83f-4a7b-8e9a-aa297a11e43e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_fdab07b8-b584-4d38-93cd-ace787cb452f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 56,244,771 and 48,958,763 shares outstanding at December&#160;31, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bf7dba79-dbb2-473c-88a5-be79b8112b76_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_84183937-05fd-4293-8307-ac1a079fb71e_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20201231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_7bca9676-231d-4926-8761-f4cdf687b33c_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_084736b4-87ea-4c1f-abb6-9cdb5137c5d1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_f7ae8a9c-f4bf-4431-8d78-73c94596f16c_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3a72fbe2-0234-4736-9951-491ccd972384_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3046c65a-e78e-4c07-a998-5f41a0d508dc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_61a08c8b-bffd-4929-8576-bf425fbb4da2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_50efb386-e134-4a5c-8ba1-556488405e1b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f584d738-4a23-4429-9583-909c67950fb7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6c5dfb9f-b692-49c1-a82a-277f37b7299b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7ccccc3d-5ef3-42e8-9df3-5b4a4a5c31ef_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_282a790f-d0cc-4992-bed0-79c8b28abf3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_be447022-e91b-469e-b27d-15e983e1202a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_115a40cd-c61b-490b-9be4-692c72d4e27d_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, TRIDENT molecule</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_aa2dfe4d-6005-4566-bfac-04e3fbb4acd4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_80cc5219-7095-401f-9085-3cdf48f56a7b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_db559a8d-c93f-48ce-9368-7aaef82db22b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b4a6d7a8-6282-49af-8093-256c70701cf7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b0e15ddd-251a-4280-9ef2-f3bfc5755532_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d04502f0-45e9-4f26-9c5b-b73a20b9a76c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d66d8f51-6c07-4b2f-84b3-8f746c9f77ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a3ea035d-4fac-408a-9eb4-fb18cf97ea23_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_5be035ca-7c7e-48b7-ba33-a0d99b22ef1d_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Percentage of Customer Concentration</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_7bd0facc-0162-4587-a1ee-64897d234077_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4776159c-c91e-4651-a01b-4c66cf6eab51_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b7fac29d-0442-4d11-946e-102149793e6c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d82183b4-4e06-4f0d-92bc-ecd2f79476b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_29749e90-8da9-4a2d-8c10-ceaa7c1f4848_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7d4418e6-ba61-49d5-9363-df4570ffb666_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_666c837f-c7b4-4d96-94f8-6234e739c6b2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fba56286-92b2-480f-93a2-6a9bfaa9b646_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive stock options</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_84d5c2fb-ee02-4748-8e3b-059fb6e10f5b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for federal or state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_5432ac0e-bc48-4db7-911b-b57c586fc0fa_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss for limited use</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Limitations On Use Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss carryforward, which are limited for use over the range of years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:href="mgnx-20201231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:to="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_31f4d788-0b86-418c-8426-99e8c1154ec6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases for prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9491b669-f88f-48b3-9a20-4c7bc456e8cd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases for current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2892fe17-6da5-4a95-807d-2e926f44c3ac_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a8806013-b7c9-44c8-824b-dbc677e6e7bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_5b86f67b-1998-4a73-941a-68534a796bf7_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, Margetuximab</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e39d2239-c5e2-484c-b848-39f6709bea69_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d3d55f33-1592-44b4-9bb8-115c5c514579_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4a85962b-4821-488a-b358-307f7ab724bd_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_53cf019e-1440-4f2b-9cce-3a89ba603c44_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_f736e860-902f-40d5-8184-b018f65701ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5b11365a-bd09-4bfd-9322-1d26733be3ea_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cf20089c-64c7-46d1-95d4-a986e3e4198f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_72034806-245a-4537-ad11-7fd681f890e3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f7a284a1-dfa6-474b-9707-2a14fa69c6bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_ce319991-67da-43ec-ba64-662f42150142_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9d696ca1-a4ac-4100-99bc-bbe199da0e7d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_caf06ec4-0297-48fd-a92e-172bc364fb3e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_29d1d9d9-be5b-4f64-8d84-a5526719d9a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the Company's Deferred Income Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_761173a7-1634-4911-b12d-3121edf929a2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_27272394-d256-4b74-9975-28cb3c34e7d4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b55b56e9-56d7-4717-808e-eb18ed1f587a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_7ac51c87-1397-4bc3-a1e1-3e2817ab9451_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of common stock share outstanding</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_documentation_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20201231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5d8608d7-85ef-41c1-bf20-a48250ede464_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_5ad06bb7-be29-4b04-a3bc-333bf3631ec7_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee contribution percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_documentation_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20201231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7c0f88ab-3a91-4c5f-8eac-450b79c19516_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_7c54a238-6460-4dea-a0e7-d7fc7146c226_terseLabel_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20201231.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3f9e9263-f943-4da5-8cc6-567b3d956717_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9de2eb17-b2c0-468e-9bdf-2d9e2ab4be4d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4b79eafb-8a66-461a-ba45-0a1fdfb4126d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_87471166-76b6-48a9-bca8-7c94bbc195bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c2641ba8-40a1-4b96-808e-59375709baab_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_66103168-2cfe-4156-90ad-1bf4e93e6df0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c904d9a-597e-4c40-8d55-ccf92bfa8321_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_bef7b5f8-1e2f-4449-8ede-dc410a517205_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ae6f2232-de34-4e83-9706-1e66be64cce7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_de22886f-fe94-4632-95e6-f21cec0bfdfc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsMember_df1fca37-2f73-4d93-a054-4a6213a69e6f_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:label id="lab_mgnx_ZaiLabsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsMember" xlink:to="lab_mgnx_ZaiLabsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_41b3252c-fba4-4941-bd95-b4bb82189269_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development funding options</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding available under agreement at counterparty's option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20201231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_f7e5c922-0c3e-4c0f-a490-4ace554e756e_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_ce449edd-6ec9-496c-923f-e5cb02352cce_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a90f87f6-1c90-463d-9c34-3bbbb2dec185_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fbe42757-e518-4bb7-b064-97341da48dbc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_5efbc328-2f9b-4c8b-9e6f-c8fc4e65a494_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_f80e90fb-2612-4852-970b-ba94fbdf70e9_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_0bee4524-5fbc-4fa3-88ef-c91b1f0b39d0_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization of molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Molecules To Be Developed And Commercialized Under Agreement</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of molecules to be developed and commercialized as per collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a6a35fd7-0c4c-422f-b845-1f7db0b4cc06_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_402ab6b4-1bcb-434e-9667-f87754fe2bc0_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ab3a562b-c5da-43af-90ec-8610c21b345b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a6835127-83de-4995-95bd-2753b3f6bf16_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating and investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_335441a6-a0eb-4b67-a481-8e3d625d7d24_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:href="mgnx-20201231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:to="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_15eaefaf-ffb7-4aae-9259-5b78dcb3d47b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d8ec00a-c4dd-43cd-b20f-8757fb11491b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e295644f-c237-4a64-add2-b2ad37d72114_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_9a8cd195-096c-4553-99bd-8fe12b8401d3_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20201231.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_70d0e3eb-dfa0-4c62-aa22-5024bf8fbe61_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4c61c934-6463-4b57-9fce-05c641d7099c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d4110744-13f0-4a23-ba24-7e3c20a16ba3_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2591f676-1184-4055-9397-f38fcc6b04d0_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierDARTMember_14df5127-aab7-4376-892e-172a9d8743a6_terseLabel_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier DART</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_label_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier DART [Member]</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_documentation_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents agreement with Servier for DARTs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember" xlink:href="mgnx-20201231.xsd#mgnx_ServierDARTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierDARTMember" xlink:to="lab_mgnx_ServierDARTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e3a48bdc-fae6-4598-919f-d50c57dfae94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dbee71f0-4044-4e84-b62f-bd9a1ac8b4ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_fd379030-9ff2-41c4-9d5d-2bf1e6d4b0e6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_954bb54c-f8b8-48c4-bcc0-68c2a5ecf8fa_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20201231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7d8201f4-2918-463e-8694-08f7dfce1da5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_74febde4-ec7d-4043-aedd-ab598c7f0bf3_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_f58009d2-d807-4a81-a853-d54f18b3be9f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7757e2c3-f20d-46cb-9dc7-7ef5cf8099fd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b40ae792-65f2-41de-86d8-354df4ec9e7b_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets modified in exchange for operating lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_6d59cd85-b5f5-4374-bea5-bb52a128aae9_terseLabel_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_label_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_documentation_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:href="mgnx-20201231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:to="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_983f1161-ee85-4712-844f-9ab9f45d6fe0_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Par Value Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_92f3bfa2-7d0c-4945-9b37-c67fc8ab86bf_terseLabel_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:href="mgnx-20201231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:to="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4ae923f8-d7e0-43cc-a3bd-fd3e1a11e67c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_9ac0a806-6ba3-4c27-8973-7f7a9ffc81cd_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7b09f638-d327-49e9-a705-1dca8b722b9c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0290f4a3-ef2d-4dc0-beb0-d6a65b85d869_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense/(benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_852d7f39-f2f1-4779-846a-03777b5ce158_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4660b78f-bd90-494a-93f8-cb4ffb10444e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_d5258b6c-41b6-4a5a-a2d9-79acf4c4c776_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6b64fc63-6f5c-4079-a3cc-7b8d0c5e45ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2bf5399e-0b65-410e-8af2-1c71219d80ce_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7df00e9c-a1f8-4b5b-8b91-e2584a2288be_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_54aa6a97-8d4e-4f09-b94c-9d0847221232_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_720cea3a-b9a8-4ffd-b290-1d0a9ae0e159_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_3d032b35-ff5c-44cf-a736-cd45f17190e5_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_cac1cd1f-42b7-41ed-bd8f-c535df532e61_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e18ef34b-9fea-40fa-976d-c5b43c7885a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_814d83bb-2e5b-4ad8-87be-d0099a66546b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_ccfabf93-d6dd-4d8c-9b6b-3012a5871591_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e3ab7c3f-43f0-4e76-8588-de8b5d8e28d8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_91a2c77f-5bdd-457b-bd5a-c4acb132b6e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_34a22154-25f1-4d22-ac01-3e6021423b2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases for prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_32a2f3c2-6e42-4bf8-ae48-99083e9af944_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ff5fb35-82dd-40ae-9ffa-c8dcdf09d7dd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f07bb938-e246-45c8-843e-dd1f7fb965eb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_5e9d64c9-a490-4441-b13c-f0a38439d5a8_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_9950fca3-63e2-4e93-81fb-2f0366e408e7_verboseLabel_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_label_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]</link:label>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_documentation_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:href="mgnx-20201231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:to="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_daa20783-9285-48ec-93e5-f8bbc0621ce4_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in deferred rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:href="mgnx-20201231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:to="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_21a62983-2708-4135-b026-348773cf9323_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_3c07e8ba-91b8-4467-adfe-a0da39c4480a_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20201231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f120825-4ce5-486a-adef-20481379a518_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_7a786e76-47d5-44e3-b0c1-2d38f8e46b5f_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c382afcd-babf-4490-a0d0-3965cff16327_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_9709b45d-f894-455b-ad38-a3b89719700c_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20201231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1a245bbb-a529-46d9-9d4b-de1415fc23d5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_65f3ef13-4a6a-47ec-88cd-e8769b48a981_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_38a024fd-41a1-4b32-be31-6d80059583f1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a2bd7045-0c16-484a-91ad-8de2498789d0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f0ddc38-3d8e-4485-96f0-26de992b10e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_79de5d74-2cea-4e31-8426-20fac7045ec2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_52208176-eb8d-4a3d-a56c-260f9be0136d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0ff3619f-a72d-46ff-9657-beacbabbfe4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_133ba900-762a-4f5f-ba10-4e845a6ace92_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a16de815-7799-4f0b-8566-70263c588f52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_77c85d2a-945e-4d6d-a613-c53ac9df3744_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance recorded</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1407ad54-4b23-42a5-81d7-2669da56c4a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_6a14680e-7806-48ab-b2ae-d8d8c9f84ef0_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_74da7c9b-607c-4398-b69d-fd87f2abb975_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_74ddb4d7-0fce-4b11-a6c0-829fb58b98ee_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ae5644a4-4192-4e22-9ce2-dcfefb26e374_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d39887f4-21c2-47fb-afea-e64b2510b4ce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioMember_a8db4ef3-925f-4316-8cf5-84785e912398_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio, Inc. (Provention)</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_label_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio [Member]</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_documentation_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember" xlink:href="mgnx-20201231.xsd#mgnx_ProventionBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioMember" xlink:to="lab_mgnx_ProventionBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_7a822512-c6e4-4268-9cbf-cd8a84ad14cd_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20201231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_1319fe63-c0a9-442a-ab23-7a7ec23f23c7_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8e244ac0-9249-4a9e-9dbd-54c49d593a08_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c6eeb06f-883b-43a3-8ac5-e08e95318065_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fcd186a3-ad7f-47f0-8490-dbe0df332da2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_193760fd-dcdf-406d-bcfb-d160a4d1ce14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_229ad477-b091-4f12-a1e5-7b7e5365de79_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ad961836-ec9d-470d-9601-5c1ab97a66ad_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_4abf5b9c-0be7-4d1c-98bd-6b6a1170dcf3_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>mgnx-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:027e117c-75c0-47f2-bc63-7ee727579094,g:55d8aba6-2c39-4104-9032-126eaff6334c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6bbe6f1d-c732-41a7-ab91-bd5726fd592c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_DocumentType_6bbe6f1d-c732-41a7-ab91-bd5726fd592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_10b87420-2856-441e-9fef-de8320eb4aa4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_DocumentAnnualReport_10b87420-2856-441e-9fef-de8320eb4aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_873e9207-eda4-4c1b-9aad-c30460e48294" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_DocumentPeriodEndDate_873e9207-eda4-4c1b-9aad-c30460e48294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4b1793ba-44a8-4dc6-94fc-63ab48b1e5e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_DocumentTransitionReport_4b1793ba-44a8-4dc6-94fc-63ab48b1e5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_68522306-b632-42f2-a5b4-c3cdda7a1ca6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityFileNumber_68522306-b632-42f2-a5b4-c3cdda7a1ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0d713712-7023-4c4c-a14c-11c81e322b5a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityRegistrantName_0d713712-7023-4c4c-a14c-11c81e322b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b4e1d6a6-c992-4a3f-bdd5-e1e68d6fe7e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b4e1d6a6-c992-4a3f-bdd5-e1e68d6fe7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9044e52a-0264-4131-9db8-eeb91d470d2c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityTaxIdentificationNumber_9044e52a-0264-4131-9db8-eeb91d470d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_57c7d6dd-d36f-4632-affd-912da7595308" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityAddressAddressLine1_57c7d6dd-d36f-4632-affd-912da7595308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7a8fcbe4-55c7-444f-8a77-24f4caf675c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityAddressCityOrTown_7a8fcbe4-55c7-444f-8a77-24f4caf675c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b8701865-6894-41d7-b69c-2adf95af2253" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityAddressStateOrProvince_b8701865-6894-41d7-b69c-2adf95af2253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fc5ccda2-a4dc-4dd3-81cb-4ef7fd1a93df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityAddressPostalZipCode_fc5ccda2-a4dc-4dd3-81cb-4ef7fd1a93df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f2781474-8a39-449c-a98b-694015020904" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_CityAreaCode_f2781474-8a39-449c-a98b-694015020904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4d3cbed6-5e87-41df-ae78-7025309c08bb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_LocalPhoneNumber_4d3cbed6-5e87-41df-ae78-7025309c08bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_72866a68-5248-4731-bf21-4c4e764223cb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_Security12bTitle_72866a68-5248-4731-bf21-4c4e764223cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a9bdb647-5622-4213-9d5f-f689b8e24d01" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_TradingSymbol_a9bdb647-5622-4213-9d5f-f689b8e24d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1744b470-b776-444a-95d5-197946ae0f6f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_SecurityExchangeName_1744b470-b776-444a-95d5-197946ae0f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_83e06bc2-10c1-4348-9714-89e855d48377" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_83e06bc2-10c1-4348-9714-89e855d48377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_1c8fa296-aa28-4d4b-9e03-0cd34be2f96d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityVoluntaryFilers_1c8fa296-aa28-4d4b-9e03-0cd34be2f96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d2315d75-f7c5-4b67-95a0-fce49806040a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityCurrentReportingStatus_d2315d75-f7c5-4b67-95a0-fce49806040a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_016dd5c9-2d49-4bf1-b301-0308c108e4de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityInteractiveDataCurrent_016dd5c9-2d49-4bf1-b301-0308c108e4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_94198743-40c7-483a-937f-191912beee65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityFilerCategory_94198743-40c7-483a-937f-191912beee65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_390fa51b-ca39-4004-9d5f-2ef4402959f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntitySmallBusiness_390fa51b-ca39-4004-9d5f-2ef4402959f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5ff0448a-72bc-4d53-b684-97073a628a8c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityEmergingGrowthCompany_5ff0448a-72bc-4d53-b684-97073a628a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_279731c5-9a7d-45ea-abf0-c0370d7adbf1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_IcfrAuditorAttestationFlag_279731c5-9a7d-45ea-abf0-c0370d7adbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9fc3a41e-857e-498a-b198-b5140a06383b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityShellCompany_9fc3a41e-857e-498a-b198-b5140a06383b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_45572236-0557-4287-b255-194dd2a61aad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityPublicFloat_45572236-0557-4287-b255-194dd2a61aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5c8676d9-4517-44e5-8f42-84f279cda366" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5c8676d9-4517-44e5-8f42-84f279cda366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_814ddcaa-0505-458e-aacb-7b20fe69f7e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_814ddcaa-0505-458e-aacb-7b20fe69f7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_aea4679f-3849-4b5b-b04a-51a064435ca5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_AmendmentFlag_aea4679f-3849-4b5b-b04a-51a064435ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e7e65cb6-265e-4fb6-ab64-c56d8fa0bdc9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_DocumentFiscalYearFocus_e7e65cb6-265e-4fb6-ab64-c56d8fa0bdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_14b327ce-618e-4b12-9513-e3066f7788ec" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_14b327ce-618e-4b12-9513-e3066f7788ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a268b900-5166-4136-9d03-68bf7d366e5b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_EntityCentralIndexKey_a268b900-5166-4136-9d03-68bf7d366e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_48b9d609-4fab-4485-af1b-1151e2118f1d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad3156a1-8f9b-49c9-bc9f-ac4903b807a5" xlink:to="loc_dei_CurrentFiscalYearEndDate_48b9d609-4fab-4485-af1b-1151e2118f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26d03eb4-c4c5-43b8-9710-05c68798e6ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7dde2be8-5d46-4324-9531-6fa42a6ce50a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26d03eb4-c4c5-43b8-9710-05c68798e6ba" xlink:to="loc_us-gaap_AssetsAbstract_7dde2be8-5d46-4324-9531-6fa42a6ce50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9c533cb5-60a2-4ca4-badc-8058024b6bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7dde2be8-5d46-4324-9531-6fa42a6ce50a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9c533cb5-60a2-4ca4-badc-8058024b6bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_acaee552-a1f0-40a5-a44d-ddc666da43c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c533cb5-60a2-4ca4-badc-8058024b6bbc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_acaee552-a1f0-40a5-a44d-ddc666da43c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_71456e41-accc-46aa-b51e-defef539945a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c533cb5-60a2-4ca4-badc-8058024b6bbc" xlink:to="loc_us-gaap_Investments_71456e41-accc-46aa-b51e-defef539945a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bc482df4-01bf-4fff-8703-d4a0529e150b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c533cb5-60a2-4ca4-badc-8058024b6bbc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bc482df4-01bf-4fff-8703-d4a0529e150b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_478caf2c-2c9d-49ea-82f8-7c229ca2d6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c533cb5-60a2-4ca4-badc-8058024b6bbc" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_478caf2c-2c9d-49ea-82f8-7c229ca2d6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_65873bbd-4e32-4519-8c39-3396832706b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c533cb5-60a2-4ca4-badc-8058024b6bbc" xlink:to="loc_us-gaap_AssetsCurrent_65873bbd-4e32-4519-8c39-3396832706b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1eb72ee6-3d67-42b5-aea1-e0569356e037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7dde2be8-5d46-4324-9531-6fa42a6ce50a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1eb72ee6-3d67-42b5-aea1-e0569356e037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bdce2581-d1a1-41a5-9040-95ec0bc5b178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7dde2be8-5d46-4324-9531-6fa42a6ce50a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bdce2581-d1a1-41a5-9040-95ec0bc5b178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_84269983-4cd0-419a-99d2-c37cd11b2ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7dde2be8-5d46-4324-9531-6fa42a6ce50a" xlink:to="loc_us-gaap_Assets_84269983-4cd0-419a-99d2-c37cd11b2ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d3d7c1c-8375-4516-8fc1-ced1673fc089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26d03eb4-c4c5-43b8-9710-05c68798e6ba" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d3d7c1c-8375-4516-8fc1-ced1673fc089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8cbe3494-de49-482d-972d-f3c60ec30ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d3d7c1c-8375-4516-8fc1-ced1673fc089" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8cbe3494-de49-482d-972d-f3c60ec30ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_05fff057-33e3-49d0-afe8-9e316b11f574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8cbe3494-de49-482d-972d-f3c60ec30ea3" xlink:to="loc_us-gaap_AccountsPayableCurrent_05fff057-33e3-49d0-afe8-9e316b11f574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_016f0605-1483-45e9-920a-b4196677c04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8cbe3494-de49-482d-972d-f3c60ec30ea3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_016f0605-1483-45e9-920a-b4196677c04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_19b3e5a5-a87e-4393-ae35-000c240ce283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8cbe3494-de49-482d-972d-f3c60ec30ea3" xlink:to="loc_us-gaap_DeferredRevenueCurrent_19b3e5a5-a87e-4393-ae35-000c240ce283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1c5be82f-5ca6-417c-b7fd-a2f91ea737b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8cbe3494-de49-482d-972d-f3c60ec30ea3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1c5be82f-5ca6-417c-b7fd-a2f91ea737b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5f4a9534-69d8-47f4-add1-bd47375a89c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8cbe3494-de49-482d-972d-f3c60ec30ea3" xlink:to="loc_us-gaap_LiabilitiesCurrent_5f4a9534-69d8-47f4-add1-bd47375a89c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_a3bc7837-2163-4dd2-baa8-84fdd2c5be91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d3d7c1c-8375-4516-8fc1-ced1673fc089" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_a3bc7837-2163-4dd2-baa8-84fdd2c5be91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75eb80e0-3c0b-45ba-b3e8-f60279279058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d3d7c1c-8375-4516-8fc1-ced1673fc089" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75eb80e0-3c0b-45ba-b3e8-f60279279058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_21964c92-3d64-4f79-9f15-aeec1c371f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d3d7c1c-8375-4516-8fc1-ced1673fc089" xlink:to="loc_us-gaap_Liabilities_21964c92-3d64-4f79-9f15-aeec1c371f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1fe50c7b-2949-42d7-8b12-13aaa8786530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d3d7c1c-8375-4516-8fc1-ced1673fc089" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1fe50c7b-2949-42d7-8b12-13aaa8786530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e801204c-1036-4f70-8abf-374dfcdd893a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fe50c7b-2949-42d7-8b12-13aaa8786530" xlink:to="loc_us-gaap_CommonStockValue_e801204c-1036-4f70-8abf-374dfcdd893a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_10633256-4c91-44dd-9790-a6d0363cffda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fe50c7b-2949-42d7-8b12-13aaa8786530" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_10633256-4c91-44dd-9790-a6d0363cffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fef57cd9-c3dc-433f-9492-34665876599a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fe50c7b-2949-42d7-8b12-13aaa8786530" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fef57cd9-c3dc-433f-9492-34665876599a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6cf5b8e1-65f1-48c9-aefc-30c896cea441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fe50c7b-2949-42d7-8b12-13aaa8786530" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6cf5b8e1-65f1-48c9-aefc-30c896cea441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_781fa0a0-9a9f-4387-9366-3e90bd71b754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fe50c7b-2949-42d7-8b12-13aaa8786530" xlink:to="loc_us-gaap_StockholdersEquity_781fa0a0-9a9f-4387-9366-3e90bd71b754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2758628-cb87-42c6-b6be-0c0063049814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d3d7c1c-8375-4516-8fc1-ced1673fc089" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2758628-cb87-42c6-b6be-0c0063049814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_59fd9d04-282f-4cec-b3e0-2d527014eb9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_71ce241c-5db4-484a-8ea6-0c02aecc03c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59fd9d04-282f-4cec-b3e0-2d527014eb9b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_71ce241c-5db4-484a-8ea6-0c02aecc03c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b70a8022-60e5-47ca-9c25-e09f4629f832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59fd9d04-282f-4cec-b3e0-2d527014eb9b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b70a8022-60e5-47ca-9c25-e09f4629f832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_73d97447-1d50-41e3-ac2b-0d0b58618bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59fd9d04-282f-4cec-b3e0-2d527014eb9b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_73d97447-1d50-41e3-ac2b-0d0b58618bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_75e279c2-c508-47cb-a3f0-ee1698a8e33a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_099bb727-275c-41f0-82d7-ac72db79d7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75e279c2-c508-47cb-a3f0-ee1698a8e33a" xlink:to="loc_us-gaap_StatementTable_099bb727-275c-41f0-82d7-ac72db79d7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bad804be-811a-4772-a582-6fa32a27ff83" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_099bb727-275c-41f0-82d7-ac72db79d7bc" xlink:to="loc_srt_ProductOrServiceAxis_bad804be-811a-4772-a582-6fa32a27ff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_406963bc-1bed-474b-a041-1c43aab51c22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bad804be-811a-4772-a582-6fa32a27ff83" xlink:to="loc_srt_ProductsAndServicesDomain_406963bc-1bed-474b-a041-1c43aab51c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_488427f1-aeef-4930-9c96-0573d837f984" xlink:href="mgnx-20201231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_406963bc-1bed-474b-a041-1c43aab51c22" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_488427f1-aeef-4930-9c96-0573d837f984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_fca0f419-25bf-410d-96b2-21099a01262e" xlink:href="mgnx-20201231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_406963bc-1bed-474b-a041-1c43aab51c22" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_fca0f419-25bf-410d-96b2-21099a01262e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_099bb727-275c-41f0-82d7-ac72db79d7bc" xlink:to="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bb9cb3f9-6ede-4694-8361-b8be8def2eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_RevenuesAbstract_bb9cb3f9-6ede-4694-8361-b8be8def2eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4eb138f8-6575-4978-8af3-496dd9da9932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bb9cb3f9-6ede-4694-8361-b8be8def2eda" xlink:to="loc_us-gaap_Revenues_4eb138f8-6575-4978-8af3-496dd9da9932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_621644ab-3670-4a93-b4a8-d3101cbb212c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_621644ab-3670-4a93-b4a8-d3101cbb212c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2ed6e011-fecf-4f0f-8487-a8596d00c95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2ed6e011-fecf-4f0f-8487-a8596d00c95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_69bcc680-e84f-4e0b-8e2a-e01dd2f83f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47d8f669-5536-454f-8893-2023b764e726" xlink:to="loc_us-gaap_CostsAndExpenses_69bcc680-e84f-4e0b-8e2a-e01dd2f83f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f4b593a-55e7-4fc9-9323-2f511b256407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_OperatingIncomeLoss_3f4b593a-55e7-4fc9-9323-2f511b256407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fd3c9071-b510-4818-930a-f9d919f78488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fd3c9071-b510-4818-930a-f9d919f78488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_977a440e-b65b-40c0-b4a1-71f873891ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_NetIncomeLoss_977a440e-b65b-40c0-b4a1-71f873891ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6fe4d71f-2087-4d28-8208-564cf8631ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6fe4d71f-2087-4d28-8208-564cf8631ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_47477e94-c566-408f-9fd8-0d1280d5bfd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6fe4d71f-2087-4d28-8208-564cf8631ded" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_47477e94-c566-408f-9fd8-0d1280d5bfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_95c7e289-ab0f-4ec2-8c8c-edbbc28b38d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_95c7e289-ab0f-4ec2-8c8c-edbbc28b38d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_84b57609-8eae-4bcc-8c94-2c1c44386369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_84b57609-8eae-4bcc-8c94-2c1c44386369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6bca035c-94fe-4e32-9cbc-19b0853ba337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_810a8db4-90ae-489f-adbb-63c8859599fb" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6bca035c-94fe-4e32-9cbc-19b0853ba337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_acd01153-c994-4540-be97-40e663465a26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d0d4600c-4592-415e-8c47-6743298e2034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_acd01153-c994-4540-be97-40e663465a26" xlink:to="loc_us-gaap_StatementTable_d0d4600c-4592-415e-8c47-6743298e2034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_342a8931-2336-4e31-b07d-7d92a600b215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d0d4600c-4592-415e-8c47-6743298e2034" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_342a8931-2336-4e31-b07d-7d92a600b215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_342a8931-2336-4e31-b07d-7d92a600b215" xlink:to="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc079f23-290d-4794-8142-5dd95e908a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_CommonStockMember_bc079f23-290d-4794-8142-5dd95e908a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2b1d69ac-2bab-4463-88cf-a438f08bfded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_TreasuryStockMember_2b1d69ac-2bab-4463-88cf-a438f08bfded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6858e1f0-8998-4372-b31d-19a17b04cdd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6858e1f0-8998-4372-b31d-19a17b04cdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad1937d2-293a-435a-92a5-750b9b77f509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_RetainedEarningsMember_ad1937d2-293a-435a-92a5-750b9b77f509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f92ff70-e0fb-4d74-a111-6b4634df965c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ee94b8a-f1f0-476e-b5a0-ce4b0539174c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f92ff70-e0fb-4d74-a111-6b4634df965c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3de9577b-b2b4-4891-9b77-6681d992719a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d0d4600c-4592-415e-8c47-6743298e2034" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3de9577b-b2b4-4891-9b77-6681d992719a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_197be2bd-e6bd-47fa-b48d-5def3bf27c88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3de9577b-b2b4-4891-9b77-6681d992719a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_197be2bd-e6bd-47fa-b48d-5def3bf27c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_43c5f071-484c-4ddc-8e04-17f819c00372" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_197be2bd-e6bd-47fa-b48d-5def3bf27c88" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_43c5f071-484c-4ddc-8e04-17f819c00372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d0d4600c-4592-415e-8c47-6743298e2034" xlink:to="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8e8fd202-19f3-4c51-9f9f-9a255798ee75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_SharesIssued_8e8fd202-19f3-4c51-9f9f-9a255798ee75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3c7774b0-0105-4b29-b0b6-f48f6e3a2218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_StockholdersEquity_3c7774b0-0105-4b29-b0b6-f48f6e3a2218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1b738373-9e76-4c94-8fa0-f810aea7f2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1b738373-9e76-4c94-8fa0-f810aea7f2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa370125-e1f4-406b-8962-6e7af71cda18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa370125-e1f4-406b-8962-6e7af71cda18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27b8c7b8-bbe4-4570-ab06-61282914bef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27b8c7b8-bbe4-4570-ab06-61282914bef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_fcd5e14a-3757-42e9-892b-e2baaf8e8ae0" xlink:href="mgnx-20201231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_fcd5e14a-3757-42e9-892b-e2baaf8e8ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_f1db5d6e-cc2a-4510-b0e8-229d1be15f9e" xlink:href="mgnx-20201231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_f1db5d6e-cc2a-4510-b0e8-229d1be15f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_0ec657ce-e08c-41be-ad5a-3b2b6bb00e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_0ec657ce-e08c-41be-ad5a-3b2b6bb00e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_d8ccabd6-512f-45b9-a06c-7b57e2e1410d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_d8ccabd6-512f-45b9-a06c-7b57e2e1410d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2d2ae2ef-fbff-4433-8e10-ec91e742f957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2d2ae2ef-fbff-4433-8e10-ec91e742f957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e2c2ef9-492a-4f65-a111-53f47ad4b99b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_NetIncomeLoss_6e2c2ef9-492a-4f65-a111-53f47ad4b99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0c8519dc-b4ea-43f9-a3ad-619344713c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_SharesIssued_0c8519dc-b4ea-43f9-a3ad-619344713c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_699a3dec-c2da-42aa-ae87-4d06c3451d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2dda3cf-aa51-453a-99d2-6d1dc77483d6" xlink:to="loc_us-gaap_StockholdersEquity_699a3dec-c2da-42aa-ae87-4d06c3451d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c1c9c5cf-e72f-4a00-9ea0-de23d4ef2430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_293e4ba2-4eb1-421b-8664-c5769940f970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c9c5cf-e72f-4a00-9ea0-de23d4ef2430" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_293e4ba2-4eb1-421b-8664-c5769940f970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_32e00785-8371-403d-b8e7-73982ac01fae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_293e4ba2-4eb1-421b-8664-c5769940f970" xlink:to="loc_us-gaap_NetIncomeLoss_32e00785-8371-403d-b8e7-73982ac01fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1f7738f-5d84-44d4-8e75-671a9aacf247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_293e4ba2-4eb1-421b-8664-c5769940f970" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1f7738f-5d84-44d4-8e75-671a9aacf247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d9871004-ab87-412f-9d6f-c464b0620c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1f7738f-5d84-44d4-8e75-671a9aacf247" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d9871004-ab87-412f-9d6f-c464b0620c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0208aea6-6b59-49a9-ad23-23457e9eeaef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1f7738f-5d84-44d4-8e75-671a9aacf247" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0208aea6-6b59-49a9-ad23-23457e9eeaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8576bedb-2c23-4b87-8222-2fdf32421360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1f7738f-5d84-44d4-8e75-671a9aacf247" xlink:to="loc_us-gaap_ShareBasedCompensation_8576bedb-2c23-4b87-8222-2fdf32421360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1f7738f-5d84-44d4-8e75-671a9aacf247" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e919da83-2f1c-48ef-b742-682edbaecf2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e919da83-2f1c-48ef-b742-682edbaecf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_c183da8c-0975-4cf5-94b5-ad66987efe22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_c183da8c-0975-4cf5-94b5-ad66987efe22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_67ae898c-6219-4f6f-a0de-abf239be0443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_67ae898c-6219-4f6f-a0de-abf239be0443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c54c8a36-7620-465f-b053-5d842e696d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c54c8a36-7620-465f-b053-5d842e696d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_46906777-6c69-44a5-bac3-9e0831f489a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_46906777-6c69-44a5-bac3-9e0831f489a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_579ebaa3-26c5-479f-8949-2e135abf9adf" xlink:href="mgnx-20201231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_579ebaa3-26c5-479f-8949-2e135abf9adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a1e97fe7-0b12-4d8f-bab8-5ad10a9c84e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a1e97fe7-0b12-4d8f-bab8-5ad10a9c84e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_9d98ea35-184f-4f78-b8b0-d6dff252460b" xlink:href="mgnx-20201231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_214c6820-19af-4cda-9d2f-9b81199e66be" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_9d98ea35-184f-4f78-b8b0-d6dff252460b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93a6176f-c3e1-4e6f-9d08-f9a7971da5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_293e4ba2-4eb1-421b-8664-c5769940f970" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93a6176f-c3e1-4e6f-9d08-f9a7971da5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_569e7cbf-9158-4d81-9257-ea36c51b2af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c9c5cf-e72f-4a00-9ea0-de23d4ef2430" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_569e7cbf-9158-4d81-9257-ea36c51b2af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0293bf3e-b530-416a-b9a1-b0b75e53126f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_569e7cbf-9158-4d81-9257-ea36c51b2af8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0293bf3e-b530-416a-b9a1-b0b75e53126f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_91dca70c-89e3-473d-8622-728fc6a828a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_569e7cbf-9158-4d81-9257-ea36c51b2af8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_91dca70c-89e3-473d-8622-728fc6a828a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_40255c57-7a86-45f4-a4d6-f97b8e7dd59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_569e7cbf-9158-4d81-9257-ea36c51b2af8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_40255c57-7a86-45f4-a4d6-f97b8e7dd59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_832d288a-c800-4874-9130-db8860b9e765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_569e7cbf-9158-4d81-9257-ea36c51b2af8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_832d288a-c800-4874-9130-db8860b9e765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b64f202e-e984-47d3-a8cd-f54d699f26bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c9c5cf-e72f-4a00-9ea0-de23d4ef2430" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b64f202e-e984-47d3-a8cd-f54d699f26bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_180b5918-ddb5-4ba2-bed3-375200b66b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b64f202e-e984-47d3-a8cd-f54d699f26bf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_180b5918-ddb5-4ba2-bed3-375200b66b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_0a8f6801-dc8d-456f-bcab-14c91ffdcf53" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b64f202e-e984-47d3-a8cd-f54d699f26bf" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_0a8f6801-dc8d-456f-bcab-14c91ffdcf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_896c1b17-2f59-4b27-a72f-dd19731d8299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b64f202e-e984-47d3-a8cd-f54d699f26bf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_896c1b17-2f59-4b27-a72f-dd19731d8299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_255575f3-3657-4374-afdb-80ce794f5467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b64f202e-e984-47d3-a8cd-f54d699f26bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_255575f3-3657-4374-afdb-80ce794f5467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35f389ae-f4cc-46e6-89f0-cea9671c7352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c9c5cf-e72f-4a00-9ea0-de23d4ef2430" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35f389ae-f4cc-46e6-89f0-cea9671c7352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1327f87-db69-4483-9fde-b4e2236c38c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c9c5cf-e72f-4a00-9ea0-de23d4ef2430" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1327f87-db69-4483-9fde-b4e2236c38c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ec5da7e-4fde-4fc6-9755-3197d11f8b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c9c5cf-e72f-4a00-9ea0-de23d4ef2430" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ec5da7e-4fde-4fc6-9755-3197d11f8b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1fcf208e-5693-498e-8b15-3320bb278a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c9c5cf-e72f-4a00-9ea0-de23d4ef2430" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1fcf208e-5693-498e-8b15-3320bb278a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dc395251-41ca-4756-b058-9768c46545d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1fcf208e-5693-498e-8b15-3320bb278a1b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dc395251-41ca-4756-b058-9768c46545d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FairValueOfWarrantsReceived_253fa3e8-da17-4cc3-a949-e69daa9d24d1" xlink:href="mgnx-20201231.xsd#mgnx_FairValueOfWarrantsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1fcf208e-5693-498e-8b15-3320bb278a1b" xlink:to="loc_mgnx_FairValueOfWarrantsReceived_253fa3e8-da17-4cc3-a949-e69daa9d24d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20201231.xsd#OrganizationandNatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d4a29063-5523-42bb-8d5a-92bc0e1da1b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5766921a-8d6c-4845-8aaa-4055ab51c7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d4a29063-5523-42bb-8d5a-92bc0e1da1b4" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5766921a-8d6c-4845-8aaa-4055ab51c7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7d509b3d-18da-4196-84f2-eb0ad20fc7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9169833c-5cda-4390-bee3-f217bda16c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7d509b3d-18da-4196-84f2-eb0ad20fc7a7" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9169833c-5cda-4390-bee3-f217bda16c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e2e125e5-2a9a-42e1-a0ca-668051a186da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e2e125e5-2a9a-42e1-a0ca-668051a186da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1fb85d90-7f41-4e1f-b152-f7ba6ecb6e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_UseOfEstimates_1fb85d90-7f41-4e1f-b152-f7ba6ecb6e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_67dcb6dc-053c-45b8-a9e1-f604f7628404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_67dcb6dc-053c-45b8-a9e1-f604f7628404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2f1198ff-03f4-4aaf-bb5f-76389ba06e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2f1198ff-03f4-4aaf-bb5f-76389ba06e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_66d1274e-d6bc-473f-89d2-d8a2634247e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_66d1274e-d6bc-473f-89d2-d8a2634247e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_82336e09-e3a1-485b-acd9-6a764b95bc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_82336e09-e3a1-485b-acd9-6a764b95bc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4181efb3-5325-4200-b311-ab86de91fcfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4181efb3-5325-4200-b311-ab86de91fcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a4fc834a-ab1b-43a6-834a-167854e35c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a4fc834a-ab1b-43a6-834a-167854e35c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_af3b34f9-1072-408a-8ddc-a68e358ee616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_af3b34f9-1072-408a-8ddc-a68e358ee616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ebdc4c83-44cc-41ad-a492-d183f7998712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ebdc4c83-44cc-41ad-a492-d183f7998712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_afade973-52c0-4a10-8583-e379e03fa1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_afade973-52c0-4a10-8583-e379e03fa1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_928d4d0e-2625-46ab-86a8-a2b7c639f478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_928d4d0e-2625-46ab-86a8-a2b7c639f478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d7e13531-825d-4d39-ac53-2115c7c83ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d7e13531-825d-4d39-ac53-2115c7c83ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_582e14f8-1607-4f7a-b9d4-df405801745c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_582e14f8-1607-4f7a-b9d4-df405801745c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82ab5c87-fcdb-40c8-8a5b-aab84ed5086a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfd07442-279c-49ea-a96e-17321e8250ab" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82ab5c87-fcdb-40c8-8a5b-aab84ed5086a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8b15922e-9ec9-406b-8012-1ee3b4b6360a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5d072e66-91cf-4bbb-96ce-61bf2b5c24bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b15922e-9ec9-406b-8012-1ee3b4b6360a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5d072e66-91cf-4bbb-96ce-61bf2b5c24bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_85bd42e5-0396-46bb-9511-3192ff366d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b15922e-9ec9-406b-8012-1ee3b4b6360a" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_85bd42e5-0396-46bb-9511-3192ff366d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_b0796b6f-9e22-4059-b6e3-4706ab8cf823" xlink:href="mgnx-20201231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b15922e-9ec9-406b-8012-1ee3b4b6360a" xlink:to="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_b0796b6f-9e22-4059-b6e3-4706ab8cf823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7467185d-3228-49fd-9737-91ef973318c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b15922e-9ec9-406b-8012-1ee3b4b6360a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7467185d-3228-49fd-9737-91ef973318c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c161a632-ba11-4b16-853e-61245805798e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_127a6f53-8d9e-446b-acec-1325cda47d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c161a632-ba11-4b16-853e-61245805798e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_127a6f53-8d9e-446b-acec-1325cda47d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_b0ecc8c1-4b8a-42b9-85bb-a96aaecb2b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c161a632-ba11-4b16-853e-61245805798e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_b0ecc8c1-4b8a-42b9-85bb-a96aaecb2b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_1f274ef4-1c04-4da3-a6f6-35ed88a1a34d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c161a632-ba11-4b16-853e-61245805798e" xlink:to="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_1f274ef4-1c04-4da3-a6f6-35ed88a1a34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_51f7be0b-0671-407e-971e-4e2f7a54ae18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c161a632-ba11-4b16-853e-61245805798e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_51f7be0b-0671-407e-971e-4e2f7a54ae18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_96334185-c902-4de0-b3c4-111e80e46491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c161a632-ba11-4b16-853e-61245805798e" xlink:to="loc_us-gaap_OperatingLeaseLiability_96334185-c902-4de0-b3c4-111e80e46491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dd7d4b61-2558-48c8-a83d-68e6d824d39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41ba53c4-0603-46ba-8139-96b13e68306e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd7d4b61-2558-48c8-a83d-68e6d824d39a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41ba53c4-0603-46ba-8139-96b13e68306e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55999aac-93ad-4718-aa35-96765f3a1c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41ba53c4-0603-46ba-8139-96b13e68306e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55999aac-93ad-4718-aa35-96765f3a1c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55999aac-93ad-4718-aa35-96765f3a1c29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_72ffbf49-aa50-464f-8f6e-7a7c8fae8ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_72ffbf49-aa50-464f-8f6e-7a7c8fae8ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_63fc0799-531f-4d31-946f-394687942042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_63fc0799-531f-4d31-946f-394687942042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8de2dc27-5f7b-41d8-8948-979210627157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f41f0799-c588-4af5-a8c4-2d6db5a70510" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8de2dc27-5f7b-41d8-8948-979210627157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b72c2f31-0a1f-4e06-b532-1c6a7b96cb66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41ba53c4-0603-46ba-8139-96b13e68306e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b72c2f31-0a1f-4e06-b532-1c6a7b96cb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b72c2f31-0a1f-4e06-b532-1c6a7b96cb66" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_aa264ecc-896d-4684-aee5-fc03674a30f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_aa264ecc-896d-4684-aee5-fc03674a30f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5b2c6e9f-548e-4760-b677-891a07dbd69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5b2c6e9f-548e-4760-b677-891a07dbd69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_51f354d2-7ffe-4ce7-aebc-d8554202af7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_51f354d2-7ffe-4ce7-aebc-d8554202af7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_bf78040b-30c3-4a41-b615-2dd16047af8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9b1118ed-bd1c-45b9-8058-1083980e15a1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_bf78040b-30c3-4a41-b615-2dd16047af8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b570e5f-676e-4b02-bee7-b72c57c93d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41ba53c4-0603-46ba-8139-96b13e68306e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b570e5f-676e-4b02-bee7-b72c57c93d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b570e5f-676e-4b02-bee7-b72c57c93d41" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ef21096c-81c5-4eae-ac52-f15cc8692e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ef21096c-81c5-4eae-ac52-f15cc8692e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b290b57-2337-4d31-a4f6-86a73f53ab85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b290b57-2337-4d31-a4f6-86a73f53ab85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_96e8d337-8368-4cab-818a-6cea598264e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_007271ec-28c1-40ec-8029-5004f559e630" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_96e8d337-8368-4cab-818a-6cea598264e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_db29ba94-04de-4d29-bd9f-1b51919c6a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db29ba94-04de-4d29-bd9f-1b51919c6a06" xlink:to="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f51f41-3d6f-4ce3-bb44-0dcc859d523d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f51f41-3d6f-4ce3-bb44-0dcc859d523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_30e5d38f-1cd4-430b-a1f1-8d1391f4661a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f51f41-3d6f-4ce3-bb44-0dcc859d523d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_30e5d38f-1cd4-430b-a1f1-8d1391f4661a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_94e781ba-3f16-49af-aa00-ca398428ae88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_30e5d38f-1cd4-430b-a1f1-8d1391f4661a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_94e781ba-3f16-49af-aa00-ca398428ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e4e26e1d-bb91-4a0c-b808-1f44d17bf0e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e4e26e1d-bb91-4a0c-b808-1f44d17bf0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8c9200e-2a15-462c-b8f5-59ae64e1eb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e4e26e1d-bb91-4a0c-b808-1f44d17bf0e9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8c9200e-2a15-462c-b8f5-59ae64e1eb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a571435b-3b5d-4d93-bf0a-c51696dc83ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8c9200e-2a15-462c-b8f5-59ae64e1eb2d" xlink:to="loc_us-gaap_SalesRevenueNetMember_a571435b-3b5d-4d93-bf0a-c51696dc83ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_80aa14d2-f20c-472c-9338-f8e87f84b3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8c9200e-2a15-462c-b8f5-59ae64e1eb2d" xlink:to="loc_us-gaap_AccountsReceivableMember_80aa14d2-f20c-472c-9338-f8e87f84b3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e16d1235-3724-4912-80bc-a7c5969caf90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:to="loc_srt_MajorCustomersAxis_e16d1235-3724-4912-80bc-a7c5969caf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e16d1235-3724-4912-80bc-a7c5969caf90" xlink:to="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_e07e4f65-959e-4a72-b76a-de3bec68b8fe" xlink:href="mgnx-20201231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:to="loc_mgnx_IncyteCorporationMember_e07e4f65-959e-4a72-b76a-de3bec68b8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_67cb1eec-9ea8-4af6-bfef-ee9a0fdec98f" xlink:href="mgnx-20201231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:to="loc_mgnx_JanssenBiotechIncMember_67cb1eec-9ea8-4af6-bfef-ee9a0fdec98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_cf6a6ee0-aa08-42b9-87a7-c778dc903017" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:to="loc_mgnx_ZaiLabLimitedMember_cf6a6ee0-aa08-42b9-87a7-c778dc903017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_f941450c-bade-43a6-adc6-bcbc377b96d5" xlink:href="mgnx-20201231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_daafe953-0884-4cde-9a0e-0a1511800ad0" xlink:to="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_f941450c-bade-43a6-adc6-bcbc377b96d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_150b6380-ed13-4a75-b08e-ca7a686286fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_732cbd91-9b74-43b5-87c1-6a306bcb8459" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_150b6380-ed13-4a75-b08e-ca7a686286fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_af4ef31a-cd4f-41a9-9c47-dabc4d5af078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_150b6380-ed13-4a75-b08e-ca7a686286fe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_af4ef31a-cd4f-41a9-9c47-dabc4d5af078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_671b0d86-e673-4514-99c9-d7b6f55ec256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01a32b3c-12e3-40fc-b2e0-3fb0688d95db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_671b0d86-e673-4514-99c9-d7b6f55ec256" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01a32b3c-12e3-40fc-b2e0-3fb0688d95db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd551520-20fd-494b-92de-6c64cbcd38c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01a32b3c-12e3-40fc-b2e0-3fb0688d95db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd551520-20fd-494b-92de-6c64cbcd38c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd551520-20fd-494b-92de-6c64cbcd38c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_cef33eda-a5fb-4fdf-9a8d-ef5b0c56d3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:to="loc_us-gaap_ComputerEquipmentMember_cef33eda-a5fb-4fdf-9a8d-ef5b0c56d3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_033e3259-395b-4bd4-b7c4-4bcf9d0c1b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_033e3259-395b-4bd4-b7c4-4bcf9d0c1b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_13bcb660-32a1-477c-9129-2f8ffc3d86ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_13bcb660-32a1-477c-9129-2f8ffc3d86ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_ad956cc5-31d4-48af-8e1f-f60621f70d1b" xlink:href="mgnx-20201231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82c766bf-2d18-42dc-b6ce-dff9b3f270db" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_ad956cc5-31d4-48af-8e1f-f60621f70d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36ff0641-2b7e-4a77-afa8-d89e928a6f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01a32b3c-12e3-40fc-b2e0-3fb0688d95db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36ff0641-2b7e-4a77-afa8-d89e928a6f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4fe5a8a5-8e8b-4345-b8ef-b502c8d2cacf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36ff0641-2b7e-4a77-afa8-d89e928a6f33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4fe5a8a5-8e8b-4345-b8ef-b502c8d2cacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5e029829-4070-4141-8731-fed88cf394af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1836ad45-4fcf-4ab0-9d1c-af7cd6dc1654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e029829-4070-4141-8731-fed88cf394af" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1836ad45-4fcf-4ab0-9d1c-af7cd6dc1654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7592184-d06b-4f74-93f5-56b5dfe009a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1836ad45-4fcf-4ab0-9d1c-af7cd6dc1654" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7592184-d06b-4f74-93f5-56b5dfe009a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2b90ae57-ccda-4008-ae9b-0bf9de676c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7592184-d06b-4f74-93f5-56b5dfe009a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2b90ae57-ccda-4008-ae9b-0bf9de676c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_a42e03f0-536b-4bdc-a7bd-68b874f577a5" xlink:href="mgnx-20201231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2b90ae57-ccda-4008-ae9b-0bf9de676c27" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_a42e03f0-536b-4bdc-a7bd-68b874f577a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa92bf05-3eb2-41fb-90e3-a080ddf9beb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1836ad45-4fcf-4ab0-9d1c-af7cd6dc1654" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa92bf05-3eb2-41fb-90e3-a080ddf9beb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d7d19180-91dd-46ba-be1b-0fc42dbe1700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa92bf05-3eb2-41fb-90e3-a080ddf9beb6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d7d19180-91dd-46ba-be1b-0fc42dbe1700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f31a0de4-1b20-46b9-9ee2-28b4957943b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6444fa10-c329-4600-81fd-ea4c78fa0eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f31a0de4-1b20-46b9-9ee2-28b4957943b9" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6444fa10-c329-4600-81fd-ea4c78fa0eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_324d928f-0453-456c-98c5-6f45f25651e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1b785a0b-05c0-4441-9fa2-c3fc868a7f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_324d928f-0453-456c-98c5-6f45f25651e5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1b785a0b-05c0-4441-9fa2-c3fc868a7f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_09d766b4-da9f-43a8-9bff-9f1bfb1b613c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb279967-5b9c-4060-a777-83b3a2daadc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_09d766b4-da9f-43a8-9bff-9f1bfb1b613c" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb279967-5b9c-4060-a777-83b3a2daadc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_51b3807a-a2e6-4bef-8f7a-11e5c7415166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb279967-5b9c-4060-a777-83b3a2daadc1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_51b3807a-a2e6-4bef-8f7a-11e5c7415166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_51b3807a-a2e6-4bef-8f7a-11e5c7415166" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2fce4961-a751-40f5-835f-098d62eb0a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2fce4961-a751-40f5-835f-098d62eb0a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_905523aa-3eea-4c89-9442-509ef09866c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_905523aa-3eea-4c89-9442-509ef09866c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_731d64a7-e874-4f61-9d5e-6565ffca0a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35a8dd91-cd39-48b7-b755-307f63f2ffe0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_731d64a7-e874-4f61-9d5e-6565ffca0a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb279967-5b9c-4060-a777-83b3a2daadc1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cde3ebdc-05cf-4e61-b216-a7a42ff41839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cde3ebdc-05cf-4e61-b216-a7a42ff41839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ef720292-c576-4926-878a-3683aa02fd4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ef720292-c576-4926-878a-3683aa02fd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d3bddab3-d9c1-4154-85bb-d844a38a5a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d3bddab3-d9c1-4154-85bb-d844a38a5a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6277ea89-1730-49ec-a4a1-6a39b45c1985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1bb0b60-0340-46eb-a857-8e5f77baf89e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6277ea89-1730-49ec-a4a1-6a39b45c1985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3fb86dd1-d841-4245-8952-d09e2848df01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_fb4745d5-0994-46ee-8c1a-fdd91067c5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3fb86dd1-d841-4245-8952-d09e2848df01" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_fb4745d5-0994-46ee-8c1a-fdd91067c5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_29fbf56f-0cf4-4268-8eb5-b65b5442c50a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3fb86dd1-d841-4245-8952-d09e2848df01" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_29fbf56f-0cf4-4268-8eb5-b65b5442c50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_121617d2-286b-46c5-abd5-1c107e7d0e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3fb86dd1-d841-4245-8952-d09e2848df01" xlink:to="loc_us-gaap_InterestIncomeOther_121617d2-286b-46c5-abd5-1c107e7d0e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20201231.xsd#PropertyEquipmentandSoftware"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_04a0ae15-a0d4-45f8-912d-520b61e67f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e037bdf2-2730-4839-ac04-c6944a12baf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_04a0ae15-a0d4-45f8-912d-520b61e67f6c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e037bdf2-2730-4839-ac04-c6944a12baf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4c0cf75e-021d-4d65-a26f-e198759defbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_24724991-3466-40d0-bd1c-f465ea54f227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4c0cf75e-021d-4d65-a26f-e198759defbe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_24724991-3466-40d0-bd1c-f465ea54f227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e195cb5e-6250-4a8a-860f-193edc5f6c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_696fe031-fde5-40e5-a3d1-1c0da1583795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e195cb5e-6250-4a8a-860f-193edc5f6c81" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_696fe031-fde5-40e5-a3d1-1c0da1583795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f8c6b31-8f0f-4490-b6af-f9f0573e5d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_696fe031-fde5-40e5-a3d1-1c0da1583795" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f8c6b31-8f0f-4490-b6af-f9f0573e5d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f8c6b31-8f0f-4490-b6af-f9f0573e5d18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_39533e2b-775b-441d-a62e-4960a155de10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_ComputerEquipmentMember_39533e2b-775b-441d-a62e-4960a155de10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7884ea17-06cd-4447-a119-a64dedda4d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7884ea17-06cd-4447-a119-a64dedda4d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_2dd8e100-f816-4ec5-82e3-8bd5aa596048" xlink:href="mgnx-20201231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_2dd8e100-f816-4ec5-82e3-8bd5aa596048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_c90b5b2b-68f3-4129-98f5-a48072ed6bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_VehiclesMember_c90b5b2b-68f3-4129-98f5-a48072ed6bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_3f48019e-cb12-41eb-8b39-6961cc4c93dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_EquipmentMember_3f48019e-cb12-41eb-8b39-6961cc4c93dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_63789c5a-4335-429b-acdc-7c7eb40f7d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1258b5a5-4079-4cd0-8b67-afdfa827ed12" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_63789c5a-4335-429b-acdc-7c7eb40f7d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_696fe031-fde5-40e5-a3d1-1c0da1583795" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78dcd7c1-6562-4503-a29a-9f374240fb7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78dcd7c1-6562-4503-a29a-9f374240fb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e121a9d5-d5b6-443d-ab08-324f4d566f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_ConstructionInProgressGross_e121a9d5-d5b6-443d-ab08-324f4d566f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f7ef6916-e1c9-4362-bdbc-6d760e526c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f7ef6916-e1c9-4362-bdbc-6d760e526c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_744b7665-ac1f-4f6a-a6df-06f1563424b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_744b7665-ac1f-4f6a-a6df-06f1563424b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_49c2ef1e-898d-4194-8580-e05628c10f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_971ee34c-e8ab-4295-9243-f2aac85715e4" xlink:to="loc_us-gaap_Depreciation_49c2ef1e-898d-4194-8580-e05628c10f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Leases" xlink:type="simple" xlink:href="mgnx-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2e2f187f-fa0b-4e22-b706-258d22ee56c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_23543dd3-e1d0-48f6-aa36-dc6a75e42d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2e2f187f-fa0b-4e22-b706-258d22ee56c7" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_23543dd3-e1d0-48f6-aa36-dc6a75e42d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_81adeb8c-622f-4941-80a7-2907b0a47b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_e573b29f-3228-4e68-b39c-82557be33e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_81adeb8c-622f-4941-80a7-2907b0a47b71" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_e573b29f-3228-4e68-b39c-82557be33e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1284eb5d-33a5-44e3-a0e3-997f76cca64b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_81adeb8c-622f-4941-80a7-2907b0a47b71" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1284eb5d-33a5-44e3-a0e3-997f76cca64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b7e69aaa-f97e-4b05-b548-8b7a858181c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b9e03186-b928-4b9e-b6c3-36c480ebd6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b7e69aaa-f97e-4b05-b548-8b7a858181c7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b9e03186-b928-4b9e-b6c3-36c480ebd6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3666b37e-9b94-4f53-bc2f-cdbc4bb6831d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b9e03186-b928-4b9e-b6c3-36c480ebd6a8" xlink:to="loc_srt_RangeAxis_3666b37e-9b94-4f53-bc2f-cdbc4bb6831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d6a8888-b118-44c1-b350-bd74e76dca8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3666b37e-9b94-4f53-bc2f-cdbc4bb6831d" xlink:to="loc_srt_RangeMember_9d6a8888-b118-44c1-b350-bd74e76dca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_49d7d7c3-09d3-4421-a305-9b8a30a8dba5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9d6a8888-b118-44c1-b350-bd74e76dca8d" xlink:to="loc_srt_MinimumMember_49d7d7c3-09d3-4421-a305-9b8a30a8dba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66f6c97a-c7b2-4273-8489-1a6af901a378" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9d6a8888-b118-44c1-b350-bd74e76dca8d" xlink:to="loc_srt_MaximumMember_66f6c97a-c7b2-4273-8489-1a6af901a378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b9e03186-b928-4b9e-b6c3-36c480ebd6a8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_887aae4f-64cb-4475-8fff-4446ba2e9599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_887aae4f-64cb-4475-8fff-4446ba2e9599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7e0dffd0-d18c-4bf0-bb4c-f811f0d15bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7e0dffd0-d18c-4bf0-bb4c-f811f0d15bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_56e61410-ca5b-476b-8e7a-2641f02b8999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_56e61410-ca5b-476b-8e7a-2641f02b8999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions_bf2cb6bc-1ea2-43ef-b238-390b845b1456" xlink:href="mgnx-20201231.xsd#mgnx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions_bf2cb6bc-1ea2-43ef-b238-390b845b1456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2a15f714-2706-46c5-86ab-9edb1c5502f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_OperatingLeasePayments_2a15f714-2706-46c5-86ab-9edb1c5502f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2a1b3ff-6b69-47a3-8ee5-2881bbafad9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_28488e42-eeb9-4011-9793-e387c3f55a46" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2a1b3ff-6b69-47a3-8ee5-2881bbafad9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#LeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c37e4063-5e09-4080-ae99-490bfc0ea620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2a84aa52-01f4-4367-ad7c-534760a3e4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c37e4063-5e09-4080-ae99-490bfc0ea620" xlink:to="loc_us-gaap_OperatingLeaseCost_2a84aa52-01f4-4367-ad7c-534760a3e4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_38477acb-7b92-445c-9691-29513713bec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c37e4063-5e09-4080-ae99-490bfc0ea620" xlink:to="loc_us-gaap_VariableLeaseCost_38477acb-7b92-445c-9691-29513713bec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_4c1a22d0-30e6-4323-b54d-b560ed594e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c37e4063-5e09-4080-ae99-490bfc0ea620" xlink:to="loc_us-gaap_SubleaseIncome_4c1a22d0-30e6-4323-b54d-b560ed594e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_41ef2d73-769f-41ba-98ae-7d2ad06b3fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c37e4063-5e09-4080-ae99-490bfc0ea620" xlink:to="loc_us-gaap_LeaseCost_41ef2d73-769f-41ba-98ae-7d2ad06b3fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ad7823ce-b5e2-4692-8e28-fa88bd414bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ad7823ce-b5e2-4692-8e28-fa88bd414bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_de9eddbb-ed10-469a-aade-cd5f63096a75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_de9eddbb-ed10-469a-aade-cd5f63096a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_99a91989-d8a4-4791-b28f-ca4dd1dde74b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_99a91989-d8a4-4791-b28f-ca4dd1dde74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2be018c0-e76c-4bdc-9290-aeb8fd2c7893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2be018c0-e76c-4bdc-9290-aeb8fd2c7893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_835e242e-66fc-405a-a8b4-5fc71238048d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_835e242e-66fc-405a-a8b4-5fc71238048d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b71cf8a4-f7e2-4966-b2cc-538a8b3ba485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b71cf8a4-f7e2-4966-b2cc-538a8b3ba485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_935372ae-2395-468f-bf6a-036ef438e0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_935372ae-2395-468f-bf6a-036ef438e0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bb66103e-c658-4da8-916a-70c9b00fc951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bb66103e-c658-4da8-916a-70c9b00fc951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ec1246ab-7702-4552-bec3-f754d9a6e275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_426af92a-dab3-43e1-b6f6-e254524c5540" xlink:to="loc_us-gaap_OperatingLeaseLiability_ec1246ab-7702-4552-bec3-f754d9a6e275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mgnx-20201231.xsd#MaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ac2891a7-e44f-4599-bec1-aa2bfb1b9f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c23c4487-e3b2-4399-8d36-6fa760b1c054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ac2891a7-e44f-4599-bec1-aa2bfb1b9f2f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c23c4487-e3b2-4399-8d36-6fa760b1c054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5cf9e0cb-9135-4189-8cc6-7285b96a1751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_53d47f4b-4745-4310-bbf8-5c097fbae425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5cf9e0cb-9135-4189-8cc6-7285b96a1751" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_53d47f4b-4745-4310-bbf8-5c097fbae425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_65464dfd-415a-4d37-9f22-c9c127e5d2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53d47f4b-4745-4310-bbf8-5c097fbae425" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_65464dfd-415a-4d37-9f22-c9c127e5d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_65464dfd-415a-4d37-9f22-c9c127e5d2f1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_af732f19-0b63-420f-9386-acb7273b27fa" xlink:href="mgnx-20201231.xsd#mgnx_FirmCommitmentPublicUnderwrittenOfferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:to="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_af732f19-0b63-420f-9386-acb7273b27fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2b338c96-d8f6-4f8d-b1e8-b3644ac9d5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2b338c96-d8f6-4f8d-b1e8-b3644ac9d5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowOnEquityOfferingMember_15518772-69aa-4aab-bec8-b0688869a8c8" xlink:href="mgnx-20201231.xsd#mgnx_FollowOnEquityOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:to="loc_mgnx_FollowOnEquityOfferingMember_15518772-69aa-4aab-bec8-b0688869a8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_bbe84446-ef3a-4f07-afc1-60a5429b1117" xlink:href="mgnx-20201231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a63151cf-2446-4362-8f49-f75beea7d14f" xlink:to="loc_mgnx_AtTheMarketOfferingMember_bbe84446-ef3a-4f07-afc1-60a5429b1117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ace19daf-1611-4e50-804f-aec14076440a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53d47f4b-4745-4310-bbf8-5c097fbae425" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ace19daf-1611-4e50-804f-aec14076440a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_986ab4fb-3894-4611-a569-c7e73efda033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ace19daf-1611-4e50-804f-aec14076440a" xlink:to="loc_us-gaap_ClassOfStockDomain_986ab4fb-3894-4611-a569-c7e73efda033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_8687b431-20d4-4c8d-a407-b7e07e72087e" xlink:href="mgnx-20201231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_986ab4fb-3894-4611-a569-c7e73efda033" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_8687b431-20d4-4c8d-a407-b7e07e72087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53d47f4b-4745-4310-bbf8-5c097fbae425" xlink:to="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3921299d-bc23-4b60-87f7-3bd2f657bd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3921299d-bc23-4b60-87f7-3bd2f657bd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ae9adfe6-c47e-493c-aff3-b0cd141db475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ae9adfe6-c47e-493c-aff3-b0cd141db475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ce8f2c39-3367-478f-ae13-85e0e04fd8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ce8f2c39-3367-478f-ae13-85e0e04fd8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_eefc20e4-96c0-44a5-a1a7-5e71235d4e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_eefc20e4-96c0-44a5-a1a7-5e71235d4e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_221e2c58-45b2-4751-8ebf-6a66240a7cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_221e2c58-45b2-4751-8ebf-6a66240a7cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_64e8cd9c-556b-4281-af58-65e920c68a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_64e8cd9c-556b-4281-af58-65e920c68a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2d448ece-8d50-4b81-855d-6f93ead8fc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2d448ece-8d50-4b81-855d-6f93ead8fc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7eeaca86-f21c-465b-bf9d-6333a2ef4659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7eeaca86-f21c-465b-bf9d-6333a2ef4659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_3dcd3384-5d80-4730-8ff7-0643b377ad2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_3dcd3384-5d80-4730-8ff7-0643b377ad2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e864e846-6dc7-47a1-8713-3753d6d70089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e864e846-6dc7-47a1-8713-3753d6d70089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_dd485cc6-481b-4ac1-b7f8-56b0db947aae" xlink:href="mgnx-20201231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_dd485cc6-481b-4ac1-b7f8-56b0db947aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_73ad3008-3da8-45f6-9d87-37cad70ea4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_73ad3008-3da8-45f6-9d87-37cad70ea4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7155ad9c-d559-4597-ba30-a73940646ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7155ad9c-d559-4597-ba30-a73940646ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40199b60-ac5f-4498-a2a9-2a079b5add94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70ac7dde-b33f-47ff-9675-a22500fcd34d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40199b60-ac5f-4498-a2a9-2a079b5add94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e72acf9a-2bb2-4e44-9728-a5f14f99cc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_40ed0439-e008-4bce-a745-588cc196430d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e72acf9a-2bb2-4e44-9728-a5f14f99cc4e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_40ed0439-e008-4bce-a745-588cc196430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_359b741f-ee69-4e7c-a254-c663b38ad9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_94c81b58-6cc8-4fd9-b46f-e01040411336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_359b741f-ee69-4e7c-a254-c663b38ad9fa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_94c81b58-6cc8-4fd9-b46f-e01040411336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_704c03a4-8a6c-42c0-a4d3-c0ffda7f0a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_359b741f-ee69-4e7c-a254-c663b38ad9fa" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_704c03a4-8a6c-42c0-a4d3-c0ffda7f0a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c8a1f411-060f-4e12-b075-dfdb4fecd8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_359b741f-ee69-4e7c-a254-c663b38ad9fa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c8a1f411-060f-4e12-b075-dfdb4fecd8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_923188a4-fb4e-46d7-8d64-a966ca356c49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_359b741f-ee69-4e7c-a254-c663b38ad9fa" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_923188a4-fb4e-46d7-8d64-a966ca356c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fb47fb6-73d8-4d66-8f80-b48d6cbe50d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a3ae3f9-81c0-41f7-a50e-40bc9d88512f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fb47fb6-73d8-4d66-8f80-b48d6cbe50d1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a3ae3f9-81c0-41f7-a50e-40bc9d88512f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_665cb6d0-67ce-4f66-b4ac-d3836fe47430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a3ae3f9-81c0-41f7-a50e-40bc9d88512f" xlink:to="loc_us-gaap_PlanNameAxis_665cb6d0-67ce-4f66-b4ac-d3836fe47430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d2be0039-1d8b-4b6e-a986-18ef9ca58166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_665cb6d0-67ce-4f66-b4ac-d3836fe47430" xlink:to="loc_us-gaap_PlanNameDomain_d2be0039-1d8b-4b6e-a986-18ef9ca58166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b6743f80-177b-4736-a57f-ac662d6884dc" xlink:href="mgnx-20201231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d2be0039-1d8b-4b6e-a986-18ef9ca58166" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b6743f80-177b-4736-a57f-ac662d6884dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a3ae3f9-81c0-41f7-a50e-40bc9d88512f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b7f09dea-20cb-48c8-bc0d-ab0b162a397f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b7f09dea-20cb-48c8-bc0d-ab0b162a397f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_dcc2cd8e-4090-4f25-931c-d6ed8f1eb47e" xlink:href="mgnx-20201231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_dcc2cd8e-4090-4f25-931c-d6ed8f1eb47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_aa2273aa-a905-4157-839f-d661ed4e2990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_aa2273aa-a905-4157-839f-d661ed4e2990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_11202d3c-59e7-4df8-9d46-0363ddbf4e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_11202d3c-59e7-4df8-9d46-0363ddbf4e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9bef5699-4916-46e1-854d-04ac5a7e5b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aeec3812-2628-4631-ad78-38066132f40f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9bef5699-4916-46e1-854d-04ac5a7e5b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_591b7af3-1713-4625-9264-f25c773a888d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7cd49bb-ff85-4840-adbf-83982391f4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_591b7af3-1713-4625-9264-f25c773a888d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7cd49bb-ff85-4840-adbf-83982391f4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_49d69145-e475-44a0-96c2-b037f9b0da00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7cd49bb-ff85-4840-adbf-83982391f4cb" xlink:to="loc_us-gaap_PlanNameAxis_49d69145-e475-44a0-96c2-b037f9b0da00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_404c785b-cc34-4c83-b375-d20cb832cf58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_49d69145-e475-44a0-96c2-b037f9b0da00" xlink:to="loc_us-gaap_PlanNameDomain_404c785b-cc34-4c83-b375-d20cb832cf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_82750355-8474-4e05-8485-fc6d474ee1b5" xlink:href="mgnx-20201231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_404c785b-cc34-4c83-b375-d20cb832cf58" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_82750355-8474-4e05-8485-fc6d474ee1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_2ceee07b-4896-482c-a54d-698b323f41b3" xlink:href="mgnx-20201231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_404c785b-cc34-4c83-b375-d20cb832cf58" xlink:to="loc_mgnx_StockIncentivePlan2013Member_2ceee07b-4896-482c-a54d-698b323f41b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7cd49bb-ff85-4840-adbf-83982391f4cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_47feef74-4ddc-4f89-835b-ab18135005d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_47feef74-4ddc-4f89-835b-ab18135005d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_0e705708-8f63-48cb-9252-88e388511acd" xlink:href="mgnx-20201231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_0e705708-8f63-48cb-9252-88e388511acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_394ef4e8-e5da-4bec-a270-9cc881c53f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_394ef4e8-e5da-4bec-a270-9cc881c53f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_416467a1-7fca-4ca1-aa04-dc4b6280b98f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_416467a1-7fca-4ca1-aa04-dc4b6280b98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_9b09f826-669a-4030-8b04-2557e8f86d8f" xlink:href="mgnx-20201231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_9b09f826-669a-4030-8b04-2557e8f86d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_f1a26556-cde3-47af-876b-2bc25d5aec46" xlink:href="mgnx-20201231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab981f33-d5f0-4506-95ef-cfefb12805e8" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_f1a26556-cde3-47af-876b-2bc25d5aec46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61366755-1926-45c6-8933-f7cb0a56e6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_591b7af3-1713-4625-9264-f25c773a888d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61366755-1926-45c6-8933-f7cb0a56e6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6dd7191a-b2ca-4eb5-9d8a-ccb6a952773b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61366755-1926-45c6-8933-f7cb0a56e6b0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6dd7191a-b2ca-4eb5-9d8a-ccb6a952773b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_caaac522-fb62-4390-baef-169bbd9b323b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dd7191a-b2ca-4eb5-9d8a-ccb6a952773b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_caaac522-fb62-4390-baef-169bbd9b323b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cab3e37a-21f0-452a-ae5f-d402f8d0264c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_caaac522-fb62-4390-baef-169bbd9b323b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cab3e37a-21f0-452a-ae5f-d402f8d0264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_47859c11-f0be-41e9-99ab-d290f331e10e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_caaac522-fb62-4390-baef-169bbd9b323b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_47859c11-f0be-41e9-99ab-d290f331e10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9fea2f79-4879-49e1-ad86-154b14630511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_61366755-1926-45c6-8933-f7cb0a56e6b0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9fea2f79-4879-49e1-ad86-154b14630511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_066e4c5a-1d01-43d2-ad02-0c6688ec4a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9fea2f79-4879-49e1-ad86-154b14630511" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_066e4c5a-1d01-43d2-ad02-0c6688ec4a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ff71b55-648d-4cdb-9a1c-636135c052c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575158e7-61b3-4192-ae2e-4725545011d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ff71b55-648d-4cdb-9a1c-636135c052c6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575158e7-61b3-4192-ae2e-4725545011d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94b10d8e-1d24-4db4-9224-2bdf97befb2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575158e7-61b3-4192-ae2e-4725545011d1" xlink:to="loc_srt_RangeAxis_94b10d8e-1d24-4db4-9224-2bdf97befb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8bbaec5c-c96d-4dc2-b0df-cbe14e691e05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_94b10d8e-1d24-4db4-9224-2bdf97befb2e" xlink:to="loc_srt_RangeMember_8bbaec5c-c96d-4dc2-b0df-cbe14e691e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4971f3be-5146-4b24-b15e-d863244083ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8bbaec5c-c96d-4dc2-b0df-cbe14e691e05" xlink:to="loc_srt_MinimumMember_4971f3be-5146-4b24-b15e-d863244083ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3c6bb5db-abcf-4038-b984-7d4fa34e33dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8bbaec5c-c96d-4dc2-b0df-cbe14e691e05" xlink:to="loc_srt_MaximumMember_3c6bb5db-abcf-4038-b984-7d4fa34e33dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575158e7-61b3-4192-ae2e-4725545011d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9530e4f1-3fc6-4be2-b51b-17bfc536a928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9530e4f1-3fc6-4be2-b51b-17bfc536a928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_93a2291d-1add-499a-b0d2-55b68f8cf44d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_93a2291d-1add-499a-b0d2-55b68f8cf44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_90f538ba-f268-43d1-b14f-0d058780b548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_90f538ba-f268-43d1-b14f-0d058780b548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7d070be9-22a4-4475-9469-99cbf218ea1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7d070be9-22a4-4475-9469-99cbf218ea1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3869ebc7-9343-40fa-ba7d-036730f41215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68c8ca7b-c77c-49b4-9523-5886ee807c6a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3869ebc7-9343-40fa-ba7d-036730f41215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_465a7829-1183-4dc8-99be-bf3f05454223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4334457-b288-4343-993e-d06a8fdb58e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_465a7829-1183-4dc8-99be-bf3f05454223" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4334457-b288-4343-993e-d06a8fdb58e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_87153bd0-ebb7-4a16-a25a-772303acfe4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4334457-b288-4343-993e-d06a8fdb58e9" xlink:to="loc_us-gaap_AwardTypeAxis_87153bd0-ebb7-4a16-a25a-772303acfe4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43880e54-e600-47f2-98da-470d5a5dd4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_87153bd0-ebb7-4a16-a25a-772303acfe4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43880e54-e600-47f2-98da-470d5a5dd4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_be5c9cbd-df28-4a53-a717-7a6d656a496d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43880e54-e600-47f2-98da-470d5a5dd4f3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_be5c9cbd-df28-4a53-a717-7a6d656a496d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_09ab7bcf-71cc-4a8e-a50a-ddc150eff08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4334457-b288-4343-993e-d06a8fdb58e9" xlink:to="loc_us-gaap_PlanNameAxis_09ab7bcf-71cc-4a8e-a50a-ddc150eff08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_added44c-846f-44c8-8c6d-0c1769edcac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_09ab7bcf-71cc-4a8e-a50a-ddc150eff08e" xlink:to="loc_us-gaap_PlanNameDomain_added44c-846f-44c8-8c6d-0c1769edcac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_ac49cf42-6f1a-4ee1-8dd1-247e1a5d5892" xlink:href="mgnx-20201231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_added44c-846f-44c8-8c6d-0c1769edcac9" xlink:to="loc_mgnx_StockIncentivePlan2013Member_ac49cf42-6f1a-4ee1-8dd1-247e1a5d5892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4334457-b288-4343-993e-d06a8fdb58e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5d6ef749-1c82-4aa8-88d1-806b25a4c183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5d6ef749-1c82-4aa8-88d1-806b25a4c183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_674f5f1c-53e3-4bff-920b-6087f5d1afa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_674f5f1c-53e3-4bff-920b-6087f5d1afa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_169bdb9c-bd6c-42f6-8d44-7425175bf561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_169bdb9c-bd6c-42f6-8d44-7425175bf561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2234c1c7-c729-4ee0-a762-f7d97313bcb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2234c1c7-c729-4ee0-a762-f7d97313bcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2bd752ca-7408-45ff-9ea1-94a6f6d6c3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2bd752ca-7408-45ff-9ea1-94a6f6d6c3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a55affae-e927-4371-b1de-00d210319d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a55affae-e927-4371-b1de-00d210319d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15a9da7d-634c-41e8-aabf-5d8830e1c842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0aa1c586-3a79-494f-9275-c7f9147b0f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15a9da7d-634c-41e8-aabf-5d8830e1c842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_940e2a7b-c63a-4b3a-815b-565b8556764d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_940e2a7b-c63a-4b3a-815b-565b8556764d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_64d5d5a8-fc42-461c-86e0-7d9462395fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_64d5d5a8-fc42-461c-86e0-7d9462395fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2236a60f-5414-40dd-bf31-38b9f38eb3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2236a60f-5414-40dd-bf31-38b9f38eb3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c7a26bac-4a8d-46c7-97d5-b8521b334402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c7a26bac-4a8d-46c7-97d5-b8521b334402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d52964c1-ac9b-4ef2-9059-c4e99b7fce35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d52964c1-ac9b-4ef2-9059-c4e99b7fce35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_398a4dd1-f905-429a-bc6e-eaae3dfd1db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_398a4dd1-f905-429a-bc6e-eaae3dfd1db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1dd282c4-e2ca-465f-9c69-b9bfaffd6ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_495c9773-dbdb-4be4-b027-a23ffd762739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1dd282c4-e2ca-465f-9c69-b9bfaffd6ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1ebfae34-f7b5-45b4-8719-55cc184c9cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1ebfae34-f7b5-45b4-8719-55cc184c9cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_db067eac-ec66-44b8-ad6d-9a317ad4b4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_db067eac-ec66-44b8-ad6d-9a317ad4b4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd88f0c7-ffa2-4e44-a6e2-26d9c587ee58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd88f0c7-ffa2-4e44-a6e2-26d9c587ee58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7e747b05-e302-4f59-a92e-448ab4ef9d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7e747b05-e302-4f59-a92e-448ab4ef9d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_58103228-eaaa-48dd-bee1-bf24b3fc55ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_58103228-eaaa-48dd-bee1-bf24b3fc55ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_087d3903-254e-4a40-bdd4-a829368f41cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f18a9027-a04c-4ee1-ab6d-89dee7dcc873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_087d3903-254e-4a40-bdd4-a829368f41cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d18adc0-d048-45d7-bc76-0c71495d12bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d18adc0-d048-45d7-bc76-0c71495d12bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33c363ec-a5da-49f6-b4cb-6de94fa798ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33c363ec-a5da-49f6-b4cb-6de94fa798ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_a957835e-16d0-4213-b127-c23cd0ffaf3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_a957835e-16d0-4213-b127-c23cd0ffaf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b8278d0b-0c43-4311-afb2-a7d78ad3e738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b8278d0b-0c43-4311-afb2-a7d78ad3e738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_54fd67fb-14ed-405c-a7bf-ca1a45c035ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b968698-f3b2-4c14-a52c-910bed1213a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_54fd67fb-14ed-405c-a7bf-ca1a45c035ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95decb6b-ea6d-4e91-8d7c-2a6e2e28ebe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95decb6b-ea6d-4e91-8d7c-2a6e2e28ebe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39835b91-dfab-4066-9aed-6f12a276ed4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39835b91-dfab-4066-9aed-6f12a276ed4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cfce2ab6-138c-45ec-a9ee-ce699aa1ea38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cfce2ab6-138c-45ec-a9ee-ce699aa1ea38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a9870a1c-2362-4ae8-874a-56a2ad840835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a9870a1c-2362-4ae8-874a-56a2ad840835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_53db40c2-ee2d-4c58-92b5-5b250beee9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_49a38232-6c74-49cb-8660-a0c0852441c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_53db40c2-ee2d-4c58-92b5-5b250beee9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d731577-e08a-4541-add2-38d10328ced6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d731577-e08a-4541-add2-38d10328ced6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_54e473af-6204-40ff-9dd0-a68e14ba325d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_54e473af-6204-40ff-9dd0-a68e14ba325d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bc6d2bf-d602-43a6-a1ab-062ade80dfba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bc6d2bf-d602-43a6-a1ab-062ade80dfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1f5c9d40-517d-4867-a324-6dd29fb09169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1f5c9d40-517d-4867-a324-6dd29fb09169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a6cfc807-c0af-4958-994d-31a06c0c5d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a6cfc807-c0af-4958-994d-31a06c0c5d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99e4fad0-523c-4faf-8c8f-2aaee8fa0e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99e4fad0-523c-4faf-8c8f-2aaee8fa0e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e7673e2-d958-4c27-8efb-d6bc0891b793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e7673e2-d958-4c27-8efb-d6bc0891b793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06255185-7182-426d-bdab-c69093821cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06255185-7182-426d-bdab-c69093821cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9be762a7-90ad-4b7d-8250-691c37d874a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b160478-3c6d-4bbe-89c6-d23218c4180c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9be762a7-90ad-4b7d-8250-691c37d874a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_47d2182c-74d7-47ab-ae0f-da1c95683915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8eaf68aa-c739-40ef-9e3e-47ccbf97c622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3f84f16e-c8d6-4e42-a951-e30c363e4d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8eaf68aa-c739-40ef-9e3e-47ccbf97c622" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3f84f16e-c8d6-4e42-a951-e30c363e4d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_75dc026f-dd7d-4d8e-b84d-154d10df2626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e2f559a3-0b28-4d54-9723-765c56533cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75dc026f-dd7d-4d8e-b84d-154d10df2626" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e2f559a3-0b28-4d54-9723-765c56533cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f576ecf6-71e6-43be-bb77-3604341c3bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75dc026f-dd7d-4d8e-b84d-154d10df2626" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f576ecf6-71e6-43be-bb77-3604341c3bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_35159193-9468-49dd-af6b-d614bf8839f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75dc026f-dd7d-4d8e-b84d-154d10df2626" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_35159193-9468-49dd-af6b-d614bf8839f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_daa8a91f-6bf5-403b-8c74-b503f04d9b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b9d01e5f-8bcf-429c-8ac7-bc38d465bfff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_daa8a91f-6bf5-403b-8c74-b503f04d9b5d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b9d01e5f-8bcf-429c-8ac7-bc38d465bfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_daa8a91f-6bf5-403b-8c74-b503f04d9b5d" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_5fe9b779-5092-4bc9-97d0-d2fc0d8cae90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_5fe9b779-5092-4bc9-97d0-d2fc0d8cae90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_641974cc-25cc-4a24-a457-14cabd09bda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_641974cc-25cc-4a24-a457-14cabd09bda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_95fc4a67-12cc-4283-bdcc-1ffba66110d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_95fc4a67-12cc-4283-bdcc-1ffba66110d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_c0405b54-2c88-42ad-97c9-e50f052cd99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_c0405b54-2c88-42ad-97c9-e50f052cd99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_9b023902-8043-409c-b2aa-f2fe4dec4ddf" xlink:href="mgnx-20201231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_9b023902-8043-409c-b2aa-f2fe4dec4ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_eb2ff156-d342-466c-ba1b-e5257adc7339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_eb2ff156-d342-466c-ba1b-e5257adc7339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_83e7b9e4-4cb8-4b31-85a4-e7afbae8a1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_83e7b9e4-4cb8-4b31-85a4-e7afbae8a1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_74bece28-b1dd-417a-9111-2d9b0cd1623a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_74bece28-b1dd-417a-9111-2d9b0cd1623a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b7e107-fc30-42ae-981d-6ac6c8cc3541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b7e107-fc30-42ae-981d-6ac6c8cc3541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5f02acae-5d5b-4682-b0a1-16076ecc7daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2de67f28-11ed-4227-a67f-0108da07bf11" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5f02acae-5d5b-4682-b0a1-16076ecc7daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5fad2448-30de-4fae-b13c-db9c775789ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_daa8a91f-6bf5-403b-8c74-b503f04d9b5d" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5fad2448-30de-4fae-b13c-db9c775789ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d5c04b40-8617-45b5-8a11-875159c8d060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5fad2448-30de-4fae-b13c-db9c775789ce" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d5c04b40-8617-45b5-8a11-875159c8d060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_fed8e6ac-8ca7-43bb-bd41-c76e15b3d5ca" xlink:href="mgnx-20201231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5fad2448-30de-4fae-b13c-db9c775789ce" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_fed8e6ac-8ca7-43bb-bd41-c76e15b3d5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_053a12c0-dbfa-4ba0-acc4-cb4aea32a373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5fad2448-30de-4fae-b13c-db9c775789ce" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_053a12c0-dbfa-4ba0-acc4-cb4aea32a373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0894a28a-a3d2-4955-8360-af39cf49a7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5fad2448-30de-4fae-b13c-db9c775789ce" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0894a28a-a3d2-4955-8360-af39cf49a7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a448dc37-78fe-487e-b7be-58275e84b92c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5fad2448-30de-4fae-b13c-db9c775789ce" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a448dc37-78fe-487e-b7be-58275e84b92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_daa8a91f-6bf5-403b-8c74-b503f04d9b5d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_88719ed3-2165-4ded-b59e-88b5810b0a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:to="loc_us-gaap_TaxPeriodAxis_88719ed3-2165-4ded-b59e-88b5810b0a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_a7f91f66-676a-47ec-9e04-6e0fe567a481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_88719ed3-2165-4ded-b59e-88b5810b0a9b" xlink:to="loc_us-gaap_TaxPeriodDomain_a7f91f66-676a-47ec-9e04-6e0fe567a481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_bffe973e-0d6f-4855-a07a-3eb568290a37" xlink:href="mgnx-20201231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_a7f91f66-676a-47ec-9e04-6e0fe567a481" xlink:to="loc_mgnx_TaxYear2025To2037Member_bffe973e-0d6f-4855-a07a-3eb568290a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_5d2b54bf-db3d-4d7d-8d4f-bfc6d41f528f" xlink:href="mgnx-20201231.xsd#mgnx_IndefiniteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_a7f91f66-676a-47ec-9e04-6e0fe567a481" xlink:to="loc_mgnx_IndefiniteMember_5d2b54bf-db3d-4d7d-8d4f-bfc6d41f528f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3492e00e-9cf1-4bde-ad80-a21eadda7e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3492e00e-9cf1-4bde-ad80-a21eadda7e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_31f1e9e5-faf7-4c91-902b-e4d38f00fde2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3492e00e-9cf1-4bde-ad80-a21eadda7e25" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_31f1e9e5-faf7-4c91-902b-e4d38f00fde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_50ffd2d6-80ba-476a-9c6d-62c725b89865" xlink:href="mgnx-20201231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_31f1e9e5-faf7-4c91-902b-e4d38f00fde2" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_50ffd2d6-80ba-476a-9c6d-62c725b89865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_436ca719-a049-4d76-9fb1-63460bc3e2c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_50ffd2d6-80ba-476a-9c6d-62c725b89865" xlink:to="loc_us-gaap_DomesticCountryMember_436ca719-a049-4d76-9fb1-63460bc3e2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b99a545-af74-4e64-818e-47383e049e14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:to="loc_srt_RangeAxis_3b99a545-af74-4e64-818e-47383e049e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4babd0a-aa80-430e-82e5-59869eda75b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3b99a545-af74-4e64-818e-47383e049e14" xlink:to="loc_srt_RangeMember_e4babd0a-aa80-430e-82e5-59869eda75b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f643e004-1d56-4b9d-9336-a883dcbcb0d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e4babd0a-aa80-430e-82e5-59869eda75b3" xlink:to="loc_srt_MinimumMember_f643e004-1d56-4b9d-9336-a883dcbcb0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_582b6aa7-c1bb-4b33-8516-58dfbf1d8350" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e4babd0a-aa80-430e-82e5-59869eda75b3" xlink:to="loc_srt_MaximumMember_582b6aa7-c1bb-4b33-8516-58dfbf1d8350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8cc01a43-ed31-480f-b5c4-d260271e4979" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_7a5d5b21-f603-438f-b5fa-0178979f567d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_7a5d5b21-f603-438f-b5fa-0178979f567d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_66aaeee4-7b4a-4ded-9c71-3cd3e234336e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_66aaeee4-7b4a-4ded-9c71-3cd3e234336e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_1f4aebc9-b739-4353-98c3-7c5d1efe3d29" xlink:href="mgnx-20201231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_1f4aebc9-b739-4353-98c3-7c5d1efe3d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_d5a57025-68ee-4bbd-ad84-626b518501f2" xlink:href="mgnx-20201231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_d5a57025-68ee-4bbd-ad84-626b518501f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_47ae8ce7-ebe9-41b3-acd2-a402bb4884b9" xlink:href="mgnx-20201231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c9cfdaec-5679-402e-8b8b-d7813edf53bb" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_47ae8ce7-ebe9-41b3-acd2-a402bb4884b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f815d7a1-fd39-4d6c-a353-cf4efeffec2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f815d7a1-fd39-4d6c-a353-cf4efeffec2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d83fa019-f7cd-4c3a-ba5f-7ee98e7736a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d83fa019-f7cd-4c3a-ba5f-7ee98e7736a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_2963f105-b5c2-472a-8973-67b0e59f9e09" xlink:href="mgnx-20201231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_2963f105-b5c2-472a-8973-67b0e59f9e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_c0f97586-284e-4398-b519-6b5e285a2ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_c0f97586-284e-4398-b519-6b5e285a2ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_679c159a-143a-450b-8f52-8cc63f3de2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_679c159a-143a-450b-8f52-8cc63f3de2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_38d903c4-f3fc-46a3-98ce-48f03e089759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_38d903c4-f3fc-46a3-98ce-48f03e089759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bdc7a698-4736-4c49-b14e-5c23c185d888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bdc7a698-4736-4c49-b14e-5c23c185d888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ba1fd597-3211-437a-95aa-e09d96b66777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ba1fd597-3211-437a-95aa-e09d96b66777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ed4b9d7c-4397-4ce5-8ccf-66e4293856c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39347dfa-9623-4f34-b0ff-b9688db21020" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ed4b9d7c-4397-4ce5-8ccf-66e4293856c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_57774eab-ba2e-416b-a9f7-524de38d03fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_2a060c23-9094-4fcc-abd7-f615ae816a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_57774eab-ba2e-416b-a9f7-524de38d03fa" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_2a060c23-9094-4fcc-abd7-f615ae816a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56087d59-e9c0-40ad-84cb-d600c198b58c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_2a060c23-9094-4fcc-abd7-f615ae816a04" xlink:to="loc_srt_RangeAxis_56087d59-e9c0-40ad-84cb-d600c198b58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05e18c70-7b34-49dd-80b1-91e9b19ce700" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_56087d59-e9c0-40ad-84cb-d600c198b58c" xlink:to="loc_srt_RangeMember_05e18c70-7b34-49dd-80b1-91e9b19ce700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88a49549-0a73-434c-b055-207adb91200b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_05e18c70-7b34-49dd-80b1-91e9b19ce700" xlink:to="loc_srt_MinimumMember_88a49549-0a73-434c-b055-207adb91200b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_2a060c23-9094-4fcc-abd7-f615ae816a04" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_861db3ec-36b8-4c7f-8853-d28501474047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_861db3ec-36b8-4c7f-8853-d28501474047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_324bf0e5-cc4e-4368-a3bc-dd6d72134874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_324bf0e5-cc4e-4368-a3bc-dd6d72134874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d9c93e92-cf34-4ab7-b63f-e5398fedc536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d9c93e92-cf34-4ab7-b63f-e5398fedc536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_56ec3518-6bb8-4897-875c-761e6dc9f483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_56ec3518-6bb8-4897-875c-761e6dc9f483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_df30bee1-631c-442d-a004-35ece228fede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f4a15799-6e3a-48d0-97fa-1bc461bddc52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_df30bee1-631c-442d-a004-35ece228fede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2a680cbb-ae9a-4bb6-87da-1454d6e4a5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2a680cbb-ae9a-4bb6-87da-1454d6e4a5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_580eed2d-45ed-4e44-ab35-97ad3a746d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5bd59891-912e-4fcf-9593-48caebeab016" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_580eed2d-45ed-4e44-ab35-97ad3a746d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreements"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4c7a42eb-09ff-40b1-bc0a-24326d824d58" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_f4c1e037-1286-4835-9b14-510ef4c5825d" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4c7a42eb-09ff-40b1-bc0a-24326d824d58" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_f4c1e037-1286-4835-9b14-510ef4c5825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_2331fb5f-a653-47e8-9fb7-6cb7516a1ac4" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_2331fb5f-a653-47e8-9fb7-6cb7516a1ac4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1bf39b04-f620-4edf-b7fd-7382696c6d35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:to="loc_srt_ProductOrServiceAxis_1bf39b04-f620-4edf-b7fd-7382696c6d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c38d918d-85d2-40c1-a672-ea841fa9525d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1bf39b04-f620-4edf-b7fd-7382696c6d35" xlink:to="loc_srt_ProductsAndServicesDomain_c38d918d-85d2-40c1-a672-ea841fa9525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_9c3ae73e-26b8-4ec2-86a1-ef3961a5b255" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c38d918d-85d2-40c1-a672-ea841fa9525d" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_9c3ae73e-26b8-4ec2-86a1-ef3961a5b255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d11dbf27-447a-4044-bf38-eabdb432a5d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:to="loc_srt_RangeAxis_d11dbf27-447a-4044-bf38-eabdb432a5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d79b12c8-7e40-472f-86a5-f725139ce6c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d11dbf27-447a-4044-bf38-eabdb432a5d8" xlink:to="loc_srt_RangeMember_d79b12c8-7e40-472f-86a5-f725139ce6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e3380326-8207-4051-82bf-6116e0328854" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d79b12c8-7e40-472f-86a5-f725139ce6c7" xlink:to="loc_srt_MaximumMember_e3380326-8207-4051-82bf-6116e0328854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eca96caa-8a17-4baa-946b-1bb22bf5c79d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d79b12c8-7e40-472f-86a5-f725139ce6c7" xlink:to="loc_srt_MinimumMember_eca96caa-8a17-4baa-946b-1bb22bf5c79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_09e68542-ddfb-493b-86e6-07ba21c1dfe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_09e68542-ddfb-493b-86e6-07ba21c1dfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_09e68542-ddfb-493b-86e6-07ba21c1dfe5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_5b6878e2-d027-4d3e-8c4f-4932162c8949" xlink:href="mgnx-20201231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_5b6878e2-d027-4d3e-8c4f-4932162c8949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_826cb5b0-61d1-45f5-9f86-0928c46685ea" xlink:href="mgnx-20201231.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_826cb5b0-61d1-45f5-9f86-0928c46685ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_07024c16-389e-42b0-ba3c-4912ea707a99" xlink:href="mgnx-20201231.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ef0a258c-a9da-4a79-9585-2a07326e167e" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_07024c16-389e-42b0-ba3c-4912ea707a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_591c78e0-e0fa-4c48-84c1-a94986f39cee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:to="loc_srt_CounterpartyNameAxis_591c78e0-e0fa-4c48-84c1-a94986f39cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee79537f-819c-4018-b4eb-3e42cfdac9a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_591c78e0-e0fa-4c48-84c1-a94986f39cee" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee79537f-819c-4018-b4eb-3e42cfdac9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_3c0dddef-73e7-41f8-8516-4dbbad0c2630" xlink:href="mgnx-20201231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee79537f-819c-4018-b4eb-3e42cfdac9a7" xlink:to="loc_mgnx_IncyteCorporationMember_3c0dddef-73e7-41f8-8516-4dbbad0c2630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ed6419a-e91d-4e00-88a9-dbe53fd18075" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_28c64443-e418-4bed-8287-4da135a8a62c" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_NonRefundableUpfrontFees_28c64443-e418-4bed-8287-4da135a8a62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_02412ca4-1c10-4665-99b6-ddef85a653a6" xlink:href="mgnx-20201231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_02412ca4-1c10-4665-99b6-ddef85a653a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_071e8aac-d413-450d-b8ac-df634412750d" xlink:href="mgnx-20201231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_071e8aac-d413-450d-b8ac-df634412750d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_10f4345a-41fa-4840-b0f8-f4e268485996" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_10f4345a-41fa-4840-b0f8-f4e268485996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized_684a4118-92a6-45a2-b7c0-98e6c0d47b84" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized_684a4118-92a6-45a2-b7c0-98e6c0d47b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_23945176-ae13-4663-9b82-2aaf2e89d9b5" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_23945176-ae13-4663-9b82-2aaf2e89d9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_d56fd159-44d4-4c05-bdaf-1e51df2c0260" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_NumberOfPerformanceObligations_d56fd159-44d4-4c05-bdaf-1e51df2c0260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_ea183719-8c92-4650-9853-21500132dc8f" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_ea183719-8c92-4650-9853-21500132dc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_6c7ad48a-f24e-4e03-abd2-3cc4314776c6" xlink:href="mgnx-20201231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_6c7ad48a-f24e-4e03-abd2-3cc4314776c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2c2288b8-da4e-4416-8de7-9366eb04f271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_965d4d81-3e09-4c29-a653-dcf69a0c3cd1" xlink:to="loc_us-gaap_Revenues_2c2288b8-da4e-4416-8de7-9366eb04f271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsServierDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_71f0adb5-2049-4775-be9d-be0f3fa0157d" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_71f0adb5-2049-4775-be9d-be0f3fa0157d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c17d6b90-51f4-4edf-9bef-75499954a1c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:to="loc_srt_ProductOrServiceAxis_c17d6b90-51f4-4edf-9bef-75499954a1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34d5f427-215c-4b43-8869-fbf4b2a22bc6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c17d6b90-51f4-4edf-9bef-75499954a1c1" xlink:to="loc_srt_ProductsAndServicesDomain_34d5f427-215c-4b43-8869-fbf4b2a22bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_9cd029aa-c4d9-43fd-8ef9-c21abeb2595a" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_34d5f427-215c-4b43-8869-fbf4b2a22bc6" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_9cd029aa-c4d9-43fd-8ef9-c21abeb2595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_20039c5f-b87d-47af-bddb-c26c7c4f6a38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:to="loc_srt_CounterpartyNameAxis_20039c5f-b87d-47af-bddb-c26c7c4f6a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e595c7af-a00f-4bb7-aae2-92216efd930d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_20039c5f-b87d-47af-bddb-c26c7c4f6a38" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e595c7af-a00f-4bb7-aae2-92216efd930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember_1000b650-5914-45ad-b136-5fba63a049ca" xlink:href="mgnx-20201231.xsd#mgnx_ServierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e595c7af-a00f-4bb7-aae2-92216efd930d" xlink:to="loc_mgnx_ServierMember_1000b650-5914-45ad-b136-5fba63a049ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_954c4f1b-a87d-491c-8ce0-c3c037eb2d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_954c4f1b-a87d-491c-8ce0-c3c037eb2d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b16a68b6-05f6-468e-85ea-012728acc56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_954c4f1b-a87d-491c-8ce0-c3c037eb2d7e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b16a68b6-05f6-468e-85ea-012728acc56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember_9dc445aa-a122-4aeb-8f67-923267f2f86c" xlink:href="mgnx-20201231.xsd#mgnx_ServierDARTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b16a68b6-05f6-468e-85ea-012728acc56b" xlink:to="loc_mgnx_ServierDARTMember_9dc445aa-a122-4aeb-8f67-923267f2f86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierAgreementMGD007OptionMember_f1105bcc-9ecf-4e94-b58a-3f25a8fc105c" xlink:href="mgnx-20201231.xsd#mgnx_ServierAgreementMGD007OptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b16a68b6-05f6-468e-85ea-012728acc56b" xlink:to="loc_mgnx_ServierAgreementMGD007OptionMember_f1105bcc-9ecf-4e94-b58a-3f25a8fc105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88a9185-6f62-4453-9164-e18b05c18de1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_3b54f2df-48e7-40bc-b53c-cd04a5ce7091" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_mgnx_NonRefundableUpfrontFees_3b54f2df-48e7-40bc-b53c-cd04a5ce7091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment_27a435fd-b491-41fe-b615-d038eb15c2d9" xlink:href="mgnx-20201231.xsd#mgnx_MilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_mgnx_MilestonePayment_27a435fd-b491-41fe-b615-d038eb15c2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6482f8b4-de15-498b-9bfc-9a9bbfe85dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_us-gaap_Revenues_6482f8b4-de15-498b-9bfc-9a9bbfe85dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_09a157b4-dc4b-4de3-8ee7-fa312c0b798d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_us-gaap_ContractWithCustomerLiability_09a157b4-dc4b-4de3-8ee7-fa312c0b798d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f267f4df-001b-4130-9150-003f1c6db69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f267f4df-001b-4130-9150-003f1c6db69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee_ec44d878-390b-4042-96bd-f824abd2848e" xlink:href="mgnx-20201231.xsd#mgnx_OptionExerciseFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_mgnx_OptionExerciseFee_ec44d878-390b-4042-96bd-f824abd2848e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_157256d4-2ca0-48f0-b669-1ae7a2f652f6" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b278dc4b-0bac-4e30-9b7e-423cec0f9f23" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_157256d4-2ca0-48f0-b669-1ae7a2f652f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5177ec86-93fe-4b35-8d00-fe1b9fb23b11" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5177ec86-93fe-4b35-8d00-fe1b9fb23b11" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0ef8e995-79de-4f68-8645-1005267b4325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0ef8e995-79de-4f68-8645-1005267b4325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0ef8e995-79de-4f68-8645-1005267b4325" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_484a90f0-61c7-4f08-855e-3e30d9265d65" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_484a90f0-61c7-4f08-855e-3e30d9265d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_48c549d4-d40d-4f8b-b473-c7af48f4e574" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_48c549d4-d40d-4f8b-b473-c7af48f4e574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_138a2263-8669-463c-9662-ef0b2f627c09" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_138a2263-8669-463c-9662-ef0b2f627c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_451ec044-5677-41ad-b189-dd2a56398502" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_451ec044-5677-41ad-b189-dd2a56398502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_77e8e657-f564-46a2-9bb8-2ee682071b35" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_09148796-e501-46fd-bc3d-1046e530cda5" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_77e8e657-f564-46a2-9bb8-2ee682071b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e415e574-2bba-4873-aa85-3ace87bdc720" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:to="loc_srt_CounterpartyNameAxis_e415e574-2bba-4873-aa85-3ace87bdc720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2591feec-3dbf-4835-af11-8984b8b1d987" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e415e574-2bba-4873-aa85-3ace87bdc720" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2591feec-3dbf-4835-af11-8984b8b1d987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember_99a26c8c-cbc7-4191-a103-4a4a598eddcf" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2591feec-3dbf-4835-af11-8984b8b1d987" xlink:to="loc_mgnx_ZaiLabsMember_99a26c8c-cbc7-4191-a103-4a4a598eddcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_efa72648-0f91-41ca-ace2-c082c48347d3" xlink:href="mgnx-20201231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2591feec-3dbf-4835-af11-8984b8b1d987" xlink:to="loc_mgnx_ZaiLabMember_efa72648-0f91-41ca-ace2-c082c48347d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed8c7d9c-09e2-4caa-8f06-bd3df871387f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:to="loc_srt_RangeAxis_ed8c7d9c-09e2-4caa-8f06-bd3df871387f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62342d92-4318-4d98-ac1e-0c4079730825" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ed8c7d9c-09e2-4caa-8f06-bd3df871387f" xlink:to="loc_srt_RangeMember_62342d92-4318-4d98-ac1e-0c4079730825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b62a4fd-a8ea-4c65-8d79-b6751f234123" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_62342d92-4318-4d98-ac1e-0c4079730825" xlink:to="loc_srt_MaximumMember_5b62a4fd-a8ea-4c65-8d79-b6751f234123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a947f8a-c65e-4c8f-85b6-0f9903abfb9b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_a900928a-9e7d-4fbb-a031-c068b7c791ec" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_NonRefundableUpfrontFees_a900928a-9e7d-4fbb-a031-c068b7c791ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_3b18ed5e-5e59-42a3-bf10-388e7fdfc819" xlink:href="mgnx-20201231.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_3b18ed5e-5e59-42a3-bf10-388e7fdfc819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_dbf48bd0-7808-4ef5-81b3-585b44772c9a" xlink:href="mgnx-20201231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_dbf48bd0-7808-4ef5-81b3-585b44772c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_b0cf0a04-a230-4d8f-b831-a21afb129717" xlink:href="mgnx-20201231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_b0cf0a04-a230-4d8f-b831-a21afb129717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_b52595ce-aa7f-4663-93c9-5b73c39aa9b9" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_b52595ce-aa7f-4663-93c9-5b73c39aa9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_934eceba-fe7a-49e8-b096-c05b00f183fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_us-gaap_Revenues_934eceba-fe7a-49e8-b096-c05b00f183fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_668fdfbb-73a3-4702-8339-e54a32e58169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_668fdfbb-73a3-4702-8339-e54a32e58169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EntitledMilestonePaymentsUnderAgreement_f053dd2b-99da-4f89-bf11-ebdee7f770a4" xlink:href="mgnx-20201231.xsd#mgnx_EntitledMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_EntitledMilestonePaymentsUnderAgreement_f053dd2b-99da-4f89-bf11-ebdee7f770a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_b2309410-4ee0-466d-bff8-f9f483151891" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2f187857-f4eb-404a-a018-25a8ae7f73cb" xlink:to="loc_mgnx_RevenuesTaxWithholding_b2309410-4ee0-466d-bff8-f9f483151891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_6031de6b-de80-4523-9005-f5296fb732bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_6031de6b-de80-4523-9005-f5296fb732bc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e4ee4825-9870-4fcd-832a-41af33a6a7cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:to="loc_srt_CounterpartyNameAxis_e4ee4825-9870-4fcd-832a-41af33a6a7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53db4cbf-6d55-4a68-bcf1-d9c6c40977a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e4ee4825-9870-4fcd-832a-41af33a6a7cb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53db4cbf-6d55-4a68-bcf1-d9c6c40977a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_908fdf59-20e3-493b-b198-54a893fc7680" xlink:href="mgnx-20201231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53db4cbf-6d55-4a68-bcf1-d9c6c40977a3" xlink:to="loc_mgnx_JanssenBiotechIncMember_908fdf59-20e3-493b-b198-54a893fc7680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a42cb4ee-1df1-4cf3-965c-97850bbb71e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a42cb4ee-1df1-4cf3-965c-97850bbb71e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc15f5a-72ab-45b0-b144-9930178153da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a42cb4ee-1df1-4cf3-965c-97850bbb71e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc15f5a-72ab-45b0-b144-9930178153da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_934c532a-9fc6-4f0f-8738-30c038531368" xlink:href="mgnx-20201231.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc15f5a-72ab-45b0-b144-9930178153da" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_934c532a-9fc6-4f0f-8738-30c038531368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c9316a6c-f63e-47a0-82de-19158d20f2e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:to="loc_srt_ProductOrServiceAxis_c9316a6c-f63e-47a0-82de-19158d20f2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_30d09ee8-e3c8-498f-833d-688ccf78bd97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c9316a6c-f63e-47a0-82de-19158d20f2e8" xlink:to="loc_srt_ProductsAndServicesDomain_30d09ee8-e3c8-498f-833d-688ccf78bd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_72535e48-c80a-496b-b8e7-c94d52d6d422" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_30d09ee8-e3c8-498f-833d-688ccf78bd97" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_72535e48-c80a-496b-b8e7-c94d52d6d422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b00483b-c63d-4a48-8b12-cb7c7b7ca281" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_b142f1cc-cf05-4221-8214-52590aad7239" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_NonRefundableUpfrontFees_b142f1cc-cf05-4221-8214-52590aad7239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_23a961c1-fc0e-4fa7-8812-1491492f1ad7" xlink:href="mgnx-20201231.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_23a961c1-fc0e-4fa7-8812-1491492f1ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_2c9494e4-22f2-4e43-829d-942a2b510883" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_2c9494e4-22f2-4e43-829d-942a2b510883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0935ff0c-a509-470e-9f3c-f4df43510528" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0935ff0c-a509-470e-9f3c-f4df43510528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0143cef-36c3-43aa-91d5-da65c6177523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_us-gaap_Revenues_f0143cef-36c3-43aa-91d5-da65c6177523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b4a4973f-3bce-4019-b9f5-47b3e9d2f2de" xlink:href="mgnx-20201231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be515f49-eed4-4e9d-9f99-89e5c5a053de" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b4a4973f-3bce-4019-b9f5-47b3e9d2f2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9443094e-f3dc-4be7-9203-66bed5adc27e" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9443094e-f3dc-4be7-9203-66bed5adc27e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3106309b-b42d-48b8-9a32-edf4e0f91c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3106309b-b42d-48b8-9a32-edf4e0f91c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0cdc54f3-0176-4eb9-960c-b0b2fca779a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3106309b-b42d-48b8-9a32-edf4e0f91c82" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0cdc54f3-0176-4eb9-960c-b0b2fca779a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_03323e6e-8865-4046-898a-d013c6d1df58" xlink:href="mgnx-20201231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0cdc54f3-0176-4eb9-960c-b0b2fca779a0" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_03323e6e-8865-4046-898a-d013c6d1df58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9aa45a5d-4250-4062-83e7-28ecab9292aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:to="loc_srt_CounterpartyNameAxis_9aa45a5d-4250-4062-83e7-28ecab9292aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194a76a4-daf1-49b8-8950-3983ff89f2c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9aa45a5d-4250-4062-83e7-28ecab9292aa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194a76a4-daf1-49b8-8950-3983ff89f2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_e99df3f9-22e0-4098-a61e-ee5d444ed66a" xlink:href="mgnx-20201231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194a76a4-daf1-49b8-8950-3983ff89f2c0" xlink:to="loc_mgnx_IMabBiopharmaMember_e99df3f9-22e0-4098-a61e-ee5d444ed66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5ea12b22-16fb-4631-a12e-bb1a13ba81b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:to="loc_srt_RangeAxis_5ea12b22-16fb-4631-a12e-bb1a13ba81b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5420e00f-634e-485a-a6c4-cf513da287b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5ea12b22-16fb-4631-a12e-bb1a13ba81b2" xlink:to="loc_srt_RangeMember_5420e00f-634e-485a-a6c4-cf513da287b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fbbcc060-d800-4c03-8fa8-32932107ab65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5420e00f-634e-485a-a6c4-cf513da287b0" xlink:to="loc_srt_MaximumMember_fbbcc060-d800-4c03-8fa8-32932107ab65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fb7f93d1-b26d-434b-b5b2-b3220061e63e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_689b1ac4-0bd7-46cc-95a9-faae117397b7" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_mgnx_NonRefundableUpfrontFees_689b1ac4-0bd7-46cc-95a9-faae117397b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_60bc949d-63c6-473d-9340-dd31d9ddf196" xlink:href="mgnx-20201231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_60bc949d-63c6-473d-9340-dd31d9ddf196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_532d602d-23fa-4852-abd0-d3eea21bfb27" xlink:href="mgnx-20201231.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_532d602d-23fa-4852-abd0-d3eea21bfb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4c35ef3f-a282-4886-8693-47bee61fe377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_us-gaap_Revenues_4c35ef3f-a282-4886-8693-47bee61fe377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1a7d1669-1485-450e-8f85-a78f97300744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1a7d1669-1485-450e-8f85-a78f97300744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_761c5514-dc25-4f0f-98d6-f29081553cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_761c5514-dc25-4f0f-98d6-f29081553cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a01e84a6-5437-48e7-96f7-e4952e35ff24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a01e84a6-5437-48e7-96f7-e4952e35ff24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_49354cf9-dd7f-4857-afde-757e1ab310ef" xlink:href="mgnx-20201231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86220d52-e787-42c1-9b65-5b4c0a750325" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_49354cf9-dd7f-4857-afde-757e1ab310ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_1191418f-5545-4b37-b9c6-b1280f8b6247" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37c34be3-8f60-4083-a8e3-5faf2969335f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_1191418f-5545-4b37-b9c6-b1280f8b6247" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37c34be3-8f60-4083-a8e3-5faf2969335f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_68db4d07-1ef9-43da-b1c1-4c71405f6b41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37c34be3-8f60-4083-a8e3-5faf2969335f" xlink:to="loc_srt_CounterpartyNameAxis_68db4d07-1ef9-43da-b1c1-4c71405f6b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b74e415-4c51-4e64-9003-bb774647508f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_68db4d07-1ef9-43da-b1c1-4c71405f6b41" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b74e415-4c51-4e64-9003-bb774647508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_9004be94-23db-4947-8418-c41441eae190" xlink:href="mgnx-20201231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b74e415-4c51-4e64-9003-bb774647508f" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_9004be94-23db-4947-8418-c41441eae190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37c34be3-8f60-4083-a8e3-5faf2969335f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ce79f164-3699-4f45-b29a-34869c71b369" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ce79f164-3699-4f45-b29a-34869c71b369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_327ffb92-314a-47ee-8f51-37d88e45ddac" xlink:href="mgnx-20201231.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_327ffb92-314a-47ee-8f51-37d88e45ddac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_836e5b96-25d0-4e3d-91ef-fbda71e4d0aa" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_NumberOfPerformanceObligations_836e5b96-25d0-4e3d-91ef-fbda71e4d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_68be85c7-cda5-4bc8-bf6e-deb0e94edb17" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_68be85c7-cda5-4bc8-bf6e-deb0e94edb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_c8d46572-e85e-40a7-9eeb-243de45b8d02" xlink:href="mgnx-20201231.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_c8d46572-e85e-40a7-9eeb-243de45b8d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2175830f-0569-4aa3-9f70-086edd846d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_us-gaap_Revenues_2175830f-0569-4aa3-9f70-086edd846d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8055baff-c39f-4300-92bb-bd87f4f319e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8055baff-c39f-4300-92bb-bd87f4f319e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_3389ae89-69b1-4e5f-a1a7-37e1efee8aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_us-gaap_DeferredRevenueCurrent_3389ae89-69b1-4e5f-a1a7-37e1efee8aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_de58a650-46d8-4152-992e-6aaa67e9be1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f484818d-81c6-4b1a-894c-daa8e74b4d3b" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_de58a650-46d8-4152-992e-6aaa67e9be1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_3403b1ff-0438-4dc0-aea3-9ec9b28cfc56" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_3403b1ff-0438-4dc0-aea3-9ec9b28cfc56" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_99194649-cf43-442e-a93a-01193e8f06fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:to="loc_srt_ProductOrServiceAxis_99194649-cf43-442e-a93a-01193e8f06fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18b528cc-b0a5-446d-bddc-2cd4fa504025" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_99194649-cf43-442e-a93a-01193e8f06fe" xlink:to="loc_srt_ProductsAndServicesDomain_18b528cc-b0a5-446d-bddc-2cd4fa504025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_8e3aba89-7125-4dba-9fb7-832dc248a881" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18b528cc-b0a5-446d-bddc-2cd4fa504025" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_8e3aba89-7125-4dba-9fb7-832dc248a881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_31842baf-e2ab-44d6-8d75-ba2c6e411d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_31842baf-e2ab-44d6-8d75-ba2c6e411d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef3a6e18-937d-4d0c-9bfa-10267c2cef51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_31842baf-e2ab-44d6-8d75-ba2c6e411d6b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef3a6e18-937d-4d0c-9bfa-10267c2cef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_8fa496f0-d53b-4178-b869-c90089607cd7" xlink:href="mgnx-20201231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef3a6e18-937d-4d0c-9bfa-10267c2cef51" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_8fa496f0-d53b-4178-b869-c90089607cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_b6fc8041-23eb-43ad-b4fd-e6a357284ae0" xlink:href="mgnx-20201231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef3a6e18-937d-4d0c-9bfa-10267c2cef51" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_b6fc8041-23eb-43ad-b4fd-e6a357284ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f03f1081-4ed5-410e-a69f-f922d34e3b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f03f1081-4ed5-410e-a69f-f922d34e3b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3b851748-d517-40ea-ac2c-a97dea48b4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f03f1081-4ed5-410e-a69f-f922d34e3b0d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3b851748-d517-40ea-ac2c-a97dea48b4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_34bfc909-9f0d-4139-8b08-dd470096548b" xlink:href="mgnx-20201231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3b851748-d517-40ea-ac2c-a97dea48b4ba" xlink:to="loc_mgnx_ProventionPRV3279Member_34bfc909-9f0d-4139-8b08-dd470096548b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_c402c678-4e1d-4005-8ba8-2521a16d4493" xlink:href="mgnx-20201231.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3b851748-d517-40ea-ac2c-a97dea48b4ba" xlink:to="loc_mgnx_ProventionPRV031Member_c402c678-4e1d-4005-8ba8-2521a16d4493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2684de9c-2c65-4ccb-b66a-3897092ee17d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f62cc0fa-26a7-4701-bffe-6f575285e5b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_cf69ae39-c020-4cac-8374-714547f68db0" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ff12c3d5-1979-4bbf-879a-25e141483fce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:to="loc_srt_CounterpartyNameAxis_ff12c3d5-1979-4bbf-879a-25e141483fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90b19504-9f1e-4572-9d01-d1caaaf0be96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ff12c3d5-1979-4bbf-879a-25e141483fce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90b19504-9f1e-4572-9d01-d1caaaf0be96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_72dc5618-82ee-4936-bae8-3bb993a9575d" xlink:href="mgnx-20201231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90b19504-9f1e-4572-9d01-d1caaaf0be96" xlink:to="loc_mgnx_ProventionBioMember_72dc5618-82ee-4936-bae8-3bb993a9575d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1fcbac6f-72e0-4e3f-8944-de080cbe058c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_0ed91402-40b1-4126-817d-a29ea5131bf9" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_0ed91402-40b1-4126-817d-a29ea5131bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_10cbae17-ac47-4f51-9f6d-685243e4bf0b" xlink:href="mgnx-20201231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_10cbae17-ac47-4f51-9f6d-685243e4bf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_490345bf-130e-4e24-b179-ed559f8e5e8e" xlink:href="mgnx-20201231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_490345bf-130e-4e24-b179-ed559f8e5e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_e81bf69e-b6e7-416f-8f17-fdee9ae96213" xlink:href="mgnx-20201231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_e81bf69e-b6e7-416f-8f17-fdee9ae96213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_241a259e-74d5-4726-8d95-467c2503e6c0" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_NumberOfPerformanceObligations_241a259e-74d5-4726-8d95-467c2503e6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a61b2a39-d988-4239-930b-1c047075e1b0" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a61b2a39-d988-4239-930b-1c047075e1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_1b0a7cb8-13fa-4561-b2b8-cb241db3597c" xlink:href="mgnx-20201231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_1b0a7cb8-13fa-4561-b2b8-cb241db3597c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_02d18167-0176-41f0-9dee-ff88e950d73b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_us-gaap_Revenues_02d18167-0176-41f0-9dee-ff88e950d73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_381161a9-54c1-4bf1-a808-b02ee2ebf160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_us-gaap_DeferredRevenueCurrent_381161a9-54c1-4bf1-a808-b02ee2ebf160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_cf358cb1-2ea5-4658-8810-84d5d730188f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a771cc46-cdec-4441-b426-c934296f152d" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_cf358cb1-2ea5-4658-8810-84d5d730188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b605eb75-47b0-41ac-b3d3-f3f4b7f6988f" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b605eb75-47b0-41ac-b3d3-f3f4b7f6988f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ccbfc3f-4f31-4b8d-8edd-7b559f9c32cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:to="loc_srt_ProductOrServiceAxis_8ccbfc3f-4f31-4b8d-8edd-7b559f9c32cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a292c76-5f61-4846-b49e-f109bdab698d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8ccbfc3f-4f31-4b8d-8edd-7b559f9c32cd" xlink:to="loc_srt_ProductsAndServicesDomain_8a292c76-5f61-4846-b49e-f109bdab698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_5503703e-7384-4010-9e49-3a975af7cf59" xlink:href="mgnx-20201231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a292c76-5f61-4846-b49e-f109bdab698d" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_5503703e-7384-4010-9e49-3a975af7cf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ff14a4d3-9dd9-4bbd-bf97-49d8f354ec91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:to="loc_srt_CounterpartyNameAxis_ff14a4d3-9dd9-4bbd-bf97-49d8f354ec91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7448c20-4e5c-4348-a1d2-2e959a0814b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ff14a4d3-9dd9-4bbd-bf97-49d8f354ec91" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7448c20-4e5c-4348-a1d2-2e959a0814b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_87a3a51b-9249-4cca-942d-591e89aca577" xlink:href="mgnx-20201231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7448c20-4e5c-4348-a1d2-2e959a0814b8" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_87a3a51b-9249-4cca-942d-591e89aca577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e39812d9-f303-4284-9efa-fa705a8b8032" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:to="loc_srt_RangeAxis_e39812d9-f303-4284-9efa-fa705a8b8032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40379132-41cf-4155-8b1f-de1d42c0a60c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e39812d9-f303-4284-9efa-fa705a8b8032" xlink:to="loc_srt_RangeMember_40379132-41cf-4155-8b1f-de1d42c0a60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ffd9aff-96ac-46e3-a694-e6b164004157" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_40379132-41cf-4155-8b1f-de1d42c0a60c" xlink:to="loc_srt_MaximumMember_0ffd9aff-96ac-46e3-a694-e6b164004157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7584339-cde4-4fa5-b26e-7ca10ed369a5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_fed94799-b059-4762-9680-21deecbd07ca" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_fed94799-b059-4762-9680-21deecbd07ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_f04aa75e-553f-4266-a597-9c16ba38e5a8" xlink:href="mgnx-20201231.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_FundedValueOfBasePeriod_f04aa75e-553f-4266-a597-9c16ba38e5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_6c2659b6-6874-43c2-9a3c-37e0712ba7ca" xlink:href="mgnx-20201231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_6c2659b6-6874-43c2-9a3c-37e0712ba7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_8775e0ca-320a-4781-93b8-cdcbee2f0619" xlink:href="mgnx-20201231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_8775e0ca-320a-4781-93b8-cdcbee2f0619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_13603b55-f71b-4918-bd69-f8453c8bec0c" xlink:href="mgnx-20201231.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_13603b55-f71b-4918-bd69-f8453c8bec0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dbecccb4-b67a-40ab-a3c4-9ceea1661b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e23f04b-80bc-4667-b03f-36c604408814" xlink:to="loc_us-gaap_Revenues_dbecccb4-b67a-40ab-a3c4-9ceea1661b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5186d6cc-4e11-4e9f-9a79-54d1e8673ae4" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a8452278-4457-418f-a9e1-5d93453cea63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5186d6cc-4e11-4e9f-9a79-54d1e8673ae4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a8452278-4457-418f-a9e1-5d93453cea63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baa3672d-0f0a-449a-bfe7-172fe7da7f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a8452278-4457-418f-a9e1-5d93453cea63" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baa3672d-0f0a-449a-bfe7-172fe7da7f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_833edc29-67eb-46a3-95fe-5626f2172b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baa3672d-0f0a-449a-bfe7-172fe7da7f4a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_833edc29-67eb-46a3-95fe-5626f2172b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_6c4ae3ff-3d4e-42ea-87ce-29b99668b729" xlink:href="mgnx-20201231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_833edc29-67eb-46a3-95fe-5626f2172b1e" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_6c4ae3ff-3d4e-42ea-87ce-29b99668b729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e831e95e-2d96-42f7-88c2-82a64770ec27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a8452278-4457-418f-a9e1-5d93453cea63" xlink:to="loc_srt_CounterpartyNameAxis_e831e95e-2d96-42f7-88c2-82a64770ec27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e15c625f-f28d-438e-801c-4cf1ca25302d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e831e95e-2d96-42f7-88c2-82a64770ec27" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e15c625f-f28d-438e-801c-4cf1ca25302d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_a38ac48d-c1e8-48df-aea6-bca79d273972" xlink:href="mgnx-20201231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e15c625f-f28d-438e-801c-4cf1ca25302d" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_a38ac48d-c1e8-48df-aea6-bca79d273972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a8452278-4457-418f-a9e1-5d93453cea63" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm_45fca647-1ebf-4afc-8c46-1e23f74b2eb9" xlink:href="mgnx-20201231.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementTerm_45fca647-1ebf-4afc-8c46-1e23f74b2eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_cca5f1ba-131c-4655-bc2b-b122ca0879ac" xlink:href="mgnx-20201231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_NumberOfProductCandidates_cca5f1ba-131c-4655-bc2b-b122ca0879ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_7bec6ae6-e78b-49ce-832c-44e944f68063" xlink:href="mgnx-20201231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_NonRefundableUpfrontFees_7bec6ae6-e78b-49ce-832c-44e944f68063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount_5692c414-b3e6-4373-b800-d54622ba9c24" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_DevelopmentMilestonesAmount_5692c414-b3e6-4373-b800-d54622ba9c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_3ae248ac-3c10-4c37-9e29-f5863c594eaf" xlink:href="mgnx-20201231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f591df40-3408-4e7c-bbf9-4a8c549d6f74" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_3ae248ac-3c10-4c37-9e29-f5863c594eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3bafbbd-888c-4065-94b3-ac73215718d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dd4db09e-8d3e-4d8e-88a3-3d1e5f8c8eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3bafbbd-888c-4065-94b3-ac73215718d5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dd4db09e-8d3e-4d8e-88a3-3d1e5f8c8eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20201231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87a2692a-3ae0-475d-9b31-15038daa9fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8d7d68f1-6dae-4456-9170-ff7e2ec23e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87a2692a-3ae0-475d-9b31-15038daa9fa7" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8d7d68f1-6dae-4456-9170-ff7e2ec23e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_62b0219e-f847-4dac-bf98-eebc90c832e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_8b9b2877-dde7-4a31-a084-2fddddedab2f" xlink:href="mgnx-20201231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_62b0219e-f847-4dac-bf98-eebc90c832e1" xlink:to="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_8b9b2877-dde7-4a31-a084-2fddddedab2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a912076b-46c1-47c4-8ae5-05f7935d1589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_62b0219e-f847-4dac-bf98-eebc90c832e1" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a912076b-46c1-47c4-8ae5-05f7935d1589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_1c86c83c-b051-4efa-a50b-ce32c289eccf" xlink:href="mgnx-20201231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_62b0219e-f847-4dac-bf98-eebc90c832e1" xlink:to="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_1c86c83c-b051-4efa-a50b-ce32c289eccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_59e5e725-ba69-46cc-89ac-ab7999270921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_62b0219e-f847-4dac-bf98-eebc90c832e1" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_59e5e725-ba69-46cc-89ac-ab7999270921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !H . # 2(  A$! Q$!_\0
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MV/N_T5__ &1_N_WOX:^ZQUIV:.]:U\37Q7)[6?-RC/RI\>6<'QF_X*13:1/
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MW3S3]I'X-VGQW^$.M^%)Y$ANY5\_3KMU_P"/>Z7YHG_W?X6_V6:OSA_9D_:
MUS]CKXE:WX3\9Z;=PZ%<3^5JVF!=TMG.OW+B+^\FS_OI=G]ROUT&"*\9^//[
M+7@7]H:P3_A(;&2VUBW7;;:SI[>5=Q?[._\ B7_9:O5P&-ITJ4\+B(<U*9W'
M;^ _B1X9^)NC0ZKX5UZRURR9=VZSGW,G^^OWE;_9:NEN+R.RMVFG>.")%W,[
MOM5:_-O6_P#@ESX]\/:C+=>#O'FFW"?PRW/GV%Q_WW%OJHO_  3=^-/B=E@\
M0>/-+-K_ !?:-1O+W_QQUVUM]2P$I<T<7[O^$#W;X^_\%%/!GPKO/[-\)P1^
M.]4B;_2FM+K9:0+_ '?-VOO;_86L#_@I+XT^W_LX^#T\B2PFU[4[6=K2X_UL
M2+ TNQO]I79*['X$_P#!/;P)\(M4M=<UF>7QEKMHV^"6^A6*U@;^^D'][_:=
MGIW[;W[+WBS]I&U\(1>&M5TVS;2)9_/BU%G1&\W8/-7:KYV[/N_[5*A4P%+%
M4>7X(_%(#JOV#/#W_"/_ ++/@O<FR6_BEOV_[:RNR_\ CFVOH>N7^'7A*+X>
M^!/#OAB"7SH='T^"P5]NW?Y2*FZNHKQZTO:UYU?YBC\GOVF+S4OV8?VPO%6O
M:+&R0Z]IT]U!\^U/],B:*5_^ SIO_P" U[W_ ,$L?AS_ &1\,O$7BZ>+][K-
M\EK [_?\B!?_ (Z[_P#?-=M^VU^RAJO[1D'A?4/"]W86.NZ2TT$IU%F1)8)=
MG\2JWS*R_P#CSU[E\&?AW;?!_P"%WA?P9;2_:$TFS6&2XV[?-E^]*_\ P)V=
MJ]ZMF%*670I0^.7Q_P#;I'+[QWV:_,7_ (*J:.^E?%?P;X@A7:]SH\L._P#V
MX)]Z?^C:_3GVKY@_;9_9EUK]I#PSX=A\.7ME9ZWHES*Z+J+LD4L4J;77<JM\
MWRJWX5YV5UH8?%0G5^$N1]!^$-=7Q)X3T35T;<FHV,%VO_ T5O\ V:OS#_;=
M^!VN? +XR+\3/"OF6FA:CJ*:E%?1+_R#M1W;W5_]AV^9?]]UK](/@YX.N_A[
M\+/"OAK4;Y=1O=)TZ"SENXEPDK(FW*UT/B+PUIGBW0[O2M9L;?5=.O(O*GM+
MN+?%*O\ M*:SPF+^I8F4X^]$9\]?LY?MJ>$?CGHUK8ZKJ%MX8\9*J)<Z3<2^
M4L[_ -^W9_O*W]W[Z_\ CU?3*9VXQBO@OXM?\$N=#U2]EOO 'B)]!1VWKI.K
M1-=6Z'T27[ZK_O;Z\Y3_ ()Y_'FPC^Q6?C>P2R^[^YUV\B3_ +XVUWRPF Q$
MN?#XCD_NR(/NOXM_M">!O@CI4MWXHURWMKA5S%IT3^;=S_[L7WJ\_P#V5/VK
M7_:;G\6?\4Q+X?M]&EB\FX^T?:%E27?\C_(NR5=OW?F^]7@WP]_X)72R:BE]
MX_\ &OVE-V^6TT2)MTO^]<2_-_X[7VS\._AOX:^%?ABT\.^%=(AT;2[<?+%"
M/OM_$[-]YF_VF]JY*\<'0AR4I<\OY@)[2Q^W^$KK3QR\3SVO_?+ML_\ 9:\I
MN;;SHI8)5^_\C5[ K_V=XEDA9L0ZB/-B/_35%VNG_?.QO^ M7(>/O#C6=X-0
MMO\ CWE;][M_A:OR_BK 3Q-*&(C]GXBCP6YA:VGEBE^^C[&H'R6O^\U=-XMT
M=IO].@7>_P!R5/\ V>N9N4V+$O\ LU^+RCR2/-E'D(J**BN;F*S@EGGE6&*)
M=[.]1']Z0>7_ !LO$273[9?]:R[V_P!S?7'?#[P/=_$3QIIOA^T5MUY+^]F_
MYY1?\M6_X"M6[F'6?BOXV>#2+&>_NKIML%O$OW(O[[_W%_VZ^Q?@-\*+;X4Z
M-+'8B'6/%-R=E_J:(?LMFO\ SR1OXMO]U?F9OO;:_HK),OE@<#2C/XCYBEAI
M9AC)S^P>NR6D'VC2M!L56.RL%BED1/X(HO\ 5)_WTG_CM=965H^D1:1;,BL9
M9I6WRS/]Z5O[U:M?0GWABZCXBM-)DCCN4N7=_F46]M++_P"@+57_ (3O3_\
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MJ3?MKDH8FKB,;.,I\D82Y>7^8?V3.\2^*K;PP+=6@EN[NY;9!!;K\[U%X?\
M%BZW<RVLNGW.FW<*;F6X7^'_ 'JR_&MMH5_=6%K>W[:=J'S2VURC;-I_WJ@\
M'Z]?'Q#?:)>74>J+!'O^VQ]1_LM7'4QU:.8^RE+W.;E]WWO_  +[49 >C444
M5]P9A1110!G:EH]IK$21WD"W"*VY0]3VMO%90+%"BI$ORJJT45E[.//<"U11
M16H!1110!E:EHUMK$"0WL,=Q$C+(JO\ WUJKI_A#2-*NVN[2P@AN'^]*B445
MQRP="I/VTH^\,W",U0L-*MM*BE6VC6%)9&E95_B=J**WY%S"#4]*L]4MC!=P
M1W,#?P.NX57T7PWIFA(_]GV<-KN^]Y2T45D\'0Y_;<OO%_9+UY9Q7]K+!/&L
MT4J[&1OXEHM;:*RMU@BC6**-=JJG\*T45IR+GN04=8\-:;KBHNH6D-SM^[O6
MI]-TNVTVU^S6L4<$"_=2)=M%%1'!T(U/;*/O%KX3+\80ZG-I>-+MK:[<-^]M
M[G[DJ?W:X;3_  A=:OJMEL\/0>';.WG6XE?<C2RNO\"_[-%%?*YA@*.(Q<'4
MU^2_R'T/7,?+5'3=)MM(MVBM(EMXG=I=B_WFHHKZ[DCS&8:GI5IJ]JT-Y!'<
MPM_ ZU%H_A_3M!B:.PM(K5&^\L2XHHK+ZK1Y_;<OO%_9':MH5CKMKY%];1W,
A7]R5:;I6@:=H4#QV5I%;(WWDB3[U%%+ZG0Y_:\OO ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>incytelogo1a.jpg
<TEXT>
begin 644 incytelogo1a.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M, Q1BBB@ Q1BBB@ Q1BBDW8]: %Q1BF[Z#* : '8HQ3?,I0V?6BX"XHQ110
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M*N/''Q]UWQ1X)T>%Q'$=:L_)U"5-WS16ED0JVR#')94 )4JLP!V_<'_!*O\
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MI.M07[R.OJ=_^Q]^TOIO[4WP:M?$]G VGW#3O:WED\F[[+.@0LJM@;EPZD'
MSNKU(2J1]Y?SK\N?^"8'[2-S\%?BDGA'465-#\57 2565U-G>Y"JR^@)^1L@
M]$Y 5J_3Z)EEC5O[V>U/A'B2GFN 5:_O1?+/R9U9/F$<713^TEKZEH'-%-C^
MY3J^N5^IZ@4444 %!.**#TH 9/+Y29]P/UQ7SY^V7XYF:[TGPW9LS-,?/EC!
MXE8MA4/UY_2OH*X.(OT^E?(NDZQ%\2?VU(UDD5X1J4OEX.X,L$<C(1]3$#^/
MMS[61T;UIUY;4TV8UF[6/J#X<>$8O O@W3]+A50MG"J,1U=^K,?<DYS[UM$'
MYJCM,K'R.IS_ )^G3\*FSD-7BU).4I5'NV:[GXX?\%A_^"L/QV_9+_;HUSP7
MX'\7VNE>';.QT^X@MI-'M+DHTL(:3+R(6.6.>3QTZ 5^CG_!.#XN^(?C]^P]
M\-_&/BB^CU#Q!X@TM;J^N!"L2RR%G7.Q<*.@.  !T':OQ6_X.'/^4G?B3_L%
M:5_Z(2OV$_X(^<?\$SO@_P#]@-/_ $8]?HG%&68;#Y!@\31@E.25WU=XW.>G
M4DZC3V1],>9@]&I=WL:\I\<?MP_!WX9>+[SP]XB^*GPYT+Q!I[*ESIFH>);*
MUN[=V575'CDD4JS*RD XR"#T-87QA_X*6_ CX#6UU_PE'Q3\%VEU8NL=S8VV
MI)?7L+M@@-;P;Y1D$$?)TYX%?!T\#BZDE&-*3OMH]3H<H]SW">3:O1NO-?*_
M_!4OXCLWP[\!?"^W%S]I^-GC+3?"5XL#;9ETIYD?46&#G;]E#QL>RRFF_#W_
M (+5_LQ_$W5DL;/XKZ#IEQ)]UM9BN-+AZ@<RW$:1@G. "PR:S=*T]?CU_P %
M?IM8W+>:'\&_A_#!;R+\T46IZK/(S.K#Y<M:0KQR=KJ> 1GMP^7XK"5G6Q=)
MPY(N6J:U6D=U_,U<+QEHF?57A+0+'PAX:L])TVSM=/TW384M;2UM8EA@MHD4
M(L:(H 55  "@8 &!Q6GOK(\0>+=-\%:+-J.L:A8Z3IEK%YUQ=W<RP6\"CEF>
M1R%51ZDU\]?$S_@L3^S7\*R!>?%OPMJ;-C T.5]8V\9^8VJR!?Q-<&$P.+Q<
MK8:G*H^MDVUZBE*,-V?3H?BC?7RW\.?^"SW[,_Q-O5M[+XK^'["1AD/JZ3:7
M#_W\N$1,^V[->S?%']I_X>?!&+2Y/&?CCP?X1CUP.^FMK.M6UB-15"F]H3(X
M\P#S(R2O3S$SC(JZV7XRC-4:E*2D]KIE1E%]3O\ =]:"V!7)?"OXX^#_ (XZ
M-+J7@OQ5X=\6:;;W!LY;O1]1BOH(IPBR&(O&S*'"NC%<Y 93W%=)JVK0Z+I\
MEU=2Q06\"-)+))((U10"223@  #.20 ,FN:49QG[.<6GV%S)K0DFO5@QNW?,
M<  9SVKSK]HG]K_X<_LH^$9-:\?^*=-\.VJY$,4\H:ZO& SLAA7,DK>RJ2.I
MP.:R_#W[</P:^('B#3]*T'XL?#/6]4O[@6]M96'BBRN9KJ5CM$:1I(69B3@
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M3.^#_MH2_P#HUZ_'O_@X<_Y2=^)/^P5I7_HA*_83_@CS_P HS_A!_P!@)?\
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M](?^#;?1=2O/V-/%'BK5KB6^U#7O$[VT=Q/(TCFTL[2VAA3)YVI^]4 ' &,
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M>A&17T7(F#_$?I2A?ESS]*^CS;BBKC\NHY?.DDJ5DG?>RL9QI*,N;N?SR?\
M!9/]F7XE>.O^"E?Q1U30_A_XXUG3M0N+%[6[L]#N;JUG L+16\N1$PW((SD
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MJ",FEI4,EIJI[>M+GEY[?<0L/&_-+5D<8P<=L=*DHHKV4K;&X4444P"BBB@
MHHHH **** "BBB@ HHHH ****  \BH_+/M4E%3**>X$91L]*-A_NU)10H10:
MC8Q@=,4NWW-+13L 4444P"FD,:=118!H7':EZ=J6BE9 )D^E+1118 [T444P
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mgnx-20201231_g1.jpg
<TEXT>
begin 644 mgnx-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0  D "0  #_X0">17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        "0     0   )     !  .2A@ '    $@   (2@
M @ $     0  $2:@ P $     0  ""H     05-#24D   !38W)E96YS:&]T
M_^$)(6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E
M9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z
M>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB6$U0
M($-O<F4@-BXP+C B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B\^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TB=R(_/@#_
M[0 X4&AO=&]S:&]P(#,N,  X0DE-! 0        X0DE-!"4      !#4'8S9
MCP"R!.F "9CL^$)^_^("($E#0U]04D]&24Q%  $!   "$&%P<&P$    ;6YT
M<E)'0B!865H@!^4  @ 2 !$ )0 [86-S<$%04$P     05!03
M             /;6  $     TRUA<'!LA)F&A)PISHT]V,':<HL56P
M                                   *9&5S8P   /P   !D8W!R=
M 6     C=W1P=    80    4<EA96@   9@    49UA96@   :P    48EA9
M6@   <     4<E120P   =0    08VAA9    >0    L8E120P   =0    0
M9U120P   =0    09&5S8P         *3$<@2$12(#1+
M
M                             '1E>'0     0V]P>7)I9VAT($%P<&QE
M($EN8RXL(#(P,C$  %A96B        #S%@ !     1;*6%E:(        '[4
M   YWP   ,!865H@        4=$  +F$   0K%A96B         F,0  #)T
M ,'!<&%R80            'V!'-F,S(       $,<@  !?C___,=   'N@
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MT]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_0%_Y<XO_P"7A]8J_P _X1_^5A_Q$G?\%J?^CS__ #73]D__ .<71_JQD?\
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M )>'UBK_ #_A'_Y6'_$2=_P6I_Z//_\ -=/V3_\ YQ='^K&1_P#0%_Y<XO\
M^7A]8J_S_A'_ .5A_P 1)W_!:G_H\_\ \UT_9/\ _G%T?ZL9'_T!?^7.+_\
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M_A'_ .5A_P 1)W_!:G_H\_\ \UT_9/\ _G%T?ZL9'_T!?^7.+_\ EX?6*O\
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M_E8?\1)W_!:G_H\__P UT_9/_P#G%T?ZL9'_ - 7_ESB_P#Y>'UBK_/^$?\
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M$G?\%J?^CS__ #73]D__ .<71_JQD?\ T!?^7.+_ /EX?6*O\_X1_P#E8?\
M$2=_P6I_Z//_ /-=/V3_ /YQ='^K&1_] 7_ESB__ )>'UBK_ #_A'_Y6'_$2
M=_P6I_Z//_\ -=/V3_\ YQ='^K&1_P#0%_Y<XO\ ^7A]8J_S_A'_ .5A_P 1
M)W_!:G_H\_\ \UT_9/\ _G%T?ZL9'_T!?^7.+_\ EX?6*O\ /^$?_E8?\1)W
M_!:G_H\__P UT_9/_P#G%T?ZL9'_ - 7_ESB_P#Y>'UBK_/^$?\ Y6'_ !$G
M?\%J?^CS_P#S73]D_P#^<71_JQD?_0%_Y<XO_P"7A]8J_P _X1_^5A_Q$G?\
M%J?^CS__ #73]D__ .<71_JQD?\ T!?^7.+_ /EX?6*O\_X1_P#E8?\ $2=_
MP6I_Z//_ /-=/V3_ /YQ='^K&1_] 7_ESB__ )>'UBK_ #_A'_Y6'_$2=_P6
MI_Z//_\ -=/V3_\ YQ='^K&1_P#0%_Y<XO\ ^7A]8J_S_A'_ .5A_P 1)W_!
M:G_H\_\ \UT_9/\ _G%T?ZL9'_T!?^7.+_\ EX?6*O\ /^$?_E8?\1)W_!:G
M_H\__P UT_9/_P#G%T?ZL9'_ - 7_ESB_P#Y>'UBK_/^$?\ Y6'_ !$G?\%J
M?^CS_P#S73]D_P#^<71_JQD?_0%_Y<XO_P"7A]8J_P _X1_^5A_Q$G?\%J?^
MCS__ #73]D__ .<71_JQD?\ T!?^7.+_ /EX?6*O\_X1_P#E8?\ $2=_P6I_
MZ//_ /-=/V3_ /YQ='^K&1_] 7_ESB__ )>'UBK_ #_A'_Y6'_$2=_P6I_Z/
M/_\ -=/V3_\ YQ='^K&1_P#0%_Y<XO\ ^7A]8J_S_A'_ .5G]:W_  ;+_P#!
M1C]LG_@H/X0_:_U3]KWXQ?\ "W+_ .%OB3X+V'@2?_A7OPL\ _V%:>+=,^)5
MQX@B\KX8^"/!<.I_;YO#^D/YFL)J$MI]DVV3VR3W*W'R/%&68++I8)8.C[%5
MEB'4_>5:G-R.CR_Q:D[6YY?#:]];VB=6'J2J*3D[V:MHEW[*/Y?==\W[8_\
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M /-=/V3_ /YQ='^K&1_] 7_ESB__ )>'UBK_ #_A'_Y6'_$2=_P6I_Z//_\
M-=/V3_\ YQ='^K&1_P#0%_Y<XO\ ^7A]8J_S_A'_ .5A_P 1)W_!:G_H\_\
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M /YQ='^K&1_] 7_ESB__ )>'UBK_ #_A'_Y6'_$2=_P6I_Z//_\ -=/V3_\
MYQ='^K&1_P#0%_Y<XO\ ^7A]8J_S_A'_ .5A_P 1)W_!:G_H\_\ \UT_9/\
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M_0%_Y<XO_P"7A]8J_P _X1_^5A_Q$G?\%J?^CS__ #73]D__ .<71_JQD?\
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M )>'UBK_ #_A'_Y6'_$2=_P6I_Z//_\ -=/V3_\ YQ='^K&1_P#0%_Y<XO\
M^7A]8J_S_A'_ .5A_P 1)W_!:G_H\_\ \UT_9/\ _G%T?ZL9'_T!?^7.+_\
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M_A'_ .5A_P 1)W_!:G_H\_\ \UT_9/\ _G%T?ZL9'_T!?^7.+_\ EX?6*O\
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M_E8?\1)W_!:G_H\__P UT_9/_P#G%T?ZL9'_ - 7_ESB_P#Y>'UBK_/^$?\
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M$G?\%J?^CS__ #73]D__ .<71_JQD?\ T!?^7.+_ /EX?6*O\_X1_P#E8?\
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M /-=/V3_ /YQ='^K&1_] 7_ESB__ )>'UBK_ #_A'_Y6'_$2=_P6I_Z//_\
M-=/V3_\ YQ='^K&1_P#0%_Y<XO\ ^7A]8J_S_A'_ .5A_P 1)W_!:G_H\_\
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M /YQ='^K&1_] 7_ESB__ )>'UBK_ #_A'_Y6'_$2=_P6I_Z//_\ -=/V3_\
MYQ='^K&1_P#0%_Y<XO\ ^7A]8J_S_A'_ .5A_P 1)W_!:G_H\_\ \UT_9/\
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M_0%_Y<XO_P"7A]8J_P _X1_^5A_Q$G?\%J?^CS__ #73]D__ .<71_JQD?\
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M#_B)._X+4_\ 1Y__ )KI^R?_ /.+H_U8R/\ Z O_ "YQ?_R\/K%7^?\ "/\
M\K#_ (B3O^"U/_1Y_P#YKI^R?_\ .+H_U8R/_H"_\N<7_P#+P^L5?Y_PC_\
M*P_XB3O^"U/_ $>?_P":Z?LG_P#SBZ/]6,C_ .@+_P N<7_\O#ZQ5_G_  C_
M /*P_P"(D[_@M3_T>?\ ^:Z?LG__ #BZ/]6,C_Z O_+G%_\ R\/K%7^?\(__
M "L/^(D[_@M3_P!'G_\ FNG[)_\ \XNC_5C(_P#H"_\ +G%__+P^L5?Y_P (
M_P#RL/\ B)._X+4_]'G_ /FNG[)__P XNC_5C(_^@+_RYQ?_ ,O#ZQ5_G_"/
M_P K#_B)._X+4_\ 1Y__ )KI^R?_ /.+H_U8R/\ Z O_ "YQ?_R\/K%7^?\
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MO#ZQ5_G_  C_ /*P_P"(D[_@M3_T>?\ ^:Z?LG__ #BZ/]6,C_Z O_+G%_\
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M%_\ R\/K%7^?\(__ "L/^(D[_@M3_P!'G_\ FNG[)_\ \XNC_5C(_P#H"_\
M+G%__+P^L5?Y_P (_P#RL/\ B)._X+4_]'G_ /FNG[)__P XNC_5C(_^@+_R
MYQ?_ ,O#ZQ5_G_"/_P K#_B)._X+4_\ 1Y__ )KI^R?_ /.+H_U8R/\ Z O_
M "YQ?_R\/K%7^?\ "/\ \K#_ (B3O^"U/_1Y_P#YKI^R?_\ .+H_U8R/_H"_
M\N<7_P#+P^L5?Y_PC_\ *P_XB3O^"U/_ $>?_P":Z?LG_P#SBZ/]6,C_ .@+
M_P N<7_\O#ZQ5_G_  C_ /*P_P"(D[_@M3_T>?\ ^:Z?LG__ #BZ/]6,C_Z
MO_+G%_\ R\/K%7^?\(__ "L/^(D[_@M3_P!'G_\ FNG[)_\ \XNC_5C(_P#H
M"_\ +G%__+P^L5?Y_P (_P#RL/\ B)._X+4_]'G_ /FNG[)__P XNC_5C(_^
M@+_RYQ?_ ,O#ZQ5_G_"/_P K#_B)._X+4_\ 1Y__ )KI^R?_ /.+H_U8R/\
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MH_U8R/\ Z O_ "YQ?_R\/K%7^?\ "/\ \K#_ (B3O^"U/_1Y_P#YKI^R?_\
M.+H_U8R/_H"_\N<7_P#+P^L5?Y_PC_\ *P_XB3O^"U/_ $>?_P":Z?LG_P#S
MBZ/]6,C_ .@+_P N<7_\O#ZQ5_G_  C_ /*P_P"(D[_@M3_T>?\ ^:Z?LG__
M #BZ/]6,C_Z O_+G%_\ R\/K%7^?\(__ "L/^(D[_@M3_P!'G_\ FNG[)_\
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MH_U8R/\ Z O_ "YQ?_R\/K%7^?\ "/\ \K#_ (B3O^"U/_1Y_P#YKI^R?_\
M.+H_U8R/_H"_\N<7_P#+P^L5?Y_PC_\ *P_XB3O^"U/_ $>?_P":Z?LG_P#S
MBZ/]6,C_ .@+_P N<7_\O#ZQ5_G_  C_ /*P_P"(D[_@M3_T>?\ ^:Z?LG__
M #BZ/]6,C_Z O_+G%_\ R\/K%7^?\(__ "L/^(D[_@M3_P!'G_\ FNG[)_\
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MZ?LG_P#SBZ/]6,C_ .@+_P N<7_\O#ZQ5_G_  C_ /*P_P"(D[_@M3_T>?\
M^:Z?LG__ #BZ/]6,C_Z O_+G%_\ R\/K%7^?\(__ "L/^(D[_@M3_P!'G_\
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M]'G_ /FNG[)__P XNC_5C(_^@+_RYQ?_ ,O#ZQ5_G_"/_P K#_B)._X+4_\
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M_@M3_P!'G_\ FNG[)_\ \XNC_5C(_P#H"_\ +G%__+P^L5?Y_P (_P#RL/\
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M#_B)._X+4_\ 1Y__ )KI^R?_ /.+H_U8R/\ Z O_ "YQ?_R\/K%7^?\ "/\
M\K#_ (B3O^"U/_1Y_P#YKI^R?_\ .+H_U8R/_H"_\N<7_P#+P^L5?Y_PC_\
M*P_XB3O^"U/_ $>?_P":Z?LG_P#SBZ/]6,C_ .@+_P N<7_\O#ZQ5_G_  C_
M /*P_P"(D[_@M3_T>?\ ^:Z?LG__ #BZ/]6,C_Z O_+G%_\ R\/K%7^?\(__
M "L/^(D[_@M3_P!'G_\ FNG[)_\ \XNC_5C(_P#H"_\ +G%__+P^L5?Y_P (
M_P#RL/\ B)._X+4_]'G_ /FNG[)__P XNC_5C(_^@+_RYQ?_ ,O#ZQ5_G_"/
M_P K#_B)._X+4_\ 1Y__ )KI^R?_ /.+H_U8R/\ Z O_ "YQ?_R\/K%7^?\
M"/\ \K#_ (B3O^"U/_1Y_P#YKI^R?_\ .+H_U8R/_H"_\N<7_P#+P^L5?Y_P
MC_\ *P_XB3O^"U/_ $>?_P":Z?LG_P#SBZ/]6,C_ .@+_P N<7_\O#ZQ5_G_
M  C_ /*P_P"(D[_@M3_T>?\ ^:Z?LG__ #BZ/]6,C_Z O_+G%_\ R\/K%7^?
M\(__ "L_L _X-H_^"@W[7G_!0+X,_M/>+/VNOBY_PMK7_AW\3O!'A[P=?_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M6OU7A7_D34/^ON(_].R/.Q/\5^D?R/YRZ^C, H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_7,
M_P""%G_*([]A/_LB\/\ ZE'B.OR#B'_D<X__ *^Q_P#34#TZ/\*'I^K/PS_X
M/)?^3=_V+/\ LM'Q)_\ 4'TFO>X*_CX__KU0_P#2ZACB]H>K_0_S_P"OT$X@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#_0 _X,VO^3=_VT_^RT?#;_U!]6K\^XU_CX#_ *]5
M_P#TNF=N$VGZK]3^@G_@L9_RBO\ V_?^S6OBW_ZC%[7SF2?\C;+_ /L*I?\
MI1O5_AS_ ,+/\?:OV0\L* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H _?S_ (-C/^4Q_P"SG_V)
M_P ??_5'>/:^?XH_Y$F+_P 6'_\ 4FD;X;^*O27Y'^II7Y.>B?XNG[<O_)Z_
M[87_ &=+^T%_ZMGQ;7[=@?\ <L'_ -@N'_\ 34#R9_'+_%+\SY:KJ)"@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * /]S"OP<]@* /_2_L2_X*?_
M /*-/_@H=_V8S^UK_P"J#\?UWY5_R-,M_P"P_!_^I%,BI_#J?X)?^DL_QM:_
M:3R@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H _O(_P"#,K_D0/V__P#L</V=/_3+
M\8Z^!XV^/+?\.*_/#G;A-I^J_4_I!_X+&?\ **_]OW_LUKXM_P#J,7M?,Y)_
MR-LO_P"PJE_Z4;U?X<_\+/\ 'VK]D/+"@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H _IQ_X-,/^4J&K?]FM?%W_ -2?X95\OQ=_R*?^
MYJC_ .DU#HPW\3_MUG^E_7Y>>@?X?_Q#_P"1_P#''_8X>)O_ $]7M?NT/@C_
M (8_D>0]WZLX^J$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0![1^S?\ \G$? 7_LM'PM_P#4XT*L
MJ_\  K?]>JG_ *0QK=>J/]LBOPP]<_S _P#@Z?\ ^4N/C_\ [(O\$?\ U%Y:
M_5>%?^1-0_Z^XC_T[(\[$_Q7Z1_(_G+KZ,P"@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /]<S_
M ((6?\HCOV$_^R+P_P#J4>(Z_(.(?^1SC_\ K['_ --0/3H_PH>GZL_#/_@\
ME_Y-W_8L_P"RT?$G_P!0?2:][@K^/C_^O5#_ -+J&.+VAZO]#_/_ *_03B"@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MA?\ 9TO[07_JV?%M?MV!_P!RP?\ V"X?_P!-0/)G\<O\4OS/EJNHD* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H _W,*_!SV H _]/^Q+_@I_\
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MVR__ +"J7_I1O5_AS_PL_P ?:OV0\L* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#^G'_@TP_Y2H:M_V:U\7?\ U)_AE7R_%W_(I_[F
MJ/\ Z34.C#?Q/^W6?Z7]?EYZ!_A__$/_ )'_ ,<?]CAXF_\ 3U>U^[0^"/\
MAC^1Y#W?JSCZH04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % 'M'[-_P#R<1\!?^RT?"W_ -3C0JRK
M_P "M_UZJ?\ I#&MUZH_VR*_##US_,#_ .#I_P#Y2X^/_P#LB_P1_P#47EK]
M5X5_Y$U#_K[B/_3LCSL3_%?I'\C^<NOHS * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _US/\
M@A9_RB._83_[(O#_ .I1XCK\@XA_Y'./_P"OL?\ TU ].C_"AZ?JS\,_^#R7
M_DW?]BS_ ++1\2?_ %!])KWN"OX^/_Z]4/\ TNH8XO:'J_T/\_\ K]!.(* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H _T /^#-K_DW?]M/_LM'PV_]0?5J_/N-?X^ _P"O5?\
M]+IG;A-I^J_4_H)_X+&?\HK_ -OW_LUKXM_^HQ>U\YDG_(VR_P#["J7_ *4;
MU?X<_P#"S_'VK]D/+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /W\_P"#8S_E,?\ LY_]B?\
M'W_U1WCVOG^*/^1)B_\ %A__ %)I&^&_BKTE^1_J:5^3GHG^+I^W+_R>O^V%
M_P!G2_M!?^K9\6U^W8'_ '+!_P#8+A__ $U \F?QR_Q2_,^6JZB0H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#_<PK\'/8"@#_U/[$O^"G_P#R
MC3_X*'?]F,_M:_\ J@_']=^5?\C3+?\ L/P?_J13(J?PZG^"7_I+/\;6OVD\
MH* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /[R/\ @S*_Y$#]O_\ ['#]G3_TR_&.
MO@>-OCRW_#BOSPYVX3:?JOU/Z0?^"QG_ "BO_;]_[-:^+?\ ZC%[7S.2?\C;
M+_\ L*I?^E&]7^'/_"S_ !]J_9#RPH * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * /Z<?^#3#_E*AJW_9K7Q=_P#4G^&5?+\7?\BG_N:H
M_P#I-0Z,-_$_[=9_I?U^7GH'^'_\0_\ D?\ QQ_V.'B;_P!/5[7[M#X(_P"&
M/Y'D/=^K./JA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MK5(TU)MP:FX<U[*,>:UKQO<TEAE&$FI.\4WLK.RO:W-=>MY>FQ_#C7W)QA0
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M .ETSMPFT_5?J?T$_P#!8S_E%?\ M^_]FM?%O_U&+VOG,D_Y&V7_ /852_\
M2C>K_#G_ (6?X^U?LAY84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^_G_  ;&?\IC_P!G/_L3
M_C[_ .J.\>U\_P 4?\B3%_XL/_ZDTC?#?Q5Z2_(_U-*_)ST3_%T_;E_Y/7_;
M"_[.E_:"_P#5L^+:_;L#_N6#_P"P7#_^FH'DS^.7^*7YGRU742% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?[F%?@Y[ 4 ?_5_L2_X*?_ /*-
M/_@H=_V8S^UK_P"J#\?UWY5_R-,M_P"P_!_^I%,BI_#J?X)?^DL_QM:_:3R@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H _O(_P"#,K_D0/V__P#L</V=/_3+\8Z^
M!XV^/+?\.*_/#G;A-I^J_4_I!_X+&?\ **_]OW_LUKXM_P#J,7M?,Y)_R-LO
M_P"PJE_Z4;U?X<_\+/\ 'VK]D/+"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H _IQ_X-,/^4J&K?]FM?%W_ -2?X95\OQ=_R*?^YJC_
M .DU#HPW\3_MUG^E_7Y>>@?X?_Q#_P"1_P#''_8X>)O_ $]7M?NT/@C_ (8_
MD>0]WZLX^J$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0![1^S?\ \G$? 7_LM'PM_P#4XT*LJ_\
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MZ3]K4G"7,H0GHHT:JM::UO'7O;W=9UH4WRRO=J^D;Z;?S1[=ONO[W*_LF_\
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M 4 % !0 4 % !0 4 % !0 4 ?[!O_!'C_E%E^P#_ -FK?!__ -1*PK\;SO\
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M*34&^7"O1CRN<59K65EHUWMW\].K>UY?RU?\$6/^"FFG_P#!++]KZ?XX>*_
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MM%KHKNVMM6WZ:WC_ !TU]D<H4 % !0 4 % !0 4 % 'U[^P/^R]9_MI_MB?
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M[?O_ &:U\6__ %&+VOG,D_Y&V7_]A5+_ -*-ZO\ #G_A9_C[5^R'EA0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % '[^?\&QG_*8_P#9S_[$_P"/O_JCO'M?/\4?\B3%_P"+#_\
MJ32-\-_%7I+\C_4TK\G/1/\ %T_;E_Y/7_;"_P"SI?V@O_5L^+:_;L#_ +E@
M_P#L%P__ *:@>3/XY?XI?F?+5=1(4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!_N85^#GL!0!__];^Q+_@I_\ \HT_^"AW_9C/[6O_ *H/Q_7?
ME7_(TRW_ +#\'_ZD4R*G\.I_@E_Z2S_&UK]I/*"@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@#^\C_ (,RO^1 _;__ .QP_9T_],OQCKX'C;X\M_PXK\\.=N$VGZK]
M3^D'_@L9_P HK_V_?^S6OBW_ .HQ>U\SDG_(VR__ +"J7_I1O5_AS_PL_P ?
M:OV0\L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M8>=>#4KPJ1C3=2-I*Z<9I*TD]G=7NCF4?>47H^;E?EK9]MO3[C_3<_X)5_\
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M_9:/B3_Z@^DU[W!7\?'_ /7JA_Z74,<7M#U?Z'^?_7Z"<04 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % '[^?\&QG_ "F/_9S_ .Q/^/O_ *H[Q[7S_%'_
M "),7_BP_P#ZDTC?#?Q5Z2_(_P!32OR<]$_Q=/VY?^3U_P!L+_LZ7]H+_P!6
MSXMK]NP/^Y8/_L%P_P#Z:@>3/XY?XI?F?+5=1(4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!_N85^#GL!0!__7_L2_X*?_ /*-/_@H=_V8S^UK
M_P"J#\?UWY5_R-,M_P"P_!_^I%,BI_#J?X)?^DL_QM:_:3R@H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H _O(_P"#,K_D0/V__P#L</V=/_3+\8Z^!XV^/+?\.*_/
M#G;A-I^J_4_I!_X+&?\ **_]OW_LUKXM_P#J,7M?,Y)_R-LO_P"PJE_Z4;U?
MX<_\+/\ 'VK]D/+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _IQ_X-,/^4J&K?]FM?%W_ -2?X95\OQ=_R*?^YJC_ .DU#HPW\3_M
MUG^E_7Y>>@?X?_Q#_P"1_P#''_8X>)O_ $]7M?NT/@C_ (8_D>0]WZLX^J$%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0![1^S?\ \G$? 7_LM'PM_P#4XT*LJ_\  K?]>JG_ *0Q
MK=>J/]LBOPP]<_S _P#@Z?\ ^4N/C_\ [(O\$?\ U%Y:_5>%?^1-0_Z^XC_T
M[(\[$_Q7Z1_(_G+KZ,P"@ H * "@ H * "@ H * "@ H * "@#_1!_X,[/\
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MCCP^VJWOSR_3\[?^2OS3M>7]^?\ P0*_X*VZ[_P5"_9X\9V7QCM_#FF?M,_
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M_P!>J'_I=0QQ>T/5_H?Y_P#7Z"<04 % !0 4 % !0 4 % !0 4 % !0 4 %
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MS":]ZJ_J]"__ #[@U*K)=U.HHQUM9TGWO(Q4]5!=-7Z]/N7Y^1_%+7VYR!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_H ?\&;7_ ";O^VG_ -EH^&W_
M *@^K5^?<:_Q\!_UZK_^ETSMPFT_5?J?T$_\%C/^45_[?O\ V:U\6_\ U&+V
MOG,D_P"1ME__ &%4O_2C>K_#G_A9_C[5^R'EA0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '[^?
M\&QG_*8_]G/_ +$_X^_^J.\>U\_Q1_R),7_BP_\ ZDTC?#?Q5Z2_(_U-*_)S
MT3_%T_;E_P"3U_VPO^SI?V@O_5L^+:_;L#_N6#_[!</_ .FH'DS^.7^*7YGR
MU742% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#^G'_@TP_Y2H:M_V:U\7?\ U)_A
ME7R_%W_(I_[FJ/\ Z34.C#?Q/^W6?Z7]?EYZ!_A__$/_ )'_ ,<?]CAXF_\
M3U>U^[0^"/\ AC^1Y#W?JSCZH04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'M'[-_P#R<1\!?^RT
M?"W_ -3C0JRK_P "M_UZJ?\ I#&MUZH_VR*_##US_,#_ .#I_P#Y2X^/_P#L
MB_P1_P#47EK]5X5_Y$U#_K[B/_3LCSL3_%?I'\C^<NOHS * "@ H * "@ H
M* "@ H * "@ H * /]$'_@SL_P"3(OVH/^SJ7_\ 52?#NOSGC3_?<)_V"O\
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MLK#13_Q.K'E_!2-,5\$?\7Z/^MON/RZ_X,Z_^3U_VH_^S6E_]6SX KU>,_\
MD7X7_L,7_IFL9X7XY?X?U/T0_P"#R3_DW/\ 8N_[+7\1O_4%TZO.X*_CX_\
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M/^RT?$G_ -0?2:][@K^/C_\ KU0_]+J&.+VAZO\ 0_S_ .OT$X@H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!_N85^#GL!0!__T?[$O^"G_P#RC3_X
M*'?]F,_M:_\ J@_']=^5?\C3+?\ L/P?_J13(J?PZG^"7_I+/\;6OVD\H* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /[R/\ @S*_Y$#]O_\ ['#]G3_TR_&.O@>-
MOCRW_#BOSPYVX3:?JOU/Z0?^"QG_ "BO_;]_[-:^+?\ ZC%[7S.2?\C;+_\
ML*I?^E&]7^'/_"S_ !]J_9#RPH * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /Z<?^#3#_E*AJW_9K7Q=_P#4G^&5?+\7?\BG_N:H_P#I
M-0Z,-_$_[=9_I?U^7GH'^'_\0_\ D?\ QQ_V.'B;_P!/5[7[M#X(_P"&/Y'D
M/=^K./JA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 >T?LW_ /)Q'P%_[+1\+?\ U.-"K*O_  *W
M_7JI_P"D,:W7JC_;(K\,/7/\P/\ X.G_ /E+CX__ .R+_!'_ -1>6OU7A7_D
M34/^ON(_].R/.Q/\5^D?R/YRZ^C, H * "@ H * "@ H * "@ H * "@ H _
MT0?^#.S_ ),B_:@_[.I?_P!5)\.Z_.>-/]]PG_8*_P#T[,[L+\$O\7Z'Y._\
M'A__ "?E^S9_V:-I/_JY/BW7K\&?\B[$_P#8;/\ ],4#+%?Q%_@7_I4C^2"O
MKSF"@ H _P!L7]FO_DW/X _]D4^%?_J"Z#7X?B_]ZQ/_ &$5O_3DCUH?!'_#
M'\C_ !;?B/\ \E#\>?\ 8Y^*/_3Y?5^W0^"/^&/Y'E/=^K/US_X(%_MW^&/V
M _\ @HK\//'_ ,2=6BT+X-_%KP_K'P'^+>O7<K1V'A?PYXVU#1-4T+QA?DAH
MX=-\+^._#?A/4=>OF4R6'A4>(9H=S%H9_'X@R^68Y;5I4US5Z4HXBA%?:G34
MDX+NYTYSC%?SN+>QK0GR5$WM+W7Y7Z]-FN_W'^D[_P %$_V&_AC_ ,%*/V0_
M'W[-7CC5H-(M?&$&E>*/AS\1K"PMO$%QX \?Z&QOO"'CK1[7[99QZG;K'<7>
ME:O9VVIZ>^N^$==UW1H-4L1JGVV#\QRS,*N5XVGBH1<N7FA5I-N/M*<M)TV[
M:--*46TU&<(MQ=N4[YP52+B]GJFNCZ/S_"^UU>Y_G7_$[_@V<_X*^> _B#J'
M@SPS^SKHWQ;T%-5O+'0?B1X$^+WPBLO"'B&QM[@1P:O]G\<^./"'B?PY!<PO
M%.+;Q5X?T>Y7=+'&DQ@E>OTFEQ/DU2FIRQ3I2LG*G4HUN>+_ )?<ISC)JUOW
M<II]U<X7AZJ?PW\TU;\91:^:Z]/M?UV_\&_G_!$CQ)_P3.T#QS\<_P!HC4?#
M.L_M1?&'PSI?A0^'_#4B:OI7P7\ Q:@NN:KX0@\512?9/$GB/Q7J]KX?O/&%
M[I<#:%82^%=*TW0-3U>T%[JVJ?'<19[#-'3P^&4UA:,W-RG[KKU+<L9<F\80
MBY\G,TY<[<HIJ*CTT*/L[N33DU;3HNU[V=W:^BVTW][\F_\ @[E_X* ^#_%#
M?"7_ ()X_#G7K'6]8\$>++7XW?M 2:;<>:/#6OQ>&]2T7X7> ;R:!S&=3ET7
MQ9XB\9>(])G&ZQ@N/ 5WS-<.EOZ_!^73@JV958N*JP]AA[KXH<ZE5J+RYH1A
M!Z;5%JG<SQ51.U-='>7EV7GU;7335W:C\$?\&L7[?'A#]E;]LSQI^SW\4M>L
M_#?P]_;#T7PKX6T/7M4NEMM+TOXU^"=0U>3X:V-[<3'[/8VWC*R\6>+/"4,^
M4-UXGU#PA9S,(7,MOZ'%>7SQF!AB*47*K@I3J.*W=":7MK+6[BX0GM\$9VNV
MB,-449.+VGU[-;=M[V_SM8_L[_X+(_\ !+#PM_P55_9DL_A@GB+2?A_\9_AM
MK\_C;X(_$C5],FU+3M(URYL#I^O>$?$BV/\ Q-8O!7CJRCL+;7I]+6ZO-,U/
M1_#GB6/2]<?P^FAZE\3DF;2RG%.HXRJ4*T5"O3B[-I.\:D+^ZZE-M\JE92C.
M<;QYE./55IJI&VS6L7Y^?D_E;?6UC^!;4/\ @VO_ ."R-EXQE\(P_LHVFIP+
M.R0^,-/^-GP)'@ZZLEEDC&IQ:C?_ !(L=0@@=8FF6POM(M->$1CWZ.DDL<;_
M *"N)LE<.?ZY;^XZ.(Y[]N7V3N]=T^5?S,XOJ]6]N7YWC;_TI?ETZG]U_P#P
M1"_X)+V7_!*G]G3Q+X<\7>(= \=?M"?&?6](\5?&/QAX;M+J'0M-AT/3'LO"
MOPV\,WE^L&H:OX<\'2ZAXBU"/7+W3])N]9UGQ-K%T^F65DFG6EO\%GV<?VMB
M8.G&5/#4(RC1A.W-)R=YU9)74932A'EYI645K=L[:-+V46F[R;NVE;T2U=[:
MZV6^I_(?_P '47_!0'P?^U-^UUX%_9K^%.O6/B3X??L?:=XNT/Q1X@TJX\_3
MM7^-_C:]T=/'^DVUQ"[6NHVG@'3?"7AOPQ]J7+6?BE_&^G(6BA6:?['A3+IX
M3!5,36BXU<:X3C%JSC0@I>R;[.HYRGTO#V;:35CEQ-12DHK50O?_ !/?UMWT
MZ[WN>N_\&=?_ ">O^U'_ -FM+_ZMGP!6/&?_ "+\+_V&+_TS6'A?CE_A_4_1
M#_@\D_Y-S_8N_P"RU_$;_P!073J\[@K^/C_^O5#_ -+J%XO:'J_T/\_ROT$X
M@H * /NC_@FE^UU)^PG^W1^SC^U))!=WN@_#3QVB>.=/L07O-0^&_C#2M2\#
M_$6VLK?(2ZU-?!?B36[K1K>;]TVLVVGNS1%$E7AS/!K'X#$X2]G5IOD;V56#
M52DWY*I"/-WC==2Z<^2<9=GKZ/1_@_ZL?ZTWQ:^&_P !?^"@O[)/BSX=:IJ>
MD_$;X _M.?"GR=.\3^';FVO[/4?#GBO3K?5O"GC?PM?21S01ZMH5_P#V1XK\
M,WTD)?3==TO3KF2!9K5HE_(:-7$9;C855%T\1A*WO0E=>]!\LZ<[6?+./-"=
MMXR=F]STVHSBUO&2Z=NZW_6WF?YS?[2W_!L#_P %2?@Y\3=;\-?!WX6Z-^TY
M\,QJ9A\(_%'P/XZ^&W@^35M-G5IK)O$?@?X@>.=!\1>%=7AA'E:Q#'_;?ARS
MOD>&Q\4ZK;O;75Q^DX7BG*:]*,JM9X6K;WZ-2%27*^O+4ITY4YJ_PO2;6KIQ
M=T<$L-43=ES*^C5EIYIR37GJ_P C^@O_ (-_O^#?WXL?L3_%@_ME_MI0^%])
M^,FC^'_$7AGX0_!G1M5TCQE-\.;GQ'"-&USX@^)_&/A[4=0\+S>*;OPV^M>&
M]#T3PU?:]IMEH?B74M1U#61K$MOIVD?.\0\14<=1^I8%SE1E*,J]>47!5%%\
MT:<(22GR\ZC.4I*#O#E2<6V;T*#@^>=KV:2[7ZMJ5KVTM:6^]SK?^#KC_@H#
MX/\ A'^R1:_L*^%->L;[XQ_M+ZCX8USQUHMI<;[_ ,&?!#P;XEM?% U;4C ^
M_3[OQUXW\-:+X?T2UG 75O#^F^.2P6.VB%U'".73JXMYA.+5'#*<*4FM)UYP
M<&EW5.G.3EVE*G9NS47B:B4>1?%*U_*/Z7:M;6_E;WOXQ/\ @CG_ ,I4/V O
M^SI?A)_ZD]E7VV<?\BK,?^P/$?\ IN1R4OXD/\2/]*C_ (+H?\HD/V[?^R*7
M7_J2>'J_,N'O^1S@/^OLO_34SOK?PI^GZH_R,*_7SS H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /]<S_@A9_RB._83_[(O#_ZE'B.OR#B'_D<X_\
MZ^Q_]-0/3H_PH>GZL_#/_@\E_P"3=_V+/^RT?$G_ -0?2:][@K^/C_\ KU0_
M]+J&.+VAZO\ 0_S_ .OT$X@H * "@ H * "@ H * "@ H * "@ H * "@ H
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M]6A;=0DKUI6T=E2YH76TJD'KL98>'-43Z0][Y]/QUZ[?./\ 4)_P=<_ML_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?OY_P;&?\IC_V<_\ L3_C[_ZH
M[Q[7S_%'_(DQ?^+#_P#J32-\-_%7I+\C_4TK\G/1/\73]N7_ )/7_;"_[.E_
M:"_]6SXMK]NP/^Y8/_L%P_\ Z:@>3/XY?XI?F?+5=1(4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!_N85^#GL!0!__TO[$O^"G_P#RC3_X*'?]
MF,_M:_\ J@_']=^5?\C3+?\ L/P?_J13(J?PZG^"7_I+/\;6OVD\H* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /[R/\ @S*_Y$#]O_\ ['#]G3_TR_&.O@>-OCRW
M_#BOSPYVX3:?JOU/Z0?^"QG_ "BO_;]_[-:^+?\ ZC%[7S.2?\C;+_\ L*I?
M^E&]7^'/_"S_ !]J_9#RPH * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * /Z<?^#3#_E*AJW_9K7Q=_P#4G^&5?+\7?\BG_N:H_P#I-0Z,
M-_$_[=9_I?U^7GH'^'_\0_\ D?\ QQ_V.'B;_P!/5[7[M#X(_P"&/Y'D/=^K
M./JA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 >T?LW_ /)Q'P%_[+1\+?\ U.-"K*O_  *W_7JI
M_P"D,:W7JC_;(K\,/7/\P/\ X.G_ /E+CX__ .R+_!'_ -1>6OU7A7_D34/^
MON(_].R/.Q/\5^D?R/YRZ^C, H * "@ H * "@ H * "@ H * "@ H _H?\
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MB$S>6)#'&7"[BBYVK]NE9)=DE]QRO5M]W_7;\ON,>F(_H>_X)I_\'(/[9'[
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M +DU!=*;;;ETPQ,HI*2YDNM[2MZ\KO\ -7\W;WOV"/\ P>/?LL?V:91^Q_\
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ML/8\O(Y.]_;5>:_-VC;SO[M5:WM4ER\MF^M[W_[=C^?W?:_G_KZ P"@ H *
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MO)S7A*-N?ZS/E^*_PR[><>B>)YXN/):_7FO_ .V+\_N/Y&:^O.4* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#_ %S/^"%G_*([]A/_ +(O#_ZE'B.O
MR#B'_D<X_P#Z^Q_]-0/3H_PH>GZL_#/_ (/)?^3=_P!BS_LM'Q)_]0?2:][@
MK^/C_P#KU0_]+J&.+VAZO]#_ #_Z_03B"@ H * "@ H * "@ H * "@ H *
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MN27,DXZ7YC>6*;BTH6;5K\U[?+D7Y_>?QPU]F<@4 ?T/?\$T_P#@Y!_;(_8
M\'Z%\&?&6B:-^U-^S]X:@CLO"_@GQ_X@U/P]X]\"Z3 JI;:!X$^*5M8^()['
MPS:1CRK'P]XH\+^+]/T>VCMM/\-?V!IT)M7^=S3AO!9C.5>+EA<3+656E%2A
M4E_-5HOEYI/K*,Z<I/64I&].O."Y?BBMDW9KR3L_Q3\K?9_?73/^#R#]EZ72
MUFUC]COX]V&M&$,^GZ9XS^'FK:6MQM3,2ZO=2:+=O"&+@3G0T<JJ'[,"Y6+Y
MZ7!>)O[N.H.-]Y4IQ=O1.23^;_!F_P!:C_)+[T_QY5]UOFM>7\Y?VS_^#N7]
MI+XM^%M9\"_L@?!+0?V9(-7M[G3KCXI^*O$T?Q3^)\%E<1-&;OPGIW_".^'?
M!G@S5MKF,7>HV/CZ:V ^TZ9<6%^(+FU]/ \'X2C.-3&5Y8MQ=U2C#V-*ZZ3]
MZ<ZB\DX)[24DK&<\5)JT8J/G>[^7NI+YI^6Q_(_XB\1^(/&&OZUXK\6:[K'B
M?Q1XDU6_USQ%XC\0ZE>:SKNO:UJES+>ZGJ^LZOJ,US?ZGJ>HWD\UW?7][<3W
M5W<RR3SRR2N[M]?&,81C&$5&,4HQC%)1C%*RC%*R225DDK):*UCE*FEZIJ6B
M:GIVM:-J%[I.L:1?6FJ:5JFG7,UEJ&FZE87$=W8ZA87EL\=Q:7MG=0Q7%K<P
M21S03QQRQ.KHK*-)III--6:>J:>Z:ZIH#^UO]DG_ (/!O$?A7P!X;\'_ +9'
M[,=]\2O&.B6L=AJGQ@^#OB[2?#=WXK@M8(H+;4=8^&7B+2O[)M?$=SY3W&MZ
MAHOC;3M$O[N=Y-,\,:#;HMDWQ.,X-IU*DZF"Q7L82=U0JTW-0;O=1JQE&7(M
MHQE3<DMYO3F[(XK1*<;ONGOYVY4K_/TMHCYR_P""N/\ P<I?#;_@H-^Q_P#$
M3]D3X6?LN^./!&G?$S5? M]JOQ&\?_$#0&O=%MO ?C[PSX]MK?3_  9X<T/4
MX-1GU>Z\-PZ?/<7'BZR33H)Y)H[;4)"J1=.3\,SRW&4\94Q<*DJ<:D52ITFD
M_:0E"[J2G?12O;DU[HFKB%.+@HO6VK?9I[*/E_-Y^1^=_P#P20_X+L?M#?\
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M]3CK3YZC?1>ZO1?YN_R]#\9:]DR"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _T /^#-K_ )-W_;3_ .RT?#;_ -0?5J_/N-?X^ _Z]5__ $NF=N$V
MGZK]3^@G_@L9_P HK_V_?^S6OBW_ .HQ>U\YDG_(VR__ +"J7_I1O5_AS_PL
M_P ?:OV0\L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _?S_@V,_Y3'_LY_P#8G_'W_P!4=X]K
MY_BC_D28O_%A_P#U)I&^&_BKTE^1_J:5^3GHG^+I^W+_ ,GK_MA?]G2_M!?^
MK9\6U^W8'_<L'_V"X?\ ]-0/)G\<O\4OS/EJNHD* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H _W,*_!SV H __T_[$O^"G_P#RC3_X*'?]F,_M
M:_\ J@_']=^5?\C3+?\ L/P?_J13(J?PZG^"7_I+/\;6OVD\H* "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /[R/\ @S*_Y$#]O_\ ['#]G3_TR_&.O@>-OCRW_#BO
MSPYVX3:?JOU/Z0?^"QG_ "BO_;]_[-:^+?\ ZC%[7S.2?\C;+_\ L*I?^E&]
M7^'/_"S_ !]J_9#RPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /Z<?^#3#_E*AJW_9K7Q=_P#4G^&5?+\7?\BG_N:H_P#I-0Z,-_$_
M[=9_I?U^7GH'^'_\0_\ D?\ QQ_V.'B;_P!/5[7[M#X(_P"&/Y'D/=^K./JA
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 >T?LW_ /)Q'P%_[+1\+?\ U.-"K*O_  *W_7JI_P"D
M,:W7JC_;(K\,/7/\P/\ X.G_ /E+CX__ .R+_!'_ -1>6OU7A7_D34/^ON(_
M].R/.Q/\5^D?R/YRZ^C, H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_7,_P""%G_*([]A/_LB
M\/\ ZE'B.OR#B'_D<X__ *^Q_P#34#TZ/\*'I^K/PS_X/)?^3=_V+/\ LM'Q
M)_\ 4'TFO>X*_CX__KU0_P#2ZACB]H>K_0_S_P"OT$X@H * "@ H * "@ H
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MW)-?6',)0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^@!_P9M?\
M)N_[:?\ V6CX;?\ J#ZM7Y]QK_'P'_7JO_Z73.W";3]5^I_03_P6,_Y17_M^
M_P#9K7Q;_P#48O:^<R3_ )&V7_\ 852_]*-ZO\.?^%G^/M7[(>6% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 ?OY_P;&?\IC_V<_\ L3_C[_ZH[Q[7S_%'_(DQ?^+#_P#J32-\
M-_%7I+\C_4TK\G/1/\73]N7_ )/7_;"_[.E_:"_]6SXMK]NP/^Y8/_L%P_\
MZ:@>3/XY?XI?F?+5=1(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0!_N85^#GL!0!__U/[$O^"G_P#RC3_X*'?]F,_M:_\ J@_']=^5?\C3+?\
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M\$?;^!K:?]ASX;I&_5K+Q-\4M-G';Y;K3_'MO=)U_@F7UZ@4?ZQYU_T'3_\
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M02% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']Y'_!F5_R('[?_P#V
M.'[.G_IE^,=? \;?'EO^'%?GASMPFT_5?J?T@_\ !8S_ )17_M^_]FM?%O\
M]1B]KYG)/^1ME_\ V%4O_2C>K_#G_A9_C[5^R'EA0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P#J+RU^J\*_\B:A_P!?<1_Z=D>=B?XK](_D?SEU]&8!0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % '^N9_P0L_Y1'?L)_]D7A_]2CQ'7Y!Q#_R.<?_ -?8_P#IJ!Z='^%#T_5G
MX9_\'DO_ ";O^Q9_V6CXD_\ J#Z37O<%?Q\?_P!>J'_I=0QQ>T/5_H?Y_P#7
MZ"<04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!_H ?\&;7_)N_[:?_ &6CX;?^H/JU?GW&O\?
M?]>J_P#Z73.W";3]5^I_03_P6,_Y17_M^_\ 9K7Q;_\ 48O:^<R3_D;9?_V%
M4O\ THWJ_P .?^%G^/M7[(>6% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?OY_P;&?\IC_ -G/
M_L3_ (^_^J.\>U\_Q1_R),7_ (L/_P"I-(WPW\5>DOR/]32OR<]$_P 73]N7
M_D]?]L+_ +.E_:"_]6SXMK]NP/\ N6#_ .P7#_\ IJ!Y,_CE_BE^9\M5U$A0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M7#VDOAA5C4HN3O9*+JPA"4GI:,9.3Z)[%2H58J[C=>5G\[+I\E_\E^6_P_\
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MBVM;:F<H2@[233_/TM=?B_.U[1^9JZ20H * "@ H * "@ H * "@ H * "@
MH * "@ H * /[R/^#,K_ )$#]O\ _P"QP_9T_P#3+\8Z^!XV^/+?\.*_/#G;
MA-I^J_4_I!_X+&?\HK_V_?\ LUKXM_\ J,7M?,Y)_P C;+_^PJE_Z4;U?X<_
M\+/\?:OV0\L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_= _X@U/@E_T?'\4_P#PSOA/_P";.C_76I_T+H?^%4O_ )0'U2/\[_\  /\
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MZOM\/0K<O+[:C3J\M[\OM(1GRWTO:]KVU\CD:LVNS:^X\;K804 % !0 4 %
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M._83_P"R+P_^I1XCK\@XA_Y'./\ ^OL?_34#TZ/\*'I^K/PS_P"#R7_DW?\
M8L_[+1\2?_4'TFO>X*_CX_\ Z]4/_2ZACB]H>K_0_P _^OT$X@H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#^NKPU_P: ?M=^)?#F@>(X/VJOV<+
M:'7]$TK6X;:72OB:\MO%JMA!?1P2.GAH(TD27 C=E&UF4E< U\C/C# 0G*#P
MV,;C*46TJ%FXNVEZZ?3JON.I867\T?\ R8V_^(.;]L#_ *.Q_9L_\%'Q0_\
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M*=:$:E*<*E.:O&=.2G"2[QE%M->CZ=-3!IIV:::Z/1_B<95B"@ H * "@ H
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M3A*HXS3E).+A"5FE&2DE?FYO<VK4(P@Y1OI:]W??3LM;OTWVT4?XMZ^U.0*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_
M $ /^#-K_DW?]M/_ ++1\-O_ %!]6K\^XU_CX#_KU7_]+IG;A-I^J_4_H)_X
M+&?\HK_V_?\ LUKXM_\ J,7M?.9)_P C;+_^PJE_Z4;U?X<_\+/\?:OV0\L*
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H _?S_@V,_Y3'_LY_\ 8G_'W_U1WCVOG^*/^1)B_P#%
MA_\ U)I&^&_BKTE^1_J:5^3GHG^+I^W+_P GK_MA?]G2_M!?^K9\6U^W8'_<
ML'_V"X?_ --0/)G\<O\ %+\SY:KJ)"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /\ <PK\'/8"@#__UO[$O^"G_P#RC3_X*'?]F,_M:_\ J@_'
M]=^5?\C3+?\ L/P?_J13(J?PZG^"7_I+/\;6OVD\H* "@ H * "@ H * "@
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M[57Y:E6JX<_)>W-""IQC&>BD^=QO#EG/T,/3<(MRT<K:=DMK[:Z]O6Q^2_\
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M^ ?_  3,_P""&]K^U]_P4;U?PM8>"KOXQ>*[6]M['2M#T>[UO2+[6='MGA^
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M64G&M4@K0K5(1M&.B]V*^>KW1E6K5(5'&+5DET3W7G_7W(_)K_B*>_X*X_\
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M0JE.47%J3MUNM))[VBUIY/;S/XY*^R.4* "@ H * "@ H * "@ H * "@ H
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M[@K^/C_^O5#_ -+J&.+VAZO]#_/_ *_03B"@ H * "@ H * "@ H * "@ H
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M<FI*47RSIS7PU*<FI)2C=K5--.2DI1<HEPG*G+FCO^#79_T_+O'[\_X*._\
M!?7]MO\ X*6?"G3?@7\4=.^$WPL^$4.N:?XD\1>#_@UH'BK21X]UC1I3<Z"?
M&>K^,/&7C+4[[2M!O<:GINA:9-I&DR:O%9ZMJMKJNH:3H=QI7GY;P_@,KJNO
M1]M5K.+A&I7E"3IQ?Q>SC"G"*<EHY/FE:Z3492B74K3J+E=E&][*^OK?7Y6M
MUUT/Q$KW#$* "@ H _J9_P"#6;]C/]EW]KS]H;]I/_AIKX*^#?C7:?"OX;>!
M/$7@;1O'EO>ZOX;TK6-8\5ZG8:E=WOA<WT7AWQ&MS:6D$'V3Q-I>L6<2JQ@@
MB>65W^5XKQN*P>%P_P!5KSH.M6G"I*G92<5"Z2E;FCKK>$HOS=FH].&A&3ES
M).R5K_/^M;_+<^^/^#OGX;?#OX5_"+_@GCX0^&'@+P7\-_"6F^*_VD4T[POX
M"\+:'X/\.V"OHWP4#+9:)X>L=.TVU5A'&&$%J@(2,'.U0OG\'5JM:KF4ZU6I
M5FXX2\ZLY5).SQ.\I-M_?]Q6*27LTDE\>BT_E[?U]Y_#=7W1R!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Z '_!FU_P F[_MI_P#9:/AM
M_P"H/JU?GW&O\? ?]>J__I=,[<)M/U7ZG]!/_!8S_E%?^W[_ -FM?%O_ -1B
M]KYS)/\ D;9?_P!A5+_THWJ_PY_X6?X^U?LAY84 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^_
MG_!L9_RF/_9S_P"Q/^/O_JCO'M?/\4?\B3%_XL/_ .I-(WPW\5>DOR/]32OR
M<]$_Q=/VY?\ D]?]L+_LZ7]H+_U;/BVOV[ _[E@_^P7#_P#IJ!Y,_CE_BE^9
M\M5U$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^YA7X.>P%
M'__7_L2_X*?_ /*-/_@H=_V8S^UK_P"J#\?UWY5_R-,M_P"P_!_^I%,BI_#J
M?X)?^DL_QM:_:3R@H * "@ H * "@ H * "@ H * "@ H * "@#]C_\ @WY_
MY3$?L/\ _8^^-O\ U3_Q%KQN(?\ D38__KU'_P!.P-:/\6'K^C/]5SXL_%+X
M7_!7X=^)_B?\:/&OA3X=_#'PI:6USXM\9>-]4LM&\+:+9W^H6>D6CZOJ.HO'
M9V\=YJ>H6.G6ZS-_I%Y>6UM&'EF1*_):-&M7JPI4(3J59MJ$*:;G)I.3LEKI
M%-OLE?HSTFTDVVDEU>WZ?G]USX$NO^"R?_!)SPY8O,O[=W[,4-HC,[6^A>/=
M)U.8N0-SKIN@K>W<C$* 62V=CM ^;"A?1629Q-V^H8EOO*-OQE9+[_6U[QCV
MM)?;C_7HY?E+Y'Y&?MU_\'7'[%GP;\(ZYH'[%UIK/[4WQAN;*YMM \0:AX9\
M4>!/@CX8U0AX%O\ Q+J/BFT\,>./%B6$S)=Q:+X1T&'3=?ABEME\=:%YL-[7
ML8#A'&UIQECG'"44TY0C*-2O-;VCR<].G=:<TI3<7_RZE9HRGB8+2'O/OJH_
ME=^EH^NI_GQ?'[X]?%C]I_XQ>/\ X]?'#QAJ/COXI?$S7KCQ#XK\2:DRA[BY
MD2*VL[#3[2()::3H6B:;;V>B^'M#T^&WTO0M#L+#2-,M;:PL[>!/T3#T*6%H
MT\/0@J=*E%0A!=$NKZN4FW*4G=RDW)MMMG#*3DW*3NWO_6NVW^6Q_=G_ ,&;
M_P#R:]^V)_V7OP9_ZKR*O@N-?]YP/_7BK_Z<1V83:?JOU/FW_@\?_: \4KXA
M_8]_9:T_5Y+7P8VA^-?CSXKT.%F":SXC?4?^$ \":C?C<5<>']/M_B!!IJJB
M -XBU)I3*5M_(ZN"\-'V>,Q;5YN<,-&7\L8Q56HEI]IRIMZZ\BTTN+%2UC'I
M\37X+[M>O7J?P_5]R<9_M&?L._#[2OA3^QC^R;\-M%M(+'3?!'[.'P5\-PP6
MX78TFE_#GP[;W=R[C_7W-[>)<7MW=.6EN[NXFN9G>65W;\3S&HZN/QM23NYX
MK$2^3JRLE>^B5DO+32UCUH*T(KM%+\%Z?E]Q_DC_ /!1WXW>*?VC/V\OVN/C
M#XNU>_UG4/%GQ]^)<>ERZBS&?3?!_A[Q/J'ACP%X<B5U1HK'PMX)T;0/#FGP
M,H>*RTN!)"T@=W_8,NH1PV!PE""453P]).VSFX)U)>;G-RDWU<F>94ES3E+O
M)_)=%UV6G^6Q\5UV$'^O[_P1J^,/B;X\_P#!+K]B?XF>,]4OM<\4ZE\%-'\-
MZYK>IEI-2UB_^'>I:K\.9-5U&=P)+R^U >%%N[N_E+S:A<2RWTTLLL[R/^.9
MY1CA\VQU*"48JNYI+9>UC&K96NDDYNR6RTTM8]2D[TX-[V_+0_B1^*OP+\-7
MO_!UY#\-QIUO)H5_^WO\,?BWJ.GQ;)+:\U"^TCPE^T!KGVM")$ECU'79KZ?5
M;=P5E%Q=P2* S*OW=&O)<)^U;:DLMJTD^JY5/#PM:UFDDEVTWLV<C2^LVZ<Z
M?ZO\=S^ZK_@J7\;?$?[.G_!.K]LOXR^#=6N= \9^#?@!X_;P9K]DQ2^T'QAK
MVD2>%_"NN6+C.R]T?7]:T[4K1V!1+BVB9PR!A7P&44(XG,\%1FE*$\1!SBU=
M2A#]Y.+752C%IKL_,[*CY:<VM&HNS[-Z+MUMU^X_QQV9F8LQ+,Q+,S$EF8G)
M))R22<DDG)/)S7[.>4?M-_P;R>//$/@+_@L%^QS/H%S<1Q>*O$OCKP'X@LHY
MYXK;5?#WBSX6>-M.N[:_BA8"[@L;LV&OVL$X>!-5T;3KME#VL;IXO$5.-3)L
M<I?9A"HG9-J5.K"2MVO;E;6O*VNK-:#:JQMU=GZ/_+?Y']ZW_!QA_P H9/VU
MO^P-\%__ %H_X/5^?<-?\CO ^N(_]1:YW5OX4_3]4?Y?O[*G_)T/[-W_ &7O
MX/?^K#\.U^J8K_=L1_UXK?\ IN1YJW7JC_9L^,WQ A^$WP?^*WQ4N$AE@^&G
MPV\=?$">.YW_ &:2'P;X7U3Q'(EQL>-_)=--99=DD;["VUU.&7\4P]+V^(H4
M-O;5J5*ZZ>TG&'G_ #=OO/6D[)OLF_N5S_%*^(OQ \7?%CX@>-_BC\0-:N_$
MGCKXC>+?$7CGQEX@OFW7FM^*/%>KW>N:]JMR0 OG7^IWUU<NJ!44R;45455K
M]OITX4J<*5.*C3IPC3A%;1A!<L8K;1))+3[CR6VVV]6W=ONW]WY?<=)\#_@=
M\6/VDOBMX*^"'P.\#ZY\1OBE\0]8CT3PGX1\/P+-?:C=F*6ZN;B:::2&RTS2
M=*L+>ZU;7=<U2YL]'T'1K*^UC6+ZRTRQNKJ*:]>EAJ52O7J1ITJ<>:<Y.RBM
MO5MMI12NY2:BDVT@BG)I15V]E_7_  /5;G]H'[+W_!G3'=:!I>M_MD_M7WVF
M>(+M4EU/X>?LZ^'+&XM=(1D1Q /BC\0K2=-1OE+-%=1P?"^*QMIHF^R:AJL#
MI/7Q.+XS2DXX+"<T5M5Q,W&__<&G=VZJ]:[OJE8ZXX7;FEKU45_[<VO_ $G[
MM&?ISX6_X-IO^",?[-O]F>+OBQ>_$?Q);:1=V]_:ZU\=_P!H[_A!=.^UZ?-%
M<Q7#WWP\A^#EL'AE2.5A#-$JD#(4$!O,EQ/G>*O"A"E%O2V'PKJ2UTMRU'B+
MW].O2RYM/J]&.KO\Y6_)1M]_S5KR_?']IR"&Z_9L_:$MKF*.>WN/@?\ %B">
M"5!)%-#-X"U^.6*1&RKQR(S(Z,,,I(.0:^>P;:Q>%:T:Q-!I]G[6/I^?W&T_
MAE_A?Y'^-U^RI_R=#^S=_P!E[^#W_JP_#M?M&*_W;$?]>*W_ *;D>4MUZH_V
M0OVG_'VH_"G]FG]H?XHZ/(\6K_#;X&?%KQ]I4L04R1:CX.\ ^(/$-C)&&RI=
M+G3HF0,-I8#.1FOQ?!TXUL9A:,M8U<30IR7>,ZL8O\&>M)VC)K=)M?)?+\_N
M/\4N\O+O4+NZO[^ZN+Z^OKF>\O;V[FDN;N[N[F5IKFZNKB9GFGN+B9WEGFE=
MY)9':21F=B:_;TK:+1+1)=#R#^_/_@S9\6ZG>_L^_MK>!9IYVT?PY\8_AAXK
ML+9IG:VAU+QIX*UW2-6FA@+&.*:XMO >C)<2HJO,EO;)(S"! GY]QK!*O@*E
MO>E2KP;ZVISIRBODZDK:]7M<[<(])KLT_OO_ )'@O_!Y7\5=?;7?V&_@C;7]
M];>%H])^,?Q5UO2XYW73-9U^>\\%^$?"]_=VV[9+?>&M.M_%]OI\[+O@M_%F
MIQJV+AQ71P52CR8^O9.3G1I)VUC&*G.23W2FY1NNO(K[(6+?P1]7^27ZG\4'
M@_Q+J'@SQ;X6\8:3/<6NJ^%/$>B>)=,NK65X+JVU#0M3M=4LY[:>-DDAN(;B
MUCDAEC='CD575E90:^WE%3C*+U4HN+3ZIJS[]'V^\Y%HT]K/?M^7Y_<?[</C
MJ&&\\#>,;>=!+;W7A/Q##-&WW9(9]'O$D1ASPZ,5/'0]Z_#:/\6ET_>0U[>\
MCUGL_1_UT_/[C_#[K]T/("@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M _O(_P"#,K_D0/V__P#L</V=/_3+\8Z^!XV^/+?\.*_/#G;A-I^J_4_I!_X+
M&?\ **_]OW_LUKXM_P#J,7M?,Y)_R-LO_P"PJE_Z4;U?X<_\+/\ 'VK]D/+"
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M/_J+RU^J\*_\B:A_U]Q'_IV1YV)_BOTC^1_.77T9@% !0 4 % !0 4 % !0
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MY-V48J[E)I)-M(<4Y-16[=E_7]>9_HS?\$^O^#7S]AW]FSP=H'B']J[0+/\
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M8VO>)+EUC1I=E[XEFP?,F"JS.[?%/,\[QU1\N+QU6;_Y=X:52*_\%8=0BO\
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M_P#'_6[&UU>[^%%UJUVWP5^%+W*07-OH%QI^D363?$SQ7IZ&6U\2:GKM_?\
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M_CX__KU0_P#2ZACB]H>K_0_S_P"OT$X@H * "@ H * "@ H * "@ H * "@
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MN)_P3CB_:X\*_M,^ OA?X)UKX ^)OAYXKT_QI^SEK]WJ7B[X5WOB/7X]#O\
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MM4<)4/9^VCRV4E5Y^7O>T;Z]MCBQ,81Y.1)7YKV_[=M^;/Y3J^K.8* "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P!S"OP<
M]@* /__0_L2_X*?_ /*-/_@H=_V8S^UK_P"J#\?UWY5_R-,M_P"P_!_^I%,B
MI_#J?X)?^DL_QM:_:3R@H * "@ H * "@ H * "@ H * "@ H * "@#]C_\
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MCRW_  XK\\.=N$VGZK]3^D'_ (+&?\HK_P!OW_LUKXM_^HQ>U\SDG_(VR_\
M["J7_I1O5_AS_P +/\?:OV0\L* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#^G'_@TP_P"4J&K?]FM?%W_U)_AE7R_%W_(I_P"YJC_Z
M34.C#?Q/^W6?Z7]?EYZ!_A__ !#_ .1_\<?]CAXF_P#3U>U^[0^"/^&/Y'D/
M=^K./JA!0 4 ?ZD__!L#_P H=_@+_P!C[\>O_5P>+:_*N*O^1S7_ .O6'_\
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M<'9M1Y'9-^?W'1'#.45+G2ND[<M__;U^7WGT)_Q!G_%/_H_+X?\ _AAO$?\
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M*SPR?.C5\Y6I3H5:M&HDIT:DZ4TG=*=.3C))]5=.SZFR::36S2:]'J?XX/\
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M5]_O/)>[]7Y_CI?[ON/]F3]FO_DW/X _]D4^%?\ Z@N@U^*8O_>L3_V$5O\
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MY$U#_K[B/_3LCSL3_%?I'\C^<NOHS * "@ H * "@ H * "@ H * "@ H *
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MO9XBFND6^:G5??WE['K;W>EV3BHKW9==8OSZK[M>G7K8]P_X,W_^37OVQ/\
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M\5?@O^RAXH^,_A[X0:0K67P1^ EGX0\%V?A?PG:P7U]J7B&73@D"Z-X%\.)
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M'_U-M;KXWC3_ '7!?]A$_P#TV=>$WGZ+]3Z1_P"#S7_D1/\ @G]_V-O[1_\
MZ9_@Q7+P3\>9?X<+^>('B_\ EW_V_P#^VG\'5??'&% !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M7F<<3AW++\=&,:]%N3PM=1252+;;=.R26K;T2U9<JD'&2YX7<6OCCV/\G_\
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M8O:^9R3_ )&V7_\ 852_]*-ZO\.?^%G^/M7[(>6% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M,?R/\=_]I3_DXSX_?]EK^*G_ *G6O5^ST/X%'_KU3_\ 2$>4]WZL_3?X+_\
M!P3_ ,%6?V?_ (3?#KX(?"S]HC0] ^&_PI\(:'X$\#:'<_!+X'ZU/I'A?PY8
MQ:;HVG2ZOK7P^O\ 5]2:TLH(H/MNI7MW?7&SS+FXFF9W;RJ_#V48BM4KUL*Y
M5:LY5*DO;XE<TY.\G:-915WTBDNR5DC15JD4HJ6BT6D?_D'^?W'IO_$33_P6
M6_Z.?\.?^(_?L^?_ #LZR_U8R/\ Z W_ .%&+_\ EX_K%7^?\(__ "L_+_\
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M %3?@ROQ3,O^1CC_ /L-Q7_I^H>K3_AT_P#!'_TE'^2%_P % O\ D_/]MO\
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M'^P%^WQ_R8K^VG_V:9^T;_ZI[QC7XWEO_(QP'_8;A?\ T_3/5G\$O\,OR/\
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ME:W_ *53.G$_P_\ MY'^8M7Z@>>% !0![1^S?_R<1\!?^RT?"W_U.-"K*O\
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MN#:6[4'!7W2<UMS>].+6L)=+-?K_ )]?N/XDJ^X.0_LW_P"#-_X9^([SX_\
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M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^WG\*O^27_#?_ +$+P?\
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M_$;=[KP7JZ6_.!)'<]-U>1QK!JME]3I*G7@O6$J3?X37K\C3"/W9KLT_O7_
M/U4_X+-_\%J?$?\ P2,U_P" UG_PR@OQ\\,?'/1_'ES9^*F^-4OPP30M>\ W
MOAF+4_#\FGK\(_B''?--I_BO2-1@O&U*P>0/<P)8LMH]P_D9)D<,XAB)?7'A
MY4)4TX>P]K>-12<97]O2:UA)6Y7M>^MC6K6]ER^[=2OKS6V_[=EW7W];>[^(
M_P#Q&@7?_2."W_\ $NY/_H8Z]S_4F/\ T,W_ .$7_P!]F/UO^Y_Y/_\ <P_X
MC0+O_I'!;_\ B7<G_P!#'1_J3'_H9O\ \(O_ +[#ZW_<_P#)_P#[F?#G_! ?
M]H?3_P!H?_@X)^(GQ_U/PW;>"K[]ID_M=_$C1_!YUK^WO^$8U3X@7.J?$R;P
M[:ZX^G:&VO2Z/H\6K6+:F-%TQM0M[:XOSI=BK-!;^AQ!AWA^'88=2<UA8X*D
MY\O+SJER4N9QO+EYI6=N:5G97>C(HRYJ[D_M<[6NU]?*^FFWR7V?Z>_^#G;X
M=^)_'W_!(GXTWGAFWU&]/PZ\>?"'XB:_8Z;"]Q+/X8TSQM8Z%J]Q<PQ*\AT[
M14\1P^(=1F V65GI$M_<,EK:SNGRO"M6-/.*2E9>UI5J46^DG'G5MM6H.*[W
MLKWL=&(5Z3M?1IZ>OZ;G^6O7ZJ><?U1?\&B_PTUSQ3_P4@^)/Q%@LKW_ (1K
MX6?LP^-FU75X[69]-AU_QMXT\ :!X=T.ZO%0P6]]JVFQ>*]5T^"5UDNH/#.I
MO"K+:S%?E.,*L8973IW7-6Q5-)7UY80J3E)*Z;2:C%NSLYJ]KHZ<*KU&^T7]
M[T_*Y^^O_!W?_P HQ?AE_P!GF_"W_P!5'\?*^>X._P"1I6_[ :O_ *?PQOB?
MX?\ V\C^:_\ X-4?^4LWAO\ [()\:/\ T@T.OI^+/^1/4_Z_T/\ THYL-_%7
MI+\C^FK_ (.VO^46_A;_ +.S^$W_ *@OQ=KY?@[_ )&M3_L"J_\ IZ@=.)_A
M_P#;R/\ -Z\"^._&OPO\9>&OB'\.?%?B#P-X[\&ZQ9>(?"?C#PIJU[H7B/P[
MKFFS+/8ZKH^KZ=-;WMA>VTJAXI[>9''*DE&<5^E5(0JPE3J0C4ISBXSA-*49
M1>CC*+33371K7RLS@3:=TVFMFM&?V2?L*_\ !W?X]\(:9H?@3]O[X+2?%&TL
M8;.PD^.7P072?#_CZYA@012:AXM^&&LW6E^"O$>K73GS[O4/"OB+X>V$,<12
M#PQ=7$IDKXS'\'4JCE4R^O[%MM^PKWE2N^D*L4ZE.*[2A6?:45[IU0Q36E17
M_O+?YJR3^3C][/[ /@7^T)^Q-_P53_9KU7Q#\.=3\!?M'? ?QFEUX3\=^"_%
M_AI+LZ7JB0137WA+X@> O%=A'J&A:Y9I/;WEJNH:>BW$#V/B#P[?7VFW.F:I
M+\;7PV/RC%*-15,-B(>_3J4YZ2C_ #4ZD&E*+V:NNL)J,DXG5&4*D7:THO1I
M_DT_\OOLG+_-V_X+\?\ !-/P/_P35_;3@\(_!M[R+X#_ !K\%0_%?X7:#J%W
MJ&IWO@)7UK5/#_BCX>2:WJ<MQ?:Y:>']7TQ=2T/4;VXN-23PUX@T73M7O-2U
M6QO=6O\ ]+X?S.IFF!]I6M]8HU'1JR2251J,91J**TCS1E:224>>,G&,8M1C
MP5Z:ISLOA:NEV[J]W?5:=MKRM<_6W_@S9_Y.#_;6_P"R-_#'_P!3;6Z\CC3_
M '7!?]A$_P#TV:X3>?HOU/I+_@\U5O\ A _^"?[8.T>+OVC5+8.T,VC?!HJ"
M>@+!6(!.2%8C.#7+P3\>9?X<+^>('B_^7?\ V_\ ^VG\'-??'&% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_H ?\&;7_)N_P"VG_V6CX;?
M^H/JU?GW&O\ 'P'_ %ZK_P#I=,[<)M/U7ZG]!/\ P6,_Y17_ +?O_9K7Q;_]
M1B]KYS)/^1ME_P#V%4O_ $HWJ_PY_P"%G^/M7[(>6% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M ?OY_P &QG_*8_\ 9S_[$_X^_P#JCO'M?/\ %'_(DQ?^+#_^I-(WPW\5>DOR
M/]32OR<]$_Q=/VY?^3U_VPO^SI?V@O\ U;/BVOV[ _[E@_\ L%P__IJ!Y,_C
ME_BE^9\M5U$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M/[K#TG2A)IZUJMM(O9\E)2YUJU[2'\UXF*E:*CUD[_)?YO\ (_SK:_1SA"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#^\C_@S*_Y$#]O_ /['#]G3_P!,OQCKX'C;X\M_PXK\\.=N$VGZ
MK]3^D'_@L9_RBO\ V_?^S6OBW_ZC%[7S.2?\C;+_ /L*I?\ I1O5_AS_ ,+/
M\?:OV0\L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
M^G'_ (-,/^4J&K?]FM?%W_U)_AE7R_%W_(I_[FJ/_I-0Z,-_$_[=9_I?U^7G
MH'^'_P#$/_D?_''_ &.'B;_T]7M?NT/@C_AC^1Y#W?JSCZH04 % '^I/_P &
MP/\ RAW^ O\ V/OQZ_\ 5P>+:_*N*O\ D<U_^O6'_P#343T<-_"7K+\S^-?_
M (.=O^4QO[1'_8F? /\ ]4EX&K[7A?\ Y$F$_P 6(_\ 4FJ<N)_BOTC^1^ %
M?0& 4 ?Z[_\ P1"_Y1,_L'?]D$\/_P#I?JE?CV??\CC'_P#7]_\ I,3TZ/\
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M_4_-C_@\2_Y/A_9A_P"S4X/_ %;OQ)KU.#/^1=B?^PV?_IB@9XK^(O\  O\
MTJ1_(G7UYS'^T7^PU_R91^Q[_P!FM?L^_P#JIO"5?B>8_P#(PQW_ &&8G_T]
M4/6A\$?\,?R/\=_]I3_DXSX_?]EK^*G_ *G6O5^ST/X%'_KU3_\ 2$>4]WZL
M\4K404 % ']K?_!F=_R5#]O7_L0O@'_ZD/Q1KXCC7^!@/^OM?_TBF=>$WGZ+
M]3W#_@\T_P"2>?L!?]CG^T1_Z8_A!6'!/QYE_APOYX@K%[0]7^A_!I7WQQ!0
M!_L[_P#!/[_DPW]B7_LT;]F[_P!4WX,K\4S+_D8X_P#[#<5_Z?J'JT_X=/\
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M_P!.2/5A\$?\,?R/\73XH?\ )3/B)_V/7B[_ -/^H5^W0^"/^&/Y'DG[I_\
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M +S@?^O%7_TXCHPFT_5?J?FQ_P 'B7_)\/[,/_9J<'_JW?B37J<&?\B[$_\
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MG$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?[>?PJ_Y)?\ #?\
M[$+P?_ZCVG5^&5_X];_K[4_]+9ZZV7HC_$Y\??\ (]^-?^QM\1_^GB]K]QA\
M$?\ #'\CR#])O^".?_!1?7?^":?[:O@/XRW%SJ-Q\'/%IB^''[0?AFR$EQ_;
M'PNUZ^M3>:Y9Z>N1=>(_ .I0V?C/P\L0BN[V;2;SPXMY:Z?XBU+S?,SG+8YI
M@:E#15H_O,/-Z<M:*=DWK:,TW">FBES:N,32E4]G-2Z;2]/32]M]_N/]3/\
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M?'VO6NA/X5\&Z0OA32]1L-!\/^$M!N-3UB_D6R;7-;DU/Q+J-]!=>(?/L/\
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MX;?^H/JU?GW&O\? ?]>J_P#Z73.W";3]5^I_03_P6,_Y17_M^_\ 9K7Q;_\
M48O:^<R3_D;9?_V%4O\ THWJ_P .?^%G^/M7[(>6% !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M?OY_P;&?\IC_ -G/_L3_ (^_^J.\>U\_Q1_R),7_ (L/_P"I-(WPW\5>DOR/
M]32OR<]$_P 73]N7_D]?]L+_ +.E_:"_]6SXMK]NP/\ N6#_ .P7#_\ IJ!Y
M,_CE_BE^9\M5U$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^
MYA7X.>P% '__T_[$O^"G_P#RC3_X*'?]F,_M:_\ J@_']=^5?\C3+?\ L/P?
M_J13(J?PZG^"7_I+/\;6OVD\H* "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M*5.C3C?EITH1IPC=N3M"*45>3<G9:MMN[8FW)W;;?=N[_$X"M!!0!]=^!O\
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MI?%)R]6W;[_Z_ \;K81]O3?\%-/^"D5Q:RV,_P#P4%_;>GLI[=[2:SF_:O\
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MJE:_+[2G*,I1NW:$^:*;;23=Y><JLX-\K=KO3=?<]$_ZNK)2^POB;_P<Y?\
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M?_4'TFO>X*_CX_\ Z]4/_2ZACB]H>K_0_P _^OT$X@H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^_G_!L9_RF/_9S_P"Q
M/^/O_JCO'M?/\4?\B3%_XL/_ .I-(WPW\5>DOR/]32OR<]$_Q=/VY?\ D]?]
ML+_LZ7]H+_U;/BVOV[ _[E@_^P7#_P#IJ!Y,_CE_BE^9\M5U$A0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^YA7X.>P% '__4_L2_X*?_ /*-
M/_@H=_V8S^UK_P"J#\?UWY5_R-,M_P"P_!_^I%,BI_#J?X)?^DL_QM:_:3R@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H _O(_P"#,K_D0/V__P#L</V=/_3+\8Z^
M!XV^/+?\.*_/#G;A-I^J_4_I!_X+&?\ **_]OW_LUKXM_P#J,7M?,Y)_R-LO
M_P"PJE_Z4;U?X<_\+/\ 'VK]D/+"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H _IQ_X-,/^4J&K?]FM?%W_ -2?X95\OQ=_R*?^YJC_
M .DU#HPW\3_MUG^E_7Y>>@?X?_Q#_P"1_P#''_8X>)O_ $]7M?NT/@C_ (8_
MD>0]WZLX^J$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0![1^S?\ \G$? 7_LM'PM_P#4XT*LJ_\
M K?]>JG_ *0QK=>J/]LBOPP]<_S _P#@Z?\ ^4N/C_\ [(O\$?\ U%Y:_5>%
M?^1-0_Z^XC_T[(\[$_Q7Z1_(_G+KZ,P"@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_;
M%_9K_P"3<_@#_P!D4^%?_J"Z#7X?B_\ >L3_ -A%;_TY(]:'P1_PQ_(_Q;?B
M/_R4/QY_V.?BC_T^7U?MT/@C_AC^1Y3W?JSC*H04 % !0 4 % !0 4 % !0
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MJM1U)<VR6B7E^&KW_#6R9^8=>H9A0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!_H ?\&;7_)N_P"VG_V6CX;?^H/J
MU?GW&O\ 'P'_ %ZK_P#I=,[<)M/U7ZG]!/\ P6,_Y17_ +?O_9K7Q;_]1B]K
MYS)/^1ME_P#V%4O_ $HWJ_PY_P"%G^/M7[(>6% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?OY
M_P &QG_*8_\ 9S_[$_X^_P#JCO'M?/\ %'_(DQ?^+#_^I-(WPW\5>DOR/]32
MOR<]$_Q=/VY?^3U_VPO^SI?V@O\ U;/BVOV[ _[E@_\ L%P__IJ!Y,_CE_BE
M^9\M5U$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^YA7X.>P
M% '_U?[$O^"G_P#RC3_X*'?]F,_M:_\ J@_']=^5?\C3+?\ L/P?_J13(J?P
MZG^"7_I+/\;6OVD\H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /[R/\ @S*_Y$#]
MO_\ ['#]G3_TR_&.O@>-OCRW_#BOSPYVX3:?JOU/Z0?^"QG_ "BO_;]_[-:^
M+?\ ZC%[7S.2?\C;+_\ L*I?^E&]7^'/_"S_ !]J_9#RPH * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H 4 L0J@DD@  9))X  &223P !^>:
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M_P .?^%G^/M7[(>6% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO^SI?V@O_5L^+:_;L#_N6#_[!</_ .FH'DS^.7^*7YGRU742% !0 4 % !0
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M@ H _KI_X-Q/^"'_ (*_; M/$'[97[9/P_/BC]G&R&M>#/@M\-]:FU;2]/\
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M?_-M1_K'G7_0=/\ \%T/_E >QI?R+_R;_P"6!_PX2_X)!_\ 1C/PL_\ !O\
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MMK[K[:MZ::?=KHY?S)U].<X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M+\;QAB*]"E@70KUJ+E4KJ3I5)TW)*-*R?)*+=M;7_#3FZL*DW.Z3T6Z3_/\
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M !Q_V.'B;_T]7M?NT/@C_AC^1Y#W?JSCZH04 % !0 4 % !0 4 % !0 4 %
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MJ?Q'YZ?\$+_^4M_["7_9:[7_ -1OQ#7HY[_R*,P_[!Y?FC.E_$A_B1_H>_\
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M7H\CYH_"WMK[K[:MZ::?=KHY?S)U].<X4 % !0 4 % !0 4 % !0 4 % !0
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MHK?V!/\ LU[X5?\ J.VU?C>=_P#(VS#_ +"JO_I1ZE+^'#_"C_+S_P""JO\
MRDW_ ."A/_9Z?[3?_JY/&%?JN5?\BO+?^P#!_P#J/3/.J?Q*G^.7_I3/@:N\
M@* "@ H * "@ H * "@ H * "@ H * "@#_0 _X,VO\ DW?]M/\ [+1\-O\
MU!]6K\^XU_CX#_KU7_\ 2Z9VX3:?JOU/Z"?^"QG_ "BO_;]_[-:^+?\ ZC%[
M7SF2?\C;+_\ L*I?^E&]7^'/_"S_ !]J_9#RPH * "@ H * "@ H * "@ H
M* "@ H _1[_@DE^Q^_[<_P#P4(_9K_9^OM.;4?!&J>.;;QE\6%*M]F3X3_#N
M-_&7CNTNYU1UM/\ A(](TA_!^G7,BM&-;\1Z7$58S*C^=FV,^H9=BL3>TXTW
M&C_U^J>Y2TNK\LY*4E_+%O35QTI1YYQCTO=^BU?WI6_X<_U?_P#AC/\ 8_\
M^C4OV;/_  Q?PP_^9>OR3^T<?_T'8S_PIK__ "P]+DC_ "1^Z)_FH_\ !Q[^
MQ/I7[&__  4F\=7G@7PSI_A?X0?M&>'M(^.?P]TG0].M]-\/Z)J&KO/H/Q'\
M-:=:V,%MIUE]A\>Z)K/B"#2+&"&#2=!\5>'[:.)8C$S_ *;PWCI8[+*;J3<Z
MV'E+#U92;<I<OO4Y-MRDVZ4HIR>LIQD]=5'@KPY*CLK*6J_5??K\S\$*]\P"
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M/QIX=M/$7P<_9YL+GX^?%#3M7L8+_0M:_P"$5N[2R^'WA/4[2^BGTW4X-?\
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MROGHU:E&?UFBN>E.4)6:J77-!Q=G975^G3[6^'2=2S2?NO1Z]N_]?<?Z+?\
MPQG^Q_\ ]&I?LV?^&+^&'_S+U^;_ -HX_P#Z#L9_X4U__EAW\D?Y(_=$_P M
M'_@N)^Q9'^PO_P %(OCW\+]!T5-$^%_CK58_C?\ !FVMK46>EP?#GXGW-]JL
M>AZ-;KE8M)\#>+8/%GP\L5#.3!X221B#*!7ZKD>._M#+</6D[U81]A7N[OVM
M)*+E+?6I'EJO73G2U/.K0Y*DET?O1]'V]'=;+;971^2%>N9!0!_J1?\ !##_
M ();_!'X#_\ !-WX%R?'+X#?"KQS\8_C382?'SQWJ/Q&^&_A#Q=KNC?\+*M-
M/O?!GA.*[\2Z-J.I:3!X>^'=GX1M]3T#SHX+'Q9+XFN!;PW-]<AORS/\WQ-;
M,\1'#XFO2HX=_5H*C5JTXR=)OVDVH32DW5<TIVU@H+5*)Z-&FE3C=)M^\[I=
M=EKV5CAO^#BG]F;]F_X??\$?_P!JSQ?X"_9]^"/@CQ9I%[\ _P"R?%'A#X4>
M _#7B+2_M_[2/PCTN^_L[6]&T&SU*R^VZ9>WFG7?V:YB^TV-W=6DV^WGEC?3
MAO&8NMG&%IU<7B:L'&O>%2O5G!VP]5J\93<79I-::/56U"O&*I2:BD_=U27\
MR['^8M7Z>><% !0 4 % !0 4 >]_LJ?\G0_LW?\ 9>_@]_ZL/P[6&*_W;$?]
M>*W_ *;D-;KU1_L$_MW_ /)CW[97_9J?[0__ *J+QA7XWEO_ ",<!_V&X7_T
M_3/4J?PZG^"7_I+/\7NOVL\H* "@ H * "@ H ^__P#@GS_P31_:B_X*9?$3
MQ1\.?V9=(\&SW?@72-+U[QSXC\>>,++PGX;\*Z/K6H2Z9IM]>XAU/Q%JBW%W
M!.GV?PSX=UV\A6%GGMXD>(R^?F.9X7+*4:N*E-*<G&G&G!SE.25VEK&*TZSG
M%>>QI3IRJ-J-M-[Z?Y_A^%[GU?\ \%7O^"+'Q$_X).?#_P#9Q\2?$_XX>"_B
MGXM^/&J_$G2]1\-^ O"VN:?X=\&-\/K+P1=K-9>+O$-_:ZGXK76#XPDB9)_!
M7A4Z<-,C<&_^W.EER93G=+-ZF*C1H5*4,.J+4JLHN4_:^TT<(W4.7V?\\^;F
M^S;WG5I.ERW:?-?9;6MU;=[W[*WG<_%&O;,@H * /[%?^#1#X/?"3XM_$O\
M;@@^*WPM^'/Q-AT/P-\#I=$A^(7@CPSXTBT>74-?^)*7\FE1^(],U)-/DO4M
M+5;M[00M<K;6ZS%Q#&%^.XPQ%>A1P+H5ZU%RJUE)TJDZ;DE"%D^246[:VO\
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M]=^5?\C3+?\ L/P?_J13(J?PZG^"7_I+/\;6OVD\H* "@ H * "@ H * "@
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M6?>DSJ_Z_P D.14^2/(DHJ'*N5*/PI1VLK*RZ=-CS+N][N_?J=M_PTA^T/\
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M_D;9?_V%4O\ THWJ_P .?^%G^/M7[(>6% !0 4 % !0 4 % !0 4 % !0 4
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ME\5\99:I65#&RC=KF]G05_-1>(O9]FT^]C7ZK.V\;_\ ;W_ _+[C\(_V[O\
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MS#%XFCS>RK57*',N63C9*[5W:]N_K:YZ-.+C",7NDD[?U_E?LMC^+?\ ;_\
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M\%(_VJ/@9\,OVA_A5HOP8E^'7Q:\,V_BWPA+X@^*MMHVM2:/=SSP02:AI?\
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M'!%?L$)QJ0A4@^:%2,9PDMI1FE*+7JFF>8TTVGHT[-=FOO\ S^\Y*J$% !0
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M^PG_ -D7A_\ 4H\1U^0<0_\ (YQ__7V/_IJ!Z='^%#T_5GX9_P#!Y+_R;O\
ML6?]EH^)/_J#Z37O<%?Q\?\ ]>J'_I=0QQ>T/5_H?Y_]?H)Q!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?L?_P &_/\ RF(_8?\ ^Q]\;?\ JG_B+7C<0_\
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M_P"P#!_^H],\ZI_$J?XY?^E,^!J[R H * "@ H * "@ H * "@ H * "@ H
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MIPQ4JBE5BYPY*;GI%V=[2C;7^E9\VE.E*I=QMIW=OTE?[E\_LZ_QG_X(G_\
M!03X+?M5?"K]C&\^%FD?$+X^?&/P.?B/X/\ #GPO\4V'B328?!T.O:UX>O\
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M/@%^T%:Z/8W&HIX;^&/COQ%I?CW48+1/,GAL- ^(O@KP;HU[J)B5Y+73=/\
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M+/P#>WOP=\0?%_4/&,?CKQBOA%5M?&^F_#NWT1],D?3;]+YO-\+:FMXFZ%H
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M>#Z.SM*/-!M-*2:DI8SISINTEOLUL_3_ (.ODMY<W^P;^P%^T)_P4<^,>N?
MO]FNR\(WWCOP[\.]9^*&IQ^-/$T7A328_"F@^(?"OAB_EBU&6UO!-?#5O&6B
M1PV:0[Y(9;B;<J0/5X_,,-EM%8C%.2IRJ1I+D@YOGE&4DK)K2T):W^^X0A*H
M^6-KVOJ[:?<^_;[M3_3>_P""'7[%GQK_ & _V O!W[.O[0$'A:V^)&C_ !"^
M)GB>^@\'Z_\ \)+HT6F^*?$+7^DA=5%G8I+<M:J))XHXF6$NJ&0N'1?R[/\
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M\7*.NDFTS"<)4WRRWM?1WTV\NW;[CXOKM("@ H * "@ H * "@ H * "@ H
M_P!S"OP<]@* /__0_L2_X*?_ /*-/_@H=_V8S^UK_P"J#\?UWY5_R-,M_P"P
M_!_^I%,BI_#J?X)?^DL_QM:_:3R@H * "@ H * "@ H * "@ H * "@ H *
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M;$?]>*W_ *;D>:MUZH_V;_C%\-=)^,_PC^*?P>U^\O=/T+XK_#GQO\-=:O\
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M4U5J.F[7LW&:<K7Y(MRC@L4KZPM'NI7:^7(K_?Z7L?OM_P %6O\ @G?\'/\
M@JM^QCKOAVQL_#6L_%#3_!EY\1/V5?C!IK6$]SI7BN]T>#7/#]GI_B6-PEQ\
M//BA!;Z9HGBFV:>?2;K2KZQ\2P6[:WX?\/ZA9?/Y1F5;*,=%R<XT745+&4'?
M6*DXR;@_^7M%MRCK&5TX-\LI(VJ4U5AYVO%]O^ ^N_WI./\ &E_P1+_X+N_!
M7_@D_P#LT_%/]G/XQ? CXP^/?%?B7]H?Q3\4?[0\%77A&PL])MM0\ _#7P++
MH&IVGB75M,OXM7L=2\ W\]R$B>$17D$6X313(OVN>Y!6S?$T<11Q%&G&&'C2
MM-3;;52I/F3AI9J:^[S.6E65*+BTV^9O2W9+KZ?UH?Z-?@?Q79>._!?A#QQI
MMO=6FG>,O"_A_P 5V%I?"(7MM9>(=)M-7M;>\$$LT NH8+R..X$,TL0E5Q'*
MZ;7;\TJP=*I4IMING.<&ULW"3BVKZV;6ESO6NO?^O+\ON/Y)O&O_  =\_LB6
MDGBWPLG[*W[1\US:OKV@)<MJGPRB@EGA:ZTY9V4>)YI(XGD42%0)71#@;V K
M[&GP;BTX3^MX;1QE;EJ^MNOY?><OUJ/\LO\ R4_ST*_1#A/])K_@TH^/ES\2
M?^"<GC+X,ZI<S37_ .SC\>/%FAZ+ Q+0VW@;XEV.G?$?2EC8G*R2>-M5^([R
MPA=B)Y$@=FG=$_-.,,.J68TJZ5EB</%R?>I1?LY?=3]BNOZ1[\+*]-K^67X/
M7\[]_P ;1_D=_P"#B;X':=\#/^"N7[5%CHD20Z)\3]4\*?'&RB5=KC4?BIX2
MTCQ#XSEEPJHSW7Q!?Q==HR9S!<1>8S3"4U]APY7>(R?!RE\5.,J#]*,Y4X?=
M34%^1S5U:K+SL_O6OX_UHS\1Z]LQ"@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _O(_X,RO^1 _;_\ ^QP_9T_],OQCKX'C;X\M_P .*_/#G;A-I^J_
M4_I!_P""QG_**_\ ;]_[-:^+?_J,7M?,Y)_R-LO_ .PJE_Z4;U?X<_\ "S_'
MVK]D/+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MVCIQ5W*G.$8J4HI7]FX)R5^64I)0DJ>)YI*,TE?9INU^S5F]>]^O35G[4?\
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MZYKUJE6$VZK;O.*BN5Z.<FW(Y9XGE;C!*T=+O;331+IYWUZ*/VOW:_X(Q?\
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MK?\ 9K7Q=_\ 4G^&5?+\7?\ (I_[FJ/_ *34.C#?Q/\ MUG^E_7Y>>@?X?\
M\0_^1_\ ''_8X>)O_3U>U^[0^"/^&/Y'D/=^K./JA!0 4 % !0 4 % !0 4
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M>LOS/XTO^#G %O\ @LE^T>J@LS>$_@ %4#))/P*^'P  &223P !S[U]KPO\
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M)WE/#4>=]YJ"C)_.2;_X8X*JY:DU_>?W/7\CX"KO("@ H * "@ H * "@ H
M* "@ H * "@#_7,_X(6?\HCOV$_^R+P_^I1XCK\@XA_Y'./_ .OL?_34#TZ/
M\*'I^K/PS_X/)?\ DW?]BS_LM'Q)_P#4'TFO>X*_CX__ *]4/_2ZACB]H>K_
M $/\_P#K]!.(* "@ H * "@ H * "@ H * "@ H * "@#]C_ /@WY_Y3$?L/
M_P#8^^-O_5/_ !%KQN(?^1-C_P#KU'_T[ UH_P 6'K^C/] +_@X9_P"4-W[;
MG_8I?#/_ -7K\+:_/.&_^1W@?\5;_P!1JQVXC^#/_MW_ -*B?Y-U?KAYH4 ?
MWC_\&9OQ#UJ_\ _M[_"BYNI&\/>%O%_P!^(>BV7SF*#6O'VB_%3PWXGNAR8T
MDNK'X;>$8F^57D6S7EUBPGP/&M.*GE]5+WI1Q-.3ZN,'1E!?)U)OYG;A'I./
M9I_?=/\ )=?N-;_@\N\+VES\)?V%/&A@A^WZ)\1?C;X7CN=JBX%IXH\-?#_5
MIH WWS"TWA""1EP55U4_*7^9<%2_>9A"[LX8>5NGNRK*_K[P8M:0?FU^7^1V
MW_!F_P#\FO?MB?\ 9>_!G_JO(JSXU_WG _\ 7BK_ .G$&$VGZK]3\T?^#Q#_
M )/J_9G_ .S3+#_U</Q2KU.#/^1=B?\ L-G_ .F*!&*^./\ A_4](_X,V_\
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M^TCP9@E"TL7BG4M\451C"_?D<)RMY>T\K]3D>*E?2,;>;;?WI+\OO/S_ /\
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MB9YCF%>O%2D\17Y:,;>]R75.A"VOO<BA'3>6NE['JPCR0C'^5:OSW;^^[/\
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MI:_=SQS,H * "@ H * "@ H * "@ H * "@#]_/^#8S_ )3'_LY_]B?\??\
MU1WCVOG^*/\ D28O_%A__4FD;X;^*O27Y'^II7Y.>B?XNG[<O_)Z_P"V%_V=
M+^T%_P"K9\6U^W8'_<L'_P!@N'_]-0/)G\<O\4OS/EJNHD* "@ H * "@ H
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M]*9_"M_P<??\IHOVT_\ K]^ _P#ZS!\%:^^X;_Y$F!_PUO\ U)K''B/XT_\
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MA^]Y?:4JBCS*+E%04U-*3BU"-N5J7V7+>C6]K=-6DNVS7?RL^]^ZZJ/X0_\
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M[B_KMJX_QO5]F<H4 ?TZ_P#!I;_RE-UO_LU;XN?^I;\+:^7XN_Y%/_<U1_\
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M+_G[45J<7V<*3<EMI6^<NW"PLG-]=%IT6^OKV[>1L_$C]M+_ (:1_P"#K/\
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M*7#K7R7&=1QP&&IIV]IBU)KNJ=*I^%YIV?6SZ'3A5[\GVC^;_P"!_5S]??\
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ME_Z4;U?X<_\ "S_'VK]D/+"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _P!@W_@CQ_RBR_8!_P"S5O@__P"HE85^-YW_ ,C;,/\
ML*J_^E'J4OX</\*/F3XV_P#!Q!_P2S_9[^+OQ*^!WQ-^,OC;3/B+\)?&7B#P
M#XVTK3_@Q\3M8M-/\4>%]0GTK6K"UU6Q\.2Z?J,=K?V\]NE[9SRV=QY?FV\\
MD#)(_50X;S;$4:5>E1ING6A"I!NO23<)KFBVG=JZ:=GKZ6L2Z]*+:;=T[/26
MZ^[^N^Y\'_'?_@[D_P""?'@3P_J#? WX;?'OX]^,_LTK:+8W7A[1_A5X'ENE
MR(XM<\5^)=4U/Q1ID,APZRZ7\.?$#;-PD2%PH;T,/P=F%22^L5L/AZ?VG&4J
MU3_MV"C"#^=6/RO8B6*@OA4F_P#P%??[S_!?B^7^)?\ X*1_\%0?VF_^"GWQ
M<M/B/\>=9L=+\+>%%U&Q^%?P@\)BYM? 'PST;4I('O4TNWN99;S6?$FL_9+.
M3Q+XOUJ:XU?69;2UM8?[+T#3M%T'2_N,LRO"Y71=+#Q;E.SK5IZU*LE>SDTD
ME&-WR0C[L;MZR<Y2Y*E251WELMDME^MWY_>]%'_2D_X(-^%M,\(?\$B/V&=+
MTE+9+>]^$UYXIG^RJJH^I^-?&_BSQAK#R;?O7+:IKEW]J8Y8W ESTPOYGQ#)
MSSG'M]*D(KTA1IP7;I%?\'<[Z*M2AZ7^]W/\]+_@X#^(/B/XB_\ !7G]L^]\
M13:B1X7\=^'_ (?:#8W\LKQZ9X<\#> O"OA_38=-@D9H[33M2:SN?$*16ZQQ
M3W6M7>H.IN;VXD?]%X?IQI9/@5&WO4G4DUUE5G*;OM=KFY?+EMK9,X:[O5G?
MO;[E;\=_^'/QNKV3(_T\_P#@U:\<>(/%W_!)CPEH^MS7\]I\./CC\9/ _AEK
MZ629%\/RZAH_CD0Z>9&;980:WXVUN%(H]L<=PERJJ,5^7<6TXPS=RBDG5PU"
MI.W62YZ=WY\M.*]+'HX9_NEY2:_7]?ZNS^6__@[$T#2M'_X*KKJ.GBV%WXK_
M &:/@]K^NF!%65M5M]5\>>%X3>, #)<_V)X;T=4=BS"T6UC!"HJK]5PE)RRA
M)[0Q->,?1\D]/^WI2VM^-Y<V)_B?]NK^OZ_R/VW_ .#.'_DU7]K_ /[."\*?
M^JYL:\/C7_><#_UXJ_\ IQ&V%^"7^+]#\Q/^#P__ )/R_9L_[-&TG_U<GQ;K
MU.#/^1=B?^PV?_IB@98K^(O\"_\ 2I'XP_\ !%7POI?B_P#X*N_L%Z1K$=O+
M9V_[1/@OQ(B72AX3J/@R2Z\8:,0IR#,NL:%8-;9'%RL1YP:]S.IN&4YA*.[P
MM:/RG'D?W*3,J*O5A_B3^[4_UH/C7\(? GQ_^$/Q*^"'Q0LM0U+X<_%CP5XB
M\ >.-.TO7=8\,WVH>%O%&F7&DZW8PZYH%[IVK6 N]/N9[>9[:[C6:"26VN5F
MM)I[>7\@P]>IAJ]+$4FE5HSC4IN45)*47=/EDI)V?EINK-)Q].24DXO9JS/P
MZ_XAB?\ @C=_T1/QQ_X?[XL__-?7O?ZTYU_S]I_^$]/_ .5F/U:EV?WR/O7]
MA;_@EK^Q'_P3CU;XC:Y^REX)USP7J7Q5T[PWI7C.;7/B9XU\9PW]CX4N=8N]
M&C@LO$_B#4K&TD@GUS4&:Z@MUNBLOE+,D+S)+Y^/S;'YG&G'%RC-4G*4.6E"
M%G-).[48O:*TO;TLN:X4H4[\J>N^K?Y_U]R/Y@/^#SBPTQW_ ."=FMV[6S:D
MZ_M5:5=21-&\TUC"?V>+NR25E)?RK6>XOVA5B4#WDY7!+5]5P2Y6S*+O9/"-
M)]W]:3_"*_ Y\7_R[[^]_P"VGZS_ /!J[_RB0\"?]EK^-O\ ZDEM7C\6_P#(
MWE_V#T/R9IAOX?\ V\S^2W_@Z5\3ZMKW_!7CXHZ5J,YFL_!/PD^!WAC08R6(
MM=)N_ MIXRF@4$D*&USQ;K-SA<+NN"2"Q8U]APK",<FH22UJ5,1.7G)5IT[_
M /@,(KIMY7ES8AWJR\E%?@G^I^&'P%UJ]\-?'/X,>(M-?RM1T#XL?#K6M/DR
M1Y=[I7C#1[ZU?(Y&R>!&R.1CBO>K14J-6+VE3J1?HX-/M^?W&,=UZK\S_97_
M &L[>"[_ &5_VE[6YB2>VN?V?OC+;W$$JAHYH)OASXCCEBD4Y#))&S(ZD8*L
M0<YK\5P/^^X/_L*P_P#Z>@>K/X)?X9?D?XJ%?MQY)_KS?\$2O^43G[!G_9OO
MA7_T=?U^/9]_R.,?_P!?W_Z3$]2E_#A_A1_F6?\ !73_ )2B_P#!0+_L[GX[
M?^K"UVOU#*/^15EW_8%AO_3,3SJG\2I_CE_Z4SYG_94_Y.A_9N_[+W\'O_5A
M^':ZL5_NV(_Z\5O_ $W(E;KU1_L!?M\?\F*_MI_]FF?M&_\ JGO&-?C>6_\
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M^?\ 8E_L\_\ I\^+U?#\:_PLO_Z^8C_TFD=>$WGZ+]3Z0_X/*/\ D@_[$?\
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M3]=>W7^GN?YZ7_!P#\1-?^)'_!7C]L^_UVXU"1/"WCS0/AWH5G?22M'IF@>
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MX:BO6DN\[?>S_5Q^,GBN_P#A]\'?BKXXT:T>[U/P1\-/'/BO2K"WB$DES?\
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M5',% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']./\
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MY:_5>%?^1-0_Z^XC_P!.R/.Q/\5^D?R/YRZ^C, H * "@ H * "@ H * "@
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ML?G,]Q(6RQ9F_4.&FWDF!YKWM76O:.*KI?<DCS\1_%G_ -N_^DH_#>O=,0H
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MO_8!@_\ U'IGG5/XE3_'+_TIGP-7>0% !0 4 % !0 4 % !0 4 % !0 4 %
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M_,XTXXN49JDY2ARTH0LYI)W:C%[16E[>EES7"E"G?E3UWU;_ #_K[D?S ?\
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M +.E_:"_]6SXMK]NP/\ N6#_ .P7#_\ IJ!Y,_CE_BE^9\M5U$A0 4 % !0
M4 % !0 4 % !0!_L&_\ !'C_ )19?L _]FK?!_\ ]1*PK\;SO_D;9A_V%5?_
M $H]2E_#A_A1_F@Z)^U1XC_8F_X+#^,_VHO#1NY)OA'^V]\8-<U[3;&7R;CQ
M#X%O_BGXOT'XB^%4D)5$/BGP)JOB+P^))-R0OJ*SE6,85OU"6$ACLGCA)V2K
M8*C%-JZC-4H2ISMUY*BC/_MWS//YN2JY=IOYJ[NNNZTV^\_TW/V^/V<?!?\
MP4E_X)Y?&3X.>&=0TGQ%IOQV^#UIXP^"WBE)(QI<GC"&RT_XA_!CQ5;7TT8>
MWTF[\1V/AN:^GB-O+<^';[4;-Y4AO)EK\MR[$SRO,Z-:HG!X>NZ>(ANU!MTJ
M\6E:\HQ<K=.>,7K9H]&<54@U_,KI^>Z?7K]ZTTO<_E$_X-%?V&-1_P"%E_M(
M?MM?$3PW<V$WPQ:[_9I^&5MJ]DT5Q8^/=1%CKOQBU!8;@1SZ?K'A?P^OA/PH
MDJJV^V\;>*-.DV26\J5]=QCCTJ.&P%.2?MG]9J\KWI1O&BNSC.?//UI1?4Y<
M+#64WT]U>O7YV\OO/*/^#O']M$^//V@?@O\ L.>%=6\WP[\!_#R?%KXIV=M.
MWDS?%3XDZ<(_!NDZG;D[1?>$/AFRZWI\Z*N;/XKW43,[)MBUX.P/L\-6QTU[
MV)E[*BWTHT6U-IZZ3JWC*]M:,='N&*G=J"Z:OU>WKI^?J?TF_P#!MI_RA7_8
MO_W?VB/_ %JWXZ5\QQ-_R/,=_P!RW_J'AS?#_P &'_;W_I4C^%C_ (./O^4T
M7[:?_7[\!_\ UF#X*U]]PW_R),#_ (:W_J36./$?QI_]N_\ I,3T?_@C;_P0
M1^+7_!4:QU;XQ^,_&\OP+_9:\-Z[/X;_ .$Z@T6W\0^-/B3XGTPVDVM^&_A[
MH5W?Z?9V=AI%M<I#K/CO6S=:3IVJSPZ7I&B^*KZS\0VN@Y9UQ!1REQHPI_6,
M7./.J7-R0IP=U&=22C+5M:4U[TEJW33C*;I474U;M%.WFWV6W?=O3:SU/ZV=
M/_X-[/\ @A/^R1X;L=>_:#TBQU.TBRL/CK]J7]IS6? MC=36RQ&=Y8?#WBKX
M1>!+LJ'0SP2Z')!&)1F%,HU?(_ZQ<08V;CA4T^M/!X156D]OCA7FO6_R5VSI
M]C0AK+_R:;_^T7];[(^W_P!@*[_X(O>%_BYXH^%__!.)_P!CR?XSVGPYU/6O
M%UU^SQ'X8\6>+Y_ACIGB;PIIVJ_VO\4=#76;C5/#B>*]8\'FXTJ;Q?=PW>IO
MI=_]BG>Q2XM>#,5GDZ,:V9_7%0=6,8+$7IP]JX5'&U#W4I<D:EI>S5E=7UL7
M#V*=J?)S6^SJ[:==>MOM??N?BG_P>0 ?\,O_ +'1P,CX]>- #CD _#V0D ]0
M"5&1WP,]!7M\%?[SCO\ KQ2_].,QQ>T/5_DCX:_X,V_^3C/VT?\ LBGPY_\
M4ZU&N_C3_=<%_P!A$_\ TV1A?CE_A_4^GO\ @\T_Y)Y^P%_V.?[1'_IC^$%<
MO!/QYE_APOYX@O%[0]7^A^AO_!J)X6TS0/\ @E'9:Q8I;+>>-_VBOC%XEUEX
M54327]E%X3\&P?;&'S-,ND^%--6/<?EMO( P,5YW%\G+-DGM#"T8Q]'*I/\
M.;[_ ()1O#*U+UDW^GZ'\SW_  =F_$'Q'XI_X*@Z3X,U*;44\/?#']G'X8Z-
MX:L)Y9?[-+>)-5\7^,-:UG3[4MY"W&H7>LPZ5J%[&BS70\/6=K,[QZ=;K%]/
MPC3C#*>=6YJV)K3D^ON\M-)^BA=+7XK];1Y\2[U+=HI+SZW_ !M\O4_F(KZ@
MYS_0-_X,X/''B#4_V:OVQ_AW>37\GAKP?\;/ 'BS0HYI9'T^WU7QYX(O],\0
MQV,;,8X9F@\ Z#-?+$J[_-M9'W,V5_/>-:<5B,#527/.C5A)]7&G.,HW\DZL
MK?,[L*_=FO[R?WK_ (!\=_\ !Y9H&E6_QG_89\40BV_MO6/AA\9M U!E11=G
M2O#?BOP/J.CB>3&YK9;OQ5KIM4+%4E:\*A3(Y;LX*DWA\=#[,:U*2]90DI>6
MT(]/6^A&+WAZ/]/Z_P"'/LK_ (,W_P#DU[]L3_LO?@S_ -5Y%7%QK_O.!_Z\
M5?\ TXBL)M/U7ZGQQ_P>1?%S7KOXQ_L:_ :/5+R/PQH'PS\>?%R]T2.0QV%[
MKWB[Q3%X-TS5+N)0%NKS3-/\$ZO::=),7-A#JVIK;"(:E=&?NX+HQ6&QF(LN
M>=>%&_51IP4[+LFZMW:U[*][+EG%/6$>B3?WNWX6[]>ES^+.OM3D"@ H _IU
M_P"#2W_E*;K?_9JWQ<_]2WX6U\OQ=_R*?^YJC_Z34.C#?Q/^W6?MY_P>,?\
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M2[Q^_5?U_P ,SZU_X/+OAKJ4?B3]A3XP06;2:/=Z'\;?AKJNH(IVV>I:=?\
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MI-6YK6NM;+K\[_,^5/\ @\[_ .1>_P""=W_89_:F_P#2']GRNK@G?,O3!_\
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M (-7?^42'@3_ ++7\;?_ %)+:OS/BW_D;R_[!Z'Y,[\-_#_[>9_(9_P<]_\
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MX[_X16+Q+-YD5L]^/#UCJ)?2[Z^B?Y;A)89YG+V_)[54)/"J=K>UYX7<+_\
M+U4^;EMKRN;7PG1B>;V?NWMS+FMV_17M^!_G<_LI?LH_'+]M+XW>#/@#^S]X
M(U?QKXZ\8:G96LC6-C>3Z+X2T.:^M;/4_&OC75+6VN(/#?@SPZEVEWKFNWX2
MVMHMD$7GWUS9VD_Z/B\70P5">(Q-14Z<$W=M7D[74(*Z<JDK-1BKM]M&<,8N
M;48J[?X>;T=E\ONNC_9*^ OPITWX#_ SX,? [1KO[?H_P:^$_P .OA3I5_\
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M_P#UZP__ *:B>CAOX2]9?F?QH_\ !SC_ ,ID?VD?^Q2^ /\ ZHKX?U]KPO\
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M_!T__P I<?'_ /V1?X(_^HO+7ZKPK_R)J'_7W$?^G9'G8G^*_2/Y'\Y=?1F
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M'5W_ "EF\2?]D$^"_P#Z0:Y7VW"?_(GI_P#7^O\ ^E')B?XK](_D?C'^TO\
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MR^=]C_3O_;,\&^#_ (A?LB?M0^"?B EDW@KQ/^S]\7])\32ZA;07=K9:3<^
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MGCX&>,?'/A'P%HNMZ_XT^(,D%MX=^''AJQ\/:5<ZUJ-OJ7CSQ+<Z3X6_MO\
ML^UFELO#5KJESXBU+;BPTNY <IRXK'X/!N$<37A3G5E&-.G=RJ3<I**Y:<;S
MY>9I.7+R+[4EO&HPG/X4VEJWT7SNOU?D?'%=A 4 % '^N[_P1L_8&\(_\$]O
MV$_A#\+[/0]/M?BOXV\.Z+\3OC_XDB@']I^(?BEXLTJUU'4=,N[UR99])\!6
M=Q;>!_#D$8MK0:?HCZM]AAU76]7GNOQ[.\PGF.85JC;]C3E*CAX7TC2@[<R7
M\U5IU);OWN7F<8Q/4I05."5M7K)^;Z;O;9;;7MJS^.W_ (+O_M0?\%/?^"A/
MQP\8?!'X:_LF?MD^%OV,OA/XOU'0/!_A#2OV??C+;6_QBUSPOJES8O\ %OQV
MUOX,C?6(-3N[8WO@+P[?,VF^%]#&GWWV"+Q1>ZO?/]ID&$RO+</"M4Q>#GC:
MT%*I4>(HOV2DK^QI_O/=23M4E'6I+>\%!1Y*TZDVXJ,U!/:SU\WMUVT^X_GJ
M_P"& _V[O^C*?VMO_$</C%_\QE?1?7\!_P!!N$_\*:/_ ,L,.27\DOND>6_%
M#]G7]H+X(6FDZA\:?@5\9/A#8:_<W-GH5]\4/ACXV\ 6FM7=E%%->6NDW/BO
M0](AU&YM(9H9;F"S>:6"*6*25%216;6EB,/7NJ->C6<;.2I585.6^U^64K7L
M[7^5]>5.+6Z:]4U^?]?>CQNMA'^I+_P;#_"/5?A;_P $C?@[J^LP_9;KXR>/
M_BS\7+>T:-HYX=*U'Q7+X)T2:XR '_M31_ ECK5I(A97TW4K(Y5]Z5^5<55E
M5SBK%?\ +BE1HMWO=\GM7Z6=7E:[Q/1PZM27FV_QM^ES^ +_ (+%?$S2_B[_
M ,%1OVZ?&^B7JZEI$O[1/COPQIVH1LKP7MI\/;U/A]#=6DJLR36,Z^%Q)8SH
MQ2>S:"9,*ZBOT/)Z3HY7@*<DU)86E)IZ-.I'VC36MFG)IZ].IQ57>I-_WG^&
MA^:]>D9A0 4 % !0 4 % !0 4 % !0 4 % !0!_KF?\ !"S_ )1'?L)_]D7A
M_P#4H\1U^0<0_P#(YQ__ %]C_P"FH'IT?X4/3]6?AG_P>2_\F[_L6?\ 9:/B
M3_Z@^DU[W!7\?'_]>J'_ *74,<7M#U?Z'^?_ %^@G$% !0 4 % !0 4 % !0
M 4 % !0 4 % !0!^Q_\ P;\_\IB/V'_^Q]\;?^J?^(M>-Q#_ ,B;'_\ 7J/_
M *=@:T?XL/7]&?Z&'_!=WX?^//BG_P $F_VQ/ 7PQ\$^+OB-XZ\0>%OA[%H'
M@OP'X;UGQ?XLUN6Q^,_PWU2]CTCPYX?LM0UC4I+/3+&]U&Z2RLYVM["SNKN4
M);P32)^<\/U*=+.,%4JU(4J<95>:=2480C?#U8J\I-15VTE=ZMI*[9W5TW2D
MDFV^71*[^)=$?YCFD?\ !,__ (*-:]<BSTC]@?\ ;.O9R5#>7^S%\:EBA#G:
MKW%Q+X)2WM8R>/-N)HXQW(Q\WZB\SRV/Q9A@EZXJ@O\ W)J>?[*I_)/_ ,!:
M_%I_E]Q^V/\ P3Z_X-:_VU_V@_&/A_Q+^V%IC_LG_ FWO;:\U^QU+5-"U?XY
M>+M*4>=+I?A'PAI<^NZ=X/N+PQG3[K6OB+<:7=Z$9TU.T\'>*DB:P?Q,QXJP
M&&A*.#DL9B+-1Y5)4(2[U*CY>>*O?EH\W-;EYX?$;4\-.33G[L?OE\M?SY>_
M+HT?WS^*O%7[*O\ P3*_9!_M76)?#OP/_9D_9M\ V>EZ986RL4L]+TU%MM*T
M+1[5WDU/Q3XU\6:M,L%K"7O?$7C'Q9JTEU=SWFJZC<73_GL(8S-L;9<V(Q6)
MJ7DW^,I.UH4Z<5T2C"$;**2C$[6XTXZVC&*_I+6]WZM^I_DZ?\%(_P!N+QK_
M ,%$?VPOBU^U!XO@N=)L/%FJIHWPY\(7$R3_ /""?"OPYYFG^!?">^$FVDO[
M72Q_:7B.[M0EMJGBS5-?U>&*%-0$2?KN6X&GEV#HX2&OLXWJ3M;VE66M2?HY
M.T4[\L%&-W:YYE2;J2<GUV79=%]WI=ZV5VC^RK_@S?\ ^37OVQ/^R]^#/_5>
M15\5QK_O.!_Z\5?_ $XCJPFT_5?J?FC_ ,'B'_)]7[,__9IEA_ZN'XI5ZG!G
M_(NQ/_8;/_TQ0(Q7QQ_P_J>D?\&;?_)QG[:/_9%/AS_ZG6HUEQI_NN"_[")_
M^FPPOQR_P_J?3W_!YI_R3S]@+_L<_P!HC_TQ_""N7@GX\R_PX7\\07B]H>K_
M $/X-*^^.(_U(_\ @V1_:,\/?'+_ ()2?"+P5:ZC;S^,OV;_ !+X[^#/C?3@
MZI=6BCQ3J?CKP1>_92?-%A>>!?&&A6,%]@V]YJ>C:W##(9K*[@M_ROBK#2H9
MM5JM>YBH4ZT'T]V$:4U?1<RG3<FMTI1;O=,]'#RO22ZQ;3_-?@_G\C^9/_@Y
MP_X)=?&_X4?M>_$?]NCX>^!O$'C/]G+X\PZ)XL\;^(_"^A7FHV?P<^(>EZ%H
MOA;Q/8^/&T];MM(T/Q=>:;:^+M%\7:FMAI-WJOB+5/#;.E]I5O)JGU'"^:T*
M^"I8&I4C#%8>].$)R2=:E>4H.G>W,X1O"4(J3BH*>D9(Y\13DIN:3<9:NRV>
MSOOOO=V[6>Y_*9##-<316]O%)///(D,$$,;2S32R,$CBBB0,\DDCD(B(K,S$
M!020*^L.8^O_ (U?L"?M>?LX_ WX;?M$_'GX(^+/A'\,OB]XEN_"WP[N?'L=
MIX<\4^(;^RT;^WWO!X#U&ZA\:Z7HMQI9%SINLZUH6G:?JT9672Y[R%EE;CH8
M_!XFO5P^'KPK5:,5*JJ;<XP3?*DZBO3<KIIQ4G*.TE'[5N$HQ4FFDW97Z_*[
M?X*_2Y_;9_P:!_M/>&/%G[*/QW_9-OM2M8?B#\'_ (M77Q6TC2I)!%=:E\-/
MB?HV@Z8UY8P.V^\7P_XW\+ZS%K=Q #'8#Q5X9AN5B>^MWN/AN,L+..*PV,2?
MLZM'V$G;15*4I25WTYX3]U6UY)/6QUX65XRCU3OZI_Y->?3O:-+_ (.@O^"1
MGQG_ &J9_AY^V]^R_P""M>^)_P 0/AKX$;X8?&7X8>&(8]0\4:K\.M%U37_%
M?A/QSX.\/1"/4O$NK^'M2\1>(]%\3Z)HXU7Q%J6E:CX8N='TB2U\/:P[/A3.
M*&%53 8JI&E"I4]K0JS=H>TDHPG2G+:"DHQE!RY8W4TY<S@@Q-*4K3BKM*S7
M6RUNM5?=]WV1_GWR:-K$.JMH4NDZE%K:77V%M&DL;I-56]W^7]C;3VB%V+K>
M0GV<P^=O.W86.*_0[JU[JUKWZ6[WVL<-GMU/I;]H']B;]J3]E7P)\%/B)^T3
M\'O$_P (-!_:%LO&&I_"FR\;+9Z1XKU[2O S>%TU[4]1\%S71\5>%;7/C#0G
MTP>*](T6XUBVNOMVF6]S8*ET_-A\;A<54KT\/6A6EAW"-;V=Y1A*?-RKG24)
M/W)7Y'+E:M*ST*E"44G)-*6U_+\5TW2^>Y^SG_!JG>VEI_P5H\+07$\<,VI_
M ?XTV5A&YPUU=QZ7H^HO!$/XI%L=/O;DCC]U;RM_" WB\6)O)ZMNE:@WY+GM
M^;2Z_FX[8;^+ZQ?]?U^I_5M_P=,?"'QU\5O^"5/B'4/ WA[5?$A^$?QN^&7Q
M8\6VFC6DE_>V/@K3=/\ &'@_6=<:SMQ)=2:?HD_C73]2UBX@AE72](@OM8OO
M(TO3[Z[M_D>$JU.EFR522C[;#U:-.[LG4<J4U%/:[5.22TYG9+WFE+HQ*;IZ
M?9DF_2S7Z_YG^8PNB:R^C2^(UTC4V\/0:G;Z)/KRV%T=&AUF[M;J^M=(EU01
M&QCU.YL;*\O+>P>=;J:UM+JXCB:&"5T_4;J_+=7M>U];+1NV]DVE?S\SS_R/
M]?;_ () ?M&>'OVI/^":O['OQ1T/4;>_O[7X*>#/AQXVCB=1-I_Q%^%&DVWP
MZ\<6MU; F6R-SK_AN[U>P@G >71=3TN^B,MK>6]Q/^.YWAI87-<;3DK*5>=:
M'9TZ[=6%MKV4^5V7Q1:T:9ZE*7-3@_))^JT?I>Q_GC_\%U?^"77QO_88_; ^
M-'Q&3P-X@U;]EWXS_$KQ)\1_A9\5]'T*\D\%Z*OQ%UW4_$C_  L\1ZI:K=6'
MAWQ7X/U&[U#0--L-5N[6X\4:'IECXDTR QWEU9:?^C9%FM#,,'1A[2*Q=&E&
MG6HN2]HW32C[:*=I2A-6ES)6A*3@VVCAK4Y0FW9\K=T[::]/)KS>N]HW][\1
M-"T'7/%&LZ9X<\,Z+JWB+Q#K=[;Z;HVA:%IUYJ^LZMJ-W(L-K8:9I>GPW%]?
MWMS*RQ6]K:02SS2,J1HS,!7N2E&*<I-1C%-RE)V22W;;LDDM6V_N,3Z<_:?_
M &'/VI?V,;'X377[3WPEUOX/7OQK\,:KXQ\">&_%5UI4/BZ30-'U&'2[R?Q'
MX6M;ZYUOP=?"[N(@NB>*[+1];6-Q)-IT(XKEPN.PN-]K]5K1KJC-4ZDH7<%)
MKF2C/X9JWVH.4?.[:*E"4+<RMS:I/?YZNV_6S\M3_27_ .#:WX\:!\;/^"27
M[/VCZ??P7'B7X%:IX_\ @EXYL8F^?2]5T#Q?J?B?PS"ZL=^+SX<>+O!6HF3'
ME-<75S#$3]G=5_,^**$J.<8B35HXB-*O3?>+IJG+[JE.:MKI;O:/H8=WI1\K
MI_??RZ-?\'<_F/\ ^#HW_@F/\8/AQ^UAXK_;X^'/@KQ%XN^ 7QSTOPE=_$_Q
M!H=B=2MOA1\5=!T2P\%75MXDMK%9[W2?"_C#2=!\/Z[I?BC4(UTJ7Q7JFN:#
M<75E<G0[?5/J>%<THUL'#+ZDXPQ.'<U3A)V=:BVYIPOI*4'*4907O*$5+5<S
MCSXFFU+G2;3WZV?Z)^F_;0_GA_8J_8?_ &A_V^?C?X8^!O[/'@35_%&LZOJ%
MC_PD_B=;*<>#OAMX6DO+>WU;QOX[UXA+#1- T6"<W#+-<#4=9NOLVA^'[/4M
M>U'3M-N_H\;C</E^'GB,344(13Y5?WZD[75.G'>4Y6T2V5Y.T8RE'"$)3:45
M?N^B75OT^7E?8_V&O@%\'O#W[//P+^#/P$\)7-U>^%_@G\*OA]\)_#U]?I#'
MJ%_HWP\\*:3X3T[4-06V2.#^T+^UTF*[OVB14>[FF< ;OF_&,37EB<17Q,TE
M*O6J5I)7M%U)N;BKW=DY66NUMSU(KEBH]DE]RL?Y$?\ P55_Y2;_ /!0G_L]
M/]IO_P!7)XPK]CRK_D5Y;_V 8/\ ]1Z9Y=3^)4_QR_\ 2F? U=Y 4 % !0 4
M % !0 4 % !0 4 % !0 4 % '^@!_P &;7_)N_[:?_9:/AM_Z@^K5^?<:_Q\
M!_UZK_\ I=,[<)M/U7ZG]!/_  6,_P"45_[?O_9K7Q;_ /48O:^<R3_D;9?_
M -A5+_THWJ_PY_X6?X^U?LAY84 % !0 4 % !0 4 % !0 4 % !0!_I7?\&I
MG['?_"A?^"?VL?M$^(M+^Q^.OVO_ !O-XJM9IH_*O(OA'\-YM5\'_#NRFB=/
M,07^NR_$'Q=:3JXBOM%\4:+.L>$267\RXNQOM\PCA8N\,'3Y7V]M62G4:](*
ME'?249*T?M>AAH<L.;K-W^2V_5_/U/E__@OA_P %\OVG/V#OVPO#O[,7[(FH
M?#2/_A$OA9X?\3_&&\\:>#%\77L'C?QQ=7NKZ%X<MQ+J-FFGQZ;X$C\-^(7:
M-&-X/%\0D;_1$%=?#_#^$Q^">*QD:K=2M.-%0J<B]G3M%RTC*[=3GCJ_L:7N
M^6*]:4)J,&M%[VBW?KY6>GWO:/X>?\16/_!63_H/_ #_ ,,S;?\ R]KW?]4\
MG_DK_P#A1+_Y68_6:O=?=$_5+_@C+_P<:?M<?M5_M[_#']FS]K[4_A1+\._C
M/I'BOPEX4U'PIX&B\'7VD?%*#2SXB\&-<ZC'JEY]KMO$!T/4O!EKIA@_TG6_
M$^CRB5/LQ#^3G?#6#PN7UL3@HU55H.%22E4=12I7Y:FC@K<BE[1OI&$EI=..
MM&O.4U&=K/1:+?Y=]M5]Q^\/_!P=^Q[_ ,-A_P#!,'XZZ5HVE_VE\1/@3;0?
MM'_#A8HQ)=-J?PNLM3N?&.FVL:J;BZN=<^%VH^.])T[3X&#7>N76CG9-)!#$
M_P _PYC?J6:T')VIXG_9:G7^*X^S?E:LJ=WTCS&U>'/3=MX^]]W_  +_ --G
M^?%_P0O_ .4M_P"PE_V6NU_]1OQ#7Z+GO_(HS#_L'E^:.&E_$A_B1_J+_MZ?
MLOV_[:/[''[17[+DNJVN@W7QD^&FM^&-!UV_@DN=/T/Q;"8-:\%ZSJ-O"#//
MIVE>+=+T6_OXK;_27L[>9;8B<Q%?RK+L7]1QV&Q=G)4:JE.*W=-WC42O9<SA
M*2C=[]CTIQYX2CW5OGT_$_Q]OVA?V;OCC^RG\5O$GP3_ &@_AKXG^%_Q*\+7
MCVVH^'?$E@]N;N#>RVNL:#J$?FZ;XD\.ZHBBYT;Q%H5U?Z+J]H\=SI]Y/"P>
MOV7#XFABZ4*^'JQJTIJ\9P=UYQ:T<91VE&24HO22B]#RY1E!N,E9K^KK:Z]/
MQW/[&O\ @U1_X)<?%CPG\2?$/_!1'XZ^!-=\"^&(? FI^"/V:].\36\VD:QX
MNOO&,ILO&GQ+@T6X^SZI;>&]-\-6<_A?PY?:G:I8>)_^$NU;4M*6>#1K6^E^
M,XMS6C*DLMH5(SJ.HIXKE=U3C3UA3;M;GE.TI).\.2TK<UCJPU-IN<DTK6C?
MSW=O33JNW:/Z ?\ !VK^T]HGPP_X)_\ @[]FRVU1!XV_:>^+'AYY=$1T\R7X
M:?!Z[M/'7B35KA0QD2*V\=K\,;*U1HU2ZDO+J2.4G3Y4;S>#\+*KF%3%-?N\
M+1DE+_I[7]R*7_<-56][>[>W,N:\5*T%'K)_@M?SMV_"TORC_P"#-O\ Y.,_
M;1_[(I\.?_4ZU&O7XT_W7!?]A$__ $V987XY?X?U/W<_X.3?^"<WQ3_;W_8Q
M\+:_\!?#]WXS^-/[-/C6_P#B!H7@#2[=;G7_ !]X)\1Z5'HGC[PWX5A,D377
MB>V2T\/^*M-TN-I+K7H?#-]H.DVM[K^I:1:R^!PQF5'+\;4AB)*G0Q4%3=66
MD:=2$KTY3?V8/FG%RV3E%R<8J4C>O3<X+EU<7>W==4M]?EZ7/\R&S\!^.-0\
M81_#RP\&^*[[Q_+K)\.1>!K/P]J]SXPD\0BY^QG0D\,PV<NM-K(O ;4Z8MD;
MT7(,!A\WY*_47."C[1RBH*/.YN24>6U^;F^'EMK?:VIY]G>UG?:W7T[G^HC_
M ,&[G_!-OQO_ ,$\/V*+[_A=>A/X:_:$_:&\7)\2OB3X9FNX+N[\$:!IMA_8
MOPY\":@]C//I_P#:VEZ2^I^)-;2%WN-/UKQCJ&@7<LKZ(FS\KXDS.GF..BJ$
MN?#8:'LZ<U>U2<GS59JZB^5M1A'HU3YE92O+T*%-PAJK2D[OR71=-O3KK;0_
MF _X.XOVGM$^+'[<WPH_9W\-:HFIV?[+?PGF3Q8D3H\.E?$OXR7NF^*M;TE3
M&SAY8? >A?#&ZNG+*\=U>2V4D22V3E_J>#\+*CE]7$S5GBZUX>=*BN2+?:]1
MUK;:6:O>YSXJ5YJ*^RM?5[_@EU^X_5;_ (,W_P#DU[]L3_LO?@S_ -5Y%7D\
M:_[S@?\ KQ5_].(TPFT_5?J?FC_P>(?\GU?LS_\ 9IEA_P"KA^*5>IP9_P B
M[$_]AL__ $Q0(Q7QQ_P_J?R-5]><I_KW_P#!&7]J'PU^UM_P33_9/^).AZE;
M7NM^&?A5X6^#_P 2+2)U^TZ1\2_A%HNG^!_%5O?VP):QDUA]*M/%VFVTF&;P
M_P")-&NT+PW4<C?CN>866$S3&4Y+W:E:>(INUDZ=>3J1MM?E;=-NWQ0EM8]2
ME)3IQ:Z))^JT?;UV^X_A _X.$?\ @E%\:?V0OVO?C)^TCX0\!^)/$G[*/[0?
MC_7/BAH?Q$TBR;5=(\ ^-_']]=^)O&WP[\9-IT;R>%?L7BB[UFZ\%7.KV]II
MFM>%+C3;33M2U#6='\0V]A]_P[FU#&X*CAY5(QQF&IQI3I-VE4A37)"M"_QI
MQ4?:6=XSYKJ,90YN.O2<).2UC)MW2V>[3[>7DM-F?C-^RA^R!^T/^VU\7O#W
MP2_9O^&VN_$/QKKMS$+F2QMI(?#OA32/.BCO?%'C;Q)*JZ3X5\,Z6LR27NJZ
MM<P1M(]O8V*7NJ7MC877M8O&8; T95\55C2IQZOXI/\ EA'XIS?2,;OKLFXX
MQA*;M%-O\O-O1+Y_C9(_U^_V;/@QX"_8?_9&^$OP43Q+;P> /V;O@SHOA[6O
M&^ORPZ7:S:?X(\.BY\6^.-;DDD^RZ7!?W-MJWB74@91::<EQ.JN((%-?C>*K
MU,PQM:OR/VF*KMPIQ]YKGE:G36B<FERP6EWYW/4C%0BHWTBM]MMV][=]_O/\
MBK]OW]HNV_:V_;6_:A_:0TX7*:#\7?C3XY\5>$(KV#[-?6_@236;BP\!6FH0
M<^7J%IX,LM"MKY?^?N*8\9Q7[%E^'>$P6%PSMS4:%.$[;.HHKVC7DY\S7D>9
M.7/.4N[NO3I^!_6!_P &>O[8/V+7/VE?V%_$NJ;;?6K:S_:/^%%G<3)'&NJ:
M:-'\"_%K3;7S3NGN]1TR3X;ZQ9V%L5,5KX?\2Z@8G4W,L7R/&>"O#"X^*U@W
MAJS_ +LKU*+W5E&7M4W9W<XK2R.G"S^*#_Q+\G^GYG])'C/_ ()T^'_$G_!9
M3X,_\%%9-'@>T\%_LB_$;P!=3VZ0KY'QCLO$VD^%_!^OZBK@O/=ZI\'_ (G_
M !)T"&:/++!X4TU6>$6L:77S5/,Y1R.OEO,^:>,IS2?_ $#N+G.,==.6O2IR
M=UK[1VOKR[NFO:JI_=M_V]?1_=?T^9_.U_P>#?ME>7;?LY_L&^%M5^:X:?\
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M5 55     K\;/4/\.76O^0SJW_83O_\ TJEK]X/',R@ H * "@ H * "@ H
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M>*P6+PZMS5\/6I1OLISA)0;WVDT_\MSB@^6<9/[,DW\GK^I_KN_M7_ GPO\
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ML>?M?BSPM\1+%Q$"D2Z;;M(0]RH;QN,L/*&.P^(L^2OAU"__ $\HSES+_P
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M_J13(J?PZG^"7_I+/\;6OVD\H* "@ H * "@ H * "@ H * "@ H * "@ H
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MFER7[NW]-_\ #/<_R)E5G94169F8*JJ"69F. J@9)8D@  9).!G(K]>/+/\
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M?23\[;&%:49U'*+NK+7;9>:7Y??<P_\ @C=_P5V^(W_!*7XX:QKRZ)>_$?\
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M_+[[/E^S/^#ES_@J5^PG_P % O@Q^S#X1_9%^.1^+>O_  ]^)_C;Q'XQL?\
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M4_9**2:LM6YN3(AB8--S?+[WNJS?NV77D=W>_;TLT?R8?\' 7[7G[//[;O\
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M<XJ4)QE"<9*\91DK2BT]&FFTT]TSF3:::=FMFOZ7Y_<?Z#__  3C_P"#K/\
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MB"@ H * "@ H * "@ H * "@ H * "@ H _2K_@CY^T#\)/V6/\ @I+^RO\
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MZTIS7M*5.T7"R=ZLX)ZZ63OY.UXF'G&$I.3LFK;-]?*,OZ[V?+[O_P ',_\
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M33MUCRM5%Y<T(/U.Q5Z4E\2]))K]&O\ R;[]CF-4_P""V?\ P0T_9TBU^_\
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MW3;G[?FA42UY9\L?>2<H.-TI+FA+HJU?9.#:NFVGW^6_X_A>YUGP\_X+R_\
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M6_FO-+K?JKKNK6?-_<WX/_X+I?\ !(GXD^$SKUI^V[\&;#2KW3WDO=$\?_\
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MS5ZLU[T)2B[QDGI)[V=FK'-6DIU)2B[IVL_2*75+JNWWG[Q?\$"_^#A?X/\
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MB/\ X)7?L3?#'Q5:?L:#X=_'?XS:S;W<GAWP'\#O!+>#OAL-?F9TMM>^(_Q
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M7_I+/\;6OVD\H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\
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MO_2C>K_#G_A9_C[5^R'EA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MWG3@HXN"2O*G'2-?NW324:FK_=J$O=C2GS=F&JV_=RZ_"[_AVUZ:_>V>7_\
M!TQ_P2CE^#GQ-F_X*-_!716_X5?\:/$=KI?[1.B6,68O!'QCU4>7IOQ!CBCY
MA\._%1H&BUR:1!%8?$:.2XN+N:?Q]IME8:\*9O\ 6*/]FUY?OL/"^'D_^7E"
M/_+O_%1NE&UKTK)1_=SG*<32L_:1V;][REWZ;^F_5W1_'?7V1RA0 4 ?UG_\
M&OW_  2AF_:2^-MO^WM\9]$<_ _]G+Q?;CX0Z3?1E(?B1\?-$%KJMAK*H?WD
M_ACX1/-IWB":8>1;ZEXZF\-V$$^H6N@^+-,3Y'BK-UA</]0HR_VC%0?M6O\
MEUAY>[)?XZVL%;FM#G;Y6X.73AZ7,^=_#%Z><E]VBT?KWLT?:_\ P=/_ /!6
MK27TG4/^"8GP(UNWU&]N[KP_KW[5_BK3+GS(=*CTV[L?$OA'X*65S#(4DU.6
M^M](\7_$%H\#3H;7PYX7,\US>^+M*T_AX3R>2:S7$1:TE'"0>[33C.N_)IN%
M/NN>3T]G*5XFK_R[CK_,[[?W=OF]?+5M\O\ "S7WAQA0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?TX_\&F'_*5#5O\ LUKXN_\
MJ3_#*OE^+O\ D4_]S5'_ -)J'1AOXG_;K/\ 2_K\O/0/\/\ ^(?_ "/_ (X_
M['#Q-_Z>KVOW:'P1_P ,?R/(>[]6<?5""@ H * "@ H * "@ H * "@ H *
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MWTE9WJ_"[TY*.V)JV7LUN]_)?YO\M]T?YXE?HIPA0 4 % !0 4 % !0 4 %
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MT/5_H?Y_]?H)Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^@!_P9M?\ )N_[:?\ V6CX;?\
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M[0]7^A_!I7WQQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?OY_P;&?\IC_V<_\ L3_C[_ZH
M[Q[7S_%'_(DQ?^+#_P#J32-\-_%7I+\C_4TK\G/1/\73]N7_ )/7_;"_[.E_
M:"_]6SXMK]NP/^Y8/_L%P_\ Z:@>3/XY?XI?F?+5=1(4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % 'Z4? S_ ()%?\% ?VG?@!X3_:6_9U^
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MHIQ@_G4E6MW5FMSGQ4KS45]E:^KW7W)'\G5?6G,% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!^I7_!)O_@F1KO_  55^.'Q6^ WA?XM:3\(/$_@
M/X!>)/C+X>UC7_"MYXHT'Q!JNA>//ASX,M_"FLG3M8TO4/#^GZ@OCR2]F\1V
M-IXBN=/.FI&GAW4!<L8O*S?-(Y3AZ6(G1E6A4Q,*$E&:C**E3JU.>-TU)KV5
MN1N%^:_,K-2TI4_:2<4[-1OJK]4K;JV^^OH>U?'/_@W>_P""M_P-U[5-,?\
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M8*O[)@L,L'A,-A8NZH4:=-R2MS2C&TI6Z<TKR^?D>7.7-*4N[N?,M=)(4 %
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M&:4Y/V,L/B(?9<:GLY-><:D5%/R4I+^^KV.Z.)IO?FB_-77WK]8_Y'T/K_\
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M22\DOOU);;=VVV]V]6<?5B"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * /[R/^#,K_D0/V_\ _L</V=/_ $R_&.O@>-OCRW_#BOSPYVX3:?JOU/Z0
M?^"QG_**_P#;]_[-:^+?_J,7M?,Y)_R-LO\ ^PJE_P"E&]7^'/\ PL_Q]J_9
M#RPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H DBEE@ECG@DDAFAD26&
M:)VCEBEC8/')'(I#)(C@,CJ0RL 000#0!J7GB'7]1@-KJ&N:Q?6S,K-;WFIW
MMU S(<HQBGN)(RR'E25RIY&.M*R6R7W6_K^NX[ON_O,>F(* "@#7LM?U[38?
MLVG:WJ]A;[VD\BRU*\M8?,?&Y_*@GCCWL%&YMN3@9)Q\JLGNE]U_Z_KL.[6S
M?WV_K^NYF2RRSRR33R2332NTDLLKM)++(YW/))(Y+.[,2S,Q+,3DDGFF(CH
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^G'_@T
MP_Y2H:M_V:U\7?\ U)_AE7R_%W_(I_[FJ/\ Z34.C#?Q/^W6?Z7]?EYZ!_A_
M_$/_ )'_ ,<?]CAXF_\ 3U>U^[0^"/\ AC^1Y#W?JSCZH04 % !0 4 % !0
M4 % !0 4 % !0 4 % 'M7P/_ &D/V@?V9O$6J^+?V=_C7\4O@?XHUW1F\.ZW
MK_PJ\<^(_ NK:OH+WMIJ3:/J=]X<U'3I[[3?[0L+.]%G<M+ MU:P3J@DC1UQ
MKX;#XF*AB*%*O",N91K4X5(J5FN9*:DE*S:NE>S:UN^6HRE%WBVGY?\ #J_W
M_?H7_CK^U+^TG^T_?>'=3_:-^//Q;^.FH>$;34+'PM>_%?Q]XE\=W/AVRU6:
MVN-3M=%F\1ZCJ#Z;!J$]G:2WD5H8DN9+6W:8.84*JAA<-A5*.&P]&@IM.2HT
MH4U)K1.7(HW:6UUITM?WB4I2MS-NW?\ X>7Y_?\ 9\&K<D* "@ H * "@ H
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MZ4(TZ4(4Z<%RPA"*A"*72,8I)+R2^_4EMMW;;;W;U9Q]6(* "@ H * "@ H
M* "@ H * "@ H * "@#VC]F__DXCX"_]EH^%O_J<:%65?^!6_P"O53_TAC6Z
M]4?[9%?AAZY_F!_\'3__ "EQ\?\ _9%_@C_ZB\M?JO"O_(FH?]?<1_Z=D>=B
M?XK](_D?SEU]&8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;-IXB\0Z?;I:V
M&NZS96L98QVUIJE[;6Z%W+N4AAN(XU+NS.VU?F=BQR232LNR^X=VMF_OM_7]
M=S)=WE=Y)'>221V>21V+O([DL[NS$LSLQ+,S$DDDDDG-,0R@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * -JW\2>(K2W2
MTM=?UJVM(U*1VMOJM]#;QHQ)9$ACN%C1268E50 EB<')I679?<.[VN[>IBDY
MY/)/))[TQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^N9_P $+/\ E$=^
MPG_V1>'_ -2CQ'7Y!Q#_ ,CG'_\ 7V/_ *:@>G1_A0]/U9^&?_!Y+_R;O^Q9
M_P!EH^)/_J#Z37O<%?Q\?_UZH?\ I=0QQ>T/5_H?Y_\ 7Z"<04 % !0 4 %
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M-_%7I+\C_4TK\G/1/\73]N7_ )/7_;"_[.E_:"_]6SXMK]NP/^Y8/_L%P_\
MZ:@>3/XY?XI?F?+5=1(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % ']=_P#P1+_X.'?V9O\ @G/^R1:?LM?'WX)_'/7WT;Q]XT\9:9XZ^$2>
M O%$>I0^,;NWO38ZAX;\8^+?AV^DOILEOY GM=<UD7B/YWE6K+Y#?'Y[P[BL
MSQ?UK#UZ$;TX4W3K>TA;DOJIPA5O>^SC&WGHSJHUXTX\LE)ZMW5NOJE;[W\M
M#ZE_;'_X/!+#6? VM^%?V%OV=/%OA?QCK5A/96'Q<_:%NO"WF>#&N$E@DU+1
M_A7X-U3Q;I.NZU;)(EWI%UKWCK^P['4(8SJWACQ)8>=83\F"X-Y9QGC\3&<(
MN[HX=22G:SM*M-1DHMZ2C&GS-/W:D&DRIXK2T(N_>36GR2L_FU^?-_$CXU\:
M>+?B/XO\4?$#Q[XCUCQ?XW\;:_JWBKQ=XJ\0W]QJFN^(_$>O7T^IZSK6KZC=
M/)<7NHZE?W,]W=W,SO)+-*[L22:^YA"%.$:=.*A"$5"$(JT8QBK1C%*R225D
MDMET.1MMMO5MW;[O\?S^\YFJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M;FBFK-4HI*-.+UO;FFT[2J27NQYJE:531Z1[+KZ[7MZ6ZJVJ/Q;KVC(* "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#^G'_@TP_Y2H:M_V:U\7?\ U)_A
ME7R_%W_(I_[FJ/\ Z34.C#?Q/^W6?Z7]?EYZ!_A__$/_ )'_ ,<?]CAXF_\
M3U>U^[0^"/\ AC^1Y#W?JSCZH04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'M'[-_P#R<1\!?^RT
M?"W_ -3C0JRK_P "M_UZJ?\ I#&MUZH_VR*_##US_,#_ .#I_P#Y2X^/_P#L
MB_P1_P#47EK]5X5_Y$U#_K[B/_3LCSL3_%?I'\C^<NOHS * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H _US/\ @A9_RB._83_[(O#_ .I1XCK\@XA_Y'./_P"OL?\ TU ].C_"
MAZ?JS\,_^#R7_DW?]BS_ ++1\2?_ %!])KWN"OX^/_Z]4/\ TNH8XO:'J_T/
M\_\ K]!.(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H _T /^#-K_DW?]M/_LM'PV_]0?5J_/N-
M?X^ _P"O5?\ ]+IG;A-I^J_4_H)_X+&?\HK_ -OW_LUKXM_^HQ>U\YDG_(VR
M_P#["J7_ *4;U?X<_P#"S_'VK]D/+"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /W\_P"#8S_E
M,?\ LY_]B?\ 'W_U1WCVOG^*/^1)B_\ %A__ %)I&^&_BKTE^1_J:5^3GHG^
M+I^W+_R>O^V%_P!G2_M!?^K9\6U^W8'_ '+!_P#8+A__ $U \F?QR_Q2_,^6
MJZB0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_<PK\'/8"@#_
MU_[$O^"G_P#RC3_X*'?]F,_M:_\ J@_']=^5?\C3+?\ L/P?_J13(J?PZG^"
M7_I+/\;6OVD\H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /[R/\ @S*_Y$#]O_\
M['#]G3_TR_&.O@>-OCRW_#BOSPYVX3:?JOU/Z0?^"QG_ "BO_;]_[-:^+?\
MZC%[7S.2?\C;+_\ L*I?^E&]7^'/_"S_ !]J_9#RPH * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /Z<?^#3#_E*AJW_9K7Q=_P#4G^&5
M?+\7?\BG_N:H_P#I-0Z,-_$_[=9_I?U^7GH'^'_\0_\ D?\ QQ_V.'B;_P!/
M5[7[M#X(_P"&/Y'D/=^K./JA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >T?LW_ /)Q'P%_[+1\
M+?\ U.-"K*O_  *W_7JI_P"D,:W7JC_;(K\,/7/\P/\ X.G_ /E+CX__ .R+
M_!'_ -1>6OU7A7_D34/^ON(_].R/.Q/\5^D?R/YRZ^C, H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#_7,_P""%G_*([]A/_LB\/\ ZE'B.OR#B'_D<X__ *^Q_P#34#TZ/\*'
MI^K/PS_X/)?^3=_V+/\ LM'Q)_\ 4'TFO>X*_CX__KU0_P#2ZACB]H>K_0_S
M_P"OT$X@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#_0 _X,VO^3=_VT_^RT?#;_U!]6K\^XU_
MCX#_ *]5_P#TNF=N$VGZK]3^@G_@L9_RBO\ V_?^S6OBW_ZC%[7SF2?\C;+_
M /L*I?\ I1O5_AS_ ,+/\?:OV0\L* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _?S_ (-C/^4Q
M_P"SG_V)_P ??_5'>/:^?XH_Y$F+_P 6'_\ 4FD;X;^*O27Y'^II7Y.>B?XN
MG[<O_)Z_[87_ &=+^T%_ZMGQ;7[=@?\ <L'_ -@N'_\ 34#R9_'+_%+\SY:K
MJ)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\
MZ-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!
M_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\
MA_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'
M?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\
M-U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1
MDG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG
M_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_P
MFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )
ML3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#
MZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM
M5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA
M_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q
M#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!
M8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^
MC<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\
M'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X
M?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@
M=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U
M1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_
MK1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_0
M7+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+
M_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_
M ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\
MK#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[
M+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[
MXA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0
MQG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\
M%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\
MZ-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!
M_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\
MA_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'
M?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\
M-U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1
MDG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG
M_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_P
MFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )
ML3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#
MZM5[+[XA_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM
M5[+[XA_Q#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA
M_P 0QG_!8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q
M#&?\%C_^C<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!
M8_\ Z-S\'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^
MC<_!_P#X?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XA_P 0QG_!8_\ Z-S\
M'_\ A_O@=_\ -U1_K1DG_07+_P )L3_\K#ZM5[+[XA_Q#&?\%C_^C<_!_P#X
M?[X'?_-U1_K1DG_07+_PFQ/_ ,K#ZM5[+[XG]7__  ;6_P#!-3]KS_@G/X/_
M &M],_:Q\ :-X!O_ (L>)?@[?^";;2?'?@SQP=1L_!NE_$6WUV>XE\':SK-O
MIP@F\2:7'#'>RP37.^5HHV2%FKY'B?,\%F4L$\'5=548UU4;IU*=G4='E_B1
MBW?DEM^'VNFA3E34E);M-:I_E_6ODS]GO^"D'P<^(/[0O[!?[6WP-^%&C0^(
M?B3\5O@3X_\  O@G1+C5=+T.WU/Q'XAT6XL--M9]7UN[L-)TZ&2>5?-N[^\M
M[>) 69^ K>)E=>GALPP=>M+DI4J].=27+*5HQ>KY8WD_1*_J:U$Y0E%;M-(_
MSHO^(8S_ (+'_P#1N?@__P /]\#O_FZK])_UHR3_ *"Y?^$V)_\ E9P_5JO9
M??$/^(8S_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ#_
M (AC/^"Q_P#T;GX/_P##_? [_P";JC_6C)/^@N7_ (38G_Y6'U:KV7WQ#_B&
M,_X+'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@
ML?\ ]&Y^#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^5A]6J]E]\0_XAC/^"Q__
M $;GX/\ _#_? [_YNJ/]:,D_Z"Y?^$V)_P#E8?5JO9??$/\ B&,_X+'_ /1N
M?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\ A-B?_E8?5JO9??$/^(8S_@L?_P!&Y^#_
M /P_WP._^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ#_ (AC/^"Q_P#T;GX/_P##
M_? [_P";JC_6C)/^@N7_ (38G_Y6'U:KV7WQ#_B&,_X+'_\ 1N?@_P#\/]\#
MO_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\
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MO_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\
MFZH_UHR3_H+E_P"$V)_^5A]6J]E]\0_XAC/^"Q__ $;GX/\ _#_? [_YNJ/]
M:,D_Z"Y?^$V)_P#E8?5JO9??$/\ B&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,
MD_Z"Y?\ A-B?_E8?5JO9??$/^(8S_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N
M7_A-B?\ Y6'U:KV7WQ#_ (AC/^"Q_P#T;GX/_P##_? [_P";JC_6C)/^@N7_
M (38G_Y6'U:KV7WQ#_B&,_X+'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_
M .5A]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^
M5A]6J]E]\0_XAC/^"Q__ $;GX/\ _#_? [_YNJ/]:,D_Z"Y?^$V)_P#E8?5J
MO9??$/\ B&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\ A-B?_E8?5JO9
M??$/^(8S_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ#_
M (AC/^"Q_P#T;GX/_P##_? [_P";JC_6C)/^@N7_ (38G_Y6'U:KV7WQ#_B&
M,_X+'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@
ML?\ ]&Y^#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^5A]6J]E]\0_XAC/^"Q__
M $;GX/\ _#_? [_YNJ/]:,D_Z"Y?^$V)_P#E8?5JO9??$/\ B&,_X+'_ /1N
M?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\ A-B?_E8?5JO9??$/^(8S_@L?_P!&Y^#_
M /P_WP._^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ#_ (AC/^"Q_P#T;GX/_P##
M_? [_P";JC_6C)/^@N7_ (38G_Y6'U:KV7WQ#_B&,_X+'_\ 1N?@_P#\/]\#
MO_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\
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MO_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\
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MO_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\
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MO_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\
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MO_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\
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M\0_XAC/^"Q__ $;GX/\ _#_? [_YNJ/]:,D_Z"Y?^$V)_P#E8?5JO9??$/\
MB&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\ A-B?_E8?5JO9??$/^(8S
M_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ#_ (AC/^"Q
M_P#T;GX/_P##_? [_P";JC_6C)/^@N7_ (38G_Y6'U:KV7WQ#_B&,_X+'_\
M1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^
M#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^5A]6J]E]\0_XAC/^"Q__ $;GX/\
M_#_? [_YNJ/]:,D_Z"Y?^$V)_P#E8?5JO9??$/\ B&,_X+'_ /1N?@__ ,/]
M\#O_ )NJ/]:,D_Z"Y?\ A-B?_E8?5JO9??$/^(8S_@L?_P!&Y^#_ /P_WP._
M^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ#_ (AC/^"Q_P#T;GX/_P##_? [_P";
MJC_6C)/^@N7_ (38G_Y6'U:KV7WQ#_B&,_X+'_\ 1N?@_P#\/]\#O_FZH_UH
MR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\ FZH_UHR3
M_H+E_P"$V)_^5A]6J]E]\0_XAC/^"Q__ $;GX/\ _#_? [_YNJ/]:,D_Z"Y?
M^$V)_P#E8?5JO9??$/\ B&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\
MA-B?_E8?5JO9??$/^(8S_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\
MY6'U:KV7WQ#_ (AC/^"Q_P#T;GX/_P##_? [_P";JC_6C)/^@N7_ (38G_Y6
M'U:KV7WQ#_B&,_X+'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]
ME]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^5A]6J]E]
M\0_XAC/^"Q__ $;GX/\ _#_? [_YNJ/]:,D_Z"Y?^$V)_P#E8?5JO9??$/\
MB&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\ A-B?_E8?5JO9??$/^(8S
M_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ#_ (AC/^"Q
M_P#T;GX/_P##_? [_P";JC_6C)/^@N7_ (38G_Y6'U:KV7WQ#_B&,_X+'_\
M1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^
M#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^5A]6J]E]\0_XAC/^"Q__ $;GX/\
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M^$V)_P#E8?5JO9??$/\ B&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\
MA-B?_E8?5JO9??$/^(8S_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\
MY6'U:KV7WQ#_ (AC/^"Q_P#T;GX/_P##_? [_P";JC_6C)/^@N7_ (38G_Y6
M'U:KV7WQ#_B&,_X+'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]
ME]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^5A]6J]E]
M\0_XAC/^"Q__ $;GX/\ _#_? [_YNJ/]:,D_Z"Y?^$V)_P#E8?5JO9??$/\
MB&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\ A-B?_E8?5JO9??$/^(8S
M_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ#_ (AC/^"Q
M_P#T;GX/_P##_? [_P";JC_6C)/^@N7_ (38G_Y6'U:KV7WQ#_B&,_X+'_\
M1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\ ]&Y^
M#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^5A]6J]E]\0_XAC/^"Q__ $;GX/\
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M^$V)_P#E8?5JO9??$/\ B&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\
MA-B?_E8?5JO9??$/^(8S_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\
MY6'U:KV7WQ#_ (AC/^"Q_P#T;GX/_P##_? [_P";JC_6C)/^@N7_ (38G_Y6
M'U:KV7WQ#_B&,_X+'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]
ME]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^5A]6J]E]
M\0_XAC/^"Q__ $;GX/\ _#_? [_YNJ/]:,D_Z"Y?^$V)_P#E8?5JO9??$/\
MB&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\ A-B?_E8?5JO9??$/^(8S
M_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ/2/@W_ ,&V
M7_!7KP5\7OA5XRUW]G;PK%HGA+XD>!O$VL26_P >/@A<W$>E:#XGTS5=0>"W
M3QV'GF2TM9FBA4AI7 C4@MFHJ\39+*E4BL7*\H3BO]FQ.[BTO^7?=C6'JIIV
M6COO$_T[*_*CT#^&C_@O3_P1)_X*)?MQ?\%"/$_[0'[-GPD\,^./AAK7PO\
MACX?M=9OOBM\-O"%Y'K/AG2+G3=7L;C1O%OB/1M35H)ECECN([:6SG@GB,5P
MTHN(HOOL@SS+,#EM/#XJO*G5A4K-Q]C6FK3GS1:E3C*.J?D[K;J<=:C4G4<H
MI6:75+9>?]?>C\8O^(8S_@L?_P!&Y^#_ /P_WP._^;JO:_UHR3_H+E_X38G_
M .5F7U:KV7WQ#_B&,_X+'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A
M]6J]E]\0_P"(8S_@L?\ ]&Y^#_\ P_WP._\ FZH_UHR3_H+E_P"$V)_^5A]6
MJ]E]\0_XAC/^"Q__ $;GX/\ _#_? [_YNJ/]:,D_Z"Y?^$V)_P#E8?5JO9??
M$/\ B&,_X+'_ /1N?@__ ,/]\#O_ )NJ/]:,D_Z"Y?\ A-B?_E8?5JO9??$/
M^(8S_@L?_P!&Y^#_ /P_WP._^;JC_6C)/^@N7_A-B?\ Y6'U:KV7WQ#_ (AC
M/^"Q_P#T;GX/_P##_? [_P";JC_6C)/^@N7_ (38G_Y6'U:KV7WQ#_B&,_X+
M'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\
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M'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\
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M'_\ 1N?@_P#\/]\#O_FZH_UHR3_H+E_X38G_ .5A]6J]E]\0_P"(8S_@L?\
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M6/\ ^C<_!_\ X?[X'?\ S=4?ZT9)_P!!<O\ PFQ/_P K#ZM5[+[XA_Q#&?\
M!8__ *-S\'_^'^^!W_S=4?ZT9)_T%R_\)L3_ /*P^K5>R^^(?\0QG_!8_P#Z
M-S\'_P#A_O@=_P#-U1_K1DG_ $%R_P#";$__ "L/JU7LOOB'_$,9_P %C_\
MHW/P?_X?[X'?_-U1_K1DG_07+_PFQ/\ \K#ZM5[+[XA_Q#&?\%C_ /HW/P?_
M .'^^!W_ ,W5'^M&2?\ 07+_ ,)L3_\ *P^K5>R^^(?\0QG_  6/_P"C<_!_
M_A_O@=_\W5'^M&2?]!<O_";$_P#RL/JU7LOOB'_$,9_P6/\ ^C<_!_\ X?[X
M'?\ S=4?ZT9)_P!!<O\ PFQ/_P K#ZM5[+[XA_Q#&?\ !8__ *-S\'_^'^^!
MW_S=4?ZT9)_T%R_\)L3_ /*P^K5>R^^(?\0QG_!8_P#Z-S\'_P#A_O@=_P#-
MU1_K1DG_ $%R_P#";$__ "L/JU7LOOB'_$,9_P %C_\ HW/P?_X?[X'?_-U1
M_K1DG_07+_PFQ/\ \K#ZM5[+[XA_Q#&?\%C_ /HW/P?_ .'^^!W_ ,W5'^M&
M2?\ 07+_ ,)L3_\ *P^K5>R^^(?\0QG_  6/_P"C<_!__A_O@=_\W5'^M&2?
M]!<O_";$_P#RL/JU7LOOB'_$,9_P6/\ ^C<_!_\ X?[X'?\ S=4?ZT9)_P!!
M<O\ PFQ/_P K#ZM5[+[XA_Q#&?\ !8__ *-S\'_^'^^!W_S=4?ZT9)_T%R_\
M)L3_ /*P^K5>R^^(?\0QG_!8_P#Z-S\'_P#A_O@=_P#-U1_K1DG_ $%R_P#"
M;$__ "L/JU7LOOB'_$,9_P %C_\ HW/P?_X?[X'?_-U1_K1DG_07+_PFQ/\
M\K#ZM5[+[XA_Q#&?\%C_ /HW/P?_ .'^^!W_ ,W5'^M&2?\ 07+_ ,)L3_\
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M  6/_P"C<_!__A_O@=_\W5'^M&2?]!<O_";$_P#RL/JU7LOOB'_$,9_P6/\
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M@=_\W5'^M&2?]!<O_";$_P#RL/JU7LOOB'_$,9_P6/\ ^C<_!_\ X?[X'?\
MS=4?ZT9)_P!!<O\ PFQ/_P K#ZM5[+[XA_Q#&?\ !8__ *-S\'_^'^^!W_S=
M4?ZT9)_T%R_\)L3_ /*P^K5>R^^(?\0QG_!8_P#Z-S\'_P#A_O@=_P#-U1_K
M1DG_ $%R_P#";$__ "L/JU7LOOB'_$,9_P %C_\ HW/P?_X?[X'?_-U1_K1D
MG_07+_PFQ/\ \K#ZM5[+[XA_Q#&?\%C_ /HW/P?_ .'^^!W_ ,W5'^M&2?\
M07+_ ,)L3_\ *P^K5>R^^(?\0QG_  6/_P"C<_!__A_O@=_\W5'^M&2?]!<O
M_";$_P#RL/JU7LOOB'_$,9_P6/\ ^C<_!_\ X?[X'?\ S=4?ZT9)_P!!<O\
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M /HW/P?_ .'^^!W_ ,W5'^M&2?\ 07+_ ,)L3_\ *P^K5>R^^)_7%_P;;_\
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M  FQ/_RLX?JU7LOOB'_$,9_P6/\ ^C<_!_\ X?[X'?\ S=4?ZT9)_P!!<O\
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M<_!__A_O@=_\W5'^M&2?]!<O_";$_P#RL/JU7LOOB'_$,9_P6/\ ^C<_!_\
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M6/\ ^C<_!_\ X?[X'?\ S=4?ZT9)_P!!<O\ PFQ/_P K#ZM5[+[XA_Q#&?\
M!8__ *-S\'_^'^^!W_S=4?ZT9)_T%R_\)L3_ /*P^K5>R^^(?\0QG_!8_P#Z
M-S\'_P#A_O@=_P#-U1_K1DG_ $%R_P#";$__ "L/JU7LOOB'_$,9_P %C_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!_N85^#GL!0!__1_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /B[7?^";G_  3M\4:WK'B7Q+^P3^Q=XB\1^(M5U#7?
M$'B#7?V6O@=JVMZYK>K7<M_JNL:QJM_X'N+[4]5U._N+B]U#4+V>>[O;N>6Y
MN99)I7=NZ.9YE&*C',,=&,4HQC'%UU&,4K))*:225DDE9+16(]G3_DA_X#$R
MO^'8'_!-+_I'C^PS_P"(E? /_P"8&G_:N:?]#+'_ /A77_\ E@>SI_R0_P#
M(A_P[ _X)I?](\?V&?\ Q$KX!_\ S T?VKFG_0RQ_P#X5U__ )8'LZ?\D/\
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M![.G_)#_ , B'_#L#_@FE_TCQ_89_P#$2O@'_P#,#1_:N:?]#+'_ /A77_\
ME@>SI_R0_P# (A_P[ _X)I?](\?V&?\ Q$KX!_\ S T?VKFG_0RQ_P#X5U__
M )8'LZ?\D/\ P"(?\.P/^":7_2/']AG_ ,1*^ ?_ ,P-']JYI_T,L?\ ^%=?
M_P"6![.G_)#_ , B'_#L#_@FE_TCQ_89_P#$2O@'_P#,#1_:N:?]#+'_ /A7
M7_\ E@>SI_R0_P# (A_P[ _X)I?](\?V&?\ Q$KX!_\ S T?VKFG_0RQ_P#X
M5U__ )8'LZ?\D/\ P"(?\.P/^":7_2/']AG_ ,1*^ ?_ ,P-']JYI_T,L?\
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M#1_:N:?]#+'_ /A77_\ E@>SI_R0_P# (A_P[ _X)I?](\?V&?\ Q$KX!_\
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M2O@'_P#,#1_:N:?]#+'_ /A77_\ E@>SI_R0_P# (A_P[ _X)I?](\?V&?\
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M'_#L#_@FE_TCQ_89_P#$2O@'_P#,#1_:N:?]#+'_ /A77_\ E@>SI_R0_P#
M(A_P[ _X)I?](\?V&?\ Q$KX!_\ S T?VKFG_0RQ_P#X5U__ )8'LZ?\D/\
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M![.G_)#_ , B'_#L#_@FE_TCQ_89_P#$2O@'_P#,#1_:N:?]#+'_ /A77_\
ME@>SI_R0_P# (A_P[ _X)I?](\?V&?\ Q$KX!_\ S T?VKFG_0RQ_P#X5U__
M )8'LZ?\D/\ P"(?\.P/^":7_2/']AG_ ,1*^ ?_ ,P-']JYI_T,L?\ ^%=?
M_P"6![.G_)#_ , B'_#L#_@FE_TCQ_89_P#$2O@'_P#,#1_:N:?]#+'_ /A7
M7_\ E@>SI_R0_P# (A_P[ _X)I?](\?V&?\ Q$KX!_\ S T?VKFG_0RQ_P#X
M5U__ )8'LZ?\D/\ P"(?\.P/^":7_2/']AG_ ,1*^ ?_ ,P-']JYI_T,L?\
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M#1_:N:?]#+'_ /A77_\ E@>SI_R0_P# (A_P[ _X)I?](\?V&?\ Q$KX!_\
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M2O@'_P#,#1_:N:?]#+'_ /A77_\ E@>SI_R0_P# (A_P[ _X)I?](\?V&?\
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M'_#L#_@FE_TCQ_89_P#$2O@'_P#,#1_:N:?]#+'_ /A77_\ E@>SI_R0_P#
M(A_P[ _X)I?](\?V&?\ Q$KX!_\ S T?VKFG_0RQ_P#X5U__ )8'LZ?\D/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __3_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H _CS_ ."IO_)^'QU_[IC_ .J;^'E?Y[^.
M/_)T>*/^Z+_ZSN4'^BG@3_R:KA;_ +KG_K1YP?GW7Y.?K@4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!^@G_!++_D_#X%?]U._P#5-_$.OUCP._Y.
MCPO_ -UK_P!9W-S\C\=O^35<4_\ =#_]:/)S^PRO]"#_ #K"@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__4_OXH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H _CS_ ."IO_)^'QU_[IC_ .J;^'E?Y[^./_)T
M>*/^Z+_ZSN4'^BG@3_R:KA;_ +KG_K1YP?GW7Y.?K@4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0!^@G_!++_D_#X%?]U._P#5-_$.OUCP._Y.CPO_
M -UK_P!9W-S\C\=O^35<4_\ =#_]:/)S^PRO]"#_ #K"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@#__5_OXH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _CS_P""IO\ R?A\=?\ NF/_ *IOX>5_GOXX_P#)T>*/^Z+_ .L[E!_H
MIX$_\FJX6_[KG_K1YP?GW7Y.?K@4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!^@G_  2R_P"3\/@5_P!U._\ 5-_$.OUCP._Y.CPO_P!UK_UG<W/R
M/QV_Y-5Q3_W0_P#UH\G/[#*_T(/\ZPH * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H __];^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#\-O^#D__E"+^WI_V)7PO_\ 5_?">@#\$?\ @QU_Y)+_ ,%#
MO^RB_L[_ /J-?%B@#^[>@ H _P H#]AK_E;#D_[2@_M??^IM\<J /]7^@#_$
M\_8/_8"\5_\ !3;_ (*#G]D'P7\0O#WPNU[QWK'QFUZ#QGXHTG4M<TC3H/ F
ME^)_%US!+IFDRP7MQ+J$6DFQ@*3Q)#).)I"ZIY; ']*__$$#^TE_T?9\#_\
MPU?CW_Y<T ?H5_P2I_X-4OC=_P $\_V_/V>_VQO%W[6WPK^(WA[X+:EX\O\
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M_!#;_@N-^UO_ ,$XOVO?"'[$W[:?C+XE>(OV8;OQX?V?_&?PU^*]W/J/B?\
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M]:\">.-,L)WDDN'T.?Q'X<O]6\,/?,-1F\+:EHMQ?HEW-.B@'Z!4 % !0 4
M% !0 4 % !0 4 % !0 4 ? /_!4G]M;4O^"=?[!?[0G[96C_  ^L?BIJWP7T
M?P;=:;X$U/Q%/X4T[6[WQK\2_!?PWMGO==M='UVYM;72)?&*ZY/;P::\VIQZ
M:VE1W>F->C4[0 _,7_@W5_X*V_M'?\%</AI^U;\3_P!H3PQ\*_!K?#'XN>$?
M"G@'PW\*M"\0Z3IND^'-;\(3:K/;:K>>)?%'BG4]<U'[7;+-)J,ES:(TLUP(
M+&TM6M[2W /Z.* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /X\_^"IO_)^'QU_[IC_ZIOX>5_GOXX_\G1XH
M_P"Z+_ZSN4'^BG@3_P FJX6_[KG_ *T><'Y]U^3GZX% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?H)_P2R_Y/P^!7_=3O_5-_$.OUCP._P"3H\+_
M /=:_P#6=S<_(_';_DU7%/\ W0__ %H\G/[#*_T(/\ZPH * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^1/VU_VZ
M?V8O^">WP1UCX_?M4_$O3?A[X&T^4:=H]GL;4_%_CKQ)+$\MEX0^'_A2U?\
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MV@ H _C._P""SW_!1[_@N;^SA_P59^"/P-_8?^#WC#Q%^SCJ^B?"^]\+>'-
M^ UI\1O"G[0VL:]J$T7Q"T[QC\3KCP1KNI>!3X=NC+H.HVGAKQ/X9N/!NA6>
MG^/-:D^PZW:S4 ?V8#.!D8..0#G![C/&<>N/RS0 M !0 4 % !0 4 % !0 4
M % !0 4 % !0!__7_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH _#;_@Y/_Y0B_MZ?]B5\+__ %?WPGH _!'_ (,=?^22_P#!0[_LHO[._P#Z
MC7Q8H _NWH * /\ * _8:_Y6PY/^TH/[7W_J;?'*@#_5_H _R?\ _@V%_P"4
M^_PX_P"P?^UA_P"JS\?T ?ZP% !0!^&W_!R?_P H1?V]/^Q*^%__ *O[X3T
M?@C_ ,&.O_))?^"AW_91?V=__4:^+% ']V] '^03_P '!DOA']HK_@O9^U#X
M8_9]?3]:O/%_Q7^!_P '8;SPU/'?VFL_&/3_ (9_"WX9>+H+./3=P75-/^(M
MEJ/AK6+>W9[J;Q'I.IW$V+ZYF10#_7PMXY(;>"*69KF6*&*.6X=51[B1$"O,
MR)A$:5@9&51M4MA< 4 1V5C9:;;1V>G6=K86<32M%:V5O#:VT;32R3S-'! D
M<2--/+)-*57,DLDDCEG9F8 M4 ?Y*_\ P6\?PY^T9_P<G?%CPE\&[Q=2N_%/
M[2_[*7P3.HZ!B=Y?BCH7@KX)_"GQ=:VD4$08:KX>\=Z9J7AN_CQ+*^MZ)>R%
MV,H50#_6HH * /S#_P""S?[27Q?_ &0O^"8O[7'[2'P#\26W@_XO_"SP+X?U
MCP/XEN]!T'Q/;Z1J6H_$/P=X>N;F30?$^G:MH.I9TO6+^)(=3TZ[MTDE681&
M2*-E /C'_@VL_;P_:=_X*(_\$]O$OQX_:T\>V/Q'^*&E_M*?$?X=6GB&P\&^
M#? T2^$_#_@WX8ZSI.GOHO@70O#VAO+;7_B;6)#?'3_MLZ3QQW$\J00A #^@
MJ@ H * "@#_)_P#^#EC_ )6%/B7_ -A#]C[_ -5/\** /]8"@#^ S_@]B_:G
M^#&N:#^R7^Q_H&NZ)XB^-_@[QIXG^-?CS3M-E2]U'X<^$-3\,'PKX8TK7;B&
M0Q:9?^.[N[OM8AT.7.IC3/"NG:Q>P6FGZIHD^J '[Z_\&QG[.GCC]G#_ ((Y
M_LUZ7\1-+O="\3_%F]\=_'I=#OWE^TZ=X7^*'B2XU+X?S/!(!]C_ +>\ 6GA
MCQ2+-0&@_MW;<I'>FYC0 ^=/^#@+_@O3\;?^"/OQ1_9U\ ?"?X&_"SXLV?QF
M\ ^,_&&LZA\0]5\6V%SI%SX:\1:9HMI9Z9%X:U"PB>">*\FGN)+HRR&18ECV
M*K[P#\_OV]_^#OT? CX8?LZ>%OV8/@O\-?B?^TW\1?V<?@+\:OCMJOC+4_%-
M[\#_ (*>,_C!\*O"_P 1KWX2Z+I'A_5?#OBSQ_X@T$>)H!J]XOC#P_I_AB,V
MFBWEQKGB7^W[#PV ?I1_P;?_ /!9/]IS_@KKX*_:MU7]IGP7\$O"6J_ /Q'\
M(M,\,W7P9\.>-?#-MJ]C\1--^(=WJ?\ PD=IXQ^(/CX2W6GS>#;06,^ES:3#
MY-W<I<VLTB1S4 ?!G_!5'_@[[^&7[-OQ'\4_ ;_@GY\,O"'[2GC/P;J%[H7B
M?X[>/M6U7_A1-KXCL6-O=Z5X#T/PAJ6E>)/BG9V-Z);.^\40>*O!OAZ:ZLY#
MX9N?%>DW5MK*@'Y"6_\ P=V_\%E/AI?:'XQ^+W[,'[.<GP\\17$=Q8VGB#X%
M_'#X>Z?K6G'=OA\(>+[CXJ/&TKA',%]<Q^)XHV5C):W**4H _LA_X(V?\%O_
M -G7_@L!\/?$9\':)??"#]H?X9V%A?\ Q7^ GB'5X-<O-.TB_EBL[7QQX#\3
M0V>EQ^-? -SJ;C2KC43I6D:WX=U=[73_ !)H>GPZMX:U+Q" ?HA^V?\ M9?#
M7]A?]E_XP_M9?%_3_%FK?#GX+>'+7Q'XDTKP-ING:MXMU*/4-=TGPWINGZ%I
M^K:MH6ESWMYK&MZ=;AM1UG3;."*22XN;N&*%VH _A"^*7_!Y9^W3\8/'^K^%
MOV&?V&/A;;:/)YH\/:;X_P!*^*WQ[^*%SI\#>4VM76E?"[Q'\.M(TZXGWQ3'
M38].\066E22"TDU;60%NI0#EOA'_ ,'DG_!0?X.?$K1?"?[;G[('P=UWPS9Z
MA /&>D>$O"?Q/^!GQGM-&N7DBFO=/@\;^,O%GAF6^L2#<6>G7WA'1[;53:R:
M9-K&EM<-JUD ?WY_LA?M7_!O]N#]G'X5?M2_ +6[G7/A;\7/#HUW07U*W@LM
M>T>[M;RZTCQ!X5\3Z=;7FH6^F>*?"?B#3]3\.^(K"WO[^UMM6TVZ6RO]0LC;
M7MP ?F5_P6/_ ."[?[-'_!(/PWX9T3Q5H-_\;_VCOB%IUQK'@7X ^$_$.G^'
M[ZW\-PM=6R>.?B/XFN;/6/\ A!?!5WJMI-HVCW::#KVN>)-4@U"+0="O;+1/
M$6I:* ?R(ZE_P=L_\%I/BA!>^//@S^R!\!+#X8:3?W._4?#_ , OC]\2--A@
MCD<#3_$WCB/XHKH\EQ;*5CGGTVP\-.TBEC!"#Y- '[T_\&]W_!P?^T/_ ,%8
MOCO\5_V;/VB_@+\(_ /BSX:?!G5OB]'\0/A)>>-= TR_&C>/O O@:7PMJ'P\
M\:ZOXXOK6\E/C8:A+K47CM$@ETF2R_X1]A?+-IX!_/O_ ,%S_P#@XW_:!^/-
MM_P4+_X)7ZQ^SW\'?#_PSTG]H'QW\"8_B;IVK^-KGQW+H?[/?[1]M=Z+K<EE
M=:H/#XU7Q$?AG8+J<:V(L[9=3NS:1 Q0T ?E_P#\$A/^"]OQR_X(_?#WXQ?#
MOX4? [X4?%G3?C'XR\/>--5OOB%J7B_3[[1[[P_HESH<5II__"-ZI8V\MI<P
M3B:3[3$TR3(=LA1@B@'^BG_P02_X*I_$S_@KI^R;\3OVA?BG\+_ WPHU_P !
M_M#^)/@S9Z%X O\ 7]0T;4-(T7X;?"WQO!J]Q)XCNKV]CU*2\\?7UE-'%/\
M9OLUE:.D:2O*6 /W!H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#^//_@J;_R?A\=?^Z8_^J;^'E?Y[^./_)T>
M*/\ NB_^L[E!_HIX$_\ )JN%O^ZY_P"M'G!^?=?DY^N!0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % 'Z"?\$LO^3\/@5_W4[_U3?Q#K]8\#O\ DZ/"
M_P#W6O\ UG<W/R/QV_Y-5Q3_ -T/_P!:/)S^PRO]"#_.L* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _#;_@Y/_Y0B_MZ?]B5\+__ %?WPGH
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MJVHR>%-*77+_ %7P+J]ZDFH^-?&MU!XXL;RWTGPWIMYXI /]#2@#\F?VPO\
M@N/_ ,$P/V"?C->?L^_M5_M)7'PR^+=AX=T'Q7>>%8?@S\>?'"P:%XFAFN-$
MO#KOP]^&7BGPXS7D-O))]DCU9[RW4 74$+.JL ?@Q_P6C_X.#/\ @DE^UO\
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MEMH(&23R30!_<1:V5G8Q&&QM+:SA+F0Q6L$5O$78 ,YCA1$+D*H+8R0H!)P
MH!9H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#^//_ (*F_P#)^'QU_P"Z8_\ JF_AY7^>_CC_ ,G1XH_[HO\
MZSN4'^BG@3_R:KA;_NN?^M'G!^?=?DY^N!0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % 'Z"?\ !++_ )/P^!7_ '4[_P!4W\0Z_6/ [_DZ/"__ '6O
M_6=S<_(_';_DU7%/_=#_ /6CR<_L,K_0@_SK"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M=?\ U ]7H _@!_X-<?\ @D)\)_\ @I+\7/BO\8?VJ+*[\;?LV_LK7?ADZ/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MTK_@EG_P3<L["!+>W_X80_9*NS&G :YU'X#> M0OIV]9+J]NKBYE/>65SWH
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MX5O=3\<W6HZIIUQ%KH\.1:1=:5<ZN ?2O_!43_@UM_9"_P"";O\ P39_:/\
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MKX;?^J]OJ /[@J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /X\_^"IO_)^'QU_[IC_ZIOX>5_GOXX_\G1XH
M_P"Z+_ZSN4'^BG@3_P FJX6_[KG_ *T><'Y]U^3GZX% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?H)_P2R_Y/P^!7_=3O_5-_$.OUCP._P"3H\+_
M /=:_P#6=S<_(_';_DU7%/\ W0__ %H\G/[#*_T(/\ZPH * "@ H * "@ H
M* "@ H * "@#X_\ VR?VG]/_ &;OAR\^FR0W?Q(\6+<Z=X(TIDCG6UD5,7GB
M?4H9<Q?V;HHDC,4,JR?VCJ<MG:"WEM!J,]II3ASRU^%:O_):/5_AOK9*02?L
M2^+OC;X\^"5IXQ^.-Q]KU?Q%K=[J7A&[FTS3M(O[SP3-9Z<-,O+NQTRULH$C
MN[]=4N-,FEM8Y[S2I;*]5IK*YLIF*JBIVCT6MNDNJZ:K1.RW[ ?7E9@% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M6 967X??#HJRD9!!$A!!&""#@CD9H 7_ (@AOV6?^CX?C_\ ^&]^'?\ \<H
M^J?^#G#_ (*/?&C_ ():?L-?LR_LW_LM^-]9\%?%G]H&VUSX;V_QCLI8+?QK
MX4^$_P #_!_@W2/&>H>%KN%5D\/>//%5_P"-?!EG8^+=/"7GARQ_X2*ZT"33
M_$+Z+K6D 'Y;?\$]O^#1S3_VN?@E\,?VNO\ @H)^U[\9I?&O[1G@[PU\8I_
MWPP_L2\\:V&A^/M'L_$OAZ?QQ\8?BA9_$";7O&6I:%J.G7>OVJ^"5CT2_DFT
MO^V-:>!KR@#\8O\ @Y"_X)B_L;_\$K/CK^S9\"_V4]6^)VJZKXP^#6N_$CXG
MR?%'QII'B_6G2[\9W7AKP7>QC1?#?A:RTH7@\.^*DF@@TJ&"Y^RPRQ*"DA8
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M_P %-'=E1$T7]D1F=B%556\_:7+,S' "@#)). .3C!H _//0]<_;=_X.M/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M._P4_9\\&_ K]M;1_%_QU^+7PY^#?A35O%'@+X&6OAK3/$OQ.\8:/X*T*_\
M$-UI/[1.M:K;:'9ZKK=K<:M<:9HVK:A#81W$MGIM]<I%;2@'W+_P<G_\H1?V
M]/\ L2OA?_ZO[X3T ?@C_P &.O\ R27_ (*'?]E%_9W_ /4:^+% ']V] '^7
M[_P=3_\ !,/7/V%OVS/#G_!0']GFRU+PE\'?VG?'!\67^J>$VGTD_"#]J[29
MF\4ZT^FWUAY,NBGXC-83_%/PI=P72W2>*['XAQV2:?8:/I*. ?UA_P#!/O\
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M:E=)96!^+'P]>ZNM*T:ZNYL6UG%XU\.W_BCX?G4;MDM-)/BP:O<N(;!Z /\
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MX@_X1N32_'ND6EO<>)-*\.:PVI6FJ1R:)%:16=[>@'WO0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]!/^"67
M_)^'P*_[J=_ZIOXAU^L>!W_)T>%_^ZU_ZSN;GY'X[?\ )JN*?^Z'_P"M'DY_
M897^A!_G6% !0 4 % !0 4 % !0 4 % !0!P?Q-^(_A;X2>!O$7Q"\9WILM
M\-V+7=R8PKW5Y.[K!8Z9I\+O&L^HZG>RP6-C$[QQ&XG0SRPVZR3Q.,7)I+=_
MUKO;[OO _$?X&_#[QE^WY^T-K7QF^*EM<Q_#'PM?68N=/\R9-,DL[.66YT#X
M:Z'.!"SVR([7GB6YLEAG\FZN[RXGM-7UVSN)^J35*'+'=Z+OYR?]/LM%>)_7
M]?\  _4_>^"""U@AM;6&*VMK:*."WMX(TA@@@A01Q0PPQA8XHHHU5(XXU5$1
M0J@* *Y ): "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^3+_@X$_P"#;ZP_
MX*1ZU<_M:?LD:EX5^'W[8EIHUAIGCGPMXFE70_ /[0FDZ%;"TTB?5-<M+&Y?
MPQ\5-)TJ*WT32?$^H0W&A^(](L=%\/\ B6;0[?3;7Q'8 'X"?!G_ (*F_P#!
MS7_P2=T2P^ WQO\ V5/B;\;? O@BT&A>&C^T9\!/B9\4K71]$TI([*#3_"'[
M07P?UW2(O&&E:8D$<-A/JWC;Q]::=8/#96+P:<NGQVX!WGQ?_P""T?\ P<L_
M\%#?AWXB^"/P2_X)]>(OAEX,^*FC:IX(\0>*?@W^QW\;=4O=0\+>+].N- UO
M1M7^)7QHU/QQ\.?#&E:IIFH7-I-XBATOPQ?:9'/)=VNOV$T<=U$ ?NA_P:Z_
M\$??VO\ _@ESX0_:J\9?M=6/@'PGX@_:8@^ Z^&_AKX9\80>-/%G@R+X5?\
M"WY=8_X3K4M"M)_!$-UJ;_$G38],MO"GBSQ9&!INH-?W5DYMXK@ _,#_ (+[
M_L9?M@?&3_@X _8L^,GPA_94_:0^*OP@\-:/^QI%XE^*WPX^"'Q,\;_#7PW+
MX8_:%\8:OXEC\0^._#/A?5/"VAR>'=(N+?5]=35-5M6TC2KBWU+4!;64\<[
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MT'3-1L1X:U*]T^TL8]9N=5U476K7H!^9O_!2;_@EI_P7&^,OB_P!^V7^U/\
ML[_M%?M!?M!?M8P>*?%'BOP7\&O@;XY^)]]\#?"/@R/PIH7P\\+^.K/X3>'-
M?\,_#2]U;2+R\_X1WX;B.WOM#T/0H[K7;NZ\7:CXGT[1@#_66^&]G=Z=\._
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M-? [_@K#_P '+O\ P2ET&Q^ GQO_ &4OB?\ &CP1X'LH]$\-+^TM^S_\5?B
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\>?_  5-
M_P"3\/CK_P!TQ_\ 5-_#RO\ /?QQ_P"3H\4?]T7_ -9W*#_13P)_Y-5PM_W7
M/_6CS@_/NOR<_7 H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]!/^
M"67_ "?A\"O^ZG?^J;^(=?K'@=_R='A?_NM?^L[FY^1^.W_)JN*?^Z'_ .M'
MDY_897^A!_G6% !0 4 % !0 4 % !0 4 % ",P4%F(55!9F8@!0!DDD\  <D
MG@#DT ?@K^T9\3?%_P"W3\?] ^ WPAEN)OAMX;UF14U%78:3?W-EOM_$/Q(U
M@QMY T;2;22ZL?#(E:6ZN+:9C8QKJ7B<:0O5"*I1YI;]>_E%;:OKT3WO:X'[
M2?"7X6>%?@Q\/_#OPZ\'6K0:/H%FL37,VUK_ %?4)/WFHZUJDRJOG:AJ=T7N
M)RH6&!6CL[.*"PMK6WBYY2<I.3Z_@NB7HM.OFW>X'H]2 4 % !0 4 % $%P9
MUB+VZK)(GS^20,SJH),,;M)$D4LG CDD)C5L>8 I+4 -MKN"Z5O*<%DP)8S\
MLD1;.!)&</&<JRE9%1U=)(I$66*1$/Z_K^OR#^OZ_K\RS0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M2XDJU*E.G]5II3G"%_:2TYI)7^5S^P2OQ@^M"@ H * "@ H * "@ H * "@
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M=-73U_I;'65B6% !0 4 % !0 4 % !0!Y_\ %KQ[#\*OA7\3/BA<Z=/J]O\
M#?X?^,_'MQI-LS)<ZI#X/\.:EXAETZW=(KATGO8].:VB98)V6252L4A&QNG!
MX=XS%X7"*:IO%8FAAU.6T'7JQIJ;U6D7*[U6BW6YG5J>RI5:MKJG3G4LNO)%
MRM\['^=!\3O^"Q?_  49^)GQ!U+Q]_PT]\1/ BW6I3WFE^#?ASJ?_")>!M L
MG<BTTBT\.Z=&EKJEG8P!(%N?$9UG4[PH;K4KZ\O)99W_ *5PO!7#6%PT,/\
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M=MW)W;?=MW?6]S[9KPCM"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /X\_\ @J;_ ,GX?'7_
M +IC_P"J;^'E?Y[^./\ R='BC_NB_P#K.Y0?Z*>!/_)JN%O^ZY_ZT><'Y]U^
M3GZX% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MU5)-TJ]*=&HD]FX5(QDD];.UGY:(NU1B% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__]7^_B@ H *
M"@#^/+_@Z=_Y&O\ 8K_[%[X\?^G+X35^T^$W\#//^ON _P#2,6?(\3_'@_\
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * /X\_^"IO_ "?A\=?^Z8_^J;^'E?Y[^./_ "='BC_N
MB_\ K.Y0?Z*>!/\ R:KA;_NN?^M'G!^?=?DY^N!0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % 'Z"?\$LO^3\/@5_W4[_U3?Q#K]8\#O^3H\+_]UK_U
MG<W/R/QV_P"35<4_]T/_ -:/)S^PRO\ 0@_SK"@ H * ,S6M6M- T?5M=O\
MSOL&BZ9?ZM>_9X7N+C[)IUK+>7/D6\8,D\WDPOY4,8+ROA$!9@*%KIW_ *\O
MS^X#YB_9L_;!^&?[2\FOZ;X:AU+PYXFT"22XD\,^(9+%=1U#06N&AM==TTVE
MQ*EW;J#;Q:M#&"^CWMS!;S/-;W%E>W>DZ<H:O5=U^O;\?Q:B'UA68!0 4 %
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MT;:S)OCD5XWV.Z[U.UV&&:&K:#+U( H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@#_];^_B@ H * "@#^/+_@Z=_Y&O\
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MXB>/_"W[>O@O3/#/CGQCX=TUOV9OA_=-I^A>)M;TBQ:ZE^('Q926Y-II][!
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'QY\4_V!?V
M2_C7X\UWXF_$WX4?\)+XX\3?V7_;>M_\)U\2]&^V_P!C:-I_A_3?^);X?\::
M3I%M]FTC2=/M/]$T^W\[R//G\VYEGGE_/<\\*^ N),TQ6=9UD/UW,\;[#ZSB
M?[4SG#>U^KX>CA*/[G"9A0P\.3#X>E3_ '=*'-R<\^:<I2E^BY%XL^('#.58
M7),DS_ZEE>"]O]5PW]E9+B?9?6<36Q=;]]B\OKXB?/B,16J?O*L^7FY(<L%"
M,?/O^'6/[!__ $0K_P R=\9/_GBUY/\ Q [PN_Z)?_S-\0__ #V/7_XCMXJ_
M]%3_ .8/AS_YTA_PZQ_8/_Z(5_YD[XR?_/%H_P"('>%W_1+_ /F;XA_^>P?\
M1V\5?^BI_P#,'PY_\Z0_X=8_L'_]$*_\R=\9/_GBT?\ $#O"[_HE_P#S-\0_
M_/8/^([>*O\ T5/_ )@^'/\ YTA_PZQ_8/\ ^B%?^9.^,G_SQ:/^('>%W_1+
M_P#F;XA_^>P?\1V\5?\ HJ?_ #!\.?\ SI#_ (=8_L'_ /1"O_,G?&3_ .>+
M1_Q [PN_Z)?_ ,S?$/\ \]@_XCMXJ_\ 14_^8/AS_P"=(?\ #K']@_\ Z(5_
MYD[XR?\ SQ:/^('>%W_1+_\ F;XA_P#GL'_$=O%7_HJ?_,'PY_\ .D/^'6/[
M!_\ T0K_ ,R=\9/_ )XM'_$#O"[_ *)?_P S?$/_ ,]@_P"([>*O_14_^8/A
MS_YTA_PZQ_8/_P"B%?\ F3OC)_\ /%H_X@=X7?\ 1+_^9OB'_P">P?\ $=O%
M7_HJ?_,'PY_\Z0_X=8_L'_\ 1"O_ #)WQD_^>+1_Q [PN_Z)?_S-\0__ #V#
M_B.WBK_T5/\ Y@^'/_G2'_#K']@__HA7_F3OC)_\\6C_ (@=X7?]$O\ ^9OB
M'_Y[!_Q';Q5_Z*G_ ,P?#G_SI#_AUC^P?_T0K_S)WQD_^>+1_P 0.\+O^B7_
M /,WQ#_\]@_XCMXJ_P#14_\ F#X<_P#G2'_#K']@_P#Z(5_YD[XR?_/%H_X@
M=X7?]$O_ .9OB'_Y[!_Q';Q5_P"BI_\ ,'PY_P#.D/\ AUC^P?\ ]$*_\R=\
M9/\ YXM'_$#O"[_HE_\ S-\0_P#SV#_B.WBK_P!%3_Y@^'/_ )TA_P .L?V#
M_P#HA7_F3OC)_P#/%H_X@=X7?]$O_P"9OB'_ .>P?\1V\5?^BI_\P?#G_P Z
M0_X=8_L'_P#1"O\ S)WQD_\ GBT?\0.\+O\ HE__ #-\0_\ SV#_ (CMXJ_]
M%3_Y@^'/_G2'_#K']@__ *(5_P"9.^,G_P \6C_B!WA=_P!$O_YF^(?_ )[!
M_P 1V\5?^BI_\P?#G_SI#_AUC^P?_P!$*_\ ,G?&3_YXM'_$#O"[_HE__,WQ
M#_\ /8/^([>*O_14_P#F#X<_^=(?\.L?V#_^B%?^9.^,G_SQ:/\ B!WA=_T2
M_P#YF^(?_GL'_$=O%7_HJ?\ S!\.?_.D/^'6/[!__1"O_,G?&3_YXM'_ ! [
MPN_Z)?\ \S?$/_SV#_B.WBK_ -%3_P"8/AS_ .=(?\.L?V#_ /HA7_F3OC)_
M\\6C_B!WA=_T2_\ YF^(?_GL'_$=O%7_ **G_P P?#G_ ,Z0_P"'6/[!_P#T
M0K_S)WQD_P#GBT?\0.\+O^B7_P#,WQ#_ //8/^([>*O_ $5/_F#X<_\ G2'_
M  ZQ_8/_ .B%?^9.^,G_ ,\6C_B!WA=_T2__ )F^(?\ Y[!_Q';Q5_Z*G_S!
M\.?_ #I#_AUC^P?_ -$*_P#,G?&3_P">+1_Q [PN_P"B7_\ ,WQ#_P#/8/\
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M ,]@_P"([>*O_14_^8/AS_YTA_PZQ_8/_P"B%?\ F3OC)_\ /%H_X@=X7?\
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M'/\ YTA_PZQ_8/\ ^B%?^9.^,G_SQ:/^('>%W_1+_P#F;XA_^>P?\1V\5?\
MHJ?_ #!\.?\ SI#_ (=8_L'_ /1"O_,G?&3_ .>+1_Q [PN_Z)?_ ,S?$/\
M\]@_XCMXJ_\ 14_^8/AS_P"=(?\ #K']@_\ Z(5_YD[XR?\ SQ:/^('>%W_1
M+_\ F;XA_P#GL'_$=O%7_HJ?_,'PY_\ .D/^'6/[!_\ T0K_ ,R=\9/_ )XM
M'_$#O"[_ *)?_P S?$/_ ,]@_P"([>*O_14_^8/AS_YTA_PZQ_8/_P"B%?\
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M';Q5_P"BI_\ ,'PY_P#.D/\ AUC^P?\ ]$*_\R=\9/\ YXM'_$#O"[_HE_\
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M\.?_ #I#_AUC^P?_ -$*_P#,G?&3_P">+1_Q [PN_P"B7_\ ,WQ#_P#/8/\
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M ,]@_P"([>*O_14_^8/AS_YTA_PZQ_8/_P"B%?\ F3OC)_\ /%H_X@=X7?\
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M'/\ YTA_PZQ_8/\ ^B%?^9.^,G_SQ:/^('>%W_1+_P#F;XA_^>P?\1V\5?\
MHJ?_ #!\.?\ SI#_ (=8_L'_ /1"O_,G?&3_ .>+1_Q [PN_Z)?_ ,S?$/\
M\]@_XCMXJ_\ 14_^8/AS_P"=(?\ #K']@_\ Z(5_YD[XR?\ SQ:/^('>%W_1
M+_\ F;XA_P#GL'_$=O%7_HJ?_,'PY_\ .D/^'6/[!_\ T0K_ ,R=\9/_ )XM
M'_$#O"[_ *)?_P S?$/_ ,]@_P"([>*O_14_^8/AS_YTA_PZQ_8/_P"B%?\
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M';Q5_P"BI_\ ,'PY_P#.D/\ AUC^P?\ ]$*_\R=\9/\ YXM'_$#O"[_HE_\
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M\.?_ #I#_AUC^P?_ -$*_P#,G?&3_P">+1_Q [PN_P"B7_\ ,WQ#_P#/8/\
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M ,]@_P"([>*O_14_^8/AS_YTA_PZQ_8/_P"B%?\ F3OC)_\ /%H_X@=X7?\
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M'/\ YTA_PZQ_8/\ ^B%?^9.^,G_SQ:/^('>%W_1+_P#F;XA_^>P?\1V\5?\
MHJ?_ #!\.?\ SI#_ (=8_L'_ /1"O_,G?&3_ .>+1_Q [PN_Z)?_ ,S?$/\
M\]@_XCMXJ_\ 14_^8/AS_P"=(?\ #K']@_\ Z(5_YD[XR?\ SQ:/^('>%W_1
M+_\ F;XA_P#GL'_$=O%7_HJ?_,'PY_\ .D/^'6/[!_\ T0K_ ,R=\9/_ )XM
M'_$#O"[_ *)?_P S?$/_ ,]@_P"([>*O_14_^8/AS_YTA_PZQ_8/_P"B%?\
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M';Q5_P"BI_\ ,'PY_P#.D/\ AUC^P?\ ]$*_\R=\9/\ YXM'_$#O"[_HE_\
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M\.?_ #I#_AUC^P?_ -$*_P#,G?&3_P">+1_Q [PN_P"B7_\ ,WQ#_P#/8/\
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M ,]@_P"([>*O_14_^8/AS_YTA_PZQ_8/_P"B%?\ F3OC)_\ /%H_X@=X7?\
M1+_^9OB'_P">P?\ $=O%7_HJ?_,'PY_\Z0_X=8_L'_\ 1"O_ #)WQD_^>+1_
MQ [PN_Z)?_S-\0__ #V#_B.WBK_T5/\ Y@^'/_G2'_#K']@__HA7_F3OC)_\
M\6C_ (@=X7?]$O\ ^9OB'_Y[!_Q';Q5_Z*G_ ,P?#G_SI/0?A9^P+^R7\%/'
MFA?$WX9?"C_A&O''AG^U/[$UO_A.OB7K/V+^V=&U#P_J7_$M\0>--6TBY^TZ
M1JVH6G^EZ?<>3Y_GP>5<Q03Q>MD?A7P%PWFF%SK)<A^I9G@O;_5L3_:F<XGV
M7UC#UL)6_<XO,*^'GSX?$5:?[RE/EY^>'+.,91\C/?%GQ XFRK%9)G>?_7<K
MQOL/K6&_LK)<-[7ZMB:.+H_OL)E]#$0Y,1AZ-3]W5AS<O)/F@YQE]AU^A'YT
M% !0 4 !&>#R#P0>] 'X>_MC?LS^)/V;_&]A^U!^SLUWX;TBRUE=3UW3M$B3
MR/ VM7LIBDO;2R"&V/@GQ";B33]1T2X@ETBS>]ET=H?[#U*UTVUZ:<U)<DM7
M;=_:7YW7??J!^E'[+7[2OAG]I3X?P^(+'[+IGC#1TM[/QOX6BF9GTC4W5Q'>
M6:S$W$FB:KY4L^F3R&1H]L]A-/-<V<LKY5(.#[Q>S_3:.J_'I;>0?359@% '
M)^.O&WAOX;^$/$/CKQ?J,6E>&_#&FSZIJEY*5R(HL+%;6T;,IN+^_N7AL--L
MXSYU]?W-M9P*\T\:4TG)I+=@?A;\/?#/C+_@HK^TKJGCKQG#=:9\(?!\T/VF
MS2:98=,\,P7,LFA>!M-N8_*>76_$#>?=ZUJ2&W$2-K&J0BW==*TJ7J;C2A9*
M\G^+_F>JM;I:_IJP/WST_3[#2;"QTK2[*UTW3-,M+;3].TZPMXK2QL+"RA2V
MM+*SM8$C@MK6UMXXX+>WA1(H842.-%156N0"W0 4 % !0 4 % !0 4 % !0!
M7N[6"^M;BSN4\R"YB>&5<X)1UP2K#E'7[R.N&1PKJ0R@T >">!M7G\&^,K_P
M!JLJ_9+R8RZ0[%51)G#/ (\RO(%OHL($E:28O'; ! 7>M)>\KKIOU?\ [;;_
M ,!^[>2OJU;Y_P!?/^F?0=9C"@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#Y<
M_;7^"&J_M'_LI?'3X+>'YHH?$OC?P%J=MX6^T2QV]I/XKTIX->\,6-]<RND=
MI8:CKNE:?87UZQ865I<S77E3>4(7^>XKRBIGW#F<911E&-?&X&K3P[GI#ZS"
MU7#J;^S"5:G",Y:\L)2=G:Q^K^!G'>$\,_%O@3C;,(.>69)GE)YJXQG4J4LI
MS"C7RK-,31I4X5*E>OA,OQN)Q5##QCS5ZU&%%2@YJ<?\Y_Q/X8\1>"_$.M>$
MO%NB:IX;\3>'=2NM(UW0=:LYK#5=)U.RE:&ZL;ZSN$CF@N(9$961U&>&7*,I
M;^#\3AL1@\17PF+H5<-B<-5E1KT*T7&K1JP=I0FG9J2^Z2:E&\6F?]&F79C@
M,WP&#S3*\9ALPRW,<-0QN!QV#K0Q&%Q>$Q-.-7#XC#UZ4I4ZM&M2G&I3J0E*
M,X24D]?>Z'X7?#3QM\8?B!X4^&OPZ\/ZAXG\8^+]9LM'T32-.@EGEFN+J=(S
M/.8TD%K86BLUSJ%_/LMK&TBFN;F2.&)W7?+<MQF;X["Y;@*,Z^+QE6-*C3@F
M]6[.I-I/EI4U[]2;M&,4VVK6EQ<1\1Y+PCD>9\2\0X_#Y9DN2X.MC\PQN*J1
MITJ.'H1YGJ]9U:DN6E0HP4ZN(KSIT*,)UJL(G^D;\#/AZ_PF^#7PN^&4MS]L
MG\">!/#'A:XNL*!/<Z/I-K9W,BA7D78T\4FPAV!7!W'.:_OK*L%_9N69?E_-
MS?4\'A\-S?S.C2C!OKNXWW^\_P";#Q XECQEQSQ=Q73I.A3XBXBS?.*5%_%2
MHX[&UL12A+;WHTYQ4M/BOL>JUZ!\@% !0 4 % !0 4 % !0 4 % !0!\"_\
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M9IDV S&IAZM>$*2K*AB,36I4:CI0G*A&DJO/44ZD_MZOK3\,"@ H * "@ H
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M?L_JE%QM:[A>I_X-_B7??F_S/Y$?^#B#XE7'B3]OP_":T:6U\)_L]_"#X:>
M?#NB+,[6%C)X@T&'XAWMW;Q.[L+FZL/%>AZ;<W$A\^>VT/3HY"ZV\35^R>&V
M%5+A[ZX[.MF.-Q6(JSM:4E2J?5XQ;TNE*E.:25DZDK6NSY/B"HY8_P!BKJ&'
MI4Z<8]%S1]HVO-J44W?7E5[6/%?^"*'[&_@G]L_]MK1O"OQ2TRWU[X6?"WP5
MKWQ?\;^&+QKF.T\7PZ'J6A>'/#OABZDMG1C9W?BKQ5HVIZM9R,L.J:#H^KZ9
M*0EX37=QUG=?),BG6PDW3Q>+KT\%0JQLY474A4JU:JO]J-*E.$)*[A4G"2^&
M\<<EP<,9C5&JKTJ4)5IQ>T[-1C'T<I1E+O&+74_T _B'^S[\$OBK\+-1^"7C
M[X6^"?$/PIU/2FT:3P-/X?T^VT&QL@@6W;1+6QM[8>'[W3G6*XTG4M$:PU#2
M+R"WO-,NK:ZMX)HOYVPV8X_"8N./P^+KT\9&?.L0JDG4E+K[24K^T4KM3C44
MHS3:DG%L^\J8>A5I.A4I0E2:Y>3E7*E_=27NM=''E:>J:TY?\Q#]K;X(I^S;
M^TY\>/@/;WUUJFG_  J^*7C#P=HVJ7R11WVJ>'M*UBY3PYJ=]'#B&.]U#0FT
MZ\NXX1Y*7$\JQX0)7]4Y-C_[4RK+\P<5"6+PE&M.$;\L:DH+VL8WUY8U.9*]
MW9*[>Y^:XNC]6Q->@FVJ56<$WNXI^ZWOJXV?^6Q_4)_P:Q?\BO\ MK?]A_X"
M?^F[XN5^4^+7\7(O^O>8_P#I6"/IN&/@QG^*A^54_"O_ (+&?&/6?C3_ ,%'
M_P!J'5=4N[B:R\!>/[WX.>'+&68RV^CZ-\)U7P7/:6"%F%O;W_B'2]=\0W$*
MX!U/6]0F*J\SBOON"L%# \,Y5""2EB,.L;5DE9SGC/WZ<MKN-.=.DG_)"*5[
M7/#S>M*MF.*;;M"HZ,4_LQI>Y9=DY)R]9-]6>V_\$;OVT/V+OV%O'WQ+^,7[
M2/@CXH>+_BE=Z9H_AKX1ZCX'\(^%/$NG^#=#O/[2E\<:BLGB+QIX;FL/$FM,
MFAZ7;W]G:2SVFAQZO8PWPM]=U*V;AXVR//,_P^%P65U\+1PBG.KC(5ZU6E*O
M4CR^PB_9T*JE2A[\W&3LZG))Q;IP9OD^,P>"J5:V)A5E5LHTG"$9*"=^=^].
M-I2]U)K:-UKS-'Z(_P#!4/\ X+(_L"_MT?L@^._@KX;^'WQU'Q.&I^%_$_PI
M\0>+_ G@?3]+\,>*]&\0:<U_>RZGI_Q)U>_LH-2\(S>)-!NS;:=>&6#5"IMS
M(L,L7S7"G!/$609UA\=5Q& ^J\M6EBZ='$UY3JT9TY\L5!X2G&3C6]E4C>2L
MX[J[/0S/.,!C<)4HQA7]K>$J4ITX)1DI*[NIMJ\.:.SWMI>\?Y<_ WC#6OAY
MXV\'>/\ PW<&T\1>!O%/A_QAH%VK.K6NM>&=6L]:TJX5D974PWUE!*&1E<%<
MJP(!7]7Q%"GB:%?#55>EB*-2A47>G5@X377>,FMOO/F(3E3G"I%VE"49Q?:4
M7=/KU7;[S_3E_;4\.>#/$?[&O[57BF;POX=O[Z__ &6_C5J5OJU[H>F7.I%3
M\(_$DMC*;V:VDN1)!"(! PFS"(XQ&RA5V_RQD52O3SO**2JU8QCFV!BX1G-1
M_P!\I*2Y5*VKO=6=_.[/TO&1A+!XJ7+%MX:LTW%-_P *5M=]#_+QK^K3\R/]
M'_\ X) ^ _ VH_\ !-?]DJ^U#P9X4O[VZ^'=]+<WE[X<T>ZNKB5O&/B?=)/<
M3V<DTTAP,O([,>Y/\/\ ,W&F(KQXHSB,:]:,5B8)1C4FDOW%+9*:2^[[[GZ)
ME%.#RW"-PBVZ;NW&+?QR/F7_ (..88;?_@G%';V\4<$$'QU^%L,$$*+%###%
MIWBY(XHHT"I''&BA$1%5450J@  5ZGAFV^)KMMMX#%MMZMMRHW;?5MG-Q#_R
M+O\ N/2_*9_!_P"#/^1P\*?]C+H7_ITM:_H"O_ K?]>JG_I#/AH?''_%'\S_
M %LZ_CP_5C_/K_X.'?\ E)?X\_[)C\)/_46CK^B_#;_DEZ'_ &%XS_TZ?!<0
M?\C*?_7JE_Z2?0W_  ;#?\GJ?&__ +-=\0?^K8^$M>;XJ_\ (DP'_8UA_P"H
MF+.CAK_?*_\ V#/_ -.TC^T;XP?";P+\=_A=X[^#OQ-T6+Q!X#^(WAK4_"OB
M;2I2$>;3]2@,?VFRN-CM8ZKIT_DZEH^I0@7.EZK:6>H6CI<VT+I^(8+&8C+\
M7A\;A:CIXC#585:4UTE%[27VH25XSB])P<HO1L^QJTH5Z4Z-2/-3J1<9+NGV
M=G9K=.VC2:M8_P Q[]MK]DOQW^Q-^TC\0OV?O'2RW3>&=0^W^#_$QMS;VGC?
MX?ZL\T_A+Q?8KEX@-3L$-OJEK!-<1Z1XAL=9T)[B:XTN=Z_J?(LXP^>Y9ALQ
MP]E[6/+6I7YG0Q$-*U&77W9.\&U%SIRIU$K21^:XW"5,%B*F'J:\KO"72=-_
M!->JT?:2E'HS&\<_M7_%[XA_LU?!7]E7Q)KCW/PL^!/BOQ]XK\&V DN/-DN?
M'3V-PMKJ@>5XKJ'PM='Q1)X:D5(Y+"W\::[9#-NUN$O#Y1@L-FF.S>E3MB\P
MHX>C7E96MA^97CU3JKV2JZ^\Z%.3LTQ3Q56IAJ.%E+]U0G4G!:[SMOT?*^;E
M[<[74_;/_@WZ_P"";O\ POOXI+^V'\7M!\_X/?!;Q!''\,](U2VS9_$#XO:;
MY-Y;ZKY4JXO/#GPU9[;5)9 !;7WC&31K..:ZAT/Q'IZ_"^(O$_\ 9^$_L7!U
M+8W'4V\5.#][#8*6CA=-<M3%:P2U<:*G)Q7/2D>UD&7>WJ_7*T;T:,K4HM:5
M*R^UYQI:/LYV7V9']NGB7_D7/$'_ &!-5_\ 2"XK\(I_Q*?^./\ Z4C[1[/T
M9_DA5_8I^4'^A'_P;W?\HR/A=_V/_P 7_P#U/=5K^<?$;_DJL7_V#X+_ -1H
M'WV0?\BVG_U\K?\ I;/Y-_\ @N!_RE+_ &L/^PW\-/\ U2?PUK]?X#_Y)+*/
M\&+_ /4_%'RV=_\ (TQ7K2_],4CZD_X-WOV5OAS^T)^UQXS\>?%'PWIOC#0?
M@#X"L_%WA[P[K=C;ZEH<WQ \0:];Z7X8U;5+&[6:TOET"QL_$&IZ;:W%O(D>
MNQ:5JBO'-I<:R^5XDYOBLMR>AA\)5E1J9CB)4:E2G)PJ+#4Z;E5A"2UC[24J
M<)-.+=-SCM*1T\/X6GB,7.=6*G&A34HQDKQYY2M%M/1\J4FKVM*S6JM+^A[_
M (+Z?L[_  [^*/\ P3V^)_Q+U/PSI+?$7X#R>$/%W@#Q5'8646M:78WGC7PW
MX:\5: -3$(O3X?U3PWK-_/<:,DZ64^L:;H6H/"\^EVVW\V\/,RQ.$XCPF%C5
MG]6S#VU'$4>:3ISDJ%6K1J<E^7VD*L(I3<7)0E4C=*;9]!GN'IU<OJU'%>TH
M<DZ<K)22YXQFKV;Y7"3O&Z5XQ?V3_/BK^C3X$_TB/^"0'[)/PR_9J_89^!MY
MH/A?25\>_&GX8>#_ (K?%3Q;<:;:-XB\1:K\1-"M?%EKH&J:@5DFDT7PAI>M
M6WAG2M*CD738X["YU'[*=2U74[R]_F3C/.,5FF?X^-2K/ZO@<56PF$HJ3]E2
MAAJDJ+J0C>RG6G!U9SMS/F4;N,(1C^BY1A*>&P-!QBN>M2A5JSM[TG4BIJ+>
M]H)\J6B5K[R;E_(+_P %V?V>O 7[.W_!0;QKI/PT\/:=X2\)?$KP1X-^+-OX
M8T6TMM/T/1M4\1?VMH?B*/1M/M(H8-/L=1\0>%]3UPV42+!;7>J745I'#9+:
MV\7[-P!F6(S+ARA/%5)5JV%KU\&ZM24I5*D*7).FZDI7<I1IU8T^:[;4$Y.4
MFV?)9YAZ>'Q\U3BHQJPA5Y8I*,7+FC*R6B3E!RVCJ]$?0/\ P;4ZE<V7_!0;
MQ5:0R.L&K_LU?$6QO$#L%DB@\:_"_4X]ZCY7*7.GPE=P^7DC'->;XH13X<HM
MK6&:89I]F\/BXNW:ZET-^'&UCY+^;#5$_P#P.D_T\OTE_95^V'\/OV9/B+\!
M_$VG?M?GPY'\!/#VH>'O&WBZ;Q=XFO\ PGX<AF\)ZS::KHQU;4].U/2;FXMI
M]5BM;3^QA<R#7I+A-(%G>R7D=N_XGDN)S7"YA2EDWM'F%2-2A15&E&M5:K4Y
M0GR0E&:34&Y<]E[.SG=)-GV&,IX:I0DL7R^PBXSGSR<(^X[J[33WM[M_>VUN
M?B[XM_X.$/\ @F_^SII\?PQ_9Q^%'C[QIX6\,J;/1(?A;\/O"WPK^%:11#85
MTB'7[[P]KL"%U ,J^ 8X9U!G2:8,C/\ <4?#GB?,I/%9GB\/0K5?>J/%XBKB
M\6V_YW2C5IOT^L76W*K7/&GG^78=>SP]*I.,?A]E3A3I?+F<)?\ E-=U>_O?
MCM_P4C_X+B^%_P!OGX ZY\ (_P!DBR\'03^(?#7B;PM\2/$7Q0C\5>(O".LZ
M!J]O<SZEHV@6?P]T.UL[O6/#S:WX4O6/B&Z3^S/$%ZP#/%&C?:\,<!U>'LQI
MYB\XE6:IU:57"TL(Z-*M"I"249U)8FHY*%3DK17LHOGI1N]U'R,QSN./H2P_
MU10]Z,HU)5.:4'&5[J*@K.4;Q?O/23]#\!M#UG4/#FMZ/XATBXDM-5T+5=/U
MG3+N)BDMKJ&EW<-[97$;#E9(;F"*5&'(901T%?H=2G&K3J4IJ\*D)4YI[.,X
MN,D_5-H\&,G&2E%V<6I)]FG=/[S_ $YO^"C4ZW7_  3S_;-N4!5;C]ECXT3J
MK8W*LWPYUV0!L9&0&P<'&>F:_E?AI6XCR-=LWP"^[%4S]+S#_<,9_P!@M?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MC;I/&WA'PI9+?+8SV45Q'>I'J.L6\NJ1WNCPVO53BJ<7.6C:]++MWN_7RTU
M_8'X'_!OPK\!_AQH7PZ\)1 VNFHUSJNJ/"D-YXAU^Z2+^U->U *7)N+R2*..
M&)YKC[#IUO8Z;#,UM90USSDYR;?R79=OZM^LC^OZ_K\V>MU(!0 4 % !0 4
M% !0 4 % !0 4 ?.?[0.D3PV&C^+K .ESI%U]GN)81,9$CEQ+;39C(2)(I(I
M%FFD4D[H(Q)&,*^D.L=[_P##?CZ_?<4KZ6=M=?ZW_'UN>P^!_$D?B[PKHNOK
MM$M[:)]K1=@$=] 3!>($620QH;B-Y($D82?9WB:1$9BBQ)6;7]?K_7;8?]?<
M=72 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* &221PQR2RR)%%$C22RR,J1QQHI9Y)'8A41%!9F8A54$D@ FANVKT2U;?0J
M,93E&$(RE*4E&,8IN4I2=E&*5VY-M))*[;LKW1XX_P"T=^SS&[QR?'CX,I(C
M,CH_Q0\$*Z.AVLCJ=<!5E8%65@"I&" <BO/_ +6RM77]IY?=.S_VS#:-;I_O
M'JGI_EL?9+PW\1))2CP%QHXR2DFN%L]:::NFFL"TTTTTT[-;7&_\-(?L[_\
M1>O@O_X='P1_\O:/[6RK_H9Y?_X6X;_Y8/\ XAKXB_\ 1 \:_P#B*Y]_\PA_
MPTA^SO\ ]%Z^"_\ X='P1_\ +VC^ULJ_Z&>7_P#A;AO_ )8'_$-?$7_H@>-?
M_$5S[_YA#_AI#]G?_HO7P7_\.CX(_P#E[1_:V5?]#/+_ /PMPW_RP/\ B&OB
M+_T0/&O_ (BN??\ S"'_  TA^SO_ -%Z^"__ (='P1_\O:/[6RK_ *&>7_\
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MX;$4US5*%:$?YITJD%WWDFMO-?.Q<JC$* "@ H * "@ H * "@ H * "@ H
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MI0PZKU$U=J4%M>YWY/A_K.84(M7A3?MY_P"&EJK[:.HX1?D^NQ_27_P<[_\
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MJ0I4J<%>=2I.2C"$4MY2DTEZGV<YQA&4YM1A"+E*3T2C%7;?DEJ?YK7_  5
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M"*G_ *C5CWLX_P"1;B_^O:_]+B?YL-?T\?G)_JA?L7_\F=_LG_\ 9M/P)_\
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M5"LDUSJ]@ZW(NM%O"\0A9%B,+B5B[(@!XS_P\X_9P_Y\OB3_ .$QI?\ \TE
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M>.XU"ZBM(7G>+Q!-*L*R3*TK1PRNJ!BD3L C 'W[0!\A_&/]MCX._ WQM=>
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M3W+:_HUEIUF=-LM2TC2IECFMM7OW:Y-UK5F4B,*HT0F<RJ45' /JF@#\\/\
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MJ-F--O=2U?2H5DFN=7L'6Y%UHMX7B$+(L1A<2L79$ /&?^'G'[.'_/E\2?\
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M'I<$-S?FU$T4+FVM[BYM(I70S!RC7$9**^S<^U' /B7_ (><?LX?\^7Q)_\
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M:*L_$E]\/XO$44/A:YTVTU-?$&F6VFR&358KN:U-L+;4-065-ME.)"S1E&V
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MMJ]^[7)NM:LRD1A5&B$SF52BHX!]4T ?GA_P\X_9P_Y\OB3_ .$QI?\ \TE
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M/_A,:7_\TE 'UG\%?C5X.^/7@Z3QSX'CUF/18]9OM#=-<L8=/O1>V$-I//\
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MO V@VOCV/6O%>LV.AZ6^H>'M/M[);W4)E@M_M4\6O7$D,/F,H>1()2HYV'%
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MQ%HGAC2FO?#FFP6:ZEK^I6NE6+7<R>()GAMA=7<1GE2&5XXM[K$Y 1@#[MH
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M/:3?NU20;-K%QNVT >(?\/./V</^?+XD_P#A,:7_ /-)0!]E_"CXG>&_C)X
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MM 'TO>74=C9W=[*':*SMI[J58PID:.WB>5Q&&95+E4(4,RJ6P"P&2H!^?/\
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M\NXZ):VM_5MC$^UW?_/S<?\ ?Z3_ ..5SF_M*G\\_P#P.0?:[O\ Y^;C_O\
M2?\ QR@/:5/YY_\ @<@^UW?_ #\W'_?Z3_XY0'M*G\\__ Y"BZO&(5;BY))
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M (J*>$/_ $2W'O\ X1Y)_P#/D/\ B'Q_:R_Z+A\+_P#P*\8?_&*/^(&<1_\
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MIZR:\I3=M]X=3T?_ (.=_P#DR#X+_P#9U?A7_P!5%\9ZY?"O_D?8[_L45O\
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MAOI)?P[@OBFOA>(ZT\PK.5'/:W+BYR;4*>*J3;P]9*[48QG-T'KRPHU;Z*E
M^SS?+85<!"-"%IX*%Z26\J:C:I#:[DXQ4[VO*<;)>\T?P::)K>L>&M:TCQ'X
M>U.^T77_  _JFGZWH>LZ9<RV6I:3K&E7<5]IFIZ?>0,D]I?6%[;P75I<PNDL
M%Q%'+&RNBFOZ!J4X5:<Z52,9TZD)4ZD)*\9PFN6<9)Z.,HMII[IVZGPL9.+4
MHMJ46I1:=FFG=--:IIZIK]#_ $>_^"9_[>FC_M]?L<#QYJ%S8P?&/P)HESX(
M^./A^V$5N;7QC:Z+,UKXJLK%-A@\/>/+"(Z]I7EQ"TL[_P#MSP[;SW4OAZZG
MK^9>*N'Y\/9T\/%2>"Q$U7P%1W=Z#GK1E)[U,/+]W/[4H\E5J*JQ1^B99CEC
M\(JC:]M!<E>*TM-+XDOY:B]Y=$^:*^%G^;A7].GYT?Z$?_!O=_RC(^%W_8__
M !?_ /4]U6OYQ\1O^2JQ?_8/@O\ U&@??9!_R+:?_7RM_P"EL_DW_P""X'_*
M4O\ :P_[#?PT_P#5)_#6OU_@/_DDLH_P8O\ ]3\4?+9W_P C3%>M+_TQ2/U2
M_P"#6K_DJ7[7O_8@?"K_ -2+Q?7R7BS_ +KDO_81C/\ TW0/3X8_BXO_ *]T
MO_2IG[X_\%F?^48W[7/_ &(>A?\ JP?!]?GO!'_)59-_V$5/_4:L>]G'_(MQ
M?_7M?^EQ/\V&OZ>/SD_U0OV+_P#DSO\ 9/\ ^S:?@3_ZJ[PM7\EYY_R.LW_[
M&F8?^I=4_3\'_N>$_P"P:A_Z:@?QF_\ !RQ_RD&\)?\ 9LOPY_\ 4Z^*U?MW
MA?\ \DY5_P"QIBO_ $QA#X_B/_?X?]@U/_TNJ9W_  ;:?\I#]6_[-V^)?_J2
M?#VGXG_\DW3_ .QGA?\ TSBA<._\C!_]@]3_ -*IGU7_ ,'+_P"R1X]@^*WP
MX_;'\-:%<:K\-]8\!Z-\*/B'?:9:7%S)X3\8>'=9\0ZCX?UGQ&\4;)::/XJT
M/7;70],OY/\ 1H-4\,O87D\-SJVBP7?D^%V<X=X3$Y)5J*&*AB*F,PT9R25:
MA4A2C4IT[[SHU*;J2BM7"KS*ZA-QZN),)4]K3QD8MTW35*HTK\DXRDXN793C
M+E3V3C9M.2B?SE_L[_M-?';]D_XA1?%/]GOXCZU\-/'":=<Z-/JNE0Z7J-IJ
MFC7DMO<7.CZ[H.OV&K>'O$&E275I9WG]GZWI5_:1WUG9WT44=Y:6]Q%^EYEE
M67YOAGA,RPL,50YE-0FYQE":32G3J4W"I3FE)KFISB^5N+NI-'SV'Q-?"U/:
MX>HZ=1)JZLTT_LRC)2C):7M)-75]T>_?&+XN?MV?\%!]"^('QT^,WC+QM\6_
M!7[.OANPU?Q3XCO[#3/#GP[\ 6OBKQ3H?A73+#2M$\,:1H7@NQ\4^)M:US38
M8[+3-+3Q#K.F:?<7UV\VD^'+BXM/.P6#R#ARIAL!@J-#!U\RJRA2IQE.KB<3
M*E2J592G4JU)5W2I0IR=Y2E3A*2BO?J)2Z*U;'9A&I6K3G5AAXJ4I-*-.FIR
M44DHJ$%*3:6BYI)7=E ^"Z^A. _T\O\ @H;_ ,HY_P!L+_LT_P",/_JM-:K^
M5>'/^2ER7_L<8'_U+IGZ9F'^X8W_ +!:_P#Z:F?YAM?U4?F9]2_#_P"*_P"U
MU^Q3JVG:Y\-_'7Q8^ =Y\3_!GAOQAI]UX=UC4M"TGX@^"-:M6U#PUK@A@FDT
M+Q3IJK<7*6L\T-\^C:DNIZ;)]AU2VU&S@\G$83)L]A.GB</@\Q6$KU:$HU80
MJ3PU>#Y:M.[2J49/E3:32G'DG[T''FZJ=7%X)J5.I5H.I",URR:52$M8RLO=
MDM^_*[K1J43QOXG?%CXG_&KQ=?>/OB]\0?&/Q-\;:C%;VUYXJ\=>(M5\3Z[-
M:6BE+*R_M'5[J[N(K"RC8Q6-A"\=G90_NK:"&,!%[<)@\)@:,<-@L-1PM"+;
MC1P]*%*FG+64N6"2<I/64G>4GJW<QJU:M:;J5JDZLWHY3DY2LME=W=ET6W:V
MQ^['_!"O_@F+XX_:"^.'@O\ :L^*GA>_T/\ 9Y^#GB"S\6^$[C6K22U'Q9^)
M'AZZBO?#-AX?MKN$?VEX0\+ZQ#!K7B;7 DVE7E[IMMX2M?ML]WKCZ#\!Q_Q5
MA\NP%?*,)6C/,L;3=&LJ<K_4\-47+5E4<6N6M5@W3I4V^>,9NL^51I^U]S(\
MLGB*\,55BXX>C)3CS77M:D?A4;WO",K2D[*+<>2_Q']W]?S^?<!0 4 % !0
M4 % !0!Y9JOP,^"6NZE?:SK?P=^%FLZOJ=S+>ZEJNJ_#[PEJ.I:A>3N7GN[Z
M^N]'FNKNYF<EY9YY9)9')9W8Y- &?_PSM^S]_P!$*^#G_AL?!/\ \HJ /8Z
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ML-0L+F"]L;ZR^'/@ZUO+*\M94GM;NTNH-%CGMKFVGC2:">%TEAE1)(W5U#4
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MKX.?^&Q\$_\ RBH ]@CCCACCBBC2**)%CBBC54CCC10J1QHH"HB* JJH"JH
M   % '#^*OA=\,O'=Y;:AXW^'7@3QEJ%G;?8K2^\5>$?#_B&\M;/S9)_LEM<
MZOIUY-!;>?-+-Y$3K%YLLDFS>[-0!R__  SM^S]_T0KX.?\ AL?!/_RBH ]*
M\/\ AWP_X3TBT\/^%M"T;PUH-AY_V#1/#^F66C:19?:KF:]NOLFFZ=!;6=M]
MIO+FYNY_)@3SKF>:>3=+*[L 5O$_A#PGXVTU=&\9^%_#OB[2%N8KU=*\3Z)I
MNOZ:MY DJ0W:V.JVMW:BYA2:9(IQ%YL:2RJCJ'8, >??\,[?L_?]$*^#G_AL
M?!/_ ,HJ .R\)?#KX?> ?[0_X03P+X.\%?VM]D_M7_A$O#&B>'/[3^P?:?L/
M]H?V/8V7VS[']LO/LGVCS?L_VJY\G9Y\N\ Z74=.T_6-/O\ 2=6L+/5-*U2S
MNM.U/3-1M8+[3]1T^]@DMKVPO[*YCEMKNSO+:66WNK6XBD@N())(I8W1F5@#
MRC_AG;]G[_HA7P<_\-CX)_\ E%0!N>'?@[\(O"&JP:[X2^%?PX\+ZY;)/%;:
MSX=\#^&=$U6WCN8G@N8X-1TS2K6[B2X@=X9TCF598G>.0,C,K 'H] 'DM[\
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MH>HHD6H:-KFG6>K:5?1QRQSQQWFG7\-Q:7*)/%%,B30NJRQ1R !U5E /,?\
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MX;T#Q7HSS0W+Z1XET?3M=TM[BW):WG>PU2VNK5IH&8M#*82\9)*,N: /._\
MAG;]G[_HA7P<_P##8^"?_E%0!U_A/X;?#KP%)>R^!? /@OP7+J:01ZC+X3\+
M:'X=DU".U:5K:.]?1["R:Z2W::9H%G,BQ-+*8PI=RP!U=[96>HV=WI^HVEM?
MZ??VT]E?6-[!%=6=[9W43P7-I=VTZ20W%M<02/#/!,CQ31.\<B,C,M 'DO\
MPSM^S]_T0KX.?^&Q\$__ "BH V?#_P &/@]X3U>T\0>%OA1\-?#6O6'G_8-;
M\/\ @7POHVKV7VJVFLKK[)J6G:3;7EM]IL[FYM)_)G3SK:>:"3=%*Z, >E4
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M?E_9Z^ 4TDDTWP.^#\LLKO++++\-/!<DDLDC%GDD=M#+.[L2SNQ+,Q))))-
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M6L%CI^G:?901VUE86%E;1Q6UI9V=M%%;VMK;Q1P6\$<<44:(JJH!SOBSX?\
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MJWTD4,=O')>:C?Z1<7=R\<$44*--,[)#%'&I"(JJ 9/_  SM^S]_T0KX.?\
MAL?!/_RBH ]=MK:WL[>"TM((;6TM88K:UM;:)(+>VMX$6*&""&)5BAAAC18X
MHHU5(T5410H 4 XWQ7\,OAMX\N+2[\<?#WP/XSN["%[:QNO%?A/0?$5Q96\C
M^;)!:3:OI]Y+;PR2?O'BA9$9_G*EN: .4_X9V_9^_P"B%?!S_P -CX)_^45
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M_AWX4UJ.&:W35_#7@KPUH6J);W "W$"7^EZ7:W:PSJ LT2S!)  '5@* /1*
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M\V*.39O16H [B2..:.2*6-)8I4:.6*15>.2-U*O'(C JZ.I*LK JRD@@@D4
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M:7?CCX>^!_&=W80O;6-UXK\)Z#XBN+*WD?S9(+2;5]/O);>&23]X\4+(C/\
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MMN['PKX?TGP]9W5X8HX#=W%KI%G9P37)@ABA\^5&E\J*./?L15H ZB@ H *
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M.E:-6VDU[.[>B2=V[).VO=7T:;Z[NUFQ)/FLEN^VK;Z+YZ:/7M'[7F7[0?\
MP6!_9\^$>LW_ (7^'6D:I\<O$&F7#VU]?>'=5L]"\")-$TL<\%IXQFM=8DUB
M2*1%VW6B:%J&BW$3^;:ZO<8*-_.?%_TCN#^'L36P&287$<5XNA)PJU\'B*6$
MR=3BVI0I9G*&(EB6FDU5PF#Q&$G%WABI--']$<(?1PXOX@PU+'YYBL/PIA*\
M%.E0QF'JXS.'&23C*KED)X:.%33:E2QF-P^,IR5IX1*2<?D&#_@NKXA6_P#,
MN?V=-&FTS>Q^Q0?$2^M[\1_PK_:;^%+JW+CC=)_9*@]HQQ7YU#Z5F/\ :7GP
M/A'1O\$.(*T:G+V]H\HE&_G[.WDS]%G]%/+_ &5J?'&,5:WQ3X?HRI<VFOLU
MF\9VO?3VG;57/T*_9*_X*9_!;]JGQ18_#F#1/$?P[^)^I6M_=Z;X9ULP:QI.
MMKIEE=:IJ$&A>)-.2(7%U8Z58W>HW,.JZ3HF;:!S:/>2(Z)^P^'GCCPSQ]CZ
M62+"8W)<]KTZM3#X'%.GB<-C%0HSQ%>&#QU#EYZE&A2JUIPQ.&P<I4X3=)5>
M67+^/>(?@;Q-P#E]7._K>"SO(:%2C3Q&.PJJ8;%8-XBM3P]">,P%>_)3K8BK
M2HPJ87$XV*J5(*M['F@Y?H_7[4?B@4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 9NLZ<NL:/JND/*T"ZIIM]IS3JH=H5OK66V,JJV%9
MHQ+O"DX)&#C-14A[2$X-V4X2@VNG,FK]-K]_N.G!8EX/&83%QBIO"XFAB5!N
MRFZ%6%51;5VE)QLVEIOJ?SFW_P#P;I?#._OKV^?]HGQ>KWEW<73+_P (=IAV
MFXF>4KD:P <%\9  /4 =*_"*O@1EE6K5JO/\?%U:DZC2PN&:3J2<FE>[LF^K
MOWN?Z64OVDF>4J5*F_"K)).G3A3<O]8LRCS.$5'FY?J4K<UKVOIMK:Y4_P"(
M<?X8_P#1Q?B__P (W3?_ )<UG_Q 3+/^B@S#_P )<,:?\5*,\_Z-1DG_ (DF
M9?\ S"?)'[;'_!'_ /9U_8O^ WB;XO>,?VD/%MWJR^7HO@#PE%X0T@7_ (S\
M9WO-AH]N'UU/)L+>!+C4M<U$AAI^DV=S)#'=7\EA8W7SG%7A5P_PIDV)S;&<
M08^;@O9X3"K#895,7C)IJA0ALU%R]^K/_EW2C.3NU%'Z[X)?3'X[\;>/,MX-
MR7PIR?"823^N\19X\_S*K0R'(J$DL5CIQ>"C&KB:DY4\'E^%>N*QN(I4VZ5)
M5<12_GEK\(/] C]K/^"+_P"P9/\ M.?'"'XS^/M+D;X*? _5M-UB:.YA(MO&
M_P 08)/MWAOPQ;M*OE76G:3-;QZ[XI\L3A+6+3=(GCA.OP74'[#X1\%RS[-E
MG6.IO^R<HJPG!2C[N,S"-IT:2OI*EA]*U=_S>RIZ\\G#^+/IH^/2\*^!7PAP
M_BE'CGCO"8G"8>=*?[W(N'7?#YGG,^6[IXK%WGEN47Y&ZTL9CJ<G++?9U_[5
M?%7B;0_!'A;Q'XR\2W\&D^&_".@ZOXEU_4[@E;;3=$T'3[C4]4OIBJLPAM+&
MUGGDV(S;$.U&.%K^LJ]:EAJ%;$5YQI4,/2J5JM23M&G2I0<YSD];1C&+D]-E
MU/\ $K*<KQ^>YKEN2Y7AZF,S/.,PP>69?A:2O5Q6.Q^(IX7"4*:;2=2M7JPI
MQNTN:6K6Y_G8_ML?M4^+_P!L+]H/QK\7_$US=1Z7=WTVD^!O#\L@:V\+>"K"
MXF70]'MHHWDA6;R&^U:G<QNYOM3N+JY+E'C5?X5XQXFQ/%>>XO,ZTI?5^>5'
M+Z#ORX?!4Y-4HI7:4JB_>U7O*<GJTD?]&?@OX5Y-X.^'V1\%Y53I2Q&$P\,1
MGN8PBE4S;/L13@\SQ]2=E*4)UH^PPD7?V6"H8:BO=IQ9\F@$D  DD@  9))X
M  '))/0#^M?+'ZJ?N-^QC_P0[^.O[1?AC2OB3\6]>B^!G@#7K2*_\/6.HZ9/
MJ7C_ %NPN(C-9ZK_ ,([(UC;Z3I5XC02VCZGJ$%_=6LIN4LXXQ 9_P!DX5\'
M,YSS#TL?FV(_L3!UHJ=&C*E[;,*M.2O&JZ+<(8>$E;E563J.+YI4J>TOXC\9
MOIQ>'OAGFF+X:X9R^KQ_Q'@)RH8^6!QU+!\/9;BJ57DJX/$9JJ6)J8W%4E&<
M:U'+\/.E1J?NJF,A7A4I0_2'4O\ @W.^"LVDO#I7Q[^(-EK1B*I?WGA_1;ZP
M6;'$C:?'=6<I0'G9]NR>FX8);[V?@/DKI6IYWF<:O_/R5/#2A?\ Z]^RBVO+
MG7KL?S?A_P!I'Q8L5S8KPSX;J8+F_A8?-\UHXE0ZVKU(UZ2FELWAI1OO%I6/
MPM_;K_X)I?';]A?4[34O%4=OXW^%6MWBV.@_%'PW;7(T<:A)%YT>B^(K27?/
MX?U=U\U;2.[;[-JGV:YET^>01O&OXYQEX>9UP=)5J_+CLKJ34*68X>$HPC.2
M35+%4G=T)MWC"3DZ=5KW7&34#^Y? SZ2OA_XZX6K1R2I6R7BC!4I5\QX3S:I
M1_M"E053D^N8"O3M1S7 ZP]IB,/&%7#SG&&+PN&YZ$Z_YTU\"?T.7M,_Y"6G
M_P#7]:?^E$=5#XX_XH_F)[/T9_IP^#O^2?\ A;_L3M#_ /3):U_H;0_W.C_V
M#4__ $TC_F$SS_DI<W_['F8?^I]4_P T7XE?\E&^('_8[^+/_3]?U_G]FG_(
MSS+_ +&&-_\ 4FJ?]-63?\BC*_\ L7X/_P!1Z9[I^P[_ ,G?_LW_ /97_!G_
M *<XZ]O@G_DK>'?^QOA/_2I'POC/_P FD\2_^R%XJ_\ 5)CC^U7_ (*[.$_X
M)U?M,Y3?N\->&%'RJVP_\+!\)$2?,&VE2,AEPRG!4@X*_P!9>)__ "0?$7_8
M-AU]^.PJ\^E_RTO<_P 3OH<PYOI(>&FMN3&9[/=J]N%L\TNNMWL[I[/>\?B;
M_@WA<G]D[XGH<83XTZ@1Z_/X7\/YSZ]!CI_5OE? YWX4Q:[9M7_&C0\E^;^1
M^V_M&(I>*_!LNLN :"?RS_.K?F_\E:\OW[K]G/\ /<* "@ H * /'_C-\?O@
MU^SSX8/C#XT?$3PY\/M 9I([>ZURZ<7-_+$H>6'2]+M([C5-4FB5E:6/3[.X
M>)65I0JL#7F9KG.59'AGC,VQV'P&'3Y?:8BHH\TOY:</CJ2_NTU*77N?;<#>
M'''/B7FLLEX%X9S3B3,*<%5KT\OHKV&#HMV5?'8RM*E@L#1NG:KB\11IOEDE
M)6;/SJN_^"X'_!/ZUN)X%\?>+;Q879%N+3P7>O;SA3CS('EN8'9'ZJ9(XR1U
M5#FOA)>+_ L6U_:5>7*VKPP.)G%V_E?LUS?UJ]S^E:/T#/I$U:=.H\DX:I.<
M5+V=7B_)U4A?[,U"I4BI+JE4EZJQ0_X?G?L!?]#?X\_\(B;_ .3JC_B,7 W_
M $'XO_PVXDW_ .)!?I$?]"SA/_Q+\I_^37Y?<'_#\[]@+_H;_'G_ (1$W_R=
M1_Q&+@;_ *#\7_X;<2'_ !(+](C_ *%?"?\ XE^4_P#RPM6/_!</]@*^O;2R
M_P"$W\9VAN[B&W%S>>"[F.T@,TBQB6XECO)&CA0MND<12%4!(4XQ50\8.!9S
MC#^TL1#FDH\]3 8BG3C=I<TYNZA%7O*3T2U=M69UOH$_2)HTJE59-PS7=.$I
MJA0XMRFI7JN*;5.C#VJYZLW[M.%US2:C=7N?DC_P<-:KHGB?Q[^R_P"+=!NH
M-4TG7_A7J.HZ/J]N\K6]_H^IZTVH65Q;A]J^3=0307 ;RHY'0Q"3.Q%7\P\=
MJE*OC^&L11G&I2K99BYTJD'S0G2G7H3A.+V:FG&2?56L?UY^SMP&,RO@WQ8R
MO,:$\+C\KX[RW!8O"U8Q5;"XNCE>+H8NA.VJE&KAE"<;R7-2NF?9G_!1BZ-Y
M_P $1?@S<$[B_@7]E9"3G),.D^&X3G/.?W?)YR><G.:^S\0Y<WA-@Y=\-PWO
MY/"J^[WWW];'XA]'&E['Z;_B!3M:V>>*SM_CS3'3_P#;CZD_X(;_ /*._P"&
M7_8X?%+_ -3O6:]WP?\ ^2#RS_L*S7_U98H_)_IU_P#*1/$/_8BX7_\ 511/
MUXK]./X\"@ H SM8Q_9&J94,/[.OLJRQNK#[-+E625)(G!'!61'C8<.C*2M1
M4TA-]H2WUZ/H[I_-?>=.#<EB\*XR<9+$T'&47)2C+VL+23BXR33U3C*,D]4T
M[,_C[_X-[U%M^V9\9K- $CC^!OB>-4)RRK;?$7P'&BY.6.U6PQSDG!.<U_+7
M@3>/$N;0_P"I+KHEK'&89/:]K.5M_6]S_9;]HI%+P8X::3M'Q)RJ*ZV3X<XJ
MT;UU]WJ];==3^Q6OZH/\8 H * "@ H * "@ H * "@ H * "@#__TO[^* "@
M H * /'OBI^SS\ ?CI)HDWQM^!OP>^,<OAE-0C\.2_%3X9^"_B%)X?CU9K)M
M5CT1_%VAZPVE)J;:=I[:@E@;=;UK&R-SYIM8-G;A,RS'+_:+ 8_&X)5>5U5A
M,57P_M.3FY/:>QJ0Y^3FER\U^7FE:UV8U</0K\OMZ-&MRWY?:TH5.6]K\O-&
M5KV5[;V5[V7+@?#G]DW]ECX/^)8_&?PD_9H_9_\ A;XPAL[O3H?%?PY^#?PY
M\$^)8M/OU5+ZQCUWPSX:TK5$L[U$1;NV6Z\BX5%6:-P!MTQ.<9MC:3H8S-,Q
MQ=%R4G1Q.-Q->DY1^&3IU:LX<T;NSM==!4\+A:,N>EAJ%*=FN>G1IPE9[KFC
M&+L^JOKUM9<WT!7G&Y\JZO\ L)_L0>(-6U/7M>_8V_95UO7-;U&]U?6=9U?]
MGGX1:EJVKZMJ5S+>:CJ>IZC>>#I[R_U&_O)IKN]O;N>:YNKF66>>625W=O7A
MG^?4X0IT\[S>G3IQC"$(9CC(PA""Y8PA&-=1C&,4E&*5DE96L<KP."DW*6#P
MLI2;<I/#TFVWJVVX-MMZMMZ^9[[X%\ ^!/A?X5TKP+\-/!7A+X=^"-"6[30_
M!W@7PYH_A+PKHRW]_=:I?+I7A[0++3](TY;W4[Z]U&[%I9P"YO[RZO)@]Q/+
M(_G8C$8C%UIXC%5ZV)KU+>TKXBK.M6J<L5"+G4J.4Y6C&,5S-VC%16B1O"G"
ME%0IPA3A&_+"$5"*N[NT8I)7;;=EN[ZW9B_$[X._"+XV:%9^%_C-\*_AQ\7/
M#.GZM#KUAX=^)W@?PQX]T*QURWM+W3[?6;/2/%>EZOI]MJT%AJ6HV4.HPVR7
MD5I?WMLDRPW4Z2Z87&XW U)5<#B\5@ZLH.G*KA:]7#U)4W*,G3E.E.$G!RA"
M3BWR\T8MIM1<55HT:T5&M2IU8I\RC5IQJ14K-72DI).S:O:]FUK?W?&--_8.
M_8<T;4;#5](_8R_91TK5M*O;74M+U33?V=_A!8ZCINHV,Z75E?V%[:^#8;FS
MO;.YBBN+6ZMY8I[>>-)89$D17KMEQ!G\XRA//,WG"<7&<)9EC)1G&2M*,HNN
MTXR3:::LT[.]V8K X%--8/"IIIIK#TDTULTU!--/9I_=8^KJ\@ZCY$^.O[ _
M[&G[2^M7'B;XX_LY?##Q]XJN[6WLKOQ?>Z$NE>,;NTM$\JTM[KQ=X>ETGQ)<
MQ6D1\JT6?4Y/LL6(X-B!5KV<OXASO*X*E@,SQ>'HIN2HQJ<]"+?Q-4:BG23;
MUE:&N[:M[W)7P&#Q+<J^'I5)6LYM<LVNSG'ED[=+R]+:J5SX"_L+_L@?LP:C
M)K7P'_9Z^&GP[\120/:GQ7INA+J/C!+26)H9[.'Q?KTNK>)K>SN8F9;NT@U6
M.WN\YN8Y6"FIS#/\YS6*AF&98K$TUK[&53EHWO=-T::A2<DTK2<&UT:'0P.$
MPSYJ&'ITY;<ZC>=NJYWS2L^JO;O?3ET/$O[$7[%_C3Q#K7BWQC^R'^S!XL\5
M^)-3O=;\1>)_$OP"^%&N^(=?UG4IWNM0U?6M:U3PC=ZEJNIW]U++<7M_?75Q
M=74\CS3RO([-4TL^SRA3IT:.<YK1HTH1ITJ5+,,73ITX15HPIPC6480BDE&,
M4DEHDK)#E@L'.4ISPF&G.3<I2EAZ4I2;U;E)P;;;W;=WUM<]8^&/P=^$7P3T
M*\\+_!GX5_#CX1^&=0U:;7K_ ,._#'P/X8\!:%?:Y<6EEI]QK-YI'A32](T^
MYU:>PTW3K*;49K9[R6TL+*V>9H;6!(N3%8W&XZI&KCL7BL95C!4XU<57JXBI
M&FI2DJ<9U9SDH*4YR44^7FE)I)N3EK2HT:,7&C2ITHM\SC2IQIQ<K)7:BHIN
MR2O:]DEI;WN/^)G[+7[,?QJ\06_BSXR?LY_ CXM>*;32[?0[7Q+\3/A%\/O'
MGB"VT2TN;R]M-'M]9\5>'=6U&'2[:\U'4+NWT^*Y2TAN;Z\GCB66YG=]L+FV
M:X&FZ."S/,,'1<W4=+"XS$8>FZDE&+FX4JL(N;C"*<K7:C%-OE2C%7"X:M+G
MK8>A5DDHJ56C"I)13;2YI1D[)MM*]KM[W]V+X;?LJ?LO?!KQ$WB_X0?LV_ /
MX4^+7TZYTA_%'PV^#WP\\#>(FTF]D@EO-+;6_"_AO2M3.G7<MK:RW-D;HVT\
MEM \L3-"C*\5F^;8ZE['&YIF.,HJ2G[+%8W$UZ7/&ZC/DJU9QYDI-*5KJ[74
M*>%PM&7/1P]"E.UN:G1IPE9[KFC&+L^U_6VG-[Y7G&Y\M_M6_MD? ?\ 8K\)
M^"?'G[0OB/4_"7@SQS\0=/\ AM8>(;#P]JWB.UTO7=2T'Q#XBM[K6[30[:^U
M:WTA;#PUJ"S7ECIVHS13O;*UJ(7DN(/6RC),PSRM7P^6THUJ^'PTL5*G*I"D
MYTX5*=-JG*HU!S<JL;*4HIJ^KV.7%8RA@XPGB).$*E14E)1<E&3C*2<DDW:T
M7JKV[:MQ^;=4_96_X)3?MXSK\38?AS^S-\<-5\31R:G>>,_A[JND67B77);@
M[[B[\2:I\.M9T;7[[5XW5HKMO$4DFK64L<EI<_99(WB7TX9MQ=D"^JO%9K@(
M4O<C0Q$9NE32V5*&)ISIQA_+[.T&M5=.YSO"Y7C_ -ZJ>&KN6KG3:4GYR=.2
MDW_BU7=V:/"OB[X[_P""4?\ P2'\%>(OB!X'^'OP+\*_&/\ L76;?P-X+\&1
MV'B3XS^+]:BT^6*VT!-=N'\2>,/"?AJ^N9(;77]=U6^L?#]G!*[7/]H:B;33
M[OT,%A^+N,J]/#U\3F%;!<\'7KUW*E@:--R5ZGLU[.A5JI)RITX*523CIRQY
MG'"K/*\IA*I"G0A6Y9*$(6E6G*WPW]Z<8MZ2E*2BNMVU$_@*^)WQ!\0?%KXD
M_$+XJ^+'MY/%7Q,\<>+/B!XE>TCDBM'U_P 9:]?^(M8:UBEEFEBMFU'4KDP1
MR32ND6Q6E=@7;^B,+AZ>#PN&PE&_LL+0HX>E??V="G&E"]DE?EBKV2]%L?"5
M:DJM6I5E\56I.I*VW-.3D[7N]WU?WG]T7_!N7^SWK7PB_8:U3XF>)M.N--U;
M]H?XD:EXXT2.Y4Q2R_#WP]IMCX3\*7,ELW[R,:CJMCXLUFQG=4%]HVJ:5>0A
M[::&:7\"\2\RAC,_CA:4E*&6X:.'G;5+$U)2K5E?JXQE1IR5O=G"<7=IGVW#
MV'E1P3JR5GB*CG'O[.*Y(-[;M2DN\9)ZWN?O]7YV>\?(OQI_8&_8O_:'U:X\
M1?&3]F?X1>-O$]Y)YM_XMNO"-AI7C#47">6O]I^+= 72?$FI*B<1QW^JW$<7
M6-%;YJ]G \0YYEL%2P6:8VA2CI&C&M*5&/\ AHU.>E'_ +=BOGL<E; X/$-R
MK8:C.3WFX)3?K.-I/?J_N^SXKX?_ ."0'_!-+PS-Y^G?L@?"VY<R&3'B!?$G
MBV'<3G'V?Q5K^LVX3/2+RO+ X"  )7=4XSXHJJTLZQ:7_3MTZ+^^E3@[^?YV
M]W&.49;';"4G_BYI_A*4E_76_N_=GP]^&7PX^$OANU\'?"SP#X,^&_A.Q_X]
M/#7@7PSHWA/0K=MJJ9(]*T*RL;(2NJCS)O(\V0C=([$YKY_$XK$XRJZ^+Q%?
M%5I?%5Q%6=:H_6=1RE;LKV72]_=[J=*G1BH4J<*<5]FG&,(_=&R_#[CN*P+/
M#/C=^S+^SW^TEING:3\>O@S\.OBS::,UPVB-XW\+:7K=]H;7BJEVVAZK<VYU
M31C=+'%]J_LR\M/M'E0F;>8HMG?@,US+*Y2GE^.Q.#E4LI^PJSA&?+JO:03Y
M)VZ<\7:[M>[1A6PV'Q*2KT:=5*_+SPC)QOORMZQOUM^A\H^'?^"0?_!-3POJ
MT6M:9^R!\*[F\ANA>)%XAC\0^+M*,P?>%DT+Q9KVMZ'-:[L?Z%+ISV17Y#;E
M/DKV*G&7%%6#IRSK%J+5KTW3HSMY5*-.%1/^\IJ76][,Y8Y1EL7S+"4F[_:Y
MIK_P&4I1^35O75'Z)Z7I>F:)IFG:+HNG6.D:/I%C::7I.DZ7:6]AIFEZ986\
M=I8:=IUC:QPVME8V5K#%;6EI;116]M;Q1PPQI&B)7S4YRJ2E.<I3G.3G.<VY
M2G*3O*4I.[E*3;;;=VW=WU/0244HQ222222LDEHDDK))+1)+[K'S+\>_V(/V
M1_VH+V'5OCU^S[\-/B1KUO;Q6</BG5] BL_&"6, 80:?_P )AHKZ9XH;3H-[
MF#3VU<V<+,SQPJ[,:]3+\^SC*HN&7YCBL+3;YG2A4O1YGO+V,^>ES/K+D4GW
M=CFKX+"8IWKX>G4EMSN-IV6RYURRLNW-;TO:7*?!#_@G1^P]^SCXAMO%WP:_
M9G^&/A'Q;8$/IOBR;2KGQ1XGTB0-O\[1?$/C"\\0:QHUP2=K7&EWMG.\?[IG
M:,;%VQ_$N?9G3='&YIBZU&7Q4>=4J4_\=.C&G":\IJ2\M>:,T<OP6&EST<-2
MA-;3MS27^&4W)Q_[=_#<]2^(G[)G[*WQ?\2S>-/BS^S-^S]\4/&-S:6EA<>+
M/B)\&OASXV\2SV-A'Y5C93:[XE\,ZIJDMI91$Q6EN]VT-M&=D*(I(;DPV<9O
M@J2H8/-<QPE!-R5'#8W$T*2E)WE)4Z56$$Y/5NUV]6:5,)A:LN>KAL/5FTES
MU*-.<K+9<THR=ETU^_[.A\,/V8_V;/@CK-_XC^"_[/7P.^$/B'5-,?1-3U[X
M8?"?P%X!UG4=&DNK6^DTB_U3PIX>TB^O-,>^L;*\>PN)Y+5KJSM;@Q&:")TG
M%YKFF/A&ECLRQ^-IPG[2%/%XS$8B$9I.*G&%6K.*GRRE'F2O:35TFU)TL-AJ
M+<J.'H4I-<KE2I0IMJ][-QC%M72=MKJ^EO>X[Q'^P_\ L6>,/$&M^+/%O[(/
M[+OBGQ3XEU6_UWQ'XE\1_ #X3ZWX@\0:YJMU+?:IK.MZSJ?A"ZU'5=5U*]GF
MO+_4;^YN+R\NII;BXFDF=W;>EGV>4*=.C1SK-J-&E"-.E2I9CBZ=.G3@N6$*
M<(UHQA",4E&,4E%*RV1,L%@IRE.>$PTI2;E*4L/2E*4F[MRDX-MMZMMW;WO<
MZGX:?LL?LP_!?Q#-XM^#O[./P&^$WBNXTRYT2X\3?#3X0?#[P)XAGT:\GM;J
M[TB;6O"WAW2=1DTRZNK"QN;FP>Y>UGGL[6:2)I+>)TQQ6;YKCJ:HXW,\PQE%
M34U2Q6,Q&(IJ<4U&:A5JSCSI2DE*UTI-)J[4JIX7#49<]'#T*4[<KE3HTZ<N
M5[KFC&+LVEI?IK:RYO>" P*L RL"&4C((/!!!R""."".?>O/-SY'?_@G_P#L
M'2.\DG[$O[(TDCLSN[_LW?!MG=V)+.[-X*+,S$DLQ))))).<U[*XBX@6BSW.
M4ELEF>-T\OXZ_+[CD^H8'_H"PG_A-1_^5GJOPO\ V=?V??@@=>;X+_ GX-_"
M%O%,-C;>)V^%_P ,?!/@ ^([?33>G38->/A/0M(.KPZ>=1U V,6H?:4M3?WI
M@6/[5/YO'B\RS+'^S^O9AC<;[%R=+ZWBJ^(]DY\O,Z?M:D^1RY(\SBE?EC>_
M*C6EA\/0YO8T*-'FLI>RI0I\UMN;EC&]KNU]KZ6N^;RC_AWY^P7_ -&1_LB?
M^(V_!K_YB3_/\Z[/]8^(?^A]G/\ X<\;_P#+S+ZA@/\ H"PG_A-1_P#E9]#?
M#[X:_#GX2^%[/P1\*O '@KX9>"]/GO+FP\(?#[PKH7@SPO8W.HW,MYJ%Q9Z!
MX<L-,TJVGOKR:6[O)8;2.2ZN999YF>5W=O-Q.*Q.,JNOB\37Q5>2BI5L35J5
MZLE%<L4ZE24YM1BDHIO1:+8Z*=.G2BH4J<*<%=J%.$815]7:,4DKO5Z:^9Y+
MXY_8Y_9%^)_BK5?'7Q*_97_9P^(?C;7FM7USQCXY^!_PR\6^*M9>QL;72[)]
M5\0Z_P"%M1U?46L],LK+3K5KN\E-O8VEK:1;;>"%$[,/G><X2C##X7-\SPU"
MG=4Z&'Q^*HT8<TG.7)3IU8PCS2E*3Y8J\I-N[;9E/!X2K)SJ87#U)RMS3G0I
MSD[*RO*4&W9))7>RMI9'5_"S]G3]GSX&7.L7GP3^!/P;^#MWXB@L[;Q!=?"S
MX8^"/A]<Z[;:?)<2Z?;ZQ/X2T+1Y=3@L9;JZDLXKUIX[:2YN'A5&FD+8XO,L
MRQZA''YAC<:J3DZ:Q>*KXA4W*RDX*M4FHN224G%*]E>]BJ6'P]"[HT*-%RLI
M.E2A3YK;7Y8QO:[M?Y6UYN^\9>"O!OQ%\,:OX*^(/A+PSX[\&^(+=;/7_"7C
M+0=*\3^&-;M$GBN4M=7T'6[2_P!*U*W2Y@@N%@O;2>)9X8I0HDC1UYZ%>OAJ
ML*^&K5</7IOFIUJ%2=*K3E:UX5(.,XNS:O%IV=NII.$*D7"I",X2TE"<5*,E
MV<6FGK9ZK[M#YJ_X=^?L%_\ 1D?[(G_B-OP9_P#F)KU/]8^(?^A]G/\ X<\;
M_P#+SF^H8#_H"PG_ (34?_E9]4Z-HVD>'=(TKP_X?TK3="T'0M-L=&T31-&L
M;73-(T?2-,M8K+3=*TK3;**&RT[3=/LH(+2QL;2&*UM+6&*WMXDBC1%\B<YU
M9SJ5)RJ5*DI3J5)R<YSG-\TISE*\I2E)N4I2=VW=W;.I)12C%*,8I*,4K)):
M))*R22T22T\CQGXF?LL_LQ?&GQ!!XM^,?[.7P'^+/BJUTNWT.V\3?$SX0_#[
MQWX@M]%L[B[O+32(-9\4^'=6U&+2[6[U"_NK?3X[E+2&XO;N:.)9+F9W[L+F
MV:X&FZ."S/,,'1<W4=+"XS$8>FZDE&+FX4JL(N;C"*<K7:C%-OE2CC5PN&K2
MYZV'H59)**E5HPJ244VTN:49.R;;2O:[>]_=;\-?V5OV7_@QXAD\7?![]F_X
M"_"CQ9+IMSHTOB?X:_!_X>>!?$,NCWLUM<7FE2:UX7\.:3J3Z;=SV5G/<V+7
M1M9YK2VDEB=X(F0Q6;YMCJ?L<;F>88RBI*:I8K&XFO34XIJ,^2K5G'F2E)*5
MKI2:NKVD4\+AJ,N>CAZ%*=N5RIT:=.7*]US1C%V;2TOTUM9<WM6K:3I6O:7J
M&B:[IFGZUHNKV5SINJZ1JUE;:CI>IZ=>PO;WEAJ%A>136E[97<$CP7-K<PRP
M3PN\<L;(S*W#"<Z<XU*<Y0G"2E"<).,X23O&491LXR35TT[IZZ6-FE).,DI1
M:LTU=-/=-.Z:?FOO/SRUK_@D3_P36U_6DU^^_8^^$T%]&SNL&BVFM>&M%)<Y
M(?PUX<UC2O#DB@@;$DTIDC'RQH 6KZ2GQEQ13I^SCG6,<=KU'"K4_P#!M6G.
MI_Y/YZ'GO*<NE+F>$I7\KQC_ . Q<8_^2^6BTE]:Z9^SA^SYH_PKN/@9IOP.
M^$EM\%[U(5U#X3CX=^$Y/AWJAM[FROHIM7\'S:3+H.K70O\ 3K#4'N]2L+NZ
MEU"RM;Z69[N%)D\>69YE/%K'RQ^,>.C?EQGUFM]9AS)Q:A6YU4@G&4HVC**Y
M9.*23<9=:P^'5+V"H4E1>]+V</9O5/6%N5NZ3NTW=7U:1Y:/^"?O[!@((_8C
M_9%!!R"/V;?@UD'U'_%$CD?7\JZ_]8^(?^A]G/\ X<\;_P#+S+ZA@/\ H"PG
M_A-1_P#E9]/^(?#/ASQ=X>UGPCXK\/Z)XG\)^(])O=!\0>&/$.E6&M>'M=T+
M4[62QU+1=9T74K>YTW4])U"RFEL[W3KZVGL[NUEDMYX7B=TKRJ56K1J0K4:E
M2C6I3C4IU:4Y0J4ZD'S1G"I%J4)QDE*,HM--736C.F48SBX2C&4))QE&23C*
M+5G%Q=TTUHTU:VCO<^7_ /AWY^P7_P!&1_LB?^(V_!G_ .8FO5_UCXA_Z'V<
M_P#ASQO_ ,O.;ZA@/^@+"?\ A-1_^5G:_$3]DG]F#XL?#OP]\)OB)\ /A'XH
M^&_@^Q33?!?@Z]\">'H=%\#V*116Z6W@:WL=/M6\%QI;V\-LG_"+R:0RVT2V
MXQ"/+K##9QFN#Q-3&8;,<92Q5:7/7KQQ%1U*\FV[XARF_;N[;_>\^KO;<NIA
M<-5IQI5*%*5."M"#IQY8+:T$E[FBM[O+MZ(^</!O_!)+_@F[X#UR#Q%H'[(7
MPGFU.VN?M<'_  D]EK'CG3HK@<HZ:)XVUCQ!H@$;8>&/[ T<$BK)"$D1&7TZ
MW&/$^(INE4SG&*+5G[*4*$FNWM*$*537K[R;Z[V.>&4Y="7-'"4KIW][FJ+_
M ,!G*4?333I>SY?T+L;&RTRRM--TVSM=/T[3[:"RL+"QMX;2RLK.UB6"UM+2
MUMTC@MK:V@C2&""%$BAB18XT5%5:^;E*4I.4FY2DW*4I-N4I-W;;=VVW=MMW
M;U=SO2222222LDM$DMDET21:I#"@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M5T>-:9_R$M/_ .OZT_\ 2B.O&A\<?\4?S/M'L_1G^G#X._Y)_P"%O^Q.T/\
M],EK7^AM#_<Z/_8-3_\ 32/^83//^2ES?_L>9A_ZGU3_ #1?B5_R4;X@?]CO
MXL_]/U_7^?V:?\C/,O\ L88W_P!2:I_TU9-_R*,K_P"Q?@__ %'IGNG[#O\
MR=_^S?\ ]E?\&?\ ISCKV^"?^2MX=_[&^$_]*D?"^,__ ":3Q+_[(7BK_P!4
MF./[8?\ @K3;/=_\$[_VG(8V57_X1'09<ONQMM_'7A6XD "JY+&*)PF=J[B"
MS* 37]9^)W_)"<165W]4HO\ \!QF&E^2\OR4O\2?H>SY/I(>&#Z3S/-Z3>FG
MM^&LYHIZRCM*HMG?R>A\+_\ !N_<V\G[*'Q1MHY$:XMOC1?-<1JREXUG\+Z
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MKT:5/$X:=+$X=U:%:E4E[37J'PX4 % !0 4 % !0 4 % !0!_]/^_B@ H *
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M=VW=WNS[2,8QBHQ2C&*48Q2LHQ2LDDK))+1)+[K&O4#"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M,HS:-1X">+Q5>=;%U,+F&'I5:^#IS<W.GA*N#Q4/;2E&.*PV'<(4/Z$/A?\
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M^&0H * "@ H * "@ H * "@#_]3^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H 0@$$$ @\$$9!'H1W_P ^M "T % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!S'C;QGX6^''@SQ=\0_'&M6GAOP5X"
M\,:_XS\8>(M0\T6&@^%O"^E7>N>(-:O3#'-,+32])L;N^N?*BEE\F!_+C=]J
M4 ?&O[)__!3S]@G]N;Q?XE\ _LF?M,> _C=XQ\'^&QXO\2Z!X5@\2P7VD^&C
MJ=EHPUBX&NZ!H\3VHU34;&R8P2S2+-=1;HU5MU 'WC0 4 ?G-\4/^"M__!.#
MX+_M#W/[)_Q1_:R^''@W]HBT\3>#O!MU\+=4@\5/KUOXG^(%CH.I>#]'EN+/
MPY<Z.ESKECXHT"XMBVJ+#$FI0BZFMV68( ?HS0!^4GQ6_P""XW_!)WX'_$KQ
MS\'_ (K?MM?"KP7\2_AIXGUCP9XZ\):E:>-YM1\-^*= O)=/UG1;Z33_  E>
M61N].O89;:X^S74\2RQLHD;!H \__P"(AG_@B[_TD!^#G_@!\0__ )B: .N^
M'_\ P7=_X)%_%/QYX*^&/P__ &Y?A+XF\>?$;Q;X<\">"?#=E9^.8KWQ!XN\
M7:Q9Z!X;T.SDO?"%K:)=:MK&H6=A;O=7-O;K-<(9IHH]SJ ?J-XV\9^%OAQX
M,\7?$/QQK5IX;\%> O#&O^,_&'B+4/-%AH/A;POI5WKGB#6KTPQS3"TTO2;&
M[OKGRHI9?)@?RXW?:E 'Y%_\1#/_  1=_P"D@/P<_P# #XA__,30!N^'?^"^
M_P#P1M\4:G#I.F_\%"?V?[:ZG^Y+XBUC7?"&F+R!^^UKQ;H&AZ-;\D?Z^_CX
MRW"JQ8 _37X3_&7X0_'GP78?$?X'?%/X=?&3X>ZK+<6^F>.OA9XV\-_$#P??
MW%HP2[M[3Q)X4U+5M'N+FTD81W=O'>/-;2'RYD1\B@#TF@#YO_:;_; _9>_8
MR\#)\2/VI_CK\-_@9X.N)Y+33-2\?>([32KOQ!?PHLLVF>%="4S^(/%NK10L
M)Y=*\,Z7JNHQVX:X>U$*O(H!^.47_!U)_P $/I/$4>A?\-:Z_':22/%_PD\O
M[._[1R>'4D5PB"1O^%6_VVL<K'*7!T/[-&F9)Y8HQN4 _87]EO\ ;)_9:_;7
M\!2?$W]E/XZ?#WXX^#+6[&G:KJ/@C6ENK_P]J3"1H],\5^'+R.S\2^$M3GAC
M:ZM=.\3:/I-[=61COK:"6SECG< ^F* "@ H * "@ H * "@ H \;^./[1/P$
M_9E\%R_$;]HGXS_##X'>!(I_L@\5_%7QQX<\"Z)<WYADGCTO3[[Q'J.GQ:GJ
M]Q%%(;32-/\ M6IWC*8[2UFD(1@#\5O&_P#P=)?\$1/!>I7&DI^UY?\ C"\L
M[M[.[?P1\"?C_K6FQ/')Y;S6^N3_  TT[0M5M!C>EWHNI:G;S1_-;R3;AM /
M4/A-_P ''O\ P15^,NMZ9X<\,_MV^ /#NLZK*L$,?Q6\%_%OX,Z/;3/@A-1\
M8?%7P!X0\$Z>O('VBY\2+:;OE%QN!# '[->$O&/A'Q_X=TOQ?X$\4^'/&OA/
M7+87FB>*/"6N:9XD\.ZQ:,2JW6EZWH]U>:;J%LS*5$]I<RQ$J0&.#0!T= 'A
M_P >_P!IC]GC]EGP8?B'^TE\;OA9\"_!33R6EMXC^*GCCP[X)T[4K^.$SG2M
M%?7]0LI-<UEXE+P:-H\=]JESP+>TE8JK 'XM^,/^#IK_ ((A^$M2ETN']K?5
M_%L]O=O9W=QX/^ ?[06I:; \<ACDEBU6^^&>EZ;J=J"-Z7>BW.I6]Q'A[:28
M'*@'MGP2_P"#B7_@C%\?=>M/"_@K]N[X9^']>O/+6*V^,'A_XC_ ?31-*P2.
MU_X2KXS^"O W@Z6ZD<JD<%MXAG>1V5$W.0M '[06EW::A:6M_875O>V-[;P7
M=E>VD\=S:7=I<QK-;75K<PL\-Q;W$+I+!/$[QRQNLD;,C T 6* /!OVDOVG_
M ( _L?\ PJU7XW_M+_%+PU\'_A5HNI:+HVH^,O%4EXNGQ:MXBOXM,T;3H;?3
M;/4-2O;V_O)0L=O8V-Q*D$=S>3+%9VMU<1 &%^RM^V)^S/\ MN?#K4_BU^RI
M\7?#GQI^'.C>+M1\!ZGXL\,0:U;Z;:>+M)TK0]<U+0W&N:7I%T]U::5XDT.\
ME>*V>VV:C$BS-*DR1 'TC<7$%I!-=74T5M;6T4EQ<7%Q(D,%O!"C233332,L
M<444:M)))(RHB*S,P4$J ?CE\?O^#@K_ ((Y_LV:Y<>&/B+^W5\*M7\16KSP
MW&E?"#3_ !Q\?/LUY;-LN-/O]6^"7A3Q]H&D:A!(&AGL]8U?3YX)TDAF1)D>
M-0#YZ\*_\'3W_!#_ ,2W!M;K]KG6?"4IE,4!\5?L^?M%6]O<8.!(+W1_A=K5
ME;1,!N#:A<6>!P^QSMH _77]FK]MK]D3]L?0O^$B_9<_:0^#WQSL8K5+R_L_
MA]XYT36O$6APR% H\3^$4NH_%?A2XS+%FT\2:-I=VOF1%H0)$+ 'O?C;QGX6
M^''@SQ=\0_'&M6GAOP5X"\,:_P",_&'B+4/-%AH/A;POI5WKGB#6KTPQS3"T
MTO2;&[OKGRHI9?)@?RXW?:E 'Y%_\1#/_!%W_I(#\'/_   ^(?\ \Q- !_Q$
M,_\ !%W_ *2 _!S_ , /B'_\Q- 'TK^RO_P57_X)Z?MM_$;4?A)^RK^U+\/O
MC1\1])\):EX[U'PEX8M_%,&I6WA'1]4T31=2UQCKGAW2+5[6SU3Q'HEI*D5Q
M)<;]0B983&LKH ?H-0!\T?M5?MB_LR_L0_#K2OBU^U;\8/#/P4^'.M^,--\
M:3XJ\51ZO+I]_P",M7T?7M?TW0((]%TS5KQKV[T;POX@U"/-J(1;Z7=-)*A"
M*X!J_LS?M5?L]?MD?"^W^-/[,?Q3\/?&'X77>MZOX;@\8^&4U./37UW0'ACU
MC3?+U?3],ODN+%[B 2B2T1")4>-G1@] 'T%0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@:^'QE#/,I^LY/BZ512P]3%P4,=E&(A5A?\ <RQ=+#.HX[T74@TU*49?9/\
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M?L\+&JXV]_EO'F_+[_@I?_R5OP+_ -DY@_\ 4F\0U_!OTX/^3E<,?]D-A/\
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MU51A-QA*K.=DYR/YH_V[/^4JNI?]E#_9X_\ 4+^&5?Q%XF_\I"8C_LHN"/\
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MJ8;%4I3P^&K5ZL%*2JTDHRY>>GP)QI'(,NXPPF1YCB,DQKQ%7"YGET?K;H/
MXNOA*M;$4L)*KB\!"GB<+5C3Q&)I4*4Y13I59-H_&_\ X*K_ +*_[(_P[^&$
M7Q4^'G_"+?##XJ7'B'2[33_ _A&ZM(='^(%A?R0VNI^3X-M9VM?#_P#PC]C
M^KKK>A6FFZ/NBN=-U6UO=4US2[FT_F[Q]\/_  \R3(XY_E"P.09_5Q6&IX?*
M<OG&&%SFA5<8UG3RNFU1P7U2C?%?7<)2H8:7+*AB56Q&,PDX?TCX!<?^(F>9
MY/(,Y>.S_(*6$Q-7$9OF,)3Q635Z2<J"JYI4BZV.^N5K83ZEBZM?$PYEB,-.
MCA\'BJ<]7_@A7J/B"33_ -HO29+F]D\*VEW\.;^TM))9FTZUU^^A\7P7T]G"
MS?9X;R^T^PT]-1DA02W$-AI@N69+:U"Z_13K8UQXVP\IUGET)9#7I4Y<WU>&
M-K+-:>(G2^PJU6AA\-&NX^^X4,,I^[&F9_2LHX)/@C$J%%9C-9_0JU(\OUB>
M!HO*:F'IU?M.A2Q&(Q4L.I)152OBG#F<JG+_ $!U_7Q_'X4 % !0 4 % !0
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M@]K5_P"?M3_P.7_RP46UL.EO"/I$G_Q*_P _R_B+1[+[@]K5ZU*C_P"WY?\
MR4OR^_[,U,S"@!K*KC#*K#T8 C\CD?Y[9S0--Q=TVGW3L_P(?LEI_P ^UO\
M]^8__C=*T>R^XOVM7_G[4_\  Y?_ "P/LEI_S[6__?F/_P"-T6CV7W![6K_S
M]J?^!R_^6!]DM/\ GVM_^_,?_P ;HM'LON#VM7_G[4_\#E_\L)$ABC.8XHT/
MJB*I_11_GUHLELE]UOZ_KN3*<Y:2G*2_O2;_ #<OS^_3EDIDA0 4 % !0 4
M% !0 4 % !0 4 % !0!__]7^_B@ H * "@ H _GM\&_\'#_[/OQE_P""FY_X
M)F?LW? ;XQ?M!^*M.\?W'@;Q1\<O FI>"X_A+X<M_"\$<OQ5\:S7.I:O!J-Y
MX+^&,T>J:;J6M11PQ^)]8TO^S?!JZW)K7AIM: .[_P""P'_!=_X)_P#!'GQ?
M\$?!WQ6^"'Q3^+E[\;_#?C/Q+I%U\/=4\):;:Z):^#=3T+2[FWU+_A)-0M99
MKB]FUQ)(/LL;1QQV[^8Y:150 _8[X-?$O3/C1\'_ (4_&+1=/OM(T;XL_#;P
M-\2])TG5&MVU/3-,\=^&-+\4V&GZBUI)-:M?65KJL5M=M;2RVYN(Y##(\91Z
M /2: /PH_P""P'_!>#X)_P#!'GQA\$?!OQ6^!_Q3^+E]\;O#?C+Q-I%U\/=5
M\):;:Z):^#M4T/2KFWU+_A)+^TFFN+V;6TD@^S(T<<=N_F.7D55 /V.^#7Q+
MTSXT?"#X4_&+1=/OM(T?XL?#;P-\2])TG5&MVU/3-,\=^&-+\46&GZBUK)-:
MM?65KJL5M=M;2RVYN(Y##(\91Z /P%_X*H?\')O[/7_!*K]J&/\ 9;^)7[.W
MQF^*/B9OAMX2^)+>)O VL^"-.T);'Q=>:_:6FFK!K^IV^H-=VG]@R27$IA2%
MOM$:1[MC.P!^;G_$;G^QW_T9?^TM_P"%3\+O_ES0!]5?L0?\'9'[+_[</[5_
MP0_9.\'_ ++/QZ\$^)OCCXP'@[1?%7B37_A[>:%HMZVE:EJB7>J6VEZM)J$M
MJ5TUH6%I')*IE5PC!2K '[?_ /!3/_@H%X$_X)C_ +)/C#]KCXC^ _%OQ)\+
M^#_$G@?PU<>$_!-UH]EKU[=>./$MEX;L[B&YUVZM=/CM[*6\^U7.^1I'CB\N
M)"S[D /YEO\ B-S_ &._^C+_ -I;_P *GX7?_+F@#W#X-?\ !YY_P3.\=Z_I
M.@?%7X1_M4? Z'4]0@M+CQAJ7A#P+X_\$:!:S2!'U/79?!?C^[\=FUME(EGA
M\/\ P^\07A19!#;3.J(P!_5!\$?CG\'OVD_A?X3^-7P%^)'A+XL_"GQQ92W_
M (5\=>"-7MM:T#5H;:ZGL+Z%+FW8M;:CI>I6MWI6LZ3?16NJZ+JUG>Z5JUE9
M:C9W-M$ 7/C%\8_A;^S[\,/&OQH^-GCSPW\,OA7\.]%F\0^-/'/B[48M+T'0
M-*ADBMUENKF7+2W-Y>7%KINE:;:1W&IZSJ]Y8Z1I-I>:G?6EI. ?QP_M'?\
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M&U*_TWXE^#]+32+^6:S\;^ C9'4-5\+W]O'J5QH]KK^J6B/;>&-8-N ?OY0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MI&HW-KIHNH+#4KO18;.\FMB+B.WFD>$K*$- '](?_!1C_E'O^W=_V9K^T_\
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M(&: /X//VH/^"#W[<7_!97_@L=^V=\2OCA\2?&GP8_8U^$_Q5M?ASX"^)'Q
ML=8U_6M:\'Z3X9T+4X? O[-G@/59]/TM_"]K=ZA<W.K^,&NM+\%6FN:SJ6H6
MB^-?%,?B'2(@#]0[[_@S<_X)/S_#R3PG8>)OVJK'QF--D@M_BE)\5O#-YKPU
M7[)Y4.HWGAMOAW#X*N+5;P"[GTVVT#3VFC\RUBU"VREP@!_%[\1?"_[6W_!L
MI_P5OT^U\+>,5\87?PZDT+QAH>IV_P!J\.>#_P!IO]FSQM/>6EQI'BSPW%J&
MK-I,.O1:7X@\-:II]W-JTW@OXA>&I-?\-WVHRZ%H&O70!_KJ_#KQWH'Q2^'W
M@3XF^$YI;GPM\1?!OACQWX:N)XO)GN- \7:)8^(-&FFAW-Y4LNG:A;221;F\
MMV*[CC+ '94 % !0 4 % !0 4 ?C%_P6S_X+"?#/_@D3^S-'X\N;'1_'G[1?
MQ1EU+P[^SO\ ![4+R>"V\1ZWI\=JVN^-O%_V&6'4K7X<^ H=0L+OQ!)8S6U]
MK>J:AH7A/3KW3+C7'UO2 #_/K_90_8(_X*L?\'+O[0WB[X__ !7^*VKI\--&
MU^;3?&/[1/Q9&LR?"WX?"]F@OI_A=\ _AUIAMM-U'4M+L)H+_P#X0/P;_P (
MYX;TJ)K*^\<>*-#U+Q!IM[K@!_4Y\,_^#*W_ ()PZ!X<M+;XJ?M!?M>_$CQ?
M]G\O4]:\-^)?A3\./#$MQC_CYTCPI)\*O&VKZ9@Y(AU+QKKZ?=!)PQ< ^;OV
MF?\ @R0^".IZ'J5_^QU^V-\3_!WBB"*2?2_#'[2'A[PO\0/#>K7'EMY>G7?C
M+X:Z#\.M7\,6KS%6.JIX*\9W$$*^6=*NY&$R '] 7_! ?]B7X]?\$]O^"<?@
MC]E_]I'2/#^C_%#P?\4_C3JEY'X6\2:?XK\/ZEH7B'Q_J>I>'==TK5[#86LM
M;TIX-2MK34;33=:LX+B*WUC2M,U%;BRB *7_  7#_P""QOP]_P""1'[-%OXN
MM['1/'O[3/Q9DU/P_P#L\_"75;FX33]3U'3DM?\ A(/B%XV2PN+;4H?AYX$C
MO["75(;*YL]1\2ZWJ&B>%=-O=+&IZAXAT  _S\OV0/\ @GA_P5/_ .#DO]H'
MQC^T+\5?BOK/_"O-/U^73?'7[3'QC_MBZ^'W@][FXCOY_AE\"O &F?9=.U2_
MT:SNDOH?A[X*_P"$6\&^';:6RD\4>(?#=UKFD2:N ?U1_#C_ (,J?^"<NB>&
M(+/XI?M%?M@_$#QB]JT.H>(/"OB+X1_#GPY]H(P+O1O"EY\)O'NHZ<RG)6'5
M?&'B&$_*&!VMO /C?]K/_@R2\.#P[<:M^PS^V!XA7Q1:).T/@3]JC1M*OM(U
MPG+0HOQ/^%/AC1[GP]+&%\K9)\*?$$5[)*KM=:7'"_F@']T?PE\*ZCX$^%?P
MS\$:Q+9SZMX-^'_@SPKJD^G233:?-J/A[PYIND7LMC-<06MQ+9R7-G*]M)/;
M6\SPM&TL$+EHU /0* /\[W_@\Y_;<U'XB?&;]F[_ ()L?#6[N]83P#%9?'+X
MLZ%HOFWUQJGQ2\?V]WX6^#GA%["VW7+ZYH/@R\\0^(([%89OM]K\4_#TD&9X
M=B@']>G_  3=_9G^&O\ P24_X)=?!_X7?$K7?#O@/2O@5\'=1^*?[2/CS5;J
M"WT2P\=ZM9WGQ$^-'B35-64,;S2?#^LWNJZ/H]VWG7!\+Z#H=A;QA8+:V4 _
MS]O^"FO_  6+_;Q_X+Q_M1V?[%W[#^@_$G2?V=?$_BO4/"/PI^ GP]N;W1?%
M'QPTZWFE#_$3]H+4H+VTLSHC:;;/XEO/#6OZA:_#3X9:##]OUZ6]U32-0\87
M !^QG['7_!D[\.U\(Z3KW[>O[57CR]\;:A9I<ZE\-_V7(/#?A[0/"]VX#)IT
MWQ/^)?A#QE=^+_+4[;Z2Q^'7A**.?S+>QO+V&.'4IP#ZY^(W_!E=_P $W=>T
M:>+X9_M ?M@_#OQ'Y96SU'7?%'PG^('AY)-F%EOO#W_"I?">K7>) LC):^+=
M-5E\R,%,HR '%_\ !&W_ (-U/VJ/^"3G_!5*'XVZQ\1?AY\=_P!F6\^ GQ7\
M'V/Q2\.[_!'B_3/$FO:CX/;1-&\7?"S6]0U.]L+G4X=/OY[6]\*>)?&VCQ0V
M<O\ :NI:5<S6=K< ']/G_!1C_E'O^W=_V9K^T_\ ^J2\<4 ?Y5?_  0._P""
M2OPU_P""O?[1GQE^"WQ/^+'CGX2:-\,?@H_Q0L-8\!:5H&JZGJFI_P#"=>$_
M"BZ;=Q^(8I[6&Q%KX@N;IGAB^T-<0P 2+'O5P#^K'_B"*_9$_P"CU?VC_P#P
MC_AC_P#*V@#]//\ @DU_P;D? 7_@DQ^TMXC_ &F/AI^T/\7?BOXB\1?!_P 3
M_!^7PWXYT+P9I6BVVF>*/%/@?Q3<ZO'/H%E!?27]M/X&M+2"%I!;F&^N)) 7
MCBH _HQH _D+_P"#T_\ Y16_ _\ [/V^%7_J@?VGZ /9_P#@T!_Y0ZZ!_P!G
M'_'+_P!*/#- ']1M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MQ GQ5_Z);_S.<.?_ #V#_AZ=^P?_ -%U_P#,8_&3_P"=U1_Q''PN_P"BH_\
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M .=(?\0)\5?^B6_\SG#G_P ]@_X>G?L'_P#1=?\ S&/QD_\ G=4?\1Q\+O\
MHJ/_ #"<0_\ SI#_ (@3XJ_]$M_YG.'/_GL'_#T[]@__ *+K_P"8Q^,G_P [
MJC_B./A=_P!%1_YA.(?_ )TA_P 0)\5?^B6_\SG#G_SV#_AZ=^P?_P!%U_\
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MW[!__1=?_,8_&3_YW5'_ !''PN_Z*C_S"<0__.D/^($^*O\ T2W_ )G.'/\
MY[!_P]._8/\ ^BZ_^8Q^,G_SNJ/^(X^%W_14?^83B'_YTA_Q GQ5_P"B6_\
M,YPY_P#/8/\ AZ=^P?\ ]%U_\QC\9/\ YW5'_$<?"[_HJ/\ S"<0_P#SI#_B
M!/BK_P!$M_YG.'/_ )[!_P /3OV#_P#HNO\ YC'XR?\ SNJ/^(X^%W_14?\
MF$XA_P#G2'_$"?%7_HEO_,YPY_\ /8/^'IW[!_\ T77_ ,QC\9/_ )W5'_$<
M?"[_ **C_P PG$/_ ,Z0_P"($^*O_1+?^9SAS_Y[!_P]._8/_P"BZ_\ F,?C
M)_\ .ZH_XCCX7?\ 14?^83B'_P"=(?\ $"?%7_HEO_,YPY_\]@_X>G?L'_\
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MSAS_ .>P?\/3OV#_ /HNO_F,?C)_\[JC_B./A=_T5'_F$XA_^=(?\0)\5?\
MHEO_ #.<.?\ SV#_ (>G?L'_ /1=?_,8_&3_ .=U1_Q''PN_Z*C_ ,PG$/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MO:0F#[.(K5[U)&G%T$@_,O CZ-4/!_B#-.)\PXFI<1YCB\JGD^ I4,G>6X?
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M&M3-M/:?VAHFLZ?HEO>Z=>BVN;B%;FUFCF1)7",": /R>_X.TO\ E"O\;?\
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MKN<$I/<Z-+-$S1.C, ?6E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0O;GXF:_XU^(GQ/M_">G)9M/_:-S8Z!\4/"5L;6UB^V0^(=0U;1YXVN[/RD
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /X
M\_\ @J;_ ,GX?'7_ +IC_P"J;^'E?Y[^./\ R='BC_NB_P#K.Y0?Z*>!/_)J
MN%O^ZY_ZT><'Y]U^3GZX% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZKA.<_\ :'#%3C7KM^TQ'+"=5SJ*4C]%:_LL_FL* "@ H * "@ H * "@ H
M* "@ H * "@ H _.;_@II\4XO!/P"7P/:W$::W\5-:M]'6'S)H[A?#FA2VVL
MZ]>0-%C.+M-#TN>.5EBEMM6G5]X!B?:C&\K](^75_P!7#^OZ_K\CYD_X),_#
M>6;6?BA\6[N"=+>QTZP^'^ASM&AM+JYU*XM]?\1B.0DR+=Z;!IOAM3M508-9
M<%CDK5UWI&/G?]%]]W]P'[:5S % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % '\K'_!=[]OZYO=1?]BCX5ZLL>F6']GZO\==:
MT^Z1Y+[4@T.HZ!\.XVASY%MI@6VUWQ(K.9;N^FT>Q\NVCTZ]6_\ YR\9^-[7
MX0RVLEI"IG56$]6G:=' 735DU:KB8O62=*FTX\ZG_J[] SZ/\<'A8^-W%>#O
MC,7#$87@'!XBFU]5PC]IAL?Q,XRN_;XS][@,I;C'V.%CC,9#G>,P=7"_S#5_
M.=X]U]Y_IV%%X]U]X!1>/=?> 47CW7W@%%X]U]X']2__  ;<D?9?VKAD9\_X
M3G'?!C\=8./0D'MV[U_2'@$TZ7$MFOXF6];_ &<9_7R\C_+G]I0G[#PB=G;V
MW&:OTOR<-:7[ZG[D?MK?L7_"W]MSX1W7PV^(4/\ 9VLZ:]SJ?@#QS9VT<^M>
M"/$4L A-[:!FA-WIE\L<,&N:.\\4&IVT41\R"\M;*[M_V+BSA7+>+LKGEN81
M<9Q;JX/%P2=;!8GELJM-O>,E:-6F_<JP]V2=HN/\)^!_C;Q3X&<7TN).'VL9
ME^*5/"\1</UZLZ>!S[+83<O8U6HU%A\9AG.I4R_'QISJX2K4J)1J4*V(HU?X
M7/VM?V(?V@/V-/&][X5^+7A&[&A-=3+X9^(VBV]S?>!/%^GB0"WO=*UD1>7:
MW;H\7VO0]4^QZQI\S^7<6GEM!/+_ !SQ1P9GO">*G1S/"REAN=K#YC0C*>!Q
M,&[0<:UHJE4:MS4*L8U(2NESQY:D_P#=?PF\;?#[QFR2EFW!V<T:N+C2C+-.
M'L94I8?B#)JK2YZ6/R_G<W2C)\E/'89XC+\3_P P^*FXSA#Y#KY0_6PH ^J/
MV5OV-/CW^V'X\TSP5\'?!M]?64U]#!XA\=ZG;W=EX"\%V&Y#>:IXE\1"VEMX
M%L[=S.FEV2WNNZDP6UTC3+Z\FBMW^HX8X0SKBS&0PV5X63H\\5B,?5C*."PL
M+^].I6Y6I2BKM4:?-6F](PUN?EOBKXR<!>#F05\]XSSBEAIJC4GEN28:=*OG
MV>8B,9>SPF59<ZD*E656HE3EBJSHX#"\WM<;BL-1C*I'G_VL?@KIO[.G[17Q
M7^"&D:Y>>);#X:^*)O#$6OW]I#87>K26-M;?:;^6Q@FN8K,7-R\TL5HMQ<&V
MA:.%[B=T:>7GXJRFAD/$&9Y/0JRK4LOKJA&K4:4ZC5*FY3E&.D>:<I-05^6/
M*KNSE+T?"GC3$>(OASPAQSBL#1RNOQ1E%/-I9=0K3Q%+!1KUJT:6'CB*D*4J
M[ITH04ZSI4E4GS3C2IQ:A#P73#C4M/)X OK0DGM^_CKP(.//'5?%'KYGZ ]G
MZ,_TX?!Q_P"+?^%CV_X0[0SG_N"6M?Z'4/\ <Z/_ &#4_P#TTC_F$SS_ )*7
M./\ L>9A_P"I]8_S1?B20?B+X_(.0?&_BL@CH1_;U_R.O7Z_G7^?N:2C_:>9
M:K_D88WK_P!154_Z:LG5LIRQ/1_V?@]_^P>F>Y_L/$#]K_\ 9OR0/^+O^#.I
MQ_S%(Q_,X_\ UU[?!,H_ZV\.:K_D;X3K_>E_6A\+XSJ_A)XEV_Z(7BI_=D>.
M;^Y*_P#PQ_H\5_>!_P V84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]?^_B@ H * "@#_ #H_^#O;
MQ5XI_:7_ ."G7_!/C]@KPW=_9XX? 7A;^Q996S:P_$+]JWXT'X<N\]NK#S!8
MZ5\,?!MPKN0P2_GCBVAI6< _T+OA]X'\.?#'P%X(^&O@^R&F^$OA[X1\->!_
M"VG+MVV'ASPGHUEH.B62[51<6NF6%M -J(N$X51@4 ?Y[7_!\+_R7+_@G_\
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MJ5U%:1SS6T$EU)!;2);I-<01/*462:)"74 _I/\ ^(S3_@DU_P!$_P#VT_\
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M!?Q[JGC!=$\9>(M,A6.]\,V7AWP_IUYYMUXEN;33P#^@O_@W8_87\:_L!_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /C7_@HQ_P H]_V[O^S-?VG_ /U27CB@#_(%
M_P""7?[+G_!2;]JKXO?$#PC_ ,$R]:^(F@_%?PY\-Y/$GCZ]^''Q\L/V?=4D
M^'G_  D^@:8UK?\ B6]\=^ O[:L)/$E[HDO]AQ7][FX@AOWLQ]C2= #]P_\
MASE_P=H_]%'_ &I__%F6@_\ T1M !_PYR_X.T?\ HH_[4_\ XLRT'_Z(V@#\
M5+KX1?M4? ?_ (*Y_"'X3_MLWWB?4_VH/"/[57[+\/Q4O_&?Q'MOBYXEN;S5
M=>^%^O>&9-3^(EIXB\5V_B1AX*U3PVMM*GB#4#I]DMMI,C6\NGO:6X!_M64
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M+Y[7]I2ZN4M(9[N.2Y>WM;F=85<PV\T@6-P#^N6@ H * /\ (Z_X);3?:?\
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M;6+[#$?-N]_V>/#R+0!_FC?\1)?_  <7?]$NA_\ $*M?_P#D&@#[/_X(Y_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /X\_^"IO_
M "?A\=?^Z8_^J;^'E?Y[^./_ "='BC_NB_\ K.Y0?Z*>!/\ R:KA;_NN?^M'
MG!^?=?DY^N!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?V&?\$LO^3#_@5_
MW4[_ -7)\0Z_T(\#O^37<+_]UK_UHLW/\Z_';_DZO%/_ '0__6<R<_02OU@_
M(PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * /._B]_R2;XH?]D[\:_^HUJ=?'^(?_) <<?]D?Q-_P"J
M7&GT'"?_ "57#/\ V4&3?^K'#'YU?\$P?^//XU_]??@#_P!%>,J_B_Z"/^Y>
M)G_81PC_ .FN(C^F_I7_ .^<$?\ 8-G_ /Z=R@_5FO\ 0 _D0* "@ H * "@
M H * "@ H * "@ H * "@ H _F-_;E^-X^.OQZU=]#NC?^$?!H_X0GP>+9S-
M;7Z65U+_ &GK%LL,LL%P=;UB2XEM;J*.*>XTJ+2H)E)M4KLIQY(J^[U?3Y?)
M?UJ!^]/[*?P=7X&_ OP/X&N+6*W\0?8/[?\ &+)'"LLOBO7MM]JD-S+;R317
M<FCJUMX=AO$D9;BQT>TD78I5%YIRYI-]-EZ+_/</Z_K;^N^Y]$U !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKJ/P9^$&
ML7]WJNK?"SX=:GJ>H7$EU?ZCJ'@KPY>WU[=3-NEN;N[N-/>>XGD8[I)9G>1R
M<ECDUQSR[+ZDI3J8'!SG-\TYSPU&<Y2>[E*4&V_5_?H?5X7CSCC X:A@\%QE
MQ3@\)AJ4*.&PN%S_ #;#X;#T::Y84J-&CC*=*E3A%)1A"$8Q6B2M[U+_ (4/
M\#_^B._"[_P@?"W_ ,K:G^S,M_Z%^!_\)*'_ ,K.C_B(_B%_T7?&/_B2YU_\
MW!_PH?X'_P#1'?A=_P"$#X6_^5M']F9;_P!"_ _^$E#_ .5A_P 1'\0O^B[X
MQ_\ $ESK_P";@_X4/\#_ /HCOPN_\('PM_\ *VC^S,M_Z%^!_P#"2A_\K#_B
M(_B%_P!%WQC_ .)+G7_S<'_"A_@?_P!$=^%W_A ^%O\ Y6T?V9EO_0OP/_A)
M0_\ E8?\1'\0O^B[XQ_\27.O_FX/^%#_  /_ .B._"[_ ,('PM_\K:/[,RW_
M *%^!_\ "2A_\K#_ (B/XA?]%WQC_P")+G7_ ,W'7>&? W@KP4EW%X.\(^&?
M"D=\\<EZGAO0M,T1+QX0RQ/=+IMM;BX:)7<1M+N*!F"XW&MZ.&PV&4EA\/0H
M*;O)4:4*2DULY<BC=I::KTM]KQ,VXAS_ #^5&>>YYF^=2PRG'#RS7,<9F$J$
M:C3G&C+%UZSIQFXIR4'%2:3>RYNIK<\<R=<T'0_$VF7>B>(]&TK7]&OX9K:^
MTK6M/M-3TV\M[B&2WG@NK*]AN+:>*:WFE@ECEB97BEDC8%'96SJTJ5:$J5:G
M"K3G%QG3J1C.$HR3C*,HRC*+4HMQ::LTVG>]CMR_,LQRC&4,PRK'XS+<?A:E
M.MAL;@,36P>+P]6E.-6E5HXC#SIU:52G4A"I"<)J49PC)6DD? GC3_@DY_P3
MO\?:G-J^N_LO>"K.[N&W2IX-UCQO\.M/W8P3'H_P]\4>%](A+=6\FQCW.2YR
MY+-\9B_#?@;&RE*MPW@(.3;?U3V^ 5WNU' 5<-%-[Z*/?NH_OV2_2V^D7D.&
MCA<#XI9W7I05E/.L%D?$F)?7W\9Q%E>:8RH_.>(DWM>RL4_"/_!(W_@G/X)U
M:VUK1OV8/"MY>6L@EBA\6^*/B-X_TIF7H+C0?'?C+Q)H=VG<QW>GS1DX)C)P
M5C"^&? N#FITN','4:::6+J8K'PNO^G>.Q&(A]\-?+51VS?Z7OTCL[PE3!8S
MQ1S6A1J1<93RC*N&^'\6D^M/'Y%DN78^C+M.EB826Z:NC[_\-^%O#/@W2+3P
M_P"$?#VB>%]"L(HH+'1O#VE6.C:7:0011P0Q6UAIT%O:PI%!%%%&L<8"QQH@
M^5%K[6C0HX>G&CAZ5*A2@E&%.C3C3IQBE9*,()1222222LNBV/Y^S3-\USS&
MU\RSK,\?F^8XF<JF)Q^9XS$8[&5ZDY.4YUL3BJM:M5G*3E*4IS;<I-O5MRY;
M5/@Y\(]<U"[U;6OA?\/=7U6_F>XOM2U/P9X>O[^\N)#NDGNKRYL)+BXFD8EG
MDE=W8G+$YK&>7X"K.52I@L)4G)WE.>&HSG)]7*4H-MONW]]T>S@N.>-<MPM'
M Y=Q?Q/@,%AX*GA\)@L^S7#8:A!;0HT*.,ITJ<5_+"$5Y+3FHI\"?@E&RR)\
M'_A@CHP='3P%X75D93E65AIN592 0PY!&1T%1_9F6_\ 0OP/?_=*&_\ X+[G
M3+Q%\0))QEQSQA*,DXRC+B3.6I)JS33QS333LTU9K>YZDD<<<:11HB11HL:1
MHH6-(U7:J*@ 5450%50  !@ # KNLK6MIM;I;M8^/E*4I.<I-SE)RE)MN3DW
M=R;U;;;NW>]]=;GF-Q\#_@O=W$]W=_"3X9W-U=3RW-U<W'@7PS-/<7-Q(TL\
M\\SZ<9)9II7:265R7DD9G<EF)KB>6Y=*3E+ 8*4I2<I2EA:$I2E)MMN3IW;;
M;;;U;WW/KJ7B%Q[1ITZ-'C?BZC1HTX4J-&EQ%G%.E2I4H*%.E3A#&QA"G3A%
M0A",8QC&*C%67NSZ=\&/A!H]]:ZGI/PL^'6F:E92^=9ZAI_@KPY97MI-M9/-
MMKJWT])X)-CLN^)T?:S#)#$4X9=E].<:E/ X.$X.\)PPU&$HNS5XR5.Z=FUH
MX[[[F>*X\XXQV'K8/&\9<4XS"8B'LZ^%Q6?YKB,/7IW4N2K1K8R=.I&\8OEG
M%JZ3Z(]*KL/DPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /_]#^_B@ H * "@#_ #D/^"QY^T_\';7[
M!<'BSY-!C^,O_!-J'1RW,<FGGXP:!/"LV\A!;2>*I=1ANCG8+?S6;)#4 ?Z-
M] '^=9_P?"_\ER_X)_\ _9*/CG_ZE_@"@#^@G]D#_@WJ_P""-WQ#_9+_ &7?
M'_C/]A[P1KWC#QQ^SK\$O&'BO7+GQ_\ &J*YUGQ+XF^&GAG6M=U:XBM/B;;V
MD<^HZI>W5Y+';6\%NDDS+##%&%10#Z*_XANO^")/_1A'@'_PX7QS_P#GIT ?
MQ.?\'7W_  3T_8W_ ."?WQ=_8YT#]C[X'Z)\$M'^)7PX^*VL>-[#1/$'C;7H
MM>U+P[XF\)66C7<Y\9^)_$LEK)96NJ7T*C3WLTF6?_24F:*%D /]'7]@[_DQ
MS]C+_LU']G;_ -5#X/H _P YC_@Z]T;3?$7_  7,^&GA_6;87ND:[\%/V9-&
MU6S,LT(N]-U/QSXSLKZV,UM+#<1">UGEB,L$T4T>[=%*CA74 _M5_P"(;K_@
MB3_T81X!_P##A?'/_P">G0!]+?LH_P#!'W_@FW^P]\4V^-?[*W[+7A3X0?%%
M_#.K^#F\7:1XJ^)>MWG_  C6O3Z?<ZOI:VGBWQMXATM([V;2K!I)TL%NT%OL
MBN(XY)DE /S4_P"#M+_E"O\ &W_LJ_[/W_JTM#H _FM_X(+?\&YO[$O_  5,
M_8%U']I7X\?$S]ISP9\2Q\;/B)\-K2'X3>,OACI'A&VT?PII/@Z^TJ[DT7Q=
M\'O&FIW%_)/KUZ-0?_A((X9X1"EM!9.C3. ? G[?G_!.C]I;_@VQ_;D^!7[0
MO@.;P%^T7\%[[Q%<:]\$OB+\4/A3X<\2^&-<O-&^SR^*OA/\4O!VMQ:Y9>%/
M'EII-V?[*\5^%-4TG5]4T6=_&'P^UKPUKVFZ[H_A8 _TU?\ @GY^V_\ "7_@
MHG^R9\)/VL?@W/Y/AWXCZ&/[?\*W-Y#>:U\.O'NDM]@\;?#OQ$T*0XU;PMKD
M=Q:1W36]O#KFD/I?B33HCI&MZ?*X!]E2RQPQR332)%%$CRRRRNL<<4<:EGDD
M=B%1$4%G=B%5022 ": /X-?^"Q'_  <G_&;XY?%N_P#^"<'_  1=T[Q-XX\?
M>*M>O/AEXB_:/^&FGW'B7QGXS\02":TUCPK^S!;:4+DVFG6,<5['J7QO=7D$
M%OJ.M> &T72=,TOXBZ@ ?6W_  0U_P"#87P]^R5XB\+?ME?\%#)-(^+G[6UK
MJ5KXU\!_"I-37Q3\/_@=XH><:I#XJ\4ZT3/:_%#XQZ=?O]J@U1);SP5X/UM)
MM4T"?Q9KMMH?C'2P#^Q>@#Y?_;>CTF;]B[]KR+7SMT*7]E_X_1ZTQ"D+I+_"
MCQ8NI$AL*<69F.&.WUP": /XP_\ @QKEU8^%O^"ED,R_\2./Q!^R9+IS9/.K
M2Z=^T8NLJ!]WY;.'0B2.3N&> M '][E !0 4 % !0 4 % !0 4 % !0 4 %
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MW>G6OQ#OO [7,/?RO[3\&:C;Y.,R6\A'RE2P!_2]0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\>?_!4W_D_#XZ_]TQ_
M]4W\/*_SW\<?^3H\4?\ =%_]9W*#_13P)_Y-5PM_W7/_ %H\X/S[K\G/UP*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#^PS_@EE_P F'_ K_NIW_JY/B'7^
MA'@=_P FNX7_ .ZU_P"M%FY_G7X[?\G5XI_[H?\ ZSF3GZ"5^L'Y&% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MXRO+ZZ>.%))G6WMH9962*.25@F(T9RJL ?V]?\1#/_!%[_I(#\&__ #X@_\
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M'@JV^'FJ(_\ S O'.J/$4N4MY$ /QH_X-C/C?_P1=_8&_92M_P!H#X^_M5?
M7PC^W+\;M4\:VOC)?'LUY%XV^#OPUT+Q=J7AGPQ\-=!9],N5TFQ\6V?ARV^)
M7B#4-->VN?$B^)]"T[4Y+VP\+Z-Y0!_45_P_P_X(X?\ 20K]GG_PH-4_^5-
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MO&BGNI? 6NV5_?75GH7PZ56 /4/^#2O_ (*YP_M#_L[:G_P3[^.OB@S?&?\
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M=N%=M.D\>?#76K*YADT/4-7M+8P6'Q$^'NI:OX.\7P6>EW6M6/C.PTG2(;4
M_I9\-?\ !\!\ +CPM%<^,/V"_C#I/C86J&;1?#7Q?\%^(?"S7HXD2+Q-JGAG
MPQJT=J2 R2/X1DE7=Y;1/L\UP#X _:M_X/,?VS_CE9VWPZ_88_9C\(_LX:[X
M@E&D6WC#Q#JLG[2/Q5O-0NY/+L#X%\-S^"_"G@;2=3E=XX18:]X-^)@N7_X]
MA%(ZB( _KC_X*X_\% O$/[!__!'?QY^T=J^KSZ3\?_'7P<\%?"_X://;Q:+K
M1_: ^,?A2'3$U>STZ.*Q@LM6\!P2^+/B;/I26]K%%;^"+VRCMDVI;T ?SL?\
M&5_["36>B?M&_P#!1CQOI!-WK\[?LV? Z[OH?WO]E6$VD>+_ (S>*++SU;S8
MM1U8>!/">F:O:;)(IM"\=:0TTB3W<*@'][U 'EWQM^"_PR_:+^$?Q$^!?QF\
M)Z=XY^%OQ5\)ZOX*\<>%=55_LNKZ#K5J]M<QI/"T=U87]LS)>Z3JUA-;ZGHV
MJVUGJNEW5KJ%G;7$0!_E7_\ !0C_ ())?\%%O^"!'[45C^U)^S#K_P 2]8^"
M'@WQ+<>)?@W^UG\--,N+V;P3I-U=R01^!OV@-+LK&ZTCP_J$EC<)X>\00^)]
M/E^%WQ1TR\>&U\_^T-:\'Z* ?KW^RU_P>V^*]%\)Z7X?_;'_ &-+/QQXKT^R
MA@OOB9\!/'D7A&'Q!-"1$;J]^%_C/3-8M--OKB$"XO;G3/B$FFS7S2BPT'2K
M-X;:U /0?CI_P>_:#_PC>J67[-'["6KGQ?.ACT7Q+\=/BI9KX;TN7:Q%WJG@
MCP!HK:IKR!@BG3[3X@>&V979_P"TU,:I* ?C1_P;I_"G]J7]JC_@MG\(/VU[
M3X)^,=8^'6G_ !F^.?Q8^.?Q3\,^$=9L?A!X&UOXE?#_ .*DL^G?\)/J<EQI
M5I-=>*?%UM8:'X8_MS4_$DEK*L@AO(;.]O8@#_2R_P""C'_*/?\ ;N_[,U_:
M?_\ 5)>.* /\FS_@BA_P5XN/^".OQY^+'QN@_9_A_:'/Q0^$;?"MO#,WQ1?X
M4C1 ?&7AGQ:-=&LI\/?B,=1(_P"$=_L\Z8=*L<_;/M7]H#[.+>< _I4_XCF=
M1_Z1B67_ (F3/_\ 0N4 ???_  2]_P"#KN[_ ."CW[=7P*_8OG_81M_@['\:
MKCXA6_\ PL>+]IB7Q^_AMO OPH\=?$Y6_P"$1?X">#%U<:H?!?\ 8A'_  DN
MF&R&I?VD#=_8_L-T >P_\%)O^#H'P/\ \$ROVZOC#^Q[\4?V3?%?Q,TCP)X1
M^&GB7PG\0? /Q)TC2]2U>]\=>!=,\67>D^(?"_B'PZEKIMK8W6IQ6=OK&F^(
M-1FDMTDDDT<RJJ. ?QD_MM?MC_MJ_P#!S+_P4#^$'P^^$OP9;0;73K:Y\$_
MKX+:-JEQXET?X4^$M9O-+O?B+\3_ (H?$$Z-I,3QW,MAI^K>-?%<NB:+I&F:
M%H?AWP_I>E76HV<4^O '^J)^Q7^RYX-_8G_9._9__92\!3_;O#?P+^&7AOP(
MFM-:)83>)]:L+3[1XL\97EE')-'::AXT\5W6M^*]2MHI7BAO]9N8XF:-4*@'
MT_0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % '\>?_  5-_P"3\/CK_P!TQ_\ 5-_#RO\ /?QQ_P"3H\4?]T7_ -9W*#_1
M3P)_Y-5PM_W7/_6CS@_/NOR<_7 H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M /[#/^"67_)A_P "O^ZG?^KD^(=?Z$>!W_)KN%_^ZU_ZT6;G^=?CM_R=7BG_
M +H?_K.9.?H)7ZP?D84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/K^"Z);[;;^MP/4JD H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%.FM=@'Z ?\ !5+_ ((8_LE?\%>?%/P>\7?M)_$']HGP1J?P3T#Q;X<\+1_
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ME 'VA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MM3U.]NKV[G=I;B9Y&+4 <O\ \.GO^"67_2-/]@#_ ,0W_9T_^=O0 H_X)/\
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MZ?:>*=*U2/3KPB*)DOK 6]Y%)##-%,DL,3H ?FU/_P &_/\ P1FN=837)/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % '\>?_!4W_D_#XZ_]TQ_]4W\/*_SW\<?^3H\
M4?\ =%_]9W*#_13P)_Y-5PM_W7/_ %H\X/S[K\G/UP* "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#^PS_@EE_P F'_ K_NIW_JY/B'7^A'@=_P FNX7_ .ZU
M_P"M%FY_G7X[?\G5XI_[H?\ ZSF3GZ"5^L'Y&% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YW\7O\
MDDWQ0_[)WXU_]1K4Z^/\0_\ D@../^R/XF_]4N-/H.$_^2JX9_[*#)O_ %8X
M8_.K_@F#_P >?QK_ .OOP!_Z*\95_%_T$?\ <O$S_L(X1_\ 37$1_3?TK_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#^//_@J;_R?A\=?^Z8_^J;^'E?Y[^./_)T>*/\ NB_^L[E!_HIX
M$_\ )JN%O^ZY_P"M'G!^?=?DY^N!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 ?V&?\ !++_ ),/^!7_ '4[_P!7)\0Z_P!"/ [_ )-=PO\ ]UK_ -:+-S_.
MOQV_Y.KQ3_W0_P#UG,G/T$K]8/R,* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#SOXO?\DF^*'_ &3O
MQK_ZC6IU\?XA_P#) <<?]D?Q-_ZI<:?0<)_\E5PS_P!E!DW_ *L<,?G5_P $
MP?\ CS^-?_7WX _]%>,J_B_Z"/\ N7B9_P!A'"/_ *:XB/Z;^E?_ +YP1_V#
M9_\ ^G<H/U9K_0 _D0* "@ H * "@ H * "@ H * $) !)(  R2>  .I)[ "
M@#\\OVE?^"A?PS^#L6H>&?A[)8?$OXBQB>W\JQN?.\'>';M$ !U[6+28'49X
M973?HVB2M*3#=6M_J>D7,2*^T*3EK+W5VZOTT=OG\DT!^0OAKP1^T7^W/\3K
MW6G?4/$=Z\EO!K/BS6#-9^#?!FF/*[6]C&\:&TTZUB\RYN+/0-'MY+Z\9;VZ
MM[&YE%Y/6[<*<>RZ+=O\KV6[;\M+H#][/V:?V5OAY^S3X=:T\/1#6_&6J6D,
M'BCQU?VJ0ZGJQ1EE:RL8/-N!HVA+<J)HM*MYY3(\=O+J-WJ%S;03IRSFY[Z+
MLK_CJ[OST]-0/IRH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H __]3^_B@ H * "@ H * "@ H * "@ H * "@ H *
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M&[K4--O/"?A_Q#;^-;OQN7U#6M,N]"\/ZUJOP]TKP[K>J)&+35?[/O-+O]2
M/WPH * "@ H * "@ H * "@ H _G1^ G_!Q-\)/CU_P5LU__ ()-:7^S=\1O
M#_CG0OC/^TA\&'^,&H>,_#-WX4N=4_9P\-?%#Q)K6LKX<M[&/6(K#Q)%\+M1
MM=+@-V]Q:2:I927>Y8IPH!_1=0 4 >'_ +0O[2GP&_9/^'%U\7OVD/BIX1^#
M?PRLM6TK0KOQMXWU#^R]!M]8UR9X-(T^6[\N3;<ZA-&\5LA7YW7;D9^8 M?
M+]HGX&?M3?#32?C'^SK\5/!?QD^%^N7NK:;IGC;P'K5MKFAW&HZ%?S:9J^GM
M<6[;[:_T^]@DBN;.[B@N45H9O*-O<6\TX![-0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 ?QY_\ !4W_ )/P^.O_ '3'_P!4W\/*_P ]_''_ ).C
MQ1_W1?\ UG<H/]%/ G_DU7"W_=<_]:/.#\^Z_)S]<"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _L,_X)9?\F'_  *_[J=_ZN3XAU_H1X'?\FNX7_[K7_K1
M9N?YU^.W_)U>*?\ NA_^LYDY^@E?K!^1A0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _]7^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M]X,\->,]<TO1-#\)0:O;#PS;^,+#6?#NG7LUU<N)[Z[T+4KA(TB-BUG,OGT
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M "@ H * "@ H * /X\_^"IO_ "?A\=?^Z8_^J;^'E?Y[^./_ "='BC_NB_\
MK.Y0?Z*>!/\ R:KA;_NN?^M'G!^?=?DY^N!0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 ?V&?\$LO^3#_@5_W4[_ -7)\0Z_T(\#O^37<+_]UK_UHLW/\Z_'
M;_DZO%/_ '0__6<R<_02OU@_(PH * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __6_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M'/@GQ3I$H@U7PUXN\)_!;QKK_AO7],F976'4-'UG3[/4;*5D<1W-O$Y5@,4
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M_#^RU'Q!I%Y\5=3^*#W'A+6]0L-7U6XU'P#=>'K22[M1(FH010V%M*)K1T0
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M4/#GANX\:^&[:]\8_$?Q9XPMQX<^#VE6NKOI%Y#"B>+/"@!\Y?M8_P#!/_\
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M /@O^SEH6J6'@AD95C@\/>+?#?A*^TU]AN=,M"7EH ^6_ /_  59_P""V/\
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MMK=>)/AW\)KKX\^/?V4=#N/"US,;O0+;0?A#\)M.OM=ATZ2WD1/#&N_&0?\
M"4ZSI<=KK5_XBU&UU"VUB_ /CSX;_P#!63_@N%_P0=_:^T?X*_\ !0#Q)\9/
MC7\.4N["_P#%WPJ^/GCB^^+=CX_^&]W>?9I?&GP!^.>OWWB#5K:>T@6\30Y=
M'\37?A6TUNWF\/>-_"::C875CIH!_IU_"?XI>!?C?\,/AY\9/AAX@M/%7PY^
M*G@OPU\0? WB2P)-KK?A7Q=H]IKFAZC&K?O(C<Z=>P226\P2>VE+V]Q''-%(
MB@'\(7_!Z]^S6WAOQ!^Q!^W7X+LY=$\1B]\5_L_>-_&&E&6PU./5-#>+XI_!
M*2/4+1HI8]3T\Q_%^>TO/-2\A2ULQ;R[+-!  ?VH_L+?M#6W[6?[&?[+?[2L
M$L,D_P ;?@/\,/B'K,< 14L/%'B'PEIEWXOT@K&!&LNB>*6UC1[A8OW2SV4B
MQ$QA2P!]64 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?QY_P#!4W_D
M_#XZ_P#=,?\ U3?P\K_/?QQ_Y.CQ1_W1?_6=R@_T4\"?^35<+?\ =<_]:/.#
M\^Z_)S]<"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _L,_X)9?\F'_ K_NI
MW_JY/B'7^A'@=_R:[A?_ +K7_K19N?YU^.W_ "=7BG_NA_\ K.9.?H)7ZP?D
M84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'__7_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MBKQ//J/B_4+&&6)[>WO8/A?%HMY;QQWFCZAJ%A-;SN ?SE_\%6O^#E7XP_\
M!5']C'XJ_LZV/[ 6D?"GX-ZUKGP^UW6/BM+X^\7?%C5/ E_X1^('AS6='O(?
M$%I\._ 7A/1;K7KVW3P?/)J5K)YEKXEN=.M&:]NK=F /Z-O^#+;5K_4?^"57
MQEL[RX>:WT']N[XKZ5I4;=+2PG^!?[-6N2V\?HC:IK&HW9Y_UEU)TXH _F5_
MX+J_![3_ -H;_@Z)\1? '5PYTGXY?'W_ ()\_![4PEQ):.=/^)GPC_9L\%WH
M2[A9);5S;:W+MN(G22$XD1E90: /]3?PGX4\->!/"OAKP/X,T/3?#/@_P;X?
MT;PKX4\-Z+:16&C^'_#?A[3K;2-#T32K&$+#9Z;I.F6EK86-K$JQ6]K!%%&
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M&O3NGCC5F\%7FI7%O?PK(O@[3H&MHPCO= ']*7_$<-\%O^D?/Q0_\/UX5_\
MG=4 ?@3_ ,$-/VB_"_B?_@Y&^$GQK^&'@-_A;\-?V@?V@?VI;G0?A3!?6=]#
MX'\&?&KP#\9+_P ->"DN]/L-)L9['P9=:QH26PM-.M;=8=#@CAA"*#0!^W/_
M  ?+_P#(&_X)D_\ 83_;#_\ 27]F&@#^NK_@D[_RBR_X)I_]F ?L;_\ K.OP
MXH _@6_X)T_\KEWQ!_[/L_X*C_\ JK?VN: /Z_?^#G?_ )09?MU_]@SX ?\
MK57P,H _)#_@R4^#WA72_P!BS]K?X_Q:58?\)OXX_:BA^#U]K9AW:H/"OPJ^
M%'P^\:Z5I2W# F&P.K_&36;MX8"GVJX$;W8E^QV1@ /Z./\ @L3X"T+XD_\
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M7[(NJZE=2<R75_J'[/\ \/KN\N'Z?/-<322O_M-WZT ?YO'P8_9T\%?M6_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _L,_P""67_)
MA_P*_P"ZG?\ JY/B'7^A'@=_R:[A?_NM?^M%FY_G7X[?\G5XI_[H?_K.9.?H
M)7ZP?D84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@#_,8_8>_P"5R_QK_P!GU_\ !0G_ -59^TM0!_7Y_P '._\ R@R_;K_[!GP
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MXC>&/B?XH\:WNF1RQOI'A>'4O!.B^$+.\^SJ=0U?7EM--AGAT_6KC2P#@O\
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M@R_X/0_V_P#X::UX(^ W_!.GP!XDT/Q/X^T?XF0?M"?'2+1=5@OKOX=)X?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'>*/_1+_ /F;X>_^>P?\1V\*O^BI_P#,'Q'_ /.D/^'6/[>'_1"O_,G?!O\
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M $5/_F#XC_\ G2'_  ZQ_;P_Z(5_YD[X-_\ SQ:/^('>*/\ T2__ )F^'O\
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MI#_AUC^WA_T0K_S)WP;_ /GBT?\ $#O%'_HE_P#S-\/?_/8/^([>%7_14_\
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M\1V\*O\ HJ?_ #!\1_\ SI#_ (=8_MX?]$*_\R=\&_\ YXM'_$#O%'_HE_\
MS-\/?_/8/^([>%7_ $5/_F#XC_\ G2'_  ZQ_;P_Z(5_YD[X-_\ SQ:/^('>
M*/\ T2__ )F^'O\ Y[!_Q';PJ_Z*G_S!\1__ #I#_AUC^WA_T0K_ ,R=\&__
M )XM'_$#O%'_ *)?_P S?#W_ ,]@_P"([>%7_14_^8/B/_YTA_PZQ_;P_P"B
M%?\ F3O@W_\ /%H_X@=XH_\ 1+_^9OA[_P">P?\ $=O"K_HJ?_,'Q'_\Z0_X
M=8_MX?\ 1"O_ #)WP;_^>+1_Q [Q1_Z)?_S-\/?_ #V#_B.WA5_T5/\ Y@^(
M_P#YTA_PZQ_;P_Z(5_YD[X-__/%H_P"('>*/_1+_ /F;X>_^>P?\1V\*O^BI
M_P#,'Q'_ /.D/^'6/[>'_1"O_,G?!O\ ^>+1_P 0.\4?^B7_ /,WP]_\]@_X
MCMX5?]%3_P"8/B/_ .=(?\.L?V\/^B%?^9.^#?\ \\6C_B!WBC_T2_\ YF^'
MO_GL'_$=O"K_ **G_P P?$?_ ,Z0_P"'6/[>'_1"O_,G?!O_ .>+1_Q [Q1_
MZ)?_ ,S?#W_SV#_B.WA5_P!%3_Y@^(__ )TA_P .L?V\/^B%?^9.^#?_ ,\6
MC_B!WBC_ -$O_P"9OA[_ .>P?\1V\*O^BI_\P?$?_P Z0_X=8_MX?]$*_P#,
MG?!O_P">+1_Q [Q1_P"B7_\ ,WP]_P#/8/\ B.WA5_T5/_F#XC_^=(?\.L?V
M\/\ HA7_ )D[X-__ #Q:/^('>*/_ $2__F;X>_\ GL'_ !';PJ_Z*G_S!\1_
M_.D/^'6/[>'_ $0K_P R=\&__GBT?\0.\4?^B7_\S?#W_P ]@_XCMX5?]%3_
M .8/B/\ ^=(?\.L?V\/^B%?^9.^#?_SQ:/\ B!WBC_T2_P#YF^'O_GL'_$=O
M"K_HJ?\ S!\1_P#SI#_AUC^WA_T0K_S)WP;_ /GBT?\ $#O%'_HE_P#S-\/?
M_/8/^([>%7_14_\ F#XC_P#G2'_#K']O#_HA7_F3O@W_ //%H_X@=XH_]$O_
M .9OA[_Y[!_Q';PJ_P"BI_\ ,'Q'_P#.D/\ AUC^WA_T0K_S)WP;_P#GBT?\
M0.\4?^B7_P#,WP]_\]@_XCMX5?\ 14_^8/B/_P"=(?\ #K']O#_HA7_F3O@W
M_P#/%H_X@=XH_P#1+_\ F;X>_P#GL'_$=O"K_HJ?_,'Q'_\ .D/^'6/[>'_1
M"O\ S)WP;_\ GBT?\0.\4?\ HE__ #-\/?\ SV#_ (CMX5?]%3_Y@^(__G2'
M_#K']O#_ *(5_P"9.^#?_P \6C_B!WBC_P!$O_YF^'O_ )[!_P 1V\*O^BI_
M\P?$?_SI#_AUC^WA_P!$*_\ ,G?!O_YXM'_$#O%'_HE__,WP]_\ /8/^([>%
M7_14_P#F#XC_ /G2'_#K']O#_HA7_F3O@W_\\6C_ (@=XH_]$O\ ^9OA[_Y[
M!_Q';PJ_Z*G_ ,P?$?\ \Z0_X=8_MX?]$*_\R=\&_P#YXM'_ ! [Q1_Z)?\
M\S?#W_SV#_B.WA5_T5/_ )@^(_\ YTA_PZQ_;P_Z(5_YD[X-_P#SQ:/^('>*
M/_1+_P#F;X>_^>P?\1V\*O\ HJ?_ #!\1_\ SI#_ (=8_MX?]$*_\R=\&_\
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M_P#YF^'O_GL'_$=O"K_HJ?\ S!\1_P#SI#_AUC^WA_T0K_S)WP;_ /GBT?\
M$#O%'_HE_P#S-\/?_/8/^([>%7_14_\ F#XC_P#G2'_#K']O#_HA7_F3O@W_
M //%H_X@=XH_]$O_ .9OA[_Y[!_Q';PJ_P"BI_\ ,'Q'_P#.D/\ AUC^WA_T
M0K_S)WP;_P#GBT?\0.\4?^B7_P#,WP]_\]@_XCMX5?\ 14_^8/B/_P"=(?\
M#K']O#_HA7_F3O@W_P#/%H_X@=XH_P#1+_\ F;X>_P#GL'_$=O"K_HJ?_,'Q
M'_\ .D/^'6/[>'_1"O\ S)WP;_\ GBT?\0.\4?\ HE__ #-\/?\ SV#_ (CM
MX5?]%3_Y@^(__G2'_#K']O#_ *(5_P"9.^#?_P \6C_B!WBC_P!$O_YF^'O_
M )[!_P 1V\*O^BI_\P?$?_SI#_AUC^WA_P!$*_\ ,G?!O_YXM'_$#O%'_HE_
M_,WP]_\ /8/^([>%7_14_P#F#XC_ /G2'_#K']O#_HA7_F3O@W_\\6C_ (@=
MXH_]$O\ ^9OA[_Y[!_Q';PJ_Z*G_ ,P?$?\ \Z3^DG]@7X6>//@I^R7\)_AE
M\3="_P"$:\<>&?\ A._[;T3^T]&UG[%_;/Q+\8^(--_XF7A_4=6TBY^TZ1JV
MGW?^B:A<>3Y_D3^5<Q3P1?V-X59'FG#? 60Y+G6%^I9G@O[4^LX;V^'Q/LOK
M&<YCBZ/[["5:^'GSX?$4JG[NK/EY^2?+.,HQ_C#Q8S[*N)O$#/\ .\DQ7UW*
M\;_97U7$^PQ.&]K]6R7+<)6_<XNE0Q$.3$8>M3_>4H<W+SPYH.$I?8=?H1^=
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M?__1_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZE/XGU_7/-\/:AXC\/>%-<N[%+?5X(?.U+P[I%PTT<O^B*@1V /QS_X+^_\
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M#Q1X)T+4/$-UI6G:SJEKH=GJFMVMQJUQIND:K?PV$=Q)9Z=?7"QVTH!^"O\
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M_%32M-:+5;>ZT>YN98/#_P 0=%6_UO1=*N)])U/0O%FF6?A^QT, _FB^%_\
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M6=,T^?[99>"_ _AJ*]U6/P+X M+[;J,^DQZOJ^K^(M7BM=3\3:[JB:5X:L-
M /V@N+>"[@GM;J&*XMKF&2WN+>9%EAG@F0QRPRQN"DD4L;,DB,"KHQ5@0<4
M?YV7[27_  :F?\%)/V8?VL/$WQX_X)-?'_PWH7@FY\0Z]K?PMETWXO>+?@3\
M=/A1HWB>]OFN/AY-KUK;2:5XD\/:'I%U%H*>(8_&=I=^+=)BD&N>%K*5WBNP
M#^IS_@A9^Q[_ ,% _P!C_P#9R^+^D_\ !2#XY/\ '7X\_%GXZZA\3;37+GXM
M^-OC+JGA_P )MX \"^#['P]JWBCQGIUBMK=Q7WA74+R#1_#<VI>'['3;JP$%
MZMT]U96@!^&W_!7;_@T?;]H;XS>,?VG_ /@G-\2/ /P?\7>/M=OO&?CKX ?$
MIM;\/_#UO&>H74^JZSXE^%/C;PIH_B&]\&-KFIN;X>!-3\-R>';#6+NZN-%\
M4>&-"%EH&G@'POX?_P""*W_!V!XCT4_"S6?V\_'W@_P';%;:*X\3?\%"?C#<
MZ)/9>6(19B7P<?%GB^31(8PJ)HUWIJV$2JHAL!M4T ?T2_\ !!?_ ((,Z_\
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MO_!'S_ALEOVEO'_P!\<-^T/_ ,,]#P6OP,\4?$7Q,-+'PE_X7@?$)\4-X_\
MA5\,39F^/Q,T,:,NDKK0G%GJIOFT_P FS%V ?T^T ?QX_P#! #_@WQ_;)_X)
M4?MR?%_]IG]H3XG?LR^,_ ?CW]G+Q_\ ![0])^#7C#XJ>(/%T'B+Q7\7/@[X
M]T_4-5L/&_P8^'>C6VBPZ/\ #O6+:\FM-?U&^CU*[TV&'3[BUDN;VU /TH_X
M+K?\$0O!7_!8;X1>!CH?CC3?A!^TM\$Y=>F^%'Q(U?2;S5_#&LZ'XB@ADUSX
M;>/[3398]2C\-:OJNG:/J>G^)-.M]6U;P=?VMY=Z=HNKVVK:OI.H '\J?PI_
MX($_\'/'P-\/#]G/X-?MB/\ "?X'3W,H5?AY^V[\4/"7PLTA-2N2=3FTOP]H
M.E:?XST:VO3)+=ZQ;Z%X,M3JBM*+JVO;B5HF /7?CW_P9>?'.3X$_ +2/V?/
MVAO@AXL_:27Q!\4O$W[5/Q)^-_B7XI^"O"&M#Q):_#]?AQX2^$ND^$/AE\4M
M0O-)\(76D^/KO7O$?C&'1_$7B74_$R:FPM[%[3PYX; /[E_V(_@GXH_9J_8P
M_9%_9S\;ZCH.K^-/@#^S%\!/@IXOU;PK<ZA>>%]4\4?"SX5>%/ VOZCX;N]7
MTS1=5NM!O=6T*[N='N=3T;2-0GT^6WEO=+T^Y:2TB /XU?B+_P &D_Q^_:0_
MX*B_M+?M)_M%?%_X!P?L?_M"?&_]K?XH'2OAKXY^*#?M">&H/C%:?%/6?@QJ
MMOX>UGX+Z7\/IO$'@7XB>)? ?B'Q3HEQ\0[O0;[3M"UG3([W6K>YCMKT ^6K
MO_@WP_X.0OV1K;5_@=^QG^W5KNK?LZS7E[%X=@^%G[77Q0^!>BVNE:C?3W=Q
M?7GPRU:^TJR\"ZYJ$LCW/B"W\$:KXA2ZDN'C.NZNKS%0#ZW_ ."87_!HKXQ\
M*_'/1?VG?^"J7Q8\%_&#4=&\3+X^A^ G@C6?$OCVQ\?>,WO9-6&K?'?XE^+-
M+T&Y\06D6L!=4UKPCHFGZW9^,KIU3Q#XPN='.K:!K@!_=JJJBJJ*%50%55 "
MJH& J@8   P !@#@8Q0!_FP_\%[?'OBC_@L]_P %U_V>?^"9'P$OOMOA7X">
M(7^ M_XEL%.I6FB^.?$=U8>,_P!JCX@/&KA?[/\ A3X2\)V.@ZUI[PI<MK/P
MI\01Q2W*WUC&H!_H]^#/".@> /!_A3P'X4L(]*\+>"?#>A>$?#>EP_ZG3= \
M-Z7:Z-H]A%C \NSTZRMK=,#[L8Z4 =)0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_TO[^
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /Y%_^"^7_  07^.G[
M5W[0GP9_X*&_\$TK[0_ 7[:7@[Q/X4'Q'2?Q58?#\>*9? L<%W\-/C%HOB6]
MC-A:?$3P%+HVE^%]3AOMT?B;PNGAS8]O+X2FMM> /Z:?V5]:_:%\0_L[_"+5
M?VL/!7A;X>_M(3>#=/M_C)X5\#^(;7Q1X/M?&^G/-IVJ:GX;U>R!MSH_B3[)
M%XFL=+6:[?0(-730)]0U*?3);^Z /?Z "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M _/3_@IS_P $\?!G_!4']EZ]_92^(WQ:^*/PB\!:UXZ\(>-/%&H_"B7PQ'K'
MBJV\&/J%_I?A+7%\5Z#XAT^;PX?$<VB^*9([>TM[X:YX6T*:.[6VBNK>Z -[
M_@G!_P $^_@S_P $Q_V5/!_[*'P.OO$.O>&/#>N>+?%6L^,_&/\ 9+>,?''B
MKQAK=QJFH:_XFET+3='TF6]M-.&D>%].^QZ;:I!X=\.Z):2"::VDN9P#[MH
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H ^+?^"A%Y^V5!^R3\6]._8#\+>%O$O[5/B715
M\*?#2\\9>*M(\):%X'G\0R?V=JWQ%:]UR.73=1U;P7I,MWJ_AS1;I6M-0\1Q
M:4-0BN=+BOK2< _#K_@W:_X(1^+O^"<%O\2_VI_VR&T+Q=^W%\7;S7-!@N+/
MQ"OCFV^%GP[O-36^UGR/%;!X];^('Q1UJ$:WXR\1PSWDD&AV^C:%:7L-Q>^,
M4U0 _J7H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H __3_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
M_]3^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /_U?[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P#*F@ _XA#?^"-O_0E_M ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\
M*F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@
M _XA#?\ @C;_ -"7^T!_X?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J:
M#_B$-_X(V_\ 0E_M ?\ A]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH
M/^(0W_@C;_T)?[0'_A]M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\
MB$-_X(V_]"7^T!_X?;7/_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_
M ((V_P#0E_M ?^'VUS_Y4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^
M"-O_ $)?[0'_ (?;7/\ Y4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X
M(V_]"7^T!_X?;7/_ )4T '_$(;_P1M_Z$O\ : _\/MKG_P J: #_ (A#?^"-
MO_0E_M ?^'VUS_Y4T '_ !"&_P#!&W_H2_V@/_#[:Y_\J: #_B$-_P""-O\
MT)?[0'_A]M<_^5- !_Q"&_\ !&W_ *$O]H#_ ,/MKG_RIH /^(0W_@C;_P!"
M7^T!_P"'VUS_ .5- !_Q"&_\$;?^A+_: _\ #[:Y_P#*F@ _XA#?^"-O_0E_
MM ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0
M'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@ _XA#?\ @C;_ -"7^T!_
MX?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J: #_B$-_X(V_\ 0E_M ?\
MA]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH /^(0W_@C;_T)?[0'_A]M
M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\ B$-_X(V_]"7^T!_X?;7/
M_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_ ((V_P#0E_M ?^'VUS_Y
M4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^"-O_ $)?[0'_ (?;7/\
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M\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\
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M_P#*F@ _XA#?^"-O_0E_M ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\
M*F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@
M _XA#?\ @C;_ -"7^T!_X?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J:
M#_B$-_X(V_\ 0E_M ?\ A]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH
M/^(0W_@C;_T)?[0'_A]M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\
MB$-_X(V_]"7^T!_X?;7/_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_
M ((V_P#0E_M ?^'VUS_Y4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^
M"-O_ $)?[0'_ (?;7/\ Y4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X
M(V_]"7^T!_X?;7/_ )4T '_$(;_P1M_Z$O\ : _\/MKG_P J: #_ (A#?^"-
MO_0E_M ?^'VUS_Y4T '_ !"&_P#!&W_H2_V@/_#[:Y_\J: #_B$-_P""-O\
MT)?[0'_A]M<_^5- !_Q"&_\ !&W_ *$O]H#_ ,/MKG_RIH /^(0W_@C;_P!"
M7^T!_P"'VUS_ .5- !_Q"&_\$;?^A+_: _\ #[:Y_P#*F@ _XA#?^"-O_0E_
MM ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0
M'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@ _XA#?\ @C;_ -"7^T!_
MX?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J: #_B$-_X(V_\ 0E_M ?\
MA]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH /^(0W_@C;_T)?[0'_A]M
M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\ B$-_X(V_]"7^T!_X?;7/
M_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_ ((V_P#0E_M ?^'VUS_Y
M4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^"-O_ $)?[0'_ (?;7/\
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M\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\
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M_P#*F@ _XA#?^"-O_0E_M ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\
M*F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@
M _XA#?\ @C;_ -"7^T!_X?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J:
M#_B$-_X(V_\ 0E_M ?\ A]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH
M/^(0W_@C;_T)?[0'_A]M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\
MB$-_X(V_]"7^T!_X?;7/_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_
M ((V_P#0E_M ?^'VUS_Y4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^
M"-O_ $)?[0'_ (?;7/\ Y4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X
M(V_]"7^T!_X?;7/_ )4T '_$(;_P1M_Z$O\ : _\/MKG_P J: #_ (A#?^"-
MO_0E_M ?^'VUS_Y4T '_ !"&_P#!&W_H2_V@/_#[:Y_\J: #_B$-_P""-O\
MT)?[0'_A]M<_^5- !_Q"&_\ !&W_ *$O]H#_ ,/MKG_RIH /^(0W_@C;_P!"
M7^T!_P"'VUS_ .5- !_Q"&_\$;?^A+_: _\ #[:Y_P#*F@ _XA#?^"-O_0E_
MM ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0
M'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@ _XA#?\ @C;_ -"7^T!_
MX?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J: #_B$-_X(V_\ 0E_M ?\
MA]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH /^(0W_@C;_T)?[0'_A]M
M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\ B$-_X(V_]"7^T!_X?;7/
M_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_ ((V_P#0E_M ?^'VUS_Y
M4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^"-O_ $)?[0'_ (?;7/\
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M\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\
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M_P#*F@ _XA#?^"-O_0E_M ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\
M*F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@
M _XA#?\ @C;_ -"7^T!_X?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J:
M#_B$-_X(V_\ 0E_M ?\ A]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH
M/^(0W_@C;_T)?[0'_A]M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\
MB$-_X(V_]"7^T!_X?;7/_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_
M ((V_P#0E_M ?^'VUS_Y4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^
M"-O_ $)?[0'_ (?;7/\ Y4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X
M(V_]"7^T!_X?;7/_ )4T '_$(;_P1M_Z$O\ : _\/MKG_P J: #_ (A#?^"-
MO_0E_M ?^'VUS_Y4T '_ !"&_P#!&W_H2_V@/_#[:Y_\J: #_B$-_P""-O\
MT)?[0'_A]M<_^5- !_Q"&_\ !&W_ *$O]H#_ ,/MKG_RIH /^(0W_@C;_P!"
M7^T!_P"'VUS_ .5- !_Q"&_\$;?^A+_: _\ #[:Y_P#*F@ _XA#?^"-O_0E_
MM ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0
M'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@ _XA#?\ @C;_ -"7^T!_
MX?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J: #_B$-_X(V_\ 0E_M ?\
MA]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH /^(0W_@C;_T)?[0'_A]M
M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\ B$-_X(V_]"7^T!_X?;7/
M_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_ ((V_P#0E_M ?^'VUS_Y
M4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^"-O_ $)?[0'_ (?;7/\
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M\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\
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M_P#*F@ _XA#?^"-O_0E_M ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\
M*F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@
M _XA#?\ @C;_ -"7^T!_X?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J:
M#_B$-_X(V_\ 0E_M ?\ A]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH
M/^(0W_@C;_T)?[0'_A]M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\
MB$-_X(V_]"7^T!_X?;7/_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_
M ((V_P#0E_M ?^'VUS_Y4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^
M"-O_ $)?[0'_ (?;7/\ Y4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X
M(V_]"7^T!_X?;7/_ )4T '_$(;_P1M_Z$O\ : _\/MKG_P J: #_ (A#?^"-
MO_0E_M ?^'VUS_Y4T '_ !"&_P#!&W_H2_V@/_#[:Y_\J: #_B$-_P""-O\
MT)?[0'_A]M<_^5- !_Q"&_\ !&W_ *$O]H#_ ,/MKG_RIH /^(0W_@C;_P!"
M7^T!_P"'VUS_ .5- !_Q"&_\$;?^A+_: _\ #[:Y_P#*F@ _XA#?^"-O_0E_
MM ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0
M'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@ _XA#?\ @C;_ -"7^T!_
MX?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J: #_B$-_X(V_\ 0E_M ?\
MA]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH /^(0W_@C;_T)?[0'_A]M
M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\ B$-_X(V_]"7^T!_X?;7/
M_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_ ((V_P#0E_M ?^'VUS_Y
M4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^"-O_ $)?[0'_ (?;7/\
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M\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\
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M_P#*F@ _XA#?^"-O_0E_M ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\
M*F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@
M _XA#?\ @C;_ -"7^T!_X?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J:
M#_B$-_X(V_\ 0E_M ?\ A]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH
M/^(0W_@C;_T)?[0'_A]M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\
MB$-_X(V_]"7^T!_X?;7/_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_
M ((V_P#0E_M ?^'VUS_Y4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^
M"-O_ $)?[0'_ (?;7/\ Y4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X
M(V_]"7^T!_X?;7/_ )4T '_$(;_P1M_Z$O\ : _\/MKG_P J: #_ (A#?^"-
MO_0E_M ?^'VUS_Y4T '_ !"&_P#!&W_H2_V@/_#[:Y_\J: #_B$-_P""-O\
MT)?[0'_A]M<_^5- !_Q"&_\ !&W_ *$O]H#_ ,/MKG_RIH /^(0W_@C;_P!"
M7^T!_P"'VUS_ .5- !_Q"&_\$;?^A+_: _\ #[:Y_P#*F@ _XA#?^"-O_0E_
MM ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0
M'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@ _XA#?\ @C;_ -"7^T!_
MX?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J: #_B$-_X(V_\ 0E_M ?\
MA]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH /^(0W_@C;_T)?[0'_A]M
M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\ B$-_X(V_]"7^T!_X?;7/
M_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_ ((V_P#0E_M ?^'VUS_Y
M4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^"-O_ $)?[0'_ (?;7/\
MY4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X(V_]"7^T!_X?;7/_ )4T
M '_$(;_P1M_Z$O\ : _\/MKG_P J: #_ (A#?^"-O_0E_M ?^'VUS_Y4T '_
M !"&_P#!&W_H2_V@/_#[:Y_\J: #_B$-_P""-O\ T)?[0'_A]M<_^5- !_Q"
M&_\ !&W_ *$O]H#_ ,/MKG_RIH /^(0W_@C;_P!"7^T!_P"'VUS_ .5- !_Q
M"&_\$;?^A+_: _\ #[:Y_P#*F@ _XA#?^"-O_0E_M ?^'VUS_P"5- !_Q"&_
M\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\
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M_P#*F@ _XA#?^"-O_0E_M ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\
M*F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@
M _XA#?\ @C;_ -"7^T!_X?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J:
M#_B$-_X(V_\ 0E_M ?\ A]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH
M/^(0W_@C;_T)?[0'_A]M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\
MB$-_X(V_]"7^T!_X?;7/_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_
M ((V_P#0E_M ?^'VUS_Y4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^
M"-O_ $)?[0'_ (?;7/\ Y4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X
M(V_]"7^T!_X?;7/_ )4T '_$(;_P1M_Z$O\ : _\/MKG_P J: #_ (A#?^"-
MO_0E_M ?^'VUS_Y4T '_ !"&_P#!&W_H2_V@/_#[:Y_\J: #_B$-_P""-O\
MT)?[0'_A]M<_^5- !_Q"&_\ !&W_ *$O]H#_ ,/MKG_RIH /^(0W_@C;_P!"
M7^T!_P"'VUS_ .5- !_Q"&_\$;?^A+_: _\ #[:Y_P#*F@ _XA#?^"-O_0E_
MM ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0
M'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@ _XA#?\ @C;_ -"7^T!_
MX?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J: #_B$-_X(V_\ 0E_M ?\
MA]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH /^(0W_@C;_T)?[0'_A]M
M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\ B$-_X(V_]"7^T!_X?;7/
M_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_ ((V_P#0E_M ?^'VUS_Y
M4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^"-O_ $)?[0'_ (?;7/\
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M\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\
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M_P#*F@ _XA#?^"-O_0E_M ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\
M*F@ _P"(0W_@C;_T)?[0'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@
M _XA#?\ @C;_ -"7^T!_X?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J:
M#_B$-_X(V_\ 0E_M ?\ A]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH
M/^(0W_@C;_T)?[0'_A]M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\
MB$-_X(V_]"7^T!_X?;7/_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_
M ((V_P#0E_M ?^'VUS_Y4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^
M"-O_ $)?[0'_ (?;7/\ Y4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X
M(V_]"7^T!_X?;7/_ )4T '_$(;_P1M_Z$O\ : _\/MKG_P J: #_ (A#?^"-
MO_0E_M ?^'VUS_Y4T '_ !"&_P#!&W_H2_V@/_#[:Y_\J: #_B$-_P""-O\
MT)?[0'_A]M<_^5- !_Q"&_\ !&W_ *$O]H#_ ,/MKG_RIH /^(0W_@C;_P!"
M7^T!_P"'VUS_ .5- !_Q"&_\$;?^A+_: _\ #[:Y_P#*F@ _XA#?^"-O_0E_
MM ?^'VUS_P"5- !_Q"&_\$;?^A+_ &@/_#[:Y_\ *F@ _P"(0W_@C;_T)?[0
M'_A]M<_^5- !_P 0AO\ P1M_Z$O]H#_P^VN?_*F@ _XA#?\ @C;_ -"7^T!_
MX?;7/_E30 ?\0AO_  1M_P"A+_: _P##[:Y_\J: #_B$-_X(V_\ 0E_M ?\
MA]M<_P#E30 ?\0AO_!&W_H2_V@/_  ^VN?\ RIH /^(0W_@C;_T)?[0'_A]M
M<_\ E30 ?\0AO_!&W_H2_P!H#_P^VN?_ "IH /\ B$-_X(V_]"7^T!_X?;7/
M_E30 ?\ $(;_ ,$;?^A+_: _\/MKG_RIH /^(0W_ ((V_P#0E_M ?^'VUS_Y
M4T '_$(;_P $;?\ H2_V@/\ P^VN?_*F@ _XA#?^"-O_ $)?[0'_ (?;7/\
MY4T '_$(;_P1M_Z$O]H#_P /MKG_ ,J: #_B$-_X(V_]"7^T!_X?;7/_ )4T
M ?TW:3I=AH>E:9HFE0?9=,T?3[+2].MO-FG^SV&GVT5I9P>=<R37$WDV\,<?
MFSRRS2;=\LCN6>@#0H __]?^_B@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * &1R1RH)(G21&SM>-@Z'!(.&4D'!!!P>"".,&@
M!] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!__T/[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?_]'^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(([6SL[6",*D-O;6\4<,,: *D:*HX%<K;;;>K;NWW?X_G]X&A2 * "@ H *
M"@""XA::(K'*T,J_/#*-Y"2@'8TD:NGG1 G]Y [!)%RI*G:Z@%&WU-#='3[M
M?LU]Y?F1HQ_=W*#B1K67"B81DC/RHY1E<Q1.9H+=VZ_UI_P->OYJ)?6W]?U]
MWXIRU:0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_L0/A5_ZD7B^ODO%G_=<E_[",9_Z;H'I\,?Q<7_U[I?^E3/[*Z_$S[ * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_4[*I * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#__U/[^* "@ H * /X\O^#IW_D:_P!BO_L7OCQ_Z<OA-7[3X3?P,\_Z
M^X#_ -(Q9\CQ/\>#_P -?\Z1^)'_  23_P"4DG['G_98M'_](-3K[KC'_DF,
MZ_[ I_\ I4#Q<J_Y&.#_ .OT?R9_IB5_+A^D!0!_'Q_P=/\ _(Q_L3?]@3X_
M_P#I?\'J_9_"7^'GO^/+?_2<<?)<4;X+TQ'_ +@/QE_X(U?\I-_V1?\ L?\
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M4IQH5ITE*26B<E"[2TN]-CZZA4=6A1JM).K2IU&ELG."DTO)-V/QH_X*Z_\
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MTT[:GUD91E%2BU*,DI1DG=2BU=--7336J:?WW-:H&% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0!F:W/J=MHVKW.B64.I:S;Z9?SZ1IUQ.+6"_P!3BM99+"RGNF^6VANKI88)
M)SQ"DAD/W:%]R[]@/S*_9,_;PUWQ[\0-7^#?[0-CIOA#Q]<:Y>Z?X6N4TV?0
M+=]8BO+B&Z\!ZU97UR[Z?KUM<*+'03-LDU22(Z1=M)KS69UG>=))<T'=;M>7
M=?\ #R[WU0'ZD5@ 4 % !0!^;?\ P4'_ &K/^%0^$6^%7@74I8OB9XZTZ5+V
M_P!/EV77@WPM=9MYKU;A"9+77=<4S6>C& ?:["V2\U826-R-%GNMJ4.9\SO9
M;>;_ !T77OMIJP-7]@+]E3_A27@L_$3QK8SQ?%3Q]IT37-G?1>5/X/\ "\TD
M5Y::"87!N(=8U)X[?4O$?VEHYK>:.PT<V=K<:7?3Z@5:G,^5;+\7W[6[67GK
M= ?H?6(!0 4 % !0 4 % !0 4 % 'G7C_2+LVJ>)=&=H-8T1?.+QD#[19(=T
ML4@8&,K%S*2^Q1$)&D9O*B6K@_LO9_F_D]_56WU"RWZ_U_7_  YT'A/Q+:^*
M='@U.WPDO,5W!R&@N(SAAM+/A)!B6/#R *WEF5Y$<K+5G;^OS?Y_=</Z_K?^
MNVQTM( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H _]7^_B@ H * "@#^/+_@Z=_Y&O\ 8K_[%[X\?^G+X35^T^$W\#//^ON
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M_P"P'%_E3+XA_P"1=+_K]2_-G\$?AS_D8="_[#.E_P#I=!7]"5OX57_KW/\
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M:3N[RNE;E?-A_L _L0_$;]O?]H?PU\%_!*W&E>'HS'X@^*/CPVIN-/\ A_X
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M==$JG*NR5E:UC^4[_@N!_P I2_VL/^PW\-/_ %2?PUK]<X#_ .22RC_!B_\
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M_9R2G"[UV;G%=HQ2TM8_?VOSL]X* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /XVO^"K'_
M  59_;X_9L_;X^//P5^"OQY_X0OX9^"_^%7?\(UX:_X5=\&/$?\ 9O\ PD?P
M8^'?BS6?^)SXL^'>N^(+S[9X@UW5;_\ XF&JW7V?[5]EM?(LH+>WB_H?@7@;
MA;.>%<KS+,LK^LXW$_7O;5OKN8T>?V.8XNA3_=T,72I1Y:5*$/<A&_+S.\G*
M1\=FN;8_#8^O0H5^2E#V7+'V5"5N:C3G+6=*4G>4F]9.U[*RT/SR_P"'Y?\
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M<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S<']NYK_T$_\
ME'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S)9M_\W!_;N:_]!/_
M )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_\R6;?_-P?V[FO_03
M_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S<']NYK_T
M$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S)9M_\W!_;N:_
M]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_\R6;?_-P?V[F
MO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S<']N
MYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S)9M_\W!_
M;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_\R6;?_-P
M?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S
M<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S)9M_
M\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_\R6;
M?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,E
MFW_S<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S
M)9M_\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_
M\R6;?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)
M/_,EFW_S<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]
M"3_S)9M_\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'
M_0D_\R6;?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP
M1_T)/_,EFW_S<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9
M\$?]"3_S)9M_\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B
M&?!'_0D_\R6;?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_
MXAGP1_T)/_,EFW_S<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*
M/^(9\$?]"3_S)9M_\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z
M2C_B&?!'_0D_\R6;?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\
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M<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S<']NYK_T$_\
ME'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S)9M_\W!_;N:_]!/_
M )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_\R6;?_-P?V[FO_03
M_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S<']NYK_T
M$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S)9M_\W!_;N:_
M]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_\R6;?_-P?V[F
MO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S<']N
MYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S)9M_\W!_
M;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_\R6;?_-P
M?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S
M<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S)9M_
M\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_\R6;
M?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,E
MFW_S<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]"3_S
M)9M_\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'_0D_
M\R6;?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)
M/_,EFW_S<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9\$?]
M"3_S)9M_\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B&?!'
M_0D_\R6;?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP
M1_T)/_,EFW_S<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*/^(9
M\$?]"3_S)9M_\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z2C_B
M&?!'_0D_\R6;?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_
MXAGP1_T)/_,EFW_S<']NYK_T$_\ E'#?_* _X?E_\%2_^CH?_,)_L[?_ #I*
M/^(9\$?]"3_S)9M_\W!_;N:_]!/_ )1PW_R@/^'Y?_!4O_HZ'_S"?[.W_P Z
M2C_B&?!'_0D_\R6;?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\
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M<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S<']NYK_T$_\
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M2C_B&?!'_0D_\R6;?_-P?V[FO_03_P"4<-_\H#_A^7_P5+_Z.A_\PG^SM_\
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M<-_\H#_A^7_P5+_Z.A_\PG^SM_\ .DH_XAGP1_T)/_,EFW_S<']NYK_T$_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MN_\ /_ZC7J>(_P#R2V*_["<%_P"GXG-D'_(RI_\ 7NM_Z0S_ $&J_G(^^/\
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M +#.E_\ I=!7]!UOX57_ *]S_P#26?#0^./^*/YG^M_7\=GZL?@!_P %QO\
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MG'&4DC=D89Y5B.,U^U9LW'*LSE%M-9?C6FMTUAJK37FF?(897Q.'71UZ2_\
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M;P'XGU(ER0@%CHFO7UT2Y!" 1_,<@ X- 'MM !0 4 % !0 4 ?D#_P %0?\
M@M[^PS_P2?LM$TG]H'Q/XE\9_&'Q5I\&M>%_@#\(M.TCQ)\4;WPY<W5U81>+
M]:M];U[PUX;\(>$6OK&[MK?5?$WB'3;O6Y;+4XO"NE^(;G2=4@M #\X?^":_
M_!TS\ O^"D'[:7PU_8Q\+?LK_&#X7^(/BV/B$?!OCCQ!XQ\%^(-'A'P]^&WC
M#XH7W_"3:5IR6-[I7]H:%X*U2RM?[*N/$/EZM<6$,I%G+<7MJ ?U.4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!_GF_\ !<O_ )2E_M0_]T3_ /6=OA)7]:>&7_)$9)_W4O\ U;X\
M_/<\_P"1IBO^X'_J/1/R9K[P\D* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#^LS_ (-=O^;Y/^[9_P#WX&OP?QM_YIG_
M +K7_O)/K.%_^8[_ +EO_=@_K,K\'/K H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /__7_OXH * "@ H _CR_X.G?^1K_ &*_
M^Q>^/'_IR^$U?M/A-_ SS_K[@/\ TC%GR/$_QX/_  U_SI'XD?\ !)/_ )22
M?L>?]EBT?_T@U.ONN,?^28SK_L"G_P"E0/%RK_D8X/\ Z_1_)G^F)7\N'Z0%
M '\?'_!T_P#\C'^Q-_V!/C__ .E_P>K]G\)?X>>_X\M_])QQ\EQ1O@O3$?\
MN _&7_@C5_RDW_9%_P"Q_P!9_P#4"\75]OQO_P DKG/_ &#T_P#U)HGC9/\
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M3!<12H484<11=9TXJ,*D9J,G%*T5-/1M+3G33:W7-K+\V/\ @IY_P5-^)/\
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MG[*A3ES*+?-*4[6YI/1:)M126G-*[=S\C/#G_(PZ%_V&=+_]+H*^QK?PJO\
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M_P#J-5/D,+_O.'_Z_P!'_P!.1/\ 5<K^2#]1/\Q[_@J5_P I%?VR_P#LO_Q
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MISE*<I/>4I.\F]M6VWM]Q_;O_P &Q'_)D'QH_P"SJ_%7_JHO@Q7X1XJ?\C[
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_GF_\%R_^4I?[4/_ '1/_P!9
MV^$E?UIX9?\ )$9)_P!U+_U;X\_/<\_Y&F*_[@?^H]$_)FOO#R0H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /ZS/^#7;
M_F^3_NV?_P!^!K\'\;?^:9_[K7_O)/K.%_\ F._[EO\ W8/ZS*_!SZP* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MG[/EY%/_ *>3O?F\OF?3'[?G[(X_;E_9;\??LU'X@'X7GQQJ'@N_7QH/"O\
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M<Y)_"Y62>JC=)G]!E?G)[X4 % !0 4 % !0 4 % !0 4 % !0 4 % 'X;?\
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MET35D6YTF_M]8B32E\2SW&G$W4K.UM%'<^8'=Z /]"/_ ((%_P#!P?\ '?\
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MV)/^S1?V;?\ U37@R@#ZZH * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * /\\W_@N7_P I2_VH?^Z)_P#K.WPDK^M/#+_DB,D_
M[J7_ *M\>?GN>?\ (TQ7_<#_ -1Z)^3-?>'DA0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?UF?\ !KM_S?)_W;/_ ._
MU^#^-O\ S3/_ '6O_>2?6<+_ /,=_P!RW_NP?UF5^#GU@4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M&5_RWA]+'QUC)3?%6$J0C*+E"?#7#GLY;M4YRIY93J)22:]RI";2;B[IN/\
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M=M-=%+NNG;>[Y:W]IZ;_ -!"Q_\  N#_ ..5'M:7_/VG_P"!Q_\ EA7LJO\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_
MT?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MN+*QO+KPWI3,SKNOKX))/<W!::\N)9W=V /X2_\ @[J^+O\ P2^_:>^&_P
MOC-^S)^T3^S=\8/VO?!/Q3_X5SXW_P"%'>-O!_CG6O$OP/U_P;XGU62_\9^(
M_!,NJV&MV_P^\9^%?#&F>%AJ&MR2Z+%X[\06]C$T-]<"( _H _X--?B7J?Q
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M-EK.F6U[HOPA^$'[1NE^/O#2VL<YCU3]D3XZQ3QZSHFG%5QJEQH'PJ\:^)_
M<D_D-"?&/A2ZD6W#VJ(H!_K:V-]9:G96>I:==VU_I^H6MO?6%]9S1W-I>V5W
M$D]K=VMQ"SQ3VUS!)'-!-$[QRQ.DB,RL#0!_EH?\' ?Q3\<?\%8_^"\OAK]B
M[X+7YU;2_ACXS\!?L3?#KR?,N=(LO'=WXD%Q\;?&6I6L3D6Z>%_'&N:_HGBB
M^$JH/#7POL[R=H([9M@!_IR_ SX-^"/V=_@O\)_@+\-=.&E?#_X-?#OP=\,O
M!M@1'YL/AWP3H%CX>TIKMXU1;B_GM-/CN-1O&7S;V^EN+N8M-,[L >J4 % '
M^<C_ ,'IO[;W_";?'?\ 9Y_8#\):OYVA?!+P[)\=OBY9VL^^"7XF_$>SGT?X
M=Z-J<&[,6J>#_AQ#JNOVK!%633?BW$3([ )$ ?V(?\$1/V*_^&"/^"8_[+/P
M&U72?[)^(ESX&@^*?QCBEA\G4!\6/BP__";>*]+U4X7SKSP8-4L/A[#-M4MI
MOA#3U.XH7< _A^_X/&_V-;OX$?M[?"G]M'P597&D^'/VK_ EK#XBU;3/,MGL
M/CE\#(=%\.7]^+JT\H:;<:O\.[OX:7FF/NBN[[5="\3ZE'+-+#<O  ?W@_\
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M++2K6Z^&/QDOQ;Q2R6UMHVK:'"#++,C '^L>714,A=1&%+ERP"! -Q<L<*%
MY+$XQR<8H _RC_VO/&'B?_@XD_X.$-%^$WP]UB_O_@7<_$FQ^!/P^UW2I#/9
M^&OV6?@G=ZQK?Q-^)^ES,KVJ'Q?;VOQ#^)'AXWJVYN]1\6^&?#$SB?[*E 'Z
M\?\ ![%X1\-?#_X0_P#!*_P'X+T6Q\.>#O!+?M)>$?"?A[3(O(TW0?#7AOPQ
M^SCHVA:+I\&3Y-CI>EV5K8VD63Y=O!&F3C- ']+'_!N]_P H6OV /^R1ZU_Z
MLOQU0!_&W_P>R_\ *0C]EG_LS72O_5V_&"@#_0,_X)^_\F&?L2?]FB_LV_\
MJFO!E 'UU0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 ?YYO_!<O_E*7^U#_ -T3_P#6=OA)7]:>&7_)$9)_W4O_ %;X\_/<
M\_Y&F*_[@?\ J/1/R9K[P\D* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#^LS_@UV_P";Y/\ NV?_ -^!K\'\;?\ FF?^
MZU_[R3ZSA?\ YCO^Y;_W8/ZS*_!SZP* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#YW_:S_P"3<OBU_P!BN_\ Z7V-?D_CM_R9SQ)_[)'.
M/_4:1]_X5_\ )R."?^RCRS_U(B?B?^S_ /#H?$W1_CGH<4/G:II7PFN_%FA
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MWO'^QO'J<Y^$_&,9SE.,89,XQE)R2:XER9)I/9I.R:U^\_H%_P""CW[8E_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MGAW1-!;4#";<WS:1IMKIYO#;F:X,!NC;F<PFXG,6_89I=I=@#_+&_P"#<?\
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M<_@OQI=26B$@RW)\(^$/%4+Q+EA:RW4I 6)S0!_JOT <5\2O$N@^#/ASX_\
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M[-O_ *IKP90!]=4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _K,_X-=O\ F^3_ +MG_P#?@:_!_&W_
M )IG_NM?^\D^LX7_ .8[_N6_]V#^LROP<^L"@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M""-YIIIG6.*&*-2\DLLCD)''&BEW=B%55+,0!F@#XN\5?\%)_P#@G5X$U9]
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MUS#>Z?J.GWL,=S9WUC>6TDMO=V=W;RQ7%M<V\LD,\,D<L4CHZLP!<H * "@
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MXAAT;Q#=>'K^!KS1_#OA3P=-=&QU75=9TBP /$_^#W7_ )-#_8L_[.0\8?\
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M67P'^%MY=0;+B/X>?#0PZ_X^U73)]O[W2O%OC[5](T.Z!=BNI_"F11&@4O*
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M"_C#3[>4K%)K'@KQ5::+XNT3S3Y::OHME(X95*L ?XLFC_L<?M':S^V58?\
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MBYU#2;B;39[[3--O);-X9+JPLYV>WB /=/\ B-9_X)A_]&\_MY?^&Z_9\_\
MHG* /Z;_ -C7]JOX?_MP?LP_!W]J_P"%>C>,/#WP^^-GA=_%?A?1/']CHVF>
M,=.L(]6U+1I+?7['P]K_ (IT6VO!=Z5<L$T[Q!JD!@:%_M =GC0 ^FZ "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _SS?^"Y?_*4
MO]J'_NB?_K.WPDK^M/#+_DB,D_[J7_JWQY^>YY_R-,5_W _]1Z)^3-?>'DA0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M?UF?\&NW_-\G_=L__OP-?@_C;_S3/_=:_P#>2?6<+_\ ,=_W+?\ NP?UF5^#
MGU@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M,WSS*,KQ&-S+V678;"T,QS#"X2I5H4J53&8C$UZ<*\W&G5IX6E&:C+VM6/-
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % '__4_OXH * "@ H ^+/^"B'[:G@3_@GG^QK\=_VNO']O%JNG
M_"7PA)>^'O"S7JZ?-XX\?ZW=VOAWX?>"+:Z\N>6W/B?QAJFCZ;>WT%K>R:/I
M,NHZW):36VFW"T ?QC_\&U'[#OQ$_P""E'[7_P 9?^"YG[=-V?'VLZ3\7=8'
MP3T[5K24:7KGQPL[+3IKSQUI^FWC7%O:>!O@-X?O-"\(?"32K5KJRTGQ);02
M:?=:=?\ PNM$N@#^L;_@K9_P5.^"W_!)K]EK5/CS\2[>/QAX]\17DWA3X&_!
MJSU6+2]=^*WCXVXN&M%NS!>2:-X0\-6DB:SXX\5M87<&B::;6QMK>_\ $>N^
M&]&U0 _SUOAG\&?^"V'_  =&_&+Q'X\\6?$*XTG]G?PGXJE@N_$/B[4=<\#?
MLG_!VXN&%['X-^&/P_T6+49O'/CC3='>UCGFM-/\3>+VMSH4WQ,\=Z7'JNEZ
MO=@'[,Z3_P &.7@S_A%HHM=_X*,^)QXUDMXFFO\ 2?V:-*/A:TNV7,T46D7G
MQH&K:A;Q.1'%</K>F23JGG-;6YD\B  [_P#X)>_\&T/[9_\ P2Y_X*W?LT_M
M':;\9_AO\=OV5_"MO\:=/^('B[PW=:Q\,O'=K:>*/@!\4?"/AF'Q;\)=9O-7
ML-1T^X\>^(/"QLX?#?CGQNUI<PKK.H6NEQ:<ETH!^H/_  =I?\H5_C;_ -E7
M_9^_]6EH= '\;_\ P2&_X-HO%O\ P5B_9-N/VJ-'_:]\._ ^RA^*OC+X8+X+
MU+X,:GX^NGD\(:;X9OY-:.N6OQ)\)1(E\?$7DI8#2W:W%GYC7<OGB.  ^X/B
M;_P96?MP> +(^)_V>OVR?@+\0O%6B-)J.F6'B/1_B+\$]9EGM4,MNF@ZYI$7
MQ)M+;69W7RK0ZA?Z)81S,AN=8M(2\Z 'R!\$O^"NG_!;;_@@M^T7IO[/W[:E
MK\4?B5\/-':"YUS]GW]H[Q+)XUL/$/@VXN/)'B/X#?'G[1XMO;"S@V7<&BW_
M (0\3>*/AO!JJWUAK_A&^U2RFM[  _TOOV/OVL_@O^W+^SA\+?VI/@!X@?Q#
M\,/BOH']KZ0]W"MIK6AZG9W5QI7B3PCXGTY99UTWQ1X1\0V.I>'M?LHY[BU7
M4=/FET^\U#39K*_N #X-_P""TG_!7+PY_P $>_V<O!7QNU;X+:W\<]=^)?Q%
M/PP\'>$M.\76'@;2;?73X6U[Q2=3\3>)+G1_$EY9Z3#::%-$(M+\/:I>7-Q-
M'$1:Q%[J( _SE?\ @H[_ ,%0_P#@KU_P5@^"'C7X\_%71_%?P^_8"\$>,] \
M,7GA7X4Z+K'@7]G1/&&LZFR>&="U_P 0:QJ4^K?&SQS;3VMO>7-AJ.M^*(O"
MUQ#_ &]8>&?!=G> N ?W(_\ !I'_ ,H7OA'_ -EC^/W_ *L*^H _IAH _P T
MS]E3_@@I_P %./\ @NGXTO/VZ?\ @I+^T3XR^#'P]\?7MU?^"KOQYX>N_$?Q
M5\4^%)+Z>2UM/A9\(;C4/#?A;X-_"IU1AX9GO$TNVNK=X->T+P+X@T;4H=<N
MP#U;_@HS_P &>.I_LX_L]^-_VA/V(OVD?'?Q<\6_!WPYJ7C[Q!\(OB3X8T73
M?%7BC0?"]E_;&MWWPV\7^#&TZ%?%FD6=E>:II/A2_P##K3:^8EL-,\00ZS'9
M6>J@'Z0_\&DW_!7;XR_M@^#/BO\ L._M->,?$'Q/^)WP!\)V7Q/^%/Q3\7:S
M>^(/&?B7X/76NZ;X5U_PKXQUG4Y+C4];O?A]XFUOPT-"\0:E>WVI7^A>+8M%
MNY$A\+V4MV ?M1_P78_9*_:__;>_83N?V<_V*O%LG@KXH^-_C#\-HO%.NR_$
MK5/A?HD/PIB?6XO&R^+-:T61M6UCPJHN=+N=9\+:=INOWNM16T:VN@:I-;I"
MH!_/-\,_^#(+X,0>"[=?C'^W5\3]5^(EQIML]U-\,_A=X4T#P7H^KO&C7EM;
MVWBG5?$FN>(]-M9B\%M?277A6ZOHT2[ET[3GE-E$ ?S]?M*_ []O'_@UI_X*
M%_#G6?A5\;KKQAX,\6VFG^/_  CXAT8ZUX4^'?[1OPVT+7Y-/\4?##XR_#F/
M6M0M5U#36?['K&FMJ&NMH"Z]H/B_P=XAL]8EL[G30#_5@^!OQ7T'X\_!3X/?
M'+PJAC\,?&;X6_#_ .*_AR,SI=&/0?B)X3TGQ?I$9NDBA2Y*:?K%NIG2&)92
M#((D#!% /4J "@ H * "@ H * "@#X__ &[OVW?@=_P3Q_9A^)'[4_Q_UIM.
M\%^ ]/$6EZ%8O;GQ-\0?&NI)+'X4^'?@NRN)8EU#Q1XIU"(V]JK.EGI=A%J7
MB+6KBQ\/Z+J^HV0!_FN^*_CU_P %H?\ @Z,_:/\ %?PP^$TFJ>#?V=-!U"WU
M&^^&.F>*=5\%?LM_ WPI=W#VWA^]^+_BFQL!>_%'QQ=I%<W-M+J>C^*O&6L7
M:^(;OP!X(T/PM97VE:* ?KUX!_X,=M&/A6)_BC_P4-U2/QO<6NZ>W\ _L]6D
M_A72+UL?N8KWQ%\4K?5_$=K&0Q^TO8>%Y9]P'V2VV;I0#E/@_P#\&EW[9G[#
M7[?'[$O[17P)_:.^'/[0WPB^$W[57[/WC[XJ7#V&K? 3XHZ-\._"GQ7\*^(/
M'TUMX3N_$'C;PQXHT5/!^G:M#J.GVGQ&CUG7$E.F6GA6^2[=$ /V^_X.TO\
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M:P\">))='^+?[/FH^>S27-W\/-8DN_$W@ZT62XN+#PY#XUT<2P:!X3\/V5N
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MF?!?XM^*-"\-/=32M+++8>&?%O\ PF^B:! V[RH]+\-V6CZ-:Q*J6>FV_+4
M>X_LK?\ !N!_P2&_9(\9:3\1_!7[+]I\1O'^@3VEYH/B7X\>*O$/Q=BT74;&
M9;JTU?3?!_B6[?X>6VMVMW%;WEAK2^#SJVEW=O#<:5>6,JLS '[GT ?B#^VI
M_P &[O\ P2L_;M^)>O\ QI^+7P&U'P?\7O%LK7?B_P"('P6\9ZU\,]0\6ZG)
M-)<7.O>)?#VFF[\#:SXGOYII9=6\57WA2;Q)K4CB36-4OI(H7B /I3_@G3_P
M26_8G_X)9Z-\1M-_9&\!^)O#>I?%V3PJWQ)\4^,/'OBCQMK_ (JB\#_\)#_P
MB5K.NKWQT'2;;0V\6>))($\.Z'H\EX^K3'5);_[/8_90#[@^+WP:^$WQ_P#A
M]XA^%'QP^&W@GXM?#7Q7:_9/$7@;X@^&]*\5^&=5B4[H7N=)UBUN[47=G*%N
M=/OXDCOM.O(XKVPN+>[ACE4 _GI^(W_!I1_P1F\=^(;O7M&^%7QB^%<%Y*\\
MGAWX<_''Q=_PCT4LJOYAM+;QZOCW4+.)I7\]+6VU-+.W94AM;:"S46R@'UW^
MQU_P;Y?\$H/V(?%VD_$CX3_LQ:5XK^*6@72WN@_$?XU>(M?^+FOZ!>PNDEGJ
M/AS2/%E[=>"/#6M:?*GFZ?XB\/>$M+\0VLC,T6JC:@4 _:6@#XE_;=_X)T?L
M:_\ !1OP=X+\ _MF?!P?&3PE\/?$MUXP\'Z5_P + ^*7P];1_$5[I<NBW6H#
M4/A7XW\#ZK?";39Y;9K+4[Z]T\$K.MJMRD<R 'KW[,'[,'P,_8S^!?@7]FK]
MFOP,/AM\$_AHGB*/P3X*7Q)XN\7#14\5^+-=\<^(!_PD7CS7_%'BS4CJ/BKQ
M-KFJLVKZ[?O;M?&TM&@L+>TM8 #WR@#F?&OC/PO\.?!OBWXA>.-;L?#7@OP)
MX9U[QEXO\1ZI*(-,T#POX8TNZUO7]:U&<Y$-CI6E6-W?7<N/W<$#OSMH _RA
M_P#@G=\*_P#A^#_P<*:O\6]3\"6^G?!CQ'^T'X\_;$^*OAN+2X$T[2O@[X$\
M41:YX4\+>*(;96M;R[\=:Z_P^^'_ (PO@\4VL:EXLUS7-PGEE% '^L]0 4 %
M 'YR_MP?\$E_^"?O_!1_Q'X#\6?MH? 6?XS:[\,=$U?P[X%N6^+GQS^'UMH&
MDZ]?VVI:Q!#I7PK^)G@?2;R?4;RSLY+C4-2L;S46CL[6V%V+:WAA0 ^J?V;?
MV;?@E^R%\$O ?[.7[.?@2T^&?P8^&5CJ6G>"?!5EJWB'7HM'MM8US4_$VK-)
MK?BS5]?\2ZM=ZGK^M:KJU]J.MZSJ.H7=[?W$L]TY84 >XT % 'Y=?MG_ /!%
MW_@F=_P4(^*FE_&W]KS]F2S^*_Q1T?P9I?P^LO%EO\5/CE\.;EO"6BZIK>LZ
M5IE_I_PH^)O@;1]6FLK_ ,1:NT.K:MIU[K/V6>'3FOVTZPT^UM0#Z/\ &?["
MW[+/Q#_8\MOV!O&GPQFU_P#9-L_AUX'^$]O\*[OQ[\2XY8_A_P##:;P_/X(\
M/?\ "?VOC*#XGNN@2>%= ^SZE)XU?6+B/38H;[4;J&2X24 Y3]B#_@F]^Q=_
MP3B\,>.O!O[&/P9'P:\.?$K7M,\3>-M/_P"%A?%7XA-K>MZ-I\NE:;>&^^*O
MCGQSJ.GBUL)I8%M=*N[&RD+M--;23GS: /N&@#X&M?\ @E[^P=9_MN7/_!1J
MV_9ZT.+]LR[AEBF^,J^+/B*7\V?P(GPSGU*+P WC%OA;;ZY/X&0^'Y_$-OX)
MBUV>"6YNI=0;4+JYNY0#[YH ^"_VY/\ @F-^P[_P4DL?AMIO[:?P0'QGL_A%
M=^*K[X=Q?\+(^+GP[;P[<^-H= @\3R";X4>/O L^JC5(O"^A*T6MRZE#:&P5
M[&.U>>Z:< ^C?V>/V>_@_P#LI?!;X?\ [//P"\'CP#\'OA;H\N@>!/!ZZ[XF
M\3C0M)FU&]U:6U_M_P 9:UXB\3ZH9-0U&]N6N=9UK4;LM.4\\1)&B@'QM^VU
M_P $>?\ @G+_ ,%%_B!X4^*7[9/[.H^,7CSP3X.C\ >&->_X6U\<_AZVF^$8
MM;U;Q%'I!T[X5_$WP/I%\$UG7=5O5O=1L+S4@;MH/MGV:*""( ^,?^(7+_@A
M1_T8S_YLS^V)_P#1!4 '_$+E_P $*/\ HQG_ ,V9_;$_^B"H _9G]GO]G[X0
M_LK?!CX??L]_ 3PB/ 7P?^%FB'P[X#\(+KOB7Q,-"T=KZ[U)K3^WO&.L^(?$
M^J%KZ_N[AKG6=:U&\9IBIN#&J(@![+0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % '^>;_P %R_\ E*7^U#_W1/\ ]9V^$E?UIX9?
M\D1DG_=2_P#5OCS\]SS_ )&F*_[@?^H]$_)FOO#R0H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /ZS/\ @UV_YOD_[MG_
M /?@:_!_&W_FF?\ NM?^\D^LX7_YCO\ N6_]V#^LROP<^L"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9_%4K5ZTI5:M23WG.4I/J]%S;%=)S!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__5_OXH * "@ H
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MVE^#M!\.Z-%(T.GHS 'Z0T % '\U7_!VE_RA7^-O_95_V?O_ %:6AT >3_\
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M5].TJ^TS5-0TR^UC2+.UO[+3=2T^_NK666"SOK2XDCN$ /\ ,;_:F_X. ?\
M@K]_P6-^&2?L)_#WX(^$]&3XG7-CX<^(WA/]DOX9_%&\\=_%&"6\C;_A%-<O
M/$/C7X@7OA?P-<W-JD_B"PL)-(2]LK>^M/%'B"?PM)J6F2@']H/_  ;H?\$:
MK_\ X)3_ +,7B#Q'\9X=-N/VNOVCSX>U[XPP6%QI^JV7PP\-Z!#?/X/^#ND:
MY8275GJMUH<NL:IK'CG6='O)-&UCQ3?C3M.N-:T7PKH.NWX!_130 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0!_GF_\ !<O_ )2E_M0_]T3_ /6=OA)7
M]:>&7_)$9)_W4O\ U;X\_/<\_P"1IBO^X'_J/1/R9K[P\D* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^LS_ (-=O^;Y
M/^[9_P#WX&OP?QM_YIG_ +K7_O)/K.%_^8[_ +EO_=@_K,K\'/K H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M2PF>PE.RYY0A6RN4(RE;F<82J5'%-M1=2;27-)R_5:O[^/Y&"@ H * "@ H
M* "@ H * "@ H * "@ H * /R:_X*J?%U-$\">$/@WIEXR:IXSU#_A*?$4,$
MZK)'X8T)Y(-,MKV#!=[36=>=[FW9=G[_ ,,2AG*AHWWH1U<NVB]?^&\_ON']
M?U_2_-2H_P#!*'X7OIG@[XA?%S4+1$F\4:I:>#_#LTUM-'<KI'A]3?ZY<VL[
MA8KC3M4U6_L+1FAW[;[PU<1NX:)D4KRU4?F_T^[7[P/USK  H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_UO[^* "@ H * /\
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MEI9]3N9(=.M;>,--=7-U#;0JTLJ*P!_"K_P9"^&M4NOVIOVX?&$0N?[%T+X
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MX:U!E1S:#5/%?Q%N-4T@3R!2B7+6G@S6S:HS*\D2WC(K")R@!_:/_P %>?V
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M""%IGAABB>XD\VX>.-$:>4(D8EF90#+((T2/>^6"(BY*@!0"6@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _SS?\ @N7_ ,I2_P!J'_NB?_K.WPDK
M^M/#+_DB,D_[J7_JWQY^>YY_R-,5_P!P/_4>B?DS7WAY(4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']9G_!KM_S?)_W
M;/\ ^_ U^#^-O_-,_P#=:_\ >2?6<+_\QW_<M_[L']9E?@Y]8% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YW\7O^23?%#_LG?C7_ -1K
M4Z^/\0_^2 XX_P"R/XF_]4N-/H.$_P#DJN&?^R@R;_U8X8_.K_@F#_QY_&O_
M *^_ '_HKQE7\7_01_W+Q,_[".$?_37$1_3?TK_]\X(_[!L__P#3N4'ZLU_H
M ?R(% !0 4 % !0 4 % !0 4 % !0 4 % !0!G:QJ^F^'](U37M:O(=.T?1-
M.OM7U;4+EBMO8:;IMM+>7UY<, Q6&UM8)9Y6"L0B,0#C%"5].KT _EB^-/Q
M\4?M4_M"ZEJ^CV=W>7GC+Q)8^%O >A,X$EMI N8])\-Z?@SRVMO-+&R7>I2P
MR):M?W-[>-M$CO7=%*$;=EJ_S?\ 7Z ?TT?"+X<:5\(OAGX*^&VC%)++PCH-
MIICW21O$-1U(AKK6M7,,DL[02:SK-Q?ZK+ )6C@DO'BBQ$B+7%)N3;?5_P!+
MY >C4@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MV>M6/P8\(>)--:6Q\5ZWK?B*PTV\^(&JZ#?7&B:)I>D-X&FN=8U37_$^G>&
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#_ #S?^"Y?_*4O]J'_ +HG_P"L[?"2OZT\,O\ DB,D
M_P"ZE_ZM\>?GN>?\C3%?]P/_ %'HGY,U]X>2% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_69_P:[?\ -\G_ ';/_P"_
M U^#^-O_ #3/_=:_]Y)]9PO_ ,QW_<M_[L']9E?@Y]8% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!YW\7O^23?%#_ +)WXU_]1K4Z^/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_
MT/[^* "@ H * /XF/^#TS]C+7OB3^S+^SG^VOX0TC[;_ ,,V>,/$'PT^+,]I
M$S7=M\/?C1<^&X_"/B+49-A4:/X:^(GAZU\.1@2K(NI?%"W(BEB::2W /Z&?
M^"+G[<.B?\%!O^";O[-7Q^MM26\\<6O@K3_A;\:;.2X%Q?:7\9OAC8V7AGQN
M=0 +-!_PE$MO8^/](@E>2<>&O&&ARSR--*YH ^I?VS_V,/V??V_/V>_&O[,W
M[3'@Q/&7PU\9QP7 -M<'3?$OA+Q-IHE;0/''@C74CEG\/^+_  Y<323:9J,<
M5Q;7$$U[HVM6&K>'M5U?1]0 /\]/X^?\&OO_  6!_P"">OQHG^,__!,WXL:Q
M\9-)T5[N;PCX[^#GQ,M/@#^T+H6B74N;K0_%/AO6_%/AK2M<B:W6"TO[?PAX
MQ\26GBN!));OPMIL<S:1  =;:?$W_@]1UZS7X=0Z;^U9!#:)';C4+OX1_LL^
M'+QU""%6;XHWW@S2[^^?:@,ER_BZ:0OF>642.TC@'Z&_\$</^"-/_!9ZS_X*
M4_ O_@IC_P %/OBF99?@_;?%R >"OBW\;[CXR?&75(_B/\&/B)\+=-L?#=IX
M0N_&/PX\$^&-/N_&EKK,^F0^--+>UM; 6-MX72:5GM #]W?^#AW]C_\ :)_;
MH_X)@?%/]GC]EGX?#XH?&+Q#\0/@]KNB^#CXL\$>"3?Z9X6\?Z1K.O7"^(/B
M)XE\)>%;8V&EP7%YY-[KEM-=+"T%E'<W3Q6[@'\5O[.G_!*C_@[8_9'^'TOP
MI_9H\'_&GX+?#B;Q!J7BJ3P9X$_;%_9"TC0CXBUBWL+75-7%FOQ_D5+R^@TO
M3X[AT*B3[+&Q7?N9@#U#7O\ @B%_P=/?MIQQ^!/VJ/COXYT?P'JZR1:KIGQ_
M_;E7Q=\.(8I\+.-4\#_!WQ7\6+6]+I\I%OX5O=R+Y1=8]HH _?W_ ()+?\&I
M_P"S'^PEXP\+?M _M2>+K#]K?]HGPO+9ZSX2T>X\.#2?@/\ "_Q/:S1W-KKV
M@>%]5:\U?X@>*=$N8A+H'BKQE_9^F:;<>5K&F^ ]+\1V&EZU8 ']8= !0!^#
MG_!QS^Q?^TK^WI_P34\0_ #]E#X<#XJ?%R\^,OPH\6VOA$^,/ ?@8SZ!X:O]
M5DUN]77OB1XG\(>&$-C%=PR_99M:BN[E2RVD%Q(I2@#<_P"#=O\ 8[_:,_84
M_P""8OPX_9Z_:H^'@^%WQAT/XD_%_P 0ZMX/'BWP-XW-EI/BCQG>:IH5RVO_
M  Z\2^+?"TYO]/>.Z\BSURXN+59%BO8K:Y#P* ?:'_!4OX3_ !D^//\ P3G_
M &TO@C^S[X>'BWXQ_%[]G?XD_#3P+X7.M^'_  V/$&I>-] N?#EWH_\ ;OBO
M5]!\-Z6=0TG4=0M1=ZWK.G:=&9/])NHT+&@#_/!_9/\ ^".G_!U+^PRGCR/]
MDCX0>/\ X$1_$]O##^/D\$_M1?L50IXH?P8/$"^%WU%=1^..HJ6T9?%7B$6K
M0" XU2X$QE B$0!]@?\ #.'_  >V_P#0Q?'G_P 2H_86_P#GO4 ?;'_!./X%
M_P#!V3X;_;B_9KUS]M?7?C!/^RGIOQ&M+CXY0^(?VAOV0O%FC2^!QINI)>1W
M_AWP-\2=;\7:K$]VUFJ6^@Z7>7XE,<J(B1O,@!^AO_!R?_P2^_;[_;P/[&WQ
MV_X)[^)-,TKXN_L=W/QRU1-)TSXHWOPA^+.H7_Q._P"%12Z%J7PI\9.=(\.V
M6K:0?ASJD6I?V[XV\'.8]4L1I]W>EKF&( _!+3?V@_\ @]1^&>G'X>/X'_:!
M\03M"EII_B'4OV?_ -EGXEZCI@A 1I!X]M_!FO:=?S2C!>[\3ZGK3N09(W#E
MW8 Z#]EO_@VB_P""H7_!1[]H:Q_:C_X+1_&+Q1X*\._VOI%WXB\+>*_'ND?$
MOX\?$/PM9W_]J-X%\,P>"M;U'P#\"O UW%<7UC;16NHP:AX2DNKB/1_AC;&4
M7MN ?Z&7@3P-X.^&'@KPE\./A[X:T?P;X#\!^'-&\(>#?"?AZRATW0O#7ACP
M[I]OI6AZ'I%A %AM-/TS3K6WL[2",;8X857DY+ '5T % '@WQ<_9=_9V^/?C
M#X/?$#XT?!CX>_$WQK^S]XPD\??!CQ-XQ\.6&LZO\.O%TMK]E?6?#MU=1.]O
M*3'9:@MM-Y]BFN:/X>\11VJZ]X;T#4M- />: /)?CI\!_@Y^TS\+/%OP1^/O
MPY\+_%?X4>.K*/3_ !5X'\8:<FI:+JL-O<PWUE-LS'<66HZ;J%M:ZEI&K:=<
M6>JZ1J5K:ZCIE[9WUM!<( =WX4\*>&/ OACP]X*\%>'M%\)>#_"6BZ9X;\+>
M%O#>F6>B^'_#GA_1;.'3M(T31-(TZ&WL-+TK3+"W@L["PL[>&VM+:&*"")(T
M5: -^@ H \M^-OP3^%?[1WPF\?\ P+^-W@K1OB+\*/BAX<OO"GCCP9KT<KZ=
MK>C7P4M'YMM+;WVGW]G<Q6^HZ/K&F75EK&AZO9V.L:/?6.J6-I>0 '^>-^VU
M_P &D_[=_P"RY\8F^.?_  2D^*]Y\3_#FBZY=^)_A[H*_$FU^"7[3?PGN8Y)
M);"PT3QW=ZMX5\(^+7TVU=X+7Q;I_BOP/XAN^+5_"K2%[V[ .6T/XC?\'I?A
MG3;?X76&G_M<7-K%;I:1ZGKGPL_9I\6ZD8X?D5KCXP>)/".MZQ+<'=E[VZ\:
MO=S?ZR2>78'0 ^A/V+O^",7_  <$?M4_MQ_LF?M=_P#!2KXJ:OH/@G]F#]H[
MX)_'!?#W[0'QVL_'VOZGI/PK^(GAGQQ?Z-\+?AA\*=0\;^"_"&IZ[%HLVF23
M:S+X!19;B6_N1J&U(;H _IR_X.'?V/\ ]HG]NC_@F!\4_P!GC]EGX?#XH?&+
MQ#\0/@]KNB^#CXL\$>"3?Z9X6\?Z1K.O7"^(/B)XE\)>%;8V&EP7%YY-[KEM
M-=+"T%E'<W3Q6[@'\5O[.G_!*C_@[8_9'^'TOPI_9H\'_&GX+?#B;Q!J7BJ3
MP9X$_;%_9"TC0CXBUBWL+75-7%FOQ_D5+R^@TO3X[AT*B3[+&Q7?N9@#U#7O
M^"(7_!T]^VG''X$_:H^._CG1_ >KK)%JNF?'_P#;E7Q=\.(8I\+.-4\#_!WQ
M7\6+6]+I\I%OX5O=R+Y1=8]HH _?W_@DM_P:G_LQ_L)>,/"W[0/[4GBZP_:W
M_:)\+RV>L^$M'N/#@TGX#_"_Q/:S1W-KKV@>%]5:\U?X@>*=$N8A+H'BKQE_
M9^F:;<>5K&F^ ]+\1V&EZU8 ']8= '\(W_!7C_@EQ_P70^'O_!4GX]?\%*?^
M"6_B75[S1/CM%\+H+C1_@M\6- \->/=+LO 7P7\ ?#6^TKXI_#7XFR^&_!7C
M_1;G6_!U[J^AV%C)\0K:&.^L+ZZTS2M1MW-N ?&NK_''_@].^+6BS?!UO!?[
M0_AZ74X)] U+Q;I'P3_9A^$&M7D-[&81+#\7XO"_A2S\,3VZ-F#Q-X3\1^&K
MZSD47)UA9@): /TJ_P"")O\ P; >/_V>OCYX7_;V_P""F/CC0/B;\?-#U6[^
M('@OX(6VJ7'Q'A\,_%6_NAJ%M\3_ (O_ !.U*ZN+'QU\0/#^H37NKZ;I6A1Z
MYHMCXN_LWQC_ ,)UKE_IUO:0 ']K- '^:!^W'J;_ /!=/_@YT^&OP#^&\(\4
M_ C]GGQCX1^"_B35U<W6@7'P@_9P\5:U\0/VC?$[R1!]/CM?$7B[4/'7@;PE
MJOFS6GB5[CP(JW!35;.V@ /]+^@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MM/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\
MR\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_
M $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/
M_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_
M -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\
M\]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->
M_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI
M_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;
M$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V
M%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\
M,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB
M9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[
M1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_
M *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#
M_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P!
MW_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\
M,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0
M[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;
MH_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\
MS-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\
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MP_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\
M0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__
M #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\
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M_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\
MHU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^
M'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?
M^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P P
MA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O
M_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC
M_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,
MV?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $
MM/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\
MR\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_
M $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/
M_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_
M -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\
M\]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->
M_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI
M_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;
M$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V
M%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\
M,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB
M9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[
M1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_
M *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#
M_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P!
MW_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\
M,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0
M[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;
MH_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\
MS-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\
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MP_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\
M0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__
M #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\
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M_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\
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MM/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\
MR\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_
M $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/
M_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_
M -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\
M\]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->
M_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI
M_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;
M$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V
M%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\
M,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB
M9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[
M1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_
M *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#
M_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P!
MW_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\
M,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0
M[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;
MH_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\
MS-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\
M!+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_
M ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95
M_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y
M3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;
M_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_
M //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C
M7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<
M:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y
M6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"'
M]A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__
M #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^
M(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9
M^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T
M_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+
MP_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\
M0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__
M #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\
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M_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\
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MM/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\
MR\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_
M $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/
M_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_
M -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\
M\]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->
M_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI
M_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;
M$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V
M%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\
M,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB
M9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[
M1/\ \]NC_B)G&_\ T.__ #&Y3_\ ,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_
M *->_P#,V?M$_P#SVZ/^(F<;_P#0[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#
M_AQI_P $M/\ HU[_ ,S9^T3_ //;H_XB9QO_ -#O_P QN4__ #"']A95_P!
MW_E;$_\ R\/^'&G_  2T_P"C7O\ S-G[1/\ \]NC_B)G&_\ T.__ #&Y3_\
M,(?V%E7_ $#?^5L3_P#+P_X<:?\ !+3_ *->_P#,V?M$_P#SVZ/^(F<;_P#0
M[_\ ,;E/_P PA_865?\ 0-_Y6Q/_ ,O#_AQI_P $M/\ HU[_ ,S9^T3_ //;
MH_XB9QO_ -#O_P QN4__ #"']A95_P! W_E;$_\ R\^L_P!EW]AG]EK]B_\
MX3G_ (9I^%__  K;_A9/_",_\)K_ ,5M\1/&/]M?\(=_PD'_  CG_(_>+?%/
M]G?V=_PE.O?\@G[#]L^W_P"G?:OLMG]G\'.^)L\XC^J_VSCOKGU/VWU;_9L)
MA_9_6/9>V_W6A0Y^?V%+^)S<O)[MN:1UX7 X7!>T^K4O9^UY>?WZL^;DYN7^
M)4G:W/+:U[ZWLCZSKP3K"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H \[^+W_))OBA_P!D[\:_^HUJ=?'^(?\ R0'''_9'\3?^J7&GT'"?
M_)5<,_\ 909-_P"K'#'YU?\ !,'_ (\_C7_U]^ /_17C*OXO^@C_ +EXF?\
M81PC_P"FN(C^F_I7_P"^<$?]@V?_ /IW*#]6:_T /Y$"@ H * "@ H * "@
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M[M]W^/Y_>!K4@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#SOXO?\DF^*'_9._&O_J-:G7Q_B'_R0'''_9'\3?\
MJEQI]!PG_P E5PS_ -E!DW_JQPQ^=7_!,'_CS^-?_7WX _\ 17C*OXO^@C_N
M7B9_V$<(_P#IKB(_IOZ5_P#OG!'_ &#9_P#^G<H/U9K_ $ /Y$"@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]+^_B@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * //OBU')-\*OB9%$CRRR_#[QG'''&I>
M221_#FI*B(B@LSNQ"JJ@EB< $G%?(^($)5. ^-H0C*<Y\(\20A""<I3E+)L:
MHQC%7<I2;222NV[*^A[_  I*,>*.&Y2:C&.?Y/*4I-*,8K,<,VVW9))7;;=D
MM78_.C_@F"K"R^-3%3M-[X"4-@[2RP^,"R@]-RAT+ '(#*3C<*_B[Z"*?U'Q
M+=G9XGA%)]&U1XB;2?5I-7[77<_ISZ5[7US@A7U6&S]M=;.KE-G\[.VG1[V/
MU8K^_P _D0* "@ H * "@ H * "@ H * .#^(?Q/^'_PGT";Q/\ $7Q9H_A/
M1HO,$<^J7(2XOIHHGF:STG3XA)J.L:@8HWD33]+MKN]D1&:.!@K&G&+D[)7_
M $]?Z_0#\7OVE/\ @ICXE\8)?^#O@);W_@W0)Q/:77CJ]'E>,=3B=!%G0((7
MDC\,0.6F*7F^YUU@MK<6UQHLZSV[=,**6LM7VZ?.ZU_);>]HXAPO[-/_  3W
M^(WQFN[7QQ\7I-6\"^!+R2+4=E\KKXX\817$GFM)86MXKOI%G=Q!I/[<UF%I
M)4GM;G3=,U2VF>X@<ZL8WM[TOP7W-7]%\VK ?O/X#\ ^#_AEX7TSP9X$T&Q\
M.>&](B$5GIUBKD%MJB2ZN[F9I;N_O[@J'N]0OI[B]NY/WEQ<2N=U<K;;NVV_
M/^ORT ["D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!_]/^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MMLK"564M-EV7GW=VW^"\MP/L>LP"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H __U/[^* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\
MT15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/A
MW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\
M1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?
MO_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\
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M ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\
MT15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/A
MW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\
M1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?
MO_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\
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M ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\
MT15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/A
MW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\
M1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?
MO_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\
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M ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\
MT15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/A
MW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\
M1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?
MO_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\
M!7[_ ,1(^'?_ -$50 ?\14W[*_\ TCM_X*_?^(D?#O\ ^B*H /\ B*F_97_Z
M1V_\%?O_ !$CX=__ $15 !_Q%3?LK_\ 2.W_ (*_?^(D?#O_ .B*H /^(J;]
ME?\ Z1V_\%?O_$2/AW_]$50 ?\14W[*__2.W_@K]_P"(D?#O_P"B*H /^(J;
M]E?_ *1V_P#!7[_Q$CX=_P#T15 !_P 14W[*_P#TCM_X*_?^(D?#O_Z(J@ _
MXBIOV5_^D=O_  5^_P#$2/AW_P#1%4 '_$5-^RO_ -([?^"OW_B)'P[_ /HB
MJ #_ (BIOV5_^D=O_!7[_P 1(^'?_P!$50 ?\14W[*__ $CM_P""OW_B)'P[
M_P#HBJ #_B*F_97_ .D=O_!7[_Q$CX=__1%4 '_$5-^RO_TCM_X*_?\ B)'P
M[_\ HBJ #_B*F_97_P"D=O\ P5^_\1(^'?\ ]$50 ?\ $5-^RO\ ]([?^"OW
M_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\ T15 !_Q%3?LK_P#2.W_@
MK]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/AW_\ 1%4 '_$5-^RO_P!(
M[?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\1(^'?_T15 !_Q%3?LK_]
M([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?O_$2/AW_ /1%4 '_ !%3
M?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\ !7[_ ,1(^'?_ -$50 ?\
M14W[*_\ TCM_X*_?^(D?#O\ ^B*H /\ B*F_97_Z1V_\%?O_ !$CX=__ $15
M !_Q%3?LK_\ 2.W_ (*_?^(D?#O_ .B*H /^(J;]E?\ Z1V_\%?O_$2/AW_]
M$50 ?\14W[*__2.W_@K]_P"(D?#O_P"B*H /^(J;]E?_ *1V_P#!7[_Q$CX=
M_P#T15 !_P 14W[*_P#TCM_X*_?^(D?#O_Z(J@ _XBIOV5_^D=O_  5^_P#$
M2/AW_P#1%4 '_$5-^RO_ -([?^"OW_B)'P[_ /HBJ #_ (BIOV5_^D=O_!7[
M_P 1(^'?_P!$50 ?\14W[*__ $CM_P""OW_B)'P[_P#HBJ #_B*F_97_ .D=
MO_!7[_Q$CX=__1%4 '_$5-^RO_TCM_X*_?\ B)'P[_\ HBJ #_B*F_97_P"D
M=O\ P5^_\1(^'?\ ]$50 ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?
M_I';_P %?O\ Q$CX=_\ T15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(
MJ;]E?_I';_P5^_\ $2/AW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@
M _XBIOV5_P#I';_P5^_\1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J
M@ _XBIOV5_\ I';_ ,%?O_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\._
M_HBJ #_B*F_97_Z1V_\ !7[_ ,1(^'?_ -$50 ?\14W[*_\ TCM_X*_?^(D?
M#O\ ^B*H /\ B*F_97_Z1V_\%?O_ !$CX=__ $15 !_Q%3?LK_\ 2.W_ (*_
M?^(D?#O_ .B*H /^(J;]E?\ Z1V_\%?O_$2/AW_]$50 ?\14W[*__2.W_@K]
M_P"(D?#O_P"B*H /^(J;]E?_ *1V_P#!7[_Q$CX=_P#T15 !_P 14W[*_P#T
MCM_X*_?^(D?#O_Z(J@ _XBIOV5_^D=O_  5^_P#$2/AW_P#1%4 '_$5-^RO_
M -([?^"OW_B)'P[_ /HBJ #_ (BIOV5_^D=O_!7[_P 1(^'?_P!$50 ?\14W
M[*__ $CM_P""OW_B)'P[_P#HBJ #_B*F_97_ .D=O_!7[_Q$CX=__1%4 '_$
M5-^RO_TCM_X*_?\ B)'P[_\ HBJ #_B*F_97_P"D=O\ P5^_\1(^'?\ ]$50
M ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\
MT15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/A
MW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\
M1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?
MO_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\
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M ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\
MT15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/A
MW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\
M1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?
MO_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\
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M ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\
MT15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/A
MW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\
M1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?
MO_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\
M!7[_ ,1(^'?_ -$50 ?\14W[*_\ TCM_X*_?^(D?#O\ ^B*H /\ B*F_97_Z
M1V_\%?O_ !$CX=__ $15 !_Q%3?LK_\ 2.W_ (*_?^(D?#O_ .B*H /^(J;]
ME?\ Z1V_\%?O_$2/AW_]$50 ?\14W[*__2.W_@K]_P"(D?#O_P"B*H /^(J;
M]E?_ *1V_P#!7[_Q$CX=_P#T15 !_P 14W[*_P#TCM_X*_?^(D?#O_Z(J@ _
MXBIOV5_^D=O_  5^_P#$2/AW_P#1%4 '_$5-^RO_ -([?^"OW_B)'P[_ /HB
MJ #_ (BIOV5_^D=O_!7[_P 1(^'?_P!$50 ?\14W[*__ $CM_P""OW_B)'P[
M_P#HBJ #_B*F_97_ .D=O_!7[_Q$CX=__1%4 '_$5-^RO_TCM_X*_?\ B)'P
M[_\ HBJ #_B*F_97_P"D=O\ P5^_\1(^'?\ ]$50 ?\ $5-^RO\ ]([?^"OW
M_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\ T15 !_Q%3?LK_P#2.W_@
MK]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/AW_\ 1%4 '_$5-^RO_P!(
M[?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\1(^'?_T15 !_Q%3?LK_]
M([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?O_$2/AW_ /1%4 '_ !%3
M?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\ !7[_ ,1(^'?_ -$50 ?\
M14W[*_\ TCM_X*_?^(D?#O\ ^B*H /\ B*F_97_Z1V_\%?O_ !$CX=__ $15
M !_Q%3?LK_\ 2.W_ (*_?^(D?#O_ .B*H /^(J;]E?\ Z1V_\%?O_$2/AW_]
M$50 ?\14W[*__2.W_@K]_P"(D?#O_P"B*H /^(J;]E?_ *1V_P#!7[_Q$CX=
M_P#T15 !_P 14W[*_P#TCM_X*_?^(D?#O_Z(J@ _XBIOV5_^D=O_  5^_P#$
M2/AW_P#1%4 '_$5-^RO_ -([?^"OW_B)'P[_ /HBJ #_ (BIOV5_^D=O_!7[
M_P 1(^'?_P!$50 ?\14W[*__ $CM_P""OW_B)'P[_P#HBJ #_B*F_97_ .D=
MO_!7[_Q$CX=__1%4 '_$5-^RO_TCM_X*_?\ B)'P[_\ HBJ #_B*F_97_P"D
M=O\ P5^_\1(^'?\ ]$50 ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?
M_I';_P %?O\ Q$CX=_\ T15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(
MJ;]E?_I';_P5^_\ $2/AW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@
M _XBIOV5_P#I';_P5^_\1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J
M@ _XBIOV5_\ I';_ ,%?O_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\._
M_HBJ #_B*F_97_Z1V_\ !7[_ ,1(^'?_ -$50 ?\14W[*_\ TCM_X*_?^(D?
M#O\ ^B*H /\ B*F_97_Z1V_\%?O_ !$CX=__ $15 !_Q%3?LK_\ 2.W_ (*_
M?^(D?#O_ .B*H /^(J;]E?\ Z1V_\%?O_$2/AW_]$50 ?\14W[*__2.W_@K]
M_P"(D?#O_P"B*H /^(J;]E?_ *1V_P#!7[_Q$CX=_P#T15 !_P 14W[*_P#T
MCM_X*_?^(D?#O_Z(J@ _XBIOV5_^D=O_  5^_P#$2/AW_P#1%4 '_$5-^RO_
M -([?^"OW_B)'P[_ /HBJ #_ (BIOV5_^D=O_!7[_P 1(^'?_P!$50 ?\14W
M[*__ $CM_P""OW_B)'P[_P#HBJ #_B*F_97_ .D=O_!7[_Q$CX=__1%4 '_$
M5-^RO_TCM_X*_?\ B)'P[_\ HBJ #_B*F_97_P"D=O\ P5^_\1(^'?\ ]$50
M ?\ $5-^RO\ ]([?^"OW_B)'P[_^B*H /^(J;]E?_I';_P %?O\ Q$CX=_\
MT15 !_Q%3?LK_P#2.W_@K]_XB1\._P#Z(J@ _P"(J;]E?_I';_P5^_\ $2/A
MW_\ 1%4 '_$5-^RO_P!([?\ @K]_XB1\._\ Z(J@ _XBIOV5_P#I';_P5^_\
M1(^'?_T15 !_Q%3?LK_]([?^"OW_ (B1\.__ *(J@ _XBIOV5_\ I';_ ,%?
MO_$2/AW_ /1%4 '_ !%3?LK_ /2.W_@K]_XB1\.__HBJ #_B*F_97_Z1V_\
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MUO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H __7_OXH * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#YM\=?ME?L@_"[7I_"OQ,_:K_9M^'?B>UNOL-SX<\=?'/X8
M>$=>M[WC_0Y]'\0>*-/U"*ZY'^CR6ZS<CY.: /5O /Q3^&/Q6TR?6OA=\1O
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M "@ H * "@ H * "@ H * "@ H * /_0_OXH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H HZAJ>FZ3 ;K5-0L=-M5R6N=0N
M[>S@7'7,UQ)'&,#KEN.X.?ETITJE:7)2IU*LOY:<)3D_E&[_  ^^Q$ZD*:YJ
MDX0CWG*,5]\M/S_)Q^0?BK^WW^S!\'KU]/\ %/CR74;N.01-%X-T;4?&?[S^
M[O\ #T5\@P0023@'J0"-WV.4^'O%.=4U4PF C3@U>^-KT\%IWMB'!_F_2_*?
M.9AQ?D.6R<,1BW.2=FL-2J8G7UHJ:\]&>7Z=^W9XC^);$_ #X*Z]\0X9C_H,
MFO37?@KST;F-I!JUBIAW9^8/M*=UY.WU:G 6&RS_ )*'/,/EKCI46'C#'<K7
MQ)>QJ.]NZ6O2[T."GQ96QW_(GRNKC$_@=5RPU^U_:1BU_P" _..TNOT[XW?M
MI3R1I?\ [(FCV4;-B21?BQHDVQ?7:L()..PSSVY-<=7(N"(I^RXQKU&MD\HK
MQO\ -O3U][]3IAFG$[?O\.TX^F84G;\'?[UMYH]"M?B?^TQ(%-Q^SOIT!.-P
M'Q TN3;SSTB!/'/ _.O.EE7"Z;Y>(ZLEK_S+JOYN4?RZ]-.;L6/SUVODU./_
M '.4W;_R36WR]'H=Q8_%^]T=8XOB;X7N?"&H7!1;6WT]YO$,4I=@O,]C$R(.
M1RQ SQGG*\,\EA6O+*\7#&4XW<I5+89I+^[4DVWZ/IHG]KJAF4Z=ECJ$L-.3
MM%0;K)O3[4?5=->^ON^UVEU%>VT-U 6,,Z+)&75D8JPR"4;YE.#T.3_)?#G!
MTY.$K<T79VUU7GU/4C)3BI*]GJKJS_K^NY8J"@H XOQ;\1? G@6PO=2\7>+?
M#V@6MA!)<7/]IZQ86<PCB4LP2"XN$ED?'2-$+'L!BN[!Y;C\?4A2P>#Q.(E4
MDHQ]E1JSC=NVLHQDDK]6TO35QY<1C<)A(2J8G$T:,8*\N>I"+5NT7)-OR2;\
MC\Q/BS_P6O\ V$?A?)?:4/B1=^)/$EF<?V5HWA_5KR'/S@&2^M[:2W169,+\
MQ)&YOX<-^J9-X%^(6<*-6.4^PPTE=U:M:DI*_P#T[<HRTU^ZVF\O@\R\4N$<
MN<J<L?[6O'_EW"E4:?\ V_\ "O+?O9Z(_/GQQ_P<F?#/1)W3P=\%M2\5Q!F"
M2S:Q<:4749VDI/IY()/4;N/49K]&P/T8<YK13QN;K!RM?E6%]JK]KJ5KW\TN
MV_O?'8KQPRZF_P#9LN>(CW=?V=[[-)P>G]:7L>3'_@YSFWY'[*R"'T?Q[.+C
M'?\ =KH3Q9]!YP]R*]E?16]R[XM?/_*LLG_\DU_Y/UW1YO\ Q'A\R2X>O'^9
M8V/_ ,K>E_+[STGP9_P<K?#[6+F.+Q9\"M1\,6[;?,GBU^74BF?O'RXM/5CM
M'NN>Q)/R^3C?HP9I1C?"9VL7/L\)[)?C4T_/OT/0PWCC@JDDL3E;P\>LO;\_
MW)07YVTZ7/OGX4_\%R/V$OB*UEIVJ>/=1\(^(;QT2/3]3\/:PMH[L,[$U![6
M. E>^YEXY&<-7Y[G/@+X@Y4IU899'%8:&OM:=>DI?^"^;F??2W91=KGUV7>*
M_"..Y83QLL/7D[>SE1J./_@>V^FKCZGZB^!/B[\-/B7I-AK7@CQMX;U^RU*)
M9;9;'5["6[*MT$EDMRUS$YX^1T4\C&,U^48_)\TRNM4H8[ XK#SI/EDZE"I&
M&G53<.5KT?SZGWV$S' XZG"KA<50K1FKKDJ0<OG&]T_E\]D>CUYIVA0 4 %
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MP#^;#_@SH_Y/:_X*N?\ 7MX,_P#5M?%.@#_0%R,XSR,$CO@YP?QP<<=CUQ0
M4 ?AW^SW_P $"OV./V;_ /@IC\2_^"HG@KQ5\9=0^,7Q!\2_%?QQ9?#_ %[Q
M#X;G^&7@WQO\<8]=A^)WB#1;:R\)V/BB\35(?$_B*+1-*UCQ+?:?H,>NZB!'
M?M%HK:, ?N)0 $@ DG '))Z >IZ=/K^5 !0 4 &0,9/4X'N<9P/? )[\#ZE0
M H * "@ H * "@ H * "@ H * /_T?[^* "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M$O+&\:SGEM[>2:V,_DRO!"\B,T2%0#^>#]@G_@F;_P %-_\ @X,_9?\ A?\
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M>(?">O\ P\\2ZQ=^9J>NQ?#SQ+X3LY='UG6;[5M9^S>+[C0[C4/[*T+0K:
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M0\0ZZDH!_=I0 4 % !0 4 % !0 4 % !0!__TO[^* "@ H * /Q1_P""N/\
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M1;?)&*LH_!XC,,9B9.57$5'=Z0C)PIQ\E"-HZ+2[M+NVW<^IO^"-7Q=^*_\
MP\=_9>\-_P#"S_B'_P ([XC\;:Q9>(= _P"$T\2?V+KMFO@GQ5<K::SI?]I_
M8=4MEN8HKA8+ZWFB$\<<H7S$1E\CC?!X/_5G-:OU7#>UI4*<J=3V%+VE.3Q%
M%.5.?)S0=FU>-G9VN[OEZ<HJU?[0PL?:U.651J4>>7+)<D]&N:SUUUC_ )G^
MB]7\U'Z$% !0 4 % !0 4 % !0!_ M_P6'_;,_:^^&/_  4A_:9\"_#;]JC]
MHSX>^"?#^K_#V'0O!_@?XU_$GPIX6T:*\^$'P^U*\CTKP_H/B2QTG3UN]1O;
MS4+H6EI"+B^N[J[FWW$\LC_T-P5DF38KAC*\1BLHRS$UZD<4ZE?$8'"UJT^7
M&XF$>>I4I2G+EC&,5S2=HI)622/A,XQF+I9CB84\5B*<(NGRPA7J0BKT:3=H
MQFDKMMNRW=];L_2?_@V^_:1_:&^.OQ&_:ET_XV_';XQ?&&Q\/^"?AI>:!9_%
M'XE^,_']MH=W?:[XK@O;G1X?%>LZJFF3WL,$$5Y)9+"]U';P+.7$,03Y?Q-R
MS+<!ALIE@,OP6"E4KXN-1X3"T,.ZBC3HN*FZ-.#DHMMQ4KVN[6N>CP[B,17J
M8I5J]:LHPIN*JU9U.5\TKM<TI6OUMOUO9<OW=_P7>_;Y^,O[$GP&^&>D_ 6^
MC\+_ !!^./BGQ)H9^(3Z=::I=>#_  SX3TK3KO6AH5MJ5I=Z5!XDUFXU_2K;
M3]2O8+A].L+?5[C3[4:F+/4M-\#P_P"'L%GN88J>81]KAL!2I5/JW,X*O5K3
MDJ;FXM2=*FJ4W**MS2E!2?)S0GWYYCZV"H4E0?+4KRE'VED^2,$G*R::YFY)
M)M:*[5FHG\KW[.W_  6B_;\^"7Q6\.^-_$OQ_P#B!\8O!\>N6<WC;X<_$O63
MXJT3Q-X=DNX&UC2]-EU>*ZNO"FH2VB2?V1JOAV:P;3;T1-+#>Z>U[IUU^M9E
MP/P[C\)5H4LNP^"KNG)4,3A:?L9TJMGR3DH.*K14K<\*BES1NERRY)1^7P^<
MX^A5C.5>I6AS)SIU7SJ4;^\DY6<';X7'9]T['^CA!,ES!#<1[_+GBCFCWH\;
M[)4#IOCD"R1OM8;D=5=3E6 8$5_,[5FUV=M/(_0R6D 4 % !0 4 % !0 4 %
M !0 4 ?RN?\ !R3^T5^T!\"=>_9!@^"/QQ^+WP=A\3:1\<)O$<7PM^)'C'X?
MIX@ETF\^%*:5)K:^%-8TH:J^F)J&H+IYOQ.;(7]Z+;ROM4_F_K7AAEN79A#.
MGC\!@L:Z4\O5+ZWA:&(]GSK&<_L_;4Y\G/RQYN6W-RJ][(^8XCQ%>@\'["M6
MH\RK\WLJLZ?-;V5N;EE&]KNU]KNUKOF_)G_@DY^VG^V)\1O^"B'[+O@GXA?M
M6_M(>._!GB'QMJ]GK_A'QG\;OB7XH\,:W:)X(\4W*6VK:#KGB6]TK48([F""
MYBCO+69([F"&XC"S11NOV'&&1Y+AN&LVKX;*,KP]>G0IRIUJ& PM*K3?UBDF
MX5*=*,XMIM-QDKIM.]['DY5C,94S#"PJ8K$SA*;4H3KU)QDN26CC*;3[ZKST
MLC_0)K^=3[T* "@#^>G_ (+X_M6>/O"_P^^$_P"PI\!+FZF^-G[8^O6_AC5K
M'1Y=FLK\,]1U6W\+0^'H9%:.6Q;XH>+=0A\-_;%9X;CPYH?C32[J-8[Y95_1
M_#W*,/6Q.+S_ #!)8#):;JPE/X/K<8>U]H^DOJM&+J\NC56="2^&TO SW%5(
MTZ6!H7]MC)<K2^+V;DHJ/E[63Y;_ ,L9I[H_6+]B+]D?P!^Q'^SAX!^ ?@*"
M"4Z#8KJ?C;Q*L(CO/'/Q#U6"W?Q9XNU!RBS.=0O84M-)MYVE;2?#EAHVAQ2&
MVTR&OD,^SG$9[F>(S#$-KVDN2A2O>-##0;]C1CT]V+O-JW/4E4J/64G+U<%A
M*>"PU/#P^RKSE_/4=N>;ZZO:^T;1^RCU'XB?M$_L_?"&[^P?%CXZ?!SX87WE
MPR_8OB)\3?!/@J[\JY&;>3[-XEUS2YO+G',+[-LH_P!66KDPV6YCC(\V#P&-
MQ<;M<V&PM>O&ZW5Z5.:NNNJMYFE3$4*3M5KT:3[5*L(/[I./];6U4NV\%^/O
M GQ(T5/$GP[\:^$O'OAV29[>/7_!?B/1_%.BO<1QQ2O FJZ'>7UB\R130R/$
ML^]8Y8G*A71FPKX?$86?LL30K8>HE?V=>E.C-)]>2I&,K735[=.FJ+A4A4CS
M4YPJ1_FA)2C?M>-UV_X%['X2?\%X?V2=6USX5^&/V_/@6^H>%OVD_P!D/4=$
M\3R^*?#86+6=4^&.F:TM_/<SD1O]HNOAIK-ROC&QGN-UK;^&G\;6M[;7L5U;
M);_H'A_G$*>+J\.YARU<KSF-2DJ-76G#%SARI+LL5!>PDDFW5^KN/+RRYO$S
MS".5*./H7AB<(XRYX_$Z2E>_FZ;?.KNW+SIWNC]0_P!@7]JO2?VT?V3OA!^T
M#8BSM];\4^'ET[Q]H]CE8= ^(_AR1M%\;:5% \DD]M8G6[.XU+0TN6,\WA[4
M=(O&++=([?)\0Y1/(\XQN72YG"E4YL/.6]3"U??H3O9)R]G)1J6T52,XZ.+4
M?3P&*6,PM'$*W-.-JB7V:D?=FK=%S*\;V]UI];R^Q:\4ZPH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MP-X@T"XU".XLH88Q;Z@]S#$R"2%(W+LX!_G]?\%A_P#@G3^R=_P38_X+1?\
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M_P!BO_L7OCQ_Z<OA-7[3X3?P,\_Z^X#_ -(Q9\CQ/\>#_P -?\Z1_.+^Q_\
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MJ1OM.$:KE!V=IJ+L[(\?*J$,3C\/1JKFIN4I2CTDJ=.=3E?DW%*6]TVO./\
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M4GRU:<Z<OY:D)0?W22?X?>"E&2O%J2[IIK\+_G]^IL5 S_."_P""X'_*4O\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MX5I''X$@;0/AGJ/@S1'L_#7FV-@^GM8M<W=S!<74H!_+M_P37_9*_:I\"?\
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M%//HVE:]K5W>:1I=W<0)'#=WUAICVEM?7D4<:7EY%/=!%$H5?Z?RG _V9EF
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M2&C]%)6FET4DC^'C_@N!_P I2_VL/^PW\-/_ %2?PUK]XX#_ .22RC_!B_\
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MI\5>3MTVDMF[>5TY?U+U^3'TX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M (>G?L'_ /1=?_,8_&3_ .=U7D_\1Q\+O^BH_P#,)Q#_ /.D]?\ X@3XJ_\
M1+?^9SAS_P">P?\ #T[]@_\ Z+K_ .8Q^,G_ ,[JC_B./A=_T5'_ )A.(?\
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M **C_P PG$/_ ,Z0_P"($^*O_1+?^9SAS_Y[!_P]._8/_P"BZ_\ F,?C)_\
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M'_$<?"[_ **C_P PG$/_ ,Z0_P"($^*O_1+?^9SAS_Y[!_P]._8/_P"BZ_\
MF,?C)_\ .ZH_XCCX7?\ 14?^83B'_P"=(?\ $"?%7_HEO_,YPY_\]@_X>G?L
M'_\ 1=?_ #&/QD_^=U1_Q''PN_Z*C_S"<0__ #I#_B!/BK_T2W_F<X<_^>P?
M\/3OV#_^BZ_^8Q^,G_SNJ/\ B./A=_T5'_F$XA_^=(?\0)\5?^B6_P#,YPY_
M\]@_X>G?L'_]%U_\QC\9/_G=4?\ $<?"[_HJ/_,)Q#_\Z0_X@3XJ_P#1+?\
MF<X<_P#GL'_#T[]@_P#Z+K_YC'XR?_.ZH_XCCX7?]%1_YA.(?_G2'_$"?%7_
M *);_P SG#G_ ,]@_P"'IW[!_P#T77_S&/QD_P#G=4?\1Q\+O^BH_P#,)Q#_
M /.D/^($^*O_ $2W_F<X<_\ GL'_  ]._8/_ .BZ_P#F,?C)_P#.ZH_XCCX7
M?]%1_P"83B'_ .=(?\0)\5?^B6_\SG#G_P ]@_X>G?L'_P#1=?\ S&/QD_\
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M_P"=U1_Q''PN_P"BH_\ ,)Q#_P#.D/\ B!/BK_T2W_F<X<_^>P?\/3OV#_\
MHNO_ )C'XR?_ #NJ/^(X^%W_ $5'_F$XA_\ G2'_ ! GQ5_Z);_S.<.?_/8/
M^'IW[!__ $77_P QC\9/_G=4?\1Q\+O^BH_\PG$/_P Z0_X@3XJ_]$M_YG.'
M/_GL'_#T[]@__HNO_F,?C)_\[JC_ (CCX7?]%1_YA.(?_G2'_$"?%7_HEO\
MS.<.?_/8/^'IW[!__1=?_,8_&3_YW5'_ !''PN_Z*C_S"<0__.D/^($^*O\
MT2W_ )G.'/\ Y[!_P]._8/\ ^BZ_^8Q^,G_SNJ/^(X^%W_14?^83B'_YTA_Q
M GQ5_P"B6_\ ,YPY_P#/8/\ AZ=^P?\ ]%U_\QC\9/\ YW5'_$<?"[_HJ/\
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MZH_XCCX7?]%1_P"83B'_ .=(?\0)\5?^B6_\SG#G_P ]@_X>G?L'_P#1=?\
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MR?\ SNJ/^(X^%W_14?\ F$XA_P#G2'_$"?%7_HEO_,YPY_\ /8/^'IW[!_\
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MW_14?^83B'_YTA_Q GQ5_P"B6_\ ,YPY_P#/8/\ AZ=^P?\ ]%U_\QC\9/\
MYW5'_$<?"[_HJ/\ S"<0_P#SI#_B!/BK_P!$M_YG.'/_ )[!_P /3OV#_P#H
MNO\ YC'XR?\ SNJ/^(X^%W_14?\ F$XA_P#G2'_$"?%7_HEO_,YPY_\ /8/^
M'IW[!_\ T77_ ,QC\9/_ )W5'_$<?"[_ **C_P PG$/_ ,Z0_P"($^*O_1+?
M^9SAS_Y[!_P]._8/_P"BZ_\ F,?C)_\ .ZH_XCCX7?\ 14?^83B'_P"=(?\
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MK_T2W_F<X<_^>P?\/3OV#_\ HNO_ )C'XR?_ #NJ/^(X^%W_ $5'_F$XA_\
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M=_T5'_F$XA_^=(?\0)\5?^B6_P#,YPY_\]@_X>G?L'_]%U_\QC\9/_G=4?\
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M ,Z0_P"($^*O_1+?^9SAS_Y[!_P]._8/_P"BZ_\ F,?C)_\ .ZH_XCCX7?\
M14?^83B'_P"=(?\ $"?%7_HEO_,YPY_\]@_X>G?L'_\ 1=?_ #&/QD_^=U1_
MQ''PN_Z*C_S"<0__ #I#_B!/BK_T2W_F<X<_^>Q^@E?K!^1A0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M3C]]BL+2KX2IAY4X\GLY*FE&*5.2C[DH+:+B[6LX]KV;/\N>OZN/S(_T0/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Z
M"%?ZP'^1X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M[CAQIY>TGK'$5$UVO&#_ ":/;O\ @OK_ ,HM/V@_^PW\%O\ U=G@"O/\/?\
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M_BXO_KW2_P#2IGV__P '/7_)EWP/_P"SH-"_]51\5Z\'PJ_Y'N/_ .Q35_\
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MIL5Y<.VG>']'2XDE>ST#P[IPM=%T+3U?R['2K&TM8\+$-W[_ )=@,-E>"PV
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M_P#2_P"#U>/X2_P\]_QY;_Z3CCJXHWP7IB/_ ' ?A/\ \$N?C%X3^ G_  4
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M/_\ !-WPS9:,DC>;:ZS^U+JNJ:G<1#A3'?6/P&T>ULY&&&96TZ^5,[ TF-[
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M>TN^DU#3;>RAO-)\1>'_ !!IM_IUXEC!%]K35=+#S7&DW3T ?J10 4 % !0
M4 % !0 4 % 'YV_\%:OCM\5/V8_^";'[9?Q^^"'B@>"OBU\*O@CXE\6^ ?%9
MT3P]XC_L#Q%9/:1VFI#0O%FE:YX;U1K<3NRVFLZ/J-@[$&:UE"A: /P:_P"#
M4K_@J)^W1_P4FM?V[F_;4^./_"Z'^#,_[,H^&SGX:_"+X>-X<7XAQ_M 'Q>A
M'PI\ ^!DU<:J? WA@@ZZNIM8'3C_ &:;,7M\+H _KWH * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /X\_\ @J;_ ,GX?'7_ +IC_P"J;^'E?Y[^./\ R='BC_NB_P#K.Y0?Z*>!
M/_)JN%O^ZY_ZT><'Y]U^3GZX% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 ?Z"%?ZP'^1X4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?S%_\'&_[0G]B_#+X>? +
M1+^:QU?7=;/B/Q$(9D!O/#S:9?0PVC1$']U)=PJ)2P.Y"RIL<AU_JCZ,W#*Q
M>;YAGV(@IT*.&GA\,VM(8F#4^:^NO+Z=M=3\(\;<[]AE^#RFC)QJU:T:U:W6
MA).%K)MO779>KU1^E_\ P1^^ "?L_P#[$_P]TB6#;J/C1Y_B#=W4J_Z3<)XI
MMK&]A$DA 8QH-QBC&$0-A54<5^7>,W$<^(^.LSQ#FY1P=LOBOLJ6%E.$G:[2
M;TOMV6UC[GPVR99+PM@J7+:6)OBV_M6KQA)*^[2Z=.VEC]1:_*#[X_GO_P"#
M@'XJ_$+X6_!GX<WWP_\ %6K^%KN]U34X[NYTF]N;*:6-)+!5!>WEB)*"1RNX
MD ^Q-?T5]'C*<MS;/,QI9CA*.*IPIT7&-6G"I:_.G92C*WR>O6]ER_CGC!F&
M,P&68.>#Q%3#SE.HI2IRE%M*VCY6O.UTSYD_X-Z/C7\5/BGXG^,\7Q \<>(/
M%D%G_8LEI'K6I75Z+5I;6Z$@@$\L@1&V(<9)+;B>HV_5_2.R')\HPN12RW T
M,)*K3K.HZ5*G#F:J65^6,7I;_AK^]X/@UFV89C7S58S%5<0H2I<OM)RE:\;O
MXGU?KMUO>/\ 577\E'] A0 4 % 'XZ? +3)_VF_^"@7Q>_:!U2VDNOAC\+?#
M^B>$/A?%+B6/3OB#X<O9=(\47T4W"K-+!N$BH 1RN2"53]GXAJKA?P\R?AZE
M+DS7-L16QF:..GM,NQ,%6PM-JZ;2E:S::[6N?FV44WGO&&8YS4BY8#+Z-+#8
M!-\RIXRC)T\1-.R2<E?1-_*Q^Q=?C!^DA0 4 % !0 4 % 'P!^UK_P %)_V8
M?V0+:^T_X@^-;2Z\=Q6ZSZ?X$L/M#ZK?[F3.ZXCM9[:UC6-O,:64A%5?FQFO
MT/@_PQXJXRE"IEN JK -R]KCYI>RI1BKN7*VI2M:VEO^WMSX[B+CC(>&XRAC
M<7!XO3DPD6W4J-[)-1<8W3OK^-FCZ'_9J^.>G_M'_!_PO\7M*T.[\.Z?XH6Z
MDM=+O;F*[N(8K>=H4D>>%(XV\Y0'  X!QP0=WSG$^0U.&<YQ63UJ\,34PO(I
MU:<7&+<E>R3U5MM?\CV\CS6&=9;0S&G2E1AB.9QIR?,THNUVU;?\-M=SWBOG
MSU@H * "@ H ^>OVJ_@=H_[1_P"S]\4/@UK4$4MOXW\,7>EQ2.@:2VN=T5Q%
M+;OC=#,6@$0D0JV)",X)*_1\)9]7X9XARO.J$FI8'%0JM)Z2CK%J2LTUK>S7
M3H>-Q!E5/.\GQ^6U4FL50E!-KX9;IK56>EM/33>/\$G[ /Q.OOV0/^"@WA%]
M6GO+'1?#_P 0M9\)>)=/F<P+?Z?'/J^FVOG,X)<F;R)H96)4K)(2F]@5_P!!
M?$/*J/&?AQBW2M5Q.)R[#8O#55%2]E4FHUZB2Z[-:2OJ]M5'^1.#\?4X;XRP
MRJ-PH4,96P]:#=N>"<J5.[NDEUZ_FC_15T^\CU&PL=0A&(KZTMKR(9SB.ZA2
M=!D  _*XY &>N!G%?YM5(.G4J4WO3G*#]82<7^*/[2A)3A":VG&,EZ22:_,M
MU!04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!S'C;QGX9^'7@[Q3X^\::M;Z#X1\%^']7\4^)M:NQ(;?2]"T*PGU+5+
MZ5(4DGD6VL[>:7RH(I9YBHBAC>5T1L,5BL/@L-B,9BZL*&&PM&IB,16J.T*5
M&C"4ZE23U=HPBV[*_:]SU<BR3-.)<ZRGA[),)4Q^<9YF.#RK*\%2<(SQ6/Q^
M(IX;"T%.HXTZ?M*U6$74JRA2IQ;G4G""E./\8/[37_!=']K3XF^/=8F^!&OQ
M_!#X86E]/!X5TJST/P_JWBZ_TN*:5;74_%6K:Q9:Q NJW\'E3W6F:24TW3'Q
M9V\]Z8I=1N_Y0XD\9.),QQ=59'6639=&;6&Y:-"MC:E-/2IB*E>G7IQG45I.
MC3IQ5*_)[2JTYG^U/A?]!?P?X5R#!T^/,I_U^XHK8>G/-L;B\PS7!91A\5**
M=7#9/@LNQ>75%A*$FZ=/$XZ57%8JWMZD,,IQPE#T[]BG_@NI\>O!_P 1] \+
M_M6:O:_%#X5^(M2M=+U;Q8NCZ3HWC+P0;V=8$\10RZ/:Z?8:YI-D\D<FK:3=
MVJW(L(Y;C3;I+J)K6]]'@_QDSC#X[#X3B>I3Q^7UZD*53'*E3H8O".;Y56E[
M&-.E7HQ;3JP]E"<8<TX5'RN)\UXU_02\/<_X>QV8^$^7SX0XMP&&J8C Y5''
MX_&Y#GDJ,)S>7UZ>98C%XG 8O$K]WA,;0Q2H0K<L<5AYPDZ]+^PO3]0LM6L+
M'5--N8KW3M2L[;4+"\@;?!=V5Y"EQ:W,+C >*>"1)8V ^9'!XS7]1QE&<8S@
MU*$XJ49)W4HR5XM/JFFFG_F?XVXG#5\'B<1A,52G0Q6%KU<-B:%6/+4HUZ$Y
M4JU*I%ZQG3J0E"<7M*+70N51@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M[C*:3OR15^2GVNKN4VFTY2MIRIR_:6OASV0H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!_'G_ ,%3?^3\/CK_ -TQ_P#5-_#RO\]_''_DZ/%'
M_=%_]9W*#_13P)_Y-5PM_P!US_UH\X/S[K\G/UP* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _T$*_U@/\CPH * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJO#U+JZV7+.45%OFTM?S:=U$]^_X)S?#VY^'_P  =5%XC";QG\5OB'\0(Y)
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MT]ZSZ^<OS!@_X.(_V:Y-:CLYO"FMQ:0TX1]6"7[E(2^/.^RBP,C$+R4!SGC
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M;7M=VN?1%?-GM!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M3<I6BKR=W=NYK4PF$JR<ZN&P]2;M>=2A3G)V5E>4HR;LDDKO1::Z<O5?"O\
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M49R2:4I*12PN&HRYZ.'H4I-.+E2HPIR<6TVN:,8NS:3:O:Z6UO>UOBI^SU\
MOCH^B2?&[X'?!_XQR>&5U%/#<GQ4^&G@OXA/X?35S9-JR:(WB[0]8;25U-M-
MTYM16P-N+TV%D;GS?LL&R,)F68Y?[18#'XW!*KRNJL)BJ^']IR<W)[3V-2'/
MR<TN7FOR\TK6NQU</0K\OMZ-&MRWY?:TH5.6]K\O-&5KV5[;V5[V7+QG@O\
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M)2YD]I<C:Z-62+H8+"89WH8>E3E_,HWGKTYVW*V^E[>A]35Y)U!0 4 % !0
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MBI^US^VGXGTF&]UCX5:#X,^!7PIO+@).FF:I\1EUCQ/\4-5MHG!-GJ]KX?\
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M3#: ?17_  :J_P#!9[]I.?\ :DT?_@F1^U=\0O&_Q.\#_$#PWXKT_P#9\O\
MXAS3ZSXS^$OQ%^&FA:SXPU;X?7WB/61_PDS^"M<\&>'O$MG8:+X@O]27PEXD
M\.^'=!\,V>E6&MZE"@!_6S_P7D_Y0[?\%#?^S;_%W_H_3J /Y>?^#&7_ (]?
M^"GW_7Q^QA_Z+_:MH _OTH * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /X\_P#@J;_R?A\=?^Z8
M_P#JF_AY7^>_CC_R='BC_NB_^L[E!_HIX$_\FJX6_P"ZY_ZT><'Y]U^3GZX%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?Z"%?ZP'^1X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MYXASS-.+<\J3JRG4<Z_L,-0C)\L81G[.,DD[-\K3U5O=Z6][^G/]D;_@WZ^
M_A?P%HVM?M"W=WX_\8Z[I]OJ&H:)AK/3=">Y3S8[2VN[&[ADG9$D DWQG85"
MF1FW[?Y<XO\ I%<0XC,:]#AM++,%0J2ITZT9.52NHNSE*G.+Y5=67O2OO;1'
M[KP[X.Y/0PE*KG-\;B*L%.=)KEA2YE=*,XRBV[-7VUZ:VC[/XF_X()?LP'QK
MX)\;_#'6M8^&5]X-\3Z+XD6VL+9M6AU!M'U&"_%M*]_?,8EG\GRBZ1EE#;@6
MP*\3#_2#XLE@<=@,VIPS:GC,+7P_-5JNDZ?MZ<J?,E"+ORJ7,M=6K:)GJ5O"
M+(%BL+BL!.> EAJ]*M:G!5.?V4U/E;E.ZO9INS?34]#_ ."TW[%T7[4'[,>K
M>+/#&EVLGQ,^%4#^(M.U-XP]RWA;2HKS4M;TR)=ZF3SPH=(T;S68_)C:RMYG
M@AQQ+A/BJCA<34E_9>:R^KU*5WR?6ZW)2H5)?#;EO9MZ=6TM9=OB?PNL_P B
MJ5Z%-?7L O;0J6][ZO3YJE6"T=[VOI;]3^=;_@A;^V3+^SO^TFOPA\::M/;>
M _BO*-$MM+E)@2W\<W<EC8Z;=R^8 $)B0PRAPH0)(6PS93^DO'S@N/$?#+SG
M!0A5S'*5[6=:*YKY?2@Y2A%Q:YKMZ=;K5H_%_"?B:639W_9F)E*&#Q[]G&G)
MV4<7.2C!M->[HFG=O3[3/WN_X+H_MG+^SW^S7>_"OPIJ5O\ \)Y\88;KPW>V
M*RB.]T_PI?V-U]IU6)O]8NZ6#R8VCV[F#(S')"_SYX"\$OB/B>&:XJE+ZADS
M6)A4<;PGBZ4HR5)Z6NHN]GS;[*SYOUWQ7XG639'+ 4)KZUF5Z$XI^_##U(M.
MJK:[JR:MW?12_%#_ (($_L7O\9?CQ<?M">-M)G;P?\)I8=7\)WTZ&YM=3\:6
M]^T4]I*LF8F-O:W0D9Y-[Y:4A,D%OW/Z0O&_]B9!'AO 55#%YNI4L;2C+E=+
M!2CS4Y1MKNDDE9?G+\M\(>&/[3S9YUBZ;EA\OY9X>I)753%1?+-.ZMMOH[7Z
MZ&G_ ,'%^C@?M4>&M2(P+[POHEL7 Y(@TE.,G'3/'/;MU7'Z-E5RX4Q=+_GW
M7Q51+_MYR_&UNGX7EIXTT[9_AI_STZ,=NBC;?R;V_&.Y]"?L>_\ !!_X+_M"
M_L]> OBSK?Q5\3:7JWBFWGN;K3[30[6>U@$4VP1K++>P.Y;:2P\O858#<2&1
M?F^,O'[/>'.(LPR>AE6&JT<*U",YXB<92YE=OEC3DEZ7[W:/:X;\)<KSC)\)
MF-;'UJ=3$*4G"%&,HJTK6UDNW=]ELS]O_'>H^$O^"6W_  3_ +R#3KZY\0:-
M\*- GT30[^ZC2RN)]4\07=TNFS/# TRAHK^[0K&C$OL'(RPK\+R^EC/%;Q$I
MRJ4XX>OF^(C7KTX2=2,:6'C#VB4I)/6G!ZVZ];GZGBYX?@'@^2A.5:GE]%T:
M4Y)1;J5I24&[::2DNJ3VTUY?X;?A!X7\;_\ !0?]KJSL/B%X]L;/5OB'K]QK
M_BCQ1XGU2UL+.STNTDLOMPBGOIX;6%HK%Q%;6\959&61HT:21C7]WYUBL#X=
M<&RJ99@)5*.78>.'PF&PM&4ZLZ\X7C=0BZDDZJUD]MU8_E3+J&*XQXDC3QN+
MC"IC:KK5ZU>HH0C3A.TDG-\M^39+MHNI_6^W_!(C_@ERWPP?P/'J7@ >,9-)
M:QC^)'_"P]..LKJ3Q;%U-=+_ .$D_L\NKGS%MMK*S 9D()1OY!7C/XL_VFL=
M+^U/J*JJ;ROZA7^K^R3_ (7M?8*I9K1O\[)']$_\0VX!^HO#+ZC]:]GR+'/%
M4O:J=OXG+[3DO?7EO)>>Q_*_I_B+Q3_P30_;HNSX%\:_\)'X?^'?CY[&35-!
MO[6ZLO'/@RUU2,RPW7V)YXBM[;P':@;S(9,M&S+*ZO\ U?/#83Q1X"IQQN =
M#%9EEZG&C6I<E7 YA4A:+BYQYY*GTO:+[J[1^ PQ&(X%XLF\+BU5P^#Q;BZE
M*IS0Q.%A.[347**<EU6WGJC_ $-?@]\1;#XN?"SX?_$[3(U@L?'GA+0_%-M;
MH_F"WCUBPAO! 6.26A,IB;=\P92#@@BO\X\YRVID^:YAE=5N53 8NOA92M;F
M=&;@Y:76MKZ/[[G]EY;C89C@,'CH*T<7AZ5=).]E4@I6^5[?F>D5YAVG\=7_
M  <E^"H=)^(_PB\=QQ@7'B*WU"Q>0#!8:3I]JJ M\O(R!^?(ZM_:7T8<<Z^6
MY[@&VXX:"FE?;VTY7TMIOOUMO96/YJ\;\*J6-RS%VLZ\I0O_ ->X)I];VM_=
MM_>TY?W-_P"",^O77B/_ ()X_ O5+R1I+A[;Q!;R,S;FS::W=VX4]<%!'MQG
MC;QFOP/QKPZPOB-GU&,>51GAW;;XJ$&WKKOWM^-Y?K'AG6=?@W*:DFVW&LKO
M=\M62OUW]?O/U(K\I/O0H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H @N;JULX6N+RY@M($^_/<S1P0KGINDE947..[#\>E)M15Y-17=
MNR_&WY_<:4Z56M-4Z-.I5J2VA3A*<WZ1BI-_=]_V6VE[9W\(N+&[MKV L5$]
MI/%<0E@ 2HEA=T+ $$C.0",@9!84HR5XM27=--?A?\_ONQU:-:A/V=>E5HU+
M7Y*M.=.=M5?EFD[-IJ]K:-:V99IF04 % !0!^!/[5_\ P01^"OQL\<:G\0/@
MG\0)_@#J'B&]FU#7_"L?A2+Q9X$:_N9GGN[W0=&BUOPY>^'WNI)7,FGV>IMH
MT.V/[#IMJ/-\W\6XG\%\HSG&5<?E..ED=;$3=3$8=858O 2J2<I3JTL.JV'J
M4)U'+WHTZ_L%:\:$9.3G_H+X4?3^XRX,R&AP_P =\-QX_AE]"EALNSI9N\FS
MQ4:,:=.%/-:\\OS.AFTJ=*FHQQ4J6&QU6<IUL9BL74E>/=?L8_\ !#_X&?LR
M>-M+^)_Q'\77?QZ\>>&]0CU'PG_:GARW\,^#-!O[242V&LQ>%?[4\0RWVL6L
MH6XMY-4UF_M;*YCMYK.!+B$7#=O"7A#DO#F+IYECL3/.\PP\^?"RJT(X;!X>
M<6^6M3PBG7E*LKIJ=?$5E!Q3IP@[N7@^-'TZ../$O(L5PMPMDE+@#(\TPCPF
M<U:&:3S?/,?1K0<,7@Z>:+ Y93P6 Q$7[.I##8.GBZE&56C4Q<J-6I2/V\K]
M</X8"@ H * "@ H * "@ H * "@ H * /QQ_X+M?\H^/&G_90OAE_P"I-#7Y
M9XR?\D)C_P#L-RS_ -3*7]?\,?VA] K_ )2!RW_LF>)?_4.)TG_!$&1G_P""
M<WP?5CD1>)/BO&G&,*?B7XGEP>F?FD;GTXYQFM_"%M\!92OY<1FR7I_:N,?Y
MM]OUEY7TY8J/TC>+&MYY5PK*7JN'L!#Y>[!?GU9^M5?IA_(@4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % '_]'^_B@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M )2-?LR?]F3^&O\ U>OQTH _T*/V$/\ DQ[]C7_LU/\ 9X_]5%X/H ]]\?\
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M %>K.?[5:6MR5V&YMX)R@.[9YT2R;=V!G;NQG SUP,XH _";_@H%_P ''/\
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M_9M_B[_T?IU '\O/_!C+_P >O_!3[_KX_8P_]%_M6T ?WZ4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % '\>?\ P5-_Y/P^.O\ W3'_ -4W\/*_SW\<?^3H\4?]T7_UG<H/]%/
MG_DU7"W_ '7/_6CS@_/NOR<_7 H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#_00K_6 _R/"@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_//FNQX8_X+&7]]=,8H
M]/\ VM=2OC*Y"CRYO%5]=!L\@!?.VGITP/6O]((/ZYX)>S@M9<'8>C;S5%/U
M;U76/K9(_C-KZOXFRJ2=DN)*M1O:R]I-7?\ 6F]W>T?]"+3+M+_3K&]C8.EY
M:6]TC Y#+/$LH8$<$$-GC^M?YQUH.G5J4VK.$Y1:[<K:\OR^X_LFG)3IPFMI
M1B_6ZWZ;_P!7W+U9EG\UW_!R!_R0WX7_ /87U7_T;IO^>OYU_3?T:/\ DH,S
M_P"O5#\YGXAXU_\ (JP/^.K^2/E/_@VH_P"1I^.'^YH7_I->5]C]*#_=.'_^
MO=;_ -.GSG@;_'S?_%1_](/O/_@XL_Y,VT;_ +*)X3_].!K\^^C7_P EO+_L
M"Q/_ *:/KO&O_DEX_P#850_]+/R\_P"#;G_DX?Q]_P!B1J7\K/\ PK]2^DPO
M^,;R]_\ 4?27X3/AO!/_ )'.-_[!JOYQ/[3:_B(_IT_S7/C9]D/_  4>^)WV
MXA;3_AHOQ)YV0" G_"27V>#@<^_UY(Q7^F^1\Z\,LJ]GK4_U:P;@O^Y9::6=
MO^'=[6/XAS3E_P!=L=S?#_;>)O\ *K^I_<9^VCX?U3Q3_P $T_B;X?\ "Z3R
MZGJ7P'\.PZ4ELKM.Q6TT"91&%PV1!&Q/W< '., -_"/!.(I83Q/RO$8MQ5*E
MG^(E5<G:*]^NKMZ?::Z^2M<_JCB>E.OP-CJ-!-SGE5%4U%:OW:3T2OT3_P"!
MN?P?_L.>+?#WPP_:[^$^O^/%MQH^B>-!%JPORJPB1TO+!3,7P!_I<L9^;HPZ
MDC-?W]QWA,3F?!><87 *:Q&)PE.=#D3<N5)U'RK2Z<;==MK:'\E\*5Z&!XDR
M^OB^7V-'$2C4<M%>_+KZ2Z/KU5K2_P!,+0KVTU+1-(U"PEBFLKW3+&ZM)8'5
MX7MY[:*2)HG4E60HPVD'IZ5_E]7A.G7K4ZBE&<*M2,U)6DI*3333O9W\_O/[
MFI2C.E3G!IPE"$HM--.+C=6:T>G]:FK6)H4]0T^RU:PO=+U*VBO-/U&UGL;Z
MTF7?#<VEU$\-Q;RKQNCFB=HW&?NL<8JZ=2=*I"K3DX5*<XU*<XZ2C.#4HR7F
MFDUZ$SA&I"5.<5*$XN$XO:49*TD]]&G;;[S_ #[O^"L?[+WB+]B;]LN]\6^$
M5ET[P]XSUJ3XF> KG3X66ST+&K&2WTV.YB3RXKBTN+42I!*_F[<[=Z#Y?]$O
M"+BO#\<\$1P6,<:F)P-!95CX5+>TQ,73YIU6NL6G9RMK_=V/X\\0N'ZW"W$\
ML5AU*%#$U98_"2BK0H^_:%-25DFFNOJ[W2/DWXU_'[XU_P#!0+XM_"^T\2(=
M;\=)H'ASX8^'H%N)YFU"2WFG2WFD+H2L]R\^Z;9&V1&,$<5]?D/#V1>'F3YM
M/#)4<O\ K.(S;%3<5'V49)<T$[_"NEW'TTO'YW-<VS7B_,<OA7O4Q;I4L!1B
MI-\]G[K>K]YW[=-WJ?W_ /[ ?[,/A_\ 9,_9D^'WPNT6R^Q7\NFVGB3Q6C1"
M.1O%FLZ?92ZV'/WV\N[1TS)AMP<X&2*_SQ\0>*<1Q?Q1F&:UZGM*:JSPV$?,
MVOJE&I-4;7VO%INUM_*\O[ X0R*CP]D6#P%.')-PC7Q"LE_M%2$75[[23Z]]
M[G\J?_!Q+XC%U^U_H?AO>"=+\)>'+TQYY47NDK@X[!B._7.<D +7]:_1MPW)
MP?B<5;^-7QU.^GV'--;7NK__ +.\OY^\9ZW-Q'0H7_ATL-.W;F6GX)_>?TY?
M\$M/^3(O@W_V#;S_ -*3]/\ /KUK^6O%?_DN<Z_Z^0_])^?]=MC]WX"_Y);+
M/\$__2V?/_\ P7:T;5-9_P""=OQ)32HKBYDL?%7@+4;FUMXVE>6SM-?AEN)-
MB!F;[.BF3 !!&2>@KZ3Z/^(HX;Q,RB=>481=#&1527V9.C9)7LO>V_*^QXOB
MW1J5^"<PC23;57#2<4KW2J>7;]3^'G]E#]F[XC_M5_&/2/@]\*]7T30_&6MZ
M?JU]I]UX@UO^P+%DTV*"6:U%_P!1<W GC2W@7<T[_*!\H#?W3Q=Q)EO"625<
M[S>C7KX&C5ITJD,/0^L5$ZGPS]G_ "1O=S>RU/Y:X?R;&<09G2RO+ZE&GBJE
M.4X3K5/90:IZ./-_,W\*YG?IOS1_73_B'W_X*+?]#-X!_P##E3?_ !L_R_.O
MQW_B87PT_P"@;,?_  V_\/\ UO;8_1?^(/\ &?\ S_P7_A5+_P"6&9+_ ,&[
M_P"W_-*;F>\^%EW/NW;KGQZCN[?[4TEK*WX[?^ \_-T4OI'^'=)QY89M&,6G
MRQP#BM-OZ_R1E/P9XOG=N>7MM;O$_F^:7Y/\#^P7]BWX1^-_@7^SE\-OA=\0
MIM/F\3>$?#VFZ/>MI=V;ZQ!LK*"WQ;W!"[XPT;!>/NX/&1N_C/CC.<#G_$N9
MYKERJ1PN,Q%6M!58<E3]Y.4O>C96=FN^OWG](<,9=BLIR7!8#&.#KX:C"G-P
MGSQ]V*6DNNM^^_RC]55\D?0'\HG_  <V?9O['_9H$8'VK^T/&AFQ][9]CM/+
M!Z=2#CVP>>E?U[]%CG]KQ:W\'U3"6[753_+SOZV/YZ\=^7V>06^)U\0I>CII
M+^M/5;GZM?\ !$FTDL_^"<?P,CE#!Y6\6W1#<$?:O$NH3X[<#S,+QTQTR:_(
M/'6JJWB;Q!46SEA4OEAJ:TW_ !_#8_0O"RFZ?!&41:::5=N_G6F_Z_X!^L-?
MD)^AA0 4 % !0 4 % !0 4 % !0 4 % !0!S_BVYN++PKXFO+65X+JT\/ZS<
MVT\9Q)#<0:;<RPRH>SQR*KJ>S*#65>3C1K2B[.-*I)-=&H-I]=FNWWGHY12I
MU\VRRC5@JE*MF."I5(2UC.G4Q-*,X2752BVGY,_S_=>_X*5?MW6VN:S;P?M1
M_%Z*&#5=0ABC3Q=J@2...[E1$4>?@*JJ%4#  & !TK^*,3XB\;0Q.(A'B/,(
MQAB*\(I.E91C5G%)7HMZ)+K]Q_T)X;Z-G@%+#X=OPCX(DW0I-REE,7*3]G&[
MD_;*\F]6[:O74R?^'F'[>?\ T=-\8/\ PK]4_P#C]8_\1'XX_P"BES#[Z/\
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MUS*<SA3_ '3Q>&A7H5:>(I*G2QF'JJI&E2J4Z]*'Z85]Z?S$% !0 4 % !0
M4 % !0 4 % !0 4 ?__2_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H _#;_@Y/_Y0B_MZ?]B5\+__ %?WPGH _!'_ (,=?^22_P#!0[_LHO[.
M_P#ZC7Q8H _NWH _S%_^#HK_ ();^*/^"?G[8'A3_@I%^RQ;:KX)^$7QW^)5
MIXQO]3\&>;I<GP(_:QTJ];QBU]I%S9*C:'8?$6[TNY^(_A"XA?&G^,-,\;Z?
M;QZ7IUMX:M)P#\J/^"UW_!2O2?\ @J?X@_8?_:'NXK;3/B_X8_8\T?X/?M#^
M';.W^R6.F_&+P9\6OBCJ.L:SHEN/DC\->.M%\1Z%XWT." S0:/%KL_AA[JYO
M] OY6 /]9/\ 80_Y,>_8U_[-3_9X_P#51>#Z /??"7Q!\!>/F\3)X%\;^$?&
MC^"O%6K^!?&*>$_$FC>(G\)^-O#\B0Z]X.\3+I%[>-H/BG1)9(X]6\/ZH+75
MM.>2-;NTA+J& .OH _C8_P"#TOX=? V__8"^ _Q1\36GAZR^/WAS]I70/"'P
MKUL06'_"9:MX*\0^!_'NH_$?PHDK.FIR^#8YM'\,>)-4DC2>STWQ%IGAN%GM
M)==*WH!K?\&55WXLN/\ @FM^T)!JLUU+X3L?VT?&%OX36Y>9X[:ZD^#'P3N_
M$EO8"7*16)GN--N3';XA_M&YU&5E%Q+.[@'\?W[;OPR^,G_!!S_@MWJOC+P!
MI$UG9_"#X[6O[1/[/KRQ7&DZ!\0?@-XXUB^U>R\()?)"QET:Y\+:CXH^"'C>
MZL(OW6I:3XI@LT3RK<T ?ZJ?[#'[<7[/O_!0S]G/P/\ M+?LY>,++Q)X0\66
M%K'KNA/=6I\5_#;QFEE:W.O_  Y^(&DP2RRZ'XO\-3W2P7EM*#::E9R6.OZ%
M=ZKX<U;2-6O0#Z_H 0L%&6( R%R2 ,L0JCGNS$*!U)( Y(H _#?_ (.3_P#E
M"+^WI_V)7PO_ /5_?">@#\$?^#'7_DDO_!0[_LHO[.__ *C7Q8H _NWH ^)_
M^"CW[)=K^W7^PO\ M0?LF375EI]_\:/A3KOA_P *ZGJ2&33='^(&EO;>*/AM
MK6HHJM(UAHWC_0O#6J7HB'G_ &:TE,#)-Y;T ?Y?_P#P02_X*.:M_P $:?\
M@HYXH\*?M+Z5XC\$?"#XD7-Y^SO^U/X=U*RNX]6^%7B7PQXHE@T'X@ZMH,,,
MM]=WWPI\51:UI?B*PMHKB^C\'>)/&DNE6.J:S'I=E< '^MOX2\7>%?'WA?P]
MXW\#>)-"\8^#/%VC:=XB\+>*_#&JV.N^'/$>@:Q:Q7VE:UH>LZ9/=:=JFE:E
M93PW5C?V5Q/;75O*DT,KHP:@#H: $W#(7(W$%@N1DA2 Q ZD LH)' + 'J*
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MAO\ ";P_-J-A>V]E:W^G2RPW/V?8X!_6Y_Q!,_\ !/S_ *.I_;&_\&/P4_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!_'G_P %3?\ D_#XZ_\ =,?_ %3?P\K_ #W\<?\ DZ/%'_=%
M_P#6=R@_T4\"?^35<+?]US_UH\X/S[K\G/UP* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P!!"O\ 6 _R/"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_/8_X*
M<:-<? /_ (**^*?%,=M-#-)XLM_'T:HH1Y%N]4OI_,C&4!WB$D8< X(!'-?Z
M->%=7_6+PTP^#YE)?5H9:_[OLZ-[:O33IKONO=YOXVX[IO)^-:N(46O]H>-5
MEJ^:I>]^O7M^;E_>7\ O$MOXQ^"/PD\3VLZ7$>N?#GP=J1D1P^);O0+":9&(
MZ/'*SHX."&4@],M_G]Q#A98+/<XPLXN+H9EC:5K6TAB*B37DTDU;37S/ZWR>
MO'$Y5EU>+YE5P6&FVN\J,&_G=_UH>N5XQZ1_.7_P<1^%O$WBCX*_#&W\-^']
M8UZ:'5]5:>/2;&:^>!#)IQWR10!I,85CA5+D*=N3A6_I3Z-^*PN$SW,IXK$T
M<-!TZ*4JTU!.W.W9N^R\M/.Z/Q;QFP^(KY7@E0H5:[4ZEU3CS-;;]M_/\+Q^
M7?\ @W'\%>+_  KXJ^-G_"1^&-=T..5=#6*75=+O-/25UM;LND?VN*%I-H*Y
M>,.AW  @APOUWTF,=@<7A,@6$QF'Q3C3K*:H5%/D_>=;6W]'VON?/>">%Q6'
MKYM]8PU:A>5*WM8N-_=MIZ/3?R=C[P_X.!O!_BKQG^R)I.G>%/#NL^([V/Q]
MX7N);71=-N]3N8X(KYFDE:WLXIIRB@?,4CXR"<@$K^?_ $=,;@L%QI*KC<70
MP=+ZEB5[3$5%3A?V>UW?7733[SZWQDPV)Q7#4:>%P]7$3^M47R48<\K<][V7
MIY_C>/YI?\&\?PO^(_@?]H'QU=^+_ OBGPW82^#-1ABOM:T:^TVVEF/V0>4C
M7<,)+Y5@!M 8#*%@26_3?I'YIE>-X>R^G@LQP>,J+&T92AAZJJ22M/5I*-DM
M-?RLW+XGP9P..PN;XN6*P>(P\98>HE*M3<$VVMF]]M._R/[$Z_C _I,_S=OV
MK_@W\;;?]LGXY^+-)^%WCV\M(_C7XMU.QN;3POK$\-U"/$5U)#+;7$-K+!(E
MQ&Z-$ZS;,2 NZ;7K_3+A'.<AGP1D&$K9SEM.I_8.$I5*=3$QC*,UATG&4;:-
M/2SD_172/XDX@RW-H\3YKB*>6XR<%FV)J0G&C)QE%UM)1[JVMS_0L^$-C'K/
MP)^%^G:_IP=-1^%G@JVU;2[^$,0T_A73$N[2ZAD'RR1R%XY$8!HY%XPZU_G-
MG-1T.(,UJX>HTZ>;8Z5&K3DUHL55Y)PDK.S5FG?5/IJ?V3EL%5RC PK0NIX#
M#1J0FM=:$.:,D[ZIWOY]K7/XO_\ @I[_ ,$<OC!\"_B1X@^*OP%\/:OX_P#A
M3XGU.?5K>PT&UN]4\4>';^[E:]U87MA8VLOEZ=%<7!-H\/SF-'91(^43^VO"
MKQHR;/LLPV4\0XJCEN;X:DL/*MB)QHX/$4DO9T^6I-R;G*"_>*VE[:H_F/CW
MPUS+*<96S#**%7&9?7J2JJG1BZE>C4;YYMPC9)*3]QVUMT///V>/^"T'[:_[
M('AB/X<^)-%LO'EGI>;6RM?BG!X@6_TR%"PCM8GAFLYXA"@2(;\L0@5\$DUZ
MO$G@CP%QEBY9GAL7/+9UI<\GE$:4J56^\VY\RDW>^W5VO]GAR;Q.XKX;PZP5
M:C'&1I^ZEF+J^TI]HKELU;:VFBUMH>J^(?\ @M5^WY^TMK'ACPUX&\.Q>!UN
M_$>B1SS?"S2_$37UQ:2:C +BW>::6YQ') SB268[ @PQ53FO*H>!OAQPQA\9
MBL=F$L>Z>$Q$H4\V]C&GSQIMP:Y-+\UK)<NO5VO+OK>*/&6>5</0PN$6%4J]
M*,Y9>JCFX<ZNFWS:-/73N]7;E_L[^"L_B"Z^%'@.Y\527\WB*?P[92ZQ)JBL
MNH/>ON:4W:L RS<C((R!QSBOXASR.'CF^81PBIK#+$S5%4G>FH:6Y'UC_74_
MI[*W6>78-XCG==T8NHZBM-RZN2Z-_P!;'\\?_!R-\0?A1!\%? 'PVNX;)_C'
M?>)M+\1Z1/Y<(OK?PA;&_@OE$V[SS!-<Y4IM$:MCYB9"%_H[Z,^79O+/,PS.
M$IQR6&$K8:JKM4YXR2A*&EN5R4>[N[].7WOQGQMQF7K*\)@I*#S*5>G7@[+G
M6'7-&6M^;EYK:6MUUN^7X*_X-^?V*1\4_BWJ'[2?C31!=^"OAI+Y7@Z],98#
MQ[:7-K<(VYT:,+;6DK'"$2;E=?ESNK] ^D1QQ_9&3TN&,#7Y,=F:Y\;&+>N7
MU8-6T:U<E;563[ZGR/@]PO\ VCF,\\Q5)2PN":6&DU>V+IR6NO:.NEOR<O[8
M:_AP_J,_@(_X+*VGQ(^-_P"U_P#$'XR>'?!7B;4OA[I^GZ+X/M/%6G:3?7N@
M17/A2&ZT[4;87\$<EO'-#*(_/$CJ=P4$G;M7_0SP5GE61\%8'),3C\)1S2=:
MMC)86K5C#$SIXNTX-4KMM23T;M==-#^0/$J./S7B7%YE0PF(JX&%.GAXUX0D
MZ,9X>\9>_P"\DU;77K;7>.Q^RK_P7!_:8_9B^"OA[X!^%_A]X%\70>'Y;V#2
M=<\1+KLVO(;VX>8V\T-I/%!<>4QV0[HPRKC=D *N/%7@1PKQ5GE?B'&9KC\"
M\2HRKT,-&BL.O9PM%Q<KS3G9.6JW??W-,A\5<]R'*Z.3X? X7%*@Y*G5K.K[
M;WY7L^7W=+Z:>O+:Q_7!^RKKVJ_MJ_L+^#M9^/7ARRCUCXK>%=;B\2:/+;N]
MO8W$]UJ-E:7$$5P3();1/*N+9GZ,B'#+C=_'G%E"CP1Q[C:/#^)G*CE.+H/#
M5E)<U2,84ISC)I134]8R6ETWKHD?T7P_5J<3\)X:IFU"*JYAAZJKTFG:$G.<
M8M*5VG%6<;_AN?QW_M<?\$W_ -JG_@GW\<$\:_"S3?%OB/P78:J^L^"OB!X2
MMK_4+G3M/MY[>6*S\2/IMD([*Y8QE"K-(+B!=\FV52S?V?P=XE\)>(V1?4,W
MK8+"8^I15#&X#&SC3IU)N'*IX6#;E-*.[:>O\NA_-?$?!/$/!V:_6LNIXG$8
M6%5U<+B\,IRG""ES.->2BU!MNW+[R<5?0^JO"_\ P<9_M:>"="LO"OB?X3_#
MKQ)KFDVD5D^LZT?$EKJUY/'E/-U6)+M TQ(PTD:9<\%"RX;Y+&?1KX.QN(GB
M\'G694,/6DY^RH+#NC2OO&ES0DW!+57>W1WO'Z'#^-7$>%HQP^(RS!U:U./(
MIU?;>TFU;6IRR2YN]EWV;N</X]_X*M?\%*OVO;W1=!^&OAKQ'X*@N;^TCN+?
MX-Z+XC,E]:R2".6&XEF:Y0PF-][-+(H.T $.0:]+ ^$7A9P;1KXG,,PPN85*
M=*4H_P!MRHQY9I:.%E&T^JLK+^\D<>+\0N.N(YTJ6#PE?"1E-*3RR-1WB]+2
M;4KIWUT\G:SD?VA? 1?$:?!/X4IXP_M#_A*E\ ^%AXB_M5634_[8&D6O]H?;
MT;#+=_:?,\\,,B3=G'-?Q!Q \,\\S9X/V?U7^T,5]7]D[TO8^VE[/V;N[QY;
M6=]NUS^GLH]O_9>7_6>?ZQ]3H>V]I_$]I[.//S[>]>_-IOO8];KQST3^.[_@
MX[\9PZW\6?@]\/U8--X?BNKV2,'YU76+"T89';( QP,]<XX;^U/HR8)T,HS[
M,+-1Q-&I"]MW0E-O6ZT7W>::/YI\;L4JN895A+W="HI-?]?5%+3_ (>_E=2/
MZ-?^"=/P_D^&/['OP;\(R6K6;6F@?;/(=-A U*3[:K;3T#B;=VZ]^M?S+XD9
MBLUXRSK&*?.I8CV?,M?X2]G;KLX]_OLC]MX+P;P/#>6X=QY7&ES6?3VCY_U\
M^^E['VY7PI]2% !0 4 % !0 4 % !0 4 % !0 4 % &'XGL;C4_#7B'3;15>
M[U#0]6L;5&8(KW%W87$$*LYX16DD4%CPH.3T-9UHN=*K".\Z<XJ_>46EVZOO
M]QW977IX7,LNQ-9M4L/CL)7JM*[5.CB*=2;26K:C%M);[=3^);6?^"'/[>]]
MJ^JWL7@KPAY5WJ-[<Q?\5WX>YCGN99$/-TIY5@>54^JJ?EK^1<1X.\;U,17J
M1PF <:E>M4BWF%-/EG4E)77([.SVN[=WN?[EX?Z<7T<X8>A"?%&=QG&C2C./
M^JV9OEE&$5*-U&2=GI=.SW5]&9O_  XO_;[_ .A*\(?^%WX>_P#DNL?^(-\<
M_P#0)E__ (<:?_RLV_XGE^CC_P!%5G?_ (BN:?\ RL\_^*W_  1__;'^"WPX
M\8?%7XB:+X#\/>"_ VCR:WKVJWWQ!\,PI%;)-#;0V]N)+Y6NM0O[RYMK#2]/
M@62ZU+4;FUL+2.6YN(D;CQ_A5Q;E>"Q.88^GEN&P>#HSKXBM/,:=HTX*]E>"
MO.<N6%."]Z<Y1BK<UX_0<*_2[\$.-N(\FX3X8SGB#-,_S['4\ORW!4N%LUC[
M2M44ISJ5JOLW'#X7#4*=7$XO%5%['#8>E5KUI0I0G*/Y;5^;G],GWC_P3J_8
MT\0?MK?M'>&?A\EK<Q?#GP[-:^*_BWX@02Q6^E>"]/NXC<:9'=1[6CUGQ1,%
MT'18HF^T">ZFU JMEIM]<6_V_ '"57B[/J.$E"7]FX5QQ6:5M5&.&C+2@I+7
MVN*DO94TFI*/M*FBIMGX3](GQFR[P1\.,SXEJ3I5>(<P53*>$,MGR2ECL\KT
MI.G7G2E?FP&54W+,,PG)>S=.E2PC;KXS#0G_ *"VA:)HGA'P]I'AS0;&UT;P
MYX9T>PT;1]-M4$-EI6C:/9165A96Z<B.VLK*WBAC7/RQQJ#G%?V[2I4L/1I4
M*,(TZ-"G"E2IP5HTZ5**A"$8K11A%**2V2L?\]F8YAF&=9GCLUS+$U\?FF;8
M[$8_'XRO)U,1C,=CJ\Z^)Q%:;;E4K5Z]6=2<F[RG)O2[/X7/^"L7[?6N_M@?
M''5?"?A36KF/X!_##5+W1? VDVMR?L'BC4K262UU+Q[?I$5BNIM6="NB"3S1
M8Z.L C99[JZ%?QYXG\;5N)LXJX'"5I+),LJRI8:G&5H8K$4VX5,;42TE>7-'
M#W7N4USJ\IL_W;^B?X X#P:X$PF99I@J4O$#BK!8?'<18RI33Q&6X>O&&(PO
M#F'G).5*C@8N$L=&FXK$YC[6=1SIT,+"E^3=?EQ_5Q]7?LW_ +$?[37[6%Q<
M?\*4^%VN>)-'LI&@OO%=W&NC>$+6Y169[)O$NJ&VTF2_54.ZSAN9)XV:))EB
M:6+?]-D'!W$?$S;R?+:N(H1DX3Q=1QH8.$UO!XBJXPE-?:C3YW%^[))M'Y?X
MB^-'ACX4TJ<^.^+LMR7$5Z?ML-E:]KCLYQ='VBINKA\JP4*^,E24N9>WJ4J6
M&O"<?;IQER_>6I?\$'OV\++27U&UT7X?ZK>+$9!HUGXUT^._=P,^2LEXMK8!
MR?ER;L)WR>"WVL_!;C2-+GC#+*D]_8QQK4_3FE1C33\N;_MYV/PG#_3N^CS7
MQ7U>><\28:GS<JQF(X:Q7U;712?L*U?$*'5VH2:6R/RV^,?P.^+/[/WC*Z\
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ML\<T5KXG\%^)+/2_$_AZZDBE@CU72[47<%S9O<6TH!_D"?M$?\$/_P#@J-\
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M-?#NK7MK/K$?PL^#!T3PYK&H6US%:PR3?\*W^'DMGKM_I=C#XH\1PW,2:A
M?Z1O_!.[]A7X4?\ !-_]D;X3_LD_!^:[U70?AYIMU<^(O&&J6\=KK?Q"\?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % '\>?\ P5-_Y/P^.O\ W3'_ -4W\/*_SW\<
M?^3H\4?]T7_UG<H/]%/ G_DU7"W_ '7/_6CS@_/NOR<_7 H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_00K_6 _R/
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M/Q-'!X'!8>MB\9B\34C2P^&PN&I3K8C$5ZDK1IT:-*$ZM6;=H0A*3LHL_O\
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M /@FA;^O^ ?MW[1AO_B+'!R>RX!P[6G?/\[OKUV733SN?OS7[.?Y\!0 4 %
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MA*_+-Q:C*UTU&5K.S33LW:S3V]V6F2% !0 4 % !0 4 % !0 4 ?_]3^_B@
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M^&WAJ66WC1?[5UW7]?T:!9M('P]TII4O+( ]Z_X,?O\ DX']O?\ [(Y\&_\
MU-O%] '^B_0!_FQ?\%I_A1XK_P""#_\ P6_^ G_!23]F?0+OPY\$/C]XEF^*
MNK^#_#+-IGAW4_$%KJ=EI'[57P7-NA%C;:3\1/#^O6?C73+>Z*V&EZUX\N)/
M#UC90^"[#[$ ?Z,OPR^(_@WXQ?#?X?\ Q;^'6M6_B/X?_%'P3X5^(G@?Q!:;
MOLNN>$/&FAV/B/PWJ]N& <0ZCH^I6=Y&K@.JR[7 8,* .XH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * &NVQ'?:S;%9MJ+N=MHSM11RS'&%4=3QWH _A
M)_X-Y_\ @G-^V!KW_!73]LK_ (*7_MQ?LV_%GX$W]S+\6?&WPNM/C!X/U+PG
M?ZI\3OVG?'NOW6L:AX8_M6*,W]KX*^'*^,O"VJQZ<K6^G0^-M$B$L4$L$-P
M?W<4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?QY_\%3?^3\/CK_W3'_U3?P\K_/?QQ_Y.CQ1_W1?_ %G<H/\ 13P)_P"3
M5<+?]US_ -:/.#\^Z_)S]<"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /]!"O]8#_(\* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MBO\ /J491E*,DXRBW&46K.,D[--=&FFFO\C^NDU)*47=-)IK9IZIKU1+2&%
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MWG6J.I+>_P!J3Z_>?H^'HPPV'H8>FK0H4J=&"_NTX*$?PB;]<YL% !0 4 %
M!0!\W?M<_'C2OV:OV>/BA\8]3GMT/@[PU=W]C;S. ]Y>EHH(8($)4R2@S>:%
M''R '&0&^FX/R"MQ/Q'E62THR?UW%0IU)1VA#63E)V=E[MMUOY'B<1YM3R3)
ML?F5245]6H2G!.WO3T226EWK?Y7ULT?RZ_\ !!W]GO4?C;^TU\3_ -KKQ=I]
MY#9^&=9U+5O".J:A&\AU'6M?UC5QJ<-K,Q8@6-M<16\F2GE&((J%-F[^KOI
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MY--\(^*?LQ<] 4-[,5!ZY8@'&5_&_&^I*/"6'IJ_+4S7#<W;W*=9QO\ ._\
M5C_0']G7A:53Q<XJQ<DG5PO >+ITF_B4<3G>3*K;O?V,+[]/6/\ &K7\EG^R
MY_57_P &X'AS3D\/?M.>+0B'5KC5?A[X>+GF1+"UMO$FH[4Y^1);BY!DPH\P
MP1;BWE(%_I?P$P]-8'B#%)?O9XO"4)/K[.E1G4BNZ7-5D][._2S/\JOVDV8X
MEXSPJRF\EA(83B7,5&[Y98FK6RS"N;5K.4:5!13O[JD[+WFS^G6OZ!/\O H
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M7.<;PUD640S[-,3[**_>X_B/$9MBI-2E'$<\<:F_K)^]M?L9_GX% !0 4 %
M!0 4 % !0 4 ?__5_OXH * "@ H _P Z/_@[V\5>*?VE_P#@IU_P3X_8*\-W
M?V>.'P%X6_L665LVL/Q"_:M^-!^'+O/;JP\P6.E?#'P;<*[D,$OYXXMH:5G
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M%>#);RX.9YH?AH+SX;V7G2'+3316/A.WADN)&:6X=&GF=Y9'=@#]8* "@ H
M^=_VO?\ DTW]J#_LW?XU_P#JM?$M '\%'_!C]_R<#^WO_P!D<^#?_J;>+Z /
M]%^@#^7G_@[M_9XL_C'_ ,$AO%?Q02"(Z[^RY\9OA-\6[&X"C[9+HWBG73\$
M?$.EPN02;25?BGINO7L(*ASX:M9R2ULB, >Z_P#!KK\>M2^.W_!&7]FB+7)9
M;G6_@KJ?Q'^ M[=R2!Q/IO@/QCJ%YX+BB7<[11Z7\/O$/A+1!&YR6TQY45(I
M41 #^A&@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _CS_X*F_\
M)^'QU_[IC_ZIOX>5_GOXX_\ )T>*/^Z+_P"L[E!_HIX$_P#)JN%O^ZY_ZT><
M'Y]U^3GZX% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?Z"%?ZP'^1X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M\@H<-Y)A,MH*SA#VE5OXO:U4I5$Y;M1E=+\#Z_KXP^D"@ H * "@ H * "@
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M'GB(\$YKBL%G<:4;RH91Q"L+2H9A4UO['"YIA<-A*G+&;4LSIU)<E.G.<?[
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M7B_\0[X*_P"B<RW_ ,$?_=#[_P#XFT^D3_T=+/\ _P  R[_YA$_X=6_L ?\
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MU%<6</[;_P 7(M!.2=VE'X/?L]S3$ \ #7)=97Y>,J3]XM0!_6[0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?QY_\ !4W_ )/P^.O_ '3'_P!4
MW\/*_P ]_''_ ).CQ1_W1?\ UG<H/]%/ G_DU7"W_=<_]:/.#\^Z_)S]<"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M /\ 00K_ %@/\CPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MW14WSJLF_A<U)V@E[NM^6UC^C"OYK/VD* "@ H * "@ H * "@ H * "@ H
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M_P!*D?"^,_\ R:3Q+_[(7BK_ -4F./\ 1WK^[S_FS"@ H * "@ H * "@ H
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M &O?^33?VH/^S=_C7_ZK7Q+0!_!1_P &/W_)P/[>_P#V1SX-_P#J;>+Z /\
M1?H _F/_ .#M[]H+3_@Y_P $>?B%\.VEB&N_M._%WX0?!O1HM_\ I<5KH?B=
M/C9X@U"*($$VJZ5\)9-%NYW5H8FU^UA.V>ZMVH ]'_X-7?@;J_P4_P"",O[/
M=]KT+6NJ?&[Q7\5/CDUC)$8Y+;2/%/C&\\.>$YF;_ELNL>#O!_A[Q#!*,#[+
MK$$76(E@#^BF@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _CS_X
M*F_\GX?'7_NF/_JF_AY7^>_CC_R='BC_ +HO_K.Y0?Z*>!/_ ":KA;_NN?\
MK1YP?GW7Y.?K@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!_H(5_K ?Y'A0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MN?MJ2BE&*225DEHDELEMMZ?<2TAA0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'X:_\ !:7_ (*"Q_LV?"I_V?\ X9:P8_C;\8=$N8M4OK";;<_#[X<7;26.
MHZK)*H)M]<\5JMYHV@I$RW5G9IJNL^99S0Z/)=_D?BQQO_JYE?\ 9.7U>7.<
MUI3BIP?O8'!/W*N(>NE:LN:EA]/=:G5?P0YO[L^A+]'U^(_%B\1>*,%S\$<%
MXZE/ X;$4^:CQ'Q10Y,1AL)R2TJ9=D]Z..S+F3AB*T\%@5&K3J8U4/XJF8L2
MS$LS$LS,22Q)R22>22>23R3R:_D,_P!K!* "@ H * /ZF/\ @VY_X]?VKO\
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M /)I/$O_ +(7BK_U28X_T=Z_N\_YLPH * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__0_OXH * "@ H
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M;PHD4,2)'&BHJK0!:H * "@ H XWXB^!](^)WP^\=?#;Q!-J%MH/Q"\&^)_
M^MW&DS06^J6^D>+-$OM!U*;3;BZM;ZU@U"*SOYI+.:YLKR"*Y6)YK6XC5HF
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M=E_\W!_PX7_8"_Z 7Q1_\./J/_QBC_B#/ W_ $!X_P#\.6)_^6!_Q/YX^_\
M/S@[_P 1V7_S<'_#A?\ 8"_Z 7Q1_P##CZC_ /&*/^(,\#?] >/_ /#EB?\
MY8'_ !/YX^_\_.#O_$=E_P#-P?\ #A?]@+_H!?%'_P ./J/_ ,8H_P"(,\#?
M] >/_P##EB?_ )8'_$_GC[_S\X._\1V7_P W!_PX7_8"_P"@%\4?_#CZC_\
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M^>DX58PG']::_23^0 H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /__1_OXH * "@ H * /YU/A9_P &
M[7P?_9Q_X*>S_P#!27]E7]HWXC_L^#6O&.H^)/%O[-_A3P?X9OOA?XAT+QA#
M"?BA\.UN;J]M[C3O OCC4Q<Z]9:(NEW<'@76WTV]\(C3_P#A&_#2:4 ?T5T
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M1:_G]YU]<9TA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_TO[^* "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H __3_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_]3^_B@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M\,*?\'/W_2<7]G__ ,0C^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE
M!_PPI_P<_?\ 2<7]G_\ \0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_Y
MPE !_P ,*?\ !S]_TG%_9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?
MP!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\
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M^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE !_PPI_P<_?\ 2<7]G_\
M\0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_YPE !_P ,*?\ !S]_TG%_
M9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<
M7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\ B$?P!_\ G"4 '_#"G_!S
M]_TG%_9__P#$(_@#_P#.$H /^&%/^#G[_I.+^S__ .(1_ '_ .<)0 ?\,*?\
M'/W_ $G%_9__ /$(_@#_ /.$H /^&%/^#G[_ *3B_L__ /B$?P!_^<)0 ?\
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M%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H
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M\,*?\'/W_2<7]G__ ,0C^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE
M!_PPI_P<_?\ 2<7]G_\ \0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_Y
MPE !_P ,*?\ !S]_TG%_9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?
MP!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\
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M^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE !_PPI_P<_?\ 2<7]G_\
M\0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_YPE !_P ,*?\ !S]_TG%_
M9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<
M7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\ B$?P!_\ G"4 '_#"G_!S
M]_TG%_9__P#$(_@#_P#.$H /^&%/^#G[_I.+^S__ .(1_ '_ .<)0 ?\,*?\
M'/W_ $G%_9__ /$(_@#_ /.$H /^&%/^#G[_ *3B_L__ /B$?P!_^<)0 ?\
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M%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H
M/^&%/^#G[_I.+^S_ /\ B$?P!_\ G"4 '_#"G_!S]_TG%_9__P#$(_@#_P#.
M$H /^&%/^#G[_I.+^S__ .(1_ '_ .<)0 ?\,*?\'/W_ $G%_9__ /$(_@#_
M /.$H /^&%/^#G[_ *3B_L__ /B$?P!_^<)0 ?\ #"G_  <_?])Q?V?_ /Q"
M/X __.$H /\ AA3_ (.?O^DXO[/_ /XA'\ ?_G"4 '_#"G_!S]_TG%_9_P#_
M !"/X __ #A* #_AA3_@Y^_Z3B_L_P#_ (A'\ ?_ )PE !_PPI_P<_?])Q?V
M?_\ Q"/X _\ SA* #_AA3_@Y^_Z3B_L__P#B$?P!_P#G"4 '_#"G_!S]_P!)
MQ?V?_P#Q"/X _P#SA* #_AA3_@Y^_P"DXO[/_P#XA'\ ?_G"4 '_  PI_P '
M/W_2<7]G_P#\0C^ /_SA* #_ (84_P"#G[_I.+^S_P#^(1_ '_YPE !_PPI_
MP<_?])Q?V?\ _P 0C^ /_P X2@ _X84_X.?O^DXO[/\ _P"(1_ '_P"<)0 ?
M\,*?\'/W_2<7]G__ ,0C^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE
M!_PPI_P<_?\ 2<7]G_\ \0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_Y
MPE !_P ,*?\ !S]_TG%_9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?
MP!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\
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M^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE !_PPI_P<_?\ 2<7]G_\
M\0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_YPE !_P ,*?\ !S]_TG%_
M9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<
M7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\ B$?P!_\ G"4 '_#"G_!S
M]_TG%_9__P#$(_@#_P#.$H /^&%/^#G[_I.+^S__ .(1_ '_ .<)0 ?\,*?\
M'/W_ $G%_9__ /$(_@#_ /.$H /^&%/^#G[_ *3B_L__ /B$?P!_^<)0 ?\
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M%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H
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M\,*?\'/W_2<7]G__ ,0C^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE
M!_PPI_P<_?\ 2<7]G_\ \0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_Y
MPE !_P ,*?\ !S]_TG%_9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?
MP!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\
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M^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE !_PPI_P<_?\ 2<7]G_\
M\0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_YPE !_P ,*?\ !S]_TG%_
M9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<
M7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\ B$?P!_\ G"4 '_#"G_!S
M]_TG%_9__P#$(_@#_P#.$H /^&%/^#G[_I.+^S__ .(1_ '_ .<)0 ?\,*?\
M'/W_ $G%_9__ /$(_@#_ /.$H /^&%/^#G[_ *3B_L__ /B$?P!_^<)0 ?\
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M%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H
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M\,*?\'/W_2<7]G__ ,0C^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE
M!_PPI_P<_?\ 2<7]G_\ \0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_Y
MPE !_P ,*?\ !S]_TG%_9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?
MP!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\
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M^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE !_PPI_P<_?\ 2<7]G_\
M\0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_YPE !_P ,*?\ !S]_TG%_
M9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<
M7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\ B$?P!_\ G"4 '_#"G_!S
M]_TG%_9__P#$(_@#_P#.$H /^&%/^#G[_I.+^S__ .(1_ '_ .<)0 ?\,*?\
M'/W_ $G%_9__ /$(_@#_ /.$H /^&%/^#G[_ *3B_L__ /B$?P!_^<)0 ?\
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M%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H
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M\,*?\'/W_2<7]G__ ,0C^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE
M!_PPI_P<_?\ 2<7]G_\ \0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_Y
MPE !_P ,*?\ !S]_TG%_9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?
MP!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\
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M^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE !_PPI_P<_?\ 2<7]G_\
M\0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_YPE !_P ,*?\ !S]_TG%_
M9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<
M7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\ B$?P!_\ G"4 '_#"G_!S
M]_TG%_9__P#$(_@#_P#.$H /^&%/^#G[_I.+^S__ .(1_ '_ .<)0 ?\,*?\
M'/W_ $G%_9__ /$(_@#_ /.$H /^&%/^#G[_ *3B_L__ /B$?P!_^<)0 ?\
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M%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H
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M\,*?\'/W_2<7]G__ ,0C^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE
M!_PPI_P<_?\ 2<7]G_\ \0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_Y
MPE !_P ,*?\ !S]_TG%_9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?
MP!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\
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M^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE !_PPI_P<_?\ 2<7]G_\
M\0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_YPE !_P ,*?\ !S]_TG%_
M9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<
M7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\ B$?P!_\ G"4 '_#"G_!S
M]_TG%_9__P#$(_@#_P#.$H /^&%/^#G[_I.+^S__ .(1_ '_ .<)0 ?\,*?\
M'/W_ $G%_9__ /$(_@#_ /.$H /^&%/^#G[_ *3B_L__ /B$?P!_^<)0 ?\
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M%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H
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M\,*?\'/W_2<7]G__ ,0C^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE
M!_PPI_P<_?\ 2<7]G_\ \0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_Y
MPE !_P ,*?\ !S]_TG%_9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?
MP!_^<)0 ?\,*?\'/W_2<7]G_ /\ $(_@#_\ .$H /^&%/^#G[_I.+^S_ /\
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M^ /_ ,X2@ _X84_X.?O^DXO[/_\ XA'\ ?\ YPE !_PPI_P<_?\ 2<7]G_\
M\0C^ /\ \X2@ _X84_X.?O\ I.+^S_\ ^(1_ '_YPE !_P ,*?\ !S]_TG%_
M9_\ _$(_@#_\X2@ _P"&%/\ @Y^_Z3B_L_\ _B$?P!_^<)0 ?\,*?\'/W_2<
M7]G_ /\ $(_@#_\ .$H _INTFWO[/2M,M-5U'^V-3M=/LK?4=7^QPZ?_ &I?
MP6T45YJ/V"V9K>Q^W7"R7/V.!FAMO-\F)BB*6 -"@#__UO[^* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 9')'*@DB=)$;.U
MXV#H<$@X920<$$'!X((XP: 'T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__7_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /RW_X*(_M4S^!-
M&_X4-\.KW?X_\96<2>++RP=Y+SPYX9U13'!I%N( 3%KWBB-@NQY//L]"D\X6
MI;6]-O;?>C"[YFM%M?J_U2^6OHU(_K^OZ_,^B?V(?@CXF^!7P-T[0/&6H7,_
MB;Q-JMQXTU;1Y9'DB\+3:MI^F6L7AZ-G8[[JTMM.@FU9XPL*ZO<WMM US!;1
M7MW%62E/35)6OWMU\M6!]?UF 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M5?V<?^"LWP5\4?&G]G71?B9X7L/ ?BZ'P%XX\+?%3P_H^A^(-"\52:'IVO\
MV>VG\/>(O%.AZQIDMAJ4$MKJ5CJQ=URMW96%QOMD /TQH * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M[4-1O[F&SL;"RM(GGNKR\N[AX[>UM;:"-YKBXGDCAAB1Y)'5%9E /Q>^-/\
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M:QJ$\<FJ:M>S1),MO'*((H8X@#^?O_@S^^._P8_9K_X)N_MP_&#X_?%#P/\
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MX5_^6U:_4<;_ - >*_\ ">M_\K)]K2_Y^T__  ./_P L#_A=GP9_Z*Y\,?\
MPO?"O_RVH^HXW_H#Q7_A/6_^5A[6E_S]I_\ @<?_ )8:6D?%/X8^(-1MM'T'
MXC^ ];U:]:1;/2](\7^'M2U&[:*&2XE6VL;/49[F=HX(I9I!%$Q2&*21L(CM
M4SPN*IQ<ZF&Q%.$=YSHU(Q5VDKRE!)7;2U>[2UT&JE-M*-2$F]DI)M^EIO\
M+[CO*YRPH * "@ H * "@ H * "@#\FOVXO^"R/[,'[ 7Q@TKX)_&/P3\=?$
MGBO5_ >C?$.WOOAIX7\!:SH$6BZYK/B/0[2UN+OQ1\3/!VH+JB77AB_EN(8M
M+FM$MIK-H[V65YX;?[#(."LUXBP4\=@L1E]*C#$3PSCBJN(A4]I3A2J-I4L)
MB(\G+5C9\Z=[IQ5DY>5CLXPV K*C6IUY2E3C43I1A*/+*4XI>]4IN]X.ZM)6
ML[ZVC2_8G_X+/_LM?MX_&=_@7\(? _QY\.^+D\(:[XU^W_$?PKX T?P\VE^'
M[G2[:]MEO/#/Q.\7ZC_:$C:M;O;1-I2VSQQ3F6[A=8DGK/>",VX?P*Q^-Q&7
MU:/MZ=#EPM7$SJ\]13<7:K@Z$>5*#N^>^WNO<6"SG"X^M["C3KQGR2G>I""C
M:-KJ\:LW?7M;[C]<J^-/6"@ H _%3]JC_@N_^R#^R)\>_B#^SK\2?A]^T9K?
MC;X;7.A6FNZGX'\'_#;4O"UU+X@\+:'XML_[*OM>^+?AK5IUAT[7[."Z-WHE
MD4OHKJ.$3VZ17,OW.4< 9SG.78;,L+B<LIT,4JCIPQ%;%1K+V=:I1ESQIX&M
M!7E3DURU)7C9OE;<3QL5GN$PE>IAZE+$2G3Y>9PA3<7S0C-6<JL'M)7O%6>F
MNDI>_?L$_P#!5']GG_@HIKOQ'\/?!+PE\8O#-]\,-)\/:SK[_%'P[X,T2VO+
M3Q)>:G8V2Z/)X4\?^-7N)X9M*G-XE[%IZ)'+ 8)+@M*L7G<0\)9EPU3PM3'U
ML%5CBYU84UA*E>;BZ482ES^VPN'234UR\KGUORV][? 9IA\QE4C1A6@Z2C*7
MM8PC=2;2MRU)WM;6Z7E>[/K']I3]IWX(_LC?"[4_C#\?/&UGX'\$:?=V^EP7
M,MM>:EJFNZ]>Q7,VG>'?#FB:9!<ZGK6N7\=I=2PV=G;N(;2UO-2OY;32[&]O
M;?R,KRK'9SBX8++Z#KUY)S:O&$*=.-E*I4J2M&$(\R3;>KDHQYIN,9=>)Q-#
M"4G6KS4()VOJW*3VC&*NY2=MEZNR4F?G;^S[_P %V?\ @G[^T1\3]#^$NA>+
M_'?@'Q3XKU>WT#PA<?%'P8GASP]XFUR^N(K73-)LM=TO6?$%EIMYJUQ*MOIB
M^)&T*.[NS'8I+]ON;*UN/I,QX XCRW"U,94HX?$4:,'4K+"5_:U*5.*O.;IS
MA1E.,$KS]ESN,?>LXQE*/GX?/,!B:L:49U*<Y2Y8>UARQE)Z)*2E))MZ+FW>
MFK:Y?V.KXH]<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * /P.^*G_  <6?L1_"+XG_$?X3^)/AI^U'?>(OAAX\\7_
M  \U^]T/P/\ "JYT6\UKP5X@U'PWJMUH]QJ'QJTN_GTNXOM,GET^:]TW3[N6
MT>*2XLK69G@3]#P?AKGN-PF%QE+%Y3&EB\/1Q-.-2OC%45.O3C5@IJ.7SBIJ
M,TI*,YI.Z4I+4\*KQ#@J-6I1E2Q3E2J3IR<84G%RA)Q;3=:+:;3LW&+MNE>Q
M^A7["'_!0/X,?\%#/ /C/XB_!7P[\2_#6B^!?%\?@K6+3XG:+X8T359]4ET7
M3]<2YT^'PMXP\9V<VGFTU&*+S;B_M;D7,<R&T$0BFG^;X@X=QW#>)H8;'5<+
M5J8BC[>#PDZLX*'/*G:3JT,/)2O%NRBU:WO/51[\#F%',*<ZE&-6"ISY)*K&
M,7>RE=<LYJUGW3]3[GKP#N"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#G/%W
MBWP[X#\,:[XR\6ZI;Z+X;\-Z;<ZMK&IW6\QVMG:H7<K%$LD]S<2MM@L[*UBF
MO+Z[EAL[2">ZGAB9I-M):M[ ?@_X6TOQC_P4=_:>O?$6O&\T?X0^"6MGN+-
M^S0O!D=W,VD^'+9@6MSXK\9SP7,^I7TLK>5_Q-;VVBFL-%T_2$ZFU1@K:R_-
M]WMIY?+7</Z_K^OR/WSTC2=,T'2M-T/1;"UTO1]'L+32]*TVRA2WL]/TZP@C
MM;.SM8(PJ0V]M;Q1PPQH J1HJC@5RMMMMZMN[?=_C^?W@:%( H * "@ H *
M(+B%IHBL<K0RK\\,HWD)* =C21JZ>=$"?WD#L$D7*DJ=KJ 4;?4T-T=/NU^S
M7WE^9&C']W<H.)&M9<*)A&2,_*CE&5S%$YF@MW;K_6G_  ->OYJ)?6W]?U]W
MXIRU:0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5^&K^_GM?$GBWQ[+XJLO%7B2&_U5-"LK"XBLE /C[_@ZV_;N^+>B^*OV;_\
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MNL>"O%.F_%/Q3XUET_5=?T?3KVW\.:YX:U#PY]E\32:;)K?V[2'O+>@#IO\
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M_P#POT"[(B:>VT'XK>(_BEXJ\5PH2#+$EU?_  <\'LQ!1)C:X^<Q'8 ?Z(-
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M598M*EU3P?X$U)O%7C2&SU'6?#_A[3(/#^@#1M0\;_\ "0:: ?TJ_P#!7_\
MX-;O^">WAK]A+XV?&7]A_P"&'B+X%?'/]GCX:>)?BW90P_%'XE>/?#GQ3\/?
M#K1;OQ)XP\+>*-,^*/BSQC]CUC4O#&GZO<>&]4\+7/AQU\3P:7;Z@EWI,]S;
MJ 7?^#+C]J[QS\6?V-_VD/V7_&&M2:WI'[*GQ,\%ZQ\-_MDTLU]X?\#_ !XL
MO&FK2^%8"\A4:'8^-/ 'B_7M,C">9!=^)]6A,K6B65O:@'U_^VG_ ,&U7PI_
MX*+?\%.?B+^VQ^U9\8=?/P/U?P/\+_#/A?X%_# 2Z!XLU_5/!GA"UT#4[OQO
M\0=1M;I-"T#[;:M-:Z+X1TRXUC5H;D32>*/#<EJ]KJ !\^?\%+O^#7;_ ()4
M^'OV&?C=XK_9O^'&H?LY?'+X4?#/Q=X_\ ?$6]^-?Q/\2:7XO\1>#?#^I^(K
M;P5X\TKXH^-?%GAR72O&;V,FD&^\.Z7HFN:1>W5E?:;<RV%C/H>I 'SK_P &
M37[3WCGQQ\ OVP_V4O%.OW&J>$O@)XS^%_Q)^%>F7K/-+H.G_&N+XB6_CW1]
M+F=F-OH4?B/X?:9XACTQ!'!!KGBS7M1C#3ZM>%0#^XF@ H * "@ H * "@ H
M __2_OXH * "@ H _CR_X.G?^1K_ &*_^Q>^/'_IR^$U?M/A-_ SS_K[@/\
MTC%GR/$_QX/_  U_SI'\FE?KY\J% 'ZB?\$6O^4GW[)/_8Y>*_\ U6/CBOD^
M.?\ DE,X_P"O-#_U+PYZ>3?\C/"?XY?^FZA_I*5_,9^BA0 4 % !0 4 % !0
M 4 % '\'O_!R[_RD#\$_]FO_  [_ /5A?%VOZ \+O^2=Q'_8VQ/_ *BX(^'X
MD_W^G_V"T_\ T[6.;_X-OO\ E(M)_P!D#^)W_IS\&UKXG?\ )-+_ +&.%_\
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MS".(G5C3A[.<(P5-26DHMN_-*5WHM5;\;1_:&OASV0H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P L?]M[_D]']KS_ +.@
M^/W_ *M?Q97]99!_R(LE_P"Q3EW_ *AT3\QQW^^XS_L*Q'_IV9_61_P:]_\
M)KO[1O\ V7RR_P#5>>&:_(/%;_D;99_V+G_ZDU3ZGAG_ ';$_P#7]?\ IM']
M.%?EA]*% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M7ZG95(!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_(?_ ."F7_8'_9"_]+?VEZ / _\ @X__ .5DC]A+_L!_L,?^M+>-: /[5?\
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MLYA1W!#LIB .2_X,<_\ DJ'_  45_P"Q"_9N_P#4A^,= '^AS0 4 % !0 4
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MQDXT:D'AZLG:"E)2ISETBJGN6D^BE!)OW8WDUS?O#7Y^>X% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MW!R&@N(SAAM+/A)!B6/#R *WEF5Y$<K+5G;^OS?Y_=</Z_K?^NVQTM( H *
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M$-WH_CW0[[PMJ4'A3X<^!/ OPWG7Q5]CU2<Z)<S^)?$5FE^;=KG0-0B1K:<
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M_'GXA1_^(U^W78^[_AI+PP^W:<[/^&-])DWXQG;Y?[S=TV?-G;S0!_I&T %
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M (+_ '[9G_!<3X>>,?V O^"9W['OC3X7^'_B9X6U2+]HOXN^)_%3^(]6\/\
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MBO*,XW_[B6V2/Y^?^"X'_*4O]K#_ +#?PT_]4G\-:_1> _\ DDLH_P &+_\
M4_%'@YW_ ,C3%>M+_P!,4C]4O^#6K_DJ7[7O_8@?"K_U(O%]?)>+/^ZY+_V$
M8S_TW0/3X8_BXO\ Z]TO_2IGV_\ \'/7_)EWP/\ ^SH-"_\ 54?%>O!\*O\
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M;LDU&<X>IEV6U\SG+][[.E248RJ3O.VCY*<(\RO9*]KQC&.[UCS4_P#@IO\
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M^?/],W_@EC^TMK/[67["/P!^,'BN^;4?'<WAN]\%_$"^FD62\U'QA\/-8O\
MP9J>NZ@45(UOO%<.CVGBZXCB5(XVU[9''&JB-/Y;XLRN&3\09A@J,>7#JK&O
MAHK:-#$PC7C3C>S<:+FZ*;_Y]]=S])RS$RQ>!H5IN]1Q<*G=SIR<')]G/E4[
M?WM#]!J^<.\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M7_S&/P;_ /G=5^>_\1Q\4?\ HJ/_ #"</?\ SI/T7_B!/A5_T2W_ )G.(_\
MY[!_P]._;P_Z+K_YC'X-_P#SNJ/^(X^*/_14?^83A[_YTA_Q GPJ_P"B6_\
M,YQ'_P#/8/\ AZ=^WA_T77_S&/P;_P#G=4?\1Q\4?^BH_P#,)P]_\Z0_X@3X
M5?\ 1+?^9SB/_P">P?\ #T[]O#_HNO\ YC'X-_\ SNJ/^(X^*/\ T5'_ )A.
M'O\ YTA_Q GPJ_Z);_S.<1__ #V#_AZ=^WA_T77_ ,QC\&__ )W5'_$<?%'_
M **C_P PG#W_ ,Z0_P"($^%7_1+?^9SB/_Y[!_P]._;P_P"BZ_\ F,?@W_\
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M!/A5_P!$M_YG.(__ )[!_P /3OV\/^BZ_P#F,?@W_P#.ZH_XCCXH_P#14?\
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MW_\ .ZH_XCCXH_\ 14?^83A[_P"=(?\ $"?"K_HEO_,YQ'_\]@_X>G?MX?\
M1=?_ #&/P;_^=U1_Q''Q1_Z*C_S"</?_ #I#_B!/A5_T2W_F<XC_ /GL'_#T
M[]O#_HNO_F,?@W_\[JC_ (CCXH_]%1_YA.'O_G2'_$"?"K_HEO\ S.<1_P#S
MV#_AZ=^WA_T77_S&/P;_ /G=4?\ $<?%'_HJ/_,)P]_\Z0_X@3X5?]$M_P"9
MSB/_ .>P?\/3OV\/^BZ_^8Q^#?\ \[JC_B./BC_T5'_F$X>_^=(?\0)\*O\
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M]._;P_Z+K_YC'X-__.ZH_P"(X^*/_14?^83A[_YTA_Q GPJ_Z);_ ,SG$?\
M\]@_X>G?MX?]%U_\QC\&_P#YW5'_ !''Q1_Z*C_S"</?_.D/^($^%7_1+?\
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M\Z0_X@3X5?\ 1+?^9SB/_P">P?\ #T[]O#_HNO\ YC'X-_\ SNJ/^(X^*/\
MT5'_ )A.'O\ YTA_Q GPJ_Z);_S.<1__ #V#_AZ=^WA_T77_ ,QC\&__ )W5
M'_$<?%'_ **C_P PG#W_ ,Z0_P"($^%7_1+?^9SB/_Y[!_P]._;P_P"BZ_\
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M_P#14?\ F$X>_P#G2'_$"?"K_HEO_,YQ'_\ /8/^'IW[>'_1=?\ S&/P;_\
MG=4?\1Q\4?\ HJ/_ #"</?\ SI#_ (@3X5?]$M_YG.(__GL'_#T[]O#_ *+K
M_P"8Q^#?_P [JC_B./BC_P!%1_YA.'O_ )TA_P 0)\*O^B6_\SG$?_SV#_AZ
M=^WA_P!%U_\ ,8_!O_YW5'_$<?%'_HJ/_,)P]_\ .D/^($^%7_1+?^9SB/\
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M /GL'_#T[]O#_HNO_F,?@W_\[JC_ (CCXH_]%1_YA.'O_G2'_$"?"K_HEO\
MS.<1_P#SV#_AZ=^WA_T77_S&/P;_ /G=4?\ $<?%'_HJ/_,)P]_\Z0_X@3X5
M?]$M_P"9SB/_ .>P?\/3OV\/^BZ_^8Q^#?\ \[JC_B./BC_T5'_F$X>_^=(?
M\0)\*O\ HEO_ #.<1_\ SV#_ (>G?MX?]%U_\QC\&_\ YW5'_$<?%'_HJ/\
MS"</?_.D/^($^%7_ $2W_F<XC_\ GL'_  ]._;P_Z+K_ .8Q^#?_ ,[JC_B.
M/BC_ -%1_P"83A[_ .=(?\0)\*O^B6_\SG$?_P ]@_X>G?MX?]%U_P#,8_!O
M_P"=U1_Q''Q1_P"BH_\ ,)P]_P#.D/\ B!/A5_T2W_F<XC_^>P?\/3OV\/\
MHNO_ )C'X-__ #NJ/^(X^*/_ $5'_F$X>_\ G2'_ ! GPJ_Z);_S.<1__/8/
M^'IW[>'_ $77_P QC\&__G=4?\1Q\4?^BH_\PG#W_P Z0_X@3X5?]$M_YG.(
M_P#Y[!_P]._;P_Z+K_YC'X-__.ZH_P"(X^*/_14?^83A[_YTA_Q GPJ_Z);_
M ,SG$?\ \]@_X>G?MX?]%U_\QC\&_P#YW5'_ !''Q1_Z*C_S"</?_.D/^($^
M%7_1+?\ F<XC_P#GL'_#T[]O#_HNO_F,?@W_ /.ZH_XCCXH_]%1_YA.'O_G2
M'_$"?"K_ *);_P SG$?_ ,]@_P"'IW[>'_1=?_,8_!O_ .=U1_Q''Q1_Z*C_
M ,PG#W_SI#_B!/A5_P!$M_YG.(__ )[!_P /3OV\/^BZ_P#F,?@W_P#.ZH_X
MCCXH_P#14?\ F$X>_P#G2'_$"?"K_HEO_,YQ'_\ /8/^'IW[>'_1=?\ S&/P
M;_\ G=4?\1Q\4?\ HJ/_ #"</?\ SI#_ (@3X5?]$M_YG.(__GL?TD_L"_%/
MQY\:_P!DOX3_ !-^)NN_\)+XX\3?\)W_ &WK?]F:-HWVW^QOB7XQ\/Z;_P 2
MWP_IVDZ1;?9M(TG3[3_1-/M_.\CSY_-N99YY?[&\*L\S3B3@+(<ZSK%?7<SQ
MO]J?6<3[##X;VOU?.<QPE']SA*5##PY,/AZ5/]W2AS<G//FG*4I?QAXL9#E7
M#/B!G^29)A?J65X+^ROJN&]OB<3[+ZSDN6XNM^^Q=6OB)\^(Q%:I^\JSY>;D
MARP4(Q^PZ_0C\Z"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M/A[X#\&>!--V+'_9_@WPOH?A>RV)C:GV31+&Q@V*1\J[,#C &* .SH * "@
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M0AN+.ZB#HK^7/"Z;U5L JIH X;P5\$?@Q\-;B6[^'/PB^&'@"[G>26:Y\%>
M?"GA6XFDESYLDLVAZ382R/)D^8[,6?)W%LG< >GT % !0 4 % !0!Y_XX^$W
MPL^)T4,/Q*^&GP_^(4-O$T$$7CCP;X<\6100NQ=X88]>TZ_6.)G)=HT"H6)8
MJ230!/X.^&'PU^'<'V;X?_#SP-X%MO+\K[/X.\):#X8@\KC]WY6BV%E'Y? ^
M3:%X''0* =S0 4 % !0 4 % !0 4 % ',>+/!7@WQ[I,F@^.O"/ACQIH4Q)F
MT7Q9H.E>(])E)4J3)IVL6E[9R$J2I+P-\I(Z$B@"#P7\/_ ?PWT@>'_AYX)\
M(^ M!$IN!HG@OPWHWA;2!.8TB,PTW0[*QL_-,44<9D\G>8XT0DJ@"@'74 %
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M\D[B/^QMB?\ U%P1Q\2?[_3_ .P6G_Z=K',_\&X&BZ3JG_!1C[=J(A-YX;^
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M7RWBMR_V5EB^U_:$[?X5AJG-^+CU^\]+AF_UG$]O8+[_ &BM^3/SE_X+@?\
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M+_%C_?,F_P"P;%_^G:1]'PQ_"Q?_ %\I?^DS/Z*_VJ/^38?VCO\ L@WQ?_\
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M?[$W_8$^/_\ Z7_!ZM_"7^'GO^/+?_2<<1Q1O@O3$?\ N _%;_@CWIMGJO\
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M_9*#Z_64OOI5+_DC^0O]D'_D[/\ 9>_[.)^"?_JRO#-?LF=?\B;-O^Q9C_\
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MCW_%*/W?#M_[.]:]6WI:'ZW_ *9^]M?GI[H4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\>?_  5-_P"3
M\/CK_P!TQ_\ 5-_#RO\ /?QQ_P"3H\4?]T7_ -9W*#_13P)_Y-5PM_W7/_6C
MS@_/NOR<_7 H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /[#/^"67_)A_P "
MO^ZG?^KD^(=?Z$>!W_)KN%_^ZU_ZT6;G^=?CM_R=7BG_ +H?_K.9.?H)7ZP?
MD84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MN'FPL6TQJI*TGVW7_#:V_K;8I'IU2 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?YQO_!<W_E*C^U;_ -A#X2_^J%^%E?TQP#_R264?X<9_ZL<6?GN>?\C3%?\
M<#_U'HGZA?\ !K9_R5G]KG_LG?PP_P#4E\45\IXL?[GDW_83B_\ TU2/2X8_
MBXO_ *]TO_2IGPA_P7R_97\0? ']O'QO\28M*FC^&W[2@C^*/A'6(H)?L/\
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MW_TA^,E?D'BU_%R+_KWF/_I6"/JN&/@QG^*A^54XO_@Z?_Y&/]B;_L"?'_\
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MEK'Z3EF&>$P.'HR5IJ'/4753J-SE%^<;\G3X?G+[ZKYX[PH * "@ H * "@
MH * /C_]NW]N'X$?\$[OV9_'_P"U+^T1KEQI?@7P3;PVFG:/I4*7GBGQYXSU
M59H_"_P_\&Z<\D,=_P")O$UY"\-J+B>UTW3+*#4->UV_TW0-)U74K( _SB_'
MW_!;O_@OQ_P65^-&I_"[]A/3OBA\,?#]G<R:C8?"S]C?3[_PYJ'A3P]>7DMA
MHVL_%K]H&[GMM?TO*R)87GB#5O&7P\\ 7VK?OK'PWI=R;>"  ;XK_P""3_\
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M%M?\/>-8?#/@N;4(=3CTK6K>_P!,O?"VFW6CW6G!1-J-M=V]VP!^U- !0 4
M% !0 4 % !0 4 ?G1_P5G_;5\6?\$[?^"?'[0_[9'@;P7X=^(7BKX,V?PYN-
M(\'^*[W4M/\ #^L2>./B_P##[X:W(U&[TAX]1B2PLO&5SJ< MG1I;JR@AD=8
M9)&H ^8O^"#'_!4SXC?\%<OV0/B+^TA\3OA?X*^$WB#P3^TAXP^"%MX=\!ZE
MKNJ:-?:3X;^&7P@\>6^MSS>(9KB]BU&XNOB5?:?-!'*;9;?3+66,+)-.* /V
MTH * "@ H _(G]JC_@N#_P $_?V//VL?"G[$OQ=\=>/+G]HCQ@_PYMM,\&>
M/ACXI\>K!JWQ6U5=*\#Z!J%[H%O.EMX@U@W&FZA%HZ1SW@TO6M&O!$XU&%*
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /[#/\ @EE_R8?\"O\ NIW_ *N3XAU_H1X'?\FNX7_[K7_K
M19N?YU^.W_)U>*?^Z'_ZSF3GZ"5^L'Y&% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M)XM+LP@L=&L]D8M["%)9D?4;F_NKKGG-S=WMLEV7ZOS=_DDD!] U !0 4 %
M!0 4 % !0 4 % !0 4 % &5KNF+K.BZMI+,(QJ6G7ED)"N\1/<0211R[,J'\
MIV63:2 VW!X)IIV:?8#XK_9=\2_V=XS\6>";F79]LM6N;9)_,2=K[0[J6":%
M(=SQQ2/:74\TZD[L6:@2.$ K2HO=3\_P>W_#K[W>T96[W;ZNVB\EUT\_7JS[
MIK(H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MIXFC4H55>%2-GW7527:49)2B^Z78_BM^//\ P;;?MK^!O%6IQ_ W7?AM\<O
MDEU,^@7\WB:U^'OC2.QSF&+Q)H'BDV^@6U\H/E>9HOBS6+:YV?:66P,OV.+]
MQR_Q.R+$48O'T\5@,0DO:15)XJ@Y=72J4OWCCUM4HP:V7-;F/C:_#F-A-^PE
M3K4[^Z^?DG;^]&7+&_\ AD^^EW$]"_96_P"#:S]I#Q;XRTG4OVL?%_A#X2_#
M.QN[>?7/#W@?Q#;>,_B9X@MD_>2Z7I5U965SX,\.I<@"VDUV[U77)[$L98/#
MNH!0S<V;^*&64:$XY/1K8S%234*F(INAA:3Z3G%S5:K;?V<8TE+K5A=\VF%X
M<Q$IIXJ<*5-/6,)<]27DG9PC?O=M=GN=_P#M*_\ !MO^TIXV^.WQ,\4_L_\
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M '^6%_P9[_\ *8.R_P"S8_C=_P"E/@J@#_24_P""C'_*/?\ ;N_[,U_:?_\
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MQ5KO[01L=0_T_3](^(_C:ZU'PA^S-\.4G926A^&7A#1]0UWP[=I,9K6?X1:
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M?7_#5O<GSYO"&N>'K\[DO4=@#]%* "@ H * "@ H * "@ H * "@ H * "@
MH * "@#^//\ X*F_\GX?'7_NF/\ ZIOX>5_GOXX_\G1XH_[HO_K.Y0?Z*>!/
M_)JN%O\ NN?^M'G!^?=?DY^N!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#RWXV^-]0^&_PF\?>.-)@@N=4\.^';R]TV.Z!:V%^^RVLY;A%P98;>XN([
MB6 ,AG2(P^9%OWK\/XE\1XWA#P_XRXGRV%&IF.1\.YIF& CB(N>'6,H86I+"
MSKTXRA*K1IU^2I4I*<'5A%TU4AS<\/J."<FPW$7%W#>1XV56&#S7.LOP6+E0
MDHUOJU;$4XUXTIR4HTZLJ7-"%1QFJ<I*;A/EY)?B>G[>/[3H;S3XTTV2)'3?
M&W@[PKY9R21&[IHZ. X5A\KAR,E64C*_Y;P^ECXZQDIOBK"5(1E%RA/AKASV
M<MVJ<Y4\LIU$I)->Y4A-I-Q=TW'^\I?1Y\*6G'^P\7"4HNSCGF;N<>CE%2Q;
MBW%M:RC.-VKQ:?*?KU^S_P#%+3OVC?@O;:]X@TK2IY]135?"7CG0/(-UHLU]
M' L6HV1M;W[1YNGZII-_9W4EG<^<J0Z@UF\ERD9GE_TD\#O$R7BMX>Y7Q5B*
M.&PN<4\1B\IS_"8+VBPN'S? 3ASO#QJU*M6G1QF#K8+,J-"I5JSP]+&PP\ZU
M>5)UI_Q1XI<#_P#$/^,<?D%*I7KY<Z5#'Y3B,3R.O7R[%Q?)[9TXTX3J8;$4
M\3@JE6%.E&M4PLJJI4E-0CRGP/\ V,/@O\ ?&WB/Q[X,M-8N]:UF.XM-)'B"
M]M]2M_!VE7<TD]YIWAP_8X;F/[2&CLI-1U&YO]3_ +*M8+%;L?:-8N-5_8)U
M935G9);VTYO-]MK]%?9*R1^>'YW_ !3_ &_/C+>^.?$8^&NMZ9H/@JQU&\LM
M!B_X1O2M1N;[3+2ZDM[75[^;6K"[N8;G4HQ'<26R>3#:>;';"-Y(WFG_ ,J.
M//I>>)F-XJSJ7!.;8')^%</CL1ALEIPR7+<=7Q>7T*TJ.&S/&5\UPF*K0KYA
M%1Q3H0C0I86->GA.2=2E/$5_[YX4^CGP1A\@RQ<48'&9AG]?"T:^92>9XK"4
ML/C*U*-2M@<-2P->G2E2P<G*BJLI5JE=TYU^:$)QI4OM3]AOX^_$/XWZ-\08
MOB'>V.J7WA34/#QL-3M=-L]+FEM]=@UCS;2XMM.@M;)DM7T=9()5MUG8W4RS
M2.JP*G]/?14\7N,O%++^,Z'&6*PN8XKA[%9)4P>84,#AL!6J4,YIYHIX:O1P
M-.AA)1PT\I4Z-2%"%5_6*L:TJBC3<?POQ^\.>&N <9PU4X:HXC"8?.,/FD<3
MA*V*K8NG"KEM3 N-:E5Q,JE=.M#'\E2$JDJ:]C!TXQ<I\WW?7]:G\]%!M5TM
M)C;OJ5@DZOY;0->6ZS"3./+,9EWA\\;2F<\8ZUSO%X6,G"6)P\9J7*X.M34E
M*]N5Q<[J5]+6O?2W0U5"NTI*C5<6KJ2IS::[II6MY^]^A?KH,@H R-6\0:#H
M$2SZ[K>D:+"^X)-JVI66FQ/M4NVV2\G@1MJJS-@G"J2>%)7@Q^;97E5-5LTS
M+ 9;2=VJF/QF'P=-I6NU/$5*<=+ZZOI>UUS=>$P&.Q\_9X'!8O&U%O#"8>MB
M)K_MVE";[]/U+&G:KI>L6PO-(U*PU2T9F5;K3KRWOK9F4E643VTDL196!# -
MD$$$#&*UP>.P6848XG 8S"X[#RTCB,'B*.)HR?\ =JT9SIOY2?YF>(PV)PE5
MT,7AZ^%K1^*CB*52C5COO3J1C-:IK5='M9HMR30P@&:6.(,<*9)$0$CJ!N*Y
M(]C]<9&[HG4A35YSC!-V3G*,4WVO+=^GZ&48REI&,I/M%-_/12_+[]>6);RT
M9@JW5LS$X"K/$6)]  Y)/X?G4+$4&TE6I-O1)5(-M^26_P#7<ITJJ5W3J)=6
MXRLO_)%^?WEFM3,* ,S5-:T;0X!=:WJVF:/;,Q5;C5+^UT^!F R5$UW+#&6
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MVO)I*^NFKCKH^O?:RYOY.C&4G:,92>]HIMVTUT4NZZ=M[OEK?VGIO_00L?\
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M'T<CI(JO&ZNC#<KHP96!Z%64D$'U!P?:OH4TU=.Z>S6J/83OJM5Y#J "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * /_]#^_B@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@#X0_X*2_\$_O@]_P4S_9(^(W[*7QD#:;8^*(X->\!>/+.PAU+7/A
M7\4="AN_^$.^(N@VLUQ9_:;G1YKV\T_6-+6_TX>(_">K^(O"T^H6=KK<]Q$
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MJ7P^N8I/%VC^%-)DT0Z':_#7Q?%*EB?"XN$U :I&UQ]M\DV47V;SIP#]3?\
MB.0\>_\ 2-_PA_XE%K7_ ,XN@#/U?_@^!\>ZKI.IZ7_P[D\(0?VEI][8>?\
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M4 _T-Z /Y)?^#O\ _;N_X9T_X)^>'?V4?"&L_8_B3^VIXM;0-9BM)_+O]/\
M@9\-+G2/$WQ"NM\+>=;#Q+XEN? ?@LPS*EOK7A[6/&-JLD@LKF!@#ZZ_X-MO
MV I_V,_^"3'PZAUO3SH'QG_:STZ^_:)^(=W<0/#J>D)\1M!M;3X4Z#<.1%J%
MJOAOX9VWA74+S2)O)DTCQ9K?BQ%AAN)[AYP#^#;_ (+/_P#!&/\ ;+_X)?\
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MPCISS&W\#?&+PFR:1\0_#%NES/<7D>DKK$9UKPJ]],][>^#=9\.:E<DRWKT
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M>+M2T_Q FHVOBKQ, ?GAJVH?\%(/^#7#_@HKX-\$ZE\4+SQ'\/KN/PQX\O\
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MEC? MID'A/X71HH!>?=<>8(_LR>: ?WL4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % '\>?_  5-_P"3\/CK_P!TQ_\ 5-_#RO\ /?QQ_P"3H\4?]T7_
M -9W*#_13P)_Y-5PM_W7/_6CS@_/NOR<_7 H * "@ H * "@ H * "@ H *
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MKN%_^ZU_ZT6;G^=?CM_R=7BG_NA_^LYDY^@E?K!^1A0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_%>\B;;_ &MX2\":%()U9&8ZSIFM^(VDM@,I+$%\/1VUPS$M'<7T2!5WE_\
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MPO3EB(TWAZ6)KTI5:=?$4ZM6%:NI>VG]MU^GGY>% !0 4 % !0 4 % !0 4
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M4YP:E"<6XRBU*+:=S[Y-22E%J49).,D[IIZIIJZ::U33U\R>M!A0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!__T?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^(/PBU^T\96WAVTC)5))KCX?7WQ)UXDEG">'#'&I\YJ /]/&@ H * /Y-_\
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MNY%1;;3=)TNSO=7UG4I[72M(L;W4KRUM90#^(?\ :#_X/./$?BOXB:C\,?\
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MM)_:P^.NEZ= /]BUL+2VMH^F(XE';+ 'SQ_P5L_X.@_V5O\ @FK\4M>_9O\
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M3, "SG2[#3K3YMQ$=E& VTA5 /\ 3%^%/P\\/?"+X7_#?X4>$;*UTWPK\,O
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MA7]JCX0:1X=PO'_'SIFL:E+!QPD4@P,G: ?Z/E !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MU:2PTXW<MCJ5LUG#<:?<(O\ <'AOXBY5XCY+/,\#1E@<;@ZL<-FN55:T:]7
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M*W[NI>_\UZ=K+7EE>^A^X7[%/[<_B+X!:O8>!/B!?7VO?!C4KO9)#*);[4O
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MI&BS1J,M)%JFH>*;>QD11RS).P Y)'"T ?GKI_\ P7X_X)F^,OVP_@U^P_\
M!7XU3?M%?&3XS>+[GP98:Q\#=+MO&7PF\)7T&AZOKJ7WB/XJW&IZ/X/UG3+F
M'1Y[6.3X:ZA\0+J&ZFMQ>6MK SW" 'YK?\'EO_*)7P9_V>5\'?\ U77QKH T
M/^#-_P#Y1&ZY_P!G=?&;_P!0_P"$U ']7% '/>+O^14\3_\ 8O:U_P"FVYH
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M^#CWQKXP^*GAO5Q\)_!7[0GQ.&KI;V][+<ZU^RW^T=#KS>'?&^AI#$3X@O\
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M-QI>I06-W-"D%W-IU]%;R.]G<*@!_F4?\$Z?^5R[X@_]GV?\%1__ %5O[7-
M'^D_\9?^20?%;_LFWCG_ -1C5* /\[#_ (,CO^3S/VRO^S8_#W_JU?#U '[_
M '_!X1K'C73/^"/M[9^%?/\ [#\0?M.?!+1_B289I8D'@J*U\;:[9?:DC^6X
M@/Q#T7P$HAGS$+AH)Q^^AA*@'D?_  9Q#]DS_AW9XC/PT/@1OVK1\5_'7_#2
M@5=/'Q332FU2V_X5>+LW)/B _#5O!RZ.=!:S \)'Q:/%ZP9\1IKU 'G?_!WE
M_P %-/@9X*_8UUO_ ()T>"/'&A^,OV@?CIXO^']_\4/"7AK6K34+GX3?#/X>
M>*M#^)MO<^/!8FY.C>(/%OBGP]X1M?#OA6_:TU.]T(ZQXAN$@T^WTU=9 .\_
MX,J?^46?Q]_[/^^*7_K.W[*U 'X*_P#!ZW_RDT_9T_[,3\!?^M ?M(4 ?Z=%
M '\EG_!YK_RB;^'O_9ZOP@_]59\>* /K_P#X-8/^4&G[''_86_:3_P#6IOC1
M0!_)7_P4[_Y7&O@]_P!GV?\ !*+_ -1_]DV@#^OW_@YW_P"4&7[=?_8,^ '_
M *U5\#* /SM_X,J?^467Q\_[/_\ BG_ZSK^RK0!^"G_!ZW_RDT_9T_[,3\!?
M^M ?M(4 ?Z=% '\#'_!\O_R!/^"9?_85_; _])/V9* /ZYO^"3?_ "BQ_P""
M:G_9@7['/_K/'PZH _!K_@]$_P"44OPC_P"SZ/A-_P"J3_:/H ^Y?^#6_P#Y
M05?L/?[_ .TQ_P"M?_'^@#^'#_@@SJ_P"\1?\%[K[7O^"@1\%CQ-KGC3]HC5
M?#*_%>6TNO")_:SU/Q5=W6DQ:Y<^(C_8LNM?:)_&X\'S>("?.\?KX8&EY\5/
MH= '^G5^V-^V;^SM^P=\"O&'[0G[2OQ$T+P!X%\*Z;?3V-M?ZA9Q>(_'&OV]
MC<7>G>!_ &A33Q7OBOQGKSVYMM*T33$DE^:2^OGL]*L[Z_M #_,3_P"" GQG
MU;]H[_@Y>^"7[0NO67]FZW\=OC/^W/\ &+5M-^U&^&FZC\3/V<_VG/&=YIZW
MAAMS=)8W&M26J3_9[<2I"KB"$-Y:@']T_P#P<[_\H,OVZ_\ L&? #_UJKX&4
M ?S#?\&>O_!47X%?L^W'QJ_8#^/OCC0_A@_QG^(VE_%_X$>+/%VLVVC>$O$7
MQ&O_  _H/@'Q;\-[G4[\V^GZ1XJ\0Z5X:\&7W@P7MY!;>)+C3-6T"&9->;P]
MINN ']^/[17[2_P'_9,^$GBOXZ?M%?%#PI\*/A;X,TN?5=:\4>)]02WBD2)1
MY.G:)I\(FU7Q+K^ISR066B>'/#]CJ6N:WJ-S:Z=I6GWEY=0PL ?Y@_['EUXY
M_P""ZO\ P<H:-^T;9>%[^'X<G]HOP[^TEXGCN+%C;>#/V<OV86\+6?PRT?Q<
M;0RP6VH^*-$\"_#3X;ZG/ ZQ7OC+Q?)<QE(II9T /[_O^"X_[=B_\$\?^":/
M[1GQWT?5UTKXHZYX=_X4]\"V280W[?&#XI0W?A_P[JVEY9%FO/ NE?V_\39+
M=F'GZ?X(OHP&9@C@'\_/_!F#^PFW@#]GOXY?\%!?&ND,GBG]H37YO@W\(+Z]
MA/VJ+X2?#?5_M/CW7-.NB,RV/CCXJ0)H5_&[LRWGPA@E78LS>> ?VYT ?Q)_
M\'NNAZC<?LA_L5^)(H"VDZ3^TAXPT.^N><1:CXA^&-_?Z7 >,9N+;PQK$@R0
M?]&. >2H!^UG_!O;\</ACX^_X(O?L8>(-$\9^&FT[X5?"&?X=_$B:;6;&V3P
M+XD^&VKZSI/B"Q\6M<S0CP]+%96EMX@3^U1:I+X>U33-;A>72M0LKR< _GD_
MX/:?V5?%.N>&_P!CC]M3PSI=SJGA+P>WC7X ?$[4[2.6YBT$^*+G3_&_PHO[
MCR$D2WTO4[RS^(VF76IW+06D>J3^&]-662[UBUB8 _<K_@WJ_P""LGP#_;T_
M8A^!'PEE\?\ AC1?VL?@#\*O"?PK^*_P?U76H;3QCK%M\-=(L?!VD?%3PSIV
MHM;W?BGPUXTT73='UW6K_0HKVW\*^)M6OO#>JO T6FW&H '[&?M)_M9?LU_L
M>_#O5OBO^TY\:_A]\%O >CVSW$^L>-]?MM/N=0=0YCT_PYH,?VCQ#XLUNZ,;
MQZ?X?\+Z5J^MZC,K0V&G7,P*4 :7[-'[17PQ_:V^ _PQ_:0^#&HZGJWPM^+W
MAJ+Q9X)U+6='O- U2]T6>ZNK.*>\T;4%6]TZ5YK.;_1[E5E5-I91NPH!_E">
M,_VQ+7]@/_@Y7_:$_:YU/2]1UOP]\'O^"F7[5MYXRTO1Y$CUB\\ >+OBG\4O
MA_\ $*/2!+MAGU5?!/BO7Y--LIY(+>_O4@LKBZM89WN(@#_6(^!7[1'P._::
M^%'AOXX_ +XI>#?BM\)O%FG?VIHGCCPAK-MJ&CR0(FZ[MM1^9+K0]7TIQ);:
MYH6N6^G:WH-_!<Z?K.G:??VUQ;H ?Y^7_!WK_P %6/A#^TMJWP?_ .">?[-W
MC?0_BAH_P<^)-_\ %+X^>)O",HUK0H?B_IVAZOX%\"?#C0-?LO,LM:U+PGH_
MBWQW<>-XM'GU/3K;7-;T+0I+F/Q%X;US3K  _K7_ ."/W[ MW^S=_P $:?@+
M^QI\7]+N]%\4^//@?XZN?C7I#Q/:ZUHNO_M'77BKQ=XJ\+ZE'(,0Z]X)TOQU
M#X'O0J^4MWX;.UI5 FE /X"/^"-/[5^I?\$$/^"POQ0^$7[9-A/X/\!W4GC'
M]EG]H?6WTK6KP>#+>W\1:9XA\"_&/0]-L;2;5-=\*3:MH6@:K;WME9WQU+X7
M^,]0\1Z):ZI<_P!EV]P ?ZKG@+XF?#KXI^"-$^)?PT\=^$/'_P ._$FE0:[H
M'CGP=XBTGQ'X3UC1KFV2\@U/3M?TFZNM,NK*2UD2<3Q7+QB)MS, /E /\]7_
M (.[_P#@J?\ !S]J"^^"?_!.O]F3Q?H?QB7X6_%6X^*7QO\ $G@6>7Q'I5G\
M7-.T/7?AWX"^%GAS5M+\W3O$>N:/I_C3QK<^,X-&EU6WL-:U'PYX?6ZB\0Z7
MXATNP /[#?\ @B5^Q[XE_83_ ."7G[)/[.?CNP?2_B1H7@*_\;?$S2YM_P!K
MT7Q]\6?%&N_%#Q'X9O\ <%3[?X-NO%J^#;HPC[.9?#Y,,DZ$7$H!_"C_ ,'-
MVM0?![_@X1^$?Q6\7J]GX6T;PO\ L=_%*6Z$<TK2>%?!OC&[@UB[2*&*2:0P
MW/@_6X1'!'+([6Q6-&D(1@#_ $UM'\>^!_$&C>#O$6A>,?"^L:#\0[>RN_ .
MLZ;KVEWNE^-K;4='G\0V$_A.^M[J2W\0QWN@6MSK=JVDR78FTFVN=1CS:02R
MJ ?YMO\ P>+?LY?$#X'_ /!17X"?MN>%[*]M_"/QE^&'A#3K'Q9#%-+;Z1\;
M?@+K=TEQIMU-&OD6,DO@J]^'>K:''/-%/JTEEXE:TB>/1;R50#^Y+_@E_P#\
M%1/V;O\ @J%^SIX+^+OP@\;>%D^)"^&=";XV?!*/6H6\<?!_Q[/8QKK^A:MH
M5X8-;G\,_P!L0ZBGA#QD+$:-XJTB".[LKG[9%J-E9 'K?[9W_!0W]C?_ ()^
M_#V]^(W[5_QV\%_"_3HHI#H_AFYOQK'Q%\8WJP^;'I7@GX=Z,+WQ?XFOIMT8
M=].TJ33].BE6^UF^TS34FOH@#ZJ\$^+]%^(/@SPCX]\-RSS^'?&_AC0/%^@3
M75N]I<S:+XETJTUG2Y;BUD_>6T\EC>P/-;R?/#(6C?YE- '^9]_P9A_\I9OV
MD_\ LQ/XQ?\ K2G[+5 '[_?\'H__ "BH^#O_ &?9\)__ %1W[2= 'W9_P:X_
M\H*/V&?^[F?_ %L/]H*@#^17_@IW_P KC7P>_P"S[/\ @E%_ZC_[)M '^G10
M!_F,_P#!ZY_RDR_9R_[,5\"_^K__ &C* /\ 3D3[B_[J_P J /X'/^#Y;_D
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M'G!^?=?DY^N!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M98NO3E12<,52P;S+,X5;Q<\30YYR<YOF_6']O7_DVWQ3_P!ACPQ_Z>(*_O\
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M.#Q%/3$2>9PO&%*#K^3])[C?!8F.6<"X"O3KU\'C5G&=NE4YEA*]/#5L-E^
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MXO,:U3ZI@%7H\F*QE6O2Y:CQ$+OV<US>ZK2NNAU>+W@QQGQKQOC<_P E65/
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M]I$Q#R6VFC7--M?M@3[/+<SW5K!+)-8WJ0>U]%?)\?0P?%N>5J,Z>79C5RG
M8&K).*Q5?+'F53&RIII<]*@\;0I>VCS0=9UZ*DJE"K$\7Z5&<8"OBN$<BI5H
MU,RRZGFV88VC%J3PN'S-993P2J-7Y*N)6!KU?8RY9JA'#UFI4\12F?O37]:G
M\D!0 4 % !0 4 % !0 4 % !0 4 % !0!^0O_!8__@HY8?\ !/S]GG2!X8U&
MQC^.WQRUUO WPL@NX'N4\-:1!)8#XA_%&ZB,MO;&/P+HFJ6L>AQW4TT<WC37
M?"\EWI6L:!9^(;>+[SP^X77$F=1EB8.659:Z>*Q^R5;WO]GP>MW;$RA+VME_
MNU*LE.%25.1\;QOQ \BR>I'#3Y<RQ\:N&P+UYJ+<+5<6K-6>'4H^SN]:\Z5X
MR@JA_/#=W-S>75Q=WEQ-=7=U/+<7-S<R/-<7$\SF26:>61FDEEED9GDD=F=W
M)9CDG=_I%"$*<(TZ<(TZ<(QA"G"*C"$(+EA"$8I1C",4HQBDE&*LDK6/\M)S
MG5G.K5G.I4J3E4J5)R<YU*DY.4YSG)N4YSDW*4I-N4FVVV[E>J((;J9H+29]
MOR2M%;%VB9U4R2"7:LH^6&5XX)<$\O$LT8!#.5_@3]HYQ'B,H\ \'DF&Q/L?
M];N.<CRS&T(U.66+RW*\+F?$,XR@M:E&CFF5916GIRQJQP[=IRIGZMX/X.-?
MB>OBIPYOJ&68BK3FXW5.MB*M#"JTMH3G0JXF*ZRA[2*33;CIZ?-;+#\^W[N!
MD]_7OQ_^KC&ZO\#<3"KSZ76NO73[X[>=[[^<OZGHR@HNZ]%M;OWU^?GS*YS>
MNO$5?&,$D_I_P'GKW[X'3+>IE\9)J_2VOEOW?3S]+W2.:NXMMKL[_IM9=^GK
M:YXYK94!^.?7KD%CQU/\A^.*^TR]2O#NOENM/N/$KOXM=+_=KKK9=N[MMH>0
M:T0=V/4_T^G^?7K7W&7IKE_K[+_JYY571-==?RU_3I]QUO[.T\<?Q,G@DSF[
M\-:U%$ 2!YL4EE>C([X2TDQUQU]UP\0L-"OP9F=67Q8*MEF)I>52>887!2;Z
M/]QC*T;-;RNK.)VY#*V8QC_/0K+[N6?E?X'Z;Z['W)7\UGVY^U/_  2Y_:?O
M!?2_LW^,KYI[.>"^UCX8WUS(!]@GMP;O6O" R#NM[V-KK7=*W,@M[J#5K<M.
M^I64-K_9GT8/$ZI#$/PWSG$.=&M'$8OA:M6J7E2K04\3CLFCS7;IU::K9AA%
M>*I2I8NDN?VV'A2^ZX2S9J3RNO.\7S3PDI/9KWJE!7Z-7J0VLU.*O>*/V_K^
MW#[X* "@#\]/VXO^"EW[/_\ P3_U'X<Z9\;-#^*.L7'Q/LO$U_X=;X=>'?#F
MNQ6\/A2?1+?4AJK:]XP\+M;22/K]D;-;9+Q952X,K0%$$OU/#G"&9\40Q<\O
MJX*FL'*C&K];JUJ;;KJHX<GLJ-6Z2I2YN9QZ6O[W+\WGW%&7<.RPT<?#%S>*
MC5E3>&ITZB2I."ES\]:DT_WBM92ZWM]KO?V)OVZ?@[^WKX \5?$?X,:3X_TC
M0?!_B]O!6J0_$+1=$T34Y=631M+UPS65OH7B7Q/;RV'V35K:,337=O.;A)D^
MS"-$EEYN(>&\?PSB:&$S"IA:E3$4/K$'A:E2I!0]I.G:3JTJ4E+FIMV2:M;7
M6QT9%Q!@>(</6Q.!AB(4Z%?V$UB:<*<G/V<*EXJ%6JG'EFE=M.]]+),^SJ^?
M/<"@#\4OC5_P7E_8R^ WQ<^(_P %_&?A']H.Z\6?"_QAKG@GQ#=>'_!/@:^T
M.YU;P_>RV%]-I-Y>_$W3+RXL'GA?[/+=:=93NF&DMHR0M?H67^&F?YG@<)F%
M#$97&AC:%/$48U<1B8U%3JQYHJ<8X5Q4DM&E*:OM)Z'PN.\0<CR_&8K UZ68
MNMA*]2A4=.A0E3<Z<G&3A)XJ+<6UHY1BWU2M8]V_8J_X*Q_LP?MW_$CQ%\*_
M@]IGQ3T+Q;X<\'7/CF:'XC>&_#6@VFI:)9:QI&BWRZ3/H?C/Q/)<WUG=:WIT
MLUK/#:YM)9+B*25;>=4\WB'@C..&L)2QN/G@JM"KB(X9/"5:U24*DJ=2I'G5
M6C22C*-*:4DW[RLU[R9Z&1\893Q!BJN$P,<7"M2H/$-8FE3IQE34X4Y<CA7J
MMRBYQ;32T=ULS]#?'7C3P[\-_!'C+XB>+[Y=+\)^ O"OB'QIXHU)QN73O#OA
M;2+S7-:OF7(W+::;8W-P1D9$>,CK7RV&P]7%XG#X6A'GKXFO2P]&'\]6M.-.
MG'K\4Y);=>I])B*]/"T*^)K2Y:.'HU*]66_+3HP=2<K:7M&+>_3H?A:/^#C_
M /8,[^"?VF@>X/P_^'9Q[97XN%3CU!(]"<YK]'_XA-Q+_P!!.3_^%.+_ /F0
M^!_XB;P]_P ^<T7E]6P^GW8MK[G]Y^HG[&'[:'PG_;J^%.J_&'X.:7XXTCPM
MI'C;5? 5U;>/](T?1=:?6M'TG0=9NIH;31/$7B6T;3VM/$5@D$SWT<[3I<H]
MLB)')+\=Q!P_C>&\;3P&/GAJE:IAX8F+PLZE2G[.=2K32<JE.G+GYJ,KKELE
M9J3NU'ZO(\\P>?X2>-P4,1"C"O/#M8B$(3<X0IS;485*BY;5(V?-=N]XJUY?
M6[,JJ68A54%F9B JJ!DDDX  &223@#DXKPCV3\(?%'_!Q'^P7X9\2^(?#8T#
M]H'Q /#^MZKH@U[P[X'\"WGA_6AI5]<6/]K:'=WGQ/T^[NM'U'R/MFFW%U86
M5S-9S0R3VEM*SPI^E4?"OB6M1I5O:Y72]K3A4]E5Q&)56GSQ4O9U%'"RBJD+
M\LU&4DI)I-VN?G]7Q*X=I5:E/DS&I[.I.G[2GAZ+ISY).//3<L5%N$K<T&XQ
M;BT[+8_87X$?&OP'^T;\'_A]\</AE?7%_P"!_B3X=MO$.AO>QV\.I68D>6UU
M'1M8M[2[O[6UUS0-6MK_ $/7;.WOKR&SU?3KVUCNITA65_@\RR[$Y3C\5EV,
MBHXG"572J<K;A*UG&I3<HQ<J=6#C4IR<8N5.47;7W?M,OQ^'S/!8;'X63EA\
M52C5I\R2G&^DH32<E&I3FI4ZD5*2C.,DF[7.B^)OC_1?A1\-_'_Q1\20:C=>
M'OAQX*\4^.]>MM'@M[G5KC1O".B7VOZG#I=M=W=A:W&H2V6GSI90W-]9V\MR
MT:374$9:1<L'A:F.Q>%P=%P57%XBCAJ3J-JFJE>I&G!S<5*2BI37,U&32U49
M?":8O$T\'A<3BZJG*GA:%7$5%!)S<*,)5)*"DXQ<G&+Y4Y13=DY1^(_#O_B(
M_P#V#/\ H2OVFO\ PWWP]_\ GM#^7Y5^B_\ $)N)?^@G)_\ PIQ?_P R'P?_
M !$WAW_GSFG_ (34/_FLF@_X..OV")I%23PE^TI:J2 9I_A[X%,:@_Q,+7XI
M74I [[8BWH&Z4GX3\2I:8C*)>2Q6)3]/>PJ6OF_NN"\3>'6[>RS1>;PU"WX8
MIO\ #[C[Z_9/_P""F_[''[9VMW'A#X+_ !.+>/[>S?46^'OC/1=1\'>+KNQB
MCEFN;G1;758ET[Q,+&&WGGU*+PSJ>L7&E6T?VO4HK6TE@GE^9SO@_/\ A^FJ
M^88/_97)0^MX>I"O0C)NT8U)0DYT7)V4'6A34V^6#E)-1^BR?BK),\J.C@<7
M_M*CS?5J].5"LXI7;A&?N5>5)N:HSJ."UG9-'WY7S!]$% !0 4 % !0 4 %
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MBOPXOQ$^)7]EG0/ +:UXLMO L[>)K1=;T<^((XM-?2]"FOS97VIQW^G:O;6
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y&_\%=/^".G[/_\ P6!^
M%WP[\"?&;QQ\2/AGXE^#VL^)=?\ AAXY^'=UHTQTG4/%]GH]AX@M/$OAG7]-
MO]/\3:+?P:#I3FU@NM!U:VN;*)['7;2&:]M[L _D0^(O_!D#^T)I^IS+\)?V
M[_@UXLT8RN;>;XB_"CQM\/=32$O\B36WAK7?B=:2RI&</+'=0I*Z[E@A5]J
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MXOQ4_P"%V:)]C3QM_P *OCE;5C\.;IO#O]M.@T[7/[/5[L _7W_@IU^Q"O\
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M-X*'P[/B1OB+\7O'WQ68CP</%GCC^QQI#>.3H2C_ (2G5#?#3!J9-J;PV-J
M?@3_ ,%8?^#3?X,?MU_';QE^U#^S3\<!^S#\5/B?K-WXF^*W@G7/ R>-?A/X
MQ\77T*'4?&&APZ-JOAK7O ?B'Q'J*S:QXQ<'Q;I>OZS>WFL6VF:/?W.H2:@
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MUK6+S7]7CTFQ:67S=3UB^8W%_?7=U<7-W<RD10B:=X[2WM;5(;= #^8?5O\
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M8_#FZ;P[_;3H-.US^SU>[ /Z<: /YC_^"UO_  ;CI_P6%_:9^&W[13?MC/\
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MP.99':>QL?BMX$U*&YUVSM Y32)KOP1INKPVBQ6FJ:GJUXL^K78!](_LA?\
M!G%\%_ACX:^,?B']JK]H^3]H#XW_ !"^$OQ6^'_PXU"T^'EQ;_"_X.>-/B3X
M(U_P=I_Q@U#P[K7B^3Q!\8/&7@BYUI/$_A>VU?6_!.CV6L6R71LY=;M-%\1Z
M0 ?JI_P0Q_X(8K_P1<'[4/\ QE$W[2;_ +21^"N3_P *4'P>7P8OP>_X6UM
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MEQ]3/O$[.,/A[U?JU; 9'A(+5NI0H4:=6FM]\PJXE67\VMG='] >"N I</\
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M_89_P2R_Y,/^!7_=3O\ U<GQ#K_0CP._Y-=PO_W6O_6BS<_SK\=O^3J\4_\
M=#_]9S)S]!*_6#\C"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M,V,&FK8^$X18+X=M]..E::;( _5R@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _DUG
M_P"#=KXU?M0_\%;;_P#X*,?\%)OVA/A7\>/A=H'B>3Q!\-OV=?!?A[Q<FBV.
MB>#;]C\%?ACKD7BF*+28_AWX0BE7Q'XNTNS%\OC_ ,61:G)KUM=6GB[Q)+<
M']90&.!P!P .U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?QY_\
M!4W_ )/P^.O_ '3'_P!4W\/*_P ]_''_ ).CQ1_W1?\ UG<H/]%/ G_DU7"W
M_=<_]:/.#\^Z_)S]<"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MEO>SM8_H*K&<Z56%.I[*I.G.-.KR\_LIRBU"IR-Q4^234N5RCS6M=7N?M/\
M&S_@L?>?%CX._$/X4Z1^SZO@F7Q[X/U;P:/$4?Q6_MM='T[6[1M,U%H]&3X:
MZ(+L2Z7-=6<<*ZG9B/SQ)O81^4_](<2_2'J9]P]F^18?A-9:\UR^OEWUM9]]
M96'HXFFZ-5K#+)<+[2]"4Z:BJ]+EYD];*!_-/#/T<J>0<1Y/G^(XN>9K*LQP
M^9?4WD'U5XFMA:GMZ*>)>=8GV=J\85'+V-6_+:VO-'\5K*]O--O+34=/NKBQ
MO["Y@O;&]M)I+>[L[RUE2>VNK6XB9)8+BWFC26&:)TDBD171E95-?S?3J5*-
M2G6HU)TJM*<:E*K3DX5*=2$E*%2$XM2C.$DI1E%IQDDTTU<_I>K2IUJ=2C6I
MPJTJL)TJM*I%3IU*=2+C.G.$KQG"<6XRC)6E%M.Z9^Y/P4_X+8^,O#?AW3]!
M^.'PNB^(6JV06!_'/A77+7POJ>H6R(BK+JWAF;1KO2+G5&.]Y[S3-0T*RE'E
MJNE0N'G?^FN&OI)9C@\'2PO$V21S:O3M%YI@<53P->K!))2KX*6&J8>I7>KE
M4HUL+3EHO81:<Y?R[Q-]&;+<;C*V+X7SQY/AZMY+*\=A:F.H49MW:P^-CB88
MB%!:*-.O1Q-2.K>(DN6,?1/&W_!<G31IMU#\.?@'?-K$D6VSU#QMXP@33;2<
MC/FW6C:%I;W6HQ*<KY$6NZ6[CYOM*8*-[&9?2:H^QG')^%:OUAK]W6S+,(JC
M3EWGA\+A^>LD_LK%46]^96M+Q\L^B]7]O"6<\5TEAU*]2CEF73=>I'^6&)Q5
M6-.C)Z>_+"5TMN1W;E^%?Q7^)OB;XR_$?QC\4O&3V3>)O&^M7.N:LNFP2VVG
M03SA(X[33[>>XNIX+&SMXH;2SBFNKB9+>&-99Y7!=_Y@S[.L;Q%G&8YYF+IO
M&YEB9XFNJ,90HQE*R5.E"4ZDHTJ<(QITXRG.2A%)SDTY']39!DF!X;R;+LBR
MU55@<LPT,+AW6E&=:48W<JE:<84XRJU)RE4J2C"$7.4G&$5:)^L?[+'_  5_
M\1_![X=Z!\,OBY\/+GXCZ=X1T^ST3PSXLT/78-'\0V_A[3;5+73=)UK3[^QN
M[+6YK""**TM=6CU#2[@V4$4=];W]V)+Z7]XX&^D#C.'LHPN2Y_E,\XHX"E3P
MV"Q^&Q4,/BX82C!0HX?$TJM*I3Q,J45&G#$1K4)^RC%5859IU9?@/'?T>,'Q
M%G&+SOA[-X9-6S"M4Q6-R_%866(P<\96FZE>OAJU*I"IAHUI.52=!TL1#VLI
M2I2I4W&C"S\??^"R'C'X@MH6@_"WX?3^ _!MMX@T/5/%\VH>(H[GQ;XST32M
M4M[^^\)07MEIGV+PGI6O6]NVG:O<VT>MW]S:S/ DT-G+=VE[IQ5](?,<V>%P
MN1Y3+*\NAB\+7S"5;&*>/S'#4*\:M7 1JTZ'LL#0Q48NEB)PCB:TX2Y5.%-U
M*=6.$OHY9=E"Q6*SW-X9KF,\'BJ&71HX.4,ORW%5Z$Z5+,)4ZE=5<?B,).2J
MX>$WAJ,9Q4G"52-.I# _:<_X*VS?M%? WQY\&(/@+_PA#>.+;1K1_$__  M/
M_A(SIT.E^)-&UZ=1HW_"N=!^V?;H=*?3C_Q-;7R5NS<?OO*^SR\G&OCW+B_A
MC-.'(\+?V8\SAAJ;QO\ ;OUSV,:&,PV*FOJW]CX7VGM8T'1_CPY54Y]>51EU
M\$?1^CP=Q1E7$DN*_P"U%E<\346!_L'ZG[:5?!XG"1?UG^V,7[/V4JZK+]Q/
MF=/D]WFYX_CA7\\']&A0!Z-\(/'5E\+_ (J_#GXDZAX>7Q9:^ ?&OAOQB_AI
M]2_LA-:?PWJUKJ]OI\FI?8-4%G'/<6D2R3-IU\@3(>UF1F1O8X?S2GDF>Y/G
M-7"+'PRK,L'F+P3K?5UB7@Z\,1"BZWLJ_LU.=-)R=&JK:.$DVCQN(LJJ9YD.
M<Y+2QCR^IFV68W+EC50^LO#+&X>IAYU50]K0]HXPJ2:BJU)WU52+2D?IA^UG
M_P %6K_]IWX(^(_@Q9_!3_A7D'BC4/#UQJ>O_P#"RSXJ+V&@:U9Z\NG#2QX
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M/*<"L_>24<MQ6(Q=2/\ 9G]I+%5:M*G1HMK^T,![)X>'MTG>KS^W:]SE]_\
M1_\ X?L?]6L_^9O_ /Q0U^P_\3/_ /5#_P#FS?\ XO'XS_Q*Q_U7?_FL?_C"
M'_#]C_JUG_S-_P#^*&C_ (F?_P"J'_\ -F__ !>#_B5C_JN__-8__&$_//\
M;H_;KO\ ]M.[^'#-\._^%;:7\/+?Q,(=,7QB?%_]JW_B:71#<W\MS_PB_A9;
M;[-;Z%:V\$!MKLCS;B19T\UXZ_)/$[Q/J^(]3)V\H_L:AE$,:HT%F/\ :'MZ
MN-EAN>K*?U+ J')##0A&/LYVO-J:YG$_7_"WPLH^&M/.;9Q_;5?.)X+FKO+O
M[.]A1P4<3R4HP^O8]SYYXJ<Y3YZ>T$XRY4X_)/P@\=67PO\ BK\.?B3J'AY?
M%EKX!\:^&_&+^&GU+^R$UI_#>K6NKV^GR:E]@U06<<]Q:1+),VG7R!,A[69&
M9&^"X?S2GDF>Y/G-7"+'PRK,L'F+P3K?5UB7@Z\,1"BZWLJ_LU.=-)R=&JK:
M.$DVC] XBRJIGF0YSDM+&/+ZF;99C<N6-5#ZR\,L;AZF'G55#VM#VCC"I)J*
MK4G?55(M*1^F'[6?_!5J_P#VG?@CXC^#%G\%/^%>0>*-0\/7&IZ__P ++/BH
MO8:!K5GKRZ<-+'@#PW_Q]:AIU@[7!U+$:0,AMY?,RO[/QYXZU>->&L9PY3X;
M_LB..JX2=?%?VU]>O2PN)IXI450_LG!?'5HTFY^V]U1:Y)<UX_BG '@+2X(X
MGP7$E3B;^V)8&EC(4,)_8GU"U7%X:KA'6]O_ &MC/X=&O52A['WG)/FCRGY$
MU^ ']"!0 4 % !0!_89_P2R_Y,/^!7_=3O\ U<GQ#K_0CP._Y-=PO_W6O_6B
MS<_SK\=O^3J\4_\ =#_]9S)S]!*_6#\C"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H X#XL3S6WPL^)
M5S;2RV]Q;^ /&4\$\+M%-#-%X=U)XI8I$*O'+&ZAXW1E9'4,I! -?)\>U:N'
MX&XTKT*E2C7H\)\1U:-:E.5.K2JT\GQDZ=2G4C:4*D)I2A.+YHR2:LTCW>%J
M=.KQ-P[2JPC4I5<]RBG4ISBIPJ4YYAAXSA.,KQE&46XRBU9IM.]S\Z/^"84D
MAL/C3&9',:WW@.18R[%%DEA\7K)(J$[5>18HED< ,XBC#$A%"_Q;]!&<_P"S
MO$JESR]E#%\)SA3YG[.$ZE#/XU)QA?E4YQI4HSDDG*-*FFVH04?Z<^E?""Q_
M!53EBJDL)GL)3LN>4(5LKE",I6YG&$JE1Q3;474FTES2<OU6K^_C^1@H * "
M@ H * "@ H * "@ H * "@ H * "@#\FO^"JGQ=31/ GA#X-Z9>,FJ>,]0_X
M2GQ%#!.JR1^&-">2#3+:]@P7>TUG7G>YMV79^_\ #$H9RH:-]Z$=7+MHO7_A
MO/[[A_7]?TOS4J/_  2A^%[Z9X.^(7Q<U"T1)O%&J6G@_P .S36TT=RND>'U
M-_KES:SN%BN-.U35;^PM&:'?MOO#5Q&[AHF12O+51^;_ $^[7[P/USK  H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M_H7OB5_\\T_S/U/6OJ_^(29!_P!!^<?^#<%_\R'S'_$4<\_Z LK_ /!>)_\
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MITL3"3_>1P6.7M'6A*W+&EC,;"G4CS*E2:@X_P!2-?"'ZT% !0 4 % !0 4
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MSKOC3_ZC_P -* /UX_X*\_ +]LK]IG]A?XD_"+]@GXO:A\#?VEM<\2?#>_\
M"?Q$TKXI^,_@SJ&FZ-H7CG1-6\76-O\ $#P#;7/B;23JOAVUO[&6WM%2'5()
M9=-NY!;7,B. ?P$?MA?\$!?^#DSQ1X.UK4/C5XX^(O[:GA[1O+UN\\.Q?MD^
M(OC-J-Y)8Y9+W2/!GQ=\3:-JNNZI9J[R6MEI&EWFMS?-%IEG/<,L3@'WC_P;
M4?\ !5S]CS]CSXLG_@G=\=/V+-(_8S_:+^)OC73?ACK_ ,?_ +3XQDUWQO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\>?_!4W_D_#XZ_]TQ_]4W\
M/*_SW\<?^3H\4?\ =%_]9W*#_13P)_Y-5PM_W7/_ %H\X/S[K\G/UP* "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MU<PR2SM!)K.LW%_JLL E:."2\>*+$2(M<4FY-M]7_2^0'HU( H * "@ H *
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M].+A@W).24,OH<F%Y*<I4G7CB*\)2=><Y?8E?FA^HA0 4 (2%!9B%502S$X
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MP[QC1;?LH9Y@:L5T52MERA5:U>KAAZ-]%HH[V1^B<%M_5<;'HL13DO5T[/\
M"*Z??8_7>OZ[/M H _D7_P"#G?\ Y&_]CS_L6_C5_P"G/X:5^Y>#_P#N^??]
M?LO_ /2,6?C?BK_%R7_KWC?_ $K#'U5_P;3JK_LF_'=' 9'_ &@+A64C(96^
M'7@H,".X()!'^->+XN.V=Y8^JRM/_P N\0>MX6_\B?,?^QD__47#GZO'_@FE
M_P $_B23^Q[^S]DG)_XMOX>ZG_MTKXG_ %NXG_Z'V:?^%E;_ .37Y?<?8?ZK
M<.?]"3+?_"2B>L?"#]DC]F/]G_7M1\4_!/X$_#'X6^(]6TE]!U/6_!/A/2M!
MU*^T66\M+^33+FZL8(I9+*2]L;*Z>!F*-/:P2$;HD-<6.SS.,SI1HYAF6,QE
M&%3VL*>(KSJPC447%3492DE)1E*-^TFM?L]F"R;*LNJ2K8'+\)A*LX.G*IAZ
M$*4I0<HR<&XZN/-%.U]TMS_/>_X*4_\ *0#]L+_LX7XF_P#J47]?U%PE_P D
MQD'_ &*L)_Z;1_-_%'_)1YW_ -C+%_\ IV1_0;_P7!^"T'CW_@G-^QG^T/9V
MTTVM_";1/ASH6I7$6[RT\'?%OX>^'1>W-[MC8R&V\5^&/"5M8O,Z) =8OE3,
MEVRM^7^'68/#<5<095)VIXZIBZM-?]1&!Q56RCZX>MB)2LM?9Q;ORH_1^/<!
M]8X9R/,HIN>#AAJ<VME0QF&I<S>O2O2H*+?-;GDE\39_-)\"/!?C3]JOX]_L
MZ? C4-<U'4/^$A\4>"OA!H%U=?Z6?"?@C4/%EU?7YA4;)9-*\.0ZYXBUYH2[
MR16JSP6^(HK>!/UO,L1A\ERW-<RC3A#V5'$8^JH^[[?$PH*,+[KGK.G1I7MN
MTVF[\WY=E]"OF^8Y9E\JDI>TK4,%3<M?8X>59RG;=N%)5*M2W:Z7*K*/[]_\
M',=O8:3XF_8R\.Z;"EK9:+X'^*]O96D?$=M81ZA\.[&RAC7LD46G^4O'W4 Y
MQ7YEX12E.CG]6;;E4Q.!E*3WE)PQ<I-O2[O*^W7H?HOBFHPJ9'2BK*%#%J*7
M2*EAHQ5K=$K+7Y=3[]_X-P/^3$/''_9ROCS_ -0'X5U\SXL?\E)A?^Q1A_\
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M4L0Y.\G7IX:E"JY-W;DZD97;>K[GN=>:>@% !0 4 % !0 4 % !0 4 % !0
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M\':7_*%?XV_]E7_9^_\ 5I:'0!Y/_P &='_*(>]_[.O^-/\ ZCWPSH _JMH
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MD\#_ +(O[-OA"2V=#&]N_AKX->#-&>%T8!D>)K(HRL 59<$ C% 'UW0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!_'G_ ,%3?^3\/CK_ -TQ_P#5-_#RO\]_
M''_DZ/%'_=%_]9W*#_13P)_Y-5PM_P!US_UH\X/S[K\G/UP* "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#^PS_@EE_R8?\"O^ZG?^KD^(=?Z$>!W_)KN%_\
MNM?^M%FY_G7X[?\ )U>*?^Z'_P"LYDY^@E?K!^1A0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MU^7FP/VMKF * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M,*'M:+J13YZ*<M%>]/>:?^'X_M67-\-[R\_KWSYX_HH_X)/:%]@_9V\2:W+
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M\.]+NS:QZE%\.?V;_ UGX?GC\6ZO:6L7G1Z/X \,6VN7.GV2>-/&6G;;6^4
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M'WBWX9^,#H6I:)\/K?3M9_X1GQII&B:V-+U">PO8[*_:Q%K=M:7 MY9/*<J
M?TK4 ?SZ?\'/'P6^,?Q__P""1GQ?^&_P(^$_Q)^-7Q%U#XF? [4=/\ _";P-
MXG^(OC;4+#2?B/H]WJM[8>%?!^EZQKU[:Z99J]YJ,]KI\T=E9QRW5RT5O$\B
M@'FO_!J;\!_CA^SK_P $M+CX?_M!?!OXJ? OQ[+^TO\ %WQ G@?XQ?#[Q9\,
M_&!T+4M%^']OIVLGPSXTTC1-;72]0FL+V.QOVL5M;MK6X%O+)Y3F@#\AO^"M
M/Q)_X."/^">W_!5?]I3]K']BWP#\=_B3^QW\:KCX377AWPCI7A/4OVD?@7J;
M^&/@+\-/!7B:3Q'\*_"M]KOB+X/ZM%XR\+ZT'\26MK\.-6\0""U>/7=5TN^^
MSS@'R5J__!T%_P %]_B7HLWPO^&_[ O@+P]\5]2@GT5_$'@/]E#]ICQ;XVT[
M5+J,Q6=[X8\#^(O'GBO1;?7;=R)H;7Q)X>\7Z7<3+B31'@;R% /;O^"0?_!N
M_P#MI_M+_M@Z1_P4M_X+'V^J112^*XOC#!\)/BCJ27_QF^,/Q,L9;&X\'7_Q
M8\+6-N--^'_PY\-RVMI=K\/]4N--UN>/P_H_@>]\!Z%X*,UO. ?Z"M '^:5_
MP6:UIO\ @L7_ ,'(7P&_8@^%IN?%WP^^"_B+X>?LS>,9=-D\S3+:W\(^*-;^
M*'[6'BN-D<M%+X'T*\\2^%-;9S UQJ'PR^R6JN7M)[H _P!+"""&VAAMK:&*
MWM[>*.""""-(H8(8D"10PQ(%2.*-%5(XT541%"J  !0!+0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!^//[4_P#P2=_X:7^/'CKXV_\ "_/^$*_X37_A&/\
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M^;/_ /B\'_#B?_JZ;_S"'_XWJ/\ B6#_ *KC_P UG_\ &$/^)I_^J$_\V?\
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M_P 2P?\ 5<?^:S_^,(?\33_]4)_YL_\ ^+P?\.)_^KIO_,(?_C>H_P")8/\
MJN/_ #6?_P 80_XFG_ZH3_S9_P#\7@_X<3_]73?^80__ !O4?\2P?]5Q_P":
MS_\ C"'_ !-/_P!4)_YL_P#^+P?\.)_^KIO_ #"'_P"-ZC_B6#_JN/\ S6?_
M ,80_P")I_\ JA/_ #9__P 7@_X<3_\ 5TW_ )A#_P#&]1_Q+!_U7'_FL_\
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M_P 33_\ 5"?^;/\ _B\'_#B?_JZ;_P PA_\ C>H_XE@_ZKC_ ,UG_P#&$/\
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M )L__P"+P?\ #B?_ *NF_P#,(?\ XWJ/^)8/^JX_\UG_ /&$/^)I_P#JA/\
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M_P 7@_X<3_\ 5TW_ )A#_P#&]1_Q+!_U7'_FL_\ XPA_Q-/_ -4)_P";/_\
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M^;/_ /B\'_#B?_JZ;_S"'_XWJ/\ B6#_ *KC_P UG_\ &$/^)I_^J$_\V?\
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M_P 2P?\ 5<?^:S_^,(?\33_]4)_YL_\ ^+P?\.)_^KIO_,(?_C>H_P")8/\
MJN/_ #6?_P 80_XFG_ZH3_S9_P#\7@_X<3_]73?^80__ !O4?\2P?]5Q_P":
MS_\ C"'_ !-/_P!4)_YL_P#^+P?\.)_^KIO_ #"'_P"-ZC_B6#_JN/\ S6?_
M ,80_P")I_\ JA/_ #9__P 7@_X<3_\ 5TW_ )A#_P#&]1_Q+!_U7'_FL_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'G?Q>_Y)-\4/^R=^-?\ U&M3KX_Q
M#_Y(#CC_ +(_B;_U2XT^@X3_ .2JX9_[*#)O_5CAC\ZO^"8/_'G\:_\ K[\
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M3>5%!!!%;Z?I]O9Z99V5E;\DI.3NWK^7DM_S];ML/Z_K;\O2QZ94@% !0 4
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M^?\ 7GN3^)VK_2U*M9KR\[W3[;72M?\ SW/YUQ.%NW96_K?X?-=?792/T?\
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M9SM*C-\T>:$8S4)#S/A['5LME0P^<XZK5PD:5?+J%2AE5*G'%8+EJ8*/M*.
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M 4 % !0 4 % !0 4 % '_]+^_B@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@# \/>%/"WA&UGL?"GAK0/#%E=7+WMS9^'M&T[1;6XO'2.)[N>WTVVMHI
MKEXHHHWGD1I62.-"Y5%KQLDX<X>X9PU;!\.9#DW#^$Q&)GC,1A<DRO Y5AJ^
M+J0ITJF*K4,#0P]*KB9TZ-*G.O.+JRA2IP<G&$%'TLTSG.,[KT\3G6:YEF^(
MHT8X:EB,TQV*S"O2P\)3G"A3JXNK5J0HQG4J3C2BU",ISDDG*1OU[)YH4 %
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M.,88;#0E*GA:-&E[A]5AL+1PE/V=&/*OM2=G.;[SEU>K[);126AZU7VYT!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!__3_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MG&U^6'M*C2?+3IPI8:BI2AAJ%&#<9>U5\L?6!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MP]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10
M?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4
M '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY
M% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^
M>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/
M_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G
M3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_
M9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R
M/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q
M,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _
M\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V
M/_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]
M@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL
M_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)
M+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\
M22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_
M $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE
M_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)
M9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^
M"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'
M_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]
MA_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\
M/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '
M_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY%
M!_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>1
M0 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#G
MD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\
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M(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\
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MP]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10
M?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4
M '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY
M% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^
M>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/
M_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G
M3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_
M9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R
M/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q
M,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _
M\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V
M/_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]
M@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL
M_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)
M+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\
M22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_
M $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE
M_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)
M9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^
M"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'
M_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]
MA_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\
M/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '
M_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY%
M!_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>1
M0 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#G
MD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\
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M(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\
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MP]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10
M?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4
M '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY
M% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^
M>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/
M_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G
M3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_
M9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R
M/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q
M,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _
M\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V
M/_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]
M@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL
M_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)
M+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\
M22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_
M $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE
M_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)
M9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^
M"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'
M_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]
MA_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\
M/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '
M_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY%
M!_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>1
M0 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#G
MD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\
MYY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_
M .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T
M_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V
M=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C
M]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3
M(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\
M$R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_
M !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#
M_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8
M _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/
MV /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22
MS]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_T
MDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?
M])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"6
M7_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@
MEE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_
MX)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8
M?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#
MV'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_
MP]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10
M?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4
M '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY
M% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^
M>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/
M_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G
M3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_
M9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R
M/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q
M,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _
M\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V
M/_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]
M@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL
M_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)
M+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\
M22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_
M $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE
M_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)
M9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^
M"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'
M_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]
MA_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\
M/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '
M_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY%
M!_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>1
M0 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#G
MD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\
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M(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\
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MP]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10
M?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4
M '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY
M% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^
M>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/
M_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G
M3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_
M9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R
M/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q
M,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _
M\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V
M/_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]
M@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL
M_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)
M+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\
M22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_
M $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE
M_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)
M9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^
M"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'
M_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]
MA_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\
M/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '
M_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY%
M!_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>1
M0 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#G
MD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\
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M(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\
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MP]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^>10
M?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4
M '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G3_YY
M% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_9T_^
M>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/
M_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q,C]G
M3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _\3(_
M9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R
M/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]@#_Q
M,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL_8 _
M\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)+/V
M/_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\ 22S]
M@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_ $DL
M_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE_P!)
M+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)9?\
M22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^"67_
M $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'_@EE
M_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]A_X)
M9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\/8?^
M"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '_#V'
M_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY% !_P]
MA_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>10 ?\
M/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#GD4 '
M_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\ YY%
M!_P]A_X)9?\ 22S]@#_Q,C]G3_YY% !_P]A_X)9?])+/V /_ !,C]G3_ .>1
M0 ?\/8?^"67_ $DL_8 _\3(_9T_^>10 ?\/8?^"67_22S]@#_P 3(_9T_P#G
MD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\ $R/V=/\
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M(_9T_P#GD4 '_#V'_@EE_P!)+/V /_$R/V=/_GD4 '_#V'_@EE_TDL_8 _\
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M^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K:
M#_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V
M@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#R
MMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\
M\K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_
M /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $
M_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\
M!/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_
M  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8
M_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^
M&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('
M_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R
M!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_
ML@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<
MO[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I
M'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\
MZ1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_
M .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C
M_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!
M(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_
MP2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I
M?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'
M*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\
MARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_
M (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@
M_P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH
M /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K
M: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\
M*V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__
M "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/
M_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P
M3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/
M\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_A
MC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_
MX8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@
M?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[
M('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+
M^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1
MR_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^
MD<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(_
M_I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2
M/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\
M$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7
M_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_AR
ME_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X
M<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /
M^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K:
M#_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V
M@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#R
MMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\
M\K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_
M /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $
M_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\
M!/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_
M  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8
M_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^
M&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('
M_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R
M!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_
ML@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<
MO[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I
M'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\
MZ1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_
M .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C
M_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!
M(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_
MP2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I
M?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'
M*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\
MARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_
M (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@
M_P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH
M /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K
M: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\
M*V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__
M "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/
M_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P
M3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/
M\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_A
MC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_
MX8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@
M?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[
M('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+
M^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1
MR_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^
MD<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(_
M_I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2
M/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\
M$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7
M_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_AR
ME_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X
M<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /
M^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K:
M#_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V
M@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#R
MMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\
M\K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_
M /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $
M_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\
M!/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_
M  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8
M_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^
M&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('
M_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R
M!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_
ML@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<
MO[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I
M'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\
MZ1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_
M .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C
M_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!
M(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_
MP2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I
M?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'
M*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\
MARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_
M (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@
M_P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH
M /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K
M: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\
M*V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__
M "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/
M_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P
M3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/
M\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_A
MC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_
MX8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@
M?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[
M('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+
M^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1
MR_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^
MD<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(_
M_I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2
M/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\
M$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7
M_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_AR
ME_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X
M<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /
M^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K:
M#_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V
M@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#R
MMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\
M\K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_
M /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $
M_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\
M!/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_
M  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8
M_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^
M&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('
M_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R
M!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_
ML@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<
MO[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I
M'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\
MZ1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_
M .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C
M_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!
M(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_
MP2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I
M?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'
M*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\
MARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_
M (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@
M_P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH
M /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K
M: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\
M*V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__
M "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/
M_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P
M3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/
M\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_A
MC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_
MX8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@
M?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[
M('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+
M^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1
MR_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^
MD<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(_
M_I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2
M/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\
M$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7
M_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_AR
ME_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X
M<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /
M^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K:
M#_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V
M@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#R
MMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\
M\K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_
M /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $
M_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\
M!/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_
M  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8
M_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^
M&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('
M_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R
M!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_
ML@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<
MO[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I
M'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\
MZ1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_
M .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C
M_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!
M(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_
MP2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I
M?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'
M*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\
MARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_
M (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@
M_P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH
M /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K
M: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\
M*V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__
M "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/
M_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P
M3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/
M\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_A
MC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_
MX8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@
M?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[
M('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+
M^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1
MR_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^
MD<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(_
M_I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2
M/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\
M$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7
M_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_AR
ME_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X
M<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /
M^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K:
M#_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V
M@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#R
MMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\
M\K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_
M /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $
M_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\
M!/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_
M  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8
M_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^
M&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('
M_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R
M!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_
ML@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<
MO[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I
M'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\
MZ1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_
M .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I?\$C
M_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!
M(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_
MP2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_ (<I
M?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@ _P"'
M*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH /\
MARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K: #_
M (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\ *V@
M_P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__ "MH
M /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/_P K
M: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P3_\
M*V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/\$__
M "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_AC_!/
M_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_X8_P
M3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@?^&/
M\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[('_A
MC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+^R!_
MX8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1R_L@
M?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^D<O[
M('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(__I'+
M^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2/_Z1
MR_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\$C_^
MD<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7_!(_
M_I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_ARE_P2
M/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@ _X<I?\
M$C_^D<O[('_AC_!/_P K: #_ (<I?\$C_P#I'+^R!_X8_P $_P#RMH /^'*7
M_!(__I'+^R!_X8_P3_\ *V@ _P"'*7_!(_\ Z1R_L@?^&/\ !/\ \K: #_AR
ME_P2/_Z1R_L@?^&/\$__ "MH /\ ARE_P2/_ .D<O[('_AC_  3_ /*V@#]-
M[2TM=/M;:PL;:WLK&RMX;2SL[2&.VM;2UMHUAM[:VMX56&"W@A1(H88E6.*-
M%CC4(H"@%B@#_];^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M * "@ H * "@ H * "@#_]?^_B@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H _/[]O/]JT? ?P4G@GP;>@?%;QU92+ITD$P6X\)>
M')6FM+GQ,P3,ZZA=313Z?X="",?;(KW4?M"/I*6U[K2AS.[7NK?S?;_.WZH#
MO_V'?#WQ@T3X%Z;??&GQ)KNO>(O%>JW/BK1[;Q+J-YJNN:!X8U.PTQ-+TS4;
MJ_EGN8KBX>WN=9_LYIG.G1ZI';3I;7ZWMK JKBY^[T5FTK7?7UZ*_6WH!]A5
MF 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M!MYX-O\ P5:Z'8JWPXL[B&T?6(?$>ISNNK.)9A8(;1 D5PS '^>?_P $3_\
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MMZRLKV5EH?7Y1B:V*P-.M7GSU'.HG+EA&ZC.RT@HQT5EI&/SUD?J+7RAZ84
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MR?+*@;^(#E74'Y6>-Y(\[6CDDAD@EE/Z_K^OS0?U_7]?DR_0 4 % !0 4 %
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M6ENM1U>^N9Y96!04 ?YQ/_!V'^T19_&K_@LE\._V;OBQXNUWPQ^SW^S-X/\
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M?LD7VG12/']IET&PO/VD+?69+6/B7R+?4-2T);]QNC\RZTU3M;;O /\ 01H
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M'Q'8_'G1-:;RB=JR7%MX6T >8@RZVNV0XCC% 'RE_P ''_\ RLD?L)?]@/\
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MMJ ?@O\ \%!O^#K/_@DA^T!^S%^T)^S#I_PB_:A^-VF_&KX4>./ATMS-\-/
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M5'_TU6/X[_V4_P#DZ+]FW_LOGP>_]6'X=K]ISC_D4YI_V+L;_P"HU4^0PO\
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MM!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MM\/S:QK-B+-;BT3XB6M]%)=VS7ITT _L9_X<#_\ !&W_ *1[? #_ ,%.O?\
MRYH ]T_8=_8V_P"";/[.5]\3/&/[ ?PL^ 7@Z]U/59?A;\5?$/P0UNQ\1!=?
M\$72W]YX"\47VGZYK<&F:]X9N]6CGU/P_</::IITUY"-0M8F:%: /X>O$/\
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M-J%S/!96M[>P '\TO_!CG_R4_P#X**_]B%^S=_ZD/QDH _T.: "@ H * "@
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M<,&!!)XEN?%6B,RYFT8RN;F+YC.?#_(<SI3>%P\<KQ=I.G6PBY:+F]E5PO\
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M%'J9[_R*\3ZT?_3](_SN*_I,_/C_ %F?A1_R2WX:_P#8@>#O_4=TZOX_Q?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % &9K>H3:3HVKZK;Z?=ZO/IFF7^H0:58*'O]3FLK
M66YCT^R5L*UW>O$+:V5C@S2H#@&A?U?^G^7W@?"W[)O[=7A[]HG7M7\#>)M$
MM/ 7CZ"6\O/#ND#4I;RT\2Z/;FXFN(+&:YMK:0:]HEI&'U.P;+WMM'<:O8PI
M;6VH6NFZSI.*NG===-5_7]; ??E9 % !0 4 ?$'[<'[4MM^SS\/6TCPW?0'X
MK>-[2[M/"=N%2XET"P_X][[QA=V[*\2K8ES!H<=XODW^L#>(+^STK5K:M:4.
M=W>RW\_+_/:RVWM(/"?^"=?[+EQX7TP?M%?$>%[OQSXVM;BY\%VNI0M-?:'H
M&L"1KOQ1<7%T&E&N>+X)Y/L\L(5X/#=P[->77_"1WEI855G?W([+XO.W3Y6\
M]?2\0_56L "@ H * "@ H * "@ H * /,_'-C?:5+%XRT,8O[$1Q:E $#K>V
M.Y5&]%Q([(=D;;2[>7Y>%1$D9[B[KE>W3ROV6WXKYWO$MK?^OZ_KHCL] URR
M\1:7;:K8N&BG!#H&W-#.AVRPOE48%6Y7>B,\31R;%#J&EIIV?^7ZO\_NN!LT
M@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#\G_P#@JK_P1S_9*_X*U?#+3/"OQUTK4?!_Q2\%6]TOPJ^/
M_@2#3H/B-X#-TYN)]%N&O[>:Q\7>!-1N\3:OX+UQ6MFD>>_T"_\ #>OR)KD
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MGAC0O PUGQ-HVB6NCIINM>$/$^M1^&?"-H_A#38O$*7%A<-J%]JL, !_-O\
M\%%O^#2OXU6W[2>K_M:?\$E/CQX:^#VK:EXSO?B18?"+Q1XH\6?"K7?A-XRO
M;^34KBY^!'Q6\"Z3JTECI']I7=Q-H/AO6[;PK)X.L4^P6'B[5K0V=C9 'D<O
M_!&O_@ZX_:)\/#X7_'#_ (*)GP3\-;N&7P_XBM_$W[7?Q(G77_#-X3;ZK!K5
MO\)/!^LZEXXM[RQEF0Z3XQU/R-25EL]0GM('=X #^M3_ ((^?\$S]+_X)/\
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M3NFFM&FOON?$IVU6C6J:Z']X'_!4/XEZC\9_^""-I\7-8<2:U\3/A/\ L?\
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M)7<G1@FWJVX+D<F^KDXWZ;[+8^XJ\$[0H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@#_/-_X+E_\I2_VH?^Z)_^L[?"2OZT\,O^2(R3_NI?^K?'GY[GG_(T
MQ7_<#_U'HGY,U]X>2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_H9?\$-/
M^46G[+W_ '6S_P!:)^+=?R7XF_\ );YW_P!TW_U48 _0LC_Y%>%_[C_^I%8_
M6:O@SU@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@FU2#HG)4HJ,5JUIZ.Z<NEW>]G;1]K(#]Y0      , #@ #H .P KE 6@ H
M* "@ H * "@ H * "@".:&*XAE@GC66&>-X9HG&4DBD4I)&X.05=&*L".0<<
MYH ^=_#NHR_#OXA77A2_E9=#UV0-832[E@BE?<]HZ'RD@C),GD7*P%(H_-0S
M,Q@C#:/WHWZK?3]=/6UGO;S%K=]NG]7?GT7S/HRLQA0 4 % !0 4 % !0 4
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M=A(M6;HJ7RFW-?>I7/T1KYL] * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /A']KG_ (*=_L!_L(26=G^UE^U1\*_@_KVH1+<V7@O4=3O?$OQ$
MN;%XS+'J<7PV\$:=XF\?'2)%7;'JY\-_V:\S1P)=M/+'&P!^7TW_  =:?\$0
MX]7DTU/VH?&4]FDJQKX@A_9T_:"&D2HQP9XXIOAS!KWE)U;S-#BF(^Y QXH
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MMW9KJ%K9WJI'?V-Y:R)<VL$JS6\BF-<4 >IT % !0 4 % !0 4 % !0 4 %
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M^#+;Q;XI359-.G\4ZU9ZIJ&EZ+%'HVFZK>M=WEEHNJW,>+7RA%8SM)(FU=P
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_H9?\ !#3_ )1:?LO?]UL_
M]:)^+=?R7XF_\EOG?_=-_P#51@#]"R/_ )%>%_[C_P#J16/UFKX,]8* "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MGED6*)&2-.:4G)MOK^'E_7ZA_7]?U^1VU( H * "@ H * "@ H * "@ H *
M/GO]H30VF\.V7B:V7%SH5R(YY%\I6%I=.OER/*_[S9!=*JQQ0G<\MT"8Y=JF
M+2F];=_S_K\O(F2O;6VO]=NMMW]USTCX:>*T\8^#='UAIDEO1"+'5=KAV34K
M,+'.9@$C$<MRGE7IB"[8TND56=0':9*S:Z=.GZO\_NN5O_7;3R_KON=Y4@%
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M:E%[QE%IJ2=MFM&KJS2/VCD_X.8/V_7T5=-3P'^S!#J(&QO$4?@#XB-J3*%
M$GV27XM2:*)RV69QI?D$85;1"K.WPZ\+N'>?F^L9JX_\^WB,,H^E_J7M+?\
M;S:WN[V/9_UDQ_+;V>&3_F]G4O\ C5Y;_P#;J7DKGTM_P1M_X*!_M=_ME_\
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M\*E_U[A_Z2C_ #!OVWO^3T?VO/\ LZ#X_?\ JU_%E?U5D'_(BR7_ +%.7?\
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MC_@BU_RD^_9)_P"QR\5_^JQ\<5]GQS_R2F<?]>:'_J7ASR,F_P"1GA/\<O\
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M>/O#FGZYH^FZ_I1UG2];T6^BGT+Q-XC\/ZKIFK:5>6UYI&MWPMS8ZI%IVJ6
M!YS_ ,$I_P#@D=^S7_P2+^$7CCX7?L_ZQX_\::G\4/%MIXP^(OQ%^)NI:-?>
M*?$=WI%C+IGAO2(K;PYHGAW0M*\/^&K*YU Z996VF/>O>ZQK%Y?ZE>&ZMXK0
M _4V@ H * /\IWQ1_P K=EM_VEF\(?\ JS=$H _U8J "@#\/_P#@L7_P0Z^#
MO_!8Z\_9\OOBI\;/B7\'YOV>[;XHVNAK\/\ 2/"^K1^((_BC+\/IM1.JCQ':
M7#0/I;?#ZQ%D;1T65;^Z$ZL4A*@'XI?\017[(G_1ZO[1_P#X1_PQ_P#E;0!_
M&W_P15_X)V>!_P#@J-^W1X:_90^(?Q#\5_##PSK/P[^(OC6X\4^#-.TC4]=B
MN?!>DPW]I8PVVN)+IX@O)IPMS+)%)(L2$1!7<.@!_9)_Q!%?LB?]'J_M'_\
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M3IX[74+OP=XGT3Q/;6-S+'YL5M>3Z+>WD5K/)%^]CAG9)'C^=5*X- '8T %
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MLO&L&A6WC7PWJ-AXGT+Q#HFJZ'XC7PQX;NY0UC;ZG8:GH&F7-AJ<%JVJ6.J
M'T7_ ,$[/^"?GP)_X)E_LP>%?V5_V?#XHOO"&A:QKGBK7/%/CC4K/5?&/C?Q
MKXGF@DUSQ3XBN=+TW1M'CNIX+/3=*L;+1]'TVPL-%TC3+-89KB&XO;H ^Y*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#_/-_X+E_\ *4O]J'_NB?\
MZSM\)*_K3PR_Y(C)/^ZE_P"K?'GY[GG_ "-,5_W _P#4>B?DS7WAY(4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % '^AE_P $-/\ E%I^R]_W6S_UHGXMU_)?
MB;_R6^=_]TW_ -5& /T+(_\ D5X7_N/_ .I%8_6:O@SU@H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;IV_#[]#[7K(H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MP=:>'KTWHK\E6G)7M9K5731M5H< 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M--/5-/[K U?1ZIZ-/J?DI\;_ /@AS_P3>^.6N7OB>]^!\GPU\1:G<O=:C?\
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MIR4X2M).+M))VDFGLTUH=LHQG&4)*\9Q<9+57C)6:NK-73>SOVL?E1_PX?\
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MS!8:%2G2HI*K"5.I)N3J3A)6E'GYN:*:>T'%==))./@7_#A__@E-_P!&K_\
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M#PGX1TKP9IZ^#=!^$_P0\7Z;;7&E:.J6DU]'K/COQ \E^46:6WEM8'RMLC,
M?JS^W'^VQ\!_^">W[-7Q!_:E_:*\0SZ+\/O EM;PV^FZ5#%?>*O&_BS5I#;>
M&? ?@K2);BU75O%/B6_'V>R@EN;73]/LXK_7M=O]*\.Z/J^K60!_GE^/O^#D
MK_@NK_P4E^.&J?#O_@F_\.=9^%NCF2>]T3X6?L]_!K1/CK\1;'PH)4M8M7^)
MGQ&\=^"_%MO8I#<3Q"^\3Z/H7PS\.6LLMM;2HI#370!UMG_P6K_X.6?^"6_B
MSPIXS_X*$_"3XC?$?X%7^NZ=H^IZ/^T!\#?"7A'PSK9G$EU=Z)X2^/WPH\':
M-'I/CF\TR&ZETE-;UOQC:6CVK7<_@S5+>UO;>4 _-K]GK]HSP9^UW_P<L_ 7
M]I[X>6.LZ7X+^.O_  4;^$OQ+\/Z3XA@AM]=T>S\3^.O#U^VCZO';RSVIU'2
M;B2?3KN6SN+BRN)K9Y[*XGM9897 /]>.@ H * "@#_)__P"#1'_E,KX#_P"R
M"_'C_P!1NQH _P!7/4[B2TTW4+J+;YMM97=Q'N&5\R&"21-PXRNY1D9Y''%
M'\+O_!NE_P %Y_\ @HE_P4>_X*#:C^SS^U%XW^'/B/X9Q? #XD_$"'3_  O\
M+?#7@[4XO$OAK7O MGI5RNKZ/''=M;Q6VN:C%+:2O)#-YR.X,D4;J ?W7T ?
MR<_\'0W_  5O_;._X)9P_L/_ /#(?BKP7X8;XZR?M)_\+!?Q?X!T+QPUXOPQ
M7X"?\(JNG#6XY%TP0'XA>(S>&W7=>&6T\Q@+5 P!^Y7_  2Q_:#^)/[5W_!.
M[]D']HWXPWVF:G\3_C#\%O#/C3QOJ&BZ3;:%I=YK^HBX6\N++1[/%IIT,IA5
MQ;6P6&-BWEJJD*H!_'C^VI_P<E?MP_LE_P#!;#QQ^S+XJ^)/P^T#]B#X4?M9
M_##PA\1;-?@[HFN^+=-^ LE_X&O/B;):ZY;6\_B6]UR/POJ/B.ZL+BS,E^MW
MY"6<1*10T >1?%/_ (+B?\'#O_!3K7?&_CO_ ()6_LV?%CX2_LJ>&=:UC1=
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MXB^!WPP\%?#[PO\ #G7?B%^T9=?%+X2>%O _AN3Q+I5N);/P]'X:\2>-]?\
M%L[V]\^G^&M"U/5K#3M3U73[#2[T \#?_@N]_P '+GQFUW1OVD/!^@_%_P
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M_@\M_P"42O@S_L\KX._^JZ^-= &A_P &;_\ RB-US_L[KXS?^H?\)J /ZN*
M.>\7?\BIXG_[%[6O_3;<T ?Y87_!GO\ \I@[+_LV/XW?^E/@J@#_ %3-9UG2
M/#ND:KX@\0:IIVAZ#H6FWVLZWK6KWMMIVDZ/I&F6LM[J6J:IJ%Y+#:6&G:?9
MP37=[>W4T5M:VT4L\\J1([J ?Y[_ /P4B_X.V/VEOBM\;[K]FO\ X(_^!H8]
M%F\2'P3X4^-M]\.)/BG\8?C-XFFG&G6<_P '_A+JVEZMHFBZ)J-^TD?AVT\3
M>$O&?BOQ/;?V=J,ND^$9YKC0J /B;XA?\%'/^#MK]D#PPO[0_P >4_::\.?"
MJS:UU7Q+JOQ2_95^$5]\/-,LKFYBLH;?QO%IWPIBNOAU97MW-!9I]KN_!EY]
MJN+>&UN8KF>(. ?U8?\ ! O_ (."O"__  5ETWQ%\$/C1X4\-_"/]L?X=>'!
MXIU#0?#%S=)\/_C#X*MIK.PU3QG\.[36;_4-:T35O#^HWMI%XM\#:AJ6M2V-
ME?Z=K^B:WJVG3:W9>% "M_P<U_\ !3S]K+_@F#^SS^S9\0OV2_$GA+PSXG^)
MOQF\0>#/%5WXM\%:/XVM[C0=-\$7NMVUO9V>M));V4W]H1Q2R7,2><R((@ZH
MSJP!^#&F_P#!U'_P40^/'[,G[,'[-?[&'P<_X7[_ ,%*/B1X>^)&K?'KX@>%
MO@QJ'BN'P?)9?%#XDVW@W0?A7\&?#UI+I&J^(-.^$NE^!_&'B[QMX@M-7\ Z
M!97LD%WH6IZC-K%WX9 /@[XS?\%D/^#H;_@GQXW\*>,OVO/$_P 6_!6E>*M5
M5M-T+X\_LR?!VS^$WQ!DTQ(K_4/#.GZQX6^&WAZUMY1:31/J]A\/_&'ASQ+9
M6DH<W-EE9$ /W\U+_@\*_9^L_P#@FIH/[0=I\-](OOV]=:\1ZK\*)_V68]<F
M'A;1O&NBZ#INK7GQIU341>OXE@_9^O+?5]/FT.U>1/%NN>*?[4^&UAJ<B^'/
M$/Q%TT _%KQ7_P %*_\ @[D^+7@U_P!K+PIX,_:0\#_ ^:S?QYX?A^&?[''P
M]@\!6'@V73O[:AUS1]#\5_"_Q;\0O%_P_P#['_XFMKXF\47_ (RTFYTPK?\
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MLM&TGX8^'8])U'Q9XFN;W19[VQN[SQ?9:7:3-8V\_A[Q D\\$0!_/2?VR_\
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M  UUH^']9U+^S=5U_P"&/CGP#X4^&*^)-4T]Y5(U#4-0\=:/;SJL=U8.'**
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M1GLM;\->(]/AU+3+Q$D5)[6<V]PL=Y87D5O?Z;>QW&GZA;6U[;7%O$ ?P_\
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M_N!_ZCT3\F:^\/)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _T,O\ @AI_
MRBT_9>_[K9_ZT3\6Z_DOQ-_Y+?._^Z;_ .JC 'Z%D?\ R*\+_P!Q_P#U(K'Z
MS5\&>L% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!Y]\5_'2?#+X<>,O'KV1U(^%]"O-3@L _E+>7:*
M(K*WEEZPP2W<L"W$RJ[Q0&22.*5U6-ODN/.)GP7P7Q3Q9'"K'5.'\CS'-:6#
ME4]E#%5\)AJE2A0J54I.E2JUE"%6K&,YTZ;G.$)SBH2^@X4R-<2\2Y#P^Z[P
ML<XS7!9?4Q*A[26'I8FO"G5K0IN454G3IN4Z=.4X1G.*C*<8R<H_DLG_  4P
M^+@D4R>!/ART6\;U2'Q,LA3/(60Z^ZARH(#&(@'DJP!5O\[8?3@\1U.+J<+<
M$2I\UY0A0SZ$Y13UC&I+/*L8R:TYW2DHO5TY;']E2^BQP;ROEX@XF4K>ZY3R
MN45+HW%9?%R2>O*I1;VYE>\?TK\!^*/ G[5OP/%YKGAZVO/#?C/3[W1/%7A2
M_F6]&GZA;2B.[L_M<20.ES:S):ZKH^I6XM;^UWZ=J,!LK^)!!_?GA3XBX#Q1
MX)R?C+ 89X"6-^L8?'Y9.O'$SRS,\%6GAL9A)5XTZ7MJ?-%8C"UI4:$Z^!Q&
M%KU*%"=5TH?R-Q]P=B^ ^*,RX:Q=98I81TJN$QL:4J$<;@<52C6PV)C2<JGL
MYN,G2KTXU*L:6)I5Z4*M6,%.7SS^SE_P3]\#_ +XEZM\1[CQ-=^.+FU^TP>
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MH8C+IX557[7#TZ-.=*K#'4>2+HQG"5.I>4U*/+]B5_2A^)!0 4 % !0 4 %
M!0 4 % !0 4 % 'YP>%(+OPE^TIXX\07*66B^#/ =WXMUWQEKVJ7\6D>'_#G
MA2YTW49TU/5=2NV%K D=K/'J&R:5$*V]Q<DP6MK<31+%XK#8+!U\9C*]'"83
M"T)U\3BL34A1H8>A0I^TK5JU6HXTZ5&E3A*=2I.480@G.3LK&V%PN)QN*H8/
M!X>MBL5BJ]/#X7"X:E.OB,3B*\XTZ-&C2IQE4JUJM22ITZ5-.<YN,8IMJ,OB
M_P#:#_X+9:1H>LW_ (?_ &</A]I_B^UL;AX4^('Q".KV>AZKY32QM+I'@_3I
M]'UU[";$<UK?:MK6D7KQLT=QH=LY#K_)7%_TGZ&&Q-;!\%9-1S"E2DXQSC.G
MB:6&Q#3:<L-E=">&Q;H2TE3JXG%86MO&>#A[LC^L>$/HP5L3AJ6+XVSFME]6
MK!2>39)]6JXG#\R34<3FE>GB<(J\'>-2CA<+C*&SACIZJ/R+!_P6=_:[AO\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MW'AY=0M[A/"^BW" '[6?\%GOV?O"'[2__!+']NOX:>,-&AUD6?[-OQ3^)/A
M-%$]SIOQ)^$7A34_B;\.=5L97CDDMIK;QAX6TB.Z:V,<UUI4^HZ:9!!?7",
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MQEA+9W5A\&=(\?W4%_"RE)]/DC%] _[N6W1SB@#_ #^O^#H/_@H;_P $[?\
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M*LM"\.^'-!TJVCL],T?1='TV&WL--TVPM8H[>TL[2"*"&)%2.-0,4 ?P,_\
M![?^S'X(TRZ_8Q_:^T+0X-.\>>*+KQ]\!?B)K-K;P1?\)+I&A6&E^-?AL=3>
M**.2?4M"^T^/K.&\GDGGGTR\M+$LEMI-FB@']''_  ;G?%9?&'_!#C]B#QQX
MFOI(;;P?\-?B;X1U*]O7EE^Q:'\'/C%\4/ 5FY;$CFUL_#OA"R,$<0<16L<4
M$:#RQ&H!_GK?LB?#/Q1_P<"?\%SI+SXS:YJ,'A/X\?%WQK\:/BF3/=1WVA_
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M$9)_W4O_ %;X\_/<\_Y&F*_[@?\ J/1/R9K[P\D* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#_0R_X(:?\ *+3]E[_NMG_K1/Q;K^2_$W_DM\[_ .Z;_P"J
MC 'Z%D?_ "*\+_W'_P#4BL?K-7P9ZP4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M H * "@ H * "@ H * "@ H * "@ H * "@ H __T?[^* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H ^ /^"C7_  39_9E_X*<?L_>)/@9^
MT-X,TN\OY=+U(_#/XJV6EZ>WQ'^#GBZXB1K'Q7X%\030->V.R]MK)]?\/F?^
MP_%NF6[Z/K]I=V<BB( _S4?^#8CXM?%#]F__ (+<_!CX0:-K=Q_8/Q;N?C+\
M!_C#H&C7TMYH7B?3/#_@'QSXHTJ\Q#(MG>IX<\=^"-#U_3=7:"22'38-3CMG
MAM]3NPX!^MW_  ?#>#=;M_BO_P $^_B$T%T_AS5_AY\>/!L-R!NLH-;\.^)/
MASK=S Y&1!=7=CXIM9(Q)L^U164OD^9]CN/* /ZO?^"!'Q7\+_&#_@CQ^P)K
MOA:]TJZB\*_ /PS\*-<M]+F@D.F>*/A$]U\.-=LM3AA8O9ZK+>>&SJ=U#<K'
M/,FHPWX5K>]@EG /V"H _P [/_@^$^)WAW5_C-_P3]^#EG>:9-XI\ _#;X]_
M$77K*&:&35K+1OBKXE^&/AWPU)?Q*QGM[.\NOA%XE.G^:JI/);WS1[O*8J ?
MT^?\$Q? 6M?#7_@WP_9X\,^(+:XL]3G_ ."?OB+Q>UK=9^T0V7Q&\!>*OB'I
M*RHQ+PM_9/BFQ;[/(%DM@1;R1Q/$R* ?QN?\&4__ "E#_:#_ .S"/B5_ZT-^
MS!0!_4-_P=R_\H9/B9_V6_X"?^IE0!\[_P#!E?\ \HKOCC_V?O\ %7_U0'[+
M] '\U'_!XMX<U?1?^"O%IJNHQW"V/B[]E7X+Z]H,DRD0R:;9Z[\1O"UQ]D;H
MT2:UX=U42<Y6X\T' *T ?Z;G[,GQ%\-?%[]G#X!?%7P;<:;=>%/B/\&?ACXW
M\.S://%<:6='\3^"]&UBPCL9H'DB:WAM[M(8PK'8(_+;#*P4 ]PH _R4?!'Q
M,T3XP_\ !U=H7Q%\,W=GJ/AOQ!_P5Z1/#NJZ=<1W=AK.@Z+\?9/#^CZW8W,,
MDT-Q::UIVE6VJV\T4C1RPWB/'A" H!_K74 % !0 4 ?Y/_\ P:(_\IE? ?\
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M:*"&-I"QCBC0A% -J@#XU_X*,?\ */?]N[_LS7]I_P#]4EXXH _A _X,B?\
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M ,I0_P!H/_LPCXE?^M#?LP4 ?4G_  ?"Z!J]O\;?^"?WBB:.X_L#5OA9\=-
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M$;_@H/\ &/X'>,?%'AJ\T2Q\6:/JFN_%WQGX8\.W.FWWB73-:T/S=0\62Z%
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!_H9?\$-/^46G[+W_ '6S_P!:)^+=?R7XF_\
M);YW_P!TW_U48 _0LC_Y%>%_[C_^I%8_6:O@SU@H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G?]K/
M_DW+XM?]BN__ *7V-?D_CM_R9SQ)_P"R1SC_ -1I'W_A7_R<C@G_ +*/+/\
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MQ+_LOQAXM^%M_<L+7Q58)XAT**67Y$UK0DD74;>UA_YZZAH\S75RXS^[T.+
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M4O\ ^2M^!?\ LG,'_J3>(:_R^^G!_P G*X8_[(;"?^K_ (@/[L^BQ_R1>?\
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MP7\//ASXAT'2-1UG4K?4_$=EXKFU26;6;Z2^N8Y9-*\2:;9&.*60I"([56"
M"1F8%J_*."O';B+@/(,/PYEV69#B<+AJ^*KPK8^&/>)E+%UYUYJ;H9A0I\L9
M3:A:E%\MKW=V?K'&O@3P[Q[G^(XDS+,<_P -BL30PF'G2R^>!6&4<%AX8>FX
MJO@,14YI0@G.]5KFO915D?OY_P $]_VK?'/[77PE\5^/?'OA/P_X5U3P]\0;
M[PC;1^&(M7ATB]L[?P]X<UE7*:S?:G<#4(9-9D6ZV7K1&WDLB((69GE_K[P<
M\0,R\1N&L?G6:83 8.OA,\Q&5PAET<1'#SHT<!EN+C-_6<1B9^VY\;.,[5%'
MD5.T4^9R_D#QD\/\L\..)<OR7*L7F&+H8O(L/FM269/#O$4ZU;'YGA'!/#4,
M-#V7)@H3A>ES<TIWG).*C^&W[<LSV_\ P5;O9XB!)#\1_P!G:6,E0P#IX-^&
M+*2K JPR!E6!5NC @XK^5_$QM?2%KR6\>).!Y+9ZQRKAMK>ZW2Z?>?U3X:*_
MT>:">J?#/'2?H\UXG3_#T]5N>-?M8_#/Q-^PQ^VC=:CX##:+8:-XKTKXN?"&
MZ"2M9+X=O-5?4[#2&CDNI9;_ $_0]1M=2\'ZE#>SD:M;:7<"[C>VOG5_FO$#
M(\=X5^)E2IE">&I83'X?B/AJI:7LE@JM>5:AAFFY.I1PE>GB,KKPJ3;Q%'#R
M=5*%?WOI/#[/,!XJ>&=&&;VQ53%X#$<.<2TN:/M7C:-"-"OB4^5*G7Q="IA\
MUH5*<4L-6Q$%2:G0;C]C?\%=/BEX?^-WPG_8F^+7A9E_L/QUX>^*&MP6XG6Y
MDTR\EC^&L6K:'<SI'"DM[H.K0WVBW\D<:1->V%QY8";=WZ)](C/\%Q3D_A7Q
M#E[_ -ES;+>)<5"',IRH5.;AR.)PM22C%.M@\2JN%K6BE[:C42NE<_//H[Y!
MC.%<X\5>'<>O]JRG-.&L+.IRN$<124.))8;%TXN4FJ.,PTJ6*HWDW[&M!NS=
MC]/_ -CG_E&?X'_[(G\1?_2GQE7[_P"'/_)E,H_[);-/_>@?@'B-_P GNS?_
M +*O*_SR\_ '_@ES_P GV_!+_KX\?_\ JM/&=?QUX%?\G7X-_P"OV;_^LWG!
M_8?CQ_R:GC/_ *]Y/_ZTV3'U5_P7"\4ZI=_'SX3>"Y)F.BZ#\(U\2V5L?NKJ
MGBGQAXETW4[@#I^]M/".D19ZY@8=A7Z']*3'UJO&'#^62=\/@N&UCJ,?Y:^9
M9GCZ&):_QT\JPJ:U^!/RC^>_1;P%&EP=Q!F<5_M&-XEE@:SZNCEF5X"OAD]7
M?EJ9MBVM%\;W/U$_X))^#-"\+_L2_#[6]*@:/4?B%K_CSQ;XEG=]YNM6L_%^
MK^"K4QY ,4$.@^$='@$ +()TN9QA[F2OW;Z/.787!>%^48JA3<:V<8[.<?CI
M.3E[3$4<SQ654Y*^D8K!Y;A8\D;1YHSG\4Y.7X3](?,<5C?%'-\)7J<]#)\#
MDV P,4DO9X>OE>%S:I%V2YI/&9GBI\[O+EE&%U&$$?I97[>?AY_/9_P5P_8H
M^)OB[QY'^TI\+/#FI^-=*N_#6E:/\1- T&TFU/Q%HU[H :QL?$MMI=J);W4=
M$N-&:QM=0&GVEQ+HC:1<ZIJ##3KIYM/_ (\^D-X89[F&;KC;(,#7S3#UL%AL
M+G6#P=*>(QV%K82]&CCZ>&IJ57$82IAG1I5_81G/!O#RQ%9+#U9U*']A_1Y\
M3\BR_)Y<$Y_CL/E>)HXW$XK)<9C*D,/@<50Q=JU; 5,34<:6'Q=/%*O6H.O.
M$,8L1'#4O]HI4X8CY*_9<_X*Q_'']G_0] ^'OCC1=+^+WPX\.6L&E:39:K<2
MZ#XW\/Z-9VHM=-T?2?%5M#=VUUI>F*J?9K3Q#H>L7J6D46E66KZ;IT%I%;_G
MW ?T@N*>$<)@\GS/"X;B/),%36'PU.O4E@\TPF&ITE2P^%PV84U5I3P^&Y;P
MIXS!XFMR6PU/%4*,*2I?H7'?T?>%N+L9C,WR[%8KAO.\;4>(Q-6A3CC,KQ6)
MJ575Q&*Q.75'3JPQ&)YFIU,'C<-1Y_\ ::F%Q%:=:4_Z4_V=_P!HOX9?M/\
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M2C"G#$).%64'+\0/^&</^"^'_0Z_%_\ \/EIG_S2G^?YU^0_V#XX?]!V-_\
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M5_T5#XO?^)+:I_\ -)1_J?XS?]#?,_\ Q):G_P O?Y?>'_$<OH*?]"3P]_\
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MAU?5-$MM6\&Z4^N7'C*RLGO-)GGM8_%OASP[J4VFRVUQ=:=IUV\FGP '['4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?R4_P#!T_\ MY_MH?\
M!.ZP_P""??Q[_9"^(OBOP']F^)/QMTKXCV4>GS:]\*?&UK+X?^&\OAWPK\5O
M#-W%-X:UNWO8D\3'PX-2^RZ_IK_VUJ7@_5-)U2WEU"W /S7_ &>O^#WLQ:#8
MZ9^U9^PP;WQ-;VT2ZCXS_9^^)RV.BZM=<"9[3X;_ !$TJ]O-"AP#(BR?%+Q
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MTL='^ /P,AN[F?[7KUSH>EVOABUATV^UF[\'6=[=>/\ QYJ6I:[>Q+XK /\
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MV4J "@ H * /\G__ (-$?^4RO@/_ +(+\>/_ %&[&@#_ %@* /\ (M_X*0_
M/]J#_@@O_P %E;W]H#X6:-J]AX9TKXY:S^T!^RW\1M>T+5#\/?B+X'\7W5QK
M7B/X7ZIJFG2:5#JYT32?%.M?"+XHZ'INI:1K4VDRS:K;1Z/I_B30=0E /Z6M
M(_X/<_V4C\*;?4=>_8O_ &A$^."Z3;&Z\&Z1XI^'$OPIFUW[!F[CM_B5>ZU#
MXNMM).ICR[:63X475XM@_G20M<1^1. ?QO\ _!5+XS_MO?MQ^-? W_!33]KK
MP6_@CP?^UAJ?C[P!^S?I,%KJ^E>&+3X>?L]VO@+^TM*^'&EZ])<:G>> =+O?
MBM8!?&(N9['QAX_N_B%>PNM_:ZG;VX!_J7?\$'_^4/'_  3Q_P"S:_!?_H5]
M0!_ /^U!_P K=GAG_M+-^R%_ZLWX*4 ?ZL5 '\/'_![Y_P FS?L+?]EU^)__
M *@&DT ?M7_P;,_\H.OV$/\ L7?C5_ZTO\9Z /TX_;D_Y,I_;!_[-;_:!_\
M53>+: /\^7_@R8_Y/]_:L_[,]N__ %=/PJH _I6_X.8O^"./BS_@IS^S3X0^
M*7[/>D6NJ?M8_LP_\)#J/@OPP9+.PN/B_P##?Q&+&?QC\,X=2NYK6VB\2V=W
MI-CXH\ -J5Q]A;4X->\.)]DF\9/J=@ ?R+_\$>_^#C/]HC_@D!H6K?L9?M.?
M!'Q-\6/@'X'U_P 2Q:3\/-2>?X=_''X!>*]0UBXU3Q/X?TR/Q-8BWO?#UWKU
MUJ^HZIX#\4V6DZCI?B#4[S4=,\1:= U[HU^ ?M+^TM_P>T_!)?AKKEE^R!^R
M1\6[WXN:CH9M_#^O?M$7O@KP_P" O"GB"X14;4]0\/\ P[\9^,=;\:Z=IA9Y
M8--CUSP5-JKI$MQ?:;&SK0!^7/\ P05_X)/?M/?\%5?V[(_^"GW[;&C^(9O@
M#HWQ?N_C_K_C/QOI":;_ ,-.?&FW\1)XHT;PQX,T.>"VM;SX8:1XD^S7WBW4
M].TW_A"(=%T6/X7Z##))=WZ>& #_ $@OVFO^3;OV@_\ LB'Q7_\ 4#U^@#_-
M[_X,I_\ E*'^T'_V81\2O_6AOV8* /\ 3SH _AW_ &R/^#I+X[?\$X_^"K_[
M7_[+'QF^"7AGX^?LQ?#_ ,8>#K#P'#X8NX_AW\7_  %:ZQ\)? /B6Z2VUZ2V
MU3PWXYT>ZUG6-0OQIOB'1],UI'U%S;^,H],M+/2* .D^)O\ P>U_L<6GPUU.
M[^#7[(W[3'B#XPOI=PNC^'_B;-\+/!_PUMM;>-TM)=3\7^%?B'XY\47VEVLQ
MCN+B"U\$:==W\:/9QW.G-*+Z( _(/_@UA_8(_:*_:I_X*26__!3SQKX4?PS\
M"/@UXH^,/C*_\8SZ9-HF@?$CXU?%'PIXQ\-)X+^'=FZDZA9>%)O'M]XL\07=
MA+-IGAR/2M%T&^NS?:W:6[@'^G!0 4 ?AA_P<'?\$NO$'_!4W]@K5?AM\+1I
MJ?M#_!KQ;:?&;X%QZG=6NFV?BG7M*TC5M#\2?#2^UF\ M]*MO'?AC6+V+3+J
MZGLM,B\::3X.N-;O['1;;4+N  _@T_X)7?\ !;#]M/\ X()>-_'W[*GQ]_9^
M\6>*O@_=^+H]>\:_LZ?%8>(_A;\3OA5XIN(19ZKXG^&E_KFEW46D1>)K**RO
MM8T'6/#NI>'/%CZ5IFI:'J?ANYOM6US50#^B_P 3_P#![I^R%:^&7NO!O[%G
M[2.N^,OLDSQZ%XG\6_##PGX9-^(LP6[^+-*U3QIJJVDD_P"[FO%\%M-#%^]C
ML9W_ '% 'X!_M"?M[_\ !9/_ (.:/BC9_LT_ [X57NA_ K3]8TO5-0^#/PH.
MHZ3\'?"JP7?FZ?XX_:.^,/B!X(=<ETMP+O2[?7KO2M$>^T^VD\"_#Q_%S(=0
M /,O^"@?_!);]O7_ (-WOC/^S7^UM\*/BG=^,]'TP^&-9T#]I3X<^&+S2O#W
MP^^-ZZ=/#XO^$OC#1]3N=76;PYKULVJ6>@7/BB&UT7XK^!K_ %?1]0T*UO+7
MQ'X?M0#]R_!O_!\%HMI\(-+/C_\ 8%U;7?CU::;!;:PGA+XUV/ACX2ZYJT:B
M.YUG3[G5O!/BKQ?X9L;HC[7%X=GL/%4UGN^P'Q->!1J# '][>EWO]I:9IVH^
M7Y/V^QM+WR=_F>5]JMXY_+\S:F_9YFW?L3=C.U<XH O4 ?R;_P#!Y;_RB5\&
M?]GE?!W_ -5U\:Z -#_@S?\ ^41NN?\ 9W7QF_\ 4/\ A-0!_5Q0!SWB[_D5
M/$__ &+VM?\ IMN: /\ +"_X,]_^4P=E_P!FQ_&[_P!*?!5 '^B3_P %6_V!
MO#W_  4N_84^-_[)FJZA8>'_ !)XPTBQ\0_"WQAJ-O)/;>#/BSX-OHM?\#:W
M<^0DEU'I-UJ-J_AOQ.]G%+>OX1U[Q!;VD37$T08 _P R']@/_@H1^WA_P;A_
MMA?%?X5?$WX+7O\ 9FMZAHFB?M#_ +-GQ%GO="@\46?ARZU#_A&_'WPT\96
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M4]?\-Z3J7C5+CQ-X_=UT[Q3\0]9\40:4MO\ V-?Z#X= /]-;_@W>_P"4+7[
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MIHR0J\X!PW_!87_@[!^!W[:_[&_Q8_9#_9-_9O\ B[HG_"^-%M?!_C;XC?M
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#P;]J%$?]GKXO*Z*Z
MCP1J[@.H8!XXUDC<!@1NCD59$;JCJK*0RJ5_)/'G_DS?B1JU_P 8IFFVF]+5
M?-:/NM'NS]"\)U?Q)X*O_P!%!@']U6Z^YJ__  Q^9?\ P30_Y*_XX_[)M=?^
MI/X:K^&OH/\ _)R>*/\ LA\5_P"K[(3^JOI3_P#)%Y!_V5%+_P!5.:'4?\%*
MOANUCXE\%_%*QMB+77=/E\*Z[)%"H1-5TAGN]*N;N?.]I]0TVZFLX%PR"'0\
M91B!+[?TW^"_J?$/"O'N%HM4,[P-7AW-:D4E".994Y8S+*E1_%/$8[+\1BZ*
M>T:&30B[6BY>5]%KB?ZQE6?\)5ZB]KEV)IYSE\)-N<L)CE'#XZG!;1I87%4<
M/5>S=7,9-7N^7Y%_9^\':E\<_COX \/^()I-8LEN=)FU^34%N+F)O"'@?2[<
M?V5.\/S06\VC:/:^'+%W988YKFSC<MG:_P#._@]PQC/%/Q9X0R?-I3S/"_6,
MMK9W/%4IUZ4N&N$\NP\5@,6Z:3IX;$97E>#X=P]:;]R>)PD93<FG+]E\2<]P
MOA_X>\19CET88'$2IXVEE<*%2-&:SOB'&5IRQF'Y^=2K4<;CL5G-6G%2YHT*
M[C%15H?KK^WK_P FV^*?^PQX8_\ 3Q;U_H?]+_\ Y,AG?_8ZX9_]7&&/XV^C
MI_R=/*?^Q=G?_JMKGS?_ ,$P6"Z?\:F8A56Z\ LS,0 H$/C$DDG@ #DD\ <F
MOQ?Z"32I>*;;22EP6VV[))1XK;;;T22W;_0_3_I8)NKP&DFVX\3));M\V0:+
M?5^GWGQ%\7=:U_\ :0_:.\0MX2MI-6O/%?BA/#G@^T$DD,;Z1I2)I.E3/]LE
M6/3X'L++^UM2<F"VMGFOKN0#,LC?R[Q]FF<^-_C1G-3AVC+-,1Q'GSRCAC#T
MZK5&>49;#ZCEF(4J[4,'AZN78+^V,?*7)1H5*^-Q$[+G9^[\'X++?"WPPRQ9
MU4C@:.390LRSVK*G%U(YCCI_6\91:I)O$UZ>,Q2RW")<TZT:6%HP?P(^@3^S
M5^WB=/.DGQ%XH.EFS.G'33\7T^P'3S#]F-B;/_A(OL_V,V_[C[-L\GR?W6S9
M\M?LO_$$OI;_ %+^S?\ 6#B7^SOJOU'ZA_Q%"M]2^I>Q^K_4_JO]M^P^J_5_
MW'U?D]C[']W[/D]P_,EXH?1V6)^N+(\E6,5?ZTL6N!:/UE8GVGM?K'M_[/\
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MPD/VL? 7BCXL> ;>'7/B1^RWX[^(/@_X@:1I5DTVL:U\$[WQ+J%_X2\6VL<
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M]X?B.6+K5\#B:=#"T,HSE8FK5JT9PA34<1@,/2I-RE\>(K4*:U;DE8_G')_
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MK^*_$W_E(3$?]E%P1_ZJ>&S^U/#/_E'K#_\ 9-<<_P#JUXF/UF_X*W_LV_\
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M83$1H1Q"JUL'-TH8"OB\0XRBYT*>I^9W_!5GQC^PQX^^%\'B3P)XA^'OB?\
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MA5*4;1S+$U:U# 99.4&ZD:.(Q#QCARU%A'3J0G+]%=2_X-R_B_'I+S:3\?\
MP!=ZV(BR6-]H>NV>GM/CA&OX1=SB/=_RT^Q$D?P*3\OW<_ 7,E2O3S_!2K?R
MSPE:-._;G4Y2^:A]_P!G^=L/^T>\/YXKDQ/AYQ90P?-;ZQ2S+*L1747]KZK*
M-"+:WY/K,;[*2W/QF_:K_8P^/O[&WB^V\*?&KPC)I<&JB63PUXLTN7^T_"/B
M>&%(I)O[(UJ)1 ]W:I/$+[3IO*O+1VVO$RC?7Y/Q+PAGG">)C0S?"\E.J_\
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M-3_]5)XQH _:;_@W/_Y0I_L!_P#9+_%7_JV_B)0!^UU !0!^*7_!P?\ MO\
M_#!__!*_]HWXAZ)K']D?%#XK:,G[.WP;EBG^SWZ>._B]9ZCH]]K.E3 [HM4\
M%?#^V\<>/=.D"2#[=X6MHW4"7<H!_E"VOP&_:-_9B^"O[(O_  44T>*]\*^&
MOB1\<?B$/@+XRLXI#<Z?XX_9AUWX?:K'XF-P 8(%F\8ZMJ%EX?C?$EU??#WQ
M24\Q+*41 '^T+^Q-^U!X3_;4_9*_9Z_:J\%?9XM#^.7PL\+>.I--MIOM"^'?
M$-_8+;^,?"$TVYQ)>^#/&%KKOA342'<"_P!&N0)' #N ?45 '^?Q_P '._\
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MI(>-\;844 ?,/[%?_!LI\"_^">7_  4D^&7[</[,/QW\=+\,O!^A_%+2M5^
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M? K]IR;P6_@ZR\;Z9;Q"PU&]T?2/B!X%\6:D]O;16]MXM\+0ZUI$-F;6TC0
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MO2[^[\+>,M*UG0[F]TVZ5;K3[J:PDGL[A1-;/%* ] &=\%OV?O@+^S=X4O/
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MDM+22^T\WWV2[>UMVGBD:&,J ?55 'S=^T=^QU^RI^U]X?M/#'[4/[/'P?\
MCSI&F+<+HJ_$[P%X>\5ZCX<:[,9NYO"VN:E8RZYX6NKD11K/=^'M1TRZF1?+
MDF*'# 'PUX3_ .""/_!''P7JDNL:/_P3T_9WO+N:83/#XL\.:EX^TL..T6A^
M.M8\1:+!%QS;PZ?% >\7)H _4+X>?#;X=_"+P?HOP\^%'@+P7\,? 'ANV^Q>
M'? _P]\+Z)X,\(:#9[B_V71O#7ARQTW1M,M][,_DV-E!'O9FV[BQ8 X?XW?L
MT_LY?M,Z-HWAS]I#X ?!/]H+P]X<U.36_#V@_&[X5>!/BMHV@ZS-:R6,VKZ-
MI?CS0=?L=+U.6QFELY+^QMX+N2UEDMVF,+NC '7_  P^%7PO^"7@70OA?\&/
MAOX"^$7PT\++J">&?AW\,/!_A[P#X%\.)JVJWVNZJFA>$O"FG:3H&D+J>N:I
MJ>LZ@NGZ?;B]U74;[4;D2WEY<3. =;JVDZ5KVE:GH6NZ9I^M:)K6GWFDZQH^
MK6=MJ.E:MI6HVTEGJ&F:GI]Y'-:7^GWUI--:WEG=12VUU;2R03QO$[I0!\Z_
M!/\ 8J_8V_9I\1:IXO\ V<OV2OV9?@!XMUS19/#>M>*/@G\!_A9\*O$6L>'9
M;ZQU270-4UOP)X4T#4M0T634],T[49-*N[F:Q>^T^QNV@-Q:P2( ?35 'RM\
M3_V%/V(OC=\0#\6/C/\ L;_LK?%WXIF/2(O^%E_$_P#9Z^$?C[X@&+0$CCT&
M,^,O%?@_5O$?EZ)'%$FD)_:6W34BC6S$"H@H ^J: /'?C?\ L\_ ;]I?P9+\
M._VA_@S\+_CAX%EG^UCPG\5O WAOQYH=O?\ DR01ZG8V'B73M1AT[5K>*61;
M35K!;;4K,OOM;J)P&4 _-_2/^" ?_!&O1-<;Q#9_\$]_@'-?N5)M]7TSQ#K^
MA@J=PV^&->\0ZEX:09/S*FDJ&'RMN488 _2KX-? 7X'_ +.G@Z'X>?L__!WX
M7_!'P'!=2WT?@WX3> _"_P //#/V^XV_:=0?1/">F:5ITNHW14-=W\MN]Y=.
M-]Q/*_S* >L4 % &/XA\/:!XNT#7/"GBO0]'\3^%O$^CZGX>\2^&O$.F66M:
M!XAT#6K*;3=8T/7-'U*&YT[5M'U;3KFYL-3TR_MY[*_LKB:UNH98)71@#P?X
M(?L<?LA_LRZKKFN_LW?LK?LW_L^:YXFT^WTCQ)K/P0^!WPQ^%&J^(=*M+G[9
M:Z9KFH^ _"V@7>K:?;7>;JWLK^:XMH;G]_'$LOST ?2% 'B/C/\ 9F_9O^(_
MQ1\$?''XA_L^_!'QY\:OAG%90?#?XO\ C/X4^ _%'Q1^'T.FZC>ZOIT/@CX@
M:YH%_P"+/"D5AJVHZAJ=E'H.KZ>EKJ-]>WL 6YNIY& /;J /)OC-\ _@5^T;
MX2@\ _M"_!;X3?'CP):ZU9^)+;P5\9OASX.^*'A*W\1:=;7UEI^O0>'/&^C:
M[HT.M6-GJ>I6EGJD=DM]:VVHWT$,Z17DZ. 3?![X&?!/]GGP<OP\^ /P>^%G
MP-^'Z:G?:TG@;X/?#[PE\,_!R:SJ?DC4M67PSX*TC1-%74]0%M;_ &Z_%B+J
M[\B'[1+)Y2%0"Q\7?@Q\(OC_ . ]8^%WQR^&/@+XP?#?Q (?[:\"_$KPGH?C
M3PIJ3VTGFVD]UH?B&RO]/>ZLIPMQ8WGD"ZL;E4N;2:&9$D4 _-[P]_P0>_X(
M]>%_&$?CK2?^">W[.C:]#>07\4&K^%;OQ'X8BN;:3S86C\#>(M3U3P0D2R ,
MULOAT6TFT++$RA10!]R_%K]D3]D[X^^'O!?A+X[?LP?L\?&KPK\-X9K?X>>&
M?BU\%?AM\1_#W@*"XL['3KB#P7HWC'PQK.F^%H9]/TO3+&:+0[6P26STZQMG
M!@L[=$ /5/A[\.?A[\(_!?A_X;_"CP'X,^&/P[\)61TWPKX"^'OA?1/!?@OP
MSIQGFNC8>'_"WANQTS0]&LC=7%Q<FUTVPMH#//-,8_,E=W /"=4_84_8BUSX
MOQ?M":U^QQ^RMK'Q\@\5:/XZA^.&J?L]?"/4/B_#XW\/36-SH'C&+XE7?@^;
MQI'XJT.XTW3I]'\0IK:ZOILVGV,ME=P/:6Y0 ^G=1T[3]8T^_P!(U>PL]4TK
M5+.ZT[4],U&U@OM/U'3[Z![:]L+^RN4DMKRSO+:66WNK6XCD@N()'BE1D=E8
M ^;O@I^Q+^QE^S5XGU'QK^SG^R-^S%\ ?&6L:%<>%M7\6_!3X"?"KX5^)]5\
M,7>H:;JUUX<U'7O OA/0=5OM"N=5T;2-3N-(NKN73YM0TK3;V2W:YL;:2( ^
MD[N_L=/2*6_O+6RCGNK6Q@DN[B&V2:]OIX[6QLXGF9%DNKRZEBMK6W0M-<3R
M1PPJTCHM 'Q!^T__ ,$R?^"?O[9^L)XF_:>_9%^"'Q>\8)!#:'QWK_@RRL?B
M%+8VL'V:TT^Y^('A_P#L;QG=Z;9PC99Z=<Z[-96?#6UO$XWT <G\!/\ @F!_
MP3+_ &';V]^*OP2_9*_9X^"VM>%=*O-4NOBM=^&M-O/$WA+1M,MIKS4]2C^(
M_CFXUG7O#&GV]G%-<ZM?6VNV$#6UOYVH2O%;(8@#_-$^*GQ M?\ @LS_ ,'(
MFC>+/@[8ZQJO@+X[?MC_  =T/PS<F!FO6^!/P*L/!7A?7/B#]@DBC:QM'^$W
MPKUKXDSZ;<(LUC;S36UZS7<=P[ '^NA0!\K>!OV%/V(OAA\4T^.?PU_8X_96
M^'GQLCU'Q%K$?QB\#?L]?"/PG\4TU;Q?::G8>+-43X@Z!X/T_P 6KJ/BBQUK
M6;+Q%>C6/M.MVFK:G;:G+=0WUTC@'U30!XM\;?V;?V=OVF-"TCPM^T?\ _@M
M^T#X9\/ZN=?T'PY\;?A;X&^*VA:)KIL[G3CK6D:1X[T'7]/TW5SI]W=6)U*S
MMX+PV=U<VOG&":1& .I^%OPF^%?P.\"Z)\+_ (*?#/X?_!_X:>&CJ1\.?#OX
M6^#?#GP_\"^'SK&JWVNZN=$\)>$]-TC0-*.JZYJ>I:SJ7V#3[?[=JNH7VHW/
MFWEW<3. <3^T#^R_^SE^U=X-A^'W[2_P.^%OQV\&6E\-4T_P]\4O!.@>,K'2
M=5$30#5M$&MV-W-HFK"!WMQJFDR6=^+>26 7'E.Z, ?$GPL_X(@_\$E?@OXT
MM/B%\/?V!OV>=/\ %VGW_P#:NEZIKWA.7QU%I&I+S#?:+I7CR_\ $NC:-=6C
M@36$VEZ=:/IUPB7-B8)T1Z /KKXV?L6_L<_M*Z[H_BC]HW]DW]FCX_\ B;P]
MHX\/:!XB^-GP(^%OQ4UW0] %Y<Z@-#T?5_'?A37M0TW1QJ%Y=WPTRRN(+(7E
MU<W/D>=/*[ 'T)HNBZ-X;T;2?#OAW2=,T#P_H&F6&BZ%H6BV%KI6C:+HVE6L
M5CIFDZ3IEC%;V6G:9IUE!!9V%A9P06MG:PQ6]O%'#&B* ?-/@;]A3]B+X8?%
M-/CG\-?V./V5OAY\;(]1\1:Q'\8O W[/7PC\)_%--6\7VFIV'BS5$^(.@>#]
M/\6KJ/BBQUK6;+Q%>C6/M.MVFK:G;:G+=0WUTC@'U30!XM\;?V;?V=OVF-"T
MCPM^T?\  /X+?M ^&?#^KG7]!\.?&WX6^!OBMH6B:Z;.YTXZUI&D>.]!U_3]
M-U<Z?=W5B=2L[>"\-G=7-KYQ@FD1@#J?A;\)OA7\#O NB?"_X*?#/X?_  ?^
M&GAHZD?#GP[^%O@WPY\/_ OA\ZQJM]KNKG1/"7A/3=(T#2CJNN:GJ6LZE]@T
M^W^W:KJ%]J-SYMY=W$S@'9ZCIVGZQI]]I.KV%EJNE:I9W.GZGIFHVL%]I^HV
M%["]O>6-]974<MM=V=W;R207-M<120SPR/%+&Z,RL ?E+\0?^"$G_!'[XG^(
M[CQ5XJ_X)\_L[1:S=W8OKI_"'A:Z^'&FW-UG<\T^@_#K4_"V@RM.^9;L2::R
MWDKO-=+/)([4 ?6_[-O["7[&7['B:C_PR[^S!\$?@7>:Q EKK.M_#KX>>'=
M\3:U:1[#'::UXJM['_A)=6LXF0216FHZK=6T<I>:.-97D=@#T3XW?LT_LY?M
M,Z-HWAS]I#X ?!/]H+P]X<U.36_#V@_&[X5>!/BMHV@ZS-:R6,VKZ-I?CS0=
M?L=+U.6QFELY+^QMX+N2UEDMVF,+NC '7_##X5?"_P""7@70OA?\&/AOX"^$
M7PT\++J">&?AW\,/!_A[P#X%\.)JVJWVNZJFA>$O"FG:3H&D+J>N:IJ>LZ@N
MGZ?;B]U74;[4;D2WEY<3. =Q/!!=036MU#%<VUS%)!<6\\:303P3(8Y89H9
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M;GP%I_B?QKH-RI4B\T3Q=XQ/B+Q%I-^-H4:AI^I6U[L:2/SS'+(C@'Z+4 %
M!0 4 % !0 4 % !0 4 % '^>;_P7+_Y2E_M0_P#=$_\ UG;X25_6GAE_R1&2
M?]U+_P!6^//SW//^1IBO^X'_ *CT3\F:^\/)"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H _T,O^"&G_ "BT_9>_[K9_ZT3\6Z_DOQ-_Y+?._P#NF_\ JHP!
M^A9'_P BO"_]Q_\ U(K'ZS5\&>L% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M([94T#P'X:TSPQI68(?W<<CV6F0R2A2<RL[%F)9F /\ /^_X/A?^2Y?\$_\
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M[_DR3]C[_LZC4_\ U4GC&@#]IO\ @W/_ .4*?[ ?_9+_ !5_ZMOXB4 ?M=0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % 'XT_\%Z_V(OCW_P4'_X)O_$S]G+]FA?#,WQ?U#QO\+_&_ARR\5>)
MCX0LM1C\!>+[+Q!?6-AK[6ES:6.MSV]NW]D/J4NFZ<;M5%UJM@F)E /XC? O
MQF_X.^/^"?\ I\?PRTWP%^W)XR\(^#9'TZ/3-=^ FC?MG:!!:6P6.*TTSXF6
MW@SXPZN?#UG$B1:<OA_Q['HMG:HEO9&&U014 >>_&'PY_P '6G_!6_3(_@M\
M:OA1^V/>_#36-3LKR\\&>-O@SX=_8U^$=XBS@V;^*;G5_"?P6T7QCI&ERA=1
MM[3Q/J'BAK>X@@U&UMY=0BLY* /ZR/\ @@!_P;QZ)_P2L75_VBOVA?$?A;XI
M_ME^-?#DWAFUF\*)<WWP^^!?A#4I%EUCP_X'U35]/TW4_$'C#Q-'#:6_B_QM
M-I>E1VVG12>$?"]JNCW'B#6O&(!_4%0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?YYO_  7+
M_P"4I?[4/_=$_P#UG;X25_6GAE_R1&2?]U+_ -6^//SW//\ D:8K_N!_ZCT3
M\F:^\/)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _T,O\ @AI_RBT_9>_[
MK9_ZT3\6Z_DOQ-_Y+?._^Z;_ .JC 'Z%D?\ R*\+_P!Q_P#U(K'ZS5\&>L%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MQO\ XA%/_P"B@CE_X..KX12&#]E!WGV-Y*R_$>:.(R8^42.GA25U0G 9E1F
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M[Q]2#>6<:<(<;_7,+'$2=53C#,\HS+.L-.*_>5E*<*?/4G%'O'_!,;X9^./
M'[8_QU\0?$Z2[G^)GQK_ &:_A7\>?B(UPLR1:?XL^*OQ \9>(IO#5M!.TDMA
M'X3TB31_#!L))I&271Y9X]L$T4<7J<"9=BL#QCG5?&QJ?7LVX;RK.<PG*_*L
M;F.99E5EAXO5)82BJ&%C"_NQHIJZ:9^:_2FXGR/B'P:X"P/"\:$.%^"O$SBS
M@#AI4G"4Z^3\(<.9%E-/'U:L+1Q#S/%4\5F5/$*/[RCC*2J.5:-64OWOK]D/
M\_ H * "@ H * "@ H * "@#_]7^_B@ H * "@#_ #D/^"R__%6?\':?[!7A
M[Q)_H^BZ=\7O^";VBV)G^:*_TV7XQZ-KYMD'.$O];U?4-+]IG=N.M '^C?0!
M_G6?\'PO_)<O^"?_ /V2CXY_^I?X H ^7OA/_P $L?\ @ZN^*'P0^%%UX"_:
M2_:'T[X)>+OAGX"UCX>Z*/\ @HIJ7A_0K#X<:OX5TN^\&:;_ ,(UI_Q5\W2]
M,L_#=SIMO#H"V+1Z?%%%:?95^S*B 'V1^Q-_P9P?'SQ[\5;/XN_\%1?VBO#L
MWANXUF/Q+XK^&?PB\5^*?B#\4_B9>/(9[S3/'GQ?\4:/HUCX36_N%7^V-4\-
M#X@:UJFGO<VVGZUX;U.>WUFP /[^OAW\// WPD\!^#OA?\,O"NB>!OAY\/\
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MG3=7T6ZN'T^U2W8W(NV2SCE>9X' #H ?R?\ _#TK_@[Y_P"D<_\ YJ)XP_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _SS?\ @N7_ ,I2_P!J'_NB?_K.WPDK
M^M/#+_DB,D_[J7_JWQY^>YY_R-,5_P!P/_4>B?DS7WAY(4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % '^AE_P0T_Y1:?LO?]UL_]:)^+=?R7XF_\EOG?_=-_
M]5& /T+(_P#D5X7_ +C_ /J16/UFKX,]8* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M?U_F![)4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MAB4;*_AC.<WQF>YGC,VQ]3VF*QM5U:G\L(_#3HT](I4Z-.,:5/17C"[U;/\
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MF'_J?5/\T7XE?\E&^('_ &._BS_T_7]?Y_9I_P C/,O^QAC?_4FJ?]-63?\
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M12UOLNQYJ?V6_P!FIB6;]G_X,$DY)/PS\&DDGJ3_ ,2;J?Q^IZUQ_P!B9/\
M]"O+O_"+#?\ RL^F_P"(J^)W_1P^-K?]E/G7_P W"?\ #+7[-'_1OWP7_P##
M9^#?_E-1_8F3_P#0KR[_ ,(L-_\ *P_XBKXG?]'#XV_\2?.O_FX4?LM?LT@@
MC]G[X, @Y!'PS\&Y!]1_Q)AR/K^5']B9/_T*LN_\(L-_\K?]=MP_XBKXG?\
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M[?Y(B5:M*G&E*K4E2C.52-*4Y.G&<_BG&#DXJ<DES244WU;LBQ3,PH * "@
MH * "@ H * "@#__UO[^* "@ H * /\ .(_X.I4U3]E;_@MU^P#^VM=:;//X
M0L_!7[/_ ,0X)K562XU#Q/\ LT_M!:[XC\5:5 VW:]S;>';_ ,"RQN&9PVJ1
M(T:A$>4 _P!&?2=5TW7M*TS7-&O;?4M'UG3[+5=*U&TD$UI?Z;J-M%=V-[:R
MKE9;>ZM9HIX)%.'C=6&0: /\[S_@^%_Y+E_P3_\ ^R4?'/\ ]2_P!0!_=)^P
M9_R8U^QC_P!FH?L[?^J@\'T ?5] !0!_EZ_\'5MW:V'_  7;^$U]?7-O9V5G
M\'_V6[N\O+N:.WM;6UM_B!XPFN+FYN)F6*"W@B1Y9II66.*-6=V"J2H!_HQW
M_P"W1^Q+I=M)>ZG^V)^RQIMG$,RW=_\ M!_"6TMHQR<R3W/BV*)!@=6;U],4
M ?D+^WM_P<X?\$O/V,_!GB _#[XT>&OVP/C/#:7L?A3X6?L[Z]9^,/#]_K,2
M%+4^*_C'I4>I_#?PMH"7C1)JEW8ZMXE\30VWG3:3X0UN2!X* /XTO^"=O[&W
M[6O_  <E_P#!3WQ/^V;^U9IM['^S;H?Q T3Q/\=O%PTW4].^'Y\*^%)K&7PE
M^RA\(6DDQ<7-WH$%AX?U(VM_/J'A?PE<ZKX[\6:E=^+]<TA/%@!_JBV=G::=
M:6NGZ?:VUC86-M!9V5E9P16MI9VEM$L-M:VMM"J0V]M;PHD4$$2)%%$BQQJJ
M*HH LT % !0!\[_M>_\ )IO[4'_9N_QK_P#5:^): /X*/^#'[_DX']O?_LCG
MP;_]3;Q?0!_HOT % !0!_-W_ ,'+O[27_!23X%?L@>$/"'_!/CX1^-_$+?'G
MQ=+\*/BU\;?A9;ZEXB^*/PDLO$TFEZ+X0\->"/"F@6MQK^E:Q\6M5U6[\,VO
MQ1LQ*/!MU:V^B:9_9GC+QEX0US2P#R7_ (-[?^#?#PO_ ,$X?"NE?M3?M3:3
MHWC3]NWQOHKRVUK+)::[H7[-'A_7;0K?>$O"=\AN++5/B=JMG<2V7Q"^(%C+
M+#;0RW?@KP7>/X>;Q#K_ (Y /B__ (.%?^#>KQ)XN\2:O_P4W_X)D:1J_@S]
MI;P9J\?Q/^,'P?\ AA)=:%KGCO7-!NUUUOC=\$5T)K6]TGXU:3>VRZUXC\.:
M*T%Q\0KB!O$GAQ%^)27EE\0@#]]/^"'/[2O[;'[5W_!/7X4?%O\ ;R^$D_PQ
M^,5[)=:3HNO7]LF@:Q\;/A[IMEIJ^&?C5K?@'[+:3_#[5/&#RZA!<:/)!;66
MO_V4/'?AW3M'\*^+=#TJU /UZH * /XJ_P#@]N_Y,D_8^_[.HU/_ -5)XQH
M_2K_ (-^/VK/V7? W_!'/]A?PGXU_:1^ ?@_Q3HGPW\4VFM>&O%/QB^'GA_Q
M!I%T?BMX_G%MJFC:MX@M-1L+@PRQ3"&[MXI#%)'(%*.K, ?L?_PVQ^QI_P!'
M;?LR?^'Z^%G_ ,U% '\UG_!WG^WII?P<_P""<'@3]G+X=>*=/O?$O[=7BO3X
M?[1T'4[>\@O?V?\ X='0O'?BW6]+U/3I9XY]/\4>(K[X9>'K:>&7^S_$'AG7
M?$L45Q/;)/&X!X=_P;9?\$.OV-OB+_P31\&_M$_MG_LO_#3XV?$G]HWQQXN^
M(?@RY^)OA]M5O_"/PATRX@\$^"M)T^&25([>V\1W7AK7O'\-U&&?4-+\6Z.9
M&V6T*( ?OU_PXF_X(]_]([_V9O\ PA(?_C] '\=G_!V?_P $@?V>_P!D3P!^
MS+^UE^QY\#O!_P %OAQ<^(=<^!GQI\,?#W27TS0?^$CU>UNO&?PM\7SV$3RI
M#=7]MI7C[P[K6JRB*.1K7P;IQE,SV\3@']9O_!OG^W!_PWC_ ,$L/V<OB+K>
MK_VO\4/A7HS?L[?&666?[1?OX]^$-GIVC6>M:K,SL\VJ>-O %SX(\?ZC*5C4
MWWBJYC1-L6: /X-O^"K?[*O[17_!OU_P5_\ #7[7_P"SGI+:1\(?$_Q6UWXZ
M_LO^)VM;JZ\&2:9K\MT?BE^SIXJ,7D/!%HVG^)=>\"WVD+J U/5?A9K^@Z[9
MZI%JUY>G2@#^]O\ X)N_\%VO^"?O_!2'X?>&=0\&_&/P;\(OCE=V-E%XQ_9M
M^+7BS1O"OQ'\/^))$V7MCX2?6I=(LOBIX?\ /0RZ9XF\#?VB'T^YL/\ A(M+
M\+ZY/<^'[( _4SXB?&OX-_"'P[=>+_BQ\6OAI\,?"=C8OJE[XG^(7COPOX,\
M/VNFQKNDU"XUCQ%JFG:?#9HHRUS)<K"/^>BYPP!_F#?"KXM_#7X[_P#!VUX3
M^+OP>\9:)\0OAGXZ_;UCUCP=XV\-W+7F@^)-)7PS+9#4](O#'&+RPEN+6=;>
M[C4P74:">WDE@>.5@#_5&H * "@#\_\ 3?\ @J+^PQ=?M@_%;]@W6?C[X3\"
M_M2?"*?PI%K/PV^(LS>!V\4Q^,_ /ACXCZ-+\.?$/B 67ASQW<+X<\5Z?)J&
MAZ%JL_B73IK;4)+G1$TVV34K@ ^V_%7C/P?X%\+ZOXX\;^+/#7@[P7H&FS:S
MKOB_Q5KNE^'O"^B:/;Q>?<:KJ^OZO=V>DZ;IL$ ,TU]>7D-K%$/,>54RU '^
M5U_P7N_:6T+_ (+8_P#!8?X3_!W]A"RE^+EAX>\)^"?V4/AOXJT&T^T:7\3_
M !>/'/C7QAXP\=:+J$4;3GX:>'W\87%N?$=X(M&BT#P=KWCF&=?#>H)J#@'^
MJ'X)\,P^"_!GA'P=;W,E[!X3\,:!X9@O)5V2W<.@Z5:Z7'<R)ODV23I:K*Z[
MWVLY&]L;J /\_C_@]K^+D'B_XS_\$^OV5?#,,^I^,] \(?%;XL:GH]F3<7=Z
MGQ=\4>#?AY\/+6WM(P7-U<ZE\+/&\$*G>]PUQ$D:IM)E /[R/V<?AK<?!C]G
MKX#_  >NS;M=_"CX,_"_X:W36C;[1KCP+X(T+PO,;5\#=;F32F,+8&Z/:<#.
M* /9J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_/-_P""Y?\ RE+_
M &H?^Z)_^L[?"2OZT\,O^2(R3_NI?^K?'GY[GG_(TQ7_ ' _]1Z)^3-?>'DA
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Z&7_!#3_E%I^R]_W6S_UHGXMU
M_)?B;_R6^=_]TW_U48 _0LC_ .17A?\ N/\ ^I%8_6:O@SU@H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * /._B]_P DF^*'_9._&O\ ZC6IU\?XA_\ ) <<?]D?Q-_ZI<:?0<)_\E5P
MS_V4&3?^K'#'YU?\$P?^//XU_P#7WX _]%>,J_B_Z"/^Y>)G_81PC_Z:XB/Z
M;^E?_OG!'_8-G_\ Z=R@_5FO] #^1 H * "@ H * "@ H * "@ H * "@ H
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MZ];"X/#S/N;_ (?O?\$^O^AO^(O_ (;'Q'_\;KZW_B,_ O\ T&8__P ->/\
M_E9^$_\ $A/T@?\ H7\,?^)+A/\ Y6'_  _>_P""?7_0W_$7_P -CXC_ /C=
M'_$9^!?^@S'_ /AKQ_\ \K#_ (D)^D#_ -"_AC_Q)<)_\K/J#X%?M:_LM_\
M!1_P%\9/ /PXN]>\4>%X/#Y\(?$/3?$7AC5_#9;2/'VF:QI\8M);Z.-9GFM[
M34 DMG.+JQGABG'E.T$R_39'Q3PYQW@\SPN73K8K#PI?5<=3Q&$Q&&3IXVG5
MARKV\8\_/&,T^36-DVU>+/R[CWP@\5?HU9[P5Q+Q##+LMS.IFG]K<-XS+,SP
MV8\F8<.XG XN3JPI^_!4JE?"2M5I^QKPJ3IWGRU(1_AD_:U_9N\8_LH_'GQ[
M\%_&-K<++X;U:=] U:2W>"V\2^%;QS<>'_$%B2HC>#4-/>%Y4A>5;.[%Q8O*
MTMNYK^.N*N'<3POGF-RC$1ERT:CGA:S5HXC!U)2>'K1>SO"T:EOAJQG'I$_W
M4\*?$C)?%G@/A_CG))TU1S;"0^OX.%15)Y5G%&,89IE=;:2G@\5S1IN<82J8
M:5"NHJ%:+/G:RO;O3KRTU"PN9[.^L;F"\LKNVD>&XM;JVE6:WN()4*O%-#*B
M212(RLCJ&!! -?/PG.G.%2G*4*E.49PG!N,H3@^:,HR6L91DDTUJFKKH?H-2
MG3K4ZE&M3IUJ-6$J=6C5A&I2JTYQ<9TZM.:E"I3G%N,X3C*,HMQDFFT?T[?L
M2?\ !?>WT'PWHWPY_;)\/ZUJUUI*6NG:=\:O!UJ=2O\ 4=/14B63X@^%VE%W
M<ZI9JKM-XA\,F[EU>-X([KPW;W\%WJVJ_P!$<(^-E.EAZ.!XLH5YSI*%.&<8
M2"JNK!*W-CL)%JHJD4DG6PD:OMF[RH49*4Y?YC>.'T ?[5S3'\3>#699?EE/
M%NKB\1P/G$ZN'P='$OFE*EPYFE.G65'#UY./L\NS6-.CA)>VE3S58:>'P6%_
M3>^_X+<?\$];+2VU-?BGK]ZXB61=,L_ ?BB74V9]F(O(:PCC5U+?/NE"J%8^
M8<?-^@S\7^!(4E5_M2O*ZNJ<,NQSJ7>R</8JS[WT75JQ_-%/Z"/TBYU_8U.&
M\BHTU*T\5/B[A^=&,;_Q%&ACJN(FMGR4Z-2;_ET]W^?7_@I!_P %A/'7[8&G
M7GPC^$6F:S\+?@)-)'_;=O>W4*>-?B1Y:HWD>*)=-FFM=+\-1S[VC\,V-Y=Q
MZF%BN-;N9"L>FVOXGQ[XJ8OB>E4RK*:=;+LEG95_:2BL;F$;:TZZI3G3HX5R
MWP\*E1UHI>VFHRG0/] /HX_0[X>\&\12XLXKQ>#XMX_@JL<)B:%&I_87#L92
MG!SR>GBZ=/$8K'5J%N?-,7A\-5HQJ3P^%PN'M/$8K\4Z_(#^TR]IG_(2T_\
MZ_K3_P!*(ZJ'QQ_Q1_,3V?HS_3A\'?\ )/\ PM_V)VA_^F2UK_0VA_N='_L&
MI_\ II'_ #"9Y_R4N;_]CS,/_4^J?YHOQ*_Y*-\0/^QW\6?^GZ_K_/[-/^1G
MF7_8PQO_ *DU3_IJR;_D497_ -B_!_\ J/3/=/V'?^3O_P!F_P#[*_X,_P#3
MG'7M\$_\E;P[_P!C?"?^E2/A?&?_ )-)XE_]D+Q5_P"J3''^CO7]WG_-F% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!_]?^_B@ H * "@#^5O\ X.VOV!=2_:R_X)TVO[0O@?3I]3^)
MG[#>O:U\4S8VL/GW.I_!7Q;:Z3I'QJMK>-4W1OX?MM$\(_$B]NGF6*'P_P"
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MW7?_ ,1,XW_Z'?\ YC<I_P#F$Q_L+*O^@;_RMB?_ )>'_#C3_@EI_P!&O?\
MF;/VB?\ Y[='_$3.-_\ H=_^8W*?_F$/["RK_H&_\K8G_P"7A_PXT_X):?\
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M1,XW_P"AW_YC<I_^80_L+*O^@;_RMB?_ )>'_#C3_@EI_P!&O?\ F;/VB?\
MY[='_$3.-_\ H=_^8W*?_F$/["RK_H&_\K8G_P"7A_PXT_X):?\ 1KW_ )FS
M]HG_ .>W1_Q$SC?_ *'?_F-RG_YA#^PLJ_Z!O_*V)_\ EX?\.-/^"6G_ $:]
M_P"9L_:)_P#GMT?\1,XW_P"AW_YC<I_^80_L+*O^@;_RMB?_ )>'_#C3_@EI
M_P!&O?\ F;/VB?\ Y[='_$3.-_\ H=_^8W*?_F$/["RK_H&_\K8G_P"7A_PX
MT_X):?\ 1KW_ )FS]HG_ .>W1_Q$SC?_ *'?_F-RG_YA#^PLJ_Z!O_*V)_\
MEX?\.-/^"6G_ $:]_P"9L_:)_P#GMT?\1,XW_P"AW_YC<I_^80_L+*O^@;_R
MMB?_ )>'_#C3_@EI_P!&O?\ F;/VB?\ Y[='_$3.-_\ H=_^8W*?_F$/["RK
M_H&_\K8G_P"7A_PXT_X):?\ 1KW_ )FS]HG_ .>W1_Q$SC?_ *'?_F-RG_YA
M#^PLJ_Z!O_*V)_\ EX?\.-/^"6G_ $:]_P"9L_:)_P#GMT?\1,XW_P"AW_YC
M<I_^80_L+*O^@;_RMB?_ )>'_#C3_@EI_P!&O?\ F;/VB?\ Y[='_$3.-_\
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M_P#GMT?\1,XW_P"AW_YC<I_^80_L+*O^@;_RMB?_ )>'_#C3_@EI_P!&O?\
MF;/VB?\ Y[='_$3.-_\ H=_^8W*?_F$/["RK_H&_\K8G_P"7A_PXT_X):?\
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M1,XW_P"AW_YC<I_^80_L+*O^@;_RMB?_ )>'_#C3_@EI_P!&O?\ F;/VB?\
MY[='_$3.-_\ H=_^8W*?_F$/["RK_H&_\K8G_P"7A_PXT_X):?\ 1KW_ )FS
M]HG_ .>W1_Q$SC?_ *'?_F-RG_YA#^PLJ_Z!O_*V)_\ EX?\.-/^"6G_ $:]
M_P"9L_:)_P#GMT?\1,XW_P"AW_YC<I_^80_L+*O^@;_RMB?_ )>'_#C3_@EI
M_P!&O?\ F;/VB?\ Y[='_$3.-_\ H=_^8W*?_F$/["RK_H&_\K8G_P"7A_PX
MT_X):?\ 1KW_ )FS]HG_ .>W1_Q$SC?_ *'?_F-RG_YA#^PLJ_Z!O_*V)_\
MEX?\.-/^"6G_ $:]_P"9L_:)_P#GMT?\1,XW_P"AW_YC<I_^80_L+*O^@;_R
MMB?_ )>'_#C3_@EI_P!&O?\ F;/VB?\ Y[='_$3.-_\ H=_^8W*?_F$/["RK
M_H&_\K8G_P"7A_PXT_X):?\ 1KW_ )FS]HG_ .>W1_Q$SC?_ *'?_F-RG_YA
M#^PLJ_Z!O_*V)_\ EX?\.-/^"6G_ $:]_P"9L_:)_P#GMT?\1,XW_P"AW_YC
M<I_^80_L+*O^@;_RMB?_ )>'_#C3_@EI_P!&O?\ F;/VB?\ Y[='_$3.-_\
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M_P#GMT?\1,XW_P"AW_YC<I_^80_L+*O^@;_RMB?_ )>'_#C3_@EI_P!&O?\
MF;/VB?\ Y[='_$3.-_\ H=_^8W*?_F$/["RK_H&_\K8G_P"7A_PXT_X):?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M]O@G_DK>'?\ L;X3_P!*D?"^,_\ R:3Q+_[(7BK_ -4F./\ 1WK^[S_FS"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MU*$YP/MJOJS\*"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H _]'^_B@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * /._B]_R2;XH?\ 9._&O_J-:G7Q_B'_ ,D!QQ_V1_$W_JEQI]!P
MG_R57#/_ &4&3?\ JQPQ^=7_  3!_P"//XU_]??@#_T5XRK^+_H(_P"Y>)G_
M &$<(_\ IKB(_IOZ5_\ OG!'_8-G_P#Z=R@_5FO] #^1 H * "@ H * "@ H
M * "@ H S=8UG2/#VF7VMZ]JFG:)HVF6\EWJ.K:M>VVG:;86L0S+<7E[=RPV
MUM!&.7EFE1%[L,BFDV[+=@?DW^TK_P %-M#T./4/"'[/<<7B#6R)[6X^(VI6
MI.@Z5($">9X;TB\AW:]<QR.YCO\ 4T@T>.6V!CLM;M+E)EWA1ZS_ / >_J^G
M3:_WW40^$_@=^RI\<?VNO%-UXY\0WNIZ=X9U74/M/B/XH>+%N;J;59/-\BXB
M\/V]Q)%<>([^%()85$$L.DV)MTM;[4+%WMH9=)3C!6TOTBNGKKHO7F;Z:78'
M] ?P6^!OP[^ ?A&#PA\/='%G;D0R:OK-WY-QK_B.^A1D&HZYJ$<4/VJ?YY3#
M!%%!86*S2QZ?9VD3O&W+*3D[MW[>7EU_%W]0/7ZD H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_TO[^* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__3
M_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@ _X>D_\'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]*^W_ )N;\,?_ )!H /\
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MZ3_P<$?]*^W_ )N;\,?_ )!H /\ AZ3_ ,'!'_2OM_YN;\,?_D&@ _X>D_\
M!P1_TK[?^;F_#'_Y!H /^'I/_!P1_P!*^W_FYOPQ_P#D&@ _X>D_\'!'_2OM
M_P";F_#'_P"0: #_ (>D_P#!P1_TK[?^;F_#'_Y!H /^'I/_  <$?]*^W_FY
MOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\ FYOPQ_\
MD&@ _P"'I/\ P<$?]*^W_FYOPQ_^0: #_AZ3_P '!'_2OM_YN;\,?_D&@ _X
M>D_\'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]*^W_ )N;\,?_ )!H /\ AZ3_
M ,'!'_2OM_YN;\,?_D&@ _X>D_\ !P1_TK[?^;F_#'_Y!H /^'I/_!P1_P!*
M^W_FYOPQ_P#D&@ _X>D_\'!'_2OM_P";F_#'_P"0: #_ (>D_P#!P1_TK[?^
M;F_#'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\
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M^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\ FYOPQ_\ D&@
M_P"'I/\ P<$?]*^W_FYOPQ_^0: #_AZ3_P '!'_2OM_YN;\,?_D&@ _X>D_\
M'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]*^W_ )N;\,?_ )!H /\ AZ3_ ,'!
M'_2OM_YN;\,?_D&@ _X>D_\ !P1_TK[?^;F_#'_Y!H /^'I/_!P1_P!*^W_F
MYOPQ_P#D&@ _X>D_\'!'_2OM_P";F_#'_P"0: #_ (>D_P#!P1_TK[?^;F_#
M'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H
M/^'I/_!P1_TK[?\ FYOPQ_\ D&@ _P"'I/\ P<$?]*^W_FYOPQ_^0: #_AZ3
M_P '!'_2OM_YN;\,?_D&@ _X>D_\'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]
M*^W_ )N;\,?_ )!H /\ AZ3_ ,'!'_2OM_YN;\,?_D&@ _X>D_\ !P1_TK[?
M^;F_#'_Y!H /^'I/_!P1_P!*^W_FYOPQ_P#D&@ _X>D_\'!'_2OM_P";F_#'
M_P"0: #_ (>D_P#!P1_TK[?^;F_#'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0:
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M3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\ FYOPQ_\ D&@ _P"'I/\
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M_P#!P1_TK[?^;F_#'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0: #_AZ3_P<$?\
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M?]*^W_FYOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\
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M@ _X>D_\'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]*^W_ )N;\,?_ )!H /\
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MZ3_P<$?]*^W_ )N;\,?_ )!H /\ AZ3_ ,'!'_2OM_YN;\,?_D&@ _X>D_\
M!P1_TK[?^;F_#'_Y!H /^'I/_!P1_P!*^W_FYOPQ_P#D&@ _X>D_\'!'_2OM
M_P";F_#'_P"0: #_ (>D_P#!P1_TK[?^;F_#'_Y!H /^'I/_  <$?]*^W_FY
MOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\ FYOPQ_\
MD&@ _P"'I/\ P<$?]*^W_FYOPQ_^0: #_AZ3_P '!'_2OM_YN;\,?_D&@ _X
M>D_\'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]*^W_ )N;\,?_ )!H /\ AZ3_
M ,'!'_2OM_YN;\,?_D&@ _X>D_\ !P1_TK[?^;F_#'_Y!H /^'I/_!P1_P!*
M^W_FYOPQ_P#D&@ _X>D_\'!'_2OM_P";F_#'_P"0: #_ (>D_P#!P1_TK[?^
M;F_#'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\
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M^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\ FYOPQ_\ D&@
M_P"'I/\ P<$?]*^W_FYOPQ_^0: #_AZ3_P '!'_2OM_YN;\,?_D&@ _X>D_\
M'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]*^W_ )N;\,?_ )!H /\ AZ3_ ,'!
M'_2OM_YN;\,?_D&@ _X>D_\ !P1_TK[?^;F_#'_Y!H /^'I/_!P1_P!*^W_F
MYOPQ_P#D&@ _X>D_\'!'_2OM_P";F_#'_P"0: #_ (>D_P#!P1_TK[?^;F_#
M'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H
M/^'I/_!P1_TK[?\ FYOPQ_\ D&@ _P"'I/\ P<$?]*^W_FYOPQ_^0: #_AZ3
M_P '!'_2OM_YN;\,?_D&@ _X>D_\'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]
M*^W_ )N;\,?_ )!H /\ AZ3_ ,'!'_2OM_YN;\,?_D&@ _X>D_\ !P1_TK[?
M^;F_#'_Y!H /^'I/_!P1_P!*^W_FYOPQ_P#D&@ _X>D_\'!'_2OM_P";F_#'
M_P"0: #_ (>D_P#!P1_TK[?^;F_#'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0:
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M3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\ FYOPQ_\ D&@ _P"'I/\
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M_P#!P1_TK[?^;F_#'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0: #_AZ3_P<$?\
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M?]*^W_FYOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\
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M@ _X>D_\'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]*^W_ )N;\,?_ )!H /\
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MZ3_P<$?]*^W_ )N;\,?_ )!H /\ AZ3_ ,'!'_2OM_YN;\,?_D&@ _X>D_\
M!P1_TK[?^;F_#'_Y!H /^'I/_!P1_P!*^W_FYOPQ_P#D&@ _X>D_\'!'_2OM
M_P";F_#'_P"0: #_ (>D_P#!P1_TK[?^;F_#'_Y!H /^'I/_  <$?]*^W_FY
MOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\ FYOPQ_\
MD&@ _P"'I/\ P<$?]*^W_FYOPQ_^0: #_AZ3_P '!'_2OM_YN;\,?_D&@ _X
M>D_\'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]*^W_ )N;\,?_ )!H /\ AZ3_
M ,'!'_2OM_YN;\,?_D&@ _X>D_\ !P1_TK[?^;F_#'_Y!H /^'I/_!P1_P!*
M^W_FYOPQ_P#D&@ _X>D_\'!'_2OM_P";F_#'_P"0: #_ (>D_P#!P1_TK[?^
M;F_#'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\
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M^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\ FYOPQ_\ D&@
M_P"'I/\ P<$?]*^W_FYOPQ_^0: #_AZ3_P '!'_2OM_YN;\,?_D&@ _X>D_\
M'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]*^W_ )N;\,?_ )!H /\ AZ3_ ,'!
M'_2OM_YN;\,?_D&@ _X>D_\ !P1_TK[?^;F_#'_Y!H /^'I/_!P1_P!*^W_F
MYOPQ_P#D&@ _X>D_\'!'_2OM_P";F_#'_P"0: #_ (>D_P#!P1_TK[?^;F_#
M'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H
M/^'I/_!P1_TK[?\ FYOPQ_\ D&@ _P"'I/\ P<$?]*^W_FYOPQ_^0: #_AZ3
M_P '!'_2OM_YN;\,?_D&@ _X>D_\'!'_ $K[?^;F_#'_ .0: #_AZ3_P<$?]
M*^W_ )N;\,?_ )!H /\ AZ3_ ,'!'_2OM_YN;\,?_D&@ _X>D_\ !P1_TK[?
M^;F_#'_Y!H /^'I/_!P1_P!*^W_FYOPQ_P#D&@ _X>D_\'!'_2OM_P";F_#'
M_P"0: #_ (>D_P#!P1_TK[?^;F_#'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0:
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M3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\ FYOPQ_\ D&@ _P"'I/\
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M_P#!P1_TK[?^;F_#'_Y!H /^'I/_  <$?]*^W_FYOPQ_^0: #_AZ3_P<$?\
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M?]*^W_FYOPQ_^0: #_AZ3_P<$?\ 2OM_YN;\,?\ Y!H /^'I/_!P1_TK[?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __6_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MV&;4O[7MKX65AIE^+^RO_L&FF2(C4Q:S1&U_=7-M*!,^XHCJ0Y)6O?1/MO\
M\-_5P/I:H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /__7_OXH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]#^_B@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * /BK]MG]J2S_9U^'4EEH-[ WQ4\:6MW9>"[,Q17;:-" (+[Q?
M?6\H>W%OI/FA=*AO(Y8=2UDP1&TOK"SU=+?2G#G>OPK?S_N_/K;;[@/G3_@G
M3^R_=Z)8C]I+XDQSWGC+QG;7-UX'M=5A>2^TS1=8\UKWQC=W%V7N)-7\6P7#
M_P!GS*J%/#]Q+>&YO5\0*FGW6G]A;+?_ "^7RUTZ7D?U_7_#_>?K!6 !0 4
M% !0 4 % !0!RNIO=>'V_M*T1[G2AL34=/4YDM(1M1+K3T(&5A7Y'M0<>5Y:
MQ[88HT@I6>CT\^_ETZ^?DK"VN^G;^K6^_P ]-3HK6[MKZWAN[29)[>=!)%+&
M<JRG]00>&5L,K JP!&*EJV@RQ0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M*7IW[/?_ "7SX'_]E?\ AI_ZFFBUR9E_R+L?_P!@6*_],5#7#_[Q0_Z_4O\
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MEYDE*>LC3*\KEEL\3>M&K"LJ7(^5QDN3VE^97:^VK--WU;Y;)'U__P %*O\
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M!X424<3G4I-1BL-@VY2:22]I7U;=DE\_N.+B9-TL(DFVZE2R6K^&)_-9JO\
MP3I_:\\+?LW>.?VKOB#\(M>^%WP<\#?\(M&VH_$JWNO"'B3Q5<>+O%>A^$=+
MB\)>#M2ME\27]N+O7[34I=:U'3M*\.3:5#=2:?K-]?I;V%Q^GPXER:KF>'RC
M#XVGB\;B/:VAA6JU*DJ-&I6FZU:$O91?+3E%0C*=53:4J48^_'YMY=BXX:>*
MJ494J-/DUJ^Y*7/.,%RP:YFKM.[48VU3>BE\0U[QQ'^M!\,?^2;?#W_L1_"?
M_IAL*_C[%?[SB/\ K_6_].2/U2C_  J7_7N'_I*/RV_X+J?'37O@7_P3B^+\
MWA:^N=+\0?%;4_#'P6L]3M9?*FM-,\;WDTWC&-6!#XU7P)HWBC0R8V62+^U/
MM"$F'%?6< 9?3Q_$V"5:*E3P<:N.<'M*>'BO8=_@Q$Z-356?);6YYN=UY4,N
MK<K:E5<:*:=K*;]_H[WIQG'2V][Z'^=]H.B:CXEUS1O#FD0_:=6U_5M.T33+
M?.//U'5;R&QLH<X./-N;B),X.-V<'I7])5*D:5.I5F[0IPE4F^T81<I/Y),_
M/HQ<I**WDU%>K=E^)_HG_ ?_ ((H?L#_  M^ NC?"7QU\"/ WQ;\67?AZUM_
MB#\4O%MA->>-->\3W%HHUK5/#7B%9K?6/ ^EK>O,F@:;X7N=(?3].BLQ>SW^
MJ"\U*]_FS,..N(<7F%3%X?,,1@Z*JR>&PE&2C0ITE+]W"K3]Z%>?*E[2=7GY
MY<UHPARPC^@T,FP-*@J4Z$*LW']Y5FKSE*VKC*]X*]^51Y;+?6[/X??^"CG[
M)4?[$G[8'Q9_9_TS4;W6/"6@WVF:_P##_5M2DBFU.]\"^+M+M=?\/1:K-!#;
M17&K:/!>2^']6NXK2S@O=3TF[O+:UAMIX47]WX9SAY[DN#S&<8PK5(SIXF$$
MU".(HS=.HX)RDU";C[2"YI.,9J+=U[WQ6883ZEBZN'3<HQ:E3;W<)KFBGM[T
M;\K=M7%M631_1]_P;"?M&:MKG@?]H+]EK7;^:ZLO FI:'\7/A_#<7#SFQTOQ
M:\WA_P =:7:1R,?L>F6NMZ;X:UB"VMQY#:IXFUN[=(KBZD>Z_,_%7+(4\1EV
M;4XI/$0J8/$-*W-.C:IAY-KXI2ISJP;>O)2@EHCZ+AK$.4,1A9.Z@U6IZ[*?
MNS2[)247IUDW97O+^K>OR(^I"@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MLIP0<C(-9C'4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M.KY7GB)UI7M>SC%N7*N7]!R.A&CEU%I+FK<U:;[\SM#[H**WM>[TN4_VW/\
M@MA^S;^PE\<;KX"?$[X:_&_Q5XJM/"WA[Q7-JO@/2? EWX?-EXD2ZDL[:.?Q
M!X\\/ZBUU"EHQN0VG)"K.JQ2R@%JK(N!LTX@P"S#"8K 4J+K5*/)B)XA5.:E
M;F=J>'J1L^96]Z_I=H,;G6&P-=T*M.O*2C&=Z<*;C:6VLJL'?3MZ;L^1/^(G
MG]BO_HB'[47_ ((/A1_\]>O9_P"(5Y[_ -!V4_\ @S%__,AR?ZS8+_GSBO\
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M1:KI\*XZ*=O;5L'2?I]:I5&OG[.SVT^:ERY#%2S.BW]B%:7S]G*/X<U_R/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^7/_ -P#_B*)_P"K&_\ S9G_ /)]H_X@G_U4O_F&_P#PL'^M'_4#_P"7/_W
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ML;_\V9__ "?:/^()_P#52_\ F&__  L'^M'_ % _^7/_ -P#_B*)_P"K&_\
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M^7/_ -P#_B*)_P"K&_\ S9G_ /)]H_X@G_U4O_F&_P#PL'^M'_4#_P"7/_W
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M2"-:J:O[RZ[_ -?\#3SN*_3MK^7^:_X9'M%0,* "@ H * "@ H * "@ H *
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MC?W<Z^\_JZK\B/J3\;O^"^O_ "BT_:#_ .PW\%O_ %=G@"OM?#W_ )*W+?\
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M^OF<:J7>G0PV(C/[I5Z7W^9['#4&\77J=(8=Q^<ZE-K\(2_JY_<+7X,?:A0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 ?YYO\ P7+_ .4I?[4/_=$__6=OA)7]:>&7_)$9)_W4O_5OCS\]SS_D
M:8K_ +@?^H]$_)FOO#R0H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /]9BOX//U@* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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ME-0U9V[?UY_G]Y1J4@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^&G_ *FFBU^W9E_R+L?_ -@6*_\ 3%0^.P_^\4/^OU+_ -+1_JA_$OP!X?\
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MA[VB4^63WLE9R^7S[&8?%UJ/U>HJBITY1FTI**DY723DDI:+>-UYMZ1^4_\
M@B;_ ,I1/V3/^QG\=?\ JH_B#7K\=?\ ))YQ_P!>L/\ ^IN&.7)?^1GA?\53
M_P!,U#^ZW_@I5_RCY_;3_P"S9?C+_P"H+K5?@7"W_)1Y'_V-,%_Z?@?;YE_N
M&,_[!JW_ *0S_,#K^JC\T/[IO^"<'_!6;_@GK\#OV%/V;?A?\4_VD-%\)^/O
M ?PYAT;Q9X:F\#_%+5+S2=3AU;5)I+0RZ'X'U.RO'$4T4BOIUS=QR*X,;OR%
M_ N)N#^),?G^:8O"99.MA\1B7.C55?"0C.#A!7_>8F$HZIZ2C%]-/B/M\NS7
M 4,#AJ57$J%2%.TX\E5M.[TO&#3T[/[[,YS]KK_@Y(_9G\"^%-9T;]D71/$/
MQP^)%Y:W%MH7BSQ/X;UOP-\+=!N9(MD.KZC:>(H-'\=^(WLY7$R>'X- T&#4
M5BDCF\2Z:-C3ZY-X8YKB*T)YS4I8#"QDG4HTJL,1BZB3UA&5+GP].ZT]HYU'
M&^E*=FXSB^(\-"+CA(RKU&GRSE&4*4?-J2C4E;^7E5^KCHS^+7XF_$KQQ\8_
MB#XP^*?Q+\17_BSQYX\U_4/$OBGQ#J;J]UJ6K:E,TT\FQ%2"UM804MK#3[2*
M"PTVP@M=/L+>WLK:W@B_<,+A</@L-0PF%IQHX?#TXTJ-.*TC""LN[<GO*4FY
M3DW*3E)MGQM6I.M4G5J2<ZE23E*3W;?W671)*R6BLDC^JC_@V\_8)\0VFM^(
M/V\/B5H5YI6DC1=4\"_L^P:A$8'UR35FET_Q]\0[:)_+G&G6=E;R>"]!O,26
MNJ/JOB\A!_9EE<2_DGB;Q#3E3I\/X6HIS]I&OF+B[JGR6EA\,WJN9R?MJD='
M#DHZ^]*)]3P[@))RQU2-ERN&'OUOI4J+R2]R+V=Y]D=Q_P '0GP(U+5/!?[-
M7[2.E6DDUAX2UOQ5\(O&4\4#2FWB\6V]IXI\$W,\D8)MK*&\\.>+K*6>?]P;
M[5],ME>.>Y1+C#PIS",*^:99.24JU.CC*";M?V+E2KI=Y-5:,K*SY82>J3Y;
MXFH-PPV(2TA*=*??WUS0?I>$UTUDEU2E_,!^QG^T)=?LI_M3? S]H2"UN;^V
M^&'Q TC6]=TZR*+>ZKX1N_-T7QKI-B\I6*.^U7PCJ>MZ=9R2GR8[FYBDE#1J
MRM^JYWEJS?*<?EK:B\5AYPIR?PPK1M4H3E:[Y8UH0E*RO9-*[9\S@\1]5Q5#
M$6;5*HI22W<'I-+S<')+U/\ 0J^,W_!4?]C;X7?LPZS^TSHWQR^&GCK1YO"=
MQJWP^\*Z!XNTFZ\7>.O%5Q8R/H7@JU\+17#>)-.UJ?4S#8^(;74=+M+CPA"F
MHWOB2+38-+OGB_G' \)YWB\UAE<\!BL/-5E#$UJE&:HX>BI6J5W5?[J4%&\J
M;C.2K-Q5+F<HJ7W];,\'2PTL3&O2J+E;IPC.+E4G;W::CK)2;TE=)QU<^6S/
M\U;Q+XAU;Q=XC\0>+-?NFOM=\3ZWJOB'6KUE"M>:MK5_/J6I73*N%5KB\N9I
M2H& 7P,8K^GZ5*%"E3HTU:G1IPI07:%.*C%?**2/SF4G.4IR=Y2DY2?=R=V^
MF[?;[C_09_X('_L[:G\ O^">7@75?$5C<Z=XF^/7BCQ!\<]0LKV!H;JTT7Q%
M:Z3X<\#K\ZJYM-4\$>%-!\46JGA?^$CE( 9W+?SGXA9E#,>),1"E)2I9?2IX
M",HNZE.FYU:^S:YH5ZU2DWI_#5UH??9%AW0R^FY)J5>4J[3WM)*,.VCIPC)?
MXGO>Y^TE?#GL'XW?\%]?^46G[0?_ &&_@M_ZNSP!7VOA[_R5N6_X,=_Z@8H\
MC/?^17B?6C_Z?I'^=Q7])GY\?ZT'PQ_Y)M\/?^Q'\)_^F&PK^/L5_O.(_P"O
M];_TY(_5*/\ "I?]>X?^DHZ?6-5M-"TC5-;OV=;#1].OM5O6B0RR+::?;2W=
MRT<8(,CB&%RB @NV%!&0:RA!U)PA'XIRC"-^\FDOQ9<FHIR>T4V_1*[[=//[
MCX6^ 7_!4']@[]I#P_:ZW\/_ -I7X9Z9?3F.*X\&_$;Q)IGPS\=V%TZY>UE\
M+>-;C1]0U 0MF)M1T$:QHLLG%KJDX*,_OYCPIQ!EE1T\1E>*G%7:KX:E/%8>
M4>ZK4(3C&^_)45.HOM17V>'#YG@<3%2IXBFG_)4DJ=1/MR3LW;O'F7F[6(_V
MH?\ @IS^Q=^RAX(U?Q5X[^.'@3Q)K]I8SSZ%\,OAYXHT'QG\1?%5^L4ALM/T
M_P /:)J%Y+ID%[<1_9CX@\0MI/ARQ<DWNJQ$!'>4\*YYF^(A1P^ Q%*FY)5,
M5B:52AAJ,;^]*56I!<SBKOV=-5*LOLTWJ&*S/!X2#G.M"4DO=I4Y1G4F^B45
M=J]K<TN6*ZOJ?YSG[3G[0/C3]J?X^_%/]H#Q_*3XE^)_BR_\02V2SO<VV@Z3
M^[L?#?A;3YI%21]+\*>'+32_#FF-(JRM8:9;O-F9G9_Z6RK+J&49=A,NP_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H _SS?^"Y?_ "E+_:A_[HG_ .L[?"2OZT\,O^2(R3_NI?\
MJWQY^>YY_P C3%?]P/\ U'HGY,U]X>2% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_K,5_!Y^L!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M]O3_ *,C_:[_ /$;?C-_\Q-?T#_K'P]_T/LF_P##G@O_ )>?#?4,?_T!8O\
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M (8\0^%M-U2&.WU"\TA;GPE=W>D6=_%%J5K?7-@'CN$CO[>YEB5;I'E /1Z
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M?AS1/VAOA7<ZQJ]Y<.D<$/A^P/BA;CQ'YLLB0I)H4>HQ&:2.$.9'1& /O*@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?YYO_!<O_E*7^U#_P!T3_\ 6=OA
M)7]:>&7_ "1&2?\ =2_]6^//SW//^1IBO^X'_J/1/R9K[P\D* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_68K
M^#S]8"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]?^_B@ H *
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MUE\Z'0M6E@\FX /PQ_8!_P""@7[=?_!NG^W[K'[,/[2*^+(/@OX>\<Z3X?\
MVE_V<;O7!XI\)?\ ",>)8;+4[;XQ_!OR[JYTFQ\4#P[K&G^-M UCPZ^FQ>/]
M*^S^&?%Z([POH !_J4?'GQ!HGBS]D_XS^*?#6JV.N>'/$O[//Q%\0>'];TRX
MCN]-UC1-9^&VL:CI6JZ?=1%HKFQU"PN+>[M+B-FCF@FCD0E6!H _SDO^#*?_
M )2A_M!_]F$?$K_UH;]F"@#^H;_@[E_Y0R?$S_LM_P !/_4RH ^=_P#@RO\
M^45WQQ_[/W^*O_J@/V7Z /MG_@XT_P""O^L_\$J_V2="L?@U<:</VKOVD]0U
M_P '?!>ZU&UM-4L_A]H7AVUTZ;X@_%N\T:\+6NJ77A6WUS0](\)Z=J$,^F7/
MB[Q'I6I:I8ZQHNA:QHU^ ?Q??\$G/^#?7]K#_@ME;>)_VV?VF/VA_$GPU^#?
MC+Q=K,/_  N'QI;:I\6_C9\??%.C7[:9XIOO#T7B#7M.CBT#1]1M+OP]?>//
M$NMWJQZ[IT^B:+X8UQ-+U:32 #]#_P!M'_@S\^.7[+7@6[_:1_X)R_M7^-_B
ME\5/@\X\?:5\-=;\/CX<?%R4^%H'U@:M\'_B5X&UWR;OXB6%U:1W'A[PW-H7
MABXU&13'I7B=M:2PTO50#^>K_@FA\:OB5^T7_P %S?V(OC=\8]8/B+XI_$C]
MN'X&^(O'WB![&#39]=\3R^-?#]MJNLWMC:QP6MMJ.J7%LU]J4=K;VUK]OGN#
M;6MK"4MT /\ 9CH * "@ H _R?\ _@T1_P"4RO@/_L@OQX_]1NQH _U;-<_Y
M NK_ /8+U#_TDEH _P LW_@SD_Y2[:I_V:7\:/\ U*/A;0!_JC4 ?P#_ /!\
MW_JO^"7O_73]M3_T']DR@#^H[_@@_P#\H>/^">/_ &;7X+_]"OJ /\US_@L9
M\9_%O[.'_!PC^T[^T)X!BTJ?QU\"OVQ?A]\8?!D.NVDE]HDOBKX:P_#_ ,9>
M'X]7L8;BUEO-,?5M&M%OK6*ZMWN+4RQ)/$S;T /WG_9C_P"#4+]HS_@H'X#;
M]M#_ (*9?MJ?$7P;^T3^T790_$67P?:^$+/X@^.=$L?$6G6=]X9N_B?XG\2>
M(M,M+#64TR:"W?X6>&]"LK#P+I-OIGAZ#7K&XMKCP]H(!^ /[<_[%_[:'_!N
M5_P4"^&NL_#_ .,<DNN65J/BC^SO\?\ P787V@Z;X_\ !]OK%UHNN>&?&GA*
M]GU"R@OXS;_V-\2_AK>ZIXGT"]T'7=,,M_JFD>(+9Z /T^^%7P6_X*"_\'='
M[6WCSXQ_$_XBK^S/^Q=\";JST+2M-MUOO'O@GX2WNL:0EQ:> ?A=X/DOO!T?
MQ'^*OBJ.S37_ (B^/]<NM&;2-*O=.DOY[?2U^'O@"Z *O_!8#_@U+\2_\$_/
MV7?%O[7/[.G[0^J_'WP'\*(K#4OC!X"\;>![3PMXXT#PG>ZCIFBR>-?"FJ>'
M=3U;2O$]AH^H:DE[XGT>^TSP]/H7AN*[UR'4]833[NW0 _=__@T%_P""DWQ4
M_:P_9K^-?[*'QV\7>)?B#XX_9.U+P5JOP[\<^+-6N-;UO4?@M\0K;6--T?P7
M>ZI?SW.JZBWPW\0^#]3M].O-0N)3#X9\4^'/#]F4L_#L*4 ?H-_P</?\%BKO
M_@D[^RMH*?"9=(U']J_]HB^UWPI\$(-8MK35-+\#:7X?MK";QS\7=;T.Z)@U
MB+PE%K&BZ7X:T>]BET[4_%VOZ5<:G:ZIH6CZYIET ?Q*?\$SO^"%W[>/_!>3
M6O%?[9O[1_[0WB+P#\(?$^MZS8R_M'_%:#4_C%\2OBWXIT349+/5M&^'W@^^
M\5^'99O"WAN]2[T.]\0ZCXBT'PMX>O8/^$>\):3XAFT;7-+T$ _5_P#:3_X,
MD-5T/X9:]XA_92_;3N?'?Q3T31IKW2/AM\8?ACIGA30?'FIP-YC:3:?$/P[X
MNO1X*N;JV5XM+;5O"?B#3I]3-M!JNK:%ITUQJU@ ? /_  0(_P""OW[3O_!,
M7]MG1_\ @G-^V1K?BV/]G7Q%\69OV??%GP\^(^J&_O?V5?C$WB/_ (0VPUOP
MKJ%Y>W4'A_P1:^+TCT?XA>'-/U$>#5TF_O?'VD1?VCIT[Z\ ?Z4W[37_ ";=
M^T'_ -D0^*__ *@>OT ?XOG_  3I_:1_:N^!/Q-^*/PZ_8IM/$$O[0_[:'P>
M;]C7P9J/@V?[+XZTA/BE\6?A/XDU)O ]ZS0QZ3XEUZU\ GP?;^(GN].D\*V7
MB._\366JZ3J.DV>JV@!_4[\-O^#*?]I;_A"?"GQ(\;?MN_"C0_CG%?>&_%&J
M_"E?A?XJ\1>#+74%N['5-7TC4?C1#XP@U6XU"SD^U6TE_8?"G4[&]O(=\-T]
MK<"\0 \Y_P"#J?\ X*=?M-_&[]NC4O\ @E-\$?$NM^#_ (/?#:\^%_A?QCX=
M\)ZQ<Z%>?'KXO?%SPCX7\3V.F>,]5M[ZV74? WAG3_'>A^'-+\'7HM]$?Q3%
MKWB#7TU:6#PQ+H !]B?"/_@R%\&7'PMT:;XY_MR^+M-^,^H:7:W6N6?PP^%N
MA7_PY\+ZO/$LEUHUC/XFUZ#Q#XRM-/E+6Z:Y(?!K:EL\\:+IX98J /T&_P""
M'7_!OG\>/^"0'[?_ ,<?BYKGQF^'/QQ_9]\?_LT:]\,?!?B[1].UGP7\1HO%
M-_\ %/X7>+(++Q=\.KX:YI.EVPT;PGJI35-#\>>(X)YTA6>#3WG2!0#^M&@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /\ /-_X+E_\I2_VH?\ NB?_ *SM\)*_K3PR_P"2(R3_ +J7
M_JWQY^>YY_R-,5_W _\ 4>B?DS7WAY(4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^LQ7\'GZP% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __0_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MO=9UG6/AUX8TR[N>JRR:78Z#J\-E@*T"ZQJ&[>+E-@!_49_P;W? [PK\!_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_GF_\%R_^4I?[4/\ W1/_ -9V
M^$E?UIX9?\D1DG_=2_\ 5OCS\]SS_D:8K_N!_P"H]$_)FOO#R0H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\
M68K^#S]8"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MN'IVHYUA)99F$HQT6898HO#5:LOY\5E]6%"DE:\,LF^EY>5?\%+O'VIS^)_
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M*M:I.K.<Y^C5[)XP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_]'^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MH$\\&8)7T+3=3M-(\R$F-A9@H67!H _V,* "@ H * /\G_\ X-$?^4RO@/\
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M]:M=(\36%E=3W6@ZI=:/J.GZM;Z?JD-K=S:9?6=_'$]K=6\K 'XX_P#!1O\
MX(#_ /!.K_@HYX?\7:IXR^#?AWX._M :[::A<Z/^T?\ !S1K#PAX[@\4SPRF
MSUOQYI>DI8>'OBS:&\:#^U[3QO97NM7FFQR66C>)O#=VUOJ=J ?P9_\ !L1\
M4_BG^R__ ,%R/ G[.?AWQ5<ZIX.^+5]\>O@1\7]*\-7GVKPOXUM/AIX ^)7C
M'PUXGBMI"]K<Q^'O&'@.SUO2-;CVZC9>'K[7[6SNOL>MZE:WH!_J^4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!_GF_P#!<O\ Y2E_M0_]T3_]9V^$E?UIX9?\D1DG_=2_]6^//SW/
M/^1IBO\ N!_ZCT3\F:^\/)"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _UF*_@\_6 H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M\&J=6<Z,\=A9U*^>UW2?NTL5#-J]?*J[A_%I93A9-OE2C^L?1^X5_P!7/#S
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MC*F'I5)QC&K7P6+C!R]E/E_%_I&Y'CLM\1L7FU>$G@N(\#EV+P-=0G[+FR[
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MM\-/"WA/5]#\3?$ZRBNF:WA\8S>)O"/ARYNK-[CP[:>,_#]]8ZU. ?EMI?\
MP4[_ .#P+XY:6OQ)^%WPH_:.T;P1>&35M+C\'_\ !/\ ^&Z>'M2T]VW1IX>E
M^(_P5\1>(_$.FJK>5;3:=JNK37"J3]JN9XWE4 ]Q_8A_X.&_^"X?P]_;Q_90
M_9 _X*!?!_38;#]I3]H3X(_!O5;3X^?LR>(OV>_BEH?AWXH_$WPQX U#Q9X'
MCT&T^&>EW5QID>OM?PR:QX.\1Z3=RPI;J+591,@!^J/_  75_P""GO\ P6N_
M8]_;/T#X4_\ !/O]FSQ)\5/@3>? KP/XPOO%.D_LF_$OXV6O_"?ZOXI\?Z=X
M@TUO&/A6*;2H9K/2]%\/.VB K<V*W"7,RXOD9@#\)OB3_P ''?\ P<A?!GPK
M=>.OC!^S7#\*?!%E=65C>>,OB3^P]\3O WA6TO=2G6VTZTNO$/B>;2M(@NK^
MY9;>RMY;Q);J=EB@220A: *WPN_X.2?^#C;XX>&I/&?P5_9WL/B_X/BU.ZT2
M7Q9\+OV)OB3X_P##4>LV,-K<7ND2:[X3N=7TM-3LX+VSFNK!KO[5;PW=K)-$
MB3Q%@#]I_P#@BQ_P55_X+G_M7_MW^#?@Y^W7^S%XF^&?[/&J^!/B1K&O^+]4
M_8_^*'P>M+#7]!\.2W_A:!O''B:&'1[)[_5TALTLKDL^HF7[+;KY[1LH!RO_
M  7(_P""\_[>G_!/_P#X*D_#G]DG]GZZ^#T/PB\1>!/@7XAU6#QG\.9/$OB*
M?4?B!XQ\0:1XA*:V/$.G-#"]CI]K%9Q16J_961I SR.S4 ?VP4 % !0!_.;_
M ,''_P#P6 ^(O_!*#]FSX.W/[/<W@N7]I'X\?$V[TGPE:^.-%/B31M+^&G@3
M2!JGQ(\3R:(FH:>UU=0ZKK7@/PS8K-,D*_\ "3WEZC--IJ1N ?/O_!M/_P %
MR?C3_P %47_:5^$/[6%Q\/8_CK\*%\+?$?P+)X"\-GPC9^)/A-KA_P"$9\1H
M^C?VIJHENO _C"'0VO\ 4_-A,\7Q#T>U$;_8RR@']6E !0 4 % !0!PWQ.^)
M/@CX-_#CQ[\6_B7XAL?"?P\^&/@_Q)X^\<>)]3<QV&@>$_"6D7>NZ_J]V5#.
M8;#2[&YN62)'FD\L1PQR2NB, ?Y^_P"QA_P=-?M_?M>_\%3_ (#_  'L-+^#
MGA7]ESX\?M7:'X"T?PC<_#IKGX@Z'\(/%?C)].T33-0\8Q^)G2X\8VGAN:S&
MIZU!8"REUI;FXMK".R9+5 #^V;_@HE>?MH:/^R)\6O$__!/^Z\$/^U'X-TA/
M&'@/PQX^\*-XNT;XAVWA]S?^(/A[I]D-6TA+'Q5XGT>.ZMO".H7$TUFWB2/3
M=+OUL[+4[C5]- /QE_X-WO\ @NUK7_!4'PW\2?@%^U+!X4\&?ML_!ZZU3Q#=
M:/X?TB?PGI/Q.^%LFJQV3Z_HOAJ^O;VYTKQ-\.]9O+?PKXZT,2*L=K=^%]?M
MO-EU+7;71@#^G6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /YG?^
M#E;_ () ?M*_\%7_ (-?L[1?LO\ B#X;V_CG]GCQ1\2M>O?!7Q$UG4/# \<:
M;\0-*\'6 M_#7B2#2]5TFQUK2I_"BN+/Q'_9.E7]M?RR'7;*:RCM[T _D!\
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M@#_.(_:4_P"#93_@KQ_P3E^/_P#PO+_@FCXO\3_&SPSX:U/4M1^'7Q*^#7Q
MT?X8?M#^#-$O&DMAH?C7PAJVM^%AXAO)K&?^RM5_X5[>>+-%\56/VBYU7PYH
M%G>3Z': $FO+_P 'D7[1WAQ?@?K^G?ML6OA[5["[\,7<DFA_![X!O?Z9J:W%
MC?6^O_%NST_X<:I<VUS T\-Q?ZWXU?=9R &Z:VFC+@'[*?\ !"[_ (-9;W]D
M/XI^#OVQ_P#@H-K'@[QQ\;? UY:^)?@_\!?"-XGBCP1\,_%T.^2R\<?$/Q/<
M6<6G^,_'GARX:*[\+:1X<2Y\*>%==M8?$T?B+Q1JL.D/H(!_8-\<O#6L^,_@
MI\8/!_ART%_XA\5_"WX@>&M"L6N+:T6\UG7?">KZ7I=HUU>2V]I;"XO;J"$W
M%U/!;0A_,GECB5W4 _B<_P"#7S_@C1_P4D_X)V_MX?&/XT_MC?LY#X/?#7Q3
M^R/XV^%^@>(O^%O_  '^(#:AXXUGXR? KQ7I^BC1_A9\3_&^NVHFT#P7XCOF
MU*^TVUTF(V"VLM\EY>65O< '[R_\'%?[&_[1_P"W=_P3*\=_L^?LJ?#L?%+X
MOZO\4OA'XETSP@?%W@7P0;O1O#'B<7^N7:Z_\1O$WA'PO";&R8W'V>ZUN"YN
M55H[.*YG*Q, >,_\&PG[!G[5W_!._P#8!^*?P3_;#^%@^$/Q.\3?M<?$#XH:
M-X8'CCX<>/S=>!];^$/P(\*Z7K3:S\+_ !?XU\/6YNM<\%>)+/\ LVXU>+5H
M5L%N;FQAM;NRFN #[S_X*V_\$MO@[_P5D_94U;]G[XD7[>#/&V@:D?&GP1^+
MMAIL.I:O\,OB);6-Q907DMF[V\FM>$/$%G.^C>-O# O+-=8TMX;RSNM/\0:/
MH&KZ: ?Y['A[_@D=_P '(/\ P20^,7BO5?V1O!/QG']KA-*N?B3^R7XGT/XE
M?#[XG:)I5\TVEW.N^ +EI]5N(+6>26;3;#XF?#/3M3L/M-\;*T6VNKF6< ^U
M?#W_  2A_P"#DC_@LSXQ\'^&?^"EWQ8^)/P9_9MT7Q-::[K^H?&*\^'WANRL
MY8K=HY]1\$_LU?"4^';77_&UO8S26>BZCXLT#PMHVG_VA?1Q>*(&?4K.X .A
M^!7_  ;A_M]?LP?\%MO@S\7O@]^R_J,/[!7P0_;+^''C#PE\4];^//P%U76)
M/@MX,\3:->R^,-7\,W?Q5C^)EYJUU9V=UJ5_I,/@FWU1[Z:6WTW0+6U%K9H
M?Z.E !0 4 % '^?%_P &YW_!#K_@J)^P=_P4Q\*_M _M6_LR)\+/A#I/PD^+
M7AB\\7CXT_L^>. NN>)M'M++0[&/0/AQ\5_%_BB3[=.D@%R-$^QVR(6O+BVW
M(& /]!V@#^!O_@OY_P &Q7[1/QS_ &D_'_[<G_!.K2/#WC[4OC+X@M_%7Q=_
M9R_MOPU\/?$^C_$">TA_X27XE?#WQ)XNUS0O".O67C+4[:X\4^+M!U/6=#\1
MV7BW4M1U'PZOB>#6SIGAX ^!? &D?\'D^H>'+/\ 9?\ #P_;1T3PY;06'A2+
M7O%O_"GO#]YIVG168TN"2/\ :9\6Q6_BP6MG9<RZMI_Q1N+D-$ERMS)?I$[
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M!7BO3]%&C_"SXG^-]=M1-H'@OQ'?-J5]IMKI,1L%M9;Y+R\LK>X /[M: /\
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M6T\3WK:[J.E:+/XF^).OV$]UX:OKVQL5\.>'=!EUC3]'OO$/]ORZG: ']:%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?YYO\ P7+_ .4I?[4/_=$__6=OA)7]:>&7_)$9)_W4O_5O
MCS\]SS_D:8K_ +@?^H]$_)FOO#R0H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * /]9BOX//U@* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MJ_$+PCXA\ ^$+GQ%I.G^#8]&O+FVOM*B>#44UO6;YH&M;J^M[O:+:ZMY!<"
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MC"8EP^LSEB94Y8S'XM4ZE:E3Q.+]CAZ;H4JDZ5"AAJ%-3JU%6KU?O&OUH_)
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M>+-1\/:>6<Q16<7BVX\1^(WMXD4K?^*;ZXD+&Z3: ?@%_P '4?\ RGE^#O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!_GF_P#!<O\ Y2E_M0_]T3_]9V^$E?UIX9?\D1DG_=2_
M]6^//SW//^1IBO\ N!_ZCT3\F:^\/)"@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H _UF*_@\_6 H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MG^PK^SQ_P3K_ &<_!_[,_P"S5X27PYX)\-*VH:WK=\8+OQA\1O&E[;6L&O\
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M^(^B75Y<>8DFH>-?#MBK0N8DG /Z'_\ @WS_ &W_ /AO'_@EA^SE\1=;U?\
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M0/VFM?-^INGUKQ__ &AJ6A_#N\N#$\OAG4/$_BZ*VNK#Q/X.U6  _,']J?\
MY7-O#'_9[W['7_JF_@A0!_IM4 ?QN?\ !ZI\&]&\4_\ !/;]G3XVFUW^*OA!
M^U/I_A*RO-BM]G\'_%SX<>-7\46^_&^/[7XC^'GP_DX.QOL>'5G\ID /VY_X
M(0?%35_C+_P1^_X)^>-M=O3J6J0?L]^'? -Q?.2TUQ'\(M1U;X2VCW,C,SSW
M@L_!-NM[<2,TMS=K-/*QDD8L ?K50 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M ?YYO_!<O_E*7^U#_P!T3_\ 6=OA)7]:>&7_ "1&2?\ =2_]6^//SW//^1IB
MO^X'_J/1/R9K[P\D* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#_68K^#S]8"@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /._B]_R2;XH?\ 9._&O_J-:G7Q_B'_ ,D!QQ_V1_$W
M_JEQI]!PG_R57#/_ &4&3?\ JQPQ^=7_  3!_P"//XU_]??@#_T5XRK^+_H(
M_P"Y>)G_ &$<(_\ IKB(_IOZ5_\ OG!'_8-G_P#Z=R@_5FO] #^1 H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_$PM=MM;_$KX(:[>^%-=TFTF>-H+J[T#1+;X9Z_<*Q=HT\3V<<L0C,9E /\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0!_GF_\ !<O_ )2E_M0_]T3_ /6=OA)7
M]:>&7_)$9)_W4O\ U;X\_/<\_P"1IBO^X'_J/1/R9K[P\D* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_68K^#
MS]8"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M272_^2N!_42B+&JHBJB(H1$0!515&%55& JJ   !@ 8&.*X@'4 % !0 4 %
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M\)\#([:1],_X)_\ Q8N[P#]U!?\ QQ\(:=;.>>)+NW\!ZI+$,XY6RE[\<8H
M_,[]IW_@Z7_X*E?\%'9;C]F7_@G[^SEJ'P#O_B-'=Z&MK\"U\8?';]IK4].O
MA]EFM?#?C33O#GA^V\'H]K)*;SQ#X8^'^F^)='++?:7XOT0VINF /UV_X-ZO
M^#:WQ=^RS\0/#G[>W_!0[3]+O?VA=-:37_@K\!9[ZT\4CX1^(KUVD_X6C\3=
M>M+J_P!&UOXJPI)-+X6T+3;O5]-\#W%U_P )-?ZM=^.DTVV\% ']K] !0 4
M% 'SO^U[_P FF_M0?]F[_&O_ -5KXEH _@H_X,?O^3@?V]_^R.?!O_U-O%]
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MW1_Q$S@C_H=_^8W-O_F$/["S7_H&_P#*V&_^7A_PXT_X*E_]&O?^9L_9V_\
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MV&_^7A_PXT_X*E_]&O?^9L_9V_\ GMT?\1,X(_Z'?_F-S;_YA#^PLU_Z!O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'G?Q>_Y)-\4/^R=^-?_ %&M3KX_Q#_Y(#CC_LC^)O\ U2XT^@X3
M_P"2JX9_[*#)O_5CAC\ZO^"8/_'G\:_^OOP!_P"BO&5?Q?\ 01_W+Q,_[".$
M?_37$1_3?TK_ /?."/\ L&S_ /\ 3N4'ZLU_H ?R(% !0 4 % !0 4 % !0
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MOUU?KIY@?5U9@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__T/[^* "@
M H * "@#X/\ $_\ P3#_ &!O&/[4&F_MI>(OV7_AO>_M2Z5XE\,^,K+XT0PZ
MUIGBM?%7@^TL=/\ #FOW(TK6++2K_5-.L=,T^S^UW^FW,MY:VD,%^;F)0E '
MWA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >"_M)?LP? 3]K_X6
M:E\$OVE/AKHOQ:^%.L:IHVM:KX(\0W&K6^CZAJ?AZ]34=%N;L:-J6EW4QTZ_
MCBO;>)[DP"YBAF:)WAC9 !_[.'[,7P _9#^%NF?!3]FCX4>$?@W\+=(U'5M8
MLO!_@VQ>TT\ZOKMT;S5]6O;BYFNM1U35+Z;8DVHZI>WEX;6WL[%)ELK*SMX
M#W>@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__1
M_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_TO[^* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % '_T_[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M_B&@_P"LR'_!7[_Q)[_[Q4 '_$-!_P!9D/\ @K]_XD]_]XJ #_B&@_ZS(?\
M!7[_ ,2>_P#O%0 ?\0T'_69#_@K]_P")/?\ WBH /^(:#_K,A_P5^_\ $GO_
M +Q4 '_$-!_UF0_X*_?^)/?_ 'BH /\ B&@_ZS(?\%?O_$GO_O%0 ?\ $-!_
MUF0_X*_?^)/?_>*@ _XAH/\ K,A_P5^_\2>_^\5 !_Q#0?\ 69#_ (*_?^)/
M?_>*@ _XAH/^LR'_  5^_P#$GO\ [Q4 '_$-!_UF0_X*_?\ B3W_ -XJ #_B
M&@_ZS(?\%?O_ !)[_P"\5 !_Q#0?]9D/^"OW_B3W_P!XJ #_ (AH/^LR'_!7
M[_Q)[_[Q4 '_ !#0?]9D/^"OW_B3W_WBH /^(:#_ *S(?\%?O_$GO_O%0 ?\
M0T'_ %F0_P""OW_B3W_WBH /^(:#_K,A_P %?O\ Q)[_ .\5 !_Q#0?]9D/^
M"OW_ (D]_P#>*@ _XAH/^LR'_!7[_P 2>_\ O%0 ?\0T'_69#_@K]_XD]_\
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M 'BH /\ B&@_ZS(?\%?O_$GO_O%0 ?\ $-!_UF0_X*_?^)/?_>*@ _XAH/\
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M/?\ WBH /^(:#_K,A_P5^_\ $GO_ +Q4 '_$-!_UF0_X*_?^)/?_ 'BH /\
MB&@_ZS(?\%?O_$GO_O%0 ?\ $-!_UF0_X*_?^)/?_>*@ _XAH/\ K,A_P5^_
M\2>_^\5 !_Q#0?\ 69#_ (*_?^)/?_>*@ _XAH/^LR'_  5^_P#$GO\ [Q4
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MXD]_]XJ #_B&@_ZS(?\ !7[_ ,2>_P#O%0 ?\0T'_69#_@K]_P")/?\ WBH
M/^(:#_K,A_P5^_\ $GO_ +Q4 '_$-!_UF0_X*_?^)/?_ 'BH /\ B&@_ZS(?
M\%?O_$GO_O%0 ?\ $-!_UF0_X*_?^)/?_>*@ _XAH/\ K,A_P5^_\2>_^\5
M!_Q#0?\ 69#_ (*_?^)/?_>*@ _XAH/^LR'_  5^_P#$GO\ [Q4 '_$-!_UF
M0_X*_?\ B3W_ -XJ #_B&@_ZS(?\%?O_ !)[_P"\5 !_Q#0?]9D/^"OW_B3W
M_P!XJ #_ (AH/^LR'_!7[_Q)[_[Q4 '_ !#0?]9D/^"OW_B3W_WBH /^(:#_
M *S(?\%?O_$GO_O%0 ?\0T'_ %F0_P""OW_B3W_WBH /^(:#_K,A_P %?O\
MQ)[_ .\5 !_Q#0?]9D/^"OW_ (D]_P#>*@ _XAH/^LR'_!7[_P 2>_\ O%0
M?\0T'_69#_@K]_XD]_\ >*@ _P"(:#_K,A_P5^_\2>_^\5 !_P 0T'_69#_@
MK]_XD]_]XJ #_B&@_P"LR'_!7[_Q)[_[Q4 '_$-!_P!9D/\ @K]_XD]_]XJ
M#_B&@_ZS(?\ !7[_ ,2>_P#O%0 ?\0T'_69#_@K]_P")/?\ WBH /^(:#_K,
MA_P5^_\ $GO_ +Q4 '_$-!_UF0_X*_?^)/?_ 'BH /\ B&@_ZS(?\%?O_$GO
M_O%0 ?\ $-!_UF0_X*_?^)/?_>*@ _XAH/\ K,A_P5^_\2>_^\5 !_Q#0?\
M69#_ (*_?^)/?_>*@ _XAH/^LR'_  5^_P#$GO\ [Q4 '_$-!_UF0_X*_?\
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M(?\ !7[_ ,2>_P#O%0 ?\0T'_69#_@K]_P")/?\ WBH /^(:#_K,A_P5^_\
M$GO_ +Q4 '_$-!_UF0_X*_?^)/?_ 'BH /\ B&@_ZS(?\%?O_$GO_O%0 ?\
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M (D]_P#>*@ _XAH/^LR'_!7[_P 2>_\ O%0 ?\0T'_69#_@K]_XD]_\ >*@
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MP5^_\2>_^\5 !_Q#0?\ 69#_ (*_?^)/?_>*@ _XAH/^LR'_  5^_P#$GO\
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M_P 0T'_69#_@K]_XD]_]XJ #_B&@_P"LR'_!7[_Q)[_[Q4 '_$-!_P!9D/\
M@K]_XD]_]XJ #_B&@_ZS(?\ !7[_ ,2>_P#O%0 ?\0T'_69#_@K]_P")/?\
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M?O\ Q)[_ .\5 !_Q#0?]9D/^"OW_ (D]_P#>*@ _XAH/^LR'_!7[_P 2>_\
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M_B&@_P"LR'_!7[_Q)[_[Q4 '_$-!_P!9D/\ @K]_XD]_]XJ #_B&@_ZS(?\
M!7[_ ,2>_P#O%0 ?\0T'_69#_@K]_P")/?\ WBH /^(:#_K,A_P5^_\ $GO_
M +Q4 '_$-!_UF0_X*_?^)/?_ 'BH /\ B&@_ZS(?\%?O_$GO_O%0 ?\ $-!_
MUF0_X*_?^)/?_>*@ _XAH/\ K,A_P5^_\2>_^\5 !_Q#0?\ 69#_ (*_?^)/
M?_>*@ _XAH/^LR'_  5^_P#$GO\ [Q4 '_$-!_UF0_X*_?\ B3W_ -XJ #_B
M&@_ZS(?\%?O_ !)[_P"\5 !_Q#0?]9D/^"OW_B3W_P!XJ #_ (AH/^LR'_!7
M[_Q)[_[Q4 '_ !#0?]9D/^"OW_B3W_WBH /^(:#_ *S(?\%?O_$GO_O%0 ?\
M0T'_ %F0_P""OW_B3W_WBH /^(:#_K,A_P %?O\ Q)[_ .\5 !_Q#0?]9D/^
M"OW_ (D]_P#>*@ _XAH/^LR'_!7[_P 2>_\ O%0 ?\0T'_69#_@K]_XD]_\
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M 'BH /\ B&@_ZS(?\%?O_$GO_O%0 ?\ $-!_UF0_X*_?^)/?_>*@ _XAH/\
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M/?\ WBH /^(:#_K,A_P5^_\ $GO_ +Q4 '_$-!_UF0_X*_?^)/?_ 'BH /\
MB&@_ZS(?\%?O_$GO_O%0 ?\ $-!_UF0_X*_?^)/?_>*@ _XAH/\ K,A_P5^_
M\2>_^\5 !_Q#0?\ 69#_ (*_?^)/?_>*@ _XAH/^LR'_  5^_P#$GO\ [Q4
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MXD]_]XJ #_B&@_ZS(?\ !7[_ ,2>_P#O%0 ?\0T'_69#_@K]_P")/?\ WBH
M/^(:#_K,A_P5^_\ $GO_ +Q4 '_$-!_UF0_X*_?^)/?_ 'BH /\ B&@_ZS(?
M\%?O_$GO_O%0 ?\ $-!_UF0_X*_?^)/?_>*@ _XAH/\ K,A_P5^_\2>_^\5
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H 9')'*@DB=)$;.UXV#H<$@X920<$$'!X((XP: '
MT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % '__6_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!__U_[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /FS]J;]HG0OV;OAA?\ BV[-G?>*M4,ND^!?#D\I
MWZSKSQ;OM,\$3+<'1=$C9;_6KA&ACV?9=,6[MK_5M.+W"#F[=%N_+MU5WTNO
MOU _._\ 8"_9VUSXF>+KW]K'XR/+K5S=:W=ZKX'75$\R;6_$RW<OV_QI<HR"
M!+31[Q6MO#\<"E5U:"6YC^Q#1K1+O:K/E7)'32SMLH_R_BOU _:.N8 H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5'*,KF*)S-!;NW7^M/\ @:]?S42^MOZ_K[OQ3EJT@"@ H * "@ H * "@ H
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M.3;G*G=1DI-_$X2<;2>K4K=#^EFOR\^C"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _#3
M]M'XY^)OVF_BUH/[+'P/FGU;0[;Q$NE:Y/8"067BGQ;:2O\ ;)[FZACED?P?
MX'@@N[R[O0$T^2>UU+6Y/MMCIFCWZ=5.*A'GEO:_HON5F].KW25G<#]8_@!\
M$?#/[/WPRT+X=>&V^UM9*;[Q!KLEO':W7B3Q)>)%_:FM7,*-)Y*RM%':Z?:/
M/=/I^E6MA8/=W;VQNI>><G-W?HEV7;=^O37H![14@% !0 4 % !0 4 % &/K
M>D1ZQ9^3O,%W"XGL+Q"5FL[I.4ECD7YE!QM<?,"IR5+*I5IV=_Z_)_E]UP,7
MPUXDFOKBZT+6(OLFOZ<#YR!6$-[ NT"]MVV! )-RL8P5W*WG0!H2Q5RC9*2^
M%[?Y;OTWZ6=@_K^OZ_4[*I * "@ H * "@ H * "@ H * "@ H * "@ H *
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M1=C_ /L"Q7_IBH/#_P"\4/\ K]2_]+1_J5_&OXI:%\#_ (/?%+XR>)B#X?\
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MZC35*"493DHJ-HVNS"EA</0G4G1HPI2J\OM/9KE4N6_+[JM%-<TM4DW?6Y\
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MNO>7M+7Y6:\-49O%5J]G[.G1=-OHYU)Q:7_@,)-]M+_$C^W6OPD^T"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M?__3_OXH * "@ H _CR_X.G?^1K_ &*_^Q>^/'_IR^$U?M/A-_ SS_K[@/\
MTC%GR/$_QX/_  U_SI'YP_\ ! KPIH7CS]OH>!/%5A'JOA;QO\ ?CGX0\3:5
M-_J=3\/^(_"8TG6-/F_Z97EA=3V\G#?*YXKZ7Q#JU,/P]]8I2<*M#,<!6I36
M\*E.MSPDO-22?_#'G9%&,\?[.2O&I0KPDGUC*%FOFOZU/R\_:/\ @KK_ .SC
M\>_B_P# GQ-YKZO\*OB#XF\&27<L7D_VK9:/J<\&CZ]#'VM/$&C_ &#6[$X&
M^SU"!]J[MJ_699CJ>9Y?@LPI6Y,7AJ5>R=^24X)SIMZ:TY\U.7]Z+WW/,Q-&
M6'KUJ$MZ524+]TG[LO24;27DS^X;_@WE_:7C^,G[!D'PTUW4TE\4_LR^+-5\
M WANIP;C_A M<,WC#P)J=R[,$AL;:"^U_P )6 ;8(K/P7ALA1(WX-XD96\%Q
M \53C:CFM&&(C9:?6*=J.(@N\FXTZTM]:^EKV/M>'\3[; ^SD_>PTW3=WK[.
M5YTWY)7E!>4/(_C;_P""A7[1\G[6/[9G[0'QSANWO/#_ (I\>ZAIW@9V9BB?
M#SPE'#X2\!F.+)2W>Z\+Z)IFH7L,7R'4KV]F+2R322M^V<-Y8LGR3+L!R\M2
MEAXSQ&EF\36O6Q%^KM5G*,;W:A&*TM8^0S#$_6\97KWO&=1J'_7N%H4^UKQB
MF_/5WO<_5/\ :R_9M_X9R_X()_L>'4K#[%XP^-W[5F@_'CQ;YD>R<CQY\&_B
MR/!4#[P)T%O\.-,\'M+:2[?LNI3ZEB-'FE+_ ".3YG_:?B%G7)+FH8'**F7T
M=;K_ &?&X/V[737$SKV:WBH]D>KBL-]7R'"75IUL7"O/_N)1K\F]GI3C#3O>
MU]S\/_V>_P#DOGP/_P"RO_#3_P!331:^\S+_ )%V/_[ L5_Z8J'B8?\ WBA_
MU^I?^EH_T)_^"VNN7?A[_@ES^UE?V2R--<>&_ &AN(\[A:>)_C!\//#6H,<8
M_=I8:M<O+V\I7SD9%?SCP+3C4XLR>,ME5Q%37^:E@L35CVU<H)+S[['WV=2<
M<LQ;7\M./RG6IQ?X,_S>:_IL_.S_ $O?^"1?AG1_"?\ P38_8_TS1(H8;2\^
M$FG^)KA8/NOK'C+5=6\7:_*Y(!,TNN:WJ$D_7$S. =H6OY=XQJSK<3YU.HVY
M1QDZ2O\ R4(0HTUZ*G3BEY>I^CY3!0R["*.SI*;]9MSE^,G_ $C\#/\ @M;_
M ,%-/VX_V6/VWM4^$_P#^.^H?#WX?6OPQ^'VNP>';7P1\,]=C35M:@U.74[P
MZAXI\&ZWJSO=/#$3&]\T$015ABC7(K]"X%X6R'-\ACC,QR^.)Q+Q>(INH\1B
MJ;Y(.')'EI580TN]4KOJ>%G.98W"XUTL/7=.FJ=.7+R4I:N]W><&]?6WI=GY
M)?\ #\+_ (*F?]'7ZS_X;#X(?_.WK['_ %"X3_Z%$/\ PKQ__P O/*_MO-/^
M@I_^"J'_ ,K/T"_X)8_\%7O^"@7[0/[?/[.WP>^,'[0^I>,_AOXVUWQ=9>*/
M#-QX!^%&DPZK;:?\-_&6M64;ZCH'@;2]8M?L^J:98W:O9:A:NSVXCD=X6DC?
MYWBWA#AW+>'LRQN"RV-#%4*=&5*JL3C)N#EBJ%.3Y:E64'>$Y1]Z+WOHTF=^
M5YKC\1C\/1K8ASISE-2C[.BKVISDM8P4EJD]']Y]9_\ !TYKMS;^#?V+_#*F
M7[)J_B;XY:[.!N\G[3X=TKX6V%J9/X?-$7BB\\G(W;#/MP"]>/X34TZ^>5=+
MPI8"FN]JL\7)V\KT5?7MO<ZN)Y/DP<>CE7D_6*I)?^E/K]Y_*3\ /#>D>,?C
MQ\$_"'B".*70?%7Q<^&_AO6XI\^1+I&N>,M&TS4HYL<^4]G=3+)CG83CM7Z[
MF-6=#+\?6IMJI1P>*JTVMU.G0G.#7FI)6/EJ$5.O1A+X9U:<9>DII/\ !G^K
MV % 50%50 J@8  X  &  !P !Q[5_(9^IBT % '\AG_!U%?RFY_8=TP!EA2#
M]HV_=OX)99)/@=;QCW:!(I3UX%QWS7[+X2Q5L^GUOED?1?[>WUZMKITWZ'R?
M%#_W)=/]H?\ Z8_K?[K'X1?\$H;.WO\ _@H]^QQ!<JC1I\;O"]XH?E?M&G?:
M=0M6'^VMU;0M'Z2!3VK] XODX\,YTUO]0JQ^4K1?;HW_ ,'8\/*DGF.#O_S^
MB_FM5^/]:'^FA7\M'Z0?YXG_  7^MH(/^"HGQSEA"B2]\,?!FYNBH +3I\(_
M!MFI?U;[-:6Z@GG8$'0"OZ1\.VWPI@$]HU<<EZ?7*TOSDS\_SY6S.OYQHO\
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MK2-HI'Z2U\P>B% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M=8;VOU;.\RPE']SA,SP^'AR8?#T:?[NC#FY.>?--SG+YY_X;E_:E_P"BH?\
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M?^BH?^65\.__ )D*/^)FO&__ *+;_P UOA'_ .AX/^(#^%/_ $2G_F<XC_\
MGR'_  W+^U+_ -%0_P#+*^'?_P R%'_$S7C?_P!%M_YK?"/_ -#P?\0'\*?^
MB4_\SG$?_P ^0_X;E_:E_P"BH?\ EE?#O_YD*/\ B9KQO_Z+;_S6^$?_ *'@
M_P"(#^%/_1*?^9SB/_Y\A_PW+^U+_P!%0_\ +*^'?_S(4?\ $S7C?_T6W_FM
M\(__ $/!_P 0'\*?^B4_\SG$?_SY#_AN7]J7_HJ'_EE?#O\ ^9"C_B9KQO\
M^BV_\UOA'_Z'@_X@/X4_]$I_YG.(_P#Y\A_PW+^U+_T5#_RROAW_ /,A1_Q,
MUXW_ /1;?^:WPC_]#P?\0'\*?^B4_P#,YQ'_ //D/^&Y?VI?^BH?^65\._\
MYD*/^)FO&_\ Z+;_ ,UOA'_Z'@_X@/X4_P#1*?\ F<XC_P#GR'_#<O[4O_14
M/_+*^'?_ ,R%'_$S7C?_ -%M_P":WPC_ /0\'_$!_"G_ *)3_P SG$?_ ,^3
M^A:O]:#_ #E"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__4_OXH * "@ H
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M=>KW.&?^2BR+_L;8#_U*I''F'^X8W_L%K_\ IJ9_E^U_5A^9G^G+_P $NO\
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MO'9SC3D_@1QY'B)4<PI03]RO>E-7T=TW!^JFE;39R2<;OF_T0:_FX_0 H *
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M>!DC"@&Y:W=K?6\5W97-O>6LZ[X;FUFCN+>9#T>*:%GCD4_WD9@?T4 L4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 ?ST_MR?\G2?%#_N2O_5=^$:_R7^DU_R>_C;_ +MO_P!9'(#_ $:\!O\
MDU'"O_=<_P#6DS@^3:_!S]>"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H _K(K_ '@/\APH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_IR_\$NO^4=G[&?_ &;Y\.O_ $QV]?ROQ7_R4F=_]C+%?^G)'Z3E?_(NP?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M  9(E]XTM->O=&32X9+G4GOT^S^'-0:[D_<+ S6RCS#*VP ^Z_B)_P $.O\
M@Y5_9'T+6?BCX"UWXZ^(H_#MC_:FJ7?[+O[7OB'6/'J6UOR?[(\(:)XT\-_$
M3Q/>PELIIOA+0-=U-QODM[21$=U /O3_ ((*_P#!S1^TII/[1/PX_8E_X*3>
M/+OXF?#GXAZS:?"OP#\<?'&EO%\7OAE\4-1U.UT;PEHGQ2\2Q_9;KQCX1US6
M7D\-:QK_ (PTV^\:^'==U/3M9UWQ6_AO3M6AM0#_ $6Z /\ 'W_X*"+^U?\
MM$?\%S_VM?V7O@E\7?B!9>,OBM^WY\4_A1\-M$NOBMXK\,>%;+5-=^*.J:)H
M-C-<0ZF;/1-%M"\,9,%FT5G:Q;8;=MB(P!]S:Y_P;7?\'$WA6U&K^'_&$?BC
M4K=BT&G^$?VSYM.UC<!D-!=>*M=\(Z9&S?=4MJ\1!Z[5R6 /FSX;_P#!5G_@
MNW_P1)_:!T[X8?M'^*OCQ?6>BSV\^N_LZ?M?ZIX@^)O@/QKX0M[F6SEE^&WC
M?7=3U^[TS0I)8[E-(\:?!7QL/#CZO;8O?^$@LX+_ $>Z /\ 3I_X)_?MO_"3
M_@HK^R;\)OVM?@P;JS\+?$K2;C^U?"VJW%M/X@\ ^-="O)M'\9>!/$1M2(SJ
M?AS7+2YMX;Q8H(=;TA]+\16$0TS6+)W /&O^"IW_  5._9U_X)/?LZS?''XX
MS7GB/Q+XDO+WPY\&_@YX<N[6#QG\6O&MM9?;'TW3I+D2Q:'X7T6*2UN_&OC:
M]MKG3O"^GW5G''::OXBUCPWX<UP _P Z7QA^WW_P7P_X."OC1KWPU_9ZN?BS
M!X#B9DOO@S^S9K6J?!SX"?#[PSJDL_V$?&+XB3Z_HMEKIO(+2=H+GXM^-M2?
M6+^TOHO!F@VK;-&B /HS0O\ @R[_ ."I&N>'!KNN?&S]BKPUXDO(%O!X5U;X
MD_&34M0M[B7+SVFMZSH?P&U;1XK]&+;Y-*OM>LI9#D7Y4M)0!R?PD_X(U_\
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M/CWQ?\8M3LKW]_&^IZ9X7\._&'Q)I&HXD\ZZT3QSJ7AC6K*1GAU"QM;Q9+=
M"+XH?\&E/_!9C]FZ"X^)/P8UWX(?&#7_  LW]J:1'^SQ\;/%'A/XF(MN?,-U
MH@^)7@_X10IJEM&AG6RTKQ-<:C<.HM]*6_O'BMW /[?O^#>(_MBQ_P#!,KX>
M:;^W9_PO[_AH30/B9\8?#VM+^TN/&[_%6/P[HOC2]L/#,.HWGQ"!\3:EH\&G
MP^3H.HSSWEG<Z:D1TZ[GLUA90#^(G3?C'\73_P '74GA _%3XCGPG_P]NU70
M?^$7/CCQ.?#O]ACXUWED-%_L3^U/[-_LD68%H-.^R_8Q;8M_*\KY: /]3F@
MH ^1OVXOVW?V?_\ @GG^SCXW_:?_ &DO%$OA[X?>#4MK.ST[3(8;_P 6^.?%
MNJ>:GAWP%X$T2:ZLQKGBWQ#/#,+.T:ZM+&PL+74M?UW4-)\.:/K&KV !_FQ?
MM)?\%M?^"T/_  6X^/ES^S[^Q!I?Q=^%W@/6;V^?PE\ ?V5-1UC0/%7_  B)
MNDL%UWXZ?&W3+K0]5N-,6&\M;;Q1J>L^(/ GP@M)+FW6YT&TE=;RZ /2_!?_
M  9N?\%8_B5I$OC/XD_%K]DSX=^*];$^H7OAWQ[\6/B;XN\9C59CYDG_  DV
ML^!_A)XU\,R33R,3/?Z9XM\1N7#N5?(+ '@WQ1_X-^_^"^'_  3(D;XR? 2W
M\:>)FTD23:CXW_8!^,GCG4O&.G1VQWH)_!NDV7P\^+NN6=Q&DDDBZ+X(UVQC
M@21-6^S+*B2@'^IW\&IO$=S\(/A3<>,/[4_X2V?X;>!IO%/]N0W%OK7_  D<
MOAC2WUO^V(+J.*ZAU3^TVNO[0AN8H[B.[\U)HTD#JH!Z30 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\]/[<G_)T
MGQ0_[DK_ -5WX1K_ "7^DU_R>_C;_NV__61R _T:\!O^34<*_P#=<_\ 6DS@
M^3:_!S]>"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _K(K_> _R'"@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M?>[VC*W>[?5VT7DNNGGZ]6?=-9%!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MO_9F/Y_Y?:8?EO\ X_:)_P#DC/(_U9Q-_P#>:%N]IW^[DMMTO\^I^NG[!/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _GI_;D_Y.D^*'_<E
M?^J[\(U_DO\ 2:_Y/?QM_P!VW_ZR.0'^C7@-_P FHX5_[KG_ *TF<'R;7X.?
MKP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % ']9%?[P'^0X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MLS$X"K/$6)]  Y)/X?G4+$4&TE6I-O1)5(-M^26_]=RG2JI7=.HEU;C*R_\
M)%^?WEFM3,* ,S5-:T;0X!=:WJVF:/;,Q5;C5+^UT^!F R5$UW+#&6 Y(#9
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MN:)>WKK#]O\ #7@^/X<?#;P[<:\C2"/1XO$%MXITD7GE27^A:K$QL& /5?\
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MSC5G=I&\0>$/'/Q,^+6@RS&;+FZM?$7AW3)H(Y/^7F"&(@CY: /]<Z@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M7MI_;=?IY^7A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!__]#^_B@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ /]#B@ H * "@ H * "@#_)_P!,_P"5MR3_ +3":M_ZO6\H _U@* /\VO\
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MVL5]INIZ=>6[/!=V-_93PW5I=0N\,]O+'+&S(ZF@#3H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^>G]N
M3_DZ3XH?]R5_ZKOPC7^2_P!)K_D]_&W_ ';?_K(Y ?Z-> W_ ":CA7_NN?\
MK29P?)M?@Y^O!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 ?UD5_O ?Y#A0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % 'SO\ M9_\FY?%K_L5V_\ 2^QK\G\=O^3.>)/_ &2.<?\
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M<JGU?&8:;BL3A?;5O9QJT*D:M2E7ISE]:U^AGYX% !0 4 % !0 4 % !0 4
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M_P"4,GQ,_P"RW_ 3_P!3*@#YW_X,K_\ E%=\<?\ L_?XJ_\ J@/V7Z /Z]:
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M7CSPIXIA5^L,O@WQ)X/TSQ7]JC8%7MX]'DD_B4-&R2, ?G?^V)_P=Z_\$O\
MX!^'YHOV<+GQ_P#MI?$.6&86.B>!_#7B;X4?#[3[R(D)#XJ^(OQ5\,:-J%O;
MS *T-WX(\"?$)&W!)EMR'9 #^GOX<^+A\0/A[X$\>+IYTD>-O!OACQ<-+-U]
MN.FCQ)HECK(T\WHM[07ALQ>_9S="TM?M'E^;]GAW^6H!V5 !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?ST_MR?\
M)TGQ0_[DK_U7?A&O\E_I-?\ )[^-O^[;_P#61R _T:\!O^34<*_]US_UI,X/
MDVOP<_7@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * /ZR*_W@/\APH * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9DV+PTE45.5?"2K1K8.O&2BYT_K678RG4BG%N*KX=3CS+E<OOS]OWX>3>/\
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M\M+2YN8!,=+U1O''BW^R]7@QB1;C3+X07D11EW^28I-T,CHW].^$G!N5\?\
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MB"]\':)X"N[UY?#7AOQ%XD\3Z-I[JN+'6/%EAX;TWQ!.C\2$7UMX1T!6B?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /_TO[^* "@ H * /BS_@HA^VIX$_X)
MY_L:_'?]KKQ_;Q:KI_PE\(27OA[PLUZNGS>./'^MW=KX=^'W@BVNO+GEMSXG
M\8:IH^FWM]!:WLFCZ3+J.MR6DUMIMPM '\8__!M1^P[\1/\ @I1^U_\ &7_@
MN9^W3=GQ]K.D_%W6!\$].U:TE&EZY\<+.RTZ:\\=:?IMXUQ;VG@;X#>'[S0O
M"'PDTJU:ZLM)\26T$FGW6G7_ ,+K1+H \W_X/A?^2Y?\$_\ _LE'QS_]2_P!
M0!P7P;_X,P_B?\:/@)\(OC5H7[?/@+2;OXM_"CX>_$^R\*:M\ ?$/V;1AX^\
M(Z1XJ31+KQ%:?%*YDNCI:ZL+%]2B\/Q_:V@^T+8VWF"!0#\N_C%\+O\ @K)_
MP:_?M9^ )M(^+/\ 97A_QZS^+?"FK> ?$/B'7_V</VC_  MX1UFRB\2^$/&_
M@K7K/0XKG6-*M]2TVR\4Z1J6CVGBKP=!XJT[6/!_B6 ZGH_B64 _U/?V,_VE
M?#W[8_[*'[/'[4_A?2WT'2/CU\(_!'Q,7PY)?)JDWA;4?$NB6M[KOA.XU*."
MVCU"Y\*ZXVH^'KF^2VMDNY]-EG6WA$@C4 _BI\:_\&1.M^+?&7BWQ5'_ ,%*
M-*L(_$WB;7O$$=B_[)%Y<O9)K.JW6HK:/<K^TA MPULMR(6G6"$2E/,$48;8
MH!S/_$#3KW_23/2/_$0;W_Z)6@#^7+]H'_@F%=>#O^"H<?\ P2[_ &6?C5;_
M +67Q%_X6=X9^"MS\0[/X>R?#7PY:_%"]\O_ (6!I4FE1^-?B)<)X=^$).H0
M^/?$\^IVXT^Y\,^+R=+2PT2._P!0 /\ 8W_9N^#&F_LX?L[? 3]GG1M8O?$6
MC_ ;X+?"WX,:5X@U&"&VU#7=-^%W@;0O ]CK%_;6^;>WO=3M=#BO;J" ^3%/
M.\<645: /:: "@#^:K_@[2_Y0K_&W_LJ_P"S]_ZM+0Z /)_^#.C_ )1#WO\
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M]@;]I?XA_$CX1:-\/[[X??%SQAJ?A76?"?P_\37'A'P[:Z?XQTSXA>$?$7Q
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M\-](OO@KJVC_  VTR>PU5M#CO=+U!K]]=-A#J>D6R^5D7'O#V?+,'1KU\O\
M[/H2Q[6;T)9:\5DNOL<_P?UEP]MD]=0ER8N\?9-6Q%.ESTN?Z[C_ .COXD^'
MTN'(XO!8#B3_ %BQ]/AV+X,QU/B=91QRN18SP]SIY;&K]3XRP+JTE5RI<\,5
MSR>7XC&JAB7A_P!%O@Q^V[\"OC4GCA].U76/ G_"$Z/-XV9?BEI$W@%O$WPB
M/FG3/C9X5&O-;G5/A=JZV]P8/$)^SR:>8D76[+3&O; W9D7'O#V?+,'1KU\O
M_L^A+'M9O0EEKQ62Z^QS_!_67#VV3UU"7)B[Q]DU;$4Z7/2YSC_Z._B3X?2X
M<CB\%@.)/]8L?3X=B^#,=3XG64<<KD6,\/<Z>6QJ_4^,L"ZM)5<J7/#%<\GE
M^(QJH8EX?\ O^";?_!*#_@E+\%/VXO%'_!0'X+_%_P#:]\._&+X;/\7?BM#X
M7_:.\1_#'PO\-/%'PR^,6@>,O#NJ_&WPUHS?!?PGXKU;X47FF^*M=D\.ZX/&
MEK)HMU:Z:WBFU036\6J&1<>\/9\LP=&O7R_^SZ$L>UF]"66O%9+K['/\']9<
M/;9/74)<F+O'V35L13I<]+G./_H[^)/A]+AR.+P6 XD_UBQ]/AV+X,QU/B=9
M1QRN18SP]SIY;&K]3XRP+JTE5RI<\,5SR>7XC&JAB7A_W]^#'[;OP*^-2>.'
MT[5=8\"?\(3H\WC9E^*6D3> 6\3?"(^:=,^-GA4:\UN=4^%VKK;W!@\0G[/)
MIYB1=;LM,:]L#=F1<>\/9\LP=&O7R_\ L^A+'M9O0EEKQ62Z^QS_  ?UEP]M
MD]=0ER8N\?9-6Q%.ESTN<X_^COXD^'TN'(XO!8#B3_6+'T^'8O@S'4^)UE''
M*Y%C/#W.GEL:OU/C+ NK257*ESPQ7/)Y?B,:J&)>'_$7]N/_ ()V_P#!,C_@
MNU\3-,^+?Q^^+?[5?P.\2?L[?"O4;+0;/0]:^&_P=TCQI\![SQ!J?B;3_CII
MUK\6OA#\0;W7/ .J7MSJ*6?BBRU#18=/MHH(=?T?3Y[FPN+TR+CWA[/EF#HU
MZ^7_ -GT)8]K-Z$LM>*R77V.?X/ZRX>VR>NH2Y,7>/LFK8BG2YZ7.<?_ $=_
M$GP^EPY'%X+ <2?ZQ8^GP[%\&8ZGQ.LHXY7(L9X>YT\MC5^I\98%U:2JY4N>
M&*YY/+\1C50Q+P_ZY_L:_M&?LU1?!_0_@SX!U_Q?X2\*?LU?"#P;HOAN[^.5
MC%X,\0>,O@%X!\,6/A7PG\=K"ZOK/0['7O NOZ7H(FN_%5GIFC06MZCMJ6AZ
M#'?Z;;RF1<>\/9\LP=&O7R_^SZ$L>UF]"66O%9+K['/\']9</;9/74)<F+O'
MV35L13I<]+G./_H[^)/A]+AR.+P6 XD_UBQ]/AV+X,QU/B=91QRN18SP]SIY
M;&K]3XRP+JTE5RI<\,5SR>7XC&JAB7A^D\#_ +5G[+O[5?A7XK>"_%FF6L7@
MNR\*:CK?BCP?^T!X.L]$\-?$CX$ZA%-%%\5K+0/&T$NE^*_@WXCMX;J-]3U&
MT\FW2-8?$.FZ=]ML/M9D7'O#V?+,'1KU\O\ [/H2Q[6;T)9:\5DNOL<_P?UE
MP]MD]=0ER8N\?9-6Q%.ESTN<X_\ H[^)/A]+AR.+P6 XD_UBQ]/AV+X,QU/B
M=91QRN18SP]SIY;&K]3XRP+JTE5RI<\,5SR>7XC&JAB7A_Y>_B+_ ,&\?_!$
M+]NCQ!\3/&GP4U_X^?L):YX>M;SXBW?AZ"_T[0?AEXF^%-VT\MM\;?!7@;XP
M:/KE_!\*-9D@N9=,OO#/BWPQH?AU$^QWOAK1+6ZT>!C(N/>'L^68.C7KY?\
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M=3XG64<<KD6,\/<Z>6QJ_4^,L"ZM)5<J7/#%<\GE^(QJH8EX?X7_ &J_!O[
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M;'3?$'Q!\-_":>:TF"I<V&K:@\T4LS31S@'^E]0 4 % '\^4'_!MI^PQ;_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /YZ?VY/^3I/BA_W)
M7_JN_"-?Y+_2:_Y/?QM_W;?_ *R.0'^C7@-_R:CA7_NN?^M)G!\FU^#GZ\%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!_617^\!_D.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M3O ^BZ<L?AC2]-;2;72[V:?5(VT^02"6UN9-2ENI;J&832K)%</)$8W,*QK
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /__3_OXH * "@ H _@>_X/8OVF=?N1^Q)^PQX/U&^G;Q
M3>>+?VA/'OA33R[W&MW<=W%\,/@J#:P9GO VH3_%^."T<-#/?I92QQO<VD;P
M ']CO_!/O]E/PS^Q#^Q7^S5^ROX6TZTTZW^#OPH\,>'O$#691DUCQ_=V@USX
ME^)YI(P(Y;OQ9\0=4\3>)+R2,+$;G5)!"J0B.- #^'#_ (/A?^2Y?\$__P#L
ME'QS_P#4O\ 4 ?VN_L7?&/X1>#_V#/V/-4\6_%3X<>%],L?V4OV>$OM1\1>.
M/#.B6%FZ?"'PCO6ZO-2U2VM[=D*,&$LB%=K9'RD* ?P:_P#!U%_P4,^#?_!3
M']H_]D7]C/\ 85O/^&EM8^#FM>/K/4?%GPIM7\9Z3X^^+/QAO? _A[0/AO\
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M5'M[75_$/AOQ5=_#7]HWPM#!"JEE\?\ P\L;2]\7+"QEU*Y^)NL3EEN;UV4
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M[/><Y;0QG]F5XUL)S<U/E2MS8:I[.4/;8&LXP=?!55/"UW2I>UI2Y(<IX?\
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ME;FPU3V<H>VP-9Q@Z^"JJ>%KNE2]K2ER0Y3P_P#&/Q(\+X\1QX(XHQ^2KBK
M5,#G'L_9U_:3ESJEFF%^LQK?4<]P<:V(C@,\PCHYI@8XG$K"XJG[:?,?&?\
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MT^'M7:PL3J&G7'V2(*9[PEP]Q+_9[SG+:&,_LRO&MA.;FI\J5N;#5/9RA[;
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MG5+-,+]9C6^HY[@XUL1' 9YA'1S3 QQ.)6%Q5/VT^8^,_P"R]\"OV@6\#O\
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MJ3E*<YSDY3G.3;E.<I-RE*3;<I-MMMMMWN?KK3)"@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@!KKO1TW,F]67>APZ;AC<A((#+G*D@X(S@]* /
MR2_X)K_\$5OV,O\ @E?XO^,7C_\ 9M;XLZ[XS^.&F>'M&\8>)/C!XUTOQMJU
MKI?A_5-9UIK+0;K3O"GA=[*+7M5U>._\1M>?VE+J5SHNAR"6W-G)]H /UOH
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH _GI_;D_P"3I/BA_P!R5_ZKOPC7^2_TFO\ D]_&W_=M_P#K(Y ?Z-> W_)J
M.%?^ZY_ZTF<'R;7X.?KP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % ']9%?[P'^0X4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0!P'Q8GFMOA9\2KFVEEM[BW\ >,IX)X7:*:&:+P
M[J3Q2Q2(5>.6-U#QNC*R.H92" :^3X]JU</P-QI7H5*E&O1X3XCJT:U*<J=6
ME5IY/C)TZE.I&TH5(32E"<7S1DDU9I'N\+4Z=7B;AVE5A&I2JY[E%.I3G%3A
M4ISS##QG"<97C*,HMQE%JS3:=[GYT?\ !,*20V'QIC,CF-;[P'(L9=BBR2P^
M+UDD5"=JO(L42R. &<11AB0BA?XM^@C.?]G>)5+GE[*&+X3G"GS/V<)U*&?Q
MJ3C"_*ISC2I1G)).4:5--M0@H_TY]*^$%C^"JG+%5)83/82G9<\H0K97*$92
MMS.,)5*CBFVHNI-I+FDY?JM7]_'\C!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % 'Y-?\%5/BZFB>!/"'P;TR\9-4\9ZA_PE/B*&"=5DC\,:$\D&F6U[!@N]
MIK.O.]S;LNS]_P"&)0SE0T;[T(ZN7;1>O_#>?WW#^OZ_I?FI4?\ @E#\+WTS
MP=\0OBYJ%HB3>*-4M/!_AV::VFCN5TCP^IO]<N;6=PL5QIVJ:K?V%HS0[]M]
MX:N(W<-$R*5Y:J/S?Z?=K]X'ZYU@ 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!_]3^_B@ H * "@#_ #C?^"YD4?QC_P"#J?\
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MUK6F:8\VU;S5;&%FG4 ])_X(O?\ !:KXH?\ !*3]HVS_ ."47_!0[]F3X3_
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /YZ?VY/^3I/BA_W)7_J
MN_"-?Y+_ $FO^3W\;?\ =M_^LCD!_HUX#?\ )J.%?^ZY_P"M)G!\FU^#GZ\%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!_617^\!_D.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /__5_OXH * "@ H _P X/_@XEO[;]G/_
M (.5?V _VA=?8Z)X5A'[#/QCU/Q!.K1Z>-/^&G[1OB#2?$DLMQCRW&FZ1X)B
M;4("S/'9SVYE00W,)< _T?* /\ZS_@^%_P"2Y?\ !/\ _P"R4?'/_P!2_P
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MZU82X,MCJVC:K;W>G:C9RE5,EM>6TT+[1N0XRH!\Z_\ #"O[$?\ T9U^RO\
M^(]_"3_YE* .V\ ?LP_LU?"?Q OBWX6?L\_ WX:^*DL[G3D\3> /A+X"\&^(
M%T^]V?;+%=9\.Z%I^HK9W?E1?:;47 AG\M/-1MB[0#\'/^#M+_E"O\;?^RK_
M +/W_JTM#H \G_X,Z/\ E$/>_P#9U_QI_P#4>^&= ']5M '\U'_!VI_RA8^-
M7_96?V?O_5GZ-0!Y5_P9T?\ *(:\_P"SKOC3_P"H_P##2@#^I>PUW1-4OM:T
MS3-9TK4=2\-WMOIWB+3[#4;2\OM!U"\TVRUFTL-:M+>62XTJ]NM(U+3]5M[6
M^C@GGTV_LKZ)'M;JWD8 U: /\MS_ (/"?&/PT^*7_!6CX?>"_A#)9^*OB7X)
M_9I^%_PS^*<'A>:/4;M/B7J/Q#^)GB/PWX+O;2Q5I'\7V?A#Q=X3GGC+27C6
M6O:%I;K'+IWDH ?Z>OP_L_$.G^ _!-AXMN&N_%5CX1\-V?B:Z:19FN?$-MHU
ME#K5PTR,R2M-J27,AD1F5RVY6((+ '\(?_!\3\2=,71_^">/P@MM0CDUF74O
MVA_B3K.E(W[ZSTR"U^%'ACPSJ%PG&(]3NKCQ9;6;#=N?2;X';M&\ _M+_8B\
M"W?PN_8O_9$^&=_93:;??#K]F#X!>!;W3KB)H9]/N_"/PI\)^'[FRGA8!HIK
M6;3W@DB8!HWC*D @B@#Z?H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _GI_;
MD_Y.D^*'_<E?^J[\(U_DO])K_D]_&W_=M_\ K(Y ?Z-> W_)J.%?^ZY_ZTF<
M'R;7X.?KP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % ']9%?[P'^0X4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M^0&XAENKC7"T=O=:7;.SK3TY%Y-_HOU^7FP/VMKF * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M\"*MP4U6SMH #_2_H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MPY_\Y@_X8:_9:_Z)?_Y>OQ$_^:^C_B67P0_Z(G_S9.+O_HA#_B/'BM_T5?\
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M_##7[+7_ $2__P O7XB?_-?1_P 2R^"'_1$_^;)Q=_\ 1"'_ !'CQ6_Z*O\
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MXEE\$/\ HB?_ #9.+O\ Z(0_XCQXK?\ 15_^8/AS_P"<P?\ ##7[+7_1+_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MMK>($LY$<2*I>1GED;,DKO(SNW&VVVWJV[M]W^/Y_>!K4@"@ H * "@ H *
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M/AV]@T:>T\#?';P\OD/:I;?VE:W'B&#P)X837 #^Y^@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MV?\ _IW*#]6:_P! #^1 H * "@ H * "@ H * "@ H * "@#X$_:X_;F\'_
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /__0_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
MS[XM1R3?"KXF11(\LLOP^\9QQQQJ7DDD?PYJ2HB(H+,[L0JJH)8G !)Q7R/B
M!"53@/C:$(RG.?"/$D(0@G*4Y2R;&J,8Q5W*4FTDDKMNROH>_P *2C'BCAN4
MFHQCG^3RE*32C&*S'#-MMV225VVW9+5V/SH_X)@JPLOC4Q4[3>^ E#8.TLL/
MC LH/3<H="P!R RDXW"OXN^@BG]1\2W9V>)X12?1M4>(FTGU:35^UUW/Z<^E
M>U]<X(5]5AL_;76SJY39_.SMIT>]C]6*_O\ /Y$"@ H * "@ H * "@ H *
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M*A[O4+Z>XO;N3]Y<7$KG=7*VV[MMOS_K\M .PI % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_1_OXH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * /_]+^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H __3_N@^.WQL^'7[-OP9^*'Q^^+NLW'A[X8?!WP/XB^(GCS6[32=4UVZ
MTSPOX6TVXU75KJVT;1+6]U;4[B.UMW\FSL+6>XGD*HJ@%F4 _!G_ (BP/^")
M?_1QGQ _\1W^-_\ \QE !_Q%@?\ !$O_ *.,^('_ (CO\;__ )C* #_B+ _X
M(E_]'&?$#_Q'?XW_ /S&4 '_ !%@?\$2_P#HXSX@?^([_&__ .8R@ _XBP/^
M")?_ $<9\0/_ !'?XW__ #&4 '_$6!_P1+_Z.,^('_B._P ;_P#YC* #_B+
M_P"")?\ T<9\0/\ Q'?XW_\ S&4 '_$6!_P1+_Z.,^('_B._QO\ _F,H /\
MB+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\ HXSX@?\ B._QO_\ F,H
M/^(L#_@B7_T<9\0/_$=_C?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC*
M#_B+ _X(E_\ 1QGQ _\ $=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,
MH /^(L#_ ((E_P#1QGQ _P#$=_C?_P#,90 ?\18'_!$O_HXSX@?^([_&_P#^
M8R@ _P"(L#_@B7_T<9\0/_$=_C?_ /,90 ?\18'_  1+_P"CC/B!_P"([_&_
M_P"8R@ _XBP/^")?_1QGQ _\1W^-_P#\QE !_P 18'_!$O\ Z.,^('_B._QO
M_P#F,H /^(L#_@B7_P!'&?$#_P 1W^-__P QE !_Q%@?\$2_^CC/B!_XCO\
M&_\ ^8R@ _XBP/\ @B7_ -'&?$#_ ,1W^-__ ,QE !_Q%@?\$2_^CC/B!_XC
MO\;_ /YC* #_ (BP/^")?_1QGQ _\1W^-_\ \QE !_Q%@?\ !$O_ *.,^('_
M (CO\;__ )C* #_B+ _X(E_]'&?$#_Q'?XW_ /S&4 '_ !%@?\$2_P#HXSX@
M?^([_&__ .8R@ _XBP/^")?_ $<9\0/_ !'?XW__ #&4 '_$6!_P1+_Z.,^(
M'_B._P ;_P#YC* #_B+ _P"")?\ T<9\0/\ Q'?XW_\ S&4 '_$6!_P1+_Z.
M,^('_B._QO\ _F,H /\ B+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\
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M !_Q%@?\$2_^CC/B!_XCO\;_ /YC* #_ (BP/^")?_1QGQ _\1W^-_\ \QE
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MC?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC* #_B+ _X(E_\ 1QGQ _\
M$=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,H /^(L#_ ((E_P#1QGQ
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M")?_ $<9\0/_ !'?XW__ #&4 '_$6!_P1+_Z.,^('_B._P ;_P#YC* #_B+
M_P"")?\ T<9\0/\ Q'?XW_\ S&4 '_$6!_P1+_Z.,^('_B._QO\ _F,H /\
MB+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\ HXSX@?\ B._QO_\ F,H
M/^(L#_@B7_T<9\0/_$=_C?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC*
M#_B+ _X(E_\ 1QGQ _\ $=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,
MH /^(L#_ ((E_P#1QGQ _P#$=_C?_P#,90 ?\18'_!$O_HXSX@?^([_&_P#^
M8R@ _P"(L#_@B7_T<9\0/_$=_C?_ /,90 ?\18'_  1+_P"CC/B!_P"([_&_
M_P"8R@ _XBP/^")?_1QGQ _\1W^-_P#\QE !_P 18'_!$O\ Z.,^('_B._QO
M_P#F,H /^(L#_@B7_P!'&?$#_P 1W^-__P QE !_Q%@?\$2_^CC/B!_XCO\
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M,^('_B._QO\ _F,H /\ B+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\
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M !_Q%@?\$2_^CC/B!_XCO\;_ /YC* #_ (BP/^")?_1QGQ _\1W^-_\ \QE
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MC?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC* #_B+ _X(E_\ 1QGQ _\
M$=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,H /^(L#_ ((E_P#1QGQ
M_P#$=_C?_P#,90 ?\18'_!$O_HXSX@?^([_&_P#^8R@ _P"(L#_@B7_T<9\0
M/_$=_C?_ /,90 ?\18'_  1+_P"CC/B!_P"([_&__P"8R@ _XBP/^")?_1QG
MQ _\1W^-_P#\QE !_P 18'_!$O\ Z.,^('_B._QO_P#F,H /^(L#_@B7_P!'
M&?$#_P 1W^-__P QE !_Q%@?\$2_^CC/B!_XCO\ &_\ ^8R@ _XBP/\ @B7_
M -'&?$#_ ,1W^-__ ,QE !_Q%@?\$2_^CC/B!_XCO\;_ /YC* #_ (BP/^")
M?_1QGQ _\1W^-_\ \QE !_Q%@?\ !$O_ *.,^('_ (CO\;__ )C* #_B+ _X
M(E_]'&?$#_Q'?XW_ /S&4 '_ !%@?\$2_P#HXSX@?^([_&__ .8R@ _XBP/^
M")?_ $<9\0/_ !'?XW__ #&4 '_$6!_P1+_Z.,^('_B._P ;_P#YC* #_B+
M_P"")?\ T<9\0/\ Q'?XW_\ S&4 '_$6!_P1+_Z.,^('_B._QO\ _F,H /\
MB+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\ HXSX@?\ B._QO_\ F,H
M/^(L#_@B7_T<9\0/_$=_C?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC*
M#_B+ _X(E_\ 1QGQ _\ $=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,
MH /^(L#_ ((E_P#1QGQ _P#$=_C?_P#,90 ?\18'_!$O_HXSX@?^([_&_P#^
M8R@ _P"(L#_@B7_T<9\0/_$=_C?_ /,90 ?\18'_  1+_P"CC/B!_P"([_&_
M_P"8R@ _XBP/^")?_1QGQ _\1W^-_P#\QE !_P 18'_!$O\ Z.,^('_B._QO
M_P#F,H /^(L#_@B7_P!'&?$#_P 1W^-__P QE !_Q%@?\$2_^CC/B!_XCO\
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M,^('_B._QO\ _F,H /\ B+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\
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M !_Q%@?\$2_^CC/B!_XCO\;_ /YC* #_ (BP/^")?_1QGQ _\1W^-_\ \QE
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MC?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC* #_B+ _X(E_\ 1QGQ _\
M$=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,H /^(L#_ ((E_P#1QGQ
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M")?_ $<9\0/_ !'?XW__ #&4 '_$6!_P1+_Z.,^('_B._P ;_P#YC* #_B+
M_P"")?\ T<9\0/\ Q'?XW_\ S&4 '_$6!_P1+_Z.,^('_B._QO\ _F,H /\
MB+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\ HXSX@?\ B._QO_\ F,H
M/^(L#_@B7_T<9\0/_$=_C?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC*
M#_B+ _X(E_\ 1QGQ _\ $=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,
MH /^(L#_ ((E_P#1QGQ _P#$=_C?_P#,90 ?\18'_!$O_HXSX@?^([_&_P#^
M8R@ _P"(L#_@B7_T<9\0/_$=_C?_ /,90 ?\18'_  1+_P"CC/B!_P"([_&_
M_P"8R@ _XBP/^")?_1QGQ _\1W^-_P#\QE !_P 18'_!$O\ Z.,^('_B._QO
M_P#F,H /^(L#_@B7_P!'&?$#_P 1W^-__P QE !_Q%@?\$2_^CC/B!_XCO\
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M,^('_B._QO\ _F,H /\ B+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\
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M !_Q%@?\$2_^CC/B!_XCO\;_ /YC* #_ (BP/^")?_1QGQ _\1W^-_\ \QE
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MC?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC* #_B+ _X(E_\ 1QGQ _\
M$=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,H /^(L#_ ((E_P#1QGQ
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M")?_ $<9\0/_ !'?XW__ #&4 '_$6!_P1+_Z.,^('_B._P ;_P#YC* #_B+
M_P"")?\ T<9\0/\ Q'?XW_\ S&4 '_$6!_P1+_Z.,^('_B._QO\ _F,H /\
MB+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\ HXSX@?\ B._QO_\ F,H
M/^(L#_@B7_T<9\0/_$=_C?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC*
M#_B+ _X(E_\ 1QGQ _\ $=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,
MH /^(L#_ ((E_P#1QGQ _P#$=_C?_P#,90 ?\18'_!$O_HXSX@?^([_&_P#^
M8R@ _P"(L#_@B7_T<9\0/_$=_C?_ /,90 ?\18'_  1+_P"CC/B!_P"([_&_
M_P"8R@ _XBP/^")?_1QGQ _\1W^-_P#\QE !_P 18'_!$O\ Z.,^('_B._QO
M_P#F,H /^(L#_@B7_P!'&?$#_P 1W^-__P QE !_Q%@?\$2_^CC/B!_XCO\
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M,^('_B._QO\ _F,H /\ B+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\
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M !_Q%@?\$2_^CC/B!_XCO\;_ /YC* #_ (BP/^")?_1QGQ _\1W^-_\ \QE
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MC?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC* #_B+ _X(E_\ 1QGQ _\
M$=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,H /^(L#_ ((E_P#1QGQ
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M")?_ $<9\0/_ !'?XW__ #&4 '_$6!_P1+_Z.,^('_B._P ;_P#YC* #_B+
M_P"")?\ T<9\0/\ Q'?XW_\ S&4 '_$6!_P1+_Z.,^('_B._QO\ _F,H /\
MB+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\ HXSX@?\ B._QO_\ F,H
M/^(L#_@B7_T<9\0/_$=_C?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC*
M#_B+ _X(E_\ 1QGQ _\ $=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,
MH /^(L#_ ((E_P#1QGQ _P#$=_C?_P#,90 ?\18'_!$O_HXSX@?^([_&_P#^
M8R@ _P"(L#_@B7_T<9\0/_$=_C?_ /,90 ?\18'_  1+_P"CC/B!_P"([_&_
M_P"8R@ _XBP/^")?_1QGQ _\1W^-_P#\QE !_P 18'_!$O\ Z.,^('_B._QO
M_P#F,H /^(L#_@B7_P!'&?$#_P 1W^-__P QE !_Q%@?\$2_^CC/B!_XCO\
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M,^('_B._QO\ _F,H /\ B+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\
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M !_Q%@?\$2_^CC/B!_XCO\;_ /YC* #_ (BP/^")?_1QGQ _\1W^-_\ \QE
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MC?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC* #_B+ _X(E_\ 1QGQ _\
M$=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,H /^(L#_ ((E_P#1QGQ
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M")?_ $<9\0/_ !'?XW__ #&4 '_$6!_P1+_Z.,^('_B._P ;_P#YC* #_B+
M_P"")?\ T<9\0/\ Q'?XW_\ S&4 '_$6!_P1+_Z.,^('_B._QO\ _F,H /\
MB+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\ HXSX@?\ B._QO_\ F,H
M/^(L#_@B7_T<9\0/_$=_C?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC*
M#_B+ _X(E_\ 1QGQ _\ $=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,
MH /^(L#_ ((E_P#1QGQ _P#$=_C?_P#,90 ?\18'_!$O_HXSX@?^([_&_P#^
M8R@ _P"(L#_@B7_T<9\0/_$=_C?_ /,90 ?\18'_  1+_P"CC/B!_P"([_&_
M_P"8R@ _XBP/^")?_1QGQ _\1W^-_P#\QE !_P 18'_!$O\ Z.,^('_B._QO
M_P#F,H /^(L#_@B7_P!'&?$#_P 1W^-__P QE !_Q%@?\$2_^CC/B!_XCO\
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M,^('_B._QO\ _F,H /\ B+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\
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M !_Q%@?\$2_^CC/B!_XCO\;_ /YC* #_ (BP/^")?_1QGQ _\1W^-_\ \QE
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MC?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC* #_B+ _X(E_\ 1QGQ _\
M$=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,H /^(L#_ ((E_P#1QGQ
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M")?_ $<9\0/_ !'?XW__ #&4 '_$6!_P1+_Z.,^('_B._P ;_P#YC* #_B+
M_P"")?\ T<9\0/\ Q'?XW_\ S&4 '_$6!_P1+_Z.,^('_B._QO\ _F,H /\
MB+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\ HXSX@?\ B._QO_\ F,H
M/^(L#_@B7_T<9\0/_$=_C?\ _,90 ?\ $6!_P1+_ .CC/B!_XCO\;_\ YC*
M#_B+ _X(E_\ 1QGQ _\ $=_C?_\ ,90 ?\18'_!$O_HXSX@?^([_ !O_ /F,
MH /^(L#_ ((E_P#1QGQ _P#$=_C?_P#,90 ?\18'_!$O_HXSX@?^([_&_P#^
M8R@ _P"(L#_@B7_T<9\0/_$=_C?_ /,90 ?\18'_  1+_P"CC/B!_P"([_&_
M_P"8R@ _XBP/^")?_1QGQ _\1W^-_P#\QE !_P 18'_!$O\ Z.,^('_B._QO
M_P#F,H /^(L#_@B7_P!'&?$#_P 1W^-__P QE !_Q%@?\$2_^CC/B!_XCO\
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M,^('_B._QO\ _F,H /\ B+ _X(E_]'&?$#_Q'?XW_P#S&4 '_$6!_P $2_\
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MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
MA4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL
M_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP_
M_P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_
M "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T
M '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_P
MJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^
M'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&
M>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_
M .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /
M^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HF
MGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_
M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
MA4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL
M_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP_
M_P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_
M "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T
M '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_P
MJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^
M'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&
M>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_
M .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /
M^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HF
MGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_
M /PC/#G_ ,@T '_"IOA9_P!$T^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\
M",\.?_(- !_PJ;X6?]$T^'__ (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(-
M!_PJ;X6?]$T^'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA
M9_T33X?_ /A&>'/_ )!H /\ A4WPL_Z)I\/_ /PC/#G_ ,@T '_"IOA9_P!$
MT^'_ /X1GAS_ .0: #_A4WPL_P"B:?#_ /\ ",\.?_(- !_PJ;X6?]$T^'__
M (1GAS_Y!H /^%3?"S_HFGP__P#",\.?_(- !_PJ;X6?]$T^'_\ X1GAS_Y!
MH /^%3?"S_HFGP__ /",\.?_ "#0 ?\ "IOA9_T33X?_ /A&>'/_ )!H /\
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M'_\ X1GAS_Y!H /^%3?"S_HFGP__ /",\.?_ "#0!Z!0 4 ?_]7^_B@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /_UO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@#Q?X^_&WPQ^S_ /#/7/B'XE*W#6B_8?#VB+.EO<^)/$MU
M#,^EZ+;2.&\L3&"6YOKA(IWLM+M+Z^2WN6MEMI:C%RDDOF^R[_U^J ^#/^">
M^O\ [0_Q;\:?$;XX?$7Q?KMS\.M9BU#1=)\.ZAJ%_)H=UXEGU/3M1:?PKHMQ
M-+:Z;I/ABPAFTO[5;1P)))J2V%L]T]KJ@M-JW)&,8I:[^BVU>]Y/6W_  _5N
MN< H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#E
M/'?C/0_AQX'\9?$/Q/+-!X;\!^%/$7C/Q#/;0_:+B'0_"^D7FMZM+;P;D\Z:
M.PL;AXH=Z>8ZJFY<YH _F5_XC!/^"/7_ $%/VE__  R"_P#S7T '_$8)_P $
M>O\ H*?M+_\ AD%_^:^@#^GOPUK^G>+/#F@>*='>632?$NBZ5K^ER3Q-!.^G
M:S8P:C9/- V6AE:VN8FDB8[HW)0Y(- 'Y5?\%'O^"W?_  3[_P""7$^G>&_V
MD?B9J^L_%G6-,36])^!7PBT.'QW\69]$E8+!K.JZ7-JNA>&?!NFWQR=(N?'G
MBOPLNOK#=OX?&J+I^H&U /RV^"7_  >+?\$H?BKXYTWP;XT\/_M1?L_Z?JM^
MEG;_ !!^*OPT\%ZCX$L%GFCAMI=>G^%GQ0^)'BK2E=I US/'X2OM,L(E:>[U
M..!'D0 _J7\)>+O"OC[PMX=\<>!O$FA>,?!GB_1-,\2^%/%GA?5K'7O#?B7P
M]K5G%J&CZYH.MZ9/<Z=JVD:I87$%YI^HV-Q/:7EK-%/!*\;HU '0T ?-W[7?
M[5_P9_8?_9U^)G[4G[0.N7GA_P"$_P *-+T[4O$U[I=A_:NLW$NLZ[I?AG0M
M(T/2A-;MJ>M:YX@UK2])TRR6>$2W5Y'YDT,*R3( ?/\ ^QK_ ,%//V9_VZ?V
M4OB#^V;\%(OB99_ _P"&^I_$#3-;U3X@>!Y?".LZ@/AEX5TSQ=XLU+P[I;ZC
M?)K6D6EEJ9T^'4(+Q8IM<TW5]*(CGTZ<T ?CW_Q&"?\ !'K_ *"G[2__ (9!
M?_FOH /^(P3_ ((]?]!3]I?_ ,,@O_S7T ?T]^&M?T[Q9X<T#Q3H[RR:3XET
M72M?TN2>)H)WT[6;&#4;)YH&RT,K6US$TD3'=&Y*')!H _*K_@H]_P %N_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?7DQ>YOKR:XO+J66YGED?E;;;;W8'24@"@ H * "@ H * "@ H * "@ H *
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M-S;0PP6H!_;I0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M7!:O.Q?A1@Y1?U'-<32FMEBZ%*O&79.5'ZNX>O+/T6\MZ7$]9/\ ?86G)?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MKH=X2F4)M[&*^MX'5BFR_E"[MX9 #_2VH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)),S_8?!T%E=> I_+?\ ??9O^%=:MX6TQ;ER\=SJ&DZF(W#PS0Q?S9Q_E?\
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M5SX-UF*[=DC*6(#3-P83Q4KR4Z>9Y92E"=.4?:8"I.G*,G%J_LL1.JIIM_\
M/^#BM?>=D=%7AF"M+#XF:DI)\M9)IJ_\].*:=O[CO_=/ZLJ_(SZ@* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ^&?VY/VJ(/V>_A^=#\+W]H?BQXUM9;?PU:DB>;P]I#L]M?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^\^(C)QDI1=G%J2?9IW3^\_ULM)U"+5M*TS58/\ 4:GI]GJ$/_7*]MH[F/\
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M&E([,'Q!A\3.-*O3>&G)VC)R4Z3;V4IVBX-O;FCRZZSC:\OZ):_-CZ * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MAS_Y\A_PW+^RU_T5#_RROB)_\R%'_$S7@A_T6W_FM\7?_0\'_$!_%;_HE/\
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MQ$_^9"C_ (F:\$/^BV_\UOB[_P"AX/\ B _BM_T2G_F<X<_^?(?\-R_LM?\
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MR'_#<O[+7_14/_+*^(G_ ,R%'_$S7@A_T6W_ )K?%W_T/!_Q ?Q6_P"B4_\
M,YPY_P#/D/\ AN7]EK_HJ'_EE?$3_P"9"C_B9KP0_P"BV_\ -;XN_P#H>#_B
M _BM_P!$I_YG.'/_ )\A_P -R_LM?]%0_P#+*^(G_P R%'_$S7@A_P!%M_YK
M?%W_ -#P?\0'\5O^B4_\SG#G_P ^0_X;E_9:_P"BH?\ EE?$3_YD*/\ B9KP
M0_Z+;_S6^+O_ *'@_P"(#^*W_1*?^9SAS_Y\A_PW+^RU_P!%0_\ +*^(G_S(
M4?\ $S7@A_T6W_FM\7?_ $/!_P 0'\5O^B4_\SG#G_SY/K*OW@_(0H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M(;=HDFM?$VDV6N^)O%7B73K@K=:%K7C6[\,7T$5_H-PS@'])= !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M6+P%*=1WJ4VZ,Y?S.G;EEYMP<>9ZWE=];1_5JOD3U H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^>G]N3_DZ3XH?]
MR5_ZKOPC7^2_TFO^3W\;?]VW_P"LCD!_HUX#?\FHX5_[KG_K29P?)M?@Y^O!
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?UD5_O ?Y#A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#^>G]N3_ ).D^*'_ ')7_JN_"-?Y+_2:_P"3W\;?]VW_ .LC
MD!_HUX#?\FHX5_[KG_K29P?)M?@Y^O!0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?UD5_O ?Y#A0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M9+3>8^YK]$&U$1I;FK-/O_6]WT\EYW!62MY7^_\ X;OKVC;WOHZLQA0 4 %
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M/\[_ '-:/5=/U/IV@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_P#\B')/^Q1EO_J'1/S/'_[]C?\ L+Q/_IZ9_5!_P:Y_\D#_ &H_^RO^$/\
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M'A26:*XG\)ZOXLOX/"MW<6Y!MY[[PUIC6&AWT]NPWV\MY83R0.6DB=7=V;+
M\/Y+EM3VV!RO!X:MLJT*,75BGNHU9*52*?51E9];615;'8S$1Y*V(JU(_P K
MDU%^L4U%V\T_E8XW]FW]E[XY?M:_$K2OA5\!O .L^-_$^HSVHO[BSMID\/\
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M!FGZYK-YXAU:VTZYU;4=;G%]K-^6N[^:34=5O9?-EQM218HU2.-$4 ]_H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _GI_
M;D_Y.D^*'_<E?^J[\(U_DO\ 2:_Y/?QM_P!VW_ZR.0'^C7@-_P FHX5_[KG_
M *TF<'R;7X.?KP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % ']9%?[P'^0X4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M+B9H]VCSW.KA[]==L9K(JS_Y=K96O;\(Z-*RT>SU5M+,#];*YP"@ H * "@
MH * "@ H * "@ H * "@#X)M=1/PW_:2^PO)'#I^KZR;*2&"3[/;I8>)HP;
M7)DCCCQ;7%Q:7DJH/*,L.%D.U@NWQ0;[*_W;O\-=K?A*=GT2Z+O?KY?C^3C]
M[5B4% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\I
M?MW7_P 2M*_8E_:]U/X-R>(HOBSIW[,_QQOOAO-X0%TWBV'QK:_#7Q+/X<F\
M*K8AK]O$L.JI;2Z"M@KWS:JEH+-'N3"C U:ZOM=7Z:>NMON^\_QH(FB:*-K=
MTD@:-&ADC<2))$R@QR)(&82*Z%663<V\'=N.<L&Y_79_P9]W_P 0(_VR?VIM
M,TJ;6?\ A5UU^S7IU_XYMX/M!\.GQS9?$WPS;_#"?5=N;1-;&AW_ ,5X_#_G
M%;F6P;Q/]EWPPWNP(GLN]]/U\NBO\K=3_0@H,@H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#__UO[^* "@ H * /'OBI^SS\ ?CI)H
MDWQM^!OP>^,<OAE-0C\.2_%3X9^"_B%)X?CU9K)M5CT1_%VAZPVE)J;:=I[:
M@E@;=;UK&R-SYIM8-G;A,RS'+_:+ 8_&X)5>5U5A,57P_M.3FY/:>QJ0Y^3F
MER\U^7FE:UV8U</0K\OMZ-&MRWY?:TH5.6]K\O-&5KV5[;V5[V7+Q/A#]BW]
MCGX?>)='\9^ OV3?V:/!'C#P]=C4- \6>$/@1\+?#?B70[]4>-;W1]=T7PI8
MZIIEVL<DD8N;*[@F"2.H?:S*V];/,[Q-*=#$9QFE>A47+4HUL?BZM*I'?EG3
MG6E&2O;22:(A@\'3DIT\+AH3B[QG"A3C*+[J2@FGZ/[]3Z4EBCFCDAFC26*5
M'BEBE19(Y8Y%*O'(C JZ.I*NC JRD@@@D5Y:=M5HUJFNATGR/_P[\_8+_P"C
M(_V1/_$;?@U_\Q)_G^=>S_K'Q#_T/LY_\.>-_P#EYR?4,!_T!83_ ,)J/_RL
M^F/"/@_PEX \-:/X,\!^%O#G@GP?X=LTT[P_X4\(Z)IGAOPUH6GQLSQV.CZ%
MHUK9Z7IEFCN[);65K! K,S+&I9J\NM6K8BK.OB*U6O6JRYJE:M4G5JU)/>4Z
MDW*<I:;R;?W'3"$*<5"G&,(15HPA%1C%=E%627DE]VAROQ0^"GP:^-^DZ=H/
MQI^$GPR^+VAZ1J/]KZ3HWQ0\!^%?'^DZ7JQMIK,ZGIVG>+-)U>SLM1-G<7%I
M]MMH(KG[-/-!YOE2NC:X3'8W 3E4P.,Q6"J3CR3GA,15P\YPNI<DI4IPE*/,
MD^5MJZ3TLB:M&C72C6I4ZL4[J-6G&HD]KI24DG9VO;[[^[P7@+]C_P#9*^%7
MBK3?'7PO_9<_9U^&_C?1EO4T?QCX"^"?PT\'^*M*74K"YTO45TWQ#X>\+Z;J
M]BM_IE[>:=>BUO(A=V%W<V<XDMYY(VZ,1G6<8NC+#XO-LRQ5"?+ST,1CL36H
MSY9*<7*G4JSA+EE%2C=:22DM49T\)A*4E.EAL/3FKVG3H4X25TT[2C!-73:=
MGJFUKJ?15>:=!\MZ_P#L-_L4>*]=UKQ1XI_8]_9;\2^)O$FK:CKWB+Q%K_[/
MWPFUC7=>US5[N;4-6UG6M7U'P?<ZAJFK:G?W$][J.HWUS/>7MW/-<W,TDTCN
MWK4\^SVC3ITJ6=9M2I4H1ITJ5/,<7"G3IPBHPITX1K*,(0BE&,8I1C%))))(
MY98+!2DY2PF%E*3<I2EAZ3E*3=VVW!MMN[;;NWJ[GJ?PN^!_P6^!^G:II'P5
M^$'PN^#^DZW>Q:EK6E_"[P!X3^'^G:OJ,$'V6&_U2R\)Z1H]M?WL-L!;Q75W
M%+/' /*201C97)B\?CL?*$\=C<7C9TXN,)XO$5L1*$6[N,)59S<8MZM)I-ZZ
MZFM*A1H)JC1I45)WDJ5.---]VHJ*;MUM]UO>]1KD-0H ^/OBM_P3]_8C^-VH
M2ZQ\4/V6?@EXHUVXDDENO$1\!Z)H_B6]>7)=K_Q'H%KI6N7_ ,S,ZB\U&=4D
M=Y(PCL[M[6#XCSW 14,)FV.I4UHJ7MYSI1_PTJCE3C_V[%?.ZY>2KE^"KMRJ
MX6C*3WER14GZRC:3W[^EK)G@UK_P1F_X)C6=T]W%^R-X#>5WWLEUKOQ!OK4'
MT2RO?&,]E&G_ $SBMPG;&#7H/C;BII)YSB+>5/#I_-JBF_F_ON<ZR?+4[_5(
M?.51K[N=K\/OU/K?X1_LF?LP? .9+OX+?L^?!SX8:FL)MVUOP7\._"VA>(KB
M$J5*7GB.STQ->O@58J3>ZC.2I()()5?&QF<9KF*MCLQQN+C>_LZ^)JU*2?\
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M"%.*A3A&G!;1A%1BO1122^[[SJ:R*"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^5'_@[A_80^)W[6_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\
M]/[<G_)TGQ0_[DK_ -5WX1K_ "7^DU_R>_C;_NV__61R _T:\!O^34<*_P#=
M<_\ 6DS@^3:_!S]>"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H _K(K_> _R'"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M#;^&$ZF"Q47*RJ2I1<JD?Z)J_LP_C(* "@ H * "@ H * "@ H * "@ H *
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M%[X?7^MR732>2MM'I5KXBFOGN&E(B6%;?S#)\@0L<*#L^S[[=#WJ@0A(49)
M'J2 /U_S^E #?,C_ +Z?]]+0 ^@!I= <%U!]"P!_6@ #JW"LI/LP/\O\_K0
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M8O!/Q!U_Q3K-UKE]X;-KY2VUDGQ;\ ^(_%&E06R6\.D-J TBR1+73;=J /\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!_/3^W)_R=)\4/^Y*_P#5=^$:_P E_I-?\GOX
MV_[MO_UD<@/]&O ;_DU'"O\ W7/_ %I,X/DVOP<_7@H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /ZR*_W@/\AP
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _FP\'Z#8>*OVD
M=)\,:JADTSQ'\5WT'444(6:QU?Q%+I]V$\Q702>1</Y;,C!'VM@[:_Q4R_*<
M%G_C[_8694W5R[.O%/'93CZ<6E*>#S'B;$8/$QA)J2A-T:TU"=FX3M):I'^G
M.+S#%91X/1S7 S]GC<LX!P>882H[M0Q.#R2AB*$I)-<T54IQ<HWM*-XNZ;/2
M/V;_ !'J/[/W[4MEH6O3+9VZ>)-5^&7BWYUAMC;WM^=,CN)9Y"%6PL=:M],U
MAI<O'+!9*RL5=)T^C\$L\QO@_P"/&!RS.JBP].&>9CX?\2OVD:5!T\7CO[,C
MB9597IK!8;.L/EN:2K/W)83#2G&<8SN>1XH95A?$CPEQ6/RV'MISRK!\7Y)[
MKG5C4P^%^O2H*$5SO$ULLK8[ *FES+$UTI0;CRG[\ZIJ=AHNF:CK.JW45CI>
MDV-WJ>I7MPVR"SL+"WDNKRZF?!VQ6]O%)+(V#A$8X.,5_K_C<9A,NP>+S#'X
MBEA,#@,-7QF,Q5>:IT,-A,+2E7Q&(K5)>[3I4:-.=2I.6D81<GHC_.3#8:OC
M,3A\)A:-3$8K%5Z6&PU"E%SJUZ]><:5&C3@KN52I4E&$(I7E*22O='\_G@>T
MU/\ :=_:8UKQ/J\-S/IMSJ'B'QYK$4R)J,&G>&?#=M+<Z+H=V\RHAT\QVVB>
M%(Y/*W>7<1%44Y=/\?.%</B_';QRS7/LPHUZF!Q.+SSC7,Z&(E1K3P7#^14'
M5R?*L3=*&(PU-T\AX:J\D>:6'K*>B4IP_P!&^(*U#PG\*,NRC!U:,,92P^5\
M,X*K156G'$YOFM51S/'T/><Z5:7/FN<PYYI*M3Y7>\8%O]A@ ?M2>! !@"'Q
ML !T _X0SQ%P.G3Z?E1]%#_D^O O_7GB7_UC\]*^D#_R:?BG_KYD?_K194?T
M".Z1H\DC*D:*SN[D*J(H)9F8D *H!))( ')(P37^Q<I1C%RDU&,4Y2DW91BE
M=MMV226K;?W6/\W$G)J*3;;226[;T26^K?E]Y_.U\5OVBOBO\0?B5XZ\0^%O
M&WC:S\-'5-2N="TS2]3U73[/2?">GS+9:9*^FVUVUO8,UC':3ZG(NQ)M4N;B
MXES-<G=_C!X@>,/B!QKQMQ;GV0<7<:8/(I8[&XG*\#E&>Y]E6#R_AO"5H8/+
M:U3+L%CH8?!3EA%A*N8SC"$:F8XBO6J7J5I,_P!+^$?#/@[AKA?AW*LYX=X<
MQ&;+"86AC\5F&799C<3B\[Q-.6)QM&.,KX:57%*&)>(I8*+E.4,'1I4X14*:
MC'] O^">WQNU_P =Z3XT\ ^,_$6HZ_KV@S6WB/1+O6=0N=1U.;0KWR[#4K83
M7+/(++2=06P:)3(X1]99%$:*BM_8/T-?$_-N)\OXIX,XFSK,LZS;*:U#/LIQ
MF<YCB<RQ]7*,8H8+'82.(QE6MB9X;+,=2PM9.I.7)+.E2CRTX0B?SE])3@++
ML@QF0\29%EF#RS+LPIU,IQ^&R["4L)A*>8X;GQ.%KNE0A3HQK8["2K4WR0AS
M++74DG.4Y2^\?B)X\T'X8^"O$7CSQ-++'HWAO3WOKE;=!)=74I=(++3[.-F1
M'O-1O9K>QM!+)##Y]Q&9YH8!)*G];\:\791P'PKG?%V>U)PRS),'+%5H4O9_
M6,56E.%#!X#"JK4I4I8S,,95P^!PD:M6G2>)Q%)5:E.FY3A_//#/#V8\5Y]E
M?#N50C+'9KBH8>E*IS^QH0M*IB,5B'3A4J1PV$P\*N*Q,H4ZDXT*524*<Y)0
M/PR\5?M"_M'?M+^.E\,^#K_Q#90ZU=3V^A> _!MY+IMG;Z>RA6_MB_@>R:^2
M"%3<:GK&N7*6-ION9E_L[3U6WB_RDS[Q@\;O'#BREDW#V.SS"/,L54ADW"'"
M6/KY9A,-ANBS''T*N!ECX4*,56Q^:YWB:>!HS5;$TZ&5X1K#T/[_ ,I\-O"[
MPLX>GF>=X7*L2\%0A/,N(N(,)3QU>O7_ .H/"5:>+CA95*DG2PF!RRC/%5HN
ME1G/'8E>WJ]'-\(_VW_@E:/XWLCXTM;73C'J&HG0?%UGXJ"+%YUS,VK^'['5
M-4;4+"W FEU!Y]/O--CC=I;B0IF1?9Q'AU]*?PNPSXIPTN+L)AL!_M>+J9+Q
M10X@IT%%2G4JYGD.&S+,(8_"T8QE5Q4\3EN.RZC"$JN)E&G%SEY='C'P"X\K
M+(:T.'JM?%+ZOAO[2R&>3U)N34(0P.:UL)A7A:]1M0P\:6,PV+J2E[.C!SE:
M7V[^UM\2/'FE?LI^ O&.E:WJGA/Q5XGN_A[+KMUH,]QHUW')J_AB^U?5+"*2
M"7[59P'488P\,=P'"1?9Y)7C,@?^IOI&<:\78'Z/_!W$.!S/,N&<_P"(<7P=
M+.:N3XG%91C:,LPX?QV:X_ TL1AZM/&X.G]?P]*-2G2K0J2ITI8:M*=&I6A/
M\&\&N%^'<7XO\0Y-B\#@L\RC)Z/$BRVGF-*CC\-4C@LVPV!PF*J4JL)X?$R^
MJU9N$JE*<%.:K0C&<83C^>_PDB_:X^.">('^'?Q%\>:K_P (P=+&KK=?$J_T
MHPG6!J)T\1_VEKEJL_G?V5>AO*9O*\M?-V>9&7_CGP]R[Z1/BC1S6OP9QIQO
MF-/):F%I9@Z_B1FV7NG4QL*]3#Q@L;G-%U>>.'JW=/W862E)<RY?Z2XQQG@Q
MP'5P%'B7ACAG!U,RIUZN$5'@S 8Q3AAI4HUG)X;+*BI\LJT+*6LKMI.S+<'[
M07[5'[.WCZX\/^-/%'B/4-1TF:U.K^%?'&J/XLTR\LYHH[B(6M[+>7KQ6US;
MRI)#>Z%JEN<_+YW$T3=-#Q=\?O!CBRKDW$7$&>XG'9;6P]3,^'.+\REQ-@L9
MAJU*-:E"GCJ^+Q]6CA\11J*I2Q>2YE2:GI.=3DJX>.53PX\(?$SAZGF>291E
M6'PN-IU88'.>'<$LDQ6&KTIRI5'4PE.AA:=2M2J0<*F'S+ SO%\RY>>E6E^U
MUA\6O"\_PCLOC+J4K:3X7F\(6_B^]69XY;BPAELDN9],W9BBNK^&Z9M,B2(J
MEY>A(X&Q,C5_J'@_$;AZMX;83Q0QE2I@.'JW#%#B?$1J+VF)PM"K@X8FI@5"
M*7UC'4ZTG@*=*DG]:QBA3H<WM*?-_"&)X,SBEQKB.!<-".,SBEGE;(Z+A>%'
M$5:>)E0ABKRNZ.%G2C];G.I_ P[<ZMN27+^,/C+]I?\ :*_:5\=VWA+X?W.N
M:%::Q>SVGA_P1X,OI=/9[1A)F7Q#K,<EE+?I#:+]IU6]U*>TT*Q$4U^MKIUO
M$SI_F5Q1XW>,_C?Q92X?X/Q.=93ALRQ4Z&1\)\*XZIEM5T(JI+VF<9Q0JX.O
MC'##IULQQ./Q>%R3#0HRQ,<+@J4*E2?]R9%X6>&?A;P]4SCB6CEF8UL'0C5S
M//\ /\+#&TU5;@N3+<MJT\13P_/5_=X.AAJ%?,J\IJ@ZN*G*$(M\0?L[?MA_
M#+2;WQTY\4P0:/:OJ.J7WASQY%?ZKIUO&2L]R]KINL2ZC.EM&[7%U/8Q7*6E
MIYMW.\5O#<RI6>^"_P!)+@7*L5Q74K\0T\/@</+'YGB>'N-:^(S/+Z%.TJU>
MO1P.94<;7C04I5,14R_Z_&A1A6Q-9QPU*=:.>5>)?@AQ7CZ'#\<-D[JXNM'#
M8*CG'#%&C@<76FW&G2HU<1@YX>E*JTH4H8MX7VLYTZ-.,ZU6%&7TC^QK^V1X
MJ\1^*M/^$_Q9U,:VVMA;7P?XNN_)BU2/58HOW>AZW,HB&J)JHC(T[47#ZFFJ
M,+2Z:\M[Z"72_P!G^C3])7B'-N(<!X>>(>/>;QS?_9N&^),2J<,QHYC"DY4L
MIS:M'DCF%''PING@<?5B\RCF4H8;$U,?#'TZF6_FWC?X(Y/EN3XKC'@["?V?
M_9[]MG>2T7.>#J8.<U&IF&7TWSRPE3"3FIXK"P<<$\$IUZ$,++"3IXOV#_@H
MY\84_9]_9[\0_%+1;EK'XE:A;3_"CX::BJ,7TG6_B 89]7UNQFA>&XL-:T;P
MIX<U[4M%U**=1;WUM'#-%/#=20O_ %QXR<85^#. <VQ^"K>PS3,)T<GRJJG.
M,Z6,QRJ*KB*,X-.GB,)@*>-QF&FWRQQ.'H\\9QO"7X=X-<(4.,^/LJR_'4?;
MY5@(ULYS:D^24*N$P')[+#UJ<TXU,/C,PJX'!XJ"M-X7$5W"49)2C^ /_!-3
M]CO1_P!K/XO:U=^/S=3?"OX86FF:WXRT^TNVM;SQ3JFM7-W'X<\*27L%U!J.
MG:?JQTO6+_6=3L ;S^SM)N-,LKK3-0U2TU:R_CGP2\.,-X@\1XJ6;.;R#(:6
M'Q69T*525.KCZ^+G5C@,O]K"4:M&AB/JV*JXJO1?ME1P[P]*>'K8FGB:7]C>
M-OB/B?#[AS#+*E!9_G];$83*ZU6G&K2P-'"4Z4L?F/LIJ5*O7PWUG"4L+0K+
MV,JV)6(JPQ%'"UL+B/ZS?!_P]\"?#[1(?#7@7P;X8\'Z!!%Y,>D>&]#TW1]/
M*$88RVUA;01SR2Y+3S3B2:=V>29WD=V;_0?+<HRK)L)# Y3EN!RS!TURPPN!
MPM'"T$K6UIT80BY/[4I<TI-MR;;;/\]\SS?-<YQ<\=F^98[,\94?-/%8[%5L
M57;OLJE:<Y**VC&/+&*TBDDD?-_QR_80_9>^/]I+_P )A\,=&T3Q"\ZW,7C?
MP':V7A#Q?'/Y\$LLEUJ&G6:V>O":.%K4Q>)]/UR""&XN);**VO&CNHOB>+/"
M?@3C&G/^U,CPV&QDI<_]JY3"GEN9<SE%R=6O0I<F,4HQE3Y<?1Q,(1J3E25*
MLX5(_;<)^+/'?!M2']EYYB<3@H1<?[)S:=3,LLY>62BJ6'KU>?!N,I*ISX"K
MA9SE"$:TJE)2IRP?^"COC+Q9\/\ ]B_XU>+/ _B+6?"?B?3;7P1#IWB#P_J%
MSI6L:>FJ_$KP;I&H&QU&SDBNK5[K3+^\LI)()8Y/(N)55QFN/QKS+,,I\,>)
M\?E>-Q678ZC#*84<9@J]3#8JC'$Y[E>%K^QKT90JTI5,/6JTG.G.,U&<N5IL
M[?!/+<OS;Q.X8P&:8+"YC@:LLWJ5L'C:%+%86M+#9#FF*H>VP]:,Z56-/$4:
M550J0E!S@KIJY_-[\!+W_@H9^TU?>(M.^"_Q=^,_BN\\*6EA>Z[#/\=K_P .
M_8[;4IIX+.16\2>,]*2Z\V6VF5EM&E>+:#*%#H6_BKA)>+_'%;&T.&>).+,P
MJY?3HUL7&?&>.P?LJ>(E4A2:>-S?#QJ<TJ4TU3<G'E3DE=,_M;BU^$/ U# X
MCB;AKA+ 4LQJUZ.$E#@K+\9[2IAH4IUHM8+*,1*GRQK4VG44%*[4>:SY?T*_
M9F_9L_X*F>&OCY\*O$'Q5\6?$>/X;Z/XOTW4/&P\0?'[3?%.DW/ANV9Y-4L+
MKP_9^-->N-4.HVJO86]NNF3)]IN(9)I;.%)+R#]CX%X%\=\OXOX?QN?YEGZR
M7#9C3JYFL;QHLSPL\'&,_;TJN!6<8MXCVT+TJ<?J\^2K.%1\BASP_&^.N._
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MOP^.-(&OKK]IIEK9>'/&":AJ4L$5WI"ZK=W?ABYG@NK)+>QOKC3-.-VCW_\
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M'((/(((X((Z$?UH,1: "@ H * "@ H * "@#_]#^_B@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ R,XSR<D#O@8R?PR,\=QTS0 4 ?//[57[+/P
M0_;1^ WQ#_9N_:'\$Z=X\^%OQ)T6?2M8TN]C07NF7H4OI'BCPUJ6TW.@^+?#
M6H>3J_AS7[!H[W2]2MH9XG*>9'* ?Y5?_!M7XC\5_";_ (+N_LQ^$/ 7B-M;
MTKQ%XA^/GPI\4W>BR/%I/CCP#;_"/XE:I<7<L39:;1X]0\)Z%XZLH93E+O0=
M,G.7A% '[<?\'POPPUR+QE_P3^^,\-I)-X;O?#/QT^&&H7R;S#I^N:7JOP^\
M5Z/:7.0(XY-8L-8UR:QVLSS+H>H;PBP1EP#^FO\ X-U?VBO!W[1G_!'S]C.^
M\+Z]8ZMJ_P '?AM8_L\>/M,MF O?"OB[X.)'X6@T35[? -O>7G@V'PCXHM,E
MOM6B^(]*OP1]J*J ?MO0!_G!_P#![;\?/"?C']I?]B_]G31=<LM2\2_ [X5_
M%/X@>-=*LW$TOAZY^.>N>!+30+'59$!C@U*[T;X2IK":;*_VN#2=2TO49(8[
M76+*6X /ZSO^"=_PFUSX(_\ ! WX"?#OQ+9OINOV7_!/G4_$NL:9*CQW.F:A
M\0_ACX@^(ESIE[%(JO#J&G2>*C9:C"1^YOH+B(,X0/0!_%U_P93_ /*4/]H/
M_LPCXE?^M#?LP4 ?U#?\'<O_ "AD^)G_ &6_X"?^IE0!\[_\&5__ "BN^./_
M &?O\5?_ %0'[+] '\WO_!Y#X$UCPQ_P5F\.^*KRWF72?B3^RC\)-?T:\)9[
M>8Z%XH^)'@S4;2-_N1W%I<>'4GN+8'?'%?VERRA;Q&8 _P!)O]BSXZ^$OVFO
MV1_V;?C]X'UFPUWPY\5_@M\//%]M?::5%O%?ZAX:T\:]I,L("FSU#0-?BU30
MM6TV5([C2]5TV]TZYBBN+62-0#Z6N;FWL[>>[NYX;6TM89;FZNKF5(+>VMX$
M:6:>>:5EBAAAC1I)99&5(T5G=@H)4 _R+/@=\;?#W[1__!S]X ^.7@[4[76_
M!/Q,_P""LUIXE\"ZW8G-IK7@2?X]R0>"=8@)CB)CU3PK;Z1?!F16)N,MEB6H
M _UV: "@ H * /\ )_\ ^#1'_E,KX#_[(+\>/_4;L: /]76_MC>6-[9AQ&;J
MTN+8.1N"&>%X@Y7(W!2^<9&<8R.M '^4[_P:9^(X/A1_P6O\.^ ?%4EKINN>
M,/@]^T'\)X+>[N$@=O$^A:=9^-+K3[42M&9[S[/\.M55(%5I7CCF98\J2H!_
MJVT ?YVG_!\)\5O#FM?&/_@G[\%+*_T^?Q3\.OAU\?OB1XAT^"ZBEU'3])^+
M?B'X5^'?#4E_:)(9+2&]G^#OB)K)Y8T^T^1<%"RQ9H _KA_X(/\ _*'C_@GC
M_P!FU^"__0KZ@#^ ?]J#_E;L\,_]I9OV0O\ U9OP4H _U8J /X>/^#WS_DV;
M]A;_ ++K\3__ % -)H _:O\ X-F?^4'7["'_ &+OQJ_]:7^,] 'Z<?MR?\F4
M_M@_]FM_M _^JF\6T ?Y\O\ P9,?\G^_M6?]F>W?_JZ?A50!XY_P>6?##7/"
M/_!5#P-\0KJTD'A[XM_LK?#;4='U(;S;S:IX.\6?$#PCKNEAF "WFG6]CH5]
M<11[D6VUNPE+;YW1 #_1I_8)_:*\'?M9_L7_ +,?[1/@77K'Q%H?Q1^#/@;7
M;F^L&!2S\46^BVVD^./#UW& OV;5O"OC33M?\,ZU9$9LM6TF]M<MY09@#ZXH
M _RE_P#@[-^,6D_M(_\ !9.?X<_#.\3QIJWP4^"_P?\ V;)['05-XTGQ$F\2
M>-OB%J'A6U>(>7>ZQ8ZK\6K;0K^&!Y'L];@N]%N3'?Z==6\ !_I2^)? $WPH
M_8 \0?"VX>"6X^&O['FJ^ )Y+9F>VDF\'?!6X\.RO;LRJS0.^G,T3,JL8RI*
M@DA0#_/._P"#*< _\%1/V@C@9'[!'Q* ..0#^T-^S!G![9P,XZX'I0!_IZ4
M>+_'_P#9T^!7[5/PPUWX,?M&?"GP3\9/A=XD\E]5\&>.]$M=;TIKNUWFQU6P
M\X+=Z/KNF/(\ND^(-&N;#6])N&-QIFH6L^)% /XNO^"CG_!F?\*==T#Q?\3/
M^":OQ0\0^ _&EI:ZCK6F?LV?&+5AXH\!^(98(9KB+PMX#^*EYY/BSP;=7(C2
MTT?_ (6-<^.[*\U*>--9\7>'--:74K( _/;_ (-1?^"G7[2WP=_;C\-_\$P/
MC!XK\1^(_@;\5;;XE>&_!G@;QSJ=Y=W'P$^+?PT\,>*_'=Q9^#'OC<RZ%H/B
M:+PIXC\->(/ ]N]MHTGBF^TG7M/CL=3BU=/$(!_I;4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_/3
M^W)_R=)\4/\ N2O_ %7?A&O\E_I-?\GOXV_[MO\ ]9'(#_1KP&_Y-1PK_P!U
MS_UI,X/DVOP<_7@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /ZR*_W@/\ (<* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MT'2R[B/(,;AZKJX2$ZK6']JH8S 8[!QQ-2=2SIRJTY^TAA\3A_:UW/\ H_\
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MS^SM:@MYQ) NK:-I=X8C-9P.I_7]?U^82MRRO?1)JW>Z6OE9M=.CZ-2^X_\
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M<O@EZQ_4\J_X.0_^4T/[8_\ UP_9U_\ 66O@K0$?@CZR_0^2O^"5'[%VB?\
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M5+@37,7A_P -IH_A?0DF^PZ#H]C91)%08N3NVFU?HF_NZ?C^.Y_$W_P<G?\
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M:)XUT ZM=:1;7KR7O]DI=/<)875V(+B\L88K^>TL7G>SMP#_ &)* "@ H *
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M\$._V$ RLI/ASXT-A@0=K_M*_&9T;!P<.K!E/1E((R#F@#]-_P!N)6?]BO\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?ST_MR?\G2?
M%#_N2O\ U7?A&O\ )?Z37_)[^-O^[;_]9'(#_1KP&_Y-1PK_ -US_P!:3.#Y
M-K\'/UX* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@#^LBO]X#_(<* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * /YV?A^B1_MC>'(XT6.-/V@(D2-%"(B+XX<*B*H"JJJ JJH
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M.:L:&%J2P5"&88^;Y/\ 8,K>-Q-#ZQ-OE5'!_7<=54FERJO5NW%+E_I,\&^
M;7X7_ [3/ -H+;_BF? =U8WLMHLB6UYK#Z;<W6NZC$LI,JKJ>LW%_J&V0EU-
MR022":_VUX;X0PW 7A3@N$,,J+61<(XC"8JMAX2IT<7F4L!6KYMF$82O*+S'
M-*V+Q\HOX9XAK2UC_+O.^(Z_%O'N*XCQ'M$\VXAI8BA3JS4ZF&P2Q5*EE^#<
MTHJ2P6!IX?"1:6L:*>NKE^+7[#/_ "=+X$_ZX^-O_4,\15_E[]$__D^G G_7
MGB3_ -8_/3^[_I _\FGXI_Z^9'_ZT65'KG_!1_XD#7_B1X;^'%E,6L_ FD-?
MZFB-,H;Q!XF2WN?+E3<+>?['HMMICV\NQY8)-1OH0Z;Y5?\ 3/IJ<<?VQQUD
M_!6%KJ6#X/RSZUF$*<YV_MS/HT<3*E7I:4YRP>3T,KJX:IK*G_:>,IW5YH^'
M^C!PO_9W"N9\3XBERXCB+'K#8.4HP;_LO*'4HJI2G;G@L3F-;&TZU.\5/ZCA
MJC4K0E'EO!7[,_[;&F>&]+/@S4/$?AC0-3M;?6K32=.^)D7AZ.+^U;>*Z\RY
MTF'7+7[+?/&\8NXYH4N(Y4\J8!TVKX_#/@=]*7+<EP4>&<PXAX>RG&TJ694<
MLP'B!/(J=*6.HTJTI8C+,/FV&CA\8XN$<3"I1C6C4A[.JW*%H^AGOBGX"8[,
M\5+/,!E&<YAAJL\%5Q^+X0IYK.I'"5)THJECJN"K.MADXR="4)NG*$E*%HR1
M\X?&GX5_%?X6^)K;_A;,%S_PD/B2W?7(]5GUF'Q!+J1^U2V\T]SJL%S=^;?+
M-"7G2>=KD(\,S_+,C-^(>*/ ''W N>4J?B+2KSSGB##U,U^OXC-(9U5S)>WG
MA\15Q&8QQ&(E7Q<:D(O$*M7E7C"KAYU'RUJ;/U3@+B_A#BS*JCX,E2AEN3UJ
M> >"I8!Y93P5Z2K484L%[.E&EAYQE+V3IPC3E.G5C'6$^7]&_B%_:O[3'["_
MAKQ'H[2:CXL\ 2V%]KUA;[+F]O;GP?;7FA:XL[R-$!<W.AWL'C"9(6:1U"6\
M,+32K;U_:/&DL=XZ?10R+B#!.MF/$O!5;!YAF^&I2C5Q>+QW#.&QF1Y[4KJ5
MFZV)R;'5.)XT*?M:]:,J%"C&=6M"!_,7#,<)X3_2!S/*,5[/!Y)Q'#$8/+L1
M.+IT,/A,]JX?,LJC3Y>9*G0S+#0R2=6IRTJ3C6K5>6%-SC\F?L8_M%Z/\!O&
M.O6?BZ*<>"_&UMIUOJM_9V[W-YHVIZ1+=G2M2-NFZ6YT]8]2U&WU&V@4W.V>
M&[@\Y[,V5W_/?T9O&C+/"3B;-J/$4*W^J_%6&P%#,L;A:%3%8G*\;EE3%2R[
M,/J])RJU\#&GF&/HXZAAJ-;%S57#U\/"H\*\/7_9/'+PRQ_B'DF75LEE3>?9
M!6Q=3!X6O5IT*.887'0H+&83VU1PIT<4ZF$PE3"5:]6GAH\E>E6G#VT:U#]/
MO$W[<O[.6@:-/JEAXUD\4WBINM-#T'1M8&HW;D[0N_5+'3;*T120TCW=U&XC
M#M#%.ZB-O[NS_P"E5X*Y+ED\?A>)Y\0XET^?"Y3DF6YC4Q^)D]J<I8W#8/!8
M)J]YO,,5A7%7Y:<ZEJ9_)N4> ?B;FF/C@Z^0K)Z*GRU\PS3&82GA*,4]9Q6'
MK8C$XI=(_5*%=-O6487F>0_MV>(H?%_[*G@;Q9;6\EI;^*/$G@+Q%!:S.LDM
MM#K7A77-2BMY9%"J\D*7*QNZJJLRD@ $"OS3Z66=4>)/ +@WB+#4:N'P^?Y_
MPGG6'P]=P=:A1S7AG.L=2HUG!R@ZM*G7C"HX2E!SB^5M69]Q]'S+*N2>+O$.
M35ZE.M7RC*N(<LK5:7-[*K5P&<Y=A:E2GS)2]G.=)RAS)2Y6KI.Z/"?^"=?P
M^\"^/;3XS0^-?!_AOQ6EF/ D-BVOZ-8:I-IZ:A'XU2^_LZXN[>:XTY[I;:V\
MZ6RD@DD-O;L7W01-%^;?0VX*X/XORGQ$CQ5PMP_Q%]7QG#]'"SSK*,!F5;"4
M\1ALV=:.#KXO#U:V$=24*<Y2PU2E+GITYW4X0E'[;Z2O$W$?#N9\'2R'/LWR
M;VN&S:K6CEF8XO!4Z\Z5? *F\12P]:G3Q'(I2BE6A4CRSG%IQG)'RI\4M UO
M]F;]HC6;;PG=W.F3>#O$UOKOA*[$TLSMH5\(M5TBVNY%:W^WQ/I=TFEZS Y2
M"]VWUI<(T+NC?SEQ_DV:>!WC+FF&X=Q-7"8CA7/:&;\,XIU*TV\KQE.EF664
M,34?LIXRG]1Q2RG-HMNCC73QV'J<]&K.!^T\(9E@/%7PSP-;.J%/$TL^RJME
MN>8=1I1MC\-.>"QE:C!<\<-4>*H+,LO:M4PCGA*T+5*<)'ZR_M(Z6G[0_P"R
M:_B;PC;O?W,NE:#\1]'T^WF26;S=/B9]8TTM'N$U[I^G76M6KVT89YK^T^RQ
M@2,M?Z%>-V$CXR?1VGQ#PSAYXRM4R_)N.,KP4;UL1%8-1JYM@5"C&<ZN883+
M*^;87ZM2A.K5Q]#ZK"+G)<O\<^%V)?AKXR4\ISRM'#TJ6-S+A?'XE_NZ+^L\
MU+ 8J\VE#"5\;2P%?VU1J%/"U/;R:46S\XOV*/V@]#^!OCC7[#QI/-9>"_&M
MC96VIZA%:2W;Z/K&CSSOI.HW$$$<MX]BEO?ZM:7D-I#+<%[JVG6*7[*8W_BO
MZ,/C%E/A3Q7FU'B6=2APOQ7@\%ALPQ]##5,74RW,,LJXBIE6.JTL/&IBJN!C
M2Q^98?%4\)1K5N?$X;$*E*&'G&7]/^._AMF/'^09?6R.$:V>\/XG$UL)A*M>
M%".-P>.A1AC\+3G6E"A'%\^$P=>A*O5I4^6A6HJ:J5H'Z>>/_P!M;X#>#_"]
MYK6D>,;+QCK+6,DNA^'=$BO9+K4;UX_]$BNYY;1(-)M!*Z-?7%XRSV]NLQM[
M2\NT2S?^[>,/I1>$?#>0XK,LKXGP/%.:O#5)97D>2NOB*^+QCBU0HXRNJ/L,
MIP_M&I8FOCITZM/#QJ2PV&QF)]CA9_R?PWX$^(F=YO0P..R+%Y#@%7A''YIF
M<:=&CAL,FG5J8>E*K[7'UG"\:%+"JI"5:4%6K4:+G7I?DG^S/X%U_P"-W[0G
MA^]N8I;NUM?$H\=^,]0D1WMX[&QU :M=17,H#,KZO>"+2;=AN?[1?1N=B+)*
MG^=O@;PGG'BAXQY'6K4I8NEA^((<:<5XV4)?5H8;!YDLWQ2Q#3O%YQF"AEU&
MG&;FZF-<U^YHUJM+^R_%;B#+>!/#7-*%*:P\Z^3SX8R##1FO;.MBL$\OHNC?
M?^S\(YXRI-QY5'#<NDZM.$_NO]N&PT3]HFX\=?L=W%]I-KXQU[X9^'/B-\'+
MG45BC2V^+/A?6O$U[)H3W;F!+6X\8^%/+T>"]N;E;;2]/?6)A!<7-Y!;77^K
M_B?P9+CG@?-\DH>S682C#&Y5.HH<L,RP,U7P\.>3M1CC(QJY?5K[T:&,JU%&
M?*XR_@[POXRCP-QOE&>5_:/+U.I@LVA3E.\LLQT'0Q%3V=-.5:6"DZ.8TL/>
MU>O@Z-/W>;GA_/;^R1^TOX\_87^/&IZMJ_AG5Y++%]X'^*WPXU-[C1-2DAL[
M]?-#6MW$R6/BCPQJEJTMC)>VGFHCZII#26EOJU[+7\$>'O'&;^%?%=;$U\#B
M)4OWN5\09)7=3"8B4*=7WER54E0S' 5Z?-1]M3NE]8PDI4H8FI4C_>WB%P/E
M/BGPI1PM''8>-7]UFO#^>4%#%X>-2I1]R2G2;=?+LPP\U&M[&K9_[-BXJO/#
M4J<_Z./#?_!57]A_7M$@UB\^+5UX5N'@6:YT#Q)X(\;#6[!F7)MYUT'0==TN
MZG7HPTC5=2BW# E.1N_L_!>/WA9B\+#$U>(*N FX*53!XW*<V^M46_L3^IX+
M%8>K-=?JN(Q$.U1W]W^,,;X >*>$Q4\/2X?HYA34^6GC,%F^4_5:R_GA]<QN
M%Q-*+_ZBL/AYKK35O>_F'_:U^)/A7XP?M/\ Q;^)7@BYN[SPGXM\:-J.AW=[
M9R:?<W5E';6-DMR]G,3-;I/):O+ DXCG\AXVFA@E+PI_#?B/GN7\3<<<1Y[E
M4ZM3+LQQRJX2I6I2H5*E*GAZ%#VCHS;G34Y4I2A&IRU.1Q]I"$^:$?[E\-LB
MS#AG@GAO(LUA2IYCEV#=+%TZ%6->G3JU,36K^S5:'N5'"-6,9RIN5/G4O9SG
M#EG+^H?_ (*F?\F'_'?_ *Y?#C_U;G@&O[I\>_\ DTW%?_="_P#6ER<_A7P#
M_P"3L\*>F??^LSG)^+W_  24_:$^"WP!\5?&6_\ C+XZTOP19>(_#WA6TT27
M4['5[U=0NK#4M5FNXXETK3=1*-!%/$S&=8@1+B,MA]O\T_1YXLX9X4S'B>MQ
M+FN%RNEC<%EE/"2Q,*LU6J4:^+E5C!4J56SA&I!OFY;\VE[2Y?Z6^D/PEQ+Q
M9E?"]'AO*L3FE7!8_-*F+AAI48RHTZ^'P4:,I^VJTDU.5.HERN5G%WM]K]Y?
M!7[>'[('C_Q7H/@GP9\;/"^K^*O%&I6^C:#I46F^)+"74]3O&V6EA#<ZAH-E
M9BXNI=L-M'-<Q^?</%!%OFECC?\ K/+/%+PZS7'X7+,LXGRW$8_'5H8;"8>$
M,33G7KU':G2C*>'IPYZDO=@I27--QC&\FE+^2\R\+/$7*L!B\SS+A?,L/@,#
M1GB<7B)RPU2%"A35ZE:<:>(J3Y*<6Y3E&+Y(*4Y6C%N/Y;?\%W/^/7]EW_KX
M^,__ *+^%=?@'TK_ (^ /\/%?Y\-'] ?10_A\?\ ^/A/_P!)XG/M_P"#7P3T
M7]HC_@F7\-OA%K9AA7Q9\&-+BT?4ID9AHOB:QDEU#PUK68U:?RM/UFVLY;V*
MW,<MYIWVRP\Q8[M]WZQD'"^%XS\#\CX<Q3C#^T.%<%'"UYQYEA,?1IQKX#%V
M7O-8?%TZ52I&-G4I*I2?NSDI?DV?\4XK@OQQSWB/"J4_[/XLS"6*P\9<OUO
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MSV+W=GI&M/?Z%IY_7];_ )_>9.$NBNNZO^.KM\[>A_%Y_P '#/\ P5-^%O\
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M/V<+*ZC/PV\/63S!S9VGQ!N[2Y^*VH3V$L<7B'1M9^'ZZG$UQX8LA  ?UDT
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M>\#VNI0?:M*E^(6I1P^&OAX-7M1)"UUHZ^-];T!]7M8YHI;G35NH8I8I71Z
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M9IWD\.Z7K7P\DNKJ66_U"_\ AI?:O?R2SZD)G /Z9: "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M*WDGC/P_\*O FC>+'NT^Y=/XBT[0;;6&N5R=L[7?FKGAUS\P![90 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /YZ?VY/^3I/
MBA_W)7_JN_"-?Y+_ $FO^3W\;?\ =M_^LCD!_HUX#?\ )J.%?^ZY_P"M)G!\
MFU^#GZ\% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0!_617^\!_D.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M6,*.'AF\:_U_#8:G'EAAZ&8X;$4:DJ=.*4:2QU/'.C34:-)PHPA3A\]^"?\
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M>L:Y=WNH3QEFP(Y;IT!( 6C^OZ_K\PVVZ;=/^&_KL?ZO/_!'S]I/XY?M4?\
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MAXITV7PM>^#;2>XC779_#^L:);EM<GT/3]4 /]!3X^_M!_!7]EOX4^+/C?\
MM!_$KPG\)_A9X)L)+_Q!XP\8ZK;Z5IT.(Y&MM-L%E;[3K&OZK*GV/0O#ND07
MVN:]J4D.FZ/I][?3Q6[ '^3W^Q7^T];_ +4G_!RK\%_VI_"6EZAX9T/X]?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!_/3^W)_R=)\4/^Y*_]5WX1K_)?Z37_)[^-O\ NV__
M %D<@/\ 1KP&_P"34<*_]US_ -:3.#Y-K\'/UX* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^LBO\ > _R'"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\B/AEXS\67O_!13
MQ-877B'5YK"YU[XB^'+BQ>]F^Q2Z%H&A:[/HVEO:AQ ;33KC3K*YMH_+^2Y@
M^T9,SRN_^=W W%7$>*^F7Q!@,1G>9U<!7S7B[)JN!GBZSP4LKRC)\PJY;@OJ
MO/["-'!UL'0KTE"G%K$1J5VW5KUYS_L3BC(,EH?1IR;&4LKP5/&4L+D.8PQ<
M</36*6-S#,L/2QN(>(Y?;2J8BEB*E&ISS:=+V=-6A1I1C^N]?Z(G\=A0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % 'AW[2/Q3A^#'P2^(7Q ,ZP:CI6@W%IX
M=RBRM)XGU@C2?#P6!I(_M"0ZI=VUY=1*RD6-M=2%D2-Y%J$>:273KZ?U_6@?
MU_6W]=]C\#?^"?OPXD^)?[3_ (0O+N 7.F> UOOB/K#><(&CGT-HDT"6/"XE
M=?%U_H,KVZA=]M'<MPD;BNJJ[0?GI]^_X7 _ICKC * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H _$R]_X-TO\ @C?J-[>:A=_L
M=PRW=_=W-]=RK\=_VF8%ENKR=[BXD$%O\8X[>$232NXB@CCACW;8XT0*E [R
M[O[S[<_8X_X)V?L<_L 6OQ!LOV1_@\GPEMOBG<>&;OQY&OCKXE>-SKUQX/BU
MR'PY(TOQ'\8>+9]._LZ+Q)K*"/2I+"*Y^V;KN.X>&W>(_K^OZ_(&V]VW;O\
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M_%/XU>#C_P (WX>GU*YT?33I'@'XB>&-!/V.?5]1<79TS[=-]HVW-S,D4"Q
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M[IM[<VQN;&ZMKR 2^;;7$,RI(@).VI^,X_X-QO\ @C,  /V-XP!P /CY^T^
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M+NC8KE&5AG*D$ T$GXCQ_P#!N'_P1DBC2*/]C:)8XT6-%'Q]_:?PJ(-JJ/\
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M /[H/CS_ ,D-^,W_ &2CXB?^HAK% '^=7_P9)_\ )\O[7?\ V:A:?^K?\"4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_
M/3^W)_R=)\4/^Y*_]5WX1K_)?Z37_)[^-O\ NV__ %D<@/\ 1KP&_P"34<*_
M]US_ -:3.#Y-K\'/UX* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#^LBO\ > _R'"@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#\8OA1_RD>U__L>?BY_ZCWBNO\S_  __ .4U
ML[_[*CQ _P#5'G1_;?%O_*,&5?\ 8HX5_P#5K@3]G:_TP/XD"@ H * "@ H
M* "@ H * "@ H * "@ H * /PF_X*C_':+Q)XMT'X&Z!>+-I?@ET\0^+VA?=
M#-XMOK1XM-T]CY;(\F@Z-<S,[P3CR[K6[RRNHA<615.JC"RYGO+;T7^;_(/Z
M_K^OS/K+_@F5\&)? 'P9OOB-K%J]OK_Q9OH=0M$F5EEM_!VAFZM-!S%+;Q2P
M2:I>7&KZMOBFEMK[2KC0K@!70UG6E>5ND?S_ *T_X<#])ZQ * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZST$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__5_OXH * "@ H
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M!:STO2+"STO3;./X8>"S':6%A;QVEG;1F31'D*06\,<2F1W<J@+,S$F@"_\
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MSPBGCGQ!/;2JXGT[XB:!=IL**7 /ZKO^"/W_  33^$O[(/\ P3?_ &4_@O\
M$;X-?#K6?BO;_#73_'/Q>U'Q9X#\,ZUXB'Q/^)DT_C[QAHFI:EJNE7%Y<CP;
MJ/B ^!]/+NBII7AJPC2*,+MH _2K_AG+]GK_ *(/\&?_  U_@C_Y14 ?YW7_
M  >*_L':7^SS^TW^SK^VU\&O"VG^!?!GQQ\*GX<>,QX*TNV\.:=H'QG^$)AO
M_#.O@:/!8V^FZIXN^'VH:=:Z7]C5)6D^%VJW[,D[[W /[E/^"2_[:5G_ ,%
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_%#1=,O]2O)KR]AT:YN-'\'Z]'II>8_9H-7UG6KV!MYDU*Y1DBB /?OV.O\
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M8_!+0[JVG4-%)K5AK?B;XF"5-CS:;\0=&LKR&*YT@HH!_4E0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % 'XQ?"C_ )2/:_\ ]CS\7/\ U'O%=?YG^'__ "FMG?\ V5'B
M!_ZH\Z/[;XM_Y1@RK_L4<*_^K7 G[.U_I@?Q(% !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M% 55     H ?0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'XQ?"C_E(]K_\ V//Q<_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H __]#^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__1_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H \QL/@S\,-,^(NH?%FQ\(:?;_$'4X)(
M+SQ$LU^TCK/;0V=Q-#I\EV^DV=Y<VUNL-U?V=A!?72277VBX<WMX9_@L'X8<
M!X#C;&^(N$X<PM'C+,*,Z&*SE5\=)R56A1PU:M2P$\5+*\+BZ^'P\*-?'87
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /__2_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M $M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % '__T_[,?^"AES\?K3]AG]K&7]E9?%#_ +2+_ CXC6WP0'@F
MTMKWQ</B7>^';VS\)MX<AO(+BU36$U6XMWL;NXC6*PG5;YY[46QN8@#_ #RO
M^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@
M_P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D
M_P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_U
MD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\
M=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4
M '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R
M?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_
M^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^
M.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P L
MB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9
M/_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?
M_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\
M'9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"6
M10 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?
M^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/
M_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".
MR/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+
M(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\
MLB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_
M %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'
M9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^61
M0 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'
M_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_
M *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _
MX[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(
MH /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#
M_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_
M -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?
M\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610
M ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!
M_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\
MZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /
M^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@
M_P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D
M_P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_U
MD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\
M=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4
M '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R
M?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_
M^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^
M.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P L
MB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9
M/_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?
M_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\
M'9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"6
M10 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?
M^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/
M_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".
MR/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+
M(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\
MLB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_
M %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'
M9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^61
M0 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'
M_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_
M *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _
MX[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(
MH /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#
M_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_
M -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?
M\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610
M ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!
M_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\
MZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /
M^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@
M_P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D
M_P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_U
MD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\
M=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4
M '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R
M?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_
M^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^
M.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P L
MB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9
M/_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?
M_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\
M'9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"6
M10 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?
M^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/
M_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".
MR/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+
M(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\
MLB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_
M %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'
M9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^61
M0 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'
M_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_
M *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _
MX[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(
MH /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#
M_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_
M -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?
M\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610
M ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!
M_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\
MZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /
M^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@
M_P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D
M_P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_U
MD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\
M=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4
M '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R
M?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_
M^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^
M.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P L
MB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9
M/_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?
M_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\
M'9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"6
M10 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?
M^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/
M_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".
MR/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+
M(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\
MLB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_
M %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'
M9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^61
M0 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'
M_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_
M *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _
MX[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(
MH /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#
M_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_
M -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?
M\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610
M ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!
M_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\
MZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /
M^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@
M_P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\=D?_ %D
M_P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4 '_'9'_U
MD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R ?^610 ?\
M=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_^L@'_ED4
M '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^.R/_ *R
M?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P LB@ _X[(_
M^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9 /_+(H /^
M.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?_60#_P L
MB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\ '9'_ -9
M/_+(H /^.R/_ *R ?^610 ?\=D?_ %D _P#+(H /^.R/_K(!_P"610 ?\=D?
M_60#_P LB@ _X[(_^L@'_ED4 '_'9'_UD _\LB@ _P".R/\ ZR ?^610 ?\
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MU/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MW_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\
MYLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?
M\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\
M$$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,
M-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X
M6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\
MJ!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+
MG_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_
M !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8
MW_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\
MYLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?
M\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\
M$$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,
M-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X
M6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\
MJ!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+
MG_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_
M !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8
MW_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\
MYLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?
M\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\
M$$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,
M-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X
M6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\
MJ!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+
MG_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_
M !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8
MW_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\
MYLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?
M\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\
M$$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,
M-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X
M6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\
MJ!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+
MG_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_
M !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8
MW_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\
MYLS_ /D^T?\ $$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?
M\03_ .JE_P#,-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\
M$$_^JE_\PW_X6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,
M-_\ A8/]:/\ J!_\N?\ [@'_ !%$_P#5C?\ YLS_ /D^T?\ $$_^JE_\PW_X
M6#_6C_J!_P#+G_[@'_$43_U8W_YLS_\ D^T?\03_ .JE_P#,-_\ A8/]:/\
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MY=?\/V/^K6?_ #-__P"*&OQ'_B9__JA__-F__%X_<_\ B5C_ *KO_P UC_\
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M #6/_P 80_X?L?\ 5K/_ )F__P#%#1_Q,_\ ]4/_ .;-_P#B\'_$K'_5=_\
MFL?_ (PA_P /V/\ JUG_ ,S?_P#BAH_XF?\ ^J'_ /-F_P#Q>#_B5C_JN_\
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M&C_B9_\ ZH?_ ,V;_P#%X/\ B5C_ *KO_P UC_\ &$/^'['_ %:S_P"9O_\
MQ0T?\3/_ /5#_P#FS?\ XO!_Q*Q_U7?_ )K'_P",(?\ #]C_ *M9_P#,W_\
MXH:/^)G_ /JA_P#S9O\ \7@_XE8_ZKO_ ,UC_P#&$/\ A^Q_U:S_ .9O_P#Q
M0T?\3/\ _5#_ /FS?_B\'_$K'_5=_P#FL?\ XPA_P_8_ZM9_\S?_ /BAH_XF
M?_ZH?_S9O_Q>#_B5C_JN_P#S6/\ \80_X?L?]6L_^9O_ /Q0T?\ $S__ %0_
M_FS?_B\'_$K'_5=_^:Q_^,(?\/V/^K6?_,W_ /XH:/\ B9__ *H?_P V;_\
M%X/^)6/^J[_\UC_\80_X?L?]6L_^9O\ _P 4-'_$S_\ U0__ )LW_P"+P?\
M$K'_ %7?_FL?_C"'_#]C_JUG_P S?_\ BAH_XF?_ .J'_P#-F_\ Q>#_ (E8
M_P"J[_\ -8__ !A#_A^Q_P!6L_\ F;__ ,4-'_$S_P#U0_\ YLW_ .+P?\2L
M?]5W_P":Q_\ C"'_  _8_P"K6?\ S-__ .*&C_B9_P#ZH?\ \V;_ /%X/^)6
M/^J[_P#-8_\ QA#_ (?L?]6L_P#F;_\ \4-'_$S_ /U0_P#YLW_XO!_Q*Q_U
M7?\ YK'_ .,(?\/V/^K6?_,W_P#XH:/^)G_^J'_\V;_\7@_XE8_ZKO\ \UC_
M /&$/^'['_5K/_F;_P#\4-'_ !,__P!4/_YLW_XO!_Q*Q_U7?_FL?_C"'_#]
MC_JUG_S-_P#^*&C_ (F?_P"J'_\ -F__ !>#_B5C_JN__-8__&$/^'['_5K/
M_F;_ /\ %#1_Q,__ -4/_P";-_\ B\'_ !*Q_P!5W_YK'_XPA_P_8_ZM9_\
M,W__ (H:/^)G_P#JA_\ S9O_ ,7@_P")6/\ JN__ #6/_P 80_X?L?\ 5K/_
M )F__P#%#1_Q,_\ ]4/_ .;-_P#B\'_$K'_5=_\ FL?_ (PA_P /V/\ JUG_
M ,S?_P#BAH_XF?\ ^J'_ /-F_P#Q>#_B5C_JN_\ S6/_ ,80_P"'['_5K/\
MYF__ /%#1_Q,_P#]4/\ ^;-_^+P?\2L?]5W_ .:Q_P#C"'_#]C_JUG_S-_\
M^*&C_B9__JA__-F__%X/^)6/^J[_ /-8_P#QA#_A^Q_U:S_YF_\ _%#1_P 3
M/_\ 5#_^;-_^+P?\2L?]5W_YK'_XPA_P_8_ZM9_\S?\ _BAH_P")G_\ JA__
M #9O_P 7@_XE8_ZKO_S6/_QA#_A^Q_U:S_YF_P#_ !0T?\3/_P#5#_\ FS?_
M (O!_P 2L?\ 5=_^:Q_^,(?\/V/^K6?_ #-__P"*&C_B9_\ ZH?_ ,V;_P#%
MX/\ B5C_ *KO_P UC_\ &$/^'['_ %:S_P"9O_\ Q0T?\3/_ /5#_P#FS?\
MXO!_Q*Q_U7?_ )K'_P",(?\ #]C_ *M9_P#,W_\ XH:/^)G_ /JA_P#S9O\
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MK_8W]H^T]A@LOQ?M_;_VO@.7F^O>S]E[&7+[+G]K+GY(?//_  ]#_P"J'?\
MF2__ ,7U?DO_ !.U_P!6R_\ -S__ !4/T;_B57_JO/\ S5O_ ,9 _P"'H?\
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M?_XOJ/\ B=K_ *ME_P";G_\ BH'_ !*K_P!5Y_YJW_XR!_P]#_ZH=_YDO_\
M%]1_Q.U_U;+_ ,W/_P#%0/\ B57_ *KS_P U;_\ &0/^'H?_ %0[_P R7_\
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M_P 9 _X>A_\ 5#O_ #)?_P"+ZC_B=K_JV7_FY_\ XJ!_Q*K_ -5Y_P":M_\
MC('_  ]#_P"J'?\ F2__ ,7U'_$[7_5LO_-S_P#Q4#_B57_JO/\ S5O_ ,9
M_P"'H?\ U0[_ ,R7_P#B^H_XG:_ZME_YN?\ ^*@?\2J_]5Y_YJW_ .,@?\/0
M_P#JAW_F2_\ \7U'_$[7_5LO_-S_ /Q4#_B57_JO/_-6_P#QD#_AZ'_U0[_S
M)?\ ^+ZC_B=K_JV7_FY__BH'_$JO_5>?^:M_^,@?\/0_^J'?^9+_ /Q?4?\
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M !4#_B57_JO/_-6__&0/^'H?_5#O_,E__B^H_P")VO\ JV7_ )N?_P"*@?\
M$JO_ %7G_FK?_C('_#T/_JAW_F2__P 7U'_$[7_5LO\ S<__ ,5 _P")5?\
MJO/_ #5O_P 9 _X>A_\ 5#O_ #)?_P"+ZC_B=K_JV7_FY_\ XJ!_Q*K_ -5Y
M_P":M_\ C('_  ]#_P"J'?\ F2__ ,7U'_$[7_5LO_-S_P#Q4#_B57_JO/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__];^
MT7]OC_DQ7]M/_LTS]HW_ -4]XQKWN%?^2GX<_P"Q]D__ *L,.<F/_P!QQO\
MV"8G_P!,S/\ ,:K^TC\R"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /__7_M%_;X_Y,5_;3_[-,_:-_P#5/>,:][A7_DI^'/\ L?9/_P"K
M##G)C_\ <<;_ -@F)_\ 3,S_ #&J_M(_,@H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /Z&?\ @VG_ .3ZOBO_ -FF>.O_ %</
MP(K\E\9/^28P'_8^PO\ ZK\T/H>&O]^J_P#8)4_]/4#^W^OYI/MPH _'G_@M
MI_R:KX _[."\*_\ JN?BO7\]_23_ .2&RK_LK,#_ .J?/3^BOHR_\EYFW_9(
MX_\ ]7.0G\NM?Q&?W,% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#__T/[1?V^/^3%?VT_^S3/VC?\ U3WC&O>X5_Y*
M?AS_ +'V3_\ JPPYR8__ ''&_P#8)B?_ $S,_P QJO[2/S(* "@ H * "@ H
M * "@#[FT?\ X)G?M^>(-(TO7M%_9+^-.HZ/K>G6.KZ3J%MX3N'MK_3=2MHK
MRQO;=BREH;JUFBGB8JI*.I(&<5\S4XSX5I5)TJF?9;"I3G*G4A*O&\)PDXRB
M_.,DT_-':LNQ\DI1PF(::335*5FGJFO5'Q5K&CZIX>U?5- US3[O2=;T/4;[
M1]8TJ_@DM;_3-4TVYELM0T^]MI0LMO=V=W!-;7,$BK)%-&\;@,I%?1TZD*M.
M%6E.-2G5A&I3G!IQG"<5*$XM73C*+333LT[J]SC:<6XR34HMIIZ--:--:6:>
MCT^XSJL1]7?"?]AC]L#XZ^#+/XB?!_\ 9V^*/Q#\#ZA>7]A8>*?#7ANXOM&O
M+O2KEK/48+6[^1)VLKM)+6X,6]([B*6$L)(G1?"Q_$_#^5XB6$S#-\#A,3",
M)2H5JT8U(QFN:#<=US1?,KVNK/9IRZJ6"Q=>"J4</6J0;:4H4W*+:W2:[/U_
M&T?$_BE\)_B3\$?&^K?#?XM^"]?^'WCS0H].FU?PKXFL7T[6-/BU?3;75],D
MN+5\E$O=,O;2]MV!(>">-AC)"^E@<?@\RPT,9@,32Q>%JN:IUZ,E.G-TYRIS
M49+1N,XRB^S371F-6E4HS=.K"5.I&W-":Y9*Z35T^Z:?H_(\]KK,S[I^$W_!
M,S]O;XWZ-:>(OAS^RU\4]1T#48H+G3-<\0:79> M(U:TN4\RWOM(U'X@:AX8
ML]5T^9#NCU#3IKFR8'_7&OF,?QGPMEE25'&9Y@858-QG2I5)8JI3E'>%2&%A
M7E3FNL)KF\E>QW4LMQ]>*E3PM5Q>JE*/)%KNG/D33[IM=[W.L\<?\$E?^"CO
MP\L;K4O$/[)?Q-N[6RB,]Q_PAO\ PCGQ'N1&H!9HK'X=ZYXIO;DJ#N9;:WF=
M5#$@!6*X8;CS@_%RC"CGV"BY.R^L.K@U?SEBZ5",?^WG'RV?-=3*<QIIN6$J
MM?W.6I^%-S?W+\F?GSJFEZGHFI7^C:UIU_I&KZ5>7&GZII6J6EQI^I:;?V<K
M07=C?V-W'#=6=Y:SQO#<6UQ%'-#*C1RHKJRU]9"<*D(U*<XU*<XJ<)PDI0G&
M2O&491;C*,D[IIM-:IN]SSVFFTTTTVFFK--:--/5-/=/]#[7T?\ X)G?M^>(
M-(TO7M%_9+^-.HZ/K>G6.KZ3J%MX3N'MK_3=2MHKRQO;=BREH;JUFBGB8JI*
M.I(&<5\W4XSX5I5)TJF?9;"I3G*G4A*O&\)PDXRB_.,DT_-'8LNQ\DI1PF(:
M:335*5FGJFO5%37/^";/[?OAZUFO-2_8\_:%-O!&TLSZ9\,/$^NM'&HR[F+0
M]/U&;:BC<^$.Q 78JJL5JGQCPK5DHPXARB[=ESXZA2N^UZDXK7\=KK0)9=CX
MJ[P>)MY49O[^5/\ &WKH?'OB#PYXA\):Q>^'O%6@ZSX9U_3)?(U+0_$&EWVC
M:QI\X&3#>Z9J,%O>VDH!!\N>%'P<X&:^@I5:5>G&K0JTZU*:O"K2G&I3FN\9
MP<HR7FFSCE&46XRBXR6CC)-->J:37W??<QJT$% !0 4 % !0 4 7M,TV_P!9
MU+3]'TJTGU#5-5OK33=-L+6-I;J]O[Z>.UL[2VB4%I)[FXEBAAC4%GD=5 )(
M%3.<*<)U*DE"%.,ISG)VC&$5S2DWT22;;[>@TFVDDVVTDENV]$EYMGW3_P .
MM_\ @H?_ -&?_&__ ,)&?_XY7S'^N_"7_1099_X41.W^S,P_Z \1_P""I')^
M)_\ @G;^W?X.LI]1\0?LA?M#VUA:KONKVS^%7B[6;:VC'6:XFT72[^.&%?XY
MI62%,@,_(#;T>+N%\1)0I<091*<M(QECL/3E)]DJE2+;\E9^MB99?CH*\L'B
M4EU]C4:7K9-+Y_C>TOCZ^L;W3+RZT[4K.ZT_4+*>6UO;&^MYK2\M+F%S'-;W
M5M.D<]O/%(I26&5%DC<%64$$5]#&49Q4H24HR2<91:<9)[--7336S3^^Z.1I
MIM---.S3W3[/;5>GW%6F(U-#T35_$NM:1X<\/Z;>:SKWB#5-/T31-(TZ"2ZU
M#5=7U6[BL--TVQM8@TMS>7U[/!:VL$:M)-/+'&@+,!45:E.C3J5JLXTZ5*$Z
ME2I-I0A3A%RG.3=DHQBG*3;LDKNUAQBY-1BFY2:C%)7;;=DDEJVWHDOU/JSX
MD?L ?MI_"#P3KWQ'^)O[-'Q9\%>!?#$-K<^(?%.N^&+FVTG1[>]O[72[:>^N
M 7\F&2_OK2V\QEV(\Z&0J@=U\+!\5\.9AB:6#P6<X#$XJNY1I4*5:,JE1Q@Y
MR45U:A&4K=D['54P&-I0E4JX:M"$;.4Y4Y**N[:OIJTO^'/C^OH#D/:O@I^S
ME\=?VCM7UK0?@3\*_&/Q4UCP[IT.KZ[I_@[2I-4N=*TVXN5LX+V]5,"&&:Z8
M01LS L^0 <$UYN99QE>3TZ=7-,=A\#3K3=.E/$5%!3FH\SC&^[4=7Y>J-J.'
MKXAN-"E4JN*O)0BY-)Z7=MM?ZU9]&'_@EQ_P4. )/['_ ,<, $G'A"Y)X] K
MEB?0 9/09S7D?Z[\)?\ 1099_P"%$3H_LS,/^@/$?^"I'S3\5_V>_CQ\"+BQ
MM?C5\&?BC\)I=4>9-*/Q$\">)O"$&KM;@&?^Q[K7=,L;75EA!!E?3IKI$R-Q
M6O9P&;97FBG++<QP6/5.WM/JF*HXAT^;;VBI3FZ=^G,E?R.>KAZ]"RKT:M&_
MP^UISIWMOR\R5_DW^*,OX2?!GXJ?'CQC;_#[X-^ _$GQ'\;75C?ZG;^&?"NG
MOJ6JRZ?ID2S:A>+;QD$6]I$RO-(QVKN4<EEJ\?F.!RO#O%YCBJ.#PT9Q@ZU>
M2A34YNT(W?63VW_%.,TJ-6O-4Z-.=2;3:C"+E*RW=EV_KJ?5?_#K?_@H?_T9
M_P#&_P#\)&?_ ..5X?\ KOPE_P!%!EG_ (41.K^S,P_Z \1_X*D'_#K?_@H?
M_P!&?_&__P )&?\ ^.4?Z[\)?]%!EG_A1$/[,S#_ * \1_X*D>._&G]CG]J3
M]G3P]IGBSXY_ KXB?"[PUK.M1^'=*UOQ?H4VF:=?:Y+8WNI1:5;W#LR->R6&
MFW]VD/WF@L[AUR(GV^AEW$.29O5G0RS-,'CJU.G[6I3P]53G"DI1ASM+7E4I
M1BW;>26AE6PF*P\5.O0JTHN7*I3@XIRLW97W=DW\O)'S57LG,% !0 4 % !0
M 4 % ']#/_!M/_R?5\5_^S3/'7_JX?@17Y+XR?\ ),8#_L?87_U7YH?0\-?[
M]5_[!*G_ *>H']O]?S2?;A0!^//_  6T_P"35? '_9P7A7_U7/Q7K^>_I)_\
MD-E7_968'_U3YZ?T5]&7_DO,V_[)''_^KG(3^76OXC/[F"@ H * /8_AC^SW
M\;?C19:KJ/PI^&/B[Q[8Z'=6]EJ]WX;TJ6_@T^[NHGGM[>YD1E5)988VE5.N
MQ=QP"N[Z#)>%.).(J=>KD62YCFM/#3A3Q$\%AIUXT9U%*4(S<=%*48MI=E?J
M?.9YQ=PQPU4H4<_SS+\IJXJ$ZN'IXVNJ4JU.G)1G.">KC&346^[MT,OXG?!7
MXL?!>]TK3OBM\/\ Q/X!O=<M9[W2+?Q+ILVGOJ5K:RK!<S6ADRLRV\LD:3!&
M+1F6/>JB1"V.<\.Y[P[5HT<\RK'955Q,)5:$,;AYT'6IPERSE3Y])*,K*5G[
MMU>UXF^1\2Y!Q+2KUL@S? YM2PM2%+$3P5>-94:E2+E"-2VL7.*;C?27+*WP
MR/,*\4]P[KX=_#'X@_%KQ$/"7PT\'Z[XW\2FQNM2_L;P]8RZA?+I]D8A=7KQ
M1?ZNV@::%))G94$DT4>2\J(WIY3DV:Y]BU@,FR_%YEC'3G6^K8.C.M5]E3M[
M2HXP3:A'FBG)V2<HJ[<DCRLXSO*.'\'_ &AG>8X7+,%[6%#ZSC*JHTG6J7=.
MFI/><E"345=M1D]HMQ[CXD?LS_'[X/Z!!XI^)_PE\;>!_#MSJ=OHL&L>(='F
ML;"35;NWN[NVL5G9F7[1-;V%Y+&AQN2WDP<KBO2SC@WBKA_"PQN=Y#F>682=
M>&&AB,9A:E&E*O.%2I"DIRT<Y0I59*/50DULSS,EXUX2XBQ<L#D?$&69IC(4
M)XF>&P>)C5JQH0G3ISJN"UY(SJTXR>MG.-][Q\-KYH^H.X\!?#/XB?%/6?\
MA'OAMX'\5^.];$:S2Z9X3T'4M=NK:W9Q']KO$TZVN/L5FKD"2\NS#:Q]9)D
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MR6IC:N)A@Z>'AC8.<\54JJC"C&SY7.55J"L[-O>SN?,]?''VP4 % !0 4 %
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MFG],G_DYV1?]D'E?_K0\4']U_1B_Y(+-_P#LK\?_ .J;(#\]*_DL_HT* "@
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MRE2JP=M)0E*+Z/1\VU7*= 4 % !0 4 % !0 4 % !0!_3?\  /\ Y(7\%O\
MLDWPY_\ 4/T>O]I/"S_DV/AQ_P!D'PA_ZSV7'^6WB#_R7O&__97\2_\ JYQI
MZS7WA\@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % '__T?[1?V^/^3%?VT_^S3/VC?\ U3WC&O>X5_Y*?AS_ +'V3_\ JPPY
MR8__ ''&_P#8)B?_ $S,_P QJO[2/S(* "@ H * "@ H * "@#_4R^ 5U:VO
MP$^! N;F"W-U\*/AC:VPGFCA-Q=2>"M(>.V@$C*9KAUC=DACW2,J.0I"L5_B
M#-8REFN:<J;Y<?C9.R;M%8FHFWO9*ZU>GIHS]1P[2P^'NTKTJ25^KY%HO/\
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M$9_<P4 % !0!_2)_P0X_Y)C\=O\ L?/"_P#ZCUU7]A?1D_Y$_%7_ &,LO_\
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MS*G&[T2E]0JPIQOK/$U++WW+^?ZOY3/ZU"@ H * "@ H * "@#ZV_8:^"/\
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M5&-.O&<.6K["K)P56*FE=QYE&5GHW']$_P!I_P#;M_:_^-?P0/PP^*OPPMO
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M?^J?(C^&?I-?\EYE/_9(X#_U<Y\?L-7]"'\ZA0!^(7_!2K_DNGA3_LDVA?\
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M5# 49PU?M</A(UJL;+6GF,;7=SXS_P""6/Q'\7_L0?\ !272_A+\4(7\,_\
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M^''_ &0?"'_K/9<?Y;>(/_)>\;_]E?Q+_P"KG&GK-?>'R 4 % !0 4 % !0
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MZ3J-I<- )IX]LJO#/-$R2L >NT % !0 4 % !0 4 % !0 4 % !0 4 ?F_\
M\%!?^"LG["W_  3'\.Z9JO[6'QDL_#7BGQ)I\FI^"_A)X5T^Y\8_%SQI81W4
MMDVHZ)X+TIA/9:']KM[NU'BGQ1=^'?"9O;*ZTX:Z=1C-HP!^$L?_  >F_P#!
M+IO$7]F/\#_VX8M!,L<*^)V^&_P2:(,S[9+J724_:%;45T^,8D\R-)M0=,@:
M6) J, ?UQ>'M:M_$>@:'XAM+:^L[77M'TS6K:TU2V-EJ=K;ZI90WT-MJ-FS,
MUI?01SK%=VS,Q@N%DB+$KE@#8H * "@ H * "@ H * "@ H * "@ H * "@
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MQ;X*\9>&=0@U30/$OAO7+.*_TK6-*O[9GBN+2\M)HY8V!#H28Y525'10#M*
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MQ+8V9$EM<W2:A#)9* >A?\$PO^#BO]C#_@JM\=;_ /9R^!GPM_:9\"_$S3/
M&O\ Q*NS\5/!GP\M/"/_  C'AO4-#TO4IH_$'@GXI^-KJ*X6_P#$6D6L,>I:
M+IL,\]W%%%<O(RHP!^^] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!\X_M<?M4_"/]B3]G/XH_M2_'?4=6TOX4?"'2--UG
MQ;=Z%IG]LZT8M8\0Z/X5TFSTK2OM%I]OU#4M?U[2M.M+;[3#YD]V@,@H _&G
M]FG_ (.?_P#@F!^UC\?/A-^S;\(KK]H6\^)?QG\:Z1X#\&0:S\''T[1SK>LR
MF*WEU;48?$MZ^G:7;*LEQJ&H&UFCLK2*:ZF"PQ.Z@']$E !0 4 % !0 4 %
M!0 4 % !0 4 % 'SC^UQ^U3\(_V)/V<_BC^U+\=]1U;2_A1\(=(TW6?%MWH6
MF?VSK1BUCQ#H_A72;/2M*^T6GV_4-2U_7M*TZTMOM,/F3W: R"@#\:?V:?\
M@Y__ ."8'[6/Q\^$W[-OPBNOVA;SXE_&?QKI'@/P9!K/P<?3M'.MZS*8K>75
MM1A\2WKZ=I=LJR7&H:@;6:.RM(IKJ8+#$[J ?T24 % !0 4 % !0 4 % !0
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M_LTS]HW_ -4]XQKWN%?^2GX<_P"Q]D__ *L,.<F/_P!QQO\ V"8G_P!,S/\
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M_P K#_AGK_@VQ_Z+)I__ (=?XS?_ !BC^UO&/_H72_\ "#+O_E@?5^&_^?\
M_P"5:W_RL_";_@I/X0_8M\%?M :1I'["/B6/Q5\&9/AGX=OM5U&+7?$GB*.+
MQ_-KWBN+6[-=0\4Q1:D/+T6W\-S&W3?:1M<%HW$CRHGZ?P=B.(\3E,ZG%%'V
M&8_7*T80]E1HMX54Z#I2<*$I0UJ.LKNTGRZJR3/"S*&"AB$L#+GH^SBV^:4O
MWG-+F5Y*+VY>EO2_O?GY7U9P'JGP*_Y+=\'/^RJ?#W_U+=(KAS/_ )%N8?\
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M6/0+K2A<RSWBW+O_ #=XF>'G^KWB!A^'\DC'ZKQ'4P5?),/*<VL,\SQD\#'
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M^,,NGAJS<OK7#6>YQFTJ5.?/?GA3K2S'!2BKPHX:.$IV2E%'POB=P]B.&:W
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MX8\K#_AHW_@X:_Z(OJO_ (:'X;__ !RC_4WZ'O\ T4F%_P#$DSH/]:/I,?\
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M6["/S8-]YI1U#[?:IY\.Z>",>;'G>H!_E6'_ (-*/^"R?_"[F^%Z_"7X7_\
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MOPX^%<'B.]@%K>>((?A[X.T;PC%K=W:K-<K;7.JII"W\\"W$XAEG>,32A=[
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MNAVOP9T'S"WR&[M]8^+=MJ^GQY\T7&D_;(E(LI&4 _UBZ "@ H * "@ H *
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MN /] B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /X1_\
M@N]_P<Z_M?\ [$O[;/QA_8E_9!\*? W2].^$FF> [+Q)\7?&GAC7O'7C5O%_
MBWP#X>\=ZE9>'K"7Q3IG@:QMM @\46.DW":SX7\32OJ=E?1R&W,;0L ?M5_P
M;4?M,?MC_ME?\$\M9_:@_;3^+FI?%[QQ\5_VA_B=-\/M4N_"W@GPA8:)\,O"
M&F^$/ \.BZ-H_@7PSX8TF*QC\?>'O'TYQ:2;9)2H83"X>< _H.H * /\:+_@
MX2^/?_#1/_!8W]NKQA;WOVS2/!WQ;/P0T14D\RUM;3X">']%^#^HI8L"RFWO
M/$?@W7-79XV:*:ZU*YN(R4F4T ?Z(W_!K=\ _P#A17_!&/\ 9KO+NR^P^(/C
MGK/Q,^/GB&/R]AG_ .$R\::EH7@Z]+$*TOVWX9>$? MR)&'"RB)"\42.P!_0
MO0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^)G_!>C_@JGXM_X
M)(_L8Z#\>OAGX,\"_$'XK>/_ (Q^&?A%X$\,?$1M=D\+1RZIX8\9>+M:\1ZM
M8>&=7T#6]1L=&TOP@]L;:SUO2@]_JVFQRWL8E17 /YG_ /@AO_P6Z_X*L_\
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M/>,:][A7_DI^'/\ L?9/_P"K##G)C_\ <<;_ -@F)_\ 3,S_ #&J_M(_,@H
M* "@ H * "@ H * /[LO^"L/_*$J3_L0?V4O_4J^&%?S#P)_R<G_ +FL]_\
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M$K]H#5K39>^+]1C^'OA":6,K(OAWP_)#J7B:\MGZ26FKZ_+INGL1REUX3G7
M!RWPOT;.&O89?G7%E>G:ICZL<GR^334EA,*X5\=./25.OBGAZ5]+5,#-=6Y?
M>_2:XG^L9GDO"6'J7I9?1><9C&+NGC,6I4,%3FNE3#X2-:JM-:>/@]3WSXQ?
MM!_\$I/B%XXU"_\ C)K/PX\7^-_#_F^$;[4M8^'_ ,0]6N;>/0K^^C;38]2T
M_P *3V5[;6E]-?>1<6MQ<6THD,EO/+ T3U]1Q#Q;X#YQF=6MQ#B<IS#,L+?
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M^QQE?_I58_@3Z.__ "<C#?\ 8HS7_P!-0.$_X(G_ /)J7CC_ ++[XL_]5_\
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MXVT_V')?K&-Y>K=7#8F%-Z_95K:B_P#!;WPWX@U#X._!WQ/8V]Q-X=\.>/\
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M ,&]'_)\_BO_ +-T\>_^IO\ #"OZ0^F#_P FKP'_ &664_\ JLSP_#_HT?\
M)PL9_P!DQF/_ *GY4>P_\'%OP2UO1?CC\'?V@;6QG?PIXZ^'P^&VIWZ#?;6?
MC#P5K&M:S;073@?Z/+K'AWQ'"=/CD/\ I2^'M4>'/V6;;\Y]#;B?"XGA7B/A
M&=6*S#*LX>=4:+=IU,MS3#87#2E37VXX;&X*?MFK^S>,PZE;VD.;V_I/9!B*
M'$.2<20IR>"S'+%E=6JM8PQV KUZ\8S:7NRK87%0]DI/WUAJSC?DER_M!_P2
M%_; \$?M*_LE?#3P;'K.EVWQ8^!_@_0?AGXY\'/?V_\ ;C:9X,TVQ\/^&O&T
M&GO,;ZYT3Q)HMOIDESJJ0+9P^)1K&DAPUI&9?YI^D3X=9IP5X@YWF<L-7GP_
MQ3F6+SO*\R5*?U55\SK5L9C<KG6Y?90Q6#Q,JZA0<G4E@OJ^(LN>:C^[>"?&
MV7\5<%Y5@%7HPSGA[ X?*<?@?:Q^L.C@*5+#83,(TF_:2P^*P\:+G6Y>18OV
M]%-<D7+JOVDO^"='[$NO>#?CW\5]7_9X\$WOQ$UCPQ\4?B#J7BJ277UU&[\9
MW^DZYXBO/$$@BUF.U%]<:W+)J,FRV6$W#$B()\C</!/C-XGX3,^$>'\/QCF=
M+)L-C\AR>A@%#!.C3RREB,+@J>#3GA)5'2AA8JBKU'+D5N;9G7Q5X7\ XC <
M29S6X9P$\TKX/.,SJXQSQ2JSQ]2CB,5/$M1KJ'M)8ANJ[)1YGM%-H_G<_P"#
M>+_D^/QO_P!FV>.__5@_">O[$^F'_P FMRS_ ++7*O\ U4<0'\R_1F_Y.#C_
M /LELQ_]663GRE^V!HOB_P#8@_X*?>.O&$&DL]UX'_:(L?V@? MK>R&*Q\0>
M&=9\80_$SP_:?:X(V\VPG@N)/#6I30H7AN;/4K61%N;:5%^_\.L3EWBAX&95
MET\3:GFO!M7A'-:E)7K83'8;+IY'C:GLY/W:L9P^N4(R:4Z=6C43=.I"1\;Q
MMA\=P!XLYCC8T??R_B>GQ)ET)Z4L1A*^.CFV$ASI>]3<)_5:SBGRSA6IM*<'
M$_N1_9Z_:#^%W[3OPK\,?%WX2^)=/\0^&_$>G6=Q<VUM>6L^K>%]8FM(+G4/
M"OBBRMYII-'\2:+)/]FU'3KD(X95N;8SV-Q:W,O^6O&/!^?<"Y_CN'>(<%6P
MF-P=:I"G4G3J0P^/PT:DX4<PP%6<8K$X+%*#G1K0;ZTZBIUH5*4/]!.&>)LH
MXMR?"9WDN*IXG"XJE"4X1G"5;!UW"$JN#QE.+;H8J@Y*-6E*SVG'FI3ISG[-
M=75M96UQ>7EQ!:6=I!+<W5U=2QP6UM;0(TL]Q<3RLL4,$,2-)++(RQQHK.[!
M5)7YJ$)U9PITX3J5*DXPITX1<YU)S:C"$(Q3E*<I-1C&*;;:23;L>[.<*<)5
M*DHPA",ISG.2C"$(J\I2E*T8QBDW*3=DM7:PZ">"Z@AN;::*XMKB*.>WN()$
MF@G@F02130RQEHY8I8V5XY$9D=&#*2I!I3A.G.5.I&4)PE*$X3BXSA.+M*,H
MRM*,HM-2BU=/1VL.,HSC&<)*49)2C*+3C*,E=2BU=-----.S3NKW1+4C/R9_
MX*8?\%#OBE^PWJ_PATWX=? J#XPQ?$?3?&=]JMW<7?B*V70Y/#-SX:@M+>-=
M"TK4%<WRZW<2.;F2-@+9!$A!=J_H/P0\',B\5,-Q%7SCBFIP[+):^64J%.G3
MP<WBHXZ&-G4G)XK$46O9/"QC'D4E[\KO1*/XQXK^)N;^'U?)*66</PSJ.:4L
M=4K3G/%0^KO"3PL817U>C53]HL1)OG<;<JM>[Y?R\_XB /VF_P#HR73O_!I\
M0?\ YFZ_=?\ B4/@C_HYN(_\)\I_^;C\C_XF2XK_ .B$H?\ @[,O_F0/^(@#
M]IO_ *,ET[_P:?$'_P"9NC_B4/@C_HYN(_\ "?*?_FX/^)DN*_\ HA*'_@[,
MO_F0_ID^#_C74/B3\)/A;\1=6T?_ (1[5?'WPZ\$>-=3T /-)_8>H>*?#.F:
MY>:/YES%;W#_ -F7-]+9;[B""9O(S+%&Y9%_B'B3+*.2<19]DV'Q/US#Y1G6
M:990Q=H+ZU1P&.KX6EB;0E*"]O"BJMH2E!<UHR:LY?U=D685<VR3)\TKT/JM
M;,LJR_,*V&O)_5ZN,PE+$5*%Y1C)^QG5=.\HQD^76*=U'T6O%/5/QW_X+@?M
M'?\ "C/V)/$W@_2-0^R>,OV@=4@^%.DI%*R7<?A:YA?5/B'?K&N#)92^&K5_
M"MX=P\N3Q;9MM?)5OZ.^BYP9_K3XGX+,L11]KEO"&'GGV(<HITWCXOZODU)N
M^E6.-J?VA2T=UEU35:J7X?X_\4?ZO\ XK T*O)CN):T<GHJ+M-8*476S2I;2
M].6%A]2J:Z/'0T9_,-^Q-^SQ_P %,+S0=2^.'[$OACQ_IFB^(3J'@?4/&WA#
MQ;X%\,/JT>DWEC?:CH^SQ1XATR^N;.VOTLI))X+1K-KRW,*7#SVMQ'%_<WB=
MQCX)4L51X6\3\=E%;$X3V.:T<KS'+\TQRP\J].M1HXF^!PF(I4ZLZ4JT8PG-
M5%2GSN*A4@Y?R7P%PSXJU,/5X@X"PF9TJ&(]KEU7,,#C<!A'65*=*K5H6Q6)
MHU)TXU%2;E&,J;J1Y5+GA.,?7/VI?V:_^"QOCGX8:GXC_:G\,?%+QE\-/A7;
M:IX_O[KQ1XX^&?B*#PM:Z7I=R-8U^&ST3Q/=ZP8[726N9+\65K<?Z+$T\T)2
MV#I\[P)QM]'#*L\HX+@/'9#EN=Y_4H932A@<KSK!RQ]2M7A]6PDJN*P-+#J4
M\1R*E[6<?WDN2+3FT>WQ=PKXWYAE-7%<7X3.,=E63PK9C4GC,PRO%1P<*5*7
MM\3&G0Q=2M:%'G=3V<7[B<I)J-X_I)_P;G_M&_:]'^-/[*VMWV9M)N(/C-X
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MGLN/\MO$'_DO>-_^ROXE_P#5SC3UFOO#Y * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H H:KJFGZ'I>I:UJ]Y!I^DZ187FJ:G?W
M+^7;6.GZ?;R7=[>7$AR$@MK:&6:5R/EC1CSB@#_"*_:@^,VH?M&_M*?M!?M
MZL9_[1^.'QK^*7Q;NTN23-#+\1/&^N>+#;,,L$6U&K"VCB0^7#'$D486-$50
M#_9W_P""2_P$_P"&8_\ @F?^PW\$IK+^SM7\(_LV?#"]\5V7E^5]F\>>,_#U
MKX[^(,>S ;CQQXF\0'>X623/F2*LC.M 'YU_\'3?Q[_X49_P1D_:*TZTO?L&
MO_'CQ)\+O@)X?E$FQIO^$J\96/BGQ?9*N5,OV_X:^"/'%FT8/$<SRL'2)T8
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MM$\3>#M4\::H+GQ-XNT/Q+I?C1=;LY_%>L:I=>&[KPG]@TJ=+'6Y+>W /O\
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MU=[C^S=:G\)>-_$EDVI:/J$]G>107EQIMQ8SW=E>6^XW-G<1Q ']W7_!I?\
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M?'SQKHO@CX(>-=(36-'LQ/K?A?6=(U1;1+=SN_M5H9L"=* /S(_89_X*V_\
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M4^Q-%?\ B?79?"7B339Q)&EM:RC4-.E1HHXX63RTH _TBO$__!7"W_X)D_\
M!&/]D/\ :F_;[\97WQF_:N^+W[/W@'7_  S\/$7P]X1\??&SXJ^,?"6F^-AH
M-Q;:%H=MH_AK1_ >C^)-$L?B9XZ7P]/9Z%#:QSR6GB#Q?XAT'1?$0!_!U^U/
M_P '%/\ P6,_;Z^*,>@?#+XT?$GX%Z7XFU)-(\ ? C]C'_A*O!6M22S3-]BL
M+;Q/X0GN?C)XV\27L2Q)>%_$SV5U<)*VC>'=&M9WL5 /E3XP?M/?\%R_V1M8
M\)W7Q^_:(_X*G?LZ:WX[L;O7_!__  N'XN_M5_#.]\8:?I\MO!J5[I5MXU\0
MZ.^O06,MY9Q:K&L-T+07UDM]&B7MMYX!_6C_ ,&E_P#P4#_X*3?MM_M(_M$>
M&/VEOVI?B'\;?V?/@U\"-.OSH/C^P\*:_JL/Q4\:^.M#L? VH2_$"Y\.MX^:
M.'PIX:^):OI<OBA[#4)WBN[NUN9K"%X@#T__ (+Q_P#!TIK_ .R?\4_&7[&7
M_!/"W\*:S\9?A]J5YX:^-7[0WBO2;+Q=X7^'?BFVA\N_\"?"_P ,W%Q)H?B7
MQQX9U!_L?B[Q!XOL]5\+^'-8L-0\*)X7\0:HE]?Z" ?QK7/_  4D_P""U'[4
M.IZ]XCT3]K__ (*#?$B309#K6OQ?"+XE_&RR\.>&#=/-+'?7/AKX37NF>%_#
M-OE)Q9,FE:=;6\,<D-F(H(C&H!^]7_!*_P#;,_X*]?'?_@E]_P %H?'^H_MK
M_M%ZG<_LD? [X8^*OA9XD\9^('\5_$CPKXY\-^,]3^)_Q/ETGXB>+;'5OB#'
M]C^$/PJ\2>&?$NB:AX@FL(['QK%<_84OXX;FU /SX_X)L_\ !<G_ (*?>(_^
M"A'[$?A7XR?MQ?'?QU\)_&7[57P'\$?$?PEXF\5)>:!K?@KQK\2_#GA7Q):Z
MK:FU43VB:5J]S</'N4L81AE(W4 ?Z@_[<_[7/P]_80_9*^.W[6?Q/DC?PQ\&
M/ >I>)(-(-REI<^+?%4[0Z1X&\#:;.X98]4\<>,]1T+PKITKJT5O=:M'=7&V
MVAF= #_*=^$W_!8;_@NE^V)^TEX.^#_P<_;8^/\ <_$_]H+XIV_A[P7X(\*^
M(UT7POI>L^-==DDCL["SALKB'PWX)\,0W4US=3R;K#PSX5TNXO;N5++3IIE
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M*]T+3O#,@&US/K5NL<L+E9H@#_17_;I_;@^ G_!._P#9J\>?M2_M&Z_=Z/X
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M/C+XP^!_Q9^+G[06K7EUXK\":FNE^(-0^'7PZ^'>NQ^)M ,[1RYTNZ\3>//
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M6>XU+6=2?RT9B6DG +$G- '^ZC^S)\&M-_9T_9O^ '[/^CB#^S/@A\%OA?\
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MTNVSM+*.:ZFE18VDVPQLZJC/P%)4 _MV_P""%_\ P5%_X**:'\1/VP_VM/\
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MP<4> ?\ @E3)8_ #X%^&O"?QO_;-\1:3#K6H^&/$6HW_ /P@'P,\-:I8_:M
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M/QKO?#.O?#X^*-.U'XE3:+H'QO36/"VM);> ;'Q%=R7&D6LGRVQ;[5"T7FQ
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MMR(;>)OA_P#LZ6NDP1Z)9LT5E;:AX@M+^<[!)?:I=7KW%Q* >":W_P %&O\
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ML0V>HW^BZ/;WVK:7I>J:E9V>G70!Y+^VE_P7._X+$?M.>,K?XB_$+]ICX_\
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MU8&^U&2-(E0 ^=?B3^VI_P %K?V/?B%'X'^,W[5?_!2O]GSXD#2M/\2CP/\
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M^*OA1I-I:(D]R=#\.>'_ (43P>-->C@MQ<O-=>(]=\4^(+JT1AJ6KW5O @0
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MF)$!\$:)X<L+BR@\=?$[1T::X\1?VAJJ>%/ >JQ66@:UIGBS7/\ A)O#WA@
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M5-*\8V&JW?@K7?AIX6_>V8\4^(;SXG:9J'@?P9;YT^X\07\NF-=PZ2UQ<I9
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MC'3M2U3P#X]C\/6DAM_#NN:I'H7B71?$FDZ=##H4FJ>'9-9T*#3;'6!X>T$
M_@:_:[_X+X_\%0]8_:N_:;U7X0_MV_'KPA\)M1_:"^,EY\+O"GAOQ8EMX?\
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M;?&&AP:S90W5M::K#I>O_!74;*+4K6VOKZW@O8X$N8K>\NH4E6*XF1_YAP7
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M+K7\1G]S!0 4 % '[9?\$JOVN_V>?V;? OQ9T7XT_$ ^#-2\3>+- U30X/\
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MH5EX@\4>)M7>ZUKQ;XHM=)U.^T'1K?1-+\-:-%;:E>>7X=EU&\DO& /ZG/\
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MCC5;6ZT*R\0>*/$VKO=:UXM\46NDZG?:#HUOHFE^&M&BMM2O/+\.RZC>27C
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M+8^,/@A\6],O-2L58B>S\2_#7QC#/>6JLP0B6WU319(0S*A#IDA>E ']G/\
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MQ!KT7AS1KG5]3U34==\2ZQJET+G4M3U?7=<$+,UN ?VL_$+]F;Q]_P $1?\
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M_*3Q7>:7\/?A9=3(IVPSHGA;XL#9)F4P7D$JK'%(K3@'!?\ !D3\ O[:^/\
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MZY\7)=*A@BN-6^(A\=?%_2++5->,,C-)K3_#/2/AU8EYXXIFTBPTASYB,CL
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M _P_UJ7X<^ KD,,@";P7X3T&01JS)$&\M'=%#L ?Z0G_  :]?\$V/ 7[&/\
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M0^$+'4;.:6RUCPG\/?"NK6Q4WLI< _K1_P"#:_\ X)Z:7_P3%_X)L?$[]O\
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M&<T_B&+_ (*[ZA'HKRKIMS^R=\:8/%RQDA)/#R^)/AC<VR3@*P:(>++?PQ(
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M^#W_ .//DZ%^P?\ LPZ?>[O[0U;XM_'GQ=IWF8\K^Q[/PY\/OAW>F($[_/\
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M%?#CX1V/BOXWQ17"?O+1_$OCO3_#7A_6;,%4OO#GBCQ#I<Q-M/+%* ?RY_\
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M/CA\>/A/\*IC!N#V]AXZ\<Z'X<U._9TP88-.T[4+J_N;C*K;6UM+<.RI&S*
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M-,T.SUCQ3JNG:1I>D:9:1ZAJT]R'N)P#^@G_ (.-O#_B[_@GO^P!_P $DO\
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MURU;[-=0:-^V'\4O%'Q U>Z0Y6:*2^_9UO\ 4?#UA=VKI<V]Q<V6J0NKPY4
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M^ROQ_P#ZIL@/STK^2S^C0H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * /Z;_@'_ ,D+^"W_ &2;X<_^H?H]?[2>%G_)L?#C_L@^
M$/\ UGLN/\MO$'_DO>-_^ROXE_\ 5SC3UFOO#Y * "@ H * "@ H * "@ H
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M*\<^$_#?C2]T[P]KD$ELFHZ)XDT2XU+2[JZL;^UU.QOY+C11HVL@']=>I_\
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M@NSNO$6N_$YO'7EZ'8:%X0\1^++>U_L>'P-=W3WK>(+QKJ"]MS<V6E.;=+L
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M>WM[<37=Y>7<TEQ=7=U<2--<7-S<3,\L]Q/*[RS32N\DLCL[LS,30!_IJ_\
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MO?$_Q"\4ZCXBU"*$!?.NI[G5=7F2,!?-FD<87>P% '^XY^QS\#;;]F3]DO\
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M/Q,^,WP6^(7Q9?XN?"K0? _A*[^&UWX9@UKP_?:)XDD\07>F:C'XHU/1[9=
M\43+I3:AJ-G=W=]IL^@V+1:-JBSN+< _9_\ X/2_@AXYU_Q!^P3^V@G@GQ!I
M'@WQ3\*-;^"WC!]06*1O ?C1-0;XI>$/!WB1K6::UMM<U73O$WCU;8V[RV]Y
M)X+UH).R6<&\ _);_@WJ_P""YOA3_@C[XU^.'AGXT_"_QK\3_@'\?8?!VIZX
MWPSD\/R?$3P-XS\!1^(K;2=:T'1?%.L>&?#_ (DTS7M-\2W>F>(-,O\ Q1H%
MQ;OI^C:GI]]+]CO-,U( _LE_8,_X.:? /_!33_@H1\(OV//V5OV6?B)H7PQ\
M1:!\3/&7Q/\ C#\;?$/A[0_%OA[PWX(\ :]J^EIX?^&_@2]\<:-YFK>-U\):
M)<:KJOQ#=(;'5KA(]&-V\$\0!_!?_P '!GPE\2_!W_@L=^WCHOB73M2L?^$P
M^-.I?%KP_<:A'((]7\-?%K3=.\?Z7J.F7#9CO--0Z]<:7');N\=K=:;=Z9+L
MN["X@@ /W._X)Q_\'6_PU_84_P""5O@C]DW4/V</'_CC]J3X&^'O&'@[X0Z[
M;7'ABW^ _B33=7\1Z_XC\(^(/B)J3>*+#Q]H]UX9;Q"NG:WX8\.>%=83Q7!H
M4=S;>+O#-QK\RZ  ?QQ?&#XL^/?CS\5OB/\ &OXIZ_<^*?B3\6?&_B;XA^.O
M$5V%6;5_%/B[6+O7-:O1$@6&UADOKV;[+96Z16MC;"*TM(H;:"*)0#_3B^ O
M[#'B/QW_ ,&C^C_LR_#?PW>:]\0OBO\ L4ZY\=O#7A[3(_\ B=>,O''C/QI>
M_M1^&=&M!N1KW4];N)M%\/:/#(X$\9T[3P5@"*H!_FK_ ++'[0?C#]D?]I?X
M%_M+^"+&SO\ QA\!/BOX*^)^D:+J_G1:;K-WX,U^RU>?P]JS1#[3!IVN6]K<
M:-J4D 6ZAM+V=[<K.B,H!_H+>,O^#V_]C>T^%MOJGP^_8\_:7U[XU3:7&]SX
M'\8ZU\+_  I\,-/UMK9#/;Q?%#1?%/C+Q3JFDV]VSI!?-\(]*O+^VB\R73=+
MEE\F( _KV_9J^(7C/XM_LZ? /XK?$;PSIW@KX@_$WX+_  N^(7CGP;I%S=WF
ME^$O%WC/P1H?B/Q'X9TZ[OTCOKJRT+6-2O-+M;B\C2YFAM4DG42,P4 _QWO^
M"[OP-_X9X_X*^?M]_#R.S^PV.H?'[Q%\5M)MD3R[>'1_CQ9:9\;M,@LE ""S
MM;3X@QV=O''\D"6_V8!6A9% ,'_@G/\ L<_&W_@LA_P46\%_"+6?$/B'6M2^
M)WBJ^^)G[1?Q5E1+B]\(?"K1;RTO/B#XOD/D-I]G>-:W%CX0\#Z<;>#1E\5:
M[X3T".&RTN15MP#_ &<?AA\-/ WP9^''@/X1_#'PWI_@_P"'7PR\(^'O G@;
MPMI,9BT[P_X4\*Z5:Z+H6DVBNSR-%8Z=9V\ EF>2><H9KB629W=P#NJ /YY?
M^#HO]F/QK^TW_P $?_CA;?#SP]>^*O%?P-\5^!/VB(-#TU3)J$_AWX>7>H6'
MQ!U"U@'-T?#OPX\3^+O$UQ;)F:>RT>Z2UCFO#;P2@'^:%_P26_;^N/\ @F5^
MWA\%_P!KQ_!DWQ#\.>")/$_A[QWX*L[V'3=4UWP+X\\,:IX2\1#0K^Y4VL'B
M#2+?5$\0:%'>-%8WVJZ1:Z;J%S:V%Y<7,0!^[_\ P7B_X.<-!_X*3_ *V_9$
M_9$^&/Q-^%'P+\7ZCHFO_''Q1\8H/"FF_$+Q\?#&K:=XA\,^ ](T#P3XN\;Z
M'H7@_3_$VF6/B/6M4F\2W^L>)+[2]#LH[/0-,LM6@\1 'DO_  :E_P#!,KQS
M^UC^WIX._:\\5^&=2L_V</V-M<3QZWBF_P!,F71?&OQXT^V67X:>!/#VH3QB
MVN]6\):G>V/Q/\136)NGT&T\/:!8ZBMC-XPT2X< ]Q_X/2/CY_PGG_!0KX#_
M  #L+W[3I'[/_P"S?8ZQJ5MYF?[/\=_&7Q=K.M:W 8@65&F\$>%/AG>&0['D
M6X560)%&\H!^K?\ P9&_ +^P/V:OVT?VF[RRVS_%#XS^!O@OHMW/'B0:9\&O
M!L_C#5WL6;YA9ZAJ/QHL[>[EB_=7-WH*0L3+IQ50#^X:@ H _P >#_@Y?UWQ
M%KW_  6[_;GE\2)<07&F>)?A+H6F6L^0L'AW2/@!\*+3P^]O'DK'!J.E);:N
M-@42RZC+<L#+/(S '] __!K3_P %H_@5\(/AM\!/^"5<OP'^)=U\8OB/\:/C
M#XMU/XL:+?\ A!/AO#X<N/"^M_$76/&OBEM1UBR\16MSX0\'^"6TS5+*UTB\
MMCH6A1:K%JXF5M*H _BF_:Z^.%Y^TQ^U5^TE^T1?/.\_QQ^.OQ6^*ZK<;A);
M6OCSQQK?B6QL51\&&'3K'4K:PMK8!4MK>WBMXU5(E50#_9N_X)4_ E/V7_\
M@FM^Q%\%+JU72]3\#?LT?"V7Q?;.H@2U\<^)/"]EXR^(;.'V^6I\;:_XAF9I
M0KX8O-AR] '^-M^W5\=W_:@_;1_:N_:(^U-=VGQH_:%^+OQ%T9V9F6#PWXG\
M<ZWJ7A>PA+9;[+I?AR;2]-LU8EEM;2%6+$$T ?[&7_!(7X"?\,R?\$POV%O@
MO-9?V=JWAK]FWX;:SXJL/+\LVGCKQ_HD7Q&\?P%<*2T?C;Q9KZM(RJ\K RR(
MKNR* ?Y@?_!S+\,O^%7_ /!;']M:R@M_(TWQEKGPO^)NF2;-BW?_  G_ ,%_
MAYX@URX4=#CQ;<^(;9GYWR6[N<,Q% 'YZ?!CX:_M'?\ !3_]K_X&_ OP[<S^
M,OC'\5H_A!\"_#-]=QSOIWACP!\)/ASX;^'&BZOJRPF:6U\*?##X2> 8-8\0
MW,"M+'HOAS4KY8IKM_+E /\ :)_8X_93^%O[$'[,?P9_96^#.G_8? 'P9\%Z
M?X6TZYEAAAU'Q'JNZ74/%/C371;@0R>(_&_BB]UCQ9XAEB"POK&L7GV>.*V$
M42 '^+I_P4;_ &:_&O[(?[='[4_[/7CS0+[P]JOP^^-/CF#1[>^!)U7P-K>M
MW7B+X=^*+*8Y^U:7XK\#:MX?\1:9<9WO9ZE$)UBN5GA0 _K"_8)_X+/?\&X_
M@7]GKX9-^TK_ ,$NOAWX/_::\"^"M!T3QUJ7AO\ 9$^"7Q=T3QUXMT'2K33[
M_P :>"O%'BC4H]5TRY\675M+K4VG>)+71IM O;ZYTM-=UFV@35[T _=S_@DS
M_P ' G@O_@IS^VY=?LB?LE?LA3_!7]F'X6? CQQ\4=:\:^-]0T#1/%D5OHGB
M;P1X4\+:)H'PS^'L5]X%\&6MSJ_C*,W5FOC#Q1-?VPN)[(::NE7!OP#"^-?_
M  =>_L:_LO?MU?M)?L<?M#_!SXNZ'X=^!?Q%_P"%=:/\<OAG-H/Q&TC7M4TO
M1=';Q<?%O@B[N/"/B#PFOA_Q7-KWA^+_ (1RY^(,^H1Z7!=2VFFR7$UO  ?R
M!_\ !Q3^U_\ \$>_VS?'GPF^*7_!.#X=ZMX?^-.HW_BW4/VC/'FD?#"\^#_@
M3QU8:C#I<GAU]6\*ZD-,DUCXDVNL1ZS=ZKXNT_POIK:I8ZC(OB#7O$]VNEC1
M0#]5O^#(?X4_$E_C'^V]\<%L-6M/@_;?#/P!\*I=3FLIX]#\0?$F^\5/XNMK
M'3]1<+;7NJ^$/#&G74^L65L99M-M/&^ASWH@35;$W !^!O\ P<@^(?$WB3_@
MM?\ MY77BH3)?:=\0/ WA[38)2=L/AGP[\'/ASHWA0P)DK'#=^';+3M0P@42
M27DL[!I9I'H _?O_ (-X?^"__P"SO^RY^S7^R1_P3&@_9I^-7C3]HCXB_M,C
MP"GBSPO=^!;/X;ZU/^T!\9Q;:9XPU75=2\0IXGL]0\):+XDTK2[_ $5?"5S8
M7=AX62[/B;3H[J46 !\/?\'FNN^(M2_X*M_#O2-62XAT;P[^QI\*;;PM&^1;
MW.GZC\3/C7J>I:E F=IDFUNXU#39Y]HD?^R(H6+);1!0#3_X-CO^"ROP7_X)
MZKXP_9.\5_L^_%+XG_%O]L7]I;X)^'OA]XF^'-WX22S>X\276E_#/1O#GBB+
MQ%J^DWMM%HNK>(+W6M(ETJ#63J4VMWVGSPZ4$2^E /)?^#OKX4^*? O_  5\
M\1>/M7L-3C\-_&SX$_!OQ?X1U2XC<Z7=Q>%="F^&>N:?IESS#YVFZKX,:YU"
MQ#BYM6U:UNYH4@U.TEG /9_^"$G_  <D?!7_ ()5?L5?%+]F'XT_ #XI?$[7
MX?B;XH^*OP;U?X7W7@ZRT;7+WQ?X>\.Z?J'A'XEW_B?7=+U#PK:6.K^&8[RS
M\7^'=$\>7<^GZW+8R^%8'T"WFUH _F]_;I_;,^+7_!0']JKXO_M9_&JXMAXV
M^+'B%=031-,>=M!\&>%]*LK71/!_@;PXER[S+HGA+PUI^FZ-:33'[9J4EM/K
M&IO-JNHWUQ. ?VK?\$ZOV*O$NH_\&@_[9Y\,Z#J6H>-OVG(?CI^T?8Z?IMO)
M)K^K:1\$O%_A+0]/TFTMHU^UW<5YI_[.VK7NF:9"))-137)C8PROJJ+* ?Q*
M_L3?M+:A^QM^UU^SC^U1IOAV#Q?/\!/C!X'^)D_A.XN_[/3Q/IGAK6[6\UKP
M_'J7DW/]EW6LZ.M_IUGJIM+Q=,N[B"_:RO%MS;2@'],W_!=G_@YYT/\ X*0?
ML[V?[(W[(?PQ^)_PB^#?C:YT76OCYXI^+J>%M-\>>-?^$=U*PUW1/AUX?TCP
M1XM\9:/IG@FV\1:?9Z[KNM7FNOK/BB;3='TQ=*T#2K?5[?Q" ?BU_P $*?@[
M:?';_@KY_P $_? &H6JWMA;_ +0_A?XCWUFZ"6&[L_@I::G\9[JVN8C\LMI/
M!X >*\B<&.6U:6.161F5@#^UC_@]E\0^)K/]@G]E3PS8B9/"6O?M:IJ?B*:,
ME8WUKP_\(?B)%X8LYR""Z36VN>);M(6W1M+I\<Q7S((V4 _CD_X(/?\ !2'X
M)_\ !+']N>7]I_X]?#3Q]\3?!TOP7\?_  VL++X91^&[GQCX:\1>+=3\)7MI
MXGT[3_%FO>%M&U&)=,T#6/#E];3>(-,ECL_$<U[!)<O9_8KH _T4/C=^WW-^
MWK_P;R_ME?MM?"SX8>,_A3I?Q2_9$_;%M/"/A?Q9J&E:AXKM?"GAJW^)7PKU
M3Q;/<:)(;.S:XTO0M:\1V\<$LK:?%&K6U[?PQVVI70!_DL?!KQIHOPW^,'PI
M^(GB7PX/&'AWP%\2? WC37_"37"6@\4Z+X6\3Z7KFJ^'#=213QVPUNQL9],-
MP\$R0BZ\QHI%4HP!_H=_\%)/VQ=&_P"#A#_@A#^V#\9/V6_V?_C!X5LOV0OC
MQ\/O&EOI7C\^%9==\5_\*W\,:9XA^+>H:'9>$]<U^V9/ ?PQ^)^LZ_?V<MZ]
MU>Z;:17%G$U]<KIL !_$Y_P26_;^N/\ @F5^WA\%_P!KQ_!DWQ#\.>")/$_A
M[QWX*L[V'3=4UWP+X\\,:IX2\1#0K^Y4VL'B#2+?5$\0:%'>-%8WVJZ1:Z;J
M%S:V%Y<7,0!^[_\ P7B_X.<-!_X*3_ *V_9$_9$^&/Q-^%'P+\7ZCHFO_''Q
M1\8H/"FF_$+Q\?#&K:=XA\,^ ](T#P3XN\;Z'H7@_3_$VF6/B/6M4F\2W^L>
M)+[2]#LH[/0-,LM6@\1 'DO_  :E_P#!,KQS^UC^WIX._:\\5^&=2L_V</V-
MM<3QZWBF_P!,F71?&OQXT^V67X:>!/#VH3QBVN]6\):G>V/Q/\136)NGT&T\
M/:!8ZBMC-XPT2X< _-7_ (+W_'[_ (:2_P""O_[>'Q!@O?MVE:%\;=4^#N@R
MQR>99_V/\!-+TOX*V\VG8)C^Q:C-X$N=8CDA)CNI=1EO@SO=.[ '^CY_P;"?
M 7_A1'_!&+]E8WEE]B\0?&9OB%\>O$/[O9]J_P"%A>.-93P;>\@,_P!H^&.B
M^!#YC?>VXC)A$98 _P Z_P#X.(?CU_PT/_P62_;D\56][]KT?P-\48/@7HL2
M2>9;64/P&\-:)\)]:@M6R1Y5SXN\*>(]5EVDHUYJ5T\>U&1: /[OO^""?['^
MI:9_P;C1_#*QL9;+QO\ MB_"+]JSQK=Q0%;6XN-2^,UEXS^'/@"\BN9#$!+?
M?#W0O -S#<RE%B\U%#F&%)7 /\LG1]0\2_"[Q_I>JMITND^,/AUXPL=0;2==
ML9X9M-\2^$=:BN3IVLZ9/]GN8I;/5-/^S:C8S&"='CEMY/*D!V@']K'_  5&
M_P"#NK0?VK_V(-8_9P_9)^"'Q0^#?Q3^.W@F7P1^T%X\^(E[X6?2? _A;Q!I
M+V'C[PG\&+OPMXDU75?%$OBF"YO/#T?CGQ7I'@B\TKPU<ZA+:>$TU_4;+4?#
MH!_'+^S-\*O^%Z_M(?L^_!$>;GXQ_&[X4?"H>06$W_%PO'F@^$?W)4AA+_Q-
M_P!V5(8/@@@@&@#_ $7O^#T_4-6\/_\ !-O]E_PAH-D=/\%WO[8/A:+4EL8Q
M;V-M)X<^"7QAC\+:(4BVJMJ]O=:I=6UH%,(?18I H>UB90#^*S_@B!_P4.^$
MO_!+_P#;R\-?M6_&;X8^+_BEX2T7X<?$7P7#I?@*70E\7:#J_C33;73[;Q)H
MUOXDU'1M(OGBLHM1T2\M+G6-,;^S==O;F&XEEMDL[H _U]/V1/VA[#]K;]F#
MX#_M/:3X+\1?#S1?CW\,/"7Q5T+P=XLFT^X\0:-H'C32X-;T%=1N-*FGT^=K
M[1[NRU*WFMI2DEI>6[LL<A>- #Z+H _QG/\ @X,^$OB7X._\%COV\=%\2Z=J
M5C_PF'QIU+XM>'[C4(Y!'J_AKXM:;IWC_2]1TRX;,=YIJ'7KC2XY+=WCM;K3
M;O3)=EW87$$ !^YW_!./_@ZW^&O["G_!*WP1^R;J'[.'C_QQ^U)\#?#WC#P=
M\(==MKCPQ;_ ?Q)INK^(]?\ $?A'Q!\1-2;Q18>/M'NO#+>(5T[6_#'ASPKK
M">*X-"CN;;Q=X9N-?F70 #^.+XP?%GQ[\>?BM\1_C7\4]?N?%/Q)^+/C?Q-\
M0_'7B*["K-J_BGQ=K%WKFM7HB0+#:PR7U[-]ELK=(K6QMA%:6D4-M!%$H!_I
M7>"/V1]>C_X,[7^#?@+1M1O?%?B_]B34OVD38:/ \FM:_-XE^(C?M4WT,4,6
MZXU*XN_#<@TJUM(EEN;O3H;73+2&5C;V[ '^=5^Q3^TG>_L=?M<_LX?M36/A
MJV\92_ 3XQ^ _B?-X2NKK[#'XFT_PKKUGJ.JZ#'J/D70TN\U72X[RRL-6-I>
M#2KZ>WU$V=V+8V\H!_3A_P %TO\ @Z!T+_@HW^SC'^R)^R'\+/BE\(/A)X[N
M]"U;X[^,?BU)X5TWQUXRM/#]_;ZUIWPUT#0?!'B?QCI6F>#O^$BL=,UO7=?N
M?$S:OXE&F6.BG1-$TAM8AUP _&C_ ((*? 3_ (:/_P""OW[!GP]FLOMVF:-\
M<=(^+^N0R1^9:-H_P$TS5?C7=PZAD&/[%J#> HM*ECF!CNGOXK'#/=(C@'ZM
M_P#!XO\ LU^-?AE_P4ZT3]H:ZT"^3X<?M-?!;P//H'BS!DTJ]\<_"73HO 'C
M+PNLG/D:IH?A^T\ ZS<V[!4DLO$]C/"TKF[6  \E_P"")'_!1[_@C/\ LW?"
M/7OA!_P4W_X)^> ?C%XTL?&FJ>)O 7[0[? ;X<_&^_OO#>L0Z>S>"?'V@^-[
MN#4+<^'=3M[^YT#5M&MM<M+_ $O5!I-]I6EOHZ7VM ']#/PZ_P"#H3]BMOCA
M\ ?V./\ @E)^P =&O?CW\>/A)\(CKWB;P;\.?V=?AQI(\=^.M#\)SZ[IGP_^
M$1\1ZMXF^PZ9JMQ)!/KMSX'72662_NX+VRLGLKT QO\ @]P^/W_"/?LQ_L9?
MLR6=[LN?BK\:_&WQEUJU@DQ*=)^"_@R+PEID5\JG<+*_U3XT37-K%+B*YO-
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M[V?:O^%A>.-93P;>\@,_VCX8Z+X$/F-][;B,F$1E@#_.O_X.(?CU_P -#_\
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MR]\7^'O#NGZAX1^)=_XGUW2]0\*VECJ_AF.\L_%_AW1/'EW/I^MRV,OA6!]
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M%+OV]OA7X1/AG4I_V>_A#XH\.?%']I/QG)IDT_AK2_ OAO4AK%GX"NK]X_L
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ME<ZM>@']Y_\ P;Q_$S0?^"9__!NG^U!_P4&U[PC#XOO+SXG?&;XQV&@3ZO\
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MXI\566O_ &%X7N_AMXZ\"^)=8TSPKXCR\MMH7C*P\;^!-9@C<27%YHR2S0Q
M'^;8_AU/'/Q*?PG\'_#GBS6X_&'CEO#WPN\(O;#7/'.KQZ_KQT[P3X<>ST6)
MQJ_BN_6[TS36MM)@<7^KRF*QB831)0!_NL?LX>#O%'P[_9X^ WP_\<7IU'QK
MX&^#'PN\'>+]0)5C?^*/#/@?0M%\07I9'D0FZU:RNYR5=U._*NP.Z@#V>@#_
M !Z?^#E']F/QK^S7_P %@/VKKGQ%X>O=+\*?'WQ7#^T1\,]<E4MI_BWP[\3+
M2*_\1ZAIL_0G2/B/;^-/#-_;/LFMKW1I'\LV=Q93W !^S/\ P2-_X.LO@?\
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M;>*-/G^[<Z7XH\"ZMH&N6,P/F)%>_9KI(;V"YMX@#^OW]G__ (/'?AA\%O\
M@G9\-/A!=_LQ?$OQ%^VA\)/@QX9^$?AW4)+CPDG[.GB'5/ _A:T\'^&/B'XC
MUZ/Q=:_$6V%U;:9I_B#Q)X%TOP*J75^;[1=+\9Z;:W-OJ]D ?QB^%/"'[2O_
M  47_:X?1?"^CZ]\9_VF_P!JCXMZYX@OH]/LV>\\0^./'NNWWB/Q5XDU/[)$
M;30O#VGS7NI^(/$&JRI;:'X6\/6=]J-Y)9:3ITCP '^S+^R3^PQX*_9:_P""
M>GPM_8&TZ^@UGPUX*^ =[\(?$VNQ68M;?Q1KWB_1]6;XE^+$TX\VL7BWQAXE
M\3^(Q8R/)) NJ?9YIYI$>9P#_%-^'_CKXC_LT?&[PG\1?!FH2>%?BS\"_B5I
M?B?PWJ:IYDOA[QY\/?$45]IUV(V*B232]<TJ*4(V%=H=K @D4 ?M)_P;K_\
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M=+>;XW>-[?2[B0_:IM#MKOX5?V!+=2?Z^RU:WM;EO^)@4E /XHO^#8CX"_\
M"^/^"SO[*8O++[9X?^#;>/\ X]>(?W?F?9/^%=>!]:?P;>\@JGD_$[5O @\Q
M\;=^4)F\H4 ?W4?\'9/QZ_X4O_P1M^+7A6VO?L6L?M&?%'X/_ O2Y8Y-ERT,
MOB5_BQXC@A4$%HK_ ,(_"G7]*O<AD^QZC,AVO)&U '\'W_!M%\!/^%^_\%G/
MV/[*[LOM>@?"?7/%_P >_$$GE^8+#_A4W@O7/$'@^]*D;1CXF?\ "#6HD8KY
M372RH6D1$< _V%: "@#_  W/^"C?[-?C7]D/]NC]J?\ 9Z\>:!?>'M5^'WQI
M\<P:/;WP).J^!M;UNZ\1?#OQ193'/VK2_%?@;5O#_B+3+C.][/4HA.L5RL\*
M ']87[!/_!9[_@W'\"_L]?#)OVE?^"77P[\'_M->!?!6@Z)XZU+PW^R)\$OB
M[HGCKQ;H.E6FGW_C3P5XH\4:E'JNF7/BRZMI=:FT[Q):Z--H%[?7.EIKNLVT
M":O>@'[N?\$F?^#@3P7_ ,%.?VW+K]D3]DK]D*?X*_LP_"SX$>./BCK7C7QO
MJ&@:)XLBM]$\3>"/"GA;1- ^&?P]BOO O@RUN=7\91FZLU\8>*)K^V%Q/9#3
M5TJX-^ 87QK_ .#KW]C7]E[]NK]I+]CC]H?X.?%W0_#OP+^(O_"NM'^.7PSF
MT'XC:1KVJ:7HNCMXN/BWP1=W'A'Q!X37P_XKFU[P_%_PCES\09]0CTN"ZEM-
M-DN)K>  _D#_ .#BG]K_ /X(]_MF^//A-\4O^"<'P[U;P_\ &G4;_P 6ZA^T
M9X\TCX87GP?\">.K#48=+D\.OJWA74AIDFL?$FUUB/6;O5?%VG^%]-;5+'49
M%\0:]XGNUTL:* ?JM_P9#_"GXDO\8_VWOC@MAJUI\'[;X9^ /A5+J<UE/'H?
MB#XDWWBI_%UM8Z?J+A;:]U7PAX8TZZGUBRMC+-IMIXWT.>]$":K8FX /Y#O^
M"A'B'Q-XL_;V_;:\3>-!,GBW7?VM?VC-3\20SDF2VUJ[^+WC"74+/!)$:65R
MTEI%"N(X(H4AC58T55 /[^?^" O_  7_ /V=_B=X7_X)S_\ !)WX:?LT_&JS
M^+^D_"<_#/QSXYN[OP+:_"S2)OA)\*/$OC3Q5\0M+N[;Q#?^)]9@\6WGA34-
M1NM+U+PYX8DTW4?$'V:"_P!9FAMTU  _C<_X.#/A+XE^#O\ P6._;QT7Q+IV
MI6/_  F'QIU+XM>'[C4(Y!'J_AKXM:;IWC_2]1TRX;,=YIJ'7KC2XY+=WCM;
MK3;O3)=EW87$$ !^YW_!./\ X.M_AK^PI_P2M\$?LFZA^SAX_P#''[4GP-\/
M>,/!WPAUVVN/#%O\!_$FFZOXCU_Q'X1\0?$34F\46'C[1[KPRWB%=.UOPQX<
M\*ZPGBN#0H[FV\7>&;C7YET  _CB^,'Q9\>_'GXK?$?XU_%/7[GQ3\2?BSXW
M\3?$/QUXBNPJS:OXI\7:Q=ZYK5Z(D"PVL,E]>S?9;*W2*UL;816EI%#;011*
M ?Z47A36;3]@'_@SK37+!UTK6OB%^Q3JTEG=H1#J5WXD_;L\<W=CI^H6\@(G
MEO\ 3=.^.%M=64Z%I;+3=%@F3R[>Q4Q '^<1^S'XD^&'@S]I+]G[QA\;;;6[
MSX->$_C9\+/$WQ8LO#6FVFL>(;WX;Z#XXT+5?&UEH>E7^H:39:CJUWX;M=2M
MK"SN]2LK>>ZEBCFN8D):@#^\[_@J5_P=_?L_^(_V</&WPA_X)Q:!\6=0^,WQ
M0\.:EX3E^-GQ!\-6W@'0/@_HNNV8LM6U_P ):8=9U/Q%XE^(D-A<7UIX=>>Q
MT+0O#6K/:>*&U'Q!_9J>'[\ _DD_X(W_ /!+GXI_\%4?VQ/ WPA\/Z!KJ? _
MPEKOA_Q5^TW\3;1'M=*\ _"N/4?.U.P36I/]'C\<^.[>QO\ PUX!TF$7>HW.
MJS7.NO8OX>\-^(]0TT _I>_X/<3=^&]5_P""9?PUT33!HGPU\,>!?VBSX8TZ
MR3R-)BN[.Y^!6@G3+>)6VD>'=!TO0X+1&#?9+;5&6)E%S*' /Q'_ .#??_@K
MY\#O^"07Q@_:)^)GQF^"WQ"^++_%SX5:#X'\)7?PVN_#,&M>'[[1/$DGB"[T
MS48_%&IZ/;+H'BB9=*;4-1L[N[OM-GT&Q:+1M46=Q;@'[7_\'LOC;Q5XEN?^
M"8$6H:'K'A?P]J_P\_:$\;+H>JF$7=AXJUZ3X#KK.AZM]DEEM9M8\+6,6F6=
MR8GFAMY=2N?LLICN79P#\4/^#??_ (*^? [_ ()!?&#]HGXF?&;X+?$+XLO\
M7/A5H/@?PE=_#:[\,P:UX?OM$\22>(+O3-1C\4:GH]LN@>*)ETIM0U&SN[N^
MTV?0;%HM&U19W%N ?V7?$'_@[6_8]^ /[8?QO_99_:3^ ?QM\ Z/\*?$^D>$
M['XH^"9O#7Q'4ZY_PBOA_4/&NC_$#P0;SPMJ_A.^\%^,+WQ!X1N/^$4OOB-_
M:$NB)=B"Q^T2PP '\D/_  <4_M?_ /!'O]LWQY\)OBE_P3@^'>K>'_C3J-_X
MMU#]HSQYI'PPO/@_X$\=6&HPZ7)X=?5O"NI#3)-8^)-KK$>LW>J^+M/\+Z:V
MJ6.HR+X@U[Q/=KI8T4 ^Q_\ @U+UOX@?LT?"_P#X*[_M\7%KJ&G_  =^ _['
M.LJNIWEC(F@>*/BSX4T_7_BAH6AZ9?3 6FI:YH.E>'_(OM*M_/N+5?B!X>^U
MI"-9T];L _D?^'/@CQ/\:/BKX#^&^A--J7C/XL?$'POX(T9[@RW5Q?\ B?QW
MXCL=!TYIV)::XFNM5U6$RDLTLKNQR7;- '^X[\3?%'@W]BK]C?Q]XRL+>&U\
M ?LG?LU>)_$6G6=P5C@B\)_ WX87NH6%E)Y?E@+_ &5X8AMMD6TL2$B 9D%
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M5_Y*?AS_ +'V3_\ JPPYR8__ ''&_P#8)B?_ $S,_P QJO[2/S(* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^AG_ (-I_P#D
M^KXK_P#9IGCK_P!7#\"*_)?&3_DF,!_V/L+_ .J_-#Z'AK_?JO\ V"5/_3U
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M\7ZND!9L1/K6E:9X)LY)0FU3.N@1*6!;R!N"J ?H;^PE_P &J?\ P3*_8O\
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MMCK'B7QU\4=:^)7PA^*.N>,/'NJW.FV-O+KYU+3DATBST[0K6Q@T71]%L--
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M?V"XCE;P=K?B;P_\,OA_J<:.CF'5K+X?:%8^/Y Q0H3IGQ*TE#"\B/&[E)$
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M ?R<V/\ P99?\$K[.]L[N7XX?MZZC%:W5O<R:???%3]GTV5]'!,DKV=X+/\
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M3_%-A%>ZSJM_<_9+OQMJ=O;I+';VB6T$*1T >%?"3_@RD_83\+>)-.UCXO\
M[3W[2OQ:T6PN8+J;PGH5OX ^&&FZSY,RR-I^LZE;Z#XOU[^R[N,-!=IH6I:!
MJVQR]EK-C,%DH _J_P#V:/V7_@#^QW\'_#7P%_9G^%WAKX0_";PE]JDT?PEX
M9BNFB:]OY?.U'6-8U;4[K4-=\2>(-4F"RZIXA\1:GJFMZBR1?;+^<0Q[ #\<
M_P#@JQ_P;E?L4_\ !5/XF6WQ\\8>)/B3\"OV@O[#TWPWK_Q'^%T^A7FG^/M)
MT.U6P\.CQ_X.\3:9J%CJVI^'=/CCTO2]=T/4/#.LRZ/#9Z3K%[JUAI6AV^E
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M_P"TQ\'?"&KZC/?P?#>UOO WCG2?#45Q.DG]C^&?$'B?PRWBA=(M(O-@L?\
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MK3+2*22."%'="R11J0B@'=4 ?C5_P54_X(9?L4_\%;$\*>(OCI:^-?AY\9O
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M1V\96.C^"/@A\.=0F\5:3I5UJ5IH-W?ZS>:=I<NIS:I%I;:U9Z/J>E@']&%
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M.ZO%TO1X9IK/0--TK3W6R0 ^,?\ @K!_P0Z_8\_X*ZV7@G6/CA/X[^'7Q?\
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MX)Y?'GXJ^(/BA\'?B?\ &;]EJU\6ZVVMZU\+O ]OX-\5_"S2)+EA)J=O\/\
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MES&DZ@']-D,,-M#%;V\4<$$$<<,$$,:Q0PPQ*$BBBB0!(XXT54CC0!44!5
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M[%J6CZFO@_X;Z#X6U;4VL[^"WN9=,\3>,O$.@7Y@CM[_ $>YLWN+:< _J9H
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MYB-[<>!_&AL-1-O:7S06\FI^&M>T[7_!NLS6UE<ZSX<U&YT_3Y;4 _F8O/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _H9_P"#:?\ Y/J^*_\
MV:9XZ_\ 5P_ BOR7QD_Y)C ?]C["_P#JOS0^AX:_WZK_ -@E3_T]0/[?Z_FD
M^W"@#\>?^"VG_)JO@#_LX+PK_P"JY^*]?SW])/\ Y(;*O^RLP/\ ZI\]/Z*^
MC+_R7F;?]DCC_P#U<Y"?RZU_$9_<P4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % ']17_!$O_DU7Q__ -G!>*O_ %7/PHK^W/HV
M?\D-FO\ V5F._P#5/D1_#/TFO^2\RG_LD<!_ZN<^/V&K^A#^=0H _$+_ (*5
M?\ET\*?]DFT+_P!3#QW7^:?TR?\ DYV1?]D'E?\ ZT/%!_=?T8O^2"S?_LK\
M?_ZIL@/STK^2S^C0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * /Z;_ (!_\D+^"W_9)OAS_P"H?H]?[2>%G_)L?#C_ +(/A#_U
MGLN/\MO$'_DO>-_^ROXE_P#5SC3UFOO#Y * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MMA_M=:AK/B'5]2US5[^Z7X/27-]J>K7DU_?WES(/ARHDGN;JXFFF<*H:1V8
M9 H _KS^$_PV\-_!KX6?#3X0>#H9+?PA\*O '@WX;>%8)?+\V#PWX&\.Z;X8
MT.&7R8XH?,CTS2[5'\J*./<I\N-$PJ@'?T % !0 4 % !0 4 % !0 4 0W,K
MP6]Q-';RW<D,,LL=K 85GN7C1G2WA:XEM[<2S,!'&9YX(0[ RRQH&=0#_'=^
M-'_!&7_@MU\;OV@OBUXD\5?L!?M%R>,/BQ\6?'_Q3\1LVGZ7-X)?Q9X\\3ZG
MXAUN^3QRVO\ _" W#R7FJS(-237BMS"-ZSF($J ?TI_\$/?^#47QK\*?BCX(
M_:R_X*=Z?X0:^\#W5GXI^&O[)FE:QI_C..#QGI]U#=:'XC^.'B/19KWP?J-I
MX=N8!J>G?#SPMJOB?2-:U'^S)O%FNC3;'5?!VK@']ZM !0 4 % !0 4 '^?\
M]?Y?G0!_&;X@_P"#+']BCQ/KVM^)=:_;#_:ZU#6?$.KZEKFKW]TOP>DN;[4]
M6O)K^_O+F0?#E1)/<W5Q--,X50TCLP R!0!_7G\)_AMX;^#7PL^&GP@\'0R6
M_A#X5> /!OPV\*P2^7YL'AOP-X=TWPQH<,ODQQ0^9'IFEVJ/Y44<>Y3Y<:)A
M5 ._H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * &N7".8U5I
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M\#O@/\)_A5,T&PI<W_@7P-H?AS4[]I$^6:?4M1T^ZU"ZN<DW-S<RW#,S2LS
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M;_[N'_$+M_U?)_YK-_\ E!4?\1L_ZIK_ ,S/_P""0_U7_P"H[_RV_P#NX?\
M$+M_U?)_YK-_^4%1_P 1L_ZIK_S,_P#X)#_5?_J._P#+;_[N'_$+M_U?)_YK
M-_\ E!4?\1L_ZIK_ ,S/_P""0_U7_P"H[_RV_P#NX?\ $+M_U?)_YK-_^4%1
M_P 1L_ZIK_S,_P#X)#_5?_J._P#+;_[N'_$+M_U?)_YK-_\ E!4?\1L_ZIK_
M ,S/_P""0_U7_P"H[_RV_P#NX?\ $+M_U?)_YK-_^4%1_P 1L_ZIK_S,_P#X
M)#_5?_J._P#+;_[N'_$+M_U?)_YK-_\ E!4?\1L_ZIK_ ,S/_P""0_U7_P"H
M[_RV_P#NX?\ $+M_U?)_YK-_^4%1_P 1L_ZIK_S,_P#X)#_5?_J._P#+;_[N
M'_$+M_U?)_YK-_\ E!4?\1L_ZIK_ ,S/_P""0_U7_P"H[_RV_P#NX?\ $+M_
MU?)_YK-_^4%1_P 1L_ZIK_S,_P#X)#_5?_J._P#+;_[N'_$+M_U?)_YK-_\
ME!4?\1L_ZIK_ ,S/_P""0_U7_P"H[_RV_P#NX?\ $+M_U?)_YK-_^4%1_P 1
ML_ZIK_S,_P#X)#_5?_J._P#+;_[N'_$+M_U?)_YK-_\ E!4?\1L_ZIK_ ,S/
M_P""0_U7_P"H[_RV_P#NX?\ $+M_U?)_YK-_^4%1_P 1L_ZIK_S,_P#X)#_5
M?_J._P#+;_[N'_$+M_U?)_YK-_\ E!4?\1L_ZIK_ ,S/_P""0_U7_P"H[_RV
M_P#NX?\ $+M_U?)_YK-_^4%1_P 1L_ZIK_S,_P#X)#_5?_J._P#+;_[N'_$+
MM_U?)_YK-_\ E!4?\1L_ZIK_ ,S/_P""0_U7_P"H[_RV_P#NX?\ $+M_U?)_
MYK-_^4%1_P 1L_ZIK_S,_P#X)#_5?_J._P#+;_[N'_$+M_U?)_YK-_\ E!4?
M\1L_ZIK_ ,S/_P""0_U7_P"H[_RV_P#NX?\ $+M_U?)_YK-_^4%1_P 1L_ZI
MK_S,_P#X)#_5?_J._P#+;_[N'_$+M_U?)_YK-_\ E!4?\1L_ZIK_ ,S/_P""
M0_U7_P"H[_RV_P#NX?\ $+M_U?)_YK-_^4%1_P 1L_ZIK_S,_P#X)#_5?_J.
M_P#+;_[N'_$+M_U?)_YK-_\ E!4?\1L_ZIK_ ,S/_P""0_U7_P"H[_RV_P#N
MX?\ $+M_U?)_YK-_^4%1_P 1L_ZIK_S,_P#X)#_5?_J._P#+;_[N'_$+M_U?
M)_YK-_\ E!4?\1L_ZIK_ ,S/_P""0_U7_P"H[_RV_P#NX?\ $+M_U?)_YK-_
M^4%1_P 1L_ZIK_S,_P#X)#_5?_J._P#+;_[N'_$+M_U?)_YK-_\ E!4?\1L_
MZIK_ ,S/_P""0_U7_P"H[_RV_P#NX?\ $+M_U?)_YK-_^4%1_P 1L_ZIK_S,
M_P#X)#_5?_J._P#+;_[N'_$+M_U?)_YK-_\ E!4?\1L_ZIK_ ,S/_P""0_U7
M_P"H[_RV_P#NX?\ $+M_U?)_YK-_^4%1_P 1L_ZIK_S,_P#X)#_5?_J._P#+
M;_[N'_$+M_U?)_YK-_\ E!4?\1L_ZIK_ ,S/_P""0_U7_P"H[_RV_P#NX?\
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MO_V=[/V^,P&+]O[;ZGCN;E^H^S]E[*/-[7G]HN3DE^77_#B?_JZ;_P PA_\
MC>K\1_XE@_ZKC_S6?_QA/W/_ (FG_P"J$_\ -G__ !>#_AQ/_P!73?\ F$/_
M ,;U'_$L'_5<?^:S_P#C"'_$T_\ U0G_ )L__P"+P?\ #B?_ *NF_P#,(?\
MXWJ/^)8/^JX_\UG_ /&$/^)I_P#JA/\ S9__ ,7@_P"'$_\ U=-_YA#_ /&]
M1_Q+!_U7'_FL_P#XPA_Q-/\ ]4)_YL__ .+P?\.)_P#JZ;_S"'_XWJ/^)8/^
MJX_\UG_\80_XFG_ZH3_S9_\ \7@_X<3_ /5TW_F$/_QO4?\ $L'_ %7'_FL_
M_C"'_$T__5"?^;/_ /B\'_#B?_JZ;_S"'_XWJ/\ B6#_ *KC_P UG_\ &$/^
M)I_^J$_\V?\ _%X/^'$__5TW_F$/_P ;U'_$L'_5<?\ FL__ (PA_P 33_\
M5"?^;/\ _B\'_#B?_JZ;_P PA_\ C>H_XE@_ZKC_ ,UG_P#&$/\ B:?_ *H3
M_P V?_\ %X/^'$__ %=-_P"80_\ QO4?\2P?]5Q_YK/_ .,(?\33_P#5"?\
MFS__ (O!_P .)_\ JZ;_ ,PA_P#C>H_XE@_ZKC_S6?\ \80_XFG_ .J$_P#-
MG_\ Q>#_ (<3_P#5TW_F$/\ \;U'_$L'_5<?^:S_ /C"'_$T_P#U0G_FS_\
MXO!_PXG_ .KIO_,(?_C>H_XE@_ZKC_S6?_QA#_B:?_JA/_-G_P#Q>#_AQ/\
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M/_QO4?\ $L'_ %7'_FL__C"'_$T__5"?^;/_ /B\'_#B?_JZ;_S"'_XWJ/\
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M_P",(?\ $T__ %0G_FS_ /XO!_PXG_ZNF_\ ,(?_ (WJ/^)8/^JX_P#-9_\
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M #3/_P :P_XFJ_ZH/_S:?_Q;#_AUY_U7'_S&G_XP:/\ B27_ *N;_P":9_\
MC6'_ !-5_P!4'_YM/_XMA_PZ\_ZKC_YC3_\ &#1_Q)+_ -7-_P#-,_\ QK#_
M (FJ_P"J#_\ -I__ !;#_AUY_P!5Q_\ ,:?_ (P:/^))?^KF_P#FF?\ XUA_
MQ-5_U0?_ )M/_P"+8?\ #KS_ *KC_P"8T_\ Q@T?\22_]7-_\TS_ /&L/^)J
MO^J#_P#-I_\ Q;#_ (=>?]5Q_P#,:?\ XP:/^))?^KF_^:9_^-8?\35?]4'_
M .;3_P#BV'_#KS_JN/\ YC3_ /&#1_Q)+_U<W_S3/_QK#_B:K_J@_P#S:?\
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M_BV'_#KS_JN/_F-/_P 8-'_$DO\ U<W_ ,TS_P#&L/\ B:K_ *H/_P VG_\
M%L/^'7G_ %7'_P QI_\ C!H_XDE_ZN;_ .:9_P#C6'_$U7_5!_\ FT__ (MA
M_P .O/\ JN/_ )C3_P#&#1_Q)+_U<W_S3/\ \:P_XFJ_ZH/_ ,VG_P#%L/\
MAUY_U7'_ ,QI_P#C!H_XDE_ZN;_YIG_XUA_Q-5_U0?\ YM/_ .+8?\.O/^JX
M_P#F-/\ \8-'_$DO_5S?_-,__&L/^)JO^J#_ /-I_P#Q;#_AUY_U7'_S&G_X
MP:/^))?^KF_^:9_^-8?\35?]4'_YM/\ ^+8?\.O/^JX_^8T__&#1_P 22_\
M5S?_ #3/_P :P_XFJ_ZH/_S:?_Q;#_AUY_U7'_S&G_XP:/\ B27_ *N;_P":
M9_\ C6'_ !-5_P!4'_YM/_XMA_PZ\_ZKC_YC3_\ &#1_Q)+_ -7-_P#-,_\
MQK#_ (FJ_P"J#_\ -I__ !;#_AUY_P!5Q_\ ,:?_ (P:/^))?^KF_P#FF?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__T?[^* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H __2_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#_]/^_B@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * /_U/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0$$ @@@C((Y!!Z$'N
M"* %H * "@ H * "@ H * "@ H * "@ H * "@ H * "@! 00"""",@CD$'H
M0>X(H 6@ H * "@ H * "@ H * "@! 0<X(.#@X[' .#Z'!!^A![B@!: "@
MH * /*O"_P =O@AXW\7:G\/_  7\9/A5XO\ 'FB?VG_;/@GPO\0_".O^+M(_
ML6\33]8_M/PWI6L7FLV']DW\D=CJ?VJRA^P7CI;77E3,$H ]5H * "@ H *
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MDC(R "1W .<$CT)!QZX/I0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MV5PA#P7=G<302H0T<C*0: -G(R1D9 !([@'."1Z$@X]<'TH 6@ H * "@ H
M* "@ H * /*?$_QW^!_@CQ=IOP_\:?&7X4^$?'FLG3!H_@GQ/\0_".@>+M5.
MM7;6&CC3?#>JZS::S?'5KY'L],^RV,OV^[5K>U\Z92E 'JU !0 4 % !0 4
M<MXU\<^"?AKX6UGQS\1O&'A;P!X*\.VOV[Q!XP\:^(-)\*^%M"LO,2+[9K/B
M#7;NQTG3+7S98X_M%]=PP^9(B;PSH& /F/X2?\%#_P!@?X^?$*V^$WP/_;6_
M93^+_P 4+XZC_9GP]^&OQ_\ A9XV\9:RND:?<ZOJTFA>'/#OBG4-5UV'2M*L
M[S4=3GT>UOHM/L;.ZNKN2&&VG= #[%H * "@ H * "@ H * "@ H * "@ H
M* "@"*>>&VAFN;F:*WM[>*2>XGGD2*&"&)#)+--*Y5(XHXU9Y)'941%+,0 3
M0!Y?\.OCK\$/C!<:I:?"3XR?"KXI76APVUQK5M\.OB'X1\;W&CV]Z\L5G/JD
M/AG6-3DT^&[DMYX[:6[6)+AX)4B9FB<4 >JT % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 >8_$3XV_!CX0R:3%\6/BY\,?A?+KR7DFAQ?$3Q]X5\%2:S'IS6JZ
MA)I*>)-7TQM12P:]LUO&LQ,MJUW:B<H9X@P!Z1;W$%W!!=6L\-S:W,,=Q;7-
MO(DT%Q!,@DAG@FC+1RPRQLLD<D;,CHP925(- $U !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ><?%/XQ_"+X%^$Y_'OQM^*GPX^
M#O@:UN8+*Z\:?%/QQX9^'OA.VO+H2-;6D_B+Q;J>DZ/#<W"PRF""2\6641R&
M-2$:@#Q_X#?MS?L7?M2^(-7\)?LV?M9?LX_'OQ9H&EW&N:WX5^$/QH^'GQ"\
M3:7H-K?V>ESZ_?:!X6\0ZGJUOH$>I:CIU@=<DLUTHWE_96ZWC37=NLH!]3T
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 ("#T(/)''/(."/J""#Z'CM0 M !0 4 % !0 4 % !0
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M ,"?$SP];>+OAOXU\)?$'PI>S75O9^)_!'B31_%?AZ[N+&=[6]@MM:T&]O\
M39YK.YC>WNHHKEWMYT>&54D5EH ZS(R!D9() [D#&2!Z D9],CUH 6@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * $)
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MY=I%?2OBC:Q_*[3/<>7#M*2AP#^V[]BGX&0_LQ_L??LN?L[Q6\=O+\$_V?\
MX1_#'4!$%Q<:UX-\"Z%HFO7\I3*R7.IZU:7^HW<JG$UU=32\[Z /IR@ H *
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M]LCQCIFM>.=5^,'B;QYX-\#:/XOF\=:=\(/ &J^%?!.BV7@.+Q$5.F"5M?\
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M%_PBWARU,^G7>BP^(DNHKB:  _?^@ H * "@ H _C4_X+U_\$5O^"H_[??\
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MZ)H.I336VG^)/%FB:#=R>"_"UY<6[+<6]OXH\6OHGA^6>W/GQ+J1DA#2*BT
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MIVC:3:0:?I6DV-IIFF6%L@CMK+3["WCM;.TMXQQ'!;6\4<,2#A8T51TH O4
M?C'_ ,%@?^"VO[.__!'7PQ\)[GXN?#WXE_%GQ[\<T\>/\-? _P .F\,65LT7
MP[7PH->U'QMXC\0ZU9OX8T:6?QEHUGIMWIF@^*;Z^N1?"+2_)T^YE4 _3K]G
M?XI:E\<O@!\#?C7K'@VY^'.K?&#X0?#7XHZE\/KW5DUZ]\#7WQ \&:-XLNO!
M]YK<>G:1'J]WX:FU9]&NM2CTO3H[Z>SDN8[*V2184 /8J "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@!"0 22  "22<  <DDG@ #J3_2@#_+@
MN])^,'_!TE_P7%\>_#K5_B]XB\+?LC?"F7XCZMX2O- A^U6?PY_98^&WBBT\
M,:'JG@SP]?O+H2_$WXT:[K7A6XUG7]774);34O%EQJ$UOK7AKP1I'A10#^T[
M_@EY_P $ /V0_P#@DQ\=_B-\=OV<_B#\<_&6L?$CX2V_PEOM-^,^M> _$;Z+
MI9\5:'XLUB]T75?!OP_\ 21_VYJ'ACP\UY8WEE>1Q2Z=YMO/%%)%:P '[I4
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M>-?&G@V>WUBS&G>![7P$OBKPKH]GXGL[+6-&CE^(WB'4K-;7R+^_U1Y(YK4
M_J[H * "@ H * /\T+_@B+_QL(_X.A?V@/VM)/\ B=^%/ 'B_P#:[_:3T6>7
M]_9)X5O=5O?@A\([8S',<LVC:3\3O"=SI95@[RZ E[#&([601 '^E[0 4 %
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M@2R<_,;;4+OXRZ$EXZYBEN-$@C!\RSD50#^Y6@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H _C4_P""]?\ P16_X*C_ +??
M_!0K]G[]H;]D;XVZ)HOPH\+>"O!7AG2IM=^*VL_#V\_9K\:^'O$'BG4?$'C_
M $30=)LWN=7MM=M-4TR_37O"9U3QU?:K]I\.ZGIUIX;T?1;Z@#^R&QAN;>RL
M[>\NS?W<%K;PW5\T,=LU[<Q1(D]V;>']S ;F4-,88OW<1?9'\BB@"U0 4 %
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M !9K_C/6=7U>/2;:STU=0U'7?$FIW=R;.U@A:24LL2;MM 'UO0 4 % !0 4
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MM",+:TNIK>>SOOB3X/\ %WA?PCK,\4L+V4BZ5X5T:Z>[@N(XHDE!B@ />O\
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M^I6OA>TU+4M/TVXO]4U_6+W3M)_L?PWH&OZS=:4+C3?[)G /Y0=+_P"#G_\
MX+L?M/0Z[\3OV*/^"6_AKQ=\#O#^MZA#+JOAS]G+]JG]H^&QCMY"R:#XF^)/
MP\\6^$/#-UJ=A9302:HND^'- O=RO??9K&SW0J ?T>_\$"_^"K_[2'_!5GX.
M_'WQA^TA^SQX.^!GBGX#?$_1OA5<WO@FY\8Z?I?BCQ5-H=SKOBS1KGP)XX_M
M77_!.I^";>?PTE];7GB_Q#-?2>(MDUMH[Z<%OP#]]* //_BSX_T[X4?"OXE_
M%+5_+_LGX:_#_P 9>/\ 5/.?RH?[.\'>'-2\17OFR#)CC^S:;+O<#Y%RW.*
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M+OAK4/$GC3Q#XFBTW3/#MI#\2+*VL=0LET.P\2:EJ$NFNUU8SV>FI*ODWH-
M'E?_  5V_P"#HG]F;_@GAXZ\5_LW_ ;P1/\ M4_M4^$[U-$\7Z39ZS_8'P=^
M%VO%8VN="\8>,K.+4=5\2^,M+,T4>H^"?!VF2QZ??"\T3Q'XM\->(-/N=)0
M_&"[_P"#B7_@Y<N/#>I_&*P_X)5>'[/X0Z39WVLW>NS?L-?MHW/@VQ\/64,E
M]<ZSJOBQOBO;AM-T[3XVFU+7X;[3]'@1);B9;2/Y$ /V7_X-[?\ @O)^TO\
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M1!-<>']%L=!UWQ1XB2!9DTS2M"ND\10 '\U<G_!SY_P7WN/!<G[3EE_P3(\
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MV7@KX>>'9[NR&KZU<QQM-=W5W=Z?H.@:>LVL>)-8T?28)[U0#^,2\_X.IO\
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MKS2M#E2<67B[XI^*I[75H_A_X5U"Y@:UT?&BZ[XF\0SB671?#=UI-EJVKZ:
M?S$WO_!T)_P7LU/P5=?M,^&_^"97P]M?V4]+L#K-Y\0KG]F#]K;6_AU#X;G
MG36]2^-EK\2M+\)"U@MRFW7X+>PT-//B>ZM)//MUH _J&_X(A?\ !;+X9_\
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MM5O[.TG /X@OVA/^#OG]H[XT?%S4?A-_P20_8/U#XTP:>LC6/B7XJ> _B?\
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M1M'6[<SS+M /]!3_ ()X_P#!;SXS_%']BW]LK]N'_@I=^S9;?L6_"G]EW4=
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ME?7+)''&BXCAB7?<7=S)#:6D4UU/#"X!_#[^T+_P=\?'CXP_&6_^#7_!(_\
M80U;X_M8_P!J)I?B?XD^"OB?\1O&/CJWLKN*R_X2'P[\"/@KJ6C^)]"\-;WA
MN+.ZU[Q?<:Q>V^I6"ZQX?\*7Z3::X!3_ &2/^#EO_@KQ9_ML?LX?LB_MW_\
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MX$\/?$3X@:W?67B'7](MM>\9:/X@T70O"6CV&K>)O&5YI$D6D0:7IS7NMZ:
M?GKXN_X.O?\ @L?^RK\5_!S?MQ?\$X?AW\*_AOXT>#6=-^'OB_X+_M(_L]?$
M+Q!X.L[FWBU:Z\ ^,OBCXUUW3[Z^BBN8XKS4KKP/X@TVUU&2VBEL+!9&MZ /
M[VOV9?VA?AW^UE^SY\'/VE?A/>7-[\._C;\/O#7Q$\*M?1+;ZG:6'B+3HKR3
M2-8MD>5+37-"O&N=%UNT269+35M/O;=)I4B$C@'N= 'X?_\ !>O_ (*F_%?_
M ()'?LG_  R_:,^%/PF\#?%R_P#&W[0GAWX,:SI/CW4_$&FZ7I%AK_PY^)WC
M6#5+8^'9K:[DO&NOA^EDK3W"VL<5Q*K12S2P-$ ??G_!/G]IO5/VSOV)?V8?
MVJ-=T#2?"VO?';X/^$OB%KWAK09[NZT70M<UFRSK&E:5<7\DM]-86.I175O;
M/=RO<F)%\YV?<6 /P=_X+S_\'&][_P $G_C5\*_V<O@5\*_A[\<?BUK?@R[^
M(7Q=M?'&N:]I^D_#OP]J]W%9?#O28AX8N8)YO$WB5;'Q%KFH6-_/ ^E>'HO#
M-^MK<P^)[6XMP#^B;]D[XT3_ +2/[+/[-/[1%UIMEH]S\>O@!\'/C/<Z1ILL
MT^G:5<?%'X=^'/&\VFV$]R6N9K*PEUQK6UEN&:=X8D:8F0L: /YO_P!O'_@X
M7^.GPN_X*Q>!O^"6'["?[/7PJ_:$\=ZKK7PZ^'/C/Q3X[\0>+K*UT'XK^-7;
M6_$.E0GPE.MK%X5^&?@.]TC7O'>MW NI]%O+7Q=8WMK;'PS<>> ?U@4 ?Y]?
M_!SQ^WG\3OV]?VN?@[_P0^_8H>X\97T?Q+\)V?QN@T&[86/C3X[ZK+%)X2^&
M^J:E:&2"'P;\%])NI?&GQ'O+N272=*\42&;78-,O_A3/<, ?TK:=\._AQ_P;
M[?\ !%CQZWPCT/0?&6I?LL?!76?B#KNH:XEQI-G\:/C]KYT^UU/Q+XHFL775
M(;/Q?X[U+3-)TZU%W-?:%X/MO#_A>RO3!HMFZ@'\_7A/_@\DUZ;]C#Q-\2O%
M'[-?PYU;]L/Q5\;-5^%'P+^!O@3Q%XON/"W_  C6D^#/!>M7WQ1^)LETVH>(
MUTQ/$?C&V\.>&?#&@7%GJGQ U*UU/3M,O]$CT+6M:M0#]$/^#?\ _P""S_[>
MO_!23XO_ +7?A+]MGX3_  .^"O@O]G+X=^#/&ES<^%_A]\3/A;XB\.:OXZUG
M73IMEXJ;XF?$GQ5;0^%XO"_A/Q-JB7-WIVG7R?8!>3ZO/9K*B@'R3^WG_P '
M>%MHGQKN_P!F[_@E7^S=;_M=>-;/7[KPY;?%;Q/9^,_$7@GQUK5A#,;RQ^$'
MPL^&L^F>/OB)I"RQ3&#Q;)XC\,VVH1Z;=W6AZ)K>@WFG>))0#Y$T/_@["_X*
MI?LE?%/P5H/_  4]_P""<.B^ ? ?B]I-5&EVGPA^.W[,WQ8O/#$DL45WK?@>
M/XT^*_%?ASQ;#X?>YA)TU]*TY+V94T?4?%&C75P=2@ /Z$_^"J'_  6;^*_[
M+O[*W['W[2G_  3^_9LU/]M33/VMC)XLT&:S\&_%'6M&T/X6?\(7I/B6RUO5
M[?P#IL^JZ!X@U.]\3Z%8VNE>(#9RHUEXCM)+5KW2[E;4 _SMOV=/^"B'[4OB
M'_@KKXA_X*F^ /V9!^T7\;A\1OBG\:+KX,>'_#?Q$\8>%_#L/Q!\+^)?A]H\
M1'@^._\ %%MHOP[LO%NDVOAO4[]G5K[1M'6[<SS+M /]&W_@D!_P50_:K_;9
M_9[_ &J/VAOVW/V5+7]D7PM\ +Z$Z#;_ -C_ !&\/ZCXGT30O!&L>./B)K-U
MIGQ+MK2[-CH&G1Z EA?Z>39W,]YJ5O.R2666 /F7_@@)_P %VOVB_P#@L1\6
MOVBO"WQ%_9W^%?PG^'OP,\ >$O$)\2^!-=\7ZKJD_BOQSXEO].\->']1CU^X
MN+$VMYHGASQ=?FX@6VG^TZ.@CB:&641 'XW?\' __!>?]M31/^&[OV ++]CJ
M3P%^S5XF\0:Y^S/HG[3GBGPS\6-"U'Q38^3;KXM/A_5=3M;#P#K'_"6P:)XS
MT_1ETZ6ZAU#P>\NJVOVQ(9+E@#\E?^"+'_!5K]O?_@F+^SWX]\*_LS?\$Y-7
M_:-\,?''XER_$:Y^+=Y\/?CEJL.J1:+HFG>![+PSHVI^ ]+DT'4=)\.ZIHGB
M*8317$]S%K.M:S8SE&M0B@'^B9^W)_P5*_9[_P""9/[+O@3X]?MM:H_A;QKX
MRT32+'2?@S\.8D\4>.?&WQ,7PY9ZMXL\)_#W2]0OM*CNM'\-WT\D&H^+/$>I
M:)X<T>VGTE-9UBVU+6]'L=2 /Y%)/^#IS_@LI^UWXHUZ?_@G+_P3"T?Q5\-;
M'5+W3[:>U^"_[17[3_BRQ%L(YX%\0^*_A?KO@7P3H^H-8S6]U?:;-X;G%HUW
M#%%?W$?EW%T 9/PV_P"#KO\ X*Z>"_VEOA_^R[^U+^P!\#_#_P 4O&WCGP!X
M"M_AMK/P_P#VA/V<_B=%J/Q$U[3="\.S7VF?$/QMX[N+9-4FU2VET^?_ (0Z
M.VNX726V6>-@S ']?O\ P6&_;^U7_@F5^P%\8/VNO#/A3PYX\\:^"=6^&OA[
MP5X)\67NHZ?H/B77/'7Q'\+^%;RVO[K298-2C72_#&I>(?$4:VD@>:714A<K
M"[NH!_/MHO\ P=N:'H?[!WPF^+_C;]GS0_'O[<_[0OC#Q]HWP>_92^#.O^(;
MC28?!GAWQ3>>!/#WQ$^(&MWUEXAU_2+;7O&6C^(-%T+PEH]AJWB;QE>:1)%I
M$&EZ<U[K>F@'YZ^+O^#KW_@L?^RK\5_!S?MQ?\$X?AW\*_AOXT>#6=-^'OB_
MX+_M(_L]?$+Q!X.L[FWBU:Z\ ^,OBCXUUW3[Z^BBN8XKS4KKP/X@TVUU&2VB
MEL+!9&MZ /[VOV9?VA?AW^UE^SY\'/VE?A/>7-[\._C;\/O#7Q$\*M?1+;ZG
M:6'B+3HKR32-8MD>5+37-"O&N=%UNT269+35M/O;=)I4B$C@'^=M_P %'/\
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M#USPWH/@YM'B\-7EJ\O]MWLGC%+YKT2C.CV:V@4_:0X!\I_MN?\ !SI\<_\
MA;=Q^R=_P2;_ &.;W]MC]HCP+HMJWQM\8Z%X*^*GQA^&_A+QA96T5IXT\+>
M_ OPA_LOQEXZT?PEXCFDT:^^)-]XE\/>%SJ-A-::19^);"YM]<4 X3_@D#_P
M=(?&S]I/]L73?V'O^"CGP,^&OP.\=^*[[Q%X3\-?$'P9H_COX8IX.^(_A'3=
M7U*_\#?&+X?_ !+\2>+[_1+S6!I%YI,6M0:MX>7P]XDM[72M7\-FSU:XU30
M _:^_P"#IG]H/XE_''QI^SY_P10_8KUK]M.;X<F\3Q3\:9OAC\8?C!HNNQ6[
MM9W&L>!/A5\')=!\2P>#K:^CFBTKQ]XM\26UEXEE0O8>%AIALM2U4 ZS_@B9
M_P '.WQ>_;:_:[L/V%/V[/@;\/?A)\8/&3>*-$^'/C+X9Z5XX\&6*_$#P-IF
MIZMKOPV^(_P]\?\ B'QAJNA>(K_3]#US[%JUOX@TV&V\0Z6GA>Y\+K=:M;7-
MH ?UO?'+XX_"?]FKX1^/OCM\<O'&B_#CX3_##P]>>*/&WC+Q!,\6GZ1I-IL0
M!(H(Y[W4M3U"[EMM,T31-+M;W6=>UF]L-%T6POM5O[.TG /X@OVA/^#OG]H[
MXT?%S4?A-_P20_8/U#XTP:>LC6/B7XJ> _B?\4?'?BZT@NX[.YUK2O@?\#-?
MT?5O#6BF::V33+O6/&FLWMR+RT?5M%T2\=M)H ^;?B7_ ,'1?_!>S]D2Y\-W
M7[8W_!.OX4?"WP]XJN[B/0I/BU^S)^U-\#;GQ*UI''<7NG>%?$?BKXKQ:)?7
M5C!/"]W%!HVL75BCQF\B4L2X!_;)^Q%^VCK?[1/_  3G^$'[=WQO\":5\&Y?
M'7P/UCX[>+?"&BZU>>(=)\-^#;"+7M=T_4K+5]3L=)N[F#5O VF:=XG"7-M'
M]D.IM9"ZO([9+ZX /\O_ /X)&?\ !4'X7?L3?MN?M9?\%*_C[X4U?XL_&'Q)
MX&^*+_!SX0Z#>_V;J7CGX]?M"_$S2M=UK5M2\77.GZG!X8\(^'_"EMX[@\1Z
M\=*U;5&E\1Z39Z7HNIWE]]G4 _;/XD?\'47_  6__9ZU/PK\4OVCO^":/P[^
M$_P \>7MNG@VW^(WP _:E^$Z>*M.G6;5+:T\+?%SQIXZ_L#5O$5WHL,MPE[:
M^%+^QFL475[?PR+1LN ?VU_\$YOV]_A#_P %+/V2OAM^UI\&;?4M&T#QLNJZ
M1XD\%:]<6-QXE^'?CSPQ?R:5XJ\%Z_)ITLEM+<6%W'%J&DWZI:_VYX7U30?$
M2V-C%J\=K$ ?<= %2_O[+2[&]U/4KNVT_3M.M+B_U"_O9X[:SLK*TA>XNKN[
MN9F2&WMK:"-YIYY72.*)'DD944F@#_-D\$V/BW_@Z=_X+G:IXJ\1+K5I_P $
M\/V2T@N(=%GDN;"/_A1/ASQ)*OAWP\]O')$;+X@?M1>,;6YU3Q+/%)!K&@^!
M4U6RMM2O7^'&AI. ?TB?\%O?^"R'[3__  2?\7_!GX;_ +*O[$5M\<_A])\%
M]<^(7Q!\77/@[XG1_#GX5>&/#6ISZ#X?T:VU?X>:?%X8\/V>C:)X;UW4];M=
M4O+>+0]"CT6Z\JRT^597 /X%O^"6W[>W[6O[-7[=/QA_X* ?!?\ 9.U/]KWX
MK^*-.^)<7BO3[?PE\3/$VB^#?$_QX\6Q>*=6\67%S\/;*_U&PU;4H-(\5:)I
M4.J3QQ7VGZIK<BF::R)4 _TD/V4?^"MNHI_P2S/_  4D_P""FO@'1/V,+./7
MO'MM_P *_%CXPMO$.HZ9X=\4:AX0\(Z1HO@WQK%;>,-0\>^.]:T35T\/^&XX
M?^)AIPLM>66UT)[R_M #^:[QC_P=E?\ !2S]K3XG^)_!W_!*K_@FW'X]\*^'
MQ/-M\0?##XT?M+_%E]"^T/%IOB?Q!X>^!NO>%?#?P]^WI'F?2;V7QQI]G.S6
MD'B?4BBW#@'T#^P/_P ';?Q&U#]IG1_V4_\ @JU^R]HG[,GB;7_$V@> I?B)
MX.T+QY\.8?A?XSURZM;2P3XT_"GXP:_K7B;PMX7O#J5A<:EXIM_$GF^%K8KJ
M%_X<O-$NKC4]& /[2_BQ\0-.^%'PK^)?Q3U<Q?V1\-OA_P",OB!J9ED\N'^S
MO!WAS4O$5Z991GRXOLVG2[Y /E3+#.* /X>/V=O^#S*\UCX(_M._%']I7]G'
MX:Z+XR^'-M\,=#_9[^%/PL\7^)[?6OB[X_\ 'TWCJ35(_$6I>)EUZ/PUX$\%
MZ/X/75_$OBJUL+J6QDO]+T6WL-1U?Q%H]O0!])_\$3?^"]__  4P_P""BW_!
M1"#]F?\ :0_9X^!GPD^$FH?!;Q_\:9TT#X6_&3P;X\TSPWX;?0=&\,ZAHFM^
M.?B;K6G:OI6J>)?%&A6>IZA/X9GMKY;F0Z5+I9,<2@'J'Q._X.7M:^%__!9O
MXA_\$^?%/PY^"GAC]E7X2>+?%6E?$G]HSQ-XC\76_BOPSX:^&/P(O?BG\4-:
MET^QEN]&N]0T;Q%H/B/P]HNB6.E7.HZVT&FZ/96MSKU]"DH!\ ?M#?\ !U9_
MP4B^+<_Q'^*/_!,G_@G#J?B7]CWX37NI)XB_:!^+'P1^.OQ=@GTOP^[7FH>(
M?%VI_"?Q#X.^'_PETZ72V@N]1T#6/$/B?4M'TLMJ-YXBL7G,6F@'Z8?\$KO^
M#H/X$?M7?LJ?M*_&+]MW3O!O[,GC_P#9'T7P]XI^(P\(W6N:KX.^)7A3QEJ-
M[HOAB^^%7AS5I]6\5)XKN/%$-GX-G\ 3ZYXDO9M5U?P]J=AKD]GJ^HV?AT _
M)[XS?\'6O_!5CXHZ3XX^/W["_P#P32MK']B_X>W]VVJ_&7XI_!CX^?&?3[32
M]%E,=]>^/_B5\,?$W@/X5^!4E0I-K.BQ7>K2>&FD2T/B^]VK?7 !_0C_ ,$$
M/^"X&G?\%A_A3\3K7QS\.]#^$G[1_P ![OPTOQ(\*^%-0U._\#^*/#/C-=6'
MAKQWX(76Y+G6=*LY+_0M8T77/#.I:KX@NM#N[73;Q]?O;?Q!:06@!]7_ /!5
M/_@K[^RG_P $EOA)I_COX[ZG?^*_B-XT^U6_PE^ W@JYTZ3XC?$:ZLVCCO=2
M2.^GBM/#/@G1))HCXB\:ZR5L+(NFGZ3:Z[XBNM.T&] /Y'8/^#HO_@N=^T!9
M:Y\8OV2?^"77A/7/V>/#EUJNI7>O:;^SS^U3\?=,T_0]-GN([NU\4?%OP)XN
M\%>$IGTB*&;^UK[3?#GAXP36=U=3V]K:07%O$ ?NQ_P0@_X.'O"G_!6W6?&/
MP&^*WPOTKX'_ +5/@/PD_CM='\+ZMJ.K_#GXI>"[/5+72M>USP7_ &R)=;\,
M:MX6O=6T.'6?"&N:IKUQ/8ZE#KFC:[J-M;ZY9:  <K_P< ?\%^?BA_P2 ^*G
M[._PM^$?P7^&/Q>U;XM_#_QCX_\ %G_"PM8\4:;-X>T[2_$>G^'?"_\ 9<?A
MN\M!)'JUS;^*?M;WAD^;3+=;?9B;< ?EI^WW_P '<G[06F_%/Q5\+_\ @FA^
MSC\/?BIX7^$&G01_%[XZ>.?"_P 2?B?X:U#Q!9PPKXHN/ >A^ /$/@N'0_AU
MH>MVVJZ-IOC_ ,7:OJEOXUM()-8TG2]'TY;#4-0 -?\ X+__ +?_ ,6OC1_P
M;E?L.^,?C)IO@[PG\9_^"@GB_P"$'C/QMX4^'UEK>C^#O^$ T+1/$OQB@O-!
MTSQ'K_BC6X;$7UA\'+R2VO\ 7=4Q=ZL\\=X(DMXF /U1_P"",7AWQK^P)_P;
M;>$_C-X#\$Z5XM^+EA^S5^T+^VE9>$=<DO;#2_'6O:Q#XW^*'P^TN^ETY?[1
M6+6/AUI/@31EDMW6:XV1-#/;1S(\ !Z%_P &^_\ P6R\?_\ !8WPO^T_=?%#
MX3_#_P"$GBS]GW7_ (5V]OI7@#5?$.I66L>'?B?IWCJ2QU"]_P"$CNKJXCNK
M;4O .KVW^C.(3$\6]%<[G /Z'M0U"PTFPO=5U2]M--TS3+2YU#4=1O[F&SL+
M"PLX7N+R]O;NX>.WM;2UMXY)[FYGDCA@A1Y975%9E /Y&?V)?^#C7]HW_@H]
M_P %4=3_ &./V1?V8?A=XB_95T#QKXFU/7OV@/$VM>.(/%&G?L]> [VWTO6O
MBK=65E*FC6.H^.M2>RL?AUH=WIJE=2\7^%=,U\((=8U"U /Z\: /&_VB_B_I
M/[/G[/OQS^/6O>2=$^"?P>^)?Q:U99WV0OIWPZ\&:UXOO(Y&#*0LD&CO&=K*
MQW84[B-H!_DF_P#!.[_@GKX@_;T_8._X+/?M/WMA<^(/B=^SQ\,?A?\ $CP)
MK=S ;F[U?Q.OCKQ+\8_C;]C5%,MUJ]S\+/AQK]J;>WVSR:CXHTE8X[CSG@8
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M>&].\&:#!9^%=%T6;QWI]OX=N)]1\07GA_2%TUY5N?[*DOKJURUDRL >A_\
M!9#_ (.=/V?/^":WCK5_V;O@?X$@_:D_:JT58X?&>C0^)5T'X4_!Z_NH6D@T
MCQUXDTVVU75_$/CB$/:3W?P]\-V=H]A;7#1>(?%OAS5XH])N@#\/=>_X.?\
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M@1>_%/XH:U+I]C+=Z-=ZAHWB+0?$?A[1=$L=*N=1UMH--T>RM;G7KZ%)0#X
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M$][:7!A9[ZYO-UHB1J ?U9T ?RH?\%5O^#@SXW?L2_\ !3WX(?\ !.G]G;X
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MN;;4YHDTF31OBSXK^)&J>'1/K8N8(K"ZN[;5+/4Y'B;2K-=S(X!_7I_P2/\
M^"M7P&_X*Z_L]:E\8OA-H^K_  _\<> M:L?"7QG^#?B;4-/U/Q!\//$^H::-
M2TZYL]4L/)3Q)X&\2PQZ@?!_BYM-T6367T;6[*\T72-6T;4]-M0#\SO^#@#_
M (+\_%#_ () ?%3]G?X6_"/X+_#'XO:M\6_A_P",?'_BS_A86L>*--F\/:=I
M?B/3_#OA?^RX_#=Y:"2/5KFW\4_:WO#)\VF6ZV^S$VX _+3]OO\ X.Y/V@M-
M^*?BKX7_ /!-#]G'X>_%3PO\(-.@C^+WQT\<^%_B3\3_  UJ'B"SAA7Q1<>
M]#\ >(?!<.A_#K0];MM5T;3?'_B[5]4M_&MI!)K&DZ7H^G+8:AJ !^=O_!2G
M_@XX_P""BO[1_P"PMXQ_9\^*W['/A'X8_"[]IWX5_!W2;W]I#0/ GQP\$>']
M9E\;^&O!GQ8U_1O )\<ZKK?AJ_M-?L++Q)X:L0GB37O[5\+)J.OZ;/<P!)H
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MGC/0=,EEU;4O!&I_VY]H\.Z5JOB72_$=U#8ZOIFB@'TK_P ',7Q\_P"%!?\
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M  D?@S1=4M/#EEJGQ!^('C'7O!EUH_B1/AQX8>RU'3--U);O7?%.DN=.LM4
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M_:(@#[9_X/*/CY_PK;_@E]X(^#%A>^5JW[1_[2'@;0M1L!)L-YX&^&6D:_\
M$K6KDJ#F5;+QKH_PU0QE=@:\24NKQ(C@'WY_P;2? /\ X4!_P1D_8^L;NR^R
M:_\ %C0O%OQ\\02>7Y1O_P#A;?C/6_$7@^]*D;CGX9GP-:K(Q;SDM5E0K$Z(
M@!^\% "$A068@  DDG  ')))P  .22?RQ0!_')_P4I_X.WO@]\!?B=JG[.'_
M  3T^#X_;$^,VE>*+CP5J7Q U*XU>+X+)XJM[R32O[!^'VG>$6D\:?&B_;68
MVT[[5H$_A7PU>MY-SX6\2^*[>Z210#\U/&/_  <=_P#!R9\*/!6H?'#XI_\
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MB%<_LP?M;:W\.H?#<X$Z:WJ7QLM?B5I?A(6L%N4VZ_!;V&AIY\3W5I)Y]NM
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M::7XD\8Z?I4L'@?PSJ-U;%;JVL?$GC&ZT+0[NXM3]JA@U!Y+8-.J*P!^8?\
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M'_ OB7X2?%.]\6>(-)O]7TRQ\3:]'JT_B^S>"+P_]D&@7*:A]ML@#^GF@ H
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MQ/\ M*:_\7/%G@[P;X;^#=SX8\8Z[K'A'Q#<:KKEC\3-(\?:=\.K74=8LY/
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M / 5O\-M9^'_ .T)^SG\3HM1^(FO:;H7AV:^TSXA^-O'=Q;)JDVJ6TNGS_\
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M6W<?LG?\$F_V.;W]MC]HCP+HMJWQM\8Z%X*^*GQA^&_A+QA96T5IXT\+> _
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M>K:[\-OB/\/?'_B'QAJNA>(K_3]#US[%JUOX@TV&V\0Z6GA>Y\+K=:M;7-H
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M<\+2>&I&N(=(O_VEOVDWTJ73O$_B1[='6YTGP;\+/&?@:/3[N6.1O#5OKOQ
MGCE2/5;U$ /[N/V%/V'?@'_P3S_9M^'_ .S/^SUX5L="\+>#=)M$U_Q&;&SA
M\5_$OQB]O&/$/Q$\>ZI;Q)-K7BGQ)?++=3RSNUMI-C]B\/:%#I_A[2-*TRR
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M'H)9ONF6'3_A7XCV+G<$G<\ T >>?\%L_P#C8)_P=%_L_P#[*"?\3OPI\/\
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MHK3O MA,\>)-0\(_ _P/83Z9>QR8^>U'BOXJ>.=.1<Y2YTZ[)50RLX!^0?\
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M?_@K)^VU^W)XULVO+[P_\.OB'XOU"[?,YL/BK^U+\6H]8CNS=,,M+/X:\/\
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MC822,@MM4\(>*?#VD^(=/N/,1!/IPCN"]K+<1L ?R;_\&.'C+7KOPG_P4?\
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M-_'+P1_PBL"7$KI+):PWN@^$XH9Y5E>0B(N@>0R( 6?^"V?_ !L$_P"#HO\
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M6LZ%>^"O"_@CX1>!Y[*7XB3:-?P:[?WFL#7-)\/:GK>M0:!;Q>&7CT6'4;@
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MVDQBVEU;X@_#[XJ>-O#GA3QU>K;R)*=8N]$\&:!H4MU&(#/#X0M)0[WANIF
M/Z4_^#NO]H!OA7_P1[UOX?QS-8:Q^T[\;O@Y\*FT\2@7T>D>'[^^^.&N.2A1
M_LD$WPJTS1]1E4"-_P"V(;24;+W8X!^?/_!I/_P1M^'WAOX.Z'_P5&_:#\'Z
M=XH^*7Q$U'6K?]E/1/$-C#>V7PS\!Z#J-YX=U3XM6UC=;TB\>>-M>L-8T_PQ
MJ4UHMSX=\&:5!K.AWC-XWFDL@#W3_@]:\9^$-,_X)W_LV^!-1LK&Z\<>+OVO
M=&U_PK/-'']NTWP]X,^$GQ1MO&-[8SX,ZI)>>+O"&G7=NI6WF6_BFGS-:VE
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MQDTO]G7]G3X]_'_6_).D?!#X,_$[XMZBEPVV&:T^'?@K6O%LUNY!5C]H32#
MJ(?,D>18X\R,H8 _RM?^#<__ ()0V7_!67]M3QCXZ_:"6]UW]FO]GU])^)7Q
MXLWN+^TN?BSXS\;:KK%QX(^&,^J6$EK<6>G^*]4T3Q#XD\:7MG<Q7_\ PC?A
MV^T>QET[4/$5AK&G@'^IS\4_^%1_ ']E[XF27G@SPGH/P+^#GP*\<7FI> =+
MT33-'\$Z;\+_  +X#U6\U/PO:>'K&WM](L/#D/AC3;C35TNWM8K&&PS;I$L(
MVT ?P"?\&0WP^UW4?VH_VX/BK 91X9\'_ +X>?#[5 %;R)-=^(_Q#G\1Z"6;
M[IEAT_X5^(]BYW!)W/ - ' ?\%LOB'\5?^"U'_!?;X5?\$O_ (;>)K_2OA%\
M%_B-9_ /3DL;EKO3=+\0:=IC>-OVJ?C+=Z,\OV.Y\2>"M!T?Q)X<M[.1\3Z9
M\+K&WA>RN=;U)' /]"?]D[]DGX ?L1_ [P7^SS^S;\/-#^'7PV\$Z79V4%KI
MEC9Q:OXEU2"SMK2_\8^-M8M[:WNO%?C?Q"ULE[XA\3ZJ9M0U.\8L[QP1V]O$
M ?Y[O_!?"5/^"@'_  <O?LT?L<6L@UCPUX'UC]D?]F?Q#:6[?:;"UL/&OBR+
MXP_$_4I8TWQR3:5X5^*ES#KFS?,D?AO[#,HFL3"@!_6Y_P '*/QZ'[/W_!&/
M]L?4K.\%GKOQ2\+^&/@'X?A#^4;\?&#QCH7A'Q=8HP(/'PVNO&UZT8#>;%9R
M0L DC.H!^?O_  9L? 3_ (5M_P $O/&GQFO[+RM6_:/_ &D/'>OZ=J!CV&\\
M#?#32= ^&>C6P8C,J6/C31/B2ZR [ ][)$%5XG9P#T+_ (._?CU_PJ?_ ()%
M:M\-;6]\G4OVE_CY\)/A8]K%)LNI?#_A:[U7XV:Q=  A_L45_P#"W0=-O64X
M8ZQ;6TBO%<NM 'N'_!K'\"%^!7_!&']GK5KZU73=;^.WB7XJ_'WQ$KJ(@R>)
M?&-]X3\)W\DK;?,6]^&O@7P5?"5PH2&9(@6CA21P#^.3]G?P#JO_  <C?\'"
M/Q \4?%R[U?Q!^S+H&O^,OB%X@TF#6;VR31?V1_@SK4'A;X6_#C0[JSEM)M+
M'CW6=;\%:9XEFT";3;]K_P <^.O&VGO#JIGN* /]1GP/X'\'?#/P=X7^'GP\
M\+Z#X)\">"="TSPQX0\(>%]+L]%\.^&O#NBVD5AI.BZ+I.GQ066G:;I]G!#;
M6MK;0Q111(JJ@QB@#_,\_;?\)^$?V6O^#OGX.Q? C2;3PU;>*OVU?V)/$6O^
M&]!1;2TMO$?[0T?PJA^+$%M# ^+9_&Q\<^(?$5]"52 7?BR["6WV!HX6 /V4
M_P"#V7X]KX4_8W_9+_9PM+P0:A\9_P!H'Q!\3=0ABD_>W7AGX'>![C1[BTN(
MP2/L<WB+XQ^&[]=X!>[T>$Q,?(G6@#VO_@UR_P""+OPV_9<_9F^&_P"WS\<?
M!ND>*?VK/VAO"UEX\^%U[K^G_;'^ WP4\7:;]H\)6?A2WOT:/3?''Q%\.WR^
M)O%7BB""'5;/P]KVG^"=/EL;6+Q3)XF /$_^#W#Q=X-LOV*_V.O =]8V$GQ!
M\2?M1ZUXN\,:G)%&=3M/!O@GX3^*M&\=V-I,1YT=AJ.M^/\ X=7&HQ(1'+<:
M7I;R@O#"5 /W=_X(%_#[7?AE_P $</\ @GQX:\1F4ZE?_ #1_'L0G5DD31OB
MMKFN_%'PW$5;#!8O#OC'2HHP1_JT3I0!^OE '\O/_!WSX,_X2C_@CEXHUSRO
M,_X5Q^T3\"_&>_;GR/MVHZ]\//-S_#G_ (3SR-W_ $VV_P 5 'I?_!&3]K;X
M:_LU_P#!N!^S9^UA\7]6_L_X=? GX!?%W5?$<R20B]U!?AO\9_BAX-TOPQHZ
MSND5QXA\3:WH^F^$_#=@SJ;[7]4TVP3#SJ* /\_/XZ_ S]H?]OW]F/\ ;Z_X
M+G_'N^U&S@U?]J3X>_#_ ,):>F]]+US5_&^I_9O$.E:1/>1F['@?X(^#W^&O
MPZ\+;&:.[_M)+!KHW?A34;>4 _T$OV5_^"@'@W]B?_@VM_9J_;-\926>H?\
M"H/V(/AUX;\&:!>3E%\9?$[0-*@^$WPT\$+Y;I=&+6_&EAHVFZI+:"2?2M"3
M5=89/LVEW#H ?C?_ ,&BO[#/C+XM?$#]HG_@LG^TFM[XH^('Q-\8?$'P3\%O
M$GB* /?Z_P"*O%NLW.L?M$_&:W=XU4W.IZQ?-\-]'U2R**CO\5='EB$9B*@'
M]&__  7)_P""HOA__@E9^PWXU^+NG7FF77Q^^(WVSX9?LT>%+T071U+XEZMI
M\KR>,=1TR3>UUX4^&.E&7Q?X@\V'[!J%Y;Z#X2N+JSN_%FG2L ?@S_P:4_\
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MZ])_ _P*T&_^ _P3U<2'>L"6^KR_"K4(.76(Q16L3AF22@#^Z[_@JG^U[/\
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MT_P[X:T'38,E;?3]*TR"WM8C+(SW%U.4:YO;N6>\O)I[N>>9P#_.,\#R1_\
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M+[%XA^,__"?_ !\\1?N_+^U_\+%\:ZN?!E[R S^?\+]'\!_O&SNV?NSY(CH
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MB>$/!2K9:?KYTW[,_C?Q9IUUXAU=I;&W\,:3X> /YF_^#X'Q9X/U#X]_L ^
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MI=3LRS.WPG^ GA'5&0EF8_\ "0_$3XE6;3-DDDGX57!1&R3\\V<PF@#^_J@
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M3_2+*TT']B+P%=>"/A[JUDH!B6QU/Q]\,?!$MK-'L5Y]<74"6GE82@'^E[0
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MO-XP^-E]I-SYUEJ,GA77)!X7^'\-U%):Z?XNT_Q;XDFL5UK0/">JVH!^X_\
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MHT^+28;-+!+("U6W6$!& /\ -A_X-B-'T_X=?\'"/[5O@'X66Z6OPVT;X?\
M[8W@>RMK.22YM+;X;^&_CEX(_P"$5@2XE=)9+6&]T'PG%#/*LKR$1%T#R&1
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M>/-:\#^#M,M(X ((-.M9_BIX42QBC"QK':PI$-JB@#R#_@M3^TGX7_X*A_\
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MOPV\)Z]KUE:V>BZG\2?B7=:-X?M]8TVP=]2U2[U'QKXNB@O-)T/5[] #O?\
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M+J^MZS:ZE$@N[/4O#/PQT#XG:OX3U!)0^B^*VTZ_M3%.S,X!_+%_P;$^(/\
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MKX/\023:]I>D>(+&<Q3Z9KD?@?0-/\3:[HE\EIJ7A_5=:O= U>WM=4TR]AB
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M_P"T3\1U\*Z'I/((M2W@CQY\0HK=$95@M=):SAC,).P _H8_X._?CU_PJ?\
MX)%:M\-;6]\G4OVE_CY\)/A8]K%)LNI?#_A:[U7XV:Q=  A_L45_\+=!TV]9
M3ACK%M;2*\5RZT >Y?\ !K!\!?\ A1W_  1D_9XU.[LOL.O?'GQ/\4_CUK\1
MCV-+_P )/XSOO"7A&]9L S?;_AOX%\$WJ2,!MCGCA4LD2.X!_(!_P<L2^/\
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MAZ98B;)BTOPIJWQGT2#PS;?+]AMM!TN.%5CLPE '^@E_P5C_ &TM._X)^_\
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MGQG<V\>V".Y\;KX;C\77'V6."R:;6W>RM;6T:"WB /TJH _B_P#^#UOX]_\
M"&_L._LO_L[V5[]EU+XY?M$ZCXZU"!),2:AX0^!_@B^AU.RDCW?-:CQ7\5/
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M7T4<<NO?#OQK#;SW^AW<K6]G)J.E7,6H^%O$0L;*U\5>']=L+>.SH _SQ?\
M@G5X=^,?_!%__@Y3TC]A+X5_%N_^*'P[\2_&WP?^S[\2DTQ9+;1/B9\,/BUX
M+T?QCX0U+QAX=M;J2PMO&WPDB\;Z5K>HWMI(S>'?%'AOQ3IUC</X?U35[#4
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MWCW%YX>^'GP?^&%E9QYG>Q^*W[3?Q6NUF5+96(+W/A:7X63*GR2S$X(*")J
M/[!O^"Y/Q&T[]D7_ ((E_MK7G@R$Z-I>B?LW67[/GA.UM3LETK3/B_J7A;]G
M32H[)DVO'+I6F>.TEAGBVO;"T^TH4\G<H!^-/_!E)\%;+PK^P9^TY\=W2%=<
M^,?[3B>"&>,H\LGA;X,_#OPU=:&;AU^:-E\0_%+QLL=M(,I$%N5RMV* /[+6
MN[5;J*P:YMUOIK>>[ALVFC%U+:VTEO#<W,5N6$TEO;S7=K%/,JM'%)<V\<C*
M\T8< _D0_P"#C;_@@E^R'\</V<OVE_\ @H1\*M/T?]GK]IKX,?#;QO\ '#Q[
MJ?A^*WTSX>?'O3? ^C7WBGQ/IOC?PM"D=C:_$_Q!96-Y%X<\=:"+#5?$7BJ\
MM;'QK#XD_M"UU'1@##_X,T_VK?C/\;_V(OCO\"_BAKFM>+/"G[+?Q.\'Z#\'
MM>UV>YOKK1?!'Q \-:GJ4GPTL=1N)7>;0O!.J>&KC4M#L) SZ'I_B^+1[65-
M%L]'L+  _L3H :[I&CR2,J1QJSN[D*B(@W,S,<!5502Q)P ,G'- '^:?_P &
MR1'[;/\ P7__ &L/VT?$6)9]+\+_ +4W[1^C/=$&ZMO$OQS^*6E^#--L[>"0
M^9;V]KX+^)_BZS4QCR[*WM[>P")'/&J@']Q7_!9#PWX@\6?\$HO^"BNA^&"3
MK$W['/Q^OHHE1I)+NRT7X=:]K6L:?!&I#27.HZ/I]_86L:Y+W%Q&@5LA6 /Y
M;/\ @R!^('PZ/PJ_;N^%D>H6,'Q:7X@_"?X@7FE2SK'J>J_#J3PYX@\.:;J%
ME;.%:[L?#_B6/5;;5)[=I5TZX\2Z/'>"W.J6)N@#^O+]O?\ ;B^!_P#P3Q_9
M@^)/[3OQW\3Z9HGA_P &Z+?IX4\.W-\EOKGQ-^(<VFWUQX0^&?@ZS5)[K4O$
MGBS4;06D0M[6:WT?34U+Q+K4EAX=T35]2M #^#[_ (-,?@%\5/VPO^"GG[3W
M_!4+XKV#7-AX$7XJ:]J'BU=->TTW7?VE?VH-7U.^\0VN@R.6MR-(\#:W\0+[
M7K2TFGN=%A\5^$8[H)!KEL\H!_I%4 ?FA_P6:M_$%S_P29_X*.Q>&1G4O^&,
MOVA)9P-V6T*W^&NOS^*E 7DL?"\6L!1R&)P05)% '\S/_!D#K/@J3]GC]NWP
M]9W%C_PL6T^,_P *=9\0VBM$-3/@K4? ^O6/@VXE3 G>Q&NZ7X[BMV):**X-
MR $>9BX!^K/_  <Q_P#!4+P?^P3^P'\0?A#X8\4VB?M0?M<>$_$/PE^%WAFP
MO57Q#X;\!^)+670?BA\6KR*'-SI.F:#X9O=1T#POJA>VN;GQ[K.CR:4+N'0]
M?ETL _*K_@R(^!<>C?LZ_MN?M*W%JIN/B)\9OA]\$M+NY4_>06GP@\%7'CC6
M8[1BN5@U"X^->C_;"C;)IM(M5;+VH"@'\\W[-W['/[-'[3__  <3_M/_ +'?
M[?FN>,=%\+?$7]JS]L?PMI.K>&_$\/@75==^,,'Q-\9Z_P"!H6UN_P!'U> 6
MGCQ+*^M=#MO(@.O:KKN@6NG7;W-]9V]V ?W ?"O_ (-5_P#@BO\ #+4K35[_
M /9O\6_%:_L)UN+4_%3XT_%'5]-$J_=^U^'O#7B/PGX;U:$#AK36='U&SDSF
M2W<@%0#]M?V?? 7[-GPE\&7_ ,(_V7O"WP;\!>!?AEK]QX5UOX?_  4T[P?H
MFA>"O%\6FZ7J%_HWB+0O!R10:1XPDTN_T;4]5@UJ"+Q!=6VH:?J6H><M[!<2
M@'\AO_![C\(_[<_8_P#V,_CFEMYLOPS_ &C/%OPPDN%3<]K9_&;X;WGB:4N1
MS';S7?P0L(G<XC^T?98R?,DB5@#\%_BU\>/CC_P<5_M(?\$L?^";?P4U#6M-
M^$WP%_9D^ FB_%GQ*UI=G3=*^(FG_"'P*_[5OQQUVUF%O%=6OP_6QF^&OP^M
M=7$<>J^)K.XM-$U-%^)T1E /],?P'^SMX)^ _P"RYHO[,/[/NDV_@+P7\//@
M]-\+/AA8VY5FT:*R\-7&CZ1J=]=;(WU'6+C4)!K6NZQ= WFLZS<W^K:A++>7
ML\K '^5Q_P &ZO\ P3P_8A_X**?M;_&+]E_]MZ]^(F@^+--^&<WBWX/^&_"?
MC6+X?:EKGB/P=XA6R^(WAN\%[H.J3ZGJ^G:'?P:U%HUN]EJ%MIVA>(]0\J>V
MTZ]>R /[SO@Q_P &P/\ P1:^#&IV6O)^R@WQ2UK3F5[>\^-'Q.^)7C[2W*LK
MG[=X+N/$]C\/=41BHW1ZIX2NXPNY %1W#@'[:?!Z#X-V/P[T#2/@!#\,[3X3
M>'O[3\,^%M,^#T?A:W^'>AGPYJ]_HFL^'] LO!87PWIIT'7K'4])U32M.C@_
MLO5[.^L+N"&\M[B) #_.0_X(+8_;V_X.;/VC?VMK]EU#2_!.K_MB_M.:&+EA
M+#!I'BKQ2_P4^'^G1++N,IT'P_\ &'2AI>[=)"NAPW8836RR* ?LM_P>N^&_
M$%__ ,$[OV9_$UB3)X=\.?MC:)8Z_ B,S1WOB#X-?%P:%J$A!Q';0?V3JEB\
MC#'VG5+.,,K2JK@'ZT_\&XWQ ^'7C_\ X(Q_L0M\.=0L;NW\&?#[6OA_XQL+
M2=9+G0_B+X9\:>(X_&>GZK;X2:RO[W5+EO$<,$\:-<:3KNF:G;F:QO[2YG /
MCS_@Z9_X*:_#W]D#_@G]\2OV6O#?C'1;C]IK]L7PG=_"_1O EO.E[KOA[X'^
M*WN=&^+7Q"\0:?&&&EZ%K'A:'7/AUX;N-0FLKC5O$?B*:]T*'5(/"/B3[  >
M2_\ !H#^QQKW[-'_  3D\>?M)_$;3'\,ZW^V#\08O'^A+JMNVFW"_ _X8Z1>
M>'? &MZC]K\J6*TUK6M2^(_BC1[B15L[SPIK&AZY9RRVFJ+,P!^$W_!MQ82?
MMX_\'"?[4W[<.M6DE[IGA2V_:E_:4T>^O(F>/3?$/QP\?GP!X.T>))%_T:2W
M\#_$OQ8NEQ,J+:6>@/%%L>&$4 ?Z*OQZ^//PC_9B^$'C[X\_';QSHGPX^%/P
MS\/WOB7QAXMUZX\FTL-/LTREO:V\8>\U;6=3N##IN@Z#I<%WK.OZQ=66CZ/8
MWNI7MK:R@'^<3_P2L\.^/O\ @NI_P<7>./\ @H+XB\*7=C\"_@=\3-,_:+U>
M+5%:2'PKH/PVL(/!_P"R)\.Y)HVN+!_&=QJ?@[P?XCU:VB:*QU.'P3\0]8M0
MCK'#. ?Z:E !0!_FA_\ !!/;^WG_ ,'-?[1_[6U^RZAI?@K5OVQ_VG-"^TL)
M88-)\6>*V^"O@'3HA+GS?["\/?&/3%TO<&DA71(;M2);99$ /Z/O^#N[XW77
MPF_X([>+O!=E-)#-^T9\>_@M\%YGA8K,-/TZ^USXXWPWJ0Z6]Q%\&5L+H@A)
M8+UK27<ET48 ](_X-3?@K9?"+_@B]^S_ *]$D*:M\=_''QF^-7B+R"CAKV]^
M(6K?#?1'DE3B2=_!/PT\*&8-A[=\VC_-;DL ?T6&XLKF>ZTTSVL]Q#;P2WM@
M9(99XK2^-S%;275KDNEO>&UNXX'E01W!MKE(RWDRA0#^!;_@Z"_X(+?LC?!+
M]G3XC_\ !2W]ENSTKX >)?"?B_P1'\7?@GHB067PO^(J_$KQSH7@6'7OAKX:
MB2.+P'XTTW7/$MCK.M:!X>\KP9JWAJRUK4[30M$UG3[N\UP _=__ (-@_P!J
MWXS?M:_\$F/A;XG^.NN:UXO\9_"OX@?$#X&V'COQ'/<7NO\ C;P?X%;1;[PG
MJNL:I=2RSZU?Z+I'B.'P3+K,Y-[J0\*+<ZI+>:N]_?W0!_0I0!^1G_!>7X]_
M\,W_ /!(/]O3XB0WOV'4]6^!>M?"/0YXY/+NTUKX]:CIGP3L9]/(_>"]T]O'
MS:I%)$#):K827GR);/(@!^%G_!E'^S]%X._8E_:A_:0O=/6VUCXX_M":=\/M
M.NY(OWU]X,^"'@NQN]/N8)2/^/-O%OQ3\:V!1&RUUI,QD!"0F@#]T?\ @M)_
MP5$^&G_!+;]B_P"(7Q4U7Q'H_P#POGQMX?U_P9^S+\.Y9X[C6_%WQ2U'39;7
M3=?;1T;[0W@OX>R74'BOQKJLXM=.2RLK7P]'J$7B#Q+X>L[\ _FW_P"#+S]A
M/Q9X?\-_M&?\%'_B-I-Q;Q_%NS_X4'\#=4U,3-J?B'PUH_B>+Q-\;/%T<MP&
M-UH^J>.-!\%>&-/U*.9Y;C7?!7C6UN0/LL4DX!\ ?\$$]O[>?_!S7^T?^UM?
MLNH:7X*U;]L?]IS0OM+"6&#2?%GBMO@KX!TZ(2Y\W^PO#WQCTQ=+W!I(5T2&
M[4B6V61 #^DK_@[A^/?_  IW_@CQX\\#6U[]EU3]I3XS_![X+VPADV7;:=IV
MMW?QGUTQA?W@M)],^$DFDZA)CRF@U<6<K#[:B. =7_P:A_L_1?!#_@C;\&?$
M]QIZZ?K_ .T9\0OBQ\=]=5HMES-'>^*9/AGX3N)I, R17O@7X9^&-4LP"R+;
M:BA&)'FH YG_ (.?O^"IGP]_8G_8/^)/[-/A?Q7IMW^U)^V!X'USX6^%O!MA
M=^=K7@_X1^+H)O#WQ1^)WB""UD6?1-/G\+7&L^#_  7<7,UG>:KXNUA=0T6/
M4K+PEXF_L\ _(;_@DM_P3D^(_P "/^#:/_@IW\;]:T2YT+XM_MS_ +,?QC^)
M'A?3%M9CKUU^S[\,OA#XO?X;V$]F8O/-W\08]4^)GB30X;;S4U+PMXV\*7<8
M^T73P( ?EU_P;1_\$G_^"<?_  51T']I;PO^U7J7Q,E^.7P@USP?XA\+^$_
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MT^)B1J-W\1/$VA_#[P;-)']TRZ=_PK;QK!:,,$_VQ=!LC9M /[A?@A^SU=?
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M/ ][?1YT]_%\-SH/PWB\OS5N-5L_!7C'7K&W*:7<+  >J?\ !TYK>J?MG_\
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M%+:=HDU&X\+:-\3-.C\=K9*X$SPP:IJ?@-[Z.(@ _99)4/EHR ']I'_!8/\
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M7G6T:E3'E6 /Y^/^#(SX%P:%^R[^VC^TG-!$;WXF_';P7\%[*9]K3Q:=\%O
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M^+WQT\6_%O5K>"3$LNA?!'P4/#<%M>JN2+*\UOXSV-[ DH5+B\T%98M[V#[
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MN:Q\8?&1+;X.>#KVV.1FZLO$_CS2KRV7Y@TT"AE*;A0!_.?_ ,&27P!'AO\
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MD^7X\USPM8>*/B$_E8#)Y_CC6_$%QM?,H\W]ZS2;V8 _,+_@H'_P;@_LU_\
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M7QFJVMW9VMGX;\0^'=/N=/@UBUU0N ?H[_Q!-?\ !/?_ *.G_;*_\&GP2_\
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M  <_8BN/BO9"-HS#KGB7XN?"KQ3X[(C 4C=\7O$R3MYJ[]K-)+B;+4 ?2_\
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M!3P6?%%Y-8NXW+87VL_&>:TN7A(CNKW0!%+ODTU/* /W:_X.$_CW_P ,[?\
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M?O[RVE\;>%/AW\!OA]H\$LH?4W\._$OQ1\2O$_BV\/F8E>V?5OA7X.2:6-I
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MSN[,0JJJ@LS,0  22 ,T ?Y>_P#P<'_M7W'_  6I_P""M'[.O[$7[&&KZ?\
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M[H/"/A7X<:=;^!_V5/ ][?1YT]_%\-SH/PWB\OS5N-5L_!7C'7K&W*:7<+
M=]_P<C7=Q^W;_P '#/[,?[$6E7$UUIOA>V_93_9GU*QM9':/3]:^.'CF/XB>
M+-;D,9S;21>#/BIX9;4YU9%MK#0(9I/+:"5V /\ 2MMK;3M%TVWM+2&STK2-
M)L8K:VMX$ALM/TW3K"!8H888T$=O:6=G;1+'&BA(8(8PJA43% '^91_P7_\
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M_L0_LN_LZ65[]EU+XY_M#:GX\U&!),2:AX/^!O@J[@U&RECS\UK_ ,)9\5?
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MX3[K?:8[BX\ ^!M#\,7EZ77B::_O-,GO;BX.Y[FXN);B1F>5W8 _A5_X//O
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MZ_X&A;6[_1]7@%IX\2ROK70[;R(#KVJZ[H%KIUV]S?6=O=@']P'PK_X-5_\
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M-+"$OY=*TC6[?X,^'HII& F-BUC\*7UC2X6/D"+7)KZ!1_:,DDX!;_X.?O\
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M?&%W]@T_P3X%\%S:M!H\OC2;P;'XH\3^-]%LKGPW+=:'"]MJZ 'V/_P;N_\
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MDL]Q-I6H6LMW-91 'WE^P]_P;O\ _!4SQK^VE^SK^V=_P5A_;LL_BY#^S/\
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M':OI4GPT\90>$?#6GZ/H%AJ5YXCUA+\:4+\:)H>^"R@ /#;'_@V<_P""R_\
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MXSGUN_\ A?X$T[9IFD^#/"'A?5/$FCZ%'KCW5GJ.G@']X'_!N=^S'=_LL?\
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M WPMTW1M!^#EEKFHVR_V=<ZZ?&FFW-O#*MQ+!K,4)T^< _M(_P""?'_!//\
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M>*;SQ'XEFMM<\0:);HWB Z7/X?U!+:XU*Z /SO\ $O\ P;V?\'#/_!12_P#
MGA3_ (*/_MW^%],^"_AW7X=4O='\5?%SQ+\6=0T*6.VGL3XE\,_"7P-X=T7X
M;>)O%\=E<7%G9:CXB\:^';ZWLK_4(UUR)+FZM;L _M]_88_8R^#_ /P3]_99
M^$O[)WP.L[N/P-\*]">R;6=5\E_$'C+Q/JMW/K'B_P =>)IX%2&77O%OB*^U
M#6;V.W2*PTY+F'1](MK+1].T^RMP#ZUH _C=_P"#TWX]_P#"#?\ !/[]GSX!
M6-[]FU7X]_M(0>(-1MA)@ZCX'^#'@W6-1UFV,0(+I%XT\;?#>^,A#)&]K&I
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M.H:8L>KQZSHH!X1_P;__ /!,K_@K;^P/XR\56W[>7[55G\1?V=O#'P4'PG^
M?P \/?&_X@_$_P ->"M5;Q9X4U.#7K+0?$WA+1-#\-Z3X9\+^%[CPQX1M--U
M.=]*TWQ%J>F6>D:;8,5H \;_ ."0O_! /]L']CG_ (*J?'3_ (*,?MB?$W]F
MOQ__ ,+&TOX_:_X5T_X.>+?BAXD\5V?Q7^.OQ#TS7M4U_6X/'?P=^'VEV>E1
M>$-0\>:7<R6&N:I?OJ6M6<:6[V8NKA0#^O*@#^0S_@GS_P $ ?VP?@/_ ,%L
M_BW_ ,%3/VI/B;^S7XO\(^*?'?[4?Q.\">'OACXM^*&O^/=+\6?';4?$6D>'
M8-4TCQ=\'O!?AO3=*T#X?>-?$NE7)T[Q=J\NG7<.F6&FV^H6;2ZA:@']*7[9
M_P"R%\'/V\?V9OBO^RE\>=-O[_X:?%O08M)U6YT6>UL_$?A[5--U&RUSPUXM
M\+7][8ZE:6'B7PKXBTS3-=T:YNM/O[(WEDEOJ-C?Z=/>64X!_!O8_P#!MM_P
M7G_X)[?%'QV__!-+]L+1IOAIXNOPD6N>!?C=X@^!WB'Q+HEI-<Q:))\5/AIK
MUA_PA<WB+2;:YN#!-INO^-(+)9[B;2M0M9;N:RB /O+]A[_@W?\ ^"IGC7]M
M+]G7]L[_ (*P_MV6?Q<A_9G^)GA+XN> OAC-\2?BA^T#KM[XC\'ZW;>)]'T1
M+WQG;^$O!/PLT2#Q+I^E:Q<2>#8O%B:@]A):'2[-KE-0B /[=Z "@#^2C_@X
M&_X-R_&'_!2WXI>&?VP/V0O'O@3X<?M.:3X;T+P?\0?"_C^?5_#?A3XIZ5X6
MEN6\*^+K3QKX<TK7]2T#XC^&=/DM_#<+:AH=SI6O^'].\.VTFL^&I/#,<FJ@
M'YU_"#_@WC_X+9?ML>)_AWX$_P""N_[>7BRY_9$^'^NZ5K.L_"ZU^/WBSXQ>
M-/&H\/R1P6ECI.F_9(_ ^F:EJ>F+=V,7Q*\6:QXB\3^&8K^6[M/#FK7=U>0Q
M 'V)_P $J/\ @V__ &COV!?^"N/B[]N+Q;XK_9;'[.%EJ?[2$GP>^'/PL\5_
M%34?'O@_1/BG<ZYI'P\T>?0?%/P?\-^&M/M_#G@;7+C1M62T\?:P]E(BVUC<
MZW"7O& /HO\ X+[?\$B?^"D7[>'Q\_9S_:>_8!_:7\*_![Q1^SO\-->\'Z3X
M<G^(GQ'^#'Q!M?$7B7Q5/K>O^*?!/Q)\"Z9JT&_7M,M?"NCWNC:K/X5A@C\,
M_:7UG4A?1V-H ?C!XP_X(<_\'/O[;WA.T^"'[8G[<GAVP^!LFJ:0OB70?B+^
MT;XE\5Z5K>G:7?07<.HZCX5^%_@S58OB%?:9-#'JFC:=X\U2UBDUFSLKF74M
M*N8HM2MP#^B#P?\ \$'M$_9Q_P"",?[0W_!,3]E7XL:;I7Q;_:%\-:H?B%^T
M;\0?#=Y:V_C[QKXBU+P[#XFGUSP]X?U#5;[PUX3OO .B2?#CP_I&EWNNGPOI
M-R-:NHO%.M3:Y-KP!_._\/?^"/G_  =D_L_:;'\$_A%^W(+7X6VD/]C:1JNF
M?M>>)=4\&^'M(A7R8(?"L'CSPE_PG_A#3(XP&M;+PSX;TIK4L7BM8I2Y8 _5
M3_@BI_P;3^+OV(_VD9/V]/V\_CCH'[1/[5\$WBW4_".C>&+[Q;XO\*^%?&?C
M1;JUU_XK^*/B7\0+/0O%WQ)^).I:5JFM6<3:CX7T_3M!O]8U36_[1\4:V=&U
M?10#]SO^"HW_  31^"7_  56_98UO]F;XSZAJ_A5X==L/'/PS^)?AJUL+SQ)
M\-/B/HMCJ>GZ3XEL;'44^RZQI=QI^L:GHGB?P[-<6 UWP_J=]:6NJZ)JHTW7
M-+ /XI?AM_P0!_X.4OV$;_Q%\,?V)_VP- TCX0Z[KUQJ N?A;^TMXG\ >#;V
M2Z$<(\3ZM\./&7A_3ET#Q1/96UG#K5QH&G:U? P1V5OKNL6=M;W+@'Z^_P#!
M(O\ X(#?MV? 7]N?PC_P4=_X*9_MFV7[1'QM^'7AKQOX?\ >$XO&/Q-^-VKV
MS^./!VL^!I-2UOXK?%!?#L^A0:!H'B3Q#9Z;X0\->&M:TECJ44UOKNGI:-:7
M !^M_P#P7'_X)>WW_!6C]AS4/V<?"WCC1OAW\4/"'Q(\,?&CX1^)?%%O>S^$
M#XY\*Z+XI\+MH?C!]*M+_6K/P[X@\*^-_$VERZGI%CJ%YHVIS:7K7]E:S#IL
MVD7H!_-'_P $X?\ @@)_P7@^ WQ7_9R^'WQ>_;;L_AK^PO\  OX\>!OBKXH^
M"7PX_:H^-%YH'C#P]X4^(UI\1/$'A3P7X!\/^&=(T.UL?'6L+J5SJ=EK][X9
MTP:EJ^H>)+O3[C7"OF@'V#_P61_X(R?\%@_CQ_P4)\0?M_\ _!.K]K'P[\.I
M]2^'/PZ^'.C^#]"^+_Q&^!'Q.\/:)X*T<I>Z#+K&BZ9>>#O&WAC6O%-YXC\2
MS6VN>(-$MT;Q =+G\/Z@EM<:E= 'YW^)?^#>S_@X9_X**7_@3PI_P4?_ &[_
M  OIGP7\.Z_#JE[H_BKXN>)?BSJ&A2QVT]B?$OAGX2^!O#NB_#;Q-XOCLKBX
ML[+4?$7C7P[?6]E?ZA&NN1)<W5K=@']OO[#'[&7P?_X)^_LL_"7]D[X'6=W'
MX&^%>A/9-K.J^2_B#QEXGU6[GUCQ?XZ\33P*D,NO>+?$5]J&LWL=ND5AIR7,
M.CZ1;66CZ=I]E;@'UK0!^1O_  6U_P""8\__  5B_89U_P#9FT'QSI7PY^(V
M@^/O"OQ@^$WBGQ':WEYX2M_'_A"P\1:%%IOBZ+3+:[UB'P_KWA?Q?XIT.XU/
M1[:\U#1+O4;+6X],UN+3IM#U( _#_P#X(5_\$8O^"S/_  3R_:4^'D?[1'[6
MGAA?V&?AA;_%'47_ &<_AQ\>_B;XM\&^+?%OC7PKXDT?2+C3/AWK'@'0?#FG
M:);>*O$TOC_4A<W.@RR>)]-M-:;2KS599IJ /0/#O_! /]L'Q/\ \'!%]_P5
M@^.GQ-_9KU[]GNT^.GB+XH^'/!/AWQ;\4-1^,J:)X2^&-]X#_9_L+[0-7^#N
MD^"+35?#%WH_P]O_ !$EM\0[VTLK?1;Y-&N]2E%IO /Z\J /Y#/BW_P0!_;!
M^//_  < >'_^"IGQ.^)O[-=Y^S)X4^.?PE^)V@^ ;3Q;\4+GXQ6F@? CX?\
MA?2OAQIB>%;GX/0> H]1?QWX*T36M9A3XE&S2WN]4U.&ZN[]ETV< _KSH *
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M+>$O#NI:UX_N+=[>*YT>R\>"W/\ :JQ7=S=:5,TFH( ?U<_\$>O^"*?[-O\
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MR*_%3X/_ !%\-:=J<=IX@\5:E80:]XAT[6G\+RV/BU]3\36/BB].NOI>E '
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M^;%H_CG5[*WO[E5-_>V;O)<* ?UW?LS_ + ?BC]B?_@E-:_L!?L_?$+0M?\
MB?X%_9X^,O@7X=_%/Q7I>H>!O#.I_&?XDP^/?$MGXU\1:9H;^-]8\-^'3\2_
M&CZI?QZ8?%6KZ=H\;FUBU:]BC@G /RT_X-R?^"%_QY_X)"ZA^U3XQ_:8\;?
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MB;P=?:MKVA^)3I6A)J'CS1H-2DTG3;359M%MXFO6 /ZX0 H"J     !@ #@
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MI_AJP^#NL>!7U7Q'KVN>/5\.1W/Q"M;">'5;&XU:XTZ1[JWB /Z\J /Y#?\
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M>\\7V?B2[O\ 3UN$N1HVN)$;9@#^_E55%544*J@*JJ %50,!5 P  !@ # '
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M[57Q-^(-KXG\*JD<,WVOP;X-TP3_ !*BGCAB>WT7XDZ]HT-S,OFWUU939EH
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MSK6D_#S1[C0O%7P?\-^&["W\.^!]:GT?5DM?'NL/92(MM8W.M0E[UP#^R>@
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MM7T[X>>#HM.TOX5>$[[5[>U2WU+Q&^O>:+HV5_>Z'XH%HUK0!_<=^QC^QG\
M/V!OV>O W[,O[-7@Y/!_PU\#VTC[[F6.^\2^+_$E\L1U_P =>.=<6WMI/$/C
M+Q+<PI<ZMJCV]K;Q1Q6FD:/8:5X?TO2-(L #^;/X,?\ ! /]L&U_X+^>*O\
M@K#^T%\3?V:_$OP+_P"%Y_&3XI>"O _A/Q=\4-5^+*:-?>"O%/@'X Z?KFB:
M[\'?#_@ZRU/P7I%UX,U'7QI_C_4;6RU'PXUOI%SK%L8Y' /Z\J /Y#?V+?\
M@@%^V#\*O^"Z7Q-_X*L?M+_$W]FOQ9\.-;^*O[3GQ3\ >$OA[XM^*&N_$+3+
M_P"+]OXO\*_#K3=9T7Q5\'O"?A>TM?!W@/QA/9W,EGXTUB73M4TG3%TW^U%7
M^TH #^O*@#^1+_@E_P#\$!/VOOV8/^"Q/QQ_X*:_M:?$S]FWQMH_CW4_VF?'
M?@G2?A-XM^)_B+QOIWQ)^/GC.2:*[UG3_&GP>\!Z%IFC6/@#Q/X[TN[ETOQ-
MJ]U:ZA=:9IUG8W6G37-_: &O_P '!_\ P0F_;:_X*\_M.?LZ>./@S\6OV</
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MI]M)>ZGJWA75O%^J6^AV<>C07?B(LLUWJ<NJ7#@'[ST % !0 4 % !0 4 %
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MOB3XCLTG73],T^S-S?S^'?A_X2BN[FR\(>%$U&ZCM3<ZEKFH3WGB#7=7OK@
M_6N@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#^<C_@X,_P""M7[6'_!)S2/V2_B1^SO\"=/^
M,'P^\9>+OB2/V@]1\6^#?&E_X$T+PUX=LO!%IX3\.7GQ$\,36ME\.O%OC#4/
M%.MW?A6^U634$O'\)ZANT'6+2VN;24 _(J;_ (/A?@M_PA1O(/\ @G]\4/\
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M _@WX>>%[467AGP'X4\.^#/#MD-N+30O"^D6>B:1:C:%7%OI]C;Q?*JK\O
MP* .KH * "@#_-%_X*8'_AX5_P ':?P;^ 47_%0>"_A9\:/V7O@Q>6P_TA)O
M OPATS3/CE\;=,$676$66HZI\5+"7=NCCEMY;J:/#2QJ ?Z75 !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M=/L=/U/0H+/X>ZMKD":Y=0:7)HMU9V-S>*MO<. ?V/T % !0 4 % !0 4 %
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MZ[XG\<Z%8 ']=M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M/B\+OXVTTS^=+=7$^O0AHD1)MP!_8_0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 <[XP\5:)X$\)>*/&_B:\73_#?@WP[K?BKQ!?O
MC98Z)X>TVZU?5;Q\LHVVUA9W$S991A.6')4 _P XG_@TD\+:W^U7_P %=?VS
M_P!N'QI9M=7OA_X<_$_QY?W;YF:P^*O[4'Q9M[^*=KIL@O/X8T_XI6IZ2S^>
MT@8(DR. ?Z3% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MW$<'VO5=4NFDOM5U.>[U*_FFO+N>9P#U*@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * *]W9VFH6MS8W]K;WMC>02VMW9W<$5S:W5M.ACFM[FWF5H9
MX)HV:.6*56CD1BKJ5)# 'SM'^QK^R##X@D\6P_LJ?LW1>*I9DN9?$T?P,^&"
M>()+B-@\<\FLKX8&HO,C@.DK7)D5@&# @4 ?1T<:1(D42)''&BQQQQJ$2-$
M5$1% 5450%55 "@   #% #Z "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ///B%\(OA/\7+33M/\
MBO\ ##X>?$ZPT>YFO-(L?B%X*\->-+32[NXB$%Q=:=;>)--U*&QN9X56*:>V
M2*66)1&[%% H [#1-$T;PUHVD^'?#FD:9H'A[0--L=%T+0M$L+72M&T71]+M
M8K+3-)TG3+&*WLM.TW3K*""TL;&S@@M;2UABM[>*.)$10#3H * "@ H * "@
M H * "@ H * /*=>^ _P.\4^-].^)GB?X,_"GQ'\1](NM(O=)^(&O?#OPAJ_
MC?2[WP]/%<Z!=Z=XKU#2+C7K*ZT.YAAN-(N+:^BETV>**6R>!T1U /5J "@
MH * /*;/X#_ [3_B _Q9L/@S\*;'XJ27=]?R?$RS^'?A"V^(#WVIV$^E:E>/
MXSATA/$;7>H:7=76FWUPVH^==V%S/9SO+;S21, >K4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M#)(TE1XI422.1&CDCD4.DB."KHZ,"K(RDJRL"&!(((.* /%O /[-/[.7PIUR
MX\3?"_X ?!/X;^)+N266[\0^ ?A5X$\':Y=2SQO#/)<:MX>T+3[^:2:%WBE>
M2X=I(W>-RR,U 'ME !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!5OK&RU2RO-,U.SM=1
MTW4;6XL=0T^^MX;NROK*[A>WNK.\M+A)(+JUN8))(;BWF1X9H7>.1&1F6@#S
MWX=?!7X.?!_^V/\ A4OPE^&?PN/B'[!_;_\ PKKP'X5\$_VY_9/VW^R_[8_X
M1G2]-_M/^S?[2U'[!]M,_P!C^WWOV?R_M4^\ ],H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H __]3^_B@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mgnx-20201231_g2.jpg
<TEXT>
begin 644 mgnx-20201231_g2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-   U%@  TOL  0WC  %*(O_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@!.@*\ P$1
M  (1 0,1 ?_$ 3\  0 # 0 # 0$!           '" D&! 4* P(! 0$  @,!
M 0$!            !@<$!0@) P(!$   !@$" @D"!@$$ P$    " P0%!@<!
M  A -1 @,!(3%#0V-Q$54#$S%A<X(6" H#)P(B,8$0 !! $"! ,#" 8$"08(
M#P$" 0,$!081$@ A$P<Q(A1!(Q40,%$R0K46=B! 83,D=5*RM AQ@6)R0S1T
M)1>14W.&ML9@L8+31#4FEE!P@*'ADJ)C@Y.S5-4G-Q@2  $! P8'"PD' P4!
M 0    $" !$#$"$Q01($0%%A<;$R$S"!D:'!T7*R,W,44/#A(D)28B-T(/&"
M)#0%%<+2)8"@DD-CHE03 0 ! P(#" ,!  ,! 0    $1 "$Q05$087$@,$#P
M@9&AL5#!T>%@@/&@</_:  P# 0 "$0,1   !W\
M
M                                                    /Y*M%BCW
MH     (+)/.E      *O$]'3@     A4[LZ\                    &)N@
MV4<<47[#73=2_27;<*]F    #)3!R*A\77U&%XU[]-EW5_Y0    !BMF8V0W
M0E2=]5DY^L&!2OHP    9:?3\8*WW5730F2_7A6TS]^  ?/V7=.M*\DADCD^
M&6A;@_<]J>L(]+B%@BGI3$E,D<K.3P?D2.5_)X(@.R.*.A-'0  #!2&[VT'G
M/U'R6VPHE]%>7MTM_K0   *P&.7&UZWPYWL_.+I^HOH]ZRICW@    !@1M<"
MCO5=$^/\OW;OER\?HFT^Q    @,^6.[*TDJW*_ARJYU]>%%VC(( /R,PR0C\
M#FB2BE)H\5S/(.D.G(P)!)K)U*P$!G='%GEG:F?1I&0X>\.[(7.F/V+_ ( .
M8/G^BVW\C796D4ZCV5_,-N:)<F714&X8/H-W=SG?3]   /2GSA4I/M&^&>AH
M.FV@['T.YA@W$^WK8QMM#I]'+Y?T  /6GS>[+#]5G8^KL?VF"%I0;K;VJV.H
M?(=[^:;HTD_/Z   \(^5*:QKU/2--<WI]CIWR[>'"_G]1!M\'3F/[31G^?T
M>D/7G2E#2^)_A^AQ!V! )_A8H  X$[4B4X M">*?V<2?F0@263,  5B*.4U.
M;^1?;8TVW#+MR_256X&Z2M954QSG[!H_Z%>D*K[\  &#4;VL[>=?4/0:_)I'
MZ$\RV(FL?ME1U@31KLK,>_*YW!V&,  (7,.Y?HKV[C SFBNZTOT6QP-Z,I^3
M9Y%8^I>R/JVI^PY9  !@_L,3//J2C?<['#[7FBZ=$HION?G,<FS+^%4H')=[
M<3[@"A92,T0,_2/SJ"!CMS2\K"2X:7@ &3)4<UJ,_B.R*COBP9YIPQIT3^
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M>L=:41I3Q;?5YZ LJ@?2E4[9]>TC84_@^<FN)3>_S\Z7X_;X4/\ HIR]'O\
M&P]*SSA\GY9^7E7VZ&?C@   "M)C!*=-?;?:RANFV%WHCO,.+RK"3+6@<7UE
M-OIVH2U;4 ^9N0Z>"NH*1\?X_2W7+EX^/B9-V)Q'/7?G]5A@TC^@;%^P
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M?\X^II"C^R\GT\Y'H)QO>FCW.UH55]$N8/UV^!J[34YI))-7(5SP71W]?P
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MS2-"R7@         #. @KS8ZLZS59GJ/3SD>G7%E]Z$4#9-9?1?ES=:=1X
M        4@/G7ZBH[L9!J=4>/>A\4KPK&9+8@5DN8[L^CR)[\
M5))X(>)P.O           !G 05YL=6=9JLSU'IYR/3KBR^]"*!LFM?HYRSNA
M-="          *0'SK]14=U^_P!5JSQ]T-B9>%8S);$"LES'=GT>1/?@
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M"$"%M@           0X<V6'..*ZEN3^@          1R>B)+(9)F/\/[/;
M                                      &?1PI48\LC8YPF(WW
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ME3IC] >.>0         97%.C0D_4Y [$C(S)-6B/3PR="S1G>>W-6#V
M !E<58+NGNB,B6B'C.\T*/0GYEA"Q1GD>V-03I0     97%2"^IYYP!(Q%!F
MX:7'+GH3V!,9[,G0IV=D:3@      RH/'*R$T$7DVDV$&'KSNSVI2P^@<Q^(
MR-L3I0     #*@Z0H\6:*W%J21CCR&"63WQ30WW,JR"S9 D@     &5!YQ4(
ML 0<6,)8(N(_)3/:D?'"G\FM)DD2*:\       CLD0CLD0   $9DF
M $=DB$=DB    C,DP       $=DB$=DB               RC.I)X../<GJ"
M*"_ACL2Z20:4@        S3.8+.'$GDGX$7&AIB*6)(\-FSR      0J92EX
MS^STYV1"Q*A9 SI.J)&)P.#.+.G(L/2'/'.DQ&BX      ,\R'RH9/1Z8J,7
M^+K&<Q_)WQL2        "EY4,@,DLYXJF:!FAYCL>Q)@-:#J      #%HJX:
M*&1Q:HZ$[HN*9NFAA7<D@H03^>$6&*W'7'4'L#5L        @$CTN   5^+
M@         $(D.ET  "OQ8$       'XF<QH,>Y      /6$2$W
M
M                      __V@ ( 0$  04"_P!AN<X#A9=U2(%C:Z-KRB[1
MYLZNH\M:7EH?D7:N-U5.TK&AZ9Y A[1\L> 1E6RR!BDB+\*W.RU_?)0@HRN$
M:%E<W3;3.T2Q*XH^RW(V\YL>H_0,,2-Z@MUVXRL@XI23V>[>Q7EM FAK$03
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M"4:Y$=^CLJ^+(IZC6U7YSXAXJ^N9 N4;<:V.DR>G*H2G8Q@..(W8?"4"]C2
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M8:HXHH!)8QX!C"G_ #^#(A8$1I8G\,6,YQEF<L."?4B:_"'UT20U<H3)RTI
MQ@+ Z. W%2  C!$E!)!H[.!&]=1C/?T09]>AT1>5-TSKOKV!YP$Y2@\:DW&,
MBRW(\)"<YQC!@\C%HO&< _!2#LDC"+ PB#@83BLDC1+#$*A.H+5$F%@- YH!
MMZGJXQG.69LPWI]2)T\06DB?P0Z6J/IV(P8&'.,ASC/TT6/OA/) H*4$#3&X
MSD.6]9A83UG1=YHW3.AZ#S.]G1!?U_"$:CP\Z4$X/!G&0Y87/R9VG1O XIC
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M!G>P,(1A6I!)#M-2WS)6AB" *Y6)8=IJ0^7+SG <#'D8M$E]S' 1]$4L69
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M1K0H:TFAK*J"UDT,+Q"JI&,8F3'@SH4&,*('H4'%C"/9F=)QCT5_:<*6>O\
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M&B<-V5':5]Q7O:HU.K)D>=$-4TW"+\9QQI2'7FFNJ?/.5\[/\:;ELKM=;;L
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MKANO(W&:0?Z;\A41/V(O&,XZIHXM#C]-2JX.JBXM771H.]%71="Z&OZ)HV2
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MWD2>847>R>[<TZ.K3C2HJ+IIK\.I.K9VD_2)%:ALNO%U9"]($;$0W/ODI:
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MN%-RB-71IA&=$#.,NU[]:L>JG(Z\V!R3E.,@8DO2Y[N.X62779<<PKK*XO\
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MZJ3;&N06E@@"(NY#+=RUTV\^(.=8)T;M^ZE^EJEL:NR=K8SL27&:M8]X,:1
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M.C?=<KGA:4+!.G7N;=O(N6GCQ@K%2W,%[-LWH&:F+.B/0IZ([$M6]ST)\1<
MQ>=;':NG[Q/U/.HT.._+DNP(/3CQFG'WW-MS6F6QIH2,]H"J\D\$X[!1*V5;
MXO0SL=QROSO)ZV@6XM\:C,8[1 RRD,XDIV(<DC?0B1OJB3*(G/RE_>3L63S*
M_@WG:.8-)?Y33R(-QD0_AMZ&PX,?T,)31UQA0C#T@<..(*HZKQ'@OUK<5U^G
MH^O$DDE6\,Q[*8DU9"M.HTX_,ZH=7I_7<_:G$1W,,MRA,XFX1.PS 6K[ ','
M@N1G6'S]<KD>?9C+L#4B7Q;;U705(NF*3>V7<&W[RT]FS92 ?[>X[CD>P@VJ
MA8#/B2*PCK'!=)R2T);CD"!$.X2V+QVIRVPKK^?BU3A-CC16%=7N6<A9PL6<
M=AET6$ 5E/>K:73R[MRJG@NF53<?GN5%JSCLRSB22JAMG@2'']>_$^%FOO9$
MZ*R<=/K$V;FY!)1VK_=ZK"REQF! Q^WS"(RYA;"#B(3XC#\JJL))6"%8R;7U
MI,H3I-G'+GTN6B.89EU)FL3M9B5DIS8>.T4N9/S2WA+M'U,H7(S<6E$R+I],
MR)13?]<@5AJ11U5E4P;F\HZ"EJ+*M6JFLE661JW&;KA5Q ;Z%0?21%TV:?X.
M*BO=5%=@U<"&XJ>"N18K3)JG->6X/GO[R5E24<QZ_',,CF4$.57OEZ]X%L%;
M.-%,!6QVH6X6PUZJZ#]KCL;</9-W S:TB]P\/DYC'LL6<JL;Q"U=L(#TB#&-
MFIA,]9M&'?,V;C71:WET]4'C^\+9RZUYCKW&,MUL^1$<;Z\9QN[<EA"DN-HC
MK)FTPKFQ5340U]G&24&47>34W;*=W)M+J^C4.%#D-4R06@&$-C/H]FNL=U&V
M?.,=PMR"0H2%SL^X$S),WQ[!L]P^CDXWFF#UWQ%MUA*VD$:Z7U*Z>K4>2<(I
M&P01S4VBTVDJIFK&$1\WMV;7+&\G/\4501+R5T[*D9L9\2NBL-.+6=*OZR*H
M;M.H2\N,#OK7_B3BTBKDV3>-9E2T,U)./VU;#HEFMR0CJ\]Z>R>?:1@A%%<<
MAN;7 0?,$W/DF'8#<3X]1/L:[X58V^.M!%6OLYT'0>F\\Z;HHNB;VP$M2UWE
M_>.OH^4/>F@T=/C:-CA#+JY717T%\W,?KR]1OB.4834C',;!\WU7J>[\.,8K
M,N?M[^2%0QCT9RDQEXWXZ)5O?#H,F% >F],*V$P,<GR/5X@W+S+C\"3*R]@7
ML%^XO'EG4TV)7K">FPV0%N>^V#)RE*0B]/ZVU%7V+Q@L"/<7.'X);%:CE>9T
M%#\=LH+K3(G!KQVP;!R ,IT1\P!U#U4DW(T0K_>K-8^767QBOQ)^IL,DJ)$.
M\OHY)>OMS3BI$CJ;CT5YMS:+8D+9CN$5Y<?W7&(U1+617Y!VQ*<RQ >ZT)5I
M(QSBEMMM;XRK)15=WZ>?ZW/CNA89/B^274?/8=>[BDRDIW+8[+IMM;J9CFG-
MQQ49,=?*K ZIM45XM8UG62JB3^.,A/T,M@X[C0JU6CM$2 $)L#!10A\J[>7'
M>#)*S*G8J8QVN<@P7$PIB:%A36BS;UG"HA%)$'9GJF_]?$7W44M%%--O&&0J
MV-,R'*;J##8K";H";##HT^J:L'H\Z+'.<5C,J'G#;;-Q!%YQ=Q#M#ID]C-54
MYV]EM\+][E66Y/CKM>W<V+6YU[?+<ER":9!R4?0;+554B(E4R55[Z9.SSKK[
MNA:I"/Q$^A+LIY[2Y;DZ-RU[$_4H=7=/VD$ZNTCW53:4TL8=E6V<47 9E1W7
M&9#*J@NKR,"^E-"1%2-FMUDV5YMDU?">KZB?E$^,\W3Q9(.-2/AT6%#AMMO/
MM/N 9EOU$U\%Y_I89E=M+G.%@STV94U +'2L=L9@LH-A,0F"DN/PSCMFUH8H
M)@B_3K^JN8UD7K@AE*CSF)5;)2+/A38N_H2XKIM/L]4!<)/.V8Z%X<5&69'E
MN8YW<8\#X8^N46$5Z'4%)!&WY,:)#A1$.8X(\S<(O 5TW"))^CAL^YESO38;
M=+?QZEE8_H+.Q;1GT1V:.L.N.-P2:7:(J*$CA(6J+^HFTX*&VX!-F*^! :;2
M%?V*B\/XS&SCN'%P>5*.2_AC-U"2J+J/I).)UBJRG>A-X44AZBD7BI;O-Q!J
MJZ.$2OK(<:O@16]>G&APV0CQ8[>Y5+8RPV@IK[$^>EQ6I+T)R3&?8;F1MGJ(
MAO-$V,ECJ";?68(MPZHJ:IQ Q.B60[#A')><E3%:*9-E2WB??DRB9:9;)SS(
M Z"FUL!3V?\ Q;__V@ ( 0$# 3\A_P"AKAG/@24( %VEA/@>28XR7ALBKT+Y
M!,!F(EX>]A7V8NN4Z;)NE,\K 2X:;(,AWQVDRZ"  T -@4[7XBNOR3%UV ]Z
MZ)IJN!@Z0.)J)+G$+'K,^38/XMYQ[^46FX1I84-2S6 Y:5^9!NP-A\]S<'@R
MR4%T5*O)DK:RN[/AS03!JNY)2U,&LLF/2_%Q-UT7ZEX-=L8?A?=5KB7*NM01
MR>\@A\A)H8+<M4]:*BT4R4N D,JWJYE+)$$1"EZS._J^+H$LH4%,"'=%P'@$
M6H=N"5!#0C""0@=3]D;LF*+K<N9)0GF6-%L>/Z!,.+JDL.O:!=UE^L4S,H!U
M!VH]$!%D78<I$35!_F6/S)J0. 6WG#YMM4J4]KIQ+(1BT\=)]/HV5)_6%P,:
MKJ-73;JG09"!J*80<S0Q.1-3 B\U(,A:1ETI3JHA-!59LRIKL78I\'$96TW4
M(]FVY1J+KR 5)4<3S=AXC;]I_P EWQ0Q"#]9<I,87T&%9;-0.6;A3=@EJWV@
M>UTXED(Q:>.D^GT;*D_K"X&-7%F("YG*;\9S$$?89C!7P*T#6>%8KN[)RU6[
M.@2#]$W&J,U$VP=L YH,144/!IBG.3'X@:P)H4FHY'T121+Z1[$#.\DQXV#:
M;,AD52X-R$7=;@D0%I(^9[9"]25U\6>C#-H6,[KBKYD.S4?8T_H@S"1J(HT*
MG/CN!E47NEP#3)O\C,4! E7\0.![#%!VB%1T3\[<6!H!S$%,TLPS73."PO>!
M^.:1Z7*F"206\0C9)-Q,(W&S>@YZ@)-W7B#3 U?2 RL)]GLL!(O=$.E"+_V)
M" H@AC]',0R<D?8 7@E0:V2HQ7TZW#!2 M008*KP2##V6 5):0$D.MDM)F@2
MLYER7)9A,4L/H^-M[(2II. I;T3PX)&. @H)9 9J)D1!4@(L0%/Q<$64@"4-
M1WI8JL@ #C5&P7U&2^(C"42LQ>&*D4^=;THQ"ZG3)(FAM3O,:@ XU\+$R4!W
M8%)++CVY/;6WM^7$T',:L)8,^@> X^5,FM(MX!E*7 D-8 5)*Y5$8N+=F@3-
M)*(G[1HZPBJ,6("GXN"+*0!*2#);)VG0U#H+9W<OGF@=LZ)QI2RV4^3_ &]3
M8%%IT[>!;.!L\#<4"+?BN QM4VA)#@I/4!!_B&@BIB/0ZM1* PAI# 8/.T4F
M$=CEB6V0MJN!4K08T\?()%Y6B, IHA;1 )KIQV3ZK^B[.-D5XQ=J>J>OV@#1
M#&U:YHA>#9)29M2R!J]FC]APQM--;)_Z$AD2VRMV.! ?B>N"R?+&(C2Y9564
M@$V)@2=Q)@@%87R$RVM>EZ%$$KZ*L7UM@  $!8"P!H5B#"=B' 1 BR&/1K-&
MI'>JR$!%*F[MO]E-!M+G1<I')A0GH4@HI*-]^9S?NP((.V_Q"$2] 0B&Q09E
M@+Q9Q+M5V4J:=,I?&R*EAI*0 PTY413!>BC:[BRZI*(4DA+J*68XT<6AAN$>
M":!Q(A(2U18)0H+]M3GVL.5=2+*Q4=98=C(*9(3Q4F&<>!( @ 6*4D0MP!]1
M$FJ=*OT>.OQ4SIDY4:N2A0Q+EU!:$J:W.R\BZ+*6,V8Q'H]_@H0O9()G[]8O
M1S&2P6U6Y_?1"]=KLAJ/,*TKQ(5+!58J1<F2CR3G=L%J.)]\1@6;(.:%&( 5
MF9!C@&>S1]B9G&%=R)9*:UFT4F0C= 31:8B;OITK58#:FR<NB/BSN$I>:,$A
MA'VZ7#SM+1?3@ 3C)%%!B"@BY&@B4N+@BE[E>8-Z\0_JH$;2"VOL8(R-%0*
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M\"=?_8:BU('&U!_S]O"5QZ)I4_P^S;*8D48TO1JLQ4J]@6)&$,BH0 $-I B
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MPAR@@(0(%C,:4!F&^E'JYCF'XEVWX(\I0%97'([T(I-8X?Y-GCVNDX=;_/\
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M;_>FA-<X"$=+%Z\&WK("%>@(D0PP)0)!-HTJ7J/'BPR\&E 8!T# 8DF;SE=
ME<5<@ 9EC)R-P-6C5&RV4GBQ0=!'NCP,4(*MR7.?UV6+1WA%:=$;*:".[OG@
M_O AA5C:<[=\Q-.GQ?\  YKE /\ @$1>5TB63NF:>FZ)5-"2UGN]>W-<W6>K
M(@QVTM?$;GT_)QYHH451%)4CL(QW6R;,!9JT262:      0 6 # =R,#NA9Q
MF[54DCC.U-D8A6BJ).QZAAT$'JF ,PT?8F9QA7<B63C*=9!Y!<BZ(,>$N]>D
MW^LDF6  O@+4J7D<3ZV@5QB:$8A?8I$E(4B>E"(?BM[9TA'!$M0G!MMP1-2K
M[Q&B_P#0N8%1 I<QJG3%"2H'5'<<"">VH4;>M;1=\N!_RM-A:](VUHW4_4*H
M_<;LB>='G9*HNSGJF1$%([DI6=9\@"82AN!D%[O!$>9&D79^5D#$XH%$T6A'
MH,DR08>^S\1/NZ,1L"W"#+HOQ]Y40N]8T;D_1)Z&LM5 [8)=A(&B<$!=<* >
MAA\1Q-"Q5NX1QQF' A1+:3<L'R"D5X(CL<0QZYV91616CXCK",M6%<I6&(X
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MVW6+8X0IWX'0Z3OMIF:D5DNA!\W])K2+G7GZY_\ E3__V@ , P$  A$#$0
M$
M
M                (      (      !      !
MJ@    !E@     .L     %2    (!(  () ( (     !LZ    (?P     .L
M@   !,?     )   (( !  )    H+QP   "T:2   &9B>    FC^@     !(
M   )  !(  (OJ.(   !ASD  !)@X=    ;,O@ !! (!   ()!!)(  !I^R@
M +ONNH   #*JXP !P4!C    !(      )      -RYP0!#\EVP   !&DA6
M2.\B    !  ! !         !/9?H K)E"    !!I 1 /6I=     ! !/)!(
M       !?3*4'FD8@     ),#<P202\     ! !$PD4         )8,<!VYU
M      !.F]Y"A<(     !  /CVR          _I/+X^\       !X 829N
M !  ! !+?&M          "1/+XK    (   )] 92:8   !( !!)#+L+
M      !/+X    !)    ! 8B0     ! !( !R!D((         !/+X
M    !(8B0        ! N8#KP          !/'X           *8B0
M  "_0!-H          !/-X           *8C          #\7+W<
M  !/-X           *8C0        !$1ABE6           ?-X
M *8C0         ( P_)(          !O-^           *XC0
M)(            !O-V           +HC0           ((            !C
M-V           +HC0          ( )(           )M-           !*PI
M@          ! (!           !(!            )             )!
M                                        !
M                         !        !  !  ((!( (  !(  ( !! ) !
M    !   ! ())    !!)))!)) !)(   ! )) ))!!!)(    !!!  )))
M !( !  )!! !!(    !! ((((( )        (!
M                                (  !!()(      ! !!()!)
M!    !(!(       !)!!((!       ! ( !  ((     !(((! ())
M((   !        !!    (       !!               (( !)
M)   )      !( (  !(!!(        )!)!(         )))(!        ! (
M) )))!        !   (          (  !                !
M
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M7=4/QV.[YRXNU:>$2%,F\\6_<(Z;@&HQM0B$ H%M^C9*;-J84:@)@   @ @
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MU>'P,C2V19-8,UJW^-Z,C(E$+A!TR)-B[0@T.(50OCKTD2CB5R+%'= S#%K
M&8I&0QD,L,'J<U"6%[P3_P!%W WP7KB2HZ4(B"U=LE[KXW[!X8DPSX[Z (!S
M!I$$ ! 4$B$B(V:1_J@I-$F\K%**$T^%+*:2 !VC\+0I]26MOL4MS(BP'"MV
M) D46FX!BFD)+"068( ITM61 'I-C$6$CN)5&::I2.&>,B;0HZZR-[J,"]I2
M=!SPY0  2K8*-F:)@S-T&@,R3*"@>0L<E8.3*T$F&&D+FV<800W9 /\ X8B\
MHE!I;([S@3*.I%*X"MO(6HI.SM20+5L,FC4A1.?U%VBT*!W:6L^:)M!#[ (
M#+B?[4\+DK4)X-FWZ*K\!30U]J9O.64AM9BT@*4AS/,(6GQA45">X$KM$0
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M,5&'WC5@  2_\\&VH(G!\<,T@-AY)U$[)G7_  T2,H;E>6+Z?V/](AP&H=&
M C2E([![B$%,T-8-*#3*S5(56T"(CW5L4< 4,W ) ,1M-8!UOV>0->_!A5$M
M$F^;574IIT(CA4Y[@7/8#Y]E]-*K)&R CFZF-26 I.*A-"4I_C0+I,C: PN<
M V#>"F )#X,U\49!2?&LW9NO^#]VU-8"14I?19/O)=#ZM"K:L=9RA^.,:"3)
MS1-IMB,C5+3.&(IF9./2P01&8>IDLYYM( <?;.AD3%R_EU0N=D,=JZ+Q=EA"
M"UI@#\C7MR=)2"KRC,M(6S0()$A5*$>?<MJ-;8"Q^UVTXJ(H*'6X 9_3B%0!
M)LPLI%/I?1KVM*8LQEF4D E.MQ\B(:]6A)&7@ I@"0^#-?%&04GQK-V;K_@_
M=M36 D5*7T5_;PM^6HU3 0C[KKU_%)5=Q*T/]^8<OZ(*4",'%6PT*FKN7HT$
MG=NHA\F).((-[[4&O2L3#H+Z8"[\T;PG3;:$ <:V!2A-*T>K60S%K$)-OR7#
M#H9! V0?]>RTV+!) 2LWJV$F:/7E1EG?K"9JLRNPQ.S3<"_@0%#$CL:UF&V*
M0^%_%Y8RMV*HJ[@7J3,1,D57;#$P;"@WH@H@_EO.UD(PPB)7<+.4O%%JO=&8
MA*3;[$"(U>M0D]DZPDN+9%,]5IW.!!*)<V\(<UKPF5.((%./ORK7&4?5TUF!
M,:J.#.Q870H=H+6ROVI(D+'2N<W[W).!U\[]ZJ/<S>"J^#HR@,+G -@VKHQ;
MDB2 DR!-&,'QKNHD4*>CS3*9I%%WY1%0PG=G!!LJKBA4BO@N:$1.W1)<Z2:*
MBN3,R&(<D*Y0/B0 #N4BNMJZN,)X19ISJG<+>LX23"*7SWY3.E6]'*!-(.<8
M%!@85<***??]06M#5X>%B/>N2S262BT,I0R/%5ND3?TB-2QHHP8/XHAP?A8S
MCGT)HS(>AB(4J2H'PR LCT]XH!1#3OUWGR$6VXX@8]OX5D< H?L/7$Q.AZ4*
M!F51&9%(&)!N$]$,;9#>UF$0!7*AEKV2$!00CC-4?I0C'V4JC!C03I;I[Q ]
M%G62A/PF\#5$>R$564FS6MN(12D9'\ACM[)+CR@,J,GS]24Q7/%$;A(&HV,'
MK%%*FL 3E!4AN#V&RFN5-$V0("),T)D3#HK&E(&%2X$+")K)7JVJ#(>AB(4J
M2H'PR LCT]XH!1#3OUWGR$6VXXAO9A0,TR(:OADFF,%BF  $F@Z@J@ZBC9V:
M%%EV]<_0* !^G*'05NWYV]5;N?\ <E.82>7=1449[J_:+*O"WE)DU;N+J0=(
M)!31*VJHZ]"+-$!5F8X3QCA$\$>@MW.H!J;*"%F 4?Q2(14)0F IFY%U0GZ
MX+S:TIYG@+:$Y1Q54D^> UFA,HQ>[^(MY6CQDR,K'>J=Z>*1()!Q>@R;4LT=
MR@PB><CH/N6'R'W[>[$7(PS*JE"DW(@:A:LDB7,IJ-@F%>I=\ /?$LPQ"E,,
MSGUDGW%;"@QB@A7QX!&*#QA 9'@'YD<ZVD.)W($E2=EII0T1'8Y$J3!+(98C
M^):-X,+UIY46(2I1Q99Q5(2,!!)")L\15+B1>65@O#42A,+"-B0S%B(" (N%
M\7SB$A*^"%:J.WR>0<@#0BF0F*$BMQ@BGO\ C5N*V+XG!G[?/1BK3R,^AE /
M!;C6@""@1CNA3@06(K9%("7[OJEQ,<PPJ82.TLXE")/  "JRT6@@6)?D2@C#
MW7.OE^H4!"$+@T=!SPX   0!8.Y-V::\.Y7B:Z$<(*XC;Y2B<+3)V$6 YA9*
MSWMGD%-2I)4,57U BCQ#R(K134$"2Z(\(Q,WA@F"#4B-NLZ&%B?2SV8@-9@-
M!#7 +\["@'<'HW#*0GI6]SLN\!Q ]Y40XUU1G@;!=16/<CXRZ,.(PY<>I_U]
M]<!(VJ42\0#K,9OLK!$#'7!-*(/2E!P:A"/Y$Q@-K"X"4O@MMU!R4XA_*Y6H
M&M5ZRQU1],MOYM. K!$-Y*R,S$0%"B0>2@7&,@V[YE):=J'*/@60K2A6//(I
M<5P0&H4<RAKWR.0A;="[@K'D:H$@6UL#4C^%TM&T4C#T[^ KA]J'[8!+I3 F
MO/0Y+X18-W3+"D3!#+,?T=>=H$TEA^$<I4E1=% W* #V.!GBIURG8ZT#U52"
M[X4$0B\)(14F?"MR)M@*G:!H-URH:4Z/!FWQ6P>*W#',0&(=Z@$_$RTV$@%[
M'H!SC/P%1$8"MH'D7_<5J6?)P(I<J YDRT_-T@0APQ4B:**@<,:)72>\&MD<
MDETB@0_&$@5'PH>=+";"=5LMW]U"K)2!!1CBQ^>GH+A*:UWB*),!FD /B@+J
MP=VT5K=6B-C"W/@'59%R]-&AC?0G20>;/)@MX=CC*BO&9&/^2<H=6K4BA+&1
M$7)WZ3I5GFU2%4*% LK?ADQ5UL0&A$Q#MPQ5YQ)L0=P&,%/DZF I\&H%F&6K
M.&+M560(XS4K KNI763!CXEM^,04E0,Y8%(41F0!#4&&S)IQP$TGS%"\R 8!
M42@9"6>)Q:&N%""*8[U$3;@@:.%HEV\FB5!@ *AG&CNM]65.'BM#N'[ 3R3(
M\*YRK:(.3S>W>^E^"U#4$6*ET/<3DER-(CCV:33D]JJO&(%9F24E42HMJ/TH
ME;0OUD0Z 4:%+$F<< +HN;,%<Q1C'A93=0'\'1;:4)#)+5:$T)DZII<)HCVD
M';NE2^EP+0Q.#)\*PV18&V(J60JH4,R#P0M?A I4,FI%X6<RK38PTD,41VQI
MZA$C1QE)BR#$=<DR(.]=P?=AEI=CBQM7*X:JI]P&F'JM.0AKEH>Z/)TP5D"G
M7$NFE!-M-A\&;7JZ,+(4<(I3X=[^C/&#-HTD\DI4;U*AR\ &!:@T;8+$>5]U
M8&-5#IR !Z$^9 ,T![J8+W533%!@,O\ $#&LRCD*'+7)*#LG#@R=K9V$*<+3
M33DPIBH+AHB!$H([R\ADGKBJ&H-B1=%1P>_.,O, 4X*J X%R!' C PB2:U/<
MIS$%D:1(@X /@ML2&@4!P+6@4A1"C6IJX+;LHE[B_L-ZG4"8/%X$"B5R$-:
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MF1HH6C)9QGOA',1M *RZ0&PD <R1\BP.W92J+,*[28,IF" 5!U" 0%:?5]!
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MU$N-%A'Q("@Q()V1A"*)G* Z=B-)HHM9E([9!(V4&BJ314\'=216WAUTV]H
MT%"E5D2SUY)9+BC24R4^$34)#5)K46:9<H!)N:K4&!D+9IJ&!/1!AJ@#R*@\
MJ2JDNN B-Q*:%>% *MQ2A1CN,4BHC(MYO# &8*^"X2PMR$02$DI(*D441( )
M5L :M2)3".,:^6DL2;+"L@M;92RC8QS3I;WUQO#<,G74=$*;2#(_IV3":-J.
M$D(ZCYLZ-RE\J[^8N8??"59[4>JW0D-2M>4DK%60(4B>CAN8;T-1?FR;0*MP
MFW HTYMI#S"7(CJX3,.^%Y@W-QJ8%X#0IV'6TZN=EC?A.6W<:GV&=NJW@3D*
M61<60T3G/:X(<#PA<KB!0&2Z R2QOCU8=T97)' .,8#EC,9&!&2&<-+BQNB@
MB(89\-P23A!3)'R/V /YX24GV,7-HU+&LI='@\B$-,RYB@\YKV>'SX;CKWUB
M<&1'+9 ]Q&O"%B.8$\JWU#59%D8 8!  0 %@"P:> N/=R^]T<>AT9J'B>WRH
M)[E].7<0R@<<J5 X5$^2?3@C$,YSMW+5NP:TZ*I5<JW7P5EGQS-N=87Z5D*"
M@()V)E62@%J)P&H84K V+Q*01:%L71$C7V$&!VD(K%D!.L5(>@+-[NM+N#*+
MF)6@ Y*P%6223Y;3FQ'AAP\  +=C.7,2#0$!:Y.SL8 6'0:W58CL</GPW'7B
M)15J=2XC")<02Y5P(8(&T6>C&ZN>SET9>TZC 8  !X$,Q84@-!8#&EIW6@0#
M)'$[JY=)L!@)9[$.X=H;JI]?KQ#2HL1,B8J H&2!YLB>C?E2I"=@,#0#;Y<O
MA#&B"AMC$B :&1$4D#.FG(-@@- &E11O#FZNP)5H%<4# 3AQG+O2R$X90>$O
MSYK.OL>X.E%80"Q,,',);8$"3Q?#Y\-XW7P_(-WB0\R5$C;!SR]^DQPR5[A2
M^K=AP6R13ANU( ^0Y/,G7A;FYAY=_4=SQG#Y\-XK7FQ1G]%Q]1$Y<?(-WB \
M%R8F^'E(,MKH3/@3Z1&T+8NB6:A!-&" 1B=LP 2DDF4 *L4Q61R.6\ A;H4M
ML,CR?-]F@,F-T=$YC"<RC-PN2:)R2$\7P^.:L0-!"O4]@\4O^,XGD&[PX8GW
M': EZK@"ZP%VI01>I4?0NC*U*?H4 E4P &5;!0[P3[TCH22*TJ:A2K_/*2-#
MH'@1+ ^%!%O"WI(TI8;APIR&P!.1L3A9.U]E]<NG1^5X? Z_XSB>0;N$X\'J
M%OD8Y>%2U 7N;]$0]%=? +@H!*)@,#S,2F1JM:9O.@N$ " LR4C.A^8Q'G8G
M.24A(Z0+=0/=*Z875@;:6"MD +1>?-58D9J>8!9V&?1R<F,C2"0XH,!NF*SZ
MF.4?E.'P.O\ C.)Y!N\/#>$T!AH(+F0H,E($K.9@1'4 <@-UT 4&H<7(U=U;
MK*JMVE%+"D2J%L(TAIFR,%Y*@_MM=A-$$R+5_,!/ 8JE"<V"UCX-+*-@=MNI
M?"F8J<)&;$1S9MSG&M"A3".Z94Y8#>)Q'AWLDX@6:M& )RQ+++XWX'7_ !G$
M\@W>*A@R0 2E39*I,(T05#$:95"0D4K@*$((A*"XB")<;U &M9<08DA*F)L$
MV/,@F9;*!54A? %O'@I? YGMTW&P]+.<3XCXRA0T;$R(H>'D&[_BL.E\#\/C
M*/-=W#R#=^9ATB-1P%U4 .:V/&!^'QE'FN[AY!N_,0TK-D[#.)(-LET0P-Q2
M,%;.(R0N 9<U;-*:8(GE"I'<",3[F(<Q["92Y01L,D$ +)1$BZ^(='&.@B8$
M )+$540HZ$$9! @N*%K-&TYIF0D"ZH -H&5%S,S%8D74"@8S9A7%@8"V>1 F
M\!-__E3_ /_:  @! P,!/Q#_ *RN47,)"%IK:%IB)*MI  )$/H<$.>:4I9+\
M%P@%C &0NL]V6Y Y4@Z!E-@4@+37N%(LO9*X9F;3!B;9%U8N>6ER)0N\G'DH
M98+#FH#24HL\]S!H*XW5A< 6K*W#@8]HD!6N"!3O#:VHL E7D%ZF'86GW0BY
M (65$H_%YD"@& F'"1^+ 4 "9ED-41K2@F]*22Z0A!U$1*MMEDP;MTC#1B!2
M,.2W B;[VZY,JX'=0D*V5]E<!KF$DAX*)6ZO*SM-CD8V9[S.YD<!A6- $\II
M0ZJLB,/4V2R0EFDZGI\([A(:I-:>^(1/<(EZ3*M)!?NYK2B<-SI=]\2TYHSU
M$[6$-QWJYD?B$L'8F)0S"Q!JNM@;P)15$$#*BS!D@=I;<#N)%UEO(X'([AE,
MJ ]3#G(^ZZN,@)2(T+"-D3(G<I= $"RU%FT%[EU&+&*OS(UN@P.NN:""P<U@
M"E)>0& @   "D4%P^)8ZKH?1>E82?H#(G8;;I2 $#".1[B()&F)@#=_1KRH6
M4K$&QU'3G/IPDY=F%Q>\<ZNJTT(6K&PV3>=XO S$  &4,B)(B61+B9[F(*)'
M;A3V3S&R4.'52K=5RKJM6?# R!E^AJ@UJ"K(:[JNJ2FJ76LCUL!E?YNZ>U11
M4U&4]()\V:!-*)'<?PSRDP=E0>B,SO)H\.9+!A].638S9:3X*00#(B7$;B7&
MCYA82,0;%A 8! IU82,"MB1"S9N%,L0[8#WYCD:=.-B20;%19Z&),K(ERFJL
M 04SQ2H"E.0'\JXHR=[!B4%ONM(7),&QNNP%UVJZ-%]1,K]&@!I2@4@5=<56
MXJ_KGN-)2CT(3]^O"^EJ[<-.I\G1I 9!I[.0QQG7E]BZ:U$6,K:A='E?D;![
MBX43FL;I(#FW@EI3[UI6?LA[LJZTM8H!*C  756 U:'$,&5#H/,>JP(#LP$K
MY^*56<1L?W5Y\HX8C?LF\>A;\-/PJWF+F5OR6CE2PFW]T3(V:#]")YPF1T;U
M/6Y>T/71-'E%-=+0C'-I88881)%08634<"T,AH&Z7K'P8($)N6PD(W$2KCZ+
M,K87$UJUR 2.R?!0"H8 "ZK8"ZT28LD89<:3EBB++!K"@9UD23,O"-3(&X%8
M+K00=N_O'7KS0:2U,70O-#]W/);5[EAZ3LZ/]Y4:<-'^]'2@Z0TCSH<(#8;/
M\<GMI4Y2%.OL)(331D41#BR=&OR1?DR-Q*=88!A1(CHB24H0B/R6)RE-DN7/
M94"7%-<:"&,7-,]1JA4<7-PGHA[_ -'PNE=N[OX:;YVX67O6;IKT/EZ/XCG(
MQU_K4V8=^#UP7MC8^P^CDI\20CD2L<C7+N+BQ;>P0Z$U7"E7IF3F"U>T185D
M H2I ]$Z.G9R3P-8;(.CGDQA=4'L$&<#FD:NHD@T]14JK*KE75=6HFXK74?5
M?9HFKO":';=\M&[!B83HH57*MU>ZL#;]FW74]M>!J[@-S^[<Z5F0D?/S4*TA
MAG(N\YGBVPU(I! W*F[Z#1]PLF@-)$;8(-G1V1L&X(W.S+0;.R+VAG;1:E!Q
M# +3LO)9C LQ)L% ( "  L 6 P5?VQ=N:=7X.IPS27%L;=73U=*/A!0&Q^)Y
MHL=/[P.Y#>_"3T@&C]#._0&L[!3+Q N[#4RB/A>P"&N""!D -YDA?Q&"#"T3
MN-%'8"-M2BL= 0 6   T*@;3P1)L5S&#0NH"D[:R"P;%<#8W94HH"4@>1H'?
MX$N@(!@  L 6 Y!3K0?JN@YK8^;4Y]ZQH&!R/EE;KWEC[EFRZ]'7GUX7&NV?
M)9UVSOPFX=I%FQU'HNEM*Q7NQL]HOC$Z$6PKL1/]8(M.NH[$%TIV:JLJ978Y
M!8+ %/WC30W3H$IH"T=\PF.Z1+UB!>"2U+E=V&[_  R^VM)TEI6B)E(/.QEH
M!><KNZO\Y>!2+),$&3R<:/MXEY4L)O\ S1,)9J/@%O,6<K;F/#IV1C.\@YV7
M-"7R'&W,B:A*+(JRU'PF;* GW+BZI9D'H D1)$<B:CJ5/3,3)G=^3L2GP2P<
M;5=5T"46!5AJ#@<>$A+R0#HC+*HG DJV ,J[5*2I(MLAW&\N)6(41TK'(-5V
M NU@&N6J97738@P4@0 2K@*F&SH=V%]<2QL5[UZ$E";C6?6XN6W4U]'7A?*S
M=L?L^2^C0Y4U80A/-S)4_EW-9P^VVO8<!E&,ER<'-L9)9&4%#E35@"5\W<%2
MWR7;F72>[?23P&,H8$N]SELZI@&1"8"7S]4XLX#8\YY\++6_9MU=?;2_@+ X
M^E!#%="L@!09P522W&2Y(BE&/Q+.0K=D;+ *HK$ D)2P8E?H+OO3$.)N3Y*4
M7:?92(T+".1,E.K.*QD >4SN!9,@8(LO-08@\QO<AAJU6*] 3J 0=0\&)D;'
MR![BZF%H2 2)J/G&3#5G0B?2;(W'1!JY1EI)AZZ)HB<Z>."#+E9:NH(E#A"&
M%&Y($@ED1$=J&A+,75YP&Y(JX<#=$,[L;& N8@0259T"NN221@KG1A"3 5@N
MM'"V_M!YZ[FUP/" W3%H;.N>6-0[]!;<CLZ/]Y4!,)#YV=**-"2-%K0L-G^.
M3^C4=\ENUA<Z;>T044N5-61(3S9R4CP%Z,)U2Y/!H"(VY.Y%(U1:<(6??A8[
MX<YG1A<!X7\N^[?H:>^W"&.Y9NFO0TY]/!.+8KI"%Z@CJX.=#S><$%X1&[8F
M\$#,ASTZ!;:9=>$KCIA&0\V4WFB_$^"2,B3I G"CPG0@SJA][7PD7K)=?3E[
M!=JN$$T86MC#HA+T<//=O9 %_-46"L8=1CVN.9/"=HBAVW?(TWW TX=6E6ZK
ME>;X"UEGV;=3)[;<!.>>@)/F/?N.W":TQ /10?CA(DEY<MCF_P"T9$"0&P>"
ME^XWD?B%$L?#0)>JX!=(%TH'4DZYCF2UD+ (N< 60%Y_F;+>4I-M'](:]5O\
M:40%< R<H][S!NI4Y$]: ^$GPP!8()(-)0(;P+JK>AT7(HG+?*[^P<//=O9
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&_P"5/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>mgnx-20201231_g3.jpg
<TEXT>
begin 644 mgnx-20201231_g3.jpg
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M  (1 0,1 ?_$ /<  0 " P$!               $!0$#!@(' 0$  P$! 0
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M^J     &DP0B620  :#<8()8         ^<&#26QY+<HCV3CJ#ABR(A1GU4
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MD9B=?5YVGTOGVN&R8DVC?6)54[Y_UI7%U:?0Y*_V_+LZ6O\ .]YEIMB0
M.,Y?;X;+TO*<PR$Y,F35U>;X]'P9&_-F7F$_FUOO ]2R[^23U8>*ST$6V@
M  'F)^3\/U50G*<F2YORY/1[129]OCJ\[/K_ #&ZT1*3ZEW_  [V-)]$.5O$
MV0    !4Y]GRSD^AC(&3*94Y[IK,G./&E?3<:_<^/D[\_;<>]E2<9SI-Y$E=
M1-@     <OS^M\WQ]769"<PR#*<F0EKRSMN3Z8X;33DUG,3$N$25[$S@
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MRO.A   -)SR/9X.G2   !R!4$(MC24)>G8D H"*3#OP   5Y5(C2Z6)D@
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M(N"M) *$O2M+DM
M                                                    #__:  @!
M 0 !!0+IF\R"^=GQA:5QLQY,>2WS.R&&L145")!'W\/Q]E>>#\[:Z)\<MV;
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M]T)6'+9*:OJVO%JI2#[^3ZBPF*FS-.4X2()Z5+@^$Q,9&.SGH1;TZB'4N<6
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M"6,38139MI&HM0-6H?A'\NV+&PJ*&KI:M8IP)2@3I[YPMVW9#:Z"F8GE"+I
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M79J@!;;@QE?!4)((@M(.;Q500V*ICV&L5CPT"]4G_P!V?901\="&8#G 8^8
MY.!N8H@Z[?Y-H^I^#?QVX^D-B\_QB8 'R^1LY_B(K5KM?(%U#F?\<7Y6PO\
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M5!T^$.!2HVF\K69E+N$REN_KX9KGX6GR%+VC\..A NCB)O&%6/2!#!X.9<^
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M:\&,?(6&O*%7N^Q=/> $I+$X2"-SAT4R?7X_];K 5+,UM3@*<$(HDA6ZB6Y
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M-)>? R810K7 #:P*! !U@6(C8D!MC?$#FLR87Q*-96S+$*D,GC14 HM%%2]
M7N)ECFI"[@!!67Z1JS5<6L(A43<!/B8"@2T#(N&3"*%:X ;6!0( .L"Q$;$\
MXH%JH0O0F2]Z@7>5F8''6UZWE)B48:(#7D V+%++ZEQWB,42@5KJ1@QK>UQX
M9IK-&*JBFZM553IREZ\Q[,WP[S7:#L.%(&U^^S#M"ZHM6\56QD0#0&J&4!B!
ML$ ;SJQSLQBG"7/NQ2D!E(X;Y B-I9T@03>!%R<QT3#>%K$">%USE%=L"XJ
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M)]R((CJ$1'?F6=CR!3),+@^_UE\@\%RO^@Q8E<"[Y_8G3E^OFK1<;%^%ETA
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MGIS!ERYL2GJ3*.GT8Y0I^ SF\JO/I]C^L0*=,-E273W/^3'_ / Y^\(TP3&
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4=!@_[[_-C4"_HQ<EO_\ )?\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mgnx-20201231_g4.jpg
<TEXT>
begin 644 mgnx-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 4Y R # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#SG]K7]J7PG^Q3^SMXF^*'CF:^M_"GA&".XU"2SMC<3JCS1PK
MMC&"WSR+^&:^!O\ B+R_8V_Z#7Q _P#"8E_^*K[)_P""F?['-S_P4!_87^(7
MP>L]>@\,7/C>T@MDU2:U-U':&.ZAGR8PRELB+;]X?>SVK\5_^('3Q5_T<3X?
M_P#"0F_^2Z /M_\ XB\OV-O^@U\0/_"8E_\ BJ/^(O+]C;_H-?$#_P )B7_X
MJOQ _P""U/\ P0=U;_@C9X8^'^I:E\2=.\>KX]NKVVCCMM&?3S9FV2%B26FD
MW;O. XQC;WS6#_P16_X(K:I_P63\3_$#3=-^(%AX";P%:V5S))<Z2^H"\%R\
MR@ ++'MV^23SG.[MB@#]W?\ B+R_8V_Z#7Q _P#"8E_^*K[E_8C_ &U/ _\
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MF8L5/S!;>(D*25'ZO4 %%%% !1110!^.O_!S'_P6H^.7_!+?XY_#+0/A/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#GCB=)]4MK+#W6B7J@(+^!&(#Y0*DJ9!940@DQA6 /ZWJ*^?_@)_P55_9O\
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MKZ@_X,E_^3!?BO\ ]E ;_P!-UG0!]/\ _!T=_P H*/CG_P!P#_U(-,K\(?\
M@T__ .4VOPY_[!6M_P#ILN*_=[_@Z._Y04?'/_N ?^I!IE?A#_P:?_\ *;7X
M<_\ 8*UO_P!-EQ0!_6[1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)Q_P;N_M[^ Y+C3;3X.^*K6$/ND33_$^FM;R$J/FS'=E&R, ]^,'IBO[ :*
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M"PU.VU2+S+6X@N$_O12!Q^8J>L30**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBN=\:?%?P]\/HS_:VJ6UM)C(A!WS-]$7+?CC%5&,I.T5=DRDHJ\CHJ*\
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M>#F6!M^^I[=5^I[&!Q=_W<_D>P4445XIZ@4444 %%%% !1110 4444 %%%%
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MZU,J\_3B@"2-:L1+4<2U8C7%2P'(M3H.*9$M3(,FD!)"G-6$&34<2[5J9%I
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MZ/I*=13BI1"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X/\
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M(!@4U!3J0_,*>@P*8HR:DHD0 &34E-08%.J0"G(,FFU(!@4 %.09--J11@4
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M %%%% !1110 4444 %%%% !7Q[^TM\2#\0OB7<B&3=I^EDVEM@_*V#\[_P#
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MES0YUT.W U.6?*^I[;1117BGKG0_"KQN_P ._'^FZLI;R[>4"<#^*)OE<?\
M?)./?%?<,$Z7,"21LKQR*&5@<A@>017Y^U]>?LK^./\ A,?A/:PR/NNM'8V4
MF3R54 QGZ;2!]5->+G%&\557HSU,MJV;IOU/2****\$]@**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O$_VUO&G]F^$-/T.-OWFIS>=, ?\ EG'T!^K$'_@!KVROC_\
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M_P#!>_QC\.OBEXI\.VO@'PS.F@ZK=Z=#/+=SYD$,SQJ[ 8Z[02 :^<_VD?\
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M-*Y>25V.69F/)))))/))IZ# KOIQY8J/8XY2YI-DD0[^E?N%_P $D]._M?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !114.I7JZ;IUQ<-]VWC:0_0 F@#X?\ BGJW]N?$G7KK.5FOYBO^[O(7
M] *P:=+*TTK.QW,Q+$^I--K[:,>6*B?*RE=W"BBBJ)"BBB@#\:_^"@=T]_\
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M6A6^I8WXNC[_ -?UJ5C,'3E3^LX;X>J[?U_6AY3$M6$6HXEJ:-<U] >221C
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MP:C_ &C\#]#8_>A66$^VV5P/TQ7D9Q']W&7F>EEDO?:\COJ***^>/:"BBB@
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MXOBCP[P&/I2J8**I55M;2+\FEHK]UKWN?)\29-647FKOB?PM<>#M>N-/NO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXZC_ +YJS9_'NV=O](TZ>,?],Y1)_,"M_K6:K65)6]?_ +8S^K9:]%5?W?\
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MB9Q+2,?4];*XZRD%%%%>$>L%%%% !1110 4444 %%%% !1110 4444 %%%%
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ME=CC%MV1]&?L_P#A4^%/AA8*Z[9[[-Y+]7QM_P#' HKM*1$6)%55"JHP !@
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M<"NBCAIU)JG35VVDDMVWLDNYC4K*,7*3LEJV9?QGUT+H\%FK?-<2;V'^RO\
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M)W!]#[_SKKO#FNKKNGB3[LJ?+(OH?\#7@T,94J2]G7^)?B>W6PL*<>>C\+_
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M[G/W .23Z >]?-/Q"_X*#7=]+-;>%])C@CR52\O3N=AZB,8 ]1DGW%?=\/\
MAQG^<6EA,.U!_:E[L;=[O?\ [=3/F,TXORK 7C6JIR7V8^\_N6WSL?3'C?XB
MZ3\/]%DU#6+Z&RM8^[GYG/\ =51RQ]@":^0?C]^T=??&O4/LMNLEEX?MWW0V
MYQOF89 DD([\\*.![GFO._$GC+6/B#JYOM:U"XU"Z;^*5N$'HJCY5'LH HM(
M:_J3P\\'\%D$UCL8U6Q"V=O=A_A3U;_O/7LEK?\ &>*N/,1FD7AL.O9TNJZR
M]>R\E\VR>TAK2M8:@M8:T+>*OVR$3\[DS8\'>)KKPCJJ75LQZ@21Y^65?0_X
M]J]ZT36(=?TJ&\MSF*==PSU4]P?<'BOGF&.O3O@3J[&&\L&/RH1-&/KPW_LM
M8XRBG#G6Z.:I'2YZ%7TM^SI\+?\ A!O#7]H7D>W4]34,P(Y@BZJGU/4_@.U>
M=?LW_"7_ (2S61K-]%G3;!QY2L.+B4<_BJ]3ZG ]:^BZ^5QV(_Y=Q^9UX*A_
MR\E\BOJNF1ZO8202?=8<'^Z>QKB-)O9?">OE9?NJ?+E [CU_K7?UR_Q$TC='
M'>(.5^23Z=C_ $_$5\WCJ3LJT-XGOX.HK^RELSJ%8.H9>0>01WHK#\!ZK]OT
MCRF.9+8[?^ ]OZC\*W*[*-15(*:ZG-4IN$G%G1?"GP0_Q$^(&FZ2H/EW$H:<
MC^&)?F<_]\@@>Y%?<$,*6T*QQJJ1QJ%55& H'0"O#?V+?AW_ &?HEYXDN(\2
M7Y-M:D_\\E/SL/JPQ_P"O=*^=S2OSU>5;1_/J>UE]'DI\SW84445YIW!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?G/\ \%1_V!]#^,NI75G<1KI]Y<![W1-3
M2/YK1V.7B/\ >CW=4]"I&#@U^C%<'^T5\,?^%F_#NXC@C#:EI^;FT./F8@?,
MG_ EXQZA?2O0RW&/#UU).QR8VA[6GYH_F0^*/PNUWX)^.KSP[XBLWL=2L6Y'
M6.9#]V2-OXD;J"/H<$$#(@GQ7ZT?M8_LG:'^U-X'-C?!;'7+%6;3-35,R6KG
M^%O[T;?Q+^(P0#7Y7?%'X7:[\$_'5YX=\16;V.I6+<CK',A^[)&W\2-U!'T.
M""!^H8/&1K1_O'RTH6*T$]>E:*_F:/:M_>A0_H*\G@GQ7J7A:3S?#MFW_3("
MO:PDKMHXZZTN6I.E59N*MR_UJM<=*[)&1GW0R*R[SH:UKJLN[%<LS6)CWXX:
ML74AR:W+WD&L/4N]<M0VB>Q>'&\[0K)L[MT"'([_ "BM)!@5@>";W'AO3PWW
M?LZ+],*!711?,,CIVK.I2<-7U.*6C)(UQ4L:YIJ+5B%:Q$2(N!BI4'-,05,B
MT ?9/[*<RR?L_P"AJIR8S<*WL?M$A_D17;W5<'^R6/\ BQ&E_P#7:?\ ]&M7
M>7?6O\WN/(\O$V8+_I]5_&;/[,X5E?),(W_SZA_Z2C%U_28M8MFBE'NK=T/J
M*X6XMI=)NVAF^\O((Z,/45Z)<]36#XATU-3@VM\K+RK#JIKPL/4MH]CTJL+Z
MK<Q;2ZS6E:75<\/,LK@QR#:R_K[BK]K=9KHG QC(Z:SN\UHV\]<Y9W>:U+2Z
MW5R3@=$9&]:LTS!5Y-:<48A7W[FJ6D1>3;!S]Z09^@JPTM<4M6=<=B9I,4QI
MJB:7%1M/4CYB8RU&TN*@>XJ)IZI1)YBR\]1//FJ[W-0R756J9/,6GGJ%[G%5
M)+NH)+['>M(TS-R+CW50R7>*SY;^J\U]_M5K&F2Y&A+?8[U7EOZS9;ZJ\M[G
MO6L:9FZAH2WW^U5:6_JA+?8JK+?>]:QIF;F:$M[[U7EOJR-0UZ"P7=-,B?4]
M:P-2^(T296WC:4_WF^5?\:^JR+@S.<W?_"?AY37\UK1_\"=H_C<\#-N)LMRY
M?[9647VO>7_@*N_P.MEOO>LW4O$UMIP_?3*I],Y/Y=:X;4/%E]J).Z8QJ?X8
M_E_^O6:3DU^T9#X UI6J9QB%%?RT]7_X$U9/TC)>9^8YMXO4XWAEM%R_O3T7
M_@*U?WHZO4OB/GBVA+?[3_X5A7_B*\U+_63-M_NK\HJC67XT\6VO@;PO>:I>
M-B&TC+;<\R-T51[DX'XU^U9#X>Y!E%I83#IS7VI>]+U3=[?]NI'YCFO&&<9E
M[N(K/E?V8^ZO2RW^=SRW]K/XG_V3I,?ANSD_TG4%\R\*GF.'LOU8C\A_M5X/
M86V,5-KFNW7C+Q'=ZG>MON+R4R/Z+Z*/8# 'L*L65O[5^@4H6/,IQY(V+5I!
MBM*UAJ"T@K2M8:[(Q)D3VL.!5Z".H;>*KD*5U11DR2)*]2_9)\%2?$#XQ6NE
MK)Y,<T$C3/W6-<,<>_&![FO,8UXKZ,_X)O: U[\8=4O]O[K3]+9,^CR2(!_X
MZKUSYA/DPTY>0Z<>:2BS[,T71K;P]I5O8V<2PVMJ@CC0=@/Z]\]S5JBBOST]
M;;0*@U.R74=/F@;I(I7Z'L:GHI22:LQIM.Z.&\"W;67B 1-\HF!C(]QR/Y8_
M&O3?!/A.Y\=>*['2;4?OKZ41@XR$7JS'V502?I7EMW_Q+O&C$<;;D-^!.?ZU
M]F?L9_"_[!IMQXHNX\2W8-O9!ATC!^=_Q88'LI[&O&HXCV%":>Z=D>G6H^UJ
MQ:ZK4]J\.Z#;^%]"L].LT\NULHEAC'L!CGW/4GUJY117@MMN[/86FB"BBB@
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M-H*_9!1117.;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5_*?\ $?X_^/(/^#I&WT%/&WBY-#/[1>G67]G+K%P+3R#KT"F+RM^S
MRRI(VXQ@XQ7]6%?R1?$O_E:]MO\ LY73?_4@@H _K=HHHH *_GS_ .#SC]O'
M4F^)_P +O@!X3U:^MY=*@;Q9KZ6$[*\EQ/NM[&$["#N6,7+E2#D7$1'O_0%K
MFMV?AK1;S4M0N8;.PT^![FYN)FVQP1(I9W8G@*%!)/8"OY3OV'K>\_X+D_\
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MA][^=/L[S)X/0X/M23UYIXQUR\\.^-IIK69HV=$)7JK<8Y%?:\&\(UN(L7/
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MF<J>8X.A_P"^SQ] U.*N[%4XN4K(\C^-OQ(;XH^.YKB-F_LZSS!9KV* \O\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\-OVY/\
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MS4;W-4WNJC>ZJ>8I1+;W%?J3_P &T.AW4NJ_%[5=F+-8M+M YS\\A-TQ [<
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M='C8%AYMPVY_]U2H+?@#7EOB_P")W@WPTS)IVJ:EXBF7H8;+[+;G_@<C%_\
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M_P"TY51ZU^J'_!/_ /X-Y+7PCJ-GXJ^.EU9ZQ=PE9K?PK8R>9:1L,$?:YO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4^0M=#IS\+7F':;EFWRUI6QXK*LFS6E:GBD!;IKP+)(CLH+1YVD]LTX'(HH
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M+C]MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGVFD:'H-E#IVG6-K&(X+*VA01Q11J.%1$55 '   K^=3_B-Y^*G_ $0_X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP+_P3?D\%_%CPY_PBOBB^\57VM)IYO;>[>.VF@M5C+M [HK$Q/E=VX8Y /%
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MQZ991V\2[8XEVBJD239Q4$\N!3YI-HJG<2YJ0(KB; K-O+C%3W<]9-[=8!H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5E+<J(4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445@
M_$?QM'X$\,37C;6N&_=V\9_C<]/P'4_2@#@_VB/B#DKH-K)Z/=D?FJ?U/X>]
M>1R-M%37MY)?74D\SM)-,Q=W;JS'DFJ=Q+@5H9D5Q+5"[GQ4MQ-M%9EY<8H
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M!J9%1+E%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U[68?#V
MBW5]/_JK6,R-[X[?CT_&K=><_M):ZUAX2M;%6VM?S9;W1.3_ ./%: /&]>UJ
M;Q!J]Q?7+;IKIR[>V>P]AT^@K+N)<"I9I,"J-Q+6AF17,VT5FWEQBIKNXK)O
MKG&: *]_==:PM2O, U:U&\P#6!J=[UJD!3U2]X-8-W/YTE6-2O-[8J/2H1+=
M*S=%.?J:H#IO!FG#3[?<P_>R\M[#L*[+36Y%<OI#\K72:8WW:E@=!8OPM:ML
M>:Q[%^*U;8]*D#2B/RU].?#>Y^U^ -&?K_H<:G\% _I7S# >*^CO@I<_:OAC
MI;9Y570\],2,*F143JJ***DH**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/!^A?\(SX6L+#C=:PJCD=VQEC^)S4R*B:5%%%24%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N)_:0L/[2^ GB^/^[I4\O7'W$+_P#LM=M6/\1-
M._MCX?Z[:8S]JT^XAQZ[HV']:%N!^;>COTKJ-)?BN1T9_NUU&DO6YF=1IK<5
MN639Q7/Z8W-;EB_"U &O;'FKZ\"J>G1;OF[#I[U<H "<"JMQ+4D\F!5*XEH
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ([NZCL;62:5@D4*%W8]%4#)-?,?C7Q3+XP\2W6H39_?/^[7^X@X
M5?R_7->V?'O7CHOP\N(U;;)?2+;#!YP<LWYJI'XU\]S28%5$F1'<2XJC<38%
M23RYK/N[BJ)(;RXQ6/?W56+ZYP*Q=0N\ _K3 JZE>8!_SBN?U2]QGFK6IWO7
MFN=U.\W&J0%>]N?.DKH/!.FBV7SF'[R08'L/_KUSMC#Y]PN[[H.3[UV&D/\
M=I@=3IC_ ':W;%N!7.Z8WW:WK%^*S VK9NE7X3Q69:MP*T;<\4 ?1GP-N/M'
MPPTWUC\Q#^$C8_3%=;7!_LYW/G_#UE_YXW4B?3A6_K7>5#W- HHHI %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!Y1^U)>-%8Z-#SMD>5S]5"#_ -F-
M>*W$M>T?M5VK'2]'N.=L<LL9],L%/_LIKPZYFVBKCL2]R&ZFQ67>W.*FO+C
MK(O[K&:9)6O[OK6%J=[UYJSJ5YC-<_JE[C-4@*FJ7N,\UC22>8^:DO+CSGK:
M\2?#;4O"G@G0=<O8_)M_$9N#:(1\S)$8P7/L2_'L,]ZH#'TYL35U&D/]VN4L
MVVS"NETA^!0!UFF/6_8-TKFM,?(%=!I[XVU &Y:'*BM&V;BLNS/RUI6S<4@/
M<?V9+K?X9U*'_GG=!\9_O(!_[+7IE>3_ ++KL8=;7^$& CZGS,_R%>L5$MS1
M;!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R
MFO\ P-\(>)KEIKSP]ICS,<M(D7E.Q]24P3^-+H?P.\(^'9UDM=!T]9%.0TB>
M:5/MO)Q7544 "J$4 # '  [4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445S/C?XU>#?AGJ$-IXD\6>&?#]U<1^=%#J6J06DDB9(W*LC
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M T=O^S3?RZ7O %Q)X]2.X*<9/E#3V7/7CS.?44 ?O?17YV_\$LO^#D_X,_\
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M)_&'Q&U*$S:;X/TF=%NF3'$UU*<K:P$X 9@SMDE(W"OM](_X*O\ _!0K1?\
M@F)^P_XN^*NJ1P7NI62+I_A[39'V_P!K:I,&%O!Z[1AI'QR(X9".0!7\9/Q.
M^)?CK]L/X_ZEXD\07>K>,_B!X^U4/,XC,UUJ5W,X1(HXU'<E42-!@ *J@  4
M ?H=^TG_ ,'=O[7'QEURX;P?JOA+X4:0S,L-KHNB07UQY9S@23WJS;GP?O1K
M'R,@"O*O"W_!S3^V]X4U-;F/XXWUZ. \-]X>TFXBD&<XPUJ2,XZJ0?>OUC_X
M)6?\&AOPQ^''PQTKQ/\ M,6MUXZ\>:E )YO#%OJ4EKH^@EL%8GDMV62YF7^)
MO,$.25"N )&^O/B]_P &U/[%WQ?\-2Z?)\%],\.SLN(;_0-1N]/N;9O[PVR^
M6YY/$B.OMP, 'QC_ ,$'O^#F;XO?\% ?VJ-!^"GQ%^&VAZ]J&M07-P/%'APO
M8_V;#!$TKRW=O(7C93@)NC:/YF10C%J_;JO@7_@CE_P0-\$_\$?/B?\ $SQ+
MH/BK4?&MUXU6"PTJXU.QCAO-%TZ,F1[9I(SME:278SNJQJ?)B^0$$G[2^-'Q
MJ\)_LZ_"[6O&OCKQ!I?A;PKX>MS=:AJ>H3"&"V08 R3U9F(557+.S*J@L0"
M=117XB?M&?\ ![3\,_ OCBYT_P"&7P9\3_$+1[65HAJNJZXGA]+H D>9%$+>
MY?8< CS!&V#RJGBOJW_@E%_P<B?!7_@J%XGG\(_8]1^&/Q#@M9;Y-%UNYCEM
MM0@B4O*UM=KM60QH"[(Z1L%#, RJY4 _0ZBOR-\&_P#!X=\#?B1\<M*\"^'?
MAG\5M6O=>UV'0=,NHX[%8;R2:X$$4@!N-X5RRG!&[!Z9XK]<J "BOR1\7_\
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M[??QD^(,<PGL_%7B_4KVQ<'(^R?:'6V&>^(5C&?:O[)O^"DWQ[;]E[_@G_\
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MV!(!\/\ _!&O_@F?)_P5?_;4M/A6WB*X\)Z:FCWFM:CJL%D+R2TA@557$9=
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M= !7Y"_\'Q7Q0M9]:_9W\%PR1M?6L&MZW=H1\T<<C64,!'/1FBN,Y'\ P>M
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M7&?^?@VC9Y V^I! !_.G^VA^U]XS_;O_ &EO%7Q2\>7[7WB#Q1=F9D#'R;&
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M  ;C? 7_ (9]_P"",WP2L)(/)O?$>E2>*;ERFUIO[0GDNH6/K_H\D"@]PHH
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M 4444 %8GQ+\>V/PK^'/B#Q1JD@CTSPWIMQJEVY.W9#!$TKG/;"J:VZ^:?\
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M$_;6_93T']N+]E'QY\)O$LLMMI'CK29=.>YB7?)92G#PW"*2 S13+'( 3@E
M#P:_DY_:;_X-QOVO?V;/B1?:&OPB\0^.]-AF9++6_"<7]J66H1CI(!'^]BS_
M '9D1@>Q&"0#^CO_ (*<?\%U?@C^P#^R_JGBO3?'7@WQSXTU*R/_  BGA[1]
M7AOY=5N'4^5+((7;R[53\SRL0"JE5+.RJ?X]?'_CO5OBEX\UOQ-KUY+J6N>(
MK^?5-1NY?OW5S/(TLLC>[.S$_6OV!_X)(?\ !I?\4OC#\5-+\5_M)Z.WP_\
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M^WUXF^-'PP\'V7CSPKK^G:?#]ETW4X8]3LFMK1('WP3&,OEH\KY)D)##(!R
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M2OX=3U;P?I!CU&XA8M"UW--)<SB,D F-99G520"553@=*^@* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **_!'Q9_P>__
M /"+^*M3TS_AF+S_ .SKN6U\S_A8VWS-CE=V/[+.,XSC)K/_ .(YS_JUW_S)
M'_WKH _?ZBOP!_XCG/\ JUW_ ,R1_P#>NC_B.<_ZM=_\R1_]ZZ /W^HKR_\
M8I_:1_X;"_9'^'/Q4_L7_A'?^%@>'[37?[,^U_;/L'GQB3RO.V1^9MSC=L7/
MH*]0H **** "BBOYRO\ @ZF_X*-?'G]E;_@IM8>&?AO\7/'W@?P])X)TZ];3
MM&UB:TMVG>XNU>38A W$(H)[[10!_1K17R'_ ,$%_B]XH^/7_!(_X+^+O&FO
MZKXH\4:UIMW)?ZIJ5PUQ=7;+J%TBEW;)8A55>>RBOKR@ HHHH **** "BBB@
M HHKB]0_:3^'6D_%%/ ]UX^\%VWC21TB3P_+KELFJ,[H)$46Q?S260A@-O*D
M$<&@#M**** "BBB@ HHHH **_F5_X.4O^"FG[0G[-?\ P5P\>>$?A_\ &;XB
M>#_"]AIND26^EZ3K<UK:P-)I\#N516 !9F+'U)-?N1_P16^*/B+XU?\ !*OX
M'^*O%VM:EXC\2:YX;CN=0U/4)VGNKR4R2 O([<LV .3Z4 ?45%?C#_P=&?\
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M5YFU=^W?MW;5SC.!G%=A0 4444 %%?'W_!:'_@KKH?\ P1Y_9NT7QO?>%_\
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M_3?^R@:7_P"DU]0!^4/_  ; ?\$R_@__ ,%,_CQ\4-"^+^@7VO:;X9T"UO\
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M'^%!=&/2_#5F SL[?PY2%&DGG(+L$.. D8 /Z3]1_P"#AO\ 8NTOQ"VF2?M
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M2-TCMM1%SRSJ.] &K\6OC-X1^ G@FY\2^./%'A[P?X=LR!/J>M:A%8VD1.<
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M_P"#4']B3QMX>DLM-^&^O^#[F12JW^D>+=3EN(R>A NYIXLCMF,CGD&OR?\
M^#*G_E*;X^_[)5J/_IWT>OZ?J /XM?\ @L9_P3#UK_@D5^VK=?#R76Y->T6\
MLH?$'AG61'Y$]U9222(OF*I(2:.6&1&VG!V*X"APH_IR_P"#>S]MW6OV]?\
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M),##9\T\C'/]2W_#IW]EG_HVG]G_ /\ #>:1_P#(]'_#IW]EG_HVG]G_ /\
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M?M%6]TGF11^!]0NE'I)#'YL9_!T4_A7IG_!/;_DP7X'_ /9/]!_]-UO7G_\
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MWH:_EW_X-5?'Z>!_^"VGPPMY93#%XCL=8TIC@$,3IMQ,BG/(R\* 8YR0.A-
M']=%?G!_P=@?\H2OB-_V%=$_].=O7Z/U^<'_  =@?\H2OB-_V%=$_P#3G;T
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M#_P?%_\ )5/V=O\ L%:Y_P"CK&OJ#_@RI_Y19>/O^RJZC_Z:-'KY?_X/B_\
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M??\ P3\^'7_!2GX&0_#OXGVVK77AN'5(=85-.O6LYOM$22(AW@$[<2OQWXH
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M .4R7[0G_8UR_P#HJ.@#^MW_ ()[?\F"_ __ +)_H/\ Z;K>O8*\?_X)[?\
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M.+_@Y"_Y3:_'S_L*V7_ILM*_L=HH \?_ .">W_)@OP/_ .R?Z#_Z;K>O/_\
M@M;_ ,HC_P!HW_LG^K?^DSU]044 ?R1?\&G_ /RFU^'/_8*UO_TV7%?T9_\
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M5TVZAOM-U*WCN[6XB;='<12*&1U/=64@@^AK\[/^#L#_ )0E?$;_ +"NB?\
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MU#2;>YD[?Q.A/8?D*M^#OA3X7^'8QX?\-Z!H?!'_ !+]/AM>#@G[BCK@9^E
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P_\
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MH='1MRNIY!!'4'UI]?R!?\$E?^"[?QG_ ."2'Q:M_"^M7&N>)?A;:WILM?\
M!&KN_FZ5M<K*UGYGS6EQ&=V8^(W(*NN[:Z?UI_ _XU>&?VCO@_X;\>>#=4AU
MKPMXLT^+4],O8@0)X9%#+D'E6'1E8 JP((!!% '54444 %%%?E'_ ,%Q?^#F
M;P;_ ,$_(M8^&OPCDTOQU\:$#VUW-N\[2?",G0_:"IQ-<KSB!3A&'[PC'EL
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M4D)NRJ@D>8UY))#D<LL$>>F!PW_!++XUZU_P1K_X+=:+8^,+A=/M_"_BF[\
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M]C_8V74_!7PH^/>FV?\ I.EW$G@K79E&6:"4/=6)/<*DBWBY/&9T''&?R/\
M^"/G[(UY_P %$_\ @IE\)_A_J@GU;1[C4H+O7C<LTJC2-/C$LT+$YVJ8(!;H
M#\H+QKC&!0!_4-_P;]?L6?\ ##'_  2I^&7AJ\M3:^)/$EI_PEFOJPPXO+X+
M*$<?WHH/(A/_ %QK^9+_ (+[_P#*9+]H3_L:Y?\ T5'7]GB((T"J JJ,  <
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M!#';OYA4.2!YBY('/:OSY_X-O?\ E-K\ _\ L*WO_ILNZ /[':_AC_X*$_\
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MPG7S7B[^;!+$D@ .)%0KGYPP_3[_ (-"?^"0W_"#^%9?VIO'VDA=6UV&2P\
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MOX^TGQ1\9/AW_P )CKNAZ?\ V797/]O:GI_D6WF/+LV6MS$C?/(YRP+<XS@
M5[!^S=^SAX+_ &1O@EH'PY^'FC?\(_X-\+Q/!IFG_:Y[O[,CRO*P\V=WE;+R
M.<LY/..@ KN** //?VI?V5? '[:OP0UCX<?$[P[#XI\&:\86O=/DN9K7S&AE
M2:-EE@=)8V62-3E'4G!!R"0?(_V*_P#@C1^S7_P3P^)U_P",O@]\-(O"/B;4
M]-?2+B^;7-3U%FM7DCE:,+=W$JKEXHR2H#?+C.,@_3U% !7QA\?O^#>S]C_]
MJ'XR>(?B!XZ^$7]N>+O%5V;[5+__ (2K6K7[5,0 6\N&\2-> .$4#VK[/HH
MS_"?A:Q\#>%=,T32[?[+I>CVD5C9P[V?R88D"(NYB6.%4#)))QR2:T*** /.
M_P!H_P#9)^&/[7_@O_A'OBAX#\+^.M(4EHH=7L([AK9CU>)R-\3<8W(5..,U
M\/\ CK_@TY_8K\8ZNUU:> _$OAM78LUOIGBF^\DDXZ"=Y2!D$@ @#<>V /TD
MHH _.+P-_P &HO[$_@^YCEN_ASKWB-HWW@:GXJU':>F 5@EB! QT/7)SD<5]
M<_LV_P#!/#X%_L?F.3X9_"7P'X-O(U*?;]/T>%=0=3QAKH@S,/9G->R44 %?
M#'Q"_P"#:[]BGXJ^/M<\4:]\%_M^N^)-0N-4U&Y_X2[78OM%S/(TLK[$O51=
MSLQPH"C.  .*^YZ* /@#_B%Q_83_ .B&_P#EY^(/_DZO6_@?_P $3OV3OV=-
M7AU#PK\!?AW;ZA;.)(+O4-/_ +6N+=QR&CDNS*R,/[RD'WKZDHH 1$$:!5 5
M5&  . *6BB@ KY9_;<_X(L?LT?\ !0K7FUOXG?##2M0\3LH4Z]IL\VEZG)@
M+YLUNZ&?"C:!,'"CH!@8^IJ* /SK^$7_  :N?L7_  F\40ZM)\.M5\536[!X
MH-?U^ZNK5#_M0JR)(/\ 9D#+[5^@7@_P;H_P\\+:?H?A_2M-T/1=*@6VLM/T
M^V2UM;.)1A8XXD 5% X"J !6E10 4444 ?-_[;W_  2/_9[_ ."COBK0];^,
MWP__ .$RU3PW:/8Z=-_;NI:=]GA=][+MM+B)6RW.6!/OBO0/V0OV,_AK^P;\
M&X?A_P#"CPW_ ,(KX1M[N:^CL/[0NK[;-*09&\RYEDDY('!; [ 5ZA10 5\T
M_P#!1;_@DM\%?^"ING^%H?B]HFK:I)X+^U_V-<:?JL]C)9_:O(\_A#M?=]FA
M^^K8VG&,FOI:B@#\U?"/_!I?^Q9X9U1;B[\$^*]>C4@_9[_Q5>K$<>OD/&W_
M (]7VY^S%^Q?\)_V+_"<FB?"KX>^%? FGW&TW(TFP2&:]*\*T\V#),P' :1F
M..]>G44 %%%% !7#_M+_  "T/]JG]GOQI\-_$T;2:#XXT:ZT6\*CYXDGC9/,
M3T="0RGLR@UW%% '\>__  3V^+7B;_@@[_P6TTZS^("RZ9;^$==G\(^, 498
MKG2KDB-KM1U:(*8+R/'WA''V-?V!:=J-OJ^GP7=I/#=6MU&LT,T+AXYD895E
M8<%2"""."#7Y]_\ !8__ (-X/AS_ ,%<_'7AWQE-XDO?AQXXT: V%[J^GZ;'
M>#6K0<QQSQLZ9>)B=D@;.UV5@P";/IS_ ()X?LH:]^P_^R=X9^%NO?$*\^)B
M^#XS8Z9K%YIHL;E+%<>1;.HDD#^4,HKY'R!%QE=S '"_MD_\$4OV9?\ @H%\
M7(_'?Q=^&?\ PEOBJ'3XM+2^_P"$BU6PQ;1,[(GEVMS%'PTCG.W<=W).!CVC
M]ES]ESP)^Q;\"=#^&?PST/\ X1OP3X:^T?V;IOVVXO/LWGW$MS+^]N)))6W3
M32-\SG&[ P  /0** "BBB@ KX0\6?\&S7[$7CCQ3J6M:I\$_M6IZQ=RWUW-_
MPF&O)YTTKEW;:M\%&68G   SP *^[Z* /@#_ (A<?V$_^B&_^7GX@_\ DZO8
M_@7_ ,$8/V5/V;M:AU+PC\!_AW9ZG:MOM[V]TT:G<VS9SNCENC*Z-VRI!QQT
MXKZ<HH **** "BBB@ HHHH ^?_VY_P#@EQ\"?^"E'_"+_P#"Z_ O_":?\(7]
MK_L;_B=:AIOV/[5Y'G_\>D\6_=]GA^_NQLXQEL]!^Q5^P5\)_P#@G;\+-0\$
M_!WPI_PA_AG5-5DUNZL_[3O-0\V\DAAA>7S+J6609CMX5VA@HV9 R23[!10
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M'/@+0_BAX2OO#_B;1=)\1:#JD?E7FFZG9QW=I=ID';)%("CKD X8$9 KX/\
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M=7UU\$/-NKR5YYG_ .$RU]=[L2S' O@!DD\#BOO>B@#X _XA<?V$_P#HAO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>mgnx-20201231_g5.jpg
<TEXT>
begin 644 mgnx-20201231_g5.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO:&XN4V-A
M;&QO;@    60 P "    %   $*:0!  "    %   $+J2D0 "     S(V  "2
MD@ "     S(V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_P"%U>(O^?+2_P#OU)_\<KSRDS1[6?</['R__GTCT3_A=7B+_GRTO_OU)_\
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M$2[41>BBNVE1Y'S7N?GN<9S];I>P47%IZ_(GHHHKI/E@HHHH **** "C%%%
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MQ'Q9\27GACP3]JT^\ALI9[J&W:XEB\WRD=L.P3^(@9.#[T >>Z=8^"];\9:
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M=!Y([B*,\.KQG!_$9%=W8Z[I>HQJUG?029[!QD?A04:%%&110 4444 %%%%
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MVE)#M=I=8U+:5LEXR%7J6/Y<5Z+5/5=)L-;T]['5[2*\M7(+0S+N5L'(X^M
M'B7A_2[*^@D\(_#.6ZDMW,::WXH=CED3_EE$W<]5&.%%>[QJ$C5!DA1CDY-9
M&IL?#7AMGT+2!.EOMQ9VJA3LW ,4'0D+D@=\5Y)X/UV\\(-ICZE-JESJ6JR3
MK)IEPQ\R6,396[<,<1!8\Y'&<"@#W2BJ>F:M8:S9B[TJ\AO+=B0)8'#+D=1D
M5<H **** *6J:BFFVGFL-S$X5?4UPUS=2WD[33L69O?I["M7Q/=^?J0@4_+"
MN#_O&L6F 4R6"*=-D\:2+UPZ@BH;S4+73XP]W,L:GIGJ?PJ6&:*YA66!Q)&W
M1E/!H$+%!% NV&-(U]%7 IS,%&3@ =23TI:P/%EE?7FGQBQ!=48F2-3RW% S
M=1TD7<C!AZ@YIU<GX+MKRW>Y^T1O'$0N%<$<^U=//.ENFZ0\>@ZT 2UDZKX<
ML]6N5GG,B.%VY0CD?E4YU6//$;$5)%J,,C!3N4GU% !INFV^EV@M[4-MW%B6
M.22:N4TL%4DG '>JG]IP;R/FQV;% %RBHXYHYES&P85)0 4448H$*I*.&4D,
MIR".U=EHVNI?J(9_DN /P?Z5Y/XA\3RZ7>"UM8E=PH9F<'C/:M+P]J\NJ6'V
MED$4J.5.P_K0,]>HKG-'\1APL&H'#=%E['ZUT8.1D4@"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 0C(XKSK6/ ^I0Z#=W%O!9ZYKM_&UMJ%S,/
ML[W$!# *A&0A4%>G!V\UZ-10!\Z6_BG4/"'A!--\(:4IUN1[?3-1U #;;)<_
M<41J<!Y,'YB!CY<G->O>"]?L9$E\.3:W-J.M:63'=F[C\J60Y/SA<#*^A&:T
M-?\ #FF:I+I]]?JX&DW)O8TC^ZSA2,LO\77/UKC_ (?Z;=>*O%E[\1-;MV@$
MZ&UT:VD7:\-L"<NP[,_\OK0!Z;6!K'B)+<-!9'?+T+]E_P 36GJT_P!GTFXD
M'!"$#ZGBN [9H <[M)(SR,69CDD]Z;UKG]-\5V^N^&[O5-(20K \D>V5<$LO
M]*PO#&J7<GB "2=Y5GSY@8Y'3K3 T/%ND7UY>1W%HC31JF"JG[ISZ5J>&+&Y
MT_2/)O%*-O+!2<X!Q_\ 7K9^M'''- !12,X5<L< =34+7MNH/[U2<4"*SZGM
M=AY><''6J5Q<-<2;CP.P]*BSNY]Z3\:0Q:.M<_KWC'3_  _?06ES'<7$]PA=
M$MH]YP.O J"X\;VT6GV=S'I]]))?3F&"V,6R1F'7@GI0!U1FD:+RV=BH[4RN
M?TWQ6NJ:Y/IMOIMT/L^%GF8+MB<C.T\YSVKH,\_I0 JLR-E&*GVJ_!J948G!
M/^T!6:SA5+$\*,GVJ#3[^VU2QCO+"436\N=CJ.#@X_F* .B2_MW;&_!/]X8J
MR"&&17.=1UK1TISND7.> 0*8"ZGH5CJTBO=(V]1@,K8.*GT_3K?3+7[/:@A-
MV[YCDDUA>(?'NE>'M133Y8[J]OF3>;>SA,CHOJWI6SH^KVVMZ1#J-EY@@F!*
MB5"K*02""#T.0: +QYKK?#.I?:+8VLK9DB'RY[K7G.O^);?P_<:7#<PRR'4K
MH6L93'RL>YSVJ[X*\4PZQXANHK6.6%M.OC9RE\8<]R,=J /5Z***0!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %   XX%%9NN:@VG6&^,9D<[5
M/8'UH SO%&HQ^3]BC.7)!?'8>E<L?NFG.[2,7D8LQ/+$]::"&]_I3 \"LVF/
MPWTZ&WN9K<S^)FB9X7*MAN#S6M'X1LQXI\6Z7'=WR66GV:W%O$MRPVR%,[B>
M_3]:]67P[HZV\=NFF6HACF^T(@B&%D_O@>OO4XTJQ%S<W M(?.ND"3R;.95Q
MC#'O0!Y' ]UX@_X5W:WVH7:K>6]P+AHIF5I0HZ$@]P,5G3:2\/A7Q;<KJ>H[
M]"U Q6 -TV(E#CMGG(->MQ1Z!#X@M-)M[*$7MA;--;A(N+>-CM.#_#GT[U>.
MAZ6UO=0-86YBO',ERGEC$K>K#N: /-+GQ"+'Q],^JW_D0W&A02 2R85GQDD#
MIFN5MI+B_P##?@^%[VY076H2QR21RD,5+8Z_2O7=;T;2-0O83<Z?;3M:H$C+
MQ@[ .@%54T3342W5+"W5;9S)" @_=L>X]#2 \SO+B]T+3/&-GI=U<"*UGA$1
M:4LT2O\ >P3R*V/#-C>QZXDUI<VL-I/9'=!%?F<R-VDP>G7DUW']E6.ZY;[)
M#NNL>>=@_>X&/F]:AT_0-)TN9I=-TZVM9&&"\484D>E 'EWB!;FT\?:0/MRZ
M7,(W!N90"$]^>.:T]=L(-1U/PHUQJ1U)YKEX9;J"7:K@<\;3@'G&17H%_HNF
M:K(CZE86]TT8(0RQABH_&B+0]+@6W6"PMXQ;N7A"Q@>6QZD>AH \K>U.CVWC
M.ZTI[A+BSG$4;B9B51N&)YY..YZ5IZ-!J%I<1ZAIMQ;1Q-ITA>&/4&G:=PF5
M?:1U!ZUZ,NFV4?V@I:P@W1S.0G^MXQ\WK5>Q\/:1ILYGT_3;6VE((+QQA3CZ
MT <-X2M-%U/PY!-<ZI--JMW!+YZ"\;<YYR"N>,8%8=G<1V/PQTXV-[)"UU>Q
MQ:@T<YS#'O?MGY,C\Z]272-&T=I]1@T^VMW6-GEF2(!MH&3T]J9IVE:%<Z69
M+#3[7[)J"K(X$0 E'4$C\: .)#1:=XIU2R\.WDD^G_V+)+.HG,BQ28."#G@]
M/SKH_AK8M8>'+75?M5Q/=WUNOF--*6 &>  >F*W+/0]+T^WEAL;"W@CF&)%C
MC #CT/K5FVMH;.V2VM8EAAC7"1H,!1Z 4 <CX9UJSTCXL>)_[?GAM9[P1O;S
M3L%!0#H"?P_*F>*M8&M^.-(M+&:"ZT>>TEDC1KQK>&>0.5)W#J1CBN@UZUT5
M;5M1UW3X+N*T7<3)")"%[_A6S#IWAW6],M;>33+.:U10UO&T(**#S\M,#SF[
MMK^STSP?!J=[#>/'XAQ$\5QYP5,C"ESU(Y%==\+Y!#XA\62'HFNNW%7=<_L7
M0K6SM(-)M7:W?SK:+RP%A;^^/0YK2\.3Z==6\]QIUK';2S2[[I47!:0]6..N
M?6@#V"">.XA66%@R,,@BI*X;2-7ETV8*Q+V['YD]/<5W"L'4,.A&12 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q?%*YTE3_ '90?YUM53U6
MS^W:;+ /O$97ZCD4 >5>)DF?P_<"VSN&"<=<9YKEO"-Q>_VPD43LUN03*I)*
M@>OUZ5W[#!(/'."#3(X8XL^5&B9.3M4#-,!^****!'F5YJ-YINN_$34+)2U[
M:VEMY'&=J^6>1].3^%9_A+Q/=Q3RW<VJF33EL ]P+B]$[B08S(!C*CG&*[O5
MO"R7>HWNI6D[PW-W:K;2IG"2A6R">^<9'T-8&G>"CILS7,]M:Q1D%72-5_>
M]C@<BD,Y'Q=KT]WKHAL-2FA2:P22V>.Y$"!V;[S9QN&*[.VUG3["%K&YOQ)-
M8VBS7#NQ8[,??+=ZI:KX*MM3O9KA+J2W%Q"L$D2QHR[!V7<#MZ]JT)O#5A+H
MW]F>64A,*0,ZXWO&N,*6ZD<4 4/&>IR1^ ;K4-+N6C+1QO%-&<'!9>1^!KE;
MNWU.+4]5LE\0:D8[?3%O5/F?,9,'OV7V%>E&T@:U%LT,9@50HB*@J .@Q0;2
MW,C.T$99UV,Q499?0^WM0!Y?K7B&XGT6"1+Z\BOXM*CN69;H0QY/<+U=B>HJ
M]%JDNH^)%CU?6Y].BAT^WFA6.41B5V +$_WN>,5WKZ3I\K(TMC;.8UV)NB4[
M5]!QTI9-+L9GC::RMY&B&(R\0)0>WI0!YI>ZQJ5M!XFU!-6NC/9W<EO;6^<H
MB$C+8]L\>F*D35)K.\NXM'URYU.W;1GN)'DEWF&4#@@_P_2NRUG1//?S+2WB
M._/FJH WD]SZTMGX9MH="N[#RH[<WB,DC0J!@$8H X.SU:XD:!+?6Y]3%[HU
MQ)>Q.^Y8F$9Q@?P\\?\ ZZN: ]UHCZ S:E>36U[I4TLL+'*Q[$##8.Q ./PK
MO=,T*PTNR2W@MHLK$(GD\M0T@ Q\Q YJV+.V'EXMX@8E*QX0?(#U ]!0!Y98
M^(;N+45DLK^Z:"XTJXGQ=7(G8,JDJQ4?<.1TJ.QU;51HM_JUAJ5Q,8-.7]S+
M>"5C,2 \@49P "37I-UX<TRXL+BU2TBMA/&R-);HJ,-PP<$"L_1_!=KI>H)>
M2W#W4D=O]FC#QHBA/0A0-Q]S0!A:";J>WU(7=^MSILVF%C&]Z+AU;!RW'W01
MV]:[7X:6\A\ Z/<7/,K6PQG^[SC],56N_#MA-I5W96L$=B+N,QR26T:HV#UZ
M"NGT2.&WTF"TMUVI;1K$H]@,#]* *^M>'8-9ECDDE:)T7;E0#D5/HVBPZ-!)
M'"[2&1MS,V!6C0.U,"UIMO\ :M2@BQD%^?H.37H(X%<7X9Q_;*Y&3L;'M7:4
M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,>X\,V5Q</,
MS3(7.2$( S^51_\ ")V/_/6X_P"^E_PHHH /^$3L?^>MQ_WTO^%'_")V/_/6
MX_[Z7_"BB@ _X1.Q_P">MQ_WTO\ A44_@S3KB/8\UT!G/#+_ /$T44 5_P#A
M7^E?\_%Y_P!]K_\ $T?\*_TK_GXO/^^U_P#B:** #_A7^E?\_%Y_WVO_ ,31
M_P *_P!*_P"?B\_[[7_XFBB@ _X5_I7_ #\7G_?:_P#Q-'_"O]*_Y^+S_OM?
M_B:** #_ (5_I7_/Q>?]]K_\31_PK_2O^?B\_P"^U_\ B:** #_A7^E?\_%Y
M_P!]K_\ $T?\*_TK_GXO/^^U_P#B:** #_A7^E?\_%Y_WVO_ ,31_P *_P!*
M_P"?B\_[[7_XFBB@ _X5_I7_ #\7G_?:_P#Q-2V_@?3;=RT=Q=G(P077_P")
MHHH L?\ ")V/_/6X_P"^E_PH_P"$3L?^>MQ_WTO^%%% %BR\/VMA=+<0R3%E
@!&&88_E6I110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>mgnx-20201231_g6.jpg
<TEXT>
begin 644 mgnx-20201231_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K\3=<_;W_:*_X+D?\%F-;_X)L_L\_'GQ-\,_V>_A;%J-UX^UGP%J
MC6&L>+([">.UGQ>QXDA@ENIHX42-@&A+RL&8JL?[95_.;_P;_>'=8_X)M_\
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MQ+X\M]"N/BAIO@[71!#J%L8KDZ?=+%!%-'%/%(C*^55R!M+['2OIGX4_M?\
M[,G[('[#_P !3\4?VI]5^(">+O#&BZ-X%\41^']0U#6O']RUG&4N8+"WCFNY
M7E3$K95B@<>8^3D_&G_!T/\ L\_ C]F[_@B7XI\(_L^_!SPSX)TK4_BOI&JZ
MCIOA;18;&"XO992)+ATA55:1@B MC.$4=  /+OVG/^"=_P ;/VY?^"5'["'C
M7]B_XWCPW\?OA1\#[/Q)\//#W]IM92ZW:)8:*MX]M<\)!<PRFPV%RJ-Y[*Q
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M\M8VQ+=WBM%Y#H\GG3D*R%F"+GH?A_\ \%@?^"<?Q6^ 7BW]J+X;_M*VNM>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;J"V5-BH+R>9[G*K@*YDWK@8(P,=-10!\H_!_P#X(C_\$TO@%X2^)'@;X/\
MP)UO0M*^+VC'2OB3:VOQ1\2-_;MJ6D8I*SZBS GS9E+H5<I/*A8I*ZMZ7^Q;
M^P+^RE_P3S^'=_\ "7]D'X;W?A/PWJ6IG4;K1Y?%6IZG"+HHJ-+&+^YG\DLJ
MJ&\O:&VJ2"0*]CHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH_8KR71O#&K7<]O)B,[Y+>*T:6.+]]&/.91&68(&+_+4'_!.+]O6S_X*._\
M!&RV_:,O-2BF\2CX?ZEHWCN)"-T.M6EH\5RS*/N>;\ERJ]DN$K\?O^"-FAZ+
M)_P;*?MR:M)I%L;J:[O8YKHP+YDB0Z79R1*S8R0CN[*#PI=B,$F@#]G?BU_P
M7@_X)/?!/PMX5\<>./VOM*;1_&5I;76CZEHNB:CJ4,<4X8Q&Y:TMY/L3,$<^
M7/Y<GR/\OR-CWKXR?M6_LX?L^? 6?]J#XR?&70M!^']OI\-[_P )5=7@:UF@
MF"F%H2FXSF3<OEK&&9]P"@DBOYZOB#HVD6/_  98>!KVRTJVAFO/BQ-<7DT4
M"JT\P\0:A$)'(&6?RXT3<>=J*O0 5J?\%O-1^)>H_P#!''_@FEI4TUS+X$N_
M">D#Q5YC'[.]\FCZ4E@)#TS]G;4MN>P?T- '[J? K_@HI^R7^T/\5#\"O WC
M_4M.\<'08M<MO!WC3PCJ?A[5+S3),[+VWMM3MX)+F#@@O$&"D$-M((KF?B!_
MP5__ ."</PH^/&N?LQ_$[]IW3_#_ (]\.QN^K>&M8T34;>= L0E787MPLQD1
MD,0C9C/YD8BWEU!_-O\ X+EWWQ L?^#D7]AB7X.F8>(O-TE+G[(#YATU]<F2
M[#D<^2;0W@?_ &#)5*_TK2]4_P"#VF'^T]-M[G[-X&6>W\^%7\J5?"1VR+D?
M*PR<$<C- 'ZH?L0?\%*OV*O^"C6B^(-;_8]^-4/BH>%+Z.T\16<ND7FGW=A)
M(',9DM[R&*4(_ER;7V[28W&<HP'(>)_^"SW_  3A\)W/C*6]^/MQ>Z1\.]5@
MTOQWXMT/P9J^HZ%H-[-)Y4=O<ZG:VDEK&YDPA_>85F4,5) /YA?\&^.@7?B[
M_@L-_P %#OA]8Z]<Z4FL:[XAM5O+$XDM7?Q!?QI,G3#IYA*].:YC]AW]C;]J
M;X3?\$>?VK?^"7?P]^ -_P#%'Q3XS^*%SIW@WQ]X&N[6?PSJYV:?:W#G4)YH
MXX!:/9RF02!6$C&,;G1P@!^X?[,?[6?[/'[9?P]G^*_[,WQ,M?%GAZWU)M/E
MU2SM9XH_M"PQ3% )HT9OW<\3;@"I#C!ZX^/O^"_'[-OQR^-OPC\"Z7^R3\;/
MB!X&^)>N^+M3L])NO!7CC4=-&IFU\)Z]JL5B\4$ZQMYT^F6\88KE=Y(/)S]"
M_P#!*S]E'XB?L._\$]?A7^RG\6?&D6O^(_!OAO[+JVHVTKR0B5YY9_L\3. S
M10B40(2!E(5.U>@T?VL&4?'K]F12PR?C?J&!GK_Q0OBR@#X1_P"#37_@I3XW
M_;,_8W\2?L]?'SXBZKXB^(GPHUT^;JGB+4I+J_U'1[UGEMY999F,DSQ3+<PD
MDG8BP GD"OA'_@O7^V)^V!JW[>OPR^)7PP_:O^)7A#X?_$W6I],\)^'_  =X
MXO\ 2K6;0M/U---%]LMID5WNYUOKE)L9:WGM1_!D]'\8_P!E?]J3_@G'_P '
M+M[\)OV*8)=+T?\ :JT74HM*N[8,L>E:?JJ2/J5TFT%0^FW<$M\D>.(X85.!
M)FG_ /!U?X \(_"?]N/]CKX6^ -&BT[0O#?ABTTO1=/A^Y;6EOJ=O%#$OLJ(
MH_"@#]U_B9\;/V<?V)?A]HMO\3?'LFBV&HZK'I/AJPN9K[5]4UB_F8E+2T@7
MS[R_N&))$4:R/@'C XYG]FG_ (*2_L=_M9_%SQ5^S[\(/B==KX_\$J'\4>!?
M%'AC4=#U>QC.S]Z;348(97C_ 'D>7164>9'DC>N?C#_@X\\8_L/>$?%O[-FL
M?'OPYXM\1?%_3_B(TWP,\-^&_%ZZ):37SW-@)9=4NVBD\BR69+++QKYV<B,J
M#(R_+_[&O_"RH/\ @\@^),/Q;\7Z!K/B8_#Y%UV^\*6$EIIYG_X1G22T,,<D
MLKA8B!%EW+,T19@A)50#]8_VEO\ @J+^Q'^R5XJUKP/\9?BS>+J_AC04UOQ;
M8>&_">IZW)X>TQW5%O-0_LZVG%E$2ZX,Q0L&W*"N2)/BK_P5$_8+^"O[.WA;
M]K;XB?M$Z=;?#3QHRIX<\;66F7M]I]R[!BL;2VL$@A<[)!LEV-NCD7&Y& _)
MC_@A1XM\#?&__@I[_P %"OV*?VX;=+[Q+\9-9O+?4-&U:Y:*2^L;.^U:UO;.
M!\JXVP7T!01D%8H0ZX$>1W__  <;?LU_LW?L=?\ !OOIO[,/[*-M%;^#O!OQ
M:L+2WLUUEK^2WNGGOKBY2:5W9O-\Z9RRL05W8P    ?HIX5_X*[?\$Z/'/[2
MG@[]D3P9^T]I&J?$'Q[H$&L^&=!L;"[?S[2>R^WP&680^5;226O[Y89G20J5
M^7+H&9\4?^"NG[ 7PA\:>,? _BKXT7MU/\.98(OB/J7ASP9J^KZ;X3DF<I&F
MI7UC:RVUFQ<,I620%"C;PNTX\Z_X)O?L5?L\^#?^"<WP!^-OPZ_9^\(S?%+1
M/@%IUUX8\:3^'[9M4BU"_P!'26=Q<LOF RRSR;LMTD9>A.?RR_X(;2-<?\&_
MW_!0G6OB1-<S>(KK2_%8UTZHC&Z-U_PC<A1IB_S&0W#R$[N0P)/)- 'ZS?\
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M^-]*T;4SI^JSZ8)8WM+@#(62*9$D4,.5<KM< E2P!H \H_X+!?\ !5GX6?\
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M#&H:->:=K.AW'S8CNM/NXHKJ$MM?:6CVOL;86P:\<N?^"[?_  2EMK/Q;/\
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MO^"*VCZ1J7_!<_\ X*.W&H:7;SR)=>.XDDEA5F6.3Q+/O0$C(#;5R.^T9Z4
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M\T__ (-</V<](\"7TPLKW1OAQ%XSAMGS_P 2L^'YI(C* >(S>PVF">"ZCN*
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MX7,<GEI=Q1.ZJX9"X4KN1USE6 _"CX7W?QA_X(:?\%X_B]^Q3\"O"MP_A?\
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M6ODI<#G*>5'@7,@8 _H@@F2X@2XC#A70,HD0JP!&>58 @^Q&13J** "BBB@
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M9/VK_@AK'C#Q%IL'DZ7?77Q+\16Z6$?F&7;;PVVH1Q0#>Q;]VB\X]!CZBHH
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MQ4M?@MJFER?$B*8>-O#NB>,-1L]$U:>028N9M.BF%N\B/*\D>4*1RGS%4/\
M-7V+10!\O_"G_@C1_P $X/@K^RWXP_8P^'_[//D?#;Q\B_\ "7^&KSQ3JEW%
MJ$J["MQNGN7:&<&*)A+$4<&*,@C8N//KS_@W%_X(V7OP1T_X!/\ L;Z?'HNG
M:TNJQWT'B#48]4FN0I4^;?K<"YDC*LP\EI/+7<2JJV"/N&B@#YU_:Q_X)3?L
M,_MI_##P?\*?CE\'3/9_#YT?P+J>CZO=6.I:$RA!F"[AD67YO+C+!F8.R*[9
M=58?D1\9OA9\&_V>?^#JKX&:K\+9]3F\&^&M$@L?&7C;6M:O=7/]LO:ZK#(=
M1U6[>5Y;G=+;1L9924^2/Y @5?Z :* "OG_]L;_@EY^P_P#MX:UI'C/]HKX*
MPWGBKP\R-X>\;Z%J=SI.MZ:R/OC\J^LY(YL(^65&9D5B6"@G-?0%% 'S_P##
MG_@FQ^SYX+\2Z/XP\<>*?B/\3-1\.W:7?AZ3XL_$O5/$-OIERG,=Q%:W4S6P
MN$."MP8C,A&5<'FNB_:J_87_ &;/VRI?"VK_ !M\%W$NO>!=875? _BW1-5G
MT[5] O 5/FVMW;NDB!BB;HR3&^Q=RG:N/7J* /&_V9/V"OV9OV2=8\8>,/A%
MX.O/^$I^(-_]M\<^--<UJYU#6=;FY"F:[G=I JACLCC*1IDE5!)-<+\$?^".
M/_!/3]G#Q[XW^*/P3^$'B#0/$/Q'LKNU\<:O;?%/Q))-JZ7,C23-*TFH-^\9
MV9Q*N)%9F*LI)KZ>HH ^4?A5_P $1O\ @FA\#_@1XW_9D^$_P%UC0_ ?Q(2-
M?&OANS^)WB/R=3"# #%M0+Q[E^1_+9?,3Y7W+Q7S'_P6=_8H_9@_8._X(#_&
M/]E_]D/P'>^'M+U^ZTI] \(?\)+J>K275ZVM6,\RVD=[<3R ^7%)*Z18&$=R
M.":_4JB@#\??^"+_ /P2:_8._;-_X)5?!8_M$^%/$6KWOAZ>XO\ Q=\.)/'>
MJVNDG6([Z[2&XO\ 1TN%A6X-N4&\QHTL;#<75N?TP_:>_8L_9A_;'^!__#.G
M[0_PBT[7?",4D$NGZ:A>T;39H!M@FM);=DDM9(U)57B92%++]UBI]2HH \+^
M!G_!.G]F+X#?'+4OVH=*T77/$OQ,U31HM(N/'_CKQ+=ZSJD>GQ@!;2&2Y=EM
MX^,L(E4N22Y:N-\:?\$;_P!AKQ]'XJT;Q%X9\7OX<\>^-)_%GC[P3%\1-630
M_$FK37IOGN+JQ%QY)S/M8HBHKB*,.'"*!]344 ?.'[4W_!)3]@+]M+X@>%?B
M?^TA\$[[7-9\#01Q>#9K+QUK>F0Z*J.CK]F@L+V&&%@T<9W*@8^6F3\HQ9_:
MY_X)8?L0?MQ^*/!/CS]HWX3WFJ^(OAY(A\)^)M-\5:EINIVBJZN$-W:7$<T@
MWJ'!9RRON965F8GZ&HH ^<?VQO\ @DO^P)^WA\(O#/P4_:,^ =EJ&C>"H?)\
M'2Z9>36-UHL>Q$:.":!U<1LL:!HV+(Q125+*I'9_L??L._LV_L*?#V7X<?LY
M>";C3K:[DC?4]2U75[G4=0U!HTV1^?=73O*ZHN52/<(XP2$503GUNB@#S[]I
MC]EWX+?M?_"G4O@A^T!H6J:MX5UBW:#5](T[Q3J.EI>PL5+12M87$+R(=HRK
M,01D8P3G@?V3?^"8/[%W["_P^UWX4_LG_#SQ#X,\.^(Y)I=4TFP^).ORQ&>6
M)(GN(A/?.;><I'&OG0E)!L7##:,>_P!% 'R7\)O^"&O_  3"^!?P;\>?L^?"
M3]GS5M"\&_$VTAMO'6@V7Q.\2>5JL41)16+:@63AF5C&5+HQ1MRDK7>?!7_@
MF7^Q!^SY^R[KG[%?PP^!Z0_"SQ&ERFK^"]9\0ZCJMI*MQ_K@GVZXF>$,?F_=
MLN'^<8;FO>** /ABV_X-R?\ @E ?A+!\"M?^"OB36_"-EK7]HZ3H>M_$C6KB
M'2\L[/;V>;K-I#([[Y1"4:9E0R,^Q<>U_%O_ ()A?L/?'/\ 9&T[]ACXH_!"
M'5_AIHD4">'M$O=8O99M',*E8&M;IYC<0&-"47;( (R8\;"5/OE% 'SI^Q7_
M ,$JOV+?V ?#.I>'/V;_  #JUC+JNFMIUSK.J>*K^]U"&R9MWV:VN)92]G%N
MPVRW,8+JKG+JK#,^(7_!''_@GI\6O@7>?LU_%#X/^(/$/@O4/&,WBJ_T?6/B
MEXDN&N-8E+&2\>=]0,S.Q=R07VY9CC))KZ>HH X3]FO]FKX/?LB_!W2?@%\
M]"U'2O"6@QF+1M*U'Q)?ZH;*+M#'+?SS2K$O18P^Q!PH KRG]L[_ ()&_P#!
M/C_@H-\3_"_QC_:W_9\MO%?B'PC:_9=)OFUB]M-UL)&E6WG6VFC$\2RLSA)
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M"C28--^'DMS\4_$J2:);PNKQ")DU%6+J8X_WKEI"(HP6(10/JFB@#YQ_;O\
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M<?!'0?@SKFN^*;76=+U*"VOM:@B9[#2M*DO9[F.ZO9GC7+VK-L0LDJY:,/\
MM310!\ ?L/\ Q'\#?\%?/C!\%O\ @H[XI_9:U7P-K7PE\'^(+>:W\16=P);#
M7=2G6S^Q03S00B[2&TM;B=G$>%.I6X4JXF6OO^BB@#Y\_;7_ ."6G[#O_!10
MZ4G[9/PGU3QG;Z),\VDZ?)X]UNQM+:5D"-(MO97L,6\JH&_;NP3SR<R_$/\
MX)A?L7_%C]D^S_8=^)'P]\0ZS\++".SBMO"E[\2O$#*(;39]E@:?[=Y[PQ&*
M,I$TAC4QH0N5!'OU% 'R5\1?^"&G_!,+XM_ +P7^RY\2/V?-6U?P!\/)KB7P
M;X9NOB=XD\C3'F.9"I&H!WZD*'9@@9@FT,0>V_:M_P""87[%G[:_[/\ H7[-
M7[1_PIF\0^'/"QB;PQ<W6OWIU/2WC01K)%?M*;DL5 #;Y&#A1O#8&/?Z* /C
MI?\ @@Q_P3)NOBMX7^.OB;X->(-<\:^$+6WCT;Q;K/Q'UR;4O/@F::*\FNA>
M"6XN%+!5DE9O+2*)$"+&BCIOV[_^".G[ '_!1[Q/H7C_ /:@^#LU]XG\-P+;
MZ3XJT37+K3M1CMU<R+"\UNZF5%=F=0X8HS,4*[FS]/T4 >(VO_!.O]DBP_9<
MN?V-=+^'^JV'P_U%9AK.FZ3XUU>RN]7,RE9VO;^WNDN[MI5.V0S2OYB@*V5
M X?X[_\ !%S_ ()P_M,>/?"'Q2^-_P #]:USQ'X!TFSTWP=K;?$[Q';W.E6]
MI)YEN(I(-00[TD.\2'+[OF+$\U]344 0Z;80:5IUOI=K),T5M"D4;7-R\TA5
M0 "\DA9Y&P.68EB>223FIJ** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2.?44 ?5U%<=\._"6G7_ ,/]"OKF[O3)-HUK)(?M;\L8E)[^];/_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
M&Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%
M8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (
M/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@
M^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S
M\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D
M?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\W
MO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_
M .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M
M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%
MM1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q
M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7
M_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\
MDF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31
M_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KYP_X*W_\ */?X@?\ <)_].UG7<?M/?MI_ #]DK0_[0^*W
MB]!J,L1>P\/:?B:_N_0K'D;%Z_.Y5.,9SQ7Y9?MJ_P#!3WXT_M=V=UX"MK6'
MPUX(FE1CH%HPDDO-CAXVN9B 7(958*H5 0,ABH:O'S7,,+0P\Z3=Y235EYKK
MV/ROQ+XXX>R;(\7EM2KS8BK3G!0CJTYQ<4Y=(I7OJ[M;)GS/7T?_ ,$D/^4A
M'P__ .XM_P"FF\KYPKZ/_P""2'_*0CX?_P#<6_\ 33>5\;@/]^I?XH_FC^4.
M#/\ DL,N_P"O]'_TY$_:VBBBOTH_T#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#N
MOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$<MQ$LMY9K(9[*UE>TN1',X) BW2I$IW#X4_:%_X+5ZO_P %'O\ @VV_:/\
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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MZO\ ]"A>_P#?2U[NQ^RI**LC8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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M7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M5/Q!XAT'PIHMSXD\4:U::=I]E$9;R^OKA8H8$'5G=B H]R:^"/VP?^"VGAGP
MU]J\"_LEZ;'K%\NZ.7Q=J<!%I">A-O"<-,1V=]J9'"R URXK&X;!PYJLK>75
M_(^<XCXLR'A3"^WS&LHWVBM9R_PQW?KLNK1]F?';]HWX,?LU^$F\9?&3QU::
M1;$,+6"1M]Q=N!]R&)<O(W3H,#.20.:_,W]KS_@L?\9/C7)<>!?V>[6[\&>'
MIF,7VZ.0'5KU3QRZ$BW!_NQDM_TT(.*\U^#O[+7[97_!1WQ_+\0-2O+^^MKB
M;;J/C;Q/,ZVD2@\QQ''S[>@BB7:N0#L'-?I5^R'_ ,$S_P!GG]DZ.W\0VVE_
M\)-XMC4%_$VLP*6A?O\ 9HN5MQ[C<_)!<CBO%]MF6;Z4E[.GWZO^O+3S/R)Y
MKX@>)[<,MB\#@'O4=^>:\FK-W[0M'=.;/B[]@K_@EC^TIXN\=:)\?/B1KM]\
M/[+3M1BU&QDFCSJUVZN'!$3\0JW.6E&2#_JV!S7ZM445Z^"P-' 4^2G?7=OJ
M?J?"'!N5<&9?+#8-RDY-.<I.[DUUMLODO5O<****[3ZT**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_
M^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K
M3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1102 ,DX
MZF@ K+\9^-_!_P .?#5UXR\>^)['1]*LH]]WJ&HW*Q11#W9B!D] .I/ YKY=
M_; _X*Z? G]GG[5X.^&#P^-_%<64:"PN1]@LGZ?OIUR'8'K''D\$,R&OSWUG
MQ3^V[_P4[^*2Z:L>I>)9H9=\6G62_9]*T=&R-Q!(CA&,C>Y,CXQEC@5X^,SB
MC0E[.DN>?9?U^"/ROBGQ4RC)Z_U#+(/%XMNRA#5)]FU>[_NQN^CY3Z@_;!_X
M+<_\?7@7]D+2_6.3QIJUK^MM;N/IAY1Z_N^AKB?^"6OP[_;B\>_M-6G[4^Z_
MFT&^+P>*?$7BN[D"ZO:/C?'#N!>9E*JR%1Y:M&JEE'!^@/V/_P#@C3\(?@[]
ME\:_M!3VWC7Q&FV1--,1_LJS?T\MAFY(]9 %_P"F>1FOM&WMX+2!+6U@2**)
M D<<:A510,  #H .U88? X[%5HU\7.UG=173^OF_,\;)>#.,N(LUHYUQ/BG3
M=.2G3HTW91:U5[72[->])K24EL/HHHKWS]M"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN!_:KT#XO^*_V7OB3X
M6_9\UG^S?'VI> =8M? ^H>>(OLNL264R6<N\\)MG,;;NV,T <_XZ_P""@'[#
M7PQ^+EM\!OB+^U[\-]#\8W23&/P[JOC*S@N4:,Q!HY%>0>5(3,FV-]KN-Q16
M".5[OXF?&#X4_!CX=7WQ=^+?Q)T/PUX6TRV%QJ'B+7-4BM;*"(X"LTTC! &)
M '/S%@!DD5_.O_P2'_X**?L^^ ?C=\-O^"<O_!53X-Z-\-T^'?@KX@^"_%5Q
MXZTXK::_?:_JFA7B+JD<R$03?\2^Y62XF;RW!A;<N:_9?3?^"/O[)OB[]F7X
M4_LH_&9+OQ_\-?A7;79\.^%M1NY$T_4'D<_8KFZ6.3-R]K;O+%'EO+;SY)"F
M[R]@!Z[^R_\ MS_L>_MIV&HZC^RG^T?X2\>+H[JNK0^'M72::SW9VM+%D21J
MV#M9E"MM."<&K_QV_:__ &8_V9;RPTSX[_&S0O#=[J=M-<V&G7MUNNI[>$9F
MN%@0-)Y$8Y>;;Y:9&YAD5^,O_!,_]@O0OV<?^#J?XL^%?V&K6]TGX/\ PS\*
M,?&-K#=236EJ^I:7;NFD>:[,9,7TGG(C$LHLG7DQ$UVG_!(SXWZM^UM_P<V_
MMC^-_'\K:C%X=\):OX-T&&[^>.UTNPUNRL1#&IX1)/LYE91C+2NQ&6:@#]F_
M!?C7P;\2/">G>/?A[XKTW7=#U>T2ZTK6='OH[FUO('&4EBEC)21".0RD@UYO
MX2_;T_8R\>?%6/X)^#OVE_"&H^)Y[^XL;/3+76$;[9>6XS<6MO+GR[B>(?ZR
M&-FDCP=RC!Q_/;_P2N_X*(?%W]GW_@WQ_;5^&7AKQEJ*77PRU+2;3P9>I.PF
MTR/Q+=MILHMV!_<[&AN+A=I&V21V'S-SN?MEI<_#S_@TC_8_^)'@"^ET;7?#
MGQIBU72-6T]O+N+6[,WB27S4D'*-YNR3(YW1KZ4 ?THT5YW^R#\9+O\ :*_9
M,^%_[05_"L<_COX=Z)XAFC1=H5[VPAN2 .P!E/%>B4 %>4?MS_\ )H_CW_L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFN[[6Z)=WV/U'@'@W_4?)ZF ]O[;FJ.?-R\EKQC&UN:7\M[WZ[:!1117H'W
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/\
M\FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z
M)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF?P!Y.I_%[Q!JWCB^3!:"1S86.?^N43&0\^LI![K7D?6<ZQO\&"IQ[O?\?\
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M7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110
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M'C6RT2WO9C%:RWKD"1P,E1@'G'->#?M=_M=_LT^.?V:?&/A+PE\8]'O]2O\
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MD#MUK:EF&"KU%"G--L]3+..N$LXQD,)@L7&=25[15[NR;>Z6R39[5_9VG_\
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M_/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\
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M\WR#P1XIRO/<)C:]:@X4JE.<DI3;:C)2:2=-)MI:7:7F>UT445]<?U&%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+0PL.6E&R/TS).'LEX<PSP^6T53@W=I7=WM=MMMOU84445N>T%%%% !1110
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MEZM(\S&YUD^63Y,9B:=)VO:<XQ=N^K6A[O17S'JG_!8+]@73R1:_%V]OL?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **X#]I']IGX2?LH?#L?%'XT:
MS=6.D/?QV4<MII\MR[3NKLJ[8P<9$;?,<#@#.2*_.7]NC_@MGIWCW6/!-M^R
M4FN65MX<\2QZSKEUJ]LML-2,.!%:!4D9C"P:3S P7/R8'%>1F>=Y?E47[::Y
MM/=6^OD?H/!7AEQ=QW7C_9^'DJ+<DZLDU33BF[.6U]E97=VC]6:*_)3XD?\
M!PS\>=9WP_"KX&>%] C;@2:Q>3ZE*H]04\A<_52/:O1?^"2__!1K]I_]J/\
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MS021QO)Y$0(5)6C?<['&WK7ZWU7TK2-)T*PCTO0]+M[.UB&(K:T@6.-!Z!5
M JQ7T.48#$Y?AY0K5G5;=[N^FB5M6]-#\B\0>+,FXOS6GB<MRV&!IP@H<E-J
MSM*3YGRP@N;WK/1NR6KL))''+&T4J!E8$,K#((/8U\1>"/\ @@A^QIH&H/J7
MC#7O%WB'?,S"RFU..VME4L2$ AC$G XSYG;M7V]171B\NP..E%XBFI<M[7Z7
MM?\ )'CY#Q?Q/PO2K4\IQ<Z"K<O/R.S?+?EUW5N9[-;GC7PW_P"">?[$GPG\
MM_!G[,WA198L>5<ZGIPU"9#ZB2Z,C@^X.:]?L-/L-*LX].TNRAMK>%=L4%O$
M$1!Z!1P!4U%;T</A\/&U*"BO))?D>9F.;YMF]3VF.Q$ZTN\YRF_ODV%%%%;'
MG!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6@ KXN_:O_X*<_L._$?]G+Q?X'\&?&\7FJ:EI#PV5L?#>IQ>8^Y3C=);*J\
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MM-#U";)YXREN1V]<5S6K?\%FOV%=.S]C\::Y?XZ?9/#DZY_[^A/\FOG#2O\
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MQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\
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M$NWS[F0$I$OJS;3@>U)M15V73IU*L^6";?9:LZ*BLW_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZID&E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF
M/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U
M!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\
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M*;7WVM^)]745A:'\2?!?B'1+/7]-UV)K:^M8[BW9C@E'4,I_(BK?_"8^&/\
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MZ_OA\(^#/!&@1'.R2+3)[F9?JTLQ0_\ ?%>;7O\ P4A_X*=_'6Y?3O#OQ?\
M%=XS':+7PAH<4#IGL#9PA_S)-?KMX)_9;_8=^'6Q_!OP#\ V<L>-EU_PCEO)
M./\ MJZ,_P"M>DV7B/P7IMJEEIU]9V\,8Q'# @15'H !@5\O_J[GF(_WC'2]
M(W_S7Y'[E_Q&/POR?3)^%J3:VE5<&U]\*C_\G7J?'?\ P1;;]KF+PAX\M_VK
MM(\>QS3ZE8W>B7WCU;OSKA7CE258S=?/M7RXB1T^<8K[<K-_X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^J^IR_"?4,'&AS.7+?5[O6Y^%<6\0_ZU<0U\U]A&C[5I
M\D/AC:*CIZVN_-L\3_X*<_"_X<?%/]C#Q;8?%7QC-H&CZ1%%J\NIV]JLTJM;
MN'6)$9E!>7_4KS]Z4=>A_ J0H78Q*0N3M#-D@>YP,U_3#_PF/AC_ *#4'_?5
M'_"8^&/^@U!_WU7@Y[PQ'.L3&LJG(TK?#>__ ),MO0_5?"OQOK>&F3ULOE@W
MB8SGSK]ZJ:CHD[+V4VV[*[<K:*R6K?Y+_P#!#.']F'XB^//$/P7^-?P9\+:Y
MXD>(:KX6U/7=*BNG>- %GM@LH*Y4;)5P-V/-.<*,?K?H?A_0?#&G)I'AO1+/
M3[2/_5VMC;)%&OT5  *@_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZKU,GRM95@U0
M<E)J^O+RNWGJ[^MSX7Q%XXGQ[Q%4S.-*=&$TOW;JNK%22LW&\8**=D^5+>[O
MK9:5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU7K'P)I45F_\)CX8_P"@U!_W
MU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O
M_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_
MZ#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!
M_P!]4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%
M9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\ H-0?]]4?\)CX
M8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_
M *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU
M0!I450MO%'A^\G6UM=5B>1SA$4\DU?H **** "BBB@ HHHH *P?BG\1?#/P?
M^&/B/XM>-994T;PMH-YJ^K/;Q>9(MK;0O-*57^)MB-@=SQ6]69XU\&^&/B+X
M-U?X?>-M'BU'1M=TRXT[5]/G)V7-K/&T4L38(.&1F4X(.#0!^"?_  76_P""
M,_PT\)_M$^&_VO\ _@E=K,7PW\67/PI\9?%74CX9U9[6QNUT*70W,^F- 1]B
MGEAU:>4>6?*<PQJJQEV<_IC_ ,$G/VK?C+^VK_P1?\%?M*?M#1_\5=KG@C6(
M=9OC;+"-0-I<7EFEZ44!5,T=NDK;0J[G8J I6J5Y_P $'?V0I?%WA73[3Q?\
M1!\,O#7@[7?#O_"I[SXD:W<:=+9ZE<:7,;6.9[WSH+)?[-VR60+0SB1 P"Q;
M7^H_%/[.7P?\5_!>/]GA_#5SH_@V'2!I5MH?A'6[S0T@L1"81;1OITL$D<0C
M.T(K  8XX% 'Y$_\&1Q'_#%_QD7(R/BA!D?]PZ&LO_@B'\)O$/P%_P"#F3]M
M?X>>,87M[J[L-<URP6<8:6PO]>L[ZWE]"##=PDD<9;\*_3O]BK_@E3^PM_P3
MMN]4N?V-OA+JW@N/6I$DU:PB^(&NWMG=R(CHDCVUY>RPLX5V ;9D<<\#&O\
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MW_P3&_:#\FW\#_M?>%K&\FP%T_Q5.^C3;S_ !?+$';M\A8'L37H8_P ../\
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M-]KVL6ME .LUW<+&@_%B!2;25V5&,IR48J[9)_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A6#X5^,GPA\=Z_/X4\$?%7PWK.J6UN9[G3=*URWN+B*(,%,C1QN65
M=S*-Q&,L!WKI*49PFKQ=T:5\/B,-/DK0<7O9IIV?DR'^SM/_ .?&'_OT*/[.
MT_\ Y\8?^_0K ^,OQ-TSX+?";Q)\7=;TJ[OK+PSHMSJ=Y:6 4S210QF1PF\J
MN=JGJ0*_/[Q5_P '%G@NVW)X)_9<U2\_N2:KXGCML>Y6."7/TS^->?C\XRW+
M)*.)J<K>JT;_ "3/K^%?#OC+C:E.IDN$=:,'RR?-"*3:O9N<H]#](/[.T_\
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M-)/)GZ[1]*_1+P#X2M_ /@71? MIJ$]W%HNDVUA%=76/-F6&)8P[X &XA<G
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MF66T<PPN <Z-6,9P:J4M8R2:?*ZBDKIK1I,_1_\ L[3_ /GQA_[]"C^SM/\
M^?&'_OT*^ ]+_P"#AK]FN4#^VO@AXXMS_%]E^QS8_P"^IDK["_9@_:.\$_M8
M_!C3/CI\.]'U:QTC5I;B.UM];@BCN 89GA8LL4DB@%D;&&/'ITKKP>;Y;F%1
MT\/44G:]M=OZ9\]Q'X><:<)818K-\%*C3<E%2?*TY--I73>MDW\CNO[.T_\
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MK[1>+F;8Y<N>8+#8U=ZE**G\IPY;/SL8?4H1_AR<?1GXQ^$_^#H#X3:_>_\
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MDM[H>M6IMM3LX;Z:V,\1()3S('210<8(##()!R"0?G*O!N2N#Y(-/I[SM?\
M$_8\!]([Q*IXB"Q6)A*G=<S]C!RY;ZV2Y$W;9-I-]4?S52HL<K1I*L@5B Z
MX8>HR <?4"OV+_X(8?M9_P#"X/V?;C]GWQ7J?F:]\/\ :EAYKY>XTF0GR2,]
M?*?=$<<*GDCO7I7_  YM_P"";O\ T;E_Y=^L?_)==E\"?^"=W['O[,_CU?B;
M\#_A-+H6MK:26OVR/Q+J4X>&3&]&CFN7C<$A3AE."H(P0#7FY%PUG&3Y@JSG
M!Q>DDG+5?^ [IZGVOBGXU>'7B'PC4RR.'Q$:\6ITI2A2M&:[M5F^646XNR=K
MWLVD=A^TO^SWX+_:G^"FM? GXA7M_;:3KGV?[3<Z7(B7$1AN(YU,;2(Z@[HE
M'*G@FO O!/\ P1$_X)_^$MC:OX!UOQ$Z='UOQ)<#)]2+8PJ?IC'M7UQ17V&(
MRW+\7656M2C*25KM7T^?J?SIE/&G%N0Y?+ Y;CJM"E*3DXTYN%Y-)-WBT]HI
M;]#R;P3^P?\ L8_#S8_A3]F'P3%+%_J[FY\/PW,R^XDF5W'YUZAI.BZ/H%DN
MFZ%I-M96Z?<M[2!8T7Z*H %6:*Z:6'H4%:G!1]$E^1Y&.S;-,SGS8RO.J^\Y
M2D__ "9L****U//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]
M#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH R?&G@'P+\2-#D\,?$3P7I.OZ;+_ *W3
M]:TV*Z@?C',<JLIX/I7RE\<_^""W_!+'X[>==:A^S!I_AB^ESMO_  ->3:3Y
M1/=8(6%O^<1K[#HKULKS_/,DGSY?B:E%_P!R<H_?9J_S(G3IU/B29^/OQ9_X
M-._"VE:G_P )3^R7^V=XB\/7ULYDL+?Q5I:7#JW;%W9M T>/41,:X\_LL_\
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M (+4_L8$6O[<O[!8U?2[7_CXUJZ\,7FD&;!^8B]M_-LS_P  CXS]*]R^!O\
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M5_V$/'OG7WP6^(_CCP#=OGR;<7L>J6,?_;.X43'_ +__ .-?,WQ=_P""/?\
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MQC\*/K?@K/XL-C8^DZ3_ ##EQW>/XG%Z?_P<9?\ !(B]"?:?VF;VTW9W?:/
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M7BG]Z]I>1(R0L<CS$^92<$J&RQ^V/A]_P=Q_">Z=;;XO_L7>)-'=&VSOX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 ?T,T5S7P9^*&@?&_X/^%/C3X4##2_%_AJQUO30YR?L]U;I/'DCJ=L@KI:
M"O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\
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MX2_\&J%YXQUO_A.?VWOVU];\0ZG=$-J-MX4M2TTC=\ZA?F1I/Q@!KWO^(?\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\
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MA^)_PKT3Q(CKAUU[2X;P,/0B5&S7H%%:4JU:A-3I2<7W3L_O0FD]SY2\>_\
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M?POO,YQ]E\?:=)TZ_=F-<%3(\ZH_Q,-47K"2_0I5*;V:.W_X0?2/^?F]_P#
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MVF5(;6#W\U&4=,GK4'_#K'_@X._;X7[3^V7^UTW@K0[WF\T*^\4?*R-Z:=I
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M=%HVRH>Y8C\16I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\MMSTQYL3].WZYK]#J*[Z?B-Q[2^'-*_SJ2?YMDO"X9_87W'YF:I_P &IO\
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MNMJK^Y'XL?\ $5%^TAX>^;QK_P $WA&HY/\ Q4=Y:_*>!_K+)^_?OTJUIO\
MP=Z::'\GQ!^P!<P,K!9#;?$Q7.>_RMIJXY[9_&OV=JKJ6B:-K,?E:QI%K=KC
M&VYMUD&/3Y@:/]</#.I_$X;7K'%UE^%@]ABEM5_\E1^1^D_\'<GP+FV_V[^Q
MQXLMNF[[)XFM9L>N-T:9_P ]*Z33/^#M#]BV4#^V?V<?BA;G!S]EBTZ;G/'W
MKI.U?I3JOP#^!6NDG7/@MX2O-V=WVOPY:R9SU^]&>M<WJO[#W[%>N$MK?[(/
MPNO"2"3=?#_39.0, _-">W%'^L/A+5^+)*L/\.)D_P#TI![/&+_EXON/B#2_
M^#K#_@F]?G%W\.OB]8\D9NO#.G'MU_=Z@]?G9_P5%_X+Y?'O]K[XT://^R_X
MG\0?#WP'X,U6+4/#,,%P(-0U"^C.5O+SRV93CD)!ED )+;BW'[D>(_\ @EA_
MP38\4Z?/INI_L(_">*.XA,4C:;X%LK.0*002LEO&CHW/#*0PZ@\"OPO_ ."J
MG_!"?X[?L=?';38_V;_"&M>./A_XXUI++PA)8VS7%Y87DK?)IUT%'WNNR8X5
MU4YVLK"OTWPKQ/@YB^(7['#3I5U%\BQ$XS@]/>Y>G,E?XNE[:G)C%CHT]7=>
M1]#^$_\ @Z>_:O\ 'W@+0/AC\*/V)]-\2?$Z2R$-]J$%U=WD%_<*,&6'3;6-
M91N W%!,<$D#C%7QX+_X.BO^"@W.O>)+SX/>&[T?*DMW%X86$-U4I;A]3QCL
MX/IZU]A_\$8/^",'@?\ X)U>!X_BM\5K:RUOXPZW9;=3U- )(= A<?-96C=S
MVEF'+GY5P@^;[RKY#B'CO@KAW-ZM+A3*J$DF_P!]5C*I>5]73C*5HQ6T7M;9
M6L;TL/7JP3K3?HM/O/Q]^#G_  :DZ/K^L?\ ":_MH_MDZ_XEU.Z<2:A:^%+0
M1O(_?=?7IE>7/J84.._I]L?L^?\ !$__ ()D?LW>1>>#OV5-!UC48<'^UO&8
M?69BXZ.%NR\4;>\:)@\BOJJBO@\Y\2N.<^BX8K'34-N6#]G&W;EARIKUN=$,
M+AZ>JC^I#IVFZ=H]A%I>DV$-K;6\82"VMH@D<:CHJJH  'H*FHHKX=MMW9T!
M1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_P#DT?Q[
M_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA
M?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M _\ Z&[QW_X5\]'_  [J^!__ $-WCO\ \*^>O>J* /!?^'=7P/\ ^AN\=_\
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M_P#"OGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\ 0W>._P#PKYZ]ZHH
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M5\]'_#NKX'_]#=X[_P#"OGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\
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M _\ Z&[QW_X5\]'_  [J^!__ $-WCO\ \*^>O>J* /!?^'=7P/\ ^AN\=_\
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MBM"P96 G=,JRMT8$]9^V+^W-^RK^P-\*I_C'^U=\8]+\)Z/&&%I'=.9+O4)
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MO;Q17CR>6LWSP31M8W$;PN6P0C!SN*H ?HS17XOQ?\%W_P!JOX5_L5?LX_\
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MW_9;_8&_X+JZSH7[/'BCQIXF@\ _L^1ZIXCUGQQJUO>7,6MZSJ4EO;QJT%O
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M1L0 ?I5:WMG?Q>?8W<4R;B-\4@89'49%25^-_P#P12_:1_9[_;:_X*_?$/\
M:D_8+U"Q^''PPU'X'Z9!XX^#\[VUA=:CXG%RH-]'ID#[#';P(D3WJ#!:8+DF
M5\?LA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45CZY
M\0O OAGQ5H?@;Q#XOTZRUGQ-+<1^'M*NKQ$N-2:"(S3"&,G=)LC!=MH.U1DU
MXCX5_P""L/\ P3@\;_M,G]CKPC^V)X+U'XD"]DLE\-VNH%C)=IG?;)/M\B2<
M$,#"LADW*5VY!% 'T-17S=_P4-_X*Q?L0_\ !,/P,OBO]J7XK);:G=1%]&\&
MZ)&MWK.J=?\ 4VP8;5X(\V5HX@1@N#@'Z*_M33O[+_MHWL0M/L_G_:2X""/;
MNWY],<YH GHK\]_BO_P5B_;O\>_LH^ /BM_P3X_X)NW?Q&\:^./!(\::AI6H
M>(XH=.\.:!--,NGRR22&W>^NKJ.%G2U@PXV2'YL*'P?V0/\ @X/T#]HS_@DE
M\6_^"A_C7X(/X<\5?!F.\LO$W@T7CM;76II#&UHL4K*'2*:2:*-@P+Q,''S@
M*S 'Z345^2OA#_@L;^TQ^S[XU_8E^)W[1_Q)L?%_P]_;"\-A/$=J= M;)?!6
MNRFS\K[#);HKM9J^H10NETT\FV&23S<_+4W_  7P_:T_;J_9!_;6_9(N/"/[
M2:Z3\)/&OQFL(/$WA7PYHK6$\T5IJ.G,T-[?&>1[J*:&XG5HD6"/:A#I+D%0
M#]8W=(T,DC!5499B< "D@G@N85N+:9)(W7*.C AAZ@CK7Y6_\'%_[2_BKX,?
MM0?L4_#7QQ>>1\$_%WQG63XL07:YT[48[:[TQ8(+[/R26R)<7,[0R923R=Q5
MO*XX_P#X)P^._%O[%W_!R!^T'_P3*^'=[)%\&O%/AT>,_#/A&W8_8O#VH36M
MA>R-:Q#Y+2)FNKN,QH%4@0<?(HH _82BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBL?5?B%X%T+QGI'PYUGQ?IUKK^OVMW<Z)HL]XBW5
M]!:^5]IEBC)W.D7GP[V POG1Y(W#(!L45\\_";_@K'_P3@^.O[0\W[*7P@_;
M#\&>(/'\,LT2:!IU^SFYDA!,L<$VT0W+J%8E8G=L(QQA3BC^WA_P5K_8:_X)
MSR:3H?[1GQ<BC\2Z]>0VVC>#-#07>JW!E=5$C0A@((1NW&69HT(!"EFPI /I
M2BLOQOXPT/X>^"]7\?\ B>Z\C3-#TNXU#49L?ZN"&-I)&_!5)KX!_:/_ ."K
MW_!163]F/P+\4?V%/^"9%SX]\5:W\+=,\>>/K6_\0J=.\)V=];F>#3XR3;S:
MI?E%9F@@421KY;&-O.04 ?HE17YI?"K_ (.&O#?Q:_X(>?$+_@J]8_!M-*\1
M?#^ZE\/ZCX/N;YIK1_$#/9Q6P24!'DMG.HVDK<!U4R)DE-YP?A]_P5C_ &B/
MV>/VO?V2/AI^TG\3X/''@+]KKX6:9J5MJEUH5I8S^&_$]U'$Z06AM(HQ)82/
M=6L*Q3^;.AD#F=\%6 /U+I))(X8VEED545269C@ #J2:_%K_ (+Q?"7_ (*]
M_LQ_!WQ)_P %8_!__!4CQ-X93PCXJM&M?@MX81[31=+TBYU".SLXVQ,8M4N5
M,T#S_:(&1S)-MPD:ANH_X*K_ +9/Q<\1_';_ ()M_L\_&S0(]-TCXS>+M%UG
MXP^#9HO]$O[]GTJ*+3[B)\^9;Q75Y,S0R;E9DB+ E!0!^OD4L4\2S0R*Z.H9
M'4Y# ]"#W%.K\E?^"/?QY\3? '_@M[^UQ_P2D6\EA\ V5Y+XX^'7A\G%KX>\
MZ2TEN+2SCZ002+J<3B% (U^SDJ%W-N_6J@ HHHH **** "N2^.&F_&O6/ACJ
MNE_L]^+= T'Q9/:R+I6L>)M%EU&TM9-C;7:VCG@,IW;1@R*!DL0^-C=;3+BX
M@M('NKJ=(XXU+222, J@=22>@H _,W_@UY_;C_:6_;L_84^(_P 1_P!IGXFW
M?BOQ[IOQBU.U-YJY")# ^G:?-#"L<2A+>%97F CC557!(&2:^/\ _@M7_P $
MJ?C1^P]XK^"_[?\ ^S%^V=\4O%G[2WC?XSZ7X8O;O6=80Q:MJ-[%/.HLX(8U
M-M9K+;^5]C+21?9Y50\*=_I'_!J1\3OAYX"^/W[8/[+Z>-]+3[-\8#>>$H!?
M1[=5@%QJ%O+):\XF"K!;DE,\2H>A%=%^V5_P4?\ VS]9_P""FL_CCX#_ /!&
M#XO_ !J\._!ZVNM%^%>O76F:AI.BQZQ.#'J>M*SZ?*MVQ14M;=Q(BI")Y%)^
MU#8 ?<?_  4F)^('Q+_9H_9IMOWA\8?'[3M:U2!AE6T[P]9W>NNS>H^U65@F
M#P3(!Z _&/\ P<^_LV?"+P5_P3L\0_\ "NO^"?.H>+]6UOQA#XD\5_%C0-'L
MY;SPXBWJW-_>W%TQ:[W20[[=28VMXH7P6C2&-*^J/V>?!_[5_P =?VMO@=^T
M1^U5\*[C0;GPC^S=?WVK0B!4MM/\5Z_?6)N-/7#$E[2TT]XB#DA;@98ECG7U
M#Q=_P5SU7XZ_$OX1^,_V4?@MXE^$^L-/;_#[Q6?'5U8O#8R1%/*U6T:"X>Z8
M@G>(EB7.5!8-O4 X<_$'X"?M^_\ !O+XF\3?LW:9J1\)ZY^S?KNC>&K/Q"$>
M_LIK'3;BS$$[#(:6.XM "XX<QAQP0:XO_@U.^)%GXA_X(A?#^TU#446/PCK?
MB+3[J:63B)?[4N;SYB>@"7(^@QVKZ3_98_X)^V/[%?\ P3AT']@'X%^++*X_
ML?PQ=Z9-XC\1Z:\L=S=7C32WEX]M%*C,&GN)76$2C:I5/,^7->1_\$V?^"-/
MC?\ X)W?L,_$#]A/3?VP?^$GT3QO#J\EKKR^ _L%]HU[?V,=HTT/^G2H\:"-
M9!&PR7)^< XH [O_ ()&:KIVC_\ !.G3/VE_B!?0Z6OQ*U;Q)\4-?U+49!#'
M#;:QJEWJ<4LC,<(D=E+;C)X"QCH!7SS_ ,$YOB)^Q9XM_;>^*/[=_CGX]^"Y
M?BM^U-KMKH/PZ^'&G>)K2?6].\)V-DD5JT]G'(9K>:Y@LEO;A7&(0L,;;9 R
M'[-^)W["/P:^+W[$]G^P-XNU+7[;P#!X5T[P[=P:!JIL+B[TVSBBC6V:6,;E
MC=8E614(W*60G:S ^2_LB?\ !!#_ ()4_L-_%S1OC[^SM^S'_9OC;P_Y_P#9
M/B34?%NJWTMN9H)+>0K'<7+P@F*61<^7D;LC! ( /QD^!_P5\3_ S_@@[_P4
M4_X)W?%1'M/$OPE^*^D:G<6URA1G5KW3E@N4!ZI<)I89&'#HZD<$5^@'[9'P
MIN_AU_P:8VWP*^.>IP:-XBM/@%X<7^R]8G6&X_M"W:QNX[%4<@M,KQI%L )W
M+BOT<\=_LD_LN_%#XDV?QB^(_P"SSX,UWQ58) EKXAU;PW;3W:K#)YL ,CH6
M812?O(]Q/EO\R[6YKT%X89)$F>)6>/.QBN2N>#@]J /SX_X(]?M8WWAO_@@W
M\/\ X@>#OAIK?C[QE\-/AH;2^^&7AT*-;GFLY9K>"W$$F'1I(X5=,J2Z<HKG
M"GF?BKX!^&__  7"LO@Y\2HOV$OBG\*/'O@'XI:)XAU3Q9\4/AY)H%_H>GV%
MSY]U:0W4NUK]9_+$,:0^8J2,DLBQ>617Z7T4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!YC^V-<_M#:?^S=XOU;]EWQ?H.A>,K'0+V[TK4?$6
M@2:G"LD5O(ZHL"3P@R,ZHH=F94SN,<H&P_&'_!MO^U]^TC^W)_P2GU3XJ?%?
MXLS^)OB-#XZ\0Z=_PD/B,>:BW1$=S;AXX]H6"/[5&!%&%54 50H  _175YM*
M@TJXEUV>".R$+?:I+EPL:QX^;<3P!C.<U^+W_!FQ\3_!'A3X$_&W]E=O'&G/
M?Z5\7IM2T2S:]02:C;R645N\]NI(,R@6 +,@.T%2<9% 'GO_  4M_P""5OQ.
M_P""=7[;W[,G[5/[&7[7OQ7\7?&CXH_&&TT#Q3<>,==2ZFUMV*S3W!6&.,1V
M003+- ^^)870#:J,6_4/]NXGXB_MA?LH_L[@YM[CXE:KX[U=%R2UIH.CW'E9
M']T:AJ.FMD]U7Z5\$_'C_@IE^W?XC_X*2>(?CC\!?^"(OQ@^+6G> +"Z\+?!
M?Q1KFG:AH^DV,4I U+5H4ET]Q+->/''&)?.C*VD$:@*9IL_<?[-'P\_:4^(G
M[;?A?]HS]I#P-<Z=<^%?V5M#T6YO);=8K>;Q/J][]KUR*! 2%\G^S+!6QP/.
M"@D"@#X9_P"#H[]F[X%?"K]B?0-*\&?\$]-8UO3T^(%KXA\>?&+PMI=D+O2[
M9[B0Z@]Q?$O=-=W32#,L\36Y:169RZ(E?4_[='C_ .#G[?/_  ;M_$GXR_ R
MTNI?"OB#X WNMZ%!JD0-U;II]N;GR)>6S+%+9LC89AOC)#-P3U.M#_@KI\8]
M1^,_[,?QV_9A^"MW\/?%J:OI/@/Q[8>-;J%(-%NDE@B&H:<\,\EW<+"X9U1K
M>-W!C!56\U?0?#O_  3\TSX0_P#!,V#_ ()L_ ;Q79V&EQ_#JZ\(-XB\0Z8]
MV?+NK6:*YO6MXI8O,E>6:27RQ(BY<C<  * /#O\ @W?^.&A1_P#!!#X3?%3Q
M5?[++PCX6UU-7D)Y@@T[4[]3G/\ TQA5OH17JO\ P3!O=)_9Z_X)/> OB_\
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M:_LX?!:P\,>.;+5]!\._$SP_XQNFAM=(O$D@CGDTN6&66XNX8W$B_O;='D4
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MO##^*?'>E71;6($EL[9M3>VGD#;+N4">);A@3&\OFX9D .?_ ,%\M'\/:_\
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MJVF7;-;W$0=''H58$$?6IJ* ([6UM;&W2SLK:.&*-=L<42!54>@ X J2BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH KZKI.E:Y82:5K>F6]Y:RX\VVNH5DC?!!&58$'! /U J:&&&VA6W
MMXECC10J(BX"@=  .@IU% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 56U71](UVR;3=<TNVO;=F5FM[N!9
M$)4AE)5@1D$ CT(JS10 D<<<,:Q11JJ*H"JHP !T %+110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5M5T
M71M=@2VUO2;6\CCE$L<=U LBJXZ, P.",G!Z\U85510B*  ,  < 4M% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 54U;0=#UY(8M=T:TO5MYQ-;K=VZR"*0 J'7<#M;#,,CG#'UJW10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% %74=#T36)8)]6T>UNGM9-]L]S;JYA;IN4L#M/N*M444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"@&O_$7PI\!G\01ZG\*_$"Z)XTL=?TC[*]I?%YT,2D.RR;6MY064D<#!((-
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MS[?U^)/;_P#!W#^SXUNC7?[(/C))2@,J1Z_:,JMCD!BH)&>^!GT%>D?LD_\
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MEW/PF\-Q:1%X*3X>2S)J:?Z;Y\ANCJ:F$L;^78/*?9L3/F<D@'RI_P $\?\
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MJ^//QJ\1W\FH^,O$OQ4A7Q%K%Y-YEU>(EFLZ/*Y^9B9KNZ8L3RSL>N:^L_\
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M^S3:Q!%X0\-3?V:\P(*.'S);RDCRIB1E5E=A]#_ W_@C?XLT#_@K/KW_  6
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MDU\=_B7\&;NYMO$5AX#GCL[VS8K-:1SR1V\]Q&PY1XX)99 PY4H&&,5\\_\
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M^T!HOBGP-^R<99/ NE:#X3EL;KQ'<*]N;.74GEN94C6!;2 &*)2)F#EF56V
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M'GZ7J,L\GDWUK/Y1\^P5T\LJ LKJ0?EV^N?!W]L/]N?X/_\ !Q./^"=OQ?\
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MV_A6\T_6O"OB7PE-?7VO:C)9FWM]1O+V._A1S [O<)$MNH$^R561X86CP?\
M@C]_P3F^,/\ P2X_9H/[*?C7]K6W^*GAC3=2GNO"+R>!6T>YT>.=S)-;;_M]
MRLL)E+RJ-JLK2R?,P*JH!]94444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 1VUK:V4(MK.VCAC4DK'$@502<G@>I)/XU)11
M0 4444 %%%% !1110 V:&&YA>WN(EDCD4JZ.N0P/!!!ZBB***")888U1$4*B
M*,!0.@ ["G44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<+KO[+W[-'BCXA1?%OQ-^SOX%U'Q7#-'+#XGO_  C93:A'(GW'6Y>(R!E[
M$-D=J[JB@ HHHH **** "BBB@#B?B;^S5^SG\:M:M/$GQD^ /@GQ;J.GP^38
M7_B;PK9W\]M'N+;(WGC9D7<2V 0,G-=E9V=GIUG%I^GVL<%O!&L<$$,85(T4
M8554<     =*DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .$T3]EO]F3PS\0F^+?A
MO]G3P)I_BMI7E;Q/8^$+*+4#(XP[FY6(2;F!()W9.>:[NBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K'\=_#OX?\ Q2\-S>#?B=X&T?Q'H]P0;C2M>TR*
M\MI2.FZ*565L>XK8HH Y+X<_ +X$_!ZUO+'X2?!7PEX6@U%0NH0^'/#EK8I=
M # $@AC4.,<<YXK0^'?PP^&GPA\-KX-^$_P\T+POI"3/,FE>'=)ALK99'.7<
M10JJAF/).,GO6[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>mgnx-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20201231.xsd" xlink:type="simple"/>
    <context id="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc371ef99f5f4a54a624cc69d77a088b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iee4457baa35447a49304e676fa213609_I20210222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-02-22</instant>
        </period>
    </context>
    <context id="if8c8761deec04f95aecb8597243730f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d808e02b5414fd683b155299253411e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id64fda6eae444b93b571cf566d3a92d0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaaef0c61fb24481cbdacd565ae79023e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ied1559cf83494ef1ad022048d27be8c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24fcde07e22449f18988a9bb4909c03b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3742a3dcd1cd4e018f4a0e55e544bf88_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i58c726f956aa424aa075e2563e67512b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3e9de6b275e1488fb3fb628e6f009da2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2e401a1ba9e34e4b90951902947848c6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i36d36892fdb74f70add306d4b9acf8f2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ide6e365cd9374fd0bc37f252d29fd753_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i1c020d90e65547508df10ef8295c9c46_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia662d353fd8d45c0b6ef76a73d9eab63_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i54c8abb81fc54045a728f7789e5eb590_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i92ef7adb07344ad083846bfb3d0940f6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id00868bdc70444b5996012f6dc5d03f8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i03dc58ff992a4affb3ae912e7726fd5f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i32cb1a93d9784446861b4351c65a06ab_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i34837cef321c44a6880d4682ed958ef8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie9a43579b4d5441d9adfda3882db2702_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i17c88315085b4a6b86cc704010cbb3b8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2ffdf5a5082a4f03a6ddd2697f0ab3aa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7a45855556604f00a3ab1c5a555208a8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i826687038ea842c986973786b645a9e0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36ad1dc4801847e1b315ea5729b88e91_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i901563a826804698862205071e209880_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a1a0c6402b943b9b4b2ba26940be870_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e6db4aa25b74df5abc90db0f02b82a6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie09fcd6ed15e4fc0be1acdc77c4500f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ef16e4c63d6480f96951c6f7eac9ca2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff38bc7672c14b59938322f49d658a0c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0267b9d993f432e9f8c8b2e9d4c1098_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9104c83bf7314b29a4d988eed8111854_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1ca2685a1e44ec89c539d7bc50c9ed0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedec7a9d1790449ea17afb27d64d25ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib51c8e9f97bb45179d0e2ff8204fe9a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i148cd0120f7c4ce5b2a1fe9a8db994bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibddef6e763f54b939c512d3cd30c5215_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice95d2414f2f4667ad6a137abdaf65e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if031a3629d9d479b8b2e1574bc24c45e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if51e190b234e40b892b75daf5576b090_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icea874c5381443b5b673e08d90e90c40_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5a9f46e4b864266974d1b6fcd23b90e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i552151630ecd479daefd899d23524d35_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i005b3bb8d084456ca8d49ff0bad27cfb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0947be2b25de4cfd818cbc871c8cf1e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9446d440a99142d189e04019aee224ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b532567296e49e3bdaf3330f2450754_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ae57da2f7894541b48732b70a7018b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51251d2fc1ee4652bb119cd46a05d7a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d860c4ec4674c37864b79c7a8a1c51c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58a8fbc39ff647a59227c8eecd606e91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e38b6ae03674f649d3803b90d7ecfea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieed6dd67ee254fca90e4fe1683b8a032_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ae333e83a0b4c128a73b9846f7961d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b35d230e32a43dfba261f095d9b94a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46eba3f4322a4bbca90a630e001423f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie97ced64b0db4ea9832f1407780172eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib963d0612f344980abb58b7bbfdec3d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a721e8181644e798dc6e4780d90abcb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i271fe1de3f1742e1ad5139de5d7b263e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i68822e067a8340dfbe694836cdf653da_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i80b9fa1115d242cb8ff80ac0457e0b0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieb40a146a60543f19cb68d866fb7a671_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9db1598c868945aa9827bc1240c7542f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i72ea4b2f306047a48020bb482e53e79f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic41258fa77ab4a088f6a5f9eb5a20970_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c0cc75cee534fd1a8112f063a35cb0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i531f3aa6b1134103965b1b4eda0c293b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a4891f769084a18ac2931ba572ae079_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5588a07194ab4de79f27e05259cfb283_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i100b91d4dd344890967b03a9795b715a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i97d18cede0b144daac71f46d3da90aef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee3f25bbd99943aa9498aad2fe62b342_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3c1d63dd293345108c3e566e01ade176_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i969a47c5754c4c6985ffd28981d702a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if953214a30c54a4ab6b4b51e83fde241_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i72c1b1bc8c454a148cb38c5196d6024e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i613ecacdf38948c6a00165721abcb9ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16e8408688034e0cace6fc6275751598_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a9f85aa087344ca8008b4576a668e22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i30f500d13f114fd6b9ece35c3c1ddbbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9eee20aa82a04eb881c0f50c7193c079_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29d23911aba345f1b5c80d016b475232_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6db0ce0a36bd44c89f32be0a7f6f3ccf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie2e19ae8025c48e5b2df7b9cd421d21d_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i5c6be239fac74a39a6efe1cf2153245a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id41ac2377a9e406db348d5b48d784025_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f933200f33a49139ed9cdf99b46accb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3f3c1f82e424f279963729cfc905770_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f26754d1c12437385b6f0b131ab7e1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6eda115843604d8ab1d5b0ec51dd4f34_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8932c76412aa40acaf76c7c665350985_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5794801343ac425dbba4fec50029d947_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibce024e3e9fa467bb2616f6adf5778e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9ae1c0908e54561a39ca4b4e76062a3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f8089d6e3024b72b2fa7b1b126799d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2336b1857bf400c9efe189f44310e5f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5172dbbe4a1a40ffae37000e9a89f01c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b1a45648e254a7dbb5b5d67c3ef2ec1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18f77e8a6d744b82b3f3741e0299c45d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id08fe2220367435fa71093334d9c684a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9c6bda6395f466b9aeb7ea0c330cb71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibafe419048424d72ba9dcb437c36a6fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic72a8361cda6471c8e38d658753f0573_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id073a704e63548588d4eeca08d057674_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40138f5330944173b29c88382128a064_D20180402-20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="ia4d7688a5ca1483790dd77c9300f82c4_I20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-02</instant>
        </period>
    </context>
    <context id="ica23de68e9494461b000d56dee219d8f_D20180402-20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="i52765134bddd477d901a12882bde3b9d_I20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-02</instant>
        </period>
    </context>
    <context id="if094d8df39954207bb5391061c867477_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i5d3c43517af54165896bef6f429afdf8_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i3b54527c45444217a8e26ea5f21c66dc_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i0fc973fcb7d148828513059e1601a77a_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="ib66b02d54eed4262b672c427d7af10e9_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i70810fe71eab4695bfbdd5efe0c1c9b3_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i97895a6a80e148b1a904880526f25594_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e277b27463146b29c014a1f9710d329_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie71f6f7825d94e5b829714cea61564c2_I20170518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-18</instant>
        </period>
    </context>
    <context id="i194f187d59c94fd0be7ab2993ff54938_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i57f99a9224f74d71a7ddf204e8b0610e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb896738d1f544f3af00d62fa6613580_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if65e3aa5584c442f98a84ac8dcd7ea53_I20131031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="i0302cc9696d04655b132ed6718400098_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a3833260ec34d169d4087f7cc599a38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2267b398358d40628d513e840da1acd3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77ef4253bc71484f944278fc62928061_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1eaa927f30f243e1bc5fa261ed93065a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1b6e20121a2f4c0abc7b278e428bded7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c05145d2dd243aa946509d98e419c02_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i03544544417f4f4c9d465e8f28185dc4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idb0b4fc7e6824deba0edf9c15b602152_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i847642b8e010448c92e39737e6b98cd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f613cb53e594b4ea341386947101b5a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie734a52f70924b7d8ef283a737651cf5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7975540d8d9b4164b34b19720b17c21c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id3fea8f715e94127942cb6f892c9f8d7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifdfaf6831a2d4d289947607db7469eff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if2a4fb10b7154f3ebaf1b668d5d5333c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia12ba1f486ee48b387eed8cf479dabb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iede31b1fe9ba4eb59488549ad0ed810f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8760a3584cb24373bea7740e94ca3528_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4deebaa10a1a47c48da755ae23565886_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i787eb452c45b49288fbda9f5890e9106_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0eced2ea218c49c0a97e0443fe143c83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02d5390f0831417aaa47113ae87c3835_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35285b9536cb42819f07a5e10f10a803_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="if008047c1927420f94d6d0b9470befc2_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="if40f0f15e6a24dc0ae3308ba4fd42d06_D20171001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d3801ae5b2b4734b7b504e59402757a_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="ic88b6f87de8b48c1aefa96bec6d6e029_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i79ca36c995024fcda45aec3f3a112ef3_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="ic9abc33023e44114b55b4f12898b8282_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i921686739722463c9fad09ea5aea9c8f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a4db4be284f4edfaa25820bc601700f_D20170101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0274a39f90984b378198325f447e1d04_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic43e5cf8fc164202a6ba3322517e2e89_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia989b7cb90484d43be29e03fd1165709_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia4744971aa884484b209865c89d5a5d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic889e33f540545a6a24b79e6435032eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i19c7230b384645a48a881abee6fc9595_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i31b103b2021742a2aa611443cc804a22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69b00209713a42919d237bd84b5347ff_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="if5b5d258671b4db29f62cd54a91316b0_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i761691dda30f487faa377ea767d90b27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2421978c32548a692cbb679e16f1769_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40903b6d1a844575b81590c15ea6ad69_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="idaa6b8a1bef549409289b02f594e0e03_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i264b652dc2a449aaad3d8d44d6eac051_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i7528a17162cd4516ba9f826eb391dfe2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icdb32608cb0a4fa2ab949afb86d7f2ea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if5002f370ab2410aa505e7023a7c03b1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie5b5491ae6264b9a977e0986eb5f5f09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79fe409dced14166bc3d283feb339c66_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4cf709b6a97f4324bf07c7b35ff8dcf8_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4936e447493b4718a73a3e856e8466cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8d4cb3c32ee4849af0342d8ac09701d_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28f6817da3524d99a079cfc05dadfb58_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if317058b73fa4c929dab128dd0783ce9_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ib65817edf9ea4a70a15c2ee1b06d2435_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5198817fd6ce48d5b36e1a65aa5dceb0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i883a0b58cc464c758fb7cd4f1a43cde7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2794f662b6aa4beaa84d0ce6906344ec_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="id66268ce470743409fc8e1e2f94e9801_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ic6b51b6783874d27a5e578d32a2386c7_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i0bc2607458784ba0a39a83024e0690aa_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i5506bcb7455143afb88326e2bc2e1766_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i8bdcb76501ca490393d206ec8477ba60_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="iaf67de44e2a04b7c9869197b5d5a8db3_D20120901-20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-09-01</startDate>
            <endDate>2012-09-30</endDate>
        </period>
    </context>
    <context id="i22e923f8da4f403d9f71bbc5dcacf4c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0913a1b864a54032af94f46428788ecb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1b4293b73e6b48ab8ca56a0aa4f4a336_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i78b72bb5c40c49d9b35cc590ba9cafc3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i799c2d0004184beeab2fb18bb2844605_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idd6f1db210074fa491c51e6386544604_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iff5d8a80f0b24b2f8b060afc429d38e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i36820e64f4634e7892f209af43a3a307_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i481a6c266fd34525a08d8b19efb3a3a5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i311557add6db476c974b15fe543b53a3_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i81b5a53b426d4596a8deebbcbbd64643_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50ebf3ffdbfd4f73a07d547a319c5d2c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i68fe313822074061be5bf3c037d98d1e_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i42ab5ff2130a40b1a0aec0d6d8f54c67_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd0782694ada422ca317357bc074882c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie9bbec66f02a478c848c4c9082abfa02_D20101001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i1d18f8528615463aa7159bbb5c8c9ca7_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i8dfc6229eff84fc5bc5f1546988286eb_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic3620e7cdab24c1b9ca940443012e7d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33759800192341f2aad1c701d3f8d023_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="iaa516c3811054de6a63d0438076fc6d1_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="i9149ccf8fad640259305ee4963fe44d6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i73fce89d7ee84c7f9e43c656a72d517e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6be2dbbda2c4a37b4060f380fd2b3b1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i541afd290f08418499ed50f29b1803fc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7d3639bf682f4179b89f96aa342a7e53_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mgnx:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="renewaloption">
        <measure>mgnx:renewalOption</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>mgnx:performanceObligation</measure>
    </unit>
    <unit id="productcandidate">
        <measure>mgnx:productCandidate</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF80L2ZyYWc6OGRjMzU2ZmJhZDdkNDgwOGI5YTI3ZTAxZTYzZjFkMmIvdGFibGU6Zjc3NDBjNjM3N2JlNDdjYzgxZGIyZTM3NmExMGZiZTEvdGFibGVyYW5nZTpmNzc0MGM2Mzc3YmU0N2NjODFkYjJlMzc2YTEwZmJlMV8xLTEtMS0xLTA_e7562db9-2e13-4f99-8b68-a627e8801ae0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF80L2ZyYWc6OGRjMzU2ZmJhZDdkNDgwOGI5YTI3ZTAxZTYzZjFkMmIvdGFibGU6Zjc3NDBjNjM3N2JlNDdjYzgxZGIyZTM3NmExMGZiZTEvdGFibGVyYW5nZTpmNzc0MGM2Mzc3YmU0N2NjODFkYjJlMzc2YTEwZmJlMV8yLTEtMS0xLTA_81d970d0-8ea9-44cf-9364-9336e298497d">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF80L2ZyYWc6OGRjMzU2ZmJhZDdkNDgwOGI5YTI3ZTAxZTYzZjFkMmIvdGFibGU6Zjc3NDBjNjM3N2JlNDdjYzgxZGIyZTM3NmExMGZiZTEvdGFibGVyYW5nZTpmNzc0MGM2Mzc3YmU0N2NjODFkYjJlMzc2YTEwZmJlMV8zLTEtMS0xLTA_e60bbf62-3a03-4280-9047-c40fada89aa6">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF80L2ZyYWc6OGRjMzU2ZmJhZDdkNDgwOGI5YTI3ZTAxZTYzZjFkMmIvdGFibGU6Zjc3NDBjNjM3N2JlNDdjYzgxZGIyZTM3NmExMGZiZTEvdGFibGVyYW5nZTpmNzc0MGM2Mzc3YmU0N2NjODFkYjJlMzc2YTEwZmJlMV80LTEtMS0xLTA_36faa437-0ff3-462d-ab4f-ceddf42d0e34">0001125345</dei:EntityCentralIndexKey>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic9c6bda6395f466b9aeb7ea0c330cb71_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzQxNA_c7bd66aa-5f7d-4552-b4e9-c0686ecd66a9">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM184Ng_858b0a52-6729-4451-ba04-ba1783d054bf">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6NmI2MWViYTAzMmRhNGQwYmEyMDkwZGU1N2E1MzY1ZWQvdGFibGVyYW5nZTo2YjYxZWJhMDMyZGE0ZDBiYTIwOTBkZTU3YTUzNjVlZF8wLTAtMS0xLTA_91bf2672-9022-4002-a98c-366833d9cdf1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xMzE_545ed643-fad9-4f17-b5a8-99f5e686b3c1">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xMzE_d26bed40-e4d9-48aa-8b82-5e947a9a0181">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6ZWVjYzNmN2RiMDQ4NGYwYTkwY2FkZjFiMzIzZTY3MTUvdGFibGVyYW5nZTplZWNjM2Y3ZGIwNDg0ZjBhOTBjYWRmMWIzMjNlNjcxNV8wLTAtMS0xLTA_da0d685b-d671-46e2-b6ae-36f668082eae">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yMTQ_2a20c65a-f75a-4417-9349-29266849d627">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yMTg_e018c280-b44f-42c5-aaa0-dac33a006d17">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6OWQ1YTQ1NmM0N2VmNGU0YmE0OTlhMjNmOWJjNzJhMTcvdGFibGVyYW5nZTo5ZDVhNDU2YzQ3ZWY0ZTRiYTQ5OWEyM2Y5YmM3MmExN18wLTAtMS0xLTA_ca6d2572-91b6-46b7-8e19-78ec797d772b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6OWQ1YTQ1NmM0N2VmNGU0YmE0OTlhMjNmOWJjNzJhMTcvdGFibGVyYW5nZTo5ZDVhNDU2YzQ3ZWY0ZTRiYTQ5OWEyM2Y5YmM3MmExN18wLTItMS0xLTA_ea28e984-5599-48e9-9aa0-2bc7c0ed7acc">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNTM_b7685c3e-01c2-47e5-9f31-4cbf56174420">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNTc_b2e8ee66-d38a-45ec-8612-464b09f62071">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNjE_adbd3cb5-fae5-48da-a8c8-5a5212e1d247">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNjQ_8d320041-469e-4374-afe9-ad52cf56a6eb">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18zMjQ_8f015a39-6b67-4741-b222-9bbd13035bdc">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18zMjk_be3f8625-5c49-4209-9bc0-135fb49843cc">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6MjVmMzcyNjJlNmYzNDE3MGJiNjgxNjBhMTFmM2Q5MTQvdGFibGVyYW5nZToyNWYzNzI2MmU2ZjM0MTcwYmI2ODE2MGExMWYzZDkxNF8xLTAtMS0xLTA_8de0be68-f1db-42cb-be28-2c7c2a8501eb">Common stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6MjVmMzcyNjJlNmYzNDE3MGJiNjgxNjBhMTFmM2Q5MTQvdGFibGVyYW5nZToyNWYzNzI2MmU2ZjM0MTcwYmI2ODE2MGExMWYzZDkxNF8xLTEtMS0xLTA_bc782b9f-0e3c-4410-8ca3-62a51829d2dd">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6MjVmMzcyNjJlNmYzNDE3MGJiNjgxNjBhMTFmM2Q5MTQvdGFibGVyYW5nZToyNWYzNzI2MmU2ZjM0MTcwYmI2ODE2MGExMWYzZDkxNF8xLTItMS0xLTA_3ff1e921-756e-4a9d-ad6c-f965f39fba70">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM182MTg_d6b05f53-3980-4bb9-8fce-eb5393c90fac">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM183Njk_b73afc2b-10d9-4cde-a65b-a321008adc5c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xMTIx_72b323c0-4b89-4fd1-9779-5a0f74f83bc8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xNDE5_2a53d6a0-871b-4339-97a7-59a0d21431fd">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6NjQyYTM3N2U2Mjg4NDQzMThlOTE4MDFmYTBlZWRiZmUvdGFibGVyYW5nZTo2NDJhMzc3ZTYyODg0NDMxOGU5MTgwMWZhMGVlZGJmZV8wLTAtMS0xLTA_2a3bb969-62bd-43ca-b0f0-522c1ba5253e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6NjQyYTM3N2U2Mjg4NDQzMThlOTE4MDFmYTBlZWRiZmUvdGFibGVyYW5nZTo2NDJhMzc3ZTYyODg0NDMxOGU5MTgwMWZhMGVlZGJmZV8yLTQtMS0xLTA_62a16613-99a4-4fe2-b4fd-fa26de757843">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGFibGU6NjQyYTM3N2U2Mjg4NDQzMThlOTE4MDFmYTBlZWRiZmUvdGFibGVyYW5nZTo2NDJhMzc3ZTYyODg0NDMxOGU5MTgwMWZhMGVlZGJmZV80LTEtMS0xLTA_79c67990-5a8e-4ce3-a579-199e2e791658">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18xMzc0Mzg5NTM1MDY3Mw_1846ed15-807f-4e27-911b-3d0a3e309dec">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yMTYz_730d5ec0-c81a-415e-9474-26960dbc2729">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ibc371ef99f5f4a54a624cc69d77a088b_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yNDI3_8f48be96-a844-485a-9b02-3953d2e88816"
      unitRef="usd">1500000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iee4457baa35447a49304e676fa213609_I20210222"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18yOTEw_b1343aad-d7b8-4c84-a68d-faa0c4e03915"
      unitRef="shares">56258468</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xL2ZyYWc6M2U2MzgxMzI1YWI2NGQyOTgyYTQ3NDk2ZWQyMTU5YzMvdGV4dHJlZ2lvbjozZTYzODEzMjVhYjY0ZDI5ODJhNDc0OTZlZDIxNTljM18zMTE5_aaa5dd46-40ef-41d4-ac51-4ca8d97f83e3">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2021 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzQtMS0xLTEtMA_69cd1bf5-2d48-4e70-918a-8b0d4dcfefdb"
      unitRef="usd">181131000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzQtMy0xLTEtMA_9b6d7e54-f5b8-4b85-8cd5-f157f807e890"
      unitRef="usd">126472000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzUtMS0xLTEtMA_bae57728-4a23-4559-8231-3c98559ae88f"
      unitRef="usd">91400000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzUtMy0xLTEtMA_c5a77be7-785c-44b3-94f8-c32222b55c95"
      unitRef="usd">89284000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzYtMS0xLTEtMA_a99e62e9-ec2f-4c35-8392-5e4e870fb35f"
      unitRef="usd">23081000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzYtMy0xLTEtMA_228d9040-7db1-46e9-865d-7860115801f1"
      unitRef="usd">12744000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzctMS0xLTEtMA_f7d17490-79f6-4f8f-b09a-95a101a31c2b"
      unitRef="usd">16982000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzctMy0xLTEtMA_5aa78ce5-731c-4eb4-883d-ffac5fa770d0"
      unitRef="usd">11285000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzgtMS0xLTEtMA_a97f545f-8f32-4146-89ec-9246cd6d1a2f"
      unitRef="usd">312594000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzgtMy0xLTEtMA_091b7ded-38da-45b7-8584-fbfefdc66a78"
      unitRef="usd">239785000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEwLTEtMS0xLTA_fa63bbd3-38e0-40c2-b50c-dd863e01ffce"
      unitRef="usd">42225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEwLTMtMS0xLTA_ab6ec637-72e6-43dc-aa78-e73b97d6611d"
      unitRef="usd">48211000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEyLTEtMS0xLTA_721bc0cf-2d3a-4ab1-9b0e-e9e023a0129e"
      unitRef="usd">23924000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEyLTMtMS0xLTA_0f6b328e-ab84-434b-8ec3-8709b160706f"
      unitRef="usd">24505000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEzLTEtMS0xLTA_8d443e8c-2adc-40fb-9f71-32e59379edd3"
      unitRef="usd">378743000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzEzLTMtMS0xLTA_6c69417c-19f5-44de-8335-1c0678aab9c8"
      unitRef="usd">312501000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE3LTEtMS0xLTA_bd144eca-1aef-4e0a-830d-790e65cc3cb1"
      unitRef="usd">8031000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE3LTMtMS0xLTA_3dfe91a0-576d-44bf-8fcd-b53c17472bc1"
      unitRef="usd">4308000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE4LTEtMS0xLTA_de9e0b8d-a7fc-4f9d-a6ff-2de65358582d"
      unitRef="usd">34198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE4LTMtMS0xLTA_7dab686c-4e2e-4a2f-97f1-5851cb06a22a"
      unitRef="usd">27139000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE5LTEtMS0xLTA_9858a8b2-85da-4e53-9d0c-ef9768eed325"
      unitRef="usd">4456000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzE5LTMtMS0xLTA_7951e1e6-a26e-48a1-893b-792ba9992fa6"
      unitRef="usd">10700000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzIxLTEtMS0xLTA_be198c08-2552-475e-b72c-e75c3abb7937"
      unitRef="usd">3988000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzIxLTMtMS0xLTA_9c3cf3e2-ae74-4b2e-9fca-64f13744c19b"
      unitRef="usd">3020000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzIyLTEtMS0xLTA_83f553df-f943-4e57-a969-054ab8d5a1b6"
      unitRef="usd">50673000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzIyLTMtMS0xLTA_ca58380c-bb0b-4091-8545-33ae31a49449"
      unitRef="usd">45167000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI0LTEtMS0xLTA_fcb4cffe-6656-4465-8519-f55c7f519b07"
      unitRef="usd">6926000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI0LTMtMS0xLTA_6eca7302-1c02-48e7-9821-476319ed2179"
      unitRef="usd">9153000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI1LTEtMS0xLTA_3b01757d-8ba1-4466-bd26-c6fc8ca995aa"
      unitRef="usd">25260000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI1LTMtMS0xLTA_74ee6b7d-96b9-42d3-8f3c-5d2391f05506"
      unitRef="usd">27553000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI3LTEtMS0xLTA_233e0f52-f70f-4f4c-b17c-64566971b4fb"
      unitRef="usd">82859000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzI3LTMtMS0xLTA_991bf9d7-c282-4e23-b89b-8552d7f76179"
      unitRef="usd">81873000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YTQxNjYxMTkxOTE0ZWU2YTZhNGE5YmQ4MzZkMDk0Ml8xMjA5NDYyNzkwNTcxMA_c74e454c-fcf2-4815-b7bb-230f3a8455e7"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YTQxNjYxMTkxOTE0ZWU2YTZhNGE5YmQ4MzZkMDk0Ml8xMjA5NDYyNzkwNTcyNA_1badbbec-521c-46a9-8eeb-8f4fd81e0295"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YTQxNjYxMTkxOTE0ZWU2YTZhNGE5YmQ4MzZkMDk0Ml8xMjA5NDYyNzkwNTczNw_87091f99-9164-4b73-9d69-149921b6063c"
      unitRef="shares">56244771</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YTQxNjYxMTkxOTE0ZWU2YTZhNGE5YmQ4MzZkMDk0Ml8xMjA5NDYyNzkwNTc1MA_181da95b-8567-48e5-93b8-e585d458ed13"
      unitRef="shares">48958763</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTEtMS0xLTA_dcb77079-7f26-4f0d-aadb-5da7dc702cf7"
      unitRef="usd">562000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMwLTMtMS0xLTA_b2bc59a3-3f21-4b86-9707-23854e34e493"
      unitRef="usd">490000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMxLTEtMS0xLTA_9749ecf0-3550-4c67-9ac7-387dbf0db54a"
      unitRef="usd">1067150000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMxLTMtMS0xLTA_24309a09-5bf2-4987-9fc7-eaafde64061d"
      unitRef="usd">872204000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMyLTEtMS0xLTA_e98d4bd7-c1d5-4f88-b603-84d3a2ee3809"
      unitRef="usd">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMyLTMtMS0xLTA_0c264a54-be69-4598-a973-1695e5356893"
      unitRef="usd">16000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMzLTEtMS0xLTA_b66f3f1b-dd15-4d5b-99ec-05a007bfd5a7"
      unitRef="usd">-771821000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzMzLTMtMS0xLTA_51b5dbed-5328-400d-a3eb-e4c889faa9e7"
      unitRef="usd">-642082000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzM0LTEtMS0xLTA_e22a51d9-37ed-4166-9aee-e492205d5eef"
      unitRef="usd">295884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzM0LTMtMS0xLTA_cdb28905-d9e8-4788-9120-0001e1bae6cb"
      unitRef="usd">230628000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzM1LTEtMS0xLTA_13656696-ede5-418f-b484-f1e849c8ba2f"
      unitRef="usd">378743000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMjQvZnJhZzoxYzQzNzQwN2VjZmM0MWZlOGQ0NWJhZDM0NGM1MTk5ZC90YWJsZTo1NmI0NjI1ZWUyNWI0ZjIzODFlNTkxZGUxZTMyZmViOS90YWJsZXJhbmdlOjU2YjQ2MjVlZTI1YjRmMjM4MWU1OTFkZTFlMzJmZWI5XzM1LTMtMS0xLTA_0455d6b5-2e5b-49f2-a38f-61ec1770465f"
      unitRef="usd">312501000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i3d808e02b5414fd683b155299253411e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzMtMS0xLTEtMA_7498dffe-4ab4-4f64-a1bd-56eefbca3562"
      unitRef="usd">97764000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id64fda6eae444b93b571cf566d3a92d0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzMtMy0xLTEtMA_5e3513bd-eb56-4fae-b59a-e4220114ae8d"
      unitRef="usd">62024000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaaef0c61fb24481cbdacd565ae79023e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzMtNS0xLTEtMA_02141b58-7e27-47c3-9e40-e67984ab5484"
      unitRef="usd">58644000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied1559cf83494ef1ad022048d27be8c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzQtMS0xLTEtMA_64399e32-81e4-43b7-899e-6778c45aa3b6"
      unitRef="usd">7119000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i24fcde07e22449f18988a9bb4909c03b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzQtMy0xLTEtMA_262331b6-2224-402d-bd24-f43168b02d4e"
      unitRef="usd">2164000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3742a3dcd1cd4e018f4a0e55e544bf88_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzQtNS0xLTEtMA_1eda37e2-dbd5-4da7-a6ff-c046b76c097f"
      unitRef="usd">1477000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzUtMS0xLTEtMA_48ef908d-e677-4e52-88d8-1b1d2513f647"
      unitRef="usd">104883000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzUtMy0xLTEtMA_bbacd4d1-805a-4d28-a80b-7784e5520439"
      unitRef="usd">64188000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzUtNS0xLTEtMA_21ae7cc4-14d0-42da-a7a6-0fb4a9a426bf"
      unitRef="usd">60121000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzgtMS0xLTEtMA_e0128c10-716a-4c55-9229-89b428a6fc83"
      unitRef="usd">193201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzgtMy0xLTEtMA_e9643b9e-308b-49ad-bbf1-50b3dd79570c"
      unitRef="usd">195309000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzgtNS0xLTEtMA_2bd21668-f088-452d-a6be-e478590aef0e"
      unitRef="usd">190827000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzktMS0xLTEtMA_fdb2a10d-bf3e-4382-aee5-7f24fb98a479"
      unitRef="usd">42742000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzktMy0xLTEtMA_78b0e341-5e0a-477e-8ca0-d71b41d4f36b"
      unitRef="usd">46064000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzktNS0xLTEtMA_6a07773d-a0be-4709-8f02-c0b75bf66e5c"
      unitRef="usd">40500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEwLTEtMS0xLTA_13dcc533-024f-4266-8bb0-a0dc43cf3954"
      unitRef="usd">235943000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEwLTMtMS0xLTA_8e88c751-b71b-4548-b030-c222d88054a0"
      unitRef="usd">241373000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEwLTUtMS0xLTA_b40708de-80d5-4c90-b698-f59f300f786c"
      unitRef="usd">231327000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEyLTEtMS0xLTA_895c256a-24f7-4d4a-b238-6953d49ecdb4"
      unitRef="usd">-131060000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEyLTMtMS0xLTA_dfe27487-06ab-4871-a911-2a8ac00061c8"
      unitRef="usd">-177185000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzEyLTUtMS0xLTA_bd26dada-3025-4956-86d0-9a8f4da92996"
      unitRef="usd">-171206000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE0LTEtMS0xLTA_8e372d93-0362-4a90-852c-e719ad9dc5cd"
      unitRef="usd">1321000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE0LTMtMS0xLTA_f5392724-90ee-4c41-b4aa-748d8835bfa7"
      unitRef="usd">25374000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE0LTUtMS0xLTA_80109485-963c-48d5-a9e2-0f516394c214"
      unitRef="usd">-247000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTEtMS0xLTA_ccdf9bae-4b08-4de2-8718-17bde981d665"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTMtMS0xLTA_7938d377-40c4-4d50-bb48-94f980e068e4"
      unitRef="usd">-151811000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTMtMS0xLTA_87bc885e-4bb6-47f5-b432-1c88b8fdad11"
      unitRef="usd">-151811000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTUtMS0xLTA_18676b7a-f21d-4f3e-b3ea-de5ae60b1d90"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE1LTUtMS0xLTA_722bad81-c7bb-4101-85c3-682ff2680af3"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE4LTEtMS0xLTA_9e8d0925-9b02-4a08-b70f-80a0f13afeb7"
      unitRef="usd">-23000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE4LTMtMS0xLTA_3dea409f-6f6d-4c94-9042-46a4c47f484c"
      unitRef="usd">19000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE4LTUtMS0xLTA_7394003c-d985-4b43-9453-75045994e29a"
      unitRef="usd">58000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE5LTEtMS0xLTA_b2f5930b-e590-47fc-9cec-75f0e0596b24"
      unitRef="usd">-129762000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE5LTMtMS0xLTA_cfb9bc7f-96bd-438b-8b6e-f41b78d447a4"
      unitRef="usd">-151792000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzE5LTUtMS0xLTA_8fb12bce-643a-47fc-aaea-d91ed7cc9e0e"
      unitRef="usd">-171395000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIyLTEtMS0xLTA_9ae5542d-487f-43c8-8f93-499780197076"
      unitRef="usdPerShare">-2.47</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIyLTMtMS0xLTA_2d40f29b-c4dd-4410-9632-38130bb1e344"
      unitRef="usdPerShare">-3.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIyLTUtMS0xLTA_59ce7e99-4283-479e-8207-e6f2436ae6a9"
      unitRef="usdPerShare">-4.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIzLTEtMS0xLTA_915ac1a4-3724-4f9b-a689-d19cea95d0e8"
      unitRef="shares">52442389</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIzLTMtMS0xLTA_11338f96-78ad-493e-9519-e757f6507771"
      unitRef="shares">48082728</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzAvZnJhZzpiNDkxZWFlZjA0NTE0YzMzODU3MTExZGIwZjM1NDA0Zi90YWJsZTplMzdjMTQ0N2E5NGM0ODcyYjVmYzMzZDE1MDAyNGFmMi90YWJsZXJhbmdlOmUzN2MxNDQ3YTk0YzQ4NzJiNWZjMzNkMTUwMDI0YWYyXzIzLTUtMS0xLTA_5d383816-df58-4dee-bd64-f91cf7840b5b"
      unitRef="shares">40925318</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="i3e9de6b275e1488fb3fb628e6f009da2_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMS0xLTEtMA_17abb31d-eb9e-452b-88d0-7b93f4c2306f"
      unitRef="shares">36859077</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i3e9de6b275e1488fb3fb628e6f009da2_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMy0xLTEtMA_721dc3c9-ecd9-4664-b03b-2aabaca762d6"
      unitRef="usd">369000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i2e401a1ba9e34e4b90951902947848c6_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtNS0xLTEtMA_c5f5742a-a095-42d6-a76f-7e29d5875352"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i2e401a1ba9e34e4b90951902947848c6_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtNy0xLTEtMA_d7d23fd3-65a0-4696-b92c-fd409a71c616"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36d36892fdb74f70add306d4b9acf8f2_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtOS0xLTEtMA_f08c2ad6-ffb8-4608-ac73-5ead95bec810"
      unitRef="usd">611270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide6e365cd9374fd0bc37f252d29fd753_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMTEtMS0xLTA_0d46bcd8-8067-422e-b26a-7c942f751f4f"
      unitRef="usd">-312340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c020d90e65547508df10ef8295c9c46_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMTMtMS0xLTA_507bdb4f-84ea-4e22-ae94-a91e991919de"
      unitRef="usd">-61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia662d353fd8d45c0b6ef76a73d9eab63_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzMtMTUtMS0xLTA_d6a0287b-99be-44c1-91eb-e41e4907d92f"
      unitRef="usd">299238000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54c8abb81fc54045a728f7789e5eb590_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzQtMTEtMS0xLTI5NjQ_c1f0f23a-7f3b-42da-8d1f-1a5927309f8d"
      unitRef="usd">-6478000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92ef7adb07344ad083846bfb3d0940f6_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzQtMTUtMS0xLTI5NjQ_a3282664-3cfb-4400-8ccf-b3725f8dfd1b"
      unitRef="usd">-6478000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzQtOS0xLTEtMA_befe111f-0199-4110-9891-d1a90fc4fde7"
      unitRef="usd">16520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzQtMTUtMS0xLTA_c915002d-fde1-4c0c-b8b5-99e130bf39a4"
      unitRef="usd">16520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzUtMS0xLTEtMA_ca37a27d-2be7-4890-956c-4e8348b05fb8"
      unitRef="shares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzUtMy0xLTEtMA_d6330369-5986-47c8-ba6a-f3c05bb50b24"
      unitRef="usd">52000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzUtOS0xLTEtMA_a4f440c3-c197-4fe2-bfdc-239abbda274e"
      unitRef="usd">103207000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzUtMTUtMS0xLTA_21c1bd45-c68c-4075-8f9c-f4dcddd77d88"
      unitRef="usd">103259000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtMS0xLTEtMA_2233279b-8966-4079-a23c-29a20ad68a89"
      unitRef="shares">319224</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i930a1c6c8b6f43769b0d5efe5cfed8e5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtMy0xLTEtMA_a76ca471-9bb5-42e2-9e57-2e0e32064aec"
      unitRef="usd">3000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtNS0xLTEtMA_bb75434f-9e5b-47cc-a226-153e021239b5"
      unitRef="shares">11070</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtNy0xLTEtMA_21449a88-820b-499d-b667-c08a0de48709"
      unitRef="usd">-260000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtOS0xLTEtMA_0c3bced3-ad8a-4f2d-8023-d1ff7a4f5740"
      unitRef="usd">1990000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzYtMTUtMS0xLTA_7e44b43d-e629-4143-b0e5-2631f670b65c"
      unitRef="usd">1733000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzctNS0xLTEtMA_7c6597e8-c03f-4ad0-8e4c-d6f16e664dc1"
      unitRef="shares">11070</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="i5fa5b896be1c4305af532847d2f8df11_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzctNy0xLTEtMA_318b691e-a980-432f-b083-e938c5f3faf9"
      unitRef="usd">-260000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="i52c1b9c6327f4f4aad81c035132ef40d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzctOS0xLTEtMA_4e08f7f6-3ef4-4e98-9185-f3241e48eded"
      unitRef="usd">260000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzctMTUtMS0xLTA_eee1d6de-98c6-4f97-8a46-fa1f5eac57b1"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="id00868bdc70444b5996012f6dc5d03f8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzgtMTMtMS0xLTA_2a440000-8048-455d-af62-9c99e1bd5d2a"
      unitRef="usd">58000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzgtMTUtMS0xLTA_e953070b-48b1-4540-8ae9-fa678ee05f4f"
      unitRef="usd">58000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i03dc58ff992a4affb3ae912e7726fd5f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzktMTEtMS0xLTA_5f35e5b4-4960-4970-bc96-5475190742e5"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzktMTUtMS0xLTA_991844bf-e554-4459-9636-1e4d587c6c1a"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i32cb1a93d9784446861b4351c65a06ab_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTEtMS0xLTA_96846b4d-aa44-4116-bc25-cdd176c3936a"
      unitRef="shares">42353301</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i32cb1a93d9784446861b4351c65a06ab_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTMtMS0xLTA_acabf7a0-a879-474c-a8d3-7464164471ea"
      unitRef="usd">424000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i34837cef321c44a6880d4682ed958ef8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTUtMS0xLTA_15490734-0773-4070-917e-2d8ca7f82e45"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i34837cef321c44a6880d4682ed958ef8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTctMS0xLTA_d9eef554-4be7-4ace-8a87-4f1080b6717d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9a43579b4d5441d9adfda3882db2702_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTktMS0xLTA_6fe0ce15-a4ce-48b0-ae36-3e717529082a"
      unitRef="usd">732727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17c88315085b4a6b86cc704010cbb3b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTExLTEtMS0w_101048f6-e654-4df8-8c03-cee3371b661b"
      unitRef="usd">-490271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ffdf5a5082a4f03a6ddd2697f0ab3aa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTEzLTEtMS0w_39f0eaa4-1c7b-427e-b6fe-b6715f0ec9bf"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEwLTE1LTEtMS0w_67867ee9-0dd7-420c-99e7-0344fef25b03"
      unitRef="usd">242877000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i826687038ea842c986973786b645a9e0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEyLTktMS0xLTA_963a983b-bc1a-449a-8eac-67300ff70af3"
      unitRef="usd">19571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEyLTE1LTEtMS0w_8353e228-d556-4aa4-b2bd-80251882f704"
      unitRef="usd">19571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEzLTEtMS0xLTA_72c41cee-8f28-4eb2-ada4-a5d7eb0d502d"
      unitRef="shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEzLTMtMS0xLTA_31feae28-899c-4089-bbb4-c64ec5559449"
      unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i826687038ea842c986973786b645a9e0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEzLTktMS0xLTA_78e3a52c-bf34-422e-8e77-0a36667c49aa"
      unitRef="usd">118594000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzEzLTE1LTEtMS0w_cc9ee109-fce3-498f-beb0-d48783cbd05a"
      unitRef="usd">118657000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE0LTEtMS0xLTA_f0d66c37-affc-4d47-966e-f7a548d72759"
      unitRef="shares">280462</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i0037e986c6074d3d9eb970d01b4e8230_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE0LTMtMS0xLTA_8e590438-91f8-4dcc-b7f5-c0ddf4b724d2"
      unitRef="usd">3000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i826687038ea842c986973786b645a9e0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE0LTktMS0xLTA_d911ff74-c0e5-4915-92a1-cd9887f8bfc3"
      unitRef="usd">1312000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE0LTE1LTEtMS0w_a7d079f8-0952-4aa1-9e23-61b3f512d1b2"
      unitRef="usd">1315000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i36ad1dc4801847e1b315ea5729b88e91_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE2LTEzLTEtMS0w_d958116b-d7b8-406b-9894-9384a8d5f5fc"
      unitRef="usd">19000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE2LTE1LTEtMS0w_a3142c06-5860-4210-80a5-2c8e1ad3e2ca"
      unitRef="usd">19000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i901563a826804698862205071e209880_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE3LTExLTEtMS0w_9f998843-815e-4ef9-a18e-384bb76f1f66"
      unitRef="usd">-151811000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE3LTE1LTEtMS0w_799cdbd5-4d19-4a59-83d5-b7c0833cfb75"
      unitRef="usd">-151811000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i0a1a0c6402b943b9b4b2ba26940be870_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTEtMS0xLTA_c4e886a4-88be-48b2-ab35-89d4d01595be"
      unitRef="shares">48958763</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0a1a0c6402b943b9b4b2ba26940be870_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTMtMS0xLTA_3b5dff68-56cf-42d3-be40-457f1af854da"
      unitRef="usd">490000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i6e6db4aa25b74df5abc90db0f02b82a6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTUtMS0xLTA_89dd57f0-3444-472a-a200-43c185eaaa85"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i6e6db4aa25b74df5abc90db0f02b82a6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTctMS0xLTA_aa3c539c-4133-41f6-841e-38385df32e68"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie09fcd6ed15e4fc0be1acdc77c4500f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTktMS0xLTA_ef9fe4f5-0015-4eea-95ba-3049f169f91f"
      unitRef="usd">872204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ef16e4c63d6480f96951c6f7eac9ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTExLTEtMS0w_8edb270f-f81d-46d4-ac08-0dd4f4546d13"
      unitRef="usd">-642082000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff38bc7672c14b59938322f49d658a0c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTEzLTEtMS0w_7bf9ec6b-e1d3-4608-b847-fb2229847354"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzE4LTE1LTEtMS0w_3f5df558-3851-49e8-8e79-9f949c6a27d3"
      unitRef="usd">230628000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIwLTktMS0xLTA_dc596316-b3ea-4bb0-9e27-5fc50909e9c0"
      unitRef="usd">20676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIwLTE1LTEtMS0w_38c3a676-2ed4-494e-8c62-68734b918c5f"
      unitRef="usd">20676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIxLTEtMS0xLTA_d070db29-6bb4-4f01-b8f9-443bcf986669"
      unitRef="shares">6612815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIxLTMtMS0xLTA_2ea13662-6072-4e6d-924b-d050ea242d29"
      unitRef="usd">66000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIxLTktMS0xLTA_04e9bd92-f2eb-42c8-a4a2-c81bc9404fd1"
      unitRef="usd">170390000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIxLTE1LTEtMS0w_2cc9738d-c3f1-4995-82f6-044cc1983af9"
      unitRef="usd">170456000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTEtMS0xLTA_ef62218e-857e-408d-8846-38fea3356a3f"
      unitRef="shares">673193</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ifed306eb666844c083263e91bce8bb5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTMtMS0xLTA_4666944f-72dd-4b36-aff5-332dd58dc3eb"
      unitRef="usd">6000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTUtMS0xLTA_bcdbc68f-2bc8-446e-9396-c887f5306fa5"
      unitRef="shares">74632</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTctMS0xLTA_d40ad346-064f-4ba9-800a-92c186c8c389"
      unitRef="usd">-2012000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTktMS0xLTA_47a9c84d-cc36-4ebf-bcb8-28f14b0db2fe"
      unitRef="usd">5892000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIyLTE1LTEtMS0w_a41c4eff-5307-4414-a05f-b25caed6648f"
      unitRef="usd">3886000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIzLTUtMS0xLTA_de6f7547-b25c-41d5-92ed-e2dff60b2aef"
      unitRef="shares">74632</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="i16a653853bfc46bfb39271b1c414ea21_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIzLTctMS0xLTA_0f62d69d-dde2-4745-af68-35a5005a203d"
      unitRef="usd">-2012000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="i5c907e40381f4735ac0349c43c44f4a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIzLTktMS0xLTA_4c0f98a4-7f02-4a5d-846f-9331cb84f6e8"
      unitRef="usd">2012000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzIzLTE1LTEtMS0w_92ff219c-932b-4cf3-8ac8-9d5fe10d3722"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="id0267b9d993f432e9f8c8b2e9d4c1098_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI0LTEzLTEtMS0w_b6379234-084a-4a7f-9638-4fea0796fc3e"
      unitRef="usd">-23000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI0LTE1LTEtMS0w_ae696ad1-2c45-4ec9-82a5-056fa66493fd"
      unitRef="usd">-23000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i9104c83bf7314b29a4d988eed8111854_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI1LTExLTEtMS0w_f0ce53a6-1ebd-4a20-8667-2750299eb13c"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI1LTE1LTEtMS0w_bd0e7ae9-c579-4c2d-a6ad-3d08e8d8405c"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ic1ca2685a1e44ec89c539d7bc50c9ed0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTEtMS0xLTA_6d3c4bfe-67e0-40d9-a96a-cdff67d3b87c"
      unitRef="shares">56244771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic1ca2685a1e44ec89c539d7bc50c9ed0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTMtMS0xLTA_37cd0303-dc41-489c-a83c-1e59f8175834"
      unitRef="usd">562000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="iedec7a9d1790449ea17afb27d64d25ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTUtMS0xLTA_b010fe68-df8a-4c77-9ffc-c900c50de2d8"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="iedec7a9d1790449ea17afb27d64d25ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTctMS0xLTA_c3f6d226-275e-4d20-a281-a39dfa178c87"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib51c8e9f97bb45179d0e2ff8204fe9a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTktMS0xLTA_71fd483c-7780-4709-a868-edad79f75ca3"
      unitRef="usd">1067150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i148cd0120f7c4ce5b2a1fe9a8db994bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTExLTEtMS0w_0913d12f-beb5-4533-ba56-2fa5d4f865f0"
      unitRef="usd">-771821000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibddef6e763f54b939c512d3cd30c5215_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTEzLTEtMS0w_62712a81-ddc4-4ef6-ba34-188be0051cca"
      unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzMvZnJhZzoxYzI1OWE5YjNmNTI0YzcxOGQ1OTQyMGRiZGNhYjEzMS90YWJsZTo2OGMxODJiZTI2YWQ0ODUxYmJmZDRiOTU5NjVlYzI2Yi90YWJsZXJhbmdlOjY4YzE4MmJlMjZhZDQ4NTFiYmZkNGI5NTk2NWVjMjZiXzI2LTE1LTEtMS0w_22a43ba2-341f-4b5b-b824-b5d18adba80b"
      unitRef="usd">295884000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMtMS0xLTEtMA_5b0ec87f-8a14-438c-9bb5-145057a189ad"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMtMy0xLTEtMA_729c37be-d48a-438e-ab6c-a0c36602f144"
      unitRef="usd">-151811000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMtNS0xLTEtMA_2c15afda-468b-4ed7-8ffb-cff5021311f0"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzUtMS0xLTEtMA_7780a488-028c-4f86-ba45-11e560071594"
      unitRef="usd">11957000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzUtMy0xLTEtMA_a26a338d-c3a3-467b-a88a-157ccc327f35"
      unitRef="usd">12306000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzUtNS0xLTEtMA_49a1ebfd-3d06-4d4c-9cab-a80f769e37b8"
      unitRef="usd">9160000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtMS0xLTEtMTI5_dfcbdfb8-110a-46e2-ab4e-5bc97439f9f6"
      unitRef="usd">260000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtMy0xLTEtMTI5_fac96b43-57f6-405a-a002-b3a364f86c09"
      unitRef="usd">1461000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtNS0xLTEtMTI5_fc2833ec-7013-4bc1-b92e-e755734cd6a7"
      unitRef="usd">881000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtMS0xLTEtMA_897d65f4-814a-48f3-8721-94e7d2fdd249"
      unitRef="usd">20676000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtMy0xLTEtMA_484ac33d-3e25-482d-be8f-ba4a8cb4df34"
      unitRef="usd">19571000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzYtNS0xLTEtMA_a1b3fd80-a50d-4029-b02f-718352187ca2"
      unitRef="usd">16520000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzgtMS0xLTEtMA_cc353fe8-c642-4fa5-89a0-40b7d336cc96"
      unitRef="usd">10337000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzgtMy0xLTEtMA_7b030849-5b91-479d-9ca1-bf66828e6408"
      unitRef="usd">-16839000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzgtNS0xLTEtMA_b25d1adb-5ee9-408e-9552-017eb64875a3"
      unitRef="usd">15941000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzktMS0xLTEtMA_14ffcce3-c698-4cb1-83b0-b5be62a98b80"
      unitRef="usd">5697000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzktMy0xLTEtMA_21a6242b-f07c-4a03-8851-f24c11b38142"
      unitRef="usd">4878000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzktNS0xLTEtMA_65d5059a-742e-4071-a6fa-8fdfb92ea109"
      unitRef="usd">3255000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzExLTEtMS0xLTA_1f8df8bf-e276-41bf-a823-0b6ea0cd65a3"
      unitRef="usd">-581000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzExLTMtMS0xLTA_c59fcfea-1548-4d6e-8cfa-3a05915dab33"
      unitRef="usd">1578000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzExLTUtMS0xLTA_db3de445-8898-4aec-8e65-83a2a632df7f"
      unitRef="usd">4580000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEyLTEtMS0xLTA_b60cedf9-bdeb-4afc-a014-86b5edd8943c"
      unitRef="usd">3723000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEyLTMtMS0xLTA_a9b4f7fb-e880-43dd-96bb-8410aa5c699e"
      unitRef="usd">787000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEyLTUtMS0xLTA_d3165823-8c72-4cf8-ba51-2a65899da7b3"
      unitRef="usd">1554000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEzLTEtMS0xLTA_c465acc0-3cb5-4fc7-bf47-7930bcb45527"
      unitRef="usd">6994000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEzLTMtMS0xLTA_9ddbaac7-83ca-4008-8f95-968c0a166a25"
      unitRef="usd">-6057000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzEzLTUtMS0xLTA_758614e7-da3b-41e2-ae40-b70035ae4a68"
      unitRef="usd">3208000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE0LTEtMS0xLTA_e27cd8c3-48ee-4436-8920-f83b8727750e"
      unitRef="usd">-1324000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE0LTMtMS0xLTA_c7aefd63-8a4b-4b5f-87b7-817ae6c869b8"
      unitRef="usd">2881000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE0LTUtMS0xLTA_e6f6cd19-3fbe-4bab-abf1-15d9b75cc3ba"
      unitRef="usd">0</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE1LTEtMS0xLTA_911ecf16-532d-45d1-b308-66c730c3013d"
      unitRef="usd">-8472000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE1LTMtMS0xLTA_b28b918b-b720-4d44-8c33-6c39fe8ba04b"
      unitRef="usd">-20869000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE1LTUtMS0xLTA_e145becc-5503-4959-84e1-a7629a9a293c"
      unitRef="usd">13405000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE2LTEtMS0xLTA_e3cc61af-1531-445e-a94c-73a87fa51b9c"
      unitRef="usd">0</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE2LTMtMS0xLTA_4b3ceee2-1dd8-4cee-bdbf-01c2b4510281"
      unitRef="usd">0</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE2LTUtMS0xLTA_18fdc29e-6790-43b5-9217-3358e2648bcc"
      unitRef="usd">-971000</mgnx:IncreaseDecreaseInDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE4LTEtMS0xLTA_629926d8-253d-4d75-b958-c7f32e0ddc0f"
      unitRef="usd">-111898000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE4LTMtMS0xLTA_7a7d0575-acf7-4ce5-a8d3-af0194f9983a"
      unitRef="usd">-134270000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzE4LTUtMS0xLTA_91a644a0-1bb6-4e35-b020-03288bfcc713"
      unitRef="usd">-153234000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIxLTEtMS0xLTA_d3a0b061-8244-4fe0-9e40-d4360a084f19"
      unitRef="usd">223745000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIxLTMtMS0xLTA_d5ae7b41-b60e-4331-b190-b469c95c4adb"
      unitRef="usd">264399000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIxLTUtMS0xLTA_7f6abb49-b4c5-4382-9c12-5c9b9b1bfebd"
      unitRef="usd">132750000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIyLTEtMS0xLTA_ef90b096-95bb-4430-a305-f6bb7ca07de2"
      unitRef="usd">221866000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIyLTMtMS0xLTA_934ed471-4b24-4494-94fd-473e79c64786"
      unitRef="usd">189330000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIyLTUtMS0xLTA_8fc32be3-a722-44b0-afd0-58c425690e33"
      unitRef="usd">214348000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIzLTEtMS0xLTA_8536e411-ad28-4f09-b483-1a22b7c901b7"
      unitRef="usd">5906000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIzLTMtMS0xLTA_a30eba95-bd95-42d6-a6c0-25315476be0d"
      unitRef="usd">4289000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzIzLTUtMS0xLTA_687f8b58-d566-4909-874a-153ed176c089"
      unitRef="usd">24954000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI0LTEtMS0xLTA_87bb87fb-d9c5-416b-9d94-0f05b8d4af46"
      unitRef="usd">-7785000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI0LTMtMS0xLTA_88be25fb-89aa-44dd-ac1a-626d3e6cec36"
      unitRef="usd">-79358000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI0LTUtMS0xLTA_eea1d5c9-6f94-4927-ab41-b4e62eff553b"
      unitRef="usd">56644000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI3LTEtMS0xLTA_643029cf-2696-462a-a7b7-72a4f0c77263"
      unitRef="usd">170456000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI3LTMtMS0xLTA_cad2f146-095c-4b26-8c04-eeffc4478105"
      unitRef="usd">118657000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI3LTUtMS0xLTA_d2d7fadc-284c-49cc-8616-44b83639da46"
      unitRef="usd">103259000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI4LTEtMS0xLTA_c6f3fd34-ba94-43ae-afd0-d79fe93c3aa6"
      unitRef="usd">5898000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI4LTMtMS0xLTA_2b5818e2-13da-4023-a50a-a59319674993"
      unitRef="usd">1315000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI4LTUtMS0xLTA_39459c22-9df5-4766-8d2e-552c376640e6"
      unitRef="usd">1992000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI5LTEtMS0xLTA_97b13c1c-df89-4d9a-885c-ed8f2a48177e"
      unitRef="usd">2012000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI5LTMtMS0xLTA_fa439d26-c6f3-4dea-911e-6cfd00be0af9"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzI5LTUtMS0xLTA_05a783cd-6bf9-4bb2-ae82-e4d2fc61df32"
      unitRef="usd">260000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMwLTEtMS0xLTA_0c3347f0-137e-4539-939a-4874a2c0002c"
      unitRef="usd">174342000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMwLTMtMS0xLTA_0196a387-7074-4c67-b7b5-03ded124bdd7"
      unitRef="usd">119972000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMwLTUtMS0xLTA_dacc2c0f-37ac-4992-8b14-3ada1ccdcbff"
      unitRef="usd">104991000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMxLTEtMS0xLTA_f33546bc-c8f7-42b3-ae0f-140ca92947c2"
      unitRef="usd">54659000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMxLTMtMS0xLTA_8f97ab70-c504-4a70-a7ff-c48ad7cc1fe8"
      unitRef="usd">-93656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMxLTUtMS0xLTA_8925c884-381f-4782-a37d-0f0f18dce602"
      unitRef="usd">8401000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMyLTEtMS0xLTA_6d7835bf-4e3b-4d28-b166-2aebef0dd9e3"
      unitRef="usd">126472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMyLTMtMS0xLTA_26a06462-2909-47ce-8095-df2afa089319"
      unitRef="usd">220128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia662d353fd8d45c0b6ef76a73d9eab63_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMyLTUtMS0xLTA_3c7e6491-7f5a-4d4d-bdd8-a4b91373d0de"
      unitRef="usd">211727000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMzLTEtMS0xLTA_ce66c715-c961-415c-b4c1-fd75d3407bff"
      unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMzLTMtMS0xLTA_9274b7bd-883c-4631-a8ac-7b2830e9ccc9"
      unitRef="usd">126472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzMzLTUtMS0xLTA_9f5d091c-05f6-4b2b-b782-33e0d0c02bdb"
      unitRef="usd">220128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM2LTEtMS0xLTA_3d500518-58d5-4205-8d3d-5142683c5cb4"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM2LTMtMS0xLTA_b631f9f4-c857-4f94-bd29-bf8a5ad26197"
      unitRef="usd">6408000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM2LTUtMS0xLTA_892b824c-dc84-4f74-bf1b-cff7aa01acae"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM3LTEtMS0xLTA_66ac7c44-1350-477e-bec7-55d5f55efe10"
      unitRef="usd">0</mgnx:FairValueOfWarrantsReceived>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM3LTMtMS0xLTA_3eac1d89-db1e-43f9-8a5b-c493869feb88"
      unitRef="usd">0</mgnx:FairValueOfWarrantsReceived>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xMzYvZnJhZzphNGRhNDllNTY1ZmE0YTI4YWY2YTg1YzdkZDlmZjhiMS90YWJsZTo3YzhjOGM4M2M5ZGY0ZDg1OTliNDUyMjQ4NGM2Y2RkNC90YWJsZXJhbmdlOjdjOGM4YzgzYzlkZjRkODU5OWI0NTIyNDg0YzZjZGQ0XzM3LTUtMS0xLTA_628be2f4-bf48-4f6b-9126-2d83cca26bd1"
      unitRef="usd">6130000</mgnx:FairValueOfWarrantsReceived>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDIvZnJhZzpjYzhjMjA3ZGNjMjY0OGM3YTQ4MDU5OTVhYTI3YTQ0OC90ZXh0cmVnaW9uOmNjOGMyMDdkY2MyNjQ4YzdhNDgwNTk5NWFhMjdhNDQ4XzcxMg_0b9c0551-6dc2-4490-8f91-25131233c1c4">Organization and Nature of OperationsMacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb).  In addition, the Company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjI0_3c42dac9-8181-452c-8003-106bd09ee167">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:25pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU) 2016-13,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2016-13), which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 3, Marketable Securities, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2020 or 2019, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Active Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Active Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $73.2 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model. There were no transfers between levels during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen Biotech, Inc. (Janssen)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Les Laboratoires Servier and Institut de Recherches Servier (Servier)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Equipment and Software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2020, 2019 and 2018, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASU No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Collaboration and Other Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expenses, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467,603&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,159,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,273,964&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $16.4&#160;million and operating lease liabilities of $27.7&#160;million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets. Refer to Note 5, Leases, for additional disclosures required by ASC 842. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjEy_85cad632-743c-4149-80bf-b3fdc87d35c2">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM3OA_5a690c8f-534d-4bc7-b67f-54808279928d"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzcwOQ_5a690c8f-534d-4bc7-b67f-54808279928d"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjI5_f1eaabb3-aca9-4fa0-9874-395bf05ab461">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjIw_d18039b8-5145-4d02-9db0-ce3a96740f0e">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:25pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU) 2016-13,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2016-13), which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results &lt;/span&gt;&lt;/div&gt;from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 3, Marketable Securities, for additional information.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjMw_f3d14cbc-7327-41d9-b597-b2fbc775c97f">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2020 or 2019, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzQ3MTQ_3f5c87d4-914a-4fb1-ab40-3267073b8616"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzQ3MTQ_41001eb2-839b-41e2-b070-ca55e89e0d18"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE3_ceb8742e-3643-47e0-9673-6f0e522feb0a">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjI1_f2b0cb53-02d8-4613-97f2-539592da5a74">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Active Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Active Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $73.2 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ice95d2414f2f4667ad6a137abdaf65e6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzQtMS0xLTEtMA_5927dffa-cfc1-4494-b0bb-c91f29d85a2d"
      unitRef="usd">49004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if031a3629d9d479b8b2e1574bc24c45e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzQtMy0xLTEtMA_8d7f61da-9277-412c-acdc-c036ff158c30"
      unitRef="usd">49004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if51e190b234e40b892b75daf5576b090_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzQtNS0xLTEtMA_d7df2d4a-d182-4155-9880-64c89081e03e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icea874c5381443b5b673e08d90e90c40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzQtNy0xLTEtMA_820b3258-f2ea-476f-8a1d-064998d9477f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5a9f46e4b864266974d1b6fcd23b90e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzUtMS0xLTEtMA_776d89ec-0bec-4399-b57d-8051137c8d28"
      unitRef="usd">60623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i552151630ecd479daefd899d23524d35_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzUtMy0xLTEtMA_99fe60c2-d031-413b-8ca2-969a51b2706b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i005b3bb8d084456ca8d49ff0bad27cfb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzUtNS0xLTEtMA_368be1b4-8626-42bd-b8cb-e492bcf3ff2a"
      unitRef="usd">60623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0947be2b25de4cfd818cbc871c8cf1e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzUtNy0xLTEtMA_73099bcf-2fca-4e03-a74a-03aae2003a56"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9446d440a99142d189e04019aee224ae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzctMS0xLTEtMA_1b8aec1c-8492-4ea7-9185-ecf939b3713f"
      unitRef="usd">33776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b532567296e49e3bdaf3330f2450754_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzctMy0xLTEtMA_722a6995-e2d8-4385-9081-f55fa52dcb29"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ae57da2f7894541b48732b70a7018b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzctNS0xLTEtMA_f7421d3d-de38-47d3-841b-19f54e1fd1a8"
      unitRef="usd">33776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51251d2fc1ee4652bb119cd46a05d7a0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzctNy0xLTEtMA_6951ca52-e21a-4ed5-b7fe-fbf3364a1f81"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzktMS0xLTEtMA_3166acb5-da21-4e13-a074-df9c5d12a2ca"
      unitRef="usd">143403000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8d860c4ec4674c37864b79c7a8a1c51c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzktMy0xLTEtMA_83882795-46b2-43b5-8160-976950aaba73"
      unitRef="usd">49004000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i58a8fbc39ff647a59227c8eecd606e91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzktNS0xLTEtMA_607643f3-62ea-42c1-b2e6-f85391539376"
      unitRef="usd">94399000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e38b6ae03674f649d3803b90d7ecfea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxMzU4NmIwZjMwOTE0YzNhYTQ3MzFhMDllZmRlMDgwOC90YWJsZXJhbmdlOjEzNTg2YjBmMzA5MTRjM2FhNDczMWEwOWVmZGUwODA4XzktNy0xLTEtMA_28998a4d-c198-44e9-ad25-1b777c0ba383"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieed6dd67ee254fca90e4fe1683b8a032_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzQtMS0xLTEtMA_7c45f8d3-1235-4cc8-94e7-b4850ffb946c"
      unitRef="usd">46149000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1ae333e83a0b4c128a73b9846f7961d2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzQtMy0xLTEtMA_879755b5-5335-47ef-a27b-e93df0c428aa"
      unitRef="usd">46149000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2b35d230e32a43dfba261f095d9b94a7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzQtNS0xLTEtMA_89592c9f-602e-4258-93a4-e369cf2cdf4d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i46eba3f4322a4bbca90a630e001423f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzQtNy0xLTEtMA_4a33b373-eae9-4cb7-b75f-79920152f71d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie97ced64b0db4ea9832f1407780172eb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzYtMS0xLTEtMA_93da4b97-498d-4503-8f41-1cee79c147ec"
      unitRef="usd">13222000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib963d0612f344980abb58b7bbfdec3d2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzYtMy0xLTEtMA_663703b8-1f83-491b-b368-b7ed5b5fec39"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a721e8181644e798dc6e4780d90abcb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzYtNS0xLTEtMA_80dca987-853e-42b9-ae1b-56b07839da1e"
      unitRef="usd">13222000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i271fe1de3f1742e1ad5139de5d7b263e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzYtNy0xLTEtMA_c88fe28d-0994-4f87-abb5-59c70ebd2e13"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68822e067a8340dfbe694836cdf653da_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzctMS0xLTEtMA_628a1c2a-91b2-48d0-8ac8-1c47362f945e"
      unitRef="usd">103135000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80b9fa1115d242cb8ff80ac0457e0b0d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzctMy0xLTEtMA_cd5d17d0-3ead-4f85-a7e1-bf6452057f47"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb40a146a60543f19cb68d866fb7a671_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzctNS0xLTEtMA_47817d81-085b-43ae-a50c-85c73fe45258"
      unitRef="usd">103135000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9db1598c868945aa9827bc1240c7542f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzctNy0xLTEtMA_23832efd-0cd9-4495-bdb5-0c747212f0a6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzktMS0xLTEtMA_854ccafe-693e-4a68-8a94-6f3d4b534e57"
      unitRef="usd">162506000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i72ea4b2f306047a48020bb482e53e79f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzktMy0xLTEtMA_8ca6d2ce-bc4a-48d1-ad06-04740a025548"
      unitRef="usd">46149000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic41258fa77ab4a088f6a5f9eb5a20970_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzktNS0xLTEtMA_c8188ab0-3aba-4b6e-bd52-b14a954153b7"
      unitRef="usd">116357000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c0cc75cee534fd1a8112f063a35cb0d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo1YmZkZmVhMTFjMGI0YmI0YWFiZTZjMGRiMDM1NzE4OC90YWJsZXJhbmdlOjViZmRmZWExMWMwYjRiYjRhYWJlNmMwZGIwMzU3MTg4XzktNy0xLTEtMA_fe1e8e4e-830f-4e07-b451-635855a120c0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzczNjY_47ded896-6379-4373-b2d9-c39bd9425940"
      unitRef="usd">52000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0Xzc0OTg_76ffe55e-38b7-4c48-8033-c2562362b764"
      unitRef="usd">73200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjIy_15a2965d-4d40-48f2-8176-9339f8a6281a">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjMz_26a57e1a-817c-47ad-8177-b015e5a6c238">The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen Biotech, Inc. (Janssen)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Les Laboratoires Servier and Institut de Recherches Servier (Servier)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i531f3aa6b1134103965b1b4eda0c293b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzItMS0xLTEtMA_bd6c59c2-fda9-4343-b47d-d38760becc8a"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9a4891f769084a18ac2931ba572ae079_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzItMy0xLTEtMA_740c040f-f2d6-42fe-8929-fe090f42b443"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5588a07194ab4de79f27e05259cfb283_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzItNS0xLTEtMA_8a9e9b00-0eb7-4489-ade6-201760778d18"
      unitRef="number">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i100b91d4dd344890967b03a9795b715a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzMtMS0xLTEtMjYyMw_4c69fdc1-8b86-4c70-8e4d-30786aab2bf3"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i97d18cede0b144daac71f46d3da90aef_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzMtMS0xLTEtMA_80ad3ac1-7d6b-49cd-bd60-c8cfd479a2e4"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iee3f25bbd99943aa9498aad2fe62b342_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzMtMy0xLTEtMA_181a3f28-eb9d-456a-a4a1-c8a96af020e9"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3c1d63dd293345108c3e566e01ade176_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTphODcwMzhkNTk3NWM0ZDAzYWIyNzFiMTMyMjFmNzRjYi90YWJsZXJhbmdlOmE4NzAzOGQ1OTc1YzRkMDNhYjI3MWIxMzIyMWY3NGNiXzUtMy0xLTEtMA_9867943f-2444-47b2-bd59-ede2e2529a07"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i969a47c5754c4c6985ffd28981d702a1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo3MTZiZTc3MThlNTk0YjVhYmVhYjIzZDNhMzZmYmM0Yi90YWJsZXJhbmdlOjcxNmJlNzcxOGU1OTRiNWFiZWFiMjNkM2EzNmZiYzRiXzItMS0xLTEtMjYzOQ_25d4a353-a478-4ada-bbb1-325702254276"
      unitRef="number">0.87</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if953214a30c54a4ab6b4b51e83fde241_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo3MTZiZTc3MThlNTk0YjVhYmVhYjIzZDNhMzZmYmM0Yi90YWJsZXJhbmdlOjcxNmJlNzcxOGU1OTRiNWFiZWFiMjNkM2EzNmZiYzRiXzItMy0xLTEtMA_a07465f4-5108-4912-a9d5-dfa4b53078be"
      unitRef="number">0.62</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i72c1b1bc8c454a148cb38c5196d6024e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTo3MTZiZTc3MThlNTk0YjVhYmVhYjIzZDNhMzZmYmM0Yi90YWJsZXJhbmdlOjcxNmJlNzcxOGU1OTRiNWFiZWFiMjNkM2EzNmZiYzRiXzMtMy0xLTEtMA_0c82a4c6-93e5-4f12-bfaf-a5ebc10c3636"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjIz_9c3a1dc5-c9e8-470f-acd6-6968c9b65531">Property, Equipment and SoftwareProperty, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE4_964c85b7-d831-4064-9bb0-db6b0f53f657">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i613ecacdf38948c6a00165721abcb9ae_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxM2ViZWNiOWQ2MTY0MTk1ODkzY2IzOGZiMTFiNzUxZi90YWJsZXJhbmdlOjEzZWJlY2I5ZDYxNjQxOTU4OTNjYjM4ZmIxMWI3NTFmXzAtMS0xLTEtMA_337e3a1b-e72c-4f08-b544-3131cb8a3d63">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i16e8408688034e0cace6fc6275751598_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxM2ViZWNiOWQ2MTY0MTk1ODkzY2IzOGZiMTFiNzUxZi90YWJsZXJhbmdlOjEzZWJlY2I5ZDYxNjQxOTU4OTNjYjM4ZmIxMWI3NTFmXzEtMS0xLTEtMA_72924e2d-72ab-425d-a24f-648b056c4934">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0a9f85aa087344ca8008b4576a668e22_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxM2ViZWNiOWQ2MTY0MTk1ODkzY2IzOGZiMTFiNzUxZi90YWJsZXJhbmdlOjEzZWJlY2I5ZDYxNjQxOTU4OTNjYjM4ZmIxMWI3NTFmXzItMS0xLTEtMA_b5eef1cd-19f0-43c5-ada8-dc3d12dedfb3">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i30f500d13f114fd6b9ece35c3c1ddbbb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZToxM2ViZWNiOWQ2MTY0MTk1ODkzY2IzOGZiMTFiNzUxZi90YWJsZXJhbmdlOjEzZWJlY2I5ZDYxNjQxOTU4OTNjYjM4ZmIxMWI3NTFmXzMtMS0xLTEtMA_3e0cdff1-4b30-4dbd-b981-b6d57781ac75">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjA5_66de764e-253d-4a0e-ba4f-4f06995b9d38">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2020, 2019 and 2018, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzEwODYy_24140375-8cc4-4938-8dc3-b879d0d2e14a"
      unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
    <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
      contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzEwODYy_51f81f65-ff7c-471d-8da0-1201bcbc97a0"
      unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
    <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzEwODYy_572bfc3a-7f30-46f7-ad86-a361ba95c13b"
      unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjI2_3c3e3b39-5dc8-4e05-9015-380add5090f0">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE0_27a36990-62e7-45d6-9052-4742e28a7158">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASU No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Collaboration and Other Agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjAz_bc04dc98-735d-4d58-968f-6e56e6298810">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expenses, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjEw_c29a09bd-f61b-4f49-a4c3-7cff380ea200">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE1_df75d2d0-2a89-4118-a735-9e7b7e1fdd0c">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjE5_e8168622-4033-46df-a3eb-e25cea5a1736">Net Loss Per ShareBasic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjA0_09a74f33-76eb-499e-9a35-94821fe8ceaf">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467,603&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,159,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,273,964&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9eee20aa82a04eb881c0f50c7193c079_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTpmYzU4ZjlmYWY5ZTU0MDBkOWM0MDEwYjQzZTE1MDY2My90YWJsZXJhbmdlOmZjNThmOWZhZjllNTQwMGQ5YzQwMTBiNDNlMTUwNjYzXzItMS0xLTEtMA_1b31419e-eee5-4edb-bc6a-744e1e1af500"
      unitRef="shares">7467603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i29d23911aba345f1b5c80d016b475232_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTpmYzU4ZjlmYWY5ZTU0MDBkOWM0MDEwYjQzZTE1MDY2My90YWJsZXJhbmdlOmZjNThmOWZhZjllNTQwMGQ5YzQwMTBiNDNlMTUwNjYzXzItMy0xLTEtMA_d7d3e464-e61e-4d9d-bb0e-cabb571458c3"
      unitRef="shares">7159494</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6db0ce0a36bd44c89f32be0a7f6f3ccf_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90YWJsZTpmYzU4ZjlmYWY5ZTU0MDBkOWM0MDEwYjQzZTE1MDY2My90YWJsZXJhbmdlOmZjNThmOWZhZjllNTQwMGQ5YzQwMTBiNDNlMTUwNjYzXzItNS0xLTEtMA_b5ed4421-210c-411c-902d-a466045adf6a"
      unitRef="shares">5273964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzM1NjEx_bc20275b-738b-4535-b9cf-e6aaaf17bcf0">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $16.4&#160;million and operating lease liabilities of $27.7&#160;million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets. Refer to Note 5, Leases, for additional disclosures required by ASC 842. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie2e19ae8025c48e5b2df7b9cd421d21d_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzMyMTc0_4f3fa643-67a2-4f06-8d38-ebd18f79325e"
      unitRef="usd">16400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie2e19ae8025c48e5b2df7b9cd421d21d_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNDUvZnJhZzpiNGUyODZlNGQzMGI0MDRhYWVmZGViZmUyZTUxNzhhNC90ZXh0cmVnaW9uOmI0ZTI4NmU0ZDMwYjQwNGFhZWZkZWJmZTJlNTE3OGE0XzMyMjEy_2647cadc-bbeb-48f9-9343-e9f80408e0d2"
      unitRef="usd">27700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzY4OA_ae130106-6e4c-4347-b10b-1358045ba9d9">Marketable Securities&lt;div style="margin-bottom:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's available-for-sale securities held at &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2019 had contractual maturities of less than one year.  All of the Company&#x2019;s available-for-sale marketable debt securities in an unrealized loss position as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2019 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020 were not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the year ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No  losses related to other-than-temporary impairments of the Company&#x2019;s available-for-sale debt securities were recorded in Accumulated other comprehensive income during the year ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company recorded interest income of $0.8 million, $3.4 million and $2.3 million during the years ended December&#160;31, 2020, 2019 and 2018, respectively, which is included in Other income (expense) on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzY4OQ_7d679a8a-14c0-48a1-afe7-f432e226ffd6">&lt;div style="margin-bottom:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's available-for-sale securities held at &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt; and 2019 had contractual maturities of less than one year.</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5c6be239fac74a39a6efe1cf2153245a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzItMS0xLTEtMA_651d66e2-2fec-4a25-8625-6aeac81c4014"
      unitRef="usd">60630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5c6be239fac74a39a6efe1cf2153245a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzItMy0xLTEtMA_2e54df03-7325-43e8-8821-f456a07fac7f"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5c6be239fac74a39a6efe1cf2153245a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzItNS0xLTEtMA_2f4df206-c880-4437-ae6b-77f9e1c322ba"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c6be239fac74a39a6efe1cf2153245a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzItNy0xLTEtMA_54d1b027-ea5e-4507-97ac-d0c3a6b9800a"
      unitRef="usd">60624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id41ac2377a9e406db348d5b48d784025_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzQtMS0xLTEtMA_18fd960c-d8ab-4655-8c05-30b1a5e1610b"
      unitRef="usd">30777000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id41ac2377a9e406db348d5b48d784025_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzQtMy0xLTEtMA_255b4aaa-f796-4fd7-98bb-b9df8a69e868"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id41ac2377a9e406db348d5b48d784025_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzQtNS0xLTEtMA_7fc2dddd-815a-4567-a5ec-b3e829467b6d"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id41ac2377a9e406db348d5b48d784025_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzQtNy0xLTEtMA_3723fb76-74c1-4081-8fa6-7bcd7221a7ce"
      unitRef="usd">30776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzUtMS0xLTEtMA_bfff9a42-c154-48a7-af01-5d92135d048b"
      unitRef="usd">91407000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzUtMy0xLTEtMA_98258613-35b8-4ae8-8f49-4817a3c83310"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzUtNS0xLTEtMA_ec65920d-2a0c-4f00-b7c5-10ab62eaa08f"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTo0NmIzMzk5MGNlZGY0NTZiYTRiMjM0MmEyNDVmOTdlOC90YWJsZXJhbmdlOjQ2YjMzOTkwY2VkZjQ1NmJhNGIyMzQyYTI0NWY5N2U4XzUtNy0xLTEtMA_9c40251a-05db-4fd1-b684-44ee21c9d7fd"
      unitRef="usd">91400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9f933200f33a49139ed9cdf99b46accb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzMtMS0xLTEtMA_ca5a7fb6-52a1-4fc1-a6a9-3b09372b6c96"
      unitRef="usd">13216000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9f933200f33a49139ed9cdf99b46accb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzMtMy0xLTEtMA_75835472-669b-45db-8949-94affd2c5c36"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9f933200f33a49139ed9cdf99b46accb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzMtNS0xLTEtMA_b3bac36d-fbc8-47f8-9fbc-c939e73d1944"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f933200f33a49139ed9cdf99b46accb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzMtNy0xLTEtMA_b7ed40b9-9b42-48c0-9af4-da6fa288024a"
      unitRef="usd">13222000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie3f3c1f82e424f279963729cfc905770_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzQtMS0xLTEtMA_498a5572-0476-47f8-a62e-a3224108a9e7"
      unitRef="usd">76052000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie3f3c1f82e424f279963729cfc905770_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzQtMy0xLTEtMA_6d81647d-1181-42fb-87ce-797ebf99f011"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie3f3c1f82e424f279963729cfc905770_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzQtNS0xLTEtMA_af96520c-5a97-4c61-ad62-a297bdbe0ab3"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3f3c1f82e424f279963729cfc905770_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzQtNy0xLTEtMA_cf1d0348-f9b3-4084-bf1b-ad46c1383805"
      unitRef="usd">76062000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzUtMS0xLTEtMA_fec84f31-6538-40d4-9dd1-6effc80e953f"
      unitRef="usd">89268000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzUtMy0xLTEtMA_54a8dd6e-b573-4273-b163-83e094cb87cb"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzUtNS0xLTEtMA_a044e0e1-67a1-4638-882f-f07aeb86e42d"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90YWJsZTozZWU0NjM5OWNkNzg0OGYyODY4MzU2MzkwNjM2YjY4YS90YWJsZXJhbmdlOjNlZTQ2Mzk5Y2Q3ODQ4ZjI4NjgzNTYzOTA2MzZiNjhhXzUtNy0xLTEtMA_1b60618c-00fd-4594-80bd-3960c43bb797"
      unitRef="usd">89284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzE2NDkyNjc0NDI3MDU_5060ba12-4aa2-4c1e-a420-b60077cc66d9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzM4Mg_aea569ce-17dd-4c78-a26d-d7ab5603f011"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:InterestIncomeOther
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzUxMQ_8e9227dc-4d83-4a03-9414-6583b8ba7005"
      unitRef="usd">800000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzUxNQ_9af7527c-1cd0-4c47-9b5e-11535235fcde"
      unitRef="usd">3400000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTEvZnJhZzo2YzExYTk2ZDM4YzE0ZmE2YjAyMTI1MzFkNWFkYTM1NC90ZXh0cmVnaW9uOjZjMTFhOTZkMzhjMTRmYTZiMDIxMjUzMWQ1YWRhMzU0XzUyMg_53268c33-89d2-4b9d-b5c1-b03e294b0f2d"
      unitRef="usd">2300000</us-gaap:InterestIncomeOther>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUyOA_3c2be250-c5fd-4843-aecc-c0b011b96774">Property, Equipment and Software&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2020, 2019 and 2018 was $12.0 million, $12.3 million and $9.2 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUyOQ_5ab5d6c3-e6fa-4488-baf7-1ac11213b046">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3f26754d1c12437385b6f0b131ab7e1d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzItMS0xLTEtMA_805b3848-0382-45ec-8774-29c86c4081fb"
      unitRef="usd">2663000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6eda115843604d8ab1d5b0ec51dd4f34_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzItMy0xLTEtMA_78772c9a-15af-494c-8dcd-6b24bea446a7"
      unitRef="usd">2430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8932c76412aa40acaf76c7c665350985_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzMtMS0xLTEtMA_eab73c5f-d907-40ab-8665-0159287526d1"
      unitRef="usd">8242000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5794801343ac425dbba4fec50029d947_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzMtMy0xLTEtMA_156288b2-576b-42eb-bdd6-cea46f99a68b"
      unitRef="usd">7513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibce024e3e9fa467bb2616f6adf5778e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzQtMS0xLTEtMA_9d290891-042b-42d9-81f4-e63e5fac82ca"
      unitRef="usd">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if9ae1c0908e54561a39ca4b4e76062a3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzQtMy0xLTEtMA_cb7d70f3-65ad-4b95-a485-07927a902c08"
      unitRef="usd">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0f8089d6e3024b72b2fa7b1b126799d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzUtMS0xLTEtMA_0c64fa76-8505-4b39-baf8-852f6f08d676"
      unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia2336b1857bf400c9efe189f44310e5f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzUtMy0xLTEtMA_83fc97f8-c7b3-45ff-8ff3-2cc3cd8c5ede"
      unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5172dbbe4a1a40ffae37000e9a89f01c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzYtMS0xLTEtMA_f8b548e4-58af-45bb-8ebb-3b0b24d8448e"
      unitRef="usd">41202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1b1a45648e254a7dbb5b5d67c3ef2ec1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzYtMy0xLTEtMA_e0fcf98b-b665-4e02-b211-5be2033d7cc9"
      unitRef="usd">38368000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i18f77e8a6d744b82b3f3741e0299c45d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzctMS0xLTEtMA_280c99b7-bc47-4670-a458-5753a01e8427"
      unitRef="usd">48884000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id08fe2220367435fa71093334d9c684a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzctMy0xLTEtMA_5a6f7ce2-8807-4f2c-9873-ee5effe562f7"
      unitRef="usd">48675000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzgtMS0xLTEtMA_d77fd80a-2d44-40e5-9dc3-848c3bdd4ab8"
      unitRef="usd">2022000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzgtMy0xLTEtMA_a1d7a2e6-a493-47e0-8902-3959d84a97fc"
      unitRef="usd">187000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzktMS0xLTEtMA_978d9ac0-519f-47d6-a497-8ee6be35b921"
      unitRef="usd">103776000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzktMy0xLTEtMA_15fe2bbc-2fb2-4385-af0f-ac06908183b5"
      unitRef="usd">97936000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzEwLTEtMS0xLTA_12f32371-5f7b-4222-b2c3-46ff4185ace9"
      unitRef="usd">61551000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzEwLTMtMS0xLTA_c6efcabb-a5d6-4474-8b9b-4b462bc487cd"
      unitRef="usd">49725000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzExLTEtMS0xLTA_3c62b5b1-2f63-45bc-b12b-7d8fde6740e1"
      unitRef="usd">42225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90YWJsZToxYTJhYTI1ZjkzNDc0ZWE1OTNmZDZhNGZjOGFiNmVkOS90YWJsZXJhbmdlOjFhMmFhMjVmOTM0NzRlYTU5M2ZkNmE0ZmM4YWI2ZWQ5XzExLTMtMS0xLTA_530b2480-8686-4fc0-8c6a-c5982eb444bd"
      unitRef="usd">48211000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUwMQ_468b6025-9c6c-4029-b48c-9906ebe15936"
      unitRef="usd">12000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUwNQ_dc3a2c8e-1758-4b2c-b139-d706246db2bd"
      unitRef="usd">12300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNTcvZnJhZzoyMDE0MWRlMmQ2YjA0MDM4ODdkODc4MTFmNGIxYTNlNi90ZXh0cmVnaW9uOjIwMTQxZGUyZDZiMDQwMzg4N2Q4NzgxMWY0YjFhM2U2XzUxMg_6ad4ad3c-7b19-4bc2-a9b6-74c4cae53bea"
      unitRef="usd">9200000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzE0NzA_7a5cdb26-ee4b-4e64-a5f2-a2f4d83cc970">Leases&#160;&#160;&#160;&#160;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 2. Summary of Significant Accounting Policies, the Company adopted &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Topic 842&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of January 1, 2019. Prior period amounts have not been adjusted and continue to be reported in accordance with historic accounting under &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Topic 840&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in  Maryland and a non-cancelable operating lease for laboratory and office space in California. A portion of the space under one of these leases is subleased to a third party. All of these leases include one or more options to renew, with those renewal periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzQxNA_c7bd66aa-5f7d-4552-b4e9-c0686ecd66a9"&gt;five&lt;/span&gt; to fourteen years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents supplemental balance sheet information related to operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon adoption of ASC 842 on January 1, 2019, it was not reasonably certain that the Company would extend any of its operating leases, therefore the options to extend the lease terms were not recognized as part of the ROU assets or lease liabilities. During the year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2019, the Company exercised the options to extend two leases for an additional five years each, therefore the Company remeasured the lease liability and adjusted the carrying amount of the ROU asset related to these leases. During the years ended December&#160;31, 2020 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2019, t&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company made cash payments for operating leases of $5.9 million and $6.4 million, respectively. As of December&#160;31, 2020 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2019,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company&#x2019;s ROU assets were valued at $19.3 million and $20.2 million, respectively,  and are included in Other assets on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ibafe419048424d72ba9dcb437c36a6fd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzEzNzQzODk1MzUwNTMz_1bb21eaa-d2f6-471e-83e5-6b3431e3b971">P14Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTo5ZTY5ZjQzMTg3MWI0OTYyOGFkNGFhMmEyNmQyYWE3My90YWJsZXJhbmdlOjllNjlmNDMxODcxYjQ5NjI4YWQ0YWEyYTI2ZDJhYTczXzItMS0xLTEtMzg2Mg_41d7c68a-e5c2-498f-8207-791dfaa84374">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTo5ZTY5ZjQzMTg3MWI0OTYyOGFkNGFhMmEyNmQyYWE3My90YWJsZXJhbmdlOjllNjlmNDMxODcxYjQ5NjI4YWQ0YWEyYTI2ZDJhYTczXzItMy0xLTEtMzg3OA_82a83b52-f55d-467b-b6e0-a2921f76533d">P5Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTo5ZTY5ZjQzMTg3MWI0OTYyOGFkNGFhMmEyNmQyYWE3My90YWJsZXJhbmdlOjllNjlmNDMxODcxYjQ5NjI4YWQ0YWEyYTI2ZDJhYTczXzMtMS0xLTEtMzg3NA_73765d13-58fc-4732-aa4e-dd5d3f8c938c"
      unitRef="number">0.097</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTo5ZTY5ZjQzMTg3MWI0OTYyOGFkNGFhMmEyNmQyYWE3My90YWJsZXJhbmdlOjllNjlmNDMxODcxYjQ5NjI4YWQ0YWEyYTI2ZDJhYTczXzMtMy0xLTEtMzg4Nw_6e402c91-398e-4a25-8cd0-779abbd16ef5"
      unitRef="number">0.099</us-gaap:LesseeOperatingLeaseDiscountRate>
    <mgnx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzE2NDkyNjc0NDUyNTU_6c28f68f-c06b-4b7c-974e-86d7cc6a74bc"
      unitRef="renewaloption">2</mgnx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzEzNzQzODk1MzUwNTM0_61706e4b-321b-43ea-b2af-8ad2c736dbc6">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeasePayments
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzExMDA_6dbe7a91-0aeb-4f30-898d-9235db2f1393"
      unitRef="usd">5900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzM4NDgyOTA3MDAxMDE_0a7f4c7f-ac65-41c0-90de-97c49c22647b"
      unitRef="usd">6400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzEyMDg_4e02540b-72b0-4c55-9654-51617cc8f209"
      unitRef="usd">19300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzM4NDgyOTA2OTkwMzY_9b53446d-83d9-46ab-87d9-377fcac6e5b5"
      unitRef="usd">20200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzE0NzE_ad5f0846-51f1-4732-811a-a84e18a4e777">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzAtMS0xLTEtMA_f7ec1003-283d-4767-a95d-ecc2f88318aa"
      unitRef="usd">5410000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzItMy0xLTEtMzY1Nw_fdf7997d-0780-40e9-8667-9a95b2fd33f1"
      unitRef="usd">5463000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzEtMS0xLTEtMA_d7e5d258-16bb-4b2e-862c-69084a9cf50e"
      unitRef="usd">1083000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzMtMy0xLTEtMzY1Nw_d75029ab-d374-416e-8245-0e52a874ab62"
      unitRef="usd">1366000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzItMS0xLTEtMA_c45cb6c0-f9c7-492c-8b1a-f7674fe5fe60"
      unitRef="usd">770000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzQtMy0xLTEtMzY1Nw_bc4abe13-b3ba-4574-823d-80194ba2d3d5"
      unitRef="usd">942000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzMtMS0xLTEtMA_42b6fd64-fffe-40cd-9477-e2e9db285dee"
      unitRef="usd">5723000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpmMzA3Njg4NGQwNzk0YzBkYmYyNDI1YmY1NjgwYjE1Yy90YWJsZXJhbmdlOmYzMDc2ODg0ZDA3OTRjMGRiZjI0MjViZjU2ODBiMTVjXzUtMy0xLTEtMzY1Nw_51bfa763-f88c-4b1c-b580-89d133fc2ddb"
      unitRef="usd">5887000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzE0Njk_775dff51-4ee0-430c-9c31-8822918686b5">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzAtMS0xLTEtMA_9b68ad0a-5bc3-4ace-a8cd-9f0c3d50c3e5"
      unitRef="usd">6726000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzEtMS0xLTEtMA_a240dd6d-348f-4835-9ec7-35d3e35c79f0"
      unitRef="usd">6940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzItMS0xLTEtMA_aae84cfa-9ab2-4898-9bce-6f47206336c1"
      unitRef="usd">6796000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzMtMS0xLTEtMA_0600eeb6-05c2-49e7-be70-a5abf628149f"
      unitRef="usd">5856000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzQtMS0xLTEtMA_be56c2aa-d5d1-4bbf-84b3-15103621093e"
      unitRef="usd">5084000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzUtMS0xLTEtMA_f575c006-97e5-40db-95e0-7eb8d71c93dc"
      unitRef="usd">7764000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzYtMS0xLTEtMA_a9772435-5184-4ebb-99ce-061f1a80ef45"
      unitRef="usd">39166000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzctMS0xLTEtMA_f573840e-84f5-4e98-b475-d0ad8961bc5e"
      unitRef="usd">9918000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90YWJsZTpjYTJjZjMzMzQzNTg0YjQ5OGQ1OTY4MGUxYjhjZGYxNC90YWJsZXJhbmdlOmNhMmNmMzMzNDM1ODRiNDk4ZDU5NjgwZTFiOGNkZjE0XzgtMS0xLTEtMA_c785e13d-7f15-4a54-a58c-22f0b64307f7"
      unitRef="usd">29248000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzI1MDM_cf464f77-a8c9-484a-ba67-01ee24e23df0">Stockholders' Equity&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2020 or 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold 4,500,000 shares of its common stock at a price of $21.25 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 675,000 shares of the Company's common stock at a price of $21.25 per share. Upon closing, the Company received net proceeds of approximately $103.3&#160;million from this offering, net of underwriting discounts and commissions and other offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, the Company completed a &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;firm-commitment underwritten public&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; offering, in which the Company sold 5,500,000 shares of its common stock at a price of $20.00 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 825,000 shares of the Company&#x2019;s common stock at a price of $20.00 per share. The Company received net proceeds of approximately $118.7&#160;million from this offering, net of underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/div&gt;In December 2019, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock in amounts of up to $50.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. This agreement was amended in June 2020 to increase the  maximum amount of the offering to $175.0 million. The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on December 23, 2019. During the year ended December&#160;31, 2020, the Company sold 6,612,815 shares of common stock at a weighted average price per share of $26.46, resulting in net proceeds of approximately $170.5 million, net of underwriting discounts and commissions and other offering expenses.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzEwNA_905c5585-dc68-4b8b-a5cc-3c45e200e77a"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic72a8361cda6471c8e38d658753f0573_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzEzNQ_52f2a0a0-d613-45dc-b0f5-c1dd9b6fa393"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic72a8361cda6471c8e38d658753f0573_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIwMw_63b88725-053c-4fc0-b702-b358f3bbff2e"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIwMw_916eb128-580e-4be5-97ae-99ca90f7a3bb"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id073a704e63548588d4eeca08d057674_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyOA_78f3687e-0a7a-45f9-b141-6d6540a859af"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic72a8361cda6471c8e38d658753f0573_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyOA_b6e2dc51-3d36-4d81-9b3c-d8db68179bfa"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id073a704e63548588d4eeca08d057674_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyOA_c36dc595-860a-4713-8caf-0c8ef20ef302"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic72a8361cda6471c8e38d658753f0573_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyOA_e41c9998-9fcb-41dc-95ea-43334c935ce7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i40138f5330944173b29c88382128a064_D20180402-20180402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE1Mzc_26d08eab-748a-4f13-b940-94049154c712"
      unitRef="shares">4500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia4d7688a5ca1483790dd77c9300f82c4_I20180402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE1ODE_c2895c65-f503-4d82-876f-b7234b62f303"
      unitRef="usdPerShare">21.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ica23de68e9494461b000d56dee219d8f_D20180402-20180402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE3Mzg_0d5536ca-39b6-460d-8627-a9874aa44f09"
      unitRef="shares">675000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i52765134bddd477d901a12882bde3b9d_I20180402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE3OTI_2dd53181-f329-4c98-b564-182c435c506c"
      unitRef="usdPerShare">21.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i40138f5330944173b29c88382128a064_D20180402-20180402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE4NzE_ef973415-3e43-4eb4-a4cd-0a09ff1459cb"
      unitRef="usd">103300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if094d8df39954207bb5391061c867477_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIwODU_1b94deae-7286-4ebd-8011-601bd33c661d"
      unitRef="shares">5500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i5d3c43517af54165896bef6f429afdf8_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIxMjk_909adf08-3476-4054-b585-2b2d75bf46f7"
      unitRef="usdPerShare">20.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3b54527c45444217a8e26ea5f21c66dc_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIyODY_bb359bb7-c5a4-4e5f-9c56-2633b23856ba"
      unitRef="shares">825000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i0fc973fcb7d148828513059e1601a77a_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzIzNDA_f5ef94c3-6815-415b-8609-b1b081deced6"
      unitRef="usdPerShare">20.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if094d8df39954207bb5391061c867477_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzI0MDU_d7f4f408-9140-4cee-8a29-60fb884ef19f"
      unitRef="usd">118700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="ib66b02d54eed4262b672c427d7af10e9_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDkzMTA_19149966-71ae-4e1e-a170-1617804a819f"
      unitRef="usd">50000000.0</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i70810fe71eab4695bfbdd5efe0c1c9b3_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDkzMzA_1ad79133-1673-4490-96db-60119b0803ce"
      unitRef="usd">175000000.0</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i97895a6a80e148b1a904880526f25594_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDkzOTY_ca98d132-2a60-4363-81b6-aefc1f3aea84"
      unitRef="shares">6612815</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0e277b27463146b29c014a1f9710d329_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDk0MDU_d5043e35-2aa9-447b-bbd4-d0fb610a1df3"
      unitRef="usdPerShare">26.46</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i97895a6a80e148b1a904880526f25594_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjMvZnJhZzpkNzg3YmNiNjAxOTk0NTRjOGNhYmM2ZTJhOTdiNzJjNS90ZXh0cmVnaW9uOmQ3ODdiY2I2MDE5OTQ1NGM4Y2FiYzZlMmE5N2I3MmM1XzE2NDkyNjc0NDk0MjI_a131a7ad-ed74-465c-9cd2-fe4d08721df1"
      unitRef="usd">170500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5Mzk_3b3f872f-e8e2-4cee-9de5-1bcf9b253b3c">Stock-based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period. During the year ended December&#160;31, 2020, employees purchased 32,430 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of December&#160;31, 2020, under the 2003 Plan, there were options to purchase an aggregate of 249,959 shares of common stock outstanding at a weighted average exercise price of $2.79 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was 1,960,168 shares.&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2020, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 11,896,613.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2020, under the 2013 Plan, there were options to purchase an aggregate of 7,008,394 shares of common stock outstanding at a weighted average exercise price of $22.14 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68% - 72%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4% - 3.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods through December 31, 2019, the computation of expected volatility is based on the historical volatility of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;several public entities of similar size, complexity and stage of development, as the Company did not have sufficient history of its own volatility.  &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2019, the Company had sufficient company-specific historical and implied volatility information.  As such, beginning the first quarter of 2020, the computation of expected volatility is based only on the historical volatility of the Company&#x2019;s common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company uses a simplified method to calculate the average expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,706,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,851,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(504,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(795,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,258,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,660,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,973,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 2019 and 2018 the Company issued 504,445, 219,045 and 274,362 net shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $5.3 million, $0.7 million and $0.9 million during 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during 2020, 2019 and 2018 was $10.68, $13.98 and $17.90 per share, respectively. The total intrinsic value of options exercised during 2020, 2019 and 2018 was approximately $4.3 million, $2.9 million and $5.2 million, respectively.&#160;The total fair value of stock options which vested during 2020, 2019 and 2018 was $16.7 million, $17.7 million and $16.4 million, respectively.&#160;As of December&#160;31, 2020, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $27.5 million, which the Company expects to recognize over a weighted-average period of approximately 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company awarded RSUs under the 2013 Plan to all employees except executive officers and employees with less than six months of service as of the grant date. Each RSU entitles the holder to receive one share of the Company's common stock when the RSU vests. The RSUs vest in two equal installments on the first and second anniversary of the grant date. Compensation expense is recognized on a straight-line basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, there was $2.0 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of eight months.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie71f6f7825d94e5b829714cea61564c2_I20170518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzQyMA_0e48b6b7-7ea5-4bdc-aba6-70f580eb7d89"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i194f187d59c94fd0be7ab2993ff54938_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzYxOQ_074bb7c0-37d3-40af-ad7c-305000a74074"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i194f187d59c94fd0be7ab2993ff54938_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzg2NQ_a9dc4ff1-834d-4b3f-879c-25395ca73fb3"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i57f99a9224f74d71a7ddf204e8b0610e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzEwMDk_1ff207d4-8ce2-4568-9ce5-c61509241a86"
      unitRef="shares">32430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i57f99a9224f74d71a7ddf204e8b0610e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzExMDQ_4b7503c5-4c74-4019-b120-4ac04844f8b4"
      unitRef="usd">600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="icb896738d1f544f3af00d62fa6613580_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzE5ODk_d43be4ba-0942-410c-82ac-799a3668c39d"
      unitRef="shares">249959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="icb896738d1f544f3af00d62fa6613580_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzIwNjc_f614828c-1ad1-469e-b51f-c048bdd6811e"
      unitRef="usdPerShare">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if65e3aa5584c442f98a84ac8dcd7ea53_I20131031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzIzODc_2149e7aa-00c2-4dba-8631-1a8c15756655"
      unitRef="shares">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="i0302cc9696d04655b132ed6718400098_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzI1OTI_10e17dd3-2419-485a-9f83-e353e3d0fd9b"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="i8a3833260ec34d169d4087f7cc599a38_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzI2MDc_2ede6f70-1462-410f-87ea-960ccdfe0079"
      unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease
      contextRef="i8a3833260ec34d169d4087f7cc599a38_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzI5NDQ_77cfd556-933e-4b0f-b87d-515e0c0c32cb"
      unitRef="shares">11896613</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0302cc9696d04655b132ed6718400098_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzM1Mzg_3f252ee5-dc01-4c48-aeb9-1a4affaa52f1"
      unitRef="shares">7008394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0302cc9696d04655b132ed6718400098_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzM2MTY_3f4b57b5-c108-4c9c-b7c5-75d459f9b485"
      unitRef="usdPerShare">22.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5MzU_8c134ded-58e5-41ec-b7d3-61a300fedd0f">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2267b398358d40628d513e840da1acd3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzMtMS0xLTEtMA_cfa0bf27-8892-4547-aff9-22e98525057a"
      unitRef="usd">10833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i77ef4253bc71484f944278fc62928061_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzMtMy0xLTEtMA_34fa5910-f70f-45e5-9828-baafdc9119e9"
      unitRef="usd">10023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1eaa927f30f243e1bc5fa261ed93065a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzMtNS0xLTEtMA_025c30c0-0530-4830-ac5c-46048739be9b"
      unitRef="usd">7919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1b6e20121a2f4c0abc7b278e428bded7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzQtMS0xLTEtMA_3a23e501-caec-4f79-8ee0-c8865694d760"
      unitRef="usd">9843000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c05145d2dd243aa946509d98e419c02_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzQtMy0xLTEtMA_f2809d5f-8d08-4f18-9379-425b1b725d1e"
      unitRef="usd">9548000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03544544417f4f4c9d465e8f28185dc4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzQtNS0xLTEtMA_ebf1d0ab-aac2-46f6-a7bc-49afedaead31"
      unitRef="usd">8601000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzUtMS0xLTEtMA_9855b465-99a7-41e6-b60c-24bf6df5f604"
      unitRef="usd">20676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzUtMy0xLTEtMA_eed5b35a-b630-4aa7-bd16-bf581a4081da"
      unitRef="usd">19571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkZWQ1MjVjNGY2NmY0MDc0OWE2YzNlODEzNWRhN2U5ZS90YWJsZXJhbmdlOmRlZDUyNWM0ZjY2ZjQwNzQ5YTZjM2U4MTM1ZGE3ZTllXzUtNS0xLTEtMA_53740af2-2f99-406a-89c9-b04865d5ab10"
      unitRef="usd">16520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5NDE_b3dd2f34-36f7-4388-a3e2-e31bfe596c36">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68% - 72%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4% - 3.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzItMS0xLTEtMA_102b81b0-bb03-4882-9226-e12a07585497"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzItMy0xLTEtMA_b513f20f-5710-4cfe-9079-b4e78963ea5d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzItNS0xLTEtMA_f6192624-28a3-4b1d-ab58-379439eeee85"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idb0b4fc7e6824deba0edf9c15b602152_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjAzOTU4NDM4ZTVlMDRhOWU5ZjMzMzU5YzhkZWQ3ZTk4XzExNTQ0ODcyMDkxNjY1_3f06e838-7eef-4e4b-a595-0418400e3038"
      unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i847642b8e010448c92e39737e6b98cd4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjAzOTU4NDM4ZTVlMDRhOWU5ZjMzMzU5YzhkZWQ3ZTk4XzExNTQ0ODcyMDkxNjcy_9b83715f-9fe6-463a-961f-aa456dd2a30d"
      unitRef="number">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2f613cb53e594b4ea341386947101b5a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtMy0xLTEtMC90ZXh0cmVnaW9uOmQ1ODExNDEwNjIxNDRiY2FiMGJjMzU5Mzg0YjZmZDk5XzExNTQ0ODcyMDkxNjY0_ce91ccdf-3f73-43cc-b6e4-daeeb634ae54"
      unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie734a52f70924b7d8ef283a737651cf5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtMy0xLTEtMC90ZXh0cmVnaW9uOmQ1ODExNDEwNjIxNDRiY2FiMGJjMzU5Mzg0YjZmZDk5XzExNTQ0ODcyMDkxNjY5_1b3ab835-b7fd-4386-a1fe-f05f708138a2"
      unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7975540d8d9b4164b34b19720b17c21c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtNS0xLTEtMC90ZXh0cmVnaW9uOjQxZDMwMDJjMjY1MzRhNWZiY2QwMzg1MmE5NzMzZjZkXzExNTQ0ODcyMDkxNjY0_b61fc7cb-f7ae-4766-8ba2-c7b0f83ba803"
      unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id3fea8f715e94127942cb6f892c9f8d7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzMtNS0xLTEtMC90ZXh0cmVnaW9uOjQxZDMwMDJjMjY1MzRhNWZiY2QwMzg1MmE5NzMzZjZkXzExNTQ0ODcyMDkxNjcw_a6edf57f-d7f3-49bf-892c-f32c331cbf21"
      unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idb0b4fc7e6824deba0edf9c15b602152_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmJmZDE3NTg3YTk5NzQ4OGQ5MTdmNTAwZDdhMDE3MTk4XzExNTQ0ODcyMDkxNjc0_ac998f05-5739-46f4-adff-869509a95ca5"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i847642b8e010448c92e39737e6b98cd4_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmJmZDE3NTg3YTk5NzQ4OGQ5MTdmNTAwZDdhMDE3MTk4XzExNTQ0ODcyMDkxNjY3_06664023-09de-423e-b208-7f9c32ec6e98"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2f613cb53e594b4ea341386947101b5a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmNiNWUwZThlOGM3ZjRkNzA4Y2I2MzZiMDIxYWQzMzQwXzExNTQ0ODcyMDkxNjc0_b29abf5d-5015-435c-a18a-243c9a147a7d"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie734a52f70924b7d8ef283a737651cf5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmNiNWUwZThlOGM3ZjRkNzA4Y2I2MzZiMDIxYWQzMzQwXzExNTQ0ODcyMDkxNjY3_fe362b14-2a1f-49d2-acba-d56b35e7b735"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7975540d8d9b4164b34b19720b17c21c_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtNS0xLTEtMC90ZXh0cmVnaW9uOjFmNjZiZThhNzQxODRkMGQ4NDUzOGM2NDBkNmZiNDcwXzExNTQ0ODcyMDkxNjc0_48d75c59-5cb3-46c6-b445-b113e89b5a62"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id3fea8f715e94127942cb6f892c9f8d7_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzQtNS0xLTEtMC90ZXh0cmVnaW9uOjFmNjZiZThhNzQxODRkMGQ4NDUzOGM2NDBkNmZiNDcwXzExNTQ0ODcyMDkxNjY3_57094d57-752b-4571-86c2-a9a18472c927"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzUtMS0xLTEtMA_372a248f-99fd-4eee-a61a-70ca90ff3e40">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzUtMy0xLTEtMA_5df9df6d-fd9c-4dc7-af56-88d495ecd0be">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTo5MThlOTg3NzNjYmU0ODg2OGVmNWRjYWUzNzZiZDMxYy90YWJsZXJhbmdlOjkxOGU5ODc3M2NiZTQ4ODY4ZWY1ZGNhZTM3NmJkMzFjXzUtNS0xLTEtMA_5b7730d8-e6af-4ba5-86e3-919035e2c79f">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i847642b8e010448c92e39737e6b98cd4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzQ4NDQ_4506d773-c381-4bc0-84cc-4434e77c0585">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5Mzc_05f799b4-75b7-4611-940b-c74b0606da54">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,706,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,851,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(504,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(795,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,258,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,660,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,973,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzEtMS0xLTEtMA_b94fbad2-e58a-4226-a061-6d2873b25138"
      unitRef="shares">6706994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzEtMy0xLTEtMA_f2e51185-0b50-4d74-aa4f-0a096dbb2980"
      unitRef="usdPerShare">22.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzEtNS0xLTEtMA_d82624fc-6f22-4be7-92cd-621be1461dc8">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzItMS0xLTEtMA_261304e5-78b3-4302-acee-a74124448e66"
      unitRef="shares">1851327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzItMy0xLTEtMA_68a8df7a-7de3-4a1a-a44a-edf329d1ba82"
      unitRef="usdPerShare">15.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzMtMS0xLTEtMA_ddf8b29e-011c-43d0-9321-e1ba3984b7a6"
      unitRef="shares">504445</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzMtMy0xLTEtMA_005c418a-ca36-4196-91be-d78dab7ff2a8"
      unitRef="usdPerShare">10.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzQtMS0xLTEtMA_a7d21839-3602-48fb-a912-bcdbb11e5613"
      unitRef="shares">795523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzQtMy0xLTEtMA_043de83a-c364-4ded-a9d8-0511e36195d6"
      unitRef="usdPerShare">20.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzUtMS0xLTEtMA_ad528403-8034-4da6-9455-8079f1657057"
      unitRef="shares">7258353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzUtMy0xLTEtMA_c0977dc4-a946-42e9-af0b-32db79ba8ffb"
      unitRef="usdPerShare">21.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzUtNS0xLTEtMA_8b88f162-a809-4b40-820f-e2a7d0e83e70">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzUtNy0xLTEtMA_49891b77-7bd9-4750-9456-225b9117a674"
      unitRef="usd">27409000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzgtMS0xLTEtMA_e68377c3-10b6-4ef0-8b08-edc8d751a1e3"
      unitRef="shares">4660921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzgtMy0xLTEtMA_ed12ac5f-97f5-4544-ad63-1275b0408ef0"
      unitRef="usdPerShare">22.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzgtNS0xLTEtMA_ab01098f-744d-480d-859f-05bdc4acbf42">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzgtNy0xLTEtMA_4623b03e-1671-40d3-8fed-5e6b2f962017"
      unitRef="usd">13906000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzktMS0xLTEtMA_eb1e4394-6a3c-4cd8-8964-64ead01f3db6"
      unitRef="shares">6973272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzktMy0xLTEtMA_87ecf432-0de4-41bb-9c9e-d74694ad04ba"
      unitRef="usdPerShare">21.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzktNS0xLTEtMA_9aefc305-1335-4f79-85d9-d8a3a03a60cb">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZTpkNTEwYjFiZTIwM2U0NWZkYjA5ZGNhZTI4YjQxNDE5My90YWJsZXJhbmdlOmQ1MTBiMWJlMjAzZTQ1ZmRiMDlkY2FlMjhiNDE0MTkzXzktNy0xLTEtMA_30992fbf-137c-4b8c-a57d-1c2257c6e4ba"
      unitRef="usd">26011000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzUzODk_9b9b8350-1c31-4bbe-aabe-0bd6af4c63cd"
      unitRef="shares">504445</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzUzOTM_5bac09ee-7c24-40e9-80b6-56c72ddd1f8d"
      unitRef="shares">219045</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU0MDA_dd4d116d-c093-4534-8c19-0860cd570c49"
      unitRef="shares">274362</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU1NzY_394c546c-b7a7-4b05-a59f-98191fd09346"
      unitRef="usd">5300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU1ODA_4f414824-4712-427d-bd0c-ecdd5f4c5b68"
      unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU1ODc_2d9e17e8-3488-417e-ae12-59c349858d8e"
      unitRef="usd">900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU3MTM_9c73edb7-96f1-4fc9-9b76-fe0ecb1982b4"
      unitRef="usdPerShare">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU3MTc_c47d8b1d-23cc-466f-a2b1-50867f399101"
      unitRef="usdPerShare">13.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU3MjQ_1f032af2-9032-4792-a8e2-9fd0dea1ff20"
      unitRef="usdPerShare">17.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU4Mzg_d633dc4a-7dbb-4a14-aa72-0a0db4d5d094"
      unitRef="usd">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU4NDI_52d8085c-5766-499a-85a2-d30c5397d97d"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU4NDk_d20e88de-78b1-459d-8125-ab21703fca77"
      unitRef="usd">5200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU5NDM_47f84773-8503-4feb-a472-10c205335e13"
      unitRef="usd">16700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU5NDc_40587cfe-e5ca-4ee1-a6e4-397a10de798e"
      unitRef="usd">17700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzU5NTQ_4c075771-63c2-4220-a17a-e6c0b981ee8c"
      unitRef="usd">16400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzYxMDQ_5cb3187b-3343-4106-b63a-e812318a3127"
      unitRef="usd">27500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzYxOTU_2c940fb2-7e98-4bfd-9f59-2033d30a5ea3">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5Mzg_38fb23a4-61c1-421c-adc4-e10424724580">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifdfaf6831a2d4d289947607db7469eff_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzEtMS0xLTEtMA_8d62149b-ca3f-4182-9605-87a76092207c"
      unitRef="shares">452500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifdfaf6831a2d4d289947607db7469eff_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzEtMy0xLTEtMA_7c86ea61-0b7f-4a85-9811-0a6bd75ae09f"
      unitRef="usdPerShare">15.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzItMS0xLTEtMA_7c1f5f0d-2e1b-4433-a89c-0b634529edc5"
      unitRef="shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzItMy0xLTEtMA_b250df52-7e46-4f6d-999b-a8e7cc4034e4"
      unitRef="usdPerShare">23.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzMtMS0xLTEtMA_5516588f-8f35-4d43-b629-50bb71b23ff1"
      unitRef="shares">210950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzMtMy0xLTEtMA_26b0ea46-627f-424e-a066-d8cb645c46ef"
      unitRef="usdPerShare">15.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzQtMS0xLTEtMA_d181da71-6074-4328-a1d0-97c6fd7589dd"
      unitRef="shares">47300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzQtMy0xLTEtMA_aff138cf-0463-40a5-af34-2a2c7482d77d"
      unitRef="usdPerShare">15.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if2a4fb10b7154f3ebaf1b668d5d5333c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzUtMS0xLTEtMA_041afdfe-5b8c-45c0-a4a4-bf605d89eeb0"
      unitRef="shares">209250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if2a4fb10b7154f3ebaf1b668d5d5333c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90YWJsZToxYjE2MzIyODJmNjY0NDM3YWNkMTljZWI0N2ZhZmE2Mi90YWJsZXJhbmdlOjFiMTYzMjI4MmY2NjQ0MzdhY2QxOWNlYjQ3ZmFmYTYyXzUtMy0xLTEtMA_cf3fe9ce-dcc1-4e01-a1e2-4679055263ba"
      unitRef="usdPerShare">15.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="if2a4fb10b7154f3ebaf1b668d5d5333c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY3ODA_44169134-6eaf-4a4c-a9c4-eeb0783e7460"
      unitRef="usd">2000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5115c589aff440c49c4928eb7197bfd0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjkvZnJhZzplNDUyYzA3NTQzNGY0OWZlYjBjNTFlZjYwZWU3NzgxMC90ZXh0cmVnaW9uOmU0NTJjMDc1NDM0ZjQ5ZmViMGM1MWVmNjBlZTc3ODEwXzY5MzI_3d200630-ba25-490f-955a-51e1aec09374">P8M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzMzMjY_c005e6b3-0ba1-4ccc-aa5d-e1e88a167525">Income TaxesFor the years ended December&#160;31, 2020, 2019 and 2018 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $648.0 million. Of these NOLs, $237.7 million will expire in various years beginning in 2025 through 2037. $410.3 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $69.6 million which will expire in various years beginning in 2022 through 2039.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2020, $13.5 million of the Company's U.S. Federal NOLs are limited for use over the years 2021 &#x2013; 2028 in which a range of such amounts could be utilized on an annual basis of $0.2 million to $1.4 million. The remaining $634.5 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, of the total gross unrecognized tax benefits, approximately $6.1 million and $4.9 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%"&gt;The Company's U.S. Federal and state income tax returns from 2001 &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%"&gt;forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzY2_5ef256e9-cc05-4fa5-9897-fce81bd0a9b1"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzY2_6bf8fd7a-92f3-4cd4-ab24-2f9896741b12"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzY2_b8d84fca-cd16-4209-b078-3ba60cff412b"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzMzMjE_07d4b954-00f5-41ce-a65b-f68d3380119e">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzMtMS0xLTEtMA_f153485b-ccc0-434b-a7fb-8eea7bffd40c"
      unitRef="usd">136086000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzMtMy0xLTEtMA_74da60ab-fb18-4322-87d8-476a71756871"
      unitRef="usd">116436000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzQtMS0xLTEtMA_ffea8365-309b-4000-be3a-4b48c39d8c49"
      unitRef="usd">37465000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzQtMy0xLTEtMA_d7285d44-d3d8-492b-a599-175a63e9896f"
      unitRef="usd">31110000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzUtMS0xLTEtMA_f046abc5-66a8-45d7-96e9-e631ff025240"
      unitRef="usd">50271000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzUtMy0xLTEtMA_9f23a0d1-376b-4d6b-8b98-53866b73df0b"
      unitRef="usd">35580000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzYtMS0xLTEtMA_0ef2dc4f-4462-4d28-b7b8-074424f360d2"
      unitRef="usd">23409000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzYtMy0xLTEtMA_a774f83e-5b95-4be8-84b8-f518f87f8cd7"
      unitRef="usd">22881000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzctMS0xLTEtMA_48a71f56-97df-44c7-9d3a-846bb1e481bd"
      unitRef="usd">8048000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzctMy0xLTEtMA_92ccec19-1b41-47ce-844d-bfe7b7a5991b"
      unitRef="usd">8413000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzgtMS0xLTEtMA_93579692-d59c-4252-b62c-23071139b48f"
      unitRef="usd">3132000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzgtMy0xLTEtMA_18b7039c-e6c1-490d-93ae-b503a9e9128a"
      unitRef="usd">367000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEwLTEtMS0xLTA_ae098346-a455-4924-94c4-f8d8bf72fd02"
      unitRef="usd">14285000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEwLTMtMS0xLTA_fa23f3b1-59c8-44f1-bbbb-197f3c228878"
      unitRef="usd">9123000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzExLTEtMS0xLTA_c2acb574-48ce-48d4-8c93-eb13b91adc13"
      unitRef="usd">272696000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzExLTMtMS0xLTA_c6a5bced-2de0-4a75-a168-c476324d47b6"
      unitRef="usd">223910000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEyLTEtMS0xLTA_549d8963-2357-49d6-94c2-b0ef0e9a2d54"
      unitRef="usd">263403000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEyLTMtMS0xLTA_f445c4bf-6a73-474f-a246-6b0fa3506153"
      unitRef="usd">214893000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEzLTEtMS0xLTA_3ce3d551-3341-4472-8652-1a0d8667910d"
      unitRef="usd">9293000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzEzLTMtMS0xLTA_32d5fb86-8f70-432c-b8ec-c531cf98160e"
      unitRef="usd">9017000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE2LTEtMS0xLTA_0811a382-adc5-482c-815c-36bb3c6256bf"
      unitRef="usd">2123000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE2LTMtMS0xLTA_f3696096-4733-4e73-8167-1220050696f5"
      unitRef="usd">438000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE3LTEtMS0xLTA_e0a08fc9-5a43-4641-abec-65af971e9dad"
      unitRef="usd">5316000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE3LTMtMS0xLTA_8df7bf7f-09fd-4d9e-b2b8-956371ad628a"
      unitRef="usd">5547000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE4LTEtMS0xLTA_1d099c26-535d-4110-a4d8-d5b9757e4dc1"
      unitRef="usd">1854000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE4LTMtMS0xLTA_f614a963-49d1-4e5d-a54d-41a681974bcb"
      unitRef="usd">3032000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE5LTEtMS0xLTA_4f8b751c-e450-43b9-aa54-e441452dfdeb"
      unitRef="usd">9293000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzE5LTMtMS0xLTA_b609d3c0-fe49-45c2-9986-61aae5edb92f"
      unitRef="usd">9017000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzIwLTEtMS0xLTA_b2115db3-fe81-4dd6-989e-773ebc1855d8"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTpkZjMxNjdhZjY4YmQ0ZTg0YTliOTI2ZjRiYTEzNTY5ZC90YWJsZXJhbmdlOmRmMzE2N2FmNjhiZDRlODRhOWI5MjZmNGJhMTM1NjlkXzIwLTMtMS0xLTA_dabc62db-15d6-449e-a17c-6d6f836d3b0b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="ia12ba1f486ee48b387eed8cf479dabb6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzEwOTA_5864957b-bf48-42b9-9cf4-3e322d5c1f0c"
      unitRef="usd">648000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="iede31b1fe9ba4eb59488549ad0ed810f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzExMDk_66cd1a18-0cce-4d15-a8c7-7ffa8e21c647"
      unitRef="usd">237700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i8760a3584cb24373bea7740e94ca3528_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzExNjk_c294cd90-e20b-4bc0-a4af-151c76498fe6"
      unitRef="usd">410300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i4deebaa10a1a47c48da755ae23565886_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzEzMDY_e9b1b683-7213-4301-9082-bc0c88d50fb6"
      unitRef="usd">69600000</us-gaap:TaxCreditCarryforwardAmount>
    <mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount
      contextRef="i787eb452c45b49288fbda9f5890e9106_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE1OTA_a1de2d04-3a3f-4e30-892b-915f49416d7a"
      unitRef="usd">13500000</mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount>
    <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount
      contextRef="i0eced2ea218c49c0a97e0443fe143c83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE3NDQ_0af53157-8e7e-4e16-b7ad-3510d28fcbf9"
      unitRef="usd">200000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
    <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount
      contextRef="i02d5390f0831417aaa47113ae87c3835_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE3NTA_ea37e691-0e91-488b-a94a-0d394d59430f"
      unitRef="usd">1400000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
    <mgnx:OperatingLossCarryforwardsNotSubjectToLimitation
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE3Njg_bcd0686c-d02d-4b6f-b8b6-9800f6f4d936"
      unitRef="usd">634500000</mgnx:OperatingLossCarryforwardsNotSubjectToLimitation>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzMzMjM_e9c96dc1-f72e-4a81-a45d-45cbc7b48d53">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzMtMS0xLTEtMA_ac6bbcff-bb75-499e-a1c4-6a924de12c2d"
      unitRef="usd">-27245000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzMtMy0xLTEtMA_450554ee-5337-421b-9beb-a966db6c9268"
      unitRef="usd">-31880000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzMtNS0xLTEtMA_fba5eaaa-0973-489f-a5d3-c2ef383ef8fb"
      unitRef="usd">-36005000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzQtMS0xLTEtMA_1c1d6771-ff98-4a8a-bb93-1c40f713cd88"
      unitRef="usd">-8100000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzQtMy0xLTEtMA_764b4363-76e5-41e0-8fe5-c61f7d93bbdf"
      unitRef="usd">-9524000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzQtNS0xLTEtMA_ee705d37-5a32-4499-8599-26968f3d9cef"
      unitRef="usd">-11133000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzUtMS0xLTEtMA_9ab20d0c-5a89-45dc-89ba-8d88781c5092"
      unitRef="usd">344000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzUtMy0xLTEtMA_f721449f-75a1-42be-9681-32e2fbc54022"
      unitRef="usd">2004000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzUtNS0xLTEtMA_9862e2c0-34bb-4651-b48e-7b8d9b9bdfb9"
      unitRef="usd">-4435000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzgtMS0xLTEtMA_0dd3affd-8045-40a2-aa6f-b6b16d79f6f0"
      unitRef="usd">14691000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzgtMy0xLTEtMA_ea64a2f0-1138-408e-8563-4f5a297c2f6a"
      unitRef="usd">5830000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzgtNS0xLTEtMA_4fd41a46-4ccf-46e3-bb93-13b9019be141"
      unitRef="usd">8466000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzktMS0xLTEtMA_09029abf-08b8-4359-a198-fc085f9a107f"
      unitRef="usd">528000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzktMy0xLTEtMA_fd21d6a7-4e39-4e94-93b5-ca04e7109c5f"
      unitRef="usd">301000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzktNS0xLTEtMA_30cdfbfc-5760-453e-b018-2760dacfe8f6"
      unitRef="usd">872000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEwLTEtMS0xLTA_0cd9d05f-850c-4424-b005-63181453c6b5"
      unitRef="usd">1156000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEwLTMtMS0xLTA_7c089986-66bb-4720-90b4-71f95ecd689b"
      unitRef="usd">1206000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEwLTUtMS0xLTA_47e913d5-b13b-4b19-b1a8-3bf6896e9270"
      unitRef="usd">148000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzExLTEtMS0xLTA_4d44431a-3d18-4b4f-a106-57d74d8c70e4"
      unitRef="usd">554000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzExLTMtMS0xLTA_4e5a4cb5-b0fa-4d41-9f11-4c44b0a98911"
      unitRef="usd">1889000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzExLTUtMS0xLTA_dab715f8-a0b7-400c-ad65-2f1fcccb8224"
      unitRef="usd">758000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEyLTEtMS0xLTA_48d6fc5c-a84f-4647-8267-82d6137a5b3f"
      unitRef="usd">48510000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEyLTMtMS0xLTA_4c23239a-3976-4f5e-907e-2c4247273ec3"
      unitRef="usd">42436000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEyLTUtMS0xLTA_b14d180c-d4fe-4ac0-ade1-65f196a76b8b"
      unitRef="usd">60005000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEzLTEtMS0xLTA_8f5ad022-1c78-44c8-9986-d9ef95a48669"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEzLTMtMS0xLTA_42190e3f-e4c3-4171-8918-fe23853602bd"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo1YjI0ODY3NDA0NjU0ZGQwYjAzNGUwMTI2NTQ5NjViYy90YWJsZXJhbmdlOjViMjQ4Njc0MDQ2NTRkZDBiMDM0ZTAxMjY1NDk2NWJjXzEzLTUtMS0xLTA_6885d486-7539-45eb-b442-e89af975edfc"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzMzMjU_303e6884-8444-4dea-a52b-525638cc6072">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzItMS0xLTEtMA_8b7153e3-7d87-4bc8-8308-f4456ee38c31"
      unitRef="usd">4950000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzItMy0xLTEtMA_7f9523af-fe14-42aa-bd4f-872574063591"
      unitRef="usd">4318000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia662d353fd8d45c0b6ef76a73d9eab63_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzItNS0xLTEtMA_3c5ebbb3-b6a5-4cb8-8ef5-630a8bb27f5e"
      unitRef="usd">3395000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzMtMS0xLTEtMA_716379a9-6ec6-4fb6-989f-ee2dabeabf49"
      unitRef="usd">839000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzMtMy0xLTEtMA_bf858099-b7e4-4de1-afee-b29e2e6db8b7"
      unitRef="usd">637000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzMtNS0xLTEtMA_2b9d500f-0bd3-4eb1-8814-ef830bfae9c8"
      unitRef="usd">642000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzQtMS0xLTEtMA_11e6539d-4b59-4b4d-ae14-307c5d2daddc"
      unitRef="usd">337000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzQtMy0xLTEtMA_03cd3998-ade3-44e4-9a22-0ed73b074404"
      unitRef="usd">5000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzQtNS0xLTEtMA_23a4eeea-7820-4d28-9660-2fc0f1065591"
      unitRef="usd">281000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzUtMS0xLTEtMA_47159093-5588-4c9d-bd5c-39712c3e8e6c"
      unitRef="usd">6126000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzUtMy0xLTEtMA_f672762c-0b58-497e-8637-d2a9730bd73d"
      unitRef="usd">4950000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7a45855556604f00a3ab1c5a555208a8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90YWJsZTo2YzI5MWNiYmU1OTE0OWI4OTAzMGQwNGU3NGRmZDdjYS90YWJsZXJhbmdlOjZjMjkxY2JiZTU5MTQ5Yjg5MDMwZDA0ZTc0ZGZkN2NhXzUtNS0xLTEtMA_fba7ce18-583e-484c-bed9-b94f3a10f997"
      unitRef="usd">4318000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="if8c8761deec04f95aecb8597243730f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzIzMDA_0e3587cc-2b36-4b86-95f1-c5d76003664f"
      unitRef="usd">6100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzIzMDc_47be3c90-1b07-45d3-ab71-95a3f0a2f344"
      unitRef="usd">4900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE2NDkyNjc0NDUzNzg_7eb742ff-3f9e-4bab-a671-a4a062b66cba"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE2NDkyNjc0NDUzNzg_8dde6608-5b01-42d3-94d3-d7c416599ef3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNzUvZnJhZzozNjZjOGFmZmRhZWY0N2VmYTdkZDg5YzJiMTIxMGFhOS90ZXh0cmVnaW9uOjM2NmM4YWZmZGFlZjQ3ZWZhN2RkODljMmIxMjEwYWE5XzE2NDkyNjc0NDUzNzg_d8a793bb-51e9-4ae1-9349-0764f2a1ae05"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzMyMzM2_777cf963-6a0d-4105-8887-c509bf8911b1">Collaboration and Other Agreements &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte for retifanlimab (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. From its inception through December&#160;31, 2020, the Company has recognized $55.0 million in development milestones under this agreement, and another $10.0 million milestone was achieved related to development progress of retifanlimab outside the U.S. subsequent to December 31, 2020.   If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte License Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three development milestones totaling &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$15.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;retifanlimab&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; meeting certain clinical proof-of-concept criteria. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. During the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for two development milestones totaling $40.0 million related to clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#x2019;s initiation of a Phase 3 clinical trial.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$150.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed over a period spanning 2017 and 2018. The Company recognized revenue of $40.0 million, $0.1 million and $18.8&#160;million under the Incyte Agreement during the years ended December&#160;31, 2020, 2019 and 2018, respectively. The revenue recognized during the year ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; reflected milestone revenue of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$40.0 million, and t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he revenue recognized during the year ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; included milestone revenue of $15.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized revenue of $8.6 million, $22.1 million and $22.2&#160;million, respectively, for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;expended) related to the manufacturing services.   During the year ended December&#160;31, 2020, the Company recognized revenue of $1.4 million for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#x2019;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million ($22.5 million after netting value-added tax withholdings of  $2.5&#160;million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0&#160;million of which ($3.6&#160;million after netting value-added tax withholdings of $0.4&#160;million) was earned during the year ended December 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#x2019;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#x2019;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#x2019;s territory, which may be subject to adjustment in specified circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Due to the  short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also  recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized revenue of $8.6&#160;million, $16.1&#160;million and $1.3&#160;million, respectively, related to the Zai Lab Agreement. Revenue recognized during 2020 included net milestone revenue of $3.6 million, whereas revenue during 2019 and 2018 reflected the recognition of the deferred upfront payment. At December&#160;31, 2019, $5.0 million of revenue was deferred under this agreement, all of which was current and recognized in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#x2019;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within the contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab. The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with an alternative use and the Company has an enforceable right to payment for the performance completed to date. During the years ended December&#160;31, 2020 and 2019, the Company recognized revenue of $2.7&#160;million and $2.2&#160;million, respectively, related to the Zai Lab Clinical Supply Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a research collaboration and license agreement with Janssen to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#x2019;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. &lt;/span&gt;&lt;span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#x2019;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $20.0&#160;million allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities will be recognized over the Company&#x2019;s involvement in the research term, which is estimated to be less than two years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I-Mab Biopharma &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0&#160;million. Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0&#160;million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0&#160;million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0&#160;million. I-Mab paid the Company for the cost of this study as the costs were incurred during 2019 and 2020, and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations. During the years ended December&#160;31, 2020 and 2019, the Company recognized revenue of $2.1&#160;million and $2.3&#160;million, respectively, related to the I-Mab Agreement. At December&#160;31, 2020, $11.4&#160;million in revenue was deferred under the I-Mab Agreement, $4.5&#160;million of which was current and $6.9&#160;million of which was non-current. At December&#160;31, 2019, $13.5&#160;million in revenue was deferred under the I-Mab Agreement, $4.4&#160;million of which was current and $9.1&#160;million of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provention Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a license agreement with Provention Bio, Inc. (Provention) pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2020, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2020, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018.  The warrants were revalued at each reporting period based on the current Black-Scholes parameters until the warrants were exercised in July 2019. The resulting increase or decrease in the value of the warrants is reflected in Other income (expense) on the 2019 consolidated statement of operations and comprehensive loss.  In July 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Servier &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In  2012, the Company entered into a collaboration agreement with Servier and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). In 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab. During the term of the agreement, Servier did not exercise its options for either MGD007 or the third DART molecule. In July 2019, Servier informed the Company of its intention to terminate the Servier Agreement and the agreement was terminated effective January 15, 2020. As a result of this termination, the Company will regain full exclusive, worldwide commercialization rights to develop and market flotetuzumab. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon execution of the agreement, Servier made a nonrefundable payment of $20.0 million to the Company. The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options. The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package. The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights. As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the $20.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Two milestones were achieved in 2014 when the Investigational New Drug (IND) applications for flotetuzumab and MGD007 were cleared by the FDA. Upon achievement of each milestone, the constraint related to the $5.0 million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue associated with each performance obligation was recognized as the research and development services were provided using a cost-based input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurred over this time period and, in management&#x2019;s judgment, was the best measure of progress towards satisfying the performance obligation. No revenue was recognized related to the MGD007 option during the years ended December&#160;31, 2020 and 2019. During the year ended December&#160;31, 2018 the Company recognized revenue of $1.9 million related to the MGD007 option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $15.0 million license grant fee. Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808. The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license. The Company evaluated its performance obligation to provide Servier with an exclusive license to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of $15.0 million and Servier consumes the benefits of the license over time as the research and development activities are performed. Therefore, the Company was recognizing the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. As noted above, in July 2019, Servier informed the Company of its intention to terminate the Servier Agreement and the agreement was terminated effective January 15, 2020. Therefore, the Company reassessed the end date of its performance obligations under the contract to be January 15, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020, 2019 and 2018 the Company recognized revenue of $1.0 million, $11.6 million, and $1.2 million, respectively, related to the flotetuzumab license grant fee. At December&#160;31, 2019, $1.0 million of revenue related to the flotetuzumab license grant fee was deferred, all of which was current and recognized in 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company follows its policy to record expense incurred as research and development expense and record reimbursements received from Servier as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period. During the years ended December&#160;31, 2019 and 2018, the Company recorded approximately $3.6&#160;million and $6.0 million, respectively, as an offset to research and development expense under this collaborative arrangement. No offset to research and development expense under this collaborative arrangement was recorded during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Roche&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets (Roche Agreement). During the research term, both companies would leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate. Each company would be responsible for their own expenses during the research period. In 2019, Roche informed the Company of its intention to terminate the Roche Agreement, and the agreement was terminated effective November 21, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#x2019;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $10.0 million. The Company would also be eligible to receive up to $370.0 million in potential milestone payments and royalties on future sales. As of December&#160;31, 2020, the Company has not recognized any milestone revenue under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period. The Company determined that the license was capable of being distinct, but was not distinct in the context of the contract because it had limited value to Roche without the research activities required to be performed by the Company. Therefore, the Company concluded that there was one performance obligation under the agreement. The Company determined that the transaction price of the Roche Agreement was $10.0 million. The potential milestone payments were &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and were excluded from the transaction price. Any consideration related to sales-based royalties would be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore were also excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $10.0 million transaction price was being recognized over the expected research period, which was originally 30 months, using a cost-based input method to measure performance. Upon notice of Roche's intent to terminate the agreement in August 2019, the recognition period was adjusted to end in November 2019. There was no revenue recognized under this agreement during the year ended at December&#160;31, 2020.  The Company recognized revenue under this agreement of $6.0 million and $4.0&#160;million, respectively, during the years ended December&#160;31, 2019 and 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim International GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.  During the evaluation period, BII selected two product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $15.0&#160;million which was fully recognized &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;prior to December 31, 2015. The variable consideration under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, BII agreed to a payment of $12.0 million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $12.0 million during the year ended December&#160;31, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September&#160;15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This contract includes a base period of $7.5 million to support development of MGD014 through IND application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September 15, 2015 through December&#160;31, 2024. In 2017, NIAID exercised the first option in the amount of up to $10.8 million to fund the commencement of the MGD014 clinical trial and development of the second DART molecule. The Company recognized revenue of $7.1 million, $2.2 million and $1.3 million under the NIAID contract during the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
    <us-gaap:Revenues
      contextRef="i35285b9536cb42819f07a5e10f10a803_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzYyOQ_b5afcc00-3f1d-46fd-bdf5-0220fa8bc721"
      unitRef="usd">150000000.0</us-gaap:Revenues>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="if008047c1927420f94d6d0b9470befc2_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzg0OA_9f16fb06-9a2e-473f-86e8-f376f92ea771"
      unitRef="usd">420000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="if008047c1927420f94d6d0b9470befc2_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzkwMw_a8d68e74-d343-4f18-a6c9-5fb1c5967972"
      unitRef="usd">330000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="if40f0f15e6a24dc0ae3308ba4fd42d06_D20171001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzk2OQ_2f6bac21-6f24-4ad4-8b7e-22199515d74e"
      unitRef="usd">55000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="if40f0f15e6a24dc0ae3308ba4fd42d06_D20171001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYyMzk_add63174-e648-4ea9-b39b-3577adbddcc2"
      unitRef="usd">10000000.0</mgnx:DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i4d3801ae5b2b4734b7b504e59402757a_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzExMDA_8037b945-ebb2-4c87-97e0-cd21ed4ceab5"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ic88b6f87de8b48c1aefa96bec6d6e029_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzExMDY_91c29194-3d58-49d0-a9eb-4dc077a6288e"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i79ca36c995024fcda45aec3f3a112ef3_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI2NDQ_f85c7057-547a-4073-8709-755e5a9cc085"
      unitRef="usd">154000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ic9abc33023e44114b55b4f12898b8282_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzUzMDM_0ffc64f2-05d2-458d-ba6c-8bd979101973"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i921686739722463c9fad09ea5aea9c8f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzUzMjA_72fc3d48-966a-42b8-bf2f-2c0167b3f50d"
      unitRef="usd">40000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i35285b9536cb42819f07a5e10f10a803_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzQ1NTU_b5afcc00-3f1d-46fd-bdf5-0220fa8bc721"
      unitRef="usd">150000000.0</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i5a4db4be284f4edfaa25820bc601700f_D20170101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzQ2Nzk_4d260b7d-9c1c-4e18-a290-b56b86470f03"
      unitRef="usd">4000000.0</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="i0274a39f90984b378198325f447e1d04_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzU4NzU_a42d0021-b352-47f4-9594-c792ee043b82"
      unitRef="usd">40000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic43e5cf8fc164202a6ba3322517e2e89_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzU4NjY_df54fd0a-71c6-4ef1-b376-b3f4c4c9554f"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia989b7cb90484d43be29e03fd1165709_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzU4NzA_dfb4afd2-361c-4c55-bf97-9864d1dba2d1"
      unitRef="usd">18800000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i921686739722463c9fad09ea5aea9c8f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDc2NjI_72fc3d48-966a-42b8-bf2f-2c0167b3f50d"
      unitRef="usd">40000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ic9abc33023e44114b55b4f12898b8282_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzY0MDI_0ffc64f2-05d2-458d-ba6c-8bd979101973"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="ia4744971aa884484b209865c89d5a5d1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzcxODE_8be19928-a24a-4866-ad90-29cdf3a3e78a"
      unitRef="usd">8600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic889e33f540545a6a24b79e6435032eb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0NzcxNzY_91e80a32-47a8-4f93-ac3a-163b0ba33af3"
      unitRef="usd">22100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19c7230b384645a48a881abee6fc9595_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzYyOTU_893d6c3e-c0ae-4f92-bb83-17e8c86dfe68"
      unitRef="usd">22200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31b103b2021742a2aa611443cc804a22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODAyNzY_fdf67cd0-0b01-4ab8-a922-2a6eb875ce66"
      unitRef="usd">1400000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i69b00209713a42919d237bd84b5347ff_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk2NDI_a4ddb75f-8152-4bd5-942e-cc21ff164f24"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="if5b5d258671b4db29f62cd54a91316b0_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk2NDc_5bbe7480-2b42-4834-8388-03de8d48fe13"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="i69b00209713a42919d237bd84b5347ff_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk2OTg_ebfa01d6-e174-4e21-9002-4282ddcae9ad"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i761691dda30f487faa377ea767d90b27_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk4NDU_afcc773f-2bf2-42b3-9dd2-9cddf5d5fdc7"
      unitRef="usd">140000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <us-gaap:Revenues
      contextRef="if2421978c32548a692cbb679e16f1769_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk4OTE_d4bc646e-067f-451b-b270-0fdb14913043"
      unitRef="usd">4000000.0</us-gaap:Revenues>
    <mgnx:EntitledMilestonePaymentsUnderAgreement
      contextRef="i40903b6d1a844575b81590c15ea6ad69_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk5MDU_4df4f7d7-e969-46a4-bed0-1870c55eed42"
      unitRef="usd">3600000</mgnx:EntitledMilestonePaymentsUnderAgreement>
    <mgnx:RevenuesTaxWithholding
      contextRef="if2421978c32548a692cbb679e16f1769_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1Mjk5NTU_2ed39e74-2e74-4e50-965f-bc9e1bb4377f"
      unitRef="usd">400000</mgnx:RevenuesTaxWithholding>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="idaa6b8a1bef549409289b02f594e0e03_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYyMTU_f8f7ac93-6989-4d32-855f-073e74f3be5e"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i264b652dc2a449aaad3d8d44d6eac051_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYyMjE_0de1b178-4d02-44a9-be62-776d2f0f6611"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="if5b5d258671b4db29f62cd54a91316b0_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzE1MzM_5bbe7480-2b42-4834-8388-03de8d48fe13"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <us-gaap:Revenues
      contextRef="i7528a17162cd4516ba9f826eb391dfe2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM2Mjc_eb20ff6d-0461-437f-b3d6-17eeaac00b64"
      unitRef="usd">8600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdb32608cb0a4fa2ab949afb86d7f2ea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM2MzI_393b59ea-a641-4fe8-b36a-a51145d1d7b2"
      unitRef="usd">16100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5002f370ab2410aa505e7023a7c03b1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM2NDA_f6340eea-314b-4762-9f1a-599967baf9d9"
      unitRef="usd">1300000</us-gaap:Revenues>
    <mgnx:EntitledMilestonePaymentsUnderAgreement
      contextRef="i40903b6d1a844575b81590c15ea6ad69_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM3NTg_4df4f7d7-e969-46a4-bed0-1870c55eed42"
      unitRef="usd">3600000</mgnx:EntitledMilestonePaymentsUnderAgreement>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i761691dda30f487faa377ea767d90b27_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzM4Njc_cc1a6f86-70c6-4f94-aa78-5645528a2d5a"
      unitRef="usd">5000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="ie5b5491ae6264b9a977e0986eb5f5f09_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzQ4NzQ_8d86cd5d-9cd8-4558-879f-aad896c30d02"
      unitRef="usd">2700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i79fe409dced14166bc3d283feb339c66_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MzQ4ODI_a222e674-7c7a-4074-a78d-8652d3dca9c3"
      unitRef="usd">2200000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i4cf709b6a97f4324bf07c7b35ff8dcf8_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwMjU_7fcefad2-b6b8-4be3-8e8e-0bd42356038d"
      unitRef="usd">20000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales
      contextRef="i4936e447493b4718a73a3e856e8466cd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwNDQ_5bea22e9-c5f7-4a9d-af90-3a0bbd5bb523"
      unitRef="usd">312000000.0</mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i4cf709b6a97f4324bf07c7b35ff8dcf8_D20201201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwNTQ_67d1cd0e-d454-4709-b4ac-07eb71232592"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i4936e447493b4718a73a3e856e8466cd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwNzA_11ebc659-b7a9-4295-ad79-8d0851137c8e"
      unitRef="usd">22200000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="ia8d4cb3c32ee4849af0342d8ac09701d_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYwODk_314a9225-8f2e-4a89-8e63-d21700c248ad"
      unitRef="usd">20000000.0</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i4cf709b6a97f4324bf07c7b35ff8dcf8_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYxMDc_e59934c5-1920-49a7-bb15-811a4b5d1cb8"
      unitRef="usd">2200000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i28f6817da3524d99a079cfc05dadfb58_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE5OTU1_4600688a-2184-443e-b8da-d5de3dbe9326"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIwMDYz_c8c5d54b-33d1-410c-b613-7a796b20b310"
      unitRef="usd">135000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="if317058b73fa4c929dab128dd0783ce9_D20190701-20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYxOTY_26f863a6-430a-4f46-9daa-a93f0bde53a6"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i28f6817da3524d99a079cfc05dadfb58_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIxMDA1_4600688a-2184-443e-b8da-d5de3dbe9326"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="ib65817edf9ea4a70a15c2ee1b06d2435_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIxNDIw_215c312f-fbd2-4e60-bc7d-be115ae0aeb4"
      unitRef="usd">1000000.0</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <us-gaap:Revenues
      contextRef="ib65817edf9ea4a70a15c2ee1b06d2435_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM0NDQ_303f8106-5469-45d3-96de-1fe9cdcdca0e"
      unitRef="usd">2100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5198817fd6ce48d5b36e1a65aa5dceb0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM0Mzk_47854ddd-f6ea-4d58-bd22-e4581bfdd3fe"
      unitRef="usd">2300000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIyODk2_474c67e5-9070-44cf-b420-2a183f5793a8"
      unitRef="usd">11400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIyOTUw_5e40788a-e98e-4058-b692-a13993dc2f3e"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id204a9cfd1f64fa7a32631d2f3fe7ebc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzIyOTc4_a93836c3-06d5-4b59-b343-a72f7f3ce59a"
      unitRef="usd">6900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i883a0b58cc464c758fb7cd4f1a43cde7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM2MzY_3e5ce385-fcac-41ca-9a2a-ca4c5cee579a"
      unitRef="usd">13500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i883a0b58cc464c758fb7cd4f1a43cde7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM2NDE_9d297296-1e41-4a67-b51c-e55f2c6abbb4"
      unitRef="usd">4400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i883a0b58cc464c758fb7cd4f1a43cde7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDM2NDY_852724ba-f44a-4487-b57a-1c3c163b1c1c"
      unitRef="usd">9100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i2794f662b6aa4beaa84d0ce6906344ec_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NTg4NTM_ce3dd18b-4539-4d24-9ec9-a21fdf209aba"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="id66268ce470743409fc8e1e2f94e9801_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NTkwMTM_543e3f58-ddc8-430e-92e9-1cfb84323383"
      unitRef="usd">65000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="id66268ce470743409fc8e1e2f94e9801_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NTkwNjg_dad11bd0-ad19-43df-b98e-5f45b089927b"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="ic6b51b6783874d27a5e578d32a2386c7_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjAwODc_62b7f6fa-2d46-484f-bbbd-1e0ad4633839"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i0bc2607458784ba0a39a83024e0690aa_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjAyNDY_cc008c5a-00a1-4f7b-8070-c9b983c183fb"
      unitRef="usd">170000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i0bc2607458784ba0a39a83024e0690aa_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjAyODU_02b263c0-a33e-463c-9240-106cece9c304"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement
      contextRef="i0bc2607458784ba0a39a83024e0690aa_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjA3Mzc_e27c900c-4624-4d98-b6c8-5ec65746add8"
      unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i5506bcb7455143afb88326e2bc2e1766_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjE1MTE_b32614f3-8d74-4297-8c53-705d4bdec4e9"
      unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="i5506bcb7455143afb88326e2bc2e1766_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjE1OTI_b54f8b1b-1a1f-4817-980a-cd5f39c7f00c"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues
      contextRef="i8bdcb76501ca490393d206ec8477ba60_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjI1MzA_95f5c55e-315f-4642-ad70-28baf9516f00"
      unitRef="usd">6100000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iaf67de44e2a04b7c9869197b5d5a8db3_D20120901-20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NjkyMTM_72958b94-3869-4ce0-90fb-0018eee6556f"
      unitRef="usd">20000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iaf67de44e2a04b7c9869197b5d5a8db3_D20120901-20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzA2MTY_dac16f26-d8fd-400b-bd0d-8a2686510343"
      unitRef="usd">20000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:MilestonePayment
      contextRef="iaf67de44e2a04b7c9869197b5d5a8db3_D20120901-20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzEzMDE_9a7b34ac-17bc-4af8-a45c-0f26955ada40"
      unitRef="usd">5000000.0</mgnx:MilestonePayment>
    <us-gaap:Revenues
      contextRef="i22e923f8da4f403d9f71bbc5dcacf4c5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzE5Mjk_5f53a1e2-4595-443c-ad41-1f4a5122747c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0913a1b864a54032af94f46428788ecb_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzIwODE_ead5e8a4-e1a3-485f-83c0-d980946b6ca4"
      unitRef="usd">1900000</us-gaap:Revenues>
    <mgnx:OptionExerciseFee
      contextRef="i1b4293b73e6b48ab8ca56a0aa4f4a336_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzIyNzg_e82195a8-1708-4725-bcca-e4310d59ce6d"
      unitRef="usd">15000000.0</mgnx:OptionExerciseFee>
    <mgnx:OptionExerciseFee
      contextRef="i1b4293b73e6b48ab8ca56a0aa4f4a336_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc2MTYxODg_e82195a8-1708-4725-bcca-e4310d59ce6d"
      unitRef="usd">15000000.0</mgnx:OptionExerciseFee>
    <us-gaap:Revenues
      contextRef="i78b72bb5c40c49d9b35cc590ba9cafc3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQyNzI_f00aaf0d-b18a-4dae-91fe-391c1f675821"
      unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i799c2d0004184beeab2fb18bb2844605_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQyNzc_26f7454d-2c19-4ab2-ad3f-87d10f5076e5"
      unitRef="usd">11600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd6f1db210074fa491c51e6386544604_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQyODY_c0f215ce-1ddb-4d2e-911e-5164772cfe3e"
      unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iff5d8a80f0b24b2f8b060afc429d38e9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQzNjA_bc7d11f1-6926-478e-8c51-ccd19c3d1343"
      unitRef="usd">1000000.0</us-gaap:ContractWithCustomerLiability>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="i36820e64f4634e7892f209af43a3a307_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQ5NTQ_7f933db4-566a-45c1-9e82-d7c3b8497fd7"
      unitRef="usd">3600000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="i481a6c266fd34525a08d8b19efb3a3a5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1NzQ5NjI_ff01067e-5380-4906-9c18-b65e098d9c9a"
      unitRef="usd">6000000.0</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i311557add6db476c974b15fe543b53a3_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI0MDMy_0079263b-e913-4496-a007-1a7b65c020fe"
      unitRef="usd">10000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement
      contextRef="i81b5a53b426d4596a8deebbcbbd64643_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI0MTIy_cc80280b-6067-459c-a6be-2f5e875d355c"
      unitRef="usd">370000000.0</mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i50ebf3ffdbfd4f73a07d547a319c5d2c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI0ODY5_77599e9f-6a31-4802-9a47-129e00a3db30"
      unitRef="performanceobligation">1</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i50ebf3ffdbfd4f73a07d547a319c5d2c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI0OTkz_319f9b04-db5c-4664-b283-1b773f8cddc1"
      unitRef="usd">10000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i50ebf3ffdbfd4f73a07d547a319c5d2c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI1MzQ1_319f9b04-db5c-4664-b283-1b773f8cddc1"
      unitRef="usd">10000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:UpfrontPaymentRecognitionPeriod
      contextRef="i68fe313822074061be5bf3c037d98d1e_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI1NDQz_91d80a38-a062-499b-8bf1-13678c3c2aa2">P30M</mgnx:UpfrontPaymentRecognitionPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i81b5a53b426d4596a8deebbcbbd64643_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDc4Mzc_dbc5f4df-ad01-4116-8e39-ab72365c59af"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i42ab5ff2130a40b1a0aec0d6d8f54c67_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI1Njky_a486fe93-b5ce-4d0d-8a8f-921836032be9"
      unitRef="usd">6000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd0782694ada422ca317357bc074882c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzI1Njk5_152642e5-58cc-4404-85d0-a74e6dd8407e"
      unitRef="usd">4000000.0</us-gaap:Revenues>
    <mgnx:CollaborationAndLicenseAgreementTerm
      contextRef="ie9bbec66f02a478c848c4c9082abfa02_D20101001-20151031"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzEzNzQzODk1NTIxNTAw_2f5d7d95-4a49-4b4c-9c51-e838e0002e99">P5Y</mgnx:CollaborationAndLicenseAgreementTerm>
    <mgnx:NumberOfProductCandidates
      contextRef="i1d18f8528615463aa7159bbb5c8c9ca7_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODQyMDQ_fcb321a0-2802-4c70-8957-372a7cc6ef60"
      unitRef="productcandidate">2</mgnx:NumberOfProductCandidates>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ie9bbec66f02a478c848c4c9082abfa02_D20101001-20151031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODQzMzk_098e2343-a8c6-4d60-8dea-44d1a49f70e3"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:DevelopmentMilestonesAmount
      contextRef="i8dfc6229eff84fc5bc5f1546988286eb_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODQ2NTc_9c7fcf38-948f-42aa-a884-e82771e633b6"
      unitRef="usd">12000000.0</mgnx:DevelopmentMilestonesAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ic3620e7cdab24c1b9ca940443012e7d1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc0ODQ4MDU_2964edd5-dfd1-477f-bd15-13a3d497e917"
      unitRef="usd">12000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="i33759800192341f2aad1c701d3f8d023_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDkwNTQ_8ea7cd27-1a50-497b-92de-6e4b6cfcf8a1"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:FundedValueOfBasePeriod
      contextRef="i33759800192341f2aad1c701d3f8d023_D20150915-20150915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDk1ODY_2439c55b-d4eb-492b-9c48-3461dc6afd35"
      unitRef="usd">7500000</mgnx:FundedValueOfBasePeriod>
    <mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="iaa516c3811054de6a63d0438076fc6d1_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDk2ODk_2ee01320-ae12-4264-812a-7e3ed690325c"
      unitRef="usd">17000000.0</mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="iaa516c3811054de6a63d0438076fc6d1_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MDk4Mzg_c158595a-3b33-44ad-950a-7674ecc357b5"
      unitRef="usd">24500000</mgnx:TotalPotentialValueUnderAgreement>
    <mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="i9149ccf8fad640259305ee4963fe44d6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MTAwMDY_8b43fae3-6545-43aa-a9c1-2312d3ec41b5"
      unitRef="usd">10800000</mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement>
    <us-gaap:Revenues
      contextRef="i73fce89d7ee84c7f9e43c656a72d517e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MTAxNDM_17fc08ab-7476-41b3-acf8-c70fbf98f597"
      unitRef="usd">7100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6be2dbbda2c4a37b4060f380fd2b3b1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MTAxNDg_436ba199-a5bc-4920-9aad-c2e93ea0dc6c"
      unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i541afd290f08418499ed50f29b1803fc_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODEvZnJhZzo3MzU2YmU2YTM5ZmU0MDNkYTdmOWY2Y2UzNTU1NDA1Yy90ZXh0cmVnaW9uOjczNTZiZTZhMzlmZTQwM2RhN2Y5ZjZjZTM1NTU0MDVjXzE2NDkyNjc1MTAxNTY_3bb4343f-3d9c-42ff-b903-36a549372d25"
      unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xODcvZnJhZzplMzljOWVhMTVmYTQ0NTU5OWRhMzU1Y2VmMzVkZWM1MC90ZXh0cmVnaW9uOmUzOWM5ZWExNWZhNDQ1NTk5ZGEzNTVjZWYzNWRlYzUwXzk2Ng_b0bcfa71-629a-4bfa-a875-06c1b613a7a1">Commitments and Contingencies&#160;On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#x2019;s SOPHIA trial.   On August 17, 2020, the Employees&#x2019; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  Plaintiff filed an Opposition brief on January 29, 2021, to which the Company plans to file a timely reply. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzY0NA_dda375c2-85cd-4d97-b4b9-c9818d0a57b4">Employee Benefit Plan&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled $1.4 million in each of the years ended December&#160;31, 2020 and 2019, and $1.3 million for the year ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan
      contextRef="i7d3639bf682f4179b89f96aa342a7e53_D20140101-20141231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzE5NA_b9ba7282-bd4a-44e6-a4e2-7186848e50b1">P21Y</mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i7d3639bf682f4179b89f96aa342a7e53_D20140101-20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzMyMw_fc717973-dc63-485f-a504-4148627f1002"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzM4OQ_29bcf327-ae73-4293-8cf5-eed189d5dafa"
      unitRef="number">1</mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ibed67df96a494a19b903e6a843a2490c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzU4Mg_4c2ee153-b4eb-41bc-8c60-92110763e3b8"
      unitRef="usd">1400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i58c726f956aa424aa075e2563e67512b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzU4Mg_ffa4ff03-6ef8-4914-af2e-4fcd5bbaadb0"
      unitRef="usd">1400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ifc8d7f9a2f5d4ebd8e7397d26cfe576c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xOTAvZnJhZzplYjE0ZWFmOTg2ZGY0ZWNkOGU1MGJlMDY3NjVkYjc0Ni90ZXh0cmVnaW9uOmViMTRlYWY5ODZkZjRlY2Q4ZTUwYmUwNjc2NWRiNzQ2XzU5Mw_11265534-6116-4253-8a35-3984ead2b8ec"
      unitRef="usd">1300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861260816104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 22, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,258,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2021 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236783544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 181,131<span></span>
</td>
<td class="nump">$ 126,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">91,400<span></span>
</td>
<td class="nump">89,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">23,081<span></span>
</td>
<td class="nump">12,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">16,982<span></span>
</td>
<td class="nump">11,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">312,594<span></span>
</td>
<td class="nump">239,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">42,225<span></span>
</td>
<td class="nump">48,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">23,924<span></span>
</td>
<td class="nump">24,505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">378,743<span></span>
</td>
<td class="nump">312,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,031<span></span>
</td>
<td class="nump">4,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">34,198<span></span>
</td>
<td class="nump">27,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">4,456<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">3,988<span></span>
</td>
<td class="nump">3,020<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">50,673<span></span>
</td>
<td class="nump">45,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">6,926<span></span>
</td>
<td class="nump">9,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">25,260<span></span>
</td>
<td class="nump">27,553<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">82,859<span></span>
</td>
<td class="nump">81,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 56,244,771 and 48,958,763 shares outstanding at December&#160;31, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">562<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,067,150<span></span>
</td>
<td class="nump">872,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(771,821)<span></span>
</td>
<td class="num">(642,082)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">295,884<span></span>
</td>
<td class="nump">230,628<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 378,743<span></span>
</td>
<td class="nump">$ 312,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861233254232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">56,244,771<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861240094696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">193,201<span></span>
</td>
<td class="nump">195,309<span></span>
</td>
<td class="nump">190,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">42,742<span></span>
</td>
<td class="nump">46,064<span></span>
</td>
<td class="nump">40,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">235,943<span></span>
</td>
<td class="nump">241,373<span></span>
</td>
<td class="nump">231,327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(131,060)<span></span>
</td>
<td class="num">(177,185)<span></span>
</td>
<td class="num">(171,206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">25,374<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,739)<span></span>
</td>
<td class="num">(151,811)<span></span>
</td>
<td class="num">(171,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (129,762)<span></span>
</td>
<td class="num">$ (151,792)<span></span>
</td>
<td class="num">$ (171,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (2.47)<span></span>
</td>
<td class="num">$ (3.16)<span></span>
</td>
<td class="num">$ (4.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average number of common shares</a></td>
<td class="nump">52,442,389<span></span>
</td>
<td class="nump">48,082,728<span></span>
</td>
<td class="nump">40,925,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 97,764<span></span>
</td>
<td class="nump">$ 62,024<span></span>
</td>
<td class="nump">$ 58,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue from government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 7,119<span></span>
</td>
<td class="nump">$ 2,164<span></span>
</td>
<td class="nump">$ 1,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232638520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,859,077<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 299,238<span></span>
</td>
<td class="num">$ (6,478)<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 611,270<span></span>
</td>
<td class="num">$ (312,340)<span></span>
</td>
<td class="num">$ (6,478)<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">16,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">103,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,224<span></span>
</td>
<td class="nump">11,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (260)<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(171,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,353,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">242,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">732,727<span></span>
</td>
<td class="num">(490,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">19,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">118,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(151,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">230,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">872,204<span></span>
</td>
<td class="num">(642,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">20,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,612,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">170,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,193<span></span>
</td>
<td class="nump">74,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">3,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (2,012)<span></span>
</td>
<td class="nump">5,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,012<span></span>
</td>
<td class="num">(2,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 295,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,067,150<span></span>
</td>
<td class="num">$ (771,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredParValueMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredParValueMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236987672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (129,739)<span></span>
</td>
<td class="num">$ (151,811)<span></span>
</td>
<td class="num">$ (171,453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">11,957<span></span>
</td>
<td class="nump">12,306<span></span>
</td>
<td class="nump">9,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(1,461)<span></span>
</td>
<td class="num">(881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">20,676<span></span>
</td>
<td class="nump">19,571<span></span>
</td>
<td class="nump">16,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(10,337)<span></span>
</td>
<td class="nump">16,839<span></span>
</td>
<td class="num">(15,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(5,697)<span></span>
</td>
<td class="num">(4,878)<span></span>
</td>
<td class="num">(3,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">581<span></span>
</td>
<td class="num">(1,578)<span></span>
</td>
<td class="num">(4,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,723<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">6,994<span></span>
</td>
<td class="num">(6,057)<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(1,324)<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(8,472)<span></span>
</td>
<td class="num">(20,869)<span></span>
</td>
<td class="nump">13,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(971)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(111,898)<span></span>
</td>
<td class="num">(134,270)<span></span>
</td>
<td class="num">(153,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(223,745)<span></span>
</td>
<td class="num">(264,399)<span></span>
</td>
<td class="num">(132,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">221,866<span></span>
</td>
<td class="nump">189,330<span></span>
</td>
<td class="nump">214,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(5,906)<span></span>
</td>
<td class="num">(4,289)<span></span>
</td>
<td class="num">(24,954)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(7,785)<span></span>
</td>
<td class="num">(79,358)<span></span>
</td>
<td class="nump">56,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">170,456<span></span>
</td>
<td class="nump">118,657<span></span>
</td>
<td class="nump">103,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">5,898<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Purchase of treasury stock</a></td>
<td class="num">(2,012)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">174,342<span></span>
</td>
<td class="nump">119,972<span></span>
</td>
<td class="nump">104,991<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">54,659<span></span>
</td>
<td class="num">(93,656)<span></span>
</td>
<td class="nump">8,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">126,472<span></span>
</td>
<td class="nump">220,128<span></span>
</td>
<td class="nump">211,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">181,131<span></span>
</td>
<td class="nump">126,472<span></span>
</td>
<td class="nump">220,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash operating and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets modified in exchange for operating lease obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FairValueOfWarrantsReceived', window );">Fair value of warrants received</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FairValueOfWarrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FairValueOfWarrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Options Exercised And ESPP Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861230126152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text">Organization and Nature of OperationsMacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb).  In addition, the Company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861229052072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:25pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU) 2016-13,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2016-13), which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results </span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 3, Marketable Securities, for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2020 or 2019, as the Company has a history of collecting on all outstanding accounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.882%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Active Markets for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identical Assets</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Inputs</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.882%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Active Markets for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identical Assets</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Inputs</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $73.2 million reported in cash and cash equivalents on the balance sheet.</span></div><div style="margin-bottom:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model. There were no transfers between levels during the periods presented. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment and Software</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2020, 2019 and 2018, the Company determined that there were no impaired assets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASU No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Collaboration and Other Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467,603</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,159,494</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,273,964</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $16.4&#160;million and operating lease liabilities of $27.7&#160;million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets. Refer to Note 5, Leases, for additional disclosures required by ASC 842. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236306552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;text-indent:31.5pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2019 had contractual maturities of less than one year.  All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2019 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020 were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No  losses related to other-than-temporary impairments of the Company&#8217;s available-for-sale debt securities were recorded in Accumulated other comprehensive income during the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recorded interest income of $0.8 million, $3.4 million and $2.3 million during the years ended December&#160;31, 2020, 2019 and 2018, respectively, which is included in Other income (expense) on the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861231597864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and Software<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2020, 2019 and 2018 was $12.0 million, $12.3 million and $9.2 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861231642968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases&#160;&#160;&#160;&#160;<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2. Summary of Significant Accounting Policies, the Company adopted </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 842</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of January 1, 2019. Prior period amounts have not been adjusted and continue to be reported in accordance with historic accounting under </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 840</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in  Maryland and a non-cancelable operating lease for laboratory and office space in California. A portion of the space under one of these leases is subleased to a third party. All of these leases include one or more options to renew, with those renewal periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNiM2RmMzRjNmNkNTQ1YjQ5YjQwYTlkMDljOTllMGEwL3NlYzpjYjNkZjM0YzZjZDU0NWI0OWI0MGE5ZDA5Yzk5ZTBhMF8xNjAvZnJhZzo5OTRlMDZjNTY3ODk0NjY2YWQwYmI4ODY5ZTUzMjQ1Zi90ZXh0cmVnaW9uOjk5NGUwNmM1Njc4OTQ2NjZhZDBiYjg4NjllNTMyNDVmXzQxNA_c7bd66aa-5f7d-4552-b4e9-c0686ecd66a9">five</span> to fourteen years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:74.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption of ASC 842 on January 1, 2019, it was not reasonably certain that the Company would extend any of its operating leases, therefore the options to extend the lease terms were not recognized as part of the ROU assets or lease liabilities. During the year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019, the Company exercised the options to extend two leases for an additional five years each, therefore the Company remeasured the lease liability and adjusted the carrying amount of the ROU asset related to these leases. During the years ended December&#160;31, 2020 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2019, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $5.9 million and $6.4 million, respectively. As of December&#160;31, 2020 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2019,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $19.3 million and $20.2 million, respectively,  and are included in Other assets on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  and 2019 were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861231644632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2020 or 2019.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold 4,500,000 shares of its common stock at a price of $21.25 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 675,000 shares of the Company's common stock at a price of $21.25 per share. Upon closing, the Company received net proceeds of approximately $103.3&#160;million from this offering, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company completed a </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">firm-commitment underwritten public</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offering, in which the Company sold 5,500,000 shares of its common stock at a price of $20.00 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 825,000 shares of the Company&#8217;s common stock at a price of $20.00 per share. The Company received net proceeds of approximately $118.7&#160;million from this offering, net of underwriting discounts and commissions and other offering expenses.</span></div>In December 2019, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock in amounts of up to $50.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. This agreement was amended in June 2020 to increase the  maximum amount of the offering to $175.0 million. The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on December 23, 2019. During the year ended December&#160;31, 2020, the Company sold 6,612,815 shares of common stock at a weighted average price per share of $26.46, resulting in net proceeds of approximately $170.5 million, net of underwriting discounts and commissions and other offering expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861230168008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2020, employees purchased 32,430 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.6 million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of December&#160;31, 2020, under the 2003 Plan, there were options to purchase an aggregate of 249,959 shares of common stock outstanding at a weighted average exercise price of $2.79 per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was 1,960,168 shares.&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2020, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 11,896,613.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2020, under the 2013 Plan, there were options to purchase an aggregate of 7,008,394 shares of common stock outstanding at a weighted average exercise price of $22.14 per share. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,023&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,676&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,571&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,520&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Options</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67% - 109%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74% - 76%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68% - 72%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4% - 3.1%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods through December 31, 2019, the computation of expected volatility is based on the historical volatility of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several public entities of similar size, complexity and stage of development, as the Company did not have sufficient history of its own volatility.  </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the Company had sufficient company-specific historical and implied volatility information.  As such, beginning the first quarter of 2020, the computation of expected volatility is based only on the historical volatility of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company uses a simplified method to calculate the average expected term.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851,327&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(504,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795,523)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,258,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,660,921&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,906&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,973,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018 the Company issued 504,445, 219,045 and 274,362 net shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $5.3 million, $0.7 million and $0.9 million during 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during 2020, 2019 and 2018 was $10.68, $13.98 and $17.90 per share, respectively. The total intrinsic value of options exercised during 2020, 2019 and 2018 was approximately $4.3 million, $2.9 million and $5.2 million, respectively.&#160;The total fair value of stock options which vested during 2020, 2019 and 2018 was $16.7 million, $17.7 million and $16.4 million, respectively.&#160;As of December&#160;31, 2020, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $27.5 million, which the Company expects to recognize over a weighted-average period of approximately 2.4 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded RSUs under the 2013 Plan to all employees except executive officers and employees with less than six months of service as of the grant date. Each RSU entitles the holder to receive one share of the Company's common stock when the RSU vests. The RSUs vest in two equal installments on the first and second anniversary of the grant date. Compensation expense is recognized on a straight-line basis. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2020:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.330%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,300)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $2.0 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of eight months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236945096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesFor the years ended December&#160;31, 2020, 2019 and 2018 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214,893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,293)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $648.0 million. Of these NOLs, $237.7 million will expire in various years beginning in 2025 through 2037. $410.3 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $69.6 million which will expire in various years beginning in 2022 through 2039.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2020, $13.5 million of the Company's U.S. Federal NOLs are limited for use over the years 2021 &#8211; 2028 in which a range of such amounts could be utilized on an annual basis of $0.2 million to $1.4 million. The remaining $634.5 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,466)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, of the total gross unrecognized tax benefits, approximately $6.1 million and $4.9 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">The Company's U.S. Federal and state income tax returns from 2001 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861231596584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text">Collaboration and Other Agreements <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte for retifanlimab (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. From its inception through December&#160;31, 2020, the Company has recognized $55.0 million in development milestones under this agreement, and another $10.0 million milestone was achieved related to development progress of retifanlimab outside the U.S. subsequent to December 31, 2020.   If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retifanlimab</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> meeting certain clinical proof-of-concept criteria. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. During the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for two development milestones totaling $40.0 million related to clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed over a period spanning 2017 and 2018. The Company recognized revenue of $40.0 million, $0.1 million and $18.8&#160;million under the Incyte Agreement during the years ended December&#160;31, 2020, 2019 and 2018, respectively. The revenue recognized during the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reflected milestone revenue of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40.0 million, and t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he revenue recognized during the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included milestone revenue of $15.0 million.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized revenue of $8.6 million, $22.1 million and $22.2&#160;million, respectively, for services performed under this agreement. </span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expended) related to the manufacturing services.   During the year ended December&#160;31, 2020, the Company recognized revenue of $1.4 million for services performed under this agreement. </span></div><div style="text-indent:42pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million ($22.5 million after netting value-added tax withholdings of  $2.5&#160;million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0&#160;million of which ($3.6&#160;million after netting value-added tax withholdings of $0.4&#160;million) was earned during the year ended December 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the  short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also  recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized revenue of $8.6&#160;million, $16.1&#160;million and $1.3&#160;million, respectively, related to the Zai Lab Agreement. Revenue recognized during 2020 included net milestone revenue of $3.6 million, whereas revenue during 2019 and 2018 reflected the recognition of the deferred upfront payment. At December&#160;31, 2019, $5.0 million of revenue was deferred under this agreement, all of which was current and recognized in 2020. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within the contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab. The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with an alternative use and the Company has an enforceable right to payment for the performance completed to date. During the years ended December&#160;31, 2020 and 2019, the Company recognized revenue of $2.7&#160;million and $2.2&#160;million, respectively, related to the Zai Lab Clinical Supply Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $20.0&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities will be recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0&#160;million. Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0&#160;million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0&#160;million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0&#160;million. I-Mab paid the Company for the cost of this study as the costs were incurred during 2019 and 2020, and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. During the years ended December&#160;31, 2020 and 2019, the Company recognized revenue of $2.1&#160;million and $2.3&#160;million, respectively, related to the I-Mab Agreement. At December&#160;31, 2020, $11.4&#160;million in revenue was deferred under the I-Mab Agreement, $4.5&#160;million of which was current and $6.9&#160;million of which was non-current. At December&#160;31, 2019, $13.5&#160;million in revenue was deferred under the I-Mab Agreement, $4.4&#160;million of which was current and $9.1&#160;million of which was non-current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention Bio, Inc. (Provention) pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2020, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2020, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018.  The warrants were revalued at each reporting period based on the current Black-Scholes parameters until the warrants were exercised in July 2019. The resulting increase or decrease in the value of the warrants is reflected in Other income (expense) on the 2019 consolidated statement of operations and comprehensive loss.  In July 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servier </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In  2012, the Company entered into a collaboration agreement with Servier and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). In 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab. During the term of the agreement, Servier did not exercise its options for either MGD007 or the third DART molecule. In July 2019, Servier informed the Company of its intention to terminate the Servier Agreement and the agreement was terminated effective January 15, 2020. As a result of this termination, the Company will regain full exclusive, worldwide commercialization rights to develop and market flotetuzumab. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, Servier made a nonrefundable payment of $20.0 million to the Company. The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options. The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package. The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights. As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the $20.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two milestones were achieved in 2014 when the Investigational New Drug (IND) applications for flotetuzumab and MGD007 were cleared by the FDA. Upon achievement of each milestone, the constraint related to the $5.0 million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue associated with each performance obligation was recognized as the research and development services were provided using a cost-based input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurred over this time period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligation. No revenue was recognized related to the MGD007 option during the years ended December&#160;31, 2020 and 2019. During the year ended December&#160;31, 2018 the Company recognized revenue of $1.9 million related to the MGD007 option. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $15.0 million license grant fee. Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808. The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license. The Company evaluated its performance obligation to provide Servier with an exclusive license to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of $15.0 million and Servier consumes the benefits of the license over time as the research and development activities are performed. Therefore, the Company was recognizing the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. As noted above, in July 2019, Servier informed the Company of its intention to terminate the Servier Agreement and the agreement was terminated effective January 15, 2020. Therefore, the Company reassessed the end date of its performance obligations under the contract to be January 15, 2020. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018 the Company recognized revenue of $1.0 million, $11.6 million, and $1.2 million, respectively, related to the flotetuzumab license grant fee. At December&#160;31, 2019, $1.0 million of revenue related to the flotetuzumab license grant fee was deferred, all of which was current and recognized in 2020.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company follows its policy to record expense incurred as research and development expense and record reimbursements received from Servier as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period. During the years ended December&#160;31, 2019 and 2018, the Company recorded approximately $3.6&#160;million and $6.0 million, respectively, as an offset to research and development expense under this collaborative arrangement. No offset to research and development expense under this collaborative arrangement was recorded during the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets (Roche Agreement). During the research term, both companies would leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate. Each company would be responsible for their own expenses during the research period. In 2019, Roche informed the Company of its intention to terminate the Roche Agreement, and the agreement was terminated effective November 21, 2019. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $10.0 million. The Company would also be eligible to receive up to $370.0 million in potential milestone payments and royalties on future sales. As of December&#160;31, 2020, the Company has not recognized any milestone revenue under this agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period. The Company determined that the license was capable of being distinct, but was not distinct in the context of the contract because it had limited value to Roche without the research activities required to be performed by the Company. Therefore, the Company concluded that there was one performance obligation under the agreement. The Company determined that the transaction price of the Roche Agreement was $10.0 million. The potential milestone payments were </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and were excluded from the transaction price. Any consideration related to sales-based royalties would be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore were also excluded from the transaction price. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $10.0 million transaction price was being recognized over the expected research period, which was originally 30 months, using a cost-based input method to measure performance. Upon notice of Roche's intent to terminate the agreement in August 2019, the recognition period was adjusted to end in November 2019. There was no revenue recognized under this agreement during the year ended at December&#160;31, 2020.  The Company recognized revenue under this agreement of $6.0 million and $4.0&#160;million, respectively, during the years ended December&#160;31, 2019 and 2018. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boehringer Ingelheim International GmbH</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.  During the evaluation period, BII selected two product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $15.0&#160;million which was fully recognized </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to December 31, 2015. The variable consideration under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, BII agreed to a payment of $12.0 million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $12.0 million during the year ended December&#160;31, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September&#160;15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This contract includes a base period of $7.5 million to support development of MGD014 through IND application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September 15, 2015 through December&#160;31, 2024. In 2017, NIAID exercised the first option in the amount of up to $10.8 million to fund the commencement of the MGD014 clinical trial and development of the second DART molecule. The Company recognized revenue of $7.1 million, $2.2 million and $1.3 million under the NIAID contract during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861231580616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies&#160;On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  Plaintiff filed an Opposition brief on January 29, 2021, to which the Company plans to file a timely reply. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861230195256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled $1.4 million in each of the years ended December&#160;31, 2020 and 2019, and $1.3 million for the year ended December&#160;31, 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236820008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:25pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU) 2016-13,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2016-13), which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results </span></div>from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 3, Marketable Securities, for additional information.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2020 or 2019, as the Company has a history of collecting on all outstanding accounts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and SoftwareProperty, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2020, 2019 and 2018, the Company determined that there were no impaired assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASU No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Collaboration and Other Agreements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs, Including Clinical Trial Accruals/Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $16.4&#160;million and operating lease liabilities of $27.7&#160;million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets. Refer to Note 5, Leases, for additional disclosures required by ASC 842. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 effective January 1, 2020 and elected to apply this standard prospectively to all implementation costs incurred after the date of adoption. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The Company adopted ASU 2018-18 effective January 1, 2020, and the adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232207304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.882%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Active Markets for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identical Assets</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Inputs</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.882%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Active Markets for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identical Assets</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Inputs</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $73.2 million reported in cash and cash equivalents on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
<td class="text">The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Estimated Useful Lives</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</a></td>
<td class="text">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467,603</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,159,494</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,273,964</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861231516632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:31.5pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span> and 2019 had contractual maturities of less than one year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861230268600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861261258840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  and 2019 were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232208728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,023&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,676&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,571&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,520&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Options Award Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67% - 109%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74% - 76%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68% - 72%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4% - 3.1%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851,327&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(504,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795,523)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,258,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,660,921&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,906&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,973,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2020:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.330%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,300)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861230142728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Income Tax Assets (Liabilities)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214,893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,293)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,466)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232936072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance recorded</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset', window );">Impaired assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU Assets</a></td>
<td class="nump">19,300,000<span></span>
</td>
<td class="nump">$ 20,200,000<span></span>
</td>
<td class="nump">$ 16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 29,248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861244560712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 73,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">91,400<span></span>
</td>
<td class="nump">89,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">143,403<span></span>
</td>
<td class="nump">162,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">49,004<span></span>
</td>
<td class="nump">46,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">60,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">33,776<span></span>
</td>
<td class="nump">103,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">49,004<span></span>
</td>
<td class="nump">46,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">49,004<span></span>
</td>
<td class="nump">46,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">94,399<span></span>
</td>
<td class="nump">116,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">60,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">33,776<span></span>
</td>
<td class="nump">103,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236939736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Zai Lab Limited (Zai Lab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Les Laboratoires Servier and Institut de Recherches Servier (Servier)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Zai Lab Limited (Zai Lab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232883672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember', window );">Laboratory and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861240126632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock options</a></td>
<td class="nump">7,467,603<span></span>
</td>
<td class="nump">7,159,494<span></span>
</td>
<td class="nump">5,273,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236600568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 91,407<span></span>
</td>
<td class="nump">$ 89,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">91,400<span></span>
</td>
<td class="nump">89,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">60,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">60,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">30,777<span></span>
</td>
<td class="nump">76,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 30,776<span></span>
</td>
<td class="nump">$ 76,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861229945304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Available-For-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Debt Securities, Available-for-sale, Allowance for Credit Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income, Other</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236690248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 103,776<span></span>
</td>
<td class="nump">$ 97,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(61,551)<span></span>
</td>
<td class="num">(49,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">42,225<span></span>
</td>
<td class="nump">48,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">2,663<span></span>
</td>
<td class="nump">2,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">8,242<span></span>
</td>
<td class="nump">7,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">713<span></span>
</td>
<td class="nump">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">41,202<span></span>
</td>
<td class="nump">38,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 48,884<span></span>
</td>
<td class="nump">$ 48,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236944472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>renewalOption</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term (in years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of extension options | renewalOption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU Assets</a></td>
<td class="nump">$ 19.3<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861229943736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 5,410<span></span>
</td>
<td class="nump">$ 5,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(770)<span></span>
</td>
<td class="num">(942)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">$ 5,723<span></span>
</td>
<td class="nump">$ 5,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861233115608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 6,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">6,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">6,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">5,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">7,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">39,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(9,918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 29,248<span></span>
</td>
<td class="nump">$ 27,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232499944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,456<span></span>
</td>
<td class="nump">$ 118,657<span></span>
</td>
<td class="nump">$ 103,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FirmCommitmentPublicUnderwrittenOfferMember', window );">Firm Commitment Public Underwritten Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">$ 103,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowOnEquityOfferingMember', window );">Follow-On Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Common stock maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,612,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FirmCommitmentPublicUnderwrittenOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_FirmCommitmentPublicUnderwrittenOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowOnEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowOnEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861233354856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Employee Stock Purchase Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,456<span></span>
</td>
<td class="nump">$ 118,657<span></span>
</td>
<td class="nump">$ 103,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum employee contribution percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair market value to purchase shares</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased by employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236838904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">7,258,353<span></span>
</td>
<td class="nump">6,706,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 21.48<span></span>
</td>
<td class="nump">$ 22.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 20,676<span></span>
</td>
<td class="nump">$ 19,571<span></span>
</td>
<td class="nump">$ 16,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member', window );">Equity Incentive Plan 2003</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">249,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized (in shares)</a></td>
<td class="nump">11,896,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">7,008,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 22.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Minimum annual increase (in shares)</a></td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Percentage of common stock share outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 10,833<span></span>
</td>
<td class="nump">10,023<span></span>
</td>
<td class="nump">7,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,843<span></span>
</td>
<td class="nump">$ 9,548<span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares authorized after increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236826856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232742248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">6,706,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,851,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(504,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(795,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">7,258,353<span></span>
</td>
<td class="nump">6,706,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">4,660,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">6,973,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 22.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">15.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">20.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">21.48<span></span>
</td>
<td class="nump">$ 22.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">22.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 21.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, Outstanding</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Exercisable</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 27,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">13,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="nump">$ 26,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">504,445<span></span>
</td>
<td class="nump">219,045<span></span>
</td>
<td class="nump">274,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="nump">$ 13.98<span></span>
</td>
<td class="nump">$ 17.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">16,700<span></span>
</td>
<td class="nump">$ 17,700<span></span>
</td>
<td class="nump">$ 16,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">7,008,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 22.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">452,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(210,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(47,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">209,250<span></span>
</td>
<td class="nump">452,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 15.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">23.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">15.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">15.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 15.92<span></span>
</td>
<td class="nump">$ 15.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted in period (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861233185736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
<td class="nump">136,086,000<span></span>
</td>
<td class="nump">116,436,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">37,465,000<span></span>
</td>
<td class="nump">31,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
<td class="nump">50,271,000<span></span>
</td>
<td class="nump">35,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
<td class="nump">23,409,000<span></span>
</td>
<td class="nump">22,881,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">8,048,000<span></span>
</td>
<td class="nump">8,413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">3,132,000<span></span>
</td>
<td class="nump">367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">14,285,000<span></span>
</td>
<td class="nump">9,123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">272,696,000<span></span>
</td>
<td class="nump">223,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(263,403,000)<span></span>
</td>
<td class="num">(214,893,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">9,293,000<span></span>
</td>
<td class="nump">9,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(2,123,000)<span></span>
</td>
<td class="num">(438,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease ROU assets</a></td>
<td class="num">(5,316,000)<span></span>
</td>
<td class="num">(5,547,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenditures</a></td>
<td class="num">(1,854,000)<span></span>
</td>
<td class="num">(3,032,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(9,293,000)<span></span>
</td>
<td class="num">(9,017,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation', window );">Remaining portion of net operating losses</a></td>
<td class="nump">634,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">648,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal tax credits carry forward</a></td>
<td class="nump">69,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount', window );">Net operating loss for limited use</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member', window );">Tax Year 2025 To 2037 | U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">237,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember', window );">Indefinite | U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 410,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss which are limited for use, utilized on a annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsAnnualLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carryforward, which are limited for use over the range of years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards not subject to limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsNotSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236249816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
<td class="num">$ (27,245)<span></span>
</td>
<td class="num">$ (31,880)<span></span>
</td>
<td class="num">$ (36,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="num">(8,100)<span></span>
</td>
<td class="num">(9,524)<span></span>
</td>
<td class="num">(11,133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount', window );">Deferred income tax adjustments</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
<td class="num">(4,435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit, net</a></td>
<td class="num">(14,691)<span></span>
</td>
<td class="num">(5,830)<span></span>
</td>
<td class="num">(8,466)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Orphan drug credit, net</a></td>
<td class="num">(528)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="num">(872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
<td class="nump">1,156<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">48,510<span></span>
</td>
<td class="nump">42,436<span></span>
</td>
<td class="nump">60,005<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861235891448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 4,950,000<span></span>
</td>
<td class="nump">$ 4,318,000<span></span>
</td>
<td class="nump">$ 3,395,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for current year tax positions</a></td>
<td class="nump">839,000<span></span>
</td>
<td class="nump">637,000<span></span>
</td>
<td class="nump">642,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases for prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases for prior year tax positions</a></td>
<td class="nump">337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">6,126,000<span></span>
</td>
<td class="nump">4,950,000<span></span>
</td>
<td class="nump">4,318,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232606728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Incyte Corporation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">39 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember', window );">Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amount of development progress recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">18,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="nump">$ 22,100<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Progress And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236528568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Servier (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2012</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MilestonePayment', window );">Milestone payment removed</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts', window );">Offset to research and development costs under collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Servier | Servier Agreement - MGD007 Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to collaboration arrangement offset to research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment from collaborator upon exercise of option to develop and commercialize product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ServierAgreementMGD007OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ServierAgreementMGD007OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232569752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Zai Lab (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember', window );">Zai Lab Agreement | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Tax withholding</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="nump">16,100<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EntitledMilestonePaymentsUnderAgreement', window );">Entitled milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember', window );">Zai Lab Agreement, Margetuximab | Zai Lab | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember', window );">Zai Lab Agreement, TRIDENT molecule | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember', window );">Zai Lab Clinical Supply Agreements | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember', window );">Zai Lab Collaboration And License Agreement | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding', window );">Non-refundable upfront payment, net of tax withholding</a></td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesTaxWithholding', window );">Revenues, tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EntitledMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entitled Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EntitledMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable Payment, Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Upfront Fees, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232041672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Janssen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Janssen Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales', window );">Potential milestone payments and royalties on product sales</a></td>
<td class="nump">$ 312,000<span></span>
</td>
<td class="nump">312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Janssen Collaboration And License Agreement | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties On Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236513144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember', window );">I-Mab Biopharma Collaboration And License Agreement | I-Mab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember', window );">I-Mab Biopharma Collaboration And License Agreement | I-Mab | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861237083272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Roche (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>performanceObligation</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,883,000<span></span>
</td>
<td class="nump">$ 64,188,000<span></span>
</td>
<td class="nump">$ 60,121,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,456,000<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,926,000<span></span>
</td>
<td class="nump">9,153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement', window );">Potential milestone payments and royalties on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties on Future Sales under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to upfront payment recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861232960504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Provention (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="nump">$ 64,188<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,456<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,926<span></span>
</td>
<td class="nump">$ 9,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Stock warrants (in shares)</a></td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember', window );">Provention License Agreement | Provention PRV3279 | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Provention PRV031 | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential milestone payment to third parties for intellectual property under agreement</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861236988120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - NIAID Contract (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>USD ($) </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,883,000<span></span>
</td>
<td class="nump">$ 64,188,000<span></span>
</td>
<td class="nump">$ 60,121,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Commercialization of molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FundedValueOfBasePeriod', window );">Base period value</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement', window );">Proceeds from additional development funding options under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement', window );">Additional development funding options</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding available under agreement at counterparty's option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercised Additional Development Funding Options Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FundedValueOfBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funded value of base period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FundedValueOfBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of molecules to be developed and commercialized as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to total potential value under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861235849352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details) - Boehringer Collaboration and License Agreement - Boehringer Ingelheim International GmbH<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">61 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>productCandidate</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementTerm', window );">Term of agreement (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfProductCandidates', window );">Number of product candidates to develop | productCandidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentMilestonesAmount', window );">Development milestones</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Milestones, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139861235864248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan', window );">Eligible age to participate in plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage', window );">Percentage of employee vested contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage vested of employee's contributions to defined contribution plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to minimum eligible age of employee to participate in benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,> 65('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #'@%E2Y)Q%A^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$Y)!R;-96.G%@8K;.QF;+4UBQUC:R1]^R5>FS*V!]C1TN]/
MGT"-#E+W$9]C'S"2Q70WNLXGJ<.&G8B"!$CZA$ZE<DKXJ7GHHU,T/>,1@M(?
MZHA0<;X&AZ2,(@4SL @+D;6-T5)'5-3'"][H!1\^8Y=A1@-VZ-!3 E$*8.T\
M,9S'KH$;8(811I>^"V@68J[^B<T=8)?DF.R2&H:A'%8Y-^T@X&VW?<GK%M8G
M4E[C]"M92>> &W:=_+IZ>-P_L;;BE2AX553U7JPEKV5]_SZ[_O"[";O>V(/]
MQ\97P;:!7W?1?@%02P,$%     @ QX!94IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #'@%E2FJ5$V$8&  !K&0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*5976_;-A1][GX%8118"\2V2-E.4B0!'#M.O3:I%Z?MNF$/M$1;0B31(ZE\
M_/M=TK+E!O*5AKTD^KI'1Y?D.9?79T]2/>A("$.>TR33YZW(F/6';E<'D4BY
M[LBUR.#.4JJ4&SA5JZY>*\%#%Y0F7>9Y@V[*XZQU<>:NS=3%F<Q-$F=BIHC.
MTY2KETN1R*?S%FUM+]S%J\C8"]V+LS5?B;DP7]<S!6?='4H8IR+3L<R($LOS
MUI!^&/O'-L ]\2T63WKOF-A/64CY8$^FX7G+LXQ$(@)C(3C\>Q0CD206"7C\
M4X"V=N^T@?O'6_2)^WCXF 778B23[W%HHO/628N$8LGSQ-S)IX^B^*"^Q0MD
MHMU?\K1YMM=KD2#71J9%,#!(XVSSGS\7B=@+./$.!+ B@+T*H(?>X!<!?M.
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M\^Z%3KF$3=M?7#9NWR3RHY .N"U6A(:>G3MHN8-)[CNA67X"8F ,[A#J1>Z
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M+W-H965T-"YX;6RE6&UOHS@0_BM6M!]VI=N S7N51FJ3[&VEMJF:=.^S&YR
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M38A5WP2J$T'WZBWYE0KYSJT.$X)CPDJ O+^E5+R?E ]HOLQ,_P-02P,$%
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M"+&PFB<ZLBG^E6[B=N%LJ%],3 =8UT2PP56+K%&)8S6/U//1 -)27I^/$6#
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M#VT+JT-8=ZZ%%W"=25,[^8S8[=P:,7"2_#[^"F!H'<J&$M>9=0G"""\+9C(
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M&DE7UKL!";J) F5H@ >AKS:0#TG;6((%?6;9'+P8K5JC3"9T4?LU\]R4QI
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M8>0=4.N!7($+%(I"T+QJZO7B-Q)YXE]% 7JJEC85(YA0,I%A#!?@ !4-8.W
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M%G>L)+4B. /OH>/R5J&CCGU%EE;XD/4;9XX+2[)&<@(\Y(P761]DV_C S.%
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MPYOA\;=O=F#&?,S:-;)8Y5;PZNG)RQ?/F,CU0]_L<$C,P/?-EO[<P!ZY%A^
MWU=-T^L'G."^:;\1>&__%U!+ P04    " #'@%E2:%/KZ?@$  !/#   &
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M"HK\R3  F@6&60-S4<.D3\",4O'!FE!X\<;DE-\%&()32RS=$;M(GT5\3=E
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M40\W/HZO]2;8=1P9%S9@ (W+ HV#' O@_=+:L-NP@?9_B+._ 5!+ P04
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M:!J?S2.@X<8Q&,ZTX93G39GO#&%8\R4-R3OP^\H8=S1\@O':M_X+4$L#!!0
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MRVVGA5OL7306JWGQ6R-=NVLM/][K7AN'Y:7$'$3)>-J/Y@EWWQ_<]2Y4$@T
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MFUXQ[;\O^QNKMNZ;[D)9JS;N<BTX(*8%>+]4RNYO2$'WD?_F#U!+ P04
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MPRKTHE0_ SD?WKLW#G,[8]+8'5.FY6^&7)2:!,OA) 3=/YIL8$*1+16,BQB
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ML*3V=Z:](&%)KCK[2JVZ&I'!G6P=!:F(=< )/Z%:5A [&%F(ZV+:Z,,^YL9
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MN(;I-]*ZM _=_-7*M%>X$HEV@Z<3!+Z-G0:&Y SE;?N=[K ]GZ7_"93;2(P
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MG=B/@F^F7P^,<H%/AA+](A.4O?,"])0K##@B<18=.P56$5#KFZOSJZOS8P*
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MZ.-2"MABO &NSS4LT7[!";!9G,![\A]02P,$%     @ QX!94DEY.@<W!
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M_+>S!%P_=/L%V38.NM(2C\TH-OR=0A<4^'QG+8V+X&#Z\FV^ 5!+ P04
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M"G?H<'LK5 V.Y0LR,OZ\!RT$W.IE-W,$W$? +W@I1(BCGY1/NS&@H$3\ 6#
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M]@3]X+Z+&A2#7"QUUD./$8?I&2ZR7QJSNRR6T,)C:Q8@^Q'0N%L!"!INQME
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M1%]LH7]UNOW]+YYO#,G>@VR\V\XU</NC@^#]C[F$U2M:,E\JP.'1'9U_=)J
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MF_&8IN[./MX;65$U$UVH/+78H,>YO<<\.SAS6:*%\P_=DVB[%9V^+9&(_1?
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M]0[D(SX OZ\;L&OE T[PT+2?"+SO_Q-02P,$%     @ QX!94BV&)$/J!0
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M_IX<!U!YKI1A+QHF:2OV:'IJ[,)8X2788NI7]Z5I-!H-6\%'T]J9S:G<%CO
M%_?3J-]+5\&/^U$Z'J]@?W;^XO'_,W_#*.Z/5P=?Y^]'<R.M9K]?N871SG!
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MO*5E 7R?&3!J,V$#[5/^Z!]02P,$%     @ QX!94@4?.>H3 P  ZP8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C N>&ULK55M;]LX#/XK@F^X:X TMN74
M27M)@+3=>@-N0+&VVX?#?5!L)A8J2YY$-^O]^J/DQ,VN+\ !^^"$I,F'?"B*
MGFV-O7<5 ++OM=)N'E6(S5D<NZ*"6KB1:4#3F[6QM4!2[29VC051AJ!:Q3Q)
M\K@64D>+6;!=V\7,M*BDAFO+7%O7PCZ>@S+;>91&>\-GN:G0&^+%K!$;N &\
M:ZXM:7&/4LH:M)-&,POK>;1,S\['WC\X?)&P=0<R\TQ6QMQ[Y6,YCQ)?$"@H
MT",(^GN "U#* U$9WW:849_2!Q[*>_0/@3MQ60D'%T9]E256\V@:L1+6HE7X
MV6S_@!V?$X]7&.7"+]MVOB>4L6@=FGH73'HM=?<OON_Z<! P35X)X+L 'NKN
M$H4J+P6*Q<R:+;/>F]"\$*B&:"I.:G\H-VCIK:0X7'P2]AY0K!2P&RA:*U&"
M8T>WWN(&LQ@IA_>,BQW>>8?'7\%+.?MD-%:.O=<EE#\"Q%1<7R'?5WC.WT2\
MA&+$LG3(>,*3-_"RGG$6\+)7\#[J!W!(<X5NR"YAA4SHDKW_UDI\/.S!7\N5
M0TM3\_<;2<=]TG%(.GXEZ?)!2.5[>DSWZ-@)!2^U]O]BT"#TI^>>*A>.F351
M*Z!>@>U[%WCR)#UE6[#@O=9&T:6DXY::865:1QYN</9"Z+(V%N4_4+(+XY!=
M6>,<N].T!E2P7M'U=\_-?Y).!7T0TK(O0K7 [D8W(W9+#JZUCX=%OV-Y,LRS
MA(24GJ/)8&?B8\II&V,% MTW.J^#J"P93B83QME1-NB4G-T:%(J"3]/A.)F0
MD'F\-!GL;<E_"5)+?AK!*_, 5OOQ.G:-T<Y8<B,-;&.E"T33;,C3W-.CY]=?
MICSEO^_,G+]!=I(/DQ-.]79LO)KSGN[T=,CS*0D\?^+KC=,Q6RKE1P(K(/BZ
M$?KQ-QJ3Y_-TD*P"53*!SV?AI=L0'RR@&NPFK%G'"M-J['91;^TW^;);8$_N
MW6> %M+&MUK!FD*3T>0D8K9;K9V"I@GK;&60EF,0*_H:@?4.]'YM#.X5GZ#_
MOBW^!5!+ P04    " #'@%E2L&0FE 4#  !M!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6R%56UOVS@,_BN$<1]:P*AMV8[=(@G0=AON@!4(UFWW
MX7 ?%)N.A<J2)\G-ME\_RD[<%.@+D%@233Y\2(KT<J_-@VT1'?SLI+*KH'6N
MOXHB6[78<7NA>U3TIM&FXXZ.9A?9WB"O1Z-.1BR.%U''A0K6RU&V,>NE'IP4
M"C<&[-!UW/RZ0:GWJR )CH(O8M<Z+XC6RY[O\![=MWYCZ!3-*+7H4%FA%1AL
M5L%U<G63>?U1X;O O3W9@X]DJ_6#/_Q3KX+8$T*)E?,(G)9'O$4I/1#1^''
M#&:7WO!T?T3_-,9.L6RYQ5LM_Q6U:U=!&4"-#1^D^Z+W?^,AGMSC55K:\0G[
M23=C 52#=;H[&!.#3JAIY3\/>3@Q*.-7#-C!@(V\)T<CRP_<\?72Z#T8KTUH
M?C.&.EH3.:%\4>Z=H;>"[-QZ8ZB^QOT*X>./0?24;@=<U7"O&[?G!N'L*]]*
MM.?+R)$[;Q15!^B;"9J] ITPN-/*M18^JAKKYP 1\9S)LB/9&_8FX@>L+B!-
M0F QB]_ 2^?@TQ$O?3?XC>2'P)_2\-_UUCI#U^;_-UQELZML=)6]XNJ>NJD>
M)()NX.CVN;^7$OPFIN_7*]OS"E<!-:1%\XC!24SXK*#V6-!*4T=99ST3UR(T
M6E)G"K6#,Z%(H@=+^O;\"BC=V&W1S"FG1W()M[KK!T?B)P=_ 0L7BW1<LS1^
MNCUER#(&19@G*7P:C!)N(*GGHYM&5'B"49"*_]]IIPT\8BLJNG>0Q_[WF6]/
M5+,D)#J0EF&Z*.$S4E>V6M8@NM[H1_0Z%K(R+,O,+XLB)]**BCE,HX#B),4=
MY<P2X9@Q2,H"WLU<$J=A42S@L@@OTP7Y)7->54,W2.ZPIF% 9:@$G\8-6?).
M&R=^3X*S11+F>7(.9]EE6+#\_%V'(2CTN<U8R%CN-Y3.)(&7KF-T,@(Z-+MQ
MT%DJ]J#<- UFZ3Q+KZ<1\J0^#>([;G9"69#8D&E\4>0!F&FX30>G^W&@;+6C
M\31N6_H>H/$*]+[1VAT/WL'\A5G_ 5!+ P04    " #'@%E2DMLE]!D#   9
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R%56UOTS 0_BNG@- J
M1<MKVW2TE?8" HG!Q 9\0'QPFVMKYMC!=E;Z[SD[62BCE"_)^7SW^+E[G,MT
MJ_2]V2!:^%D):6;!QMKZ+(K,<H,5,Z>J1DD[*Z4K9FFIUY&I-;+2)U4B2N-X
M%%6,RV ^];X;/9^JQ@HN\4:#::J*Z=T%"K6=!4GPZ/C(UQOK'-%\6K,UWJ+]
M5-]H6D4]2LDKE(8K"1I7L^ \.;L8NG@?\)GCUNS9X"I9*'7O%F_+61 [0BAP
M:1T"H]<#7J(0#HAH_.@P@_Y(E[AO/Z*_]K53+0MF\%*)+[RTFUE0!%#BBC7"
M?E3;-]C5XPDNE3#^"=LV-A\&L&R,55673 PJ+MLW^]GU82^AB/^1D'8)J>?=
M'N197C'+YE.MMJ!=-*$YPY?JLXD<ETZ46ZMIEU.>G;]#*LG R1U;"#2#:60)
MU&U%RP[@H@5(_P&0I'"MI-T8>"5++/\$B(A-3RE]I'21'D6\PN4I9$D(:9S&
M1_"ROL3,XV7'2_QZOC!6TRWX=@0S[S%SCYD?PPSA4AE[J&5'D]UW=F9JML19
M0!^20?V P?QN@[!45:TD2FM K4"X,\AG+-#'!Y8"=LBT 72-!FH35@O4?:N
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M%T#[*Z7LX\(=T/\-Y[\ 4$L#!!0    ( ,> 65(NAVQR!04  %4,   9
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M"NL]9?F4.:C.[Q/A'$^.5Y.#J5]R?I7:J@H)[P>%=0714?\W*&QU3?M6*_<
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M%^X/TBRIUZ#&!9D2I^F\,=TEMGMQ>NTOCG?:T374BRNZ]Z-A!5I?:.T>7SC
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MZ7P)B!NC?T)EJE%G,$N(4MC FTO"@$PBH$F09"'<ZGK))!1ZM7@UB] @#J=
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M]O.%M&U^<9,]Q=[_U\+X?U!+ P04    " #'@%E2(":GJ\4#  !-$   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6RU6.]OVS80_5<( 052H+-$RO&/
MPC80VQV6P06,N-N #?M RV>+B$1Z)!VWP/[X'259<AI;2CKH2RQ1?'>\]ZA'
M749'I1]-#&#)US219NS%UNX_^KZ)8DBYZ:@]2'RR53KE%F_USC=[#7R3@=+$
M9T'0\U,NI#<996-+/1FI@TV$A*4FYI"F7'^;0J*.8X]ZIX$'L8NM&_ GHSW?
MP0KL;_NEQCN_C+(1*4@CE"0:MF/OCGZ<L] !LAF_"SB:LVOB2EDK]>AN[C=C
M+W K@@0BZT)P_'F"&22)BX3K^*<(ZI4Y'?#\^A3]YZQX+&;-#<Q4\H?8V'CL
M#3RR@2T_)/9!'7^!HJ!;%R]2B<G^DF,Q-_!(=#!6I0485Y *F?_RKP419P#:
MNP)@!8!]#^A> 80%('PMH%L NADS>2D9#W-N^62DU9%H-QNCN8N,S R-Y0OI
M=%]9C4\%XNQDE>M-U):LQ$Z*K8BXM.0NBM1!6B%W9*D2$0DPY"=R-AEY3OA:
M:6Z5-L3&W)('P)UG -&?E0;R)>:2T."=F_U%69[@A">0!R"?N):P(5QN3GD,
M/HM //%U N1F#I:+Q+S'C+., ="83T88&O.YW?(@S./(MUB_J\*/BEJG>:WL
M2JV4X<JDC0WY)#>P>1[ 1^)*]MB)O2FKC3B'J$-"^H&P@ 47%C1[-9P.+\#G
MKX</:JH)R[T09O&ZU_8"3U!FG:OT@4ATG7_)O8R^64#^]5X5[-_D8^]K4G;+
ME-TL97@EY4M9R5\+G$/N+:3F[YH,MV6&V]JBEJ!=!O0PMQ'-V1[GI[VGR[UW
M:4_5A^_V.T'P[I+T];CP]@IN7H_K#5[BGO'2*WGIO5WL7[DT^ :3J5 6HMB)
MWZG)U2]S]5M2>5!F&+2K<GUX.FQ@?5BN<_AVUO_D@BSXFBQ$*BP:XTTQ4/>"
MT: R^* E\NG9(4+;I;\A/J77WK(&(&L2CK*J1O9VZ18XM"C.08&G'UF!?A)X
M7KG#[5X:*^S!XG>(.]]B)"D^FW)37-3*7'DW#=N2N3)KVFU5YEE#?-ID;K1R
M?5KODW<O%_3#AQFM/)7VVA*A\E+:;UF$^O@]UB1"9<JTWC8OB_#&0X96WDJ'
M+;'/*C=E0;M.UQ!_<.%[XOE2*U-F]=YWF?T?.6Q899*,M25!Y72L_C/U?[\
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MD8"R&\S[7$K<3:R#_HXS_PU02P,$%     @ QX!94F\FOZ.I @  HP8  !D
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M'8GMQLC:#8DG:7#DN&6)7Q%0-@#O"RG-;F,?T'^79O\ 4$L#!!0    ( ,>
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MSP]S>L/ . =:7VB-VXD+T+R*P_]02P,$%     @ QX!94N&E3!(/!   11$
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M)?H^1=,[FXGBE6T_*ZYT,[/#0G]N0)@ O;_F7.TGYH#N Y;^ 5!+ P04
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MFN1_\4LQ$#4 '+0 4 % 70%. 7"Z @8%8- 5X!8 MRO *P!>5X!? /RN@*
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M8'4RT174]SEC<O.@[VO+?TJ,_@=02P,$%     @ QX!94F7RT-2/ P  ;0L
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MQ67O"E_,R= X6(L_$[95C6MD4GD2XMG<W,27/=<@8BF+M E!X6_#KEF:FDB
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M9M(8P/.%$/KMQKR@.N^;_ M02P,$%     @ QX!94JT\9,A( P  A T  !D
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MLDG5'=]^@D+0A>&+>2KM+]KF[W;['HHW4G%6@'4$C&;Y/]D5B3@"X&X-("P
MX:F J !$IP+:!<"FVL^EV#Q,B2*C@>!;),S;FLT,;#(M6LNGF:G[O1+Z*=4X
M-;I7/'XX-YE+T!5GVDZ2V(*<H]NU'<P$C6FV1&.IO6&7)'H_!45H*C\,?*6#
M,%1^7&PXR3<,:S;$(;KAF5I)=)TED#PG\'7TI83P2<(D=#).(6ZA")^A, B#
MBH"N3H;C?@5\>CJ\YU 3E06)+%]45Y 5$5!5D+$0)%N"_N84FN_1\7LSLK?+
MXRT1"?KQ15.BSPJ8_.D(J%T&U+8!M6L"NMZM]3>J=TGH(TT@2]">0II45=Y-
M%+2"X%U5??X/-OUGV#/Y%Z7\B]/D*Q"L2K0;WD%[($*B"#'K^BK]+V:8OH3A
M658Z958Z3LH;FE&V80ZF;LG4?1M^[Y4!]4XK^"-/=20I5?NJLKM).MTZL[MQ
MW7:=VQOVZS78O5^J[SN)[JA\.%\( $0S[7B0"@FBH"H#;J*@U:Y.@!N&:V!3
M-RS\&_9,/@X.YV'@=C;9-3@;'YVM^&UX&X>'D,+7<'<#"P[Z=?YN0'8[=09O
M H8-#L>'$Q9'K^7Q!B;<ZM5DP8T+6YV:)+AQ40N[<W XU+'[>+PM.KFE-J*V
MPYGI*8WO:X^Y!CX<Y(=,57#^47O*0"QMFR]1S#>9RMN\<K6\2HQM _W'^L1<
M,6S;>Z#)[R<W1"RIEI/"0E,&K:X^$47>\N<3Q=>V"9YSI5MJ.USI:Q((\X)^
MON!</4W,!N7%:_0;4$L#!!0    ( ,> 65)8$NI^@P<  !<D   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;+5:2W/;-A#^*QA-#\E,+)%XD&+&]HQL
M)6T/G7J2)CUT>H!%2.*$(E0 LN/^^@(D15 B"%))<[$E<K'X=K'\]B%>/W/Q
M16X94^#K+B_DS62KU/[M;"976[:C<LKWK-!WUESLJ-)?Q68F]X+1M%RTRV<P
M"*+9CF;%Y/:ZO/8@;J_Y0>59P1X$D(?=CHJ7.Y;SYYM).#E>^)!MMLI<F-U>
M[^F&?63JT_Y!Z&^S1DN:[5@A,UX P=8WDT7X=DFP65!*?,[8LVQ]!L:41\Z_
MF"^_IC>3P"!B.5LIHX+J?T_LGN6YT:1Q_%,KG31[FH7MST?M[TOCM3&/5+)[
MGO^9I6I[,YE/0,K6])"K#_SY%U8;1(R^%<]E^1<\U[+!!*P.4O%=O5@CV&5%
M]9]^K1W16@!)SP)8+X#G"Z*>!:A>@,X6A+AG :X7E*Z>5::4?EA216^O!7\&
MPDAK;>9#Z<QRM38_*\RY?U1"W\WT.G7[4?'5EROCN13<\YT.)TG+ [D"Y2WP
M^[XZGR(%'YA4(ELI+5K=^U1D"BS,R67J!;Q:,D6S7+[6:S]]7()7/[T&/X$9
MD%LJF 194<K+-_JB_OS'EA^DUBJO9TK;8=#,5C7FNPHS[,$<0O ;+]16@G=%
MRM)3!3/M@,8+\.B%.^C5N&2K*4#A&P #&#@ W8]>'B:.Y<OQR^<>:U!SIJC4
MA_K.M'2X1Q%N%.%2$>Y1=,<V65%DQ0;<T9P6*P9>Z9.KSO.UZ]PJ=5&ISC#.
MTVT4!U&2X.O9DP,':7 0+XZ?!2U,U WL3CJ[AW,2(AB[=X^:W2/O[N^^,K'*
MY/#^46?_*Q)@C(E[_[C9/_;NK_EMS3)C/Q> ?=UG8AA*W(42)X1 Y(8R;Z#,
M_:XHT@NB8=X!$4,R1\2"J!ZNKIPW:I(&;#+FW.AC/H@TZ2# 410D,'0C" /+
MKH$7PV=-F?JT#'OJDV,E=RH.GO3E(4RUYA.W)+&.9M@#JD7YH9<?_BR3(4NO
M%D],Z.0.CA$.'C2],P]QA-#N ;^!.E*>YU1(L&>B,MUM>:5ZWK(<PBGJB=W0
MTF*(1M/(2"25PJ1-*60:]H6%Y=703ZRGE#(2"^YB":8DZL%BN37TDVLOO8R$
M13JP8##M#5)+NN$ ZW:I9B2@J LHG.+Y&>G48F.#S))UZ&?K<]89"3KN@H;3
MI,^+EJ]#/V$/\<](=/.NK\(IZ<FKH27H,!DN5%S%YT+H1W7#='^AP.,+:,L]
MT)?R\N*9BO1-79[JHG*1IIGY2'.PS.0JY_)@JLZ_%H^Z:-7=Q=^^,M'R.?3S
M>4.=M*9.P4QS92)UI4M2L]%!(U!,[#2V@Y**EG'L\NK 5A%X8>9H$K"KBMUP
M#E+ZXJJ7[T>J"H.C+H@=NDY]8M,)#/\_G[0>#Z=/_%N143XYM<.F+.A/61?9
MX7FPG';YMSX>T+RQ"P[:9=,>]*>]Q68CV(8JIMLNW;_IEGT%GFA^8,,16BF.
MV\]]C(/$_=Q#F_Z@/_UY$ W%1[?#"%$2]"1!:),@]"=!#Z)+3YIT?18%?24#
MM/D01I<5;64U Y8&\WN:"?#9P/4%C$UAT)_"-!7K, 32]/AOFO9=RL-PWP&[
MC<=9"U035E<.ADEP+K=TR<4813V)$=K$"/V)\9[*+=@+OF(LE6 M^$Z?;ET%
M\W5E.^!5<G$:.N\<,T%!<&YF5RH^%UHZA)*6T*F!-K="?_?38;.-B9>KU,3+
MVL1+&=[&UMK*2N"BVJ^&T*X+=$D:G9=:+C$T3>;G?G"(Q=,>LD$V92-_\FL7
M#ZMVD4%/BPS9DMO710:MB@Q^+#*.(5).L[1O,J[OGC&&RU$UQ/81XVZT.*1@
MT@D7AQ2!??&";!9'_M3Z_B0FZH?^J>0^IT5AEXBC3FS?UV+QR9EV'P&76(1[
MC;(I'?GSZJ="L!7?%-F_YX>_XKH"%BRG-9T7O+BJK*V>_8& <7)"#>8T79)>
M*UKC/'\"[[?")*1"FDJEO%]>J\+2B<^_#:R+$#R^2$0VY2-_RJ\&QK_J5JXP
M@W[PH-LZ,^]$/NTV?2/R?1-/9/,LNKCO].0[U)WYZ>B>H[[9%;))&,4_:$B#
M;!)$%X_SQA$_<C2$<!KV&6V3%O(G+><O#-Y)MDT#./C.H;BE2NRGRLO'XEVR
MQ 3V,@.V_(;]_#9R,%YK.2%KO7O?]I:8L)\Q1D_&:STG\V@8!@GI@]#ZA<+/
M*W9Z-02AVSE<X1CU.L%R#_:W#I<1!N[^2 &#!)+SQ.F0\X:,Y3?\@_L(;"D,
M^_N([YD!UZI/BD$R13UU/[:4A_V4=_D,N%9X,II#[2+W%(GE.CSJYXG+L"2N
M>72?5X@E1^*OD;]S!EQK'PO+$BWQ$^TWYZ=:[UGTM,:IU4/F%NO%;6F9?&O9
M>5G!-K#-<5KD>5B)Y7(R,"4RK8YM IO^9O!'URZU>W(+L<1._,3^!U<T!P=O
M >_$@[M%>!?.K/7&Q(Z)3?GFB=1*#X6J7AMHKC9OMRS*=SK.KM^%;Y?5.RI6
M3?7*S&]4:/J3(&=KK3*8QIK11?462O5%\7WY7L8C5XKORH];1E,FC("^O^9<
M';^8#9IW@6[_ U!+ P04    " #'@%E253Y8^ 0&   R&P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,2YX;6RU66M/XS@4_2M6M=(RTD)C.TE3!)6 [LPB
MS0/!,*O5:#^8QFVC2>*N[5!8[8_?ZZ3$+7',0X.$:)I>.^>>&Y]SG1RMA?RA
MEIQK=%?DI3H>++5>'0Z':K;D!5,'8L5+^&4N9,$T?)6+H5I)SM)Z4)$/21#$
MPX)EY6!R5)^[D),C4>D\*_F%1*HJ"B;O3WDNUL<#/'@X<9DMEMJ<&$Z.5FS!
MK[B^7EU(^#9L9TFS@I<J$R62?'X\.,&'TY"8 77$MXROU=8Q,JG<"/'#?#E/
MCP>!0<1S/M-F"@8?M_R,Y[F9"7#\LYETT%[3#-P^?IC]?9T\)'/#%#\3^9]9
MJI?'@V2 4CYG5:XOQ?H/ODDH,O/-1*[J_VB]B0T&:%8I+8K-8$!09&7SR>XV
M1&P-P''/ +(90!X/"'L&T,T ^MP!X69 6#/3I%+S,&6:38ZD6"-IHF$V<U"3
M68^&]+/2U/U*2_@U@W%Z<E[.1,'15W;'%=I'9Z)8B9*76B$Q1WK)ZS.LO/]5
MH2F?<REY:H+1B5(<@O8^9NPFRS.=<?4.[4VY9ED.1_OH^FJ*]GYY=S34@-)<
M:SC;(#IM$)$>1)B@3Z+42X5^+U.>[DXPA/3:',E#CJ?$.^.4SPX0Q;\A$I#
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M60*7Q[D7>@\W5FR[,_:&OYCMZ19NP-SNKQ7._)HE9P4(S:0@"C9S[S*\2,/
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M)D'9 'R^D=(\3.P+ZO9T\0]02P,$%     @ QX!94K5%A/R4!   "A4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULO5AM;^(X$/XK%MJ5MM)=$SL!
MTHHBM=!RE;;:JMV]^W"Z#VX8(-HDSMD&RNE^_$Y>2( $PW5[]$.;.//,//9C
MSTS=6PKY7<T -'F-PEA=M69:)Y>6I?P91%R=BP1B_#(1,N(:7^744HD$/LY
M46@QV^Y8$0_B5K^7C3W*?D_,=1C$\"B)FD<1EZL;",7RJD5;ZX&G8#K3Z8#5
M[R5\"L^@OR6/$M^LTLLXB"!6@8B)A,E5ZYI>CE@W!606OP>P5!O/))W*BQ#?
MTY?[\57+3AE!"+Y.77#\LX !A&'J"7G\73AME3%3X.;SVOM=-GF<S M7,!#A
M'\%8SZY:7HN,8<+GH7X2R]^@F% []>>+4&6_R;*PM5O$GRLMH@*,#*(@SO_R
MUV(A-@#HIQG "@#;!73V )P"X.P"W#T MP"XQP+:!:!]+*5. >@<"^@6@$Q]
M*U_=3)HAU[S?DV))9&J-WM*'3-\,C8H$<;H5G[7$KP'B=!\E#/F+D#S?&/&8
M?-$SD.1Z*@%PRVE%?B7WL;_20 9")FO+3T/0/ C5&7[^]CPDGSZ<D0\DB,G7
MF9@K]*-ZED9^:13++[C<Y%S8'BZ4/(A8SQ2YC<<P;L /#N#9(0=W9@?,/>1@
M9';@7!@<6"A-J0];ZW/#C!Z_^/J<./07PFS:;5H2,WP(_AK.[ ;X\&@XO6B
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M%/TK(]2'5MH&!MN81+:EQ(YW*S7;*&ZW#ZM]&,/%H +#S@QV*NV/W\N  <=
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MV6>76@VU6X.6OV2ZV/ ,PHLDD "ZC*\K+2=CT1\V;7U9Z+#Y()!X-%(<(Y?
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ML."[=<V<T$)6W7(V!PP/F)TD%NV(1;^X6*#UMEZ2US8[CBQTWS7OND#XN]I
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MPR]0=VAD\D4B5?:7'.I8SR%1J;3(:C RR'A>_;.'6H@6 /-T _P:X+\$C'L
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MX!N9YB(?(AN<NN'LE.QIU(SVDCTZ/AVV_/]AFOA_PQYX5F8#9D:/[DU'/\A
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M$M^LE4Z9Q:'>>";3P!('2H47^'[LI8S+WG3LYN[T=*QR*[B$.TU,GJ9,/\]
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M+P=69:[=7"J+S:M[W.(G#^AB ;Y?*RP&U: @J#^BIO\!4$L#!!0    ( ,>
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M4R0R]4A8;YPNJIGG43N<H*KE%L=H,%X S]<:ZZC9^#&J'<P7_P-02P,$%
M  @ QX!94O;C8WK\ @  OP@  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N
M>&ULG59;3]LP%/XK5L0#2!MITZM06XG2;3#!0#"VAVD/;G+:6/B2V4X+TW[\
MCITT="---UX2V_'WG>]<=$Y&:Z4?3 I@R:/@THR#U-KL) Q-G(*@YEAE(/'+
M0FE!+6[U,C29!IIXD.!AU&KU0T&9#"8C?W:C)R.56\XDW&AB<B&H?IH"5^MQ
MT XV![=LF5IW$$Y&&5W"'=C[[$;C+JQ8$B9 &J8DT; 8!Z?MD]G0W?<7OC!8
MFZTU<9[,E7IPFXMD'+2<(. 06\= \;6",^#<$:&,'R5G4)ETP.WUAOV]]QU]
MF5,#9XI_98E-Q\$P( DL:,[MK5J?0^E/S_'%BAO_).OR;BL@<6ZL$B48%0@F
MBS=]+..P!8C:.P!1"8C^%= I 9V_ )W!#D"W!'1]9 I7?!QFU-+)2*LUT>XV
MLKF%#Z9'H_M,NK3?68U?&>+L!./%Z5QI6F1!)N3:IJ#)Z5(#8'JM(6_)5$&J
MF5SB^04^>0I,X,J"EAY'.?D@YN?D< :6,FZ._L2\M'')8JP<>+;R'T8.")/D
MBG&.9V846@R"<R6,2X>GA</1#H?;Y$I)FQKR3B:0U.#/]N"C?02S9H)^DX(0
MTU?E,-KD<!HU,G[,Y3'IM-Z0J!6U[N]FY/#@J,ZQ9I89Q,C2WL<R:V:YCNV&
MI=TK63*MDCRV9YAYEE +#2YWJK+M>#.=UY?MMTO$D L+PGQOL-BM+':]Q>X.
MBY]!"Z(6A%8E>XAU^ 14F]HP-;/U"F2#KEZEJ]?(]"D7<W0<E95A)O$FSH98
MA3UPA;T]([](<QH*U86MOK?E)L9J$HW"58V\?B6OWRQ/R;?8R7.9T#D'DF<+
MC<5/,OKD8E@GH> ;;$EH]^HU#"H-@T8-LR($/FF"<<"F*J&V=0Q>VM[A_["R
M/7R%;1R8L5I*]K.^ PWWRPBW6KX O?2CTY!8Y=(6W;\ZK:;SJ1]*X?/U8K1?
M4;UDTA ."X2VC@=8!+H8E\7&JLP/D+FR.([\,L4_#-#N GY?*&4W&V>@^F>9
M_ 902P,$%     @ QX!94J-O<J;- @  +0@  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3,N>&ULG5;;;AHQ$/T5:]5*B92R%VYI!$@A4+4/D5"BM ]5'\SN
M %:\]M8>(/G[CKW+ED3+%O6%]67.F3-C>X;17IMGNP% ]I)+9<?!!K&X"4.;
M;B#GMJ,+4+2STB;G2%.S#FUA@&<>E,LPB:)!F'.A@LG(KRW,9*2W*(6"A6%V
MF^?<O$Y!ZOTXB(/#PH-8;] MA)-1P=?P"/A4+ S-PIHE$SDH*[1B!E;CX#:^
MF0^=O3?X+F!OC\;,1;+4^ME-OF7C('*"0$**CH'39P=W(*4C(AF_*\Z@=NF
MQ^,#^Q<?.\6RY!;NM/PA,MR,@^N 9;#B6XD/>O\5JGCZCB_5TOI?MB]MAU'
MTJU%G5=@4I +57[Y2Y6'(T \. %(*D#R'M [ >A6@.ZY@%X%Z)T+Z%< 'WI8
MQNX3-^/()R.C]\PX:V)S Y]]CZ9\">7NR2,:VA6$P\D\+Z1^!6!34+ 2R!:2
M*W8Q ^1"VDOVB3T]SMC%ATOV@0G%[H64=+YV%"(Y=Q1A6CF:EHZ2$X[BA-UK
MA1O+YBJ#["U!2*IKZ<E!^C1I99Q!VF'=^(HE41(U"+H[&QY_;H#/SH=?-\#G
MY\-[+<GHUN?8]7S=$WP/@,( /6 \G*1E/V^7%@T]Q5\M#GJU@YYWT#MU4:18
MBZ4$1M6#H68%-RA247 $=S$*NC9-66@G36+V"MS8%GW]6E^_E6H!)J7HG3J]
M8G"XUBG=.2.66U^52+;EDLIAD])V^CB*.E'TL47HH!8Z^!^A.[ (V1N]38^L
MG?O?*H>URF$KTXRND'JGQQ_RU4&R89FPJ0&W0RE]:\ESO578%$#IMN_=NB:V
MF\0=>@"[XX=[ALVLR:9;VY0QAT=U,0>S]@W)DE+25M:9>K7N>;>^U+];GU(O
M+%O77YJRD=YSLQ;*,@DKHHPZ0U)DRN943E 7OOHN-5(M]\,-]7,PSH#V5UKC
M8>(<U/\0)G\ 4$L#!!0    ( ,> 65(;#8_P-P(  'P*   -    >&PO<W1Y
M;&5S+GAM;-5676O;,!3]*T(IHX51V\F:T=4V;(7"8!N%YF%O1;&O;8$^/%G.
MG/[Z29;B.&E30A^V[,6Z]US=<X\^\%7<Z#6#API HXXST22XTKK^% 1-5@$G
MS:6L09A((14GVKBJ#)I: <D;F\19, W#>< )%3B-1<OON&Y0)ENA$SP;(.2&
MKWF"H_D'C!S=K<PAP8_G[WZU4M^<(3=.WD\FX67X>'&S'SGWH0L<O$A\=03Q
M0=I#I/.CU+XFUU$'?G/2N)!B=X\L8&H3#FA%6()O":-+16U603AE:P=/+9!)
M)A72YG",F,@BS9,+1\ZSY^9Y.!52];5=!?==^NE[@8UG!5+&!H%3[( TKHG6
MH,2=<?K)/?@LA+R]6-=&8:G(.II>X6U"/Y@B2ZER4$.9"&^@-&906#F*EI4=
MM:P#&]1:<F/DE)12D%[#)L,;AC8#QA[LI?Y9['!WQ>A40WNF8C"-(&\Z&N=8
M_C&;XQ[3AF_B135=2?VE-<L1O6\O"]PK*&C7^UTQ"#C$'AUF)W7-UI\9+04'
MM_BC"Z8QV>2A2BKZ9*K9JY(9 !1&*U":9F/DMR+U CJ]N4Y=<5CS]#_4_'?W
MN00!BK"Q:'/W3WF7WZS8=X%_H;G_K>PK?E'D[./I:_1=[]1%SD]?Y.SZ)#4&
MONN,6MM.8QM09!\0"?YA'RML6Q0M6\HT%=ZK:)Z#>-;?#+TF2_,4W.$W\W,H
M2,OT8@@F>&M_AYRV_'J8=6\WPL_:VM_L\J)Y7W#[WDS_ %!+ P04    " #'
M@%E2EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0
M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I
M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE
M/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6
MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#
M!!0    ( ,> 65*XA-4$6@0  ( C   /    >&PO=V]R:V)O;VLN>&ULQ9I=
M;Z,X%$#_BL7+SDK;30"3?F@R4B;);"NE(2K1O(X<<!*K8&=M)YWTUX^!9L?L
MIE?[<B=/%)LZAVO@W&OX^*+T\TJI9_*]*J49!EMK=W>]GLFWO&+F3[7CTO6L
ME:Z8=;MZTS,[S5EAMIS;JNQ%_?Z@5S$A@T\?3V,M=,_?49;G5BCI&NN&KX*_
MF)_]]2XY""-6HA3V. R:OTL>D$I(48E77@R#?D#,5KW<*RU>E;2LS'*MRG(8
MA&W'5ZZMR/_3G-602[8R38MEJR?F0(;!H.\&7 MM;'-$,SYSC ?N#F[W]E9]
M$:7E>L(L_TNK_4[(33V,.XN>=QI-'$[;-HAW^O^$4:W7(N<3E>\K+FT;1\W+
M&E":K=B9@$A6\6$P5@>NR8)M>'U2[E<>BO8$K2/SPJ7OA.O0#T7#B,B3SK-T
M]C 9+:<3\GDT&\W'4Y+=3Z?+S ., ,#H8H#DPX)YD#$ &?]"R&SI-H_3N0-,
MOY!T,7WR("D 22\&F2W3L0>9 )#)Q2#'H^S>@QP D -<R%1OF!2O30=ALB!S
M9O>:$[4FZ8YK#_(:@+S&A<SV5<7TL8;*Q$8*]V],6C+*<[675GB0-P#D#2[D
M(]//W#W*2TXRGN^UL((;#^T60+O%17.J<W-ICW^0Z=][L:N/;N8Z4VO[POQ)
M#OO0\[N/BSGCS'1"%H(V0=9)9E7^O%5EP;7YK0F</?ILD$A"9),T;%<K%ZZ"
MC%7E1C+-03X?Y) 062(/,E<5)TOVO3N?D#)";&>X!(RME/[YJ$OMUB4PHXWF
MO.KD,) T0FQKJ*H2MC[(-)!CEU:Z#(_+O/LX"2%IA,C6F%:[4ATY)Y^YY&MA
MR:)DG8L/DD5X25M\BWQ,2!<ALB]@S-C'A-01(KOCK-;(AV7=8G[W$VM('1&R
M.D##=>8\@IP2(3NE-=S9Z(%UR85T\@;J8T)6B7ZA5<[&$-)+A*P7^':F/B:D
MEPA9+S!FXF-"@HF0!0-C#GQ,2#71155S[6-"JHDNJIH;'Q-23709U4Q<FR@[
M=WH,N29&=LUYS"LR.CA,MO(Q(=?$R*Z!E>CG%S'DGAC9/6]*G#-=9^8'?GZ^
MP04Q9.TTA,Z+QKYS,4+:B9&U\U@OU[17X-N2#:O+!=)"SWQ,2#LQMG;.%-/G
M@PE9)\:VSGMYT!6I*QX?$[).C&V=]S'K+A\3LDZ,;9WW,=-=9]4NAJP3(UL'
MC&:G=*"0=2BR=3K)[U5#JF2S2N#N>[OU,2'K4&3K_ OSB>=*YJ(4;4B5CPE9
MAR);!\3L3CJD'HK],@9:L^IB@F]C+KFTUDDU*"0ABKZT!F'Z)1J%+$21+01C
M^B4:A2Q$D2T$8_HE&H4L1)$M!&/Z)1J%+$21+01C^B5: EDH0;80C'GK8T(6
M2K _!0 POS7ON/[!A"R4(%OH[#+ZV;0X@2R4-!;JG;[X*-Q0DA=S]Q/&M>>L
MS!>:U)OVO15-Z@7E];XLQZXME3/%BM,')*>/7S[] %!+ P04    " #'@%E2
M?'[I&]0!  #&'P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=D[
M3L- %(7AK41> )/[F/!00D5#B]B %28/D<269Q#)[HE"$8Y%08/F5-;8\O5?
M6)^L\?PE[=JR[0YYL^WSY+C?'?*BV932/X20EYNT;_--UZ?#^<JJ&_9M.2^'
M=>C;Y7N[3D&GTUD8?LYH'N<_9TY>3WWZR\1NM=HNTU.W_-BG0_EE</CLAO>\
M2:DTD]=V6*>R:,)Q=SV=P^4@-^?)S>3Y;=$,SV_2A-I!"D%:/\@@R.H'.01Y
M_: (0;%^T R"9O6#;B'HMG[0'03=U0^ZAZ#[^D$R11FG!$DCK FT%N1:"+P6
M!%L(Q!8D6PC,%D1;"-069%L(W!:$6PCD%J1;".P6Q%L(]%;46PGT5M1;"?36
MT<<V@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WH9Z&X'>
MAGH;@=Z&>AN!WC;:+"'0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0
MVU%O)]#;46\GT-M1;R?0VU%O)]#;1YO=!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$
M>COJ[01Z1]0[$N@=4>](H'=$O2.!WA'UCO^I=RZG7<K7GN\U/O\_J2[G>]/U
M\9?E]\G1JW+!.<!O^\<O4$L#!!0    ( ,> 65(J9-*FR@$  )L?   3
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M2P$"% ,4    " #'@%E2Y)Q%A^\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #'@%E2F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( ,> 65*:I4381@8  &L9   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #'@%E2?^MYDTP%  #/$P
M&               @(&*#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ QX!94K66$.9M @  P04  !@              ("!#!0  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,> 65)K9N>\V@0
M *41   8              " @:\6  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " #'@%E2WB)<ZY0&  "^(   &               @(&_
M&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ QX!94J3*
MZ PA!P  :AT  !@              ("!B2(  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( ,> 65)@V3+ H@,  ,$'   8
M  " @> I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #'
M@%E22W(QKYXH   AA0  &               @(&X+0  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ QX!94FA3Z^GX!   3PP  !@
M         ("!C%8  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( ,> 65*!I.HW* ,  #4'   9              " @;I;  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ QX!94K[&'4R1!0  !PT
M !D              ("!&5\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " #'@%E2 7;)1J8#   ""@  &0              @('A9
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ,> 65(N")E>
MSPT  "DF   9              " @;YH  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ QX!94F?T#EQ/"0  \!<  !D
M ("!Q'8  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #'
M@%E2%__7\18=  #UA   &0              @(%*@   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,> 65))>3H'-P0   \)   9
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M970R,"YX;6Q02P$"% ,4    " #'@%E2L&0FE 4#  !M!@  &0
M    @('!V   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M ,> 65*2VR7T&0,  !D'   9              " @?W;  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ QX!94BZ';'(%!0  50P  !D
M             ("!3=\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " #'@%E24D5LFX@%  "8#0  &0              @(&)Y   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ,> 65(2WBE=Y0(
M +<(   9              " @4CJ  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ QX!94GZPM^R0!0  P2   !D              ("!
M9.T  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #'@%E2
M(":GJ\4#  !-$   &0              @($K\P  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,> 65+?R!@;J0(  .\(   9
M      " @2?W  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ QX!94F\FOZ.I @  HP8  !D              ("!!_H  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #'@%E2-W S%*H#   G#P
M&0              @('G_   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( ,> 65(5*O\<M@(  "$'   9              " @<@  0!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ QX!94N&E3!(/
M!   11$  !D              ("!M0,! 'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " #'@%E2YAV7>&,#  #T"P  &0
M@('[!P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,>
M65)R_K ^A@(  ,P&   9              " @94+ 0!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ QX!94AV'9+NW @   0@  !D
M         ("!4@X! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " #'@%E28P#L?3H%  "@&   &0              @(% $0$ >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,> 65)E\M#4CP,  &T+
M   9              " @;$6 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ QX!94HFC-W?*!   ^Q,  !D              ("!=QH!
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #'@%E2K3QD
MR$@#  "$#0  &0              @(%X'P$ >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( ,> 65)8$NI^@P<  !<D   9
M  " @?<B 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MQX!94E4^6/@$!@  ,AL  !D              ("!L2H! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " #'@%E2.<4^>N #  !E#   &0
M            @('L, $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( ,> 65(]O=FK80,  *H*   9              " @0,U 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ QX!94K5%A/R4!
M"A4  !D              ("!FS@! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " #'@%E2-UP=^[X#  #4#0  &0              @(%F
M/0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ,> 65(9
MJ6_[= 0  #82   9              " @5M! 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ QX!94O?),>Z/ P  +PP  !D
M     ("!!D8! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,> 65+VXV-Z_ (  +\(   9              "
M@19: 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ QX!9
M4J-O<J;- @  +0@  !D              ("!25T! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " #'@%E2&PV/\#<"  !\"@  #0
M        @ %-8 $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,> 65*7BKL<
MP    !,"   +              "  :]B 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( ,> 65*XA-4$6@0  ( C   /              "  9AC 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #'@%E2?'[I&]0!  #&'P  &@
M    @ $?: $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #'@%E2*F32ILH!  ";'P  $P              @ $K:@$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     /0 ] *(0   F; $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>230</ContextCount>
  <ElementCount>374</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/OrganizationandNatureofOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Property, Equipment and Software</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftware</Role>
      <ShortName>Property, Equipment and Software</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2145110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2146111 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Property, Equipment and Software (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</Role>
      <ShortName>Property, Equipment and Software (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftware</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockbasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Property, Equipment and Software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails</Role>
      <ShortName>Property, Equipment and Software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Leases Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseCostsDetails</Role>
      <ShortName>Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails</Role>
      <ShortName>Collaboration and Other Agreements - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Collaboration and Other Agreements - Servier (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails</Role>
      <ShortName>Collaboration and Other Agreements - Servier (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails</Role>
      <ShortName>Collaboration and Other Agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails</Role>
      <ShortName>Collaboration and Other Agreements - Janssen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails</Role>
      <ShortName>Collaboration and Other Agreements - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - Collaboration and Other Agreements - Roche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails</Role>
      <ShortName>Collaboration and Other Agreements - Roche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CollaborationandOtherAgreements</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2442426 - Disclosure - Collaboration and Other Agreements - Provention (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails</Role>
      <ShortName>Collaboration and Other Agreements - Provention (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2443427 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2444428 - Disclosure - Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails</Role>
      <ShortName>Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mgnx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2447429 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mgnx-20201231.htm">mgnx-20201231.htm</File>
    <File>exhibit1015cmcagreement.htm</File>
    <File>exhibit1016incytecommercia.htm</File>
    <File>exhibit1017eversanaagreeme.htm</File>
    <File>mgnx-20201231.xsd</File>
    <File>mgnx-20201231_cal.xml</File>
    <File>mgnx-20201231_def.xml</File>
    <File>mgnx-20201231_lab.xml</File>
    <File>mgnx-20201231_pre.xml</File>
    <File>mgnxexhibit23-1202010xk.htm</File>
    <File>mgnxexhibit31-1202010xk.htm</File>
    <File>mgnxexhibit31-2202010xk.htm</File>
    <File>mgnxexhibit32-1202010xk.htm</File>
    <File>mgnxexhibit32-2202010xk.htm</File>
    <File>mgnxexhibit4-2202010xk.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mgnx-20201231_g1.jpg</File>
    <File>mgnx-20201231_g2.jpg</File>
    <File>mgnx-20201231_g3.jpg</File>
    <File>mgnx-20201231_g4.jpg</File>
    <File>mgnx-20201231_g5.jpg</File>
    <File>mgnx-20201231_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 230,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 496,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 5
   },
   "keyCustom": 53,
   "keyStandard": 321,
   "memberCustom": 45,
   "memberStandard": 29,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Property, Equipment and Software",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftware",
     "shortName": "Property, Equipment and Software",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Leases",
     "role": "http://macrogenics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Stock-based Compensation",
     "role": "http://macrogenics.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Income Taxes",
     "role": "http://macrogenics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Collaboration and Other Agreements",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreements",
     "shortName": "Collaboration and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145110 - Disclosure - Commitments and Contingencies",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146111 - Disclosure - Employee Benefit Plan",
     "role": "http://macrogenics.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Property, Equipment and Software (Tables)",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables",
     "shortName": "Property, Equipment and Software (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Leases (Tables)",
     "role": "http://macrogenics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Income Taxes (Tables)",
     "role": "http://macrogenics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i531f3aa6b1134103965b1b4eda0c293b_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i531f3aa6b1134103965b1b4eda0c293b_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i613ecacdf38948c6a00165721abcb9ae_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i613ecacdf38948c6a00165721abcb9ae_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i9eee20aa82a04eb881c0f50c7193c079_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i9eee20aa82a04eb881c0f50c7193c079_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Securities - Available-For-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Property, Equipment and Software (Details)",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
     "shortName": "Property, Equipment and Software (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Leases Narrative (Details)",
     "role": "http://macrogenics.com/role/LeasesNarrativeDetails",
     "shortName": "Leases Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Lease Costs (Details)",
     "role": "http://macrogenics.com/role/LeaseCostsDetails",
     "shortName": "Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Maturities of Operating Lease Liabilities (Details)",
     "role": "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ic72a8361cda6471c8e38d658753f0573_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ie71f6f7825d94e5b829714cea61564c2_I20170518",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "if8c8761deec04f95aecb8597243730f8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i9f6c949e8bd1430bbe594ddb5a68abf6_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ia662d353fd8d45c0b6ef76a73d9eab63_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
     "shortName": "Collaboration and Other Agreements - Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i921686739722463c9fad09ea5aea9c8f_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Collaboration and Other Agreements - Servier (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
     "shortName": "Collaboration and Other Agreements - Servier (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "iaf67de44e2a04b7c9869197b5d5a8db3_D20120901-20120930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
     "shortName": "Collaboration and Other Agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i69b00209713a42919d237bd84b5347ff_D20181101-20181130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - Collaboration and Other Agreements - Janssen (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
     "shortName": "Collaboration and Other Agreements - Janssen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i4cf709b6a97f4324bf07c7b35ff8dcf8_D20201201-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
     "shortName": "Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i28f6817da3524d99a079cfc05dadfb58_D20190701-20190731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - Collaboration and Other Agreements - Roche (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
     "shortName": "Collaboration and Other Agreements - Roche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i311557add6db476c974b15fe543b53a3_D20180101-20180131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i3e9de6b275e1488fb3fb628e6f009da2_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i3e9de6b275e1488fb3fb628e6f009da2_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442426 - Disclosure - Collaboration and Other Agreements - Provention (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
     "shortName": "Collaboration and Other Agreements - Provention (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i5506bcb7455143afb88326e2bc2e1766_I20180531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:CollaborativeAgreementTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443427 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i33759800192341f2aad1c701d3f8d023_D20150915-20150915",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ie9bbec66f02a478c848c4c9082abfa02_D20101001-20151031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444428 - Disclosure - Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
     "shortName": "Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ie9bbec66f02a478c848c4c9082abfa02_D20101001-20151031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i7d3639bf682f4179b89f96aa342a7e53_D20140101-20141231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447429 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://macrogenics.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "i7d3639bf682f4179b89f96aa342a7e53_D20140101-20141231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Nature of Operations",
     "role": "http://macrogenics.com/role/OrganizationandNatureofOperations",
     "shortName": "Organization and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201231.htm",
      "contextRef": "ibed67df96a494a19b903e6a843a2490c_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding available under agreement at counterparty's option",
        "label": "Additional development funding options under agreement",
        "terseLabel": "Additional development funding options"
       }
      }
     },
     "localname": "AdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Agreement",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering [Member]",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boehringer Ingelheim International GmbH Collaboration And License Agreement",
        "label": "Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member]",
        "terseLabel": "Boehringer Collaboration and License Agreement"
       }
      }
     },
     "localname": "BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_BoehringerIngelheimInternationalGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boehringer Ingelheim International GmbH",
        "label": "Boehringer Ingelheim International GmbH [Member]",
        "terseLabel": "Boehringer Ingelheim International GmbH"
       }
      }
     },
     "localname": "BoehringerIngelheimInternationalGmbHMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And License Agreement, Term",
        "label": "Collaboration And License Agreement, Term",
        "terseLabel": "Term of agreement (in years)"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementTerm",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20201231",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaboration and license agreements.",
        "label": "Collaboration And License Agreements Disclosure [Text Block]",
        "terseLabel": "Collaboration and Other Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to collaboration arrangement offset to research and development costs.",
        "label": "Collaboration Arrangement Offset to Research and Development Costs",
        "terseLabel": "Offset to research and development costs under collaboration arrangement"
       }
      }
     },
     "localname": "CollaborationArrangementOffsetToResearchAndDevelopmentCosts",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "terseLabel": "Consideration received common stock warrant exercise price (in usd per share)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "terseLabel": "Stock warrants (in shares)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Transaction Price",
        "label": "Collaborative Agreement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance",
        "label": "Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance",
        "terseLabel": "Minimum annual increase (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "terseLabel": "Common stock maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets",
        "label": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage vested of employee's contributions to defined contribution plan",
        "label": "Defined Contribution Plan, Employees Contribution, Vested Percentage",
        "terseLabel": "Percentage of employee vested contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeesContributionVestedPercentage",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Amounts recognized",
        "verboseLabel": "Development milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentMilestonesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestones, Amount",
        "label": "Development Milestones, Amount",
        "terseLabel": "Development milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesAmount",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Progress And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development Progress And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Amount of development progress recognized"
       }
      }
     },
     "localname": "DevelopmentProgressAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "label": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "terseLabel": "U.S. Federal and State"
       }
      }
     },
     "localname": "DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount",
        "terseLabel": "Deferred income tax adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum employee contribution percent"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to minimum eligible age of employee to participate in benefit plan.",
        "label": "Employees Eligible Age To Participate In Benefit Plan",
        "terseLabel": "Eligible age to participate in plan"
       }
      }
     },
     "localname": "EmployeesEligibleAgeToParticipateInBenefitPlan",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_EntitledMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entitled Milestone Payments Under Agreement",
        "label": "Entitled Milestone Payments Under Agreement",
        "terseLabel": "Entitled milestone payments"
       }
      }
     },
     "localname": "EntitledMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EquityIncentivePlan2003Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2003",
        "label": "Equity Incentive Plan 2003 [Member]",
        "terseLabel": "Equity Incentive Plan 2003"
       }
      }
     },
     "localname": "EquityIncentivePlan2003Member",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercised Additional Development Funding Options Under Agreement",
        "label": "Exercised Additional Development Funding Options Under Agreement",
        "terseLabel": "Proceeds from additional development funding options under agreement"
       }
      }
     },
     "localname": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]",
        "label": "F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]",
        "verboseLabel": "Roche"
       }
      }
     },
     "localname": "F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FairValueOfWarrantsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Warrants Received",
        "label": "Fair Value Of Warrants Received",
        "verboseLabel": "Fair value of warrants received"
       }
      }
     },
     "localname": "FairValueOfWarrantsReceived",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FirmCommitmentPublicUnderwrittenOfferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Firm Commitment Public Underwritten Offer",
        "label": "Firm Commitment Public Underwritten Offer [Member]",
        "terseLabel": "Firm Commitment Public Underwritten Offer"
       }
      }
     },
     "localname": "FirmCommitmentPublicUnderwrittenOfferMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FollowOnEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-On Equity Offering",
        "label": "Follow-On Equity Offering [Member]",
        "terseLabel": "Follow-On Equity Offering"
       }
      }
     },
     "localname": "FollowOnEquityOfferingMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FundedValueOfBasePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded value of base period",
        "label": "Funded Value of Base Period",
        "verboseLabel": "Base period value"
       }
      }
     },
     "localname": "FundedValueOfBasePeriod",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration And License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in deferred rent.",
        "label": "Increase (Decrease) in Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liabilities",
        "label": "Increase (decrease) in lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte Corporation [Member]",
        "label": "Incyte Corporation [Member]",
        "terseLabel": "Incyte Corporation (Incyte)"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Agreement",
        "label": "Incyte MGA012 Agreement [Member]",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Clinical Services",
        "label": "Incyte MGA012 Clinical Services [Member]",
        "terseLabel": "Incyte MGA012 Clinical Services"
       }
      }
     },
     "localname": "IncyteMGA012ClinicalServicesMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012SupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Supply Agreement",
        "label": "Incyte MGA012 Supply Agreement [Member]",
        "terseLabel": "Incyte MGA012 Supply Agreement"
       }
      }
     },
     "localname": "IncyteMGA012SupplyAgreementMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Counterparty in collaboration agreement",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc."
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration And License Agreement",
        "label": "Janssen Collaboration And License Agreement [Member]",
        "terseLabel": "Janssen Collaboration And License Agreement"
       }
      }
     },
     "localname": "JanssenCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LaboratoryAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Laboratory and Office Equipment [Member]",
        "terseLabel": "Laboratory and office equipment"
       }
      }
     },
     "localname": "LaboratoryAndOfficeEquipmentMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Les Laboratoires Servier And Institut De Recherches Servier (Servier)",
        "label": "Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]",
        "terseLabel": "Les Laboratoires Servier and Institut de Recherches Servier (Servier)"
       }
      }
     },
     "localname": "LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of extension options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment removed"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.",
        "label": "National Institute of Allergy and Infectious Diseases [Member]",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial fee received from collaboration or license agreement.",
        "label": "Non-refundable upfront payment",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable Payment, Tax Withholding",
        "label": "Non-refundable Payment, Tax Withholding",
        "terseLabel": "Tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "label": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "terseLabel": "Non-refundable upfront payment, net of tax withholding"
       }
      }
     },
     "localname": "NonrefundableUpfrontFeesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of molecules to be developed and commercialized as per collaboration.",
        "label": "Number Of Molecules To Be Developed And Commercialized Under Agreement",
        "terseLabel": "Commercialization of molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Performance Obligations",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Product Candidates",
        "label": "Number Of Product Candidates",
        "terseLabel": "Number of product candidates to develop"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OperatingLossCarryforwardsAnnualLimitationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss which are limited for use, utilized on a annual basis.",
        "label": "Operating Loss Carryforwards Annual Limitation Amount",
        "terseLabel": "Net operating losses limited for use utilized on an annual basis"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAnnualLimitationAmount",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss carryforward, which are limited for use over the range of years.",
        "label": "Operating Loss Carryforwards Limitations On Use Amount",
        "terseLabel": "Net operating loss for limited use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUseAmount",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsNotSubjectToLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards not subject to limitation.",
        "label": "Operating Loss Carryforwards Not Subject To Limitation",
        "terseLabel": "Remaining portion of net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToLimitation",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment from collaborator upon exercise of option to develop and commercialize product.",
        "label": "Option Exercise Fee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "OptionExerciseFee",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.",
        "label": "Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan",
        "terseLabel": "Percentage of common stock share outstanding"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Commercial Milestone Payments Under Agreement",
        "label": "Potential Commercial Milestone Payments Under Agreement",
        "terseLabel": "Potential commercial milestone payments"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "label": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "terseLabel": "Potential development and regulatory milestone payments"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "label": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "terseLabel": "Potential milestone payment to third parties for intellectual property under agreement"
       }
      }
     },
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payments and Royalties On Product Sales",
        "label": "Potential Milestone Payments and Royalties On Product Sales",
        "terseLabel": "Potential milestone payments and royalties on product sales"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsAndRoyaltiesOnProductSales",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payments and Royalties on Future Sales under Agreement",
        "label": "Potential Milestone Payments and Royalties on Future Sales under Agreement",
        "terseLabel": "Potential milestone payments and royalties on future sales"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Royalties, Percent",
        "label": "Proceeds from Royalties, Percent",
        "terseLabel": "Potential proceeds from royalties percent"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "label": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "terseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment estimated useful life.",
        "label": "Property Plant And Equipment Estimated Useful Life Table [Text Block]",
        "terseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_ProventionBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention Bio",
        "label": "Provention Bio [Member]",
        "terseLabel": "Provention Bio, Inc. (Provention)"
       }
      }
     },
     "localname": "ProventionBioMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention License Agreement",
        "label": "Provention License Agreement [Member]",
        "terseLabel": "Provention License Agreement"
       }
      }
     },
     "localname": "ProventionLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention PRV031",
        "label": "Provention PRV031 [Member]",
        "terseLabel": "Provention PRV031"
       }
      }
     },
     "localname": "ProventionPRV031Member",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV3279Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention PRV3279",
        "label": "Provention PRV3279 [Member]",
        "terseLabel": "Provention PRV3279"
       }
      }
     },
     "localname": "ProventionPRV3279Member",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Agreements",
        "label": "Revenue From Collaborative Agreements [Member]",
        "terseLabel": "Revenue from collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Government Agreements",
        "label": "Revenue From Government Agreements [Member]",
        "terseLabel": "Revenue from government agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "terseLabel": "Clinical trial activities selling price amount"
       }
      }
     },
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues From License Agreements",
        "label": "Revenues From License Agreements [Member]",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Tax Withholding",
        "label": "Revenues, Tax Withholding",
        "terseLabel": "Revenues, tax withholding"
       }
      }
     },
     "localname": "RevenuesTaxWithholding",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ServierAgreementMGD007OptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Servier Agreement - MGD007 Option",
        "label": "Servier Agreement - MGD007 Option [Member]",
        "terseLabel": "Servier Agreement - MGD007 Option"
       }
      }
     },
     "localname": "ServierAgreementMGD007OptionMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ServierDARTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents agreement with Servier for DARTs",
        "label": "Servier DART [Member]",
        "terseLabel": "Servier DART"
       }
      }
     },
     "localname": "ServierDARTMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ServierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Counterparty in collaboration agreement",
        "label": "Servier [Member]",
        "terseLabel": "Servier"
       }
      }
     },
     "localname": "ServierMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares authorized after increase.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase",
        "terseLabel": "Increased number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2013 [Member]",
        "label": "Stock Incentive Plan 2013 [Member]",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_StockIssuedDuringPeriodSharesStockPlanActivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Shares Stock Plan Activity",
        "terseLabel": "Stock plan related activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockPlanActivity",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_StockIssuedDuringPeriodValueStockPlanActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Value Stock Plan Activity",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockPlanActivity",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Units",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and RSUs"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TaxYear2025To2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2025 To 2037",
        "label": "Tax Year 2025 To 2037 [Member]",
        "terseLabel": "Tax Year 2025 To 2037"
       }
      }
     },
     "localname": "TaxYear2025To2037Member",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to total potential value under agreement.",
        "label": "Total potential value of agreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UndesignatedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated Preferred Stock [Member]",
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated Preferred Stock"
       }
      }
     },
     "localname": "UndesignatedPreferredStockMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UpfrontPaymentRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to upfront payment recognition period.",
        "label": "Upfront Payment Recognition Period",
        "terseLabel": "Expected period of development"
       }
      }
     },
     "localname": "UpfrontPaymentRecognitionPeriod",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_ZaiLabClinicalSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Clinical Supply Agreements",
        "label": "Zai Lab Clinical Supply Agreements [Member]",
        "terseLabel": "Zai Lab Clinical Supply Agreements"
       }
      }
     },
     "localname": "ZaiLabClinicalSupplyAgreementsMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Collaboration And License Agreement",
        "label": "Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "Zai Lab Collaboration And License Agreement"
       }
      }
     },
     "localname": "ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Limited",
        "label": "Zai Lab Limited [Member]",
        "terseLabel": "Zai Lab Limited (Zai Lab)"
       }
      }
     },
     "localname": "ZaiLabLimitedMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, Margetuximab",
        "label": "Zai Labs Collaboration And License Agreement, Margetuximab [Member]",
        "terseLabel": "Zai Lab Agreement, Margetuximab"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement",
        "label": "Zai Labs Collaboration And License Agreement [Member]",
        "terseLabel": "Zai Lab Agreement"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, TRIDENT molecule",
        "label": "Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]",
        "terseLabel": "Zai Lab Agreement, TRIDENT molecule"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs",
        "label": "Zai Labs [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "localname": "ZaiLabsMember",
     "nsuri": "http://macrogenics.com/20201231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r36",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r84",
      "r89",
      "r160",
      "r269",
      "r270",
      "r271",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r84",
      "r89",
      "r160",
      "r269",
      "r270",
      "r271",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r84",
      "r89",
      "r160",
      "r269",
      "r270",
      "r271",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r137",
      "r208",
      "r211",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r231",
      "r232",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r393",
      "r416",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r231",
      "r232",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r393",
      "r416",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r137",
      "r208",
      "r211",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r135",
      "r208",
      "r210",
      "r394",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r135",
      "r208",
      "r210",
      "r394",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r212",
      "r231",
      "r232",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r393",
      "r416",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r212",
      "r231",
      "r232",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r393",
      "r416",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r138",
      "r139"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r182"
     ],
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r43",
      "r81",
      "r82",
      "r83",
      "r324",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r234",
      "r236",
      "r275",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r236",
      "r265",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r144",
      "r161",
      "r163",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance recorded"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive stock options"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r124",
      "r127",
      "r133",
      "r159",
      "r322",
      "r325",
      "r339",
      "r396",
      "r407"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r35",
      "r77",
      "r159",
      "r322",
      "r325",
      "r339"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r151",
      "r169"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r148",
      "r152",
      "r169",
      "r399"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r237",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r23",
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r69",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r68",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r340"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r75",
      "r77",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r103",
      "r104",
      "r105",
      "r159",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration and Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 56,244,771 and 48,958,763 shares outstanding at December\u00a031, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r52",
      "r401",
      "r413"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r137",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r137",
      "r336",
      "r337",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r137",
      "r336",
      "r337",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r108",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r113",
      "r114",
      "r137",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Percentage of significant accounts receivable"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r111",
      "r113",
      "r114",
      "r115",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r137",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r206",
      "r207",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r206",
      "r207",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r206",
      "r207",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r213",
      "r227",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r307",
      "r314",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Provision for federal or state income taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r112",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r153",
      "r169",
      "r172",
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r11",
      "r12",
      "r297",
      "r397",
      "r406"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue included in long-term liabilities",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred income tax asset/(liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal U.S. net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "auth_ref": [
      "r303",
      "r305",
      "r306"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "terseLabel": "Orphan drug credit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r303",
      "r305",
      "r306"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenditures"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage of employee contribution to salary"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r122"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "U.S. Federal Government"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to non-vested stock-based compensation arrangements"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r86",
      "r91",
      "r93",
      "r102",
      "r160",
      "r195",
      "r202",
      "r269",
      "r270",
      "r271",
      "r310",
      "r311",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurement Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r328",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r227",
      "r329",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r213",
      "r215",
      "r220",
      "r227",
      "r329",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r213",
      "r215",
      "r220",
      "r227",
      "r329",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r227",
      "r329",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r227",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r72",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r162",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r174",
      "r175",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset": {
     "auth_ref": [
      "r179",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.",
        "label": "Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset",
        "terseLabel": "Impaired assets"
       }
      }
     },
     "localname": "ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r178",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share",
        "terseLabel": "Basic and diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r286",
      "r295",
      "r302",
      "r312",
      "r316",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r92",
      "r93",
      "r123",
      "r284",
      "r313",
      "r317",
      "r414"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense/(benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r72",
      "r282",
      "r283",
      "r295",
      "r296",
      "r301",
      "r308",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "United States federal tax at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Other permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes (net of federal benefit)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount",
        "negatedLabel": "Orphan drug credit, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credit, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest Income, Other"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r158",
      "r395",
      "r404",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r359",
      "r361"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r77",
      "r128",
      "r159",
      "r323",
      "r325",
      "r326",
      "r339"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r77",
      "r159",
      "r339",
      "r398",
      "r409"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r77",
      "r159",
      "r323",
      "r325",
      "r326",
      "r339"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r44",
      "r46",
      "r51",
      "r67",
      "r77",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r97",
      "r124",
      "r126",
      "r129",
      "r132",
      "r134",
      "r159",
      "r339",
      "r400",
      "r412"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash operating and investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r124",
      "r126",
      "r129",
      "r132",
      "r134"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r353",
      "r361"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r349",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, ROU Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r358",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/OrganizationandNatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r37",
      "r38",
      "r40"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Purchase of treasury stock"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r57",
      "r59",
      "r149"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r214",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r237",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Undesignated preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Undesignated preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Undesignated preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Undesignated preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r176",
      "r177"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r57",
      "r58",
      "r149"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r26",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Equipment and Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftware"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r25",
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r183",
      "r410"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net",
        "totalLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r24",
      "r72",
      "r183",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Equipment and Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r9",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r278",
      "r432"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r72",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs, Including Clinical Trial Accruals/Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r202",
      "r272",
      "r408",
      "r423",
      "r424"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r86",
      "r91",
      "r93",
      "r160",
      "r269",
      "r270",
      "r271",
      "r310",
      "r311",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r77",
      "r120",
      "r121",
      "r125",
      "r130",
      "r131",
      "r135",
      "r136",
      "r137",
      "r159",
      "r339",
      "r402"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r357",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets modified in exchange for operating lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r113",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales revenue, net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of the Company's Deferred Income Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Reported Estimated Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r236",
      "r264",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r236",
      "r264",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r26",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r237",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r243",
      "r254",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Options Award Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r32",
      "r75",
      "r103",
      "r104",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r294",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r111",
      "r113",
      "r114",
      "r115",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of Percentage of Customer Concentration"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted in period (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r245",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased by employees (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r235",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Options granted, maximum term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r260",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of fair market value to purchase shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r75",
      "r77",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r103",
      "r104",
      "r105",
      "r159",
      "r195",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r81",
      "r82",
      "r83",
      "r86",
      "r91",
      "r93",
      "r102",
      "r160",
      "r195",
      "r202",
      "r269",
      "r270",
      "r271",
      "r310",
      "r311",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r102",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "verboseLabel": "Number of shares issued or sold (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r202",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r77",
      "r146",
      "r159",
      "r339"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r202",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r355",
      "r361"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "US Federal tax credits carry forward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]",
        "terseLabel": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r33",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredParValueMethodAmount": {
     "auth_ref": [
      "r15",
      "r195",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.",
        "label": "Treasury Stock, Retired, Par Value Method, Amount",
        "negatedLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockRetiredParValueMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r15",
      "r195",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r213",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises",
        "verboseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r213",
      "r227",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities",
        "verboseLabel": "U.S Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r281",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decreases for prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases for current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases for prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r106",
      "r107",
      "r109",
      "r110",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r354",
      "r361"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Motor vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted weighted average number of common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r433": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r436": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r437": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r438": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r439": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r440": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r441": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001125345-21-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-21-000035-xbrl.zip
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MC+'A\*XY/?Z-)]SZUX%"&.!G"_28]2M=CY,_9-URF>?0/PUNP13R$'A,LZ<
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M7]K(:JL#F?H70=FIY8=MZH1!(-C+UJDZ8]_K2\^RG2_)^NE)B@6604!85HI
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MX_F:^WQ5F9G',_MH4SI.>G9V8MS +-8=IPGETGQOZB5\LWR]W9@>&='B$A)
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M#UCK"^\&8Q-!C&*PAC2O(<TO,*SO!=(\V%ICFM>8YH9-_!+ :UD$J,EJ4PT
M_AW,B<2Z3@0SA>IV3*TV57Q)-$TY&+HKL5\:3$LMEB0JO&V'N.&FZ L2(F=>
MX$W3J?5OL 6F&"OH5FISIZS^L<&DB2:BF<IY"E+LX(:VNL3P<G7B%,QEK&JD
MPPC]&KCF&.U]%\S\/X4=Y=B-82."=3U+N0U@T_N/^2P5\G6G8?(K&7CXSNL'
M8&>=A\&[CW;J)UAY#]935U*.#1X[G4TY[O8'G8 E?5]"3YFV4H3,VY%VV\IP
M0E0I8UV+J??.! ^U;7PTF0=;+"H4[%&G8KGM4>5M+,4"599T:+[I6$MM+2]%
M1&Z/F_4\;*4!=G=*GCIT$K8$A2$(23>XP5:ZT4L=AQVS9V0STKYA5W9TI#)<
M+U+LY.%DXCD"_R:F,S]\%)@(NA%<_O3)'B/Z)XP\W:1D(N*8:PEM]]Z#X<76
MPUTH<SC< [V'=;TVO&CD.8D5"*9'H:Z#8SOV*&]%\NB$:10KPDPOLMR4JB;@
M8AB>P"I@F5&)/6X +JRJ'KDJB\,9%F[1(A,3R'(^"_DY(K#'/K[9? 8<'RMI
M/"D7GC5NC\T&Y-_4VG*.ZZM"7O:;%I?Q@@:@F-"?IH%.L%&21*@*.98*0A;@
M@LGF.8*2CF/]+TKJ88!4RI/LD(5+"XX*K(%DQT>1@F]IJ3#!Q"M3UF4C@M>U
M'1Y180QSWX&4I9(0B,4N((X?>$B<JH?H_IJJEQ<O;<86A-ZVDEN;I0EV&0T;
MIJ\G;P7[@9*0L!U8:$PQ@I^H]* CK""T?.P"$@8B"E/RYP,)I6C+5>$VU'PD
M#+9>]-GE@NA-9]1@5O:3C?)-DM^&(\,RM!%OMN3,[)9@!$NUU&$'(!(!:@=X
M$\]-;1\1#U$"VRF^\V8]ZS\4?L<<?HK-BA55E^_98P8V,%+I$9$*<$*HFI0)
MN$R8\(?70?K#.'0\^0THP4!=2D"%6["G_E=^>8L-P0()];13V,@1/D/7M/04
M?P$?47B$P=<(AM ]=9$MT4>$@FMATMT+WI;/5F6RT:YHWD*]O/S7.\V7T&)T
M>KY[<ME^/&HA-BU[UN78S_^"?9C52H]EK%J9A@8,)\K9;9)WK]^<L'>I'+M3
MJ%W9G>Q[Q>VNRJ=K^?3;5ODAZM-.^RHCH(33[LZ.[J47AR8JV,#9KLSO.<P*
MN6+B!9P2RI)%,S1^A;N(V')]0+6Y37'UOM=M6A=>7[HW#YJ&<V>MTMB+K/*F
MQQX,X]9SJKZGGH]57]J5M\5)$DGZU9O:8U,-T(9F\EN*:\!._Y#Z7[@6^SH=
MQPF>V>UOXL.6.P(1=VWS^Y@>"_OX/PC&/:,RIC9KO,M6H=%@-<U'5]*V-)B6
MT$)2'M=HXS7:>(TVKD(;#RKF9XTV7@IMO-T?[.\NB3;>W:O^^AO0QCLU;[MF
M4%X]3E:9)3?"GG:"/[DR3_M:N/4XN"\[+K=#Z%,P[5Z07O,U(<&SNI4F!;P^
M$&$I 6]V=3L+N(1I>+V0R^^$P.Q?F!)(L-.1+T#U;;ASF<W6.5!RCF_6[ZC5
M$"\%EK(";4JG/"*_B88JJ(D]$9CW) 84@BFHWFQ8+'!R36E.'X$UA)Q ;,NU
MRCC*DNF8<0G15+CXC(@7RDHX@-P!87ZK0=XK^\$Z4XV'WU:H]Y7L4H(AP+[Q
MN%VT1\0'=V**+XH@J-"_9S:%B><GA+.;BNDXL@.$2'$3,_+S;&R;1=-#V\[Z
MXB7Y"\;VK41-,8# 2\0T9@355"96Z?#-HK^X_V66@(@9; =S-I2EE?W.3"@;
M:H$'@6P*L6RS,(:;)Q'<2[C%X>'Q+K.^K#)*$8,N9XR>:)#]-E ]5P+Q'2U!
M>NH?>>WVD-.8'D;O(6 /)=6-0 U21[Z80V0@ZRY""+QQJOC &#2*&!PK\1+8
M+_ !8O_".&;$*HK=7P@#] ADFNT-W*/$.H*HH1F#56%K1"ZAB?#:C2=X5E":
M[T,_97H5-6+8*L9#=*MX)% 1"0,BHX@QC9N6W+VN2)ARA%X1]E249BP?,"_J
M;K#C\)]7XA9K^;"-Y% BCCK"NU2K(<K!"U94+F3E,^>-LMSVW,YL.Z]9L3U;
MIB52J -;SEI/ 7X)W,8B^+\YD$'6/+A,6A^M0"#8!/?-A+:$BH87;B,%WVS!
MJ<; ##@?9&8UMC[)$0TS5B <W1GONV%ND.8U\@3MHGNM(G(X!>WO[D%%MK:X
MO5^R9_5SMS=FNZ<>'03+=$$O#<RLK,O+#M&ZMSQ3%QE0_0T1PI7)<I7RW6T_
M'$ ]\NP(O/E(\Y9Y$;@+L1;O%:M#JUKM+ >F*YG;H_Y1%Z86*R_ 0W%Y/T39
MUI#H5?228O-  Y^*N]5ITKE\[P/LA@S'&5S-39[!B7)M5852<-2HS;0V%I'
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M OWN!'UOFU="8,K@)$IOK=^\F*R+*PIN<Q0/8]"</Y(A;UR@S VOL4":V[3
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M&YCLS+B:4(V/[W./V;Z%'J[<9?A]K#W7K'='5NSN\H62,;PD6J6AB%GCER*
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M'50/R'D6T.@\2@YQ/3"1Z3_1"%K*P%*T==^Y02&/E\KD[]#*R:\U1;B))NC
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M/*L4M"D'B$*%8\8E:(7S'G"(@!VXS0070X<,K&NX)Y+4A*S!#',ER2$Z9K#
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M$GIP)EJ*COPIK ](@\A%(>)Q,1NEL HR:J@7P")6F+1,\)!P04-^?9(4HX;
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M'%@OM?G)IF8'3IJS ]>.WK+N![H7T40N;.*L3!VIGAIZVS@!')MTQ(#:$KZ
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M<FD$VRJHICF"&HDJYJ(#B6>E!>7)*+:4^U43L"1.&U%-U1?-P%/I2BI=@I>
M#YQ7; Z64"JK<<_[0WHMX!5+7_//8F)5@5FC%GW>Z0!E-8<M#V=]B$9?IV$+
M^[*JBZ1UC5"NA)5>K&Z@)+Y+X&-YCLX3[,3!OH @EM$P*7;(^42P#0@PCQ$W
M@U+,= (HSS'&E,5#R)]WS/ZL)L?33'"^N:=RHZFXMNA>X-!UILW$L38M>:.D
M8PD\4&?V?_I*V*!0TK>T&!I50CZRY0T>DG"B[.XD*4: NK14U <KKCUQXS7+
M9+Q]4:(>[4\+1X<_@*Z'J4TZ\.(1 )[*K<05=%$/BJ>;&T7^1HKM+0GX'R5
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M_;N:M^6/-_F<WYZ8VQ.SVXEYN-J)^0]0/)+_=Y_/HO_S_P%02P,$%     @
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M^BJO68_2<%-%OF% =+X,(ZG+TS/$<N6'#P(CDB0"X)EAQ'_@@<'$WOS58$&
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M$8S6*:L"7/[HQKXI:2Q/I9MB4*5A+:@L?;^_#2EY4S6$>HJ)%FM<=2\2/+6
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M_M'[H]JO09;6?O?88_?W^^^/]QL]]@<:,@\;%B9>V<'_?+?_76'M:%] .[6
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MB0H/1\,^-"!]L=F8H '([O!Q'#H>A2NRYH*.1GWY=AJ \5D[0%Z!G?M;07*
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MX(](*:NP;.SB,PA+$DFNMU*J<)P*C#4\I0#2[((R<F/N6A1<D*I5C+(! WH
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M[48=^1SV#PI)R\_T.!03XB41_TX&EH7PMIYI.2B/6\GT+E4@OMCVUK(@O/(
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M&WGJ&NK(&6@5-R?+Z01>,Z=LJ!#;(-R 9A3H^<5L_.'1\KVE)YU5!E??U0#
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MN*0?+"">@M[/$4_J<@7?45):/M9U=YK8>A8N74>UD9-3F_( 3@0VF-\TE9?
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MDCR]P/*$[Q^T?[YQ2*0E69<PR3;.-JS";L_(5P1N2CC=3_2"K,PDKEQNLQ!
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MADAIR.E @^/C/:[@A4]='$56[<CA@2SL!U:@ D=B%=@P!6788X:%,ABRZQE
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M;>R]:7/C2'8N_/W]%;@]85_)0;%%[=4]G@BVI.K63"VR2N6V[Q<'""1)=($
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M$FB[WCB*57&D;@\A^0?,#WQK.5!#B"+=94=-T>KH5A?LX@C,W'NZ*+J>')<
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MCG4Q6R4A@LAI'^L__$RSGRFX.[Y%A33#Y$ZB"F]]3U:5*7+3B"4'ZT(0JN"
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M.RB<?[M849&6^GVE"P"<"&:I*5N-2SQB;2C-QMP;]KQ?6#&=]VM=?T$UDE_
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MM$4EVSU$.GAX['&O2L@9T,\K'XW[WN\P"G3N"/6B M-67YC:C",Z3LSF<;K
M ZBDKCB$$"EG(W3@QBVE3QQ_%@ERFG+%-;D'+352H;A+"TZ,F\@4'1+P7K*[
M PZ*<^M6VP=P8*AC#^?<8?GAMS*7W87"JU5B-6-;L (S(0JY#%0HR>Y@)[,6
MRI!%?JZD4[>E\&/;Y>V24U 7YMW&Y$0EP:(ZA!79J9M*Z9EHSU>K)W 4\=4:
MS-5()<O.(:!#5<U;,X\[-DKLG(X2)=,33BUC.BID=2"'<J-$_QW'E59]JNF)
M2FBLEE%N^+T;0B#03*5ND\O?;')Y;7GB1Y)1K)8 /S[XX=&[L@L^ZQ)ZVDH0
M:7H <-&J>1J=;K5H(PEZ\U!6J0T2^J0B(>0<QDO1Q>6V=<D"?F4271S9S1Z
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MD?_'=Y(K2I"NEJ5\=8[YKO8MKF^J[MQF;2VX2D V+<!>!*#_$5YCZ["\VN<
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MS&"XRXZK-'Q=J3V,95"5MT]&@&>L79["X2>XIUEM*GF8]1\J53'#?M'-$<]
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ME%)9^)?!#M"M19+--6#JVA8SO)T6%D 6NAF?YAU9C]\[Z,9GSD/KA%XJLML
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MVM2.1'*_"O(\'4>Z9DL%&$1(JMC?)!V7%!/DO+5.WE4*056P5T[MO_5M57!
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MYJYUU[Q,C&A_Q1C1.LL1FL=4ZQ27UD_"G^"]QQR_Y,J:K5@E!4-76=(R/4&
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M9EJOQ$T85V?6:[T8P9A*BCE6EGIGM*M0[D!T&8AF#-)2D7_(MBNF4 *R-]D
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M 34DV1J'XEN0%.39-$-2^2L^GWQBO V,'(,3_'XZUP&'^SZ@W#.8C-<A-9.
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MD2KZWKB+, J']1)Y"*?CFD?T0'Z?K(FH^H&6M"@*L%J/-L 8GIW".<PQ\/_
M?27!#UL0!A&'$S/.ZH: J<S2.9C412A5#4D8NT+'Y'?@TG$X(15*.Z1!N#;L
M:\H:H2"AK^&D7&=4-SB^"3&% E_FE-,IFL-$^*1SD"0QKS>_"I521'_N6H4M
M\!)WP5@-N4& PI*#F,*U3^OF7UU K!@)W']:E+0A1/IV?47L[3%2J_X.MV,]
MIW2F]\1S&$Y2O/XDP^EU^NZ?'A 5"Q@DQ PV8@'_$R.* Z5X'DMR*]37:#4O
M1B': S+9(UX(F&RPBT%.@XQN=(0:[(HNN"E]>AN]=<[5:YS!:W3!3]GSG'Y&
MQU&LFK9BSRAYB+Y)A E_+J<FDVS9ZWIDS8:5##;9L 46JSUT[E[PL'WI_&%;
M->(@7J7C4>H2\OI2NY]P1*%Y0::K+,AS)JG;EJKK*[6".TDKY4X]VORK'P5*
MA:)A$WCSM)"*L@=_Y#QQFR#:YE9^D9?8)HB>.T%TL$T060FB=]L$T0LEB#;5
M!EA6(F_I8([#JCI1<8K J\'B1W%K6)MC-(3BF%8. +RF"%8+7OV:*EGA3@]:
M  U^4RTLH+(6RTSY%S/%/W9]9=NKT2]3J=:EN(ZV]5PS[Z$5\MM^.%ITPU/J
M?EBBO4KTE(**G#:QW%>8VEK*H)KYD>KME>SG9W!^&E @/J^1S.A=:ZQ,;[V^
M"EN?AW=12'W;/>SMKL07UAGRH"0J"EM.]D0Y[((<I"FG*5R'N>J?[<'9XN-]
M1^[7%#ROA\^R?<\5-\_6B_H)'9"?XB6V7M1S>U%M;_CS>%'_;Y1.%O"?FV(6
M_]?_!U!+ P04    " #'@%E2P!!+_BIJ P QTAP $0   &UG;G@M,C R,#$R
M,S$N:'1M['UI=Q-)MN#W]RLT?C/SJLY!)O:%JF:.P89V-9(IVT#;7SBQVFDD
MI3I3\L*OGQN9DC<,&+ MI:SJ!B1E9&1DW/W&7?[\?Z?]7NLX%&66#_ZQ@E?1
M2NO_/?_S?[7;_WZQ_::UGKMQ/PQ&K9=%,*/@6R?9Z+#UP8?R4RL6>;_U(2\^
M9<>FW:[N>9D/SXKLX'#4(HC@:Q>+9XC(@+%T;<D=:C,92=LZ0=LR!$DDEQII
M]N3@&>=>&6M$FSBJVPPCUM:(DC8F(I@8!:7,/?'/G*4^PD?A/&?<,FT9,MHC
M[;0.R*#TV,,1O!V\X:#\Q\KA:#1\]O3IR<G)Z@E=S8N#IUAK_?0TC5FI!SWK
M98-/5T:>VJ)7C24(T:?ILC5EF Y/5[-OC,\&Y<@,W,7X,KMI'3 6/_UWY\V.
M.PQ]T[Y^EP\7=U7SE\&M'N3'3^$"W$M0&^$VQ=/A69DS@N6WEE6/.+_A='3S
MX&P +QP2(CP=%690QKSHFQ$@"DR#>1N1-A'32<9E^\"8X?E$T92VFF1RX8:%
MGGZQVU?@DJY.AY;%Z,N9X<>;7O_T:V^.Z:4WNO3R;=C/*_=,]_=[[Z\N/;9_
M,+AX<-^X(C\(@\R5JR[O5ZO$Y-*;PZ+\-:!.H".>UA>KH<]Z9G#PCY4P:+_;
M60%L#L8__[,?1J:5[FR'_XRSXW^LO,P'(Z#1]N[9$'#&U=_^L3(*IZ.G%7(_
M??Y?__5??XZR42\\3^ML3]?SY]/ZQS^?UE/;W)\]_]-GQZUR=-8+_UCQ63GL
MF;-G@WP08 '9Z;,T,!3UQ\S[,*@^PO4N,(HB<_7S3T?;(?YC);/!"^FC%H9I
M9K"V0,A!&,6H(4PC]W$]+05A@.#%'M7;#'>?CI[9/.\%,XBFEZAN8/II42%[
MM@9<R2?.]*IG#E9:F8?AGKX_L^OY\1NR?;Q'.V-_M'&\_UH?;?6[68=L]SN?
MMX^Z_>ZG[N[?>._H;PY_3O9V>Y\ZZ[VCK=U>K_-ZX^0-[?;V/@^/]HZZG_:/
M.FCO\_[1_OH[U/VPB;;@#XSA^^MK?._S)[Z_^^*P\TJA-V3_;.^#$UNOMX\Z
MG]^1_?Y?A_OK_E-W_>!DZ_4FW]O=I/N[:Z?[NVFV5Y\Z_<UC__I59E^_$_M'
MCG;77QQUCSJT2_[J==?]T=[G@]/]UYMG^[OP6W_CM/-Z/]O?W9C<\QZ>Q0?[
MN\-^][.#]71(Y[.C>WU8(^D>;:V_^K1W]%</?B-[NQLGL)9>Y[TZ?;.[,>KL
M(/AW[6.07!!O=9L$3-LL:MU65JBV$<"?E4+8!+3R_-7:FYV-/Y]> >[=P_H"
MHE-1\RHKG>GM!5.\@E_*)6R_!]NSR[!5V&N)/&JK8$!V,A?;F@H0H)2*0+1B
M6OJ5YVG_9P;:MS!_[I? O15P/U\A7(&LC8*TJ4% N$0A4(R8;#N&HO%&:6,$
M$.[> X)V8P 2Y.PE +<PO<V!#Z?_"F=+L'X/K.@R6*F(QC JVRA& "OPYK:Q
M++9=\#XRXE&@;.4Y B!@PBGC/P)>IYVPW@BJ>61"6&V"E<$@1RER5N*/F]>A
M.M'7GKT)91G"UC 4H/(,#MX$T'NWPR"<F-YN*/JSA?%I]VCM>'\ </V<\ZW=
M[5YG??^HN[M'M]8_H>[1'MG[ ,_I;[*M]3VXY]WGSM'?>#_3:/_?A\CUWP_,
M!SW>.OK$NZ_?G73['=P]<FQK]V^ V#[@RHML[^B =8]ZO>YNYZR[_K[_[\]_
MGW;7/CIIO1#&M'F4OLTX!PN&!=UV2"@17+JF5YZ_Y5^2X-.K"E,18B@"*/GE
M#7I>TGR?E94Q %!L59KPLQ%H=_]8*;/^L)<L@^JWPR(!^8I*MWI: H/_\^G5
M.>KG7SQTLH8R'Q?5M\J0>3;!G!JR/\,8IA.%BBM,OV4^?8]9*%K5@L*-RO;+
MS7]=1?+K-S^?_G1U]F$E3J;?P'(J1NM@JCZ?6@8(3^^[N':^3'\Q% -;Q1>/
MJ*],OT\?\O3*1DWG&0^R>M/&U=[7/_:!8,9%>#XQMIZ]VUF?WCZ]-/V>[K\9
M!HY*'$!!BT"]AC/0T)AS0GLI#5+*UM2+!$5SL/6UV3J:;+QH4W0^T>3*#^YF
M>6@ 1;_8T DPJXL_O*,A,,:E-89RQB2@-D4L" D<F& JD*YV%"-"R'SM**ZL
M;?)S.WIE!Z)R2@KL0W (=']N@K.*:TE  E$4U26),%<[<(U"?V$'=!1.,QV4
M]9A14*D"U\Q[RXU0!O2KM -8S]T.8/TK.W"91X$&OI/(Y_SUP.*'95T>6LDM
M,\J+GV1G7]R??EP/@[R?#6Z:]K9$?66*IU=7_SW:IUXA%1"QG&$6O5#48I#@
M6B?X8!QF(-$FKQT.DGE4?_7PL--A+W/9J!/Z%A[A,[A:^V?+8O3L;9'[L1MM
M%3NA.,Y<6#O-@$DF)>#9=C@.@W%X5>3]EWFO9VR>E+?CL'90A) >4=93_OGT
MQB>=;^'Y@N95XEZ!JQ< 32." =[.K*:62^PB%\)3HT%]3G#%>@+7AR'L!8,K
ML)[;PO4ZE_H%N!H3(G("1TL84]B!'>,\%R"QI$:$5O2*U12N:@G7'X>KNCU<
MU9W!-7A@N]I%1<&R"!$;#_H68LH3:8-R=*'X\.O\.!2#-.UB,V'"HO,!R4"
M6'7$2BMEM+5@*FJ'J%TH)OSP0)T-!Z:2$4.]\]AY%H '@!6* N<!C"<;E5HH
M#CP#H,Z$_7+E)!%@^0EC&&'&(,D#X8*"'<PQF06E-H(8HE->1FU(Y$ ,UJL@
MJ9:>"!<#E\+-@!@:@6\T:!^$)8!EF"D5+8U6$!5$1$A[0RIS6\XC[YBZPG=&
M\.KIGHW_C--I1]X?YH/$'FI&,AT&O_?SP<XH=Y_NGF]<\@/(._.$D, 0-M@:
M'2@+8#LAS8'TB692,>7$PH!FMZA\"6=- @X%^U4H3:*WDD6)C/<4"0]0,J [
MQ\6AFS7OLQ158WIO3>8W!R_-,!N97D/ !+PM4,&=UZ M18^2SSX23CS1T4M.
M%P9,VV%DLD'P&Z889(.#>]"-[@4^V(&9XS4*@G,F.5(^8A2B(IH[[=CB\+@U
MY\;]<2^%:6Z-#D.1QA7A,,UV'#8'+N^'AH#,"$$\Y31ZY1EWR(H0I3"2>AV,
M%0](4K/: <Z<,M8J'!UGB'$CB8I2*AUXL%RC^47:9&^]K/$0T&XCQN!&=<3/
M5ESS^3 Q^AIO;S72'XW+47KT=U!WR>SJHRT"E&*\19(R9CQ25#%A0>7V2#,4
MYYC9S0AOY@5PG#ALM1.4R,@B&.5>@>"B'%. *$.^ 9Z6>=7Z9F\!:XH,=L(I
M*R*C4FB+/ \Q<!>#5X$O'G#OU12>/4!Y--PJ+6S CE'$3>24*"8]B4F]Q(L'
MT'LVH&</4H^0$LIZ)U$Z1>9:"X1)%-YQCVAL@JN["?;"[ &-*(!4Q:@U,<Q$
MT(U,T)@$F9SBGL?% _3]Z[*SARHESF*CP4*4"NA7*($M _7)"6Z0,%6DY$(
M\Z&<S.KN_)A,4>E"I 2$)3-"*>0!0"1XS56H PX7 C0/YV2^.^ $;8!,I+;,
M<\:PU\9';ZA2Q%LB$5D8X,S"R7QW8,+2*44Q1XI;("&KA$N*"D@I9RVUBT-#
M#^IWN3OXD!A]Y ;@ TI%1-0([ST16D9D0,$P"P.?63N9[PYDTC"N./PG! *0
M(4.-Q0Y@R#E!RCP@2<UJ!Q010DE$53"*$:<5X"N52EC!N-&A"7&S\RH$9A^M
M@A"5 4#J!)+,IY,36R4&@UH<%*$+"-R'\SG-)A9/&(^]8V":*B8#MJ .!,,E
MT58IL& 7#Z"S=U#,!-  0RZH >ZL$!-:*4$(XDCB0!!\6T#*?6 'Q6SXL<$&
M.<$0L9I1"P:7)=: BLB0#2"%'R[IK,EL^*ZRX:Z 1@3AP:HRA%L0E:#&6Z>1
MMR@"K$"??\!\P'L&S<,Y*.X.. 'IZ+Q(.2.!10?$@HWS3DK'.$)1+PQP9N&@
MN#LPX1"Q",P)Z@6H*%$+G9RO40;CM)L$^2X"F![407%W\(F1*NNDD,3AZG2+
M*DI(9-H+KD P+0Q\9NV@N#N0<9!",C"PSW%DDG+C$&7:,>I8BA#!#4B3FU<6
M./MTN1A2,'>P0@C%F$- C8*"%6==4-;R)N2BSY->.'N 8F$$IXI3&UT=<J>)
MQ!8[AEDP9 &I]0%#0F945P 1(:WV("PCHR3H5#K%PK^>.0RF^.*!=.8>E]D
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MV#4*7Q9>&G!E5+2.@KDHF#1<$[ 854A]!)%(*7V/ EI-X<4R4&6%"8@";0'
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M!N@1\^_^OI]*PE(SL%$IH\8QPKVUAD4@+X12?T/6@$*)30+<758U<R$=A-,
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ME_?RXME_H^J_/R*\?3N:?M8[>_8_NT!39:L;3EK;>=\,_N=):09ENX3]BO7
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MQ &K-"* 84B0XE\$6,R#K/U1K]\$ZDFC'!9 F=D0.'\X#6X\ K8//X/^ 0L
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M=T8FQE9R(R8?PR-!5++$T_G'4PX*9Y$/TS:'QX*8=(F8\X^8:N7YFW!@>BU
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M>%/1NFN/WJZB!)CWS=%Q!8=T+3VT;J./!H\?QH4+ G5WXY):#,Y<%P&>T><
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M!&@Z.6#US+CH7D,1A:K'G&V0F5H(88?:,7GM&RKZGJTJ2Z-8?EOV]WV 5AR
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M']]V%3FR.NYV&2(39OF*^+!BW,=9:H]J.WW_:M0_YC((,,:Q.$[>]\.2" ^
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MCOL%S4Y;C\N1\PXPJE)KQ]BASD)8,^ L8/@[AAW1Y(R&.C31IEBUM3I8Y"&
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M"=((F,U(AZ032FD$ZY0IUX?'.E>#1'!E2U#C(2#<JU0X^KDI'LJ^XBB^YM?
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M=)K[LG"VVT6Q;HU^07*306C1;TOP=3%P-8CF[Z\/[FE()&)JXV>S5 _-5?]
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MLE,_/2=P3&9I#>^P$&Z(T$Z,H/MV&ADYBM6?57I^77RJW>Z"PRP,"]@4#B$
M187*&,X'U4I]=4NC)3?':>WZF-O A"23R[(4EF$. ZBIF[;,O2K\6QAQ4#BC
MMOD(HFX@+P+#1-23 T% 9.9)\"$<"& DCEA&Q[S@^$5H4?8\("2(T^4S! RT
M[MZJ/=HW4RL_\EISS&HLBMH5&"?BH5[C2MPO.!)<89_5FNP'RP!# E@?(S1C
MIZ^IS50\B0]P_M1#<<,$1^-'.@?<&U4>ES"?T;Q%*UATO?)%O&(+B12X(%$C
M>LI"__SISW4TM9X4=KOML!RL=9FY@Z>[:6D%-#B(V#9JJ'S](Y;,D<M&YV-]
MB6YAR!BX;Z\N!=,!C**BPVL%82" MDA7C +-%"B![8N0U;ESXK5,0\MK0 FO
MS&:L2]_AN<FPYP,+=>/L:DW\O"HW*U70HA.O+TL#7,5X'#9VI"B*;GK&G/;!
MGG=;$CW!A8H9PP53#G2;":%,QL0=,Z#I:R"R&"2N 7]F>Y^!XV+JD'W!_ [%
M5#"\B;0:XM@](\NKKMDU9N*'SYR9%9_CCO&*K9QJ+8H"&SD(AT$*_:%'W,CP
MCGQC)W= %M ^KI#'*'D^N9-'-\_T,R;:N65[5IQT2::P-@2R/Z'/"-VGZ3XZ
M4*X1N @&/L\@LU>7$J/,UPH(8HK^:LGK%AFV/3.!HZV47?X!5 B!"@]_ !6^
M<NFTY9^$$@/I+1 V(X_AP%% \VEVA:G6,*_K.KA)ZQ$P3/!M//:?B*KUHI4+
MYP.9Z%-[G+BI. !0FB3Q1F:$BM=Z:PS\9[M(^+G56#=KZN 8A/<*4?MR(HT)
MI="&G-D^LX.11\I!;LU%ZIM@C###JJ>DTMZT6GT7);L;Z5.A>BVY@=E;)AM4
MW4(F!NX2A#JM0U<0Q5)7B/ M%J8P12=RYOOS.8!N@WWQQ;G&;E3?MPF+2;)"
M]R,(?KE&DLUD!:@@T;!-F5I)*Y*IHOYY5SN^0<0R9X_'$_+:OT5]W8##*THB
MZ8E#3J,KQB&^ IX9M7YL.(M!J#_(MP<H5S6:) &!)<D7+B#(XD54D$3&@M']
M7(?YMY"'7HH<N/5<;8DPH:B6=;/7Z<()M%[7)L N&9.E1?,6Z;46[T2A: 9:
ML]6*7),3,HMMB*!)(U!4&-0A(8%76 J&?67GIMF'6J7 /82M:D?^'%G$1D([
M=3[W[;R[G\3 X?"B'OF!)EDX\PU#Q_(L'('#EG',THQ;B[DI'CG(TRE'@Z'$
MV0>3V(9K/*HWY^>:16/-21)[M *^.>:SEF-B--Z+K9>K"%]Q7W*_VU<6:(*\
MGF3-\X,CTQY4S\5)^/;5X?%Q#_1A38UD@6*XG :![W=G?WMNCY![X,K.9MR2
M"C^+3G^X@(YS4<QR[LN8!8GHGN/T4*)%9CBE&Z:2R,N#=-WU0$M?:S[-2M!3
M<HZOR'>&WSXF>W:6K_OLO]//D:(=Z"8Y]%I6L3+'XLY+.).X"];_W7G8V3J,
M^#T^,(7)=KRMREY1%GV.1.;K[;Y<:@W-#0]@5:\O:VEDNC 98I&[_*-]+KTE
MY!F&/^*%HGD/#^U;/'F.Z<@?>D9>R%CJGC7N?'#0GZ;;1JR29&A+C.1U*WQL
MW#L= 5^[7[[QFR^KU_X/LHE+M#VT.*;D3;8!.4503"BQ6_5AK12JG[RSE3C7
M0_L4EK05+;^7>I(>:,"S12:%U2.'=>,@-YRX]U4Z^6#%%>'<E.'0])P[^[7K
M#>WL)N;/!@6>CSM&YI5J#6O=VS3K.."LSPRI1U0C%PS?V%2I7'(D9GS]?-,<
M<ZO79 %=9IF&QX(>PE4\3E^D[)A()5S-*=IIAK+QU(($P;/MJX'$")=.[UI[
MXLW'UC? W6^]4A'O8Y95X>610U24*!'N8%[7J*5&%YD^B8$J0;8>0D1"%Z6O
M>6:]7UA'.^'GA)V&!+I3V2F=*13":SZ!;W#M^NB)O812IL!B8C+YM7:Q,5T0
M )3$DF)J$B1]](\<9#/Y'G2A8!.+2Y!,;H1B)7#M3'Q[[\X6U:*VY:9P+DWC
M]9*R[UH*1.=(8?J6&7-.^(7D!U/7,9F',[EL//TN1D"?:IJ)%]/I8"^=63*$
MEITPVX98$(];\R0)TK=#ML!2!W2IL\4L4839QKI+!.GK%Z?OR"<)3-=/CH-+
MAJ33PM:*=8/63:CH=>VX+9 6F.C3@7]XV/@[-!,4/M,<J^G]%\B11YVT2-=(
MHKQ.]B8O7K^K]\746.>UU*%OU2N2Z#[N36UO%'?<L-6-S)SSG5CJN[50J5R'
M]?/XIGL*CMH=/)HC!YK":EE\MHY7X;+9]HK_:N'RH <'V\LU2 LT-Y(&Y=""
ML]9\E3?3^.1F^NF R7FZ/JD#J<$49XI< (B!FQX$56^!S2WM O!MZSP>A(9<
MBK^*HD3HY"26E825K*. FIB01]+HO2E!F?F:#45TOHI&ID.>&JMY]R3#(F6A
MM8T<_9^#$^Z(Q^%^ARZJ[ESC5O.V=&R'%^PP$4U43V6>YC+$%G3X0F<R@V6.
M@]#>-(8;9R[<M!D8L]Z%X;J;37L7KU'[G!M'?!9V06B'7UA@V@D+*M,M62&'
MTZ4NW(5L)@;Q/.Y&"R+)3:C?C8,OJR=5/FX 2=53Y2Z:G!1K*'YG45M9!7.5
M-N5T4*[F$4MJ*5CS#V&NH*>2B;J48(:FH7+VAPVW9PZ/6ZF[>!Q:P6J6I<[7
M64<6JL3'PYA17,831LU(I5]E=*%3M9 L^Q.$M3N,TU0[;.Y(*H<0-:?0Z+RL
M*^EGH$8QO!]K@]8@;G%H=6.Q91@V^?#K@%0G4/B*]^R,YW,*7)"V[15S!![!
MLH5044G_-PQDDFGJCWF^_;WS9Z\O]GD)Y5/QJX(C&<%.#&O" 7T1FGB K*H&
M/X1/AU\#\!^WR#)Z I8!F\(^1R<I9J]"$8" -?0O"!4LK,&M,^(XAK(!'->@
MT[8]*,(/.S$H_4.OR:%EY45*=8)5 B)SZ5L;E+>5H/<+H__2!8.+#M[A'KUV
M(O?<BZGSP,O^MND!EK\N*!>0;#E9;(&#(,3L>H=%@B(&DC1AIV%H?5<)?02E
M"@L&FR6*B)_ [(Z*7$*ZMEZRR"V;P27*$O#22D['(B4T0H VZ5<[0^)M0)CC
M&.GL-@"X9NC9<OA<<&36W34.J1DS2E@U<3LOP\W<J R4$F:&VF)+KFI+E+ZF
M1F ,2%,ZMD!VL"NH'+?CX8^4L-/VUV4?QO!FR3E7]\/X=PQD1,&!4*9[,5@'
M/IIG?JE#N.],$56Y]JA$T/8'KB'$-3SZ@6OXRJ4+#VA\+DG:KJ\ES:'%H,X/
M-LX\^3[P5OY2V+?[&D9K\V*"PLT"PV$K.7/"?. /K0S8<TPU39!DL-HUJ[1(
MKUO5Z;APEV3@N\HY7S..6[1![A\&N?9P<=V@(C<AD ,N1\N%VQRRQ'W<2/$
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MFI\"P& &.8:;??1&SG5XM]T^>73Z=?CW-'3./<NV5;H0S40 G(AC=R<0GK
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M&Z_N#Z6#_373 %#='P P4 6KL,]@6AHS5JRB*O J5O72E&UY%_Y=& *W62K
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MJ[V2<V]UU=,L1BU0N?=H'48/<G'/"_ X?+YCXLL,).QI8@3_"0J/9<&+1:2
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MF;%\K$AV1T)YI6P[8<;S7I$S/=&3_&>U[CX0L_[=(<I?'OB>\)N'\;*%22W
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M7/-/0Y(9RTG=EV!@L->W3F#Z!3*[G>$^TV Q"A9T(E@PJ&"!:17@B_0*(E-
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M716'=V*#\6-P,M86!HE6A<N$,:!OF0\YA $KW] ,4*#$X8R$LD62T* = 1
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MWB(/;U5=>@5R$"P@F?U'V>XH5'E<0/:>MV5XP@MFNAG"GF=9O@WM/3GH%2G
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M6$(2E1JNWOA\>9*3 Y52A#+X&H=DG=0$HHN-+>!MU11TYO)B\<C>*9T1^O,
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M-"#F@N]/>D>0,T(XD5__)^_?AHXOEN'NR&AW 96RSQDE9*71<A*8\HX7K(7
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MA6J_L7!Y$^&:P<*(%1L]C&^]WA#=:?63/V(%2BY%Z32H&$DKTD)4N6=37\0
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MU4-(NOECBC8T)R:.3X[1DH*L+ ACU^&1T,MBAL2>IU)6W@?T:[7&!@3"NR"
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M/SMUO'2;RBWM%;-1!&68#/@BR(KVZKCPO6 :E%"V<_6QW$=BV@RT;CE&CZ&
MB[#M(J;GFC)I\K0%=_\K=W3,>V^*KY@VP0: T.*3]C*<"5%/R EG.\4X4+/O
MQ"S?FZY99*ZKR^&WC-JC5C7Q2^+PI&;>TT1 -Y J<<7\8,;(9>/L3D1D1S-]
M+V1!F5UKZL[2KH7-)+*'F> A&F>6!ND+ '42L;%-#3WQ44..-=2PC;!+'S0
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M]#FX!#CD.E];7,5X;_UP4_39/?<GL^! RI!=XWL_MBX4,LI#3MS/)^Y1X&W
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M4^B% A53T*ZA[R+XIL04,^J/X:,>>W_!SV;RX-7Q\3L&D-(-+1%<<Q.9-P[
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M])J]&Y* BF;Q9'75P980]K9&SA&C&HP<G?(UL/\L#D+9.^_(HY-,PY*:($%
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MZI&CBOSU7+O3*)Q0ZXP]',,FTI+.R/K+=.D@PF0@ X]##[Q<!XOJ:DLK68
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M#XX>$L;+^D[=4MS:7XV\%>VO!;/Z.+*]X:;0\@ZY"\JN.?'A0(8Z5?0:7\=
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MFQ-N-%WI/-2;1KHO:51W&IE+:W!)HK7'LJ0/OK,^^$D_";IQ'DQ_95ZX;NW
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M(87MB+-AREE'.9DZ.-\,@DR<MFQ-7 0,0A#[;C>Y02Q(V0 C1A@"(WDP(\[
M#@?00'5R6:$!F:3!S#!*]G <!8?!(,@2QB;LDHB&C-&!QU9YJ&Z0L;?%#^_
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M#%B=YMD"^-GG-+F&7<;'QYEQERECXU/GPPRS@SZ/TO"*W/NP9.*X?\VR(?]
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M>GZO?'@EBKCPDE(]P,9A)H;!ZA'Y]7I^XW:B?5J6W_6OM+^=+,:!E6?Z6#V
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M^ S/(V)42'C=F&48I8VS*WX5F0=\@0'@/_YO"JH7@]"+\X1@U-;"N!>7IZ2
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M02UEQ5;G>KD@<44_=\ OR? ]N2+;_]*/QQ'>[(VR__GHL//^3:/*(CG,(-6
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M0+6%!#88IAWCUB,F4H::N,3&!AH!-PQ,4_A[ZA5H-Z#1FMNRI&J7+K 2$)R
M=6-VG3-Y179@MW'_8$\K'!V,U5?%OZ@Y9,Q6Q$<(BB%LQR&7WU,"!D]:<Y-B
MKC;FYA]?C4"CGE@->+V]$3C<PB-GX$N@2B7%QP2$BRNY-!%0!IHB16G/G0DQ
M5LY,,_%* "/))M^4I-,*<>+C7 F*T<.QK2FT$!F^5?;U-[F++%!*2%&&XU;E
ME;\<$7,,6?G(LZ$5AM\WWH"L7B?=ZUQ-<+4<<\\'U")XX?U+#B79*/@N/')\
M*08/NNQ6^3ZBE[G<\#T?+ZHJ<S,)01.8+WC[ !?X3U1+H/[1:JZ(46'5/.:H
M!R3\<9G"EE U9['(PO^]>S;#.4U[ =F9$=/&@)MJ\J>G3VO X!(G(+7S_\$S
M(S]8'T&5@-I*NDRHIQMA#@*Y&HC#%3+GF#N;QER^&CEL<L\-;+<!05?K'H5G
M#H"@VJ_JC4F&1^Z^N8I!#\;#0CQ6@KPU.-#87+A^-KO@F9<^_V2EIF<DM=!1
M<[0M_(IS_ 4'ZL,P!->_NT0<_(5*7OE^T]+MIU2\TKVFK\W_^*D5K]S%A]VB
M@KU\Q+?Q$%X5/GKPNW=PS#* R$%5KPK[[*5J.<Z&H,V:=8=9 ?XBDH?9%XI1
MV#@+>&+52 .['; ^.'OH8#&2@A+AW@_8_=UDP#T\_@W01MRT(MS#0FN0-@JE
M(WP<>'$VS(3^X?HP4<)"MH=<M@G:33S@(,RD<70<99YE^0#H0LQ], _3C, 5
MK#A&.2? =E['(5]*R.+KW)<JCE3&"RWF+\Q$'OR]8\-Q@.8Z@3'&$<_Q3,;;
MDTS$.O>/SCK9&XP:7^-\+@F>5G)='S$>0^&!&CZOPF_"SWG8DWO#U["W>,!9
M6@?5O1\O:>(HJ%$]_+DW>GG84]GD,A(VO;4<;\>G<O-/*N**;RVB)^FHNJWE
MD@IGH1L3'JZ+!8E^,:VF(08%H>C.L6LGSP?+8Y'I=11DY7.;6E0YIY1-3'HN
MCPO6P]^.G\49Z[ZYR)0GHB&/GB].)'0_>"[35)3Y^7<O6\\P1[A:%(,5H(<&
M<6%G3S-#SL4SP4.0=NS<%2X;#[.4SARWM^'API,KHE0<5^Y'8Y 3QI[L1$@&
MV8PRT$@B^"2.X-+DD@>J$1/Y^PL%-I;O$HL"!IY''@@K<>B>E)?AWBQ+ .'%
MJ7<V=KV!76?AV?UQ8!,R6 E./5\O,K4892%](J2,GQ--EKW>73/D]^0& V2'
ME.8'4J4A@O3'*"#GU^=9);6305BR"&471W#(0!@3YZ&1//Z8[P9E*#8Y?H/4
MY+_.T1$$@T61D+T^2@;(0G[@"?PDMK60'@S5#L5!GXA%%] _>68R!@,>#,YA
MMA!7=+ISA34+'IK*!_SR+4'9;*"?GT]Y/"=^"EM*>44-7<>PN46,9Z8>4N W
M87'ZTK@'*7@6T!OD&H.?!N0G$<,1WY>Y2FL,'J5%5H!"CC)B;_E95 A?(>'X
MO W$F8AX,V)2/C]Q0#>VJYXDS2_51JV.ACCFL.&IP@S2%QJI40;.9YU2-/#,
M 9B3&T[P9<%.>8R(<R,2C(#VR+&V/*FZ!^1<N:1I$B0\LO2#W57@6I@BP,Q@
M2Z.]APHJ*Z6S<BXAV*0P7<9,E/.-2+7E65TE"\7CX!2W)?&YD3APR,]0\2BD
MA(<98G3/EA^K3%Q^92LFMSD3NO<'GP[/%82YH%:.RY&FX:%BG\%/6=+OLVY^
MQ(%Y&XS-(&=NW7+LPW?%/%5&F 'BO=T[$2P/@7?QK&^&ON:B/9MVXR2S?!L$
M'(Z5^16APBRHN"YI,KJ\FFLW7I3[?1\/\HTI6?2F(!$_,F.T:A/D!D16G@7,
M-D5X4A*XI<$(]C _ TAF?[]1? )RS'%LQ+W(_#TWC!^;"P^N@9'. ;G+F9_Q
MF#[%L6(THI]FK_!AI@V619._%TPM?21TNL8HEJNY3XEB62\3Q5IBV-6:CQMM
M<HB=IV;6I'YJM\,YS<VW[1+6)FA19"LC+*$=FU6UQ+^RL2<(]B> EJ%ISI-[
M4DHJ/9E*[TD75&&2@C5^2M*[+JB89U)A%W#DX39;R^[)XGUTWBUQ^"0/"!5C
M-5>OK&V]>K7N,\33PZ.SSL>3=NOHO*&TVD?S#[_K,N.))D#O#S\=MH].E//?
M3TX>:/]3E[GOM]#=2T8P!L5<NEN\&*!D5SQ35B3QY?]"#_'-%MO K@5/.JOO
M7:0U'?-IIO7#G]GF"S1:PLDN-J'G1HC\IS>I6Y-6OB<0^:%T68SGA4)F3VJ1
M6<.MPNC$ C;+X\M]57NF^TNU4[V7!1B&C$71LMU4-[KHPRQCE=NP#U!YWFI7
MPT./[>5SQEARADN3/>+_5U.RSW9PCO+4 <+)__9)])]:]I,H]-)CK$B$%?ZW
M67>B8FAX'"/&4_-KTIVX[#YI62RT>DW9!G[^Y5E+K"XMQ5%KM;;?XMNW_:3_
M 8^4\"!DU(^'9UA]9931/7[8!+/GOX@C+_1<1Z>,A9H5^39A8>#9OFM8IFMJ
MD?=/"PT#W3#U/86R,.Z1;O;O/14$0IRSP!"WP[?]48\FP_SS/:5/>@Q?IEX2
M,GB+3';8I_C72<EAA\,CDJ9X7/47Z8X8"!AL'N.BQKUP:OYU%QPGUY^,L^NO
MYNF(?C^Y_O;1_][IM>-3XZQW^O/L>[O7_M&^^%/_^OU/&_Z[^7K1_7%ZW/W>
MN>AV3S^>W'PRV]VO/P??OWYO__CV_53[^O/;]V_'7[3VWRVM __!=^QOQX?V
MUY\_[&\7[Z]./WBWI]__O/[6_^/JV\_D]NO//W^V?_YYTS;^^OZM=ZJ=_OVM
MV_GX)SP/GQ^?:NV/I_KI!3Q[Y&M?__XC^W:1Z.U>2VM_;^G?_OYRA^_Y]KWU
MLW/\H=N^^''[[>.7VV\7IW??>G_%G?/\F?_^<17T:+?S_8L!:S!.O__5_7;1
M@C7!&K^?6J=_?]$[%Q]^?+OXT#W]^4?OV]\M^[\__QR>GFNWGRY.AJ>'_SA^
M2/4@LE6#6IYJ,5=3?=TCJA=HU*)AQ"(:[!WHGM[03?VW7R>98TY_ZJ? W1)2
ML4K%+K%I1[')CYS0MWSF!52W3"T(F.U;E 8V<3P21 YBD^Y+;*H?-MV-L<D/
M'.HRVU(C.P!L MVB>B&UU4BWW<C37.;Y&F"3X30LUZ@1-JW(I-\.,_"4I#]8
M'N ;7SV?:^$;R^W"3,C=:EQ:@\W4XDGK/"E"HL]2Z/.E:AD%A-FN:P#P$,-4
M+=OV50_(HIJA[\$_"/.\:._ UQO $\\%GP< X*4,HT5]X5<OL6NP)*3$/D-B
M2WLAM(GK!LQ57<\.5<L*3-6W(D\-30/^+[#MT+?W#CR_87A6C23V546-#HO+
M_2(7$.V&)QD+B_IG6PT]:S 6"GJ<C<G19L,\7BNQ:"DL^EJU'HCO,\=@OLI"
M(U*MT 3?Q?0-U686\UPM"DP;K ?#;&C>#H95I BOT7J0(KQ*$2[-"</PJ*]9
MFNK20%<M!X39<VP*UH6CZ;KM:7JD8_BAX5K/-B=D].%IDO@Y90,2/WA?F3Q\
MYOSJ_9LU&!DYE4X$D20T/06:PJIU$;E4=RT?H GTBPH^3J0&FD]4H)ZNZ<34
M0P-/;9R&[ST[,"IC$_65W358%U)V5R*[I5EA$^)Z(;-5%\14M5A@J9YG4C6*
M2&A'Q'4UBJ<:>L/P[!K)[FZEI\V6O(MDB!==GV\X/)8*-IVNN'O(M([0!:>/
M1*2G(-+E9*S"C6S+CE0O,@W5TBU']7P6JKYA.2%UJ$Z,:._ !$\'M,N*/)V%
M16.+(AFO6-S7$>:0XOX<<2\-$,W7 Y<RJIH>):IE!Z[JV9ZE1@%F>X6. _8)
MAB;]AOM\"V1=XC[G4J[]P*7<[<PQKE&><JUMN<\IE@09WC5X:K(HK<.K@R71
M\(;@#>0^FU_)Z=7'K=<2%1(4^MPE_>%AGYX4=&HSB>_+X3NL#;&=FW2'_T3$
M,8. F@#P3%,M+334P-9"E5+/,9FF1U'(]@XLHV$8J\+W+;78=EN&UQ(=DC*\
M0AD^'<LP"1P6.J:KN@9S5,NDH8IQ(Y6Y9N"[U'%TG8(,>PU#K]/Y\2.617'%
M&R;+'A;[=7WS-5R_Z_#S,'D.MG&+AQ-"^+'MI!]*5_8I,'E7-75<0P]"+8Q4
M@YK@RY) 5_U 8RKSF6:8!,CE,YYFXQMU2OF3!V';9^I(X5V-\)8VCA8Y@6EX
M3"6!9X&-8P6JQT)3]5S-#T T7<W!'#FK86OR)&P3)V&S38:7#8/7;BN6OE"Y
M^/IW!G[7=MHG\78YO/U9-98\:EDF\T+5(.!.6EH4J'[DZJII@+8T79]1:NX=
MF*[7<"US6P+_:[H(+D'MU8':VLXT):@M#6JE$>F$CF_I;JCJ?F2KED69ZIFF
MK>JAYK@>(8$?>GGR@K:J2-FK.\VL+-B$)=%DA/>]IU>\Z;/.)\QRMVSYV477
M/E4:=O$3T&$2_KA*NEBT_U_\='1X]YR2;'4IO/;JRZM5.K/)&FN[=5MV0.YF
M7965Y8MVU/9<X\W?SX*U9&+=DVQ1L^I@HZ-@L9"H.F&1:C&-@"VJ4=7U->;8
M86B&@;YWX#4T64I-8M'68-$:KS!++'HF%I5^L4DCYNM$4VW7H5@,!=/[0ZH&
MMAGJKN4:00A89#5,S:L1%KVJR\N'2S5;EID;FS66D%055UIBU),PRJK:2Q33
M- */JL2-0A5(!S\Y$29S@+EDVI[M&73OP+0:NO]LD)+9&_45X/58&%* 5R3
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M2&'>I#"7-@; KN83S5?M &/;ON=BN097981$E#F6YF!C=L\U&H;V[);#]4O
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M<W65^#I0C'@D!%YS]- #27;=AN[94I)W4Y)7X$!*2=Z,)%><2: 7)92HIF:
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M4IJ+S&JA(N(8*$MK+A'3*5K&A+0L;6Q)Q;K$W+C86-EV;PO ;S%47?IVWP&
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M1G%FDDER8XM>0%^E!\2C0/%=>A@%X'<#\),&P)/U1CK.D% )+!0L++(84^3
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M'D^!:&+>HO?#HZ-A'L_0?^EV!G&27QRF!/<!'O+#\>2IG5QLZR9](]'HS4R
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ML34!&V],Q!9_)LQLS+]UN,@7.K8'8/6/HOV";(*G?&;[W^S)>.,?IR;CJ#=
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M?GH$:^TDDU%#&)VE-#IS<5RM-B_443\>S.G!4X8IHU$3HP37PEC-@O*,NF0
M3L$N0C&WM1Y_L^/>>"^=68LG]<^GO1Y?GGS6PML@&46*YT.&A,/*Q"XAQU+P
M6@4F/#V[ON[)8[@T0G$QTU5RSQAHFO.5.?!V!#92[[@?J[=/6?\W5R9W;4EF
M)>\7CP"V0)K[*[755SDLV2CL3T.MX6V-A.KAFZ9,=18#7OYV..R#Y3'\EBVT
M\=2->Z$'QDA6U0WSL_/A_^O\WCOJY5OF;S;?FKV^60?/MOM]N#]XTW-[<C&
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MPX6O7'T7/@L6=?V6RTX&7*D YP$"QW_;^^,FP)G)M3M;ZKWQCWS\[,WY_G
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MXX3M^GJ6EBR+]G^R--9XV(TUW&TTUL"E9&<IV7E:\R?I#3=1NT XP\Y%87@
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M'OV/7]+B_#>=]\#Z,-IK75/9>T?'_E_>T,ZWKKMPH*']OR=DB,]ES$&)2<>
M+5;<MQP!SMFPPAFP:;'E.6\?&M[TAO+ZK#LZ%DY"%4Z"U3X4V--&H'?IDG.H
MZ[2FPG,)6E$V'SN<AZ=7#_5;XQM[?_]>.G5.@)^:FG=#IZ@?&-@3M-<;%R-I
MKYZO>D7U.;R@&+\276Z^MWG35A"T[K):\UX,0?'^EK,)3,BA&!R0=Y(W+HA\
MI P(-ABGHE8;/&"E8QGI,6EM\59["HUU+4R@JB\%V&E%:!D",UFI@JW<MJ>A
M07HK&H2]?DZN+*)0&@ARZUU;B(VILA3\*5<U[2:.U8LK0G=%=^454F5[5.*P
M]J>V[<L55\3NA5=YWJW+?-DF*E==17/=CC2=PKMT#U1]:N^5G!MA8E52]^4R
M>J?:E.)%SJ+VEJP5OR4NBG*[KMXMM_DW[/55)GGI*7 .$%&FI"U<N_@];WM\
M%RT"/Q,ESEJ!:XWUF<K,$-_$8+B0L@0+G]@2<]:(_VY)RJZX./G"Q"P,G[.A
M4,5F%:[CJ];6%"W5) #LVD=0;[#+YBIDIDMY.9M/;2"X4Y<F\UFQ.:""GE7>
MY*D9%699,<IFZ[6M?)[R/8Y7K.?8W?7X-<['M<*^:J3"L>,/%8A<3Z:E4>!<
M-RX/L/#TK)A30:7N:>_A*FWS87WOX"BUHI^E47Q:4+&1C7L^H +IN-Y9;=>1
MG7>UP[--P]R3O/M>6P97XUY!]2VCOKGI-SW8O(XM1(855)9_9\X'U11?L',N
MSK'ZGE^2,[W!"K$J<5G<,"NB[XH].Y[:=5FB*N@H][XLCU;V2TV_5GW'X2,H
MBSN.(IZOB*SP0U[AY1HO!60*?3K/9\L#-;;%W?P5$2 K;*E66&AS$ILE-T^-
MO"BFD/M-\II&.5CMR*SE]*8ONSJ7IX5]7]NY\J+IX_0>PHLR^K42[T#ST]S4
M/'C599:+I%VZH]X*/CJT*X?U'.0T(A'8:4RMF\ F':B*/^N[IF9L05,$3;6[
MVBL\'<6.W-KF^<'6]IVCF4J)L-O>7GL3V&O)A8_53>!SJC('-=SF1:S!2B=<
M?0'=],%=25!7WGL6&D_!676&:!4F8(7.B1AF-;A5+4 OROC?W-3C+03&/Y="
MM3ID9E%Y:DV\UL)J:*UCI<<+R+F,;I4"UES)PG969HR:&N>4&%>!X39>RL:>
MP]:-O5^Y5+R: U@[RP5WP1N4<8+/&6_.9UA$>E1.U<8\K$=F:(J5>R?DC6=7
MAU:OZ_G=*#$KQ= +BJOFZ%#]SH%.ZPU]9;!FL']6E-)^9A/-4G<CM,1:UCX&
MLQTBM*!ZU5I%4U,JONK38DK!5W@QI%'"L@Y\S]_MG+=-&W=!XN]92D4<'EZ*
MO71LE ',5OI5F<E?I3TLSGP%^-7=D<7"1/TRVW];SHP1-]Y%K8P5:6QT6TDK
M.>@J#H,I+^UGB8$5)UUWZ54ZA*[(.7$^JAH1RBVM<*YY>507F&AYK*H0LIH0
M:D]R"R$6M[RZ-EGM7(8!!L/-<D-!D [!&"S.J0A?L[>5Q>OK[)?VZ9M1"SI7
M'OM%D6;EI+:;PY7(=./I+D?3W*&-S"\;3T-><CS-3?$Q"W$N..*:F3 UF8"?
M3)(REN@L2^.0Q2&)Y)6%YQ\0'[/>LK%7Q9/^7<23/J]TW)D5SOOR)A48?74L
M9J'IYRWM?CD\]C8RM'HJ+[PAWOWD_3@^B BFX5/^8"X#X\KR $ZO#&8LDTL+
M2"M4O64!4^>N7AF?Z(#U=N%,WNHO F[.G3E<A2UM+OKGZFWRWJU!?O-\MX+>
MTN;6'B3[KL:5Y,)E065#M3UYFY7/LAGP7$1$Y)O5P+<[$">T I\_4@U2WB2[
M.^>KO#2K/*BY&GC9K#8#!71J8\F;@=F;#=>I]Z1X0V ZR+\6^^(B7*0WHGS^
MXZ2<K9?P-I1=P7C3QH$,&C%9@[P1DN4F/W5G5<69V8VH''&#\;?)\)L_P6:$
M6MMI^! Z N6BT A<P=<B0F@N<_,_<Y^IVW9H+=HT;;_80G1,L3-5XO)PV.3+
MAJ>IBJ:;7><P:\9ME&3HZFS!N"MHVY:.\L?OGO?4W8I"<)%.13<@J_:!;J5.
MT/S,QS:5RI[?,>&SP\L8<8\58FJ/HTJM*7Q^=JG5*W\2@^M#F8?PO++D[<J$
ML-)#Y,*4D%?'Z\0)?XKVX NWI(VF].G[A>J-O.N^T/^!%D\&/KC*6DGUW7+C
M[JG0A(N\=$?Y1D]&-M[(!JN:4?M6NIZ,-]9OO"HK*X:)HE2IC3^K7#"EP5^D
M@GAQ #-U064K'35M_[R?E\OM;^?T^VEZ/XR+-:P-CNI/#1_]U,.="S-L.!@.
MO ^FO4;[_*)Q8I=>O+&&J;*;EK\%&M>U%VN/<>/\UY6[;E]U$LSS"WOR[2P;
M'S#5I//J2J;$?@]MS>\4TB(X=5<E19\Q)TZK-)&6*[3(NX(1)XX]8*M._)=+
M038X$W[@XOJ^F6Y2/V*^^[)WME!=4_0XL>FO,LZ%=<0OW:\ULJ!@.2XX ([;
MKZQZ67DQT%QJ([[UFIRV!"?KEH'\NCYBV.6=QIJ>$U:#WXKM^MV&PX.(+K?/
MAI&Y@"#5FG?K+%PQ"7_1"0<S'_A:J-;.\B4BZK(?A;=(^.OA,EY-%;\[M_X@
M5\.)]3ZWRE(LT;J+E:K\S4)KYZ1NA1O:2ZI&X110&FR*9*V?_D9^]S%V3<5J
M\1+1ED'SFHSSY+BD(@!:VD+C^J5J.G#ND**B3:G@ <N5%Y3U.(WXY183YV4*
M5,L]#S Q.7:Q3EXG;0PTM.\L[FBG[LOU9T45$./RQNUU1\MCO^ ]*UL;VIG5
MF8Y%X&Q>WY&T0*J\JZGMAB)[W-*)D[)>N*+*S]62LK^9K>.MS=7H_OM56U#D
MJUXS?;])C<DWZL),@2HF8Q]]XE=APX]=X 1,(;>QST-GLPP'OEWD%9NYY<DG
M^-#,$LWK6X3B,@FYVZ1Z>Y:4D!9GM3:GJB?<&LHFZ,$LA6XK,:U':S)7$W15
M)N%B1*[P)81*->'*^[:BWDME5C5O6"H!\Q(#FIUV6=TF.3":YWE9I*C-NJV@
MI@5TK"S'^B83#L28H#^!8=/-X'6;A^#[KI9AL%-G,CS(\]DUT+Z;PY2^8(?I
MC0[0!8>I2$FB<21)2!*>&BS#5!%*0Y7&G&8D?/+>U&78PLY8-^(6WGA0\56;
M?LEB33N71U)AKE6:H)B%&G$=)BB-D@Q%)HQ,1-,D(2^T;..'IC!IAJN\MDE-
MF\&>,^$MN+XN/'/!@;M7VE%J.A?#_)\%@>1KF:YPJSB=U8)4NQ9JUW1[#JY\
MWB>$@:H*2X=IEPJ,\^.!#)M<F-I94 SMZOV46YV+(3Q8F'-%^"5\H?QJ-84B
M5F>Q,$25)%5I"I/IL1@74:>@8;_^L)__;E_XS;KMCHN[U4%9R=%.%]0@4?EQ
MX \NF:RAHOXCKURUP<P21+[0\-M==I>AK^TPH/:#U55E:PO\%MYVH>WQ%U?;
M<ZMM2/_*>U)O?K/ B"]O--8KKCB:Q@_0]%*M#W^E;-3)&&CXV&ES,(#Z6CB_
MK IC7.RJJTKB7KY9[+GK+%[?&[@%VJ#L:K<6S/Q5?OP76 'D@VM[/:NTX<4H
MLR)BPVT0RD]$&2]:]O$X+X(J9RWGC5XPB6R(Q4FIY9<T>HNR'EMM*^+:IRKV
MK/+NW+3'X\+&*ZV&5F9L&7RQ2M<O72[EP(]XNLLMHS+WGS]^U+&_;F- M7<N
M [OEKFI5M[QQ\ZM(V_HB;#[+)_.I-8061FYD%?ICJ1)YE^H?E;]>+()7$Y.=
MK[L&51O)8QP"#&;>^#@#QJ_D U@;'_;+'_V;O8%O,6T8#.N>?S,[X/AXT[IO
MQ6+ +Z";?]I;W<*+93?4ZO?6M[F#\1GL3661ME*0RT?,> I,Y*/FJF$NU+ A
MA>I+N^*-EGO*ZCLUZIX!N*'9"1#=\4ECQBYQP<W#F[V^\D#AP:^S@?7<W^G!
MOAS[FD"6QRK7D,^OJ>8Q&/N*]JY6G;?[6P?ZG#Z]\O*_Z6AJ(/O4M..6FG6W
M7!N<;P-MU]KVNM5%CGQ9Y=K;<>;\:X[(VS)ULW(6%XZA^IW7I,]ZC#J;FC,Q
M*/OE3*:>[!H"M3S:68-S&J!GWUJ[BI4=WR+UL!"&I9 MA.*".^1F &YH::M.
M^@G![Y:9:S]X5K=T-O=;*6"!T-]\%&_)56=-RET.772JH@N6D\:7%'#NF+&/
M)G"!C3[:_Q9R=X4/K$USGDR: 74+WJ^2AOP\?92<;?(T]?-JW===[RA[%L>_
M2UDN+O$KE-. CD+566 +3-<J>%/?8%6QXL5C^0Q4[+;!X8#B1/BTN<+/5D8$
M?2O\^N-ODX%J:C>%J> T\))9MX*/#0%;QDOD"Q$\%J>D#4-U\C)8<O07ZRJ0
MIXI'+$(A_-5L._QA"^Q1)P+*LG$^2V41#)M3T$4FT0E89I.I(_"&JNVE:/U]
ME^_BBT68<66R#"^J,O:-,/52&KD-><[BVZ\;YL8'3^S.K.]*</=/WYP?*9H*
MG$J-LHA(Q#.>(L$50['*,I9@(V![7Z97YV/#YFP2P<LS#YLKJ>2/,Q)4V>#.
M):+>MM]C3-;PZKGA%'#)5N2/P*U[Y=D]QREXI&SWW,M7G<R@4<%GLU0G=1$7
MYJIN;#:",?\<@LZ#/JJ3B;4G1A.0T/Y-C7"3^IWM- 6PC4!+N:BS')WIX R0
MLF!J&1E7Y0;4*J=]X)LWJQK188W8_I?'*6^+F"&;0H;*M0D?X.%VWIY(J239
M<,>1E:"N=45U("[8S_IC[/ @=L'&E?.BOX8/DG5O\8.6KD'GGA$+B5_C,MG\
MAC?:TA/#HO'EJO<U&D<L$MTJ9YI]3<M\:J>4UP9_<Z#F>N#YLHG'\*)5'LAN
M*9BATTI?\HK'RR.4YN5\E6-^!3LZ<"TX>H$=B_@OMY%5-DI!:%M%_E>COXT;
M;DGI7/'*S:H@G;=XS^;.\W,"*[#Q;#XXU5WGUC7A"A]JW3VV",*N:L8Y<\06
M,VAH;D7DJ/VJFS9R.-5>H8UOL-11VK/-,4N/CP.?0?X5N;RM:0%V94^7S9J(
MG.UNE=B+@1GJQ@??)O8>UT7G+A67LWW/*X7?3>6Y-<JI.;$Q(=^,;_GEE<E.
MI025DASI+ XUU1A1D:2($Y(@$;,0I2:6L2&9UOB%=FEIG7SPUR1__ N_)Z]:
MU5[#<.)"TXK@M]S587-_\T'BA6;I_&&^\L$2^.>5R#)%EZ:J'=2QRS)U)14F
MKGNYC2?QE5R&!L' R$8)@^DK9Z"O*!C9>2:OY^T702A/C$!OBMC^O\WTH[W1
MZ8 '@"<\,@F)DHA2Q#%CB$<Z0X(9B0P-E1&A(#&+EDI1\S@5J201CBG/PC21
MAL4932GE@J6)6 2J/C"(9?P ]CYPF[]<1_VE*4-7)"'>M#/;?XH<B-N'Q@X=
M_SOH.//1C2-7DUJ4*42CLWG1V-VI !9$*K IKB[])*TR:A-G &S&<]L^W+OM
MZ_%\D6J;!6T'6=9&@YWA<$$E\YY2T.P'3I_P']KXV3SX[</'3_GO[;3@^N+
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M5A<.:-;R"):J53QS08]K*PX\JW6Q>C-WR@*]UQOO:S!36\9^P>98QTH;+XT
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M,,#<&;.%=!.-4LI"+6E&6,I:%P4/3S_ZD:EFW:DOG'J/]W>/+_8/=AB</E#
MFR,LXHRKV-8AM$V<B,(HQ=J ,%<\591&/)8;V]'6<N>4*[*2@AT'!%<#ZW7*
M[ ]"UF<-Y&[(O__]OQ)*XC_RIDGB#)AO8CBWALOL;IE]]ZNR<G^.^F#7M9]]
MRLV.G?POS%AO+GJ[QT>V!UK(L40QE1AQ%88HC4*.0@):E%))1G&ZL4W2QTSG
MO&<UB.[0'Q%-Z?[!U_/>Y>%1*D/&>:11PG2*>"0D2F+XB<5QI@!A36B+O%)\
MZR3/S< KP5-31J2[5(U]JTY73HRQUXW!1+7WY4[_;86;;BUE)#UI0A[0R.M)
M/CNP'KQ?.Q/OS9'08883'@$$9,1?%26$" 1;:D@BN(GC>#&S[B6Z.P\< 8[.
M)F-G'H "X&TY!82PLF#%.GBTVKK)LZHE98V.U,M_82VLX7!RGKMHM9E-KX%O
MY+_?(2+\B6*U"<9;V-]7W3E8.]JB]'Y1U=<-FVZE_'XAX-=_QI+[1GE?/]>D
M"]7N0K5?RN9VH=H_?ZBV$R7/$:^]OY ':K6%A4(7MRP-?#M"N'61Q.<+G[M]
MA<2[K?S&"(#G6_(/=!G?I09BV^JU%LWZ5#Y\4"C,&<QKA_6MQ?+N_7G_\BN\
M\\^OAZ-#L%SV"/PO6#?'YX>G;\CA8BC,Z/"RMZOH_NXQACDQ>/=I[]V'P9=3
MF.?IO^%_/\%G?PYZ!_\^_<_E3K/]418;!<?-$ 73& RA*$8B#34R2M$L21@8
M0V)C.]SD9+FFV?V:MMU:-MPR1,8SR&-&QG>@UH':(]R(=*#V T&MF18 8YX?
M93J+TS36",<)MAUC4Y1$@&XIP)NDF68L(P[8HF6G[]H!VT^?G?!O,1TXI\@*
MA?.'11F_"%3ZD:I6>2H=*-T/E-ZT6UB;4-,P0222-C*+VJ LJI#M,L=%JK(0
MFXUMLHF3!P/2@T*.[Z%//7M^P(O@W!^I3W2<^S#.[2VJ$SH.,4V%1)K%''$2
M ?=2'B)L0BJ2F L94<N]+'JL+I$_7FEXD;ZJCT4!,7L/.QF9U6ZJ6R'0@UK
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M3N%=E[W+]Y?]@V-LY[;_[CW9/SCDO7>?OA^>GIQ^>7?XO?]Z41GNG_1&H#+
MD_W='MG?_3#H[W[E,-_0*M!?#MX.]M_9=;S!"T&OJ8P2H;% H50,<:$,$HGU
M&V18,1W"/R;<V(XVP<1YI-BPE^+8?6Y0I5W4U[H#T:$1TX/S28<_=\*?5B@8
MF(-8ZT@CQI,,\82%*#4J1BS4S+!0Q0!$%G]2_N"@^Q<63/+<^,/NA3\O]([Z
M!>//R=3\-/?:/PB!6M$F0IB$JTR@5$@*")0F*)6@!D49CRF.&(L4<1I0VFE
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MXL XS101"9D4)>*2Y18*)"'P880,@5J&0SZ_/GOX]/],[_W<(T&F,C<3966
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M+#DH,>H9(]XEFGMGT#M9F[>P5_^UT3U!J1-CK9%M6>SV:AT0Z67L6+PY&_O
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M-\[2^\/#3CS,'OMG6-]&JPON49'/L/KK6VP6M_MPCS!WF=_"D?B=?J_;@PF
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MEK<CUVL?+& 3C*@&L];HP3V**X[:S6)X[6'&3ZW=BF6(=WB3P5/]O^Y4MA&
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M"KEZ1J,TI[UL3FNAG^O*Y3^*,A9 :KKPZB&L2"=[1?5:ZC>;N1)-ZL9>S5V
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M-I%)7$4[GH%UG!ZV?MX4HLV+-'$\H$*GA=#)3Q(.KJTB24AD5,BLPRMD K,
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M9Z=W%#L5\BR$/"=3+H+!U%B7$-8.V 03!L'":90\U@),#,$J 9N@>C7B5U7
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M1 "4[MF+TKK(1P@"DT#P)'UVO<&YGP)\%SC?X$5-B3ZBAE>X,Q>E=Q;!'Q;
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MN#M _\T$: /HUQ69P]WWQS'3+.4& #WGCH!.,V 2BIC0.#6@-'+#8[$!]/.
MOJ70FXJ00&-9=;K"$0XM"3"^E42Y595F>5+KP<62AR/L\AF][6  O'%(CP]\
MB%6Z^W3 \%15O5H7S9_ P$XP&75!*GI#=W_S8I%OML5G-_;1X @G^4U@Y7P]
M&.[!J'K8J'6B>K!"< :/+S>;?]'FAV>:8\<RD\>Q@7W/!!$VQ^P:(TGB3)ID
M(E76RL6-FZ-V"F>5/-Y&G5L>MM=%S.VM4+:6R)/].&_G^DW=8I9M[2_<Z#6/
M1]O@6644;$>O)\-0;]R]T]#51M%@CEI!^0UI!Q/=;,BJ^D2=>,1?O\]<P67@
MFO6V;3FN6DQZU!U48[_O3&.'3^M3O+'BJS)"N 9N5"&Z&?/=AY/\) ;S_MK$
M/O+Q6+_+*_I716^\?"U;Y&O5_C],$U4U;G511>Z =MT(C+"*LS4D^MYTQGHH
M+TV-/7YUN?A29O:V(V"ZK=8E9$^2.-5&@VY/J."JT%)RECH&&M_1+$UOJ]HW
MA.QK*.U7=/_HU;&&!:"BX$3:3" A>T8 \W.2Q8D5&B99N!PSW^9S#*8]SSM-
M=7_I*?.)O#.G P0Z86LV)::N=IZ,.MX3556PP#5+I2EX6.Y$H+S?XS82=4V7
MR.C ,^,<%N^JL6^<(5[N#H_VCG4B"JFI)E31@@A),Y++6!%CDX+G)BL 2("E
ML"4XVTJEG)>^11ZW_^[ZVNZ<:#\*5$>^4K1Y?,>[U_%QCSIEJ8VTAW/&/[/:
M#8^Z_/.[J/Z\'[KRIG@SX(2;%G!N*"^NIKQ(GC#EQ944%C.4%T;&5!MA=2X$
MF%6@+@6UB9&\R. 3OI+R0CXXY<4C*T->;OP\0E/G]M6N4EO 2VD24Z-$'O.<
M6Q:GSDB195JE\14AHTW1X\V!SQ[=_[ISG"=%8I+$$4X3 #ZI8-@!*29,:E7D
M"4T!^:P&W&MQSX\6A<='"QGI*RNRP]@VC>7Z*'+P*K1<("'^7#63:;"]9T 8
M>KL<':_C)=NY ZWJW/6N_8!]UL[04!VU $WW.74HU>.%?TX !F&R^G;=71D9
MZN&19=\@*X=#O0#B&GZNLA "4=RL@>+]+D4O=/R!*P^]-D&NZ3,7/:\:S+ZH
MA^\92A!>#'JE#4A@#'_4Z H=4]5Z5)&W\Z&#90S<?X,1LJ#OM88_$]%O7K$S
M0I_,8=3HU+.JPVR6%4(:3?3(_7OB/,T$C,CZ9KGXW46H>28^/8WS#P>3D]/*
M&Q4&L!T=#!;?(WS9+\BIZ[6'4.-"1$8>.?LK@^3D:Y%*/](<]'=N^+D$T7AZ
M.20@<;@*;!T.^&[V2/WN*'5UMD0Y;J60#\Z#U,.M0DP:Y<JU6BC.46".5G-@
M=A+%1_-]X! 1@(T#J%3-<YBC[5#TP,ZJ.32?>SC^J8^=#^$S5(%QBCKBG8RE
MC%_X ?C?9EOM_F2U [4S&L^@@3O-.P&'/NKCE49H> ##>-_WS)3O4#7 V%^J
MOK)J*]IW2/"%C=)AD%O1.T TI]'_#K#ONJ<ZZMM21<_KN>Z0T_MM)+::A6AI
M0] 0L^NP>FK;,]-AYT!'84/H-\V4J9]I2^O-O":IQ?>2K!8>':%5$EJ8QZC.
M[9F?P.T9'5@_H.Q7K=G:2PGC*<<A]:CQ:S>Y;_[*N0EK6$A;4JQ&[8PY5Q2!
M2 ";LDRP:P!-MJIF+#NX[)4I6Q-8M?J;+,B;P#B9-V+AYU8WVFF?X*4] V;6
MJ6J#UUV@IZ=OWI_[\A)8Z[9+<(%$G2F+7D% /\.&*/2F%/RJ2#/KA'!,Q4)G
M)I=I3O-,)S91TFKN$2^+\X!XX0<PH#:TIG</?S]=8M)XQO)$@N%*N$2R%^-B
MDL>%)C' 2.=<FB1IL:0K5(-_NQ'I5<V0YS7 =8(\M:.L<GLU6@CWOZEJ%ZN,
MUR9:5VF^*D6UII?S1UVE";OCO"V)=-"K/GNW_:SF8*Q(IE7#ANRFKO@6UW1#
M\3SE(IX^KN%D/>^I$)L-X:7E9*TCG"H3FHC4:0DA2MEO3B#0<"=X:*BQ@BUM
M/JF3RLVU0%WCX>S7"1=C'E3X(-L2%NUZC%O7[?#M)W-4M1Z?GDA+A6LT'<<"
MH?$IU-7'#8]U.1I5!E'7#^IC@FB@^'RU'I)[>@A1,^_57D0[\+>I9F0J*N'0
MZ/)4A[[3C8]1+3<0Z]$NX^U='3;TT[8VRW<C*$^.X]OG[%8[\X:TW=.].T6.
M;4NU'0\+VWK)TOWDYPGOUD8&6\UO&^"*:17]:9?CA=#K*?G!;DMUOL$$CP(3
M?-W!QA7'5AF:%BPE5A:6P.IKHFULB50LE6E"8R[X%9C@(=L4/V@_RH5$[_5)
M^F!4[\W!=9WHZQ2]+#NAUF]V_I#R<'2Z,#6R452=9O0+$DB7(LLY3'&-"*(_
M/=$G,1U1'6GUMY@/''>\LB$([$DZ/+:=QHQ7SO']'P87@W:<UK]*-3A;^1;%
M-#B[U_^,9*E!G.!<Q4'L#B<GT?.]@]T7F*O::^@#9D_3E@<H/,;TG&=@K3Q+
MKW=WMB-OV,X$U,,!/R6-KC><G^?Q;-3\49Y>LQFRFU/+GUJOONXC@X_*-!?*
M$)II0X0J)%$B,22&DRQ/$F65B)_]O#+3?4Y+>)T 9L#@L[-7J-!I&-4B0"]'
MR[C]%V>[8#TDFA_+("JB4,]'[#_P-EQE(M^<->:QN*%J^F:8OP%8?S@M_@57
MI0&%*9\6$XQ66Q9=^Z8Q8=>B@%YZ\QMP0Z^^UQ6DT7C/6]!&7ZB[Y(W>7IXB
MN*"E$7,YXX6$O5B(F-N\R*C6)K%&F4*8-;F=0=X,:LL+6*.1ZV_"W:NU9++_
M\=-Q4B1<4<>(2/($.QH9HJR@A!9")92Q3&3FV<\'@WDEV6;$Z^0]=,[-.J80
MG$OV1HSB<TSD*[Y&90?#W3XA(\XI3)"6*<P'B"A318YM^P23F93.Z"HAHV*A
MEAL6ZKN3T+T+>/ZQ4S9Q4@GBJ.)$R*0@$DO8;"[C7*0Z-<HW/IGG_FS.\54R
M>8L(]V,Y+W=\NR$S0:P1*3WX'"*=JP*/TW!C%?55U^MPV$'>\TVL_3?FVS2O
MM>&H%BSG.N,NU4(J+8U*4A4K/"(4YR%G/+MY#Z)#_^IU.?QKMZDWJ';;Y<'7
MDV,'\" ',P50<RR)R%A"M#&*.,%I;)/<N-0NZ7#7;+=.QY2H<*XRP&H1[/AP
M?4YXJ)W!&K&V6Z%R=?A B;\7G@'3C(;%<84ZYCQ7=5:UW/1=Y;%!^Q8L>QF"
M/*;R\"^J51M-SC$MJM8=\S&7T(NSU;3=AT[[%8L$AE(_AT!R.1Z[X()7J_!>
M=2',V>+FZ'-AF*Y+'&]87^*#W#X=:!$FK39Y9TNW#NAF3N'A> (WE:88H@G>
M$M",I^'%O;-]^AS_DMX!@DR$(8.[G5=>CCY5R=LN0$OKSIW7HTVZV;3"N*)0
MF"G*O;K99SL:%V*#[6*1SL=-)9<#H8"%KR..,I8!>[<OKC):PH N!A[7@XW8
M'X]^FBW\FG-47#/<T2X;GHI.1\2V_*36PCDKF;.GVB8I?5%2>OJ$D]*O3#*?
M24J7F59,%SPS<,!:+95,N,LSQPJ&Y/KFBCZ,JY/[M#*?3H:#2=^2:@$+_[^?
MOEGFRHJT =C$\^0#LPJC' =MB8Q9=:Z!1FVJ?%_'X/X-ID2UVQ86UU1[?UE8
M>GD>L*] JN+&4_4=(O,+S[F'].Y>$Q\N*LCU@'&^H@ LP7_CL;NHYQHBB)LF
M%VW Y(-UN]^]&S#9QC-X\D[.7.VNZKNB'#>XH#EVO2<,G6!7.0';3=6'C3\K
M^&N;KGZS$:%:#32YE_,EV9\K5=1^5G#(;=4>QOXC\2ON>!J6CMGX:/,[ERQ*
MW<RSB:':,"W5^*XNNVA*_T. =?[!3]Y!L%8COZUV-]<[=Z=E4F=,Z\2(V(C<
MYIHGQB1YK%5N5&'XIIO?O1GXOX.!OW=<Q'#Z%;$EFDILZJ8<R6GA",^IH46:
M):"S%_<1GA(*K+7@>6Z8!?D65 KMG-*L@$=KS23@UCC9=/&[UP4WQRPM,I$(
M2YA!$E^8?Z(L+XC,+(V+),Y2E_@N;.F*%5^[>99-"VHU ^LG$X42(%P)=2F7
M:8*K+C9>\WM<]4,D!XP+[!CN"+56(UL];G/J2$)3D67,% Y;J=%MMF+15[9M
M["#]!1Z_.VJH512)!5LU+F+-!*@.J>,TAH,"8+WETN6;AEK?1JB^'GS<.<:&
M\Y06E*0Y2P'/2X=D-)088VENN*4^$7#5V;&"EV*U0'4:;VWYC*FEK96Z%!4!
MPSU]$'=T35.F<4<NR/M#0QN3N8-;8S#QA4R5NV.&#J/!?*'T813 ]  6IO&&
M##'GWY?93HT2;R$M&61]<;U&0_RC/-.3X:@J>VZ(U#IIDI@@@Y)38#+C*@.I
M?D#C0[YQN6_;$3YOQJW5&KN%I>=;8P]][O^-N1AY*EGL4@Q(<^$RF3/?B*00
M7,$_<787X&J69VG0WYD*U*%?E*/!VVI)=OJV1>W[$HW,C08-&C2!]SG.BIQS
MJP5)TA30=V(HR9UDQ&:&:RGRK+#9LY_Y BQVNU[:0E*5&I:FA>4B88F*I96:
MYJ[0*"K)7>"QC:#<E:!\!#.M@,5(,P!L7,9$Y'%*<D.1L3-Q<2YM;D+'TU5F
M6A>_K:U%6]2[2R-GGG#@CN_9N-F\<K373OV!8_[IDQ6\'9A3]_0JAT.=>[:2
MJ* 1CAG& A"5)<WS7F]'_P#A@M'UR6\J\G,3_38.J;?SGX3>>O[G%RB-'P>E
M9]CPY7J?*Q:$.G;1A]_T(ETVB;9-:29^%>04OM0+P6N8=*16"7?NE/>W8$#S
M=NC-W JA<>^9[7MJ,E^(UD,^-627K>LDZOV),=LQ*MA.Y+>;)>'+P>KK_*OX
M\< G+X> 6/9W0L!E=S)6KP%!^SP'6/V3,KS1R&%J RQ#ZY6#2@\KX)2M0^N1
M@=]XV+1=S6P8_ACS]8O M+LB1PB7WA/ +;C=*V7J:6G1=.-$8% =DZ.K&CB8
M'N1\J/1&!X]- ]T5& O"!X9E&.P-O=4SJ[NUCK/Z (3),P^R"O(]R>K_Q?DF
M<_,2?M% ]2DC L9.:]+DZLN+&M',Y]A,;P'KW1N4XQD5X4T:V))5?ED0JXI+
M9S[;#(#03-'5FCYJ3FF29,K:%)!:EIH\$YHFA4L$UPG I1FP%-.;@J5-]>%\
MPW?X<__R.(ZSG*5<$Y=33H3(4Z+@=X2J#!"0@;.^0/?5JI+#;@P^Z)J*W/&.
MNJ5(JA.5<"U8:D62ITI:Y[0V6MM4I(*C;^J&(8S53/@C[)E2TU["6#T)YSMD
MMIQLZ.\;.3K:NSPV1L9,QIJD *8QQ]T0E6I'6)$XF266)XD!>^O*'BE3[M=%
M!*\=%M)!PXKJN4:_75>,IW?B+"<&F3ETKD4+LI2R8Q%31WWG*5\[-MYND0#A
M7^N*&U3/X3>CB0Y8U1=RM=)QNEAM\3'7X7^?X4&HS\V6(V\5Y+FJV+X>F7>-
MJG,_6GA*U<>MHG((7?@N*J%K"![*QGN&8M*J10Y1<NU"7T$XI4^5G6%Z@)FH
M$&.+\F%J%4Y?KMV90;=R+V8(P99&_>?I/(;A;9?J[]:$3_, 9OG*8Z<+7A16
M%U84&5=Q9A.1*4YSDUAF E_YK$:?Y2M?4H<4COR*<OS-=#2'TZR$[YB"',:R
M^R$YSK(DSUU>D!0FG0C0WB17 @Y^EKLX5MQJY,\%7;BP!]NBQ+H%F_X6C19F
M%=/:+19N)&&;%@MW*6='G[X>PWP7N8X%L3K!CCBI()I)3JC.,EY(8ZVAUP*8
M*Y&!KRY]2*Z#>?J A\P;]?S0UR1&6(,0OL4 /_4H7(L"ODH1O RC:BN"074Y
M#,;9 5K\WI6T*#\U7!X40Y</*M >H,UQK1=^F@!NH_V>DO:C^U]_IW>A_9;0
M'@2$V=I^338LNO),AW2LSHF=1O$'0[#+^PIU5B55@)?@*M,5HU06CE,N&8LS
M$:=4NP3$RL0\L[FTU'D'308BZATT57KW+$ #>'T&-SWM"%#EA*GL[+?3AAIO
M_%B_0WDYV/W]ZW%.K03P)8F*4T9$GFLB=4$)Y6DF#3=,*09F=",MU:K]'/D9
M'FU=2:P "K1F'FC!N*INL&I;#@BL]G@'-^Z\#W?JJ@4C9F=R,AF-6W3=[?XH
M%4&")]^P'^&Z*G_:UP&V_+DU5?E5UL5=>8>N:4ML<I>N&U#=WS4"NQ]:;9)"
MV((H"VI!4)H2Z7A.E,X83Q.3Y*IX]G-_!=%!2ZDM\K\LB52JQ7EP/B>I;84L
M2*U>^)0U?=F"*9T4!:,\5B+65,7*F=BF5A:),&FVR;>^:WWY\=/EL1(R+5S.
MB<843!'(\F1!<D8E3V/.=.C:=D7=RUJ)DC;.),.F-%8)Q@Q@JHPGF39P1$H)
MT&J39WWG"YT<TX2E@KF$)-( D!( J61B8Z(RX5)KI8@S]^QGL6"A._D\L[D:
M:_"DM-++UK$@'DW"PR\#=XHO"YIN#_[;@P_/(NSL.^S7='"_GNE_/#W;*$2E
MXW5Z-RS/A+CF+$7/?]G;\[D/=<[#UHI _1DRVI[W9GLV!"^8MUV#<W;JFJ_D
M4JU$YR[7VIDT+6*F!,!#*:01)H\E'$6%BIG71/!/T$1('[H8G2]RGW;3R_JV
M:B$[-?4 #GYWNNC55TS0/MS]!+_;^W)PM'-QS(K$@C&4$*%$3H06AN28J>TD
MEP[DGKD<#J "U U!!3.'VRMX'!BD^[8A;4Q PJ:BV$Z%69(]H!:S5-2.$Q#7
M3H5SJ_G"5N77N20:1@@/W&HV1P!&2YD^EM"+MQHUS C\B>NCBZD%[#K.XG::
M3XNFO39?\1U"=@VZUY:&'T+60I,+,UNH;*DL9,)D2A.1<J4RFL ^ OP@36Y4
MYCTCU5ZY9>0A#.1E/9#O.>C0F GQX>[OE_N[OQ\71G,&*)DP##T(D\5$YDE&
M>,949DSJBC1^]O/X8H&=,)?NU&D3@IK9R]UH^699M+6"?-U#ELN-U/0FR^7N
MY>[K_M=/QW$N'>."$R5-"A9#"G)GG0)(:2FH\"*+'5]2*M_-#)\ZTX+OOV57
M;BAAKJ:$R9XP)<PM*5X>:-H;.NW:NHDJPR8) ;8EM+D+G2,-.?HT*E?EXLRV
M; Y!H*6MA-'KZ,;5555"A&]J.@T1-_H\"KQ7+61M 3,\P6B.;^[5=U5BDH=F
M.+/>,:IN>LQ(6YB4L=P5A12%2= -AQ GEQ+ CM.5 RJM'%!Q>E,R[%8Y29,O
M-]KQ7.J;DR:<-.S@R!QC\W93<$ER(0LBF%)PYD@!I@'+,JS1YCJ%DX9=D1&'
MU1G#@+1]XM)\8[3N)IDBZT4H!S9,JWW;7)U<R#2>J>WT52+!4[J.0!J>LMAE
M!N ($Z I 5WG(A:"QY2YS-*[\(C."B18JF^;'O%SV9SO.TF;;YLWW(AM$%NQ
MO_O^F.6I<-8FQ!:6$I%E!=&6)H1RQ:V 4RZGV55BNU8M4=6@]@R$VR<1-B=*
M^RA9E VZL&O#M#ON; 9;Y6^9Z4Z 5TYO#H=<Z/2 >8@AQT"-._&LY775T[MX
M@K.07^J;)'K:UPXO(]:GP)GG/ZFZ4'2+J:O3-)B^50:^"IV9HE/U&5F97/]Z
MV0ZK\SM:.1TXZG52.MHI&%MA5%7>][6'U@W,/*I^Z$_0Q7NPM[.W&]6ARJ>'
MBXY6.7"KK%COI47Q.*C]L7MU;Q^?I]SKN>')9=4NUI<-8?7];CG"1M>CZ+F?
MHQ=;K9JBT,;GG3L?M[13(*6"_X:_(FE@")<WWH=9H(O#M)]]4F2H<%AZ5-;^
ML-EJ&)XEN80#,0?[E!: %RPU64PM\O;'+%3#)'$.NKC^X;8NJOW:,W<T^,55
MQZBS<(B^[*#L]XN+';YC-Q;=W_UT@77FTBE . P+9A(L'\XTR9EU)'5"IP;P
MGU1TB1MKMH'SM![1-Z 74^]5.:5N7M!<MP4#1VZ1<PPK_=Z<8I]W^@.+#.P[
MI&7&!I0@.%5FWE"=N\D8"9I/4(-Z@KK0RZ]J^X';#L^ OKFLCB]_PH-M/CX+
MW_"(]+SGD"G/]7JH6(O@J_5?/IV<(1O?V=FD/[ .#L+2W^MS.83]^?P?>W^\
MJ+[@,SZ#*K,#UQ1J^-JADP&<AJC"F[XBS?%2S\EDR:0M8-QH;E^?CM5C0S2F
MU>-TMJ]EZ]X(&;#]%_*)SM$:K]DEYM&HX<[[U>A)^8Y8]9&[;JG?[93;]8V!
MU[C^]@\LDC@L?H$!UPEE&XB/2HLB9Q43/#=)HHD53H/28J"TC)"$BY1:DZK"
M\N39S]EVLK+U<,V)W3X(02J"\H*],!Q,3DZCO8/==E\Q;"Q[5HY&C4[!/?-Z
M=Z?35'[]"D&E$IH:+BF-$V%=JE)N8\%EG*6%28.MN<;9N4*^=JPM _!HF9TH
M=* . TGM:,EQ^9U+'CO<_73,G(LI9S%1CC(B6"J(I$R1S'%GTSSF#,L$:7:%
M3T0UB]"1OB(L YPIJM+D3<OI=Z%#;?AML!J;CH+>J*JNG"U^PB_5AT]@>FWL
M3Y#UQRRH1SC:IK+5*\2-8"X23+'_]>38T$0F>:((UQSKH)4E>1*#8*:9<,9@
M@A>H1"96Z,2J>5@0DL:),3TNVV53K? W]F5 $%$Q<5562%0;((TB7>@]$34I
M0[95R?:T_8ROS2R'HW'=A*9RKP>'P\W$-Z<B-P!J"V53$;,DYW'BG,A37C@A
M;'IG]$8UT[?=Z-L;B?71SL4^G/12"UXHQTF:B(0(CC[HW,#B<,HL=T90%&L:
M;\N51STJUJHX%>Q"$."V]ZPZ\+MVQ1PQ474Q&*6#_ES+[2OR<]>E/N:%<3*W
MF7-2F*S(G> F35*5,9O0S&U2<>]/ZKX<[.X?TZPPL52:9")+"<@8)PJ4!@'
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M\Q&A^M[6QR5BF%I3]3$)RV=AZC+W12W8\^5?7QCUEY_.@N+80^X9"+X]$7R
MZZ-%78C)0+R07.)OU*0:]^1+08;V"#&;BHDG,=%PYN"YJI,G6V9#AZ^:ED>6
MWZ[@&TM>P6:%3\08*P?^_&:E]M@S#Z5D-K$,BQ+-#5[-H"-U)N!%,UQ."2XE
MHINRMT):>$8.52>2Q6Q%V![G79F$-9?=CK*W1^P@[@E^(_BFALAOQ$K$6N/5
MUIQ&27NKH4Q7>*=$4\!T."VNQ81=>>.C*?-'XY"P&^HFRP^48+!W?Q \D4EO
M9%Z@K>'->GU&W2_RPS%$OHX%U?N[@L25^SR5^3?@W$?6O2\5,U)UJQNU>)"6
M+@PK2@K,M/VR; Z%K:JOC*MGU/)-[TZ$P]B"GL8%:BBJ=O CZLG%%^C( !\Q
M>=EICJ_);.4VK+9W^(?U5>%^7AQG?+EO-J^#!%A]YRU"67G/#3;0>)Y#?50?
M^/1?L0MG^E;OP+!R940[Q-WQM!"TR8*5"Y_0^'.L9S$[Y]@*/RT1W.2JTLG=
M,)'\5WD+@EP##!U3X&LS>_9^*SF,RROLOJ<O=+J@OEP4F>!7#Z'LDU1Z<]B"
M4>7F(H964TXRYRC"8VA'^;0)Z(:^)Q&0J69]RL3\B\E0?4 "DK&8J#*!M7PE
MAFWICY5?7XW5V4/$OZGZ_>M9*'D9"%] R\%Y82&W' ^?E07(SZ3IS2F'J'+3
M^;:T&173DV D#V<<LH8@7,O$/)?N0/%<1%0$K\Q^"\50Y;M=H2D9UI#@B]ER
M:BZ$CZA"H\Y4P)ZX5VS3X:2$RUE):N)5:#ZC)ZW<ON-E"<KYG1B[WFS*7B"S
M^!/U)O[LG\CTIO0!N]@+Q<C NSRCFBY[/(6[, ,2,!=.N^LXB,W?1&@W(+9H
M!Q;CWSWFZFXEO1%LR:QRLY!#"\=S(O/X1RQ<RU)=6=_>?+K*FS:%K_] D+6:
MK<LI;37;USGQ3E;QRAL2IQ"D)AS:%N735=ZT_OE7:MLN).0!JA28!\\Z%Z'1
MNZ<B;#C7MW4+1I4W/IA5%IEYUD;D 0FW55#>GL;[<C40/8BS[U$4;Q=>XR]"
MNL.Z]$%'N8?HJRER(!K:MO $J_M']1@6H:P<U7!EIM#R36V$OJ<N$EQ-N6?D
M>PO*Q,Q(3K/E!U#EMZ*H"9V_^@QS"YOQPIJ^C;OQK%PE/3%.>0ZRMEV=+4Q?
MUR59M7D839\*#O!ZFLHQ3>SZ'6X_\8^\CYA8C9PR2#A4/5=>6X)*+F:FR>O:
M#Q+0KM#DP7G0(N:0IJDMT,'&X/J"F)&SBJ:GJ;S'KV^0R/7QN2HAH@?AJ:94
MKFU"X:Y$ITU@IB[-+6+0Y7G6%ORN-UV@X%L9HB%([@OG^/IL@LIACQ;S>,_!
M<RPDZ<[1E(X@$_$(7HH 9$#6$@IS5A*+LJE^9;7HON!>-A?K@O:]G-DA*[FB
M*_%8H9=\\5TX8V3%^R*Z-*H=F%:\>+QV FPW8]B*5>4F$2Z!/_J.AY?R\Z".
M&)V8%"GAL.5-$HBY.,A^']H3Y#@R'4;&(SD#_-[XUW8\2)W8+Y(SNJ%XY:80
M>+-]>,3_&.O/WA$)]K[BO9 <,R_/J*9;*T$^4.]5IDEQU$?9?G]#R;K.3)YD
M&HCM$TL*%V[["H$U>7&9!+5U0QG)BNK;X3NG/&9QJ:\V9$)&ZC;:Q)!S^Q87
M"9<<NK*_KN<$A>MQOR.K:WMHE?"1K;X#5UMUAFDB 7CS:D7Q!.(<^LJ'AK5P
MKD3D5YL&%#E'N=M@O\\:*E=7> &'P-%#YD)T.7W;,XM7WA Q=K%-8]>37'Z8
MPM=?L;>0'Y 0P.G&O^(\:CL(9 =E<3C&A^0;SYO$E&=4USW%Z%.&<AB7"_"K
M;<'5E9"B$;8OXE4[^,;E%+UZMXX8^+-3)W=@>:C.XD55[./T3WRP,E\9VS&K
M@QKZ$#,5Y@WM*#\Z2IW.;*V6IJY=( ^B*6+NUO@&Q-4O;XI.:2)D<>&YW3%]
M@XY,=<C+!]4359VZ;*M,O&>TNBEU+'S+^LVDR1.=UC]]'EP+D./<=V=<5TM_
MOZ>:J8)TP=J.Z<DCUUN<TJY?W!E.B09$';.6K,5P:4VIS!#@_#MD6(JW=J2E
MV)+K-AQK"WNPKJBB+60568)\5[1RF+N6A8-946*KL^^KHR3!2EK1?)DM.-75
M027<:B(C;_T8_AC/%V+2(6-K=4B_R''^$LSJNF09'4TH.&'+*E[S#IV[=3H=
M#^Y[3]-'ZB#3=W)25W?C6;F+>$ \2MS$\H!Y>%Y7'D((*KN74<E"1$R+U=OP
MOYQTT-T9UT$Y'*'UWAPMFHX102_0"9U?9A\IP^) $?P6Q]_?QV93.EU@9JG<
M"L35*40/.<*4/1\ZT5R\[,'XO5125U<JQT9DA?-4N?*><RXPLWQ=A]%"3J!N
M';KO,R)X,E0VN;T 8>6-6W6L1(@&2Z2[YO?8K1G7M9<6V4S8?3NB-A:2G)3>
M.9A@$SJJBYIYYQ6+4%;>O,29^>@PL9IB=I\A5I(ESLAK%MO*,*FK=PYWBG;;
M:BO)I'+\H[@J"K+YE-ZBT&<AJTNL^"H>N<U=T/OMR+7ZH&YUK',T_MYL&T4/
M@:Z7KAS<Q"<_@\O@4M_\S'%A)1A4WM@8A5M,BP*6*%IY Z;4$S%[%#>HL+9@
M=RM 6=OUA;7.TVY=WY3H:\GBE<.WTQ5'47:>RJ05TQB57G28VY0RJCK4KI%B
MO\L\6CF>:)-K2,(;\";0T:0%;L>LKA%W'S,WOCU[Y,\<;*K^_<*P)QJJ#JOD
MS,7*L*B\*R7W-Y-#4&2Z,H+H34:CZ%RFQA#*<ZIK>!J+O+<=BEU8UE5-V5T?
M)KH^)7U?+DVHGN_ON A7G'-=/<Q:&EFTM+A%!EH&:6V#C_ 41#0Y7[\9O-"-
M!WFTE?O21 !P!Y=8!(I!ZO*CD%M,U#57XP5V7&;ROV,%%5_KF+Z")-JI'.O<
M0AY971UE7P21]&5(@EL#BYV0U=/\^VQ=?3" FPODPL\__3]02P,$%     @
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MB\F0  S_K@7-K@G.+PC8)BNWKL[OQM\K"+EB%'4K3E0N\VR\0Y<%5X^,G)'
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M;]ZLKFPIW&K!9'0S)\0Q*+2"91\P2 ^VJ"8;- ]#VW5/:N4;+M1<L*<+&O!
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MP G''-ALC04=;)-JE7M1'6'DVMSPHU96NTVIG;>@+^2<C3<>(+J8"G,BS:Z
M0P:& \LY"<.Q%.Z;=,.Y#N+[]O.V-D>#XR]+0V =-"T=M&-PK;8WSPH[[Z#;
M!NO+$BK(&;/6B7EM"Z,/GOD:2?,DG V8$Z0F>Q5'X(>T,O0F*NW0P&<?AU\7
M);K#1+-5_PM68)(+M5B&(.F0BI;U;!W,>Z7Z>CV>U X%+7#&AZ4^#/69,PL*
MN;#?@V_9OS.PB_I'+72W<@G_MU^6E/**OIS]8/;]*O1;+#_5_WYX^_)206=
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MH(?G?YLI3S!W33'O3'MW(]L=$.GS[8=I!5+,7+.S]N1C]J!<\X ^,G2QE.#
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M?!C(Z82!#G]>,M)3+=0I<+K5" 9^PJW<C$,Z;%+H7VL !6 !6  6@ 5@ 5@
M%H %8 %8 !: !6 !6  6@ 5@ 5@ %H %X+^\Z_V-S)5M@X$-43!P-S[L,PQ4
M33QA8MG/>$]!^G7NT?!15+.W3 N="%T$UW+%JYH'M]6-.JBI6O$'H"!F>Z/3
M'HQK9;_F07[K8'[/),>0DWDI-VJ8P20D*K;[2 =5-3K7I>**+*.U*\F80).@
MRQ4J'W2_%WL&>,K4Y54(5R@97#*9[IBEG&M;X%1,\,=F1C\T<<E<5Q@00L%
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M XUW>.E+J%GB%LB6@;I7KB9TGO^QKUZ8YEX% \[=16J>80/Y."=W*2=;XJT
M7[_OYV$@GT[P/I ?V70Q>]M"_JGX"7Y)K&W*5*MEH'62K6?-_O2K10\FW]59
M*RNJ[<RP-Z) J,GE;*&_^<&3E+_^W$G,O]@C& %90!:0!60!64 6D 5D 5E
M%I %9 %90!:0!>3_:_(E?E'JBO+4!@"$N_C-E%$2#'Q/P$ '@W@/.^<\8*!
MM&V)E@K^WJ,& R^Y*'ZNU3X2<QJ\BULUQ;3V4_!ZC__1?\.$\SL,A!^E?/F)
M1X&!61]>%F:QG76_7BBA7J^*JT/NW!9(UR(6\+!30GP1:1@X2.91P-G^>J3^
MTT>"<<>2P-^'T$A;"G"K%G4X>B?W$ R@W'F_?F_\Y_]]EO]7&PP)!6DT\2V?
M%((#Q2&.,-!+I*>&4*3 WTG\B><P,*6Y+5Z;A9GK!_-X84ZWA2"0>QH&'L!
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MB_ JH5:_"8LVNO.[D0J?VK<M_KP.X_;,#WW)T\FE9SJ%ZYNS.*;<ON)IQOS
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M1QS,P*9TJ2H/K?3\TR)GP6N>+QX<V4,F%SL=;NQKL1K/W^4\Z;35A)F_JR=
M :]*DLXMWL\.LJT^GA(Z+I4S,1YF/\ >ZOF&Z;G)WVP+ ^N5(4WDWWRH@J7
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M:9]KRNS+)71N'AC)]_#NX8LR/GN##;+@Z!U<*9DK(<L^@Y&O( YZ,Y;OA"E
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MEH45&*'C&9OWA)[D3"9G0VD UM7'J)O1=^D/(:2H(>U]&JA#YK\7(Q+."D)
M,8+OQ%,HYF.W08/0#T\ :0_:H0=R[/46J6!,N^&.#KIANW\=[7>4B:K;^+XD
M6O'<,Z_];Y>7E+6>H5ZPA8J4]Q?DY:.8<UZ>HE2_?;8V-5D%6A%)V9Z73M"K
MQKWH[M'D[CD1YWK#E.#[IKWKA!XT]QULX+R\?:*_JF*-%KV.BM*;-&;=U];Z
M4<^-T3M-CO>0A&A>1I7LT5.YDR>Q"76- \5U1L%&%YKRPF15KYQ;$?Z2S#=(
MO:23FY_RJM]S[M/78JE5Z$!IPYA%"/9A*JMW2%N,4,\7WH3,-U:@+F3E5ZK
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MD]:G973_;G(G@1":5 N\+6%$NLCT0*@@17B0%T<(E9Z!6#;9@H 97O/9A&E
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M, /=B1)I$',SOOVQ]P>1ZO=LY_\N+SS\KWEAUO]P7ICD,DO* PHDA4H)@JM
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M9@])+]-E7V^7%BK(TVLFW]Z8^]1Y,6"NVG.S@,Y!?T#!""^4]8!V7!!H"O>
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M4O,.6)\*".@W-SKO0IO_MD9F#'.3?H@BKP5&__OCV"4\[X"80%1T<AE0-TO
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MT$'?]CMJQ=B>]7GCYN73I[-2W=PP;T))33(M9:'4Z8*-O,WM6OY7_&<1A[;
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MIGPW,ZSP5;]V%T6]__S%U_>^+[1+^9QWH3HF>71I/N[^,W40%CH9?M.)<V,
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MZF!_U2*U/C$M']NE5?D9M8-#3@GV&^6N7#OK?,0<F2^93YFFKU&9@H.1TY*
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M6Z+<9ABA8) ]KUG3$BTNG9*>L4"@XYZ<M]'LHO=2IV BA2'QRW&B-0]W&*N
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M3^:D7G+S*TP-3H1CSM^D!S=XU>>ND=RV"8DB0>\-!HSIG-OLV)4A-I13S$_
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M"]D_"N2)FK;V9[K.NSU&CJLF-R''=5;"XF .I*M\*<AT.H&%Z%Z98+E]\E$
M\K@XX'$O4PCJY@=VC;DU 8XA9=[UK;!HO<?_W)I8D%/$OC),P5QG^^3&>,&.
M!82O\H6@OW/G/()7#[=GL!9'!3JCN$M]:)*T9V&)7Q4:8^:%KYMUJ$6.79B;
MN_EV\Z%C?!G1@'CXHS4Y5U'3![O9%)DF0/6C?O9:88O^16%=WL?<Y&<A-U&
MFC3F:N0MM)^%E"4#/VZSY<:VGJ!46D=9QX[9K1>RXX8/BCH+0WH='R?>NN[P
MVGVF.1W C_/]"1=O[H2UD&JZ/*Y,3FZW\'-:?D:LAU"<H9.P].&*74]3SM8Z
M%_\9!6@1>$IZ7!.1F'9D0I(@+"@=-"%27V^;3Q8N*:O!GEO(YBZ2Y7C^M4/(
MGR14LUX>$,B)>-&\C[F\X'31#&P<0QQJ/HG#_68B6\U8MAY5ZLS4(Z6P'=33
M H+U%7,G)"^=B0A3+?V&LM3L@3LE"T$9V3W#-AN:=FE7PES:.XL7RVP0@?A>
MU_=<S][&E_,[5.AOG.H^9-"1NFW9]9[]G<WL9OU6,UW?=(7\?[1?V1V/[U$-
M+%U8<OG[+TMLXD/"LCA+4O![JZ@T26S)3Y1G5$$#5YSW^XAA>1##N#W'UWUX
MS>Q2B"&MH#0 *SFP%G)XN<3+:4JG;VIRXQ;TU.SLJ^];I)Y'E^:01QQ.2W6[
M.2:%5\;?JG-,_)'LDW!U,.ELX'G,JZ9X'N63$ 1IYM%%51<I4FNBPOA 6?%C
M+6"_X5A.6I!H'U,@KVQI<-FZ'2:/<<EW%_2#?]/6_8D*W,3]9N-7MOR$=@A(
MF[E8\ZEL)A+6=0$AD(MH\O_ *O[GP68#SW%&#WIAYCK6J*S=SV?T>#(B-^F2
MG;0/U21^(*C@,.^05.+J>^H<Y^&+&U%R!BL3BWHQ%I[UH<L+I&8*PDR-"\:U
MJE/NK^V9;&71.0_X?UN<QYA)661NTP\+9 7] NUO-6NU'0 >.F8F7N!MG4\_
M+JY3_C4KT@]WF$A &#A9J4(/H2?G#SN:?'__.<E^L-Q-^L JS1#<G#) E&TT
M+1>_";>!RQO^R!>"M 2'^[W W2C>B<.BR<D']G&NL$2TN%K.E8:'?WW#LKL^
MLJ(M,.(=;QPV!$L1VT;8!]YF/GG%7-N[M%M8'SY)WI/ET3BT"95"XSPI(X:2
MAY=,B@FEBYE1--G<W>XVG'][LZ6SDN-?C[[J'9V9.K1XAAOH$G:ET*VQ]!WQ
MS.?SB?XRJDR%3I/FVH4SNFB?L1&<7F83=3<$431:N8'ZA6TP?@P.;GZ5,PZ=
ML&/TM^)?J+36P:JK,4;X&;Z <*_1D?V;$*34G0AN9R\I5KRN-IP>P.@V%G1H
MG$M 7CS_XGJ^-YHH]_JV[[/=)-OAR=D7''+7B;'9FV&7FKPR7<>\0V45SV5
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MZ@LLOQ.XX@3!Z[=66DP\@'/>4221+D$Y>J))Y\+#LM9610/WMR7^2X$N^HF
M!BP1]O#V, C2Y<UMJ!4ZF&?Q;16SGRUV+6,.[KBYIH!&>=6_<#@&1[K2?KRU
M&<AB9S,EM77]7Q:IH3CQ::=&-Y=ZJ4.A533I)*YIN?9PI.=CIRC/%=*82\'J
M6.]/2!]%<+B:NY=WG?\"@J*_-,ZDQ&P]9\&8W1TH>=X=0).Y-:C[EE5160 (
M01Z-[">5TPG>+K[(BP">45?^WAN N0[:MP7X.U0/\&QTDNJR9DX:SO+U3WW1
M]%U?DM#WH49?=.QPGG-XE'-Q7;.6HN,"ALL%>M_2T[QRJUGF+<.8:O^1TH?)
M6MOV!J?0#Y-E>9; .%NL#7<(>PS0[X <):N@E]WKOF$TIM<.+6:8D!O*ES+^
M7'DV^'E$&:HK/^A5-M%PW34S,E'.>'MH8MSKED-NBV?-PE".9W622?"8P;Q1
M@7S12-T@+R0<D9=L7Y.,;$D6$&:W"2M!W$/8KYI<14$7N#IC9>)= ,<D;;X5
M&N4CSZ+$&RZC-I%GA: .3AV8:F$PLO*E33;6II%M2*L.NSOF=<].+*[B]1?5
M)SS8N<[(B)-QG:J#)$^G*%A''FO(86R[X;BSS5I^PU*;V3^)$5J878'&3N,"
MH6[M*<]?Q$O'%W!U-\-'7@/0"BR=:N:)BJ?BJN%TUCL_=@BI#2G=%>HTZ;O"
M@;%(KKT=8^P&_@B%<,@W8&R1M,_IA*FVI!:G5S?UE@D7Y[>JMA\QQ?7JM&A:
MK)S?(,((1!,N";&U2&(4S^\Z8:GTZC;L**$*LGJ2:XB#>R[4XQ3)DNCE3XH6
M]9&')]T7L"IC!EH?,>?+::U'X<6B"/YIT&*[=,::H"I;I;K?[TSO3LP^Z2VS
M0"69>R.'OI6HUJ=*;\_4N3U$:C6%5BXXF VDHA#%),H2!=(L!"E!$G '+50Q
MOP,I3+THL%RS$@D# 5*FQ1^OM=-T6/BX!QI#(4@5Y^K;:<D'A\-&,QX:&%/O
M%3SP^S!2TYME#W7XV/BAJ?XCC@IW(?ID:SEF!SB5R)QQD&"GPEQV#!OAQ%+_
MU"'[XO=CO1N00@I@&,&1![+8*1SV-\@#+;I$@$GHI_[Q4%MV^0 [D%@X51'-
M!,?[Z+,<FJ9UQ%J53P[[N2/UMG 2BS1M"GNT7B<Q@\#"%^/?3BR]\K*923HU
MNU.AU3V8EV$G]B4'X_7LAM.M;T6'7I68)'N2/1Y'J$4$73*6W5%_F6B@E)G3
M\IWN=7^J'&7J(X#I[_Y738I)20S2SLGIR$?@W81;2^4\S5WL.R%(CS[N+'"(
MY03^.NR:)6)?5W L8NNZ&[=.1=#L*FKJC\U&?CW?WH.E@]?O4.H(_$S_55%'
M*HWH,@1H7J(Q=D*,'\/ ;?+U1PBM>JS>=4C7(0K"+(6K(OH1E[#2@'4'K"9T
M]2D[Q;5Z\"</QFIB&+<3Q-!7[#IM0L0O#,W4QV$<0V>0T&OQ]FT'[2GMD<8V
MS<.W71IB^MTRH![)$RY-,4SFQ:\UC*BV&PD!,F7#V:O5G'-X;:^M=S_2^[JX
MG2?=7<)LO9/MYD<B1W=VJC<A HEV?BT$@1\O^T2HFF^CC M!W5@3P)RUP;Q.
MD4%AU7F7@8B2 *P"6_*%H>3OUM--WF(,'M9PP+]VI$9<UQO2T4@CE<.-0M.3
MT:5ZE9:JR8N[1D5(2%:;_ EU=73C]_C@99>\%5];F=-$>4VN]=GLY.U;6?&.
M*3[S6G55#B9W_,^\>U>7TD)=K\LJ"^32ZV+9FMR3@J\$>2$()011-QB2GPA'
MB"]XD4R]>&7CP3_85DUEL*7P9JK&LU54?@N[.PD#+?<VG)VJ2& 0)-2+R@+D
MALRJKPU8^OO+T(@1?OXAV^Y?7$X<.%9WNB!1<Z!X\L[[AB+4XVS9A,S'-7=(
M34U5UB=.SZO)-(7OAD0:N>'F(\#+?*XMKJ>!AQ7%69/M+.(5[W"*8ANNY39E
MY31>D!VW!)W. /QVP$P$]RRNYYN@C\[Q$4CBEMI9J]BA>"'H20=N+)Z^&VB=
M6N\CRIN_]":8@NMNO_BG^CJ_ +<%17=1E'IQ/WS_%HW)23T!H3B\&E 3*&"M
M@5:W5?]D7#B,=0_%2X%,T 7=I+_!NW\!9?^EJ^@YPOJ&8%((FL"G4Z;7H3L7
M^[\W"?Y-[$#Q'6J6EJ8IV[=0_*BK0I!]2CS %("'!09EJQ+._#8SF!!T&A8/
M67$;%8(VAT)@T0,"';W='4F^IG+3^*X^SWQY^^J__]L((%B'3'\A[1R%B*+#
M/0'QA_(O\'Q)3YDHO&CF2VAMM.=\M"<N49QW?SUZZ\)]UA+%D<XU)"7@=A-]
MQK[\(*P;B<AHY6R&(!7E!@0)08<AW53*7;,/_PO@S?^@/Y*+W0+Q<T)0ZKL
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MM K42F7PG.L/$C?BLZ$&X1:XA3MM"U(X:+;Z$\/#@M\Y[0G^_%'Q5DB,X2U
M%=F;I@T,X<T'PCGI!;MSMC,M^Q9M)_X8.#.9UFY97E.6&1($>&;(V/P(4?G"
MLGW)DCQ],_:9<T9.6LVHGI.!39K^LV].[.'00?+W=2$#]245VO$4ON-&?<#X
M&U2I.?E)G?FII[G$7O).+UB<_@I];I#L8R=T]U;,%+FG-P,'-,VU_O1U9P$Q
M,J[)8UDX[\I+FO2#,T0USO=7:9U7*^OK!=F&'9DV3WP>)S4QZO_0S!A-K#)0
M4JK+NYAJRU)Y2%Q.)%&,J.7QS);R1"&1&#M<Y.D+SL*I)X4^GE@#S-MS^YIY
M)>!>UKT5TE Z+X&[=]YA,<K/4<$[2W ,'-77UFTH8'6JXI\Y8HD'P0AW[S=@
M66/E?LGRO@I9\2-@0%N_Z><5VMYA-.^EQDM]HAS+1V*JE76WZ)1P]HOF$P_#
MT@SM>S<]<5T[:SNL='P.52,O@']"TR/$2D_[0 =[7V(%/.UID%*_5\,6:"1S
M3X*C;^$]C)3A(3"3)]D^G&K.=0^K,Z-@$SL%1J,_ZZ0**/1+!XU]^_V#CN*V
M%[BNZIIFX-5OF28!X0S:A_X=PJ'B+E0]\!YE@QHO V 1=  >7@$&\+\& 4['
M;NYR,_+H"B!_>PC,:] RXS1JJH6\UVZ0CK/F"-*"!0I@E-RR.16D7?_RK[K_
MP=Z;1S65K?NBJ;)L$2.BHB"D+ 4$!%0Z02"[5$! B+21-F6#$&)((3T$LDL1
MI).21I0NI1 B;50ZI8OT!0A(&TD@(4% FD "$A:DNXN]]SEGOW'.>?>.,^Y[
M][X[WC^L$1A9S+76]_V:N;[Y3:Q-\Q=HT/?7W]+-6C>.JEGMY1Q)B YD3U]T
M'HI_+:A-L5 _BF(,8JY;>V1RHQ9NN5<W9NG6AV@M]&*IW+$P%,$CBOI("N$K
M;F>)3]QG22$'EA"2.)-U^/ S*>03Z%+9"E)(]#,Q3DC<@$LA05 @Y?MER9-F
M$*P3PM2ED$O*L/FKA*]WI! >:#V;6A<(XZ"- "7W<]ZL:#],$ ^Z3+^M&4N.
M>J<8T1K*W-,D+D)PP_@GK'@1H]1:*OO(B/F/GO-$>34>M^+=9F@<_5N=>>KA
M\IOT9P/!'</:W K=OJR;99\\-H_]'!\>HQRG;-U[X];]PMF>GK[B>XXS@0WO
M(TB^ 6BW,:^O?Q;H^"\AN$'5%31:]R:ZMBN:.+<LV1<*A'$(,$+S3S'ZS/ [
M+(=&^+Z&"%X\1XUZJZAE_4 _.T6O8]3D,"4P:*_-BO(%"X1<*T?9\A=#-[>Y
M ZSQ<^[TOKF5!BU7_=5$&U?OT4Q_!UQA;L1(S<BK\Q7K;QL7@V\>FKN LLS/
MIQ;-;F!H\^1<@C.*YT=MM0MJA_,<H0EPN5_>-FYUN&;[+K9.W1D)">?>B394
M)G0P]7D[?F-/[)OG7VO&19>BWX137(8F,T=M7YGJ%3=H]F#.HC*F]KR)0]KG
MT0SNNNAGKDW':MH[VLQ592=[5%9F-U8\SM5LM!1:B)<1W;/+%)$R^ !/M0,^
M4HAO#@^D8A=89_?&TCXIY D))_QNJRL/KP,@LJ40QI\2C!0R.0+;L#6* UGR
M/MX/1%S9?4W$)/@7A).$^@G\^/BN$1]92#VQZ0_F80UU^K $9.S*2L!."GFE
MVT[?B-DZ<3E"^/W6B5\IG__[B:40(\KWP'('54;DPZ8\(NS#(SG0;>'+S77M
M68_PZE/0/?ZT.H5'H@L5Z,K3 I.*U-*Y(0_F9V^&S0M./O-V8'>:0RYRSN7X
MGM>9)K^GV 0E);/U24<MODZ=JAJR"\:@M/1^,\P;0I=G#Q#'U!>U0 \9!JRW
M*-Z)GT0PA)-5Q(/8TS<J7Z=/935O'\3#IQ:>_?+SP>SXI)@C&"-WU/T&JU(O
MX]6E->@>((G-C3W;Y@C=Z^5I<YN2W,D+T7SL<FY3TE[#>DV)<*R?V_/&GG2^
M8O"A+]W!>VYDKY.[,U*RPIHI2]\X+UZ4?##?+OE$?&,D.H008$;PEWBS3CP%
MKC(/UH$.8<.5 =UVB:)M)6D^X0<G5+@M9^=?&Y W5%Z\P#Q%FS5.E\PK1FJW
M06]QH/M8*'2MR9UBW0Y:ZZV59,<4"R?91_%4>Y+Q'&@&#4Q^1]OHWJFH:_$_
M9Z_N[+/G26C5RV]HB1U\1;B82^UE2&1 WOEAB <7R2,%0P]:X#N8*[I_!46P
MZ!"TG?"0ON]%V"O_L*;OD:/5""A0P/Z2S21KMPO>H]EBU%4OVTO#N  =@Y,\
MVB-]KPO(AN%J#Z4)=RGD6Q/LX_R=9S"T.^MZ@<- Z<DT%\5D'\5$K2NKEJYI
MUE;YYP*3;P[?:O;.)E_0?5A*8M0U3JRYA])7JOM'68">K\0>*@ I[*T1KU,*
M<<(&-#S^YZK@"OF(3=WA35L)U, 53 NH9+?D\P6K)*K?B/:#*CT_UH[$^Y'?
M-U__J_T5UQ/G#7K^=3)515?B!488""YHT3$:Z]B-__Z[S9V;$$)S#FJ+KFN(
M(%W'L38?S(]LK"M*(;#OI!!O,'+G@OO&_S;]+]Z:(+\%GP8-=^VR.)O63A5;
MZF)FSR$VE,"$$ARRE4)LC$I%QE+(0^(4%_56Y?_^-?3_S-I8X884LJ.#T U*
M(U^X4%ZR]5+@,9^+ET(.$OY,5Y"<ADL*!XU:"8<B;5?@PX-4=3-YD1<\ +5A
M1F#(2/JR!/=!=U?)H8OKMTFF'X#JU1,.2IHO_]@F7AOI</Q_^1OH_['#3N$S
MY.3LZX/?20?_9Q<)_\>';0(M#B@.XR5[+"9Q?R7N(* )._ 'WXO_D,B)[@*V
M/ 9'D/1*TA_O J1P^O>"("J//UX8WF\]@/?B,9556CE[36JRR/[\]O)Y%67>
M[".1JH_^N5K1R5XE2Q]^L>_8;?XA7F7;:3/_0R6?,@*/54UI..:0-9Q>L2K1
M75$E3DZ816T[+\5$3>L@C9,T'8I+-)@Q9(_2%6(^';'X7.B\P#R9TUP'6^P7
M_F7!7+?VR4UB2QVBF?B(GIKP8V;?\&/LOO[6>_.!5S[N<H[RN6,*N4*QN5ZF
M?X.K^NC%$3/G:??L!UX;.<D$6+V]WY=,;H^6H)(*QIIW_#H,C#B0RIOWFQO$
M=#'A(]0 &$.AF<M;YUAT/E 'W30JEAY7L)>IS<N,3]8NC.\P-P%^(Z.75:GQ
MU0O+4'V5H[SEAS@<>>0;0QO3GL)I5+ <80],/6"?SS%[D5CX^HA&2=7X\)M#
M:>NJ?R[O"6;4FLQXKF3;F"\>5-7_$GKM)6=CIDS2S8UFK-;D1)+(NB\(S>.L
M:DI\DXJD$[87?MM,][HE\%!X"6\]B,=R9 \P.>II0VQ82X+:\'3C"'?P4J!_
M-JLM)W4'.=X[_"G#"2<#%"RN5-%/?GW_:^@^E[.9;RK@=:V#P2_4\JM+&%<:
MB:JJ.B&EWH.PWO!GQ>Z:9K>75U SH/X7+6"^!<7^%QOU-Z0">EJ2RU 0LR2=
MT#%0"UVE'EGXIXG^@+_-L4A^)TR^(:XD@N"V+NG%<%B2 H7J56-U4<I;$.SV
MD*00DM+(UKO6EGZ^@#(&/?V_O(7L_V.';9N!H-BX"I_65*S=PF"6V%IR%-G#
M#Q,E$I;\4R7IU[ZV$N0E$[Z;*-KT[!\$T*NUP3=@(O!;M^(3J-_6HE#UE_XV
M3ZUR:6*S,K5D/P@=L'D$&,T?I)!NY:VN-I^%_ 4I!+DS";-2H0E*F%["YMK6
M'@@.9L>,>%EE5#T =/T/\JC39ZE55N($(@1T=M;ABDVTAU+(%^M8*>3P"= A
M^N>^(W*H5R16D]NCO_LKR#3+6]E"G9:'OPX3_XZ @LP24XQ*]66MG =)D+8N
MA12V??LJA>Q1(9;"/\Y*]H"_T;@".MJ_$L;&1"!!#2\@*</G4C<.^; $VT%1
M-G3V/#BZ P2.[^8MPK\_<];L/Y]YN4!T*C*F3 K1(P):+!'IA&0/R&^^OOQZ
MD(#+O?\OU297V_ZEVD0CIM<D]'FI9( *T<\+Z&AU'JB&IQ#W5'%1=B/:Y<O!
MO597&_G,!UC"K5=C$YW:I(F'$V5O&4P/SW;5!L&*]<&!AH#NB?"X497Z)'^;
M%.3AO&Q_V:+L$7T!YMM/%R@N&\2O?.%-\+94P'GVJ?2@]LVL-G@<D9<?TY6O
M-=+;MEF4RG-I,%9O2;GD^.[W/^E$D9:N'%JAAJGRQ/QZP:!H>T6X;FO2@7I9
M&>Z]QJ$8S'U.0X_L=ONWY.1$NLO[S-M95JZZS.5>1[V<J)Z-^MEXLK8+1U2S
M5DE(]RHK#\H3_P:?I"V/.0FTQ'\T0(57@-(I9#LT56($N'"4<(?Q>I_6L I_
MX>V\'PP_B)YQTT?)8;*]GP16+,2<&,&;A6)#[.2<VK+-GQPN1BOWD0K]7V^$
MOG&]T1Y>%J!8I)BODJ]XZ(^YD2S34N=?GZ8E>Z2<;[<Q2J8<;4(NO:L_$Z>X
M/RT]P.Y"^6G*7.A$+9-94_6>"!@3)'O2>;:3\,54/EP X\4G?)-"%"2#U"ID
M/-94NPSP_;FQ=O@$X,2C+[@/+34X50";MA@BD#'?I#YPE])@S$;)=G>53!B2
MC1Y5E#M9#MVR<P50&A24@NV9XIU[=53LKV6DVU=[NYTJP93=4"-IL)[ROR #
M\*5R#J?>X31B9/IIF!#6Y7+=U=]Y.Y,H33!@N=G;=+#9A'@?[\'N5T!_,!S$
M-1B5N6$,_VITP?K=V]293N6(]ICT\\4MOT;9GTOZEH:6[&7;]YKW22&@P,MB
M$JJ0S=!D,+NH=W%CZ\V$(^9*_I&(-N@#JE+#3EPQO?U>#?*3U]=\U:&]BK2'
MIDY%)VM_=ULPN?&ND3>;U& <WF^>5<+P=[<0V>K+6Z$2;IY"?N"0+5]FF@"1
M3^OJUO]85OP]TDBAD'VRVM6?9G:]^GQ1M2-J,&K3@* >!>OJYU+!?]T2\X&P
MM>N"T#]FV%N&W\F%1@?Q6@41P!3?EIW5JHWK,)<G-C<=YJ/B\'(<Z $@1JO<
MGM%\F'F&O^_!2Y0;PXH\1R<^DET4#)R.7"JON&!WDHKZ*R<W1NO0_19G4IPW
M3<XRT_U-[,;T;FM+.ROZJ8N.$U6%U>NWE$YDAX=;ZJ7=&SR']O*PB.FEYE%8
MEX!]E$_[?MR"_T\(R5[0D:5[B]_ %QNWRH1<OKALS/YSY<GX_]&5)WR;X9^W
MYM<PA']?2_'HGVHI:/^[U5(\8/'N$D4'M=@LKJYP3[B\P&/4U('L'O.)]38N
M-6@RSZF9MOZ:L6"N!EB@2\!G!C4-8=?O5EVM5MYY::!:VX@M:1(0_;(L1JNT
M;%-<M<UI;1(5!4(>W][#238U_]P9G&R2/WXNZC6EQS]C9M,F0*<,%^"CH1IC
M?6_]QFSO]L/BKW.XI6^$(K%!3?P BN>  XP8 C!N[J?BK\-5&J*C^$[LG1W8
MBZWV0WC4%/Q!]FQ<%1!SG/%58*AHF10TA=W6H2+/#\B)*//+5B/B"M!US#A3
M^*L>L@4&7=Y;QD#7>;KFOL?)3:W0M:#;;:IWU;#W#.3->;VWOG@M%W:Z<#P[
M+8W:VA,1-&*S_]5&WM "!D-?%];-42U4B )#\5,I9#*'P+/L/RHZ+G[2),N<
M5X!5H;A/.-HX^S<C#9@*OR8=8(Z_TP:(FDQ5P5^LXT.34%??\$92XYH4PI'V
MO!I* ;JSE7ED0']W@T/QG(#K4[) J\LG'YP*=,L/LV\Z]]:A9;) H6=7]\'C
MFNEDQ%.%H*!R\Q#U7K5A^5&YZ4=LQ>#L^T 1$]3;;W'>71[]J)Q4F?^@I^?\
M/[7T?/4&UDP4@W%" EWH.>I_M'?&L7_>.V/ZO[9WQB"H'?0(7YY+P,$)S/"@
M>!C:V>X.J!@"*RP>AVIJ/ 8JB"RB8%8RCJ\&AYQ&Z.J(:6<)+,Q/$.9#R$CD
M=BFD;HJP^!-L\V[NWULM\TDHOWO$)3F.%+)Q0.0@A=QLJI5"BG)*1#JI?#2!
M]B=A[LH:LW^ . V70G[X3ES5L%TH"X:]S=8T,4 IA^T5:0*9[&5Y_)ZM58Y?
MTDY5+>^=H^[W&=0QA7-D(ZWS3Y6+] K#EULE!QKYVJ*TEVC%8\C-GMT=N=AI
M,>;1&;W.Z9!BQU0#_P"#.:LR$H*3.+%JDTL^HMJ0[>Y5V5M@L">A]K:8MKI<
MDU7K@EVK)DDR8+7$19C0A-!L#[\S9[X#'R 9;.3%%!3[2>"\G:FB[:5H'I#>
M+#E5/43YXY,(,SGAS>F_/H [O'!Y=,W,A",CACL/K.5!K]<_:E&-TEI ?+PG
M:I7/O-G8^$/&8*9F58EZS_D)XXL8:S72P2'/M\E9SE]2+_Z:<F6EL=8N.)K&
M LE):UQD*\XC3([W VI$D3RJ30%>@^)J\"GML(-5B-]4\=%%\P2E"KSV)/6!
MY(>F3\M<2A7\$,8;-H"U8R6*+ I9K6AH_+=>A&?C0+7='0[]B*ERB?_*G!Q=
M^"Y?]>.J_NOK5TW]>N2$-:_>.Y<;J*(M]3(+=E4Q,M[?G#H4YJAA_:SCH4F,
MJ)#NOO#2NVZ>UF7.T"#8P+<W:0&HJ<YF5BSK&'Y?77:XUI11*^)[/))W'Q/Z
MY#-&@TUXE']XL '%7AM9O/FN/K''R4O]>I6"X(G7A!4V9*8E2U[S=,K*VM=^
MJ'>-"JF1M*?Z5'\FT_1;$5O'=9'>X)7C$?K^4W::HX=^]K?(#0DA0G*.6HT2
MY4&Y)[8(8PHJ*8/+(;G/4.MWX>)PD'F*.!&Z8?/] AMQ-BAPQR5@R(X=!)!2
MR"N=!Z@D4+\QW\ %<F#,VU]9N_$/\ \&7D@AJGH<=7&JMPX8XI(7J-I_Z&YK
M(7E+#Q"Z;S1M)XR9 V#(E:2W&TP&(D0)@?"I5I!6+/3P_YA:!"WF@U)0VIJ?
M_%LBHK8V(.C>V"<'RO):<3?X% >+\_YU8O&L_S]6K I2QZ@2^Q.3NN*GJ0^I
MF[E^+IF$23!K*2[P;W$&6WE[&\F.KR \@XF4P930" 3'('Y"N _?3.I!E? H
MHH17!-JXE23OR>Q-0J+XQ :LSROZZ%__LZD'%0I/=PK71AFKGX*V$E-A.QLL
MX _-U?":?._,*=A.S&O+]/**<I+=S"[=NS.RN&*T26:])SI[-#T\[?/\IL6T
MX'GTP=&LH,MCR!<(>4O2G@$GDNN!6,YFAZV'F2(F>*C!*[OR2F" MG5 'FU-
M'$&<GP#3&+R)]QMC^H@\9]W8N@ R6QMCP[/BRK(;#W\0W0"VE\SO;^; H?YS
MN(.1Q$=X!=GACMD.F"Q.=[WI"<<,SE50O"L_-M>D53M077QX$-6EA\^1SW3U
M=P@Y,Y0N.!]+.:KS>[&/GXL-+6G0-2 GS7'Z6[%+B@6YK4EUDZ)++'\^@ZJ=
M%2F)P8$(MCP*0$$"!>"U @63G1V]D=9+:U((Z%>_7[/3:MDD)JT9G_C>[%*G
MM\)H%4HN7+>-UN&S:B ;&*RLUTY_JV<1S0G;?5<@]!%9/)OFI1SI.Y(H]S;E
M],5[@D OC>'D D=-NJ5VGYSP#/)FWBZ[B2)B^-J::Z7H0HT@==HWCC#9AQA3
MH;GHA?<(:L0%(5SY4$LB.V\;FQA;?2WG,]>DH_@%,/BI]JF#4<HNV?G!NYHM
M^FODCF=D6-#V^.3Z/I(UZ)*^2SWA_1BE!R_IW"B46'OPPX19'#0(D4CX9"KA
M]4Z1_*QD5ZT0-2^%0)IV?%V'RW^;T)V\:S5%;"N*![]^5/7I@B -,"M"C:.9
MIT>PCHQF CW2A]N75_(9;SQH>K1@WO5>C^S2<WB.1DB&K]OC6WF34X\J1HZ:
M6@G-="<^#<FX6Y\O[2:?3LN(+IO77T-</H2^F'?T7GDT*V)>HDHC=^GT;>IM
MW-G:+1L<E>TB2+#/635/GT\18>8%1HMB/L$"\9!ZC%L%W&E\]^F;5J,]F!NM
M5+G%JL^'E@QDEN/I7WX2+ V.:J5<7&V)S$K2YVJ.1KMN=FG-KXZ_F7EVU)'L
M\XBDBXT/Z+)!Z\^]1_LX:I?6^IA;+K[L\S<PRUV2*!12^Z>WUFX4[>0J"$UB
MNJ00GC-LS!$1#Y/SL !:>5!.1TYA>&=SOB%/(0%+BK+]^C(;)X.W  *GE%67
MR[$AY:<F/)64VCW$ABO,Z$L7:5433I>'0Z)_6E_=:ZA^-&/*C&3N?SY1>ZC8
MODPY-WB&Y K-?-?=51U>->RS6^/4G]]4CPRGY+_!6%)W5$]$4B^4$KM50(S9
M<?LS-=DG6E>R9WL8EB>>1;^H'H;? 7 -MW!W?7XORM%>HW:4PR\WYOVROP"#
M)E^W7&E(@T)?7G[2OU::$MU[;YF)+=(:QU%YQEFH4)";56:-1@R ;UL(M1DT
M+"FDWJ:.Z0E -WS?5M*5187BORN^CC<"S";/5Z,>L0[%:.+M^*HIC<N/# 1#
M^@L(.9$5\)"#Z5^<^(F^---J-70Z34;&2\MBZ.YI?;&6U9#VR\3S.=-GGWV\
M$YCLHFDQ4G[!L< R0[E J58Q>&K9>JS;KF9:C8$M/5%T]N&I,;^GY=3>A8U[
M%%!"&L$!':KH((<FV8,6WIX(KV>+LC-@E9W-T2K+;.*'>J^?=;35:%7MP]--
M?&2;L%%SYCQY<%GRDW\71KLZK^T:B@Y87>)%/RW'8$O'6%:HHMO&*('W;J=B
MWX1R7<PCC,M1MU.#".>1\W/!BS,S(T-61'=R52:MI0HU.T18<1^K_-MKGG]?
M*$_]9[N2_'>[\@;4+0F$+I[D(US@_RMA?@)(]R;O(/Q9+P^ZA$J0#@[NY:/:
M4).H3>?4+_9-#3-PNNZ6?$T_)4XE+(Y2?5EB9^8!2MLJ;./(+>JB'O@U<HE*
MU3\V7I? J8HB! 4X(:@$:J<0>_RSW&&)^!/"R\!JFT1Q=-'-<=V*]@V:X%Y1
M6N#_-*"[.\L]I@"-#0OX6%9Z^HK-[[MP8R 7MSK%IF7X7I3+\.X[5Y2.Z"+?
MZ@X8Q)6$B1!K[N#3MB,T7VN"@KEF#YJ=?EG115Y?Y<NO4L@QO%8!VAW)_8[W
M&^Y&JC?/*.5$K#L3XVKBF6[&I;6R%+P8X_[,/?P?;D99WYU)O]CT/JDM6^<]
MV2W&-M?'X&W9U1>GNJ]'="-DW9F+[+JD*,W?$4\#AUP^-HY9] R1')Q3:"#$
M,B3;YH":I8(-\'9OWP;>=F=P$*ET,H><8*XOZ8,?,8"/&;6;&PR'I,H!M \+
MDY>!'%ZE!]^U/'PS98;";E1NN#'9>(N]+"@7MT]W%)/1=?GOV:6AV=MYLW'Z
M6AC?RKJU%8EV&]NO(T[S?GO'GK,/4>C%DE?:!XA+\Y:EUB<+-]36<[\PGF3P
M!M(#=#.;GM91)3^4;X36#*S"QVPELLKBK*:]"\@F$W&IQ C($I0DV0XNZP03
MX^@*L<LQNX$?_,\RQC.([0J;5JEXIRG$P9\#+BL<#LWVKI^L1U456)5>*KM^
M@6[^KN),NZM-/A1Z3.N>]4CN2,3*!/YLYOFA!TM?2N:J<]Z]>)@(Y&1EOD>R
MU5@LV(5%@C*!9\UBU"Q+=O<+[XE@8I*.=H@R\D-D2%_!)#%9!3988R"IYY$[
M:A9(P(O3OSQAV_8B6U<J<J:\=K38YIPW@.X'4%N[Y=X?Q,2C*GM?RYS[@&R9
ML+QG$WQ;D.*/RU9@6;NUV-.NY6;77YDFP7T-='(NA!*V:@X#)24L.?PVH1:A
M^2KU-A;1HMB['"<Y+_G(JK)Z@*T 7>3^< ]7ZW+<HMU'Y*9N@JE!&2/^W2<1
MDFT6T\+<[)U.-$.T-JD.JK0B7]N67A ;4M5(3@J9MYP',_>Z*F+/VU] HR_:
M6IRWUR;[HB\B8S.'4ZU?#3^L3<Y"-'\;,6#8%\^G?E'BT$1'*SE.4Q<64G]#
MU73<IT)Q!FZWAZHH23"9$/DIV+ZO:<9GZ-Z8IOU\N0'\K6)ZY\,T"0P*J- W
MFFZ0/T/DFKI3%9V^H*XWVSD[C P4*^RVK4OFGK)H>NR$P733C+WE6!/Y60O*
MR EM5)?Z=/$:JID*&!@)+,79YH= 6?%<:(V_QD=Q?:<(^T0ZP&]E .)RDD4#
MH,?K;*47$2<GW%=Z'!H^X>%3,#F@MMVD*:OXYT-]Q*"H*:Q1ZXKF]F'\B=!V
M%1WW!H^D=F3K0,M W('<!<?D+U_>'/)1<-0HG-YU<8\#%C[1YW7K?.8Q_1-A
M:E^X+ZNS)!G+&Y%,$)W-$L5[V7"&@@ #@D40 *;&;2<V2O)'G6P,+$D*B=R:
M#;' B8U/C/Z]XAB>1P!.(41*7*$JH=F] 5$4PR!4[N3*8GB8=BGDB/Z"652[
MMPZ/%OL+\()'X;!K*A]<J>$?RU=*;3??-=R@//6(9B_YR,=.5Y!/U8WH+SP2
M76(KX10J&DN\Q#JHMNL?\W6_2VXU&?ACX_A1Q)CKR]HO,]/%BAF+RW9HO^H>
MUVN_)I\MOF@0#32YKJ.]X)E3E#""<_Y; 10 Y:Q(*8^W3;*[EF^B2Y?OA,GC
MI! T@;[-JO)]%6]G DZD2(0V*/'JA1ZV]8,A0I!Z 1OX0:!NRI5O^(+L;T2_
M"! ]1_/N?BN>4;1_4,#R[ \'[HAL'WW\*G;/4WW8VB41F _1A\O1&A8VGAD;
M/V7;M1AAES4L5KH&7RCBGC>A@P>[(K5Z4(821/A&JNC8WPJH>(C%>J$:T"HP
M!"(X.;;+=*3@#]YPOCPMV$MM W4-P/!TO5>U\8$<U %MZK.[ ::$@LZH2=A>
MM-&=P5G'UULM^+1\SX0'WJ#2'KXM>5;F>7;DEU$%&9UP8VU-S@F1P;[YC')'
M1W<-2SG:\Y4R"XLC[]27K3T&S7 566/HU:^$[(<QV1&SF^\)S76L8PTG^!3)
M;@VA+B.<X/%Z. 3$P3ID0HR,Z"^#VAX*,0I\W0=XAU+;PKFZ7 ND3P=YTLZI
M6:)>^T2FT^!QX]V.GTW&+12^C-O%Y^V=.J1A\0HI""GNXI[JEDO.'N$ZZB4U
M-BG1>U4R=ZO;F'LOK& DVQ 4HI\DC-!\F3HYNBPCH1-JX(^E$']X/*M:G[@]
M&)=<)TY-C%$'=CH!SA*S[)ZV7A]?-,<KK#GR2XPYK^XA_^IH/#+'<K3L=JKM
MZ'*U5HZ7(U8'HWV@=:#G7<7UTX=,M3W5:S-WK3@6*S)[;60FDZ<62;[;EU8M
M>IZK!F=GD.1;-7J[;#/-1BB4D&4K L(VFC)Y29 /(,CX[6(2P0_W6[9Y>10%
M#=]A;HQW!Q"DA;J,,Q[S)J-YO(5..GAW%JLQPBC4-S_=$"6LBE;/*RP(6P=7
MK_PNX;I2?VYU">%]CN2>JAO6< ET?U67,668/I\>>K[PO<^IY1XU"K./22 R
MP[$!_VE'J/_M>X:*[/'14L@)5@IA$<N'2?)U,>M'_F7!,=R:.OF8P'.(#I/L
M)@O] >B4=GM?02 OJ+U(-QY6!8N[&YL%8\!DJA<6G"(JW.86GH1PX)#Y:V-
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MSF17[;6PG)<CZS4U])7JJ8*6IG2[B"*JANWF,D7W&_@_?_ &K:@%&L6S3GU
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M.SER5"4[)3> 6U:Q3%"/TA5M%W$C"'D*W FA,9KP5IW[1&@=\W$3EG"''_>
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MB0 E)G%7+5=/:&74<1Y$=B* 8BDZ38D4D&&@S%!B P53X>8Z[A.H.5JVV:*
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M4@CK>S^6?^:2#M*:ATR\13/5+K(*##R9I=?N4]AZD':N)_"GHZ0(I7BYIS[
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M.3FA_VY7]232=FIRE0<"]]&O[F3_!]?'W@JP):IX(#GZ+M\&QCT +QZH0(\
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M=&FSM.!\MTGT3W!4T:UK5")#X=!^KM;2<MQ?_MD37VX&EC(HLFT<3OAK0C^
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MZUML^5$E/>$%;'7 <CIE0:T06[Y2*7( Z&NIYN[K/QOS3C=Z:?J$ 6-?-"L
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M)/#8Q[I%WZ'V8UV^DO&]&R^ZUV(\2=;/:,ZGRFRM0I;-+S^;J_0Y5G+^LTE
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MX;HHY[#Q_CY1X((3Q$(Q()H&D;5X-:-L)D))HK? .RCG1GX$(;#%4S,602?
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MP;R+P.]E",30.^A&'/9O$MN4$\D'C;71R9R*1-+W8#BOY38?M#4*LQ#AJ*Q
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M5(LSWXS8J.:&VY@XV'CJC)?A=Z8[!PX;G[2</41Y 2X7"$PBY[0H[WC!OCT
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MS@P1H;B6:S*:_MJIUOY63/C%2\O?"F9>_N2IF[Y.FWPC?L!2Z0\BJT1$E%-
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M\U:&7?!DQD#HWQDAZ@UH X_G4+P:.Y3*EQ;"N.TBD SB>XC<8"#/Z0K?Y.T
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MZ:P7H93#P@N+[@=J1PWU&#.6G1F-_94$>H(;;G6]O^1'HV%MZ'%+K0RA/3)
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M:]"='\?E<J$?68#!->:C(C9->.CU._ZU$:\49<';79 W+#;O(.<WW^E3J(.
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MOZ7S7+"#Y-\%:3@?_"L1Y*/B-4WSR_E2 ($)B7VZU"<9HQ'>U]XX/IZ1S#!
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MBW:E9O+$"Z,'$@YV<$7\V[]MJ<%O;JWUG EV+FI0^LJC (^&_\%YX1 S@31
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M;1X:::WNZDB^W)))=OP"NRQ'$#6QL+ &'P\T+.)5#4+UU? A5.!>+WB9L"*
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MCW>C]OL?)D6W2S!5XW:["<K=GO9MC?5Q/ST>KJ[NNC21GJ;4/1D8/I5LEEK
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M6/AN;88E<?9VMWQX>G@O-*B#IN^LOF4KX@:I51.T%9]I]<A /N0,Y<RR[#%
M/=&+=\TCYT:&JOW&CGG:,/HTQD( 8L?,H997G"?T=J3A,5@SOU-=Z .!6D>4
M?QJR,"*G<H0D(P0 "'.1CO$KV@ZR6$XSV>@=&VPP7\08+:TQ?\SDG+<02U1V
M<#) ;2^OJ2_75L [ML/>?CWU"U=',*<+J!LI$VA>MS-CGE= %4;-@@T\0_@.
MS)@/,?G@_Y#ZB@_QKMX[RH>$E^+4,+U3DLWX'\+34:T-?,A*[SF.')>T!8^>
M%&O2C;-"38H"QM&D"9C:M+5!WT/][B3GI=/H-^AG;I]JLIVDLIWG/QFE* ]_
M\[![,+C\5U/6"*;'\]KN:(-!HETE1?[3!Q/OHH -X_7C!9W-!%"1O")QEFVX
MWDP85V<%/$G3&T<LZ1QZR]1M7I7X=O#CQU;&^B]+Y*J6;P>N+QHH?_>E& []
M,[K9.S[KF.CY0\4RRY:;LA6&D+^_3"HX$O#GN.D_&UFX95[IIJLQ"'+0X,UI
M]5'VM$([_#GAQ J^NM$/B&((Q>+.8BJ&;N\J5V#@#YJ^$^>J7P_A^HHF>A^-
MA'B-_79\]25KY&^]?[XE(JKZRH\92MLM-@R46TC\Q>[PL788=X8%>,DF#.O5
M*9QF[)@7;?S7IL.Z,.^X"#>F]S^\7[#NW#JL8_ZN *56*\@M\ BMH'O7>B5;
MJ%%.Z81I<X3YIW_%D+RK8+KT0GIE4KNZP:E;RS5WS3BB9Z:;"D+.'#:;R(6B
M'=5WV59.60CWH^9?O K060U_?ZSR"_-W\G=>7AXGOZYFRK'Z!8+CM6"\ROB0
MQXCGLE)#E F QM(!.E>E@,DSJVO'QL)&VJD2N*\(*3UC)MKV)99B-YQ]T> 4
M&%S\QY+3.4LZ=U.NQN\WTQRAI4:Y>.+EL0K-^YX]RXC'9UT.?[>L1WXMPY:,
MAA,T+YUTOOT6/_Y3  .!$X&+H= "!.#;R<D-8C7MTY71:3[$"3\U%(Q5YT/D
M&A5 '^A>O.W 28X4'S).W;.UW/A '!;5^/]]E?\_Z:L,X'E'CPLZ]U]NO*##
M8Z]@1%GJH"[@O3.MU988A1/M>U<'FM!%Q7]P#(#>5JCH)+)VK")<(;$QP(=.
ME+C+N\XLDXX!*QA=ED /N6SIJJ<-2&R7#!1?'K-9AM],G[F_PASL9"B7G%KJ
M,;?/.N<XG(0EC@[,QQ<W=XX6+LG+NMY5O$QYX&D?H7S3:-7?XHNZ%M*EB>5"
MN[UK\5]^=\V.''G!ZSWEUE"GL@@G_47##>1 ^7*.$G,D'"O/H!U;EE4;T/,K
M,,=78%$ A?C0ATX3'_68E&P8+#_=,FHP/$:(\%?,;4Q]%ZG\X9&DY79=H)5*
MWL$WU@'3+G9Q2T:>F87]MF>=4K0+DRG#614D;,/9(26EJG"34D=8Z/9B/KYB
MV *QD,L.VJ]SBAM%L#SQ-7!>B?H9A[E=-"?N;RA+)D+0H5L]2X368MX1_*(*
M'V* !K6">(?;M5;GF8^@8WA6!#!8Q/H#5&?<-:Q]5>*L,\8) ]_FUTC6\@Z_
M4+2SWJ3O1#Y!N=QFZ*^OJY*>)G7]6_OZ9VT!0Y<JPGO5%DQC!4!+'\[RQEW5
MNO'?]!7R2K;MBU7MY,NSE^"15PD21Q^L9R .('@'V %] 3LN+&<R=%6=)RR0
MNP<=0&>!Y"KA9F:V42QB&>A$BD'EH)XN6P_[.]+^<H#+HZ]CEQ68^%?/5@I>
MK'72B<\-V[-[:ECE2,W*X$OI='VEM99U!YV<=*:4FI6#9KLOQ8->3%(Q]R[6
MSSTT8%%N[A5V@:B%<S79'BHI[F!_6:$ZC*H;A]4T]6[4,$<2>##>"%YV&RV#
MF78>X:E@@\!-YJ&!U?KXK5>:U8Q>:;#!AM3O'Z_V5>*$X^@?(UK2N*AW'L-7
M'1>EU3)%"'F+]K5.;JFD&FB939'QD5L:BQT:'O>*GJ2]?OE[Q7@#^DYF2OZX
M]T:R5VUP>=W7=4<3[BJ7EEZ0N"W09R\\<?_"?X5/)>,K25$OZ,DM>XA7->N'
M!62YC?O!X,82XG%E<KNK8M^6<_SC]I!)(D/F3?EL-1@\989>-8,*(=,M#T8^
MIV<ZDF12DEV&L,:EGH37<V\3Y&YT:JL%"<'=7K:64N[7^39?5KBX-!CHAYRT
M]E3Z'B<'M<B2N"%?L!ILL%[.2?^"4T-\V5D-$ B08%P?&2H%Z]9B*8-P '4'
ME*)//'6&BX)1TPY1>H\9O;)8HYJ!BK4+TJP\MUS,=+,3(MQ?_<0?YW/&6Z\X
M>1K(#>0>D>^-Z6<$^[,M*YJ!0 FKV(YAHLJ=O/6.E[D6V9K#?;X%5H,IYT:N
M^\11DPV[NO5LB6OR3_8F:JD;S@C>)*IG?FM<$ H/!'U3 Z)X1[^P#<#JMKW>
M\*W$*/Q9RHFE/:T(' RKWZ]>$6 I8DJY.*#FW0B;)A[%>[PER:"%P+X:HMCH
MZ$)&^V1>R4)(>A0L7FG39ECU?>4(#)'>>RW8[4RT$4S>1M31U%_)1![V>02F
MO;$P;VYZ_*N2DJD/\E+!F2VKTM5'$^7RJ(J<4B\H81I%:._EG"YEN0$['+';
M/&%A('UZO=GRP*(QW;YN&A^!K\6W(J*N?KGTFIY]O5WV,)@M0II.C#Q=M6\1
MT);9NCX-/:)95#BZ&)B(I!.$,;W&?5L_G/05SR/(GYF^/=<\4U ]KF-72I^7
M.C"R\I3L(QQ"_<Q&NQ6U=7O^3LFN&/WBI)1Z_ZM >Q=4U8=4%"NSG(()0T3.
M22A/.&)ZOSA(&R)A\B S:H4/H</#?3CG 8>7C<Z/BS'H3J?.&)HC_B0J(R%1
M/WZBHIB^>M[+>L+K0HY,M/L_E4@Y3/03_]VS.^>+4JQR[<^\&F8-R9L7#\2I
M>FRZW/CJFH9:)S<,&%67S&0%>WF3!5EZ]0</'S2VM;_+SX=P3@MW0 $3A BO
M)Z/WI<%A$#6MP8><)1%?A;BMN%YDIA73+S?J2_Y'!2L1<"JMR.S[=M3@Q4%:
M>T]5<.&HEWUSX&X'O;&L2B4CQT?%-#NX;Z_^_<A%.0.TYQ*Z^_+89&_ASB(Z
M>+ADT7=,[^?(,LJ)]M\5+SA0 0UUA4]5&NQ+^%I/Q"\!HF<X)P&R@ 5:G8:+
M/:M9P,(87.=V*O"/8")U?@+T=GQ=OY1X[,%_X*OA="&2\Y/G"IL\FJ[IXFQ'
M^<ZH@;GEY7A,2^-R:) Y^8;164JWN;)OG2MG;2>,S-8+\*QO)">JJ^Y-[I!W
M'H_S9%9Q,(>:1P(Z7"YXC[>T#5LX&L$^01' V-)MIA%%+A[_7#"SB20^9"O&
MW54\>$]]D)LMX%<1U*D4>,T(1P+:PH=4]22S-9>A1[9*>\.E^9#V)N/V/$9Z
MC& .'C/V\9HNUZ5OUR;X&W_GG&=48H NNOD=SR,!K-^.=CWYB^WP5FN48W&V
M&ZBSK42?*H6YW+O'NA='C5S:]/,SU02'R@@NE&'2HFF1@FK-7-,$F;SC-BIX
M53;\);3:DB.UP[9$R>I_]^9#4)9CPE/4YSR)\<GRSN@MZ@NGQ#B]8*:"0Q7Y
MM>-6]C6T!"C>G",&;&6\/Q0!VR4V6OBG/O2=E!G,QGU!W(R95KF([%IZ$[*M
M[#P1D*+8;[Z='.%HFTJ>M8K2_+G$Z>LXXXB@(=6^3%"SWZ>RQ^Q7UA^SY;AY
M5&3O#SZ$=T27+;]0+Y@@^@Z&H#,0*@C=+4(4]3!%>J%,#6O&( .4*)%L.B(*
M*E(CY>YEW"8]4VMO_[T[2*\<53@62S@)5CL,;)5ZF3F$,SY^^M/;)RX%66Q7
M;N]=$-+??VIP-GBH^&)&G-U$DD/:/T5"RG>64W)-I1?27IL!9HC>S-XZWET"
MR7U5:AH]-L]*!/O89M@["?WC[7R(% =? 4[;#-1P.RWZ?A^L,%W@R0Q(#3U-
M_A/H>262^0XY\&"M(:/+_(5SW=.ZX +T"/#)$_,G[)BJ\L:](FD?=+!ON9OR
MQ;K\=45'^:#W9K>_I63ES^QXS^\(^,$AM" ]$W$_""S7?5I;LJ$$6L#XD.!_
M^9"1&.J>SSG,__6=E"O4J2$\J" 4SH<@"6/"G7Q(+;3#\O@8F$ZGK52'TE>U
MZ(2H[=+#ZC70D]@ Y@%)IX+"NF!T@$1[ 0!:O7,:1[&&K[<DHAG$4QAE1"WA
MV_=)R0J5;_,O6VV:OR?'/W!*+KY<6W!,[UF&.<S=R3)MC_WZ0\9.1&1A@8)6
M3:#+.&>E/D2WO( K>+'F^P)J5BKX2OA4"NV /QJ*V;PS:' >:PTF^Y4OT [B
M3B(EB_-_8GKO?U<M4X-U.[@PCPV/5&+<FW.DI"EQ,.Y3?;C]8'Q'9<%]I)/^
MUDZ2?E'[S*XA=K(QU\(T5=KT&M')+/.U">E,A[3V($$ERVY:QK#.)+3$)<"S
MQ'3=GN6,H-0&DGM#G9T[=P4*09#/XCA/H1+^ TP^A&4.NJ@W*T_8GPGPX)U8
MSE&M ?/H$Z?1$]T??DQ@.ET&L<K3QXTM?ZHEW\UH;=;<^Q!?EE"9]S9I3[2T
MO/D-_A&/&%M6>22THBH\3U$U^=Z+XE.L.6N"&J>:K!*<ICCA9^A<3L2GKE$K
MTNNX[5AA\!60.:W00CW$\03EPMXMPT4,KBW4![6M_M;F"JVJK8QM\\%4=(P!
M2WME5PQ/3;>IO=?5#SQG)>E8.5A6- "SC61UW!>G7SU5>J]<S^"\*<S#I#_E
MR?CL#/INDZ3"_1OL"O4,+8OY)TY(DV?;;#X$L;B"?X/GG&WE0Q0SN:7PE>-L
M _SR#:P"<?#38]Z=-_ 'EKP">SV.)1.1CY=CGQ+ D0-^5DSV@ ")1IAD/L3:
MS!/L$6#ZZT;JBFS43$^6%B! ^[E0.$>"RCN:S-;#-Y_#JA=C=NZ COF</[BE
M>,\F4WT'$R ^]6?(=? #5@?8B=(3%TK *8'98CMV WJ2]..'5)5O \.O'R(O
MCO$J H1518[K=>]?H[D_LVNOH)."[*DIGOJ(;/^R_&7532DA^PQ6S2_9-ROS
M065U.JRXQ<X^'XE"?741)ZT6C%?WJ9Y.G"6JSQ9QQ @\D6BFY:H?VQ:48SWD
MEE&$L5K@,SY$&O99D/L(#(465*^X,U('G[ M=1$A#!IWC$G&-=YD*)>^:73Q
MF<&$FC!%(DIN7C10K.]7J=#3V NL]"M>D*WP:DD!WIB^*3OG23IWN#ZUV'[&
M:R"F<=["EGX@&[9^XXMCLTFQHM&5''_FV7ZK)-.]2T3JG;4<-M(K:')^38%S
M>H#U""A:=1"PEW9N.5:"<4ZIG^T,B+8D2G#\01^\:J,U;8%P@G?,0X>04..X
M%?HJ^&/#R(I_DW.SY(C5M>L+LDK#SV;0%];LT$+GVRV/9$S-GQ[T'(J4+FE*
M*1Y)"I^;7+KF\R&5<EEU);ZD,R<KW2U@B;2Q%<+MW-VWK5:D3A6X*@HRXGU<
M'T61^UY/#JC^ VSZ !9-K;\R./$ \[@-)S>(57=#/6; )4&A]@W4O26GIYDE
M/3N!9-G?2-5F#J0-MZA[.4:ILF=:>=F9;O]T_]W7:E'VX<-PA#?&T'SR:K&,
MXZ=2F.8Z+ALVM[EHZS\SD[I6CAHO"2L8)^_[E0_H\HXHLT.7:8 U_L> (,N1
MH*]P9Y'0H]MAH1T4?2"%)_:=<SN8X:5Y  BL'7LB^7TI:.]ILK\K2RS)W)N5
M;WBA]HO+.3NX>L^UA5G,Z,.']G:/B@>*>R]_@(?IJV2EI4WR(?C1+47+L9NF
MPPTAKFSX71XB:(SCN%^<&-_\A2HFP)]L0FUO6^^H;BN\JO,Y[M(B7'0+$162
MY7I]!">_S),=###!^DRIBV+Z,3/] KHB[*DY_'IQ U5D&>NULJKCQ"W@%+YI
MR9FT:3U5K7+P[!-F@*)I:4F=G*F8V>A0JO[/@:!9RICKV)O!-AT_GWL6PR,9
MXZ6KG]D[[,1_17^(.P#&G--=/.'M?*P']SU/$G0W!M!MAYK !L9ZN&*).4-=
M>&D3*P:JO@?1+9/2#75#JL_<F(?B/RQ/2@!K30SS2^N6FO6UJ;*5[R?&*&_U
M6XE]3X\&*XA:)$B7_5PTM(I ^7XUF*0VZ4,;Y*6^&!;EUSF%7'I\J-2A,2W1
MV;OIQR(^<MEBTF*\BTW<[Q/>Q(8@,C3@CQ#G> /20JU0T-&I,W(;?@2CT"(K
M)MZ=CW'M<F8&%LB^REO*4:$.3&5,_PFDQ>\4OF@Y4P$S&R@ ??O7S=+M$VT_
M@F?SU!T+=<X@AUA6*>[6^5M^/I$55RR-M1%!.+MN38)R7(-2[VCSUY&%)D38
M%H?5OP-_M5]AIWD2 5BK:K7U>^+D04OV10RAU4&KTLR'CFD48FK=3/O:['8<
M5AA!=,:Z--:3ZI).]!F'5CAADFZX- Y7OE%/1_BIB7[]:1W_X,G%],Y5I.EZ
MX_L%P7B/-U)5$RS+;5<E-SQIL=2?5/%-9YZPH4!*7@,2.1(VK!CP)OL6QID>
M%,T[,8$Q8WD!12V"L(>W2:^]96#.,P-?,148U#AB!4>+H:HS\F>R(S"3@4_4
M: @UF["\!; *1VI'F-UYK0<"1[1P.2:I78JM]JVF-2A%1I&3>-Q9F9?%5B^L
MPWUGD_PG8ZSM42Y.UTMMQDQ,AVN\4+32T-&@U9T%''SDXY/_R99I[2$B/.??
M>T+\/EX;=:J(#]F(AX.7@[AO>E=1 E(@VKE-2\5_'A# \4<.E)=O<Z$(6,*_
M0.R9P3N&J4B]=_\OAKK[KM/7\<95!-8[;J7>S8NOXXW_!(6GFF2'Q7FD%1(M
MVFJ2]IFPU:/(T2TLR^(NOE]&R'0DX:V;._/:M;7FI:W-UN?P06^'(L!\/J1A
MEPJ>HS"('%G],H0EVQ[WV>G J]\'-'I'U]MUVO.CN#8(%.'DMHRJH3AA^_4X
M&&J&Q$!57ON&*#;[(*S;NTK;+U/O]H<CX@B(3U<1I_"M>WS(O_"$>K9<RN7?
MN.J""3L@NFN($W!I=[-]YU^KQ$B[W<0S^,_#4):0,1]B8:]_[+]S$5Z#"@1J
M<0J<U-F:: ';V<,PN6%P@5;^G(O_88[G?IQOXT/$>1/&FW0 /A74GC@F()$O
M*(>Q(H!!'5.&D=ZF_TA?O 5W$N (PUAY@8_2EN88R,(D&=7K)OUEJFLDKZ '
M0VK/ML*$C*HHP[#89=5K'4M+ZN^)KFG2J:;;2T;92CYS63,K[VNWO6I3K!M2
M,F+,:^(N9&58.:#=N/A_MYT)8T(K I%TR+\SX!TRA+::S':@(7-^;[!-MP&#
MV3J@;P=CY*[1'1\(F,<\VN\_B$ZI-@PX"Q5F5-9F7&)?RBWY=U$?:Z$>UY^<
M('RD6X+TX,^? K[X-W)BO*0)U;"4FO")'CB7UF3KP/LI4);]N%6I/3\Z&M3,
MY!WN9 O$T%-, Z-]O0TOYHR4#-QAU8]TXL=T>2=<=%=#L'T/VO_>H8F>![6?
MR4I9:]^_K6&:?RSBP*%-^;;=224@]Z@5VNPA4)%/ZO])DKVPL[7<WY5I6=J7
M4,&':#MO6)%IF_:-5"P>^?E\/3<3[F&&>I.7,SD]A6^/5GAA*V:H<1TCC$BX
MGV_TM=%7[IK.E5;%WV>D=U=D4)(1**-*#>DP BFQ:'Y'QI*>#B)F\/$C*\5\
MB,)MMA9^-!34YT-*15M);"-E[OA)/L15&;]8)VL]$9+'S32XCOTCBJ[5S(?$
MT"34Q*3^ I' >"?BA$+"/'XT/ZJ9(CFD9WSAP3,,[8O_@*/;Z$7TQ]H1FTA$
M^Y6M)LJ%B.--)$_;BOI0DPY9?/?XNCY25]#/O%D_CC7E N</IB!(HF6U!*/Q
MFU,#4R&!(H<AM[EJ,].CU3,#YLB,1(FEG9"YII*?__RZ.[*7O3W457+0\)J7
MH:V=$Y>2?<.ZZ*@M(\\B2\[BI+/1B0>5,>-WDLPL/VTX>PDB9(*RO\KS$R^@
M X![U'_\5Q^S!KE%!A==G%ZM-XJR83?IV6I("1>5?.9.&_&HR\2#.U*6Z8&L
MG,-)_=K?2\L+NK>D%/]>1LAW!)S]^XPG<GSLT6#&6G%_,>B*'-VN7O"G.U 5
MQN"9?,AS[@-NV'[!5P,M3/J_^(^(9FIXCNS0VE;I_ED0:-EC9GE3:8KE"5"+
M7A1)LCQ5$1XVNF*<H-9XG"$./38R*5OYE^G%F$FM0]_C_\1=:$Q"BT;5R#C,
M9B-]-]5Z1SM\J$C84 8C^UUZ,&HNG2-C0"W#]QA136Z(KO;RCO4QYZ,?,Z-6
MQX'V"F\%H& DDB($;@AKNV>7^_>>^.%).,&!!_BY>7T:O^E3@:Q/S7?*6BK5
M'\3)]LL]]:_^@R#:4<-8_$N)6V#=I#N*DC+*(H4VW/"H?="_%D"7:9SN_\)A
M<?"W*8+/Z^%#9EP%.2T(_\.=52B(?NCH1M54]J;ZGU#>JD3LF"QQ2X<*7G>@
M\Y)1 ($U!19ZG0\+<A'P\%CZ'DUSI"[<!"B*Y#@R%&K"M4,QWNMZ3Y)=GBF1
M$]W<Y]8UKZSDP#Y,_$E)G4A1'D3E^:9>+MQSN:R+]G8G<:</UV2N];.)O##>
M,K2>"MB)@G*$%E%0B=O9[ ZV,O.FM5KC=:=2#+1=?OL#]%)_$1E?X@HR.2H!
MJ@B[\#:*Q'!%_N#J%% 0GUI6',S"E+L^>3$V:4*4;P"N92W5WBLMT;@\%#"A
MI6@[;VU*T']?]R2UB<6FA4[(V.:7C*V6(@R]*91LRJKHYUXPG,BZQ(?DO><6
M4S?%\)L4XF/N_JF1[Y<DUP4(VG6,4@J=2^>9XN\AJN'_-DFR'G%S*,*X'HHT
M$_I*SX7>^P)^7 \*4/]@0F-G!MR8EXK?8]3OU'RO*28Y]*MH-&F8GXM/.6%\
MKB#N9"OZV!4"K&\.G]K^2#ZV;:3MZ\F7I4/9CK<D9ZTS&TCC(;7C#1,TL[Q"
MY30EG86DD<]\R'E+4%$]4H.V?\KW#MR;#SGB,0R,+DR>XU;BD5YRQM7DFV=/
MAYBG=R"D6@N=[H2_-'.6>''0*N)7/0CD5^KC+G>EMX&_^@:E /<=OU"J4@]K
M\KQR7,R5S/$X1.86KV$-3Z2N+/(AEW8!!=YG6JLH]Y:_#L=/DO?_</;>84UE
M[=YP' L"8E2D"QD'%!$A2E5!]HP%! 804)":4:0$A"B(A):,**#4D:JTJ)30
M(UUJI L(2!<00@)(AX020LK.MWG.=[YSWO<]S_5>U_</?T#"WOM>]_J5M>Z]
M[JU=3QQ!87L;Y%8ZON3#Q.$(_)?M:11')@@B$&+D&*\&L0_?C/BR?M@H%[XZ
M#AYJ&\*<II.YQ[6O/_D'S<;5<Y"+E:6(+1/_0C0T9520?3K^KPZ$$C4(RQWB
M@=:-CTOM1ST6AU6 Z_1N_,*?*TV>P%V0/$SQWX&"+N ]GR1MS17;^]F/&:>_
M+7>*%PN*>01\($Y&L"DTUS;*8?WX@)M/NO>:)OB ^3=CI<06Z$&IG3GI*X><
MW4@&IE'E.QU<WM$,959DC_"&Q^8Z%XF<[6S(_?E_.3-_'9CZ2MHY D ,P3D!
MN)KQU+A.I&?3F%A(-AQ6WFA.__2OI03V;GEA&[Y3F0_#4#B:I$@\.\IQY.L,
M85VKBP];/IL,)F"L=\L]A('V,?(#W8__U]/Z__\4K+W=7:MK;$'0C8'1-=I:
M"^D9112GQAK_DQ5)3VYS_)4.CRXO J;:6U;N#Y@Q#$*W!#>+W)M&[I309VIP
MF;)%O#KF0J"K;J6?'"H5H_N/VDW>[8L8K1;S;,=$::]TMZM9,B1#;<%BM\KT
ML1KTZ-*"Q[&E_DATU9/ES:2E52AU@A ,"GAX!@I%$%:TF?T\2(3ER5B;ID2!
MW<INE=J.<GV@&%;.+OM+C(I/*^[4D"9P'/W/ET=+JLGTN1:1LD>O3SYZ7W\(
M$' 14V@HL8.'$YEISF>'@)7O9YK@<U: \O=7]]\UB$%3DRZVS>FEHR)GP5.0
MM,G"TV\CQC"@4###>X &M*>[M!O3JT(ES$M8UO3G3?=_CGQ&'-KT-+HIMP4)
MS[?.=<-!AH6\N!ZS8RRR;<JT];!S>45%. ?Y^T"Y@X Q)ZI,N6GVB<,Y7;N$
MY26KC(JS'8X])@H)3GX=!SDEM0$=/18S>19W9&=+1U62E_SFMNN/X_OCP8/:
M5$_U)@3]9NQW5^-^BU&5-9RH(S8'7YJ?KT><1LFPRMJDFSNJUNPK\XH=>'DQ
M=W\(^@P([Q".=/1>:J_JS_JM_J1^FH37:Q3=3V>^P"(\&]SVX6Z2IZ: EWKR
MK$A(<OOSRM:";FA], CE^E'YL/ QD6AN:5V :[BNR!12B(4W"3<)T7=;T5@Q
M+%P-NOK:KO"QF6^1P^+AG)],F@%/(GRA+<GLF7E5O>%@O(.SE7=JPXA':G)7
MTMBH>EAMO0VEOF$6TXYG^3!JZN/E>;I07(=()[#/6RETPUA!-_:/D8VQH(NL
M:4;\9U#*8^'!6XGF]45I(.;Z9?_7J<XOI"G1%9\LSC#;99OL\W-;<0ZMY=.'
M)CJ5%*U%KF:M#!MGI%,(*A=)QG(Q4N""OR%I9 LL[ITE@X=;OFD4(4"AXIJ8
M#)502@0DKV*?CX$U?]VPL;M3-13D3\6:3,,.)0/?,V3ZAF0CSY?;W6T4BBC8
MLC^E>.Z]8OD%S6F$0<<58&7!V .GG:RER"(P%T$R:1WPA)Z@![&CB8)$'-@C
MW$1@%S_T:)Y&;:?!>=@""+&.5DI,);/(US9$03B<#XM?AQ37<E\Y@6=/$%\:
MG.K=D;B/7];"L^\_2X)0@RO,AQF]9C7S8?ONT!N2:7P8Z^S:LD26Q]'Q+E<,
MYSH+V?(RV4A.-)>E9DR2=&M1^J*N6O+^KF:E@83RT;D#]5\7O:1,[YU9I5=D
MKJ?Y(WYD?<TM& IGQ7,J@.'GTZ@FQ"]!>-8UAO)4>*NPRC4+:!R<&AU_HPO$
M:*P@'89UU8-SL7:MTLYM\47?FXO=)&J>%OVENLEYN_(ST./3L)M"TMBL2WE*
MH#_^U^:1O#"2\5'#;*NH:8O4A-MQ"0X#LW%Q3W&V7H7]CS=G$N(C1PO4Z4O@
M20C00[3Q?:*,=A"Q%@EP1T;JP?(YU :3 (H.\&&S+H!5]BAO76^+%TJ>2B*7
M(+BBL5:LZ&)<IZ/@B*Y$7M"=@3KM;&R/IP_--3K(5807&ZKJ&UDO??%<G1E-
MQ*BM_Z;BB.8!CUR5X?G"!HNO_]1U( FQW24[:>AVB3/=%MX)E]!7Q7T,=2HD
MZS^4U]>?JRX^_MZ4F[?44 3B1W[$_MP+PB]^')#=76U(F:BUT\I:XMQ!6UM<
M[ZL;N-N$=XVL54A,2%XO<OU$=KOSZO?M^,1&2 HTJEI]_;#V@!ZM.,%# TW*
M]$L,_/H:&3(,E81""#G<U[@?KGTF,&U!""L7#3T= 7$(22=13/BU=9<W&&AB
MC7\%C?%3"RC1Q;%MKM@T+28QM\>EC&[69/9L4O*;TZF7%?U>7&'TM-*[6X9"
M,O8,KS*?T*;53PHAK='!X4)-%SIR#57<;[>8.GK?(9I":7+HMQK/67^?^[*+
M71TW<((@D1K^V<%]NQEU CR$C33!*YM_TSL7='FX?$?-(#DP&]MLT% 1%*/?
M,:7_9<8I8KO@AE'TW?ILTRQ4YG.SJKEMR7;?1;(Z+Y$/\]#!JO)ASO@QQ^&?
M"AEC<TP<JPOS>%^^]*5WJ=3>E]-)2L=GU QEU"Z_#BG\H\>#80_GK,+!IH^0
MJ0L0* !"4-3D&7Q$*.Z'OR)[ ]]XC#PK2OCHRDM="\5O^O)P5_Y[(]+!;.Y%
M?"CBIPT$1$_XL(0/$-'\3EY>Q>G@%YM&/+8.98(W;/QXS^Z1-[^:728RSN)C
M4&Q+/5=>(C SCW=9XR#Q N2M>ZRG-26HU>^Q;(8='V;R);%FRX"S!T=!K-\G
M5Q)X*:XK,I S#VS39$U"?Y<_(< +H^(W>>I#A$8DO6L=:->>&FE<@\1'.;P5
M!0L295VC!E*D@TQ8!%JT<N.D$+WU^?@UO8+B)0EAC.?Q9+\R.S3;-P%6/YF=
MOVAME>(23[2;<+=-G,T.+6IM094-%YG!C;(#!FYE&QW+L\ X2Q;4%X_/QYE4
M?;#PE.\T[,@M&B_=(4Q2EB'V/Q !?L4=HN=$TN#C&%IOK)X:5[^Z[&/]<)T(
MO>H.*APAI'O%5T'X=/9[O"<O8KL=5#<VCFH4>%6T!80O^ K5$@Y]_AI#($QC
MVT4O=4H*'5^P-,D=+ JH<"%E)5SY;EDSDIC?4)M9*7DW>ZV2$E_J:*?%"^[:
MO,E>7&)>AH3Y7WR8T]+;OQBAL<NR61XURI[UNTD3%#FM'1'$P@^GDO8&_<%*
MGIZX[Z=*['ZF>_F;?%7"Q]]*#>P)]K2Z^_9DU&Q2?W;H;7G,V8_9QFMS(YVS
MWM1,;HI?LCHG-9ZKQX//*T\Q*^CM+82#H#@V<BJ9*T^@YVA"-*-W<+@!LHM-
MLMG7WF,-0+&8 FJZ&N<S0(^83V+:>C;$4GM9-US[\1\W<S66#C[AJ2]7OK:Q
MS5+^)6@".Q0=T-?B$X@=RI/^L3Y'J+!T)^H6[V3W9'<KU]9[K?GX>J@Z%!9Y
M%O6//UGGQ#)B>?E_(RH$5GZ%P>"Q*$D8["^8WDGL2QAL"G9Y#T^9^17)J42
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M\C\L&K)J5[WXRO@N8,D?0 #S"1%P\AF0.4MJ?0<L7B7PMY>)$$2EL+>@(G0
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MT80[U#7-EEEBXYC=0%N-$0T1.5.T?J2;YM%KI>'K$"&.R/9;P7%"-H2'"MC
MQ5^B.!N\%5&N4($EGV#21\'%IZ$,^!L,C*Q[LE.;4?[/G.FR<CZ^%7PH!"0_
MKN-/6XL\)3[%-7K!1H:\(QVW[+:$[IL_.-M=X"=6'RP'Q:SZ'U9W K4-)FLX
M$DD4^\#^].ET7XO/@DI$Z@5\E)9UK_&C/V,R3Z=EX(\_)&@,3P@7HU&-:> G
M]'U\4(>: =<^BX&1X3NUY6MSBS^67GGS8_(@9SJA9-[K]!"IK"RCNG8@9$+6
MGO1Q"!2JDUAGZ_<P@'#_8VK8;<>3W]6CA?C=%KV/DDX<GM+JLCF?Y++8Y6*M
MT1 X&:^R?<><]AF^ 9SSE++I=2G +@FE2[UC612G8,'O*[)]C8KDS[,]Z(E@
M!5,=PZ'DA?P=))/HK'C4049$1<UX8H[6NIPQ)=L=3F.D1'A1VLPUA]8LLY%K
M+Q\@NI!I%_ OV<M7[XRB3!6U@UUM"G.F2QQ.IUE_7K%RR?VCD/"ESS+6V%Y%
MZ!@.K_,IB#;<'/?P@OXS(SSN+7#F(]@CPL,>U_E7&$V.QSVNBM+%RE+&*X>R
M"G[(A?B3%1OMROW5+G"'B@C?SG:?Z0\I6][)]W6N>VB+1^9<D5+F)ST/?Y#O
MMB*MF2N=+F]K*D/S_/ %/.WSL=+(V,:^5,%)ASIE*>CY9T)]/*;7,6'/1&__
MDRI&YOY/JMCP_YTJ?K-]N\J>S($AA$7&'M+\Z<+_* &4(%IIFV@]*1N&B'H<
MI,G7__@1! LS7BYJE$ZD _R]1[KG0()+>=<D &??Q+)6!GGCBZ_HJ94$8-\V
MKLBQ$D+?"!,Q+4?) :=%3\F,M]#JY8X>5^< $+.#P#K!P;,OF_;))?"=N'H>
M"'E^_*W!-A^O*,A.?_FW*(OGHT"ZO]K^2L=C/JH+P;GRO#C/!$J[%UZ35$ 2
MD4"1>XRC@L>HB,T'O/[<&OQG1]T?1-\?8E'=^#)XV)4%;,'%D95"Z3%>I[DS
M<>4HBU+A?GX*64E\=,(3,/\:.8M28(, X_-!Q(D\0B.8W1-*N/=WS;DYS%A]
M*6@\I$'KGC N([+&V^OP=U;EX:9DZ+(3[^]W[*D(I^=A=?53QPL'FXS22%N7
MB1X>4G8P+P'(8*1"8=3K%Q%. OB#OF=NTJN(7<83O6X^YSY^P_$^!QNO%PJ6
M%>KT@W[6UVV/?V;JTGR>JSA4_@\6$<T [_>R]-3<1/<]_?,.M6U:P?V:*#M1
MO)::!XLP!/H>I@[9PVB=>MIA#D_FE\$6=6S,!S&:S!B7W[2S6O 5+R\J2@#E
M1=S>YO@$\G>K% G@(T)T@_)2NNS)\ML-@JU?B+9[<W8#5V+IM TQ&>.+%4F1
M^M29TPB2 -0;-?E!P*WD6PMMF%W;"2U#8?/G;;=]H2%3-TJ\MPY>PG]1'D=D
MT,>ZV<H)J!UU-ZT,^ECCB>1=2)O9D)E0[X#(YMU<2%(1C*5UHC*%]W.+9BBF
MBC76>^GW=%"WT\&KBKK"_+7U%=[?\;T3*7<N>(UXO0B(7-PT%NEO14H'*C6$
MTEQMMR]@NQE_>H6Z"V/8$I/$*B11(1&EH+'FVH\ZE49!ZPB.DQ,*J=Q@>8J@
M[_AV9QSEA >K)VNCN,SYX[\W9T5'*PCK]IS5_S*UN&E6^D8SUHG41#358V(V
M(TM6'XU[N1HU*Q0H]"R(QL=?!7O4_2 B/DD EW%CMCP'_I0 A@KD^'X"C@E:
M5,C)J%"VG'W7L&5E92/.@I,9;[A.R,>SH2ISF;4C!Y"(EOSCMC4-(X;CG,SA
M_H=/0.9;T[T#F'XNLOZ(MD+;/7_M$$9.@_]*6'V,(C7#VNU=NV<S33_N?+#_
M>5<$9S7R,BAK(@13Y?H)&FN"^(1YC-ME+N,W@D'TB^50FOQ0#MZ&+ "/BL>+
MA9<Y:"Q35I5<M2=P)Y$6$((L%ES,QZAC,J8_UT6A=1+*N1>3+$]4N'J1W'N-
MF_+<N@*\NGB/2 O$L8>1E7=*K-YN'R7Q^[<]QD+ -5A1%CD)O/5>: $E,3$3
M[R6 =196G)/PO8E>!A[3X<$E@+1@_B\2P'TG)E3\NEX.K2LES9%2Y(Q:($27
MU(?B6X"<SA5P>QT++$P'JV%&9UA8D3G4=?&_*]O3-]#E:]@QIVW?I<!MWR5.
MU+;O4CS\K*N@5EW<Z"+-LH]V;E]^V+'=3W3%FU[K*LK&+4H9<VEBAR)_4AIX
MU(_)B.*8F#6AO".>,R/>@YD]*PZ2<IUQ>;[N)5&Q\&@!N@53(P$DFO<+?D<9
M<P06'*M.=]$20FPD_;:>$,ZI+8EZ)%@')]#E#7(>_/VMNKF #=KACGDX815,
M0/JV;?66K35"7HC<'WWY\V\IYR_186FUPZZ6X[@G4P<R+-<]G-XM9">Q=[/C
M"5\^:G!U\YM7H&$ED1,A+@\;I+O\R'8#Z"Q>&:>C2? (W:5V2%YP ZG^NS+X
M"/H8']TMTF'// G1.9=(]*LU^EPO8,T\K6D(?4X;OEA(YB['Z7I_#4@>>58#
MV3>;7<HLWYBK2OGE*)@'ZQK4_CP;GXMKT22\ZVGBX8W#N_?8_ZG3/[/!YNJ.
MK&J,VRWB:61;]P&QDC2Z+*?PH%4SBP3!6?17DYD<I<><I^P1"O@H\J/W$^L*
M#'/_ ,JM&*="V;&;H.-ES?0=/E'K;!7ZT>^?A-&'B*;_[=L/UM.IW/OB+VD8
M3>(<IF)Y$<K1;)4 :K$+R5P*XQ=D7(?\?O%7W*Y&!Z:<?$=8$*5BEG9?K,M9
MZV'*J[I9[/QR$VY4KT?0P[+@%YF-SW4MSK*N5Q2X9?H(@V6>Y?^B>NU@U^;[
M(;;6%4&5_P623>#&U".LP?'AK&&>F;6%O1[X2W:S&%NTV"P!!(E_@Y(0"_&"
MJ^)VH+*A-#"0:S 4R$&A"3<E,>K=M;M&)7@O*R;]*,S(N&K,@M7W$S_. QE"
M5^9#')%)F2K36-WVZET"P[XQ(O-C32+OQFE]^>0"%;Y_99F]-4HW^ H);?.B
MX<]LR.VNGK AM3L%9RY;&T@ 8(.U^C4A(AC+5Q"8HH)%>/2O,)PLV+<O5NT2
MOX4MNEU2R^E[; J.KO"Z$M#DG>4T5%S[;,S/7>/-GUMQ380)V)91SFYXHF#>
M3['(@_CL36SQ_#UM:H']Y=["=&>!#BG"_(5KVIC.J,V%M!HG1)7K?QF2'A7\
M)MS)QPE POM2$?D)E+2E2(Y#GQ&>'W:EB V^ZAKFJ;<I;;E4#!M%)M1@W;Z"
M0G55;XX%1 >Z1YN(YT8;+ISJJ>F/)]HJ6.:?C/DXZXPUN^3N,)TX1K.V#N"E
M1@\T/7$("@2%DM>),QNX82OAT8]1,.#B"8$OC&@*CP[G6#$7%YLJP4W95 AW
M:D&Y^NU&"BW OO72?B3\7?SELN\?^L&E?] M$K(1/0-A@H6MD!^A=\VUMD!]
MXCT;KD(U+4Y\IY>.*!=\'Y.D!N3PRLKX^DSC=OD$<S7N=!G>W3HB@)G&O4P1
M'T3LFS/I_\OZ=%Z1%Q2I)+#V=)Q2L+=SV;"EGJY/$3A3?_VPRM<C762=K_$Y
M5>J"MPQA3>1F:#G/."P-O,M+:ZI8M[&XE^9_Z$<.I(M7-R7R!,Z(@M["C2*]
M7E5XSJKD5200(._&_6CM[;&#*EZ$X(*<*V4>L]DQE1I%PBTW<J5*DDNU#<^2
M]_5.N25+5P)XXVDT-#24XSJD&>49TI1';,)Y/_M2_--O0!I=>#1/ M"XQI.2
MS4I9!E!<"#X,9UT<X1^1WQ) )8#KQ?_MXN:_K10PWW^7 A2#&1T72&G/+([1
M?K<%K.8C/@::>:8&$DM)Z[@$(( )7= ]X!HK:3 =,V9WMB[30(SACYKQ8G7A
M:>X#'(LH[[F4LQ#^]EM3<QE3Y+_;Y_&R\!(K685]DS.3$$+1MBKU,ZDHN*N^
MX\,],B*!,M#^M2R.J.;O_)II.-P'LYB'612=L9E<>)O=]*+[Z,7/UH%Y(^NA
MS>.BF2VQ^#.Y!M>"X)^I6XAF %/0"M2:OH.H<_QUCGC#GAO_V/![S?"; 2*"
M$"@TY.HP$4EGB^,7Z@9^9+\>;@257S-[5SE<7J#,J^PIG M+NX.^E-0ZTGV>
M=,;&,?F.F;-VJ#>R-LVIR%W>P_/19[=)D%6$17[AJ5(+ZP"-4OJ069.1H *3
M11<J18GW$(B8%GWP0[(2"D1=--0A/H8>:![G*O!"N7:SF=_]@?(DV<U#F-W^
M*FG*'KC#0J/!O$;=BLTJPKHHW5W^^4Q--8GK@I-#EZ1.!_6<NUE.<V8*&F\H
MCY6F;J3.[BVEQLUZ4AO23_69$,"^1LW=PZ#N.D^7B:T&3_6M=_^)-J.R5"2
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M+7P(?V:P.&VVY^(9>G5X?[6-X_>2HV9$WQ]KB(J1YLFL2G$,E!.TL8 M$X]
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MK@;KO0 10(K)/[>E%-I\^UZ\!. G"TJ![@@L7P\ .U4G4L@*XB/(.#A)*BN
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M_@H[:3KM?M<-UE8UZPLBX!;+'F6?TZ-M+S_8+\\;72*M3@L?"4TG+A)(RL"
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M!?-S_>O?[PT_ #7GXUWXV]#@#>#"%%\?!^@<@#*_!P#UPS=572#J"MH>L.>
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M5L_2-\IJD%-?4I&_ 6,]QYG8-N<]NMX:NZ\V5LF7(0LE1,3QQPI!$8E6 OT
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M;!1'.YRT]?SX24^CS1X[W,#O0^P<&H:6P8!K9.Z6( ?["X22R1SN=J3,,/X
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ME+JO$CSYRA,66XC$+\R6;5+YIW$\I+"'J@*EY0LO [%L:VZ;X'?,96!SBW$
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M1""1X\T/@8DRFN2)2^&JI@=P11.D5H(J"'T/;,.KLK$[T(S.-O=$66D97)_
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M A!]HG$".@6RJ;SG'&0T>3D6+A]$&AEE7RYU&<- ]U(O_# LQ[+"\9</91[
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M[R<=S>*((4]7WP4]^1)A]#\S,W*N\.F4U=D&A'<#HGIY+F?8.RAYKD 2&'>
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M4:&U]DI@'[R]GS<EAJ0."]_2%F8!'YC0W52'-/H6ON0"W]PF^8/98K6KH@M
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MJH#D5:+6?+O;A\=23J(>^FK.F:%1!/UN'^V/KOM92C;0$7O\FJ^;X[R^MU-
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M('.=UAW>)\*E;VBV_%>3W?G/Q)#M7L"'1YN &/*5M6D(S&9.JN*E5? /L&
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M^"&UM?PZ5*'7BZB3O;N0<@AS(:-F.=2J/.*\*8^2YEZ=IJ[DZMFY[8KA_0!
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MG"E%/FT[7O<3#T2$C[>>?R H66M6@T.Y/!Z-KHB1=BR\5S321%M+CA'@&F7
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M4MJV+/\[LPV'(3*(+3'I[.PC]I:4Z#K?Y@R,,=X/--^T.W/H](OC'79G]5T
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M>8A]>.ROIW40 Z\V$/=VLWB9M&?$R:42'S\9@"FF;@[@+OI&6SSDSUS8#1_
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M!)[=B9_4+VV1ICD\BQ_WZ"-59"H2NLWM=V,$=,$<K&,K<8//0HF7>7AHHPR
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M:=73*RR>EP:H'1 I.8J2&\>3%P96IUTCQ 3?K%Z1X\\O58/."MG5J[/HPK8
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M3-UKLU6_/\2.H &X>)#&=F;YT"%][N0NB2W%35KH"T7Z\U$FN6@27LF_;*W
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M65ON^GM4/NB;2]UBF^^W92T)MKN<,[K2)O<A=@'Y*()!-=!U9RBR6:&!T]?
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M<;0K42ZOCD['*9PQWY_&NH<CST<'9W"EO"34DOV>LH!E"([),)KRF,ZL;/
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MV%AH*3Z6O6[7(P&<[5@AUPXX$"0$[S+7MPN)JMY[1,37#$2C5*90W*3\U3:
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M'2QB[\7K-2=R N+GGNNCYC,'6GK20Z/YOB?!@'>Y+6>5AEATK-V/LXNN%/"
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M7_M0X[R37>;32B6$E?;GB4Z7YS]^VK^=PJOZ'QG&&557Q<P:#(@E9)-:Q0O
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MT'Y]ZLYK-B NFC4[MQN!JL>SI&#=O"R?]4-7IA-IZ_#\XASM23MJ.VIG"+?
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M+WL@*S;<+V\NHH +'A\I$-5<E88BIW11O^Q[N\B@GN\+<]W2-;\@;>R(-$]
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M<FC(SB7NL-IV9.]04=$,LV54AR89Q0N/Z_OFP2*,U\TX]IV>%N[=/_-JWS=
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MY?+B6%63ADI'88M&QZ6!_/\T?V0#EH"%#5AF#AO0/<>T;=J+R%-C Z0%#=@
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MM2TJ=3;RGT9P^_\\K8T3@)[I*\/=.Y%"5//G&KBH4)VQ$A1_VUG3LJ%@$DP
M_F!SDW>COPIHT-;L+&M ':O/Z0TDS?%-2>=_TXFVL%\+%7(XNUQ1.DMS,B)H
MG;O2/H9QR 3!QTY2WB\=KX"6I^][!R8YK=V'F6243/G[]F051R],9R\+O!5
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M6;VKT_[["<_>+(04+X[X2@WREJ!B)U6BVZ[YFQ]_NO3$]TFJ<HIY0G^!.U2
MFE'VZ-6-8]?+XBI<SI=4@(23S+RMO'7NY[TQ3*L8LH"4L&9Q56">_[/GLR?^
MO?U"*4"&6#T;("]/R6:FP1*!AP_K<454!99Q^-R^".<[(Y/M!#9@6S6.&<Z9
MKI)"(*K=&OPHE>8!G,8O;!$N@<U90Y00++E,7Y*ADZ+54G%EWC7^(PUK3-PE
MQ:AXDA*;-TS;F_N2OM$"%CTZG@.G2(I$NFO<]@\GS("#>I887VA8I/M9>EF?
MXY2UE;MC9+GLYER6WJM2L;7W:[LC=>*<5/4M\^9BUI1!X]FVH3L_&UEG)YEU
M04  Z[-K_5P'&_!<%-U%8@,F>\PX<=4K6;[DA<-C%G &CMQB"0K$%E3WO9C^
MWM03$S1C(@?A.2Q,KN;.4K9 W:3*2I;%#P0\L1$4*GO5)^+THPZ>:1'I &VH
M&HWQNLV\$C?Z$XX2$84_<0:ESA!DGSNL__CF6F<<9/$4,C4SNF?!LFQ30!A2
M77O B87GD2!:X<"HG@?GY:PTM1HG\#YK:6F<X58]LT:TM^OD[_O2%1BY?U-G
M7.I77?A\PS-I@]]=)ZZ]]-;BD1#C,ADNBB*,%)W<X"_[4OH:HS3B:Y1CUKHY
MLSF450&U7ANMN.EI4X)5H4)L:PZ:I;<=@:.I#,%C^T%1^^:<E:R")(!_:1L0
M:'@W7YB,_#6]V\6FHY9QBRK;X9I< *(RUJ\N#O#!"0[C:<,S^>-=2FZS4*DS
M!^"3CV":"TD<N=G\%/=7)TAH-1:3]'&$4)V%[#[?Q/)I#?8<??055;[X'B18
M&Q/NM,\&%*:AXS/-72/QV9]8'$'HB3]0*3S&!OS ,=39@%&B 6XL4.5 R)WS
MSAF.+"P% =7B_C?/; $?0UYA3>,I1D,TZ;@4I*27/L^7(&;$PGCK B_?.HJO
MLNT<W LIA8!*2%$E*H(KUW-"G[.DX<WV;T?4X4KUII,DV#%41X0?0I_UY RI
MPL@^BA47^^D],?$IS7ZB#!06K*->1O)(KMA[(EN#.<$=B(E!<T'03Q-0=H=U
MK:6LL>]#W*6:<GTK%K=!UM^60 7=^N,X]?Q%#-3ON@D;X#ZE[/Q!_0EMHF>.
M$A1'@*.;ZFFA=""-T/D%DO:QAD8G%T21Y*;D^8LT'5SBYH<N83I4\TR]->3&
M#:3UO[S>A,%X28;R=53M,5$SSJQ,4C(5=*M'RES/$3>4G35#ORZ4=>[N65$"
M<\*1VR5N/]]T8Y=;+1A)"&.J?NH"*KY-GUH8UR)92COV&S4T6<^2',G[,5QQ
M*QA-DS6:V.O?L#6C9*4'2@F..'D5B-<TQQF]S3%]+.'HJ)5/2GY9S.J)P>CI
MBYV]C?$B@RR*##/O_3Z&=0E:[;Y8I5Z=L=:KW2N+3O]VH%-C60;U?X85&0Q(
M$BSGAOK>NJE<G)^5KP/\=HHAIDD^L^&X?YKVO,3%7/$+S77_-74V%R/9X%Y/
MA+'$$9(3#N,7&-S!OI;6+<''O-*H+SU>K5-0_&6&XG=B\Z"0!NNX/,:2.$0U
M?PX5<#ZU))*WGO1!\\\W!<-=5DF([%J,3-N!Y@Y8&#R_-'=P%_@,]6."=8D-
M6.N@-;O"2*&,]/>I=+$'J#VAXW"&,8L-,&>U>[$!JU,]2RL,OHE]2/K^5V9U
MVP7DD*6W;;ALG)YEA:OWK,[X#XG3>Y?4/B+YB<H,(S)VI.1#[-JLDC<;<(]8
M,EPGOZFXY>N[5V720=X>B="JOH"L?:Z6^D,Q5^3EF[(QS&D"+Y=SMUW"B-7W
MG1+R-TGYP%$3"[\+:8GFEOW]%+QSUS!AIEO-=] T&'(F)V1NUBN@QTR*&&I<
M.->=RP8<S^<XH?\JGI=,\\._8P/:(V8NWM0Y>\/,$TJIT\2?5Y:,/3VO"668
M9;(!)#=E]+74@0+6=&?#3Q5=8SD/3QE\_E(7PTSQ3A?*UQUM^:KWMD;>T[6-
M9D5.!?EHR5&N"6I3,Z9@NB5HG0U"#JUE./GZO'?!LLZRI.>0L!WP"R!-*XIL
MW?,<#"-0<H8Q]93"'S\I423LGPC=8L7!<4%5>-2M./*EC9D6R&;'\AJA*UPB
M-]#_RLY*PY?=[XO*#50-9"^I00!*VJK6U9E,T12(K]!U@%J51[I<AYEB0)8Y
MQO8Z:?750^ED[A0[3DJI+HK#0/+<AP.-IFZT3&58ADYDNHSKV;).%]'%:++[
M0\R&.A@W TI4VMN**3R#$, A7*GX6!7195US(4+1FH-0G)XN*;%,*5]X<H96
MT>5P UMA_ZG_7-GK[X=MK^2YX&:A_N.AKE*?L(Y<FN9"B3CS$[<KGRP9C,:8
MU'M7,-^,8+1NFVP*R'*IQ%)[I-L)(LD6Y3B3#&D'_PC(@.'UW8 ,#V5JHK/Y
M[C%:'%V?<9%60:FUH$DO;,6T<5%Y._+-37Q%S8^9DYCZT[?>U9P6G*DS=12+
M<"/19[3'%9)EH<.BA/LC*I<;6XC*5=55\SDJ*T]NN*=V/%A()9#7B=V&B/7S
MY<:C&4UT8Q/6L,D&1(,?K3Z5YO^$WO<R7,!+1T#^ME7.TN*24QDJ6'JS?K@G
M$UON W'=.<^L:CN-_3%-AR#@-%Y89' Y9U5SM\G#">U3-\H0+XPBR^$1)N/*
MEH2<_-VG9.&MX+-<=>O][TD2)D[FH)YH+M<Q[1M@NB6H?^>4 -<#2H8/Y )>
MT=ODS%2WYD26AG9:ZTQ:<T1A#OD[TY'/Y9EON;7G\=E->7K55D5RX<$3U/U"
MBH\0(X$-:&ADQK%^1:TVDY>0EN0):H#*X<^7' >SDUQ][S[?C4J(6[)B<"KT
M9]T(]W$D)X2U&[$!WI=LK9K?Y_1_= &WTK1)_2*/5*>_'VIV!+N>&/+Z(^:E
MX_0<+<YT G''GWO^DKGCJ P(IY9 W^1NOW.,H&UU.2U+\MR[^H>9>2M)S,.
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M8P@(/TJV&-Z/&D\'\-(!^S?'8$<]G8@CZ4K, ?M+1EAP P:]P7RMPU+1I71
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M04Y$?H1/,;E?9=.),)XL#D,Z>4F4?M%GC@3X7.S$VY]3G(]Y8GJJ_#R#=^D
MUVTN5+@68>"],Y&=;-AI.Y":Q> .-\+R>S;<=&W@3R6R"=AL0>J<*?73 D3E
M5IR9ZC6=+[8 \E0(^":IA8R@\)$D%S-T\=LQ<(J[/"YWVKW>S^C3'U_5<6''
M0J?S61YB#9_'G^;X\1Q>.,K^:AJ??.YG/\ _E:*Y>/",D<9!D1#2/7<,9=B4
M>::5@PA.7T2PD*#= 8J_RMXN;)__DRDYG'(@_I+H,X,QJAU[:KW%E?(D[+?M
M3*=DY)5DL=0 V3* +X!8'H^I6>G 3/;1+IB0[E\CI2!(]W#UF"H(7GAX$RF'
M(\1CG*BX3:S[: T=( F93H&Z3J[XO\/ZI5;ZA:"W_S8<^]@V:*SC>=+^_*JF
M]SQJ_]W>_?WT3;81^\IPDQ;>.HXI$\C6Y>;6F':GEI">RUA9OY?1=2$J8!F*
M,6&N#0> S5W4M$]+RA0FK!Q #UZZ\U0ZKDF2H;8C-8(FU=,FWNY<[UK'Y&*F
MR\0F 2FW6Y+-0L!*?RW. SK@!::VI[U\BK=3H">L^11S%'ZTQ@A(?DY8/[Z9
ME^$Y#H775H#OUDV5?1R\EKD%G*G24?%\N.(Y!3AVW%G3$-1HFKQ38^T[,F-0
M&:JHY$O4+!,[UYO;FW66/]GP(0^3Q"T(&/,7U&N8A$/K5[Z41\ZJ$%9"T!J(
MQ0+D()<'D]&(^)@FQ G^4#Z-W^6VMQ>B=*;OHEK$1V3]&V;GN4I5]9"@^EM
M#LIM*HYV&JU$9$2 4PN&(&%&O"#96:0;C,9A\53%M6]E(F>G-ST%H2^60H>&
MAC+YL&SAL9<4"YB%_C88QVRN2*']C-R-V^,R?6[RGQ[\$\FC$9%@>?&4BRG>
M_O39[UE53!=>?@$JH7VH96#NX$''RT,4Y<6?FC8JN:5_Z(#I%-=;0YO*@L@J
M,GPL9'>I8<SG0#_F(#%XT_QV-8Q7L.X'<P2F8P#BRGZT0TJD UYWI](!_1*
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M7T (=Y0;Y:T'#!YP8P].8^$%O^2(58VCS%CN?EKF14Z$J^KVA=\B[86WFY
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M9?TG85?>9X>F2"3<?_NAP/^"?@" Q$X3]B*K8093.[&4*THXFOM5IB:2*SD
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M22TO=9]BRY_<S&<HTSVH1THW?.+"1HCAY=G>@B] @;]59R#F"VYJ$6^SR;K
MYM3A^,^KKF=KME?BJ0TH)%5XQ+@>!JJ;^@D4M8/;F+J^,_%CWYH4$U2]YET/
M!P2!_)%"L1DS&UE3,AKN6[GWV]\+:* R;2Z$.9LOF8:>Z\VM8#V1\!&(_=MS
M:J'\CO+IW7F;SFU!E/<7L% ]<51])4KY1-YJ@D<FL+*N@M?H7/7EAL_UXUM+
MD9?NFJI/?V6JVOZ9GG$+//V1/2+X,FV.#F ""Z!&.C/_(4JDQF/JT7*%_;D>
MNB8$VGODDPF.4/A!/5OYEYWV/W_^#)XS">OHCN.W9(K[*R=23U<WQAT/#!]<
M7N=>JN$UDWUQ-UJH4U^:Y9_JJ\_*F!@Q?O)$1-M#]O16C>!Q""L=X!KK=&=(
M$P-?:/"DW,DS*5K=<1,PBLM&' 0&9KLK&A\*U+ZNO%=U"OY)4D?7O(KG?-0)
M//1O=OT16N3?>9G8S%,CP2(H=3EK.2:KAM%2.*]MS<M>RK=<J%&^ []<Z=:V
MTUU5GIV(^,SO?YB2';Z8GF*/A0HT"Q%XVX9(*ST7UA7=JF JZ@)7PIW.9P4@
M$/BF3/9?)OY.?*]UG6\DW %;;IP01 +0[_\ZQ:C[Q63*&X_;%&3T!Y0B\P=M
MR$X1P?V$3M$!A#>KOHV>VR0]3!VX[0!2[6$;GA&_H3%7@]A!-[?5?Y^=!MQ,
M[:))CJ Y\1 NU. #NY1A33'\#*+SN&CR;N*L2OI']WK;TITIK9WV1/MT._V[
M%S2'Q!,V=))/R'\$LORM'@,0[<!_8=\]>&F5(4]"B$6]6JKYM'E3+1QVI[*R
M8F>OB;^6-4NBO[4Z4/1&?7UBK_ =9K24\X ;TX8T@"39B2&8X2;)[321"?3U
MPDGT'=HP8:NZR,TV?))R(\\(<; I>A $WOZ:1(JZ+@MQ8WS_S2=>HQ*SY]8A
MEX<P\SF8ZNZF$G=UB=SR3K6MVEB#'H.ZA,4.V^=V/5X%#MKNK -$U$MW:^X$
M9W=;-6?DK2Y17X9OVIX"'*DNVFRF$_X7]MXSJLGM[1L,!Q61)M($A!P%E(YT
MI45%0>#0>Q!0$6DBT@-$HE3I2CV"$.F]5R$0(!0! 2'44!.4:B!!" %"\L9G
MWEEK9OY\F9FU9F;->C[E0[+O[.SKNGYE[SO7';=\(]Z) $KT1#A=KY=-<*[*
M7P^62<Q]^L)K%=$<?O![BU>!.:)),4;DYI,[9D+A)DP?3J6,=L)QOQJP9_0L
MQ*N_0^#8A<07ZS?3:*_DSKOE 6W:K2\:*O=/?Q;[#+(@9.9F+I6:]KV\AND3
M-/ D#\%XK+X1?*YZ90O&:>B,4S]N5^E"@(K![@IBD]F(0#.6?[<;933ZDKA6
M5>,'642B9U,7&7[KGD*@$\"_J']VLB,)I%J<%X-VM7;1>N8HB6>-1(5[%C]2
M)M0U3G!\X&FD?A;F] KBV!%:$1L2UV[V!P0@N;3HS'M!@PT'?.<@87?P74/1
M\^QB7JM]0V @7FAXOPI^L:DI/<3UIZ]W$+OVZ$7F]F9HRV..V--06S-K.?"_
MI$$8\7GN\BC#'+E5QO$? GXI9MO.<:RB84NQ:-8=K).FT*_<5!V*]WG96*[P
MX;*EP%7%CQ9Y^6]>F]\!Y@!/PQ_'M[#ESTL,'5?)_2B'<]\]H2'"C;CVY_W:
MXTLF!!+<ZUES:\30622F.,ZA)?DRM,]D5_12VI5?MSYS?!%G7#&.I0'^G)2$
MAX*F.P3)K=-]NY!H%'P6AN$H<%7A:_6F3H_YX8/1OPX4MP*2!^*$S&8,6Q<U
M4V*<!"<M9QA'Z!,YA:$."-M?G'$PCG4',;0&MH@<K8M6'M9XU'>MA1?<F,I'
MRH'J[TK[!M&9LC;Z5=(7[295$Z9P.C>5=@B$CC3G"-:1WWKA8IR)EDV%_H7-
MT7OEFOKRPFDRGZR?_IC?S RY=UQ=^>V)U0-_V4 ),W'&SE///1'DV\3P;M 5
M!)?GRLZ9JK),H:G<$K=RX49GH4A*(/A%M^!;,82JJO<+L30<9%N4-5[UQ:OU
MSZSD86)2-^PO"M^-)*@;>[U6)'OQDT)])75UCZV)EHGX\A=TS/S27J,3#;43
M=?Z8;9#+F;HXR+"K>DKB(2E,__6+QJQS1.O(,"_<NT)"95.6?YGJ.Z5R315%
MX7*9'U9A,W/NF>'_'%>\9'V;KOS@?*#\8W'&18T'=)OAA#K:B?$'W=KH$![;
MU_0UX1V+><F6GN*L>;+T@4O#0W3Q 2+'POF[.MYL*WN"@7!:[N=!Q4]:.RY
MGQ&IX82E;I4.U:0>+1'J!'7TM>/=FCIT-$DGKF1K&N;Z)=RN+5UC9B/PFE#3
MKM>G7OZ9BI'/0.?O_[^7R5(KQ?TTP%_440?A,8KARHS_1L."ERVUNY[:B<8W
M"D9VJ%B#W_S&?4&BN^]Y_EH]P6E$W+(45WWYF2/C]-S/)',=:U- )WE*KP/M
M"']YC(')(6;A^A,BTWLS2EM)#8\P<2T.9YH[D+$V8,VAEF]55?$"8F:)R\)O
MB7S]F7(HCC/DI/[%:[%43XYN$I/9Q,KX<M0J!1.3%SG<V-X[7&#6RA^>ZO%N
MX,'K++C[+::>4\\UV@C6I&'R ^).GP($V#FU*)]D&Z?3/FV_/\S;;US+J\)E
M.S=Z3%:.VV#MLUL_X_WN9F>M;*XKXY8D@$(#3-+98ZE^*J','?Q@/ZG'N7V\
M>D=IKC$)!;;X4#F9T)/>S" J+,KPW8 K\M7-H3#Y#W=X$;=I@+.")W"$*4Z(
M!:7FG-$#PLMQ>J@Y1!:?Y*,RGZG0 "\G=QZC\1J'NN\*Y+5)<>\HLW_=OC_?
M)<C@RKCC#B ?X [P2(+3,CS1'QC=(=],+&BE9G@6+2RHQ.7.+-D$!1?&JT66
M)*ZNV-9]F+>;UUU-NGI/RT+128EA]51!$D#6[CGR2D#<P,+XUX=\6G7C$.IY
M$+B^W4PR2R_:_T1EVK+6KL7,-EGP@T?@Q1S13(M$^_6Z%H89QKX.32H:SD:O
M<SGR Q#V,0IGB\0J4!>H7^F\%F+0.-%$C[;F21*)!FAZ76R&IGRB_SC;UW"7
M[-6GKQ<=>NDTA#PE0:=@9T.5(>HKT^$%Q-&W*U-.8TY37@VJACY]0EI[#C/:
M;AHT0$O8[I$B<R*)\4H8M';Q@BP&@"2&X/HCJ<QD/C-RY,KE1EL_-LDUP\8V
M>]YQECGB]?+7[-GN3DTM;74)WQ\]NB^F%5QW59:GZ<,=H# -<)I([N],PK1A
M _&<91Y'H#=/B?=5.Z[4-$Q43_<(/&C*%L0LS&M6/,<8V!N87%+3?_,P.4A4
M*M=8D:.&<7UKJ.37B^T=9_8QVSEC?\D^[J]C<SV[+?&*DAF2$>+/+67>V+"F
M 2B'I^I2O)90Z!+\KXX;D#E4#@,!CTS,G=8P+6%3_2?%@G"2T/BFU=7YX]GA
MWH[F0.F'N&MOIQ;O"&6$]LQO,I 6 %!M(A-]L<G\!'1?CBB!+T8:$7+2AO4T
M\I0R4X-%[PV57V^)D/)J;/$,94KGT]75@3R%J@@KO1K\?"7PE$"L*V=/!$X%
M9-0RV53+?&Z->79!U&;[FI[)0YZ/VI&O+DLI1'UEU6$!0,>(:%(+V?)8$Q*N
M2YA.>DQ\A$EOSO\3ZVQ&W88)SZDA?+,5XVCZFB5Z]KHBQO"X4>_<<,6CEW-W
MA*^>ID])CMU),8N"Y(%E-B:<;H2Y61)J\;^@V-!A2DKF/NR9!S@Q/) 4YRK[
M$I>DBK$?B/;LR5J6?QB@J"#.I$[L7ZD.@[DL,6]0%8D_P/.M.L4X*6-6.]FW
M3[Q*%MGT#PPG]VW #U]Z57!Z1E;%081-%=4&G]SE8G*YPY%VJHW\0.8X?DC1
M.,FKH.B])E#E.!]P1%;YS1D:0N\6V;G5\2O;5*TVJG3/F4SP6LPYWWI?KV/:
M!*@05&+8RI$C:F4MPYG)^7W!@_--'[! ]JW0&Y-6@Z(YQ(8%1L/62:_T<;YT
M[LP?&(S^WS&K,:(93Y5*F/T!9(/_M)'HT(O4.1K@G)8*9,V('+*\!1-X4+V9
MCDE;*/< "R4D1&<4S@R7V#/+>NYGS7(.MR-R3'8OJV,-9'WIKL.$J4M+A,Y/
M"=3113XB>QLVVV@(!R1E1/MGF]^;T!K%#BMXP)K=^.HW#D+O%_>8?GQR_(<T
M(R^V>CZ-2VY@.!='QRV1DQSE!2>],1F9T*O]_A7N5FJ6#1G" NCD1?6$>YM2
M#QT"XWJX]&LJ4J3TQU!29><DN&K.=P)#OS-]A5VF 3R3PI&,4$__9: @&#*V
M/V3'!C(+4K+G,D;6)$^;18\TR\\;5LX.(0 #DGHO(^V-%KZ:SC .G2I9?A#D
MXOW@[QS8"=.)2J*()!VB0X)3U89;B;90.Z%VXHE=G%?C7>YI3I1\S 3"32.7
MN6_W[F<.:3+QO^*8_8*B^IKXEQRG 4?L2W\I0WDHJ,C.W8Q9J:3R>JOJM343
M])3H7 @@OORA?7-8&9\2P^_3JF,2Q-BA1KY!"B/DY*Z &'HK>PO<<JZU$7H'
MMTB\1_[8B8J&!1'+C_E1F*,3@1G,EM43,46IAKQG\N(/ @%;6M>AVM^UN"&"
M/:"+"+/FG<^0YQB6]@=^;:[;.QCUK"U[K:N>GM*DL<%5W.Z5Z)R_N4)>'K[J
M!/*<:NA5.W?F.+"J^+.X8>VN',9FHA^XXR-V#LDUWX3,MW6;<C&LFVA(D'1.
M]/!T.,'\6/"P<KYVLTSIGHM"Z0-=P%'1&Y#&:<NLAOR+!NBZV\%(QY6D* 3;
M9PR9I.G1&SR<&%W8D8O%:RT.>/DSI[/ &HUYV[U%;Q[&Y_YX*"9Y>\;[#M#'
MA*D7Q@7R,@X#,E/\<72FDF@@HCVH_%^:&R?L#+XK;0V=2U[MFS9]-_=HJ&I.
M3U(PY*N>W)E_JK]<H'QYS,[UG^F_QZ@W4>E?*6<X)6W0F%[YQ*74MN&=TX=*
MK\J5UF8%G2!=>?W(][N5[X,% (?HE6:\$P%)@DPI:7+UDQ:ETG=ZU)X=5<&O
MORV8V:1SK$MSJTJ*Z(YWN8T!]]#?5IAK?L_\I:X^7O_\I__!*8C$UPV,$^8C
MSR[;J^+XPO,FGWY7MLO6GQKS+W\H7?TMTW(/XS^6C%G<)BEI>WN)OSO\-?+F
MMN7\68#5?ZOD_[U*[G:0^U_N]B$8QVF8+@\_1^,8W:F<1-YF;()E!>)VT>AS
M3/K;4GLWZV$W17(87^;, EC_<1HVYD><4\-#O0> OCKZ^'3J2,9!>OK-68J.
M;;7LXX:8 L+(OR*7'NF_S_7IN/;\/'_7T[(>V8=F.I<9]P3>:!F2)X^?4ZZ1
MF5<N4SA6LKPN#U0,Y=MZE!P)QSF5V&0)'E;++)]0CGKCPY[(Q.,>?KMLPAW]
M>(+AQZEZR0NJ11R))BIV.0@2=Z(Z9D\B<=DJ,M:& I&MF"491,5&W>:"\\=K
M'X55=2TR+09_BOE)_F+HI/B1:8!EQ]DM% 84@PAA;U?)JMP"S5C!9@1>-^6_
M:NX;W#(1AEJK'D$>&K9_6D+HOH^^4'@./\'PI[':?P8"[?@7S!4630,TZ"15
M;84"#(.E'#G<3=S $<'4K'/9WJ2X+-- EL[T@VFB 8ONET#^M,FQ\/MEIO.,
MW[7^^Y3K_]53+MP?Q>DV&D4#U&=0KL$)-4^(TDN$C["7-, S6+=F(6;3#H85
MIO8?P^:TT*5N5"-8LW3':/W(;WFM';FG.X##I?\,Q18H#"F $")N=8U#UCJ)
M6_+KM5NJ&,&B+T[L\&"Y%U<;<F#S=X->\T?TAS DWM6RV3G+YPEP)+<3G;II
M@#,4EE+H/6(\N*+U7)IO$6:A*L[M+)Z<8MD1;=0H/_?(?E9G75;VVB6XINW%
MC MS#S]S))UV_Z3FRK(NWI[01GHWJ7P"[)2'Y DNL=N W:VW<&S7YHP2\"^W
MA:<4/<6J"DN8A<3NB.II)/-\+_X8/<.P=[VQ;&X=K%59N5 P#G;%.%/+_87J
M\N?UO(K!0X$*=Y('6 T5=5FD#41K16Z;[%Y+WF,@ $\IBD#"*&F/?)7HU.\@
M3 [!>A@+R2)Q'EEQ]K<;#1F-ZFML92I>-O(;#G\#X[]]^+NY_M^P]_K?CDWD
MAM, QV9OM 2)TQ1NP655U.AE<D8G9K\ZZ=D40J)BR34X?X,JC-Z6SCPP_OBY
MY5AZ=VMJUY#CWXI+NF'74-GA2@R#I[%R:/1WIB$:0 CDD13I6#_]3@G&!B%Q
M\ R7>@2#2#\_?E<*,=19>-$QY_]8X_"EO[UFLI-FP5*;Q?L7F-X^? ,]34X#
M'V>*.#D;BXS/ 7P/%84\4!:G:.) >.-?>Y/XIW43NB2=QI)U59AK4]CJMOCO
MUX7S_P;,ZW4P<D<[*5Y[XXN\$OI'L+PFY,!70,(/*H<*W$.O-1!ZZ]9Y>8\2
MEB>J_18<+2,+HE:/NGAGP.O-;W]R*584<7/>#/ #'-K]9]9M -_0 2@)-8J1
M'.W)6.+ $;E-R. UPX8)NDER;LJZFF(9N^UA_D*FD>VNLV&3>0R+DK/@XPM=
M]7>$BU>J+V^ .*!".,<K'J5!UQ.PA@+']I-<QE'J<2M.Q?>F^4#.8;:5*YE/
M+LD_7(2$?TA8IELUME.M6G!S5_6<]?):O[% [[+<6=3*9>79O;D3*Y$JUX
M%3FOH@IC'[AKT^3.PO/9Z^3)7(O'\:QEQYR=6E\^<XR>6%,O&!YKNF**"@L<
M;2@Z=@N2U-^&;384Y4(]@06;>3V/5Y?NXNX(G:F]9<W(VB+"S\W@@8+_UX9S
MK_#5[PC%(ML_&\Y$WOK"=3 ,HW&[2-N+A'<@L6FA1U,AL=K<(->6I.'W(JF&
MWSAK>-]HD3YSO*?*4^> 3*'GR)BM3BV5!F+^5GJ30&C!KFOK=3CL";U .+)?
M.K5DV=5G0!B2+9(7+K1FM[W/KV%*/W7C>&#9D;Z4%Q%"V.HKKGI!P@FX=H%^
M^W&T291Z"-:II+N9=\D]3*)*),J)JQ0R'G2/*^%'^!UA6^+*?YU0JLV27Q[C
MSCA<2P=RSV]:93XEP_YIFBBXY&8*-O1[^6 DM[A"KXG$P&_UOLWKK(6L*^/J
MSFE 6!;*!/4G&.//8C6U^T(9X^SB'J(U'@1BX]*F?\GL;:%*;=U:=<H5==D:
M]X^4:QNG*KKUGUN[W?_ZU"1VFV$,:OTGJ<-# =,=HI ORA(:FMC17TC\F7&9
MI^T3QJ2.QF)7%;A+4\[JN(3\ZS([_N9'NG4,TN$ADOD J-MI>@U/ ]"EZY_"
M:Y![IYS$!KG P8,J=<VD%QYV>B_$4&VAHF/.XS$TQK/1_F[.$\UY4-NS^!?S
M72,+#0Q[[3\G E0" ^NB72OPQ:UI3A>>N>)Q08]T^-,,TNYQ*TJF=TJ?TW\3
M"CTU&0/@[$BOT;>.7 A/["B '+#4;[*5(SYQ+JM(KPP2VH?IM%=2^!:VBENB
MZR-1;\X[6UY_LP\AG[[T!QR__.^;P_Z_=G/8$(X&X-KH8"; 8S5<*BJ'W(0Y
M"=O-N->6+_+T=@0-ORO-55H=>EX->J)795A9D'<^QS59+T!$_TV&"8?"_^5_
M$\VM_Z^-^#X1 R,0JBNCK%L.[,30#V[5$(\>%84-3$<:-/)S:U/&F8M?!Y3;
MAQ&E0L-I^(::11N'+J\09PV^ ,(PEV%19H!']?Y)(",AQ&X\],\#0Y1#-;2K
M7!4<R,7+!_$_7>_S>=5-]SH(A6$+U&0K14UE*I,2H0HIAZT!U5YG'G],&+03
M EI--NAN/&K,KTJV;]4Z\0N8(QI>9QJC 9I<\ M8CZ4(S(V(T+/D1$UC!W)]
M[NMBVTE/3CHE0(%8]>G,OM\/L[D;@F%QC7'OY)2"*OG7VL;]9JJ]\A.9_8$<
M[I5*&UH> Z[9R527)30AQ.]QR,ZOJ\<2_026SN+>#MFZ-Q0KXF0JESM>K$,6
M<>.SX8\%#.2>1.')KKU2+0J&<Y1Y$FMOIN[Q5P;G>D#S-*=5L7H=V1IWO+_A
M 5W,J %"K>[\1^_I/R\^':IC?#T.G,1SB=]9,A!HV0<(L28O1"1;[WN.-,YF
M3%[TB\C4JX>)=Z2,9(=!6[NPC'G>+[]O_*K&Q0A[\4(4-N\]:W3U;[-)%>D7
M9#Z775:;?3E:=LV ,W(^RW3A\CG!JKS9H^HM(OYGB)9%N\RL?W/F]._]MB\D
MF><W_T\T,&=WZEO:O0YIH_8FP&@ 0VO_1)&31>1)T)^NB8H37VF '_ZIL!DT
M/<DG6G4/4\GIF^N0. >@6TOGE#_HT/,&A6I,G:$ZIL%R6I '",>3R*>@O;W1
MHS?=$Z7[+T!(T++IL9GC[K::6&7EB9T3%SX0]ONW-UVL%]  *VDC7GA)F 8-
M0+C-A-FF =965Z@T %WI]8MSN)D?KM$ ;[]J30?2 "!5X,&1,?7VG1!]^"B(
MPGXOKKSOJA7N1_(=@.%5T1P X/:?MK.A0?D_YGXU>@V(E8>^_9\7E@#.[5 X
MJTD<<)(=^0J2ARIJ\X&(6GF9_:3"$;-P)HC"M,QLIK[$1KXKE&G+93UAB>[1
MDKR*XW1XY(;A;+*%@C2W<T^BL=;GM/@'0ML3"_(_K1**P0C[3S7_&O@^J0FL
M._E9L/7TQ5XYR&DGY.QM.C0@#8V!A;CB*[)LV%\>E9WSS+$]6-?)0LN1Q-<]
M,:W\12\+X/6E8=T^L.<_9;6FN(H-^/XUJU:S35.#P*IH@)=)<]58ZU^*A':$
MTXH>GSVQJC7#"LFA=676OI^]%M=NQGU8_'%P$.,5_4L(YVEMG<QD@Y)I;_!=
MT/\P/4&$77;^!,S0>*[F0$]30M=CB0%)<FO3K-> CN!DI6C^^5_SF1%(08)@
MIX,4<2D65*?P;'<^6M;/PUN.RSI?[5^-?!8SX_0T<0<6_DS<Q/.:6^<MPDN'
MU"8W35!FI0[ 'CZ\[7% Z!BRB2^V6GDI3OA6AP 3YD?6/7+(9V/?0H@@RFI)
M86YNXTC:M^[1/(KE<N'DODK;Y,NA0;0]S_L^9#_%N.\C#< SG?I;^ME*Y-IJ
M?L:3-4F(I-2OZF?P'1>>9YN6JY\R6]WQNB?]!'@G#<".$!@L=:8(?GBROG(2
M6YR$TW@A@6N)4\JBBA*#/N7BW="E,J'%X3:/SBH=2CQYPL:12 .D0>$&?A2M
ME?W._%W&7_!9#M(&^?B8'X)#]2RQ:I@'^6,S.IHS>AW9&LO;LJK/09JZ-$JV
M/;T:<#]?5.=,R;/E-!>_4Y;13+\>]3Q&@.F(RK/R:">BUF]SV5NQ/'S-F"M]
MZE-A1#7+\5141U^YM6FE_KBQK41!7J@F'<#?SC.N6.G:2>&^E<5^RX_.UBB.
MJ?%S,QOU<9]ZF?:/BL*@/X%0ZF(NU]/:HC:V&E]:JF=1V$^=1@KN(3$<I!1R
M&[&XF]3:$9,+U2%:+%ZO&5=6C_# *WM5>H)#!*.;G<-TF[YPW1.+L;Q^W_9>
MU6YC;^^7)J &3AJMVMU7(.Y$O("X:@DNN%V*-HNH^-$^<(,;W9"\.DY*:L?R
MG7\N+$1VZT*P_>ODZN3]22X%/>CA=#,4<_F%>:Y#6]2U-+52BZ*R\4^B&R/;
MG[*BE2J'Y>!*0VU(O SHY/H*%50)^HF _R8"3Y2JX=']'$3=WZ '_I*VU-T0
M4*/LDMQ61__1"S(('DWE';U-"(A)#AJEZ,D$KZ7 85N.ZYX<!VH@$ILQ'5]$
MJ(]]1P\E%&''PL^!1W +NHA:BK$.A!%J._Z&%<S#ON[@1@^];IPP-;('>4]7
M&P\B1W^AJ3I!Z3M4;OFV-N1!6;L##3#M2\WRL1U^=FCA)*$C/U1C&N]T/?]R
M/YO> ]$&/=%D@_L-NE^HJ -5F6/'T&%LU8W'H7(0I8O/WX>Q%[T)4WU_]TP8
MA\G#'Y<$YY83;K5%.R!W5;ME, L#FI5HY$I 4@0QSS<C(O2ZCEEJRK*#1*MG
M SYYY5E53J:>A.SP]4;= V8:X*P24?<=5/#X?.@XW=Q759:X!B\4O^D8\BQS
M\QWR>.UQKK+*34 K]\>C;BL;UJ/7)Y-M0X+YTCZU5F<N4-N(7/SO.@G6%Y^^
M:G0WJ6;E$Y4R2TG0#\4T2BIXI[Y>[P G^$HIAQ15^E(4CR1_WGX>N!=.0,F,
MW(2\0#%8:Y6"B[CX];.ARNXMTO5""=W'^LKFQ>:SN)H]]SXNL[A/USX]@TL0
MK2D75?MS)(CP7UXX V-NCZ/J=X(H(!]%MVA#8?-@6B""I.:\&(<]N>-&^FVO
M)_K!5FS^P)K33NI\?CH.=_^!HM;.1X*+8&S?J_B.QG>5,6FLHSSZG[8LTFS[
MLA($8J_\?OFHS#PEWJZNK3$%Y'[R^2.O90IY(!GG\PW)E(%8"E/XY:!V2UI9
M6D;#2#;*X],3WNN5:O(18O;8]>_YDI\0NY$7](T>Q<!;E(_&*-?_)V&&TB5U
M%SU)G$:3EIHX4#O1U,MD'J+[''9BD9]X/;<,DO5P8M_00W<<:NH6^+AI2L[;
M/[?+6ZE9X)\MD;DY^UZQ6CZ?ASF/OE8MP2&1*/XUKN6;-B]25*C?LEG_*<.)
M2+;$*A&5?K+;E!JS[2Q^:O_)^\GY]8L)VQ.[/4MB/JKZG"]5]%L+7;W57KE[
M94ZN"UM7T7\V_>?'(G6)TNA**TBF1<ULD0B+/G<ML=0 ,YWOH)S2W9T57SJ1
ME80#46Y5D\@T0-XAX8 &8)$3I %V,Y$B-, []7[0GAD624 JT0 _70YT*<;-
M8VO4=U4R-$"/;B3H\(C.;@BZ9ER.1#:OBPR1=PC$?A^HQXI?UY$0&U*#"CET
M)H/Z/5Y>0QD,K]H6P ZXD55'/N-'P2?"PA3^WKBA$U.L%UH-!E_P 9&]811N
M1FI<,0I)D=7PI $&)1V)YV_]IL:RRE&%%(VI)B RW#@?><(Y;TN?6A(+[/>/
M6&/RU68*M\*"@P>(/@WV'!R/FTPG.7PE[GF0A?-%?0T-JM[S0^BWFP[MBDUB
M6+YWG%/\),[&QM_0<=!Q&=XS^*17KCAI;+#,8I,0S5,RO#L*#[_E4'#)*T@L
MQT'OY7C<ZQ0WB: =%,<<%^D7#1!F2QT#@[J],%Y61-V$4*$AWR<WWE& .,,
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M;_29(ISY;_A-HL%;OK^C"GDG4N+S?J&MW*H2U)70VQTK>T[TM0S[1%=-_]
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M*,4D<;+0PW7'4;>FSJ.@V:W(E=?W6L_XH-,%^R& ?V"357!"]B*\!&/GN'%
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MJ,V'4^T=?PP(M]^3AU-%=F33LM*WXQCP[_KVX,&E_N _3M%J0OO>QX"OC[>
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MOS'MJ?)*_R@^?SWB#1$]+P6$*!(@"G-*VI\QRN9,-C"("RY/UB6TVM/!Q4C
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M_Y7!($+S3IDX(0%5Y:]VW$2,U,R>Z,Q]O  L>9P_:^^^K"]NP.E=Q&>OJQ<
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M("C1@?A->+*E]391.76XZDI!I6:GEXZN3O*,IV2G5;KXA]1,C*K\<$]RIXM
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MTU3/  .:"F6V/07.+C8S51,M3@VM:5YV]+&;GUQ:*DQL13!#76'&.$Y[_*N
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M4E5Z93"8MS_-XUEU[ M29I:F->^M*INVA\7ZSL_-7'*O+FRR0(7I?,AY*>*
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MG=CTGQ=$OWHA9"18;/VB\H9D'7KKY%B;PSY&_= $68!?.(MTZ&E0D7P$Y^$
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MG8-#,U?%B3_O'S@*>J ,_XD;I\KK<_@H)YDHCR"]E8V=SM>GR!O+OC7VS6"
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MAPH(<PU.OH;YFK,T0Q>89W(.$-)G,=3GX[JP(KHE&=,'2[U:_ ,M3+F )>'
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M4.P.Y%'D[Q]_WVO?V;JZK8)<YV]#LN>AP ,C%3 0H$M[T2_#@\R^QY&'2-?
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M6MPK-&RE)6CD#TSE+B[PTR<R@'K.)A_D.TP3^"X-C)+TO (GUS:/O&]20#$
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MR--@JH>/4(@;R%4HE&N$!)J<*!BZ-<G-F38"^>JUF@Z-I-4L&._*1]_+@<]
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MMO_HJ?)B3]_/1O%B@EY4QO!3Y.[*S@5Q< W!"FQ6?4<$;07%^.8K-[('A]"
MR'"1!30]\LZFH+\LX!D9W5!)BC"-3;L\\:'5OOA=GT'/;-7M /EITTD%IT*F
MD_%4P>6K]P"<$H/] @WY6DPM/B4\)LY,%*0C',%0TH==S?]!P4&,AH0I6FCZ
M;O@H!Y%?V&B.58WO3_MJ'URS%)#%;B3BF#W8F@"=J7'NTN(D0^.#FL&ET=;)
M )HF!?C+\"+E5DGLV/1B@$>>$?A+@6^G,E"'8(1O+ \"ZW9)5HJ<85=^8KT4
M0-2<;[!=(T.>NA$VX'I$^L\HB>QAN8 ,PB1=EF_RE)NVL?5">;<4N&:,/OVV
MZWN9XM81Q1.*.(?NF>SBVYFEO=Z%&B:7 3$3&>U(:BU+#F2_8"!4*D8*7&7%
MCVR$$SF$2#?,@$B':V/K MOGPU?V\<L6ZQDH^SRX]EM,Q;;-NJOY7T-URII&
M']U:N!_HIEG]T&6/OIU7_O>5%S+D$#ZV%$F (3=$JY&_SI)VC'"[I(-N".<B
M;%OF*%^V":V,=H2;"LEVC=CM/H%-22GZ29D^@L6'KUJ<[U&F;]=W;J,W+8%O
M^V9>>TN,':;M6+H7#7;*_43$Z3(=A'9Y+Q9I@= 9$M.$)W@.-W'Q3#3'H\F&
M4$]%0Q6Q.? RY$H1NFI=U3<-PGDI+8?X^-AME$#H)M?U,RO6QQ\UU:&0=@;?
M6]IZNQK'F5[>35S^]@WQ7:W-F  !^Q #:CL:.H4;"A)<7UP-RU,*Q!'*L+F<
MCJ&[WWK(!.ZU>SQ:A#EKG7702\^1%029N"O<G*CJ?1"I4:+)URUYY77=3-'C
M=)<(S<E+.W!AYX3RD>=<[LA)U)\S<$C.7\^6#OT4+%JZ(5=H"<X:=B*AJG06
M":!MC&]T*DL*P $X#[PD7!,0XQ<W&T&^D4.,@X/U" GTK:+#XE3Z1FK7B,4
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MS+\?OA;C^5*VCL'.PD$WDJ=02$ZM7MR2ES%4(;A7!@]S:5$CAM!(',^83-D
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MC7MUO;R$X%5NF7K;SU1EA.G285/Y>.,1SN^A/UYGH%YZ_G>0Y"Z^%3Q=Q&'
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MA?W<G.3D].7BZN[_'7C<<.QO4@#>0IL.1(@@4YR*\T@C"O;Q^Z.AX2::)MV
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M,=^9TH.;PX(K5?L>AHC++XV_72%>]L +9>Z%'=-*0)#>P2QY7>*R_V.(E#)
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MVF1Q#->[0YE?[\AB5NG[ZGL@Y;'CMS\;2D2ILIXPZLXN>^'\H,D$ODQM6E+
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M?18:^@J?W3PFF8V"-=64EBI;&=V@O^SJD2"< DNX)4-AR[:UV#]>N+4N\/Z
MDW]>07SJDU^+?,0U\_?%)MZ-!:=#TG[H8O4LE-" TT]H'I3RC(*]([L2\9^.
MLAW0][#$^Z6XW-(,V<-%S.MH9ATC8S]V'3TZ!)&Q0PJZWL*%S_9D+Y:O?Y[V
M60Y@!)#&K<"72D+Y,%T@#I1E]1SU(-6-BCNU@,CI:+%)4!@A&Q-!/7Q1PZ3_
MPQ,G=^9T.)L_'-R_;>&,,PY) >S;\3GD+BJZX>14L> $(EI?.HJQ$0EWG#_,
M2X$6#INH(M!5\-$8_KZX!LD">\V>QB.(Y:U51@Y$^+]8;>G%ZFH0AXGKE^\J
MZ'?R>-(S0^X <'9"-;?!IUQL)?]CEYRI%"KLS(=['34%SH=[%Z)1+I^KUSRI
MGHE9M9?:63!/]QYR3W%%RD6-R*F*RSKL5#=WF!$7>20O<^7Q53J:&\VD'RF$
M8Y: WXI,&B5J0A><'M4<$4<"4+XK %T1U G0%3:7: N)[P17G22\;8'F7O5<
M!J?UPOH4]7Z,.37'LUK8N_QS4H3S_0:SB34=?R \[,'0!4JB,K>MVH25,%1[
M0<*U;RA.LC.J]79X6=6RY51Z<2SD*4$6.=8P)]V:ZLD8Z+= "_1%;J:\\<2,
MH_%925(*NK)/^5 J[#&2D5]E^:C.=I50XOVFP5%)I\>I"P9H=AW.G@H(8 GJ
M*\I2%3T%[KO@"6Z&L@PWZV#;RHY4MY='Z=+AM-NSWB]X63*WF31I!=4T^JW@
M-5)@9J.2J3@2)FZE+F3IJGR1[8>?_-[9@L:IKJ$ZCZTJ+7]O+OAXY<]OGL[-
MI"^>F*F-VHFU:BKG1*$P-+C$A::04Y.K-XCQ#YE04@##\5!KU0(I68=%EOL5
MW1D8$=TV $5F?:*7!$X?.3(-"CW*"MWJ&$ ?#ETRAS1ANIGR=\I4L70X(P$\
M(42=4FK][%'&?9\@,PN),IJ0Q,T33C,O>WFJ0^6&N7!E/;B@H'>ASX5="IYQ
MD\(C!'^]WK9>_O!X@GU9^O*]Y%X"Q3,4)HG.:]4+\=?@](C*@2=CS!2HA)J(
M^<N#PKY>,^X(X\Q!C=W#'-VK#OK[%*R-9":=JQ"5%9-2U ?<6D:GG>_\K0+@
M$%!04P05FUP" ZGHLHGAMD(6M"VAL0$J\4^K5&]FT[MV[J)BNPK0.I_JI_#M
M][1FY&.0T& ,(@5-<K(+5-%19=75!TTJ[M]Q>$4:TR=&25>?91E-Y?&^0'3=
M0;-\CJX]43T'_I-1UC5<A$3O;(WX&G1:T4H#H=HBA%$O((M[?!;&)\0]&K+<
MB";)U+Y+V]Z4/8/'/SE%WCLK;IP=I(-G,DJ[L$RNTD4+!'Q'B%L^5)X4I(LN
M(Y8H10M\D4%,NGH92!*..R($H!Z'X*/,*]E+4'TB"OQ+4\U9CNZ9#*.*SDF*
M1Y.JS.\-ECU[RXS.\V4?K&RC+4CUW//B8GJT!]V#U\"+N>\K&K#+PXR[YE:4
M;+FABW6"TC@M !^A7N3#;A)S-@>]HQCMIA_5Y'"LL4/P:)RSB91O&I3MTHQ9
MG(>_UU3XXI6/4<66$@_/6K.QD>P-';=K/#-OUK_$;)>BF_9<+,C]:31"1[,2
M$OTFF2$<H! R M:P".:?U0%PB"!18P &"?51/FZX ]V%"&3<6(F,6<<0DU07
M-0_/1%#B?V9X2;9)H9GL$)C<X*X%#%@KUXRI#:P;HBDS?4/-YOGH>SAU?C[>
M+$U;N'6%O8XZG "@MUK@+W-<[[H6. [VD+7 +BC #, KA-+K0H(?HM9\S1^D
M8>84)X"GBIDS41LZ5NB+D/"F8H(-:8%'Y:H7A"29P VC"!9AROD,J69//5@M
M. 3_$@LN!Z6OZ7&]"UJUP(DFL42!>1_B8M;X!LV#.ZA+3,$?42%QM<)9U?/9
M-*3P9IY=W;3C3YV$#1X!2EELOKAP.O.<E=KB:JSN)*$Z+HE0_:TH<9_3[Q/_
M2&$Q1.L/9ZC6X@W\$FJR<FEU6=K(3\[;"*$CXR=603*7[:ZKGA4T7)4+9O>+
M"[)JR4X?OGW0K_R]N,9H+PDA1CYS.WL.S$V&@B@]?%5LQU@635U/S =M(6:"
M1DJ56T>6.70FA2%"/_3Z(S1SU)U<8>Y36<F(NW#NMLNW5;WW^5'GC\]^'?@P
MY&>"J]V92*NRN(-MA^E7.!0TNZ'G -R5QK:54T@LKL?+\K21IKW-F,<]W_Z*
MTM3/3U[5AX=%'8\^.UWU+6Y1RT[D^2H10:GN3Y'RR<*']_Y=$#X8FGG^K28K
M6CT75>]O/[&UWJH=LYTJ2A7=9O\C8['_B3A19L4::4'*%23],* %MM/%/:I2
M3:;P!'1ILJ]1*"Z6,^-Q8_9J^._/?RX[@BQ,__;="UGIGN6^ ^Z+J]ITDADM
M8)4W1.7NKGS9@H&R@DW[.N_Q]E2UGRAS=UFO^M:L^V,Y.D!,2#G^IGIA.W,U
M%$C_V*C@-IB[QR!;"K#]R&@<C>3EM_OR@Q<ESYHC)*D7K@^,G%UN ,V\"2UG
M^:28;]0[". '06DY.%7MZ@KQF_"-2)2';%/M;04#7E)DZ5<1QZVPH2#?#ZWT
M>XYR\UC9$Z\FTW,#(^7"N4%^%FV1?[%-S^:)FX(MX^YO3J<K]%]0;\14OXD%
MVYMPO>#'C"$)O)N'VM!>//KDTOOP"5[+>+;F\4/?7>\R/">Y!(&#)T>^R2;9
MWX]Z+!?@;5%#FRE?$?BD*@+V5!*ZD70*VXG:(.;;VC"Z-.8D/BM*?1+M$?6:
M=V2\;V5OR</,$6:#\,KWH,S2HJ6;E+:'F-R!DP^#KR>4=:S.Y]-?I/E$WYH;
M"W:(8T$>%771ES(O51TG_+,?I2*]0[^V9<@=:WCBT#J.>;.SVYKV]K97D@5L
M<X4MPQ3U[G[F/!3C(Z(M@&>^M-^^J99M]W5;D>40B_2) H?P1#ZCA)BKF0\&
M%#CN"TTJI)FB0D5YW;V*%VN:SIX,1E(:+&U;TQU_C^H9$#-2GHR%'OMCY_&V
M_9]FU[;K2!DP2\"UBVQ"E]L5YO_6LKK:4/.8,PM-^VOGYJB*BF;.<I9K)W ^
MV#4C^<RG^+[77CXCC_>2>BAP&#5QA'V N/_-FKC(37DW_4MA?GV3X8J;OQ:5
MP9#2"(%J#Y_6>;W6(3M)=VM=PN6&.N#B9DK%P?_&W:E&/K; $:?7*02:-HKF
M $2VQ2:01GP/;S[TF2 A7I]RM("KLYX6N'ZH5C)!J+Q.W@:0-O0M?/S5?WQ;
M]7^V^:6>_>\\VZ^YV"PM4$'H],?7Y1;0'4L2]+I0!JD+H"'7V_P^1IKD6R0K
M'^^')C^<ZNNWXCSE[/@_8-_PG^9_I]'1-O\G=UV)*!Z7AYL-\J>>4B932K=7
MV%W.3+\#?_="[9 5/;65]WGN\$0#=887*TU# JQORK).>G6L^7CU6<.'@0;Y
MG86Z;X32EM&43$<1$UWF6#LZ([@KFY,'DQ741BB^=W%I@/DP<UQB\1D+*W;=
MG:%VG@3K/SL%?5FR[VOH'VW6)CGD@<+8J4JM-!ZZR0??/Y64.U<+/+6)%X[?
M'7M#?+#EPO_BZYJWA7"$<%@M9_"$\(XF\2SHIX$)[^H7\#H1WU 89-PZ+/\>
MR*_CZ"(D%9-'L)B!K/($#H7%K_=;([R^RI,.:YI]W]4LTH4G\-DX*E23L9.H
M'L)4K42[X<=22Z'Z5Q95?JX<.?GJ%^Q7- 96^"".HJ9XSIIF>_.P'8UUCKU+
M6T;&7T8?0,_**0:#77Y+VEJ#)71X(IGM$NEOY.4U6'!*1T.0TCI33J-P+ 0L
M9N +A0D4[,U>DJEZ(^6CC8BV 26"P>P[N?C;KFH:ZEA K>,E5PA>"6:S';E>
M,.WEH^Z:Q^^E@CEH7(W94;M@:/F<;=:/[UALN5=26;P^,ZO*4;6_1Z2#Y4,U
MH\8FOW/>,(J,[Z=_<XC/5^HI>O1OYX"1!KVYL$1IO'XD>E>X8<:#77-&RI[Q
M93ED"8@N)B>-T8F)KS$'I7SO]#@H[$'W1VQF&WMMI,,39,^_0CD&7>.C>FA"
M[>'XSR=?M)6^-]];].+B7^EZ.:R\[5=]Y^LV_'_<5KH-U2@9WTZ S^B:+.*#
MP2PT:3.E%(*9CMB=:%Q/HP5.A>_5 AWQ"F\ MR0ZIQK3D39<?U1&C]4"B["3
MC]%U4NI%I= ?C#\L_EN5OR ]22I)@(P*JFP4E"3<I97VT;IU;,!.P#XK=^R(
M3'GL&<RH+6L9G!EML>K-0@!L>:LZJ4F$3DZE-*_)G*K_'4#I[I.1:WV-W%H+
M3BLC>21TT]8XT>2[N;65D>!<=* @ &&DE+J+EH86A(N<>O,?]*9_MZX\^W0%
MZ0<QNIIVJ,RSCMQC@L\JD*^DD5D9=(0_)9DN^QEJ;D,RNY; TBI8)90WS6+E
M-U8[(J+)F?G!]DB(F,.30XD7N)?OM2N.AT5!LLK7]GT5;0;I=\[IX+<H\$'F
MCQUT;/X!_)V[Z@7A\1 :1T D%UM(\-2-KEJ@TEH+2)[GD$>_Q8+O3JH(QG#S
M+1:J!0()2\P@0++#2^V^ES3^@V ZF[3 F]G",T+U3#:QW#H?H83DS!+"_G3L
M[EM%W]3V>3VH"61T'XX%9X#2<>&/7?E3V> #;*1431!9O#46;+M+7(2!SZXC
MC%K,:854)Z"%PO$\T/_15,VQ9.+76@BUB9K2!KK_U@;Q_]8&Y3GDL?X<\O>%
M!/C=@=[(^21P^ <DO2&9/*&Y\4!WDKC=N(IJ6U0MR\#FJD45;A<%#EE.;7(M
MT#AZ&9KE#$7G'GT=-" U[P%-69)]Q>V!\8K;:HI/)Z8O4^KN+W.;.S@G1-A=
M'NP0_W?[O%@V@R#VU_!7E*<\0E ?VP2)ZT0,/7P^.UASG[T-B993$YR/$Y-.
MLX1'>>.\.(3EMO]9&2RXA%'O#W5ZQ^=?'&%B]I/TM,)2=W-WQMS0N6C#DLA'
MG_J;@]<;;Z80DU[S20N4D6H9A.9SUT2IMGN$N\7))4H?.3]!#%ZNI@3O:%1[
M[D;/PG5RQP2:#9K;4%YQZO>&2;=X67N5T5UTZX?OPX.1!@P_'X_UIK*V\<>I
MJW4O_=\O#$ 4B""MU2NAH4V<-^TZ6"-QN1C..L=A!6%"!W1"E>"^*=6U6A<+
MT,31UJWAASPM[?C.IJ)VZHVL3UX]=N^N^I36OVX6_5P@*JH]%3GOKT2O&[H:
M5]IT+!P]I';'%J,QB$3*NS+&I&!V*%^6M:X^FXSLX48MZ"A0W7K8<Z^V=V#9
MN0R/SHC75RH"7MZ1K#8KC"OP9@2)2PONY_E'ALTA?9NZE0NXA!"7-'VH!HP$
M/W)W(=;<Q^QSFB=5KE+[=HP2^*C&)A&;"P>^\K-OY2P+Z=W4,384_*6B+<S9
M0\Z?$60YO?G P?+R.-'ZBHR4_+;E6=A:]E) 28!3DZ#[MD@X'92F.V74,TV"
MR\T"[J@/8%$(OQ[4=XT03/^&.< ?4F5-"98+*]-;7;U.F/$3G9<H?$/ISW\S
MVM=<ZD'96R8)/LMTEE+B03B<V<"W@&H()2P50,\FL'FWI=:YFKQ0.,,7SJC;
M5'3Z5$7K,G0"^394-\E/96]YK+EZV=&;6JL%$@:DXQTV-S.9LS]Y83O*K_GL
M9U[=##:72VUJ&-/PJ1U$SCP,0/WS(7\V#5T+#]40(1RCG-K.N1!D.;OY280%
M+7I@V<[Z#_G1!LF]@^7OJB/QO+.1T;\U.8\,ZPP=U,&/,> SAXN/2X7H1ET%
M*:'*XZSQU0(T>53U"=YS,[_W_7P3$S_K-O:^1ZQKWW?&6T4&"XZWLJT*/SM4
M+?G[V_":Y1^7)7W>#+:I8L'7YJI@(4H,<OK4.<H4]DGI:,^V5]7&G9R9Z";5
MK2DD:R"D4!%FF\/BU8G=ZOA7W.6V]'C*0D&$8.Y'R8!J<D;:37D3P':O%J;U
MJ+?VU!P("3N5,%!?DD,9M+J+O^8749/L8Z@BFH7FEA;P3XW>W&6O=F%L[[)G
MQ#'T(CTH1UHCS5DC8QJZ>_LP>]U9_P?!$YW7MX4'1@<[=W8=_M9H/\_Y3,%F
M2Q^$+)-@1LMDCFDT8^P7]#I<K%H->XJ@U.HEM 6HF]0"DO%JWE),V=N[YHF_
MCH32]=!@;*.F^'%]Z(PG#2I<_+YDR-2L5[_R02'5;ND-72D/W5C;JT]'ES"4
MKT-#9Q_N[!03\85)_)AMFU$U!V_7 M-R$Q8>3SV\X6ZRPQ%%FL/![8<.[<V9
M 4PE3(U;I07"!/&9;K%@,/6C?CW'IJUJ$[+-!R6D>$E&;8&YYXOB(BT0?S$_
MU'(F#,5RE@QPS#+/7_.@$\(M3C8:[W#[Y<SEH3_&+'Y5>[?)GC]MKMI&R]31
M?$(;&_SFH>=E]+GH:&.U3?/41A"I7\Q+Q#SEH_,'.YW("9AC3K!QJ]]@9N>+
M@I!P\<"D7T:^>)O=^[_'E:+U*CCW]>KD1QX =)/#5>PB_+>, 8?W7<:M,6IK
MX2C'!,U0/4.9<B5-OF'D;CP8,-J]; ]<$HZ6_2B<4Q8/IF$SX!NA>F%1I6%L
M7T6HQSSJ^L'H(X$ 3IA/^EW0_;B>,5\HY3-F"(.H^L'EW@7EP_5(]W)$[K/=
M(H+!E2R, -'M@8A#6^PIGU"0,L P+"%M5T!)K?+=KB'#.9;$\I]Y!ZK9QIG/
M:07A/7RNY)FO)&DLAJKB:JZ>0$B72@730IPZKK&NU_/UUU3M@N34Z>Q=<&?J
MZJ28:%F64Z/H7RS2T6LM9PB6-RXQ=+7.5^DSYK'.KWD%YH\:L\IK>W7A#T(%
M8Q'K^A8X*J[*]IYD"+=!&,F1T0:Z==D6S6.5Y]>,VP4>[1SW2?%U_+5U3'TD
M[\5+8?6+2YV=/_5ZY6W?_T8'][(T10@]6Q,*2OLE!MAAU.7^H#>W-J5)G"_C
MB_1C=N;>9A%HR?^H_A7V_;/WEY?!\D/-RNHE*"3S*%#&%\CU[*K<%$KJ]J5]
M^[,WC !@6[CJT=/*CJE<L^)MN]N47RJ%[9QI[.-/BTH3 WQN5PJYV4O+R\H3
MHZX%W]O9'!6@^Q* ^(V8Z5QYS+PF58&FK,HB' HS261O4]-0?9'WCMO+$:N.
MD>LR,/%9\*3R\\O*#9E!)6J!2?_<3Z_G_;*5J10]N7^D#H!.4^ CU.X)D;"4
MBAF15#+45/J2UG<$$5P! R7F#);MMF>)'M%RBBG+6DREL [4I>_+-IL0^2V&
MR[+N>@<&^:2@?SR+[\VAU&9@9OJ(0K6A#.U6;^$T\DL="4"_5-%W!=]4)Z4O
MQ)NREZ&5TB:=T*(0SBIX+V)\52Z)K]CS6*[YY=L@P87XNQ'#%#EY5M"YZ_><
M;L'"I)SD]1V%$>KH9O(803(2?M'PH/YV*$"(K85F@S]NY) WHOZY4(WS,4T.
MVQW.E?9=ADZ]A<2>TMZD?%9C?;4Q&BKEQS]E[T$9>:Q+H07F>]HC&^&&Y$QA
MW,BX2Y=QB[??T2,AUX]\=EO7HZ^O/F\#X,Z@] ?T0Q>J^04:ME$?)U@]=;AN
M,Z7+$YL7A>\CC#.]C>"<@"9UZK$V9]%>$FQ'_&U@BAY5+]8"4TF ]A$?'<:[
M['4T',)!/FB!;W'4'@%>PP? \4?5,_>2^IB8*>$[*YZA!'T*U ((70MX=:D.
MY9#[Z?@L@ENL($#@4A+16S+>19G,H2W>2T((WC5S+4%@T544M;"(_EU3$*2K
MQO^+_<3]H@7^MA.6\#5_=#4P-<'4;DZL2SE./HL*%$--XNLJ1]3"X6LQJ59"
M9NMTX;8#DQ<^O:9PQT$*JU%.P.F2)WZ[ M**?(><*%RV_ITM,]Z_V67-]Y>;
M)S[)7M ^VBG554_5B_*%:ER$QZ#N0-5A#=^!T0U))VH-]F&N<(9L(H6ANE@.
M-R:PW1 3>8$D$5MY+V3"<F,[;O7^>+B 42\W'6$<>M8V'&G.)/?#OOH6NKM;
MQ_IS2_>2Y=$XV5GS##?!SDQEK X0=C-D34DE6F!!*.49XS+'9I"Q8*0D6,F,
M^*PK)S>D2(!?4./!R=[S4:SK=7Z+T+![(=[CL;Z9V]"[77N>9ZB]+?8W>@#X
M%.1?YW]+H?Q[FYD\?);0"$KX:RSXWFVSIJ#*7#T;JFEEF('!6B"QR]$,JFOB
M2N #U![=G8BJ("R(F==<982 C8R%U?-8 I'=J5O9@V3#?LM-[0Z5#^SF^0S8
MG;9V_VD-=?><#:3)-ZQP4;8EPN..,8Q9;GXM5?MDS'G!YYSZN.Q=LL_[W_HT
M.RA-#I8E?_?H& L[Z9'91^^P?[^U->C,$^;P&9O2RK+TE3GI.[,L8L$X*NI"
M5A%6#BY@+9,Z8D;YKRR7-V-TA9(B/T4IL6G<6>)[6'](R)TJ]$E"4VJAV=A<
M^4]/^C(WN036-[.W(I0KU!+?S3Z#%0$9.2RW0]%G3\I]3/T!/!62?OXW WJ6
MC\V=4+G )JEC/:F4!OP7F)_(<63Q=U=Z)HS45#N@0E\T21:M_W;7(>NV<8M-
MK[S[+I=H?.C/#[TH[BA@WGF^\[Y;/ "N *5C$D*VQPNE?_)U..3;$FH]2(B]
M$"U 'BKSYOP]<Z@6U,<7L3<_1UR^.I[Q?XJ04S!=O;WQCB&KWO6_25E!&L['
MYMC*"A_"M_&?B.%,5\/9Q<>M;\7$P"8>Z*4P*]]K*6!*]1*$5)_UBWS[JQ43
M%8&I!51OQVG;'<V73W,E)+J@Y+]Q@_!]N7)</0WOY)MI@5!Z"L6(8\I>H04N
M9[R:*J%\V4AMY$,T0[+[J2K),#,AVQ#&\[3 /,D<5MNN#F7U^\<#3O'YDWY\
M9M]Y2[9E6,E3.A5I2JY>@(S..SL2DW7J!;GK]W=,%:.C"!3?6F\NUC"LWSZ]
M*0Q/>;?BQ)+7B74=^>HW>[]^Z>/:6YFZJ\%:R)@-ROCD;[.O;VK"\S*/"4LY
MI0GXFP]%M+=#&SO]4W+5P]8,!IG&IBU-I7_NX%,=E_\(R%\X=;S4L$A3!?;'
M0U_WH(Y:H,E8Z$)XN86<IR&(R8_;LE$\FG)7"XC.P8_Q9#Y6@U"T@-,VW.*D
MF@6US-("[[)@IA;(MJ,@NE5$-+M+")]U;**+IF-$-TJ9IV8!^"-.#N(17,RI
M4043WUB@!6YMDA+0[>P-RDFL7"VP78@'H-%$+P1[G=M3*YA<!7TGB2!L@(Q&
M\I2$N;?;:H%?HFJ$.*L$$ADB;G@2A+V')[2 2QR^K#R>,790"WPE)Q(WW$J!
MAR@]=7BB)WYJ- ["D*#_]VA(F!MSEK#_(7'KE+E:X/L]4-8)EG,U<P38:\E,
MXEOR%BTP9U,]9=**^-2Q3H*IR&A:[P*HA8C#?]"6:8&^G5#=$XA)GES"^'&]
MVH#X5GTNOC@J&1PCR.]7)E?X8YB"6%01I.YNOA;XF>VF!3[\2PMPC^"]E+&M
MPN\V;'.BDQ0W;//H?*@_@[@1"1GZ_A&4;V(=T@*N=/P8RM,"64O^1]OPT(N]
MA)NU4(DIK"9T=M]3Z!_#_&.8?PSSCV'^,<P_AOG',/\8YA_#_&.8?PSSCV'^
M,<P_AOG',/\8YO^7AL&O0<<8\=G.Z$JU%6:#^B..6[7 Y=!&2U.B&54SM^-M
M+:7\(N@TYH[P$NTEZ"T6M*^C)(5?,F!6QH_"DQX</4^#KH(WP^?#KII4V6&W
MS-\D.J<VKHF,GTP/O(2W3WXP[Y$AM+=#IA].3FV.67FCY[_+D/F/."-/?IS_
M8?-VPYNU^,_(2=J;Y[=%L[7 IM=K&;YO$&$WXY!(/7N/N5CC8_7VMZD-N;QM
M<PUW[[ L!7OW<QVISAMS9"MCN(P[E*S_^&FO?YK_S0;2MOP'C\N)A,&,B]6F
MFGPP$$KC%_.OW%N/&Z-#,$].J?4]A]BU#L8XTM&+,@_/VN^#G?_:)"J [AGL
M#KD0K7><-1H6]G=:T+WM5P'PXBCJ0%==1J!A/2TPPU13"$FO\DLBSK("1?PY
M51YR<W#VMG#[I,"PJ3/='*?Q[)?W^EL_V,DK6JMMV Z\@X@A[\G-4QU2V#$^
MMS5]GT#T00=/:@?VDNH9)?F84;[*1O.4LQ2S1TO5[IRF;#):CIA+O_DTPEWU
M?DLJ$;N76B!^66G7<<2NZMS9H(J1#/_P1=[**N_DQ@=BO_P_\W[]PU?Q&[DT
M",@A?P5Q0YH6N+2&TP["1RP<56"I)K,J!B:_^HXWE0LM;1 >1J4:8=O@=N][
MC/^+O3>-:FK=MD7C0D5!C$@I"%DJB(H0"Q!%($M<@H" 4A="EJ)21(@(2)"0
M6(#4L 2!+0A1J:2(L:"0PD1(@*5(74D04HE*$9D1"%.2S-QX]KVW[7?.>^W=
M_<Y][>S;&JW1TO_ I,_QC3Z^/I+,\:D^!"UU$Z2P=9V@/">0\:4IZRVD&R*%
M,=]6GBC>:QA3KGT$F99G%[)*5"K:C%<5V,X.B32AOV@O2>F+.O*>@O(WB-%$
M-J+%66-Z0JUA$&F!K,05<]"ME/6@!GH0;Q9=-96_LRKJX<0T4VF\.S.BXBO3
MYI$5R:BYOO$2Z6J_S^^K%L*>%T]9;>LW=91##YA(L-8C)C-\A$]?+>9HG*W]
MT$*A$]/7R/;4X(+HU><:ZL#<[)?\?F'W].[0;^32K/7%N,+^&Z@;E+%Y: ,(
M]G$HZ?4L72+['G%K,Y(M@4.;G<%3S:9 +!>5*O;[.<4#M:Z6T9RQW,_B(-OA
M\&#F#$:+D$?H0B7"4RX!B4D6IN5,YI@CEZ86LE]"/0W?E@FMDVT#\F?$UP
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MB*N.75LEL3HM+^#]VW [*JK.N14!(I>2:.Q*JAY8*#K (O28U_.WB5SP 77
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MJ#$*/)6QY%/?D,%<D)NLHH%F=&BCM>0NN99XD_6<Q!]Z.LUZ63V2]QQW#9Y
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MKI*8!9O[W4DL#<[?F2,_&MF%<'[1OS"#/10,]9PK'SL1'"A?&*$WHA)S".A
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M6>0?*B%LYB 6'Q_^00R*LYUVWD!>=";'HJOWS$&WGHD?%'74_&B@=KW^=G;
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M%&5F6>+TKN2_?HG^OJ_^PZS3?](@@7>EL-79LG*81>@@";UJB))?!V>^O>J
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M>36&/_XT6]D*O9L+B]I]Y)A_9_YW^Z6<K :1@RPQ-TLJ\"=$FE '0H,8+/,
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M/KW<L=>RWI >&_M]+#L?^C9<5_<UEL540[V@U1S9QK?,J_DTDB46YX(4#$9
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MT<.@@<?PVZ2P+W%H4^@Q0)*LGR)R;,RDL/R>XZ+ @U+8PP8BNQ$EKI:093X
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M2,2[3?,'SY9.=JO$C]NK::?<(W>M+R5XC]F^?\H=HG3J]==.RIH<L<H.89T
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M7(Q#LEJL:TAMT)PRUM&D2NV-(RM'V %M6CWZG0IY"19#]^JHJ'BDNF+:Y_Z
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M\Z[C?H6EL9 I2M' R"I-=8]099&C^=9TP.=6Z>.FGFHPB0S]YJ1!M6GE%47
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M'XO:U.$LF)_Y2:QBEZ1J(G97&$\3LF1#[O3#LF&@$A>C2)GVB0WY1&@U8UH
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M(WP[$DCJBV1=I%X8(&O"H]:15H5.B-/+*H_>\<8PO(C>&BVU61]UYU53#_Z
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MOH7/D;3G:Z)OUXOP7IT//5-?-U]VK'EF8&(J:V^<5L-WX,$?DKNKVRJ7SOL
MT*A!'&_^"%5: /'SXKCA8X48IGH%>Q*#W8?; I430*[#]H J9,\])Y,EDI-,
MI/E#LL5DZN3!I_?_#8CY/LY"3/2-"" VS\ $WN,TVBII":B(MG7TI'+,QJ-L
M4/%E2!!I6]';NQP)/-987?.+,AOHN@F[UN'8SD-/<)RA(>,AJZMM>\&6&C3.
M?:F^_D+"WUI4V_NP4DS2 YPF:,/XWK7LSL@HGD5!Q>O) _(@BAY (B,EL>HL
MV;BYL9D NS%+4CQI;X6Q8P$F5LE-3"N*+#NVZ5$X78??S9HY5W:N8.&NT_C
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M4WQ.AVW%($@L.*_P7M%LXI@+X:L_J\!BQUCVVM7F!YN4MEQEUJ5?J643XQ!
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M('VT@5WSOSM +BOP>V$9:JQ$< -)'X,OW$X*R /1%DRMYB&-!:<?'V%CHQ!
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MAQC0YXME_E<?]K? +V%(7S3"JA(6;7:3OL5W(WX5"B!EV,B-7Y'_50V,]U$
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M<5><DK82]<?HE%KW"^P^SW!AF'(9F!A@^X,2'%6L*I/PD3!!I@,Q. GN,6;
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MI8OL<@DG*WW&UXN?EOZY*")T;*T2B.LD\-]D4 VQ5,U4=!P"JG"'KH$*T">
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MBUUM9#P4!1Q#;0LJX+J^FJ,1Y9J3;RS*M12#]\W?$MAO[6'/4-,>!A=$)"5
MO2:$<B^+JE9\&UC"/,=XHPPGE=NLJK"/3G[#6UFFR@RI[+J!XBSKV<2"HR3=
M5_MFR&J#^JGH\\A?NXXI'UH?9M>WNQU#6EV?"%(]%1B6XE]]QPG&"<;8C(5K
MRK>TY9.)R,BP03GII7Z"Q=3;"=W<G\ND7W:QI#UX^$OW2G+3Z]DZ:4UK*L\?
M;&,C7?Y"':N-XK=*-JM^BO\WC"7RXV>KO1B<!:Z=LS;-'I._9X",R_=H>]KZ
MSR)8]=*Y2+HXMC! 6,?,;>,>CC^A-"U-]N;*)ZV7LJ=AG FQP?>-H3!A_7O7
M_8W36>W=YG36AK]T"HO:Q?R,6MN+7FO?'UXZ+J!3+/FS:.4@6C+'C<X%&E;1
M38'E?B?,$>0]NC50\[#&43V]5K:_B"R1X#!2!NS0M0I^%4DT^0-HS_GYZ1D<
M1KZ<+R>7^U.91-;8)S&0M\TM04G@%UM2E==9?KP RG^ [955^7I#E<9K52#<
MT[&6GR4E8Z+*NMA8 QM83ZVT^&9=JJGY:!M9G*0XPZ<>[[L$@@## ]CJ\U*3
MUFJ3,F%+CK^<56%94U;_8F]"*[QJ\-2ZA.NMIW6K_4H6=(M#R--U5Y<>[WW%
M.5QH"#NW,]TSW\<C_P8YQ_X"Z/K,2-SO\PLC5F=G63-BLS^\YR176] 2M/11
MH#"+Z;N5S\[FFE?73IFQ)5!.M='E;Z49)RO[46TN9K_/.[BZ;6Z;*SJ>T6$I
M$T<23#&J,*6REQ^7J;PT9+WRV<)L-#C&=ZL,);*O_O?QIVCMZ+$BUN:BE,)3
M8 PPK/]-+4W/?NS?,;I%#7)HSCXYBH_AQ)93*"?9L_<U,=WA@O(5#^RSEWDH
MO"%[RA^%XTA./"H<!T9?^/Q;5+272%6C6I\WA%F)L-_TCL5H\0H7)PR&\+SW
MNJ1Y;<)I\6')\&3;W$"T*-'L'#YXR?<Q6=96A4/O5&+!O>-P=F T7@7*KJ\F
MX*$"UW'UZ7^;NFDD?V=]4=0V&L>T5!MQ&Y:";I3,0*$IT$2&#F"76--I06)S
MX_!M-XP)0IE&8_U<[DY9YUJ.ETPU*T#[CC0E?W2<*>';';VI)M0XYE"C+7\(
M*>D\"Z!U ,+EH5#A.97/#:J_A;O367-@TH7ROD-GLUTF\5'>IV*,1E,C+]TW
MJ(Y>:/FN[8C^6J@"XIZ#F5D_9AY8Y2Q-^^4]\'02LN/.QYTZ\0:N\F^%^Z20
M0&J 3=9!:82ZD>2UM&R35N@ &I26=3TW=0@)VDQVA8V:E5?Y\3-Y4K,+B]&[
MG,BE%Q0+T)N8\VXL;.[VLK_+JMV8D4CSR6.MN2\^\I85S&#SZ>'%B0-@#QZI
M%5R9@M'JU'[Z@30:?G<YD43/&\6Y$S>#_)/P9A;EQWUM:S4=AN[?9V0#TBWL
MV!Z&4-]0*5SDI"59-E"KBV(@W!9];BC;V?;BVY".TCA<KW*UKJ]!&FLP5D+#
M '$%W2.,]NT8/H9RFL!Z8_C\=F% ,MTZ/4"OE]/MN_%DNR%>1W#2:&%VVOQ2
M:Z.H[(C<KWN_%,O\#[QO (NI,LO.[HSAGS/]6Y\U$CA[IN>O%^=0CWDYR<8N
M^VG<6^,X99TEU3?+@VT&GE>:E6 >OGQ]\43JA66')C+CQ6N>IG31-_T:6IPY
MWKBQ..&ADO,/P9I<7HW1U"HSJ2$,[:ZR=95EVGM?]Q#DWEA^G(SA+);8/F8"
MI:L(Z<D^5Z>['O\NU'A9B,&;Y_[>7EA)7SQ,FU]S5N9G= ZK,N:#Q0M+U\%D
MEY(ZS#"NBN9G3!NE[?]Z'XW^622E!QT8C2T]I34O_?[M'R?GUS<VPFLQM5AB
MT:/H@0CUO\VT)@&Y06>S*4XZ#_6/28QL?)BB.>78XY+2SC[%&I^&,[A!ZRNO
MKCW&-B%#I-!XWD\_2B4N 74>Q3(=?5;V/WOT?X[&>F1Q1:\F&W\2HV(X*?R4
MP!!^'HJ\[.#K3./1T)SC7S\Y?OWZZ;V+[MVYB X$!$',S>7GBOY>=(S/).F'
M=1OXV,+5+MR9KD2M\?:Y^^%+X,_@$Q9Y#_DXZ$%$N">43T.G5RDFVYFL'&)T
MN>BT-T?9J./ES(<=?Q:HC'[J:FA1+-U38,@JU3U3H]_ROE&=Q*<7OCKY9I]J
MHW_O_3V4)R-Z.O<0TNC6L\8/.-FW]A4E\>?.PIX4W7K'_ZZ=HZ[H&!<RH9]K
MQH3GG=UOGQ""+VW/MJCB[N<H-ZO&]YTM$ZH;B%MC@=@&E"_U8GE"I[;AOM(H
M2K_0NC;NLXN]08UB5CVU7/:!MY;5P7?OV#0_G@K+BE(S^TY;T? *LN)V]6@N
M=?CI@I EE2VQNO.KC;/V\['BY*_94I^SJ-D-W)7"I^T$OQTL\J:$A?#Z3Y11
M+-P57R:'^;M3U8)W/.E;].,'.5@_!'C),!GE1-&@FUXL#2AU=IH#B\FY?7)H
MQ\R;F;;9\'VWT[Z95[UJ_+3**H^GUD8>O"JS3U.YUI#SQ<_.T7AU5O9A G7J
M%, B@L2^7!(H"4GO#/Y]:X!Z&IW29YR"4=_P?(R;2!-V>;A#,HN>6FU[&(*[
M7?$YN1:N&G)6PX;13UY $(-.*J]WR!1RKVYR"Y@?P<TC8GM[J]X8:=T?(%]J
MG[ZIP\I=#?/:J=&W2^JWLRDXZU&J)Z3EYD/_^]!2!&,6T6@W@(G1U03B6[W)
M!%9G^G4@/9MB:D@*2E1[3E-@6P SC!/LFJFM"2W^'%R_UG#\.0':JZU\P?Z.
M 7%9W*ZK32O=UEQ3*PX*,;H7D8_ZYI5>+;Y,UJ#SWCR$2.*6IM-A_1[6E8LV
M*K)R\'#X%$LBCB1M^\&<36NK:F5 X%KLN37;, G!4,3E(=1=8! OSTE.+5)Y
MXW8DK?R9MT9J.0=> ZX2=W.RT"FE\DEE%D413'71T@ ]2 EI"KZRHA>:EP55
MQ1(M*V\V'4*.)QU415_ ]BGMJR'M7"?@*D0$% PRG( '^)9\=_;]C9QRI,J]
M6CTSXV]G.V:PNR P%N94 +_ZYJ,N3K=:;8-6*K+]KMV0YHHU.@T?\L;#5LU8
M!-R.9Q+K-?QF2H7AB\8.=0HPTTGKAM#8K.K;P:#1-VL@K4H%;UUKQVG67.DN
MH0<K1A_Y\8VTTS^]+L(>&)HVX.&S:--P)LXF^S:@IA-3'9NZ*7AVW4"^4&R6
MO+YFA;,J-H%J*=:FILL4@N',W7Z'>@C!,QUY!BSPIX[UMGNGP@-(4?S]6G9Q
M=X&%Z@@2> ]N5#;G+V@MF) N%V[8;;+9X#I7H%^#$JF8O1JQK.<=7C&7N.F6
M(;&G<C=OF&UQ9ERC7.Y-^E?E>7G/^,^+N;;53^)DO021J6K2,[5PD_S<^DIH
M@+3FW0L%6JUQ AY2_;SE,P51%QL[7R6'RN:C%/*F>KPB<V04\'<;OE2,#IB]
M.]UR4_=BBW!5&:]>[MQH?K'@3(%@MM3]\6IA-2/C6(07^C8L%BNLRT(_AN#H
MAJ]65B,S<-T:5+76>,D$_%'\N^<@A]C8^6_%8SLGV,+Y<M7FM5IH>>6KG$Z$
M:7M7I[GO]BM#,>:MC%P@(Z&M.*Y-_P[*SE4C-9!-9<#JP]#93YZ5 U*NG]S%
MC)L/(9&"I]_BK7$CE8+AE]R7C;-^CF2)G$6K(COPS@I]SLZ_AWC>2)^%!]H]
MJ<Q(!?R/6CHTT3"\TN/N#^_C#5[A1O%3I=+-:V2IB6K6B?&N9L8<9FQXL/=_
MRX_PAZ/_@5HX!AI-_!C K3_1S8WNT3M=7;SR,,\\T:WIRXUP-C:3T09$?+=L
M4)KI%ZYGJ9%W6/PC6%2/[.7^/66!F4<@*(Z_9UA[HX7H/@<OH\^ VJ2IC2X
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M6K!_7XP;E"\,>^=5:X=<@&!UD( S$KRDOU7&C*O@HS*"NRD;71W\PA0/>YH
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M--3=C3+SD^35(6DLXA:>*22J-6O]H$@:*7:/&U3"0$>#/L1;0F"#0+^-'EY
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MCBRU=^6LN:XA"C_S.U%^TO.W1:S^[O$ V4 +XH6<SVGTQ4UV 0TK<<MR#H[
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M+,^I5*_6F/@NA(?S5ZL^?_S\2;#3GO)AB3+64E>)J"I?,_=WGQGRGSF%_)W
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M,'I)R?*6#TJF$XXG(@_[;]GHI&?T)//;DNVX1/%AE%_OZ#OJ)W[XS6\F*4*
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M>B3#7TYTE[^'O-NW$BS6;OV65'&%_O:6'<5JY-,)R]EB]#'<L0\9F0L<YXC
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M$YLWBHP'9(R[\ F&4D W0YL91,\(8X-_[XIFIE?XDRM\IJF[N<HH'N9S %X
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M?%/"RVZFA-L(:XX4].F]]W^YQ\IV[Z%.92,T7KC=$SEM W.<,O4M.38ZXM2
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MCX^]T6Y3+?=1N8^719-3,'68M1BZ!/OD)88J($<577-DW$5LM.5>HM=AW;&
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M?[.LWFQ_WM5I>0[(UJ'ARJ2/:WR2-O^AA([.-?\G7VI7.E<"7SU<J&Q<KEB
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M?;@<J?[&XOM<2>W#)PK=1@*IO[B1+Q63;P=?9ZS+#IG7)3O6Y[O4UR_N"0=
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MN549$2!OR+<QRCRCZ0G.$S2]M(1K9P$XVTB-/ "J(1'2B7L%XM41H8H0K5B
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M44Q)K_DK-23WQJ!^[]#XQ*N!+;[KM4+R']QK>'M@=VYP')[ZJ;UZ:(^97UB
MTSA?['0YL7[K(WGS0:H]U8?LVH$MV+AEUVSJ'7YE4E[AZH26TA*(:[Z?G_P-
M7M#&O%HUAM#-=S(\U86>V:=B#F2U[_^51VE?/$%G(!1IU]@)]C-[(7Q6NY'
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M880LJ=!]MR=<BBV-3H/.>'V%IWX^ML&+-Y O52^&!7SNED9(Y3LX4U&06G*
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MC7,>Y<YD3ZY+2JOP[6ZZ5KZ!@X/\^%/B6M+2BND%IZ2DU;ZCLI/01Z7,<1:
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M"OLW>K=9 *.OVCI"3 5%9LLHV]$4A]%8  YY>'DGDX^1R#P[3W7H?'X8A55
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M@VG>9_YA$H?;-T2N!$2#CK: I/W=;R!F/);I"DQ T7?8CQZS1 AF" "/(HA
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MZ#[H"="N'\=3L7%"^WO1D&,&K"L#6U^E-GG9@.^!S%[T1HLUZR26#7B/V>6
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M!70F2_.O."5CZ-ELP.J-1.!OW&O0EM<79]8J]F!PB6MI!F6!^O+OL53X;_1
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M>D+H;WM #NE*)1Q\#+WQ)879@V&&&;,!YG:@.#9@$LRRB-[E1'G%/H43^7;
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M <0"_JTI:6]\,-F][Y-J;*VV<VWJV(PQ(=/,X807U#CB7>-NZ,#I?SJ>VB7
M-Z^<@,2WR[14EG8\+B,QBB15)6MI*E>'^P85G#QV=@TGFD7^=Z)_B@!;RIZ<
M8(3#GD$O.@$#Y.$-/*6Y*U1A7")IQ9:J'9D>0 )?\$A/-E@>",%ZB'*U4C:9
MC<7W6*!UZ'[@-M)1\9+)R*F[:U^IL NN8_EW.#+(JV9O:J4-O2M,,@S[E4F.
M5O%JA;6/\GGQEFX."E_)8BL.W":^7EL&:@9M6P^\/0_J6:!+S0#/T07F/RQ0
MC?A&!O9KXM0V*:HS/NC>TFNZ13[@-;'2 W'-@4H$JU 3*OTAE\7C1I:>5AG;
M>8K+;8J)SPWX+@O0?#.Z[]SX5F5;BOA</%1F&9C<E%X5):[PA)9^W2/?^EX3
MOYR$P'RD:*HZYF;\"M;DY6Q%6SHN;U\E4/+!_]O7A$@BQ0=#S^.C[;% 5;(D
M#!.[';YWC,X>PO8<XC$F'Y/ /CY,YPVF!0,$4AF2#RT'X$O1%RBP>#^A[.))
M#;T:$B3V06:%SKI+W^?U(./AJ?U$\/JM=F2M]LM.T_&] ^>V:MP'$.P\6K$L
M=!1/>8ZD7W$/UG;TS[V$TO]Z.$GS:N:NQCQ=Q=<.;X10.<P-//<U+P<DFCH^
M73$A/!J7<^%3%<2$ZRBAKNZ5#<0>8<!K/(ZO,.5%[<.Q^/-,&%H:"*#B2)+1
M[/8+T&\")0L,CEZGTU2]]TL5*KG<0*)IE#G!*]SK2K#1NY/KW+3< &&^0]<]
M&XW0/*1GL*=V$PB36?2_-(EX19X%XGB :5=I4PW]!X^;Q[- I[@ CR(@<GT!
MMBE.)H+ING5 !&E&]C?D="CLV82]>!N.1+RT1NM3UE 9CE&9DX"^%06-;S_Y
MDFB=:3%!AWWN5ID,V]I2> 4+Q2R\(U)>(C?ZCG0!FW;X*?Q"WG1;]I$*\_O$
M+4'3J )@O*3G#^ 4U=?\S;RL-5446S[5SLMV*Q[W:GWQK487\C/Y-F$'$]?F
M43J\L#/8DQ0O=^+HS/?]P4M=A[=2R5#N=4$XFS-6(F@9]=&5OX(B/E?D>P@Z
MTCE]74H0]MGAN"OVD;G!GF(!5]+3D@>1OB<*OO3_:O]Q''9A/4V4_[O*\,6U
MRI'54-&1?6U?\W?':WJ="Z9,,:A?Y?\4ILW/ZST8BKG7[GHR \0"78<"UTT[
MU3$+I2P0Q0D;E:,!S+%C"J=H_"(T 78%_QP3F_$T'S:SB>6(4-"Z0X7K4?8W
M;*[FCVEI!U,OFIY&63P8S;Y;T";0W%3%$_+NY.5CS);:_XG) M=9H-,:_ZZ>
M8H'>1&&F[C*R6:!]0:#J3\A<*RA4 M/>C:E5J#EB#V^[,,;35 #EOK8\W#6O
M3)&(IMS1:ZS-KO"27P06%R%@] VJ_#<^LR9C3^W<-RU&9(\!1,6NQNQ,QW7%
MBT__!"_E,\]E,)):U,F8F-RZX<TB<HB$T)P+R3IL8?@UG NI<-PDXVD)5< _
M\1+]P;CGIQ?&.5@/TK^OL&7OU(Q=Z^K5I[I%^U$&3BUU&!YC1EO^C^Z8"*$X
M(6<P3'X^)F? D2']T4@=9B,QNNTFA4B7&GXSV@V;VN<%<JDOS^+/VWH(:D7\
MC7%'\75*=L,O/M*3J\PY^^&^S]9.UHD#.Q8H3 K_&+^)$62.87"_8Y2S:3H7
M",\Q3Y'A-K@+@7_CW])UF_030Z'NUO'77B.+?^6(X@#/? <GA_1 .2T$^:P$
MRJS0Z!5X@ BHX194XS$+[XD4AR5&B<[9+K0B@NK2W7:<T= &7JNG:*P>8KJ%
M(+R%VUWQ.N1[@F>VO)X C:00E^[IRHRXUWX0X=5;N&/DIEUQMEV88MAA-(QB
ML^E\I$8',PK;1.Z+4>"]D$A1;B ]K\/-*#;^)H3W65I&]D18L9:SE3_F/'S8
M_^/Z U[]NO':F0$$CUC$R)\Z(NQ17O((FHQD@1;>P2D/N'T[F]I*/JX'(3?6
MR>OQFK8C_F=;H99?<@>_F.H,/*A*.]ML]T:SZ,/)D;9)U[DWST[0AS +'R 4
M<Q8(D,Y]W2)-)=(D&%'^T)A<'KP[>*:F._>T%G0A5Z"7'&+:':H)!),2(P^A
M/;&)(O;H6VS5D'/HJ=HN^#NZ0LNC8"UHLELV^XYI'1!"@I[RR%B?7;6AK.;(
M4;YPK+.-?6$( \C $M$B6/ICZO:FU1$,_1<CKZY9G6Y<@8)UBZH!561'3%=3
M.X'Y8UJOD!K5U78A2>1.#Y\J5Y/I=-T]<.107KU!RZ.F!YXFKW30_^[&C&FW
MQWC\F]E2GWZ9HX/X!;.)(&^+]A[IH+"+?Q%!H3?H5X'L0&^RYO8KXN7M.@,M
M[GQ43?OO29Q]Q&1$>2U4&./J@"*:?(>N4'+P) %_8W<1);/Q33\1)Q!X7^<C
M>#>?T8AW(P+0=/H5#)-+X,B%?@* 4<&]\WR,F% 0<X3(TW8)Y?"0"H_9UCD9
M^JU)(I/$[;5N0GCN#P5T]_PGF;> ZOZYDTWQ^]A(IB00=CO]P5U\YFT"LOS3
M(S 7T,UVUJ>8]MM,?KKRA(XX78*1KW,:_13()V7?6NR2I@QT%O4P.:B0M]"-
M<2\Q@M;910B/;6<!'!6S<-!KK".6V9X6$, I[./^,NG^K5<AO.SJV#C3[H9'
MJ+- [L80)N>[(QNT+A7?M7V"_B>%&,/&BJD=%H@L3%C740*,J'RDSQ'E0*<U
M$!)"UGZ"Z;C/Y)K4$B!M7YSZ\:SM#_Q8>H>3&&4[R@]R;FK56G"^D N$<8!1
MG$P/[N#HEU69@_ANXB',Y"-X:85YSI4%2H0#TK\9Z- >R"&45O$1O#WZ7V$B
MZ_^]8&JQ_:4$OQ,*$<%LO6>!UC*!0/@*/@&VXX?*9_["'PXM<1Q*+YC2,RJO
ML$!-*\S:P/:#W_#DW,K_].G9_]4*R*^K\/5C3/V(_PJ-^5\L. Z8[DU93"4V
ME'SO]$ M^\722@25'69D?]H#D5M_A(G%%]^!3E[/.8OYA'(W.K'P5.)%HB2,
M<[1RHV+;,,5JG"VW_/;JLA,7^PDH[&6$KLF:UFT-P\,IZ5^XZ2.G^81O3!9(
M_I&#@T?P$Y!XBV+'1[\9P9/\"X^<]4ZKK0[)TK>RLE:DF^?-?0*VYNA';.']
M'.-\UZ='<2.)</>39(D ?1+3_L\)IARR8]O3Q8H%&LD(.-AFV!PB?XVP0.*G
MW5@@I^)07]@%*I9YUQ9"':>_V\FE"YFQ68=I+_BW,I0AT8*M.GR :7K! C&"
M*UB@(M,LBBIP@ ?^353/,8^A>+O1/]3'LT"NESIR#U^H'/P>*:GKO8AC''N,
MQB]-[C.4UEO8^)KD!*/QWOEW#2;^,T:.2#&%_L#TPG"FW?N X\?U"M+PN1G[
M6U7DS2?#0O)IZ4CQ6E_C4W'59[:VNBR<>5)JT&_?R]W%6*-B>U'GC_459I!O
MK//&9K5&7HPM"G5/-F[7B)U_X^D^WFB.3\&?7F#R=GM[/?URV;U%1Y1SK,O*
M'"=W7:S@(##_V\:>]:2GSN1^,(:-<PSF/TA*Z4I[/7>)9 *F.F=TDBRVKC$O
M<J?_!VX748(1_P11NLC__5[^UL)*"$;\SBIO3^YT5?=8BA-\T[(HK82Y/44$
MO(M72Y33)LTP\\&0[S<I 9',/#DMRS2EJ9U>P<7MW>G9+>$MU;;FP&?OZ ^!
M25):(05/>T6UZ3CK:;Y,WNZ \ZC 3O5A!&X8H91#?(*/:<JYZF:^W0POY%LR
M_[$ $CKR.)5A_@WP/975GW+9>\I1R[=07$#&:3H7)N-KCI/Q:'Y)=(!\0Y6?
MHZ@/HNN54BD_UMY;J36K'TGO.$Y/MF+=/(A&D%45$E;H&>PTQA7&@2)VF5=\
MCE[ AH5>&*L3N/?U-/@<XE4-V*[RI]#0[6\1T7V:^&]9)AP\V=Y>2L<B3?RI
M4Q,*J2I,.2O'*[]KKV3XC=)@.*G'Q4M9VI'=UK\1SCZS6BLLD-?WB-_3.UMS
M+<S)@^W0"5AM>@]FII.6-%8G@C1KFY"8T-*'1M)%2.N(#&.-SOL).T8BJ@/U
MG,*/[R NF\\:\M"+?XO=MPG&'\IW/%1\!V Z+R.^%YFD()RO2(K$I%PJD4EZ
M4Z;6:. K4>KH:*#],N@ZL/+6]QLAUK<_N4QZS!>[<6/LNN0 OU[HT$T#3=5^
MPKC#W"HR^-"7\0Z_0,2^8O)1KL17A'['!83"J G-13-K@I'1D34$/\E&TUN:
M1A[-0@U/LM^)'3>F9D?H?A# ;3(?DEF@ IL+9"7!/35/N9I3N@4EA H!=<O*
M3QM+,KZQ2S;63GO8UEK]K1;-A2W3.YR&E;YHKVOEEU<,*FW-EVT,E>(^S=38
MS#AE3.L,DY' '^D;7]$>"[E"=,6)NL1(FWENJDXL^6[]EWI/>Y';M2%Z9ZF>
MLD2B8K3;#OK3JH K=\.5K]A+X+TP<M\C[Q_GIK.4W%'?Y-$P%?O*Y*+-U?[<
MFP]B\3+I-R>M*SZYE3ATR+U^_*6A_.3*JS3!5IF)HE,6N5/&IJF-)FLT1+,J
MP>([.UC5$JO\X'4<&[UEJ)I.0<?RW$LZO'\RKQ'J5..T!U .AC&[YA-[_Z0'
M?="BY(TJ(U7>T]]/]\^[O1'V5KA$+E5[:&R <5VN/FPUM$'G.E3T&488H&\M
MM68&^7O*N\Z0,6?+6:!K)4X1*OL;QVG?2Y#!:WL'I59O1N9I;6D,TQ4'YAF'
MHR<#1YK,40]*5$]&+6W^!("5&I&O;31X+4_W#1"/3\@,@+X'Z3Z^<RZO(YSS
MZG,E5UA!"WJA@0HYU[)RZHS5-Y_433=[V8R#$"EU0QYOCXS-U8EUZ\1NNB09
M\62*2'LJ81X)%F5D(?JF]/G4I=IK)YL_(>9:=0BP8/Q"$ZS>ASF,J7'<[L!S
MN5NSI50.VCERO3.@7E8JX;<II9 1/SGM;YO)>+R5!I:XE>BU?"ZN5PRZN_*J
MY2*0&$W*()<8K0DHV;ZW]&Z1C"V4ZC,/LE]3H*%G-LH/\(Y4>/2$\;N!8[H>
MZW:IOTRDCRB=8[$FI?7-91(5<WOF]'^79)YD=F]3TQ>[>S<Y%STE7E(P'0CG
M<;IDB(90IJ-I3]KOS<NTI/(/T?&M%=_?Y1AOIZ6$]YW"^QZRJ1=-XK:HT%>K
M!]W+:Y95M?D*-D:GI'8M4CPK5\52TU>@ ^BKI,1-K:D5VR8O6S0^#1649&.E
M:(:N,5F;0>;7'?Y"L E=]Z$:I$X_LN[:#6@+]),#WXFD/T8MXK+\AH5IF^/>
MA[>L?$CW':%LAL)K!CT*'*#6-87RI>4H$^HQD;F[A'R1)JD9C 2-[M*X)[D1
MS *=A #0(UWFL--QH*:";D6]E5Z&^CP?G%FA0[A3ES-Q[/+,20\YW!?-M&DC
M,-39^H3WU7>AR+B6T&&4[]N:<SF15I%E^EQCU]7)D@)&'QS;; E)3NG;+Q,]
M(NGB_;MQN9SO)WHGBBPN%$J>,8O[5"'K8*<P1W2M@2'I <6 $9/3D]T"%J@E
MS*2MD7HZGI+_9^Y?W[>W\HUDH_=-+SC.*60J=9ZXG_<)WZQ;E7_QB..ZG"RE
MI2U-J1O)(]U?J$9:7P;>3F)-+OI?%[1%=4Z+2XOM%W%4-.TW'N8HH$*/+1Q(
MF5B5+.TY"EHDF7D5(@QN-R,*"IH*: 0G. E'XHB@_[MC @>CLGQ#YRJ*UC-L
M#41A9SV84E3]Z'TCA[.:V@JC1E#<F:*V'"%;>UD^'@>''JLGKN_R]9+T5!C$
M[,=?=$1>/"]U?<]IF9_NO!C5X?REUE6C!JOFI/H@MD1LK>();<Z6:3E0_+BA
M-_JZJ5!LG(R+>]/XNDUQWAE"^*98%E'^X)91?6P) XFC7[S.Y/0AGH-\I:XY
M@405DPT\^)EBF(Y.0D)U4W)WE;_** M$$F,.*U2BN^NG^[^=?O)'"O(G[R(L
M%C;M(0+=-"TN+47*'D9@RH[$6*"(S9 W)4]KD;O5^GNF]#M>QPYC.Z'%#(^I
M'3G?;G-:Z4NF)+3V9^O^4DMZ3N\.O@B([891C,$SGS8 OAX\A8W<)&)B3H^Q
MQ6U\75,U=3A,WO_>MR]S(=$K;RLV6SC<3^]>3987NMF_Q@*-[W8Z:YDMR'CW
M+(B<LW9-+^F)=W^8^D(]XIZ]@H+W2E+1*"UVJW($.*?(GW"*W->B(&_5N4#U
M4BB4R?K>17+6K!U[^"DKW0J7PV8B=^!A1)[G.@IH.0!#U;P?_ZB*NA)>"[L\
MXY!_\&9>^W&'4/LQER3[2]+1.'1[2MB;,]C=1/4!]R<'E<ZIXUY6-_B; #O#
MB66_IPM+A1/U;8G;C8STM$7G]PLW4+]D]?FB"AW%MEW-N:P/G(@?5GF718JH
MXRP0AS@@(R))AG5 17KY^42OX<;DG/Z\88O0""G]*+^S<Y-CY9\UXC1<3]@7
MF[;2<'HF09 + 4=ZJL.-$&T,S];4Q&6L$*4T356N>WJHI? L"S39()'K,$V<
MP_VN76(,LB%#:7W2Z3J[1-'/CD/%$ JB,UU7=I1N+0]^Q@5X7=YOORTZZQ;?
M\A1_@HH]_Z7MNMN8BZB5 &FN'BB^C:ML_HU;# RM(F6[P<-\,I(\<8+]VP$#
MUH:,@/VCX;$8>L'1?S2O]C\H_FALJJN)J(0J/*I]K4/_K:1_4C8GLR UE4]M
MJY.Z:E#'&ZC".]<,[2'FSB),4NT)EK\()=8%]1%JAKZA[V*2,0%$F@,BV US
MIJ&JN;[U5969=@'UH:XMR##:.4#WZX5[0W]>_^/)E<OYXJ@Z\3GE21)F>+M9
MQ%ZEV'1JLM ZW@B>5*%.R*ZS6<HP&?R,]7@V4>^:\?2_SU(]!EPZLF%CV\E0
M+OIS:D\1]<1";A<G$[0F>K4U\\$D7182<8WJ]EJ0N>R6L_7[]LBG";IZ,.EW
M4Y+-300M*//9]\W$#0W/XETTL;LAMQV=K]YCU;NDMOK$O^J2OR*_?X1MR\E2
M@WZ+,J/S9<YK#[+UH4'*ZT>G/'K"G_Q<8;X!S/:8BPKG_GG&IL8BE%D44R"$
MR_9YLX9=<U]-MUX<@A"A-=&R0Q^*])3Q*RGNY96Q?>YOU^]?];[<T<!)>W+#
MA8UA,$#@Z"9JQ@C(I4*Z)S&B+8&D5EUM_0[,=(XPCC(<IBQT9/!7O> W)U[F
M&/4<;KJ[/,]+_N>X2N:1@^S[S>6:UPI7^;AG.IPN_&Q1CRWZX%*E-+1[3NN
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M73DO__Q#DBZ6/K6PX+N]_S/.YA#Y;A=[KAKK5F&Z[W%Z ;]EARC,QI/F-EV
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MTB&<L$TCDD3,4A37:8YA;Y)?+>"^4QVXQW[HP$*[_W=.^%!E=VJ2/F!%AC%
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MXY0/L/#.>1%:;MM);XF+1/H7]] R/R>!YA*X$K&AH&)MICLGBD^P*:#\G:_
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MM4G[%KW.RP'KZ_U5'&DR';WFG%F+[WL?K@^C3[6,%U?2D1'KA8HDC8S%M#-
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MP-DB2"OD-1N.0;%6_[RH+.([WP&%:WQ_@/%'-FT>U@#O*7RF>J! L26U=&U
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M\\R^:.?%9]Q0LM#SI!PV,]\U**+*W6*B)^.;7**P]V,+U\60]0)&S&X7&XE
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M6,HKSBO6IK0'[:>#7AUY>>D;R.K?,#=2FGX\E9Q5XOP?EC(ZD^UIB^"&[<U
M[!P==!%I1(I)\MI@)GD*<8Z5I9E-[;%8#P2ZN][(S,MPM.GS5ZB!^RNI)9S]
M.Y)I>)\B^%E K[=UW>9>]2G+L0#C9JD200VE-<? $<4<DPI\W82+K(]KN,UA
MJC!^LS#V;4-]6C=F5E3>_1:+<<FZ[4ZOJ=,NA]=PX]9JT"!E!1%H3*V%8#_
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MY$R(;]8M6,J1I:XL5-'$8]00RZ]186E1FR_/R>'KD*HC/!0"H.7-WH]BV'-
M[7#<#<2D%"5@Q8L"Y4.G=A,%#<\XH84[Q7.$J.Z/25D^^KI!?S:MPQX)1S5)
M'[*97 \L612_7? U83YV;MWBM,E]$*Q CYL(@-]<HIW<$7L0M5"F<#Y[?S"U
MCWX:L&.HH64IT,Y#OZ /)]?BYVE6N;,JN?$0\9AN 7/*P#)N=\ =J.C/[;UI
MK%S] +*?6D1 I_L)/]M>9ZLW1?U[:I\?Y 6QV\^]X]U]W9NWF*XC=SU<>-/
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M:18QE4^>KJ=(BVW^6EJ"1AF* ;FTRNZ :U?K_S:F(![F[*-E/+RAU=^@)F.
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M40#ARF61#\(NX=H=B*11.* PR$HR5&-:L*+8DD ,"=R[]@ 'UC>C*72.V7-
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M\;SB4ZH:Y[EENA@8!NB;=-"+'YZ3W6]E7%0?_/GQ3 /-EL8_L4W@BR*$4;S
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MHI' Y0;):]7"JG[-^&C-E052U<4KX=,'4Y8Y;PYG4SSV581>F]:1]\L <6,
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M5*>P<ZV_DMYTM^1>>70JZ6.:F]GNFM7<7/Q:X@QV-\XG!8;# 1HB7#R$\U$
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M ^;F=SHS_&9_+G\-'_5*[[W".56;#G%AAD1F:M5PG/#R#F/<U2%GU'0 )Q:
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MP@=&PVT,4G.%RSQ3);"V.O/]R]VH.S*APR-I,MU(/ J:R?%>6B3=FG&2@D[
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M5F_A 8U5M*GC4/.BU]R?4__RM\,V)?754;E@(Q*>-FM!C6Q_T@[N[2>(I_0
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M=K ;,&B:I(*L.W@<V_\8&:-U>/C,8]0[2!VFPVEJ0%OOSM#R8NY%ZR:Y&+1
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M@-;[^E [5 :R'=&V$C4ISVBF'>\$!#&!!=6ET\BH207:OGB,6<&S[AK[V>@
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M#>%9UUJ,S6-]]>7DUE3>/&*YV2QW=N(6CO\Y/Y<#2][)CD$N#6GM !8(U'9
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MSFR6DFMJ1CM8VF'UWME9/;^L]08:@QEV!+H393**!@^D,B6P':@:?"('YJ6
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M>JR']\^:.B?%P<ES%[J/[-K<!1[X4_P\0#5A\3/IRHQ8IA.#]'%LMFT.<[J
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M>TMI#E9.<A^W][X.?>7P)6WRU#!O1V:!3FZ>WR0OPOX;8;>QLK#Y0Z13P7\
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M9^2UG+/B;8<;QM7"=ROP0^6:"8;9!;_ME1A H&WVQMM.*DD16"9O*<&Z9!@
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M/<ND5^N[\W#(B3 BD.Q.,8 XJ=EB%?>LEP= ?-\+/S1T1!)<+KP.NQRK]GY
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MG==)NB65T/S^$XZUYA""O&A/<)ZCLTPZ9>7*>6KFU@3N[]4Y5/M?X@#8)W'
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M0.?5QAF%(]1+K40C,6@D9=F\F124%:R<L01>$@2ZQJX!&V-3AHSTS%HP4PQ
M/>JO.H<Z2O)SHM599*";BON+; HV?Y2".^.F& R*%(D4,@"W& "?\:3F3@TR
M'Q6"VLSCC*P*%!B6OZ1(U?V!TET[?=;8FKXT:X/)MZ]M:XE=-T_2\Q.O#[F+
M"ZF;O[ST=(EI"X=2M$^<H;G)A*HM1Z[\OUY'</<0Z_A>91?<<VP6 O'F?$7)
MJ+\:OPU2Z7Z.?-3IPBUH\?'R5WA,\ANHL?X47/L);+_HUHD&25?DMV'>6W_Y
MY<;"0.RZG6Z2N83:S%KJT%2)>1,KAR&+<Z&T>=?@4 )2VAKAA"V,\'CD!S?<
M-?GF0]SO!2:?J/7R=?Z^]&TK9^G6E+;V*Q4M)]5QPSR'\" .U]'&STW8#^CZ
M%^APH1>15LUVWQ:?-3S=JI6!F81S:SL3%6_5T^]_[+>M4G!-P.]8ZUNPOC?]
M@J_EKC0= Z\E0#U_^"ION(@+*A]D::K\_H@;-"/3WU@IA?6C*0[L7X-"WOH5
MJ%C$5A#NO@\C<N;I<46C$E")Y6PM7L_8DSVM_.XAG#2_#AQ81E<:Y%'N!A!Y
MI0_#ET$SY8<3#]%.\A*J^PA;L2VZPQ^SV=MW,]0/1EXZX0_[)W/'^;8=]WEC
MD@K$W_7T>SI67T.KB,O.9_6-;=E,SG3\:'YL]:C-P"#9AJ>Z%#%:UE:6A5K?
MCX@YV;C'!OAWNOWAAXT;<B=[S:4>M9TK&9ZXK.Q\KEWSW2;#P15=7.7(-TFV
MTJ);62L#:W/.5D;6H_?E+CGH+U:^I[T4836"0]#:3PS\)D^V3IQG'1>ASRYI
MB0#=_^YZ3D;SD+I=MI]+8'9QIOG[V",Y,*XZI\J!?534O'9:_G:N];9Q>W-G
MTTMSJTP3+[$Z'NL+=SG^>7CAZG-T%['6+H:/X,LWHJ#%*2\:WT60(G@,,@!!
MJ-MC^3_UZ2^A2:J25ZR^]N&W\1 ]0DD\W#S9=K]#,RUI!H&RT4/GR0\JWWW[
M,EL]2E Z_<\_GFY=(K2(?COS2VO[%/B[D;-_$E>0\>LDB_ :^>7R#3>^(7O=
M>QF[MY;'GR@.[\]FB[<WOF1KMA[I79$9O_$\''!-'QBW;EIW2T#?NG1^0MR<
MH_E[-@,P^[I0AHFLBAQKHJPB+2T"%O(2?9\-,#*M@A)X_-8)\J8IMV3^/K=#
MLCE]UN3O]U>SN)R&K[J]_?YVCB7]\FF[[<ZPPM#&F>N]@97Z$_X:GY0^TVZS
MUN5C])9%;([-[%Z;NS'OQ:0!2XJZG(0DKPT]W,7#JM=RUN=UIIM\N,YI*#H
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M<.KXG"F@;E=*J5)J'GQ=>UX[O>I4:E9 (AM[BQ+*K 2O/5![79-*(+]9@BK
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M.'CRPN<B>4/^2T>G2,&UWO6+_X>Z[XIJ<@NCC!<5:8;>(5>17B+2(9"K7D!
M0'HG%Q$1$ ,B$B40K_1^58K2(E)"#[TH$B$!I$OO)8F @$@"&B,I3)QYGJ=Y
MF)F7D/6OQ;_.^;Y]]MD[IWR5*\@*YYT^XL[-VU1#9<>BQS^J_PEKP#AB]Y@&
M Z(ZU[7D-K43Y;LF,<;3]0WL!3,/U5['PB]*>X:=UF$W<C8,*QEKS>+MKNVS
M;7.S!A=]/7PO"\R4;]1.+'NN>"Y;-'LM+WE?&1>EV(N4-8R*=-WOW_DR4BN
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MBF*A<A)_>-5A_A/H5/__7(W_];O>RC!J0[B;_QC0/$0W.094[Y)]  @@4SJ
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MU6AB G%/>.8;]E[^ZAA?W=4;[YXYA+:L*-LTOY_Y460=[:-^K?']-%8S- #
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M=H405Q[W><O8]'UBJM<BYJX7WT%_9I@7_4SL75Q^+2%D&14)ETF&:RGDT7"
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MXIX-@":;P'V **+CETCMAD73*A@.VCSQ*Y3);%T;@LUC17B2.%)4VXN%!LH
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M_)A^@:V:QW>"^U/% SI(J3AG.CWEX61XT]@ZAJB+2%CSZ]*&6WY.N&9/N<$
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MXU!Q(BYABV@JA/]M^$Z6U5]"Y/73SZ'\;BZ.K"'4+G79OG\Z40P)9)6C.#.
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M[+#1>,^U=\)2'O:302'2__R^M38[W$X6?.\NX'9]MP[P5;M^F122.X6*+1;
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M,,]X)#@.&G+/!<"DVNS0K#5I&CA'[= !BYD2>L@)WF5FBH?LR&7+@B@/D8O
M>,Q+OW^FD,><\N\5EE0G)AA.T-+^#2B#<&&<)'Z!8*=@G+";YPRH<-)!;P8^
MA;"G+0"M1$XT462^-5>OR[>\;[*L9&O3WI _XC08MJI)UYE-89X7N3[\:U7V
ME]1/B]'J[X_5+D!9<IPJH:G4<)(8(B62E(3PQM.XE$W(GH:HY<5[-;B#V$#
M&&LUO/[DWIY_)A=ADMBS-: #9;]?:Q1!K4LBHDN@,5;:<%*WF*E8]>98VUL(
M2.C>&K" 6'4.J;"42R8'KDW]-!VBO(GG=@NV@1G,0(MK^(625J>7)JJ!TNWX
MT/R/[S<AUO%_/X>UD@%+/&A@QKDEM%@D+P ,Y%X'N9Q'8"GW,A8/.E2[!PCV
M$&R'0O&QY#WK'D[+UJ/ZQ1&(1S7?>7[,FO ?XP/V;Y+WD 1'NDL^?KQ#Z'[[
MT1PBNH3@R3H+]D22 6?HE/HU?NX 582+4%)AJ<=TZ)#2$[KMV#=L9@\ O]-"
MH2N[ "I/?6[?&8F+V+\F4+08BG:@HJT+N?[[U:%,B#@,,(.":D>%::V*O^4V
M,.6.O8> I2WT#,CS;J"58?$LAHLI.SR+8:W%E=CJ_7L6*'?3SF)UZ_%^,,D[
MJR17>*?_8:B1Z-(,Y/I8]:Z*TB6D]S4O#].N'YUEXFT4/9TOS:=VJ%Y^0BEX
ME.LQV6L:<@'6!^5)+@LD'J/ 8\*LC8&M>N(#<\$_\]@3;')W++"?7T#M^H2]
M?29.G3."(0KDJ!3W- /]<-N5(<80I[?5F1M='G.+#ANV794!'N,0@@&R$FX'
MO -[G*P@D.#9@-=F-3RT ](8I>!C>F%()Q7E(;VD<&'L4[H!856RM-#92N%A
M,_?(J';;6@-E&WA &,T6PF")<!;L7F"SF!.]:V# 3^[5YAY8K#?#!9C@'9<$
MDD)5A=*CK[M()S!H&0:T=J@K7<]BS+_RT/?+#[(+G3#E_3DZ>QVZZ"]DX0(C
M//TE&? U[$),VW+>@!5<6YX2OX;,R&G(2$5FX_38$5UNZ*E/L.1(;9B4@=XI
ME"*FOGOC"T)1(*^DV=W;6H#O,BO'1%KO6W?%9&Y"/-KJQW85E$_Y;IP07<_9
MZL'\C#S.#GZR (*C]K'W\IQA(B8:Y:"/0%818X4Y"+YHA,D$"-0#UL KU"03
M%#_Q:&!8]?B$0,K#O6YZ3_^_IP_>A'#MMY JD.D_]2:]*<B%!W@?/*B1T'W\
MUV[>54"*:PVJL,,W(9;[\EH-'QD(J=(,6$ 7,A6I[S)F(ZM85;:AXP36,"3H
M=J9?&#H)+G_FO9CKS+_O8"-Z/"DYSI]!/+UD[A7T'8KV][@P$?*HK<2$HP"*
MJG3 )BH,O1>+!JS.;" HXGM6#JMSU2;<V]WPBF" ;?8>Y\X.+6"^3TY.<WW;
MAM>%@\H: #&.%\Q8=>OR- !F'[*@8@'C:5ZU&)\>8W@A$PH-.*/[8>UVE2^M
ML7&VH)QV[N5IMUDW:_%3&L<MTI[+X[:#P<!/AG/"2R"C:Q.R#7.:08X[W-K:
MD="MO!WH2! N"7HY*I)I.?UO PKJLDB[&^&<"?GMO.=NW:<E!9]PR*"HSP5E
M.:X=5AI%<^#X\%_B?<S8*A@#')PG#C8#=FU_M5Y@BV#L<)I")J&\$W[,8\=2
MY/'QZ4L*BV.[_@DK/.9O.K%BYO#J9]KH!5CZ'' 9!AY)%B:;G!SGQ28D]06B
MH0 W[$,OL^5I7 3N8P^21<UZ:I[K\70(R684=8HZLT#V)NWP<'S\<]UB_DOK
M?T375B$X8WPG$D]/PM<Y"[MR9^M>O-R$&QC )K]#!HX_!08X,<#.CF>"DX/Z
M54FU:#Q#BFV35W$E=$T9BS"N^4AKYJD8QVZ$ORA#V9:[@\Z4HH-OQG^];[P
M_<*T!4]%<<H'3<S*)S'J C%)H$QOQ]*C:/@FQ#6+0::@]V(R'(92"+I*9EU(
MVZ2P:+5O%@3]C=#94T5#,$U=M8/A$+Y0-SQR$BZPG%P_QSOPDY7W$.&OET)H
M,$LG^\'2YL3#OK -N\]YB'9QA#(-?A#CX.*FL:HR:N"Q'2:)F>M1UA]=2:,,
MNPR$,&=$+VBIF%5@'*[?3KX%$;PN%P&_"[^\$=])5-[);\7[Z2EM33"#K>[Q
MXI[#7@+K*P:8I&3"/IX7W;7-$5BC>"):XL<,8 J@CS/PO>+E<H=$!]M@IKVW
MA25NV:_7>W(9?GRT42GR0S1L];2+Q;;?4-Y^'\'N"+:*8(],N6!8^318S[7R
MG6L0%:[)U^,T(SS!(/<A0R+*;*1-PPOH1<E_=K/!VC)1DDM(4B)QK*#7UK\I
M[?FW?Q9E:5>LE7I?HE.1&%$"[A,9N&>"A^#I=5O[WH_>9$S+\USY[>P!S@MP
ME%R_R"<X7^(>(S00XSIT,'X\(YS6)J1K91P^7"1LM'%EORNJH/&<529TY4I3
MX+DK@B%#V0>PX8A4K$F'#I"1C#W^^TXGUIK1']+=CWV5DEOO$6#5.F)-FW[Z
MUX&"X)"%W59 DL7=4]2WD0_PYV# %31H6(&GIVU"Y.&GL>Z(QA'<4 T[A%'T
M%)@/A8+78QABX/U0H?:8!)\VQE0(D7P%B\+"GTV69DZ*2VA?4JJ5^/+&Y;C(
M[W.<%_RG@GV"R3E(QW%</PQFHB.7"I<6:JNQ@?@VAY*G.]M7Q(:[HTH#:+(O
MYJTVS))X)VN0?K-'@=YZ:7OKDF7:'4*Y:?HXXZ (Z 4*&?@N6^&U"Q0E2V=^
M'D+(Y/<]I5?5F"[J^W:H"U-K%@8^9&Q"]GFP^4_+P3S&U\:04DSS]7BIPZWM
MC8,\&>_*U9_XNH:>$/1^41IB-X+>;SNUW$FH(U#1"<KG^25K6#37$>L'_([E
MG6>0:+)<AG9DQD/!MJEO9,DV1=8,SC:!L'L>C"M%+0M4V1X)<;5M!RHQ<YY@
MC%?Y90;_#COTO-:E^-^>(V%TZ.<!\"B))_483\\@U%$S\'<>LN?)OB&LC(Q9
M#?"KP  A3NWR*FM.PBECM8'=0!>(%LC"*.3&%%7P3BN)\WZB)JTOP'2 J[N-
MF%+U:NM>$[V1L!4C@ N*%L @KQZ<:SHM^"0D'"3!+E_4SEM D#!&F ,<2J0Z
M!9K88:RL8KL?ED:0P-=[+@AD119]S ,/7'<AUV6"_J?XKVMT( BB H27)PPV
MH4SOU)43B"URU7QA=6SP"]YGY(70#/C>G>Q_05^XEGCN5GV-8)! LX)N!$#@
M&?Z(VP"G2%LS$HZ=J2FKADTU'UWIO[=M60C'$C9Y%D]_N@EY-=!)FFS':<+2
M4$"%;L>Q&5B2>B<,J,4SCJ 3\=*\ +9V.1#!4^TX*WBO8,83]L[)!\)0<JB,
M)G//<2WYT%7"7XU"A'PBGOX9(\RN30BHC8[!TVM$.;WX7<*/J@O3PP$<G8/@
M&01G"H)V"O<1B>\JV $P>3>$63'U,CK-)' 3(M9QULT)L>]>03=YVB;&9@)1
M/_;]'0*%IQ-1K[<&MIJ1O0CI<Z]#L-;HF!B6(_&!L W?(L6840XP<@'#'H0(
MS]H<P8#"-8%KXZ9EL^(*6F9"BF.:'2AG9_P@\PLM.IDNLH#^C[MS_MO="*&[
MOP@&%Z@P6)LCN[_M+DXN([;;&GT :P(ZTV'@U8EN//"J0S6ZVH74;3"&;[(A
MW[OGA@S06ZD*%OI[\/^8O[=&WLUO;95/",0O>G%/N^*[;6%3C60?RX&4WY?0
MH#V+)09VXK2Z@4]JJ3V;$'$4(WAP7RSN4)7V(P]??V_GVR<GHV,-)D67"2L$
M0 =_>VTJ@!/ SY?K$>U=YII@MX/G  .L+^TX,(UIPZJ!]QESVZ '"/O2G#T4
M]DST/N17AGK5+*M8<E&3IE7E]V$!ST3H Z .E"?5CJ>3\'5YL9N0.RKL4<&
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MG)JE;.-=%(S @%LOW4&6/1NV@N;Z]S#0NV;F+*.*,:*LB8?H7QX17=Z1_>A
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MZD*?ITOS)@2-['/6&R>#JG)"F@]>Q M3=MN<I>C4FN#(UA_*^!LRW8;3OWP
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M^.RJMAI,,IFD:V'D;Q L4R;HUSR18Y'YYY(.@4:FGG>B<L+XZ;C#?256.B]
M+^#4SV[XP6S<-[5B(L;.1)UA (']<Z9RP_TO#6T1KU/O=FU"KF&*VN&2P,\S
MF/M11E^>G738^3!S)+?QT/9W?^DTDG'?=.#.=69_7G1-1K9Y,\_8;2F*HF!K
MDWO&B .A =ZSB!.X\.=5']:B/%;P4F."N[#%\O^Z@;B-'X_OU"9_Z1;LQ,_8
M;$+&WK/WD0<S1,A?)H+(_''RKY?] S])5/0?XS:'34@H@N]S*F1=BNR"4/F_
M8$CN_Z5OG6RS^%"4/"8""9 2:^!S+\ 8VY;A7Y8G]3E?F9^63A\:JN8,7PX6
MESGK>O2QTL'M)=Y??X2LI&@R[Q:<9O!^BKV>,@V.J7GP,2B]207Z*U7WJ*Z,
M7R6(;#BI[Y;RVW^PQJ):U>]2R:UBE<$/]58X\Z=_A6!)^X&6=(^DTI1.IHRQ
M07OZT=3LBH&IFQKC+^S4&HE.V8O]476I6?YP#<"2'O&.D"#72DT22%Z\'7(_
M0FD@/LS:D]HCIWPT>6=3:V-K^]"SVA<1WN@0B9GVDCP[DX!H\1+?E<3O:7\2
MXI6E0-MW3]JH)L#:'E.7-D?C/VKG3A137..C=E]*/QIWUP8Y=I<J%_L"F:L%
MO>3(6BE.(1H=MPF."<K[S!Y(]#P<?'NOLFNO2V5MW)Z1C\ 3BY8SXII9.4@#
MOZ%>/>]'W<Y5-J5B8S(:9S_$%JL?5U?]&$G*$"B#EYD)\6@3&"M-R:!]^X:;
MW]?Z@)2WAFX%9V,YS2<\)@<"(W8,6CR/3PZ5.I*Y)]?M_ITXP>]4S.EXD'ND
M)VA 9KY/_ST[Y(53K>+RP6K5:Q-=8VG8\Y$'JV6P<,TXI.-?! .%P8680H4/
M-6*-?K9?0'122(=4?[G/,T0:9F\?5*%A<8)CA+VBI+D^;]&H^0;KJ E&CB[L
M,>BSS_YSJ]B>H.IR*8B!DQ9\FMLC$$?YMQ(?F!AOA!.K:5>]HLL]EN1H.4.O
MDKV".<>5?]S/I<U:QB9'Q3V\_ME\9\N3?W6>2V))"1U[P0@&3OU$+W#/S&37
MN=,O;,53>IDAA_I.4_KVV!";TF53?^YU.N)5;E&7AASLOI1%L2D430S#D1(X
MGK\/8O)ZW2/,1!.8=Z>\3TR*Y6AYO?I_V'O/J":V.%XT'@N"%!'I2(Y*#4T$
MI(C$ P>0( 1""3T"(@2D@T0I.2*]*A!0ZM$8(H30BT  (12E2A=0($% FB34
M "&YG/?A?;OKK??NO=_>FEEKKS4S:Z^9_\S^E37[_]]C 782/"*3)9(F\!)N
M(7&^C=72,+RY3>-QBK2EY<^]\<:CH@0P7X0LW;ACOY677IX[7?[\@XF/1M<[
MYUF[+\M3YCFWJG$#J5UU'>I61L1:T\7/:A*?Z377(^&B 9Z\@:R_DBEIH$^Z
M?3+=0WRV]6):98^XWA%C*KC-Q>ITS3GXXSI'"L1VWFI\@6<C=4)=82G+G Q=
MS<[&2<Y'C(CM/[LCC=4ZNFOEX2$WOKT^TC64MZPP#U$-(7S-]X;EOSLH:31B
M[GSW%/E,T>4XTHF09OA2AD10\(["*Q^K1R+"'QQZ)@LY^]@7+MM4^MPQ:O?M
MZIOC5-0EF,$MDK1K)VH:K0*71'.]_GVE9QJC*TA;?K[E)_T9%7:](J;O8QOG
M+N^U6*<%[2[;_AMHVV[*];_<?!9PB'-OX_L#*V/OG[VOY-7T^]V'TH[\A1T)
M8ZJ_6*"+>\92XZP/5""%LFX\4?UTM"^H_XZNY/49UT!> M: PSQ-NK><CT?>
M6-B\Y5:)7) 6)+#0F(R8<I_'=_A?ZJ&R >=0+H[0BW_YA'HBT>&EJPZOJI+V
MU'A&[;O"@J5N#-UIOD-P.M]/G;9_FSJBO0S?9@A_4KD0H3/(!DPH"U-6/SY>
M$O'^!A'Y_L@W[U%0QW G3@(Z7N)>%5JYXSU1W))%YW]'YXHI_8JWO4R@7H77
M))$<%V;5^\!5-<PED92Z27Q"22QY\>#).8W2X6;LQNH#VNMG=<C1S+U76/G>
MY-*2<8PF#"-*_O7L.(OY[6"!"E^OH3E2)Q.!7;-JM/[]J#]S)Z8'5UE]MF.U
M>\UQ@ZH\)8U)TZM:4MGG!1^8_ U9NIRF+=H9&,MT3],%T!HZ[V]%F'2)GHTP
M#X;SQ7=,=KNJI<PI'W8I*MXIO#*)C>Z&D<<($,R'TMEN#9S1Y96Q$BT83@R!
M"VA()H6WOW$*<GJAA8_O<W4@/K/S/O!S3+7VAN?<\?>P$GY187NQY/98R#CT
M$5[>7!66_[T%37;AILW%D&3Q**#A:#:8&_G,!WFKR7E]=/55?=&?+TU]@F5P
M2F,-%OTRF(=)E)\)W4N"J0^L$\'&GU&(ZY1RB4\!A5;/K;>XF__8^G[KM*!#
MJSM?B8D9E,^E6*_\6KU,@2$L,%]A+-])>CW#.LL5F#(0_'U49S PXJ_7;OG;
M$7XJ:^/T$/F1]KXUDZ[N.CE7^:]XH\" %"S(XH65TT9C@]H25)354533EN(O
MW99,SBV*42[WS*#^9-RV]=69L'\8M+FXTK!W6/[&0\C1VQ$Y\>36\)\V:=(
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M13_\-JH.26AM2-#C1 52H]RC!S[V2'>Z;TN<X_3X%F$KKCE0O:)XJ<)10$P
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M:'O7ZNQM""SBTNO\<T+F9@UB]KYHXJ*=#H2U(<'+P6G.Z:!J$CY7^7/N'I]
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MF-\:+OT8;QM8N(5?'\NSC$[_#N2)L >GL209"MW"&8;*;ZE ;J_I-*(4IT3
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M$N=G]L!GHT367J&*Y6I?LZXP].7AG5'*(^M=6_^5,GKE'>0S,6E;J$R7:@
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MC#B-!!W;5FPN'(C\S\,%EFF;+RT2MOJ;)ANCQ[.2DY*+3]GE8T B#+D%2K\
MX]1E,WAN3N]Q"X>;>;J$-39X3!VQ =P0T=ZXU/VW5YR:O5K0%!+K*'[W&&VZ
M#<.R 6?>,EP./5^T7HUP&E/BEZ$;E2#GV0#> 8W:X>_EKRB[FH>+ V6_A112
M;UN/^Z\KB;Z=JS\BP_F;XQ)?0;;&C9?8 &@S@L0WJ?/I_\/+US78>\.H80.X
MA/>"&;OT1E_WUCR*</M<(N*24LC!:\5GF/UHYI4R5!S95.K+Q4%<.+[=[9\^
M21>*\>LWBJW9T.=/"WVS/;Y\/ Z_T>$JD4U+N\YOGH6?G$_Y7K\RT</KF7P8
MYYC>XYBWBM(UES8\QNNGK,KM,/*MP]:^L@'R2I+3"S#2QS$5C^S5K<.E\.:^
MQ,0,GV1"26YXXN*3JX7VN+ PMZA'[OF_*W[GWY'K,E)UJDI:C':0:T<*5GAX
M-#<,=(-[M'HW&B$POY,MTO%9_<Z/WSL;/C.SQP''J1%VHPP#*]K9C?Z*8,I,
MHD8!+Z<#W.;KKOV^M^T$2>3?.+)CUFR?I$WQ1_J9ZG?U?7&(%LHT\U7)"\Q$
MZW1F5)+&GYL*^/>>EQO+6[ 1]>;H9/K2A<(Z[I%<VT [)\-LTC#IUY#1:%,P
M7F9]H<]$6EHE>+WW\,5VS2IZ2GC/;9(-\(8FU4?QUH;_4.D0TS<L8QQU"7V-
M5O<]I7P]E:BXG"M/Y$C0*)[S>.LX)'& \0L5]54.V5"QW&KEZ/2[W4[CX[/I
M7RT-W58TS1:6^636[$8GD09#W47U\6.T5][UR@%9S@6*NIY<WW)AX+]I?62F
M?T*^B3'H_:KK5C\H3>5V_Y]M/VZ (DH+Y"&"\I%AHE*_YBE:4!LX/R@8&T?L
M.WZ$$OC4*L! 4I0N?)KE&%8DW:&@>>VZ\"L.SBGAUY/D#C*>_M3.W6+M/<G8
MAHWYS?IL0%CAR6MKB;^7LT^4^^V:B!G5H6!%%]\\M]6%8.Y0I&VGFP)D*PM7
M^Z V5<?Z'=8\5<Q;_<-(BCPL!=FMFGYHD_GSP.^O[ =;$5A.T],Y#^2ZX\1Y
MC'2K4MQ)2[L8A_&'B[8GX@CCL(O7&??4R<Q?G)C,?_;772 7:PI!@Z+_ =?'
MQ_\V3@UQI4 3LR<NS3 \J9NQOKY$)KS8O*IG3]PW2M'0=P'!^Y<BOU2NT,<E
M'Q_YT/,D30+C$1M@D6.-R*2Z<'_YF)M7"$HB+_&_2.7NXQ/I$>!I='4LEHD.
M-)VR:4YQ&N?*DM748O9<I!7:=%KC=G.CR&+_+AC?>'N9,/IDW\8Y^UH&4L73
MID%D&Z2&U=8NZJW''UT^T1QIK;=0<R=T+UBF-#UQ1V9"Y0]&@^D4.)X93CF&
M6C4%EZ\(<!8N0W.':_^N'Z]5@HB$*NFM;H$UQ(;7_570\:3P/KJ$6DR?%EJ$
MHFBD(*[;D;*B 0H-L(/85-++CY=AZ76$Q$6\>=G3/)P+"&;]=)DQP"O:CPI7
MZQKM^2O(*"-.F)_O61JH ))Z! D:[K"PAI5 GN1+C&\*BPX1*I8,QKD K"SP
M?(ZD?".=;[W!!_==56&^31)50[[U3_F/^IS3]^D/9HI:B]<Z]Q%:\ZT[$E@0
M&X"=,UP?09U(@16*M)Y'AN=!J[V9R^_+:Y%P[<7PYN"ET<"M)[:0GE5=:?OQ
MWLOB;>-TC1(5J0.%M>VRH>$D5I)>OMSI V$VX$4!&_#3_S@=O.[(&&<#\. X
MS%'."S;@]\'^<50?&["38L^82VKK^H)>F]5D R!D((P-:*\;J057@WNFLOX8
MC@@G80Q"E(!D]-E*#A$MJ> 7HR,D?R',=C\QY.E#^%Q*IV1%[/3#@^2-UVW'
MAN1#%N+I01-Z?A$X Y9E*?&M3TZR8C<3$<QMZ#;8:J*U@G55YB\VX*^#'A9/
M.WK[ZC:0?CEXZ/"/7C: YB)[XA:*" C:O4V&@FS/W,SF0GHG- XMR.2CY9#%
M@#%10DZ,!6@S[1R&.G,%%FD+%&1XZCN&-]:Q 2*HZ/$RL5&'QI<]@OEPH%>2
MD/ ?-W[-"?=(\&-HW8ZQ7?-56H?C/@ON\1E=YC'__OMK_,-W&Y!Z;HZ&UNJ,
MK6]0<XGQ&D,S)5CR6@\UX'6_'B]&1\O8Y2:YN_;A3P(,CPR'8(25BG]D)#>9
M'VJH+":SN,R?G 3J;MOC<RL->W&,U\$KZ9?GBOR7#^#K_ZWA)=5Z\I1N9;*L
M/..?)"@;("T9R@:XZ\)9A:_V.)A"_I3"*EKXWB<&DDXF[PM\ZZ&WS?>THU,<
M)"L>Q8'7YT11[N1#>,PNZM]LWS49G&\8Q0S8)7#/7?4T];;%T7<(@1)P[F8A
M^%K7XCA<<^^)Z^L'H-',"3OO<4^7O"?3-U.?U=IN[IL1E*W#G0)C2Z('*S\>
M0G/6ODGPWLH?82@,X[FL3'V^0+) S9I,&^+F]14V@*$BO!'O<70W0N<X)D+C
M[2M/WP5P]#1BXS;55X;3)=S'S(#Z"..)902;/8V[%E[!I_=JP4?[%$(#=NQ<
M^3_8>^^HIM9N?31N"RHBTJ5&!:0)H8.(Y%.V(""$WB$B @)"1%J00-P@O2E5
M:=E(B8 A2)4:)90-"$@7$$)";Y)0 VF_[#ON.+>><<<X?]SSG3'V/[R,M<A:
M<SWO?.=\GIG)NVK^<-6*;>+LHSB;.*+;;NBYWRA,GJ[-5,XH,!Y='2D?BDT_
M?'KD6M532;H84BNFQ3V"+O&==\^=2 RU*)3G01MK334CWKXZKH*I+0Y194%?
MWS%/1;)5B3$+<!8ZHUC52,+]A@BBMI%.35>J$>B6X^W"\$I3H8=J?JV?R&W;
M<7MYK_RP?-X=PC:NJDF_GG7?]G0VZLY:4/()4G'P_RUCK3<Z5C49PYBR37%,
M(N%N>6^X]Y!T.?NIR%=/>I^/8^*^J639N3YU)M<7?:NK*S8:C=[X-35;-D0@
M4+5.,A_H]P /GK>SE<\8!]$ETIW40\]\"Z7QN['EE()(9!(QC9ZQSP)L>L6S
M *.7K7;CF!=O,]ZC*9/=[,6'JT'&F,[N02\$N2^@!.U_A.6 /L /2?).TW"H
M@>:EH_2!#ZOM G6)!YTEIC=Z%QJCI#TOBJ[39?JR195Z5H(Q0BGE^SZ\V?EO
MGTH^Q^AY,L]G+?4KIL.=&K9_T7L2IO(ZW<D.MR6\(RR!]IC+&P/QG5.6<?)V
M@3'\I>(LP-P-;$7:%+@Z=--A'AJ+(QMM)^#.XGPB[JX099*0OC0L#Q5E/=)J
M\J<)"W!N^Y6B7VQ.$5TE&W2JKN%X#AU8!(7[C)*XVK*^:<+\9.*YRLJ.7TBE
M"2T5*L+[.Q#<7=H7=C6'JB\_4#+[\/WK\#&^,G[ QZ@/_N/AL[=/'JG LT!/
MR5D^;JOC:#/U L>,5_Q+0&3LYY ")9ZN^4 3HL**)<8VH-)L?/7><ZL.L+N2
MPTVK+.E$"Q]%G?Q:(X7"+1I/Y%^$6MPFNG)=0IF1V7X9/N-"F2=CMF-U[U!:
M2-LIV*PJ=<ZIO0$3^R@:WM&T.X:\_?OH2MO(C6"%J\]K?%0,O6'-#DM&ECC4
M+J2D49SZR;',YLO/*QOSD@E6Q?'?GG042F06G_\4XU.-CL^I1M0#:XZ[80,V
M>I *G2P!69JPT,6E,+%2J&*Q*SSMT9IUSZ,-XQVTDM&8)?J<%;Y#R3SY?1M*
M=6F\Q15<@KM$HJ*(W'&1VM0"B@R),11+5YD'G8/G]4A<_40&Q2G"8'[TV\04
M^5W7,6970,O]YJ8Q]]$;7I><$CP-/G<:!2HKJ!GP1>G:D!S?.BMYD:14'QCH
MM,E?ZGC&=(I[5JI[[WY'OA[.-ENP.>!Y76F_S9VYT4K^4E!)YV"9*!=4( $K
M.X(?+H^O*+]S4S[HSW5(SOSS''EO)3_77&])\H+AWR_29++%O2 B\#U"APJN
M8 <N4SU)^EV*^&*#GMAW72X9?)L\^-(LWC<0*3OZ5 ,4K]->,L!56G*H>*K9
MVEB1E+4(4)C\:7-\/<#CO(W*46-J:\0?149R$Y60Q J+4N,MA6;HCRS9#TV]
MTD(Z!9(5U/8S8L%9I T\YQ^EG6];31V>CZ#O7K:G&626C$G>L"[9$OAV]&?;
M^$3/<.[D%@\%:T?.KB6F"3'[<60K+OVOS:7)S<CX.C![1=5"OQ"FN?$OF"FZ
MY0?]$%ZX,QS5\8)9_,CO5<H-'8W-R4Y9FBZ?V1L1./=I*OX:UAC'Q9#VL<4:
M!Q3(!F@"90<DA0VMBQ*+,I:T5XU:>J9O]"4WN69)^O:T-\!2,0:E\E,R?!5J
MSO57H0K]NR)6<=,QQF![M&6 SZ'Y<O;$],A1T@$759^M%) 4R-:]]W13LE(]
M,0F26,C?5M-,QN&!O'!L-_*B[BTB*D$G>'_LTX8MD(.I>5?7*("4Q)F5<D,=
MRTUWIC:^?W+<ED[H(@YQ.<]XYW >'X#4*3B.;%UTLO)-/8\<DNR #6E0H%0'
MPG<1$IGJEFU<"O> .]85"QE7\0FGEKL^K_K$6Q27>07>>CMJOKFI7M?F?*:M
M:E+R!Z+\!"8&;<)W#CQG>#K5=7CB%:9?Q/[;4[FQ--52HP_:+("E!CENX\Y_
MUO^$9(W_1T,L"Z"-HFJ?G^!.0Y(#>S9/D"%VR;XZ%W32-KG)>5;#OTP@C]11
M(I'#CD,)]:LR#5+=U<YKA3>SG39E56>0'W]69)Y@IHZ=8 :CR @0/0=$9:=S
M1GI:*O(XA_K;2ST(&4B_E,..CE0,[39=A:(5C?-F 7A\D6?ION26+Z[R9&Y\
M^=_UI80&P>S",Q3N&/4VNPY'J4B!<9@?0JZX+(](FQ'E'UYH2H.,\H*JIW%3
M)/U_ 0$(#6H$C4TSO[: &[3PR%1D0PZ=+X]XV(FYJQ@R?4C\U4;)7;&GP*)-
M#]+47Z1^JD)<H):2"=VYV(Y*<))@@UU(3@A;2+;>I'"[DL6_C-970LX_:7ZC
M9?4268[>/$$+HO.S%U!J9#_P(MAG^^6AW0:16_QKA$<EW-W95X "Q6^+K&I=
MQW?IG:($5Z&"PV"^F-70OAI#J<"V!NQ[UU7FM5%'%QF'ZL^9)S?7V1C? E-U
M\PY&)IE*S&%@K1>=3X:HT<7$L7/=;ZOL-1IYG>IT!Q0:2.). ?,OP+CH8N2G
MTPB'7--0?#L'#C>I3O,P,/FA!UHK#1WR3[K$<<"6D*>Z&4F(V^SQB/'W>R-9
M@"G]>PW5+G9$+'Y6I?W:>O8)$1 OW8FBQ +P(:PH5YI.#C0UC-$#*GT-#;5X
M(=(Y<:01]0]+OGYZL]8G5R'3)FQ" Z7)(,Y3"VB&")_Q[3U0#/(L0B60M"VZ
M?NR:\H$:9_YIV,\K:MKHZ9[+==$40XL"='.4>F-]S,^<GR'O6SYPS _1[Y6R
M+;)C =[/4*#LB3XDI;%UYX>3&X0?<4Q. OO<#!O76$1P#2,?YPE.:->A@+M,
M]?$2UR@1A6](P%?M.N1(E&82\8G?+XUWR(;Z656"62K\2I/1M<;LQV%?@I,"
M8PP 1YS,BR,L0*8"W8\%J,'2P,CUD>^K)ZGY[&O;,'O Y&?('O!4U 8[&Y,?
MX)((PJU<-$WNA+D;PZ7#"!Z:\QKX])X,-<&MC.H/X2?(1&U'7J$^]V@N[-NX
MD[A@P_SV.TYS7= A^<+8B6,VB[LXP4[JW;C51:0WE&Z/BL,=;9MSK*S0^0D'
MBNPSR9&<D;V%<I1#.K_O JA[2(39[XA,1/!YD0HXNY$-2FF4:/P.-<UJ\L]:
MLE_7RA]/F=<V=M<MG7QWIGM]@YIMOHSZ(RJ7E<^:=@"0+D"RER']O<@N<[!E
M <(L9@&X9$_N+S#/[Y(Y#_H894@W9 +X+.XA*FDZCATCG9PI,OAP=B*G_S[2
M+D<=FA\L*EN=%DH-,G7JFM!D 2[IGO0+)/E)K;>+U^,^9<\-6XI;GO,8]5\4
MG%25?(D\ 6P0HE\28EY\0#&,KL?H+]BEZEUC3A=*#+>V^>_B/T5.Z5VC#GR8
M,W+/-IF5_(H20I@6^S3_*O>LVG&<\A9Q66[4&A!\YW4;?\/LQ&$:7=2"!3CM
MS%8=[D-),LQSLY31@QLC8'?P-(@$2PDBQ.JP #TL0!VUVS24/3%"094)=8I@
MXF3/K )I&1V^@(RQ&Z$F7$PB,H3PQQE4(0BEK%X:0XC2%=4X0&-=7B*+Q@'(
MTV RPN[ETS)R*)T/3TK65"XK+J/F'220+Q:5ESR$!'I@UJ#G$/>*?_PT/O,X
MMB_BI//GFI2$2VT,F@$'ZNI#[DWTP45*"0O BW0;^C%$4AP8:YS4TV-DXKR0
M(LY04P53C46F'%5_GO'<J=PSQ"O;*0$T[2#MZ?GF9ZV*S(T3^W[__[<N_X\<
MD!)(LC7A",R=BCM\@-PWI>MB=PD]P",=7;:3!$$97L^C&?QD&::I'2=R-I %
M<-2=I].PO4.3__W5V?_HHMX[9)YC1ZS3@*2#^ZT42#13T@&.ZL2=U7V ^3BS
MUBX<!VF?H*LM7$Z_#*ZKR[OM9#W\\?'H?O_E]"'GAHB[0GP.WJ$3.'6M[$-<
M/=60U#PO\G83IXU.Z7[&U-#]779^P;A*YO3;+@.]&6X(#Y3;:*1S)!&=&%W)
M,6 68^_2'8 B,I7A1J!+WO.!8KE5G*<[M:]7CV)2LGSLG?U=9.1H(OO*5(2-
MC1.GK5F9H$]R1HKC7H7&@)GY?MH,X6"(D8+T)9QP'"BB:BU(_$')Z;AC&(5P
M*(=;?0V9$')$'!H?I\6T6@2Z4WX[/G Y'QRV_50Z<?#7AL%XW/338LW#Z;;"
MHFUX.4DK+O**AWFVD!))#,3S4)&1EX;YH]][I$#85.>'6-":9[V/":?4DFU&
MRLTA[OC#M=+SG^/MR+JRY)G.-&XUAQZ!=\^60;&[9^:\<H:_J<EG>4\DBQ2G
M?NFH@ACD!YC[J*]WVWA;=1(9?9C!;(E24'<%,P1<W/'_[!C'@^>SH3ML]?4;
M[A<:N;Y(C8.N&OY!V/']#&5N0(^'/5>.)A<:Z06N<BQ ,Y!9^^[F\3GH1^";
MF'^/U?!O.(01NK:/I C\X,T"ZB0+8($Q:P=W@H^N:"\P_V)>9P'&E=2/+_*Q
M .F5L<C-/WMQ^^ZQ8!W<_%LP986"9;;33[!3?*L'M(L%N ,\!/&!-R5?(?<F
M>8"C2+: /QP\RP)4/V6QB8_9$L?Z /)/CITK_YDMPM/=V#(J\OZXQI;/CO@M
MPV'UC2VH[9B2/:8M-J]LQB0L(NS9%Q5[/[^'V6'V"I?B.T\FFV?MK>^=/'I$
M':6<[ +60[8XRWV.;Q?,+JTDMQJY$V$G5A_,&_F5<+[=0W&M4=7Z?6'JGVI<
MUBWQUQSK&0-;"WZ\MR:#+%_Y3?FP %J,R)=(4^#9=C%OZ-EV8:H"L2'9T@1T
M=E4SUWU6"G9I+/B:R(;C^#=5DUMWKM=^_ E=K_DB_60^G4)*XKFF&&#4I$FP
M8X!>2Z3<_R^$&3 [)\YC&NT$4613Y(R2DZ='.B0J\EK=HZ:AJ>WEFD\MT!P.
M;M\ U89(EY)??;\$]O//"2@I$Y<4<74?</G6I4#Z.\GES]UFNJ!"#=R8?,^2
MDGW[K"B;E'QB/F7RU5LM/7X1B7RY:J9SLI 1Q0+X?4^9KC\T\9\]6$,N[0]+
M4FGBEGU.84$X?U3Q]A(0$RFP'MHN.%G7%FXZK?11>O93PKF 4\-U0IHU6R=:
M6_*\I?[H2^D#OB!F&=.HAO)6,<8OC/.;LE,<]LTF6AW]58TV!$<;5;VZ/5^C
MX_'C^(DT#?E/S])-;ST=*X;7E9YS#)H)L4S,RLJ$C!6(6M91SJ#0ZR^L=">F
M,P-:S_9U/"EUKW&ZF?F>!2AU'&J>AMU05[T?:^)]O1%> JLK<M4HEV^^IU!>
M-MDDE9&>T9YM:KQ3NQB08=%6?"0!.F=U+CY;PFA@;J^4GU#_JJ!(%C/CIUV'
M]4:+MEL/;50>B#(*MG!>D)=,L>_;=?MUE)4DMP8*LM.HX%6.''9=\Y-H!-<B
ME[R4WN71]J&2RXIEZ5WULO4N!C]06S==6( A;@'J",*WZ\=/%Y'!,HL<XS!_
M$_[\A^2@ZV,4']#<RC>%75+^<I:-@?T+-0OKJVSG+RF\1%;7%HI^IJTS9J.[
MHIJLIKOC5VYM/[U'(D8_-S/2!Q7UQBRBY2R#%^*QYXPF\Y<.I".?1+YGKXC?
M>/D%'PE8\WXS YQ,-](&G.B5HFSI>U^?J7%L.#!IF8%!/W,OWSH8H.*\*?T+
MJ,3Z))/X>FZ.U2@0!]S,UROU?E60HJ OBIKG8"8PQ@+X^N0X%G[R>M:[C,%L
MM7TD+KPJ1;Z)U*(F4Q<Z?RYH?YF,E9'J%X,CI8*F#[3SL4KE-M9==]$*5JGN
MJ97)/<2-SWT6>)(R^3!+M@DA"+,L='.MR"HU!K>@9;>?N(3?;Q/XB95MRW_\
M_E>]GM#8C<>COPIG!_=IY#[ ;_;V**4'"MJV5Q[]_K/[YLGN3M5J:#S:4L#M
M?.;2P+DN8Y!7U;KQ3MW[T>0<=8S4B)_44"+6P%K>.+_1$3UB$6[DJ^ 2U%+;
M_*+,HE(%C$#.OSX,!9%'25T9.33IQN0]I[<G:%'A Q*D6^G%8'AI017]Q&N^
MC&30(6Q8$&.(;W6_U[A95/C0IRO(1L&C3\!Q?)T85QPAF'AK"OC^F1/2IKOG
M?:=5^G[0)EN$5:$BTB9?,%OTOO]7"^@VR*]UZUC:=7JHX8DW+, 3SA@/R:M9
M[>)P667)SU=>&U(GDT@+#:'9>I4*;$FA1.' $&'TA%T@31C,N(='5?8PS_VM
MG)A2&30)YM"4C Q3$1?7C*(%81-8 *?/*&;<%)HI:,LV:W+I$.C&K'RVPCBG
M2J!+O7_1T\$])7G@SD#M;QEV@4\Q3]%5J$ZDVTY&$1Q6$W0^XFV%.V/8.@>8
M(FAQ5,G_X\-$AQLE;9]JFN'"B>H'U?<-5E]/"M[2'533L2A^ZVG_S>.R]4$U
M.AZK4YUR3TA 0]C8R,C ,H5FA(D<\N2\WE>SGLZF .2WQK71:/FW+RZ5RMWI
M4WWFK_-Y]]XM:% C>"B<>=Z*K?D C&K<)C&2G4K6+9#0,>>_R^/=_U$>WT7R
M(WL-V2C_Z&?#C7Z,O(,C.P.COL/9G&N )LS\?A R:HJA7Q_6$UMUS.IT:JTC
MAW;AXMK%A1JU6MS=KS90H+&ZTGZ/=G6D..S;K;_E/,4<(>,<HO$!=I<\+$/0
MJ>5)E:;(,0,. =L^O<\O?B08]T.]!+?[TH:IAR?V4X7_VI4M6XF.%<F?GC+O
M=BL/U,(:[WV0;1SP#Y.F:"+54;_I"BU IK$+A,TULJ3YI(:X/I,7R ]7()[Y
M(SB8F8V0F4_1[\JQFUP6$)7.,"8OZJS$UR^_:ND5J!@ZW7XM<>X4 Z;:Z;;C
MW*CQK=CLTH%UP.7C"KWMQLZ.J&10\\K'M>'2</]1[Y;=2)><[]B\Y9N>4/GT
MG#J,_FG3?JA[7):7W$P(T<BZTG*V*D>^)FV;0!?K@;F5L)6.*OE7WGG'J2?M
M'%0LS,,;R#-C;_@!<>M33:S&YIM[Z".3GME_W>R*]"#RE^K<9#@T+%GQ_9%9
M<IB9K_(\ V;2TD<+7HU,(N4FRS\.>O^Q2%_P?<[]<K=B =\@-D Y5MO_+]5O
MQ% 2<,?2#;EI$<<^\-%[S_4R"] +AC*[X6D,E1C=XLX1NCCC;:0.W9;Z5Q(1
MET9HC.OBODR-ZXR4H[9\_#'CZWJ245#4GNX'-J1ZD1.[-W5F?25.DIOMX<80
M =>.X\RUTOA@S:CI%4NR1QPE;H1SS5=/N-_CBZM87XRSK5.L_05/C<\37QXJ
ME"S$8Q+,GZ/?+1,<VL(>2LMD/U0PU1?8;QZK)#Z0%#OCE$L*>&Z]*\8"",>7
MVS9H>D.XL\M=U<EO9>NV=?@S976J=GTT,]_GX7O6AJ;L#MRH2;0[OAA*ST)#
M+7: V&9,]/\(M&_^C.2!_]"_LL,<]#<O '7$GX@2C<\&Z4P)#OW>&#7CP<#N
M&D:W<U+ B4<9%*'.?+QZ>?J"C,B83'*G31B.5_8Y#50Y5OCY0BI/FT[PAXKG
MY6>;;_K)\Q,FUB(T7:*QB1E=CTKU'-1)BXSCAIEPQ]PU+^R/.0J=35RC-N@A
MC.)6#9HI/./ $M4%(0*G:O&N0#(D04\<H4V^73<G2%Y)""KPO5\_5CI)]WSM
M8A*VP/5\J.OUQ@OHM(932\IU3LSYVX8F(W4#!N%':!;@L2Z0:,;7J^UTPNI:
MG_);^3J/>+RI5:G9#V^K2MD=MQ&3*9JC4I9CO0@\=[12RQ7C6P[,HL:\\_PT
M4.FA5K7FD;E&7"=6C_&5FGV4.2UCV;Z#T9ZTD=SN'37+S;QZKDGMF(-J2+N/
MV[)AARYWRDJ7GXEYFCD%SGC#U(2#2/Q%?S3IZ9"U\$@^*LRYM3U>4/#0]8J@
M9KN<O0&_X\9$C4$Y?WP2&;Y9^KC]BENU>70,]]8W'$^,BQXFH6NDTDPEQ,ZZ
MJ4#TL&S;UQ'\_N&N81[Y-N+Q8BF4!A37Y_V5=]P-Y++-,C()-T;+8_S'^8;5
MTQ:@S'-#E&@B"_ %-.-^$$']2H$X9N!QW'1.TL:67>?TF*,G^J.1FX=6K,:6
MCIS=@V$,J/Y6S63.Q'!82$C&_5.Q=]^KAT+GJ)4G$K]1P]6_/"RO^/S1]&Q'
MBI:VE64ZQLPO<"S@5<2/7MJ 4@&D\[.7:&S_[L]&T:0/:V[5^TLZ]?Q>>O8T
M^3>0[/-6D7OIAU8O"$6,=%\HV15*O5Z6A7:!.B"@%+OX*K_Y;/N@""&B8:=]
MO>B1Y-T-/U^E-B*#S]AH65XR 5M_ZY;?9KM?YWWA#;*QJTA L)%L_\F[B?Z#
MP0$_].RKMJPJ;T[!?G5 3/E"P'[E)"%.JZ3,@/J*NJHB"$?"<L9F6ZFLP39M
M)#F\%]@)V]*GV/8?O&&@V]7I4')<S':0"7<20:#5BH2]"'?6%^_^)"8A/;&"
M>E#?$@U1ZPK 0L\1\RQ2>]&I?H[+BTY&JJJW6 #]Q1]R'@X&T)<81PWI/[Y:
M%-G6__1N-,BU2@^LM2[VZEOR+.)?ZO<%1B__^&LYK.J6J$%F>8]P,L8Q2\'5
MV^;#3SZ+YF"IW.<6S8'^D^ 1M0,HF9!$%Z>I,X<D>*A1D[ %PGGZ!:H)$2?:
M1M]Q@8*3]L  *O(!1<'UYS='WZ2&"3^8Z;>=6B/UKL77.8]\C[1N8N(ZO82K
M),\6BRDB^L6=N"Y7WG-;)U4,)B;:&LOGOT\WN?>#6=CG;5>4Y9&IH@3A,P1]
MM>R\>:MW$AU;>K[*=+9)YTW6S(OVE:;)W!?_V6N261/_UT(YZ/8WX$G<_!KW
M#R'2KU)Y[Q>FV_'(>12*O][48*U]Z$D0E"ORNTY<]'YE0I78>\4*[_;3+0W-
M>7![4JJY0XB*.?=>R)_<NQ_9#(.(7&Q"?@6S )N9B$!V8,5]X3_!&(G\BMIQ
MAWY*8^3&;6ZQ !717_=.4(=8 (Z'ZRB.I\CY))S$TT@9HS]9@ Z7CW"V>/!#
M?PF/,*JC5 U0; DD;"QHNX0,;^/2'E=D\D_3'V0X1FASXJCZD 1,?XF6JC^
M_K<HBY:&),5MRM&<I/<"L7^ B1^+<O"6NI:8UD(%Y"L)0%KW>^&\0]5>B0R.
MEYUK$JY7OK^#IU_Y$S@5%Z_!$.UHOMA(2N-9MVT&Q[5JE?@X,ELJ"4:+4]Z.
MFFE>FD45/G;I^?&8IT_]5IH^OTY+ERUHZ@(@<Z!TGN)[$^!Y+(K\7"@>YXL2
M]<[1R8FB2U+ )/06YJ/]^ILCP@\]";(!UJ\H<K!=6,UDN>,ZV2NQ'O=*,\3\
MOD>AGT*'G>>5![S._SK!+ TZL0P69EZ@*S.*V@7AA'E4=QK'6CN8ZD"1U$?A
M([7(_ECI31U8?)!)PK5<7\ZFH)E*46JQ]\/8.]*ELZVKE&)#^3>Y 'H9"Q ?
MS$8QD4WI'D+/@\E%U&(68& ?$,%%4V8!OE[%S>?A/J5U*2!34+7<F\7SH%=@
M_BWUV^YXVSG5[QI04:B/^9,7Q_J"G] ]0O&Z5A_M;X129KK$:C@ANM>R4JWM
MGLT#WR')(3GT(N@"C)&%_+LYS38[[E\2;!)X)@C9=W4;N;G!5&>3I-ODP9?@
MBFD TP<\OP4YNMO3C:4I@&L/F1\9(B]U*YD75EF 3'U7Y-0DPIOM+DAB*0!I
MDPDPYSCR9QNZ(,+1P0)<0'ZU;SWQD:Z49CK"E*)F'#A374C0I 7\)4?'N0'*
M&4(/BD\][?Q&\VQW0<T!1-0%SF%(]JNMGW=:),_ES!^10F+#V?ZYMT=%AI+8
M,O($]3JMZ[LH3& .;H@/C91I4&;DSU!C%PQJ\AQ??HW9>>"8\;/;;;K==?;M
M9?8D7T"1$7:I?G[M$FR+="-%#,,X73?TU!CO=0.#']:4?XZ=Q#O*=$3\UK$#
MOP,2T^*EUEK&3MB=K[V-(?UN_U7Y7]R;MYCGCN8/J>&TT\S.PA/I9QHROK
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MH:LGZ/'_F1T<"VET_IZ#HL217IP7Y-3Z:2Q6KQ=) 9O7/^XJ?:M,\-:[9&0
MW1)*.8B .NV\BK2I\,[^C>31-K[YYVHQ=P/C&DZ+.N4[N_;G92#Y 7"JW6%;
M"?<$*_ CJZ[>A,%-S!?B^4MO%+[L NYTE4NZQ5-4D^P"#X6\%HWW:/X\R6D(
M"RZ=N:4S.OHF3.L8-+FT_(6!J7KX7_I*80%+E86^W.=.P%6CM\+F(Z[U14 <
M)U@ +UB2_MU117?>G^N.!P7S TZVW_<VGO2:3PI-U\<4E.@F&\D7CN_IRB3&
M<B;L7# UDK4LS9N__7%QZ[)EX?4"G5I8G=R@9:3Q+(0OX=E.US-F<!Q:2"=+
M]9M7;=1<L.3=0+3 BERW7%@MO;=5YEJ:(J3JYOZI\' OL7")+<90'#7[6"][
M8F/<J7[/<?\'$]0CX[6*8^>D4F1[SVCDI7<<.?G EDFL:'CXPN45\%OHBQAL
MR\SV_C[!M:?7_='L-"V;D.NTU]IN]X AS$C7#?2=QR4PN2:#,:=;H43N"]0D
M TIH?*O2J-2E==L72L5>-U_][/>.$,^=,SWPTUOL]2>[&NJ&C+XD>!42T,H=
MCW9U*U7[G]-]^E7>E3DE?S'O";]I>]Q*N>SS/07ZN,+B>8'ZBDY@\H)E)E;;
M); #>DM?*+JOUAFK\>T9>!K._NR798%JX_<E%&4\:770^G9EBLU9VZ44G=?Y
M'F8?%<T0[9M$1@]=B$HDSRP<1FVV!I.'H''V([\$)''5.1X-+<39W\M55YG7
M1EJG/$>#+PL[ QQ-;OW(@M6UM&SI^(;WL@!#>K)$W=WH6N-W9N'1A8*M8:5W
MZ\+0T3WFEDNI"B?CO0UY[KJ,I!@'MMVXIZ-!U#%G >YI6R7M7-3H*_<2 Z?&
M@KB5["??'[DE?WDD!KMQ'<PU($?\=&E+1C[8S>>'3U;U+MH1BYD<!#[XV_57
M@'1^CH,_DXBPJ!6JU?P&A07@Y.QY@6B8Q@S4&@P1(6=GBV*/O9T3+NCTQ"O.
MF8(?I CX/]WT:)L0#!?-'%YL85H<FU&[3*)WSM.Y7Y,FC\<[X3='>JSQ@Q?+
M#-\\>K1F5ZFU;9Q]2QV]I?Q9X')WO=BMS@6B';=CX?E@NC-!HGJO4"*/L6^_
M/LH4URJ.M,P=T:E4Z ^6@'UA9Q UR!NU_7!PH[U1_6/?/.5)Y:<N"YNK'R??
M5)\2L+@LI.<U*'GI_OD3:O<+!RWB _*K1YX'H#2,7\RIY$N&5099H46;E.KF
M<[W9BEJY:.M)\QM(8>+S8=>]PUPDD<H<S]'"A_</;1#TX,Q$\'S&M- /L!>,
MU_?Y%W<4E%J ";/,)RV8C=2!+T[/O'FMMD3HK>AY[0#ON2!F=\RW9][?CB$>
M^*5E.A9Z=6GWWH7<NZ')I]A'WAO9[H^W;[.S\U5RZM]KOUC:FSWQ8:(^(/@&
MK8-_[5[$R HS VRN<(PX_OXG]S<8519"YV4!B"@Z/]B&ZE1!OT--6TC[S8B,
MA5 \4:5X(J?I^>7;1KI.@7\ZS_8B@I.<X@P;8-PS'W\[<T]!M_WAHTO8'^1&
MX4=4V\L_W)[!GUIV#[Y:IO!B)" /*SY\")<!)DVW^WLR!7S#?Q+D.O-E8DC>
M1.GX+M(S@G7*DRYSZUQ40]#,\X/7&<T'/A,AD]9[ 7MI/S@/SI)!=+Y=(BZY
M783*T<V\01E\MP 6;4Q5VJ:[^)4XN3JX-L24K%X?' ]*\H7G_OA:HJ^W%MV_
MW'_EU)7?FK11"9]T+9+P)(JVSV4'(IE@FZS\JSBY>,O'9MG_8\GVBQ0'J8_-
MA-EUXJ XGCPGV"[$'8]-2$$83DC+K^=F>FP2(5GA&@*^=V[;_#J.P+;Z+D.*
MN'>9R*&=XF,F#ON-^TM:&I0,V_X"2R.(M,LA_"@</>"D%YJ-%*L>5RG*'+ID
M[04L>G$TJ(7 ZQ,JDC\AR!U0EI=P8W-N_NO3PQN'7.>O%AIY*&T=1SJ08CVR
MEJABS85V+RLA)V-+8U^M6/&CM4<2T]2/?)Z7&T\B*N1<>QV !9YZ8AY'V6"A
MM/)W[N5CW8_D23)G#;E[S]GD922'_;G4+SKE,HOY%5F,<&"\II^FY!S<:6*D
MTMTJ-X0D+J"(Z.A(<6S"")=&Z[U3A2>C[[  K\*[>.Y)-QX\VA"<1L4%;3F\
M44P?&ZRY)Q;0^074_3#PIQD490@N,D--"*JV*W[W]TG.OFYS&W-FU.9V?I&M
M]7:D[ZWU(4SWX\^($),;Z?7&J=$=%AVTQT5;=N/C8 \'&0G($[2Q6J-\ROC'
M#,.5GLV_-Q73H)ZD78G\+L')* KB3@3SMH:2P  \B8_(X.L2+!1I&'8?:]4G
MSD+PW.4_4U0[;B4E/%6?=3=/[U9<?0.MQZRZ2;\_?YQ,ZT0,Z?51A&T>7.3F
M-.%?"W>LDW:U$9.SB8%YMI7\M,PG2GCY?D:+6[_;#9,!>$Q=]]!71:=TD7R(
MXU /LYKWY>5C:'DS6+I*1L"KE3ZLOV=IL4G>3_#\GSBR"3 63#;'\2-N4@P[
M@0GMNF1U M<>%^S.Z V$I!>1EN?THW[ 8-*\J;G%SW60%%S@.'C9XM'K>TL?
M;IW,]MS]#$U102CJ"QER1G60LI4P.K79UVR*99O-GUFDU>3;H-3\UP^G,-8M
MU(Q7SUI-G#B=>)([B86"!<;/4LX.^QB79.;EU"47,,;J0O9;EC9Q'BBJ3'8,
M[1IS0$*-D<L41'A1X\[D+4#%?274VRGC76EQ1$K(V^:#.&(;A_7PGL/3+;?Z
MT9%P,-?7I?4/:953M_<7LX4T&SD]--!_P=\E?J,;=#Q2WMN]87B>I&(O$A:T
M>R'+ -YG;V-9MQ%A6Z9H?5S_@H*1A]I'!3_IV,4WVV3*]R"*8XLR/&QV/EX'
M\Q>[MFZT/B@VLHNKB]$VX_]IF6QEO8<"Z8:5>K;U2$"^L@!D8VQ4I!C%+(DD
M#NTJ5*'X96=]N/?!&8ZT=E'ENF6OG''-T<=RNK,1Y'%CQO2GQ5]I@=SO3KPY
M53IY!)4_EGMFRZGZ=2'PPLJM0?)G'PK62:$;?]*$,W41,5R<6 CD$AE\52';
M/$;4ICV1L\S,]+KN'D<4$SB_M]'/$U]1/E0PFEY6K-EL6K)((G1FY3E";2,+
MOYX2K-;W\[M@>S!!,3S=ULI3HGSGE*QDXN5'R3<"[O'[E(L]J8A/%/B7^6FD
M^2C:+$4GZ,EHC+QUD4A0N56RFUF!]CT#_K4..8-+KRR3W?F++Y>D&TE%/#*2
M2J]QE&HPJ9F!03[3:UB J)=LT2$3>9[]\XZN]SPX7N(F!9W<#J2BOTH(MY.C
M??2XZK[[ SM%^*>+-T1<RLH9G[R>S3\)/<P=:[A^CI\'XY)@O16/_?D,)[HL
MIAC;27Q&==942KU>%R#V.<$VK>9#T>8R<1,-)!FHCXWET%N23,/[H%<[$>)_
MD(RI"%.$F22G$[>Q]<T/!AD'=3^/YM%;DC*T)IU40>3.CEU[?B/8 TF5GOP#
MYP&=VCA(8N0A-"A))*U$Q#G:[T^F?^5]T,2Y$S]C=84_P%%?7^3\4<\(QR>X
MNXO73<>BBX>*C];*I;MP[X@#ZF</-#I:5YR]$@9W'Z U*W.(LH^>5V2NG#:P
MR0^X5!H?>SU+9_!Y9J:;A75M=%*]PY;'M9U4OJ*,I7>%-B;BB=BX;T66JL'N
MAKFO*KYGG<^2>VX@U_?L63-*U2PSM/5])%NY=:JQ +4PAABH&TL7^+O3,JM^
M'TP1JH4>\WO@J&ILF=//_8X%B+?+1GX?568!OB@3Z!\M6( S0\R!=Z*X)Y 4
MC\#=$V5P*=Y;+\W>_DN/"BMB\C&O,=E,_6YR(_OO'K$ P#GL5P:1!;B$O<$"
M%)6YL0 OB;@C)WK[[J^A*4GF63Q-*/*O=N5AIO03':%$=G1_0*8GA;(_($2W
M'Z]C!.AJE,NHK+>+DR?>E*Q&BM:,*[Z],1U2&5&V_J+]S?/*X%(?S5#Y#-"
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M"Z")_-_V(1&#L !VIBS 6WUV@-T'4FX ]YV1R[4LP,)99.<H"S!^C@7( [,
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M8Q4:P25:3BBKM^[$; ]X?D=%Z[.W1G9+_G,CS]"TYM")P5(S1U_3Q4:P%@O
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M&(F$TQ$^$3[O5K.>HF,0_F6L60Q^JY]:,KG.N/C](R0U.3)KD"81P00=*6^
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M4G91=R"*<W7JZ,OCV ]18GZ7)^Z\,.I^X)"912A*QPLL.M8=27,'<H1@ANN
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M1%]N;CQ9DW1>2W==['O$2.O9HV<OZQ6]<Z5;'KE:V7Y^+O>9R(E)!Q^E;(@
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M\1-43A0K+"5P\VNJ!;U)BGL2L(J<19(71/.<7N=)58ZZ=@4W::[5%]'5CI=
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M]L(9%W]YV=^Y*/:[-:@"@.>\!Y+9ZVVTHUS%VTP;.2!- &G9]I =Y,LBL4<
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M*EIMS!HL_3VKGI34OO@R4#>7;ZV>132VP=IM!=U'<-;6./@6.,L<_P5WC==
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M,T9V &U#1UH\6K4V+ZVMZ/4O'4^MJHEUSLJ(OG' 1R7_/-_4.EM,D'L4RDF
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M!AS1:6>F@)I4"<EPF'%AYIX[]N65%I?/0NJI;9/^D895S^KQ^BU8/.SRDJE
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MU :#@FXH$U),=BE(/T)@R4SNGU@@U)(C5D+Q7;-%:A"[4!T@QC+Q,1$.S6]
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M&1VR%>AB87:K K=/SK&%%<\#V92<L&,(;']U++;7ETL7JWN+<.(C\)VRQ&<
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MAY>RT*IH]Z+D[K($%UP=:ZC8(>P%2]WZOL%=?QGG\DA[6POF5;>5(O"O_[)
M\,]6WCD#L9;(EC3=CCKH]Q0T:HF@Z(^1_>B!N0*\!AJ823 (FSP;-KSJ;;N8
M4"FC7BF84]N?O;WJ7<?[0Q[L3_8*'?R7'_74R=>/O-N]7U'V5+C@6*7]N8M%
M246G:+55'G4>&<:S%TL<% ILLQY<V:)]W%Q7[<K--X^#=1*1TDE5J1U7*X98
MO)MO IWIR>U\W5[CKP/%MH_]G*H"Z_:5#Y78'^\-/IP:]+R;OX[X587#[UE
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MM($2 GK%7:;MF:_3X^)C#CH7'GO E^IV7KS?B*]R=NBQ- QU9C4JO^*G4\\
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MQA_'?C9@ETGR<)V9$EN,<K_T6O$%:0"YCI"&OWWQJW#5.F+,<<)Y'7%2DG5
M:BT#_A?\[0<-++<0*PRBR*XC^NG/I<1L^+;5'.EOU  <>(PF3 0W^4>$7(D0
ML(1LT!V(&UT;5'K3^/H-F!L"<%K_FISP_/M,Z"=/FRJ]?M;O,ON2G[?K*IY
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MU=N&1.-P2^/+QY](/K4Q'!.XRDO[N_.QB?,Y\N"H)LD#-LV\\&5^E!A&22+
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MI;^47/(X.9DBR72YY#@PDJQXHT^U**?$RJP3+C:/G@$HT">Z<_&1@O3LM"T
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M)X NTG[-N:5<,:<G $,Y>_S.QLW)M=6,?P:7SS"F5^S>OOK:$Z)7-9"6<:!
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MYX!!Y(-$MW@VAC *_7'J?]\X96_X_\NSFW\O( _GD-X>Y-\I]@M@OA16MYV
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M:%"MZW5%6<^]1H0F.S.2?V5:($-%J/?UU I)F*@1R##]-:S40/Y^W7S0CCK
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M^K '2:K'QZ /;^*C&?*:$\6-/@@QS@!2L#H ;D;5$C;2_\2Z1#6$GSWN[?2
M\(9O:TC"ES&[G\N2=LZ8DX2U<\BO>/+B(]PQ6FFK/"_XM[6X21UMZ!%'%FO6
M$<E#LX_3W=3^ZBTO0DM-\RK AIK67K#4J'Y1[,/(NGI ??8Z7]8MJ3*>MW^W
M?64 (+R)<TUM?H@))T21=JM;]+X<B&-)<9WDR91)Y.KO%AU@&4;+>82L2(0L
M$EWW(,=+$[A\XS9!VIP).@=;B.&"1_@>I._F*FGU*\< 6$(]*>/9E>("T!1+
MH6(9]A:_FDL-]];T'"9J,.T&R&RGR[43C$FW4Z EM6) U;G8)1.Z!SD8PQ(:
M;#5-M_PA<<2E,W7?#@^7\M6Y-PE&WM("51=7STBL*=)AC,?L5RPINL%%L(XZ
M%S-[AI;=X8HFNT3*C&BR#',TFPHL!4L3$+)@MDMCK@VM-&'3>":MT??^B<G3
M*,57E_QM="'LC#U(O!*7:?-)F\&D1B^.(.<@\">G 'H%U.#.)"2R#?@W4INE
M! X71(Z0&F8)U:SCX(MY5,*N9F:E[]R!U*?ER[/[Z-:9E&8#U/C^['89YXY2
MMUF?4S/HB/3EZ<75D?X?+B::O4(\B\#_X@P7TI4T/TG:.>^UJK4'<=N#U(=R
M&H9Z^B#LNVRNR/GQURAJ,0W0*:3=*K@5%YK=N6/BDGS?9< '8)[6XHK791#D
M.P=;JN.&GLOJO.>X7T;@SN]!;L*FN-1W#<7_A9?!51*\M[!F]G0D2]B6^KND
MI"TH4.)QRPG</_0';QNGC'6CZ!Y<:9,51G6ISYK8;E&IR?$KC#ZV?RS7_?%W
M"#(5#QKD<@Z&,8_]/1S6(L,9,6KJ'DK!R[;(LBZ#$M2T?WT8'#GPVAO<F8:W
M+32S-%TYI\7+$PTR2 E0HNMAKIM<>#M'L<9 OTE_0OZ*^'#8/_.7-QX!E_#T
M?^=8(I.<U&S&9^Z=26U03M!U"- I M!0Z%TC](P.=[;<=4?N#%SE96B0JPZ-
MML_*?H'KN"MV3B#DAH.K#O5A&E-^+]2/J-\<72O^@+WU1.(=UF^XU+L@5O^_
MFM237Z*O"KZ!@).<0US-?W*;_9&T.@#X<%G1QLVP $KFX0AP<S?C';N!M/J-
MR,W1BM.#CY"O - HE\.WO0<1S./^]U&Z5A>!UQL_C>;^P:V* 5LJ(49^8FY@
M;$LKAM(N@TIM$8]I[ST^A>?]^I5U*5WREH'$A[0.#:5V"53#)UF>G4HNK7 I
MJBW,GW0[ #SFM=9+TW*@WVQD%R"]>.,NL5/$EW\)6BSW,PK'0UQ5]Q5>4M/^
MF#%OGX;NQHMM_?LNW;!X>"M%[7)# K5NXQ?/+SS(M3*,?[([\PW!/UQ04@43
MBGN#,/-;)#:^A<?--U"7$$35$IKZBL%+$0.\-%I%DIIA'08MLC2KV K^;\YS
M9E2TO$_MNX^C)=<A[.O<DAH$%D3F!$FKC!9A8+D$9)^3([&DJ-QX/4(QC9 I
M^%T_FB $.(.D!4FLL9DVG)DYFJTY<CX3QH.SJEY"\[($Z;QD@]84&#DUBN)8
M[R="S5[;3Y=&'7(1]*!(9&A451?Y%6";NJ;-'A/U7JVDH[TYL/>T[^N)[I81
MED[OF"=Y5[56F[E+;1?9S3E":XD!F,Z<84"V19MU4=_N#S;*##0/(@,Q,/ZJ
M!K[,VQ]&[]K;T4@I\+ J)P?$W;6&1KIRS.MQ!1- \W$Q<:ET^E'DT;^OB$+3
M+.= Y766".]%=CQ1CBG/TIE@B5%)B7]PH1,MBABG[4Y"/ (^KC<GB#VMQ<5=
M40-&I#I=LZ30F\JT[VQ1P)S!&13Z0'%?EOD ]26OVT\A@-\<S7^;58AA<-56
MK5D5L-Q/'X< O'N0!EY6U109S[0T6.4"8(7!? D$*,7_?=N=TG<FMQJGA/Z:
MEC)YTCG83VYB';#EENG5/8@WDGDJ+0&]^V6N;C\DPIQ;INV_I)M)W=R!;R<J
MI5*9/':@(WWTW.C"R<B^$  *-I$9195FLL^G_?=G)]3KO]#)3&[]VG'G$;(:
M!AY=[]028%ERT^TL=_YGM^8.H5X/>!1%#G#XP/"RZA=PVYX 2D#,L ON#-U%
MPLV6E%$.M%\B1UBXFO+I6\I]JUV_].W5(Z1S&5>& _/<!$C(T>K$@UKKW24T
M]O?\PE(6@FZ_.DX;=&9*4=_%^F$Z8(=;9/HIX>;R*B>N$[^P4.48>=FQH\8G
M&EN&JS5^IMQ):7\$5(5 @&?K+*$ACET:+93]THPEJK 'N5ZZ=OX<;+GK'*S+
MBR7/=79*EY@P;IC&EM&[Y7"N0RDCT3!:K((>QJD]R-NX-;4]2)4KO>41,A$)
MGMR#K"DPT7]??,/%[=IT3CL@2(P(*F3!ZMB%."^:V3QO1_B<T+(P3ITV%-=R
M!"\R#<Y0YQ*#,?_\AYE5&B-JD;4D66:DEG N8 HY_#K2-8^&NE@%8.XV%<!&
MMENUP--,#M_HO)6,939UL3MMVI*ZF$1I:I0>79)>C$$(L1#$#Q</+&S.\?_*
MEZ%#DS=_*3U[Z_"[19E++ BGA'\+?]R#+BAS#GNS8P$/&%>ZK]70PAFA[.1(
M^5D6@K;-TH'&X #Z<2ZX]T0:T==F2ZF ",X<+"R9GIU=EC>B:\7[!Z]0R0&"
MW@&:N46:F455Q0R#:U_Y/^:^=^%AF^U!W.=V3A.^[D$X T$,8 \RCB+_M:.Z
M4/ 8GE4%FU]G&J:!)\TXY:CI)X^0XXG<J V!9S]RKB0QN)105SY&VK+!]CU"
M@'_Y%&[P!NSG"'X&Q<B"!S_I#8EA^1DCM-ED=T_SV(KJR"^D>J47I9(O^EY]
MTOQ=>'*PK_"MPR.^ B@UCB,H!V:3YV)(-$>H -:K^[3/KG4AW6,>U8V/SI?G
M?,>N*C?1$Z&"($?0:'0MTCS)N:4.#*GXQ6!$:PR,9:<OT;JW#?A$N%9L "*Z
MC\5-_K;?I UOH,:+_3(N&;GEL"RZ;W>-6RM<:.CC1[H#N]OL(M)6=22"Z^K:
MEV"UI1US*6B:R[I49#>I/C01[DI;;T,+D^:Y]E>2PXOMZ9*7)@ZKXQR+EG/6
MN^:D0(^.)B._[83@ 8S)GQ"HN&7A.7^MX)F9\(]J4_*36GK$Y7WL@O\U^7 -
MEY#5WYH"?BT!=X=8,BRA/<BBWCD8$4^ST )/++9!P1/HMJ'XN?V< ZP+8 5=
MY@+X@J[=HKQB1.A*(AW\[LMPJJ$U/B9?&MWLF-^#',):#^@NU-%8$LIK=DWV
M&D&!FIK_6CPMX$T"VJX"\X^!MRB6F#X%D,/9T!KK:'A&;)JEE7X/(P8\J_2B
M$!RR21V<-=2M0,7GZ#'P$61"PD-_O*QXXW_F%,&S\!L>13/5*5S$O5 [_68?
M2X([<*XWB(;1;%#@L895=*-6*Y"R2TKA0$$UQ]$U!7;Q'L2+C>J"\4<JXDX;
M=9?LC_UO3H0EY?7FVW*D])>0[^:5P7%CFVA1[&1;ML%DEI%!_/KF2I['E='U
M<\@Z -3'<_AYZ5J<0R7,TS@KVO;:X9R0]35EIN9*OB!7B::Q_(I\IOT32G$H
M6ERG&O*("Y:W>]OHP//&"6F#Q&)\6[[:,,[1LVAIPNG?26FWO"J?!PP%9[SI
MR"-D\?+_]6$5#^L/,/\>V'A&FH[C_,)SZIK:+3CUM'[.Y>0,#A<[FGKP^8OX
M#=TNX!N4;?8J\LKDK/SE_P%[___W'1<YL6B:"6KG4NE?&@RIVX,X*5.^ XI@
M[AY$L25T#Q(\Q[Y^$_JE%KDC1@9^(SG%=DC'BODAA_\!YT3^9UZX8GMZB&/5
M3YED)Z[O04H8>CO(U+D-+[CY7]XVW(.,^<  ,IKU,I6/^T$:5Y&/Q>-S2#0K
M[+'W7"NQ@GE>E#]+):=LBK2=5G]J)="B2/MVOTO][J%>V?@N.4DQSUO%0I<)
M9%2AHFH(\1*E3Z^\O4J5R)=<8I=YN7RTW/IUV%/3X$4^-YUHRC=/*34+C=+@
MH67N.&07+:/>/2@YTY=G@;MQX=[+$U1#:RDWKY.#1U)*I$S-#7N-7V?8U9!5
M%+F.JH%IBT!\]2/NIV:97OT5$((ZL.PWG,3+I]E MKKD$G!X.+?AYFW5ZKFG
MY;>X.GYMRCY5Y@FVN52T"&ZJ%5VWO]86E]YY1U;YQ:^9A5BEVF>>4A=TD":^
M:4FS0BNK)?$4-SGKW?8L6/Q;Z^UMOY/#[8N@C#'&2/3'2Y<[\Q%<[-LO#U8<
M;J; _L6=_M)@N*[;+&&%EL2@I[9K7*:^+^>P5/-AYNE"RW=JODRXFO9YOA@)
MUQ(I3DRNDLUD$D;1G8<<JT,[9'FS*$N3K;?!DW1]C#KB> I.[VZ_08FJ(URI
MH$0UA'8&V=1MDU/>Z\S;>?WULZ)>A0W"*Z[W0^W+\B(ZIW189&EI=Q+3M!AC
MOC95EONS!ZY_+N'5?[9TJP[F$5<N;_W0(3D_\+Y5G_8Z1QFG!SOT]WGI WGY
M=PWB.1.%@>0 $?"IT]2:/] $-WDSC;8*B!"-_J2E6Z%4,ZRD*?2TI&#C"R1S
MDW/TGLD\K'#0->/6J8V.G^\^!P@L3OU0_9(*$Y&=,1X\]6[YJ\OMXPL#\7VT
MK5-3.N4J9RSR72U8C3_2AFAQHD#5G#G\CI=%;=6C0C-X7^W["Q45YQ=VW)S1
M?!:-TM:]UWINQ-SMR4(LER>7C>]4VW'%&5>X]*1UXW>9-%Y. CT%]<4$C%0!
MTIZ0-O/5]'8=]B BC[B(W3FW:W=.F27ZD7(Y=;25Q%?Y>N?WB8P>Z=TP5.<I
M=H49;15S3];T8GK>0TSNK=3Y-G=M[0KE',Y+^-TBRV@XO'W<95S1/NE/O):/
M5'>F7F+??57<L&^FA=ZR);S"+7FG1/H=7/!ZT>_WJ&&/F)V*0*B4?>GOD6C#
M<(V,'X$AON$"D3X(N_=DFTR]+-M2&WV;6&4QZ_79:_T!4_-X4'G5MNIE%85P
M)M)P+=5!>2Y ]\*W_<\*O"OC.AJ3;+-&Q 7T)',5GW\@Y2%YG7=E1SM[!)7Q
MJBM=*S95TD_++Y3 /(;"+EF(<HN.%R5BR\<K!7B/V!,GCTU!CU1MII=;WTCO
MDS,@CR_;!CY3/I0_,I&<_@POH3(:$Z8685WR.V,[; A4&NHDK9(DL4UD/W8_
M/UK,03D^^&1)]@\KS 5SB6M-#7&<A\O2\(&0^U3DQR^4UBMGLGMVCP22&(!H
M( Q"63E)?I?$(_M')7K!NW).V:U?[D*T?1<:]FS2(:?:OD$@QK%[\/0FYQE.
M8XN8=H*R>E9MHI=^OZ^.S]0@H_^/VEC[C0K-9V^?[VHF&X\/Z(?ZPYM8HMG7
M/KP#A\DI"/,2_9S0#O;9M:I^_#%%XL16KZ;_$422+L7P^(M=XH/&Y<AY L]2
M75KG)-WV1/^B70#OH_GDQFKYJ(S@)8KVU.!#>@A9ID'Z>2+VKIQ1NOD9,WYS
MXXV+6YRD=T:Z[Z!ZW=TOQ16DNB0_A& 4F;W#[9[O[=^6J(3$J$QV6N<  A7C
M@#<;PH[5M3*XS,Z!\P:Y^_UK(,WN26BH<L.::T24PX[XYCA]&YPZ.B3^HF3I
M0QC//H7:E(,"Q4T,K6'TR;8%MX/W4J[HJ9XBY Z=&?@CO5DHV2^13'A)?;NY
M3#E!2G"*14>W+K#69Z_?NUY.>@P;R#_[T^%E3Y>F0LK#3$]+3<Y0_[WK;ZSZ
M#'%Z B1!F^N_2FDV54F$Q.[[&F>K52LYPUOC@ D^%9](HMGL07;4(O=S 3B(
MEU,\>XRPP5QJVX,HJ\4B5V/; 2Y>QD-_#[WJ83T-XSKV3#%@RS;S&4(@<I:/
M%D3FC8N4GL;I^079T-8:B5F["SV)^S.3)XU:WE=B'FP,E/04?K.^69]A>UGI
MR5F+,YKIO+??U?M</P&&;+Z+E,>&/:6YR3P6]TGY1'/XK"<[0A)FV_,[52O(
M)'?;$NSWH10)SE/#6:JJ6*Q'D6I?[K7.X<7%8G#HUYJF-E5V,J$BT.6>Y-U)
MD3@"7 S^8I)@D2>K+R-H=*^S7[?(:M W*O -;>U\KX$%CE@[3_(<>H(P +?H
MMR8IBNP/)F1!B>ZK_P=[[QG5U/:^BX8?*DHQ2I6:K2!(5SJ(Q+*5#0@1D%XB
ML@$AT@0D0$A4I$F)BH""$I$F7;H4$R$!5%2D-R$% >E9BF%)VHUGG#ONN/?\
M/]QS[ACWT_D @05KSKG>^9;GF6O.]P7QO=-;[Y5<MZ<?(O7:])++O;2K[1.P
M:QF&?Y=+Z(W3PS0.SPT+ E#7/F;GO3]'TR5ZP0X]I9-Y@(O5848FJU1SB,R(
M4G!?B5NX6"*4ZK"?J'^BWNQ"%;G;[\='Y;BKVJ-9UG=Z&+SJWNQ3=#YD_VN3
M-G%Z5?N2V1PL#_$@(/)1U1B95I%<Y(8XT>?R2*WR2X]39IG]&'?CY$$;IS*1
MW6FUJ;\&0<VBECA3"BX5JQQG6+$\M^_U^/,,V,V?GA/A:V'?/C.LT$:*1]^Z
ML)_H4(\AAK%/GSR+_QK5_<2(P-;SZ<G]:7%P'6G^^82[MW-+_:;SNPA4+-9'
MLND&2'K1NB?72HZ!^:R9@ G$G1-VF4$&Y"V,1DK+;#86H=*&!Q)GUV&M.#]E
M.?MA4B!NEZ_[3)R<RF$2X-M2_<YF-K;2FA'J?,XN3R2Y+__%<NM+:8A_:U:V
MSY/"G:3ON;FT1CY$&.TODUPBBLY<A5&>E <Y2;2E]XTPQ,D:%9ZQH9IDW0\W
M.$=+ @92LK,=+G)4E\6R>_TM+P]>NZKUH4RG22SG2L3QW-IS8I85^QY_?J23
MLY!G>KSOJG'G8MTO&[7X\'73%^ZK AK%A_1V*E\PSIN#[EJUZ%'%#2ZE/N?-
MC7QX>D<)&=RZL-=\-KMKXBOX,Y=NB-O394OV5Y4?+NXQ[T/9%5Z;-[ T:JHA
MHG#Q12>%4I]&SYF,+WT $7A*P-S1"'N,T=,0%X9.FWYA=BW]IR<P<"*B93RG
M9U[[S.J+G! 6_,B?0*?0LDA@_[V<9])[5V$[F6-?OJ+H(-32UL";RH2K:K-F
MM89N=?\>@QXRYMWD0D],9FIDN8M*_SNF,Y)JEB24<6_:/3[Z6F"$TU9OP&1@
MV\0FGN4V;"=F?9">=Z3V[Z=,\SG'>V1B0[7YU>-.;3[7_+5UN>'%/X(XLN\N
MPD.HNW]G/0J_C95%Q0Q^S>!)A:>E?;WY<?G$MZA-9"=7X\^*:FI>V\1=@QFX
M_CJ&Z[6@32(\^)9XR%/PA[C'91T,SN?50;9JZJ^I<,68A&AXA.!YGDZG/*C$
M4JA-WW;4M,.#H4D;6^RT?&)]&8CW&FE9QI?XK-[L2)Y:)L!5Z[QV"KOO@=>M
M4Y1@EOKZC=D^KG=_N^2/1TRNN<+D$]\L993YO/\5VA(] L_KNE:<3@:+^P[T
M_DSP6#1J.+ 8BW/IO1+Q^*DDPN7#JYAKQV[>LYDJQ_?Q(9E((1*M[B;1&"QF
MA*KVDA3FF>?;TC$!=<L3TZ;K&B7!%A:@KX3=)5)+Y_"6#/BLPF=Y.G[YGQR/
M9>T2#^_IF;3U/<]06AG72 7HU"3B_56CP<C7&/(]@::X^A=<?7F9'#FK8R6W
MHBWC6ZOU^/J1P9>#T-0=DLY+>IY"YLOAA;(U33.V )E>C-B6YZKXNCRX4DU#
M(]CG%Z9<9=_H((3&* PBD?DZWKB2$1F>6DT^F+;3;X2Z2FSRE*GZZ<+ZI:H7
M%P%G7MR<1K#N FWKSY@E/2K&(!7PZL/*3JSQ#I^I!A/^[)"U3H]&C8[P%,$F
MKX8XH_5PEU%=UP0?9[N&SCN+QTI>9]$F&]/*GAS]@3DP;Z7_$6-/_]IIP"@Z
M\O'5H7=!1H"[SH#Y1T-QW6M#[W[J^&A_Z;NJ/9*YS#B^%=)3JJKP(&+!^=)3
M.MRMCR=!5R*1]50_&FS(TK^VP>X4V3N+90W<\&[3ZW7,O;ZMT^.R4'^'?.DE
MW5DBO=8V>DG3^2'!,.FIGUFBJ0![SO(ACFP]W 0R"[8CTE/ )I7%<KX@MZ/Y
MD,T.#&S(.LSJ%QW)_0U-X4,"":!F?Q]A*I]N]8"9WXV#6BF!J6>&C96#G-I&
M.=8!C/86F\#Q\%)B>[:'4;UD<.L%L[+[I4=.NERYM4_^L6S]!S/M_K C-,LD
M*/G)38_[C(C7(6 5LQ:?<HH1H.,3-U%06/SX4L6 O/U+ST=(W?K8F]B&/N(N
MYJ;*$IBM]K%)B0^1N$?YTN.W9*=?M-OO480[VF_Y=14H?MXA^.R^S[\\%]\\
M<GG _LV'[-KF5F.BV#Z8HP 2CTF@PZ&@VV7F-D5Q<^^,-3VM!1V=,7,2!T5'
M>;AIUE!#8H4OI=@'GN^8BA]2C--)NR,;&(>K[U("A T Q92&W^/!=]]>6:4;
M?KS@MC=@B&(-M3"*D _3,\1Y4*X&K;<#39GKCM8/G)N=%V_P3@,Y9$X3.?OH
MP _O:KG'5[]?_:%CA7+RR"%WG;<8:_A==+#;TEC<Z%2^NJA4\G)4E&WLTYQ[
M>'K;^H#AC "*NFX&I=U6@Q_D0X*"_8^>@RS3J"DZI=7_J3'8XW+;]?O;I'L\
M-^!$RU9R_=$N=,[M;ZWQ_5KTUK:.63U"'->9_H(TM'@GOH)L&4TH^81^!B>/
MC(6A)];]F8,4ZJO^]9*8EZ"X289?";K>%FQGIGQ7J_V7J-PUAG1^-:Q@KE>6
MQX<@OOQ2]+'KWGEDVO2@VBLX]C\;IJW$&%P!(*S:CW9C!-@^.8L.<;^(A:6!
M(65E:WFBM7&NQ2G![1:/(G*7&08=S$H30#KB1XQ3,BYAV=)J\+B*%CKH@OR;
M!I<3:''K_9&Z>M?8;EDE9XVT&<X+ML\P/J*/,>/)MI%V$EX'=]M4?@F#^^.Z
M?:PTT;CYV![<9"%C(OD)[A4GAKYY3^&K+".F/>=B5QX\I2%D6OGCLI*F[D92
M];G$%]3W2L%2OI/><5?49ZDO$H\8<N2DO_%D@/V^?,A4U/6V],A+J09/7UY>
MI+]C1+2HE4BO7@&TZF1;7N2WECAJET7]'"PAGLFD>\_W^BKWU[-J*HSH-3HK
M-UY;'[0YEWXTI7<DXU%!2:: )&EE?:,VU.Y9F\6/\"&32SQ' @W'/H([B-NJ
MZ'-A\R&I\!\!!GCVT28$]SOL%CI+ +$Z!4;66*_-^?%30$+V10FNS##M>$1+
M'!]2-=(7PXFAN7&>827XD/HI$J\IKIN;.M_/*2@2T,+Z.#BO>>K$+S>.G%BO
M11FU?_#NG-C#0 N])&86QB[@.G9EI4@32$V/GG6@[2>\:69F/Y"-7]RCG(Q-
MW2KM'Z_N4X+GV5"A=^@MV26PA?HG@>B=0WFD?H163WD+*/4#OT0ZW[5;P5N9
M(O_4C7W!-#W@=LU.AWF@VZWZ%(0;UO-)JVZM7-\VW!%.>X@5_]*ESY;D6(UO
MO50X9<V0)<T/RH)YL8F+JZY- +:>5NVL<OK$F?U)=&45(8C.G>CVIWX;_];/
M$O'F-^5VT[&.]XKM^UHCLS]'@LOFY@D7SRL-RN0Z/R0^N->]\-K]QX6AQ<PE
MP,$!>9=[^*>2JVFO$G6?;\4I<8)PSI7C)VST@U+K<^E1(0]NVA4@Y)\P*CYO
MZGE<D'.\>W#' ]E&2"4,!G%DR*QC8"%C4\6:;8O182Y6S/MH;9(]7?& U.DO
MH>JCG/,EOM^%:JYC[$++IM/#8Y0EYR^@%'U.![/R);]GE7JO%"1)6"PO"J85
M;W5_[E!0>TK8ZYF_WDY\.O[KE?MUO9BD[N$B5>7DVKMO%,QVT"$A+I&';!\'
M7<C%^<D/[F'^H+C:05UCCN'\N"H8Q+M&3I&W%&'^U6]?]6Q3J7OO(Q]_N$^F
M15X^<;/62\A9RK$O#R:'D*X>?[[Z^4"?SM\1HZ1I3><4U6_U4U$\T7Z@GX7[
ML@5-)9H-19,RJ/LMS5%[<DNG0MHDOUN9,GE902&ZT;,P&\"EV?3FA*?OXRI"
M8#.P/[7&MZS4,=C5DUA8<298AK3T563K#J/H8,^5'YA!L12&9<YN>S_FZ.IH
M'M2HQZ]R^/(KT-O$S]ZES-)*,8]9D=G-0-WPDD#(G,W4U$(61U*'MI-?=\IG
M?OJQYJJ=\K,KU#J-,E;L8/:Q7B:]TF6,<K7!/,;:H>;$H:+ "F>1+++C$A\2
M7)E,<7T6C-AQYC[C0ZZ14I#-? BY&I&.%&M1['QV=&-A^)>/MFNKG3*.'#_6
M=0D168+*.X&(V67Z8.;KC+>U\;.%]>2Q+L ^.,Y"=HK;U-T5_"!RSAYQ\AWJ
M<I'R6![L8"JEQZCAM=)EU7V#8IDE\F-WM?ID-$<=GH5LA3@_U7*J=9)T@J>_
M'KSS<V[7YZI_G_Q2B*!H.5+\&LR"/]2)P>X^K=A[E1D3).K\3/-RA6MAEN?E
M:J=*A^A5I[L3:HGCQ)K?__>]@\(%0$DS=C_@7V)@@4;Y1$<?]9&/[GQ14V/N
MZB3D9+[KWYLUD?M'M5M*+H<832 BBXIL'S4]+3>P=<P+NN64X69OZ:(VXK!<
MWAQ<BQG\Z?>G[.8]389$C!P#ECGFYCZ:>QF-=X$(Q1V'",7>[L4),YIJZ%<;
M; +;']I)I=GHW-14RPTN?>BB4]/I->2CRGO,[#(DPUW)N#Y3\O2E%Z1OUKEO
M9,QJYR0W'19-.;K4>[@M1\M@/B19O98/>1^3RIJ+Y$/.71_D0\0 '.<5E>M!
MK]]1!Q/X$/$X)!]B(/(_W!.-"UV";9G\J5U DN-#!H3_?[E%;FE;9*>)#-^R
M9V[S#OT@\?Z%OX*#1Y!K#P!A.K6GDA2,S]II2P_'Q $)%].M5,!PBD5V191&
MLM6A#U]FIU=-\]I&'B5Y */ N<H9RE_Z ?3"1!7_&V$QA6QE^ ZAQU?IXRMS
MY\&HF@LFK2=-[@8DD1F 3%67N@_@5)CL\?YLZPG>K]*<+.B5LN /$7AP>^L;
MD'2$H:=51@_?3;N1:6+7_;HCURS?8.#X(26=)BM-QV<*3ZYKT:^-/&)BX+;.
M9)?%AZSV%DR,O)/CP'?7ZAT"^Q)V%+</_F]X<D%;+RYCFC;27&W/ZM#+N':U
MD&*E.Z&@GA J1IY.>"_?^88 ^:3]J+DA*>;3MR\48=/O OI](."I<;[+QY^>
M*[FBV+7#BK:M1YKKWY^#.BQ_KID>TI7L*I\_U&[]&]Y#$D63^U2T>YCY(E<2
MB5HO7'Z*8U6+BCP>+@!/_;U.? 1.W.5FJQ0^S-3L,:1<1=E*'V^N&G_JI\]@
MLRA\R)U.["BIQ:J^)KA ([U%/PFY;T/M=>L($0;*N72\:N\<GO6%$/4 W9?-
MHYQS,3%AZZQ5I_%I]=\F9\I>9JG5?]O0 A#I9O?*;-V][;T+=4)?^AUW4;88
M.]RX,ZXE6^W8 O3LEZY;>S%\D0\)Z5+<406=Z590D71*P"%?(\9*9/)%:TE
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M OU*T3EK$W.ZHUOKIKP#:=$^LO#D'7$#FUALT2&!KO^C/XWBV7>RD@1V<!A
M\B&73F%OP3]M_I<.3> P+2 \90%*QH,6=O,"N"\8#(F-Y W Y(G[T$'S2VN]
M@N?I4]G_BJED=:@33Z?V"OR>YRIL'T:8X57:.E':.F9I.O],9=5CW%@,* =3
MK4>,2Q//?R)EEHSHZFS=@RQ;J0N>=QW7T%M!]G'8I$VL9;$OHI/FQ99CQ4I
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MBWF]!-8-%0'K&O-_>4EDM8VCL,V''-/A)O,AJU16-A\RW@[^/@VK)0AFAE.
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MXO/QGDMGAW])XQVM8$S6L[J6+A/L7XW!I^&O_G?6AO^=M>%_*6M#-RE$VEK
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MJ\HSCI4=;0VEJRACO8,/?] 'H<.0"/9Q\S]E#JFA22NTG5CNCP KATC^)^9
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M"L5/-;="WP^I*Q$+4_!NO3N0J(+F>PE_9/G_:1PV"A@QPLBT616T*?#IWW3
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MW.KU+]6]S .S=GY0;O3D7;<P!5K7R GI#!,MB7;9H/N( TF\E'2Z59FU.?4
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MC\*OFW=,R97P[161J!?%\"^3#$X)!!^+)/U2@D##;_QG3&?]/\S&G/'#NSC
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M5DY2W]/H #6T25@J04-<^D.?=4KJ-,R2H"ZE=Z7/I%'A /-@(F2)V7 RY*[
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M^U@*\Y;F2*G 4VA!9J;ZN*GJE/"37Q$+<.5S)M/"K5KWRT1 ; O.JJ&7YMM
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M9"U0S(_>R7]:?RZ<%,?7\SYXUC0N^DZKB[=SGD1Y=-(5"1T^/4<#[J/ZKQ5
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M>@\C!'2=QO,QSC$KT88J[2KA8T/KR?%!5)G?QA4Q)(\6.7>X1SPB<^7B>QP
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M6Y&M@*A(1U !:0+21""0+0H("$CO9"-20H1([XF-(D64*C52(S5*[U&J@(!
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MA#2R"#G00Q7Z3-%G -J;::E:PO3!T%MY2QOS-1)OK"V(EVO,7*=Q/>V]RK3
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M*CW*Q)8FCYFXS'H#/FJ'[@!-)N*B-S=P.6:KQE@&P /!MVZ7'C=0D )%1S$
M[*(CM6Q;/&NC3]YV5)![.H7/-9Y2C^L'<WH&*MZH&W4H")^//')0L*V45RQC
MD72M<1$ SKMSQ_G%>XJ[!YV]M%&975GX. =K<C>&*)<KD"8LBXK)\JNW\R^?
M"4>KW?E%BK,K'EHL(+F1!='P$0:@AO?KSC.X8/;D.H:[!8&;9^4PZ565RH<T
MY5!='(CLX[AWJ#K"=E3FF\: LXHM:5/A'Y$:@/E:M_?'(4Z."=^E*SV<;QY
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M5J)M%->Z35.#_TP!3Y%1Z\SUQOS<N7U8WVRMCY>M,D)OGO!$8HN_#)K+2ON
M<:T(I$/+Y/_PM!/I&HHFS#@ 5WH,B= !)D>[# E\]ZUG,]2ULKZ8#+5Y,343
MPE$:G&7?[!^+7]=KH@YU.51=(O('>AE+ >])_TWDD/$S3BAU7IHB%TG[E9V>
M:TGYD!9S+"?0J7;W0F1RTTO+DHTJ9+-RL[@X+\I6U36L_[@>_2VQY!]A&?P;
M_@W_/X8_U%QC_RS,#1&-XG,)<<NTML''2F);DO1%SY<(7+FQW2G]4>SM">43
M761>//B9E@3DL G=L</[2TM^=']6.T*:OGH7$W5P8V<KY]U"PX7/P2U?V@+*
M*^,XMLKT0ES%2$E=&O6\EP6@$\?T-H)&[%__TU@1]B%"\>F1</9P$)&W$\SO
MJ"R@&KTYY0P[W8T9JST#"D)Y-#G(]56OV^4,OYF:=%Q\<7DG*$2E-J%UH-.2
MKU$Y'?PU(")PGHI^"N+!N,.BG.1IS7 0E D#;?)%,TB.<*5R[54CCT.(P*MQ
M,]GY:#H_A%.Q_*3.2(7XB\,N67;%V9DI8Y:]NZ7!Y= +_L8&V9>L2*,'R9,;
MHP<&7^ 'I9$G+%@L3UA: "Z=> 80 K "S@$6K"79_D_VT!^*964R'UW_MDQ]
M)MVG^]L/.?_T#I_HR^P?K"E&5\EAE2&1* ;@E8E]2O)Y4S$[MP)1N17!.TFW
M296\IVZ\:["R+7[5EPE1J2VLWQLU'J>&K6>:VLWW']-K,3B/XRIU@]=BWE5Z
MU\IZKMWT]_=I=.3W+2\O5*S*/N^KR.&F@/V'F&.C_U5SC+S'U*.I9(YB.A94
MH]JY,[ECSK,0;DU+AZL%^]UO:N*O'Z':P@HAF8<O5!KUU!Q9NT.U7I9O]5S_
M<J+F;3\IW.6]B73_T\9X>7IOUM_2 [*K.H,/T49>5 .N$@[ZA!&GJ/2'S[=C
M&X(8 /FGM8L\)'-3LU<M1V[)<QJPO*.,<H@ *KHVPOJO\4UOY0'WNUAT30+8
MJ"6^*PCEF>GUG4DY54V%71IJFJ/L0Q:!A9^K<J/:2KDB[VL7J4EI%[K<-E O
MT89F*IJ40HI;,E9^TT[]$IV&FGT(RBUS?$#%B[Y'8W*9A210#9*J(K%YAL#6
MTQ3) $Q3G7&)'/+MB3'R8FT!."*B0S.7/XT!,(/K35.-\NP]G!3>GTQH$XW?
M2M0R0]ST>6--2^ZT?2.LL%Q@A9ZX.66GU<--&>/;VAXID4ZQR@R3"9N_A-'M
M\P'9?GF8%90MNED:$+Y/F\:HZ>A&:,F++5,]F=0P  ,!D3T2R9+@+@Z0(8;B
M_K+MI+T-]0SA6ZSC. /@30@_K'?2:MC]<01B'A[YNBRXX $T9>90'9Y<?$9L
M^I2I#L4=X(J8;%%[E;+8#[[I^UUZ%MIO*QYM/3=O%<D_;6C@5SN=K 4"=M)<
M;I8FMTC:O8IPINIM; FE3>LX'0O5OT:XLY)_/^+[,2&]A_:HY]L$PF-G&M5>
MDC\D%ORN[7*X)-F0>-BAKOPN7?CQ];WN3&0G:X[Y$^O NDR=KXJG7E765(,J
M?%J?-%UL!59?J1A,IYW"$S,"[-(G-G^\X9<;& AK-G"-(H4H^URT2A.]S")R
M?&C\YIK,Z/SJ@54$Y]#0Y [=<)5)NR@RS*D'.E >AO[:DS_B=6$ -MFX&8!B
M:2$^Q&&LR,%Q.CTM<?_W]:&?J/I8.A?BJQH&FLCW:R+:!#N/TSQ\60%[F)HY
M21=?GS+I<,^<^NO;CSDQ)UD_5^"3JCM!2P,B0P*GZ1XX]AL^V4;)IMDA!0??
MQGU^T<O.X)]0RH8/TRT+9FB<RJ6_ELF-/7J;V5Q;6W:H@)7&_3W0]T%,">=
MXKXE\[^YJ6=^:)UECMMM.MMZW:U;Q&#DXL-QN@)YU#P!%%'J%)QNT5A%: *^
M 8Y%/R!<3\9%:'IU9/FWQ#ULB;RPLRI/'>N9C'P0Q.52(*5J>'*3H'R%],KC
MJWJ;=>ZU@*(PIT$%;X>R]'VA-Z\\EK%VAIGU*I VZN /RH?\^MKM_483T@RS
M#S_A YA/Z3V"Z&=(KC8!*HQH'5L!E,7M< ^4DCGU">+ST0/IKR^N&VIXK!)9
M$X&@C[58*8_NI5O9;\O4R\WZ3GB6QSVO-K[RY4;'F=@O9OD;%@6],;E7+5:*
MO-T]@T/?5:]8':+7 E\*YCA_4ID]6[/19Z"0L]:>E5!45U7&&J$1ZCWT#H27
M0/Y$TV.BMW28'>*,%*$>;$PR #'6N0S CT!S!N"E H+ZS1=1_E/^:"^6F2Y_
MQ%'(OL1F"0/ LD%+0T 3$QF <PAWV FJ-)F&V^&A/F@;5Z;QVA #$PC;G.=L
M30J"H79$X%:I44'XO7&5V_BTH7N-]9$5RM/U%(M/9RXX*][/]8;A2+!DUY_9
M_1?B^DM-V[LO9DL.75SO-2Z7DM,!*E^;2KTWNWR9JZYTY%?[:H.#8VAPJ/_G
M"SEZXKRWS4T=/OL&>=9DCL@_/CAPGP43S-!'>D-;S)+@UD],9P >.GJV"/,P
M $F)H@S YV(V!L#DR]9WS(P"DL1ASP#<=S]Z/G%@>I1'3T<0[B<>Z=9O1C
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M1?Y BB*B@@0"8Q96D5QS3O1)\,D6X='TT7!-BC)$G7K>7>9T$1[]F@&XN!G
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M SEPWL,! O='W?+/ETH,4]5&2U3XNZU:\O-I:X7[QF>MAV5N83$Q,+(T8BL
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M7@P-!T,2O^K?001FV[T*TY42W=B;4NA8MC&X0(98%QAI46MDBN>.>]</9@]
M2>#_NT5+$NJGZ_QD?O-'%V(M-KH7QP#,22(FUL''=J ?HW0V(UP8FI<)B3=!
M4*_K(V<J76L(0:]:'A*_E&_7,4\ N0 3<!K\>N>:H+T\YXRC@\*1V1R_XS<=
M7\P E=/2%%^>ZU68$XJMI$RT3WQ(+PNXZ 3[3J&N"!VYR<J]?<6LMHXV1O0+
MH($J#,ID,'$_B9DD>:K)<)O4;Q1&N%*VI-?Y*UOX%R@[40*TS =),Q"[H8[9
M(',"?FHN'_$Q<T^W=D1EV@-\SG_ Q>0] U#)@GE/7F0#2EQR^YP)L48+6:I"
MI3JXC+F]FS\.FA?/M>V+UY;#XY+'+'UGE$QL[HPDM6ZN]78/Z4 +"].:]*&E
MH*N@A4^_G<!I>=)W6E6 ? +BY#[GB74X2S/99P',T>6#YQ2&Y%[&ZI9]N/NQ
MZV/G<<"2K.1K._SUV+^_)Y417Y0S90UOM^UU_22]DXDE,5%7'WWF]C+AD/Z\
M5-+;=Y22CRYHJLNU\PM1:S./[W:Y['GAY4N4L6JJ#F_PW#&(K'',K#^W0'4F
MFU<IVO!V80D"[!7&0U:BP\X*O3APEM()OPQF)^=V=))&UYJ\/RCW5_MI)J$F
MW=_\^FA3!,[A4U=R;H<CDWQ.VW=>*AOO1UD][< FJ+>-QW^LE>K)L-7O6Y\U
MI]"'!EUNWHYGSQ/2C@W@2@EY7)0?& 3U L/:-H\%Z7]F,0'E'BT9M.E.G*"7
M@F)45H@3U*20'EHH$TO6O?E^]2*6W",9 &X3FM)#^@9BH0B\FXB<-J$/I"_*
MTS\TC<%9VN=W39<0).6OB#6R""P#T> "VA2HI[\=VCN)7B_8NTN38P 6WHGL
M)L!^4NB]*BAZ[D$FW7%1_DA:"4UA3Z>_.[D?CJ+K-)@<'S 5XGW:972&)A<Y
MF@%XF:VE[.&D0/NH]2>59WC':P?=QA8N/U:+O!07HEJ7C!>)G:K,^7@W;^ZZ
M#_<FG(> C%+9RH-#12[8J 7*?@8%$:I/FD59)O88RRGT/,*=5:7X$]YF.TP$
M;$$M471I7RNKEC;YUU#=X,Q+YLT%!F:I309EQD-#:1?2*/I/X'>9DU(1R!+!
M!-BS%RA"9+!)=1H-3_L %R)7D:;$9P;RPX$3%? KP;&VK"*_2%.L42HR6<6L
M,E[LY3<MK"=]K*[==A(:+.TS4.W_K.PB453Z"-*B(A/2E/JH@+81!,RNRRI)
M_-K%7)HUYLPQX%"33MHA/6(FRAO^^U:< U,/ZI#UL/8<Z_ZW]IX,0!7FQ9CK
MWW/V3I!Y;BW%#K^S"H+ZL5..6GJ68NC<HF<S16TF[;VHMRY7Q_E;$4TV#[A,
M=LSL_==#PPTJWA0> V]H'5C5SQ<UPZL((+(JQKYN!+. $F%[XOXTB9S^!<2[
M;Z@BQJFXPGG"<T[T,6"WT\Z#U\S9UX<?Y*\ UNL,]0Z7B4NR,^M<*#7L!=Z3
M C, ?Y1P3R"4%Z/NR+A93.R9EW$S ,_4X*9[5'F1?5'T*M=.XBYS,%_$0]/F
M1&EMF">S=H,Z:>/@*=BB8U'+MZ^+N9=E\.=:B_1\N"KOZJA/GLG_.R0!NY<,
M'LM6,AK!S;SAU*TJ9\^<&@SV]*O><QB'NZ^$O&K\3.X9W5!)GS5%_Z"G@!;&
M$9PS]N%:M,]4LQ_J4QM:BF05'-D[YNAZ V'\-9'-M/&Y??.T'KY?7RB0UQ2)
M1W\'VG[,E1 KBG"^>]FTIZK,G.,2W3N>62"6(D38=4J#>_W]"BY1%P42:#,;
M.Z"R4FK,<3*QF<ZVP0!(UM ^,+%<E6#/ %B[/Y/9"M=D )+J91F TQI,7:"@
M]RZ7 ?B&YMK08P!,1D"#>$SAT%#BP0>R"P,@-HW;H<70N1B 48Y(A,@CS)R/
MR &]GI[][KA(!&?& *"?,FNW:3,>QO%+6)&P@L%Q<D-XU)EU&VB9OYXK1!2.
M+/TKW<Z[-@\:J+365)?ZT?ZVE(_K1QN'&3M'[87R3P/7SM^YEI]JER(]6J'K
MB[**QUFEWM<PX+XJ+FDL7U@@EADQ;!;OSJ\-,5 R5HRS-HNS@E265(!P0[B[
M)&:I>@&@CXJ<" >7DLM(MH3M>HH.E0N[C8;Y#\AW#-_Q(=I_>0OLM@&"*LGV
M6]<HW3>GNZY-0^9$"?$"D>,?9(O3;7\H2W%@IA$1N)T+BBWM\9(K8U?3%C\4
M\ \60,_$!%:7&*,[[M27EXPOFS:1 J37"XA\U&@N;6\;F_X+=^KP!14V\LLI
M_GYU?:9&S9X%_G OL@3]3!P#P,).I&-@N%8VDA(M_TDM6]9SSWKF&#OC8=%V
M[(J'JG I\DL77"+[Y#U66<V5BE-7N,7ICV4/N,EE403LK$'&G+UDT8 G7ZE-
M9D*(64=?A14U17 7^,NUX3AI^0WG^9RMG='4V]154VV9%09 *9G&I%:/.7G@
MG2(\RJ#G#,#Y<+T\YLA?2,9A(L/=%YMA'#43ZA*1M?,\)F5S]L%6/18Y5Y)M
M(S0Z?OP*4CU^7UU3'V%&)TUU>>]3[!T-#I_$J1<@_UYW(6!+S3LB/&O9-<I<
MS6K5I<^,IW E1:OHF>H"!W9UY1RJO"_$>U^TD?Z<9V:::N)^!KM,=I&:W948
M'S9M'K4N&LOX7;U/=Y"E&0!SVB>Z6C#U+N8^(7IS%8$K>_T)X5=.GL>#F-SI
M7?/V2[FL!?0%CL+E%TE*M67X< LTW^,&=A7:\5&V9]%<#ONM:TJ4(J?T^94P
M(973Q(!U_ZC+/:OJ*5/4J_+KJX=LX)<BGO^,[4'_K,!ZQ)P?7WT9@&4I1"TG
M;1A$<X>]2J5!<.G4=_P2-"SF )8(TAP"+4%B&8 &D>/$>]0,= OP[7]>(' >
MO$<O[!T\^R?HE'_#[P$!DE&$YJ\8?N"%BG 0<2Z#5O1AX^&6+)>8>E1ZQ'D7
MU_)?AUZ7YA^-U:S9#]8V*!@RI>@X:6ZW?65],(C_=G/%Q(%[_>H:] 3YY4(B
M+]6$";9/PT-:"1()'(>OM3C(Q5O>XF'!@78;39>2(W)[NNF"L?JNB49$XT21
M;94MEDH!&;1TA!Q^Q2;K+R+[99.T<N4J*-J"HKD/S_1O[?A]"[[OM%7"3DP-
MB.>7G?7K%I62*:CZN4:7TP5%GFEF(6D3:4%GVJ1<'G&G+$K=4,PW.E5*,!'R
MT_W54J$\Y3G@C=S'R#=PE/X%UV%.\'L8".7 F7*3*IW\$ NTQKM551'WI\1\
MAT)E:V$R%-4OZH_LRM/K[7+;ZGGVH ^GKFV/NE</!SDQ )[K)*O62\ZD>:/T
MC=VURC:KDQOR/T=)SI]HV5J"/>=*V'E!%UMLTH[3$P[N>:Q0!%_-NN*\M#SZ
M>V@Y^3?BJP<N)27H62:1]@;#%(J_0G/T]_J-TN*&AE9WJPZ\?^^5!+\C<;O]
M/UTHM0?JC@M#GX7218BDY#8U*V>6C<I%WBSO\YW5)Q4_&KYGZ[YZ/_N!F7M&
M]+>$0A5C>2H#X$3/K9S;;+UE5P_;P,P+!F&/N>Z-;:G01(W'G]BH5!9!.&;
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MW@"5*C2S;@A$OZAI;@1O+HBD3D53A=48 );06JSL0?/O_?%5IS,*U^\Y0J:
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M"95K41!.LB0M_6! 74VKN/ZNN(W'Z)5/YVFG?2U0*]J2->QM-TU+_7+ B.:
M:IRUJC"UWI@NG4N@D+5Z)+8$BN35:Z#I8VTI(=]7TH] '/P,$8! :Z=K R;D
MFG (5Y<DPYDFG7EHC/9PF6!;K[];0IJVT^Y:0*2V4Z9P&@W/BM%VQI--HB@Y
M4::!65V.1<:, J6=4-^<8I.],2_!4.^_7WM^2J7ZAG!4]UB^G6VN%Z5BC#B>
M;A#?_=$J86.8+\ _H;@0IYKP<,Q+Q=_IEE'58W$9"[QE98;<67^\J<WEPC);
MDR9!Z?1OZ=OMQO!#PL?@#S5?E.DK8UV:&+%)=<27?GKUV*\A34H)<8YI;#5!
M\,#&3[&%AJL'95Z"\N. =;#;73L[X^ ([Y?JG9S_- J?ZQ8=4BL3N5&S=3WZ
MS#?^#VX%/#]E<E<B2'U7D]S#T_"R%MD);H+.[XU,9BY7+\0=0&1UCR?9?&\)
M[[U</H[JN&F=8F6':KV< F]F;4+64Q&#'NL<JQ"&0":+TY]JQ^*276J7I@F2
M\D' W-*VTDX_>:1W6_JCLE(EJB1]A\W@SM&B4E=GDP71*MYK*=L*+COC5I]W
ME91V&WF-!@]U'>HG61516@WB1)MO9?B8#].Y[K'=PZ9R)LAMSQ&$N[/^Z.I*
MFG2:S=TN>ZW]K"0'@VNO5L.&&_FM-Q7'%C.\MV_OT-O\@_V;5H88CF%C"*J^
M,B #VYJKV#!?Q'#1P+V+7 [[*;/HO26;_ *:O"ZA_O9<]<IH8 X$,/FE%RG\
M_ N-(S*PE7RL. F)^OLK;.<Z0I2ZZG%*:U6 &H3KC?XDYM>0T"Z7Z@NVW/7U
M< Q#JKLMUUW7@?',!DHYBLN9FQ9BZ1M,RA&HI0C2V\I">^%.L>2_9\I[5&&N
M 9%%"S?VD=[E:&52AK#2$>BKO=*O?Z0\(/.<.!_Y=<G$[J$ 7>&HW. .[[&4
MEM RV,@.=,^H,C!=^W687PI#!)&S+Y&^!/ER!*)7 R7!@IE$W$S%<DNB5,J=
MF(_DW4@)K8G*JD^1MS\^+[M5V)Q7,O?J0^<D<[*IT2O84$Z)ZP=%M;*(4^*Q
M*3+S,YSU\_QME3"+>)P:+LTJ!,5HL^IY4-YN1;3+;]Y#FM3D6-3OSZUX#Q[\
MQ<9476RWX+\K<X1#&M=ZDF=KZ"^;J#4]O!SDQ-7.\B^,FUU3CS%V-([>LYL+
MO#2.*%0*',NUL @$$S6N)H9N9Y[=R&:T?;5T9$:9\1;=VQ/"9?EGBGW[LE5Q
M/LU]N%GCG:Q51-VUB%)RF5S0NLW3H"*1IH=,G)Q%<5F7C[O-C.3W^MP<80-^
M8\$8BR(14Q,KE%'Q^P(99J9,KY+WQGZ;P\8R4_K?O46@URAF(BPBHFDD B-.
M9OKVALG3KFS1:-YZU-THC"9^T3O_PO3O/-WND,YF7+%GFT;6B>&B\HW,/14#
ME%O)ESFSX&#_RWYPXN7JF,4WU!5':U5&=E/(WT7Z&>X1>8Y-'B*!ZSWJ;U>T
M4U,M(BXUI15//&A"79[YA08&T I.%\\;/2%.6B18/4GU>VKQ7]?\E&\I[!SY
M67 $B@X+6\#]>HAM6F1)^O;YLAYX']@QW<B[!Y"'BT! -_;'SY^+I6Y'H._<
MPD>@B$G"OWMO$&"^9@<JL-G=(Q!?R[+R;ZHY) MB,97\.SF:\/UY*I8\<N((
M-$C<.'<$.OBCEQU4ZKXLVY UMC0'+B<S!.(IIGC4.T]$/4<O\Y)Q"GBVZX)G
M\R*/VASZA^;'@%*&7A>UL_B2^HU/^E9/E@1?+1B"])=)M&0>UP<K5M>[393>
M(#N<<K:*HFQ$"1^QSUSZ&G]4]A4U^J47'8$0DEN9BQ:]85UWF3O,"+8&F[-G
M _5WR%FL#U;X>[YDO$EKLD7TDC!QKF(S3XCE&1/JC84 1Z"G.3?GBWU@XPQ-
MLOSEE@[W&,V$=_6:&IJ(?!I'[#!>^XW3JT0C4^_T5:UT04O9'2K@^UP63JYP
M-*E8_"(K,Z!#YXB^[B[2NMYG>(/IDH.I:6G,3YI?YCWX*$W!VLT*11:B$7?&
MH.KD*LE[5+;-,;!W]M_;A,(+O\RNA^@D%JUGC#H@VVS3W\WHG<C'E=@[$'FK
M\M(KK\'GX+UB5_M>%Y:S="WQ1DU7;"O7+/&& T%RIJ8!N:O[^.L#)@.6:3E/
M4E'-<ZB%M8F^:PG6#]+<!-(L;0T5SQIZIC@GRS$+NXYAKC-+N[@8MP%>&N)>
MIA55D_2<RT34!FZ7)&YL\CX)[?OK.5;O?;9H3)7ZXFEOC9"P]X7SQK[^/-KI
MD0U?X4YSL:B5S<$ ,5.K).*C<]=E'ER=%""'MGYTZ O<N$Q9,:V4D@MP&O51
M>8K<<(\I,./7QW.5_]HP2)\+FE*)GY35-S12K'"6_WH$@OG.P5BG1@^18?\L
M*$SU1A-A_ P_P)"W=Z@_NDN><85*+Z/D&*HAM,WJ"0D8S6)=; T@:?MJ\1^1
MRI"\XBZ(\4<1<0C)D<1)CV+%_0/,20Y[CJ_V6GYP$[$H"^^SB90--0Y=Z*G<
M-NT0)4@FI.MG$HQX\9!7?0^!3PHK7E95AIJ#MFE.NQ))_HDK)S,8"QN^AG<9
M:^,L+HS[Y.^+14@89YCT1LC[S']$;'%+RH(N&_J8MV?B15%*\")9E0L_&%7[
M@:*F*X*_QOJ77"%(Z".A,T:,'R0+"V.":K;M.'9X&KJBW_#4NEQSYK8)<P!6
MN(_K@E#OL?W^ J[O")00=H,ZW:L\)]GM2.@!OW2!$)HF2P 4Y:5_(<,,**9W
M^Z :Y1./83KM/K $\_W^!E+8'BUB%EO].*+-Y^4[7<4]QF5MS;5<*\KIXR>B
M*R(^RA-%D\N$!>/P2+)?YNB$31C7[Y2I7&39F-E"F7+PC,U>_=>X3J_7%0D1
MI9_C"0T9Z7)S6S\8YM$_-0>E&PTQ%JQOE5O;:IO&SC"SII:ZVKKF5\,# \.G
MJJH4MA4?W$55H5 %=\DM+2V19V4NQ)Z5*=1+4K.V<60(63[QL?2Q3'V25CSW
M!#7?O%#54N%K^]MC[G+*O^DIXX?MBLV_#N/57C#^G6*>96@!D30W%F<[;?S#
M(C>&<QD2JZ,Q&82-"$"ZG*:"HX)JSJ$KK.-- ,+2<V.+5%/J7G1ED[C+_F.U
M37C5[5^S,X-T8U'OG(_TN6[YDFD_I2N\X10,@2^>9-[S.>):>1!-T%4_X7JM
M?8Q!-MY0GV\U+<WMF?S'XNKY9.7K)9;5SBX"!=JI/ND%IDI/GE:9M.O+MCS,
M>>IX>2$;U\/!N/&3_NL(5"3)K#X"T43#5+$_^1&?89L0,/;S(1NYB?G<;(6'
MX_W-@V4>>W $HF:W'('D8>,MY!7\9/0+*-@MU%<=OYT9SE!%!GO[BQ+]44&H
MPAE=?U^HZ?%>-96B?@6?XT5EMJ!7\OOP,Q-U@BM"N>Z.%29>V0$HM=]MWC8U
M"V'IANJFV5Y#MSE+1DLK"GW%UZ?;^E]!W8N1GW/R=*VI-3&!F]S^ERU$X^>V
M+_V8G>)3&!&[EN61H<7X^##I\GR;@37/0*G1U1K])T\3O,;3<)Y]R!;\0FP@
M FW-II-Z7E\OI^Q\=82O$P(8G5UR8218,T?W3<=E/:#H4(V!I.8--?_PV0F#
MH./-/_ND:,S^1'9=&=T*@O!N3'U?E'=:#VF:;_7A>;&D^=N'7^>C_V>;JUGO
M3M8_%[J4*Z<L.Y9;9 L>\(O_$=R(5:MXU?O91_WJ9.$TPN.*\+I:+N+CX!H=
ML]F]V##=/Q(3DMCU>DGY%4*(@2QW=JK*ZXR.[!(#""YM&2N+]R-TWWGN*8EI
M\ISC?2-%%8S[-?6I?DO-B7:.(7@*'RS76JXV9ERU8H%UWMWUX+D9DIR1)]+P
MO,#T"?:5[\&^\;\?#[Q"8;L["0(=KI3=TQ@XLRWP(?"<.JC7%6[3" C-1@B'
M08%(J6;IIB9:>E]BJ&+-*^@5*,MBXO$)!NOJI"*Y?0Q?2_V0S^M,4*=@^:AI
MGI/=W_C1N=84L@)6WAYS\Y?/JVS+&@?E**>NGM/C5A4>Q[^K[$ JKO=57P_5
M]D>6"W<:9<R8#G\.W_08_FUZ;<R2-:K&U"$:UM:--5;(FVC>&U?8;F1JFM:V
M1(WU]?0,"#0WU-<WMMQ=:FIL:DG24JPBWXDZ9R&9*"AH2SB3AK]N%,#FNH8#
MEJD^EFEY7XOGY_Z%^':?G3V/+\4IAI=3;-G@#K_<=CD^7?+_>((N802X"5N>
M3H8>.^1E#2T>[U LWQ"!1;)T,,&3NV&26(^/4$X*FTG!(@NGU+!<7O7]<OT:
MKX,HR?R>K"LI/9Y?G;SR^<9\;-+LVXR.#6"[BQ#4>[LSTIMT^7IF)^89=>[#
MHM 1R!,7@Q" !K]%>Y-T-$=_X83!KQ;$ /^JFNA?\YK=(:9UK@%(,NR\MW9D
MU5ZL.D+(01X=M79GLE%18XQ%-(7/A5+!VZ).5/I+"DH#!2%E2R13Q"\MH5K'
MFH94!FW'/9P$Y]03&9I"]8G%U9=CH\XEJ?X%$6>-L&/55/E+#MT*6*'!Z+',
M'(+'R)^,LT .+9-H*R$ ),*($1.8:V3>4./QH,SII11PM CJ%PS<*&[J;#$T
MQ*H@+_*NV\VFEFK^=+H6[ =ND3D^R%)@^ +*5'ZB\C(B"2L<=HYQGAIH<LF0
M0HA;N$FM(8[P5I!>&4IJ+\8'.4N:_.0[]2AY6ZKG[Z<_9(Y3MD59W'Q'H#_Q
MT[])U)WT?],"S/BU27R^O/VE''H\X.SF'1QP8]_OEGO9(I T;=R9@3R5)+.M
M[($4?RV@JJT("HO\KLV*I.2)FM"$H]2KKI#"(%.*;EUCZO,<E@U3:BC; =<W
MOFKS9F;9E(&#*7-5\=[&'\0+*TZ4%] <>O81*-7GOQ;NQV#LCD 38,1;\,]0
M-FN6/0*MR& ;(<PW!J0:IJ?OS*L7L+%=BG*"CBA:LB<DHXGFW:O#08U^^9 /
M&=)511.&?PX$<[9.0K;\UF?9HXCUJ5)[*I*0\CQ#WKC,;$Z<D99DBTH[IDOV
M2&3QH7=[!K%4,S8%/ UU7\J38ZW=,5Z,S/ZWGE^7C-*TCKKQ_/;/NW <I_/\
MNE P3:_,<='I"T<269+0\CY#"E[\[*^;$B]T/(&]0P_6/]CZ_B^I]#1F">L8
MYN3[";+JNF-P;TU\V FJ4$U%CV:J='(1.M5IO,G9X:_$X<!-XVJ^$5''%]=W
M7R!:IK=N'5I[C:%#Z;[,:I@'+'%!.FIFUP<J19U>!K^$VBUS>\L0&Q;FT0;&
MTTI00]2C"K&(>;-W4JV<%W^:]L\>8WEUL1$FO5V1L*VP<.8(-)E3:,YQ4&=^
M["\Q6$+7>8P&D,C,.P)Q<Y-W7S*"F<ETPA8.N-=QY2T;8Y6WCT"/#H/IP?0%
M'):NW/P\:7P;^^A'UR@=[GLC.%7B\VD(ZWPJ'<5^"84"D'\7_O^ 8(R8<^R[
MLW5#23XO-3J)S6-K)?[\C/$EF_$"@[J^+PEBU<.)E"JP,>UTFL\V0Q-)#RTJ
M\:*W9#RB@*\QLC[I/(3/#;I_G3C&>N=!=V?F" CYSOQ<\@.=-00LEBZ Q%(,
MJ0#HV,?++/NW7$<@3I8ZZY..?/8T>>3#2#SV6(>Q3CS^J_,,&DR&)>M(;*HB
MM:7P)(MYI]E_-Z-L(GY!/FVQ^RQ%&K770_+V?C.65,@\=>[X@N?Q(9U+#$_@
M!O5E8#301',CE_1\HQU'*+UBRP1,,-GWS^KF6?L&[>QU7HJSW3V15"31O%:S
MYY]/J!/;6:V<]#?&H*<ZXK0KT1C7 J2+##6CLQ H(CINYVHGQ5*43V]D:"]$
M5B+WN-L6CD!&DXT?=QJ9MX>#]@O:&ENS.8737D>9@)Y5K6T+'^H@%[3-(@^B
M^WW#G\+.?IM2P-R$$-M'8EFGFFCCFP=%\'=9!241[Z;Y$2@WB]!VF[IQ85/-
M%E203S/U??;-)3%L_Q%H3IE^EYE6.%[,?(=%UKPX H$6'5[!\\X.4A9[??\$
MN&VFW[Z,&Y)^602D.M9.!DW&IF>8;>7(]T3:7R4WO[!GXHY C\$SQO3JNHG?
MD)E,^FM G$9?U$V:=7ZNPX>QH'HD[V*T,_&];VG2.>0J-_,)S$VI48,S>E6.
M]L9*X_6JR6G')UB2;%:(I ;WB-20(/&$,PQ>:LT';1YOI??+V!B6XF<HF,PK
M(BOJ95@.9))FHS*+D*/MF/*]X-H*3=#:+@B32-UE<;%#],]IH(F"!6ZS1,,6
M(?4<"0S'O=KUJ3"Q49BG;V2P=E_-,[]UL3- V >@P =JL#IXZ7:*I\7&M?/%
M26=6#>[<!W>4@MZ"N8'Y0_.P(6R#?CJJBC6*;13N1KPXT/LN330'B#2#;ACO
M=I 8++W%-+/W8"%)G9.G:,"^DK$O@9@OS-SW/+[J^R>V&TY8RL2>53_$<J/E
M65S@0_'-?,G.=B'MI_&0;4YJWZ#%I"]\Q_$[?38SIK)X<BT5)W?SJG-CJX[+
M=O%GCN\W.WL[5SJ$GZ82@[R#>.R$IC5^%-/WA'X6#O)03435 G35'M?K*3S^
M>$FE[9HE-TAJ<K(IO:EW984DE/'T;^.@X. @!3\X''Y+U/AF+^E'?2_/&5+B
MY?I_!L7\*V[4VDC]!2TB[VV?H I3IJJ"WV+D@7EJ-.51NVN)827"DP#NN@RH
M]CDV9:3R#E6EM>$7<LA#WI8=+>-%'5WUC2D'GI8S2KZ*]Y%W6O@D7Z!'DK!+
M;.I;JTR$Q)A1,RFP[?>'4FAN2H(VCJXX0B2<8XW"3C$TE^&*#[]*E2-%DJ."
ML$(S&P=/R]0G8E$G<5BD;["_W[VK>I?+O[^%W/]XV5__Q\"Z@(4D^\6O4NS?
M%^<P/Q]C?<?<(2O&QMSPPA^>QW_^9.L+JBT"D.8@)OH!'GT$JGGRE\7;M#^#
M4[ZX>(ZQGQA7]6]QI1\<GJLM4]N!1R"!>>,"0X&8CU?H'^I/;9@S/E2!GNM2
MW>CQ3!S6<_NDKP!K!"NN \8$42<;XWFG"-10"B)<1\IS*K7N_H7VB0[1*F_;
MC!;1UQ/=_@H!\D5%E]JT2SGJ/_\G2#W]3XDHUC,"U8FP;X38UCT"!9H=@1SF
MR%)81S0;7R_K&QZ!@I29\.61D8"1?9$'A!T.5M$H3-I[%WSY?Y]4'6<^D@>@
MS/O_X=F1_]?\M^:/J(IRY*QT5JFW=N=*5QX>J6'GF(3'!E^(FQWH&Q!N;6MK
M?1W#R7-&_\<_)&JYF99@_YM'YQ1*CB4.J2K8B DY9Y"OG6.$J?*KFX$CNLDR
MPUU7^%V*J\Y9%NCG;DSD/$VX-->4E"#!+_CF ;553)"KM?*1)I\!9P31/+P,
MSA=+LDZ4$Y"]K9FV85.AU<-G]",MQ>[]SY"PF2-0P^44!6.:W;W3PV=\1J&V
ML:VYF+&N5W7E:Q4-Y<<^WE?QIFD]OP+ESET^T0^HK4@)K*7YBVM)S]?(I:O8
MCT>$#@<DG)T<F.W_M8\6IU0^^ ;H"DU8H0S$TTQ-E%<B_+^./2\2E+V9YC*V
M1O!2GB%T$YJ2B3?@><(68VZTH,CP#<)IC#_R<G#(\X&O!FO5J:7.,UDZ,^0J
M[Q6[_./06>=!O7*'7EAZ<(D7HM7]63Z':C=9%=IP/O+3DT]$L+%@>/_]BK%>
MUVMH+^I:42SQ@<R =85%&:?L>)FI901EW,Y0\B>/"[_@B]X'5^V_JF,D5#D=
MWT$$(TEC>3SZ$IVR6M9%+NEW^_!R::NY'ISZ*@GI..LPZ[!A1%UR'SAN42AP
M6W)YX>6R(H2\U@/W_)6G!S4]2._03HR,*L,&EZ#YNP_"N^;R).BLU2.0>5L'
ME3EN[^#98KDPB[@54/D]Q?D@H.Q<'PW94MZ\@&)4%;5_9XTG7S]4IQ!F=9<X
M>N;M6&<(?,#>+2H=7S0'AXMS]9M-*DN.H99C+6=[BSXW#LZ90+O_N(0//R?5
M$CT \;@[(T_KDJ%-]X3Q#-'.@_EH[Q OAJ_&@85?ED0-J8JT.MB\*N-"E[F_
MX0F"W@PVM2C;DC<53+O".<"7L!3V\C5@1^$XZSX1\#@SZMJ7CO8SWVJ!,IMN
MLBQ%X/*R[&?[KWJ<4\7O\&"4J4KQVGD]DP%%@W8@F(8@K_7F:>S9 L\H\1!^
M^_5I8_<P>MV"XPCR"6V_KJHWO\C;(_3LO9P$_J;65P$"@SQ)5%/^=4"9I,1#
M Y^(^X16U>GQ>.,D=-'5/RD2:BK1)=3QMMPJ$2-] QS9.Y9H[V(M-P(6L=F7
M*U?-P5ME$BDN8(K+:1*9BC%.>_"D'"A7YHNRP>M7:?\JTC%LLZ%.RGW.+?OH
MB->:#)+]>6LBPGII[;L-W6#H?U&J\8=*A;P\R.:E+4>!Y=5;] N4%[#K73P;
M(TN[LYHVU!SG/OK>WH(,=?+3>-X[NP;OBD/SJDL5ZJ3,ML<:&X/)UXN?YV3<
M:D=ZGWA7)AL<@@\;&-Z;/?#VOF1[V+(O-=[<E;D]_N8 NPS9-CC488#LIRF[
MO0ANM#;=<SE;\>RSG2!??F-?&:S<#HP;'39M0Q.=N9XXJ6QGK%&YN1*+Z2GH
M4H[5^AD.W!ZE*%WXX-Z$%]0B2UVG^/\HD9^M?+(E=NW<NB5*K;P2UK"Z]VP<
M:;R%]GZ![D^XCB?FPI(_E?:8\O?VG2'>E[34\$EK$'._IW-2/05Y*!Q#SYB\
M58%3Z&:KNH?,Z!7"H1B./R@'CMHBS#8 Q_L2[UL'I@XTC?H$F2<R+JP7FH8]
M=!(GG  7*T=:EFTM/(^/\/5%0>-OT+&4/3^5"M_#B.S-SX<S3(D.FTAESWH%
ML17OPW,>,U>:ON\_WPI$+I;0% D=VVY;D A<(T>W;](L9C:S!Q:K(T3[9%M7
M.=V<K?]6V&'<]1F/Q5 Y$+*OJ+XM)UM\XD*FQ3C*\I$MWWFNYL51(#A!"Q'O
M.4PX[?&&9]+2R*;,=1,N&)W0)1S;;6-=]\;]2K$XFY3"ZN>S85H4G=.4I+-5
M7%"#UZOGC<N_>MJ0++KX^60J/KK6->8Y24AUJZV6/I#30BS,/SD\\?SBSUO_
ML=^I'DW_C^J _XCB!"(.T.)@<;J7L26<#=;5Q(I<0RRK>GP$\O0-=[E\!(KL
MIYY9='98/PB.@UJ\\PRI3JYB7)M2OT&/&[\W'G;14SN-KJ&=WKN <\<#1%-J
M4D7%HFZ!O=='+8Y].OLO%6%+=;CF&L89XV4[4O+,&B6SQP1+@G#N0/W/ ^N'
M\@PSD997&,12S3E'^"W7T&5(M';B=N<':G""<B/ZUTA+3J>D/;4FN5%>D7^;
MKV_44^?*V ?8Z!Z+<X3MO\7,%]BEDK:;C;"&FM[-Y\J4CI!GA&F"!R&6-@/(
M+]M&U!+7%@U1Y*PF[B%8WZP+3N)R%PU,K/+HG3V9GT*4*"G]LF!(OP-BPM^"
M!T8 A6B&P& /CFJ$_9+<#VE,*L"OL^2 U/(-#2QOV'& VR*OH)Z&[1WAM]\(
MUI:9LN6.]YZBUD0V=LK;TS+CA09"O=L[A6_A#.HZZR?541KDOV##H?0K1Z!7
MH6Q#&+.5\0IA5I,MV" Z*IC R?M  +GFS& 1XQZS6$=::B2&H;QT4]>R.1G>
M -A1#<@:>>7?-80UGV9H/M6. R ]>Q(\5-^HQM *9UW$=."\KOVH8A 5/&\6
M"Z&Z+4:E?M!,IL:SN(Y5?\58U(_M2H]OLR0QO.-5F!,4$R_YVX_5YMIK>-$'
M:R0)[G%EWS2#X,I>[^7!*HTIA+8XMVT&6'KI.+6??HS=VY=A\UBJ#V[[L#+L
M$ZPQ#J@'OV))T(93R4>@603=OWV:(PXC=00ZU1_K6C^QW76-(?ICISHP!R(
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MQ<:1[>?@K5T*%HQVQO JQ^T$=9YHVO?)<3:1X+87-6\;7VK18WV:*,Y_E#)
M,72(X!1Y=A'3YS&S)Z'-O RC\'KL:X(_D\&_4_FS5L#7:UR:GS&3#7AOH[^:
M<H/UTUS3'Z62)O/N24@'Y6:("-POE0D-=@PCKG3(4FU=I%8<,GRM8C*,=8^_
M46C+DW'WO5;A4DZT($V6:=" 4Q8EYQ[(].'DJ^12Z+D#*1'BB.Q^A@"0P$_U
M\!NY@%ZJ-O 39?'9<9G=VWH<(L)0?WZ#%FP(P"-#-C)%)TT7[,A"J2W!>TY,
M"R9_Z9SIC?)V32*?]\X1R%Z0+;.5V[>8\E1)^AS@3RMQ;*(F+F25 J)](E&T
M=^O9^$_:2>GE S$_1$UNP%^)WEL\M_PH:8%%-!/FK><V5/+!&X<PIWM\\<HG
MT'DYKJW>@IG+K6:Q_J\S)_S0##VQIPY9MA%7+-'W"!I%/%!\0J+<DS(1K2V"
M,IU.1QO:5<YKL:PHPB\Z+#Z\?_YX)TF9FW1>^GQ-%:4VT(M<URKR),U53%_U
MF*7-A-].0(*XDX:\X%:7PNTBLT6=>IIF;"/XY'>1FCBH1?FL9_;)>*^]MORR
MYQ>3%J9.R(7?L/F6@<2CM[=1]Y/@.>UEKDU-<?"LPL0C4*'JIY\RY,HB",YC
M)@HB/Z#2 :79;SV5PZ1Y6D1FZLE.5%@^2903D.G#8TQ"TFJ!$!OOR<CK89KI
M*\^B@M^XJE26<,(A;Y8K]*.$.:.3U8V:)&HJW4[=YK*1FRR3L2PRXJ]R+):]
M'9"\:I>,7<(?/*\N"G"C+I(W-Z;,#>L7G6CZ15)_=W6[!\??&5]";I/_L7ME
MV*2?[[G([^C8MNU+=E$X>.)Z%9@%?+B6RMRH:G@MJR$@7B7C#_OH\T9R>"B.
M(YID71)=YFZ9MKD:Z*]2HE:Q1&VR)D,VAB4.Y"D5KD@[BH]T$K>@I9S58'V"
M@+]7LHJ)5;YK#,FR1*ZN/5+/F,,RP4-TK,;EK!5;]O!@NTV:K#OB8"*,J^/?
MZI\5&E9#U2N='><=/PQC9J;&;:)V;GP\JX)7')K_^^_PG,BO!1A,ZOKXFTH]
M&9HPZ+[W_14+.2 A^4:-+O_M=.;Z:/<R]4V<5ELYC%?D#4- 2G%SW*3UX'K)
MJ#'7]XD,XUX@#AW3W188<*\ZSTC="SZ?>,^47]#HG<39IZME/-+2%G#+O*VP
M3(8R@%\:29#@JZ.5O&R";8M+;R\LH!_=\BU#:B=P)085;]#A>96_12T4'M-V
M,\XO97#/R<=7<.? V1KNO19W<JL;*5^<Z _C<NMZGSF56_O[^V1T7;][ZX%Y
M"50?GD5^5DS],LM78?HD6MU(O72R*+['CK14I_58#[&2I$!6^/DJ('M?^(RK
M3E4"_MP47LMXUM6_U2C)*$GSA,M'.Z*-7Z[U>U?+='L;X@.D!>ESE3[D#;:E
MID\&Z_8<TH<]VZ'I6T+H&TEH8XY$ZYPQP7IF1Q(BU$(5.0QP_3B^2TWI'N,[
M0<8WYBT554WJ)RPTO.RFA!O@&VW*].'4H!\2&NA4.R+K7)%8M?4RR6'%Z,N]
M<AO7;=O3Z:?T[;?&9TQ5BAR6BN"\II%R5>/H3X]$JIQTY'EU^:(SOTMPH?V-
M21)2E3_O6F>>?FC]G?(3/5:Z;GS>L6--C" ?Y"HS723VN/2!UW0%FR!;=5-D
M+4GD:^I4(";L*NLCHBZZ#S$WWK<@0_.IHK0SK_0\U<XQ7MZ-[U(4B8Y55[0B
MV6TH#:<6&P0%GQB)Z[!0"S H]<)Z3FPK_,K3L?=I<M87K3+0K9T\ B5CH-21
M6*C]T#7@8";220=AP#>42Y.X7^&V2;G6E%)*G1 T>EWVYI%JB<Q4]<8#62+O
M[< -BE?95(]Y+_8^.IKBP0N8I:\ 7/9<]@D]S9!,:?*G]Z,?/A>\*KIB\L"[
M+3 /VJY8HC60"/:(+H/:H*V+HMZ2#41C>L(ZC8] ?_[%S#N=_(U(TUV^''($
M>MUR: H?.6E<Q"QZ!-W=4J>F:7:99<5"DX&[QI$#HN%_?V0*L>)SS__VL5]C
MF-=A,N@[S>94UOA^5WE]S 0]^ B4Z2V$1]VL^@W+$QY+39BZDNT$ZQGA'&*<
M,-!*NFC%0E0>@1X;Y93Y-E/+-2<M#9\,)C.S8$MOCD#"6'>S.6$REI0GV>>H
M25*.T!!:N-%".]GB!>]9N#3.;PE@*>+RQLW3&-G@T&#>WTW3,>HWM6_(JMU$
M.%TRUIQ0%U44EWR)^[24?!R=^@)C](]JAX9[Y+#6DPA5M-NUP-W,94\B7^KR
MU5^R#WX<I'OI-VF_F05\'U%;<VU6]*9KC+D_FN5,+&/% -_D#G4*3S)?!N6'
MSZ4:A4(T5/Q.@YC@,_+/7*%+G4[2;J;ILN9E9B=TSVXHV IS37@_=XE\;';3
MQ;<1ZW,$FGL'^U(^3DX+)S<P[K0!K_TIW^)4*>E4DL@]";YD(LKOAR$SLOKF
MMY8:"CPH4NA&8"3JD4>P4AP!#S10&J@]^7?(KQ5VJH.A'V4&55C#)=$E&97@
M&P'V8H'EPY5UO]+</IX0-$4-[UR#J5(S>V( '/1PUJ/F,OYUOT)'0<81"&E-
MFOB4#WLMT_'TI%J!T?7G!K(!UD\"7ED8&N+R<%1FUA'H^PSE"$2L763L5M!P
M0/:6&?-,((QVA0T'GVF'F@RC)'Y6_%<#UJ6)(]#!19U%9A1AJ7#ST!V]UJ=S
M*I-\ W,3U[/ G]QKX<6Y+$A3T_R<^*#_;O[P77"TVI6F-!V\KYI*Q5?)PGM)
M=1 %PD:^ # (._OSWKA"!3%>*@/QHB0ITNM9Q:<"1V4^'NBZB;'2!VT5T^(K
M)B5V>:%W)IY99:Z$R0.J9L1[-?)#LOZ7&TI7ST?>^_/[Q$!1QG!"453^)<'[
MRUENS$;'$BUK4[5]T>+QS)M%J["F$H9@B/),ZG))O Z7(X,OM2\%N#U-?+(
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M+H2AG-,S53=L?/*%&[(;]<>T&^G%M2>E\=^;21G99\N%XV\40,[P[3;SSH!
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MX/185;VZRL^M0'/CWT=\&/<;:J8UISD3>Q)#)AV60L2/CI8(VNU4-9K:0GS
M$FQRN[:R/1;!G^8=<=_+1:/DA"Y4"BD<N\?0$GM$3,[WEO9O#0X#OIH*)1DV
MT%&P[<=TQ-.%[J84X7]^F=]!9MZZ!R1*P6NE'(Z@SE-HP#UZABS64MJV(M)!
MT$3"C/^$:%HA73O 4Z6\!A,6M[=FS\[F\*_BS@"$I(U6: $8WI4O.*$6MJ%Y
M R@JJH[+I*UVSL]T"Q&]2SKD"&4?)]Q=-Q6Z*U 55Z4O1PI8J""V#3WF@V+
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M*Y2-7BY$T89YDPN9)'*^(/;*6EW^@BWW\Y) <WPOAS-&8/@VXO>:<6(W#I"
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MJUE^M-/?TTPG?.S?3' 7;$9C*?D+'7KW"4(^@-AZ[?E*QR?#@W9 E_B73;]
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M/'.)-M5Y4=',%L*9),V_=2 TQ*8R3V&=Z0B6*&>M \JT O6N(24Q4+*<(5"
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MMV1LO]Z</!4J+=6%'#:JC?G>LXCA;DY]'KP6*/Y["1\%28A2M/C?(@?=BS+
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M-8_"PG7SAY]2-%[S9.W4INP.TLJA]SEZWS+.U5)_<-)4[(ZD63$?W%:G7NW
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M[ 004A,=\APW@&N%)F_K,\P_UPY\L=.:>/+*$\].WDD_U?/7'=)3TO(?067
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M9G/%I,XC&D#Q>[#:Y_%FLC<6NXU<?Q\^0)/[YSN)?Y:!H>*Y@WR7VWW683-
M7/8ZE;HX9]\$?3Y#02/5J!BFX@;=J-Z,6T\:SW9$@7!$TAGZ%<I&<W _TZ3>
M@2I\@WHH^QOS>HYG%9!Z>; T;( &Q4-V:=:3W\U8@HWUOLWC6D?G@[Q=T:&.
MDI%[.U6YVY?:J^6K>GS\E]F;D2=+%7RMBOD8R:DU-4YY^<)SE?<PP.B.,>R-
M*'T%AHI#"$2(J"SQ-"VY6%S)5!DF$N+DY!D6A&J)!\T6HK9@,[OO0&YP=HC_
M-I$J?$V&'87:C>\E[K[Z1?Q4"=T[S %T?8.SG8&4.3!=$<J2V&$_[A^?Y "R
MIH#_C^:@_=;[K?=;[[?>;_T?K5$YJ2BY[)Q_@12U+_]9@F;:-G9E9TZ!UC+_
MWOJQ++4@@%I!NV>OS;&_L"]PJT\5];WCPMQ:OS@2M?:^D[CM$@G2(<[^!:(N
M4K%LPM\GK'VH=X6V<0#7@3NJPJ UF5>HK3$AX!#*E /8Z3O" 7QZ\O<6@<4\
M[THOZCWOYMG_/LMAP1@]2Q+7-" "':AN,7A')\$6 O#3Y^'M4+OMMUYK:Z7)
MR"21>&>//)<JI1 88J&V[C.BM/0!>L&=')#LW1W ^TN*8<$,I=JO/Z!&\L=+
MM]Q-_CUR%ZE*J6N*EKP'+<6S?MA1;N_Y)]\SE(]&F@?2@C8&1\I^V#&.)TJM
MKY>ENRH'W% 4JG;ZP8:LK'_X!?'<^@RL!Y7OK)%<&=>0BOBO/P>GYSJR+KAK
M$(&>?[[^RZ! YL^[2P%#'9^["^C/)H(NS;JH#WR']A>M/ VZXGE^6L4S>3$]
M:7*(Z 0MR[H?ZN3P_%]@M$\=X(S]^\X2LYSKSWJXY83>&FBV@%O?@_OC@96&
M>1 ;J'!;*:85]1R]@#WO.+$$DJ@_EFY/$/ZU,27GI&I!=4WMPU,V6B7>O@P8
M8FK,*3_<O.A,/F((0%T#4CS<F*>\N:]IERW$+9?C0?CS*VP ?9EBUDX4VL:^
MD):F%JQK66N*ZI1N<P#M\!=P-X1+VEA;MB 3*AB-#,4LPQ:_>P9?J)ZSBU=^
MPCP=.<O#.$B?8YQE=V;CYA>C\, ),,V9E4ET=[K9K#D1D1ZARK[&/$6'41_^
M:A$-QE55KE1E2==2-R+UKAO$>A7VN[IJYAQ&TP:<N]U@<EVFE!M?#ORLE8[Z
M@'#Y8X"I02H%FE$VHO3T\Y?WI%^06()@W*"?N> ?@U[G/@WB0H&FGR*G.VX/
M;G5+(B[A6 9=T_QF2K?.555%7GSXQQT!4\!%GGEX'.H3=LV888AH"#O+_@HM
M[U@KI8YU%.:-N_/-H>)0E3/-H.AI57-^\[254%U#Z$GZ9-/>0D6M^:NQL4H'
MC^+@2^NN];5)1RQ_7G #_%("T^7LF2=IS63=.B#]PL::L*L_/SQR98AFP,HJ
M+3O_@&G9*]B2DJ:Y8W3XN4$%'4Z)(H&:&D286I1P$JJ%&.$LE62IAQ9LX59X
ML,:)2\G/?W^[13SF@;:-->6Y?%+]&/TAS[$_&Z6C_\N<$-^K2LY?G7#.SUE%
M>V>7NJ/[LH/R5B4,2MV\/BX'5Z5_G#1S^^A1FY8==&HT?2)T.V\(,NTP=5,9
M/X*K:-(#"]=>YOW[?H-$#N 1=CR!T2J!61MGJ(3U$2NG,>1N,TE!$4\0#X$/
MJ4X'AY)A4BH>/]6[54\XT?E;I(&?1[W45V.+"]>\\.(J#W#HA2"O02VTT7W!
M#Q__FYUD>7H;16P6M2Y(,M'CI_Z:W6CF .+#^%/SWM0K41T;P\3H+TC;Z+M,
MS.<H$ZI=>M'X=?]/@/2GAE(]KK:YJ4YW/O(N_$(U\1!G$P1+RNI1LUG$RJ\$
MJULOD*"BCMPS&9G39\P?(8)V>0YL50&0N4<=[O'\W'@.JA!<*V0HWH4N$RN-
MUV8H-V?ERDI.P>1)\BV"O(BCJX[CE2ZP=/:9@2T&RV.H._81.K]W\F/"Y9(
MA3N"'Y9X>@F7F!+TZ]2-)IVH%G!"]M$P2:0[W:?XWO(8&MO" <0:'*9TM$(/
MK@2B#=<@"<F!'Q'V[1)VE3G.WY>#(^K%]OQV-$]VNX8<M+?K/T65^7@(%$[\
MC7"$W<?FEOX1(0P04Y)N2U%K!$U4UVXPSW( O&'2=&-2>C@'4+4M6YUH-8HB
M25#L$G.6B!.UKP+2HD,^AD:M!WK O"M[5@]>_UW?[KF!';V#<93=BL+9QXZ1
M!=</,<Z$=<U((8/1YFG/L[2X_]1GRM SR5M?<>/>F"&<+54UOAY8!E/*^V8>
M&J*1AJ[^T#?JV%UX-D*:_/BIH ('$ 5&-5TB+DN@/O&RSQ'7ECF ONGGZC@4
M78[(%%9JF<A/J'Z/:M(!/5 6A S)FY5JV0]P)P]TG'%[1)WQ\5?%0CN[F_1#
M+""YP*+S/5I;3%Z@\[V@!5V)(<3F9IE*MQA5I@]#)^Q+=B5OHZK$2JU(?\0V
M6(PI0C]$P9#<8C14CTU#EVM+%Z/@S.NS4#YW'?Q"A'^1^X1!OF_>/:=N3#\J
MWZ,Z:5*C+1Y7#@@%<1<"<IO:33-FI1 ]EIE:_@Q3=@^J<FQ=P'?V&_ZNWCD?
M:O<LL045JT:W$O!?DQTE4;Y/&U#Z7\M^)8_*#N*J1UP&)T8T>(>>2*S='@U8
M."MXER+_',E/J6Z:EJ('4;J;G$_2?2D<0+/$(PG55TR!6?!Q=_8)2F#$%NP>
MZYT)92,2"7+#+-5>>/M$_)6HA%=\:8EC8OK11S& 5?=_F_^[V;:L6)!+?.#<
M'U!<9#7C0EC/7L>ZT.'*7'J"8&(PMC$Q AW5_AIYD[1NT&'R5>,;0<&);@4_
MTU&R%&SW%N-1:_ 1O3*]C [+=G%S5=<<K:*^YWV/#*"3*"TT3[HV57YNL3U1
MY"Y"GN36##^RPM:@$J/QH@86F1^6:.OJT5[>;S\/^SO=@,O?_KH%._7.:DSC
MW:04\'9US;!JJ=?\WU<H-NAR\DW],4 *E$A7,6[]^^ H^W;P84]-4$7Z&@=
M!9E2^Q)SZ7_&9JKH@QM'+T^&]4!_PRW8)IN.X.'\$\MA4O1DJJF^ 9^ZXUN_
M=2-S3TEM@NPR[QWN:]]"_RM<4=N7??G?DE_$V)E-$\)%U+@NUR_G0C*1J->H
MS=]].EAOF.8<0-$]CZTS\AR G/TQ#F#\>C)JI>-8F#^JZ3)JKG\.R@JE\W
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M@!?I\/>'8_@X@%;!""@%'P:DYS:B*!4&(C B)8YI3#%FRDZ8CZ9SFZB^W.8
MSB\RE%HE["<,1AX$_C#HO".8KCO,LTOB %Z[@U:O BGV&TR3#3;US@$.X,17
MU.@CT"QVAIX\PR*_YV&?>\\!E'Q!-4&)5'DBH^UW7N;-ZQR PY_<@$M$D<&H
MG9CG@O3(<';E.6XH#^,297$ &R( (%6 E_7X)OLHBP.(UN< IA4!(+*$X%Y/
M%%.$P0&<#.$ ZFT J%9UX/9;0;K2#EMVAP- ? 3L,^TS[3/M,^TS[3/M,^TS
M[3/M,^TS[3/M,^TS[3/M,^TS[3/M,^TS[3/M,^TS[3/M,^TS[3/M,^TS[3/M
M,^TS[3/M,^TS[3/M,^TS_0LR"2[7F0QQ !5^I6JF#.^<0@[@L0<-@J(EE/K2
M>NWO,*1P=AR U_"&IC&M],9&]Z\-;^1G)B,]S2FVSO.Y^QW>?S@O:5_V95_^
M)W+86/;9^R1Y$Z%*_-S]I:>WKKG*GCEQO6GVY;6F][Q?_P5NS/]O!?@/9P+L
MR[[LR_]0>#9GV$=E&#;]L^:2[%-:+<53;! U-<.$W-W-&Z2JITW*M+S]U$.4
M#+@-V8F1N5\G#3;HOY'<)YJ/;]"DS01?KEN &>+WB".J:83X6VPB=O67033K
M==@1^KM9^\8IW=^I:3F^H.AZ\Z+OB"&[@?DW/V*;ASPGPM["Q*)RW5P(*X.3
M%B^]'.;XCZ[L:%5]U>@1'7">:G-0,#-/PC,FL;F$+,<7VZS'_^R \C^(,F/[
M469?]N7_578K:06L#WZJXW6D" X@UKLW<R<&?U,E>19Z'*PP4[+:+[J!ZS]X
MNYK7<$#&E3A:)I23Z#;NUU9711S!D7>.:-?Y.1)5IFQGS+#$.R!=#N"^ZOCD
M/?I;\NK,1,><3'?IO2E88##VQ9@-^*H7O+4[4'62Z?$L[N5!W,"&2&D]Z,Q1
M6W]WN9K$M9M&.+.&HO[49\;FE]8K$C?92ML\M(2:Y_\2G?3?B. _/"%K=W*.
MN.[%T CKL48\GJ$]IP_,0E\-T;N4(7#^FW-2=ST&5_]< F,*L,HO@ZQPA1A"
M*4:NY40.9/,$G]S+/8<P<_3CHN+N3]?B'KZ?+:H]M3NB9?VVR6PZ/B-%#D[9
M8MS;IMY]HJ4ZJF2=WQ_F'.CM[>@\G0X-^L4!,/51;+X6#L XGF+& 1Q%L7]@
MC5EWR/"]DW-_/P67 _"[S![N)BY=C6(?#E6EJ-'^HA]BW%[:6R!2^,D=X6%*
M2VR)X?>#&HP-WI7"0L,\3WN[#[2)0?K!A%NRG_$7W/DO=-JZ"M6I6RGN(IC8
M*UV+%EDNX=CPS+LU0_&(9]IM!G9S)<DF2]M#I3]K@MW)[@]M\F^4*'ZL,VF:
M[O?++MID]#\KX[G_7K!_E4A7Q#*%/[2O+'2MTEKH<B*]F:VCU4(<0+--XGP_
M7,90$9XP?6OFT>ON6BV_)ZY.*9'8#_=D6BM,S>0Z\++HL!:_;<=>_3KLY]F@
M F<<HDL, D+B<U%-5J#9K*QS(UNE/(:L,L(Q3YV^FL*[2WL6V7#R?6]5O+[%
MBI(2_S4>1\6W9668F"/A5U_^?/^)5Q'3C#2Q$"ZTOM!A=&I.H<\BX<TK,?4\
MULX'DVK,M,;;^4W/*VT#WN:R*7BOI:1?3QC3!,3/HX!?H!B0A,$)I-#7]-89
M<0,%I '=GK1[K/-P.96_78+WU265^1<B\]45G\>P:U9[:TH=L69J^MVX-[)/
M*[_$L.[>/JX%M!QL>G#E6FU,;XN 4;Z'H;YP$D;\67'I1#6Z/!,R[-Z!QD/\
M<@>&,^YGYR;;AYF &IF+5"VF&)#-YT."Q<;J8B?2S4>\U^<1$- QI@:]@^P8
M)*$UL0XO6IH1]-YR('_I,A?-H][.UCO>=1V>G]^(='"0/U/PU-QYV^>NHGEP
M<[Z_.C/#T<E*;]DMZ)%3EH(6:\(_#_<K7L&0M;<3_'D9 67S>W  !^NI3VBC
MM8'K4%(=W\^\!!'IBQ35MFS>Z\>2SASP_8@H;M0Q> >7R-Y.5W.6*Q)\6\#W
M2WUDUEGIP[LT2SM3'?8*X61EP+K$M>C.O6=3ZX^VDQ/\TTQ'VPRANSD04$CJ
M-6SWSSK0S3!)))0.IB8;&9RG&U-U21Q F]0!9.E>?\O,:7I(.^21T=/UD^ 0
MTOI-R^J7]D*=KPO>R/8\4_C]RPI1*Z;)Y;(U#=&C(L]G#?45OI'/IPMWM;KB
M/;9$\%[,L< K#BSDVF7>W<%<ZU6U%S=!.87U?QB[\OX.;Q=(BNB=^(T#H+FA
M0X )4)Q]<W_4WM3'> PEGP.(+O4'2W:<^9ADK,H\6PL8J7_X5>^9T:J.NQ>?
M_<T%P-+(ZOSN87^TW*7##K&M0R%V\?)'!?,)Y99#N7Y[(6;+%>7=4*E7+4[V
MK58%8^//+%#T@W!0$_8FN9M(5P4Q3Q)&=];"::GUM;\'-*QCFE )FPXRWDV[
MDZ0/YA>=Z]9GT9K.EC,R@9_K#<ACTO U7)WA7,6V_.9>&V%'TA\RK0>=K''B
M *:AV/)61P[@]LS/!@86OP5M!M(559G"JW,%I:[OD5JLXK!3,[")C$^.R\'
M:#PW)D?I]!4'^I^-F6@Q'63+++-/$48TQ'_<?^,Q*OIK1OO:B3/"SMYJ$=<2
M#_#9M+F>_C+TTMM?X<:UOVXH!5D@/.SCSJ=MIJ2@U K2W)Z7#7N0"[6U7,6U
MS*OVY"P-J\LZM28#0M>A>H'2OE0S,G=%8U]*GZJA]K>KOIX^2H?.,ASLIJ%"
M](W66G#$5EH=8CY-DA_6X+PRJMMK.G\N9<*C*C*$T7Y3JA37ISEF(7PHMF/T
M+E)4@J!8.6+5,ICI,+&LK7&DLUT!'Z31+;DRD G!?6S)PM^R?AFPD)%BRW#"
M%U=U;9@G]IJ#V?REW*E;,8B_GF_.N&,8>+Z+"@XI0,K2YPN7 ]:B#B3DN%!&
M0V ?,UB=N)WZ6*#VTVR-T#^N\<:Z'?=/P97ZB\]=I9MS ),5K1C1.G#JWDI0
MOV[74/5H\B^;8OQ.D3DHV3FD(+2!H<_^EEW! :P[//!%,?21<(I@&V]YE>,4
MV.@KW@=.[I7NG;_E4C^F)U;<44"O^P.7YG;W0<T(3O?BA91=GUL_Q6'-/<_N
MC5U,2G!]WOI .S-'Y\\&\3JG(G]2KU&NF5V.ML:X9\ #ZE]/K C2.,5)NP_K
MZG5=)W&#(YZ#3AHU6YE!;K?N'()-3NIK]FU8#GNOEZ@S^#TVX%BL6\QH7U??
MJ'S6PL^?*X$)_#"8N^5"5E#F^1C9(%E_0V6+*REYN:?F%31.MRO4F)J/RZ9.
M>OW];>">I(GF5-)(=873]&0PJV-NK!5*5]5B"MN3.N+P_8?N(5U&F=! $J.J
MO&$L#(B0;#50IL3W?K\?M)Q+S^H:]@A>KU=E5!:Z#TTOVQ_CJR#4Q,&QN!9$
M:-OIHE.K)<<NMG]8B-<S.I\JT:7JIF/E[3<YDX:L='I8I1?S=L'1XEEXR0_R
MVI2.;P9\7BZOX>'$VOA>/"6$3 P/TV$J4P3;05'5@>EL7GHJ*52^75JT?OB2
MBGK=:KP8!&]6IZ"RM9KO&*L;?NJY&5PQ,K[I3)S$[FWODP0>L==-#Q_F0ODA
M?DI&5ZUC"LTW.Q649;&5CJP.C%&)TB &\LX[\U9A&VZH\F=6X5[6FWL%D49$
ML@!O,UJED P^!0LVCF3J?G  %\(@;&*AP]*>RAL,)"=I@0.PX:Z>TK4GETKG
M#IO\+%N,.?*G:)*A);K6;\4N0\$*HX-7-#$ZM=QNG?%CR_*53)"I^5(*UQ\M
M*9A>CN6.P.F">07U#TE355LF_O MM_F.. Y@MIJ;L,UF>%:&EM")ZR:YJUJT
MP=<+J,,('G)U/.Y/+9&KU\D@?KJ8+65JR_2Z7(E&R ?[8S&DE.K1.[,62JW7
M+;1O+[<58^&OFQ\L+BW;EA2U<0 Q_/BAF@6P3O?976<%36*2R&,BY>)@"K3+
M?M7M@_XJ+9@#>)G";@'B#>J\2- 7,[C %_7VY-4!>1HJ?/MN_?59D)AG_)$I
M]6"M2(-S2P21,8W"\[>[SWN(:I5\*DD_?5GF"R' M46<;6T^VG.UQU!"\?O(
M^^6'%YL9OB,M-J46F=.Q699CYFOY!.#51G)^]TTAOMYUWEX+[YENB3>O\C>=
MW;ZGSF;F_&N4B_NR+__7Y$ ?HJZ-($4!1FK,B".J;:H'D%JD!LU%NU$-W=(%
M74==&Y7YA]&/LA;(=I.',E-+K)VA3MT"F7G"4^!CMP>]\O#P^R!>IG(^O8-]
M5)<!=J;'.FNA0<W @_C*[P[O0]%BX3)U;W'9QQTO*WLC[>>T9VNRK0AI=IM$
M,BS$Z]2HA$IVGKRU9YP(/GV!T8#;W(5]1D''MG>!A&"CY )W';MW.4M5HK7.
MB;G?(![!=N]<CSJ.+^_YOQ+Z^TSNIM,VD=,3TQ=)D>H'K-1MSQR=]ZJ:'*D.
M8! [?C$:O^;]^_L\<>_&T!]VVA!Q^\5(R_I7*3SE>?%.>DLO0/4OOLG&ILI9
MC-TYJKF'ELS%3&''L?7$J^HNC+J4,[=&*TA_-%\U"K-Y%E?V,+KGJV.=/QO'
M ;S 0GO_(%2QB=@ZJ@4$]R]3!?[CHS'9>L39Y9E="0[@(9$A1M!#+7>3-,*&
M2%H4M?X]QG,.8/"*VQ<JJ".< Q! ];UAHNU7%[NR!X!,27^&"=<HE; JD& *
M\.ZP #&2Z*'ZV_=QCZI-D_G&,%FD1I0E%1KI&A @9$Q+/&H^Q[JJ?L"U?EC5
MK\[OL<\9^&YU]#AT=-/4X95,<(WS.5,OY;#B&)]<6X^RU#3I4*N8=T/3;[;.
MZ$;3[G;>@4^U-G>S"=;UN3LMF4%5B3]'B0"#6>;?3Q/*9P^B*%VH3^GK/%2+
MECOL?JK_V"MY.HJR>6M^$VO?@1*ZAS"[.:S.-G[K3\H?_LET'EADZ^OI^[7=
M4S#:,Q#NX@#POYAU?!=_6=JFR0OGCXU09@B%X@&V02*2JQLVSMYZX@7R*Y_/
M&-JL:PFZ@1T-@K-^0'[.!1J@#0GQ9LQNI;T4YK=M#F!\@VVVV,@!,)2X/07:
M5A^ Q5[E -X$@-B-Y="]ASE50!8YBA7&]>?YN2QGV.X)UBVF[-\7.#F I@=^
MV=^,S:-FB4WN?JJGPX;8B@-].5JT6#FNZV4+N(M176Y3Y:.WONT(.+;I5.@Z
M(>R;[4].-BK+@$\BXA\-Y ^J8X79+YHRQ S.)G>X9)IJVXIOECFV%VCF01M,
M4[9_Y!^N@=F9$!XO6[/(&4N(((+W)Z5O SBJE?W8W8'8"2NG1^Q6(#C8[EX1
MM#F;FW7CL\4,0(BA._1H:C%9*Y9P@3YD=4E%@P,X#;-'MWVW6S!.T@=9))!O
MPO(\-'O6JG0TDP^EI3X0.C'NT'2T!,;XR7\@O/NCL<"+%LOFKPG#2TW7M:K5
MT:.^ 3L8;=-GP553WPGG\9[XA16[0IU*E*=7]5*M;*ULBOT?>!U@)+%2;%V>
MFM5L[DCB7=NEUI$+4H5Q5BO$XV$BB-7VB4=6Y^X/=']$P*\/E\KX7^RR,K$-
M5X#6'RFA.I39OTB_H'6E\<&%[3NM9,K6A3%_"?S9Z=6]X:*[]\Q=@Z\%;[LP
MAY<M8!MQ$E#4]\=TKG^@,RBUT^0-LEOC1ASP^+K7$;%  QVZQQSXR.1$FG^T
M8>OTV0%U.DE9Z=+]6YWIKM=_78TI,7!-?SAQ]UX8_\GI;L&8' ="K:*_[#1Z
M>^,])@IKXIQ_='AP5<?W)91^RGY[8A2$0=$U4.R;J*H=UDNB6S9+B3X"3:7C
MF7JQS*!T=O(+@_2(G?:]!QS CC;K>7("&/#,9!T:!X2@)% 4>RQ=)3$>3Q1#
M5--<6#%Z#T"OZL5)7./(0^;MX #X5L""T?5NQ>/)APMSD%=&UWJ>T0.;T:[D
M;C?_.?WS/V &\G75;I2?^1B$QZ&-:.*3V>D#.4?5?>_18DHA);:W#9P@8ODW
M3M(]'^;(CIA6Q.=]-+]F91YRJRMW/H>Z6Q6H;8&X=V;WW.$Y:R$^ P]\;KRV
M:B0?ZW-=UUA<BG_Z9EUH:&B1\]0*)'-^-/?CBIC:],S,S#WSP)"0('^E?M_
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M!H"[NCRO"A/;29=MB-&QK98M31.T5,\W+Y.=<GM[: -:_K!LC%W1QX%B"%1
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MHCYR44[<PE11,[ZL1^'!TRUY*S_WYI2B30;X<8U-#;S[9[&A1J^RE?F,8S:
M:V/A1,]2%YH=ZP7[+)1^\PZ[F[K3[F77,NOVRO]T@3O6+Y6:]:[$&5'G4+Y9
M[B,RG_X"!SYYO6#E1">_!V2*EHRLV!VX?HP#,&Q\^X=:V+D6(US0)_II,R!$
MV5F-)OPRU\)^H-UVQ>I9+#@KPTU*95[ZV*K()97?<L/QIKUWPE=JAA9@C]$O
M4]'!)IC\Q%_9V&677T.,>FZ)I(%J.DL011Z@F\VJ3MR<VWFQE2C)'N  3OAY
M*;6C13/)ZU<%K,WH"N\]:;0];)1?K]@?P[,A(?#7\2[*I3O12!-_;W^GW_8>
M4T9?/9$I'X%O<P"+;,TY/6>7N%;7MP'G_:[VZ"W>>):KQ>=2=/WS<*I)6P&E
MR]0RW]S ] UKW5#^X@V@3_*\^J>M0K+2D'6KC:F/M4G1E> V(Y5E&WQ&WL9%
M8H"*9G+ZEC;T7?;O"&@[:#R9%LIZG_U[]IQQL^ !IN&PGD*AQP0Q8IMX8DDS
M&9'8DK[GQ(1D9M0*1K]W1)WP$"I=$S+W@6%6[&CIC>I:7^_=V#1B1_)K]#S;
M</]T[;N1A$;N1=L(G22;HG8?GZ1"D^F,&24/;2.K!*J/A]K1;T\,9-(G+3&6
M;1AQ4R6TLOK8)5S2".SQT'@N995]_#Z]XR-"B:9.]Z(DFS9H8JG8.9$HINR)
MPTW#]><H<[=JJ1HCR6=EKG3,26)_6Y'KFTU\<'*])Z9[)TOL?BY4M\U%7I)E
M?$CU,0>05G7!,RF]^'VY4%6V<*BRJEBTTK7[RX,6TQ,5"TXD"Q5S)&9MY@O[
M,LB-&#'(A-.W*=:S/5=[O3D $;824Y_^S/L]H-M-+([ID$</#AG^+BZV]G3E
MI)/:Y\V!!ZH7A$R@D[\N01I=Z6LPDY(+PL+1E>.UI]PLC=G3/K?H:_JJ<.=X
MX"[#+A-D$?1QIF",P*X"C<!;I,6_ZHF1L@7I6LVUYEE1)/A1]V#[R'K=G&7J
M$3^6S/6O:V<'MS)5^H3>B.1'9GO!/>! W7/1]@OML-WSI9#4E6&LW;-".[S)
M2*&5Q6:F26>7;_*J@DG53$!8SNEVH;CS*2Y'/K8KN9XNEJU/L@/U$-E'811C
M8U8F"@Z?B"6I1CTY-XC4R&%:$,:05_(<C?Z<<)\^30\O6,X60FKG.OSQ_%*
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M!3E7?;9T>?^VRJ3(1&A09<(\J*2OLGY9MN;]SVI8=RT'$)4>LO*<=:ODWZ!
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M4FQHX>?C2+%3&2JT6*]T&CK]P\NO>EYY\]UAGY;+<A*C6QVR-RB^"-2O+)E
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MB\DXC-G;Z6W>"!W]4- _9KG%ASAANTPXDFS6;G ;>R?G!@BE()Y)9JB7]W,
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M=-\NG*N+?5.,(U^XD-%M/>AWIZ&T_M6'Y^J5W\]8R"AL^R&>RNU]$'O5\L/
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M0[XA$+Y6;&T!;R)LX0,7-G0]>&9JT;R.GV)<L^R',]!E:3)[)YX/R<D!4NB
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M_G=ES5WG'^U>G,K, OI*J\G8E,OZP!E&*(PG&LS-.5G_F/A'&3U_&OH,;1*
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M5#4+Y.[8_;#-;5NLMZ_V\-C&@/?0)\7M2JV"[98#^:WLEU ]Z%7F9281+1J
M#":K4*:<QM0AQ^TWM'(<>6"4U'7'U"^T5_!0F<YZ+$JSQ34\F'>H7"2-;/IH
MU[7YIULK?T=&QQ@+E"T1L==!51/O=1A_)ZOY<9DNG]#_\,JTHO:C]_ZZ7<K*
M)8[W J>+5;M\8GMMXY ]<MJ5-_E+3$^*[5$*,ZM-$$DL$%'O\E[P8HK^C1RE
M2Q^7U'B874*IR $+M5[7RZ[4[&K#<E\^L9R_.G6MRI]G9@O:6F&L/E3JTK_&
M+IGDSJ ;B/W$%RCQO8 7*DB#SL8)Y8[+50C$-^^P=K_B7/76@RVQ_@)XD%_E
M#9]'G[P/=#\=J_5O:FQ_Y9$Q\> >L_A #M'9YW+9G>YID-)H?[]?$/^M[F4%
M^$K),_P#^7LEA6-?SE FOB_"O_:8:,-7Y$*\;\;*X>IL4N'W+"N6 %CZ@@1E
M"K2D[5W):TEPO?*[#Z*>)LOE).@D;"[X>"9/6&R\ANQNU1Y:DKY<S74O6V/K
MP7J?DO7J81<.8['VYKEWN^,=/Z)5@_$$O?495G'2]6+02M[G#_BUU'*U8I7)
M]PO*)T6U30424L;?WY?T]C:Q:Y-/+AK'EF,BU_WC:^+"LK+%ZA6=C:T+S,+-
MY)V&%Q@G][\^.G,DHQ;Q_,97:8?]^8#;(ZY1W1<G6N05-65GRF=]<S,_IK;8
MO&HP%V13=_GN]"]O.VKR,?D>]CRMF1]L5(#/^GP%)E/>B*2LI?+]B;W.^O?M
ME#R>,/WH88Z8WB5O15(L?I)@AIIM+M$B5F[8C[4X*]NW"N<;EKO6.*JI8B:+
M(@*B?#^7U5XJGC%^J%!WXH'XV9@3(KT^S_L?-'&K$!95\NZ'23D:\3\G6!)&
M,IG;CFI%6KN9],]4$5_ST[4ER?BIGLGT7B-^DW*Q1N*3T/.B&&O'^G0?=:>7
M7JZ@+PI!?VG_973O6-K'QKL62[\]5[\7W;:V*UPZ-I]96'J&Z#,8OGX@:JB:
MDY%2=GA+Z^>(Z>[A_DIB@*)H#&:B246;NXE@C[[.\=*"]'M<X=9?HS;5FGO&
M]Y[[_9;![<]5FM38A6S(3+P;&&2!+L#0"PZ8.SU/U33,? R_+@H[+F JO&B?
M>VV7[N%:QA8].&3^GGJ,%WV@<U;S^G*,_H[05=7!M^U0^\^-@$)7?.WL4N.]
M*UG^;8SM)UFD\HG]P_KIL;AN-Y6):VDGN1)[)U@@M+VC8)"@QNQ<N:@IS*)K
M8=L9TJLO0N6COD:DWYSB<0M!?SOH0E=OW<_(%;(3R!;/CG=*J185Z77-78M0
M\B_;+23*?SD3\'F7'BT@5NH'T9JHF6@I:.KL^&68][E)=7#&GHX3?_88L%7C
M@O&L1-ED>]T\\'D3M3<^C[U+AFHLY\^2/-DL+PDMC'2O6W?A!]PI^3\=J. 4
M/>.:!*&P@X!$A<IDXU'US:O7_5LD@ZV=K4Z:*?4-B?[ AO[5UMP:\\NZH_%M
M)WFHJ; I83?%([B0O/Y ]?-Q<$ 283(@YY2Y2E+*PW(KC./$_4LDRIZK+E!X
MRQ'A?6;#MOJ$Z>BGM[[#+]3N"YEENLHM_53H:2^)[;%<6:W6$M89>%P0IWO/
M:RS5!$BYY?T/GM2PMT&6GR@WS%H##Z+2B10'7*J4\I2R.FIZ[,98ESC"\6I%
MLLG4_K:X&166OH^86+Y=KZ3.N.X=?694:)O'"O4(7[$9+M2DU%WO;-@K#J"3
MNU[.6>21-UP!K9,&TH,3YG<TE87C2_+6M),'<P2*Y$8)[N\"X*',01Y]U:#B
M;Y\J!R';+OP'ZI0NY[C*%TL2MN?U/SOK(PT%N!*QN<O?/ <C>HH<(7:?&UT&
MAKY5DZ_<+81T/GN>.BP'FPEG<D^XL@$75X%R_[>]=$6L>5,XY98GI?\?ZR]J
MVQT4GF))H1Z]=K+RV4M7CVY?[#C>#[V==(\%:K[_;FQCDH:SK^[>*X]9)A:]
MIQSB#R^VK/YR':P)&_^U\I%H]*1%RK&D&^:(>TL[ PR4!76-D99-)&Y(&+5T
M%;8/%QAFANFOL#E"%*K;K$N5[@N,D-*G#Y>,$NC0>F\IN5:J,@V6IIX, 0Q#
M:T^R0+R( "?JK7%'9JHOM#$ \\-WSWCKK)@'NF38,V2=3>/];GX2WG ! RN$
M.3,"P'>*C%0"BUJKI.EJ^T[Q&FUHMVM01"1L]<N"OGE!:VSC3! FS60*@)18
MOQ>TFFK__G&TPQ+X68<:7D(EG<P4[74+O#M8_BQ']G*O#6)+YHG(5IBP<J4"
MW\7*0V?1L>KD2EM3?I@H]_B2!I?ER_06QFP^PF\*^?,6]R.EWV6W<X,^G7P_
MD/(/%X?.XMY:^'Y*N4CM@(D<K2/?Y&"]-JU=OY/V=I5IGN(NZ]5G%3ESN<U/
M8\2T?7TVLLN1./,D@'%, 451 C-U++?AJ.$9%""!^NWJ,H"E'[##Y5-3=CC+
MQ(?Z!7_8^G7*HDF<_JHTUV-K>[ZQP'^[4G2S>4G[M[=:+'90>V!VMWD["@LW
M18W5=S1=,M=<C2V->I]IUTKK<&O;'#-_E/]C\EO<N_=M3QL&$BO2I#\&_2.9
ME5&LRKDR1+:.#<E:$NXLOX#3,3K8=O]L*)"+YS+%R?D30]P9X5,Y]LMI]QRD
M,V12W]NE9H_$!V6[RYB?./]\*DW%3$,&T7*!!I^'Y@=@T7,7\_V,U2?7:S4V
MBG#*[^(W:$-]*HK[\RV%=TA"IM7DMM3"F)N<V2.F_]3=?%YX6?OLZ2;=K/5Z
M[\PX[86YL9<Q'];#R/6CG=BQBHX)[N"JW_">4#&[9NGE[3>=+S-;9NS:;#JG
M%+ZO2RMDO&W7K2TM_<O(4-36]GZM_%'N!NWS&843%_/-U,?LS+SS(]4/*A+A
M%6-_RKE&*MK,0N#99\>;-ZN76UO&%>K]S\VYM\5L<%6^.._K=L'RW]V+4^><
M'J?6A16>OO6WCU5AX3G;PC5(DDJA^Z6#7LW)=N^,Q^6V_%9%<O\DSUC%E@I'
MV1087\6$^'YP%,US_)6$5"$YN7=2C5[L*?-.?Q T[8RT&]N+]'07?V4;=9.\
M<-$=EO?T-T?F4Y]<X;3N!Y</[X>IG8PI9X&@*H@D^R<!@\5U)*E.IH615,=%
M#LGTZJT&;3T7S9JI:=<K^XT:BL27*9[*^-U'[;(O.J!D'Y4J(,!YA'ZC,N>2
M<K.9^:!-DU+'&6%-@;D;[T[=</XMTMW'MX%_2,F;B9[E3,*3UZ\)WM?P#EW_
M!:R;!\TZTP\R$KO)%!M)"0]A_MBZEI!&=;F[5>T^W VQ;6,!2O&](1)K8#!A
M)[Y-K(W&BR,H<PS7_TX5IBGH*WQ]--$QCE)\PQPRNX'5Z_WGS*-=#D[QV__V
M_,X8VG5X&%TI053(4:(=U 7SR!,JW[0UV%S#_!AMDYX/_]5I_"AB/)!X/\<R
MWXC3A^'M$*VD[8&)/ RWF';\].%GISZRL_>)9\[_($H"84W]G[5P_Q,&\*HI
MDX_M"K-4D7=8H+=$B@ +9"T'8KK@%L>5@0NRW:C9)K)%[_#,!UHU)2R;>G41
MO46L1X3WH,!, 2##[BXE("U:=3,,3I9G6/0['FO\Y$Z&GD1 \'>]FDQ)9C:P
M6U3S6G*J@D_83%I&"1$N]@_G+\Y#MM\5QKDJSR;0/*G$;GGL=/]B AXE;KK(
ML!U;'.X-.(+4H.">Z=E0*ON%\LWV7+@GZC30Q]?%S&N#2=>T[',F+4XA+D94
M4'9>J&<5#^V8P2<'-L8YZ-DH5Q9H&KL$W0XXM$4J_2DM V1[9W:>3]'B@6&2
M,A?BUVTSF&5"SR21$F-*OEIDW<>4I7S6"EPOEL$!-J2KZ!>ZJ_&YK3^)LUS[
MR;Q23O#0V@QMS@,&<PA*N4T$9&6W<!0# X"3<DC[&Q"H!PS,1_R:T:<V80+Z
M0HB39*VTZ MS_>]W-'82NQ2IT 3E%HB(CUCV>.;<OVVSZJE*.M8FE!^9;[YK
M.OIG>A]APHF40.*6*<D"N+!#%PPP?L=X26"!N#OXR7^:^%48=<R_UHLE.W$9
MS%.("H@((MFP<Y1^%55M&AI\[(DP 1O_)#>9K@%?,PMX_?U@-;'4,;ME[&$B
M"/JUC<E=2^U:(Z H-UB@F;&E^ SU#&.J-8UK/+3*<\RT/QF:B@*K=ZJNO/8R
M?M3J Q:](U'KYV3[F/#ZXE/HRP! 5?SCS,720ROF'.2TO^(VD< &0,<I.]VZ
M9F-+V[8'4 +D1;CC:N<9#B9B;@&I3OEYOV%9H_/M,N>YI]"1'_]'S_DLD\^"
MK5;2S 4T30:IS )-,"C%3Z'#F\P3[BS0\<TF]NJH ::T)$H+<:LI]/ 6JN>
M"L$715_=#$B]\N?[#+%.S%.*:KTSP3/7ZG#<3&D6R)<%\D;UW&U2V PJ9Z1O
MF8G&;P[;O>#8MZ:ELD#/_Y3,#">Z\$T@Q0\O,_L6C@&<2^FGG/K+O%B@4WKN
M5*7#)>;[-RX+[7C:GY"N#TV \'9<#<*>OWU^A$P]WI84DA&Q8HPJ\6Y4:7@
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M$P,_UU?NE?]7P?KO!MP[/W#OP7;*>MDFE'?_6\=#V<ES%&R\U5/H*(3);37
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M*O/.\F\H0?XZ[,UWK_#6KLH=SBU;?916R#?[H*!DOFO_3[K&OIW%H-]#S[
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M!"CGR/@X>;CYW11,1<9&AP 91YA+&<F*IE24)ES[?(SZ=_=*ALSPA;&C9Q'
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M5647NFGU-/ZV]N3#N1;\FX[D9F==6%<UK,H@33LTZ&O"%D]\SEG+[COG<Y>
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M/?.P6K+.9F_IIZR[O%DGI][R5@2KOQN[\+6'O:!]3ILUZ+P[-X0.X:.8@@'
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MVI(6(VD26<&EQ<O,GZN ]27#Z(T-; (<7MLO-\WZ;NW:;T)/!T?>BH."/T6
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M2Y0^.3\J<07K1F+WZ>L450+^[-M%;_*T*3]6C Q5P[<V3TSWFI]0_E7WY+$
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MU:^Z1[7G>:'Z@Y<O?G%].H*5\)VZ?T?S<K>PFGA:N!U1>/Y=^W=CI/W0MM1
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M%7$YDR1XIFN\3.:UC[U/VD\KKHUUZ[)KFACW^#7,8D[^J=!$98H>.</E?=[
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MM65JE>/Z?B)?1C?O_99H:@N;>,6LNIX\4TX5UXP0R;TK(,5^]R!)MS@@SUW
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M$((QI(X!07\+TZJB9_,!._/9[/V[_X.]]PYJLGO7A>.+@B!%>B>O(KU)4\!
M+"\@(""]$P61)@+2(@2B](Z"@-(B(B(UTHM(@%!>0'H34$A14(H\40B/$)(O
M[K/GS/?/F6_._O9Y]]DSOW^R9C*3LE:N^[JN._>ZUP(P>'3&')H5[8DY1E.;
MY1F0=.F+49K7KN6 )O.0_=\6FJUPH]@G=UV4T.+(33#<G]>K9B-"2GCJYO36
MF<;"@7.M0M3%L FVM94TIE+_K?9P"_A.7>I&M'KW.\8H&U9\-"BN 7%$[_B[
M,9(K?I52&U?54)IE_D(E,E.A!\]L>X(CV-*T"POEOQRXVCML!5*5GO,,X\!3
M#EN/#SS1/6=^[UJ*C*#QO:7&4HPJ*U'2E)6!7[C;:'&:_"S*IM*/S@I8]D,%
MUGW]@272>,].IW?S)(ZH/K_=J;M6*,ZEL31 YZ+$.^A]+^G836+&X76>[QCZ
M"4$&Y"@>C&*NAN-A>J?_ 7R#N:X%//WF;..4E<V?%%GJ'[< X?YBQ=Y5?7F$
M*UY@'@TD@KW+)IURY$*1THZ5%WZ(I7/A&F#<Q0E5%0B\R!+4FJ9SW*2H+KF"
MA<PW#SZLPER?CCE#'[\RL,> '#%.O6L*9AG]+BG+3-)5Z.,%626C,J,K^%$/
M,QP_4F_R5EO;&^"S@?9DWQL?*7[@,+>-;0_ZGWJHQ!>F8]<DG-]D_DS'M$ S
MRA*5];"<?HIV%30L0\&[P&A*R( 8)B$,PTZ#4WX7X"_X5X"#U\ $(I07=1'(
MST2I5--@C3-U:C0%TI:MCTU+1IW/8LFSR/UK6:^6/X&\)->R S.=X6J2_0G1
MQQ/E&?V#DG=4])X%N&HS/=SB4^=FUYL(M7+=F5X/]9/YJN+"2=5&'0G?3+%?
M9U&*9&.\!'__K[M., 9$AOP1+_S82U"#^\X\;R(I7=8[E1F.L[!Y]H3X#8).
MFJA1IOCY$8WU>NOW#>F#[&D]%HV.'4@TZ^\](2CIPU@&Y 9V88^TO?GMX"RX
M3<Y(BE6!H4F6B]X.,PR(?Q26\VN7,@4>AS(F\AQ#:L#3NSC?377R RM7NT"E
M:B8!<C4-;6K;3Y#?3>VRXJ)#/URI_"8T\N66:Q1^X<=[2;'='TRSOL\WV%PX
MD>=,<5+M&H3W''KAEV[MSL@,I75&Y]CWV92/FV$VVAB0K]LDRZ0IXM\DP)&;
M"67'^ATP7"U.?08L]I*XURZDB?_X[4M]]:Z!1G='4ZYK90A><%PNGZ1>E2A#
M9*:Z79PQ2[@_NK3E,J$6LV%9?Z![^<M&R;<1J<Y_+1\)Y$>=-O"=-CB'M/4?
MO1MFF;#8L?11!'8Y9ERVQ,-P;K-IX-V;\[<-!SOU,<H]DUB$&GV\5#G*Z1V[
M%U8P>V,SA :=<]5OL72[[/KT[>""]AU#/=>=]C'X_@4PA[C3=D^G4X@E!3ZG
M'&T@F49X'V8@YV0L46>8#NSIW;_C=VB9_D:U5L9!T17H#QGZ J;[E:8@T=UJ
MH.P*C2^.SFX&V%!)%&.: !L!]WL[YAX>)](E#N]?29T $=1,"A0//4'3HACC
MU=*=V=([+U31 H"Y])5C-#G2.Q>BX6HAJ3;<DGLC;B"OP:?5OL,?^6KVZ!S%
M+_&?G,W*2ART9;L;FV%"3IIN=O/LQ@#Q7W\B%_))>8_//W#I6SF>51 ZGE$B
M*/;3I=B&&%[7LL?*<Q+3.%3Q]''86Q5U[!VNA<?!VSS>(V=#_>>9 &[\:B8U
M%WC9R;__5L>!! /"MIO/$Y S?SU?5I5"-7?AM<C75PW)HF?2SX#1JA*9:L<>
MD"QWTZ"621Z@IJ1ERIS5H-)C3YC^6(F+&,Z&K'RBVL1N.!^F[OKC?HRTV&L/
M=RA%F$IFQD X4]\TX(2W"'ZM\30TM$N%/HMFZ30YN(!2FKG3)*[/XPP& A%7
M*17=4>,G_6)DI^EZOG,XH:Z3M$OOYF$L5>X?UQ6\26DJ5PR3+%M2CX<=0BU+
M5GM).W^W[24U?GFJI[W!5)"%'9DL__.ERLVD!K?H3'3<_DA2R]#&:[,<8>2!
M;&URA5E)ONX@ V*,YD,9Y',;"\=V!\OM]V=5X.M1HID5?1ORY-R_ZTNDUBQ5
M,A"5E+QCLR^KOIB5B-3=A^%X,VS5U7CVF;:-/HEIM$6P[<#C#([,TQ!$-8Z8
M4<1QF/@+\.XV.3?=G9/"EMYU!,F&%S(0!#"#_B>JF79ET!U0Q95_/>V/$W3Z
M5J EU/IZJ](GDC-B/Z#SU3^(GYB<;J:[\-Y\>V '.I!:8VE.KYS["6_5./ST
M5E)AT(.+2+WQOX#YOJR'>O$VAL+]_BHL Q-FY2"6L)*\1>S(V-4WFAYJO3H'
M/?FM(V+ICL'<_R[_%#&Q4(9+,8":)4FG]=S0R3GT&)PF?NCB'+0AA3T)'O[L
M.,X34I$W@)T!1_Y8G[*[5S[.Z0 K020/5(GD)]'=?U^(V].)!OY26RKK@_+#
M? $;!/CK@-V_1*JY$TR+('Y5V]EB(^:G= E\:OJQA H '!YVG?79_T*#<F@_
M^[,]_UH7TR>AU$O!,/[-B"ZQ296[34B1?Q9$/R)Z&!!0^RV=/9#2P8"XMTW!
M ]"+X\35+.#WME1W90HWAF+<PS1])RK!O6[@L&;HX KRA"U%*$&P"<H*N_Y(
MT_?VFO&L&NS<7#_J4A5+I6_5P#])0O/;X)E!&E\%_7CE@3)R;H\LW*O&CK*:
M[;I XY^NBSD%>I+EMAZ25(R-*$HTC;:&=_4MX$]@'B\TM\P*!C @'"NNS=&F
M2E 1S%$&)- GB+1BVS&5L5OMQ_I/SF*:)[-C;Q/-]!TW#G,9$%_+!3E24AI=
M'G4:#"#SL/LR[4%J6-KKG:P$*9U9.I>/E,HDS)>XG0GG:H8FETA2#)(B@"6G
M&9K<4>^^R/S$[6/%CTI6'*>UHC*NF+4_^8<AA:#Q*E&M?_,LN@>&TCRX!@92
M'<&L@[\6/X ?D<:DK/3;A]A=-5:?O?VU7@:$Q9=^9IJF0FDDXGU6N&-$+P4#
M97WG]E?K59;?1@>$J;RD4J]<;P;V79T-7XL*2P%45".;T3L4[L @OG[K]HY,
M7J>]&;9^'$ [!5$7],/8[WEL0V_-U@M\"YE:T_G_:3 <_IL9C 0&Q _'2N^&
M \Z(A6I2TN;0P:5/2 :$.96X3I7[I32?B4Z'JIYRE *8409>P4><5WL>,P5E
M:\Y*UF-+T7*"L9!4Q"QYD1X_^YPK$K>)6?B"[]@*_PZ+G."J;^?3_UF&_65,
M/UY\P,,$T>_&F:[3AR]VF?!U(6]O/:SX2E<"SF74@4O$O:TP$CQ)#_ZPTP58
MP0OOY9=P'[[NY"KW11PW$/=SD(*6C*%/?J5VJ>GU?G#V%7NW59%,T_4,#B9N
M)*>G92&C#)SBRMR[$(>8RX[4QDB^$7<EF?D/:R"\IBWJ3DE'?+MZ1%:#WX?4
MT/9O(47HG0B*'/Y;T.=@I#(;'[K&<1]U0;CGZ3K*HB%3US5-E/@]],>'V7V,
MZ TW9],ZVW9BZEK."$5D]@H?0!<%'.CL<LS$YSG(M#K'>"FM-($E$[#_X":2
MA8R+-=!=IB]F(^&DK!0#820/42ZUR04CX 9V#9*V$[6@)VD"20,%F&YS;QN7
MTL"8+H.FV= EQU.M<UBM=JQR^3L-57WBYJ_;W!F1O]#4:';/Q=&O9BK(FGR$
M)X9 ;R!N-42N\WWN7S88JO90F%HK'V.F^),K?1B><OSC?L(;"1-ZO><W8!/!
MZEE)T1O6^7)/V3NI?7K$TV$=Y?4PS%>QW7HM4:G$4JW/TX[3#,^ 7(*SP@-6
M'B+$<@9Y*OPZ!A_"B>R3JY1&M7Z5TX&0UI0N7JC6-XPX3%%[M56OHG?++> [
MI]0IN'>.I?KIC7!G3_</XHVGR<M2XWDWOLYC\QD0[XD\_9KE^(;YU*$PJBZ=
M9T-5:DFNKE3UFAMYLZ#E=+%JI.L:]%"29L+D 5T)]Q-'^C ;0@88[G[@MAZ&
MOZ8LT^'T #*J&-:B'5,QX"ALGUV=JXKT:/_\@V:D?;VO4Q?PI'X"!2F5L*#]
M\.H:)#_]9+%4H+@&S7I*%CB!+"3R_K1X1FGL+7/W#ZE"J<[.+1-Z2/S4^UH_
M^51;O5YI;SU\^X^N,.:_U_+"H,<9D "U!U"I.UU_+LJLEA+%U3C F)_]$7-P
MX5!9P!R7'L/I9@RSQXC0] -(EHHJ(<1S[P(%/WJZ/#MU</K/)/<WTPF[^8O_
M9$ R(*/YOSN]O&DGY^D<ETAJJ>B3J&,O:-:'\9U1+[[-PWG#E+*.2,H1A1]T
M^@-S#L6;!A>0441XGSF+*^"'DIOW3/R<8=D=CN,A-Y<L*V7$C)AUS)R.OO[/
MBNTO(O"6SN7/%%L/VKW9L T,!WV)Z:J-\5PL3,YGIO5.)!4U$@/"C-FD&.$Y
M5!0!60"T;O$05 *=ZR>5": Z"5G*@*1X+Z+@5>[(<#,'^LKL2;^".W?^6:X_
M9#)CK _3<O+@"$P1XZ!Y5J*N-T[0M6F6X&/@IA8FS5UDG@&YLR( CV\J([SC
M0&)I\(._4/J 96(H.C%&@,*&5S&^/NTUH_7)>T O(@7WYNZI!^OAB[;3OO<^
M_=.VX??>^6^6BV(_Z1R:!TATCQ[N5N #IJ4IE:H@?+T!2&'J?",Z9.8J*2S4
MY^ G-7P@YSK_USWYCGAGAY1.!0!'7,M$:=^_'R#Q$]0<6+0OHT8YO.MHM7P^
M%()2C<Z[V7A'()BWARQY_Z972BE,WQ2,=$QM4O H,ZW8%H**<I@)QS^9\;(Y
MX9[A<%SWA_'/3#W"^WG\LN*HS@7]VGR[L0:[!^6%5Q0'K=Z_:9,8%,PC4,#W
M+UYI<GY)*O',GN^W'=:,#/6VSQ,_U^/Y9J+:6<O."?TBJULMSIWWL-B E28)
MLA!$#$8)F%@,)^H$@.VM?SJEX'()$$X,7>'T;?Q8<]_^74?SM'1'U]/&(?W/
MT^/*V2/2;R.3AJ1:_^V$"M"0*7^7F(8D$N>Q#2J='\2QT2<138B^\<6H'O?S
M@$.O)!NA+O\538""[<5R(]W7>KND*)BLSA#/Z-<?P U"15^QM5OT+CIY<5/X
M?'C';'%\ 4KLEOJW8->>D(C((P<NP,\>,4L\'((4)PX\U#X<2_B=RS %V"@M
MN&KTV$"E00[17&CDTO3MF8KFEL:6$KK+A>/N/_RC+EP]T^;K+NXC[94"N< !
MH:-P=WG <]-4D<,NW)UB;RH![*>846N!M?Z \,#$Z15D!!&;2>?]RH!P[]%4
M)[1XN'W^D)3KA_Y!\R(YSNU9 E_B_*7I_'_<575?-Q.:SOXK$\+S]=P##@AM
MC8GVI[__9<=Y,=,OQ;7N+6$"8DN;+2.T%MY;HOZ&,AX;\R=-=1:FRT13RC+[
MW%9IWJ!-%KYC.Q4E1XX6U,+P?],<>8G,-YZ%:5<Y^MEO>$8^6MR(/)=4[?L<
MJLQ\9Q4<X2&N?HW&=X64WY>5AFM,ZD,OV@PLRX*EA.,&$OYS&/%.3P#?5Z"2
ME\"6W#3.KS*6X4^ QZ&YU )VC6>TJAU+HK:,K9L/Y K%G,Z,R5WDF;1<"J%>
M GT/HF)&$,+P6X'I>O.9L O $OE<;NDW*?FY+O'U2*$,<M0)- _8BJ=KUN=?
MG*&9$[$B/O:M7-7(N[U*B3,H[2J\3-JGRX\&M1Z[7CQ"FT/W"<(!,[5]-4PK
M T*7M%R89D!*C1[H89B*TO,,#IB,<ZU3._(:*3S4.<IA<2=E1"V)YD9!$^U*
M'D>+00L6UP./T/X C#H?C4P9-<S5JEYD0.R"14?DV78N'4#IO9@&RTT>8-4R
M =T []YF18D Q9_G6ITW?$ZZ^TG)46)*O5A<%M>[SE.Z<!'5R,&!R.(F#3/!
M\K64YG<6+B*WLQ?[EES4$Q\8-#WG.0L. C9$GBTN8+L/P6Z@A]("+/MQB>[*
M+4(EIP!X'P^W;XD\L/PJ.6)I5+6P:NGC)<'#=.+=G5&+CY=>?XN8O(*N<'->
MOL3Y]0CM#7V" 0%N9]'X74B)N/LDM5@$DS-\ A>JM^:%-<_'[5CR?H7S=[+<
M:+Q@(J!GF-_');0]:#_$HIO%3%G[S.TU[]8;I?!7C\JSC1N<9(;2:?BM$:78
M9?W#%IP/AF_Q_LMDV"D".K'K>-N/""_/\\ZCK7TBZ:4&-F<;C[NLGI2_(,^R
MMT9G9Q+JT7-,)#(9ZNQN F5\<P7 ]8DE#3BA]*.( 6;D_'X>4;]E#3"KTB<R
MQ[FKO&)0 /ZABP78$8O/"]+^ <)[I"3.QVIE;E6D2/\%H?\N&66QHO$+<,(6
M/ TA&/B" 8G/(3IT\RR>&(2+-(M/&,Q6C!*@'[XTP>-7C@9Z9#3>"5TYB;H$
MK/3ZKC8]573]X+<8-RK0J#4Y=H2>/_,_&G6>0(& BDWU0"9I" 2""B]0UH?5
MEH/AAV7?X7XL1%;*2J\FD$87XAI/E:&$%CA.&'<W4RIHIZ7MGN5J;8..\$72
M]!TYMP@I+PCZ4A/D.MMG.$WP OTXYN#W.19N 71!RP.3CS1;P"&MB\>\MI\8
MF+S"TLS\,-!A4#A&@L+QUWY^+.H*FAR8A./=*?;LQ2R&4SN^8WQE4X3*RM8I
MG\S+UEN$%L>3 [0?<6%_'[[.2Z8R@SKV"M*!S!8/OSTN3@NEM!13&OL,!"AR
MJ=]C=)"8;@,97/T[(+RPQK? 5>QHR1^@)S V-S7FJ/UV2,WF>N.L7)Y70FE[
MK!;RZ1^#3.=//SYX<!S=8\N6&(98+.R6DD,GQ[!/U,'4".-I:&Z85R7R/(DM
M":8;$A5195;:MR6%):J$7'.SIFY8-S=1$/'-X,[!4EIEZ';#B8V=MQ!Z!,R%
M 6&]0A_.+V@O[,:T[&VQ$4?9QCBU5H1 %N)@1EAP8-OWY(U(..U/>R./-BLX
M39K(XM7UOCO^.4\U_#8.U"RCLR<!@?V1Z+0N=60C,R6[NAB8?R:&G;*7VH1@
MH9WO>)O15QE6Z0OE;%+C0@[0C$^?,C= 0UNR@H4+ RN_=:3S-?D=.31!J8,(
M@$S /H I 5BB\,-.)6">V/IPYZD6_#A2O$=/"D,</P&&F#PLGAHQF6QJ4ZFI
ME?8M+U@-S^25F?VX)QRAIO+^IRE!\A,DQI>^@@.N8CX(TSG<REWDMJP 3>/Y
MSH#R19FDI"YUT& UD 7E"1P6&;X7$EJ^,-'GL#B7=N=V6Q2"$]FUU+<LV%*R
M&O5WZ-5M1]?7;#^CR%F@AAKUZDR82V%6$K2E8HN?*"EDUI*]=(V2'TL71]+I
MBW]W$?WV6[+\@57QE%R-M(C#7)$QT=JBV)HC&RML:,((&I2#Q^Y^4G(&6RGS
MU!?@K&^%:8X;>-4_YB@83#2/"EQNGBW$QW"]I12=LQSRFJ#YOUB):[W[XKG&
M&[9=Z0-U^@@< O>TC.N2 %D.-&A:DUW\*&G@Y6+"6 KAD&_#<>9FXIY#1]0G
M!ZMWLZ@KE1MZ5&R57\3=^?/[)?55*RN?AI?6VN^Q3O"L+5%+F!1ARO0D19AF
M]!8O!4M]"B91,-3Y"5H$987$1+X"B+L*6/9E/8R,B _=YD5..W;,[?HCN!W]
M5QH#4YJK]:641MKS!I9L**SU]SG%/0OHQ(?A$  +QE;0V9EH-_Q)94"8+K/R
M0 ^](S_!9DG @)HV=/8$ EP4-![4LQRT7!K8M@.\4W9X!+^U%&#Z>1:H;N?6
MK@/?JWVK%Y;6>9WH(^'G[SF.!GL+1 0OKCA]?/?VZALWEV'K6Q!Z\VL6 $YE
M)O]Q=YB3R$>TCJ?L8E,,9$$7+(T%Q).$.][.&\C21SM:<@#J=E]!\_N,H/W!
M-)CP:Q#=M\+5O.6\2OG2/J=-!:+S4YL'VHJ;X2?'=5K;6B&TVQ@Z9^QA@8NC
MR1;N+C8S"$3QK_KFT%2!8V-OR-)'M#_LNKC(_^T:ZX)O^..JSO5S9]D^P1O5
M:&(GF-19#@J31& VE+]008=5VUONHK4P."5IT%Z,YX%*7>T8^-TR,88?1!/I
MY56).:S1\+YEV?D=LZ>SI]JG7J54F%R$OSZ4-IG6XI(SFVAR$0_0-)H,W5"1
M,YF^0W8,T#K4-&])'>L=F!/L[0_P]>>\?DDLHU+ IPS" 9G\/[M/!%Z"6<JA
M6^20D@Z'$/MU-&G$9]R4/]T2+8[^Q-3HFLR+Z#)W%O30:R+BH Z]85($E9TG
MK&WT_ >Z,.<,T9ULO[C_RZ\3^-?P[Z?'Q9&R.+]V:0#?FXD(7N=HW!4**R:D
M?#W/PW=KM+]XYK9NF=/6RT22D.*]!L/3>F>/71T<_;RV(&37MW#.&_]K5="S
M(9W,YG+D*5'RCA%T0\3U+U?%:3N@V<?#IU7X^VRI<ZZCZ53"U2$CX]+<VT]I
M.1K=J[_<3Q%#)-[RFPG']2F&^D=)&(HJV& :^FQJ+[\P][>H59@NV/,2E9U!
MV1#RN[<?PKG5PK+X::=CAU=_?+^ X5PO>)>5J@HS%#@1$.8?%E6FZW;Y^\#R
MJOC;*!/5%\BY?>&KDPN\G\1_\G#"9 #,0_7[F?>)RWSI]<BJL!_7PF\:)S=R
M4D\F2!AR?"AJKEK(5&._W*QL+Q5?/;A@+&P1=+V(S$I4:R=C3G9>) V+P!K3
MZ^W<./@KGA'/YMZ[(V0GI]CD-UV6[CYX+!%K7VPJ6*5H'9++;F1QW<+LZ2X"
M2M,'DOIY.)>1\$$Q/?_(8SLMTZ.WYX7#[[:>"V'?NGOC;7W)XG?VY[F7N 2^
MGKERAE^YY<?HB<-M$<";BT*]DDHL41K)\\TAK5VN=3T_I^YH^AB;4"T&1NZH
M.RJ"*#N.IJH> S_MTG$V/>U<9T&_*<P0L,*WAI(IO#ZN@Q8#1/.DM'VGL9M!
M8+*>W;?A7#^[(+#*#MBM'./SSRM7^#%D5&Y@^B:>V$M3."SNXJ<)=<V&64*0
M83M;EDY-J;T'U]_.J#4KE=T4Z"5O7M?__%.EN3.?76#OQ!^E;=DG0M0?N5P\
M_0O!@Q(%MGMI%C<S"!\SD9SAWI=+A(4S^E9U\[Q3\OB*+0,D5$1716HNXZ_G
M>HDUER8FR"47Z_&<7#]$\&R^^WZ6HI;>]CV3AZ=OH6'@YAM!17O\S=>$-SIB
MZEAK6#;66D3Y''1IUG;;HJ@ZY$#$]$79T%9UR![\9(P4:$G*2MA&29+=M)O=
M6*YGS_FG_?6VLSYGO*%8-<#+K% \S3_>YU6&BT_^R*/;NH_)MXWVZS0(8Q)D
M6IPP7L+NP?T\\XP2J=H[6L&.[P4-7=C=18JT_9!%W-)<*>5ZVM\N^V=CE:="
MUWO+1<?X 61@2D@=WRCP:_52^GZF=T*&CW7=UYOUZE1DJG69>]%7CV\.I3HS
MY;J&/VWN9?SZUC:F_K@7R4,-!<V )7S)60"; +L0[/42I/;LC LI=\PUZH]5
MWYB+S(A=2LOOXG.\;U]05RH0XEOK?>\5^;VFUN2ETZC\XT@EXCC+YX]FCX#O
MQ@CV_. 8_G4F3-L'0E)KG]Z@UV;T&L7VS0^:=G%=X7E*OLGQE..I\V38)T,K
MNP3=P:\Z67W+6J3.09G1D,ZY$CE1_(>LVEL_*_*^/(U$PHQ;>DF2#D:)W,42
M9KFN4F+6F:K%D0'6US\'/2'#LA)Q#8,]EO'+,EG]=$Z@LZ7DS]BY];$I^I[=
M3+.TI^#F;?%7C:G?5Z_>+(D*C[)OXWW6W]1X1?QER!AV#5![X"X$AA4S1<)5
M#3\;M/#^[.R;)^IM[Y?.O?^24)9BJH.IMA[TV+CY=;;6/$J!)&U($F2W*[6H
M47#HNXSU%D2V#G;ZYJ$]O7^]5Q?UQUKRVIQ(&OFQR>EO5Q9AO#330SR[ZS==
M(;<E;623*VQG4ZUXMUQ1,VEB]T#A5_W/P3[L@C>AM1_+!T_K]"8^^TZ[I%W;
M7#Q[F%=;Z;L5P57D(6X3(M@\$V2B?%*Q.SLY][V"Q#W-9/()<% ">81I^Y]]
M!G-2-3C HM4Z*$\"-KW76[3+;3?5T3$*=@%K?"R]/*G2/E?)RNY=NK]INL)T
MI750N:D6SI08*(S<B]-H^]S.&FS)D]?;[+SS9O;'QU:QUS-8U<CEX5=J;.XU
MIZPC7G^K*AFUL"[R*-=MCV1 $CM%B3AVI*4%8)!6H1PC,K4S-Q40^G:A8E8Z
MP.#2GWESJ^:F+I5W2Y^:*PX)XH=X,]XKB757\L5D/0*ZC/&NN@^(L(H_*C^+
MAA_[TG:'5;$9-0"USBXHD7IW+=K5\(ZY7NI+LHY#I4Z;V<*92OE>N&C!6ONK
ML"(2&'>V7W<5_(B8KR9]M2F/RY_+2<OPN]YK4VJ13B**&MF6LKYJ7PJYZ_V^
M1/,P >Z-%EDV0PLG:<./N[F.R_0/ >$UBV$U#7]_61F9#MS:==,85FZ9:9FN
MV0QX<;%:PA2"Q>ND?2TDM)[TJ/)4N*7S7:K6^>7Z7!+W[:?IW'S6144%Y?D>
M!NUYA$JE10$-FJI0^NDG-RT4I'>O%7X[1@JW2DH4<QJ GB^WX$W0]784T^F\
MYBF0NY91L8NZ*WMW/O>:NS2OO:6#4LL8CABQF0]<(<I6!F#!0+S&"ICY-[K4
MGR[=E>^ :_1X+AIP2HDUWS_LD5/@C6ER9U:(LDV_*._\% "=7.G%<%- %/D,
M\1?IYWOIHC?M8Q&9_;?;WFM52"%\X\OL@T:"<LG"\H.""=U6_0/\E3QWB>=%
MP"(G,A1*R>.K<RE84\QT<#.T'[GW7H635:PC;?5SG\43=S5^D[>FMNHB54T2
MI>Q1,O)RJDDD["89R"<;55;XQQ@ AV/EU;[A+*:-72USVF[ZTQ8N:87-33XJ
M@=)-S#2C.B7^U<K6T:'Z5SZYO-&!)U%\ +F/-GBL,#C3+'EP58>3;^0-6',N
ML-!KRE'&O4562\Z,):WL\HL$E&'DXTI%B^;U8=6RV/2;:T!2JH1O=]LU>Y;$
M1E-'F)0F_V['CN*7A;O:,,N&<L/9=,K3:X:.NM;EIGSQ9RJ[_OIE6WAO)XL%
ME,;#N6$J+T&UGL4(JF62UE_MYGKX+8?\5]"6%3<_ASMW [^KWOWBNXU5K1-_
M7]RK-: 3'U1EA O#2VAF ^%7\H!Q;L(RB\RPSU@BRW&*2(U+F46Y7UMJT8?T
M@#M&BC45[LW.V;G.TQ'%.=>MC(?7GBU[]SUK.0\;"X:[O/_)4=6B=O+U!+XJ
M)T/'.N,UL=*JU-RH6.>24;&\DN&%<Y_'V2G>F\$ VT")W"P*40L:?6NN#;$J
MM)\M;YS??7LU,$S\6?I>1,!1A^%')F%*6CDG$*?.-\(\Y&26?DA)[VN YYFH
M]^K3;>4D>3];$^GX0!M^)6PP'A2J[OC1W,2NC^256)J5P&&GKBVCF)M[?"I^
MW=1.UW9-=V3G6N$@E.^'!/98CM?"KOP-C4U]F"R'8$-1&;]UHEBZ@/RDW09!
MT;Y(OE=1X+#69/BL5<8O6]N8K.8IK0USJ95+9C?/Y02\PK^4*=\8>JW<$7JN
M^G;+_#V$_OOYGJTGAD%[6;#\/QM=877?1P\2)'!L5XZ8*66(S'1;]>#5,J&\
M"B0R3%)/B?OU?)YB6)6'IZ+2PFS>Z3!O)UV]Z:)R!;,?"Z1Z076;0;U,D4J2
M3&K8Z]<33X+Y7F]$F9K&^_:FV4&U!$5ZM3[EZO0;R?\R'D"_^=T9+%X9Z F,
ME1+%JU/*2X@TR:JN9X'*.08_OWQKG5@O<$NW*AX1;"GT]@H04[_$>T)J?*WK
M]+X\4JE/I^#I,$H_C;AIZ-=0[7#H,JJNPZE<5'A7JV&1 7$9?A.:>[BH(\'-
M5\37Y)&]A[LYU/5(2NX6&(GT+K8:?3T5[SM-7^B>&/ 0\,A^=^V.(&>X;("*
MGT>]]JN]>V_Y>]!O6C>W"1MMV)? 7!GIX+6LR=9X>IC]3.V+T'O=)J\^+'V+
M=-LTWSO3.E.##?C$*J;JVD$<?X&._7@AK2*C\I&G3AKOY9>*DUE\JV$_.<_(
ML(6)M7L)Q@]3GBS9YTK@V=+*M5\^WTLICOX39C$6]+-W4+<T9[*2S:)LZ*QM
MD&.*@BR6\\YA%YQ+.UKQIKK._8HJOTGO1M0=2G]^KUH<]"0J@+=IN@S(BFM6
MT'),]Q"7W[7Q/RPD%AY-%7GFD1A]FVS^)E6')!]K:WBQ3/ 0FE1JFBY/?&U=
M<3E!Q*;,*$,LN,(T0\SJ>H*>[?.RXS85%HIG*XZ)#*A;I9K(0 ?\;"OM7Z[/
M%JW/5NO:5EJ_+-?+5;2PL"E:D_VB.V8^;)US[TEA0,L2_ \TH:A+"$=!;#D1
M]:VU-)R1<&,*(BTLS^1,Z\+=4'\LST+#+RXIXN%;$I?<N;6S0\)/,VNE/M]=
MKYM +S?0 K%#!BLO2Y5\8L91 8=)<*_MQ1/7V^9CI&E*4ZHPFWO9["@WXD8A
M \*!S+Q_ZSC.?R90ZT2U?-A&VR2?SBN*8%V-1XJ]%D=R*NYIL'&"Z[$!P;7T
ML38T#ZSWQ=Y/"4'37W?/O>RPY'5@<>"NSTEUK<_3]M#U_%Y]I@PZ 2+Z[^H3
M]@6 ^VHG/6[F3T<DNF64)[U_8TNN#@5VZF>J.R5U3=I-=11N_BK?-MWZ^,MB
MD'Y\\D#*&5'[>0KE,//<X;:>UUY&Z.Z;&Y]X"_#X<\Z)?70)Q#9\8&L4)0DO
M\TX$7E? M_8G++YG7)OCK9"AU=F>M?4OGZ)4BX9G1V*B;+XID/[ZUG;E$%%V
MKJ9Z>KA"\3'Z?1E"U#W.=R>7VR*O)6D1PXJ^A5D8H4878^E\*%E@/*$Y/_6J
M>-_=U@X&)-6>G>Q8%T"@G$]1W8T.'YO:LHJ9]_1"!WK=&\Y0:?^0BBL'QI-0
M@CW386T126]T.&U??.L,?==R_BSUGGVQSJK(>EN1EYY-0YC\=*V8C:^N85,[
M6HN$YD7.I]]X31$^2:X''8?,;WAN!CE%P-R(UDXQ?^0)LUG7J/Y2LBW5FS O
MUP[_ A]<6? D!&[I!A#3$!E27(&"V+B*66_@8[W_\JF)BFD7U\Q>?3<A-S:;
MZ8P^![SIM+/C][[U+*\35]X\.^_;7W2L%Q4BP8DL4Z1/.]VJU^ANSGC_QOHY
MQ2^VKUSYK7#\$[+#^HQNF;U-:BB)E/-6@ZAJ0!ICS3-P52M@0&[#QG1\R#G=
M7]J^SCL:NQ$+$SWC^P>**J.]>4<43?G\:IZTY[;'^#,@258Q>/B.B38/30=]
MD@'Y]1*;SH DLQ#5#OFF_ZT*R<^ _/Q\  >SEE70DS8\M+-!@PR(;E8(R',@
M$C.&:71(#LL21$D!9[I$*:SORM"]\$H_!RE9BM';,P6Z7<TS+QM254(<<2T/
M9=_5-Y0XG7[H[>G/QVX'Z\M?1]K@W3D(1>YR4+SN>6JXFG#B?GGDU'M-U]"*
M1.J;VLWL]\$?VFPL:G4L+)[<5- Q-&G*-D"D=IJ1[Y[K(;Z1,"]&^Q" IYBZ
MZZ42;Q6[!W0P7GJ*->7Y-X)R7I--:Z\:VMU+MS-IJQYJ(X$'5/[# @-9FB=4
M"N9%*#RT)%WP,Q"?K9B9[B^1:ZAOGX')>+WR7>3JZ[#+JSB6'9TY;CQ]VB<@
M^T14CM^9]E0G[X[[R,9 =E#\ LFK?R'3SKDEDJ+#Z4HY^_ZGJ5:5A\:P8Z2.
M7D[O5#^>\UVNLJP87[S"Y6)#$[WZHC5[FZUAE!.Y)B<1<=QKH9;#27BVD5/B
M[/3PCXY97V*CWM/4#XO7^^UZS4X>UKJZR_J%5%K7RCD-Y%Z]+%#*@_W[Z$FC
M2X2XB:PK\]CIG]C)\='Q\0P$G=WW@'M#[U5IM3G@XV3^^M-XE/:K'+*EI*_S
M+7Y7W6S;-]/*-&/)DF+_54VM<^>L+GGZI*ML;CUOSE0*I27B'M %//SG^FR)
M5WO#UL=JR%=T2)S:QX=?%KU\37RS4"MA(%40\,.JU+18S*I)H?=LND?,NRN#
M&$%@QV<B27#X>JE%L;QIESG^0\%4ALYKP[D^#XV"I^F&1MEA2@[5>K->]V<K
M%8:M#<:!%7P@"WB%2"T&L'AWR:8I ^@W PD#OC? IZ;\VXN21VJEAEUD._)(
MYD;W5?_,\XQ !]\_5WX_6&L^WR''W5P&'Y,;.W2O\ZU<Z:,;;Q[AOXC<X1MY
M32 J9JKW',@93H5YZ3H45;"I^3J7.SE4ZIK6FF97*URC+4D6KS[+#$; !\B*
M'IHH"]U5[?K&#!D%3_VJFJJJZ_$^-NFR99M,+RTF4"IB76&A578<>A8ES8#$
M1L8,8UCHIWVA EV2((O55*<7D3J#N8SKH.2GA5T(4&B.UC@PZE)W1/CS+;K]
M*KA=?M\GSB:5=F4U[6F+NR%7+PK*#9XG;G.LZ;@>R Q5W_P)XZ\#PJI6VUL4
M12*2\;.]LT%E*8-VY5:=VI$S^2T9[G8&80<?>KV7@X73NTX%VYNG_JU9LYHH
MK3P8[>8I/S5\KTCEFBG>0\'CFX(#GE Y^RI/-D%L_(,>;(R#9\_ZB0RUJ-X0
M9GT)%CS*.=EI<T51^;&90*KUU<\9#QTR)G)#;]@]>73I:.JA@54Z67Y,T2H[
M^,FMG/07LT6WBJ?-+VC-%DPNKWVA/"F5'^8+?N+\Q$MHINS,]W*AFFES-ZWO
M)55S\ M=<@Q(C]+O=J"4CN:Q=@;DN% Y@<MBG^1?2 4#Z\R(6P:KOL]<U+\*
M!_G1):=(69S2+9-:[S26^ R^/DU.1V1XEQP!?8OG2Q1NS39$[LJNV]Z7U:AC
MC2\\.-L]ZJ&QSHM;P-_XZK^T%3.:C3P@W3:[+.+DK162*E J%CIW/ZX\$RLH
M640!D*A!W@L^7U(''"*=&)"(&E"< 3E*/GP2<P099TY)2D"=B"!!17U:_:-?
M@&6#SOV#R=L[4:^I3<)Z=TOX1O M\W,YBA\_K/N_D+3O_6(=I?152DOI:U!K
M[#(T*$\CT>O!L**G)DS%T($K:[3>+G@V:-=CFZ,I:'N!H.#P<DO1,16I,U^N
M4SE=+5KG.4["B'5>)KV7DE897-T!G&ZK%I:G=GOIF.J(.:9:VQ>+?4C84M^5
MM\L@NO# ;GVUCR]2G"YRRR23MS<-#[3I4_D,R!).P$!JZ2/8'.#18"GZ52R!
M2<*H:P%$V\RCG6^G95.GG0]@O+7-%=3#S%JJ4E"]4[*@C7=U_[(0 !>W1W8>
MR"1<&UP8R!X]&[9!"/Y^UE2+21LJSD']!_+E'&;BEKQB0:YOK++P7X*R4E'!
M/5KV/*?&*CB;[7(=<LGR-RG@,856Q9+A/,5B$Z)^S5*QP\/JQ&*G@UV)XH6?
M6?%PPB-,?7Y"\ZU9;1X>Y,H I>_*X$L0-Q#!5<XND&>,[-3T(E97/\A(//MQ
MV2S@+$*5M.SX;)*NIKJO!_H^[%/<?>-4Y_-B6TPTT]=A?=WL-O%!Q8/BOW#9
MM4[3>=,5,J74^TE3:GWOPZ5LY3TU:FK'UAW3<8HO*=QJR('["==0OEVS"C8)
MCLN4 E\=>@Z(QB_R)&BY:>)CA"=#L=S(**.F3/S5B1U]@WG3*:VW\D:GFZ9W
M-D2>-S6UIGO?.GM%C#-;^,S\UE.8%+]:[T3/C;-M*"&>$Q9:01^NR8@A4>>D
MG@B6661P6&7H74]=/)GN\39@!"S1%$U['VQ'^4"SEQ;/Z+?-O6.A)NS\2IH_
MN1J>6NZW6Z[8[&>RK3ML'>V>5NC187'C'SGR#LZ8_I]]GW0V'(&JMNB-:(?6
MRVVJ$PZ-]L,IYFMI:!]+*=#&4G5/[-/'B&#465"1JT:T!#A7"N\'"4U!$^,Q
M>=:#XA\7C0 (VA,'6.(6+/'P>IY-AP/MF&&ZT'2MU@8Z#L<!4R=NG]1^9F3N
M.;@7'N<*YI/NOTP__N4MQ;M/TJ9O^4QG]MEZ\6+K2QPO3^M,L(!!#$@<$?VY
M'=T#9T VGZ!"&) 97+? D<,Z>O^*")T7":=R'F9I6PK1;,%@8K3&(-7ZL(3O
MP(HBG G3?.'HU($Z!63N=G3.-)OY1X5?3A<Q.RVXN !5X#A"^UW?G4$ U\?C
MT( -=!%.-3QD>I&;+N.@;X G8;69O*%OW(_A"$ ,1%IF=2G3;KX#X$E-/(D,
MR EL4V%4$B6^0+(U[MI^73VQ,LR2VS^?+C^MW#1RD);%O<[Y +H\3N/7I+K/
MX3Q6/K!130_S.RWU<P?3Z#PHP=]GX@;*/ONS\!H#$D_],=N\+6GXZB-;<$1%
M#VD+X1P[L/?Y(* FV.W7]5_+URY"0R;8OF!I0IYTCF,5Z!ZMWYM=<9)P7[.H
M$1&Z+/I6!1[]H,/M!UYC R[>&<6U_(S0(F23)6?3!#RQ\L/QAFUI+VI&$[-8
M_<,I?S?";G;#<[- 332=G0%YC<2Z@UL,R#%[<-([&HM,LYI#F0"!!-5VDE'!
M@?5,\];-LMDN?92]RP@#HK'^T[HKVM@<1%> F;K+9BF!,8J^$?=,-,V:6 XH
M_P,Z_T<[+^G5\BRK#,@B#Q5_F ?WXCGN;W#A]Q4R/FKQ*ZR=FL_[;G5U4,8S
M0LU/TYW"88]]]RT>[&61N-!.;WD;/O@X<^=7^NNEIWK4UY=8\SV C_%3%:=H
MYLS)MS$A5A (#^")-SA*X2X&6(A[6Y($Z*)#W[+<O):3RB9-!2!3PZ=A:N4T
MJ:S^0(^&;QW>Z73Y=30G32' DSCWKOW=^<6\MTB$]1M@N?WU<[;]A FV7[7H
MGIA0=C0A%PX$83=_;^F%@ C_"&(@)\VN"W0X, ;K=VRCHMP0?0;B%+L5/&+Q
M/)-$."J]*,S9CHB;K0@K*WO-U,7(;O#GN13.>T$8$).WXAOZ%L/CUM-US[NF
M=T^X1&V(+SE91[F,7&BSCO*O]BU3D9APO73:C+.^\<SCCH[LEV*0YO_$Z@\!
M)PZ_#7_(@#3]13_1#O80)-4&SDL=F9>>A^EK+[FZ_(W3NN?V-;)PT8S%WYU_
M]DMK4[XK\.KUW2:NVV;BPC.A!SG^0BO%XVV626"!HZCW_3").PV;E[&)3WZ]
MV+- 1HX5O=@@5+?U.J8+WD5I1U@45EM8\ 8?:N)71%!&0%W^22N"A>S 9ZVV
M0M4\MX++L>7V:B9&B9YQ&4A;IYB(APG.P$AC)U_I,\*IE#YC]M3RK8I1Z !Z
M(8K@L/7',ALZ#<X3BA9LQ8]Z2"+P4D$%XW]GPN4_(F.8O*+APH#X(Z_8^/O+
MS:&D*Z,K\(MO'1V+KUBT'9RY9!_5ZZK?AUO8UAWQ\80W*@VT\!<68!3M5_&V
MU'M)+=USP7'8V*J*A+IOUM2F\B%N9X !&8#SP=2R> =C=<J@V76*W;;=:U+C
M"_/4G'R]\H*;,8UB*U;C0<&UR9DLL%X]W5>L.D6FO:3* ]^?4%$&Q&O[(:+I
M!%*2KDS3GZ39K_!H)X>A.>_W^L-/Z]#*@HD'#,B;H<##6B*7>6T-Q@G(+*=B
M>/RV;GJ$<>F1-Q\?TUSF(WZ7H8_?'W.Y(GKXS%W[3=''F5_6K>?$*AJ?Z+>P
M-J9+H@3M8"H1IOG-Y:I7[Y5 P4&2<0*%I ,8"WC^L.MWY'@J05XXT*-/W5NS
M;;RF-N?ILJ[[G5N[GK?;^ZFQL5;W('^*HZL=/,# DPS?? <H41\&LN#Z,4D=
M\-0EXFH]-Y:8I6/N_=D8^N0N#(ZFBJHP(,V=IRJ;FW,V#'AGNJ:)6VXURA:E
M%:[1V7^^^M]<7IO?%_/1K@)=,&.IXZ3T&-.VZB,V+$51<&_$HH7K>IYOPOY[
M_VAC_9Z!EM,ZG#^/?UU]*D(*5CJ16K%5\1[E?9C?=2QF0H40 38">\84%Q1L
M[M0L37V-O8:63/Z1,9BT3<?+X*BM\=KG6AJBO7OU\A=1^M7-"2DS6AM9#7\)
MC"/-DMKR#_37= ,XO:E>R+G>D!";+Z8?/_B5C%VG?A ;.QL&V-D"S9\4W>>>
MM)\:1J+)T!0IX<%D<H^$5=:0@^ -Q1LA6=Z;&P<F(\76HV=Q3AF!K]?:=.;Z
MC(^4W)24F&:1L)"Y&6Q[V/0KBRE'#7O=V,5CG=P,B%",U%>Z4F!209\>+A%&
MU,8\EHBQ:@,.&9 /MUKI<T#BJ[DYRQK0V/K ,JDY_$V]7F)Q,/5J[+-M]J ]
M/@;$NW--I32=_AXK]L'BKA^JTJ60RV9A6&J)Q6F NXNCJD3H;;G9XE3^&5U+
M'IHG1;H7I$@@I5/5?RF2:HY=XP[>/"Q&^^J&5#F]$MY0K]V5V&,3^Y!,T'PO
M759PPS.EKT95$=."4:=@J.Z@X,'%UH<KI''\)VA_ /#3,<D!&"R2;?PAG35\
M7@J*.^#,8Y+X\LF9Q<6A7<SQ=80O0*V;$Y*[/EUG,'321I^H*D5";.X5?6E2
MQRSDDEW81T<M<Y5";E9%Z5Y9NN&OTS/?8V?3.Q]:&>5L_3E)@<B I,><02*D
MI+..!AO!95SM'E0^'-/'-&*WY%3#S+1Z#V]K=Y65$,@NO!*L]^-#0ZYQ!NOD
M)O3;4*=7#33I(RM_X'R$@ LT)S"J#*SMDO(_N4X7^1D_%_-7\"\C,GZ/Z0BR
M5PY<>L4*79P,&HF29EL&4K.+O7WK8F&#"Z<YO#ME\!_-#DM^%K4D:AYH=/K?
MU&VO_%%^]XZVI;=\U!TN;Q$]4+$*Z?P]5\W?U/71%QB<DM67=8+<%TS(E!_\
M7)WZ1O"L[F C->SPY9>QRMM/$34#K3,A'R7\/:0?C)_-S/1]F"G']Z:M*F81
M-?B?P&77]N+;HE+0C<LA>1,#Z-L.&7?DSFL;V-:.)E9N?N$)>%A#9D,<L[,\
MX395ON5KEBU1D417!Q\34<A,&&^_""TWV/Z/5VPZU)@Q7%-1^ZSR](G=IW/[
MF5%Q&7?^"A)=Y9T</:O>1[(7%K1<LGP*CA^HH3@.G[MT;U.\B=^S2"W@_9HK
MU:#G&+_3+][!+^)9/"N'B6;HK<#C?@$!M_;'X\/4FL H!_\3_*]]YZ&WDA5*
M@'R>8#5JU-B]19'QS6%*;?SJ:L5P;ON;6?VBTJTWVD4W-@A5E43_#MMWM0KW
MKCSY%_'^BWC_1;S_(MY_$>^_B/=?Q/LOXOT7\?[W)MZ5H\BXWYT8PD@LG</J
M)0/28T,S84!.>#H?OM3B,L-'MJ3\I@8Q7PV:Y)0:31)H&">>3[@]W7D2)EN0
M^WPB-,-@O,_YSEFP]$;20/BWVE_7TJF6.R;RY2+E(OTR(N6WLB?/Y&:;^&0[
MWX<^&PNIU)VIU+6MU#4-*?K\N[+>;G$OY]Z3ETOW<@):E@*6US9J-2[_?_V;
M>J3N[>1TB.RNUW(2=V'B^5-_/A@IJOR3D$[8><XSI ;*XFB\+E0-!B36 <21
MA;,8D-MS8&,=.$Y.?$;<$A^0.@/VD-W4!A:;Z_*)AS9.<P4CESJF.Q6($0UI
M[K-AR&V:T3QFT7K=04\UZ<^\CPM#U <\<_O_=]R:\OLJF[4*ZF<&).<E6,J
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MC)0=K@^W L+L/2SA5B=9"#.J+LLQ964Q>SA(YD+C/@760.S*B9J6+#IIJ_M
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M[73+G38KP6FR;.)QFF(_U]1R#)JTTDA5UZ^5S+T4;]HKM :\1)#Y+O%4"-N
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MO1@T9[E%:2)V32ZH9*!C AR5,3T_LP^'!5$J,G=KR2IF;&X_KVSOT-1SH37
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MH]-T(G2:S/Y!F;>!Q1,?H\K48U3NB;0ZTXDQ>+G>2[#"$PB'[E?IVME5GW1
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MH>NIL4C++?H-&]WV#U"R_;CY8$,)N'B&!WBBUI7A'3R@5W6&N2#) WZZI/"
M[Y*^7(/0=%$>4,, ^3%:#E\=8'_FOJG=NBZ+_T83!]U]HY4&,HP>!42$JI/9
MJQ9VG@;J+*<"/ZGG='"KQ],OR<%!=N-E_E[>6M0AQP1E\_7[97[>JME9?E5+
M7]./-KD%ITFKDM?+FM"T-Y04]^ZP\2([8Y]"2GQ&PEBGVO6CBH?&YL>.7VF@
M3]]4\GQ9GFC;,;5%M?ZH!SYV;OAPXI(9]RW)DQA/J-1N04G@/*$^AE>Q?Y/.
M7.],GON4'[\\;*&%Z9UFQ[A2].1&A]6")Q*-F/-)>R-/W8BOZ."V.TROU77
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MFU&_%%]R:BN[0]ZS=[M4_GVBPKQ5XM+5M"1TF]=1\+Y:Z^]LSGDH:JPSWLF
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ME*26SLGJUGF;,HR'Y@8MX9/=[[%$#DB02P'4S&'UU8 ^0TK?EXQT'7?"H?2
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M4ZQR].HR!^2&8-DW72NKY+[]WHE9+%VV&[US/&9VA@.:^DJDBW)9RN @I%@
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MLX<PNH@7?C_Q.F/X_TT+/6[?!4BB['0BQ%"\Y.&$8L%V70RRZ5.'S@A.@ _
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MB[K*I/:89C:>J3%C@Y2R;&(^6!G/?H%FIVO3 IBY';HQ4WBA!FP\XD [5S5
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M5(Y\]*),K8"^IT_BL4N.US%Y)3;ZU/[.1Q%;RRWZUW=UY_^#1#H;#.@GTDX
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M)O.2B>2U6\#//[$#AR#2E"SDD-V4M^/[#V.A7,$BX2#P;<Y$A? +JU""N!%
M)8&_+;..Y6'[%P6.(KM[3Z!T*<1-87* T% G42A&$/BU:!,M;3W"TC+T\BQ=
M;=V.^SEEU1%7B2RP'PO!BR'/_?DYV>Y:N=YZS;TCX0!SA36.^!5 ;  SGPLD
MLT'[3]9_'V %H2E>4$:9 "V.@^D\0#8;5,-'OWB3>W>5#>*^%#.&X,A)+S5
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M6AG=5O^U^#*-=#OC?>A'HTB8"9KCVV#,LQ'2II3("?ID;%$2Q8#K(N:6@4F
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MSPO>+,85YZ@&7&RX7-64I*[:WZO^5ST6(9U$6M+R&NL@5?"+S3SY"\Z'\C)
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MI)#&H!--=WK(+9<!YP]]"C![1'\N9T?#V3&X10!Y3R*#>'4D=MRVB^CLU#*
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MJVPA]_1ZH.GY^("3%:/["MY_EA[M<K^K"VZ)Y9_N<H#)*"?*6]W!31*,Y8N
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M^CDMF9F!&GG1>"6JKMN3FWHZGAR75[9-YD\"$4,4@O>5E;A%2 P#5 @Q46>
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M<H2:[(",&9%B56^KV#I68FB1S=:;6]U+_C"K/I:OW>5UOXS-P JC/B:%-F&
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M[Q;'D5DV;I15>: @BDJ./V51$M"257_T1B\]VL<:&@ "EV\%>4J%^/-L"[^
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M93EXRM)4D0RDUOA+Y76O&-4/Q@4;6U2Z6BO8A#*Q=^9&'IL,-%V%+Z;_J=I
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M"O-';9"%L-;=4CBGH2!/?F9C@I:3B767I]H7_'C@>$L(7:(BN*),KUQN[3(
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M2P2!^N3%<\D9?C HVY^'Z0 =Y@)-3 P15/K3A,A 4\B"081O""F\&O<>.Q^
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M6IQWG8A_X(=!LX>_\"HO\YC7 YS_^NA_O?DV^AG]%K$D^NY^.^?W3MTC'=?
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M'6X\2)A$;.1?_0"HYC&<G9PXB4F$S$Y.] 4@Z&6J1Q3^^*]OWGF;,P)S^%;
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M[.87J/(#QMGCU)_]%AUG$ZC]D<]50F0SE+T.]E'(RP)/Q-!RY3+=%3"$Q'D
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M(3N\6;@"S?X:'78<<W!Z75O@Y+GW:BQL*B5XA62/;T<#5M;#).YZ&F<JCW>
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MFR= ?570 <AG,P96'M6JZ]-V-BM'!/+,P)0F%QWP[/[9#SX[?5+#0?,6ETU
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M!9+D"V');PF>&)XB"M,ML,*9GT"\$RW 0['Y3?H3$8 <M-4!F+OP2LNVR=
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M__><0HC V]5P8*K 6-KGCC@]XO2(TR-.CS@]XO3_[YQR[O)01.C%:$)9"'?
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M.)=;T&V\9[8OG-,3E-^EZNV$FGG:H2F#]U\F5*SOR727\48:-K&J??O3W:Q
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M]?[<]DT?#--+6*P;%>7V()1'-US^0)3X;N2_:O3%H9!8V!I9H.XW;74[,=O
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M=9:1()^0V\5J]IZYRZE:YB>Z-Q@@CU++XND</C/85!N.0\MU"E(? )C P55
M'Q2PDS@H6DW<QY_W6I29PFAIEA=0%8@UNMV:?-G=KW5^?GH9@>5<?S;]BC=
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MP*SQT4G9<%.?8.F>H0\]1C4.=UD'3/5EVIT,?49IXH#BH20@7HKHU-:^0_I
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M"J;FH&?1]/[09.R!_$OL]YW24&JFB"\#Y+:)98!L-NERQY:(KTS!B=TT3V&
M)B:"(0VKU(MR7\!B$$_S:,3EOBU1$OC"!IZ7+@A3[\M<B_\B=/USN==TE/3W
MZJ:P1L".SJT@M'NX.+J=<M/H][,QH\3V+GXYYT+H?M/0)ZN43YG__J\ @P7'
M,DG^H$PL8BO%3.!28MQI/CL.H3$&Z$&W%4HSJ43[7:E&[Z&9[8HFS/,7*9<B
MP/8S;/5X/+63J RO.OMF(/W0A5U/1)L2?,71.O?DF1CR[\Z1;,,!CKG#7W"]
M$W=$IPS6APN0*FI"]R%.4^\$B%*UR!UER%M $_F@R?P4;/R+8]/R3[5\]^U6
M A"23#/6;?PTL=+<\'$Z6/&2[[/7"T-^G*CKV;<7LNS *,"/M/H'@-,LE,EW
M9Y,=#IP(9*.Y#O.Q3RL,?=Q?,V,BH,FCCQ,?'J[?C?&T;.;AB^Z:""Z[-1IW
ME;=R 'RZSY4K," N,/[BDK+B%CN:U3::/C<H^KA%-->NPO)&F;:^H%V-$X>@
M;9;,6#>A+N1MI=&E*EGEPBN*"U! 7(#*&]\#;9J.A9N2C4G^9?Q5E!:"1ZIW
M[=JB_.Y2<QN03#ZJ]6O,"[GMNLCQ"IND?;-RP?M0<['TC-JHSV'X<&HX60<E
M5A<60JW9SR$[*9+WP"^(:0)E\A!VSYG\-T9'")5*J_Z]-*,W":,X,[^A?V[N
MRTQ5Q95)J<=6Q?58II#BBX6R(*5P5HJQ<.\;;=<[)9,V>]3BF)N\=9BZF#WM
MAF)>44=*ZCL*3',<:=9NWWNA77-?UM"H'FT9#B$[0 $9SO:3/V%2?P'J9#>+
MI#Y27X^+Y(8-XE),2VL) ?W<<L5/%:/K[?LTXPO]&D6L- "!A/DXE.:(:MY6
M=IITL3V<_GOOR;$:3#&&(J#20Y'B_I[MS_OU)N\O>9ZL4O8=]2>I[M%5&AI#
M_WRT]C2^E)KBSFJ7#5<XLR!#Y VAC/3(FY]9NC'+KV>K B1KE&F.\'D-.-@Z
MHF2A#BC6"CUB7<@#VS1^R^14Z=%N6WC3E;N65!5:# .TE $1P08,:>Z0=GK
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MPE%S8)Y-Q1U%B3$XBT <1H#PF2T'(6=25T]>S*[P\?:]=*&"CXDMJK=]K?9
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M:D+RO;-YYF-TB**AZV0#R2K'(OSRKVR.9VYQ'F<K8#O-V*K+)[]%"Q9<!,.
M/A+UL=6\67TM@(M1&R2V!A\[E/OM)[[L5L\X;T[=!^ZBXVUPHXH+L#, /#;
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MJ<BE7GWOZ$6<4+_YJ4KSYI9)7S;\$A>#R)0'PUXQSX'NP (%'G-W2_<R0.K
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MU/*N!J6)?9MQV-J^]7(R,DIT-UG7&; V!ZL7D!),RQ%=2VHY[BCT)$CL88L
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M+HD6 #UI8O0X0)S(IR^)/@Z:4LIU%+TH<='!5Q=P\7MZ?0GZYY6[AR1[D,'
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M*.Z;%JCM1$(^R##O]TSWWR _<?T0*US$G7B [<@A]ARF:!T'!P):6#7MEX<
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MTX3^.3.^/HH.=VNL0KWV<U<1*L!"+WVZ+"D5$&(1E^QEDN*D)2[U=/2K=8Q
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M.9)U+WSG[9?/ %_YH2+KK/[,]G&Y\H62"X3%QRZUYBM53DG>3?N0@VPU )G
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M"^TTR%7-$4SY[_$SB4,"P@4VJH6QA+G2N<$\(0>9LW?NEI0//?YY<V$\%^U
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M9J7NY>&]$5&S=1L$O #:#;"DNB%(1M(,V5ROP"!__Z=^1I64\+M^5]5#H'S
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M9R.,NF#/*"I11UM1UZ&D9F22N$LMKN-99VD(Y4LU[UZ$1:YJ2)/:^E>COVV
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M;WIKWC(D1NF5N9O66S;<<:G/.3N+[VK]]+V7&-[^^*O[FE=9&W\DO< UB1)
M]KEK<A!_K1?JK</]WH_@2G<(/(BX1!$3! [LV*ZI/[9S;,=E)NI^M<UFW)SI
M?'PM'E"-H/:[TEM,TIAT.BO=(B.&LF)TMKFS9FCW_MJZ^P$$+!J'=R)FM YY
M#7TC2T,4[6(FLHTL9B99G JW. NL;"2I.@:)8LRT/MVKZ55-+R6:9QQJ^6XH
M\?V]IV/F==>=$[_D.M0?SHX)B0F.LF]\<-^=0)S!]=#BERA3]X)*!5N<L;7L
M$%T-=2_J@=25O=5ZL&9:@Q;T4NUEA5B3HB-99H1ND3<!OE@G;%[(B. '[8/_
MBSG4]/B+LV>^?]R37!W@7J_<2$"7S%=XX@,L!5=-"U/S=NOR0'EVT)HNCC6Z
M'>*4Q"F:8C4E]P]U-M)4W%1I7FZ46U9)%/2@0[Q'VI[DN@4:4W2=F^*:!8;6
M9V<T>BZ4CL]NG$FX$*IH(*!+D41X'#-:!(6T@LLX T(3@?/_RC+70[X2B]E;
MB)<J.T5@CW4-VR WKDNU-W(VU!\O=DK=5NUBK2>^C I);PV;^,GL_141U;&"
MP_^<TYO]%6?H"X!<2*YQ4GMIW3UP9Z;3U;B&4-KBO"0VBV&G5*H>>JDOPF&<
MF?*!025T;V_T5M(7(C.GJ[PVP@+>,X3:[=OO0#,--^]&ZKR;('5O5N4SUIWV
M\S4\43[Y(0CYT1%G(LY6;[7[T3.(@58?/=TK# $&<A7\C!C>HC#R<L'J#?6D
M-EJ&!<<J)]#4%XZ;Y :=KQ$2D;-SA/.UP@8HB"NO5 0&5F_91FD\$W?CV?OZ
MZ[\L^#<\;R_>^?1&"O3=4U?8S@7DE6<!@YJF==V2'&;;*M<P[84AUNZ34._G
ME[)SK%\GQ3^/58WN9M%/5[*^3<1D'C_[H8:QM"!/JASKBP[!4<6+A*QQPB55
M&"E="!V=(PSXX")#[0\#$L""NI-]NLOUFLI?9LYJG]C%*)=K)U.&MU4B,6%1
M<9>#+\[F@PO#ALF]0'7,#[R3>=['/5XUUI]3_1H/!(_HP?Z8P?QRU4.$A@_O
M;6314X1WLG,-DJWU8/L'WCJ&Z$%Q%<-=HC/"SK55V #<SF66%V9ICR&QBE4Q
M@13MT6B4@=L#2AE[WQ.W7U[ULCT4'TC?PY%Y,S4XO^B-#8(FWW[L$H;+N,,K
M>]#SKK4":\1%NWX8*54<OA\6FNKVY@.Z#]?1B:8M*N^;>^TE;]_%*-UB)=0U
M]=6'+1_P8Y@+?R"(='F O$$&G2-][%<>S[Y!4L?"LG;;%LN_'W#6XLV=8/$D
M<P0+MNVSC?_'99:PO,1XF-TK&4)R#Z1OU521C!@VYK#1O:T/NAW=G,?<QA9@
M]WD$4%Z!K=3AGD6>@=L?>8%,W\&E?+?25L3#"5P5V)\AL!CY99@QR[TC#,49
M@TRBQ!QM7%1TMR[GZYFJGND&OL&XP*21Y<?@+T%*1?W2ZK.QW&?GI03P-YDZ
M3AO)&9+51"&>. 77\MKIF8!9$7)M3WD) NQ'&FZ 7Y$@T,Q_]-Y879_E975A
MQ@LJGU$PFC9CTMQV)&+]\A>'?WFU&)A(A<<U [H_&D\JR6GT2F8&M@=U@*FO
M\P,0/3$NS]V"*XXZ8@G4@B=(VE>1WZ,ON<5TZ1]9\]<;/:[];6FG6GWYU+T_
M#^63QT?QV?7M 4,S06QIC-8:$6G*X*^9@HUL%JY8^[XK0S)0?]CX82,]-@0F
M2["-<-V=:MTYKX@P9VJBW#ZV=7:#<4!KG;'_*+Q!N$.:3W[6LV#^1LB66% ^
MXD7_Z*]T2@7P./I(/P0Y24A2.Y%Q4!C= K-'7GQBR$@"(O+'O070X53%6X/T
MS:XQL(OGX1R5F"ZU?,[R:;Y9=M9O<4T1JRH -VZYHN&5!,P1!;3SS3>3H1-<
M4U;"&<0;!Q=]7_@?K$].,AZE5U%+X+;!EIQE_1?]7_F<@&*;K>+(S9Q5)H>M
MRT\%6AVG;3ST$V?TQ&;BW5 R=):'V/&;0;/P>DL.KALFDUQ/*NP9)SH=)XGL
M0\@0["OVQ@-P>6C=_3"I(+T"L5*>K2D_-RJM> A&N"65%H;?W!9[MN[Z/]*@
MP;(/]6N(LZ9O\>G]2#<2ROOBZ!H%HH:K@GKF" R:&?;WS#"E4[#S_(A@!122
MXO!V,I.'<[UB&6+Z?/0ZE?2!#3P>'*OW37"-D"^N[5%U"09*PC=+RZ=F?&-/
M!>P@0F\A$F8T[QB?L7<@@Q!/Z2GF#:[7W$%$<M("]@&(G^%Z <KV@WOVU-N*
M)TFLJ'/5O35 \NSG3SF!DQ^K:2O]_8#DZ?2/9=\JKE8/'1P;ZQIF/'M\F-"L
M*\<#O48&G:=(&6(O^&T[KX:DW@G1%5\S',OWL_1P)[;0U0NVDA-;K)9,C=?5
MIXLP8YO%/0Y6-(L UE5G#QU?&1@E&=ZY<'-1;\U@::+),^+40YRDZL&6&T X
M/5-6C<WO;&IT5=@65KJJ/%M"6<9ZZX\L@KW:[W?PT>,?T"@YG21C?0V G-)<
MPZ)VC=G80A6OY1%$R>S[W!+6$V]?>A?;O>#<2.W-WZ1!=88/?EOPG8NN;L*Q
M)$[7* QA(EN+Q4"\\&6'.@2.DM?%4\W9FQ''I^,<(XB4DNW5R6OC;(%^91_I
M<;R5RUQW*L9EB-2&K4ZZX76YO$QM0=BT6>\[K44(79M$S2;%P,MI_L0]2*0B
M29A6[*LP3]RQBB44R\@JW&TEWH9G)UN<>4F-=@4CP!+!2OO:5!"XZV"O__4
M3$ZOH9F%78^E[N&=AC?7?JCA&H1)W089\602>R4^=?U@R_DY0@@M30,:1],'
MBS7Y,"7%@;Y<$L='**H0"3\%,&<;*NT>48,78:DJ@,#V[(\I7_?-X(\'$=NG
M-E8\*C]W**HPW._L8\;E&Z$+L#+>RV)T14(K6#V#FN2*>-"IW,!=,I'?55D5
M4\Q+S]L+_;L+_WN(?QMO435_9=@<P6S*[NCVSP_&XH@><'M\X\F0)[*@':]Z
MHI<XZ(Y=.MQ@MY_\.7".0)+CG17=[T!7 )K?5KFJVHZV?XC[A90OOZZ,=RO0
M_._:HSN@_"E0V][V+D1BLTQ7*'#A= #$*2U<B-HA $13TE(Q"X]BUG6)LJZ+
M@L: D,H'TGT5D\AC7X;=&$%]CF]SM2YN-S7_=+>:.ULD*[JG2D^0U$Q,/W?^
M1"$^M7=L,5SJO&R?*'WZR5M[&&PY/$T>*%6L#EK7([ ?SYE)GY+I"[@*-Q>1
MC2W2#C><C[@^*,G;!8=DN08^1GZ-,!"55/B%6WY&_?BIKN[E8;.7\WB7E;^0
M%,QV(72.CMC[JA^IF,NM2(-$30N\N+)DXTP*A;U ZX2DMY-)T=:40]4[4S.%
MMZD_M"O&74#2Z,F:QE,=-R[_E/]OK%^ANA?M&GJ_8%Q8&8NNCOO?ODX6=7UH
M#M:@/<+>KRMN7'!AZSE6%3Z0:A<E;SG[>'>,;NV5C,#!\ZQV<6R=<+GK6OZ@
MIU6FG5^7XW32^\FWEFV9_%'&M:<!!) U1\"A:7"RC6<!RF7"^?.VAT$Y3[C2
ME0G5SQ'.?> L9M.@_C1T8XS10Y6WZ9%>JB,"X.JR0R\\*J7B8FTOF_QL#%L'
MS1'2N_XZ7&>!F?<HJYM>5VV>(9#_ZD"M9'A_[\R7.;$Y^&<#YPUOD3"T8]!*
M19/P[@+&A<B[)TAV,^8 ;QUS7EQRZ[(60$_#I,2-KZNUNV[</\\2>GRH4!^?
MWN)Z1+7AAY]($[&8D=7\N;(@L,41D#_*H\+9HDGC3*(F'9&QJ$NQCON#1Y?V
M5E-,64E_*542NO'$XU^.X:R0&"%OB*/[=\>LLJ_89H]&7).7 R=H%-]#O^DA
M!_ &+V!# !0 (EM\U2404T.#;.<C\G'W!#NXW#!$&9M1[GKZ?CLTKB F#>,=
M2 ER>K7KW-'0.F=.%EC%WL=D7ZCI8U\N93%$;:RBOK7A!*P,E L Z-HT%S7U
M/$VN[)A(O9S/INGXY>B^0F]8KSW(R58<9(20BL-G_;R?M)>%7<^^_BNK7;68
M7^0=I@QU\/90-[KDA\W,4JN4+H%Q,1Z0B@!:^,6J+\P1B"1,EF,AYG+S%B"]
M^ AO1%KDE(6Y3>[MV$:$Q$<#(5XK<UE 6&WZ<[I_BX*78*B@)>^Q?/"PJ'XL
MV\\SN=JQYZI#K>7=OAT#9GGQ5-P@WSF"3_U?8%W'Q&OM8?9V"%2[P)/M\P>-
M)EZK0$M65"O/M)J9*5C3@-Q6R1:/^ W]UV];WCZ(+!:N"/R$M';X0,5215\%
MVZUL?#8Y$?4H/A<T^O- V,U'ZN+4Z'S2MU+,8/[,<>N\I?PA'O%][&]MU*_L
M5WO#_MX]VP5&;'/+>R^ZRZ=*K;@O@MA'D4?/I+O#+2WB'<:_VS_(C0@Q&><X
M]V_[-F6]T-\NT$D\O %Z0?RWESU? _81;+DFE#\&S=XGR.E23PT/-&7=B3L,
M+F,;Z5+S8:'HC[*IOQ]^Z7)@&K -O.C6"-^[^\<('@-.*E?97_4G(7^,.ZT*
M^8D4#USM, %;W,L:O17"NR!T@F:*?2R0"(RZ/\/T!&PUIS]O'?(VIIP5\A\X
M9[ E2@D8('2E;JK?SR,[%2=8F[KJAM[J=#N68UCTBNK7K_(BUO]51\"Z /F?
MY'B!9Q(0.4>0)IQX.:0KY;,W(08*^T/M7%NM'@TFB2DI#[RV$$$IJ-B(T%W:
M,@3T >.GI"]M)_2TP_FDMP!BSU-;*2<'=F-+?;7A[)M(G/*=5W,> "6WIDSQ
M%K+:/5Z9YW0DH2$P42*P1)B*"/K1US^V&AY_&P#'9/3M4E_,WF*UX%X.CJ<[
M>?$@]%,_:N:N2&Z3W9TCF% W8 /D:HLV,H%EH"0ELB^H2'?K^[,>UW12;5FW
M1#F2HO(2%.C?_M^N28[D":M5VHD"94&2D)BHRT5C%KYG'WP/]-#?L9BHQO72
MHHKY-4).=] Z>E:0J^X9&,;%\Y_D>J$\7*_9AHP8*^DI,@)UR4?/XL"FGB R
ME +M>9PO9=6K1!>Z*&K09#QO.YQB[+&GO&(H8//O^X&G'8AC-V;P1GL*C=05
M3\T1$-LZ-0_V$M.MKPJVL(+;_&3-E+0@U[PX4'D]6<5;B'"T[<Y?;S>>5'D]
MS#X! XDQ'7JA5$I?])"7Q"2\'KNOM+9L]ZCJ*>J:?G6U.I]T&:>85X"\& ]V
M_D0LW*UQ02C:C9Q.NC%GX5BL;*E@ WH"^9TL:@J+3D5/!BOY*T/S5D#KQV\D
MG<VSMU0I)C/[CWT^Q'P>SF,)_UJ #K)Q?$AX ,B?S1'T.8LXG<-Z/6 8/U5H
M0MV&7LI5)*5#,\IBL8O:5G(*-80>Q%/7T.8?UVZ^>;TDV+&)SW5E;N++,\G'
M^[Z53]H[N)'_TT]1JTW%)8I'],,$'1[P"?@PRY\*+07D<"%TDCDX@^D3M5<X
M/>05PBN3 [<T<5#D[V6(C]*WC9<*K'# 927JCPS YCULMSHH.\$U1*E]1/)!
M?B\9Q)4\*:%QT\?*0&>9Q/?)]Y-=#GN:!'4$])L.IT7Y*!G9(E/?4)5?!!+(
M*VKH'V7R,N>:.0*ZED?"%@76IJN*NVS.7^RJ<(V%8TXVAE0@]ZX^-6"[[HR1
M3RYUZ[[1)S!/4R[9_IN>G('K)B?4/$1S%4ZL**C I'.$NKK;;)\R]S!EB@,O
M??XDR@Z&>;WZD>A+1\#]%IGYM"'=O7\;Q35A=6R_I?WG1Q,['5^'/7:W)H"/
M8U$K[GQE%TQ"S1C-=&/J,JRS-L^L$V3(;N<<?J@,/#;3ZGPU9U,BG*SP[M%8
M&K ]:SYX2'J+$I41>A*+Z\X =ZII9QGJIN&:(/ZGH:$D7MCSX=";2X@](.3/
M0[9;M'0@&XBM3?H?1ZX+S87AS#1IY.,8*$K^HB<SZ1&S\-RGN#O?E32Q^G!G
M[HD/C0N*Z0^O5@\R]F;[PWVO0V+S1TP&_$8%FV#;Q'C@?:DR&34780:9\V?<
MD8IH\D(<$:JU2*[8=&PW$BR/G? F9F*K)2%%ESKVW"M@^<O]_)!)R<W(7+VK
M6GJ&(W,5X^)'4-Q^_M5;EWA<-%QAW<?TK2\KF8;S-P#?N</B:20V]M!U'B4-
M)4,J32-LT>9?SA YAV3T#1OPC!$Z;O\L)HOJN[8UX@9[R713X7#YT_/^+:5>
M^86%[\3?PVS.O")J;N,R^C![>4V7JY66C?5*ITX,G@\(EQEPEK!N!;P>6"3@
M,11Q=F+0A+I1XMCSAT>B$K80V;W!HKVB7YIXOSJ22 !RA%D\Z"< -?-MDUD)
M=K(Z%/WJ3NU^Q$XQD\[9RCX(.]UVM7J"/+[JP%S*<@J"(_G/6<$B9V_NQY:7
MW='6)F/MQRJK70>E4H^EME?.Z>F"P0OCE#1+TL09[581_+W-N3^3NLN?\QY<
MPL1;[Y;4&>^I*D4/U4.+DTM8XR=[OS661E/(*9&.#F%%'K\=T'?K;FP]'Z"'
M/@9"9<A>*TP_6T67FJKX&1PS;(A,9IM!0@E]I6 3*UTA3& #RL3*#XVV<NN0
MMIM]C^4RPU ->.E=[</'R,\J[^YM%W[N*JPIN^A[PZF! !;HVM5P/LZ8._ L
MR>)59:N/:D'V 1@4DU,?@%5?6R[# 4[WSP6Q3R(B? #PY-;8K'\-&=W-9A8-
MTL>#S[[J._7]5,,>:#3('/I2J@P,*+.,D/]$^OY.5PO*OU*0K3)U@BKP&',A
MRNP'+_&3[$N&P=;UD% 3+FR$(LN+1V=,CYH_(J<(MI[_%S1I#.2GKV<:/8XU
MJLM'?OYZ\FB,H44+1OXN>;J?O"44@$Z0$/N99IH5R_U<MJ9\OFP8V2VQV=D7
M_9%M>QGV5?JVNWEYP+65I9_$]9>\%&"ZTVSVW<8?9S-%;>NX)[IBCD3^_G$'
M*^]@,[E0"/W$1U?$8OH[;VC].5WDE[6EL$QUACOQ1L$W8MOI>*X,Q7C$+E4K
M8"#8AJA:Z08HV5:BYC"L[$V/?8CTS!#8#;"Z_>YT>"X/^V?D0=]/ WX>Q?XW
MPA>@O>B:/L%6'+;H=QICH&-TB_/LTTB,,M! :7&[1JAWGBYC%8AL-D&1_,L5
MH53;KOO'ZUZ_NC-^L,]^&T7]+<-^A9/QP4M_KCWW_]9*XS#9<D$8*</AT'Q>
M?LZ7B>-SE2\TPUS0ZY7(K1C(7^XY40C=5VW+*:_(5I&YF$MZN^5GZ'ODU+M=
M,]Z=4]Z[.EJE=:G3!G:W[9#C9&/WBQO[E%WVWPC  L[_STHJR&-#^Q<10*X%
MNKH4GL0L< @W9VHD/1$43G\^>RL.5)R%+,Y:VS_J070K:?$(QQR.^[7V"!G^
M.1^6J XO_/=4D.M_# H:"*'8GW0(-Y;2[QIWW>UM<X0+ &(;DN38L0 ]""=S
M!;;L6-T3J@MRJ_4>2Z4,_'M64L15N-@;* 0/=0\K/K)<1)9$$?@#<O:[. @0
M='^%M_GUJGML;$"BZ/$<(9+U?WJ?:7=ED!\7V3K9(DRM#Y& AIA,5D-+<74O
M'M/,UGQ)AYU4GES.5L1 '!%Y_1$@ 4B<->."M1"GH<@K,NAO_\"1P;)RF7.
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M7XO+0+1[+_<_%*]&4LX%&I2[[&H9FGH&5;OUUI7HO]LA?0P!WS,TP[_E .%
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MWZGO9O=F):_W>7EE\_VRG7AP'93B%?*UBN9VW,:QV81MM<'O4J690J^!)40
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MEZ\ HXU:./NA.QI[<FF#W@V- \T*S8ZS:,[!A<CU:T-HQ2<Y%N'99%&S(V-
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M\)<VC;?1XJ#4*EJJ:S:M/9#D:3Y<?"H;_U'BU7SI\VRO#YU1X$?8.]CT)1G
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M3?+*!8KXT5R"WF,C7*%6 WSOLB\UQU]&ZB$IILN G/]6#ETQ<;;O(E!(W24
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M6C7VSNN9Z>P-5E@)G [-:TQNUG>J&1,EJ0.H55LDH?1W:TN6B8$'W9J'^Q-
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M3^_#VV/?I1E>]?%TEU^1X@M]*TVH1F/'-ME;KN]O[VGU*XZX=\9ZT&&;.#Q
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ML,E:[\V=&(OZT#<>JUM6!^ .J<]J83J<H!#(HL7*)""$./2C<V;J-;N+S7=
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M;G@W__#YXDBRA-(ERP2TZ:X-JP<BR(LCT$T?H^@&I7=NSV06D%/>9Y7NOL6
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M=$JM4V>N&477P+=]X&N2@( PX%KM+_BT<$/4X+;@CY&+W^!W&,^;*U=J42Z
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MW\P=G,$I;> P!3X7,.)1$^23UN@[P(AL2Y_:R[A1N?<A$R\;DK!9EB"'7<M
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M(W/K8;4L JH_7P.8T6(UXNZ.,!)\P-)\Z;.T8A-\&=W2.>%QS/V1YB@IX3(
MQF!$N+Z)"F[GB'LZ %.,?7I 9:TQ*3,X4]2(BJR'"CG"0S_U..FA5L_KH)6I
M<I$^G"]LB,F,D^A]L1C?&_)EX)Q3Q=TH:YNW<Z^=DRC;^*53[C9!N\LU?%"]
M!YA3W87R$%.\8BK597A%2\%L@^'!:FEE;FTQ@H?IE:'!(7#!#F3G]+$B!S@%
MFA.]?G32.V8Q?*<F>F6W)W'[,UXWR?$.+8B5%Y98'LJOYXXE$9X X+'\YB$_
M0]9[H([80;]YL"@FE5K=<0%=0OO^XGSWJQ\*2NNJVHYGZ47+>8D4:=>O6Z?O
M_R"_C$^<=V1)=P7N+*;7+D$_4&,1O"J@"4CZQTQ ZY[=BCS([SC46\G#V%$$
M/*D@9M46TH.36O76.(_, \N$'L)E[[\[ME0LW5Y\=C-EMC'L"TD2]3VA.F"B
M6.4[$AC-D;/; 4VFV;N3G_.,]#=(!U(BH+0JI8-D;76O"R''])^ITVVJBIO/
MM98=#>_)O*_#G=UTS*FFYK#LT);9O9$3>C+'.:J0;L%Q(,>]AF#HY+#E(H/:
M)#%W]G43/I#G_&$X@UO[%(F5<37A?^BI"Y4#1;:/'"JB;5^_PP%&'-!;()Y4
M$M27!#1]^NPYB,FL%^1%F,Z/F%S"\$8-&Y]3#H 1J<QX.3?-VK:V[^$O*_L.
MLC$HR2&>F<33+^XX49";(?<U4NSK_E;U,&8BSL/RMY/SWF+Z4L) :-D,3H<$
M-"^8P85Q\+X/@&8*15H8;X3X)+H>Z-G?3*F>:I(,Q@NC?K3Z!U.,F7^\%=3Q
M(O-67#7S+84)K:=";O_[,H&W[%]-Y0Q.V:$N1C<P8V:+D5DDM-=Z!?A//J8)
MY&4=5'CE#"Z#;$LOPH.U_<6Q90P_+[@#Y$FB_)5F07<L[OJ6,,G0GP/YCF<Z
MXR,2%K4D/]E<LIGR,DP9C:&L*(5:X]?DEX6N U^/N(!Y+9P<BA[9!BYKKALP
M$!]FU N+M*$WJ?*<6.':D,/V0T.^7%I!2/_51:U?P)8I'YOR%P]7::K/4J27
MJ6!P3 H5/$0U0-]>9.K !.B*K#X9\XMA#UGP:)$C_,PN>?P;;VL5LCO&ZNPY
MJ[14&=X0?C(RH+(F:(8,>XXQDJ&JV\_KW5R#]M\\TXA#++"7'4:U9W#1K#>"
MQV83*Z(C?B";X$[(3,JO.&O$G(R&V,W_D%W>*7CAYFN##C--^E*+=ZB>KNS]
MMG?G<^E"#?3L:60+5"L1JNUE&^"4O5=DWRXI?./E"V_*%G]PNE[D"KEFR 3Z
M42-++R^^=(S7>]+93S?R7'CUL+.\943O:D]W7ZWC]I$DH)*"6&+,9VXE9FK1
MN%TQ@RWW9F_+5^U#>R]^H2PBNZH;AE[U\\SO6IK?@R/ <Z>_+NF?E$;K'6SL
M17S"EY_M'Z%  5DG@A(:]3UV,I(H=\2SNX[M@!.2"WQ;6%]UF-5#U68>*8L*
MHJ;SS9%X^(%4_<> ?^[VR5N1(R[]T2<F!^_-X/)N)@8U.\8%6\*=0Z.N;G4#
MRB>=T;$+JC34J5V8HR73R/,P_SV"N*@Y+%VF-HS)RZ'\%HDF;QE('I/[\T>,
M@/-\PV<8LCN0,(9G1K*RS<\XR0N3XXV&:0518].$Y%J1SI<".S;))T&7.H8Z
MO/OI5@O-TP&[XN/C@+C8Q,384PD)":=<AC]^_-!]."1D^/#VGL.'/WS8)7*8
M,GXUZ="S<]+FB8=']0;CS82O%=B8].C7.(]$LV4:9LKMW59GGGMU6!#'$U7V
M>H?P5P!'CI ZGR8P9H8 2[T^714\P\#>\]Q_GR<V,#)N-US*O=NY2N<[ID"U
M6YE:&!?".*)6H?K?MH_Y0R0*&,T#($S?-F(8-8/3'6N:[H%=IRX>)'$RQ/7G
M=:[#0X)5NT;VW,9_*T87OH1_8?]#1><-0?26N@'!T7Y*I"B3HH-J?3W=L;+S
M6AK52-"69]BLFZRW%9 14MW1JPD77RH]MQWS"-TN3J*D3,*N65([A"B!'3Z/
M ^'QX<KGFC+RL]D3G5A+KW3^T&(C:V*TQHJ6@HE?][EF,W?-X"Y8]&YO8Y8V
M!.ZI24^7$@* 9@EU/N(C]8/M)]-YB>6TZ7]#K>!A<(54DLUT+/_@152&? &K
M4BE"_2BA;\,G;8ZO -PGNA^X0B^+.N'C\T"^/<Y^AQU.28&7!2!+;H  .C]
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MV'.%XC-BQP'W<)-F<+AQ(JOG'@NC5=6)N8\?!)^]@8H@23O5C.[>7Z^1;GJ
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MC=;OS>W9JJ%"=;A6#7P-%5I>RAWJO$5,F+V;J%8$1ZCOS\DSS&\:O,Z@,7:
M;J_FS8/'_E0D)Y]'K%%2$+S_TUIJC^U@9]N;V_Z:X#=$=^!_B>TX9%6\3)1M
MI@R)RE/M9O9PG(=C)A<Q>'JM@M\^36L3Z<?X:QJD%\SS7%GMI88KA+Y]#U>^
MWI:3B(L$> JK#0I'[E+GC:(BX[^/%>D]@P#57GJ:U_K;C4T*YVHI,:4IBFVY
M]X<C3V,JC=HN[I3<U'[\9I.],F-_(M,=X+')H+]\1(2L7,3(J@6%G3@K@C[C
M)/0@6E'[2H1U]Q!GDR1'(4+"R39^R*HA=M"3B";G>IH,:P@%"BUU.O*H3>OX
MY@VL^,?"\5KZ18RCQ\&H1D$B0 $:_.!UHR!9N7X '1O+:@M4K]K!( VZ.ZBB
MD+>NGM,>TLA-K1P\6/^Y79048JKXDV#^$C3) *MJ5J3<I\\D7'23&WD^=D1V
M@ <*8@IT]_VT/>QE4^USS%*GE*1Q@'>&*$XF@B=H'_B=+APLB,V!@U6_=CSZ
MXLO5=(^UXWF),(R#H'[9BL;2L=,C]&_2 WQ? :$%5'H84WW-TVZ\JY$5$NLF
M<%10>?ML11;-8/P^KE<.6U2 95)2!PW:EC;EB6VCZ@5>)> 8QVB9G-U#=9-;
M9BK==X.CKP3.)8!T<OK*IQ\W],]67ASV=S<SF99UZ0KXF779VS<Y*(LOT'[2
M4FWRT4I&!A<Q^O4H<M::35N">0<-[X5*<U\!6>BG=7\LJUCV^82BL4UN0(]H
MW^_VW'IG8>7Q#>NJOM1P+._NR]N#DY"+)ZQLH& 4^T]%N@;;=>+TV6=#'SOG
M57WHU170,AB;*@_^%C,==HPU-;_#*^P)91%S<?#2Q1^/YZYK^'KUA&:=ILH?
MG:YB@#<6B)TFJU93T8@PE0?NEZ;QN)F )=L(GT0,QULQ#K2 M>,$+; QW3'_
MF6+^!J(;# 6U%U152#,8)Y?W?$XK5O1FSN8N"Z&$F+\<M*D#"Z@+V7>*)>^Q
MLGSEQ:6=*1V^\G<UB[DRUX6X!G%A;(9^<4]JI4$O0MS?,S:I;CWZ,1^Q7<0T
M;]VOQ5NV6@\#W,?"5AV*SEX>\+QQBJ3:\N6WO64\A9D,F\6Q%U)<F1\VU8/R
M5R+-40B_OZ9 N&YE3'.6_&:V34KM5IY#5QKCGR&6]XE$W!\ >!'_B@SY+]E"
M%GD=?HJMWJ2\IBZ #PLB/^<W3Q'<45T)8.G$ Q;_C.($; .JPIFP\H^&:9_0
M;T<3F4, ;PJPXDH,U3>!\XN8D3?OYJ?F%S'FW'"/>.FAXF6_G0L2Z3+T08_.
M_+@+[F?$(\0,PH]T/Y_OJ8'?CM3O>/:UQ!<#NR_U$D!^ %I1J9-4!,W+#JKS
M"Q\A[\BUM.SZ>R@2=@NWP;$*MR!PONV>*:;]G&T+>+Q,L>7&]<;;=>%).[TV
MW=?*_W_QF;T2Q8AER>KG!!S LR"*!;2US)%K+9S;Y7"@^A$QG)AM1M1@X\I=
MY)SU#/^,;4Q=B'C\189-YH2,)]0EWRB8SV$$UI#"-[V?[;GRKO.C4T^8=Z98
M$YI59Z/^@!7@D563J@0H2*+/JJ9:;85J50<9A_GN<8HT*:?9N. !^"D->$*2
MYF81S1@!&Z^NKKMVJN1=\>/]%_M'/"OI29.>8,-??>1)U\CF1*!6--6G<H7M
MU;<(&K"=NI"@36<2=6$'R$4\9L]C&@YHW9D_$4A1U HG73L&+^]QPAM >:>*
M%C'M(7;#UAE13JS5$P5%%=&%6:\#$XDF*#9^X8[D=G+K1+ !"L$IC6V]V!"H
MH@.5%7YBDF"C'M;[I.T#8AK3*GC"%+<Z5L=?R\6SC:OO3I+*C4X'V5XLZO9L
M\O+_Q'8&CVH@X63P"&UT089HWU;1&6;J:APOC[$?_)QDK2"FL>/$%6X?8L9.
M!H/X7/<=3^A>[?OW<5^>I&JE.V8E_.R^]X$GO<]?%-%TL*KP\6G!AY#3I]LU
M5$O="%'*D?RW(P[:0GQE3T-E]P$H5.$B\7S%-9MPM>4JNCIP:^Z#I84*G:ZN
M-O.&>U*<+H0]_-[=2"JW^'+-+'D6M3W*'<*FX?HC;"_@*?V6RNO]5''M>\=N
MAT"L >8J'C;/1PW@C:)W.E1UC>ZF9"O(J;'VQ)$VI3/?J*M26JC>>:&/057(
M2 T!3'.Z49O@AB*+VA+4&GAO.K<=9;'>YZ)8>^M Y?70QY4WA3_V;5^G^<T+
MT>$KYA%S3V256G65L2]I?EH0DJ5H\X6(#[S7%5VXV\?Y@5) YGD=F95JYTX%
M9D'Z"2&[-[3'_1:Q4\3HC9D1X\;-4$7[S__R@730 9Y3YYUK?J["I1-^%$"3
M,GYZ8?=7SB@*??C.A;'/R;3#ZW?=):SY0#?$[^B^FK3Z'U\C0Q\M>0G&6 ,)
M6L2 5ZN:I0Y>R*I&4'YXZ);4TJ*-6U/66DC3.?3==-Z56:S8)0LI*X_PL;UR
MUW9XQDG/^:HR Z?:N-G_>= !8TT2HI>#HLL;&!U3TK7JF\3S<A.DEVO,L8.#
MU#4 A9;$M((2I+0T%Z:AE\L+A<UP/MA["/R<N5%A6OU(.'KPX81P?<MP74;,
M8Z>\<N]*$>5;6\DRK_$]1&NBN&41@^-*'G'%U8N8QK3V-7CF6$DXV2*6E-RD
M6_/Z4\ B)A1>UC_+36KX1OE@2ZR)V$4W_.R?<_A(SD3PH2#QN_GC*!W/98&7
M[% H_AD''L*/^ L#$K+:<6L+I69=U:L1>9B *SE+EP605@B_:A(%A#5?.,L(
MH0G3+V[^=>!"(O$=%]'?L)0YI;>4YWQ+_=+]%"U>V8)[)3(^ YD];+]U]<ZP
M#[P"',X 68%)0\\];T=+Y:OHN:?R*9OY!;<'NNK7FB82WXL0O4M+I&H5'EG9
MI7(6CHTDI)&A\2K&<6A>NA)N206@8^Z4QQ# FR])U\./,M="Q%?\?8<T=;:V
MIQ1G6+XB_HZ#W$<E^?!&'/A+;ZK0HZ%QY(*"ICP$T9Z.!2\3V"G,;L" @L2+
M XT6,0Y6HVT+Q!O_OOS/YBTET< + ^R\3!59$"GWR,H8R*BDXRF\CP_;/**@
MN/$*]\.XCU.':K\,R$1V*#KS)9;F_+>C'DBSPE[:F#X3>N[<SMZ*CF4YOX]V
M^FBJ\[CB/W#@<:X6RE)_))[-O2&JM4UOBES$Y$AK":[0M,R2\*-9%\["W8\2
MBK\Y1Y_1_;4[NOA+TL!QT._&^8(U45K);(?[.B]Z5,'=F[6^IP.\?[BH;OA?
M$_EM9M._,KSODRG,=="X;(?J ,-E.$J#BC.E!TG_UGXRL5":O_L=5,?%M<F(
MJX2MH];U@VQBW)K]ER(O_JTYRT>TUZ)KM$0LM.&UZK\8FF OLFKI\LR_4/13
MI(^H>X8SL)WC$LA\2UY%V$WAFLY^F7-336NVF\OHK7(5<$#14<JZ'/9PXEE/
M282K]]R[0K-TA]AFT\'S_8Z)6!'K QG1/[*4I$,ECE8HT0$G,0">*_&<3G6J
M:"5G$[VPXRO4W45PK0']6BMHNI ;CZP/!\E8!B&0FP3;ZJO03XZ,B]9*D7GI
MA9U6)#S^O9Y32$Q-^52LVT37&B2#/@"T&U N*3(J(FIJG I5R,1E[7(CNM=^
M* R<[Q#(.^0IKM5I[OLKZ=$=1:ZYIX8\4YV 5.8&5FO&]MQ0R16PZH4 *93%
MM_CNK3P==%!R!.FA.7S0^KJ4&FFZ5/H>$&?@0!_6#8*I8GXJ6TPT%"'_\JW<
MWU<[56<U :V6GI+=35#\BL+R42AO/\0MG^"._,PX,%AVU7&O)/[#;*\1-=!=
M<"95U&%^*)56UW)>\S4@[B6F$ T99]&I/TO+8)H^&\J7S/,6,8F \79D"_79
MR/&%=;_2I>\&6HOT04YQ.<;!H=X[NCVZBEL\_G5W\Z #PZSJ].@^Y<*IV6&Q
M&5'\%;\:*O1%)Z&!'G]XN+WO"\=4?8N#'2_2S\Y8[?50!#5*[[0\#CEP=Y1#
M-HIHFOY[(/3MY;/&Q][^?N"Q!A714Z-?53%[1. 1[$BA3,[C9I!KN9WD+*()
MLA6^4 ]EB,?(DIN(3MJAX2FB1 ?LO3'+70Z5SK<'*EE/P[T?333YUI13^ MV
M:? 9?EG[M]&&0HK-DY8O6E]PL-5W*<V$3$5!T]O;S&>@.@; $I,!"M[(X69_
MQU9\9KV%Z/J5@G?WHIWJ;@4%"R%FY^BQM)[L1YD[GKP=[E\S\^\S+53/PQ;R
M_Y7;MD1-,PGBJ0[ QZ >,$AJUI$/O00K]H+$&U6(13!T48_:-B^PR[!6+!?>
M?=PES29Y-@1K=AAM_U.06AP6%Y=0VGO_0UV@\^/:%XT8)0MR\WP5LK.?*'Y2
M+)U/A_%2HFZXJ(XTQ0>-I)ZI4_60++24DR>Q ;72V0[*P@"[9\@P^*Y6LOL<
M_U)DE3656@%5KU+GG7C^X@5FP>S_5F<M#UU@"YH*-T%"XZ("/M]7IUI[1D&>
M[M.:CJ^D/*]PJ"JQ=NV]$8L;:6Y];_WUKYZ6ER^@V,M/*!>/F)H@(WD^-Y_&
MI7IB%C&[/' ^"GRK'#=^K8+2/T[X$8J5Z5CNK;MWI9-^<8#A);&,L,\KH[JB
MC#SL96:0QTF2RKDX=$=2#/UC8]Z;WRWOXP1=2TW,]2?> Q&+F _)_NJ_B>=9
M23AC@AY\$IH6WV48H"KXF]1&GL(Z A)3V'L?M:3ELNW <_)6H?50+-G82_K7
M=IJ[!RZ'X?>(OO';47#HW0.'LAL#Y,%+]3C]1& =M]:EM1H*X=:E3:G  U=?
M0EV*9HEGZX/_3(V CE;%IV0)[M_;&VYP%2[JD1-K""O7)X9KJGVXXDD]4A"8
M!AM@99_2Q),_ASZ($#JKB]PW25?&S)J"E"*]1JA%K#XJ$%IGG4GJJ6_1:;OV
M<ZK'X^%Y\H4+/_[S18S[5+:4_:VN9*YCM@*@#W&D4%D/-8II!@Q/*!X\V1G8
ME0[OE>"UG?_DV+'-<Y/8)$FE_<GW1J=;!ARSLOW:7(4O2Z&B-]T^@[/=U.^S
MYY_GG1B YYK3-=6H9B[D@J=$2^43?B%>H"TEQ<I?D9(6,8:(!10FR<^!KX)M
MKZX 1A?!=N$FQ>=T]RT@OY7SD[>W8Z[NQ#5A8<F#%D5J8;%S48&P7O,T;WO/
M"8I>1\GO6A!O+/BT*/BT4$AR&OKXL9WO%^=GZ%C[[[__'N[O=>]_&7:+4G+E
MUA'+N_=&[F98%Z FX"6_@2(Q40/@,8CB/U#:09RR5-DSWW)-W;$R7"+QF;SU
MWL;.[O9&!)O?%CC?@<4&]#Z&':$P\=79X(LSRIAA)V[2=*2DQ_-T[7O.Z _N
MUU+OE22P8L2XSRR5-?)>N!55=*AM)(KJ&E(D7V)SC9%>XAJ&A6(-??_I^.SM
MEE'DY5#JL,H7+"W_,2FHQ9IJ>F>^R6:H/^A(7*E%V8O#5G139PS")8HK ? *
MZIQ$*NG#YPYNK=W423 49<2M7$/&%;!D_CKS)\8!J+-H56U^FY6&0K^0<$\&
MK(!_K 7];C("!6.BK*FH*'>W:!EI-4O/JY0>-?F+J96I^7#)A2=TNB9X\G^'
M9TOD%S9N5BHA/XF1Y-Y18$0NP6:Z[U9X*O,4?Q><'X"H7B ^=6[#TP!HU81:
MIL(H<!V%:GMD=8_.L9U'F-NVH]3)R"9;F"^))+_!J$XB^I\A%*%ULA =31D>
M$RA4EQU1%Q!6P1LAIQ_VVZJ<ANH3;%6RXRW;SAZY*>R*4YQSP/W\Y\53^0=S
MWIPK[0C=@QU7(;IM_ZMHO8A!M)L5\;)L=?X?%<A[5EU9NI\W^ZMRZ6JA-ALO
MD6N'I[U=OY;0(XM?Q&0\@U]FNVXQ7)N" 9RX(-VSJQH*Y(*^Y0130<CW)AHJ
MGPB,K1 M.G1=H3BY'=GE'2H[7GWMT.&@T4JLE'1C*JI!O#(FZ\ %PT,?$XG%
M+&CGJ-@.7L\"2>1<HI5\BM-3P6"J'U771;I^[N8-NNN --Z";>[#=S;KS?P9
MD=+>#-]S.UYNHEXY\_'C'ZLUX>G_1U]\F+B 1K@!*+:"V8T&RTM&C.5@R9_#
M5XA8@C[2AEL!G[1Y?O6$8)RP1C'/2W#S9;-CMTJ]J>T%-O>*RK=LFZ^==-ER
M^9-.>2,&N(>'C4*5#T"7*3_5%92YU9/;69H1(D-W(]!%>N6>[%XT;V%Y1TI#
MR^.NT-#'00$AX;<B;O%*&VKN1_CY,C?T3\NKGE9&R>L>.]AR:HYD_X?!3:%1
M8MF(NL4=AXYQFSH/QJE"&!Y0I*PW!=%4H);" !XNW1[*7-"!LDX,N"^769)Y
M?N8JK'[$-<Y=DWIE]<.(*ZT"-U5^77,-NV'7OUW&<2<3$V1[<!_MEHHG311M
M7FIHU$%/'2 'F!WI(X;AKC>1KW??V8J8W>&W-PV-[L/JK%&45DMG-S#)NVU"
MO^WR69X+;>B"U^T68R%KLZE\U1[&JN%%S$5+0(;/9:Z' [DH-I.,O@AW]K.W
M%'L#C^E:/$0GJ[7([25[H-[[^,"^OBB&5=,P*_[!N*#RWVFIWL5^KZ 3#C-?
M-,%0Y:BZ@NF!C )U_/9>09SR-J?@L[2L@SJ-;_>[LN4L\"B\R JL?Y=5=D1,
MUD-)Q&!94], P^ 1M'O6GV%[*SBD&RAVJJJ)+9_@"VZ_J[RFH?Z,XC0;,$*5
MMRT 6Y2I? #>WGKYRC:IJKLW0[26L^-#N-$$NN[9.'/L\E$(+\Y-=-='-II?
M?!93:$F2XM)B@];,.?8[!5RR4YC ?1]"7&UJ$^.9>>CL^?VO7<LE6E)@;QMK
MU$NBU5ZM'8Y8]]\1=8JT.-MATP'";KJF7[/!W65,W!"\ 9_./V4:/9VP*608
MQHNS ]]\W\2IKQ\H3;5_A(+Y[EX!WU]]CW%0Y0W'\('S@"[4R./6.M<H=G4$
MYO)PVM"G4&(FPP-<D)^X$ZEU>'!LSOO*?SKV<5\O;>3RG2I]]9PNB5%$(IW,
MF5'^BI7/*V7J%":1GH_H6:B+"&LG.08*VP>*/"45HH+QRC\56DE14U';W$_=
MIZ/S"),JH"ROP3IJ=OZ5^46,+D<?]AS</C=M.[Z)^[P1+"HV$F3O&W'8K F=
M0>WE,JI0:GNG7JH"X=U0C<H7Z6&:J)\2PT:MA^N(&8 63'KT96&PL<"YN;0[
M3"N#@0^5VN7N875P# >1MLIQWVOM#0)FM5[E3 JAN!B(J*HO2P0B!61X'0TE
M19/(FP*3ZIN+F/,XR,ZIIZSC\ .7:Y9EB=SSW)%)<6=-6<23NQGN7@J/V/+8
M;"?/A>+'T#519U[;UVU7>E?_FXA['(KHKU!@KP/BK!#=I=+IC'/JNS'Q:YE;
M&9=?@EIMI$2"!70[_L+E<OH.9 >4]\IT/H[@-LRPH4<QO"Y(B)IT4<</AV&;
MLR50:K!5.X_Z@")X4/2/IHQT$P!_8Z&,6!6/O"OH35Q"19;)W)BY_-C+IGRQ
MO!V-E*^E+), E'2?I8?()8TY;!UI<.@QL#K]Z]?1\)"=SQ3<ZTY_;;ILT_'I
MYJT>W3VX3Q\02](Z^"B@#>/ SUE.+^"SLCO@?*M\9<LSOGMT15?U9-=QD)1F
MU7LPH[-:VCS7/. XW-!_YC)0\>9<3<:-/AL,T-0U)1'+C1ENZ"IK,HB*CO%!
M!E5,2\;IL"VEZCVW0P%IKBZ$V]?'V'LMP.J [:3O\^:_;\>=Y&Z=TI_ *)?:
M5UJQH-V>2XG*4WP49Q+5%56,@Y+),7PK"\?PPTX;@+VG;WM1$ =0WMY]N!KV
M?$RIG;4[#.729"1=T2CA=65U# 77[1QG>O)?#/,MZA:; /$D_OHBYED8;%3-
M(SZG=9%'!F38=EPF6>.2N]\#>,,P9^T8M!&G"7UK$W1E.'%-OSCC5L_E&D+Y
M1_F,Y0D/A=1OT+6$_6U%6"C9\E-NF?\$ZVSPH: L6PQR@AO!$A"5R?_KBS$2
M0H#F9 E6WSI%J$9!!2ENW+F >!U>7AQQK5!=&N[(U4(!DRHF8D<MO?PY#7V.
M7GJ:K81U-7H)3R/LPV@.__(%)4-#;\6XR0THUD:I,Y\"XC]8X%&N)NP!57M4
ML621FJU")S4:URCQDZ1:CX9\625PD&1$KSUBU+:ED;.(2;DJ'M/: ^I,9/RF
M7&BF_S1QYVL'Y:KNCQ@@M_K_^@L\LRD8IA>Z)E<XZ.3* -C03/D=2A"KW4X,
MNWNZO,KVZS2_DE?<9;U06LHTF[QFUJZJT+$(C_;XV/$Q-WGFC)=.["V4J@$?
MIJ4%E'YGU%HVX#X4*N\,$D-I@DGE9?431Y$^3_H=^8%Q!B2VOX;M+L>IBXKL
M!MR=*@5":@@N]\37*.#Y3/T]2]KLI,<O@I#M=^,N+U<%A#B\;/A3<V%I;V(*
M'5ZO*PXV3E;&U:K_X)XGIA*-$ .4::)87\E@*$@=@V!#H:S7'.6,;N7^U":[
MMFKLN-5*!>UF7<(NGK-PX\#4W%A<()M/#E <$$3EEFZ_?9_BN]#"3=]#-.6*
M4XA:D00W@$<FBED<S*"#K[)5I$P#N>WQDRY[M[E< 98[.!%OSOOR=^#N!!T1
M@YH=5XV2US54;OO-?M/.9UJS*(73JF>@U.P&2]FH1CG_Q6XWD6NO>!'SBF8"
M^PXY2/)V[*V&:8J7X-?1D(V_Z\TUI(%D+T[&!=WW =3+KPU.M?S^DU8G%[Q4
M#9ML4J*/2PJ <I5-4)KJ] 31\"DC3D%J8^FP;<!.\@^P1WZG[[@$T!=!O:<5
M[UC1<9%/ KLO %639H25U/"H^XW/OLYNVM:H$IW'X-S1J4/9?Y/0%GUF"WP8
MI"4C5I!G(!2DV@2;#L4&ATI8R6QOAVK8COF3(JHZ5/]N@F*3]+3YH;(G$+/K
M5-V Z6=/,#=U-FOL!%:'<JV4TT\5U(O2HSC_:*B(*!Q_1%J%CNKKW'.]HV&(
M3K1BOJT@-]DIP4SI!;U"]8\.5'R,JN=Y @S)E1 A4CTIL^+LXW:[3%RZ<#W(
M3V&;@6_^JWPJX&0L8K0/E1C[A5@I:&ES.L^PDHAAKWAUB"#XVL*< RUV\_GA
MV)\>(GV#)X2?QH-^YN2LG8E$1-=JV'QM8_ZO"4]^-?3ZJ['NB0:2LXBI)\&6
MTRI]AK'ZSJ6E/B^[80V%BQ3;:6G_ZAH^D6.:FQFBF<4#=)@FXPM6V6'W*8'5
M6;ZTU8N8*'H5"C>Q+<WC3#-06=1TO#Z6\M]$B&W_MM:E$=&4[NI;7$HNM-5O
M.DNRB$DFZT7&+F(L85^H3U;8:P(?A[++!<*)8:O5_>CGJZL>*,QD+NTM)]8O
M+\UX1*H(IIK7?VSO.SUYK66L*/F1C3P]ML6.U(1!_@'$T]70WD5,* #9F?VO
M25(96"JE,]9*U%'!@>_6!IH,5<.[5(X,_ #!8MR\.L/[8=LZ/K)MF+!=1$\[
M<?>A?RS9@#*_D+C?XVYX(@%UPF0\\@/J#,!2QQ6H5S'@\UQU*$]%0'H*QAKN
M7@D=4[-DO5D<^_?NNQX>MEF?WM-U?1;(:%#Y7;JEY1;4'7 [D3C0F4ALJT!6
M^:EV0'REFYH-1%2/3'81K%K :?EUIB/](WNWGO1>05=;[^K)_")K*%*:30":
MHTN@XE=-#=>K_-]B__HC1%TPOJ$EZ9-P/79R7@DLM3IDKF&8HK9XA>$([8U3
M[6!X*<RF'X!YXJY4I@$4YW-+UGI$Y4I/^P4DIE2ZXR2YZ<Q-_&)%;'5[T-G8
MR%(*LEYA=SV&^\.38'+AM)F7HJB0&DVK&,$ :SC&8-JT/?J'S=15N(,@)[>:
M$:8N7<1$Y&9=^YR.+QZ8&I&[[Y?E6DTVHL+;+\.)^/Q I",>2_D6,L%<KUA1
ML34HG&D*SMU3%E^UN9-7=AC$ +7XJ3R5+MU>&;AT),!P4%^OF_SBQ-*CVXLM
MY:TX(VI-0%808$P5XOOF+D+YTO:!7.<:>F.GE8V"F-YQ,]?Z]^WERJME!0>N
M_JT)GV3BH$DI<:I/T=P*&##6/CXB(6<1?T!L*$P[4%A:_LE+(K=B>"B,_02Q
M'[(S,ZS[YWJV;MGG;"*P?+K2VD=KV@ZVJ$:#T,LF=##WF")S7:[!K%=VF/*B
M^M[%?L*/S/?S^8HCETNAFKP3=\@:L W[11[]Q4NH6.KM^H5ZY:NK]V6QI697
MG.F\S\2/_M_OXR9WH.S<(4WF,J56-(H?KHET0.P9ZZ \L'XE\6)C?5H707N8
M;5OV8]695.,AK1WXF3]^R_IZ?0].<E5*U*;W*N.AOJ=T.VE:HKA&L70[(L.%
M::7XW$9>YV]1N)G]LQAGZ)2?SK"45KKN+C8KB)]P#1[.JQCE_58C#&!WTWX+
MO6U['SLS*B;"9D&(7A9HU]:"[>+CP*/3FI+\SB /VW>1H3PK\Z4CQC  1S6U
MVI"SGM_ T8$*JZ@%WBW(K<8()N]IQ'R(_F#4-#NCNHYJD4*E8XAQ@#@3 (/L
MN9#]/$JZ!%G>$$VUJP.T4$:J"V GL- ;O%-1!159AG6%V"CP[3IR2YM[)3.Y
M#\8+@!ON.TK\H?A7WYZ!RJPXJ79,.:?;NFFNAU-.HX9K(*>X#:16P!#65E=R
M*:QDYH\#<PZ[V@$]@AM\"KQ20JUHV^;R+H9D0?6]TRC_],W=O/+/*X*2VU,7
MIN=T[+NIDP$7&EYF^F$0WG^H*_">,@S0Y>R&PE3NL FD(>-BF:,A9A!60DHR
M8QG'JK@Z+CR:U@3!&.3<%:<CV^C.]@Z_?>X0;N++';-=2084@@&?X209P[59
M;6ZJ3_H6H$C-+O%>\5P#=AX+#B8'GQ:13_\;$B(\[1T;=S76,=_,S\_/T)%O
MYN)BM*O;H_UK<[=C?_/K;3GOIMZVO]=253 [ *U(8ECUAWFE'V1TX9+#1HBH
M<F>80Y>M]_[@%D(G2N1ILP[[/EU^36WN5MD7=H^<OFO;7$1YY&"=$ZXY_@3%
M'>=%#.11(1/!UB@.<Z< E7. \/LPH(5HTJNE#>4TW;N9>H ,R.Y-NR-0&"?2
M*NN(20O!LUZ;+R9U!^4<SJR<NOZ*X(1.S@5 7(Y[1H8->]N!>GX[4?#Y9^AV
MJ(R;R5P'!4OPJ3LA,\D49V<C20>ZLHCIO/8Y)T95V!QY8CC(7AWG_Q+<'[0_
M=GE+6OZ#M1>X0M5ZS/?/B,Y2 MJPP@4VD4L]DQDXE$B[\EM%(SAQ0\6329PN
M;"FE1 (2-T575FS\FIAN>0;.4-SOY.'7IG2M+/VKT95X@^'R*&3B=WJ0UY"3
M,B]DJ K>'ZO<@_W2C.@M;5GXT[EB(!79!/!\N.'9*/Z^>L[8#P$)X+PR^CT<
M<$9PZCWD#5PNIE=TD2UF*N=6]L=;VG6$[>^;Q6E$7-KV7PM8S[KI]"CG<UO1
MYO=.%L^PXGEE S06K_)"!I=J>F*9WUIZNW Y+!/.ML@7_UHW-BKF<YQZC49&
M5H[^=?99[>#]FL8&BQ/#0J$]?>B$]<&EZXKH>M@TOB)#%U&UA)_R!K=3\5/3
M0:^(M6&M6303P4KX7I'[,+RE#"J4ZA;Y:NR_+,NFMILM)^_4Q,L#'@G?:L!1
M &]Z$5.+R[ZH($]15><H5E8M7%"/F\((5KE!D^UWWIRO!?GI#_AV4 HH(PT9
M,X9E':;7&MO]!JKV_'B7O3LZ\K+U2=*Y? PNEPM&?8;-2))&V%#SM/H^VT(Q
M+PEK)Z:C"\-QQR>Q]ZJ+P1R<;@1NM;N%+%>C36I)Z*N<Q:ZA%_("5[R\3\_W
M4MBW53@*MP[0ZN+O8;U?/&L<-/RJ7([YGHOHW$.?4JA@P:9&RF2P+&.*L0D
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MUFR)K!IR;5RJQ+R9'N8#<F'#SXBVX!M]/J A]\A 2)O$K!48B9;<S'=9'CI
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MW8/KH?V?+7;ZY3.BV["4-+?2#C;BRWJ[FE7XV@@1CDNQG[8X_O(K&(O] ;8
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M2,]]-'KZJ0F-?U]A' SC-0G1 BD' #VFUKA OJUBXS14B_7>0%0Q)C'A+_W
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MA#,)37E&.8H3M7?$;7+G6^6SL:5UD[O&O/C@U(W+A6$>KFS4 ,!+#FG  LP
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M+A9EBX_>YS(<*9#;3:_:=Z5 A-)58!IZ53FZ\ZHR->R[[68XAE<3!=YS5VD
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MA>1%(<;61HEVZ/RM.9!IP^.#-IF1'#VG*[8N:K:,LXK!$5K)$[NL-D[_5+&
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MV$+&32:E6AU6_[.;EI/(3;N<_S+P+]=L< 9J85VJ^DWOF8;: C.7G4!Z%ZC
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M9(,V+9AA_:":UY1T IZ_AV'G#!6+@'B3[)L\PAJ$!'G>4Q#P/O =H9,ZI_[
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M"3]BAXQY5F;3(PR]FF5;=(?DMA)5G'X@]!E)(DE6;7VJ\6^A"@\T%F*D8R)
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M:7/7#.-23L>A[LBR@WUO< Z[L;T^!QI7"@(Z8,NR[!M1[$P#>$K6WXQ5G]K
MD00IY]8"3H=DMJ.C>17#1_DM["1]&8-S'%IYMYP!-/NO<?.1*[PJ>+45E7V1
M?D?'W>\>[J]Z0LK]57(&A]SY3V>CG3W@*^4VTY<PST"?)TU5S@@U6R9)K]^M
M\#-M_(1/&ED!EE>6PKYG*_K*=C)]USL80%LKGC)BOBJ;/55N75%L_'!'\*>!
ML>OT:X?(,61IH01TI0YZH"LJ0-_C,$EU\@M_\TW8T?<51!924QUPO65,,D20
MU:1P+R?EEO@SZ&=ZK-OISG7=476&2=TB\_6047(9#'@9Y03.B'^E^9@GE(8<
M(G0LX!8_Q4TK]4 M$:#+4#0+J@23!R&=HV!QJC5;?XBQ6P&?E0WIA;H9>*:?
MJ>Y$7)_@E]"\C,5;P.JDUG,UW1LZZ70K\R\^H2:7[QY12@D8 L-X]SCF*2R6
M;GP;];=39R$TB-[$LH%[59;,HU!' I%$N#FRMQ/9K7)A=>39@F@=(8F_,:3/
MQ#DM,NSXI^DFGVJNK/ ];[J4019)\/8N$06.L8_]WI0'^YRL*,0!!SEFF(4_
MD.%-%$3?MS$&B]-H523: ZQE[8$U&Y<_':>N!(((JV@L#?C*$V8TY'GW,C&2
MG.CY"R/F'7D=8_ITWZ[$AO*'? ,^&)?%"?E5+$D-GQ'H#(1VO=<"[UU;S$M8
M=5CR";\4WB&>EMM@M2+]CB_L+.N(KRJEZ6A!T2*)\=KZ@U+VLB]7=_N>"Q%?
MCBFJ#'K(B#A6>6.DC?+"U=(R^&%UXFH<^8.F\H Z-Y(P2%">5N<"E\AZ<3EN
M1"FUL0/'M+:IKOA#T1=%U8%_%5(@K91_3C]QDZ3R8!YQ%?68NVY-[3U1D?6(
M.VY1<>01%0SE3.BH&,P0*'G20"98B[BKL_D[F4X]Y5B&24D%:\DKQJEZS"#Y
MY'%EK#JBU3;[.N)<P!O)Q:CEZO/G#[8(HF5<PR\^^\J>7,L9_IJP3_"$9E+]
M1*- 1<*.?8D$=&-C-8C;,I64G9/=0DX%5J'V3/L^U'A<4H5/)7&6#C&/866(
MO#IE8W\8?T6( $P8<] "S?-+Q8<BU:[47ON]\JG5PZ,V.=6)6RL6<-HH]TF(
MP?5?"979B GV%]\-+?8F!^-OD*N >/Y>=,AV*H._A.D-QT%W&\7D#(=-B'9/
M_98G<+&,FU;%70O'](NR3(@3O;+VGZ>=LCT[)Y<5T O'YP\BU2,_^X1Z1JS)
MQ9$?+99Q92SLI/)$].';*COF-3"NF.VPFGD.'&Y-K ^3T=K2V[;T6(]>NO%-
M+.]P[PZWBCIHX=5%LG,U"W+LBVPK]7,]VE>ETO.@O+KQK6OY*<U_#?O)TC?4
M@3O3S=DQ20DJ/[3'A)A@T3!=QMQ[K1"QZHL:LMQZQ^M.,_,<MLGR7-HO?V?H
M>O9[,+SK:0:\M]'L;8SKY&(B;,&9T 3WHLLYJCV,(.59==Y7)JT$Q@MKIU*9
M[E?D^)3::G89/"3*VPP%POP^$GM5J*U6,F)5X'I@-0:4KH2(E^72:47>WN*4
MW/QK'W&(OKI,(.WH6"QSIA#FH74.ZQ$W6*8BN2K4L1Z0<ZK#>G@)92F<+BO,
MJGOVX<.825E'@C75@'$UC-9TU68^MZ>F^%"R*!HUZ[KW[H$LU^)0I_Q%=QF.
M?(XLO4L%G>F#0G2Y)C@M3[[!6@(+Y=DB,XK")H5)DE-2''Z 2P&97=GI,463
M27AA$0,X_G[2?I.,O$(\&K/RSYR^RFB]W'_[N.AP*?6XN/0(./1: Z(@:[Q0
MO3@L$42P)%@01@$963\P/BM]X7:Y;UT#I86U!=9E$@,P])-B.ZSN$-/K713T
M9!,T_FEP)2/G6]#+5SVDJ>5^L-VI_BC3NC*OYKV,!/?LR1T8AV[BPGO8RN7@
M"#>HA.FK+@9"B6F>5[T@O^IX63?8+\NZ^]37<<\;]?UG)^P)"K^H9U\?42M'
MVA[1?%8^"HB.-54MKSYVG="+GRA6F:/MA JMICBRE#U1"L8V <M8)@-^;TI<
M\^%+.B5T4D,HC>9KQUG-J!3%\/H*Y=2UC*RQKK_?=7T6.6SKG0W[F>9J:7>T
M7F656[4*Q])A]0)@B 0QZ% VJ0O0O6@/V9!ER_I@1%V%'L#JM3^<+"\C-P'Z
MZ-)!AJ]K#V_HKHW2.>DR;VJP4I33GIT\DQZ5X-9Y>?8@X%W/ZPX+>\AQKXT,
M.:\Y1U2:JC-8^MAA)9,#V3<7<"\(K\<[C$.INGS\ )S9+11SV3P] T^HJ,PF
MW3Y03C0;K^6DDL@K&=%-/EN^%L;*"6M"*ZMJ@>3(TJCXAXEAR?<:KI/UR9>)
M,,D973ZG"F=UD]<*0CO2%W#K@;!<.SFY16(H2*]W+X*)<LIK-;G))_!]]T3D
M S>B\*K#1O6?S+-E@U_$X?>+SGF/*FNS4WBQ?U@]S-S+&'NR35,I4.JKT]#5
M0*.](!!(%+PP?ETG63LFT',P<)(7=I(X*3Z9B<\8BG.U4'8&TUDQ''$:VE<J
M$^C!SDX"P8/SD$/^^CW><(1KDIFMI2FIIOG)51Q2B<52(6: E\#S&L305.Z*
MQ$#AQ9"!E#BY/+K()\1_"_P O &LC+LKM[?UY 0]AED*>=!->[?\,:7YAA[D
M0*&W;XCMI5?Y$H8'E7,LJ=^ECQ?F2^F*M(S;IHD!B@M4F&2!+I>I3&GS7!%^
M#>:KY$D+Z+1"6#L2+Z,;(B[T%:,Q6D+3]NBC]9U%4+%P2G/49(WXHOG![HV"
MO&DA:Q.4.'6K7VCRS.0J3Z;2L_/IEO4\T7P]"4C;\/"6>[SVA@Z$" Q]4DQ,
M"\FWKT"NRNC8:TB)$65K)&70TX)Q<>C%V7,!EX[^].)[N]\UY[-A%6@LLYD\
M# ;(R1,JJ+NQS]P!=H$"FN9&5D&M-V?7[2K+[YE)G\SDA@'%'WQ"8XZ6%8T<
MICW]XO-I\1;<%Y_>C*2*Q_Z#8_OVU?R  S;;SB'K;%1+)8P7XZ?? Z%<L> P
M&-4\?=Y1%L)NB@OPK*B\<^YBF,-0LP=C69>-M[L\J>O3M+ _>_GZ<W6TT<<A
M9S3G'R_>C0W$)TJ>2R9:04!)@8D6*5\=3)B&8 _?!&R?2I^*;'=M]GDT,F["
M28D*"Q)YS>]CR]1;IWSZ>,-!9WJCME=-&AROC"U]X]:041\;< I?%*P)Q:(K
MVK J\<-B&[.T_#E,$)%-B,PHL$-A(0S;H1#R\7 [6#M]+$'D)C,M'<\X35G*
MJ'2&EF4_"\[;#C;PRZ*OE8Z><J47C]N:%\:5N!30JO?5MM0$E>!8X:Q6  Q:
MP"$&R<I?X?@"Q 7NED^E<7A?"V5#XV'.3B!9) (EB>BJALD_%W AO%<0,1[9
M_5,4>:WSFHK&3\%Y&Z"H_IO_!WMO'M=4%J6+AD)%1 R#@H 0)T %I%0&9<A1
M45$1XXR $"U$AH@I"Y ((4=E!@&'$DHHB,HLDPH!12!"@)0BAC%(4$(2!V20
M$Y5P)"<G[U#]^MW;W>]V]WVW^[W7[_D'O\V/A)V]U_K66M_*V7LMUIJ,*/<(
M3B0KI\?[CEH1R@>@H&E$-QLS]'N,M5A>K]5HA;Y&=:1@:PY#,^H85,L!3) %
MG40"[5?/3X;GXHH"<Q=U3K$'.*V&A==%"NN]W6?/?GMK]Y'<V]A*7>#-V3B8
M?Z!%9<:@"(.X 7"Z%(!-646(SKHQ7[CO/MHNJZG]%4A<7Q\D&L1?M:_5!XRL
M&0"W6 CG<1K5.A&+\/  J<[$^CN7Z^?7'9D)2;V5EE<H7)PK'E;]KOA_WQU/
M<&]_QH6LN(*^.$5YPU3J5+TLHL;CVL[0H(M!H;HNH93PD(WU]GK36D];G73R
M6BWW=_U5=K7Y$G"+,&B/:LXVD*&B/8 VBYU,5D-(4E?9-C[=+<)4QAH&8Z4T
MDA>\L?;K]QLGA+0(T71B]2E0I%;W&-SH;L1A6/4@!'^=\IHD4?3*Y6XX&K.)
M"6]D8PYP>.(WWG&X7>Z"^4'#L^.%R7ZBD(V3SY@:]"WWXY0X3TKY\P):0 O#
M(FK+MD]WX%).?_'6E7)<.8[QAM$_^_3A=8JL09'8..NBB5,*@MB\V7J@9W@7
M^RXM6V22"OFU\?+'<O%\IRUW:%6<+/_VT5S''N(*%_$O89-&\*W)?&ET6L-%
M$"QY$QRAGUK\U.> VE=)"=AT#7/U?]95N><S!MG5IFFQITUM)MR>D1?9^GC^
M(@FVJPJNL\W^:]ZVWP/7I#9IKU_0J3;NBB$=U<0<VI5?P29[)\H]Y!1$CL.(
M>(_D8T* ?>-2F"T=\^JNWUE,,T3=/%B/ZS#=X35'B$L@(.'<B^>K7H_5"O0:
M)%9KGJ\,&K*XLG:U*TX!W?GI[\XK5ZY@^]O ]F/":[G-(\2E:)]PX7*I3=9*
M,G"IT93V&XWN**6(HM'\!RF80:O0!JS6?WR0)ITX^[[/R;ET8(RQJ+_P08^P
MQ=>(#U2-QSU6^[I1B8-.!XS_1M_7?Q =$%;7T6QX%NNOH$MA;_.DN"<W?VX9
MLO)99&55M+MQSSFU*]U;3BM&O;<7/;^#?X/Q+'-$RQI5?X[YCK_XY4X@1!)5
M-$@U)'&_1W0.T*/AL?(@U!&^G><=;-?C^7:0ML>F0Z-Y:!X$9/N%1Q5VE- <
MFR*M$\,UUWWYN(\?WG#HE4?2I=G#-<T  1#E ,-I8"WI:L@D@UL*<T6KZ/A.
M_A:GIT]+>>E9:#H$'G#3F_/SDT?0Y%56QZE<NSTG:WK6G_OEU&J+K83WLP^Z
M0N"Y2IRFO1(WUUT1RUCD[J\H**"0JZF7Z(?%J4[<#^735XAZPMI6JK%@]^/E
M.\\/\^:,/71;L?!!V\0FBW5+[N!E+S"Q&ZP^W['L6H>AV^+BKO;%R97+KM?=
MHKW;-=?'>,^Q8W,]]\S1VGT'_PZ4E2MQ,0ZS#\!-&.O@&'%"DS!)B3-@^Y>2
M]<9"RL?(&O5XZK!P"6+9O?K)*;,B*J3$[9#.2P^IA!U>S0QW1.AEFB?;"O$C
MC_;S?4VZ;,H7#;6[5N-F+)H!*#@3T=5O)C\R3P/]+?:@FPL+I&Z^D.]3*4%V
M_9&4=*E'@C[%7V:E3RA6-<WL>EB.;)(2+M>O@F0^)UPNEL#D;9!I?=8;F:'S
M9_;]44%%4G[PL4O&^N.8(<]K1I^QH?WI@EH1<R(&\A"S)T+%PB3V@N72>J)!
M%\,"_CK\ZNGP1;:("(/B]/B9EX+";!'ADLG<_@]90@ZZOL^_Q[>]A:^QZ)Z5
M?UV:K,^LZG=51 $.2_#I(-3)ACS)@Q$MQ_K9E"Z&";*SIU%UY->RW-.&D?2%
M4$T"U-YRH6;B9BR32S26^I9L?!?WM/?<]HD#I5L)M63(#>-&:B+KB0GY3^@K
M)8[%:R4(J.*/S01#>O C*37I'*(M$LZ# =\N2\2\$-DN=8VGFY\_%5KJG'M7
MLS\1V70W"%UMK]M1['V'?TI[<$[JO9/XD1C9;/\/$GOVAF[Z54OB2EK[5CA3
M[DU[NO=&]^3N1XJ\*9XFA:#YS6=_-VD#=8)A &]J9BSJ=-IJ*G\4Q-8ND'ZX
M\=CSY,-XL4W.5GMP>(R<]@!9@!GF1OHO4&&V4^3^ OE6^E88@-0XXD%_=F9(
MA/@T?%-L1>3/$5S1X*D@ZZ7$ZS9[<[V.#[U<O';^$55$# ZG,R&2W!I>RYZ8
MAF)DN_KKW<76JK!%FU= "TD;_MJ&+F'U3(;S-&C49TH<'G$5!U+/ED\=7Q\V
M??.PU"HAH=ZF<%1]I6O_4737@E$512VLCR[\79'XK>-H!7$UHY_-(EP-"W_L
MN:(;65& K(/!"R</X0<JIMP]FLE:_.AW2VYXAQ";7FS0OKAQ[@TL@0)>1V!&
M+3?$+'%+(V&([JBXSE"'(T1Q&35UH;3VUI_<)K7HV^'+%PNX#@-#L(2;I7AU
M5^Q#%[1'@.>+@FX(=]X)/#1J+X6C7+M#SN77WL$G8+RB!("VX0>,T 4B*4G$
M;F4*W,25$]N&W_J) BZ98[/GJ T7I3;JP:'-Y84^< JVL<^5X"D).X:@PU)W
MVA8=7LSUC[@8</^U9WOAI\A]P( X*FC].9RS&ZH^VXG 7W$+&+[F +25F\L"
MI1YM/(,.Z<=#D-U=20A% B8YS17[G%F*&@O@PD&.EV\2< DUH-M4LWJ64PUH
M\9]IU/%PB]OK*]VXX8OWKCB Y[_ (7_.-OG#9*#'QKCINIJ40O:$T;"SQU8L
M2QY<^HVMCH#PP:@"&DFB%Y?OXC2]@1;YT;O7Q@?<*:7&W1!_^'S<R5%"QM.2
M.7LSE+B#3R'Q2&2.HBUOS>REN+M@TW7VPX;&^FD3,T45&)1#;G[_.S=OQ-<(
M]A1U7#Q\_DVEV-UEJW1_[KA'H(?)DJUE&DM?&_^NHL!(O2/F&)6X!QZ(CMRU
MCCP0*EI1"R>4C2AQKWTMX?=2C4-*7&R_Q#XEC./,>BG31]?E]I!Z$"#?]\3
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M<)H%'U/JETC<MX_MKH;,FZCQV%989J7#SHN6U#WMFSP;%^/;'/8A*[#"ZAF
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M&OL/O6[_0WRSY8#7)YG._@?7C=Y8QXG3]H"1-0]+OFBIRGI0]=GJ*O+9QUK
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M9F8R<;ZBC#U<% G&&LJ?31]CK(4I<K,@KS:F9/.P-)<9KLE/$ -I)JNZSC1
MC+P@T> ?\XJ*Z$Y03:DX>I57+UAE)CU39S-H[-$D>*PV7?K?-DCXB$RAY!P<
M:-"X?/98%OA+NNZ80)@47HF9$I;^,[5&9S*>E K?6C=]6D]E.7M]H<CE[;?5
M.+=T2*'AYVUZ-A_57%6%VXAY7E]0'<N!J,/]S;QXYGPGXX49J!9\=!@_#U-*
MF<YWQED3(\@^(4RX,/#7]G?<Q<33D6<R@]/?[UP6]?OW\_=.'5%E_]MN2*7B
MQ*H_^KRVEOEYA!INDKSWN'YHUTZK2Z\>_G5D6>PO=@_4ONNC_4*(:H_HS3X
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M4O#JCBPC,V)/P$+>;WQ^[:;$JP=VCZATTZ):? G2"PD%M.SFK,_I8E!SK.9
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MP(D5^+EO<UHZ]\;:_+;Q6J!JP*K5IT_C=G]6>:5N$AN3?H*P]U_@\@M3%XF
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M[* 08U(C&K4 1Y(0QS+FO"[F<7M^&6/;UNZ/S* *6"F<;LQ$B%&RMUX'>T?
M#7>_=L:$.88T;RS*F)@-+\KUJM>^Z()"#/O\85WL.0+?U%Q 0F#H/IRJIO4B
M "1MR^5G!6&)])C!4:8FL5:-<A9-\)8QW?IXUMH;*XK$LN9),\;)P-[8Q&!K
M_WF,=73\?:9G;]S5DR4N2<#I_VY;1B\+?24ED"W13JHN^@W:1; B>>.361:(
M+7BZ5LE9.GY@XN*)[CK:Z3MG8CN#;KGWUJNB)X8B>39=!?0&VB5U86F4Q3>K
MWTV8/-&#J)@;'+45_-G6EN!A*?P-O9TO&6BGU,TV<$PF@/X8BPMSX4.K^'.8
M'A4=4>#(H?ZXS",3/!.6N']_WKR&_A-=)"]ZC)*8,=W79%VQ.Y0\6+_ M9F3
M-AWS[J'>5-3_P83'/"+Q^5>/W,2\/Y]AAAKHRNAL*R=JK?%=B"V;P8GRZ%94
MYKX^5ZDI0H%]9(>Y>C,X_9&)&5P,V#[\AW4>8.X]&V4?/"_D/>BX*.-81.7F
MTGB;^[ZH:(?ZG9?H3D_"0LBWE:K+,F7NAP>4X^T]7$/PJER:Q5K#Z-8N)F6'
M+0;Q*5\IYHR4,=?3^SZ%C%H%O'F8G)/P,%2X_*'>7RF P ,X,7F="L9Z((LW
MJ/.T#R@Q^.NVF\%2P0PN]4+3CF;E$9+.YLO]KDM(,66T0,H"\APF@;YX-'\Y
M*+["];@?&68-V18F/A;+I29[3X#C1Z.; HL55.MA1OX;74W[;$=Y0&#%/RV%
M5ZW.Z=#:J6,A3AMUZ2A X'K+0L\?X2C>%\HWGQ1YKJY*<N4O>OVAR;RR6D[0
MAUUZ]O4<;X(BTN@RVC/S=3+TU;?/S\7^/F6:Q'KZCY5;PD@S9MQF9ASG$#2#
MF[#6K(W\W.G\\HZ<DT&P8>XJ"IG,I?V%A%=$4HW)RUXV5+_[X\DNF33]0L/0
M_F'Y5_V3[/GVQCI:(=H&S"G0_@R<P@\FJ.-2%A3<EN6T$*YQ%M*1>S__VL^T
MEL68;1N(TU_J<FN6UMW#:)W++_X8K7N#T;IW.6I3;)YK ,%!=+9%ZT5T%>LM
MWP(E1?)6:'._4@A(/'2Z2AD %SZBV3K <ADAW3-"Y$5,)1C%T5-F<"?3(C_#
MZS2BX25]]3:$P)0>09AAGO #Q[C>YMCKT>L%_[6( 7=G<.UF&!_"_N]5$;))
MOE&L[KA&QJ-]^7H@6$W_DF?H;*:V!LT;KY/BB]]6__%=QT%HJI6_U"=^;O,!
MWXIS7R9<;Z]\HC=][%^8\5]7L4 ]B4VB^&]-[OS1SNF.#FK&#]L4_K9PTIBM
M-6P"GA7ONR$642W0%3ZG:WU*6S6G<W:!0&J@HN<0-)7Y9T/^@+")U*!6@V/D
M5?U<MX+QY01,D='=V=BKSVBK2;LJ,=OL >B3DDR%.A-T4+B),^+H@V+U_KI?
MV4( SPP_KJCC82SO&CHEJ(K\]$&Z@.EV_)*:JA=[I#*\GQF00(M0#JGVAEKZ
M=;GA;9)8>.Q])\A.L]U2KRBQSQ>XZS$$*8/]H)7C0@Z.AT<.\V''!\$AWA?/
MR2LL15(\LOE\):MG!F=%.B+7)'0>9@8HV'-]Y6(;!JVU/V= ?:&B!-ZVI]LU
M\]X<3=OP"GXOCE(Z"3OP$6L'S>Q-IAY -">96B\6L#-F<'74+/)*Y@:P] :3
M[%J5:245)M*%GC?*E7S],5NC7J9OR1 <)&^\\M5O_L<A[_ZO0XX)[GUNF1?J
M>NU2@J(*\C]^T9WV_.\W89 ^;%KM",;14C"F=248?<M?NN(9^J(OEC+8H<"G
M,(D/+^:''&%(%1?NS> ,&EOB=P[.?:YW'8DJ]%U\K-QOY>/=O[^T2J+<I<,N
MCC*"VF'BL^8,JR<GF_H,9D, ABL"9X-/D="J"]0%3$*\,H9YN!8G#>^EDUTB
M;[[]+>]^[LAW*<[#,3]E%!#>W/NWR/O) 3$W0PTQT3-O.8BAIU+-:YP]=G*&
MGID_'W8&Q>I;4.IEL@VR&9S!I=E14V=PKX$%;B)P"2.67OM74# QLXJY.KYJ
M;%$S6[6BXNWS;P*?)A80QG0U3@@++%4%:-R1!=IBTJ+?2,Y0CYQRF;QFU+W3
MY<VNX@XET?@P+<C3YDW2NK>^PJG&>$_[,L-'OC%E45.!GW?<$GTHL)4G)H87
M#X9%7[KWKO)>R6A_HZ4DI3#QG%'QG:P[#XCGXBY>C/\>$M!H,7-_\#MW;L.#
M;UO9JVX\?-RK@U+Y8+ 4WI2G?@ /:8[2R&:S5]:BKX9),$%#9"Z-"1*$+84B
MA%G>KGX'E1UIII]<(8)(&ZRJ^+.)KO_FS:!W*>+>?6K-2?!=,YS]T7JS?UM\
MT]YL'6TW9N>%)!_-%L8XJN^GL67NUCXDKX:%BI%V=L;PG'[>6D9JA^TF;H@6
M./"*O(*A;+-="\?/S0G;CG>N8 L3_5L#&[*(N>T;IWR67RY,QE$68[2[%BN0
M<7K7@)/\M";I!$>#@P^V$NH\5';RM]&:5JHI:P4CUR@B&/8%^6T-4RY1&V!+
MX30EU<V&< CF0'9^?1Y#M$6O:1:VYF!#Q=Q@YS?HVO[VIW(M3O<3NP6H:9R]
M_A=SL&GW.[A8P9%X* D3S7**U>/@!G:XDI(UJ5F=[CKTQ<BH/J>5<[DI@"\B
M&AX>"O[Y]L2P$W@A';AHJ/\.8X"T]!'<>^9LQYXW&$P]!4XD[&*M0-RUC\@4
MUBM/(%5Y>Q^WFVR&#J#.\,BR]5ODG0(P0EG??C=.H4G_98U51"I33Q&Z>W1)
MT>M=B[*3*!68,!I2-VH;@!C\:]L1A5@U?K)4PJ1UD;V8>V!JA MS$Y#,LN]E
M.H.HN#7WT!2PB&2][()5V#UE MV6?^-+C)\KQ9CAZY?1L;O'V5K8/WVGH>@B
M2T>3BI61=U@9(0$")GDSLE;[D+E98X:V2&U(!\%<I6S5P6AI782(G=+TBWMN
M>S-$">U1Y.R%0^97+ Z:%PNDAMG\:CGLF"(YD$-V@>;FKBLUJBR2.1S90BF@
MP^Y4M1BNT- !@1-W*:2K+!6% @I^.R&5OP3]%ED#3;*Y09>:V.EQ0\W.%WH4
M^-0=M8SJMA&_8HP4>B1_27#Y[7%3:/(5TW<>3_2^X+<0GN<@RS9@8S6B4<"]
M;R/\M%E8 3'TQS,ZU5T0ZV;I6-@Z:$=1:9M"92>;GZ4XE(F:^.[DKK2@^9LA
MH5!,O>B2.)6YJ7+UR]L%D;<^-*F?%3!2!D1-Y+SO=>!RN11>S4=L[D%*>2R_
MGO=4\ST2"2<H.RNLE!UA-MI\[G[-220</@[%[_.IS\50K9MEP=C@=U56*M1&
M!-??6* $@](1'QE0\_Q2$S4C5FO\R7'<\7M\MQAVWX8:YFAVH/V &;H<RPD2
M0-]\8:0-L&'.DR=&B/CZ9'M&JK>GCXAHNDT6NK].G$XP(G^CO>M<$4=<P@@>
M?M\9\"JN[,L]RI%G/;%TRQ"X8087T.\<.YZ9A!_5H :6FM/P051_4F/%C,>*
M392\F;/T S"/M*%D;%PVOODT'A_*J#T*66;$$N8Q0H3?TW(LL'CV'0]S@-:Q
M2^LU49=NUMV(OW?F[)&Y3CK(0E87 8P+0BPBU$EPA%*:P:G)F6B\SWI!J)5>
M7=F8(YK!63.)X-5V@FTXN,R*UWA<?L\#-:VZ3B:]>@<32_,JX@.[OX3,;X:C
MBH\>I7FHU=66N0D)<3CM$)8*OF0/]+6TOJH%/V2FKM164B+IF5*;2FX,--1*
M-> :ZHG8EM&YC:G<-1Q#Q!@K4N5L',.O.+45-:Z!Y@VTJ6P'#E/U/TC\LHO/
MR\LWG@V,BOW)! =X<QK]51LB-%:L#D*=6.4??_SD8U^,X_+9K!4?<HV+7?LE
M0#KIR/U(CQ\8Q-:!'(N)1@LUN@:B?<@G9"><'Q$UW;RUJ'NM,P[ <[#:&C$)
M>U%1 _%"Z;)ZL80JHCRAM_*MM\?YSX//'X)SE/Z#E-W4A<,>DL<Q6,:-RS@I
MR"ZH2.,Z=/1J,8UJWA67"/A_.OL <B\[K1XXD,1TTVQ%+F*S3^/+WDK9@ &=
M'TF7Y&'T'B_$6_,*/5(H<C=8H)1*?-1Q<'5IY,'1>%LB>,B%&=30PTP -:)+
ML<$W[JWJB9J.N$SRGA.F;19*;E0]:"CCZFH-D&\@>P!>TXB8U6Z'RS04AJ9-
MBJOG2#K4X0U01*O4]L-4PPLE\2IY/7Q95GBQ\&UG?)1Y6\5P!:AI"_KF9*7/
MZ1+KJ6ZZ2K4Z/2+C% X]3Y$-B.&U02IO:%Q!5Z5C(/9)^XRWDL%1>*B^ ?&B
MX,D;3*("L!U;3X5;(GGFT&9.:]5U@G&<(W_EJ[=;04V'OOR9[W9GFS8D4S&#
M,_4FI1\O>BW$Z:F]_LFFT^QU.6 LJ^PA2P* 1ZM>]ZA-P;=_?A;>9T2H$^%O
MSD6<04\U18CPDB!%75-V(Q/W5\Q5AG483#MO]UO1[QG/*TMN3VCFX( '@3DE
M4=/K[I9&2OP>6+'N/'@MB<H-3ZY9H'I<IS%DJ,ZHG)7+?.;5<_<+38TM7 -L
MULSYBF-AM$EP#) U\&OYB,F D*#_D;6.N1G.@2(Z^,MZ.MC@0,L,SCA/:!'X
MPE)8#Q8,U!.L&6R19U\>?')'-K TLO]2S/#= KAD>OI/ZH(ZOH/_TSM;*'OY
M$4!&<$X',8F@RW(;MS5Z"I\O9QZ#MX(#BAO%X/14H-^EJ98!Z2+2TB)&S;A@
M*O?-I0LW;:OBY67U$5V5]6N^///T&IWX\^F-WP=7'=ZG^_KA_Y^3*W-OX7"W
M=K7@?MCED(0;\_]2@/\D:^YF?0L(NJG@4:HMXMF'$AF9K=(:C]:[++NQ85/N
MJQ6: (Z0,WA2WICA3%I?.):_$/RJZ2PDBJ195A_KY2%9$=2^@7W9/0>@\/9"
M-UZ]O&INE.WB?7B5%ZJ/1?1<G/9'K"C?)MB@=LP+VE_0Y<AY*+L:LI,[\UM#
M5!Y*<KV,8L+++.:81[*<^HFQH4$"/A[1604,Y::FD$@#V1[903?;UMU[/R1>
M?,";AM/[>.??SB0X=&!B3D^;Q])C'M,6DNV/4D.8)'@%*,:DE3E"L[]#-WI?
M.;QT5N41S<8MIMVRVOJN6Z74QY\L\:,5C7X*"\[4[J:%K#]G\HMG$BL$$*R@
MR&KS=3!VT_I"LX<V@UN ZB#>\"ZP66;[%!P22O#7R?8T=-E32$\4>K CD.76
M&^>UB^D@/_=HE&7&:0TD6W6=7==-L6(41!LJFK=D1:@=/'"$NI_^9ZML\_Y?
MFQ*3A=$6/983ZQ50W:%R RFR(%$0)BXR%:4"*@$FR/FBU<]XW3W"?*<!A))P
M\D%GW./1P('<]JO' 5+1[EZF=Z$DE#9,>,)_VE_G>+$^P7#-&UTP$S7B8",]
MPAK&,GZ/="[:YTYH8%__LN(!,P2B7EZ'6B%K,.8LVL2S"V8 !\ 'PQ1,$0TI
M5DU5%WW(7=TAVJKP-_ZIOKNRN.]K9.SV9BBQ@?/PR*CZH8YV^S\]=(E>Q"J9
MO^H.-*FNTO+0N8!@*26"8/IVB,&*.2A[>1<R; V.40W?T</0Q4Y967::90,G
M=%AFLV)S\@W!H"M<7QG;[,C@+DOU&<_&S*]^M,!J7C,XF5I9]P0_('XM18U6
M:M/YISB9A!JIRAS?425Q4.AU4 :5"LLK9,?H3S0/@M$$:L88:,\WRI<>KK6*
MOZQBSN6M!2O9$8H$+^>3.VY0TX97]#[N'_B-S^^SW?F^'H=6_MN13.057Y;&
MAYZP84]+=9*V8M4,+EV:3-*9[;\WJ;[=%9$SI=XE#WD;."5+;?4ZN?Z/'UX4
M15',N [GB^\<FUR7E/.DW:[^Q^TZ:,[?EK!L@Z !126F/F7L=DH6NFH-R0ND
MRZDB8D;35)[#;8+:0RC5CT:=^TC/_:?K-,8WR:.4).;;A[K(-$76*4V^--!6
M-712_4%;S:3R _M)*T#.+C"TOSK>UEN<!42*TRW)F_KK?>//&A>I_:]9/0YR
MV7Y$I8H;N7&@C)4?J3?M]NK_OC7XW__E2">"I8Y@C$"@R/6TEX$(^N!T^]1$
M4U4'7[*1D;>_T?1X/6$N<S%XMOSB8\G/-88=EM>1!%"A?>"5O<E)\5USR8Y]
M^$$*[-$C(R ;2A&3'O5B,+0MY_57N@6R/%-YMB&,LNZC8DKY_MECYHE:#UF2
M8JSC.ZB$7?37#\G9PT-^C?4W PH<MQ R,6G-GNU88X!)%=1X(>B +-9KD=JZ
M'N:?MMF@) BP"' ?=N7!A8^B>*MA &2W5#/PJ)EX$!V29SW[V<,=79LY^QV.
M6)7'KAN?!62G'C?7 69"^:BDO^QQ\+=Z:MJ_NN".9B<VY<4461E6H2DRF7@.
M(-C"-(*4WIGJXSWD]0@!OAVC])W,L"K)4\Q*V06(H672#$Y.TG)4O"5#@U?/
MTQ4/N12%C=[>GMB?)TEFBA<;#OK%=S3Q[E5$Y[85X?[]RJG>^RK$PD,Y@FQP
M0$P'U"KXN=&D^FQY(?J2LHBY09ZX[8]/DDX, \WJ)N$ GF[3CM_L=Y(BE'X&
MAXOF!4>9GP@,_+Y7!^D$!#>IF#JKID1PL$C\A5NCG10!F-'PJ'YDT&V?=+L:
M>)M,P[>F*=I^GJ]95W01NKW]QL?M;Q</>"Y>?_;SF0<!./3/#_^Y>N)?3L*.
M\1U\^#0%MJ>J.J%*:^F$BMH*U-)%;RFM.<,1=]1T&UBZ]5<0+QS=]FZO3Q:R
M7XZL='G^#?GHV1H7SR2 "("G_%NH$]3!S^HA;4F5$_\B9*V8$DJO!-M,=,D5
M=;"W3".U9EQV^@5I']K7#'<6KE96GLA6;K_R+;-SD_D6RM/_I2\(Z<*]&))^
MQ3QH_K<UXT8ILMA1S=(6\D_1LYKL,\&BUF$#,"@EMJQ>FB$1"X?$@U7M/%M(
M+R..L(@Q@]O^*C;/XVF?JG[([^ >OE]":\0AJ$]=KN88CUV**TWYDF@QG42I
ML5YR-F;BL6IRW0OM&XL&\"W5=?V0F^J/_2O]+\3(M7_,?[^O9\D)[1MOM<^G
M-06&A_ZV*/F^",MM2O2E5%4C)J,5VMO\XVSC,'^G,%MP:F)(0Q&?//-.Z@<-
MJ"RAU5S_BK'2I1;%B)F2D_K#RY>%QQJZ^S]%S75:N(4PNK5X-)>57A(E<;\=
M-9]3'.7NGGOZ[O'H*UXT9W+KL%>(ER^CPT00$[-XG^AJ<I:YS]8MEO\=2\)_
MGFVDN'(&U]Y*D7V@2G35=;=1!]9B4 ^+'1I?XN^=3Y4..B33XT*D5P@+5-<[
MUG>Z9SU ]H+W7F8'7.4VS0D3+KG1OW61WG38_^CD+#*%.:2+BL&8?#OV:<D,
M+JJ<YBM] E]5IA2#0S*'5,X?@VHV[(?02J)YZVL,?^S65LG9R4B<?M8"^?4;
M5FO>+M,=X<"N>!D160O JP)O0VO'.I_W\J/H;(X%NG9U;_5$4XX0M>1V\_0_
MJ!_\0GE]GP>'5(X%[A8NC,O,^WG*._9Z"Z&W_M]O4RA&$,M)U,!(08?M1Q S
M'\54NSBEZ5E#.M3<8<5/0?40P[YU,<>YH8X*@LB2G_]9=$$],,<W*HXR'R&]
M(L4K_8R(SI.N?[E-&H]^'^T>=,'LZ!89X;<@Q$0/-7H(QV%N_DZ;4^\_U*S^
M",LU6P\3;MBZ0'QD[3.BO#$-V1"AF#099,2']7+=%.P,C@DS"G(0<$PFX[3;
MJ-#;U'2G+\_6VKBW4HE"C!;\.';I8R,^[7Y/+(B?3%6;:-E,78T.^AR83SE%
M3+%ZV:@@SF6:OZK/LO:!]-)/]A0.?'U>/X.SH*$;^N,2PS;;2\1^H=OV#S!W
ME;U]D^=U>$74:J=J>U6=SM=G__ 3/ \;\PE,CUU&=3$_K2.[(R1MCCV\% I2
MIVD?L-; VUIY[F#C59)U.2.H-<R@H1N)4A(6P=9"S_@TY-RCM^-6+_,4SM00
M\.5]=6[@79G-N?GYZOB<H.SRQ#.WDECH-R<>'9UW0B<\T.G1ZS_GKRU.(LU?
M^^#&[NOR+90LZO_F?=#E-1D*27NW]9 P,8X>-3<H?G)A8,DGQ9J "&[D2NV+
MI[_>##N=0GSKS3_!S*C304.#+OFWXV%/7]0P4RE-#>:W39HP0K#Q'"2*$D-:
M@W+G4J)KX?,:)Z8[Y%V:XKKYH"#?EG\Q=C6<!Q6%]G,=SST>GVX:,Y5$ASG]
MVFO?V,]UDV79M6;H:$L! 9$B2R+4$!#3DTJ^B'Y#6LL1$6ZP7/K)JYBK&V'?
MQ!(DHI^KI_#HBJU55.#;<ML^9CZ"/>0SN*15;,WY?6!':NZG]D^_?]I8W,,=
MNJC(V%EQ#*?M_D=Z4\3Q*/X"/$XN4\[@7GNH#W6-9(?<<Q12%I,]X=L[&J6N
M Y_ASN!7O&7,3?=B3G;>/79;P#=5Q304/1..F7;8+MRS3%>3JLU YVW5?(O^
M1JB9FAA?:++504!,HNB3ETC_\EI_[C'LT2*Q3ZT<,W4)7_6T]VNYEW;'Q_"-
M^6-C44^E6PB=Q(G5F!#:][<#M;-,_#.R4]O,<D887<QM&K<Q%@6>5+R@MI=#
MVP[UD_PA80O%-%:<=H%J3+8:DQJA'8NZ1L#0J73N^O)H3W*%4>D5KJ5':A?9
M)MI34-V#$9W:_UP99G"N?'B3</\S+0:Q,AZEIFK"H^"MV(V?ZNH_>%M]H:FZ
M_L?FJ&$7;2%K)=!ZO"I:U8ANMN&:0?@6E]"=0P<,-]LZ/C_L\_0G7>U:5RVY
M<]>3ZNZZSL-.L6]=7@[Y]TQ4%!VN>#SQN-"7YAO"R#%<9@%Z+]N_HRAZ1T81
MS@#W])_<J-3_M^/0^'2*K(C:,'"9+[O'J4[MH$H^=S0 0^Y4 ^;:VPQ::]GW
MSI6D&,A0="DK)QFUA3V_20EOO!H&I50_"!Z;3N9ZN'QHPJLKF_IKA<6__Z2#
M) ""*LJ35!%U*$A]!Q9C.2O6UKVC6\.-(H()<HX.FM<_G)O=--D6&KAK@K<2
M":KN*8E:T8-X@0/^392%9(NH)W]-G\U*T/)R8ZW"Q4DDK\TX((+3,'M*SHO5
MPL<A09J=:,\PJ0$D"/T-=T4=JW'F-G'2N <5?OM^RW6XRC67#^T9LUT-!=:O
MVE"??_=4H?/CF#@;>F!33ZR10U#?F21*AK\M()!0P/V )$<1D<:=#8794T1G
M"6GD15U5)QH:?H4 (>&ZM"ZHS;&"/"D.]0@:8#J"!%'^4G R:5V]&9V47GQT
MC.=1VWA#\J?]T\2:72=P$-$*0X;7 !A,'W1H]Z1<G<'%T&&' 0$[-?=&\3')
M,W8*>05BHBVF1%19PZD^OBGUMP.ZSG+ID&/0DV<]\_[X8<C(?R^8I?KQ:2#[
M1<0VJR2@T$? MX Y'1B18YDS)MN'EUX5A+E 54) E]'8QC-JX.4=:@!STA$?
M>1;Q\ !W [WLS9'1*:OK5L;E%^.*O1,W)U\?.">I$&5?$-MM22*T4!#KO_"(
M"X LP]C\/%OM3R2RZ5"+E08=R)_[Z@LC=3#F> U\'I)NASC"YM>JDX:6$E?Q
MO,$QR9E]:SX=OWKXV;>W'N8E4;K^'M$D.KPY56E?K/1G<YY0)I+E;/(,+JB+
M9*249DXUS;M]\?:X%;]M!K?DPPS.B*1CO;5Y_M@P/1E=7]^3^ML+;6/LDIH:
M<QQ,46?#(03$&D,#/3WT>1CEE5AMV5+W"H@ +$/#)*O22]\P5T%523)M/B5J
MPXK]-O6J"<_^+,B_+?#"P;7/ZG)8UMQ[*^]63![6U:Z@G.$,X67L"6>-*W./
M]A&/!-_:;"VO$E+Q#8^?1ZRNFQ9?=RM_VS!L 09=K5B=O^ KL!CN/)PK]GD5
M0X(KF)JJQC&/"YZ;2PH?2I* NS["JH7,BUAHO$>[*0V3B+E4_;+NUQKM3<I)
M?'(^!2ZOA,-\,QO Q'=\(6'!..H"K]98(IN:[L6T_6'U[,VEQ [1L]VMUB&=
M>3;Q1P;<-L72+1$_4#LA(SS"R*=#R\E$2%?]4?OPJ^'JZQ_(IO 1T+I5DI0<
M<!9_O;[BO,)!9+CFB/D!\^I9T25__&G;$HD"U:V?NV:)[C0F :Y@3A30**<H
M\"K@:NPFU"V4QJ/ 8N4+Q_U]K"5,'?C2&7NH*OWQXW!W"G@39N_K=4C=#1(N
M _6 XBCJT+]GZM*U?DD=V0P3\!E57S:'M;_2_6M?%T7VWA\F=JCV#H2Y:3/Y
MLNQ\ N31&I3]7KFKE_2-9@.K#ZBS,Z3YEE6,U/+@V[(9G"6#VNKY!^1K.+BS
M*2@YEE;:?$6Q\?ZNK1DX_&P?U.\!P2LLVR8E7JC!/-!7;: M!K!*?IEG#G$P
M*6 A-4+.T>1:/:6_H(J K*_MJ2"ZL:VCFT:NH"OA1H7SB%J<S'1[,#;]HOWR
MPR%&8DD"I=;/_1>V.@WCNY.24G4YC->8(PNA#M52S4YX!K<;/@^6MW@"DJ\Q
M$?M/.G\L!KX]U<W=(,]::2-)32>%* SK0XQTA4V'-HQ9W5&J;JQ8>+YSD1YD
MIQ3#7D&H@;[F(',W1+F" ?5/'-"/)DTGVW0=6-S8!*4*V=<)=1YMEC5-MT9C
MF-Y5L)W,HKD@,DQ7<V+KRN#1(-9RJ/@GT\&C+Z<_%EIOKGBHUR<%=U'AC6S4
M8)MFSRQS8&$,4[ 9.$M]'2_@+^2&0VN%[;G7I]_?E$UBQ!;'C %'=H+T)"1(
MF8[L4HA3 8LX_V6^5:,Y*KD7&S]4_  U($@\DZL;\S\IYO><32)C^NY*(?;.
M=MYF[65,&DH-9W#'^,;,U?"&*F1]/WL"YIBS')'O($KZE\W^+30HOFT.T52Z
MRSXOWB(]O!BFMC1**.FFD_OK?S596AG!-96LW5Y N$6IGT1L5VNHT5(3[L4*
M0$ &PJDI4]2:*B%[$2]]!F<8KV0+)S/)&_N0L.PI%V]:%:U"QK="**"T5>L@
M>O*<'E<,^P?E'8)([EFT<_&51\+"CD:J<81>3!]34,/CH!VJ?USCC-C"-S4'
M!HD9E"AI)M68Y%4!T]41\/'S-BG-"LJ2%_)F0XX%E33]]7VI1Q++/)*UYE?.
MSKPVWO*8^'U96ZJ[8OF6X]GQ#;MUD*>C4C 6CUAF*MOS'C-CM#E\60[/&+*<
MD!=0I7YD?B'K!5"?VJZUZ-C[Y+=>)Y(?E"K(=P?YUSY6QM89.:L^YL@GC?),
M4Q+&W1I\TELHWP.R5 +X@X>0 Z\MS3H[@SM==9UCY$368?4'YA/ZD0"YBKBU
M/[R/98D<?<6DO'LS?HYAFQ@M8^1LA_*OEOBNJRACV!U$WVA\4F,K@D1-U+2/
MA=5]7UXLUAWGPQLC4 ,]!1%V"$+,'!12T0PN97B%[5)X!/(/>,6;P\3WVX5K
M6)E* J%8V_Y,\<SI+-ZX2B9-F;;,0OSD&N5B=3]K34^L;OSB'SO?_:KW>7P&
M-Q_SBL".:UB&D)]B,5&.OAHV;X#8-Q _Q0S.!$Y0[WL"^?UTJ3@G.5:L'WW[
M \\-?G>FL3V\":JL5H:$Q@MXYGWVR422,UU.742SV.!_49'@6+%&5]/Y]^._
MV[!\>#2[D\MOQ0\2%"_K-4ZHD&/P&#B#E^"_ZY=AA8@4LJX:F,$94%N'/1(^
ME[Z0Q9CB]?6Y 5!\NWO0[TT[*DH86.(+)?9YY:$^I1*X_'!_G9:ZM0Z'/.FG
MR$9G<+!SZ41S.<.K@],P@T/,B((P/=A!61&-GS@%6;;X2Q+4=#YD<V7%T^8N
MKBY$4%"O,ZGRSJR NM^*>6G#<)"HYW$X7=([^C%S"^&-QX2#)A)9CMGB*NMW
MJ3Y HUS^/&;7PE_\)22SZ/[X.1^]-"Y!D6B]K^D5][BLRD1@V'G6C6, W][;
M&YN9E[?I=$_<3I6LWS4S[YG=OIJF7W3_^AEVPXK4@<%Q"KB/+M'(_#O$J=@/
M4 M6N[2F?D#EG'@1DOKW,X^78?EFF4+&S_8D3SX'_CD:MM3#P_/L,P4_'5W9
MBSB7'&:<]ZD[<IH_H+C1'9"BOZH G\+R  2]4C"0F.XYNZ@427]]'M7/F Z:
MV"_+ZWQ:R7-G'H4=((UR?FYLHFE$YOY>!!-E\M)TDAY8)<A6U5./=L?0ZXOD
M\;>\-I%.,MJ(9W&4!,QGEZ5@J/,&U-!0AL^PM8$O@R/?P=LTNQ$C*GZ,O!$4
M7_MJLWL&U\)S!8&,TMZ*6,XRAJWSV9!GYW>D=!SH.=U%VB5_%A0P4-)]-J++
M;4'<^(>XK[7=2:0<U'@N9MHIYA;L288'U-%P''A5-H5!)-D1?BZGI_%<H7M5
M(N>3HMQ@1I!PV*:/2RR$W1/74HS>2CJ_1^UZ*YE1-LKAQAP<J*H9<JP;F+\<
M_X$O=T@C417B9,I"+&[TMM: 56RF+S@EP*"5G_QEM/*L*\8F8/X1<#CO(9RS
M]4D^%/B)YDPX\NNS'M7IYH"GMPP9PW&F.08Z2 D@.(#-'TN-J_R:G+87-'6(
M-H5E*M <1YBOF%OI6.5:Q&C[FMD&.Q;"+WT%)RE7D/66U\A#"FGFL%-MKY[:
MOO2D_"GB5G@D>DH_HA3FA/9.U#M;]>I^RFOG@.>EB.60.@$5PZ4:/T#@PC4"
MQV79I>?#5[Z!)]5!V@J>T8<!J\2WK2'!(9$<,U(49#&ULZ$W3M]J3<7'>AN/
MHQE1E2L38AP[\X<M<&@#NA%+WS#6(M;O'-!7>HT#'F!+Z )/L; /YH,<.?XZ
MX@SJ;A^(G32!1X+A=.BVH)_\+3C5"AB/3=^I2E:Y.?OZ]YPE?O4##C_KJ>-,
M $8?K-#:N&+#+ ^-_??X=WJ^F!TXF#V:"75?/"=%DZ^+4'VZO,J2:0RBC0^W
MK2N7BP<[U67:(GGUC>'OGA? >0I_H=@"WB;T"+Z7_-.K78_6W9:_F#/UP[.I
MP<=GIKXK('1-SC8U-^!K=@*"0)8QD@BEJE9H2 PO640&2Y?IW\4S/SH,VX^T
M>[)R%&QSO\(WXSRGKDJFOI*M"@4$GIPK,2-@-S4DC,$7;:#N4CC?#HF<+)W'
MQVF_%. I<*U2ZR7W:>6G XOK :+& :-Q,[BEC!G<H<^<WU,U7H+A9;U<[X3W
MO[F<9$](SC2_P=_\X8TBB9+*'AQ"\2[<?O("M(>_&(BB#G;(*S.5Q%1WZ<)8
MRN"DW+]5; GG2X/A9HQT$OR496X[$>\RQMVX#XB;S'_>!Q0?2A7QUM8_:<IN
M]]42O1N?],8!)I'J+SI?.(B)!VHHQ>CSMUC<9P*"[<NU=V=P4?A!I2RBU?]:
M;JJ 3D"B[KGBD_E+2=;*%QN$+.M$O1W@R\+[--8F.*\B2L*[\XB1TV9EGE_Z
MT%]^5U65_7Y;L6_Q[66[=3YPP   ]I3*]2;84$2P-ALX+DX.I#3HJ?0*:=\S
M?$7YSCF'^1BF$.5TZV=_];P'W=/UKET;7HO-Q-KQ7:A=8 ]I/2!7F?GU51;U
MJ)@!CVG!K*H""8YUF$8 8S%,M>A1A_9Q;93B(0#5SY%5Z2)F4'^]GMJ%D2ES
M4&W6>$CA&X)%;]Y^&-:!V1"QG4P$W[4_DIPZ(-U.9SHJHOI=&E71L5/>!?A1
M0_6/F DDH8#P <\:$/@"Q\1)PP[:8@PC,_.=P/BK3 _P[(C0=OU ''L!G*(,
M&'!BV4?9DGMX-L%CGFV_Y.-R6L-6=3WHF_C3RKBXW/URPLF'H:.>P[E3!801
M[[^M=6^G1%.Q@1I(9=*A>*Q(UBX?X'DBCO!-D!9<H_V)Z27GI^5^+2YB_6&9
M:UOT$-8+ +_L?\/<DB+Y' Q6/BN#^_MWKN1V?8R+.?M-08IU8-86RBL:NF#V
MC!]=RP-D#Z06J!M\4%VL3:G@AP.I'$.>321O13?S""65O ZF[8,<LDC;%)%U
M;S<(&WY$=M8T5/<ZY6Q[ MD7/_0M:0X]+(XH>5#^Y_#5+;9!V#LO8"EV'SB-
MR;[4&]P@C0<R']P^@ZOW5QV4>_5VD:@/L,KQFJ#'LJ2UG:3=,VRW=:G-W-_'
M]%4Z.[U8?(E]A6E3XFO+81)=_4W@1F'8\IZ/L3_AD&/-V&O3 =F[3K;1&+#D
M,45V)XQ0"V][,"BE>5R:D#X94!6=EPT1\$>VK?[ZLO817,US'$KIB561W?,.
M#,AY/5\8)JM_O1MC]]<B7345-5)A7OO$ZL9*>=!DV@QN&4I@1FKS>2:(5S>J
MC_EL,C..F,8WB*-;A1RF,O+:6/9H.R814E:!J9GU!//."./BDJA\I[Z<?;;?
MYD>&; TY'OY##O%<I$X?YK$6#A@VF48 ?:16Z NJ,6\1TQ8^!Z6V 4M)SI!E
M>_Z&>CCY,>.VK[\!G"!L:DS^0IDO+O:1-S<?.4L07;HCSK+C)O1_DMG:-(2$
M7\B5B72T!K"#PKB&K O[*$K;M&N%+>@*PH(O^#3*8E??I94.W<B*Q^SY$@:[
M71)PKVTJ)]XM-742J%,YO^>:O-E%CV2?:]B16$#HH$\0L5+-& 46D\PT@<QC
MV@8R'MD(NX%BF<\UDHV#L,)2[EZKH"Y"]L)"**1#PD\[#I:VSN",/_#L>RFU
MI<W\5XB#PN_D_OYWOW9_8>./1$X%YU?'S[MRJX!@S:1A/BH#9'67@E*=,3B8
MP<W!C.$RN^&F=NK]&JF73%[!#(,)FCUP<ZMD^$[Y&^>2=*,97,<0?C'R+1Q?
M%CJVKM/B3@(F@WSKFGOOJHZS#RSB+M318CAIP9<]'C; G,9E_1Y$L:Z3SB<*
M\1D4//,P-CBR&W-#9L#MD)XO1 N?!X=IGBR^/"LP(<2K6:K'X._A64J(0S++
MZ7!5?KU\O#EK=^BB<:L"O1$?Q$*)&N\'J1C)4MQKG,C3D)CV/1CK$$NZOHB-
MHWE.-?U?:4/^*1B;RVFCV4RF(%X*:Z(15D3TZ9F\Y;1IDH1519>IU@'&VXX7
MPJG"Z;:.M,IUQ*)7Q3@D *(CRV;[INNP7JHO<,R!:#R\6GJ5J0]N.]#\Y&E,
M"$:72E5Q8(2/5=Q$F4UQRDT,:0@F;LYS6C\?., )YP1WUS^UO\4XZSP1)HD\
M]CU^<@0KUIF(-Z0G)[9.VL+\UJLM+&>(+ZR:"_/;;.>'[O]:#T:D<7WE%1N.
M]"-KFGIS+[#M*TE>96%O/B@/W=[9/8P<T59\&;?_:6B[SH<Z'=@,2U<-9M,V
MAA)=\!=X4.;!YBU%UH.$-L":&0$75S*V,.([IO.?E8QFAUE@+.EC7,7YX%HZ
M_JADV#<QIIS*"!,YU>2%-_:>)EKO/G8*AWRK+<6JZR0ARTB&3PK3T:923OOK
M,$.T#TE4D-A",.=';MXQ[@MG07;RG%:I&:.SU=UV31]Y&<-,@!KT<2D*L7ET
M_J+:?M=14I B)D0$?N"9]N]!S;@]<=J]G8$<7YQ&V8(E+94NH;52P2VAVU"#
M1FA$[B'PE;*M&MOSV,D40_(R.&(OU'&%90/S#*F9%RC&E1_K,_VH[;;.D'-E
M=6E4$[[-* R*?7O6T3=3O# X9/4-CC[70&=:/(.;&Z#EL[ D$?A1CE,-T0%@
M"6H!>\CM2Y5 &M6$2Y'[XV'K?0-QSF8'P=3+]0_ ^^/MP"+?S6-A8D7%AK;@
M4-%ZL7--Y6VS]LY5M[<G+26 @7C8V6<B"WOUC^"Z3 #*_QP()T-Y'1:-EE0C
M((*?VAA\$)X29>];JA)G,+>1B^*,V)=YA&T/6V)'D:#RU7TOODK"@N&@K9 W
MFO-H\ @.<,KU^?OB%:(M.^, 9VHL ,$:5[X)TQKM>A;C$09.30QH M!7V5.+
M0E[^ENLJ-4%L%,!\V#>$7Y]UD]B>+J_PG#[RZH51_75OV3[\[!GR<X  FSQX
M@"#Q10T,01^U@?8!979]@FP"Y8B ##669<RXJ (84$8(I 3$I;K':3*.ORSZ
MDO@J>27<J3 ?&P\S!U_>?$PSBPPN;DC[](PS6)HML'F_!?\6@#=%*$>0-7C8
MSD&5#$0EJ/T 14<J\@V(%T)_Y>^?K>5/E<YFPK!O:Q8:*_\_]L[\KXGK__?Q
M@XJ($&55$.(&:!'3EJUE&W>TB'$K" BI162)F"I0HH2,BA 6(54K5"A$14!$
MC (!94D(86FEECU($+)562,SBF%*)L,=/O?^"??[PWT\[@_P>/  AC?GO;V>
MYYPYAYMVB_%>77QD]&*PRV$+]\2=Q'\ ;,7BV007%M%C:1QN[YG0:($1$O&8
MU2>KXZBKM;N0CC;0V&<9LEOY<5D/9H-0#O<(3!C$ "2C?,(JC%^QM0E)572E
M]R(AS1BIC\<,4;;5_[8)H?L5=;6Z$TA[:#+H9TO4?(&@.8KK=D-@> PS>"U?
MO,3"N#$,HOV$>L#Z(I[449. W'^,?+%.Q>]W);%'MR+/5>":Z/K"MO*[RT9&
M<,OXR=_R7:SBN6]8M*R?B),-V$J\PBT[!%.;0<0^3\P=5FF^0.PJL8'ZO/9_
M?59-D@R\C*)Q(3-E/],B-(^_RPSQ:5)6;FX.R,,V]=S>"_%3=?S)/WY(.0P?
MDECYHUA\!?T;_7^YB^_@'25*\S2X"KM6A[AK1F!@^@_7F1SA2FP+TTKR1!A!
M,D;H2ONFZ"A9];+W[$>3/DL&F-YFB:35&VL;)8V.O!B6*__6"IY+4F%(2&;4
MQK2!XB/$F6K,8-'>)[KG"X18\FJL3[!)5R\,'\$Y0,<%SW9=^YH9,(AM9W#V
M(75R[86XY25.;=.!9-B^?;1]:F^O%^D^TD"5G(\7V[TOBE=[ASGX=6_5^ZBO
M+$-MN-I+_]W(SPR!A)B!)>[)SWG*N;39K6=O^_>C5$BHTN^@9ED),NCQFAE5
MLJ]B4$1>,VZ5*%;;3Q2M4&_G%U+:G@VI36,\'A5!$S\32(EXFJX'Y(T =)PX
M3-3,5>M2%@CGP3=Q(NY2K_VR58TTV)DZ^(1I!//D0':CD4*VXLW>W&!!'=2G
MU%2J:,+50PBGS2KMJH+QKE8(9?-_GQ?U;\R=FP:'$G>2!M6$2UWM)%L_B*=P
M:"-G:.:-*Y3EV'KFM["0LQ%J9X<GE4^Q-N>UV*[K1_?8IA1/U)^S#,ZY_WB*
M6+:#6_;F3<BIL)&1MWN6/3$]/&%- &^34(M/F"%)&PF*#DW[$%!K71D844 =
M^I&2ZE&6*=@0Q3*L[<;LQO-G<CYXQ1D7*&*M0QMZL$W[EJ&UP9X,>FM^ #NQ
M1+J63';UOSA0>NE)8PT!RP+EV0 4Q$&V_5[TM>X**"^8XT*'W)!$*$3L@7/#
M%<%&1,A#]'&-G_K4!22@ '2G*2\3VQCC7H_E%UE4PS881Z$[WDHVFJTH&T4R
M9X/8I)C]]XC#,F0[%UV_1OL5*-IR[QERP>UJ@G8G-L"RZRD>= &NLM;"1D57
MPQ5.)I#J,.S>)EO;5%J%&?:Y[C4]Q0#W/>].D)DQ,C8$W3[46^/X$#8CD%Z?
MPGEQ#+4<58DNLOIRJ= A#L%7ZR"*37C"3=?7G-0]W2%8SUE9X2(;M@2M\Y2G
M?$S.5-5E%^>U=H=(&0PW#?>[@#-["=A=H3P=QWE>"A4Z25G.$(HKY"^QE3CE
M&+CX;PY&"J#\L:"Z01<GFEAZ9WC"#]93L&H7"!$#KER#M@K#$.+JZ/G:O,C'
M"/F$)-Y_Q_Q4$'_ )3OQ!$'W?G%ASA87&EPHA#A$P@RLY:^7@S=NT\ U A=$
MTS)W!(G6 DPO[G<^KH.SVOVY@Y@)UXP:DWCD#8/8K'<B?2)6F7W8<4J]_X/3
M;N)*1F*;9?".:MH/2]!G47AQC:.BEF6:1[7@6E8; 'U7:-DJ7)7]6CU0RE=P
MACIPZ'P0?NOO5Y.TG_M*X9EKZ$$%:27U]:J;WG<4SR#=G7=MZL8,FOGO67:/
MK[#<WZ LW6.AG ]"89PWF9V:OY' Q0ND 7,7,!-/+-8:G! 5EFRFN8JW1,H(
M472(2%8TKH7/QO$Z;!5R4TDR9S3LE)QW280_W*^0TJQN)^=.:O:[_;0[VY0
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MW<)JX=E%4GT\F<^[(=C<5CPA@XI(*T89F7Z79L'K DO8KFVD1K::>>+FTKZ
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MA8T:*JG7N68SS""ED?T"(;!O.].?YUM!46K=KY&)NE^B++<]2J[]0V_^TJ(
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M?$J&; >G*V"JZ+7V BCZAF6#.B)TE6]*4!_+%A'*A>K-6F_F;E@_Y<F'6.7
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M992RL0".F'CNC]DENN>@R V@@VE<Z)CLS2>\2L9!X@,"J+90]<8UUKG-=ND
M[T'_9SI[U!NJ+;OP@%$GFI/^[E;[5<SS-S$6,EK/Y]^FSRVO4ZCW^$I"*'U%
MNFFG9N ;0/Y,"%T@3M_'L_9>O[7"4F-<KMV##=3-+PT>*1.!^K3@\UD/$*N^
MHZEGN_G$&ZQO"EWMH1]I;EVZDH>,I(.X$S.8(8\FN&?ZG]8D6^_!->7/XWK_
M3O3A@DB&?"-4_7Q;OU6&DZF!]\,IP,"GP_9Y>&44Z?F<.@,.V8_CQ*, Y>@X
M0[8+_L!Y.&7A'Q4PZ<@Q'AJRJ#M;?\GV3?$]_3&</5,ZJ): O((+7<R[#M(
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MJD-3#.$=+QY-SI[[],7\8AR^%%O]_P-F4$\U]0-U3%<K$-LZO:OQ5N".QG:
M(_0P^9+C$E+:BSUR NV85<>@M449K,\4X&-^2PQT.-1;=Z"P)[J%8<GL Y;
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M\=A\?*+)6Q"SL+P\_NBMI>5:_M/$;YNN_/XXKOS+G:_6FY]-"SQGK";3\].
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MV,Y#+&9_4GZNJ/838ONI?72U\1<?*\-XI6R:.,S7U\"*!V_&AU8X9W"RA5_
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M,9)Y=\\V5QCP$H8\1UW?%"E/O>WBM5::64_(D/UB7YC4E.=U_U3N6W/CTK7
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M_LPB[=.",+03<KR=:G/W:7G&M<OZ&_*SSQUR?_&_<1'"L2RP'\LT?91@_ZX
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MU?1>2+7J&-T&YZBY+LRD#[<TAS,.+P036Q_M<[_I/11\^,LTPALN8B_3OR"
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MHK;*/N"8^TL?LNXI]46Y[V2]7;=]CD=3=?C]N$%>=;-!"O0PO@L+[4!3[E]
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MQ]H 4R6& N 6V8 8\<PV7<Q)-%T&T9K):T/8O O9$OJ2("?U)FCIH^%1^^'
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M9FX!J^09QW3F,95 DQ?8=-7L6#WM@RQ0^W/K$4U%FUHG"\9#T3(.HBN27>"
M )HL]@+@6*MHI=H6'A,X:U?PJ@M0=M,P]V\/7!T4]ON= Z4E3$L3%8<]&W![
M:54W8OZ,QI0.ME_$_4V#[<?4*V:4:V [!0U,0O2BI7<J)9UQG J+AY!9F\]8
M?-0\9HU#09($+]PNDUK>^CQ0,4-HM;MJ%,YK\=UHE8I+4K#60NL'HEEFH/JZ
MN)V.'9VJCO<;S]J*_;'%-+O0[9GO9+?WZ;TO1#Y#WJ*02\*&K(1/&=GFWX51
M.2.3CUZ_KGR9?;PO_Q4OPSUQP'/WW'Y]TTGQZR5"C  B)]O3L8S09I(MI"^_
M%IV$6#V>'-TT&+6<W^\=)#1):"U\/MK>^^-*U:GR]XBJSQ7%@/?(XE3.RP4G
MH4$4IS*CI9S;/@%RSJ+(>8P1<[>JF!^\WRQW<E@90X'([-*H-$/)Y<D!^N*!
M06!5;:!TL_WT@6E;>>4&<9U=:_4==O32_$+JP3C\U-DGL&5C_7J0E0/^$*CU
MP-%DL8F9 &10#H*'TQ]/5 ,W*T1:P]YIMB)!!LFDLC+I0&77H]X3P5#PUJ'\
M&Z<U0JJFEBUKP'\6H "C.6@.$'#AW]P5)2"NJ3VR$@[/8Y)59;6X@/# 39F.
M&2)MQ EJ;\2#*0V9JZL]S(N=JG$WI8E73WG=O97ZZ.K*6QJ!:JW >8PQ"@'B
MG\QCT,NA761IM(22I+93W>6?GPY9R^^Q[FV*-LIAM^%2(XHUM[7;IN4CGE!L
M54'ILT['!/._>FZ5='=I*J$%W6'FI7A%R,*6ZS Z>_69DLK!IIFA<IEA2H5C
MH&XV6W\(-O1A-\XQ+Z]?G'T".C'GF*UI:A#Z^FWG0328?^/ #N[JY2[BSN%.
M12&4.;U%N9-QK+>%7\Z5LRT39TJ8)J5#*JX T*O?P4CT*)I9,FXT\M=XV&RG
M%@-_J(?.#)#6Z438E*CSR-<C<RZT'06_U+SXX(L!\J.G 3$%@^Q:V"L13$OB
MZ%:D$8[!EZ2T.+R!/4X_V.?F_NI Q"S:=-'@AKJ_O8?EP-FJI9][)D<,8IUC
M@FSE0JM4AN].<N</]<HI>"1029P 0"_\[=RM3OX2,@J:AO(D;:V=MQ*[G=H5
MM)LOF71H][+MS<:MH!1N]MGW1X35%XWT"VT8&*=>;BFC#QDJOJ)CE8]<4/')
MXE?\"J?&&1W87W M'0E@-_"-:CWR/L#1TA\MKL#)4%S2J"8/;"T?(R>3])F;
MP/=I5F\E6E8>:=NM?+4D,PD.J52.=HA7]>&G&BHZT+C[O\;IYMQ&>AQ_-5-;
MZ<"0J8W:I(HW8K(N;-?(6@I:QC'WG@7S#O1%Q:Z8VM=3RHR2X8SA&,&H?BUX
M\L9'++^'N YWFUNI107DYWO#IKFFZC[-;U3URB)5FMH>WDX09BMZ(%YB%'\Y
MTPSF2,A8! ^[1Y5X=Q86-K?7X9N]1LTA;LKW9:7WUW&93I+3)?84G)!Q8W1'
M10[5I[_6+?^#WX%82=KYT8^:DID;9*B,#!/=F]7;T]66)!W857F<@99,#IWR
M/=7*$ZO8".H/WB"93@X<U$@.BR+CF=O /57E[F5^L9>B%OE<]3ZHH;J_(+6"
MPE:^)(<OOD/C!=[^O4YI4;+@STL W?>>2&^O?E,#_^2.B[#T^\TWUIX9&C>U
M'XBZPA@ROS'L^?I-6GS39DVH4[WR)8RBE65DN:;2C<FJ?Z5T+(*F%'?3!5E1
MC6SL4="]$5@:I'!VZ/HSSG<CQ+G#,OM0[']YC^+^;Y=[G7_!?F8CIC*HA[(*
MB5$E\@-R+((M7X/N:$J_Q3&:S;'M9'X='47.0%<>BO'+B@<@>F!-.5MBF#Q(
M23#LW%+R_N"K3HU'N E O6S!>< ?1J'SXM>J_R"64HHA@^(VP ^GI?JMZ:UD
MWYG'Z'V1]\Q0P1>A1WTF7S)7@P&S75<K*,L86TZU4P;?9RL"(7ZJ_11WU>2T
M31H_T9Z#PP!V ,C$I1+QSY@QJCBF1F&PPDUJF52_FAD*!29'+3M+F::BL$/6
MRL)V,[&%(P?S.C/0MH@:D$&LHX'YQC?]#OMN8G/#&_!=AHB!F:(,3D7[]QP-
MXV4,*T]0=,L!KZWNJEY@$$-CBNV@94I8^]X7#$"ZM 1L%5$@4;+U%Z\?P@MO
MGJ"<U["YY+A ^-0Z?2)W"Z^;NS$J:XV]!B)'I[&,] O:Y"YU"WXYT5-Y62T4
M5>+ET"/6P.A6B'"KU@EL:ZS?,2 G[I+1KHNTB>1M/:6U>_-@-\K+@5KWQVC@
M2/W*3"MZIY(+YS&AA#@;>RO?I:&>+BVY&SV#-%$F'9^&0C,)\(&O^%?U9R7^
M@YMB"P]R;_/HO$5>1=0L@<ME%OEB5WJ3GVZ7G*DG-::OFA"2!6F$UBR_!S)5
M8*OS%[Y_X823SUVP/CZ_4?)VENI*/C8(\,[Q>!AU!B >)@]A95@Y#1T;#FP)
M?I/5)[Q@N$AI;*:'3)3FS(N+:@\L'V0NR4?<^F793?4F@V'GET<4A/; U$/=
MR*[2(-[+X4F6:7_E<(?FJ<JJ?OOV#ZLT?V3$D3NUU#K#JF*U#:L/7S4F1Y/_
MX@18+R(JBA[\@FG77^LE234Y[+&?&*MT0S'V--,53!>8;N#M"_+DQ!.M7HP+
M6]F;IEZ.,@_WV9;:/*PH<?R$(9?C80NT2@<J8M Q/\MZI]:&EX#N F>RXKL1
MZ>$EB"X5C"L,1IW@MS)(J[T8+F_):KZHO6_R;916T3C17*),?2XG;I#T!CZ>
MB'-?7/X1 Q@ X#6@980BI4\'*I>IVUBZT?U1W.6( T1I]NHJ-M?Y4?\KK)1U
M$!I(:WJ_R(Y7A!P5@/?/OTS\HWQ7J-3NMY-)1]W_U)Q;$.5+9K6I75^C%[\@
MT:H4(-#*JH/6RM)2I=A3XE'$7J&]=&FX1TL5?CES@Z1F*7@E^?SS>MDQB)M8
M:W95$FO;\*OKI\_E]*"5GHZS&+4K.NN];-C*4AZE7"6 > HGU8O2"LYUTE9X
M!*+OASCQ+%?XE=#5KJGZ@2HSR7X&:]E$3C$US]D(+*+"E]7H(O8#KY1+W0QO
M/N%#]#2;J!(O06;A84^&I@K_J*H[RCB-W)P!!D?_H VE[\H/[=H;''5)E5;L
MFC#;[,QZ=OU?];O^3;W?:][F57'DO,Z LQ>E;N$7)C749U V<H2,#Q6!'@#L
MC#^CXO)#@ 1G43,W<1635:9ZQ+2A6W#"=T!)360CV)2VDA'= N">]J<5I!?!
M;''=;&]ATO3YNI<I(BE68!R[77:BU]&B:!5V;C>K':ALDW.5 +*J'*Y3.C$/
M@;16-".JMU2E'QPP*S^1.W:@IKKB^#/818J_,?N?#0.U-ESWT(MY1\&VE._9
M6F^MOVRHH09_'QZF/FP@YQ!@EQD%!-'D-<I%L)XB% [GTABAK:*JP=M$3[%H
M=8A/1&5=+[(4OO0TV">I)<U J+#V"!K]=8#H#XXU5?\5-)G%N>G T9_0P_+J
M'F[6E/!A)Z[,"]$U6W!AUH=I,G8;08A"ZLM5J@J6:Y"-#)?J?*\6P",'X),2
MXY_G7H.\1E?-_>"I)"E]#7S!Q43'U>DTI$X.#C;E%L-?%#\H@Z2A< E;VWN\
M 9\E B]Q$8-X,1TQ6"%31"YX4?_.22+KLFQ/H\M1KK:IA),O@?.8X[VUQR&[
M-I_W"3%BKA9*G VOC[W*E&X2.B!&TZK/+QTZ+ 7"7%[)KD?4%DDF>V_2T=<8
M=2-3+X\QI5Z.1M72;P<*D(-]&WO5M@M'4G"WZ0[[Q74WI";&,M)S<5WTR6XB
M/OR%CZ=-B3"(LYI)R8<=!T^^RJ*&-@::S'(>KBFSBF,M['T@:Y Z)/CA&L7C
M/FL>$ :G2]P;*,M#+(A7\6!:<-:/9O*M*QY;L("0+[&"SQ+O/:<1Y)?*$[_Y
M;]90+B@.>C)Q< U:PI;-0#P*3,X/46_DPQ$R>B)@R(R0Y"P54D>.^\"!XMC+
MP4Q?>\>M[IL&3]7KW5%WMLV]:M6D!JE7]Q'J+X5^>HW]EX 8+1 [=-$QURD)
ML)MZ>0WD[@..-5"$>H?@>[*2B,;J>4R*4:\;R)Y>=PG2:XX(]8G.E*VK37,<
MEI;>TV])$BC)*QEW0EWXNC"P$PS@Q<]$C>SB1GJNU53^R?;L?=QG.QM4;/VD
MGUX25DRO_&WZ=\_=7]L][\^%.[__,GODS!F?#Y[/)X\-4=O-!*$6CV,WK6!'
M73RS:!K#;%&&(I%)BC]4;""$(K3PN#7]";94DI$S<';ANBM2F0\8?3VJ@[[K
M91K-ROQ]88DP>"[JJ4WSH->1EE:D"PLJT1ES0[2RCT&=TV/*XY.*KP=(F9+.
M!,XBQ*&HLSJ86P!=*>,B>^'4"X/; Y#V:#!)X/'\ZY=!;=9]CXKFA 92&UI#
MAEBNW 2R/S!$4%RLJ%T5@E\WCPG"KV)Z]FU(H8R., +%T=>_V,>D>MQJ-)-'
M,%)E^,290<:2+]\9APXQDP?B7+EJ[<MH9K-%'%69Y//TQ(7376WXI1.F6U1%
MY""ZUFG&-TG4%WZAJDRMR5P#7<E6L)>?AH^-JHQ<G=KPNDP79KT%Y)7RRPV3
M4YT"H8(CSB%1C;UKCULFQQ$I:MQ%*#H^C/\'_\-40_2 XVKF+LARVKV$42,P
M^NO>OB@7RE+84D).J:";?! ><L\Q2<PK0;FDI+\U;[7N>IZ17\;7&V#3"<T?
MT>IEAJ#2][_/RRXN>'ZB].G\\><T!-.-Q*S*.;W)TUA:]:84.0I^W$M=:4#0
M@=L.IFQUGZLX_*?&W,^=^,9 Q/2>\B*CUS->L; !["+3I;]2*Y20['.<U<4W
MJG"UL0CE&T[<9;R::N1K$K>B)'VIQXB=6@^WDKD;TE<D3FWW"YW#WW P3[:U
M3PU$ZT((VHH#T&BKUD>A@@W?'T@"EG\GK P"P#JFEZ1#JX56P6M^75)B6^LF
MHZ5<R\BF1Y<&"9H7+:[);*A?4I<K$Y TN_\(BASV_?7M[!L;W,(.OU63/G>Q
M$V/)M9IBFM$HP^LHE'FCUEPZXM90OY$' 3<(M9Z2#KQ?+1B=:F-3&C;-/"JA
MYISZYPN 8Z0(WW_]VB/RZ=E4WO>XJOK-#9<'*<%'X\CON.H5F<7, VAO_P4:
M6^>P<JM'C/1C/'@OF"W]U"GG2SY8TPT\:)JPE>177SA5P863 ^@;YS$!;Z4U
M**Q:P=S]INK-??-,KRJ0'X?815]RGJ@RWTGN\4(S60Y)2_V6OY2(59+4G;D:
MW20CICG*^O8^87@U9:VW?MFXZGS6CV-]W,!@^BQ_U53TUX\AHQLA V[$U9+0
MN8Y/7XJ*_$9$(Y1+F[$_!4"CB*0#1LL7U$6#5!R2,].\5\XD0&ZM(@VU$?,/
MJ%AXZ ^A+U6*$\RDY#J"8PG$J&M57S<5>M=T$]<]"CHVLN\7.X%$ZX!;G:3Z
M81PYGPR[<!5Q] 0 =*^C2Y (A\0RY6'D KP#?%X!;3;LGC#%\^MA2>F.S4?5
M;Q>+5E1TX(\^V(EBLJH-%7^&U7T0XSED,)B,Z/(D/Q+5.N, >((NQ#7.1:>0
MMC#W]$45 4.4/9#V;:<JVDH$^VC2*=>DGV1#]1ZA[Z^]*@N_)O#N1;8]]PSB
MD4S \P^6EC\>M6.,!EO'N?:J<3X0YZ9])VP)R(?%GOO^:9UJ,[55<2/#@:;R
MCO7 A5ZFJ[CS)F=->*U_C#]IY>1]/T9-DU'42/4#WD.Z-(O9$1J\<_T/Q"A^
M8=L0:-E$&U(V+JA%B]BC:\HA"IH7TJIC.W[(I\*E5._9-; -Z.LW=:"7>/H1
MU?=JUVE8)/U+]^-DQARR:\8>2+(;=[Z02OH394JQ)3!6%\W@M7!ODP'Y59M\
M%_CEZS^M%-.%\_'P=1E%)X2P/O!8.9ATG67B_ACN^4=X;&79ATF?SF8:IC/6
M2/].\/>2'4]7=NT[HCFW<)3)"CXU(^8M;/M>6@:-3$X(#JK2:S4A[.F:OM./
M?8W=H(QXR^:_S?BBS"HCBWBI54S,LX]6P[%W]H_:!_V#1L4_0*/%/,9_#=K4
M&-!XGK69P9>^,WR%K.XG62"G5:_X0371N8H>V1F050.Y5N8X21+J'P=8ZWWX
M"$^U^&WM)MI=L:9_5[D?!L^0K/KMC?]#K_ X^0@WFPT.QA&UQ2+-<='*6DOQ
MS$H&7=*9Q'0*%D]C&[(LD@HFZE?U$"W]"TL?!$I*7 15&5T3CEGZ5?])+6S)
M=PO)\#A/>K]!-V"M)C($B#^46'K"5__["+F?I E3%U_A:W_G8-0?1I>]K'QU
MWR/5A9Y$,H9%XCR)MUFN^^E-%8E3N\"G1RB;[_T[K!NP\O->S!LTZ,O16;L!
M-'8#Z(7\$0=R 0M19+U._3>M_$KE2MJ$0;#$)>UPFRRIY<V QG\^9>[K45O
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M<-NX-_$KZMO79U]XVDTD/ NA&5>&/M+ *3:7JM>,"V-EW'^H7E55Z5LB_VG
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M_L:OW2?LKEPI^GQQ^^A."_5.P@@F';4"6)T<$V&4!-Y(GYC"V*\,WAYG_[4
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M.?\\/K]_%D!LCHY!CAJ/>%F'\N')S+Z M3@$&SII/:H)-)FK]%D]9*[3)\X
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MYF3HF; E^_I=CJYW<:WDE1ZH>DP3K.X]R^^;48?(I_SZZ%4QMNUEI8VVR!X
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MF$5"C4_4.@LL0+6XQ>YR77^Z/>(EPZ<.KWA9'W#,TY5_]5-+\4/Z@P_O/^*
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M[>_;^!+\7J7;*#=M#Z_WD]R 8I%5$A1HL:$.T$*8\=PBSM:"&C1@;2@QI>X
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M?EHB.<^AD):%ZM(\W'B*Q M2;]2S1DF''S&!H<*,VH)2>58BQV<V64\///&
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M,J#Z\]3GV;URXO']6I9(W5.(='"@WJG"BUOTDZ;;$V8<[MH7K#RTPS1GTZ<
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MW[)NCIB4:] EK/E]YC3 2JG?%KY.8M?;&(W+) %!.%B-CJQJ1Q]]JHON1U9
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M@B0.<XZXBFH(?$O-O%#:8\QJQ?+"14]K,;UZRS\W1^;(-:+<>=;S4?A'Y?S
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M 5KL4PJI>52G>X>P]P\9"X5P%Z+8Z4]\LYSB:@L;4A\7^F5D#&AHW-]T*"B
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ML'0UXE=6W=YE3B1R[^\2W->\< ;]O1+9U$-2140%L,!SC'$/\;"H'L/V1E2
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M2OO;+D^B6BK"\FR2U<E&#JX=S_@:EQR5[JP>K'*)0G[8K#K4X(43$B]:<Q,
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M'@G/I Z@T3]]@=.2"*D9)KG<Y^^X+\C>7BPV^;CM,)"/'4MJ\2Z2:HS ZWW
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M]%>F&7>8$@AD=7USP'7@Y5;/9XF;>YU(P8&!1/5.O5TG+B7^\D)+0U,.#L"
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MW4W P,$G9[TFTM4T*]YM>O$BS^QCI]R%PSL?_:9HLJ57\0M+JC7G8W@0N2]
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M$^/W?ILOI5:'#?LM^>VEL8J)+ ,T.3#& (SM =%ALCD@VBS\F6 1S@!>$)N
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ML2C1G/5%('ECPSJYVF;Z*#AZU[&87B;AC]TC]!@C2Q-0DWHH$#6)U!H-<=X
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ME%#\7GHL)F^<R20%']ISC_!(6(U!LGE<&\$:D-\878^YAUCV(OB2@I\6L:9
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ME9(K&^,EC8V0^:U(Q5:7(Q4#?)+[FU&[1.W=A* DWXUJ',6^0=\][4?L>'A
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M8\3>!R?=FPR^N!,NB,C_$E(/EKQBW)-&V^7<?])>!%=4^=?C3<>:",LG,;C
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MFMG8#CU^9?SO.@%5L8V6K;1BVS/YFLH[6J7Y.Y[=^[0N5_4;+B5;P\O&'VB
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M_(\"0A0!5&$+_&%WK;LNR# ?ZZ?60ZTD:^#1)K:G^+,<\=1'-QT^+4H+A';
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M=0T#GDQ!$?BTZ$N.G738GGNP;WM=87(6D6_25J[SPCGS;%.1S#EVE_BQ0X&
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MA *ILJA/B*T0\.2UB\'G\;K0?V950!=9![1B!5>3?CX@$.XT]8'-$%S&V.N
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M<&&P_4QT#+-XTNQ\+U4U) >>OJB=NX:1'8![Z9RCQF>3.LR%N?56@7_&#*$
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MFE#8)>NN%@0PWPB-NF-$V7W-68+5BOQP^70=?GX@-=;\(A'-1'-A4F>.)*[
M\2W!)@P8D0Z+#YA763Z[&08.^/ONB9TSE0,OX:CG@2ZP&1%9J !(ZH,@PI/S
M3!ED('M(!Y^'0**XI37\",!$L\Y*>"=HEU[TJAW%0X5LX6A<52XEE29P4[SZ
M'(,WH5IL?IZZL++_I>\.XM%A/8BALXAGU3_C6C-7,7NJA\9[4'CA02,*2C)Q
MB>"<*I^L',H@V-#YC07V4.!CR%99.S6AKKJOPETA+D%P4,@I[@'"NN[/^)@:
MGDGXB&(8WE[R/LS%TBLSI,/9"H\-785SZF7I6.!%WOC UDPT2!!#W:M(LQI
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M0WVLI]E\#_L+%MJ$&YNCJVCGJS'4>2+@QX9 2CW+ &9%@5Z*(8E+%\P8M*L
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MA[M%!"[EP%9?039B*%)QDW$5/F/-H)6B.96PA?$]E! %<!J#C*'*Q.?#02M
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MLCXZ1,X3QR?IC^%@*RXZUU&0%OU[#3JA.4BGJ+- 3CW.$NI1L26XN>%])XL
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MC+&P''RBX)A Y92R-"CX>'=AY>L.V.UI0#-3_6#'$V%H$O$[HGR !=D6-TY
M:_%UG#YL@ZC"(I.PF"Y53C?-8C+]+-+.=1,,1X,V@]B4^U"4G*??3Q6:2/%3
MQ)60GD)8KJVE*2F+&;MKJE^R=[Z2.E9HM)O#$T]^_/3G3$>=G@MB,A^="5.=
MRVX\8"'F6L-KP>)KB 72)=*;U-)V Y$U*I+W3L8RT+:N[\. \"%1W+9RU,_Z
M>BEO>/%PKB0N'DTK.T_?AS(\OM/X@.NY,?=;]--QQSLP1*XH%?>-\>+!M@9D
MN?8&*YS<KV2ERLJP[+VW%-E1XCNSF I\-N+@2Z'KB3_:/APN,(/"'_F-Q HW
M2*,G^95\8(A-6 -EBEW7LY?E__RB=W?NH?SB5_H]+'V6O*LM"U?> YOKR8O'
M+P')C;+RU&R-"6,A5 RPFPA+(-832*9,F6CN+[53A(BYBZCZ)[LG;T,.[O-9
M*IXIP^OM)L:YYX&-X-P6;V%-YT3,*6+Y^KM._H>Q?3@(3X:7?&E"09&H\R +
M$9,QC$0IP1#*D_=<CVE+B]^4H^09!='9=04>W<XT+,?$SX^>J]DG3 X$!-6.
M/_?EC>1^O/N0GG<FK.]V:5,RD6O<=4__SZ] ,6* ZEK](\S?A-;ED+[&@]GK
M%Y>"&(]\">P=?@$9J5^!'JC26.07)) .D!019HT%2SM@'X6;469)9F:O(P.O
M"'2EC=NG3RTY3SMW4U%'Z-=>$\D[<!84&"5 J0_0M10B'57<2OSUYHQGC-,)
M@*A^<#THXDS2TOU:;_D'B*/ %N4LIM';;!?(S7+BWUQ:T<6P> #%-U@?,#H5
M\1D.3RALB2L*Q# G6?71(CE79/5W)T9OF27R&^ME6X; &<V<Z-8#;C-<P*WH
M.H8<J09RKL"7%"S,I_67F2O"<OH\LL=<M]Y=DT_T?[LF[V#>'IO5 (_]C"<J
MOV#C[>.-^4*&7&C(PM>: ZQZ/$J&:4L8!MK'@G,*SF+Z:*/(VCT8/+8/X%V%
M]SRE%XLIQHPMS^DA]03K9/'6W*:BD.+^_0E//@TNZQ)0GOH/QUX:?AL(I;UL
MC7O2\C1@F_Z$!V8IYO"<'?/_WN!F.Q!$1YE;\9"]#VP65R<#3N#>\9M9+_F9
MSBVT^?2,B5/H%W$(9O !KE?$9:$5? AXT&/TD)Y&77BY6'C_W)-05VX:;,WS
M:[Y,<Q*N!/?RU/OOB_Q):4F;6/5VHF!R%CH;Y(EW10K1V"VP6%65K?&4,=9T
MNGL^H.LU^WE=<\8OJ.("33-0V* E$%04\A3*E/#]L@9-!;7=T0-VA_UK_!-H
M1GAVA5&"05&[N7)8;S(UR1 #UZ'+6<YLIE22QS]H-GWBEMN-235'();ZF)1@
M&Q@P0K&$3U^6>].:;#: +/'E9WWV7+;0NK."90Z=(1N-!*U[=>,>6-JP[L/'
MVGNV](A(A\EL4D!EUX[M1,AV%@.;VLLIL*F;.AIGQ,2UT51M6027FRW^$ @.
M3N_-W-\C7 M=;[4+)!Z4CK6VPH@UQ%)L>/[Y@F"U8G=G9%&EB^N=UX_)EY7&
M<3["5QAM^+VYZ)C1F?[G-]@A6\1D$3HYE<QN'+"_U59-@FYHW."%4N1[!@',
MR12N19'R"$A+9E!9<F\C<9#U2V!/\35X^V703&SFU\MP!6E9SMBEHW',9<*N
MLYVF(&SW./)M3"8I/&__#N*:1VAJ5C"-6 U+:3J'&1;C\"PF)2,X0K@R3\5-
M(2H,]PMX/W$M[9)8_+599/$&8.FA,U;)^FX;]+Z0U/NU-XFZ]S?;:Q##U?)9
M3'^(^CU@7BRGO<NIC_-SLJRZ3WM(3ZX7&=,(%A#YN+ [6I2$P^RM=)@19>'=
M TO?!WF">DTSS*+8ZG5"GM(QX2@X7U=XT("=,K&#*+4G=4RV8@]**P(MR"\[
MHA-M&MI('=&E6[NMK-T.2ITT]'$')XV1_=GK@QV__=:]O+0T(D)UW8J^YOJ&
M&T=.')^K_5^BXS_2L-:)@,NX9AYTD@N0* MAZ[+:/Z<H?9YJ#KHQ\CW)IA?"
M1?-@%VG,+";#K[$WL*[%FI,E< $^KL\JV7 3V4BRWWVECJ"SF LAS)W%-%S3
MN3HS?XG-B:6<!?4;2^V:N#:"'0CEKS21(HPN"^P66,<?AYOCQ-L$QI%KSPR&
M\DV]JM;OWH$=S/AWML27BVC'M3#U.2(E?O,Q*E;; MYM_96X1? / (5=T>\\
M\/U+J%AS&#YY:T^X61CG]4.N6+@,"HZ/';M)GSB=->>#[2O]F<UTL_I<"S%'
M#W)1#*6,[\E)9>@KR";0%G&59Z2C$]YHQ#Q^_8VPK2D!_B/JK2#C:<F? *;N
MGLESW3CTX':6_)$^8K,,17DJ; 7-MX"/VQA!OF"1.@CZX?(%8H<I;2Z\6NK4
M=IUB%5UO'GC:W._Z$_!H0V!_T77_RY&/.,8.87.0G./_CVOTSVB8JR 28J"G
M632, P[WHQM[(S_#N8TCLA!1K43IU6@RZ7>C9081 5$ZLC*4Z=PI?UT!#'S,
M5B3@V-7KB^9SQ48;'1P)YB/306L$54 T$P?\?J?%XTU*<1M&?WSJ?_^G<U2R
M"D(VB)>P,(3M] 2Y8&8/K\DQ03XM:;52>/2D.1MEV^VL@G*>TO'^9<#:F<$2
M:LCCP)'<W80-7-*MHYV.%_#/'<:ZP_]VX?.Y]%47L1\S$6-4>US%(1U$X !Q
M";-K%K,8%6FCG!27P6U032'L (2(8Z'3RE928QF5N0SX,)U5V69M'#1Q%&A.
M[>OVIOG4 CLK^%?=DGQV%/C^;)%^6&]&^ _#E5XF= /X4B^R8-K0)Q1D2:!A
M6R,.BZRGNTD&,6!S:B6F];02:P")]]8"TVF3_G59+Q/SCK5/&;5LS(J\:? Q
MV*HDY1P&UIT*K$&UPC+A]ZQZ&_=P#2FT'>FV)#>)>D6JB*Y4OH*5:@9O[Q1L
M5U+TH1IQ;F47C\WPC5*N</=]&OHES +1$^:(!YW9!]\ZW))8S(2DXHMRW_3L
MN/K;16P;#V5JNRC]48%H#*6Y>WZK/WH?S= RYIM8%JKE86\@E7N?_L6O6[CZ
M/92P"TKDP43MS_=K@0^RY&B--?'8VWOE4$))^$_K7\<LR%F?&1,2'$4OH5V4
MX][]WP''RZ%LY]+R-H>+]8MH#M(#HRN/[+',N>E[]B^FVU1[-GV6?/?803(G
M%X/HL\+:(/='&B5-S%G*6*&],HLYRTN[@ZN(X_"F:.S!N5"RLC2$!-Y.3284
M)T85A0XZ0(ER[*+0Z?@ACH#ZV,^C5I82;7RFWTLZV1K_^4W$ 7%C53RCS^;E
MG.DVV,H#U2\$<'HLY!&4IX:U59,DJ>8\(TJ*SZD7FH+7>BR+LYA&=(O&E_D^
MC9;-V2&=BWK,19;,#0,'><K'Q7=4_D!.:COL]D3F-RJT ]^D_#A'&_OV'P\S
M_5^X?*\&<I^_JGFL%;108,>XX!=/5 \Z0LAO1!-/D'<"2"U6>9#K"RPZW7]A
MD"_)6QSQDB!+KA=8^O'G)O$N\$A-=8[8.^K2TY$[9>$_4>,+"N9\U9VA>*/[
M9C'#1G>02P]O&OR^VSWP'*A1ET)<CREV%L$]$*).SBFB+_]D=/FT'#>':C%3
M4,NZ3XV;-E?W#64[;X_QK21:C+;WYN_:TS%I;-CT5F]:^)]-XL3K6)U3^^(<
M]7LM!Z67Q=^NT\OO4:K4]P'RB=<06X'+CN>DJ* 056MXDU\UPP_J!^UV@C:B
MYT'/2^4R8Z,( MY(E%TA)>8[=DEF)E<7[M[/Q["")_]!5%LYD>5^HI!NUA"D
MLQ7@69 !63+#K10JD5A,9-]QM4/312GEA(#Q,KNJVSS.;*OO7K,[*V]C9C';
MN)#3K88^V;@/&B0QVG)46.,L?2N[)MC(2I@,?M#V?SS_ BK1'&;X\D49L=47
MKGZ!@LG0P[!X$K&@8X'!+=LDUH/&?W1;@#I=IJMZ8(KT<_D\V,)(/CU>](P"
MF^6H\5"(<J(W^-"M@UV"RZ5VDDS>-:ZALP<6I>9F3DY $A#1]+?<5+[*FJ2T
M+K@Q%TH?#WG9.19C?_?TG82\;1ABV8SN_/488M2B261VXH!#V'<EN[2%K+,H
MU5D"GP(_\)J)>G16D[FK*,G=7R6;#_DKC@T3G$!<%L-;U0@D?LQ)1+4KB<AV
MHAARS-J>40^/S/#2)S]D# >T6F[3_S(DGX (6,7:@H6^PE7,.NZ2"XAM_;D+
MG$>0F\HGM1(W[U-NAL3\LR*FEE8?'U1SWY?\/36B%,N&O3P>''+\(!30LW^7
MX_YJ8ZLK")?+JN\55<6)[?,X*=/HMF:=X5Y#5M=*?0([2BOS.-=8<^$E)9_B
MSR*NG9_=+Y>^ZSL%!VKOP3N+J'VQ^<$/1[::&[-B@A]L 'JN"G TI?'Y3CWM
M#P0#QG(H2N/*P$%4P%:!94<([(!F!>ZJP$..TX/B.W,"W<2#EM)[T@OF2H4H
MD?7XO9=^WU3@T9$'PJZ8[9^G[+\^$M04A&"FOONO(;[_L686XX*%W&1-N1/C
M6[X5M\A@G2'.>Z^M.0*TB7'SH03O\D"I$3Z#58EMI#J=+-OZ6)/K"[LI**DN
MQ9&_VEU7+Z^S.>J6Q"JRN^*^XCYC&T!,1G-84*<O/:2.N1282'9W.[M5*=T%
M"&^$%%+-BT)/- JYP32+WYZ*\)A%AIA/PWI .6)R")J:Q2SZ=NAS5OMRRI\D
M>SDJ6LK8J! E52]:0W:LQ$(!!3^\%5@I^]=&_'9(QK88=!;>_![7FOK;OHQK
ML3$8>!1-2T[?."-*@Z\&P[LA*>O<AS!9A<^XG<KCF+?P3[55VUSX^[>Z)V![
MV)<^'@E1A1/3SVXC^.7=6GQDS8'?YVBCOL$QRYX"'"="KL%R%FQ&4Q=!,LTJ
MXMBOJED,JN&6"DU#"0M>5_94<'!TFMAF7B>#I.+-"142^&^G1FOR[4[T.&VK
M2-PBJ;8<'*!6$],^O+J3\'A/[5^[&T_I@2W(0C1'S^O2EJ)05D'D3TW YEL0
MPW3YZ+BM/):KC+!OXAHRK:!BSZX*:S/EX!.%A)^GB+L&Z\E;66]J,M47H!##
M=Y]\+(7W';O8DNSS;SR^\^>N()7"7EWC.XAO?_M'^0:X!3'2:+!(%_&;D\K'
M(LUWR*\Y7),QV%]%RR(:.W-QK(86\.1#A;6A2E%\E1L !@!^E)$"&W!M3OPK
M4'T;0)3&A(0-CH-O!I&QP;7JB_X#F'@BO%BCG@]R83-_9&$S$**F0$5V*<^9
M^!'+'@EO!7RRT]WB24"XS0H1Z)/-2.1]JK[4,>56Z[*_6LCQ!K8!J2G.DK[$
MUS>']O^UT.#@F22B__^7F>'?J)Y9Z;??#_XE<3RW=B#_T?WPJ&!6."TA^/*\
M*GYLW,4]4>$Q$:[+/_)?\^_ZK9#G;@W]D'$B](^]WWV[N.WFI;%$?OD>NDHV
M%VN^8[:VTY_ZWOQ(,?,"MBBNTJ^2TMZY1_WZC)>ZH/"+;=*(?<#=94D_UEW9
M@?/RLMR=OG3?C69+ATO-EM?VM6..[]XSY\2R'2=.H,/!8!HQA/_$EWQI2Z,8
M",W@@ II!2H/43P@V# .O6C_?%[0X<!<3;<7!SE5='S^O&9Q0""U>W"M-&;#
MA<B0E),;BZOV/;RS;DG-TL,;]%ZT.WE;B?VVWE+(3*B6YZ\HQO6\R]JC'8UV
MOZCLJ(BP\.H8/_-2ZI1O=[ L8[#ED#1Z=,.JBK*R\JM&_J139_C\C&TWENQP
M&OZWXW,O#H*P@%LCP44J7$_GRML:N$M@KXY-%9D#=LH%M<!$@Z4H>[)&AB4O
M>W,EKIC..]RQR7G4OM3DX_)(I\S,\.&'TI",C1<*]'?'8*;"_F>?C]KDQ+IQ
MHE(/]GT!;0$>-2L?Y,3U_,DX6 [%*8QH:=C$)^_(#\-\.*IMT== J\!/EH%=
MW7F)%_LX^7&GHSQ^GG 4=.RNLRG]E^N__]IFT4VGVS8;CZR]OCOTC^M[3&[:
M7GU^/<OPY>:;SYX9_+AO57(&!J1AD%9B>4Y#_E]4$ID1@F&8030EZ?6Z.Q,2
MPASHA)RL'YYSM,U*[)YCR6=7.!(0ZOJ4P8U!)#;5-BZ[Q=89DW#N_X<O_3\T
M)X1E+[L<>$ZMA][T')'&6/EG6GN2A?S4S[_-_/;9@E]=+JAXM7]5=>7KJ_M7
MO^+?M5EQ/^[Z[K/G_3!?9&S*?*8) X>\0RD<"<A1<!M42MP+%@U-G-4 +H5A
MIGVMO:66C8G&.=#>Z%H7#5GCHB$=T>CW'YS%!&L2)WIA4259H"?]#\7WO%6+
M=V*N&JS*NHJ=MYB^ZOJ]68P?YFN+K_:ZZ"QMR>A08\%J[1U6B'5"HP/))3V&
MBTJW197>B>D1DOSS&K&+9?HZX1GO-Z2H^E]_Q-YS:L5[MT=K'&WW2I]%Y]M[
M5V7HSK9;2 G&A(8W _,N^O7Z^C4;5Y96_)!T8^>\_4M#[Q\YL6/1G/A_.=GZ
M=YL_\Q-0$)A8"LD.07>5K&2B(<,+Q.VK[L!'<],LI\4B@S#$I6."X>'NXSI_
M,%]9Z[GO5<^SYQ5N?SO]JF.3(Z\PQ[M@P\.7=.LEG7I=CS'W3(C-1*S[')"X
MDV7$. "X)".KH3.DDO 1]^TJ[J)AH>/;(/7OY7Y!A!N\7LK(>$Q88&NEV/_N
M/8<FNZ--28YTM_H@8Q1]6MUT!@SP.@57CT[:IZ&HR2D"ZWLC02N CSEJS6C^
MH5F,QFUW>\2%BA9\U2<??FZ*K+>T4.,]U=7ZOG^H8/]*O4??/@^T3E"?U^;!
MQU1/"!OH7#43LE42T__RU88F\4Y0>"5-L:SWJT-75U9]<?=_'.ICJ=$6]/7U
M#1KWL3_?XZ<N!U?^< VC?CLWZ:FNQ-%RC(FNSI$^9L[7,TGF_ZHU(\YV_NO2
M_7\W_]W\=_.?;_1F>_\'4$L#!!0    ( ,> 65(@1,FV@4(! "1* 0 4
M;6=N>"TR,#(P,3(S,5]G,BYJ<&>\N 5074L3+KIQ=W>'X.[N[NX0/+@[(6AP
MV 1W=W<-'MQ=@KN[DT>2<_[[U[WOW7>K7M6;O:KV6C,]/5]W?]TS:_U:_+4!
M0):1D)8 @( " *;O/\"O$P"*F*N)M2< !  . /SI.@-0"IO:?S0#F':]]X"
M 3# P2!A$0  =DP 8/H9 (*P#0"1(?VU @@"@/R?-]#_T<#^T_X=^S,,\M\C
M_X?M5P\ !1J$![0=# 0% (H" H8"\JL/1/#='+#?%P@(X)\&!0T#"0X!"P;Z
MNP_TS\+_#@$@H< AH&'>AY#?[]]1P(!"@H"#_1X'!0.'@(0" 4 +L2,3,Z&B
MH;-Q<*)@*#&S8F)QD1CY9[,XD))AHP! P$% P<' H"'!82"AD=[-^3T-!15
M@@;%3(HN3(:!S*3,(M* Z48L9,Q*[JI26P_M^.6CDRB;"P56G*IS2.. 44W
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MPS[YK_9\J/'ORLIK?K\ ZF5\OI.+*1X:K!0UH+5Z/]Q\"<7N-_Y5%P#[)%<
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MWUC!BJ6+=(E<["9AD""* V6ZB:<>NZ)?,#X)E9/W]"F-,)DAX&;34JQ5\/9
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M4)@%8+Q4F#S.P083#ZG]4.T04*/W7#8C/7BL=X?Y!7([8Q3QQY!%R&Z*?P'
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M@:N2+5J<_A0V1-S%_K!2['[#57(1K')43CCV,(Z2.1:;W+<2]%WLQU>6SR0
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M@L*#M'11W2:J('SXVZM6>^_;?E>A7.3F3D9J0U^:FC6LZ45<S(10&HUG7Z8
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M1PWNAU'N_99 8F/PBKZ0Y^AP9(<KJL?_Q;A;!<6A1.^^D!W<W2$,[L$= LP
M PRNP8*[NR9!!W?WP0=WA^ 0W)ULW GN<O;_G(=SZ]Z7VT_]LJI65:]O?>O7
MU>T<A^>5<Q.&$<O>AQ+VI2P [KTZ"DF(KC=A#(F[*W]'^#\?3Q#_M^GLDL/A
M4&@FO(8>J$*D=0=PWD43[QV2551V-\2M15ES&. H0@*(B%(18B3X='9ODM:7
MU8;:&--[#>48LD34_L'!&A^-=>39MKOAFLSQV'2*6M3E@\=)I7DAMMFS!F3@
M/;UJ8]R1,V&MJ*WJK.MTP?E%ZLU]9K T('U<0RY#R>%&-M7EUY,ZDU.7)7OU
M'88.'0C),31!S3MU(J?!03VZFDTT3EAZ,U__BQ7_GU@S EAFW")A('?KYL4S
MN+K\[/&/5+RE]P+P!J@>++*/04 ! M(RF29M>(8D^+"@V_U:WEDB2G-&\WQJ
M+Y\IK0V'X3<KR[KTHH!(TJM#<O^\80P^L\1 /%M=44>M$G];0WTOC(1-UTD(
M43%A<A&(CSA-_]Y5E=9I_("^LBQW--@U[$WE\FR*\^E(AB90A>D<?D$$;F,>
MSMK;BQHGB254%0@I7/6[N&]>-(N2L<ECA:LE38/O<#.-L=9!M3]IRYU+Y2P-
MP$KD0N/060H2W8!":MFUJD16KIEK9S^SGQ+'!V0\C>NCGU4>,A5&C50=6D >
M$6:F47#A4;,A:;??12OYC+(#T6$;N\<3Z7NAT;*)4B75T99;X&CX*OFKE5>&
M]]7%=M;G02:5I+"ORQ\I@VGBKUJQ!?(MZZ+2_YE\,G??%BF?MQFZ8:#56A\/
MPS0TN<OR24-);YV#A:W$/3)BU$R:O38,6[0A*ZOW3G4E]X>-G2C79#/7JOVZ
MCM:;XGOJ@<'B>1O2$P!1CD-ZRC8' 4M&^/QW< Q'A.8\V6Q@1Z6KP;CTQ/Z.
MN7O'?=1E&RP>K:SE$C5(8=?*OP+.9MZ!VO330XVC?"'512\+61^CPFG8'W>-
M[T+-\'^.@FW4YV6--)6-X3NE><SA7-T\^(FU!:=(H_&@V7U'VI;KQEV0'X2X
M7K->L:C-(Y^7?%UO'O@ZJ^'B%?QCIZBHVXQ?B^%@@+('/_D>IK,:YZ9\4E1G
M;\+B**3N[]7X[\D</\@EG(_6B,WQ4V(VFR[N:4$&8XB+E9RCIJOF@KNZS?PK
M^Y"'I N''>?:>?!R-UXLN!!."0 1$&SWW[;X\.<(+0U:+(;)]@S?3@^*97+>
MG#-TA42'S1)3;J)$"4MAFO@3@]Z4C:IE;@IG]$E*96(K%F0 6BJL@$?W<['H
M"N+V@;RS7ZKB LWFD8_7I2W)M4X[EZOR.)26'$R #VSH6W2VQ[:!&LM<?]1W
M7SNK?W48IQ\0WWPG#69WD'9C_U*<0-NJ3.0_:I]9(\U7NRB68&00%2GFS_W2
M(CX2W.S<$67&J 2')A9JCS'M@16/;*-!T#UWJ></YN95 @!SV_)(P4B3-#VM
M?7!$2];OPAB!YLY#E\%5%$[_H_./ZNY%CLCZU$YE5W/.)S2BMIBKD1E2=@RI
ME;X2%=-:XQE$%NWL%#]6Q>)'IKVXN&Q+)5"ZF=;U)B9O0ZT>9'_#?KX$0F0>
MI><&JS8WW(B5LJ%#R(Q<?V?<(?".L., 2QR/ +7PP4HOP>8X$SUD<?HQU$OZ
M-AW$C"%\SM*ECS7;'T%%-AH@(ZZ3(^?GSK*Z3MM2]L8T?"76!]RCTQW?/5^#
MB(JN<+T02'KC#R>QTORXY!3\]F&2]B%;^G^O_'[J!SC?T*.EOQ 19G ?/TR*
M SZZ7">9;_]U_L=S0)K*!3V\XWO\// <<3(I?$TY1QVBIZ8M[>N_EJ&ZXK^W
M>!K+$<]GW?7%RSDW5^AT:,M2>&#SR,)G;3G&KT)Y??G">OWFM#\ZIDA^7!UC
MO&2)RM@5V9',@4KHX6'^=Z%/EB*K3U-]GJV:7)8.7?Y#"T<(<5%3S2I0V;>T
MP3B)KK,P_C_ J:HI=:=P.)!U2,F6CU1JO!#!%EO7H:2%%(_["YU_*'7FJ%]G
MPC_K7UK$YV']VDY9G!TGX_P=9T%2 V(%Z#3++U77- HW& B<3IC9V8K;:SL'
M4C6$KNN3\5AH E/(F_4D616,%35-V>788#C+!'0,-G4$=%I*:IT:F.V_:WB4
M()V;6I0V34T',K&<T\)N!RK.@*1B.F>>Y>L N=2L<*-U<:N$O>B1<VR[]>B3
MXN/"D2@"PN&4"\O<L:6B-+O+=X2M>#U3SNEUA?*2LLYO,S+((W8V;DM56QKF
M!.9+-X:U)0X'Q8WCQ-'[DE@%B/CQ79^/RU'_RHZT1G BH\0O;^OH&=@SD8WI
MYJCC.5VA5(I_"/$]H &?+=6 KFQE0S@K1-V)M-:B%TT7.;6,]_4V>2.DL_O5
M<A.(*LBP13GN^O15AH'$= X 6DU""?*"L0:]C# R2;26W\:^L_7%4:M,<)%G
M7Q5-8(VMG7;U\"$/-NKQ-90%5E(R2*T2IK]5816E/&Z]JY*G+[DXNP0G>&L7
M(Z KJY4?FS]L+6X29J&UCH)&4=6/*0AXX*]=5/0SEE:YV"FO67$2>H<]6RZX
M 9]-W?*T]2#R"6BU=-N10]@T3ER<HSQLT4:%J)8!WRL2++Y\7>MLGG3?$M1#
MC$%;FG<GXL)JS\,G#\=A[W.@OQ>(:JH213S6(\':K18EAW1ZG^-#@H],/K7.
MM&?^Q;8I:7>Q';=G?!O*HYDB^- QHI]B-.%O<T";'I,ML,Z?9$%KCG?^#4G$
M%%!B,X^3WO=<66?D1YV#8%V58T/XQ$N&=KF!?Y"?E:(^."23IEJ8=[8M-A(G
M"& OT4^@NHO :LGP5EUS1A-F3N?L5($U.OGK53'_A8C4Y='P^=BSONH4MD/!
MI\9("T0:$88QDS2K5?+.%Q4D*: TW]\J5?J.Y(=UI[CM,Y*POVIYE?DLU[RN
M+%W"Q"B5(N3U'.B3*[U&40I0F V^B-\*<IY6@:'8;^:&YYP,BB37SJ*-U-[?
M*G[XE#T\/74:LE3IF] /F>Z%@ _6(>579H95PZOZF)&;VX1II'831ZI9 ="8
M[O(:L $8_1+^=A9VGY:BYEU3]0^3=#>F_*<M *T0-RGRQU&"1+Q/=M?I.JYZ
ML;N1B[1OY V?09I0^[$,"1*-9>JF"A94I*VV*I(!;T<9Y%B>"[J83&_F-+ZM
MPT04/ZZ@GZ5O )K\7VVP9Y*@,PDMED L)Q:#@0.Q=D'LWV"N"]&H8V K5UDN
MUOC>6W**A.4P:ZNFI+(X^C*J-<[7U4ZFPY-EK04U@T_JS@D8)2-DAQW>#5-7
MX:E:@^OA]$T=AM%\-G7=/_!K%$2Y9\B_!?;3/0<JG&J7AS,9&$Y&4/,)$/A5
M4]30N61*O65=$>%)FG*13HJ4Q')@2T(4JK'AG!R&[M:B,SJ@Z7;RMXA"\Q^V
M]#_,10=45%B8';$.HTX7^+=[D$9%H2WI?/H>[3E@%((XL,CYUV5AZZJ5C9R-
MAA/<O;9]XE]80#7<)(@W.,GUN\[BWP_WEA,U0>ZS+B"[8KF8 G_=I\^L:CJ;
M^**+2^E,G*(A2]NY*?LV63K[JE5OV"$;TFJ53C_GY,/VHLJM!Q@SN'6\^$+G
MEXKW5@U_>;XCM$XM;]RCMY"69U@+S7MO:1B"Q2RG?NJ@5:A9F^I%?9D&'%:6
M[$ATA!4/>]#+C2)CO X-VW KW));N'-_)8?/5B8@)3PTR%FG.K0";8N&%NY8
MO2=#UY(GP[3B[(^<)5*4T07XKC-_4FY](5T)3I(FYN'@^Y 8,2-C3:15KZ'&
MN..Y+S8-3WN@N>AO=AB^#29VAZ>$2@RV'KX8M?F69GL0E)'#'RZCS59J7!CV
MO!WI52DK!TS,M!X6S%O84.2_4_ID-&MPDB%!-#%GT+[WM>_=%&954'5.7J,T
M&"3^8%Y[N(E(HHYB#%"RCUN"R<+3  2*<+GC']@#EP#.XU[,'%KP>6@*7H]P
M)-\[@INJV1$>E)!]^*$LNBN>S"6W>7]8[KO'&&B<W:B5D6XWH-FJV>/S<LWT
MY6_GX_;+%OH#<F6Y$MRVN:/ZB!:(CJ%WN)W?.K"YON1LHP0IIE!H3#5_FGVD
MZE>$\QB'/E.E)Y^441EQ?SSH>1H/;P>]+B8P#AEC[=$[!JC#,D.PDZI2L>BC
MUG8)F&& E3V)=R9\]^_4,.50UM>J!(<#IG=\Y=@9IO)8^Y1*2?5X45%SDLLG
MYG8CIG8+:H(3^&/;0,D+>\S/\SV4EF:WB$RS_8%,@ZQ)<Q5_"])R/%9*R=PK
MP\4"^SG'66TOVX0)A&Z\/Y]P>Q-/.Q1I:JGQ6L)65H31\)9R$J]*VO,?8/?J
M0/_X;SWK]IY)A#5J)3HR1 7P*M917#V:*#[/",NU$%FXDH.Q:6G$Z,#UL(O"
MXVMWY=EMHV>9F:X2ZY/W6RK!K1MUYI]^\! ?P2JK-!2.' :##*"N& VSB4JQ
M-=TR7?"M(7LDM)Z5&/U(/5I(H<\Q3&B20KQT7LJC:LNX=$OXI[E5JX3?^.N&
M$^0Q5>""K*9Q!%FGACL&8&Z9MEXHMR^YZ2=T%D,9,K[^R\]%XNJ1[/?%S[ZO
MH<R)BHT00 >/Q@K5R/*XEJ"^EDE8TDAQYU(TYVP2EQUA1IB>2G.TBEF,.60T
MAR']%.2C&[C8EKJ(^D^[HYP@6^Y$YS7?&"^;?1SW^ FM9D^:?$THKJV)MFY?
M2R@Z+)(E6C=ES RQ(:# @VCW61I>/*3FD&IY>>IZLLYJA*1E91R+29[M&-M+
MLLTY6/8 :^.9],G $ZMI:O"<!E(;F.BH.2:0_O+SWR>+6\HQVK4=O<N,?),_
M>4? O4Z:7OG"_(P']M#R6QEV0"&>[";Q^B&8+!=X+"LR&#ZX-I;K<J)G\T$K
MN)#\%]J@[/RZ#]^<D0SL[C:#3'&Q:BM#627C*]N"H6"]WTFCLQU#^^57^:_7
M)020W^6TYG"[\]L=G,*TI*(_/[P^/6<$,/V;@S,H\ 8W+Z$3&A[<5'@X8X^7
M7E=7?0*/';YB**X)^O+/WUZS'XA$M$FS$V,K'M/=396L'DHL[ V\A$TQY(1Z
M'F54 \N+JP5UYND]5+A I::"$C*^SRM.Y3 1. ?R_"I3VEV%<'LFX2_U2NZ5
MB+TDQ#S1=X3>X%!#VV6^R*)1'F2H:);ALT9$_.FR0ZDE]\5I9%WA(HAJ[JLH
MN3L#/YWLTT0TM*0=%A??I.DB5'>Z:.M+Z</HW15QS%WR^2FI\J,9O_$6>__F
MY\QC'"<;_S?-K:Q,R*E%Z_;3[PP\:&;2)U))U=HL=S[N $KJ(H]G+B8.0?A%
MA.F719.X0E57^4PZ\T=K*?*MU#;KB2"!CCG@43>CB,-*S=%$4T/R..OQ8<U$
M#H^4O26?[D123>>6'V+SH$X$F4,%%__:N-I5>-S"".2#49\<!4K6-9\Z8UG4
MM;\[5O1Q>8%_HD/>\ND2?XP&FD[VZ#[;' BBVB5*8SA[AQ[ FCE^ON]U,,83
M9IB%6GJ&7U*4*&Z6OO]:B*^597"S-PT-HC:<1-?=-JQH38CZYFY;N;JG%G/X
M5_=<PX&>/?V5!3K>G4&O6T7*EA_IF)J=I;^.TN&U2.(<7'4Q&LI*(6!(KZZ-
M1-/84!-?TJ.6 6&C-]:=&XX(=J'\9+$\'W9RQ?P#?:1=F2XW=;#UX" Z,24<
M8<UXHW/&&_O/7(J$72\U)>G46!KMU$8=.:_Y]5_JS.JA522M[45]GX\O,LW3
MC,+82.X$/@WIP?M.\\W]E3'15Q; 7"8#[70-H+U.'D:"Y[!@YVU*X;%A"3\M
M!?+:PL&:++G+MV5'0YTYL;Z"FJ"_<_JLE6'T%KEJW3AI<X)[A_+.7K)--7)$
MP[H6UTY5I(])7,WE\ K?JK!_ A5V>=SF=^YL6=DG@^G'9N6=C*03/<N$6.""
M]*@^#R]9&5>ZP/O:#="J?E)F4T=BJ8:RXBD'25!)U_=W!(<ZSS[^VHZ]P$74
MPW&_JLB(BB*C8^T\K=WU=KJ@O,\O;4Y-Y.S:A@F,BN<82G*QO]CB)*Y+RK :
MYTSAP,X$@B"?H(!.'#)!.O5!\=X3?LT37;'5HZ(L=0<2$%"[\%/<XH(6WG^+
M#Z@L#\U%C3@%;JW$N:WMV72Y,^5RE2V_(^P8%Q $G9\;#34OGK6V-MH@EA94
M>0@(N^9OVZXU9%[)OD4;"_)Y\.7]N$O<L.&.#)C8L)A>]P@_$$*&2-CKR6GY
M9-YZ",B2/E,F-<9]5SPN;F;9B/ZY-O+V2);$V$=!H.3_RN/BP,0GOWVU_&PY
M<[*O"?%N+OZMY\CI%-'-78U 0;IC0ADS).T+(L2+8RAGIU#7_[B,TIAD*_1#
MLD!B=?0RPE '72OZ43:D@)R0$5NI=(*"@)]8UP'L#C(RT-G%M8B86^V-L$"V
M^_?FDR_F798OQ?'ZXD[W;XDY6%D8P.!%B$EL ( >>*K51P]<&D$L)^.J(Q@.
M9R;]U='8PCW$V\"6AI28]$DN79Y[;RKF^.EB6[B&"5-52TC+YI<++I3H2\@,
M)HDTDIK6=*B_1CB>@0-1OAP5B!ODT+11T#8U@E'G4S/S*QTWG;0 ,;( #8T1
M)@T>!6E$/'),)'$S'Z^>*-<2>FK8!XFP7SE2N-)X+^Q(22$"U WYMC+8X4D\
MY YWR3_6&!RF99"TUW&=B8"=:'@::X.:OG\-W^XK1QQW>FC#]*(G&(7M^6K6
MQCS,GZ$"!(H/ZI?N>&!5C>A(9-:7T;,=!@->^]^T<I6)VF;T._["!U#C5 H
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M$ZJTHO[EJD>'PU(8MV?*TKW=>N.Y]KH&4*RX4$D4."80^ZF&WL#79XPF3&5
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M],@[0KI93T#?#OE+#^3>_7M.8,YFLM\(E5[K0D'I4TKLU+J(:>1WG+HOLG^
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MEF1?]C8$.2KF-V$-'C(E^9%4]^%CIJN#< UQJ(0C"P#.767G<RI-L5&%%VL
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MQW+8D;3XYDPR#JL3^;F:+C?A1P0YWCY">F><KJ4FE%:L;F*I/;'UN\K"6(?
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M*'%Q^TZ\40(^@U2 I)VT%WMKS7Z>IGX!M!$VBU_'D!W^V<@:VW-(7VJ]6S:
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MX\)8^PVZ+X>8XV-ZH""6(9$YT)IL!P%1X]D3%LCM$H%2@4[9PQ,O35WBS]7
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MM!^1-J R\OF+93DHH"T2+"J_)!7ZVG&48V);=9!:"^[2KW$*(ZW( =HBG 5
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M[UL1Z*O"1D3J0T*09"'$B0+Z1UC5@A#+Z*"+.&PSR1 D*1 ,O],,++%9K!6
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M#0@>W_7%M?*P[6.GY'K6&_(GFEFGOW,"1TU:D >0!B<[=RQH #A@/5J$T+U
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MKO( I>6_U</N-$%BGP&3D%@H(46YXNB,BG_%(/7@J^#"B0R8R>;,:HNDC1J
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MW%5#%#5WX4"VN%W1;GX\B(LP\-][###Q:&7,9KK(#+S.^.8:.LT+BX)B-G!
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MD@BC*BXT(ACJOJ2_7Y6I8</5LT=PV[QWQ6SJ,4@5^8]>89M67R*O^9.!UW;
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M8@3DC/#J;Y&Y*IX$&+Q!_P$ H'_3 6GF[X,[//_DB? %(9@<\G%_ <PQR'\
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MI28'(=ZE>M6HM.@4XC,XG]=8AT!.'DW"<TLR2@_E=RK+*NZ&4 'M6H)TCQD
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M&BNJ[/NULP*3=\R<+P:$R7IC/-\4#_$BVIIQ>J-^Y/)+^V5CX[:_@*)K_]D
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MH6-P=G=372)4><@O0#,_5%<3M:?!H!3.VUW<H1;'?@_N&/3>\M6I'HN?:*_
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MSB-;3J?*=W.P.'2-0S(>'EO0)@!T#4MTS4BWAYR>][/SL*F2W,/1-ST,3\G
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MV>MQK-0/MB,J'IB_H>IC>#-L;D!]?7KJ!ZCI%>NC4;K;#"85ISG:8/XQ,"Y
M^8;@->88>BF6WAE]DE"@D00?"& '  5QZKDA9("M7*SV(3B[NX..>BQ82=G3
M" LWX->+?K9I7(;B!/YXS[1LICGL9_1WWYM_L=%>1@HY;>_8&N%^9-_Q<N9I
MJ0L']^M2X9OA4]]%ME9TB_CT*PX")=B.[C_QN2NGQAP@T<[R@Y1JUI\QRF$4
M[M<H[AFN"HT99/WQW)1AKLS(ATX_:MB]'W_'#;I)F>]S7@KZ!=#?79D-S<NM
M$"$RJ7/Y0%](W&[\OKM)E,R&<&D4^WR[E)\K*?(+>,P"]ZK<9'_/'M*]IZ$6
MKG=J(/9FOH+P.][ R>0Z(\F4CODHD8 RT;7>_NH;-&5P9HP^VD\M5_,4B\C%
MJV:CM4.2O(&VUM/"[% [/T8:?B3R'4Y-2+)!%&S4#4S<MJJJ1Z\*KIV3%G9C
MU3=Z@%H(![\F<>\V>(;-N=&S_KYK;P'7\*CQ+9UU,N9A>^,2ER/RW/ZDMR]P
M_NG,T_AWM\(?O/HB4ZF3J^@*,U>6M_KI_-B;J7OE(R\U(2U?E$;IOJ&')Y31
M:H$L'+4^1'PFO'HCM.3UA^Q!=RS)^,Z4HUH-* M.SG^RH'*+O/2^)$JRZY[7
MNO.5SGOD-I6O%CILTTUD5JXA*\J:1Q]:3.\,<DJ[QR.@C;:B'<C,:7.SW9?^
M-H?8#C*GY#C7+ANDT\%V3'(.IR2X@ B3(V@VBI0JHTB->L^SEL#=9=>*,RM#
MA#%1B^@]&.??/G3U,8 DUWVY;Z+HK2TZ&Y#^ ,_=I^=@F-B27"&J=FDS5MK&
MH3]&F!&1P!ID@(1[X/7]N)&3SB[!/!3QK<%UQ-2K )*T&P1I?1/<OT/1HWVA
MA\@&_5X)@KM_3D>\[.L:/":OR_D$O"RQFU?_P+Z6\6<I ,EF?EF>35' I+-W
M2BI=RS#?G[_X,&B10RWP-8)@G*OH86"N%$+4@.X/AQEG#Y6AE7:.=(6L'(+C
M2Z^RJV]->>MQ@+:N27_KV?=]TP-S[_,Z:-4QNZ+!DNK6K\U1)]08>Y-)N1CA
MPLS3+7*,FTS45(-VWPC;DL@HT--YG+/A<X]EDR*/.0 '5PZ'HJ;JKKR.PKAT
M.%]1O0Q=:4&8<CHLC50@/P2_7[^3"?V^P$Y[GT]/LT4U>S@\J7SUXOC<E<&Y
M1)O<H,;<O<]T]M[+/9:BW6N0%R7D[#W-;QEK(IVC5#-:G[?0AA$A2WN_@$X/
M7"8/34S^D7+6YWCD@Q%<?L,FAP&'$0W1K"_#HRNS#=8WR(YSN7:C8X.8'2@P
MRWWB^-T7#PVF+Z[<>$]]:+5C[D"U)3H"V*$H#,)@GL'^QD@^#G3RHZB6GT,C
M3\(_XCC>6XE4CW\9WU*4PJ<(9=VT%3 /B\(#/MS4):\:/F/\\%6&ZG%9;UB1
MC\2N\/![\Y7,ZC_\R._T>7( 4ZY*Q-0L&KX4?7J'F]%SXNBSX0FOO;2%*S+W
M/A);(@?\:%7,#;.NB=1R*>1=HVYNX"'49H/VG=-J8Z?W=RL/3A3R6:?J,$?;
M;VRM+EW77%T&SCZ^:O'Z^V(,_;GB6O0/ZA>PVQ6$EI+TLSW0SD55M=);N9U;
M5YL=2REJ^LE_5_=I$J=55F3,-Z6WUQ[[>.K9?>'[ @L))M%[[R\YOZ#N%*EJ
MEDTZ(J?GRF&ZH%5*<SQEEI)C"2E8'Z,IYS-S%?9-NANKU^5ZDMZO#^ XQW8&
MXI@,KWR.>IITVG;_[=E)8QQ5T=?UZ3MXM;CF9]\9R JU=9"&3;K&\9JI#.'<
MAPG'%U%XQ<9C9;*FB-J ,K912OT2<UV*K,,-9(_<I9=4-/%?[P2=?<GG/AIQ
MM#$._P4H;C/E?E4_\P+,46&>.%P,\I^0FP]>4@Y&^L.+)%R-LTOTD/E,(UO]
MXP/CQJYMU:*G,XPG! Y>&GU75(5>I?T24Y__R)2!<7.9(9?1U2V#OJ5'8#FA
M_8+"\X^Q]^K?GQ;XTYGF7UH14:TSV_<"944<R&*& >B JH?(=*V495I?=^K#
MH2DH?Z9M48\0J-R/=O;SX_:OH /=.$0/7O+")Q/=?56[*^"S>G=4! ^LU%G6
M%&Z]^06X/ST29PL9/652SB36SLX?\>EX*TWT1&?=]G ]D^6G_ZB Q(=+SU85
M+,]C\&78.T]S>^HBR;M4\A-L0Z%(', .-DB&I6=)9O@VR =I_'X4 "SZ*8=&
M]^D,\F05I$3%2WFC(!\]DCXYWG&+TI_XP0H8079%7_P" J(@OP"9]>W?_= J
MN?SEWJI L%97,.2)V[7\H[>_7=KF!7Q_^KJ"4 >Z$1U? '2P+D4D"1L(*WB)
MN/)2;U(,4/AX6F8DTLP3Y="$RLH25 5/RFY@4&SD-I%1?I3-H%ZT$#V *$X2
M\I'3(7H*TB9363AMYZZ5@9&/29AN:=@-6OM,<(&C:([\060.IOH"?8N?#67U
MKY\N+/\/4$L#!!0    ( ,> 65(!!V=T)%8  /A7   4    ;6=N>"TR,#(P
M,3(S,5]G,RYJ<&>LNW-T94WW+KIBV[9MIV/;[H[1L9UT.K:=CFV[8YL=V^JX
MXYST^WZ_[YQS_[OCWMJU]WA&U:SY3%35JK7&VN]+[UL LHR$M 0  @H )A\?
MX/T,0!%S,?[J 8  X   \'\T70"4PB9V1J: 2?='"P@8@ $.!@F+  #H)0!
M@P8 @H( H'G_O@H$ I#@X. 0X) 0$) PD!]?.&A(2&@X>%A8.%A8>&3X?PHR
M/"(2,A(B/!H:.CH:&CX>'AX^T7\+"!04% (\ C8R,C8N!@H&+M'_V_+>"Z!
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M08!*L0]5_Q#;XV>+]FGFF%%1BCB:4#$/,^;>&;P#B7?,$*#$HVI,<W_7/)'
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M#!#^9?I+LY!Z5+4;P>&DE&58Q51TXR1-LI#);8][K<ME$O*K2"6C3EE%KJY
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M%C*S2N O&+Z%U#=OU!0] $40:T VZ&6Y+5E5X3'6IWG8;(W^-"V]?"\_>-$
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M%1<OR7Y/A7\9F5[G\V_M\G8CH_P>8>9AO1]^?Y\F/TOT?U+GR;E\*OL.W?\
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MH:,Y?Y[V/#4U+0,M+1T]N%#3,#(QT#.>K9\=Y&SWL[W ;_KSU.?I_S\OI%:
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M&PW?+0,,VQ.O(=I+_%)S MBST/Z.[/]=8*'_OR+[U\#^+:Y)@)Z"#)P\"F8
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M.)JL3%7VYZ/P]5]P4PM:NRV(:+S^[3_A!^93D"S#7%SC? <)N*4>@<+8R9
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MI&ZV$'/)WC;\H7R2(]GH]T -7',N_OJG/6DMY$S#,M3LT\C ODW'[]F \?1
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MA6X<UVI-N(D+) 5$_FY*NN/F8-O+?X*6/I#5YG)4ZP\N/\:K"1K;^=8_ L5
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MJ#\3B.VH/\F?O(9H".#IB<OH:1D/LX@I[4_-GN;L*WB98'3B5NB9[WQA>G)
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M2[^S]HETEQ;9M]J_^4L[3#"!Y=Z[T;\XI+FT:IV?6MR5HV93T-)63C;L_E)
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MN=2K47-#%ZKJ_]PUIA"HAUCMP=U(0)L :K:0<V6KE+%Y#L5A;J8Z'\\XU1/
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M)[YVJ.T# DPM6+ZDM9BW*$[G0?1 $'\\H\J07ZG^R_^+'TB\](HGC#P[-,N
M+(J&*[10.41;M518&.@M%2FY(7J?0_JZRJM6L!ST%H5?_79#I/7ID*ZRX;+&
MNG!> J-RLFZN&B4K\%'2:3_JAH@C4%S26@3ZB)]_/Q=G"6?$&_VAP=9EE8I<
M=2WB<;O3'6P*.>J5CE85496V9T[673UUEKMD-IH:!J4/E6?6K92898I"S4%Q
M\.+JVVN;RM7IV6NO4)ELL-@7J7N&T3'OX"JKN>*.I;Q(&T)LDP,A''O-55Q]
MBJJ6S/@<=KDG#8[W]3M)M%$QQ8LA^^?@+&;.#TE 1=47S?$9%XKXGD+O>9'3
M!V[< R7HQ<S$HPHVQAS$I=+'E&B&915/SOXK3/,F'-2[TM*!3@?_T6<"*2$7
M-Q)QMAWI)RF_=C==_[PXMW#5Z%VP;%<@=U" 8&& =.= B\L;)^YX[$TYH3UD
M.<K%G07Q",_5$&[Y++, .RDNOW!GB@1PWX-Q'E]K"1,J=G8+FEGT^YJJ-:#^
M25^5;9/'\>P/L'8'\9>8>G(PD<$],A;^O75Z%YW3&H*'CMX:QW8$0[X .8&^
MR%Z<812!'*P@RWXU.3A3?UH9CF:T(/ST@ O4CVKCK1Z".D%Q>HQ6HD%3B.)5
MC_'@8RF1$%.QA;6'K6^EO<ZU#OC3=V9*]Y9Y%*JX991Y(%EC[,K.+OC\%ADX
MNX?Q+ZK^P5=:SX?MJ<[2Y1/W/PGJF*O^GGGPMZIGG:SEU6)9),BRV0N4S&O3
M5K'\/)<H%MR':&L&';GUO/LIMQMJ_W4[ZLJ<KDLEQK0;SAXH/[SX&4,"HO!:
MN>8#(N^W]@FZ 6;9]\C316/(GK"I^<^I%[XT;Z%<N+$=8UVK;D+-6F)\&&LU
M02BA0CBA(F8.;ZTC3DS%/$%S+C:ZU%V!D!Y%CUA-6VD,#TA5VIS=KGD;SY^D
MR;^K6?RAM?+$<RDJWC;.8#GY:2(C,?4T'*P5R2.H6K"F9_)05MOO=J'ERP5>
M_9B>3)T=W(!'"'^I[&DG 5QX]]F!2]PRZMCTJ)H*^2G?5!>',BME>LN,:E=5
MC_SKFK)<27K^NWLQ#69]HN_L^NUS9L?77]CANEZ7K @$E 6KKPX4XZ_,Y*K*
MOVT1<AZ^S_2]-%\M1KU*\EVP6G/9G/IF#H:)2)-<#(N2UK&8G#$QRQ"OFJ<K
M2-IS^F97%\GJI<S'?-5+EC]F?#$@>!C.7/G8<1%[%%L0BRXK<TE7->/Y$$N
MIJ/0V[6-:^)(<3?Q[2*YET4)O7PY!CW)N/$<A?PKYEY/;C+T?-2$D@#XK8]R
MKSFSEO.U;+9^GV01:4'.HKR8?MB'%:N,GL.Y@?*8;-6;PS7_G6N600YE\-"U
MT!>OZ,[9?+AUL=\5GGY5.S.66MH>G.ZMQY_0F/U1T0>]/';.(V4R!@%5JW*E
M#PV-/42-.*1_/E4"&5D"!QW'9Q1'HC:V.TC @WQD#WM: Y(9;X]]$U-3*D6
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MY/O-_$7I\<&8HUN>X&[0_K'2SDUYNC\#C2;NE"B7=):<]F]HP0,?Y^5V5&F
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M;ZKO)$]\RW7PYGAB\7AX_]0\]KM_5$06M3O45IU.IU+*..IK.M8A&Y$! <I
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M5P]A.RXXH?T04C]&ZX_?P+QH16UAM34R080 7^W</B.X4*,WY8Q87[:VCT9
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MU6W5;WN?!<"!J5Y"'X)"C!2Q8DF\ K=H#\@ 4-^/U9&OOB5'!M#P-4EC9'@
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M44?HZ^NXY5DLUATJPYBT''"JH](N>2,Y'C5LC6O[ER'FU_M_ S /_84=(&T
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MOH^0"TRC5O[R\9I]8W537B&=@%-FWCFC>7*&#F8F.MN]%ME7(A1XE]5X-Y$
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MPM;#RA7%=!WF#QAT5%[Z-SL1"IMY0?0>2:XW9<2M<JH=J=*Y,\:(@,<7"2?
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ML8=-URI-!TT8R[6AB/NU&9IF3B%G3"MOOV294(K,_39GUCNTDEG-@9MF4+?
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M.6FI%1X:YN]EEO;F:1OP%'1]<LLH=\+3W30FE/D(Y^PF=_XJL/.Z-<9LR/?
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MU5+C*8QZAJH[Y@H%VUJH!O2+A0 (KIA,1RDI[JZ!8!+L/RB0)S\?:+;=7_4
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M5B%XKG! @5GH$#JF0D\&(WF))2)I8&+JVN:U#PF[+9[&9/>D36!Q.3@$Q'"
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M3R&&+3;<I9X/,)Z54E!W8S5>TF UWC9^#LFT1)-!U_*ZERX)9I-DULT4]#X
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M-=?Q.RAYU/[MD"^G"5&A4W9,"<[[&"6\\HC!?H,TRK9%2FD:=.60ZO(%E]3
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MAH&Z,A+6I4G5T9YR_\+<DQQ^V"DE3/;6./PV?6M^\+EC5>4K^"@>F/W@/E-
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M&3#[=3P2O1V@#L-!3Y6&YNRR6%UGA43ACH1>AG8B168!Y*+V!T<T0[\'W=6
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MD"1MFE[3>/P;8T7J>D*M^HM.YUJ=OYV_#@[9]ZH\[KG7AD,!35GHFNY0RBH
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M)]AQK49[*YD%]R/>>-N)C\RN^S5DAUSN7+N6J*WV.R(J"A#Z*\#+$W\ HZ*
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ML A _>BU8JX,Z-2B=C38[Q_$>KTV.5/@/DY)[].5NU9K>^#CD^2*P%_7 #A
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MA&\ J,R[^08>0*YN!UNHX8!,!XUP?#;-V5OWX5E/]Y%?A\W<SZJ-;M^]-^^
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M%P0=?1KD5\HG4L(7M4EJDN^JQ/0&HB* D]/1@F9+:)&XBHD-%$@H!88<62;
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MS^1 S=D>P(C$=,* &A0\FOH&O6?%"CFCEU4,>_E]\ME9O#&3H_$MWVG?IH"
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M==4\6Y;U_162PI3>=-AX1N&LG,L@U?C3VK?]VC]'*.FWC/;=^/#"_<;1(^:
M9(W+[WDX$6T\RJMH;8S!@@XLD^:MO;K=V\/]S@Z4CM73:RO2+_^P5/7;N/W#
M%I[/GW#34*&TL^H=^(RI/F_<8A'W"RDZVV!5WQ567-QRO1?2(]/[(C .Y #"
M<#@])P5&L]ZU%6 PS<FI""LP^\CLD+'8:PO1$N)A.SOQ[P>4MY]2CH>P&-HH
M==6*U(CAB(RO(Z;+%LC'R->M0=/^8^ H4[1M?!.3U.CGB@*M#LE_$ZM4M&\5
M;V?OKKY']]YX<)3\Q/:P<FA"JM"1HN5)2*S^CSH4# A*BQ>AK/U3@AQ%$IT
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M8F5/]$%PN0FMQ3+(8JERK-W71)TJUH"O5FESK7IMI#K7K7C6#;=V7,36Q9T
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MY8SA[_-;:.55<5M3S\R%B+Q\\6A*TXY,M 9-\B!155XAH#-7R%RTQ7A6>I5
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MTO.\.:*^9AS;+/34&]22RU91KWL1.CLUOOT _.=E*W7+7(KM,Q2?\ !\R'H
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M@K"M<EHKNM]\_GEYTWTRX 7C*<WV,EK1-<2S.+ 2/MQ23$(IZ^.&D9VOX']
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M9_+NX)QB2B,^'OK+- (Y_LUK?:4G4I,Y)3TJ89I.*PY7D]2XRF\Q6IF#4QZ
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MX?BK:D3IX2X-0P>RE:,<=Z #EAP]\"8#]5R_-,HZ- V46 -S6 TG?ZPI@E+
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MQ80#SV23"?8/.4(9;-Z_'VD[9A"G6?_"ZALM;]&)8_\FZDTHB<5W=:QW]*0
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MF#D*@Z$NCG3O^K(*<<GMUYWS]EULU"QJKJL"LQU8_14,Y_LAM,:L% *^DO8
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M0$A6@$\-PB_%)R#%M]T)@8$V"OW'/#[(?]_X^ 4$A81%0#/$P0/J=H'F"PB
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MMSP.^F? ZU#OE.[7ONU+MF]F/'E\V,OTY59KKW=U2K?69$$,=8Q_3V8!A!O
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MT*!;(S\WLZS[-'E#!<L'[N[7"*?2'Z:;]0LVVE0M$O)[]OI5<BXQ\U>QU'7
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M>V^[)>E2X^V^!HTWU]J</D$VO+/^<*0;6&:Y[3 )CN)S(+BK20,F_,Y EZ>
M#"%)1W\P:+&0^S+UJDQR;/+KMR*?VK/WYF,S'9JL"B]4W%*P@\1#5YEL,<Q7
M; WL-L>+P:;V=PQ$HY@B[BW#O+UDH(#EX[[1^2?6IJ*S86/&J*Y[,\@GZY=0
M$)^-/_X B+Q2,)[H/+40*PY<0A\:W80+ [#.H;C4-JQD-%EQV6Q6:<#DJ,],
MY>6AUT]>'@G5"LSJZ$X)-7WYTV2S1)9O@[Q6"H::P$TF45[,:C#&,N 1L*0Q
MGGXKX^9)XFX=>E;XZ8S3AYLL<7O<S1YT:_C+>CXHNZ9F^W0_/^X^B9)-?@_O
M)$WF'^/6<:XS"GV'K0_$A5DX_C;8[<PTZM2Y&I3WQ5WCA!=3==KHI^M=QX '
M1-HJ8O#\&3[D(8X[&&8XKV,;(F^)8@KT>/CN9"JDO@8:(O+ /QFO"P%C9P=U
MT?Y*>33>[&C ??M+OU*S^1UIH<=K4!%<*SM(W'HG.+U9CD 96^<X6RH.3U6;
M0A],0J1W62I2^Z+8#O6F5>\#DPO:XP)NZ H<KMFUEC.5IE4+,F+<.)D5RTTF
M[IKD"()S4QE+[1<9[]=MPB1?IV4YGTL9*'FTD/O9[(^,\<E!)_5'QV1K<NQ/
MAP_]>"Z&V<=@W:&M"?]I)^I\7]VT,G"MRQD[.Q0M'E PNRPJ6]ZE$276=#BG
MY,(NV[WI?RW:X(P3R/%<REA:M$\"*W#86INC5CM6V3?:2"4GX^7KGBF?;'V<
MB3)],!U_=<\E@5VXD-W>8ENL= B5)X#I T4!*/^PXMZ ,Z4G,=<Y]4QK^(S?
MU@(K88I[<>VV>U-K:V.\OH'VP;>O/>=BV]]\@P@LZ,  LU*>J$D@#:NRLL@*
M+7*&W:O0 7 =,$;^<G:HL*=97H&R8Z7\$0UA)\L&&R7)U7V& NEL]W3(WP[P
M&"?4N'8;ONIG*9L?0%*%"<&,C N-\750X2ZF#-+PDR_"](1,(=W\Q"_TFK2C
M>I!&=8[+I648XP06T$HI9Q^X@.EH2OWHXHM,5@IJV>K#)>(ZR5+< IV>H* K
M'6<VQ-9CKRKZ[XX-%E-,@[L/V,#VHP/!(M@'"@LC; CBKC4_(,HLIFA5T6 B
MG$-#!3T?"R3_=&Y#I./-71K%FF4KGRLRWMQ[?:Q+2DXVF<\!R0X&SSQ$\D>"
MTIA2F<109Q4#5Q-H*NKM8X;3<==XB%VSDJ?;W6P5HUL//YG3ORVRH<+Y*AQ1
M70Y]OO\Y-*?%"*Q\4/LD^L4YT!')\%!)*"MA>!^01/GTPD>A.Y0)1?K8%AGM
MD_%V;.A8N]90L/SKM,JS'?::<N=O;#5PI)$L\3%XQ"<LY?D6OMTJD&?HY1//
MFC5!WIO<<A;]I43N=90';-[_E1C8?<)/+?.+AV#ZECD89RTDL,^#(WU_@W6/
MB5ISJL#T% B7@:I!^7.\P3VM$8)^9<1\P>JAIB>Z<P^GNG23)S+3=E_JK'[D
MY[1""D0!FO!51?9NSDXF:I7*4*98M>*3T#=R>VAKRIXC49LGAJEYIFG4![/.
M^WZU- 2.OS+XZB24IOTC'1PNZW=@#'LRH$U8G6 $=VU#(-:[T'M&;O2+QRVT
MKR#&5K%4RU%?Y/OI!U%Z>C\ER<^")3X@#??&<68R%A0F#:=!>LY H"9 M)F@
M1"*H^:NQC&\;[=:P41.C-^207W$-;L//PVN4[(?4D#.GU6(<Z>X'&J[8?8M)
M9X%3]0Y#9+6# :=B>^"JO$%K$89>76HF4>OUXR*347\-XDMC0$G<._%*L_HU
MDK[9)9D<H?B>M4TP/37<>W#*:U^506/8))LR=Y/#4\UQ^&Y2J'<L09D--4(]
M3K/<^<[_5GF3V?3=VU.Q$(?OM6=$\C"?X56I(*CN0A_!IL!J2(D+0Q&5VIZ;
M.FO.;A^&#385$P4]]?4KGRT\?+O?S77JK/VPFZ_.\*NLP*R7?A\//SA9)<)0
MS]Z4!2_UY>(81\J )UI'@TVF82,C@RFD-&W@74&FQV<ZB%6T.Y@:.^D.Q9TF
M>_G?G:P2% C.,_5'R?U>J* :2 *I[;'60DS]+.'R8G)H_^4WH5MON6\M>H,S
MNYFG-&<6=5X<;-OX(/-T;C0+''G!R5A*&I*!0(HY4!$[>QC]WL.<?12XM L-
M*H@^,M82^H8,7#\^/!\4TYB$* JZ]V#PY)?[JL:'/[EY7"4<YWX 6^ IMHK,
MD0UOFS1()(43[J;1'"W-RL!9#O6=6LXW-2N(6)4]FD(;=9QSN_)6T2PR\I[C
MEP/(*R]O6_MP2["43#S#97URA3IVARB/OL5]YC_Z&YMZSMN)>LG2[DW;=85)
ME8 F&>^N*S4SBG-G-2J,FC]K>5?%Z/HS4!PID/=D,>BL L8V9"V:L<(Z/\"!
MTU'B2XR+(6/FFILC%4^/[>@\>W+TZA>]^4=G;3943?W<?-*BW6'GSMK CG#4
MP29TYK5A^4EAK5ZL&<"'@?,<(AX(7[L6W2_?RU1&-N6>D:FN+;,T(EL>+CYL
M'W-83MCXH[*'ZB8=(;)D;<48&;N[.=7J*N[UB>6BGU7I$]IP$#[^H3;O:+'U
MC^5P5[#K,ECFX")'L6T6I$O0/4B.'?>!M6C8K-A(] 7_#/<$^#W>W@^)?Z4R
M]A;-+O <@R8][\VF*A>JG#Y'(W&D0&W3QBQFE>-89&;#ZA]+I-S+IOHFA%)<
M;/?6;-8-[3N"5UT:$*TI1GOM=GA7+IY-T3U"* 5);"XI@@"H(3@RI:PUH.<U
MYCM9U7HGTN#^C0^7D]$>5+R,[Y)'P]EVPUU%SJ'G^@(@![]@;\H*[92%6#EW
MP=_#5^_0$1/ZBZS=3(./?0=7J#XSN(DHR_V_3DGU/&,E&3Z&%T5);$.(9JK!
M3P._)O?FC*S\/B.2R)$&'0WD=<%!WK/:5X'Y!,+JD9HXD<X"YZ6;O%S"BEG!
MT_S14_?Q0:$_2^)=-:2=YKLSRZ1B0MJ-I-%P)U"D1)(HN#S2CI> "@TQ@7=E
M0E,C38K+EO(F%SM5(N>&2G34JKV<5&@F+2X+S4ZR@>X>.WZ)A!0'L-_^FR*L
MN_^2B6F#UR$_8H5X7_&UL'85_TZ>$(!6VX;<1=BT AF$EQ=W4T/48G,LYG/F
M![7C!A9"%:6>G+_M2 @%L(S4-I@X478)'']H.=7R2"I7QTDIZ)E<S[WURJCG
M]>?'WQAH/_EYK?QV9<#LA]WJ BH@:_V% ]DOH ;GR#A3%.X2->*4*=N0C\]0
MQP:)!B$])X'<\'"F0V<6MSGLHOT!'>N77T4W@EQ_N'U!')0_H%-^$[GJQ>;G
M?0&[#YX*ZC-1;  LY0]&AC%;4O;,?L4AO^MB4>F.IOUO!KL-?@;_<C[X!F40
M$OG644.,9?[__C-4_Y?GJ;IQ,' F7N=<IJ" H_ .. 1M5T:^@)88K=4&;I7T
MQBCJ$C9C27D*HVK?Y-K#1JM#4[Q7107[QL>6\M?FF<W=)$%2L(\M$2KNA%&/
M:]\BM^,E=-<#IF2)>X=W=T1J/-W3$261GWM)>F_M8PI=#A@#Y;L*N* 9*02L
M-L&_P%4FP8E;V*)##2$%S9A*FM*1C,5.]C/_<\V#07%JA[_B2B[F9^O?C94T
M>^QY:FRG[?17"#P.C:63)-&'&*?+F3+='F:'ELSU,O,+'K(*;ORY9B<8YCE]
MG-\2ERSXX.UIOB,THL,("'54!* ^F\^HI]-52&N/2I<ORA45LW0^WT!)A(U=
MG_I\[]M?/5IMJ'_&GP'<T8?VGHG"!K^&88S3!E.C_3PQ"]#4B'INL8')_M?,
M_0"V+&36(FW'S,ZZT!"F=\U^=A'J\[7R"7UI$HQ$R2I0S=#F*!]@7PL;#)7O
M7@YO'E]H.F3P1.UXR<1GZ1I_#?7FZJ3V?+]#3L^A$^0,),,7"FC\:8.+QWGT
MJ![A$FI?#W "0R.CBY<OZJ>]63[3(TO-M)^OT)MCRQQRL/;F>>/5.21U_UGB
M8<P(J29U]2]#'CN91-?N]A&W!;"HTHX$L![=1BCAGL\?'TA^<>##MX!IXL5N
M1?P5,5$U4A'AGKEIMO^_.XYQ2JS>D_4IX?T9,MZ^+K)B%98=G4IWCSGL#<3W
M9LE<70P[^!OB7LJ1WS@+Y+\!4[8'2RFX>'[(NY?B3!)=$NCR]8?5M/X*V7*]
M( H]Q7U6I]>X"OO^7>1GZ4<"L+]T-9]]G',>SM\B2><ZGV:V??<;TVM1H2-V
M+&-41PR,/QM5LV:GSC4D.C\^LK?%-O'!\<B]Z0N8O=@VY+^Y!!>SM@S'U\ Z
MUR=C$>",P*$ME(D5U K_$\.1BS95HAZ7$Z[4*$H]Z%0/,OJ;?:\A_PP6Y&64
MQECR+ETL90XY[H=,>GV99F#FY(RO%EA0,=G\G+-Z=,]?K>^S(MN02Y_/$WY7
M&)P'D6OR,F]H*/(GIH\26$3N3T9^>836B/G4"-.1>"KUJ0^">8/IA#%<">/E
M/#&3ET"2%Q>',3E.>T%U_K%F:1>LGQU?.C/NM/>Z8L[LK]TE.WC>A<BH0?^K
M3XOY/L7A>>)68-U0&<_Z,TM: ?;5A%=HBY%+@YQ8V@RTK8!8_"+$K,9IW@%U
MO6QRTBE<^<FAU#^/W0,ESC^ +BAPE.G/?8!FGK@DB&H[@5O^!.\EIW?AQ'UU
M7KTR:7H^'%NLTJEGAY86I%N/5OJS5+A9I##473+# 3_9P!.-9?RA@"=VP62!
M?EKRMV<4,BQ.Z><H5F)Y,0@??F7Q3%$(_?9%JZ>O;?>Z2QMF1MVX<AOV 523
M:\%L2\P$%AH,$-A&Z%-US.#4BDVMH?D1W;7@='BMKN&I,Z+%]JB9?IDH2-G.
M0S?I]'7 H&=UBME+1[7#^9>PU8CN_GNJPD!^)=!\KF8PJD6.GN7@HO2DCE'4
M^K;+CVEKWCU[8RNPY7+Z?&P.5!M^#*PK'7@@[![^_3I'9HR*7"UE!G=GA_/4
M&:@47F]YF.E@RX,TWWC0KE,4([L=#VWNWGF8?'KDAS$V7/@L<X45X-JA3<>\
MN%-$8AX#JF];2X$Y=<%22JS-N#5P?ZPTIA\)LU9;)JH!:8QB'^NH,IK>2>=R
MKH-#:W#>K&?@D\Q<RW-Z7S5R8M0^BLZ) 0X\\3&V'V9<J6%MA=%+\^B 3I)H
M'G>M81R7T=(A2VTJ"%]Q(/4^65=X;&C3>,B.U1N:[?-ST6OE8:%B>/R: R/@
M-W;W-B00.YG+$^T!C]:?Y6AQTR_E.P]L0\(J%%PS3C;72U0M7<2\S;$NN5%H
M>V8K<EJ:K!%'.W+YW!VMT&T((QI[VU*=@6?1N?>)\H" ?<;I[RUFU P7 [LA
M*CMO-&_K6<N93N*7>\6,Y] 9;!I>&1X,&\^GLC)03+.>ZI!ZI?OEJKG4<O$G
MA+I;YRZ0GJ0Y.SLJ]+>0/O@Y2=E76_/1!>X'L\"%$G-X/=@Z?%>_'*:?M,-:
MVX> XTB_X)RE(&7C_,]^WTS8_:U_MM#%?D=@W#8D7M5'[F%\]ES6"CX33J'W
M[^9US$J!BF+B'3J!L9B!MF-B$<"](;0$@YS"\6W2?#76?_V29O[YYI!7OW3S
M JI[NXDQU]0/2F22#'C=)$;U<S!/GZPU.IBHKBWA&IH_XZ^"#Y%1<C>O(![/
MDWJF47NH1Z/ZPX5[4H'3-<9VC_=IGA?8Q+% H9_XDM>)K?9(KR,(< *!FK@F
M4HJQ["C'ZS*5)+I\<[I(=4AE1'[C#.];_5//$\Z5$EWBPM//*QUS:02.G Q+
M'-!A6\1YL>J!-/:)I5&RI&7(EZ(]S+J\)PFW2J>;A764G<,%$Q4L-)0UQZ>*
MLZ\V[H9^Q@'['#+0DDP23PR$5B$Q;CHV2OD&D6G0[1+TBWQFH"X\+]UY1=EB
M[>(HZYO(EP]30K^%! /DTG>MW%%UP((EH(SIP];$KOZ[#<]>(M5 5XLCY4A)
M+<K,L/;!V;[H/%+.[-(B\4.C4TELT 9ZZ6EUE5"L/P0"$?E1"E+\2C+C-&X/
M;[!H)S?;4I&-"%4J[82I_M@5;JWX/2)"G]Q?6]2[QE ,VO77?= IG#V?$NPD
M]NCOM1^*>%GP9/Q[A7:84ES/1]Y!8" A&M[QY%(&S;J$VB\<MD4LI![5NI;]
MNN26?[A>7:&"1$G  ]G]4^UK1S8(@-:?53>V)6#&$^UCB-!1'80)=KL1VG7
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MB_V6\7#DI8U]!M%BY?JQTI3K>^Y@3G)K2)1T_'M!^'M"-WE\BH5F8IXQ"!Y
M&UU%X6)K,W%,WT MU>?#\*,;CP/O/)M4]LHH2;CA!@F<KJ3O/KMAP)&R8+5P
MF[<AP0; _GH<6"Y/P:03. :XLTS474N^M]N0]@K@"?9(SJ\>.U%9<(Q_C$&&
M#KU^FJR%G>W1?-L]]\!]+W3JRU\#GCA.N/@56"UZ1"..,Z,AH\7N>5QJ.T:P
M=;C%J@+P[QQK\AEY-IR@&"!]T5G9[*"U^R?UO9F&(B/P /S4!LN,V_S.TK8,
M\XE4NS.9_J9%[XU>'HG[X)=PS:.&"-T<M:HLEO7G\[OGQJ<4ZY_&IW(4G'EG
MN&P0O28,AK&_^6Q@^[!MI219SE7F<9YH!QTQF<3* !J9XCW6ZD-$S>4F= 'A
M'AI1OE+34VI;&EJCNVNR-C=J7\FCV^E&Z@I[@^\@7?X]U-$!8SB$(U(*<%V%
M\"EGY^$;MPXNZ:VG/*+VN2\LF$9<YGW->^V_2_=%R<1\N;G.H> S&#]P/!\B
MS<NJ[M^&5%/+MR%+-4Z$?BRP+P;WR@4,)Z@9$U/"KBW%]%WC25R8I#YWG9<Y
MU7K#=?RS6.=[E32-ZS:P@?X.^"2.%0]TL"W'>:/(G3R#D/QMB.2FI+2++W1W
MW5AV0-[9E(V@1Z\G+TG]O28J>.>B:=9(^Z.]\6;M.$!GD2.S2(=WP\31H@Q4
MC_)C2SMZGV$=#-)%@^T(FW1I2-<3<"3&/+N>$"YKEGX*4=N]^%7@P(==X4SK
M/[Y R;^,/6HZ@84NMGCIX--D)H&RM6>I^24-]RJ=)!Q.@-+BP!Z!EJ2VO;P"
M7CNR!EP,SQ,39<MC>F -L3CC6^8K/H >94;D-"/O;='>G&]ZVI[USL[V54^D
M3SAY&E!L]US;Z?WZ^XGF"P*_[=.9*"%LFQWV\C;D'GX/.H%M"IBQ'C.Z%K.(
MNR_T)]#[H&N1RB$LQJX&:2?U-VEY\I=J9&-^74C.O4RKA0>@IDI9CMP6M'(9
ML UAV0&+Q0#YY$"=4>ERS5+BA=E!BD1RSH%LC3,=CZXU>_.??R]\V[*8)RX$
M=I<GX EFHI";1[ VBFNP:QKEG'W[JAXCR)B6KZZ-W4H9J)T^61PA_\/3<^*Q
MH>)YB3FQO^*L3URB/C:L'S#M\>:^(*IRXIB1^5VX'1P]AF\%C2 #1)H@=GI?
M#!_3NZ1?<,#/^4;!4<6?#^\Y=]1]H%^NV(8 EIJ>) JN1L[5!L"_E+;Y83H]
MZK'6%@_2R5U)(2QL&*X/Q_(!;JS+,QO=B@?:<\QOGWPOTGANR48:S(@FEM((
MJX*V_7O^895+@4W%LD:>\-3C"D\W)9T=L73@EKPU]ZXON3ZO_^+-O?G[$YS7
M=VDT-QT9^\6( !/, \P M@[Z$3%A0"5Q]/"3"C07?*JQ66O*E\'XEWGQA,J%
M(RFCD[-"\96EUW:.7W:(:6M_JL0#D9[R8LLZNP1<OP19];LIZE%DU!#'_4-!
M3*+0<8W[Q'W3:W=Z]TCD?O[8?_(/*&=0W2A5M#FW&%2[/"MF:N;:;X30TH'B
ME>J5@NZG8S=O%;V0^_9@3*%AEVZ5:.>NOZX1LZGA1SQ\YKZ+K)FMKK.#>=_P
M=?HD&D$8O8_9VDE49YC\=B\ZS"AJ?C$;:D[,TBU;.!:E2WB9?L-)9N&^2Y%W
MDL4%"EV9)Z9#<8:I8#I),H,HZ3B<??,@6KQ\^>9I A4IXQMJ5N^1QSKG)#'0
M'ZJ+>A0M$JJIO#OP<E><Q^H&6 .4$:(TMLVMC@3L7^\TF/)P9BID8K0YEI%*
M&VW6,,:EP=4Z'>7S[^U:,DVXO>\S/M?USF5^*[Z6*H;)YC9@YWIY!M@)@[%M
MR.\9*P@&U(UM1[&4,FR# D<JF"?&#_<'\ZZ#Z%J7BVNFXCLS+,2Y!MU$G;'*
M39,AM49;EHOO:$)>L&DD_N#"7FS,0 VT0-X3[E>+3%*5;0)AHM2%*>(,)-./
M_OZ+@;:]F_HAQ3D^HC&@NN7C'FC6&\C*C;C0R0^1"9K>]7S#%UQ*Z !XDCT:
MG%V)]=@VTQ888YGCN03?Q3&C3.F04V;U"JPC4))/O2J"+HDK>[+>.A9;.#I!
M]':+T$$S3;QH/6OQ!CWD=&Q5Z5I6< *JD@-AN."3:WM=?*!3$9$[BRTS@M9S
M--,/0W/HZE]NB'4;JD+@SAAK;)L[Z7+_1!-6OHNI0$NIB%;H^*N&HX&-=K=%
M\EUX/48AWK#*1/F9^6!<!%D0IN_A 4GTD!L#4EGKW >6>FPMZ%3I18#[7+O=
M?3#W+*Y[X-3@9*_X)S6;#*5:W(&']^X>?(TT^I-@EE4'O&#"NK UI@0J#C@0
M].\1T9$/K>\97X#P,\,8B[@>FE;+6%EYV&!OF>![!C=Q=\N;(LI,"K$QOO"G
MQM7+ RMEW"227Y\X3TSY/P_+0EFN)* KF-*:@ 2RRL#!)E06-M7WJ+M.GG!+
MK_7A/)_.GH^G[J3NF]BQ<SSK(QS)$^'-PFIBUT28QU")J@)CEG;!= ODSF<W
MU]N)>@PMP@MDQ^N_52<:7.2+P\7C(S;4RB52]GW\G-7.F0*3\^^AQ;>\CSPU
MP)!)9H4Q&M9@Y0U9'#G*,W>KXQZ,P-<-<J6I)H2J:?$C42;-NY,K'K5]<$G/
M\=8/1.IF;4,TT?\PZ^%_;CX4\R2XKUM @20(DO_$NYQ]3<,8*[0%L(\ .E$.
M9%QGSYQVMJD?TGRZT7W1ZMALZ-ZZ'.6:)AM&M6%,=CT#SHC<!).#(E$2R?4U
MX7_D!U=TB[3SD3E_.QQ9?=3D7Q?]%C44A4;%HRVX/P26_Q4'C%4 )#-E>**V
M=$06LBYXC:\BO.<84/&N<!LBC[9AGA\+ZD D.0]I1OXQNV;V2##AU?4\L>;'
MS)SPE0LD2C6)<7H32*)@4R^.=5<@3A320@6HWQIH*+[PF[XX6F07?Z'*R9_?
M+)R34:9ZE3D/L:96[V;]HCA@3A)E?3!?\K","+,U$8.UQK<KIECQ0III#2S]
M-6-UP<HV^]T-MT2+<]^__1&6M</.U#25<Y++Y]8!'6B&"7X7MLUD&^*'DHF3
M_C+6@950'ZT#B%)Q[G^\(Y&=IELW%$S?H*)=;&332O/.G)RRY7>(>"N3@,_9
M"UU*8N&YE:1@@_&ACX?0)[FO>/LG@/!3K<-^0[6U.:*549L6$]!_##]RT.GG
M8L0>.S&+!Z+=?"9MP'&>V#.V1%P/?6<VV]R66>"C0[-NK, &7N!8,,U2ZE1T
M?#9XG\;NO'K?TG _[KGI<H!7ZEGQ*R]Z=]7]30.+I)H9F[YI !S%L]2!6TS^
M&%61H8#O=5"H[8U.+Q7W6U'S6ME.]#Z]R-)*<TXV-NX\MGY:'I0$;?/PFI8\
MYLL6HF!=Z)?[GL2.BDH$\7OQ#R$(ACI&T^[ 3V%9MT%FD@2G5/#TN-E$>?1-
M)J*#-!%+M2J9F6VRAJU 7X?YFG@E/*Q#F&Y):SE6!EU;49([&RD3('K!G#?E
M.UFQ^704H?.\0.L8TU31=O<GJRRL.8D1GI)1CFVSQ%*J\<IP"AY>ZZ>?1@/I
MH^1T:($-$:G#/KG0OJ:5:=N<[[FFD;-P^$@<?=JH"X)YPQN',9Q^#VY# J&*
MH3#&:5@&68HGB[;+Z%#P[Z@.(4N;>#5;^5X6YPN.16&O&[LLX&8R'I1;ZE)'
M3RMZ_8#A\/4>JTML1<"Y'<X8($F1JDT,Y'QM7\5YV=8,1=7I>7@/[[!C6SU[
M]/3:M#=QT09=>ZED[*IRRBT9&JP3P<_19)PN96K34!D1QGHB]G7A6>?<AW^Z
M[]=[">O\.AV]EV\X!R+X0(>) ['"#%<'!2P(+*]!GEH+O7V4)Y.(%'GUBHO'
MYI8;OVM41@]=2]_-7=7UI.A!, 3>-VS]V&H_VP,F,\[9!:1/WJ^@%&[XTPTD
MPI1,%IZ]^Q$+,U5O&OI)2U^6GD*&AK"(W>->PBW7%O]+G)74US CMB&,T1A<
M-"6T "83\IEZRXM]<C PU(TF'S34G_V]S3#[[.YN]9A;;U_A;I,"6X_W2($5
ML A7U<,HEPR&& %BFLR',8N'_HH__]%I^9B"?7WORLW$\9_A]\%V$OTQ:4?F
MR,7RQ&S?^82Z#\Y,K5BK)XJ7[77/.?)JS,1((ZPS0&<W75=$I-=[,>0Y=##R
M.$]\!C2LX#VW2!<;!K+:\"SK/^TWDSN_=T\&W2GS07YD&H<;X/WEFKVG#AI7
M"6@,O,2P+ TW9&+? !D\,3NV+.#%<AR"1W$]Z(]J.&HCU'0OQ)[Q'W_&W._E
MN,P=>&PK\#F2O3Z--SD7\2'K_9P>1@+;!C7VV0,ZU01KJ*R^48BJ=RD)DW*)
MGC-XS.QYF9HE[J_I]FS"EJ+@=\B)<!(XIT[B*(K2-H,U-#E46_@-;'MDU-6U
MS]I,4(=E^?/$_X#F9WTO9A!?O,&,7[PRR$%>J=]"W)/I*"@.S3[=N9:RP+CX
M5_[:)=0!B^Y>1<_=.R:\N4)L!\PHO"9_%<>(HK/N<(NM]9>LY1FW&M/L:^+5
M'1N@^[^>M=UC.]>8_5'3/\UGG-]FKQ+'%&!2MR%\VAQ%,TIX89_Y%YTWA'=1
MOW.RU?)(*+G3.1\^+AP7F.:_28])&'N,;3MNL T)4?'XS]W2LS_(BD4<X.3/
MV:XZ:&W-[E</?4)#@X+[E5.>]L[_7 SONV]V1F2]]",*V ]=);#MT6>'>4)Q
M(CTWDU-!TJVOASC#,,A$Z[WYH=1^X0N?\ZN:X>>)GI<M\@_;OWM[07CO4P\=
MIC-/;(PM@M[#-,OBF-"1&>9E..JK<I%.E5A[AGY-6:CJGL:0KXF3&V= B!L5
M91C.&]])DCLF4%W&F0 -?(T$?O;R=LYPL^'4,QF/1LA45K;J^U&]G*WPL)M
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MS''X(&:YOQJ =FN<\H78&1*7&!I!?]@3O@#G0S#N6?N_:?M28VOAZW.R^?7
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MYLBW$A-1_I%C!"$@+K%H9HG\M5Y^?0=VNZHZR351F%O[J&V"Z<9!E@K[;?U
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MFS.L#=OJJV)JV6T],.]16S@C##2FKJ7_'5A%O :UR /=LPK C\IXW+)^IU>
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MWWXT,B^_B7H;$"&Y34[M[K(S6ECZ,>L_(?^^<N&8^ TAM;=7%R''G,L90=3
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MF@11!,5G_?+BRDH:W<CN9SXD:8G=22D_K55P_>'A<"T5H(<E>HVA MBM1$1
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MZ< &X0T=EG%+!2>+9.Y%X_Z).Z#_N)8G;X0L[#,;"NPF90\%.B\(.S<;+-7
M?&U>@4QUA/[3L#Q,OSH/.Z2!?RQ]OI?%O;!WH,TRDW^00$GN?7OO] +<[=@X
MAD9458U=UN:]/^*H T)>8N$E\LDR].!%S!Y@#Q7/VN]'V@#2BEE=*,&*_?6G
M"MPE9-.O!9.[1I[5O[49,!7M$JNHRA3.ZB(1U<2NOXU[A#H =>P!Y/&,0W.L
M?6\I<ZS]Q1PN^0E<01Y#Z-0-H,D,W^E.L.C\N#TZDE3_)7UU5>%J:("GVK>5
M1S2JH43!];Z9[SZOT$-U)W>M:K'V9V5S @_<!5A;3SBX'$>^2#^". \HT;4
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MHQ5V^V"J][0V#-793Q@GZASCBK]]Q_Q5[--]A*=:(VMPCF+G^%U/HY$]F!W
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M+;NN/Y_ZQ7O&Z?$1S_/H&DD6S^_6V-G &/TJPY"SU"!D/^986&,=.MS/HT'
MMI^E^:MJ'/F<M">\XWJOH:_,55FEQ]^4M3\D6UL??-(5.F0MD=_,!NU83-_
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M\X^9%(TZZ%K8>N0_D;#Z(1U;8@7VMM]365F97&=C/?'>5#?;,5J6NY#K$HC
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M6O]*/T;\SR;(\V=X)^P1,:4&"88:-3#:^<9J6M"'+Y6H&ZHZWR''6X,X6S#
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M;;KTQ(^5H(=Q/S,'C(ZMR79I;:!C]D!LP$=6HI]!-?)#G.' .?A3EF90T2V
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MG0[)Z48(LYV%SLSW#WL-$(C;3[<^IDCD5I5]+4]E?9;U9[R&E0"*K"/' :?
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M:Y+^F6:4Q#Y;_8I\_*6LE'_$AK .>)4F0]B.!%OM"B/J*$?J*_8Q;D^,1B5
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M[&^RH<_]DM-IFS,_GKL1 C#1^OWH[4IW(W2^W\^A!PA5DOG)#V=MS(.O9B<
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MZ4;Z-]06,D(1TJWX^7;B0MZ!G0=#:;:?E/T36?*6T%8(Y='Z*MWESTTIS=@
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MD6WL$!%=M:-?#=K8 \T$MJZ'7W"?H!7.A>%OB0]OU?;,_?5&[B_!]\?CU1Q
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M 8=GXYJKG%<9OR%7ZCSH%U@]!(&N*G0#"%"]$T@?=-<7PR5#/SZ)_:)/G&]
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MLBI'ZFQGHN:!:)ZT>YS):1 OYG6@G3@@FJ,,WGHW;%+H*;1@8-:,QS^O+06
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MS?@>7V520=]LEJ_KK*.;=T6,R=;!#IL'2D?M%A^]\JXRS$IFCKH>,CB$99A
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M(\,.Q2%/QDAMS!&Y;*]LG&O<]]=0,,U$^Z.A&Y W-6U8P+;+E&.03\5R1<?
M]-)8'[*:=Y"/A/V+.W:#&GL&@(&@$)BX 6$0,NMFXB ,)!!HV[ !69>M#=R
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M4;3?KZ+"XS,.]%U5D/ATZO@]E@A5D\G9@&Q? ;/;*37W7W^ BB[B:C#-^:B
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M;+7]4C/+@FZ'Z]07:(F:_FACBOQU#5$D7<65=']HNH2DF0TQ,%7PE,.UI(;
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MND@1$D'6',[86Q0[9MUBLR\EPJC1,\,U\:-7B!J?/:UZ#O*JJN71/1S@*JG
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M,*,ZTGH 94$:>XM 9ATFUV;^LTG=_VTF-*/W0%5[4I5IX,W[)O/A:2(X-NZ
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MKV)_<E?[:3C9V-K;TM66,_[S^?U@E^,52B=P]R<F5*)O1 /0-L$PK9(%T(0
MA.")J4\V(%4F781XEPW(D]:#H/H5EF1'H'['/VKK\Z4[5O=V/I^QCD\T,*=/
M?@VW6X1OB;\A,@@%D.M,?>H> C4^=]?@&D6VZU@^,&)^QIBI-^!"YVN?&Z[
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MSL.%!%;3O%(L[1JD\Y4UJMX\3LW>\V7?_9$63;$TA\2FR%2$Q%.2EY]EJVK
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M8"EP4+.R!%)'K0+<!7ZMYS8E'C_6=,?54##Q.BT0M$,Y07=P9Z?A5-H7($9
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M 8D,?8C4?Q$B)!">D0UUL213X[Z-9& I@6A4 ,^5V(!M:6)&A)</53<GCCH
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MO$;3B4ZFQJ>ZOH26$VA!M:VE1;4PB$]A:;!'<8#0P+1V%)P^YVFG4++8 3A
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MA%&(HUC"5 BIS\B5U20"'\:)('&0,B)]H\+F/?N?FO6DODK_\API78";\=B
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MJY@2'598ZUL_('CE$^7*^B5Y 9Y$7OM'QW*/]OQX!G:2#O])3-]5NG:&UB@
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MHP$46.C++UX"*?=2Z'N)1P(L?8*M*A&-*_[4;(2=B(YM]UU[&M'>F*E^5N>
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MBY$:F#CZ@&1_Q:X+!*=7Z8YV-.Z5N2Y=#Z[&=3[L,-PN7XGMZ+]9$(J01%C
M1 @,4:CK>WE^"$E,68BH%(@:E7"QZ71J_-!(V"9HMSQD,H+9C"-<@S>T1_ID
MZ%T%YR %)FP@&CP ;[_?UX_!.X&$41C>J7<OO,'QYJ4*.ZX8KBIV%!*._33!
MD(2ALCQXBB -2 PE\1(>1SB2">MU(V._I\GQC)8.U NM3=FH\Y":T8L3H(;>
MOYACU/_RPBG]![F,<-#9ZUPN.*7SR<L")U_HZTAMD^$5=\NV^*GX),KZJNK'
M9:%^_I84#Y_SY7.F]B%O7KX5@M\LUJF^JHN4%36MLV$DL7I0ABGT).:ZH+2
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M_Y+["H]S O#B3MONB<-MN)TTW=MWNSW!S;[^HQ8/\EV]JI[4M-=32F/.)<L
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ME4V9A?KW:EX]K9]Z>OLP;W_\1=1BJ2RI]XOE^_5JO12Z]:KV^TUQ2BA7&VU
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M PRW1OG 86_9\O) SV4>_ZB%7,\^5E)74\]06I8ED+I:$V2$ AS#!)0D@8G
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M48HLYAG+4ZN35(,QQ_9Q]R)'9,YW#4K;JN;7P3;[]CU#&-RUN8/>KHG1"1R
M*"P \ELD_?JP ]=--\;AN)2Z^:WNK1K98OF\6'8U.,E*W.M*>\N7^P474Y[
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MCL_?;&[V4FY"4>!."=\3>=!M^XKE7EIT$Y;U3?Q<O5&J_W,JDYB4$&(@\HP
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M,W"(5%MF[\.\7BV;--^Z:4VE-K;S_1KE@F_Z#A !:8%% 6)&<P!U/7 LH>(
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MY-T%_>\*,24980D3.> 9$@ 6D()2E@P44!0P$SQE++;I=F,^M!4)#]#^1I,
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M5K7C&E7G+W7TG+-'P=<S43_(O1W.@]1[G#<O^K_O"5.3LY--3H5B 48 8D@
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M!31'+"\+R6))C LIVHX^-@+2?=$6VZ,W'7&IF6BFA5<6QOJ"F\7#5%RFH>
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M5->,J+GE\]5)L[:^?:+LTT;W(M>@EKQ/) _M?:_/'H"VN_W)B6\?0YS0HL!
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M'YNOYU/7:,..Z_8!0VF<P3(N0 K5&@/S# &BZUTCR8LRD26.13;](99T8;K
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MDM8W'1,29XFI[TQU>SY*K7Z::G*,LW4LKTAY80&^'3OXA71@NO" IK_JH <
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MNLI1;5MG,L12Q8A!HB2%*% 4DBP5FE48BGF&<4*=6.5,7U/CEJ[KI[Y@Q%Y
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ML1#*5LKX;P]>NA30?M1?K\$S_-V!#@%T9HE$@^M!,F^(#XZ1D)3A.B?E>.R
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M=P69 *!L<H+HUHMU-P!APPOZ\3(J :$+(?8-A/_EA_B0#\.+X1S2BOZ8M=<
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M+R=?IM-6<=?^\TQA.@1O=135=RO0NW-_'A_CPE.RN&0HR99A# U1$5NF=]B
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MLQ9ZDX&^+>/P %%8Q@G7'%T&+1@I@VJ)L%1K)GB6M([#=C#IS32IZG&;/#(
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M+\)^7UW>'/Q?23PS'BED\D")F(TR:<!<%"!S-"436EKDG@A[>.5I4U(G0M@
M0IA_B^6[K<]7]1U]6JTOJ?Q\<;GXB)>W\L&WG5:':;"\\[(#MU<>AOP#-%?6
M41M?V,F/3K'/7[6!)"H[_M&%4#@88$:/^MH^XERANT)XI,/OB\M?B,T,GK?G
MJ2O^Y,]W6OB?U2!M\<A!46FN17$9L/D7N1I6O-;V?YQD_D&IF,E;\Y[X>S21
MX>""GD'T^PCQ=YI?WC)(9R7HBD)&J#X7,%DC)+05/%$,Y+UV.$K.;L]]SK?[
M\PA('4184WN;74:?W+Z8*O_KZN)R,^=UZUJKZ'25PK;;6 7&*X00O0;GDR ;
M:R31S?O<=R?S[<&P"_8.+YSY6L6;VZFO'5BSJ-';X$ %PP&=CH%)9(WC<(Y4
ML*@XO#N@/?QVA_.MH1K!$NXIH%G4'S]+VG6K.8XCL[0101HVZ\:*!*%:!2%G
M5C5=2(V<W_KD]J:-R"=#77_1S!ER&VINOK7\<'V5H4.)0F<#5=<,QN'FDK05
MP5:A2;!9MZ.D)_;9Y+0M30\,O_W%--\3]_=5N[BX8M\CG=,V$'MX G6;,'V6
M2O;HV,0;]FW9X341DF2SSTZ'SC+8$L(A3^-^NY^V9^J!03NB8.>+YI=_MLRD
MU\MO'M@?Z,:84-9BHP>MI&2_I?7_M(C CG*)+CGG?9>LO:&@W&/KTS9L/3".
MQQ+IG$!\;Y89E9;^Z'-SIEMI!]GFV51PCHR*.EB7Q[T"VF&>W&BM6T>'VQ[,
M'ZSQR,&>=]B3^8D^+)9+=F-P67Y>%O[B^@IA53=]D1\9.3K.L\_>VQGY.6A8
M=AW@F<BRA3.$"1(J=D6E2X"Q>K#*%&*/5>@Z2F?Q0SP3_?PW?EPL\69$\YE"
MX03[)Q!%-*S^.0.FXJ$Z:9&"="A&F5?\Z([F^WS3!Q=/6,H]!#"'.IU-J8IU
M(GCV$H!B%F $%@@FMQ')0F096Q^0+@^%(U1LC8^,_23X8*U6'W;. 0/;@@-A
M28;L!?C$7L-F4'8024*4%).,F;P8K&IC9K5:O23V2*U6'_9-7:USI\PH!#31
M<G0KT+?<:9/99;26Q>:QI"AY]2Y5&<=:J]5+;H_6:O5AXKSBK!OS]^M-YIA-
MK NAE<_+=C16]O6CC4Q6&Y*:^,P4TAW*B_BU5X7.^,_K@YP7PXMA!IBZ=T-<
M'XD#?OX[GU]]#1HNWM*: X,63K2*CL:&S:^_H\NK]?+BW>K\_)?K[,.S:E!:
M'R,X:F\<[*)!]!SJRI2-DZF4;$=Y?AJ;L/EY0CMB<#5C0,Q 01ZA_RPX69*F
M#-JU"5[95PC!:BBJ)6<;;X09Y=KUD?U,"\=Y@68UO 1W!N*G30>W/RYQ?3DF
M'-D>K%M3_Y;.<'7>TL!_82&]O%HWZ5UWD6OMY%87BTTMRYE6)E5!%G+>)#NX
M *A3AE)<\4IJ$_PH5P[#;']:K^(8P3XF/N9KI%_10U2_96K7#]!<8HZ:HH+<
M+N -)@_)Z0ID=0R5F.MZ% =ZB,U/FTIXC!HQ'C;V'APPMEH\; P>(]TZRMK*
M "ZU8S)$WP819?!.DBLY5A-&F9\RQ.:GS6D\1K48#QOS/2;.2M4B$;46;3*#
M,:H MA8^VK;)JJHI^"C5^_OX\J/E1!XC:GM)<$]?_N?E,+F4CY#R_D^\_,_5
MU7EY_?$3YLN;A/HO94,*71 Y)4"*;4Q2<JQRI:606E,<&;3CI//NMMWYW?\-
M<TMR .'-UU[>L/4M+?%\,TIG65XO>5VZN-RFH9S9((@*ZZ&Q;5HL&0.8M&55
MQZ+1&U?,*!F6>^QY)O4XAP+KX&*<:97X2SY[,*VNFP[ALFS2H%]\6!-M"H]V
M205Z[B.'2.?IM>T]4W(VM5MW%FQ5@HO<(/!UR9LL#),]&D4)1*P53'MX2UD@
M**.5*T&98L-S+.RWY%X5@\^N\C71Y#TS\B?^A_]F+R5+$MJ#5,&QFC7,)VG
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MB[\/Y@Z0Q=]'^C,(6@::5D U4(P6?"Q,='4!@C,6I!"6'>4V:^K(9Z8<4]U
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M/L:HO(AJ%%]GOVU/_9PRJ6T=0[3C1S3;'[0_$E[0__M?_G]02P,$%     @
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MUCBQ;+ZYMNV&:]N>$YMUH[WN[O[#U?UN\DEU@^YH>/!)FA\T]G$&]<)$Q,G
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M&*M+EJ#P)P3A='<@W+#QQ9RK*E"6#S!E&4I%.4=H[#TEWZJF> 0%Q]O[J\
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M;%:JK#+;)G]Q9U^/S1]$_2\S^@A02P,$%     @ QX!94DO^KP)U$   ^E(
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MX4.J2H!6I<,!9*_;$[7WSAM@0Q=(616G#9ZGMRN(ES+Y!_M0GAUY59I,!<X
M!(:AMF%40VVL$R:5?/%XK E@S53-O0M;!;8AFZ2H%P5;['E7F#D"@!OM%,Q[
MB2DZH-4J_\$#=#\;1HD5G#B3_;5K] &X5]"\Y+M.@R(I%#% _1BP(+AW!!G
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M\645=-;XMT+2[Z=\^G]02P$"% ,4    " #'@%E2:)&K/VNZ  !X-@8 &P
M            @ $     97AH:6)I=#$P,35C;6-A9W)E96UE;G0N:'1M4$L!
M A0#%     @ QX!94HW<LHJDA   A#@$ !X              ( !I+H  &5X
M:&EB:70Q,#$V:6YC>71E8V]M;65R8VEA+FAT;5!+ 0(4 Q0    ( ,> 65)>
M2Z]UI],  */0!@ >              "  80_ 0!E>&AI8FET,3 Q-V5V97)S
M86YA86=R965M92YH=&U02P$"% ,4    " #'@%E2P!!+_BIJ P QTAP $0
M            @ %G$P( ;6=N>"TR,#(P,3(S,2YH=&U02P$"% ,4    " #'
M@%E2W^ 0;\H3  "#S   $0              @ ' ?04 ;6=N>"TR,#(P,3(S
M,2YX<V102P$"% ,4    " #'@%E2@\VSJB,=  !K*0$ %0
M@ &YD04 ;6=N>"TR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @ QX!94F3V
MJ_T]:@  ",\$ !4              ( !#Z\% &UG;G@M,C R,#$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( ,> 65)Y^-T%0.87 -.)'P 4              "
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M+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #'@%E236S_U>Z1  #9X 8
M%0              @ %J+"0 ;6=N>"TR,#(P,3(S,5]P<F4N>&UL4$L! A0#
M%     @ QX!94KH8W(WV P  (!$  !L              ( !B[XD &UG;GAE
M>&AI8FET,C,M,3(P,C Q,'AK+FAT;5!+ 0(4 Q0    ( ,> 65*KYAK*\0<
M ! F   ;              "  ;K") !M9VYX97AH:6)I=#,Q+3$R,#(P,3!X
M:RYH=&U02P$"% ,4    " #'@%E2%5D99]<'  #])0  &P
M@ 'DRB0 ;6=N>&5X:&EB:70S,2TR,C R,#$P>&LN:'1M4$L! A0#%     @
MQX!94E\6-2_Q P  K@P  !L              ( !]-(D &UG;GAE>&AI8FET
M,S(M,3(P,C Q,'AK+FAT;5!+ 0(4 Q0    ( ,> 65+D?'.J^0,  "8-   ;
M              "  1[7) !M9VYX97AH:6)I=#,R+3(R,#(P,3!X:RYH=&U0
M2P$"% ,4    " #'@%E22_ZO G40  #Z4@  &@              @ %0VR0
M;6=N>&5X:&EB:70T+3(R,#(P,3!X:RYH=&U02P4&     !4 %0"L!0  _>LD
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
